0.100268394.15123537.html.plaintext.txt	0	Differential Roles Cholecystokinin A Receptors Energy Balance Rats Mice Sheng Bi Karen A
0.100268394.15123537.html.plaintext.txt	1	Department Psychiatry Behavioral Sciences Johns Hopkins University School Medicine S
0.100268394.15123537.html.plaintext.txt	2	Baltimore Maryland 21205 Molecular Pharmacology Research Center Department Medicine Tufts New England Medical Center A
0.100268394.15123537.html.plaintext.txt	3	Address correspondence requests reprints Dr
0.100268394.15123537.html.plaintext.txt	4	Bi Department Psychiatry Behavioral Sciences Johns Hopkins University School Medicine 720 Rutland Avenue Ross 618 Baltimore Maryland 21205
0.100268394.15123537.html.plaintext.txt	5	Abstract Top Abstract Introduction Materials Methods Results Discussion References Although cholecystokinin A CCK A receptors CCK AR mediate feeding inhibitory actions CCK rats mice absence CCK AR results species specific phenotypes
0.100268394.15123537.html.plaintext.txt	6	The lack CCK AR Otsuka Long Evans Tokushima fatty OLETF rats results hyperphagia obesity
0.100268394.15123537.html.plaintext.txt	7	We suggested demonstrated increases meal size elevated levels dorsomedial hypothalamic DMH neuropeptide Y NPY gene expression may contribute phenotype
0.100268394.15123537.html.plaintext.txt	8	In contrast OLETF rats CCK AR mice normal total daily food intake develop obesity
0.100268394.15123537.html.plaintext.txt	9	To assess basis underlying different phenotypes rats mice lacking CCK AR characterized meal patterns CCK AR mice determined whether CCK AR mice exhibited alteration DMH NPY gene expression
0.100268394.15123537.html.plaintext.txt	10	We demonstrate although CCK AR mice show similar dysregulation meal size OLETF rats elevation DMH NPY mRNA expression levels
0.100268394.15123537.html.plaintext.txt	11	In fact intact mice CCK AR DMH
0.100268394.15123537.html.plaintext.txt	12	Furthermore intact rats NPY CCK AR colocalized DMH neurons parenchymal injection CCK DMH reduces food intake regulates DMH NPY mRNA expression
0.100268394.15123537.html.plaintext.txt	13	These results suggest although CCK AR plays role mediation CCK actions control meal size rats mice CCK AR seems contribute modulating DMH NPY levels rats
0.100268394.15123537.html.plaintext.txt	14	The deficit CCK action control DMH NPY gene expression may play major role obese phenotype OLETF rats
0.100268394.15123537.html.plaintext.txt	15	Introduction Top Abstract Introduction Materials Methods Results Discussion References CHOLECYSTOKININ CCK IS peptide found brain gastrointestinal tract
0.100268394.15123537.html.plaintext.txt	16	CCK released duodenum jejunum response intraluminal presence nutrient digestive products proposed serve feedback function short term control food intake
0.100268394.15123537.html.plaintext.txt	17	Peripheral CCK administration reduces food intake dose related manner across range experimental situations variety species 1 2 3 4 actions CCK food intake specific reduction meal size 5
0.100268394.15123537.html.plaintext.txt	18	The feeding inhibitory effects exogenously administered CCK appear mimic physiological role endogenous CCK
0.100268394.15123537.html.plaintext.txt	19	Administration CCK antagonists results increase food intake 6 7 8 9 increase manifested increase meal size 10 11
0.100268394.15123537.html.plaintext.txt	20	The feeding inhibitory actions exogenously administered endogenously released CCK mediated interaction CCK A CCK 1 receptors CCK AR 7
0.100268394.15123537.html.plaintext.txt	21	Although satiety actions peripheral CCK well characterized role brain CCK control food intake controversial
0.100268394.15123537.html.plaintext.txt	22	Initial work reported continuous picomole infusions CCK cerebral ventricles sheep suppressed feeding 12 results rodent models mixed
0.100268394.15123537.html.plaintext.txt	23	Although studies identified feeding inhibitory actions central ventricular CCK administration issues dosage access peripheral sites raised 13 14
0.100268394.15123537.html.plaintext.txt	24	demonstrated infusing smaller doses CCK 8 specific brain sites resulted site specific feeding inhibitory actions rat 15 anorexic dose CCK 8 increase plasma CCK 8 levels sufficiently suppress feeding peripheral mechanism 16
0.100268394.15123537.html.plaintext.txt	25	Recent data Otsuka Long Evans Tokushima fatty OLETF rats 17 6
0.100268394.15123537.html.plaintext.txt	26	8 kb deletion CCK AR gene resulting absence CCK AR 18 suggested peripheral central roles CCK acting CCK AR control food intake 19
0.100268394.15123537.html.plaintext.txt	27	OLETF rats peripheral CCK satiety deficit
0.100268394.15123537.html.plaintext.txt	28	These rats feeding response peripherally exogenous CCK administration 20
0.100268394.15123537.html.plaintext.txt	29	Consistent lack intact peripheral CCK satiety signaling food intake OLETF rats characterized significant chronic increases meal sizes
0.100268394.15123537.html.plaintext.txt	30	In response increase meal number decreased decrease compensatory result OLETF rats hyperphagic 20
0.100268394.15123537.html.plaintext.txt	31	Although increase meal size OLETF rats consistent absence peripheral CCK signaling overall hyperphagia obesity surprising
0.100268394.15123537.html.plaintext.txt	32	Pair feeding OLETF rats intake Long Evans Tokushima Otsuka LETO control rats completely prevents obesity demonstrating increased body weight secondary hyperphagia depend metabolic alterations
0.100268394.15123537.html.plaintext.txt	33	Pair feeding prevented increased body weight also normalized elevated levels leptin insulin alterations arcuate nucleus neuropeptide Y NPY proopiomelanocortin POMC gene expression OLETF rats 21
0.100268394.15123537.html.plaintext.txt	34	Pair feeding also revealed seems primary deficit dorsomedial hypothalamic DMH NPY mRNA expression OLETF rats
0.100268394.15123537.html.plaintext.txt	35	DMH NPY mRNA expression significantly elevated pair fed normal weight OLETF rats elevation also found 5 wk old preobese OLETF rats 21
0.100268394.15123537.html.plaintext.txt	36	We suggested dysregulation DMH NPY gene expression may combination peripheral satiety deficit contribute hyperphagia obesity OLETF rats 21
0.100268394.15123537.html.plaintext.txt	37	CCK AR knockout mice demonstrate different phenotype OLETF rats
0.100268394.15123537.html.plaintext.txt	38	In contrast OLETF rat CCK AR knockout mice normal total daily food intake maintain normal body weight well adult life 22
0.100268394.15123537.html.plaintext.txt	39	Although mice insensitive feeding inhibitory action peripheral exogenous CCK deficit appear affect overall food intake
0.100268394.15123537.html.plaintext.txt	40	These data interpreted suggest CCK essential controlling overall food intake involved long term maintenance body weight 22
0.100268394.15123537.html.plaintext.txt	41	To investigate basis underlying different phenotypes rats mice lacking CCK AR characterized meal patterns CCK AR mice determined whether CCK AR mice demonstrated alterations DMH NPY gene expression
0.100268394.15123537.html.plaintext.txt	42	The findings studies led us compare distribution CCK AR mouse rat brains determine relationship NPY CCK AR rat DMH neurons
0.100268394.15123537.html.plaintext.txt	43	The data demonstrate distribution CCK AR differs mice rats may account difference phenotype rats mice lacking CCK AR
0.100268394.15123537.html.plaintext.txt	44	Materials Methods Top Abstract Introduction Materials Methods Results Discussion References Meal patterns CCK AR knockout mice CCK AR mice generated previously described 22
0.100268394.15123537.html.plaintext.txt	45	Both CCK AR CCK AR mice individually housed home cages maintained 12 h light 12 h dark cycle lights 0600 h
0.100268394.15123537.html.plaintext.txt	46	All procedures approved institutional animal care use committee Johns Hopkins University Tufts New England Medical Center animal research committee
0.100268394.15123537.html.plaintext.txt	47	At beginning experiments adult CCK AR CCK AR mice transferred test cages wire grid floor prevent pellet hoarding
0.100268394.15123537.html.plaintext.txt	48	The test cages contained feeding devices Coulbourn Instruments Allentown PA delivered 20 mg chow pellets
0.100268394.15123537.html.plaintext.txt	49	The pellet dispensers controlled infrared pellet sensing photo beams Med Associates Inc
0.100268394.15123537.html.plaintext.txt	50	Individual pellets delivered response removal previous pellet
0.100268394.15123537.html.plaintext.txt	51	Animals ad libitum access pellets water
0.100268394.15123537.html.plaintext.txt	52	Animals adapted testing apparatus feeding paradigm 10 d experimental data collection
0.100268394.15123537.html.plaintext.txt	53	By point pellet spillage decreased less 10d
0.100268394.15123537.html.plaintext.txt	54	Data recorded 24 hd computer
0.100268394.15123537.html.plaintext.txt	55	A meal defined acquisition least five pellets preceded followed least 10 min feeding 23
0.100268394.15123537.html.plaintext.txt	56	Meal size defined number pellets delivered meal
0.100268394.15123537.html.plaintext.txt	57	Data dark cycle light cycle total 24 h variables total intake meal size meal frequency saved computer analyzed Tongue Twister software version 1
0.100268394.15123537.html.plaintext.txt	58	Houpt Florida State University Tallahassee FL
0.100268394.15123537.html.plaintext.txt	59	Data mouse average data generated 3 continuous days
0.100268394.15123537.html.plaintext.txt	60	In situ hybridization mouse brain Five week old male CCK AR CCK AR mice decapitated brains removed rapidly frozen
0.100268394.15123537.html.plaintext.txt	61	Coronal sections 14 microm cut via cryostat mounted SuperFrost Plus slides Fisher Scientific Fairlawn NJ fixed 4 paraformaldehyde
0.100268394.15123537.html.plaintext.txt	62	The full length rat CCK AR cDNA 24 synthesized RT PCR subcloned pcDNA1 vector linearized appropriate restriction enzyme
0.100268394.15123537.html.plaintext.txt	63	The antisense sense riboprobe CCK AR labeled 35SUTP Amersham Pharmacia Biotech Piscataway NJ using vitro transcription systems Promega Corp
0.100268394.15123537.html.plaintext.txt	64	As previously described 25 35S labeled antisense riboprobe NPY transcribed rat NPY precursor cDNA 26
0.100268394.15123537.html.plaintext.txt	65	Standard situ hybridization conducted
0.100268394.15123537.html.plaintext.txt	66	Brian sections paraventricular nucleus PVN DMH regions 0
0.100268394.15123537.html.plaintext.txt	67	06 mm caudal bregma 27 selected examining CCK AR mRNA expression
0.100268394.15123537.html.plaintext.txt	68	As well brain sections DMH region 1
0.100268394.15123537.html.plaintext.txt	69	06 mm caudal bregma 27 selected examining NPY mRNA expression
0.100268394.15123537.html.plaintext.txt	70	Sections treated acetic anhydride incubated standard hybridization buffer containing 108 cpmml 35S labeled probe overnight
0.100268394.15123537.html.plaintext.txt	71	The incubation temperature set 55 C NPY 58 C CCK AR probe
0.100268394.15123537.html.plaintext.txt	72	After hybridization sections washed three times 2x standard saline citrate SSC treated 20 microgml ribonuclease A Sigma Aldrich Corp
0.100268394.15123537.html.plaintext.txt	73	Louis MO 37 C 30 min rinsed 2x SSC twice 55 C NPY 58 C CCK AR finally washed twice 0
0.100268394.15123537.html.plaintext.txt	74	1x SSC 55 C NPY 58 C CCK AR 15 min time
0.100268394.15123537.html.plaintext.txt	75	Slides dehydrated gradient ethanol air dried exposed BMR 2 film Eastman Kodak Co
0.100268394.15123537.html.plaintext.txt	76	After autoradiography slides examined histologically cresyl violet staining
0.100268394.15123537.html.plaintext.txt	77	CCK binding assay wild type mouse The autoradiographic CCK binding assay conducted previously described 28
0.100268394.15123537.html.plaintext.txt	78	Adult male wild type littermates CCK AR mice killed decapitation brains removed rapidly frozen isopentane 70 C
0.100268394.15123537.html.plaintext.txt	79	Coronal sections 20 microm PVN 0
0.100268394.15123537.html.plaintext.txt	80	22 mm caudal bregma DMH regions 1
0.100268394.15123537.html.plaintext.txt	81	06 mm caudal bregma cut via cryostat mounted cold gelatin coated slides 27
0.100268394.15123537.html.plaintext.txt	82	To differentiate CCK AR CCK BR compared ability CCK AR antagonist devazepide CCK BR agonist desulfated CCK 8 dCCK displace binding site 125I labeled CCK 8
0.100268394.15123537.html.plaintext.txt	83	If binding inhibited devazepide dCCK binding occurring CCK AR
0.100268394.15123537.html.plaintext.txt	84	In contrast binding inhibited dCCK devazepide binding occurring CCK BR
0.100268394.15123537.html.plaintext.txt	85	Thus preincubation 50 mM Tris HCl buffer pH 7
0.100268394.15123537.html.plaintext.txt	86	5 BSA 20 min 24 C slides incubated standard binding buffer containing 50 pM 125IBolton Hunter labeled CCK 8 PerkinElmer Boston MA 2 h 24 C either alone presence 10 nM devazepide 100 nM dCCK 100 microM sulfated CCK 8
0.100268394.15123537.html.plaintext.txt	87	After incubation slides washed ice cold 50 mM Tris HCl buffer pH 7
0.100268394.15123537.html.plaintext.txt	88	5 BSA six times 10 min time
0.100268394.15123537.html.plaintext.txt	89	Washed slides completely air dried exposed BMR 2 film Eastman Kodak Co
0.100268394.15123537.html.plaintext.txt	90	Dual immunohistochemistry rat Coronal sections 14 microm brains LETO OLETF rats obtained Otsuka Pharmaceuticals Otsuka Japan prepared described fixed 4 paraformaldehyde
0.100268394.15123537.html.plaintext.txt	91	Dual immunohistochemistry modified procedure previously described 29
0.100268394.15123537.html.plaintext.txt	92	Sections incubated primary antibody mixtures containing 11000 mouse anti NPY monoclonal antibody gift Dr
0.100268394.15123537.html.plaintext.txt	93	Eric Grouzmann Centre Hospitalier Universitaire Vaudois Lausanne Switzerland 30 12000 rabbit antirat CCK AR antibody targeted amino acid sequence SHMSTSAPPP corresponding C terminal rat CCK AR Accurate Chemical Scientific Corp
0.100268394.15123537.html.plaintext.txt	94	Westbury NY 4 C overnight
0.100268394.15123537.html.plaintext.txt	95	After three washes secondary antibodies added slides goat antimouse conjugated fluorescein 1 ng microl Roche Indianapolis IN detecting NPY peptide biotin labeled goat antirabbit IgG 1250 NEN Life Science Products Inc
0.100268394.15123537.html.plaintext.txt	96	Boston MA detecting CCK AR
0.100268394.15123537.html.plaintext.txt	97	CCK AR signal amplified TSA tyramide signal amplification Biotin System NEN Life Science Products Inc
0.100268394.15123537.html.plaintext.txt	98	stained streptavidin Texas Red conjugate 1500 NEN Life Science Products Inc
0.100268394.15123537.html.plaintext.txt	99	according manufacturer protocol
0.100268394.15123537.html.plaintext.txt	100	Sections examined LSM 410 confocal microscope Zeiss New York NY using 488 nm laser excite fluorescein 543 nm laser excite Texas Red
0.100268394.15123537.html.plaintext.txt	101	DMH cannulation CCK 8 injection rat Fifteen male Long Evans rats Charles River Laboratories Wilmington MA weighing 275 300 g implanted chronic indwelling DMH cannulas
0.100268394.15123537.html.plaintext.txt	102	Animals individually housed hanging wire mesh cages maintained 12 h light 12 h dark cycle feeding schedule regular chow food removed cages 2 h lights returned cages dark onset
0.100268394.15123537.html.plaintext.txt	103	At time surgery rats anesthetized im mixture ketamine 100 mgkg xylazine 20 mgkg placed stereotaxic device
0.100268394.15123537.html.plaintext.txt	104	A 26 gauge stainless steel guide cannula Plastic One Wallingford CT implanted DMH following coordinates 3
0.100268394.15123537.html.plaintext.txt	105	1 mm ventral skull surface 15 31
0.100268394.15123537.html.plaintext.txt	106	These coordinates chosen based results pilot experiments
0.100268394.15123537.html.plaintext.txt	107	A 33 gauge stainless steel obturator inserted cannula maintain patency
0.100268394.15123537.html.plaintext.txt	108	After surgery rats given penicillin 60000 U im prevent postoperative infection banamine 1 mgkg im pain relief
0.100268394.15123537.html.plaintext.txt	109	After 7 d postoperative recovery 15 cannulated rats randomly divided two groups
0.100268394.15123537.html.plaintext.txt	110	Just lights one group eight animals injected 0
0.100268394.15123537.html.plaintext.txt	111	3 microl artificial cerebrospinal fluid aCSF 147 mM Na 2
0.100268394.15123537.html.plaintext.txt	112	8 mM Cl group seven animals injected 500 pmol CCK 8 Bachem Torrance CA 0
0.100268394.15123537.html.plaintext.txt	113	All DMH injections made Gilmont micrometer syringe attached polyethylene tubing 33 gauge stainless steel injector Plastic One
0.100268394.15123537.html.plaintext.txt	114	The tip injector extended 1
0.100268394.15123537.html.plaintext.txt	115	0 mm past tip guide cannula
0.100268394.15123537.html.plaintext.txt	116	Injections made 10 injection remained place additional 20 removal
0.100268394.15123537.html.plaintext.txt	117	Chow food returned immediately injection
0.100268394.15123537.html.plaintext.txt	118	Food intakes measured 30 min 1 h 2 h 4 h 22 h returning food cages
0.100268394.15123537.html.plaintext.txt	119	After 7 d period recovery rats given second DMH injections aCSF CCK 8 500 pmol treatment
0.100268394.15123537.html.plaintext.txt	120	rat previously received CCK 8 administration given aCSF injection time vice versa
0.100268394.15123537.html.plaintext.txt	121	Food intake measured described first injections
0.100268394.15123537.html.plaintext.txt	122	Thus rat received aCSF CCK 8 administration served control comparison CCK 8 feeding effect
0.100268394.15123537.html.plaintext.txt	123	After feeding tests 15 animals 10 additional DMH cannulated rats body weight matched randomly divided two groups aCSF control n 12 CCK 8 treatment n 13 assessing whether CCK 8 injection DMH affected hypothalamic NPY mRNA expression
0.100268394.15123537.html.plaintext.txt	124	Animals maintained feeding schedule described regular chow removed cages 2 h lights returned cages dark onset access water ad libitum
0.100268394.15123537.html.plaintext.txt	125	Again rats received either aCSF CCK 8 injections described without access chow food injections
0.100268394.15123537.html.plaintext.txt	126	Two hours injections rats killed overdose sodium pentobarbital brains removed rapidly frozen subsequent analyses hypothalamic NPY gene expression 25 32 33
0.100268394.15123537.html.plaintext.txt	127	As described series 14 microm coronal brain sections ranging 2
0.100268394.15123537.html.plaintext.txt	128	6 mm caudal bregma cut 31 mounted slides series six section 1 slide 1 section 2 slide 2 etc
0.100268394.15123537.html.plaintext.txt	129	fixed 4 paraformaldehyde
0.100268394.15123537.html.plaintext.txt	130	The site DMH injection rats anatomically examined via cresyl violet staining process brain sections
0.100268394.15123537.html.plaintext.txt	131	Data rats incorrect cannula placements excluded subsequent statistical analyses
0.100268394.15123537.html.plaintext.txt	132	The situ hybridization determination hypothalamic NPY mRNA expression conducted described
0.100268394.15123537.html.plaintext.txt	133	Quantitative analysis situ hybridization data performed NIH Scion Image software NIH Bethesda MD
0.100268394.15123537.html.plaintext.txt	134	Autoradiographic images first scanned using EPSON Professional Scanner EPSON Long Beach CA saved via computer subsequent analyses Scion image software using autoradiographic 14C microscales Amersham Pharmacia Biotech standard
0.100268394.15123537.html.plaintext.txt	135	Data animal mean product hybridization area x density background density subtracted obtained four sections reflecting level gene expression region 3
0.100268394.15123537.html.plaintext.txt	136	4 mm posterior bregma example one section 3
0.100268394.15123537.html.plaintext.txt	137	452 mm posterior bregma 31
0.100268394.15123537.html.plaintext.txt	138	Data group normalized aCSF treated controls 100 data presented mean plus minus SEM
0.100268394.15123537.html.plaintext.txt	139	For statistical analysis data analyzed test two groups comparison
0.100268394.15123537.html.plaintext.txt	140	05 taken statistically significant difference
0.100268394.15123537.html.plaintext.txt	141	Results Top Abstract Introduction Materials Methods Results Discussion References Altered meal patterns CCK AR mice As shown Table 1 CCK AR mice slightly significantly increased total daily food intake compared wild type control mice
0.100268394.15123537.html.plaintext.txt	142	However diurnal pattern intake meal patterns altered CCK AR mice
0.100268394.15123537.html.plaintext.txt	143	Although CCK AR CCK AR mice consumed majority food intake dark period 83
0.100268394.15123537.html.plaintext.txt	144	1 total intake knockout 75
0.100268394.15123537.html.plaintext.txt	145	8 wild type mice respectively CCK AR mice significantly elevated food intake dark period P 0
0.100268394.15123537.html.plaintext.txt	146	05 tended decrease food intake light period P 0
0.100268394.15123537.html.plaintext.txt	147	05 compared wild type mice
0.100268394.15123537.html.plaintext.txt	148	Meal pattern analysis revealed CCK AR mice significant increase overall average meal size compared wild type mice Table 1
0.100268394.15123537.html.plaintext.txt	149	CCK AR mice consumed 35
0.100268394.15123537.html.plaintext.txt	150	3 food per meal wild type mice
0.100268394.15123537.html.plaintext.txt	151	This alteration meal patterns mainly occurred dark period majority food consumed
0.100268394.15123537.html.plaintext.txt	152	Meal sizes elevated light period
0.100268394.15123537.html.plaintext.txt	153	Although meal frequency differ significantly two groups CCK AR mice appeared slightly decreased meal numbers total daily light periods compared wild type mice
0.100268394.15123537.html.plaintext.txt	154	Thus similar OLETF rats absence CCK AR mice resulted dysregulation control meal size
0.100268394.15123537.html.plaintext.txt	155	However contrast OLETF rats CCK AR mice able maintain normal daily food intake
0.100268394.15123537.html.plaintext.txt	156	Whether difference due smaller magnitude meal size increase CCK AR mice OLETF rats 35 vs
0.100268394.15123537.html.plaintext.txt	157	80 20 another explanation addressed next series experiments
0.100268394.15123537.html.plaintext.txt	158	Meal parameters CCK AR CCK AR mice
0.100268394.15123537.html.plaintext.txt	159	No NPY mRNA expression detected DMH mouse Our prior work demonstrated DMH NPY mRNA expression elevated adult pair fed young preobese OLETF rats 21
0.100268394.15123537.html.plaintext.txt	160	In study determined whether mice lacking CCK A receptors displayed similar alteration DMH NPY
0.100268394.15123537.html.plaintext.txt	161	1 NPY mRNA expression evident arcuate nucleus CCK AR CCK AR mice
0.100268394.15123537.html.plaintext.txt	162	DMH NPY mRNA expression detectable either CCK AR CCK AR mice 5 wk age Fig
0.100268394.15123537.html.plaintext.txt	163	1 OLETF rats elevated DMH NPY gene expression
0.100268394.15123537.html.plaintext.txt	164	View larger version 66K FIG
0.100268394.15123537.html.plaintext.txt	165	In situ hybridization NPY mRNA 35SUTP labeled NPY riboprobe CCK AR CCK AR mice
0.100268394.15123537.html.plaintext.txt	166	Within hypothalamus NPY mRNA expression evident arcuate nucleus DMH CCK AR A CCK AR B mice 5 wk age
0.100268394.15123537.html.plaintext.txt	167	CCK AR absent DMH mouse The absence DMH NPY mRNA expression CCK AR mice raises possibility DMH NPY may differentially controlled rats mice
0.100268394.15123537.html.plaintext.txt	168	Both CCK binding situ hybridization studies demonstrated presence CCK AR rat DMH 28 34 35
0.100268394.15123537.html.plaintext.txt	169	To determine whether differences distribution CCK AR rat mouse brains determined distribution CCK AR mouse hypothalamus using 125I labeled CCK 8 binding autoradiography situ hybridization histochemistry 35S labeled CCK AR riboprobe
0.100268394.15123537.html.plaintext.txt	170	Autoradiographs CCK binding assay mouse brain revealed within hypothalamus CCK AR binding sites present PVN Fig
0.100268394.15123537.html.plaintext.txt	171	2 A C CCK BR binding sites found ventromedial hypothalamus Fig
0.100268394.15123537.html.plaintext.txt	172	2 E G CCK binding activity detected DMH Fig
0.100268394.15123537.html.plaintext.txt	173	Consistent binding data situ hybridization histochemistry revealed CCK AR mRNA highly expressed PVN Fig
0.100268394.15123537.html.plaintext.txt	174	3A expressed DMH mice Fig
0.100268394.15123537.html.plaintext.txt	175	There evidence CCK AR mRNA expression arcuate nucleus Fig
0.100268394.15123537.html.plaintext.txt	176	3B although CCK binding activity detected Fig
0.100268394.15123537.html.plaintext.txt	177	Thus neither CCK binding assay CCK AR mRNA expression determination detected presence CCK AR DMH mouse
0.100268394.15123537.html.plaintext.txt	178	View larger version 111K FIG
0.100268394.15123537.html.plaintext.txt	179	Autoradiographs 50 pM 125IBolton Hunter labeled CCK 8 binding wild type mouse brain A D 0
0.100268394.15123537.html.plaintext.txt	180	94 mm posterior bregma E H 1
0.100268394.15123537.html.plaintext.txt	181	94 mm posterior bregma 27 four conditions alone A E 10 nM devazepide B F 100 nM dCCK C G 100 microM sulfated CCK 8 sCCK D H
0.100268394.15123537.html.plaintext.txt	182	Within hypothalamus 10 nM devazepide blocked 125ICCK 8 binding PVN B 100 nM dCCK blocked 125ICCK 8 binding ventromedial nucleus VMH 125ICCK 8 binding found DMH
0.100268394.15123537.html.plaintext.txt	183	View larger version 103K FIG
0.100268394.15123537.html.plaintext.txt	184	In situ hybridization CCK AR mRNA 35SUTP labeled CCK AR antisense riboprobe wild type mouse brain
0.100268394.15123537.html.plaintext.txt	185	Within hypothalamus CCK AR mRNA expressed PVN A slightly arcuate nucleus B DMH B
0.100268394.15123537.html.plaintext.txt	186	No hybridization signal detected incubation sense probe C
0.100268394.15123537.html.plaintext.txt	187	Colocalization NPY CCK AR DMH neurons rats Our previous data demonstrated NPY mRNA expression elevated DMH specifically compact subregion young preobese adult pair fed OLETF rats lacking CCK AR 21 presence CCK AR rat DMH suggests DMH NPY gene expression may normally regulated brain CCK interaction CCK AR
0.100268394.15123537.html.plaintext.txt	188	To investigate whether NPY CCK AR colocalized DMH neurons performed double immunostaining anti NPY anti CCK AR antibodies rat brain
0.100268394.15123537.html.plaintext.txt	189	4 LETO OLETF DMH contained NPY immunostaining neurons Fig
0.100268394.15123537.html.plaintext.txt	190	CCK AR immunostaining neurons detected DMH LETO controls Fig
0.100268394.15123537.html.plaintext.txt	191	The absence CCK AR immunoreactivity OLETF rats Fig
0.100268394.15123537.html.plaintext.txt	192	4E consistent absence CCK AR model
0.100268394.15123537.html.plaintext.txt	193	Confocal microscopic analysis revealed NPY CCK AR colocalized DMH neurons Fig
0.100268394.15123537.html.plaintext.txt	194	As shown high magnification Fig
0.100268394.15123537.html.plaintext.txt	195	4G CCK AR staining found surface NPY neurons
0.100268394.15123537.html.plaintext.txt	196	View larger version 90K FIG
0.100268394.15123537.html.plaintext.txt	197	Dual immunohistochemistry LETO control OLETF rat brains anti NPY anti CCK AR antibodies
0.100268394.15123537.html.plaintext.txt	198	In LETO OLETF rats NPY immunostaining evident DMH neurons green A D
0.100268394.15123537.html.plaintext.txt	199	CCK AR immunostaining neurons detected DMH LETO controls red B OLETF rats E
0.100268394.15123537.html.plaintext.txt	200	NPY CCK AR colocalized DMH neurons LETO control rats orange C G confocal microscopic analysis
0.100268394.15123537.html.plaintext.txt	201	Brain CCK acts DMH NPY neurons inhibit food intake The finding NPY CCK AR colocalization DMH neurons overexpression DMH NPY rats lacking CCK AR suggest brain CCK may normally play role controlling NPY gene expression DMH NPY neurons
0.100268394.15123537.html.plaintext.txt	202	To test hypothesis understand basis brain CCK actions food intake assessed whether injection CCK DMH affected hypothalamic NPY gene expression
0.100268394.15123537.html.plaintext.txt	203	5 NPY mRNA expression significantly regulated parenchymal injection CCK DMH
0.100268394.15123537.html.plaintext.txt	204	Exogenous CCK administration resulted 27 reduction NPY mRNA expression ipsilateral compact subregion DMH Fig
0.100268394.15123537.html.plaintext.txt	205	We also found relative controls arcuate NPY mRNA expression significantly reduced 24 CCK injected rats Fig
0.100268394.15123537.html.plaintext.txt	206	These data confirm CCK within DMH capable directly regulating NPY gene expression
0.100268394.15123537.html.plaintext.txt	207	View larger version 68K FIG
0.100268394.15123537.html.plaintext.txt	208	Effects CCK injection DMH NPY mRNA expression
0.100268394.15123537.html.plaintext.txt	209	DMH CCK injection decreased NPY gene expression DMH B C arcuate nucleus B C rat compared aCSF treated controls
0.100268394.15123537.html.plaintext.txt	210	Values mean plus minus SEM n 6 7
0.100268394.15123537.html.plaintext.txt	211	05 compared aCSF treated group
0.100268394.15123537.html.plaintext.txt	212	As well altering NPY mRNA expression found exogenous injection CCK DMH resulted reduction 30 min food intake
0.100268394.15123537.html.plaintext.txt	213	21 g vehicle controls n 9 1
0.100268394.15123537.html.plaintext.txt	214	31 g CCK treated group n 10 P 0
0.100268394.15123537.html.plaintext.txt	215	Discussion Top Abstract Introduction Materials Methods Results Discussion References Together data provide complete understanding consequences CCK AR deficiency mice
0.100268394.15123537.html.plaintext.txt	216	We previously demonstrated OLETF rats lacking CCK AR deficit ability limit size spontaneous meals disruption regulation NPY mRNA expression DMH
0.100268394.15123537.html.plaintext.txt	217	We suggested alterations may contribute hyperphagia obesity OLETF rats 19
0.100268394.15123537.html.plaintext.txt	218	The current results demonstrate CCK AR mice also altered meal patterns
0.100268394.15123537.html.plaintext.txt	219	However contrast OLETF rat overall food intake affected CCK AR mice
0.100268394.15123537.html.plaintext.txt	220	Thus although rats mice lacking CCK AR demonstrate deficit peripheral CCK satiety actions leading increased meal size overall control food intake energy balance appears differ
0.100268394.15123537.html.plaintext.txt	221	Assessment distribution CCK AR mouse brain revealed CCK AR binding activity CCK AR mRNA expression DMH normal mice
0.100268394.15123537.html.plaintext.txt	222	Previous work consistently shown rat DMH contains CCK AR 28 34 35
0.100268394.15123537.html.plaintext.txt	223	Furthermore contrast findings elevated NPY gene expression DMH young preobese adult pair fed OLETF rats 21 NPY mRNA expression detected DMH either CCK AR CCK AR mice
0.100268394.15123537.html.plaintext.txt	224	Moreover CCK AR mice normal levels NPY mRNA expression arcuate nucleus NPY mRNA expression reduced ad libitum fed OLETF rats normalized pair feeding 21
0.100268394.15123537.html.plaintext.txt	225	Finally potential role altered DMH NPY expression hyperphagia obesity OLETF rats suggested demonstrations NPY CCK AR colocalized DMH neurons intact rats CCK plays role controlling DMH NPY gene expression
0.100268394.15123537.html.plaintext.txt	226	Together results suggest differential distribution brain CCK AR determines different phenotypes expressed rats mice lacking CCK AR
0.100268394.15123537.html.plaintext.txt	227	The actions peripheral CCK control meal size well characterized
0.100268394.15123537.html.plaintext.txt	228	Peripheral CCK produces dose related suppression meal size results earlier appearance behavioral satiety sequence 11
0.100268394.15123537.html.plaintext.txt	229	These actions exogenous peptide appear mimic physiological role endogenous CCK administration CCK antagonists results increase food intake
0.100268394.15123537.html.plaintext.txt	230	The feeding inhibitory actions exogenously administered endogenously released CCK depend upon actions CCK AR
0.100268394.15123537.html.plaintext.txt	231	CCK mediated inhibition food intake blocked CCK AR antagonists unaffected CCK BR antagonists 7
0.100268394.15123537.html.plaintext.txt	232	The current finding increased meal size CCK AR mice demonstrates action endogenous CCK control meal size mice consistent prior data antagonists previous findings OLETF rat also lacks CCK AR 10 11 20
0.100268394.15123537.html.plaintext.txt	233	Thus data provide additional molecular biological support physiological role endogenous CCK short term control food intake
0.100268394.15123537.html.plaintext.txt	234	The magnitude change meal size CCK AR mice quite bit smaller 80 increase found OLETF rats lacking CCK AR
0.100268394.15123537.html.plaintext.txt	235	This difference may reflect relative difference contribution CCK meal termination rats mice
0.100268394.15123537.html.plaintext.txt	236	The current data demonstrate CCK AR mice altered diurnal feeding patterns
0.100268394.15123537.html.plaintext.txt	237	In OLETF rats lacking CCK AR increased food intake characterized increased meal size dark light periods
0.100268394.15123537.html.plaintext.txt	238	In response increased meal size meal number decreased dark period decrease compensatory 20
0.100268394.15123537.html.plaintext.txt	239	However analyses feeding patterns CCK AR mice revealed increased food intake dark period characterized increase meal size food intake tended decreased light period characterized reduction meal frequency leading absence significant changes total food intake
0.100268394.15123537.html.plaintext.txt	240	These data suggest CCK acting CCK AR plays differential role circadian activities rats mice
0.100268394.15123537.html.plaintext.txt	241	Even though rats mice lacking CCK AR peripheral CCK satiety deficits resulting increased meal size total daily food intake body weight normal CCK AR mice whereas OLETF rats lacking CCK AR shown hyperphagic become obese
0.100268394.15123537.html.plaintext.txt	242	Although may reflect differential ability compensate smaller rather larger increases meal size present data also suggest difference phenotype may outcome different distribution brain CCK AR rats mice
0.100268394.15123537.html.plaintext.txt	243	The potential importance differential distribution derives findings intact rats NPY CCK AR colocalized DMH neurons CCK plays role modulating DMH NPY exogenous administration CCK DMH regulates DMH NPY mRNA expression
0.100268394.15123537.html.plaintext.txt	244	These results consistent previous findings demonstrating NPY gene expression regulated DMH OLETF rats lack CCK AR 21
0.100268394.15123537.html.plaintext.txt	245	Although pair feeding OLETF rats prevented increased body weight normalized altered arcuate NPY POMC gene expression pair feeding resulted significantly elevated NPY gene expression DMH
0.100268394.15123537.html.plaintext.txt	246	This elevation NPY mRNA expression DMH also documented young preobese OLETF rats 21
0.100268394.15123537.html.plaintext.txt	247	Therefore CCK acting CCK ARs DMH appears suppress DMH NPY gene expression rat
0.100268394.15123537.html.plaintext.txt	248	Such suppression inhibits energy intake DMH CCK injection reduces food intake
0.100268394.15123537.html.plaintext.txt	249	The hyperphagic obese OLETF rat deficit CCK NPY signaling pathway resulting lack CCK AR production
0.100268394.15123537.html.plaintext.txt	250	CCK acting CCK AR appear play role controlling DMH NPY mouse
0.100268394.15123537.html.plaintext.txt	251	We failed detect NPY mRNA expression DMH either CCK AR CCK AR mice situ hybridization determination
0.100268394.15123537.html.plaintext.txt	252	DMH NPY mRNA expression ad libitum fed rats normally low elevated experimental situations lactation 36 response chronic food restriction 25
0.100268394.15123537.html.plaintext.txt	253	In rat clear differences controls DMH arcuate nucleus NPY expressing neurons
0.100268394.15123537.html.plaintext.txt	254	In arcuate nucleus NPY containing neurons express Ob RB long form leptin receptors NPY expression leptin control 37
0.100268394.15123537.html.plaintext.txt	255	Elevated leptin levels reduce NPY mRNA expression whereas food deprivation increases arcuate NPY gene expression
0.100268394.15123537.html.plaintext.txt	256	In contrast DMH NPY containing neurons express leptin receptors DMH NPY mRNA expression increase response acute food deprivation 25
0.100268394.15123537.html.plaintext.txt	257	Moreover within DMH region altered NPY expression response variety treatments appears differ
0.100268394.15123537.html.plaintext.txt	258	The current data demonstrating reduction DMH NPY expression CCK localized compact subregion consistent previous findings 21 25
0.100268394.15123537.html.plaintext.txt	259	Whereas lactating rats Smith 36 reported although slight increase NPY mRNA expression compact area DMH NPY mRNA expression mainly induced diffuse portion DMH
0.100268394.15123537.html.plaintext.txt	260	However yet clear whether NPY mRNA expression different subregions DMH differentially regulated
0.100268394.15123537.html.plaintext.txt	261	Controls DMH NPY expression mouse extensively investigated
0.100268394.15123537.html.plaintext.txt	262	Evidence NPY expressing neurons mouse comes data demonstrating induction DMH NPY expression several obesity models disrupted melanocortin signaling lethal agouti yellow Ay melanocortin 4 receptor knockout MC4R mice 38 diet induced obese mice 39
0.100268394.15123537.html.plaintext.txt	263	Such data suggest interactions melanocortin signaling metabolic status control DMH NPY functions mouse
0.100268394.15123537.html.plaintext.txt	264	The finding decreased arcuate well DMH NPY mRNA expression response DMH CCK injection surprising
0.100268394.15123537.html.plaintext.txt	265	Consistent previous studies rat 28 34 failed identify CCK AR binding activity arcuate nucleus mouse
0.100268394.15123537.html.plaintext.txt	266	This absence arcuate CCK receptors implies DMHarcuate interaction controls arcuate NPY
0.100268394.15123537.html.plaintext.txt	267	Although main hypothalamic output DMH thought PVN projections DMH arcuate nucleus identified 40
0.100268394.15123537.html.plaintext.txt	268	These projections may basis arcuate NPY reduction response DMH CCK injection
0.100268394.15123537.html.plaintext.txt	269	A role DMH feeding control long suggested
0.100268394.15123537.html.plaintext.txt	270	Bellinger colleagues 41 demonstrated small DMH electrolytic excitotoxic lesions DMHL result hypophagia hypodipsia reduced body weight reduced linear growth rat
0.100268394.15123537.html.plaintext.txt	271	Pair feeding experiments one group sham operated rats pair fed computerized feeding system presented food pellets amount pattern yoked DMHL rats demonstrated altered body weight DMHL rats primarily result altered food intake 42
0.100268394.15123537.html.plaintext.txt	272	Despite findings particular contribution DMH interacts hypothalamic nuclei involved energy balance well understood
0.100268394.15123537.html.plaintext.txt	273	Our findings rat suggest basis DMHL induced hypophagia may elimination NPY ergic output output normally control CCK acting CCK AR
0.100268394.15123537.html.plaintext.txt	274	Although distribution mediation CCK AR human brain unclear data primates demonstrated DMH contains CCK AR binding site monkey 43 central injection CCK AR B receptor agonist inhibits food intake baboon 44
0.100268394.15123537.html.plaintext.txt	275	Such findings suggest DMH CCK AR may play role food intake control humans
0.100268394.15123537.html.plaintext.txt	276	A polymorphism CCK AR gene patients obesity diabetes reported various studies 45 46 47 48 providing support role
0.100268394.15123537.html.plaintext.txt	277	We interpreted current data support view different phenotypes OLETF rats CCK mice derive differential role central CCK AR energy balance rats mice
0.100268394.15123537.html.plaintext.txt	278	OLETF rats targeted deletion CCK AR arose spontaneous mutation
0.100268394.15123537.html.plaintext.txt	279	It quite possible genetic alterations OLETF rat alone combination alterations CCK AR signaling account hyperphagia obesity diabetes 49
0.100268394.15123537.html.plaintext.txt	280	However additional genetic defects yet identified
0.100268394.15123537.html.plaintext.txt	281	In summary present results suggest although rats mice lacking CCK AR demonstrate deficit meal size control differential distribution CCK AR rat mouse brains may determine divergent effects CCK AR gene disruption
0.100268394.15123537.html.plaintext.txt	282	In rat brain CCK acting CCK AR appears play role regulating DMH NPY gene expression
0.100268394.15123537.html.plaintext.txt	283	DMH CCK inhibits NPY mRNA expression food intake
0.100268394.15123537.html.plaintext.txt	284	In absence CCK AR OLETF rats deficit control DMH NPY gene expression resulting increased DMH NPY gene expression increased food intake eventually obesity
0.100268394.15123537.html.plaintext.txt	285	In contrast found evidence presence CCK AR DMH mouse
0.100268394.15123537.html.plaintext.txt	286	Thus CCK AR contribute control DMH NPY gene expression absence central deficit mice lacking CCK AR able compensate absence CCK satiety signaling become hyperphagic obese
0.100268394.15123537.html.plaintext.txt	287	Acknowledgments The OLETF LETO rats generous gifts Otsuka Pharmaceutical Tokushima Japan
0.100268394.15123537.html.plaintext.txt	288	Footnotes This work supported National Institute Diabetes Digestive Kidney Diseases Grants DK 57609 T
0.100268394.15123537.html.plaintext.txt	289	National Institute Mental Health Grant MH067638 S
0.100268394.15123537.html.plaintext.txt	290	Abbreviations aCSF Artificial cerebrospinal fluid CCK A cholecystokinin A CCK AR cholecystokinin A receptor dCCK desulfated cholecystokinin 8 DMH dorsomedial hypothalamic DMHL DMH electrolytic excitotoxic lesion LETO Long Evans Tokushima Otsuka NPY neuropeptide Y OLETF Otsuka Long Evans Tokushima fatty POMC proopiomelanocortin PVN paraventricular nucleus SSC standard saline citrate
0.100268394.15123537.html.plaintext.txt	291	Accepted publication April 22 2004
0.100268394.15123537.html.plaintext.txt	292	References Top Abstract Introduction Materials Methods Results Discussion References Gibbs J Young RC Smith GP 1973 Cholecystokinin decreases food intake rats
0.100268394.15123537.html.plaintext.txt	293	J Comp Physiol Psychol 84488 495Medline Anika SM Houpt TR Houpt KA 1981 Cholecystokinin satiety pigs
0.100268394.15123537.html.plaintext.txt	294	Am J Physiol 240R310 R318 Gibbs J Falasco JD McHugh PR 1976 Cholecystokinin decreased food intake rhesus monkeys
0.100268394.15123537.html.plaintext.txt	295	Am J Physiol 23015 18AbstractFree Full Text Kissileff HR Pi Sunyer FX Thornton J Smith GP 1981 C terminal octapeptide cholecystokinin decreases food intake man
0.100268394.15123537.html.plaintext.txt	296	Am J Clin Nutr 34154 160Abstract West DB Fey D Woods SC 1984 Cholecystokinin persistently suppresses meal size food intake free feeding rats
0.100268394.15123537.html.plaintext.txt	297	Am J Physiol 246R776 R787 Shillabeer G Davison JS 1984 The cholecystokinin antagonist proglumide increases food intake rat
0.100268394.15123537.html.plaintext.txt	298	Regul Pept 8171 176CrossRefMedline Moran TH Ameglio PJ Schwartz GJ McHugh PR 1992 Blockade type A type B CCK receptors attenuates satiety actions exogenous endogenous CCK
0.100268394.15123537.html.plaintext.txt	299	Am J Physiol 262R46 R50 Reidelberger RD O Rourke MF 1989 Potent cholecystokinin antagonist L 364718 stimulates food intake rats
0.100268394.15123537.html.plaintext.txt	300	Am J Physiol 257R1512 R1518 Silver AJ Flood JF Song AM Morley JE 1989 Evidence physiological role CCK regulation food intake mice
0.100268394.15123537.html.plaintext.txt	301	Am J Physiol 256R646 R652 Moran TH Ameglio PJ Peyton HJ Schwartz GJ McHugh PR 1993 Blockade type A type B CCK receptors postpones satiety rhesus monkeys
0.100268394.15123537.html.plaintext.txt	302	Am J Physiol 265R620 R624 Smith GP Gibbs J 1994 Satiating effect cholecystokinin
0.100268394.15123537.html.plaintext.txt	303	Ann NY Acad Sci 713236 241Medline Della Fera MA Baile CA 1979 Cholecystokinin octapeptide continuous picomole injections cerebral ventricles sheep suppress feeding
0.100268394.15123537.html.plaintext.txt	304	Science 206471 473Medline Schick RR Yaksh TL Go VL 1986 Intracerebroventricular injections cholecystokinin octapeptide suppress feeding rats pharmacological characterization action
0.100268394.15123537.html.plaintext.txt	305	Regul Pept 14277 291CrossRefMedline Crawley JN 1985 Clarification behavioral functions peripheral central cholecystokinin two separate peptide pools
0.100268394.15123537.html.plaintext.txt	306	Peptides 6Suppl 2129 136 Blevins JE Stanley BG Reidelberger RD 2000 Brain regions cholecystokinin suppresses feeding rats
0.100268394.15123537.html.plaintext.txt	307	Brain Res 8601 10CrossRefMedline Blevins JE Hamel FG Fairbairn E Stanley BG Reidelberger RD 2000 Effects paraventricular nucleus injection CCK 8 plasma CCK 8 levels rats
0.100268394.15123537.html.plaintext.txt	308	Brain Res 86011 20CrossRefMedline Kawano K Hirashima T Mori S Saitoh Y Kurosumi M Natori T 1992 Spontaneous long term hyperglycemic rat diabetic complications Otsuka Long Evans Tokushima fatty OLETF strain
0.100268394.15123537.html.plaintext.txt	309	Diabetes 411422 1428Abstract Takiguchi S Takata Y Funakoshi A Miyasaka K Kataoka K Fujimura Y Goto T Kono A 1997 Disrupted cholecystokinin type A receptor CCKAR gene OLETF rats
0.100268394.15123537.html.plaintext.txt	310	Gene 197169 175CrossRefMedline Bi S Moran TH 2002 Actions CCK controls food intake body weight lessons CCK A receptor deficient OLETF rat
0.100268394.15123537.html.plaintext.txt	311	Neuropeptides 361 11CrossRefMedline Moran TH Katz LF Plata Salaman CR Schwartz GJ 1998 Disordered food intake obesity rats lacking cholecystokinin A receptors
0.100268394.15123537.html.plaintext.txt	312	Am J Physiol 274R618 R625 Bi S Ladenheim EE Schwartz GJ Moran TH 2001 A role NPY overexpression dorsomedial hypothalamus hyperphagia obesity OLETF rats
0.100268394.15123537.html.plaintext.txt	313	Am J Physiol 281R254 R260 Kopin AS Mathes WF McBride EW Nguyen M Al Haider W Schmitz F Bonner Weir S Kanarek R Beinborn M 1999 The cholecystokinin A receptor mediates inhibition food intake yet essential maintenance body weight
0.100268394.15123537.html.plaintext.txt	314	J Clin Invest 103383 391AbstractFree Full Text Castonguay TW Kaiser LL Stern JS 1986 Meal pattern analysis artifacts assumptions implications
0.100268394.15123537.html.plaintext.txt	315	Brain Res Bull 17439 443CrossRefMedline Wank SA Harkins R Jensen RT Shapira H de Weerth A Slattery T 1992 Purification molecular cloning functional expression cholecystokinin receptor rat pancreas
0.100268394.15123537.html.plaintext.txt	316	Proc Natl Acad Sci USA 893125 3129Abstract Bi S Robinson BM Moran TH 2003 Acute food deprivation chronic food restriction differentially affect hypothalamic NPY mRNA expression
0.100268394.15123537.html.plaintext.txt	317	Am J Physiol 285R1030 R1036 Higuchi H Yang HY Sabol SL 1988 Rat neuropeptide Y precursor gene expression
0.100268394.15123537.html.plaintext.txt	318	mRNA structure tissue distribution regulation glucocorticoids cyclic AMP phorbol ester
0.100268394.15123537.html.plaintext.txt	319	J Biol Chem 2636288 6295AbstractFree Full Text Franklin KBJ Paxinos G 1997 The mouse brain stereotaxic coordinates
0.100268394.15123537.html.plaintext.txt	320	San Diego Academic Press Moran TH Robinson PH Goldrich MS McHugh PR 1986 Two brain cholecystokinin receptors implications behavioral actions
0.100268394.15123537.html.plaintext.txt	321	Brain Res 362175 179CrossRefMedline Broberger C 1999 Hypothalamic cocaine amphetamine regulated transcript CART neurons histochemical relationship thyrotropin releasing hormone melanin concentrating hormone orexinhypocretin neuropeptide Y
0.100268394.15123537.html.plaintext.txt	322	Brain Res 848101 113CrossRefMedline Grouzmann E Comoy E Walker P Burnier M Bohuon C Waeber B Brunner H 1992 Production characterization four anti neuropeptide Y monoclonal antibodies
0.100268394.15123537.html.plaintext.txt	323	Hybridoma 11409 424Medline Paxinos G Watson C 1986 The rat brain stereotaxic coordinates
0.100268394.15123537.html.plaintext.txt	324	San Diego Academic Press Sergeyev V Broberger C Gorbatyuk O Hokfelt T 2000 Effect 2 mercaptoacetate 2 deoxy D glucose administration expression NPY AGRP POMC MCH hypocretinorexin rat hypothalamus
0.100268394.15123537.html.plaintext.txt	325	Neuroreport 11117 121Medline Seoane LM Lopez M Tovar S Casanueva FF Senaris R Dieguez C 2003 Agouti related peptide neuropeptide Y somatostatin producing neurons targets ghrelin actions rat hypothalamus
0.100268394.15123537.html.plaintext.txt	326	Endocrinology 144544 551AbstractFree Full Text Woodruff GN Hill DR Boden P Pinnock R Singh L Hughes J 1991 Functional role brain CCK receptors
0.100268394.15123537.html.plaintext.txt	327	Neuropeptides 19Suppl45 56 Honda T Wada E Battey JF Wank SA 1993 Differential gene expression CCK A CCK B receptors rat brain
0.100268394.15123537.html.plaintext.txt	328	Mol Cell Neurosci 4143 154CrossRef Smith MS 1993 Lactation alters neuropeptide Y proopiomelanocortin gene expression arcuate nucleus rat
0.100268394.15123537.html.plaintext.txt	329	Endocrinology 1331258 1265Abstract Schwartz MW Woods SC Porte Jr D Seeley RJ Baskin DG 2000 Central nervous system control food intake
0.100268394.15123537.html.plaintext.txt	330	Nature 404661 671Medline Kesterson RA Huszar D Lynch CA Simerly RB Cone RD 1997 Induction neuropeptide Y gene expression dorsal medial hypothalamic nucleus two models agouti obesity syndrome
0.100268394.15123537.html.plaintext.txt	331	Mol Endocrinol 11630 637AbstractFree Full Text Guan XM Yu H Trumbauer M Frazier E Van der Ploeg LH Chen H 1998 Induction neuropeptide Y expression dorsomedial hypothalamus diet induced obese mice
0.100268394.15123537.html.plaintext.txt	332	Neuroreport 93415 3419Medline Thompson RH Canteras NS Swanson LW 1996 Organization projections dorsomedial nucleus hypothalamus PHA L study rat
0.100268394.15123537.html.plaintext.txt	333	CO2 M 442CrossRefMedline Bellinger LL Castonguay TW Bernardis LL 1994 Hormone somatic changes rats pair fed growth retarded dorsomedial hypothalamic nuclei lesioned rats
0.100268394.15123537.html.plaintext.txt	334	Brain Res Bull 34117 124CrossRefMedline Hill DR Woodruff GN 1990 Differentiation central cholecystokinin receptor binding sites using non peptide antagonists MK 329 L 365260
0.100268394.15123537.html.plaintext.txt	335	Brain Res 526276 283CrossRefMedline Figlewicz DP Nadzan AM Sipols AJ Green PK Liddle RA Porte Jr D Woods SC 1992 Intraventricular CCK 8 reduces single meal size baboon interaction type A CCK receptors
0.100268394.15123537.html.plaintext.txt	336	Am J Physiol 263R863 R867 Inoue H Iannotti CA Welling CM Veile R Donis Keller H Permutt MA 1997 Human cholecystokinin type A receptor gene cytogenetic localization physical mapping identification two missense variants patients obesity non insulin dependent diabetes mellitus NIDDM
0.100268394.15123537.html.plaintext.txt	337	Genomics 42331 335CrossRefMedline Miller LJ Holicky EL Ulrich CD Wieben ED 1995 Abnormal processing human cholecystokinin receptor gene association gallstones obesity
0.100268394.15123537.html.plaintext.txt	338	Gastroenterology 1091375 1380Medline Funakoshi A Miyasaka K Matsumoto H Yamamori S Takiguchi S Kataoka K Takata Y Matsusue K Kono A Shimokata H 2000 Gene structure human cholecystokinin CCK type A receptor body fat content related CCK type A receptor gene promoter polymorphism
0.100268394.15123537.html.plaintext.txt	339	FEBS Lett 466264 266CrossRefMedline Marchal Victorion S Vionnet N Escrieut C Dematos F Dina C Dufresne M Vaysse N Pradayrol L Froguel P Fourmy D 2002 Genetic pharmacological functional analysis cholecystokinin 1 cholecystokinin 2 receptor polymorphism type 2 diabetes obese patients
0.100268394.15123537.html.plaintext.txt	340	Pharmacogenetics 1223 30CrossRefMedline Watanabe TK Okuno S Oga K Mizoguchi Miyakita A Tsuji A Yamasaki Y Hishigaki H Kanemoto N Takagi T Takahashi E Irie Y Nakamura Y Tanigami A 1999 Genetic dissection OLETF rat model non insulin dependent diabetes mellitus quantitative trait locus analysis OLETF x BN x OLETF
0.100268394.15123537.html.plaintext.txt	341	Genomics 58233 239CrossRefMedline
0.30595517.15525658.html.plaintext.txt	0	Orexin loss Huntingtons disease Asa Petersen1 Joana Gil1 Marion L
0.30595517.15525658.html.plaintext.txt	1	Maat Schieman2 Maria Bjorkqvist3 Heikki Tanila4 Ines M
0.30595517.15525658.html.plaintext.txt	2	Arauacutejo5 Ruben Smith1 Natalija Popovic1 Nils Wierup6 Per Norlen7 Jia Yi Li1 Raymund A
0.30595517.15525658.html.plaintext.txt	3	Roos2 Frank Sundler6 Hindrik Mulder3 Patrik Brundin1
0.30595517.15525658.html.plaintext.txt	4	1Department Physiological Sciences Section Neuronal Survival BMC A10 22184 Lund Sweden 2Department Neurology LUMC Leiden The Netherlands 3Department Cell Molecular Biology Lund Sweden 4Department Neuroscience Neurology University KuopioDepartment Neurology Kuopio University Hospital Finland 5Center Neuroscience Cell Biology Department Zoology Coimbra Portugal 6Department Physiological Sciences Section Neuroendocrine Cell Biology Lund Sweden 7Department Experimental Clinical Pharmacology Institute Laboratory Medicine Lund University Hospital Lund Sweden
0.30595517.15525658.html.plaintext.txt	5	To correspondence addressed
0.30595517.15525658.html.plaintext.txt	6	Tel 46 462220525 Fax 46 462220531 Email asa
0.30595517.15525658.html.plaintext.txt	7	Received September 26 2004 Accepted October 22 2004
0.30595517.15525658.html.plaintext.txt	8	ABSTRACT TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS SUPPLEMENTARY MATERIAL REFERENCES Huntingtons disease HD devastating neurodegenerative disorder caused expanded CAG repeat gene encoding huntingtin protein unknown function
0.30595517.15525658.html.plaintext.txt	9	Mutant huntingtin forms intracellular aggregates associated neuronal death select brain regions
0.30595517.15525658.html.plaintext.txt	10	The studied mouse model R62 HD replicates many features disease reported exhibit little neuronal death
0.30595517.15525658.html.plaintext.txt	11	We describe first time dramatic atrophy loss orexin neurons lateral hypothalamus R62 mice
0.30595517.15525658.html.plaintext.txt	12	Importantly also found significant atrophy loss orexin neurons Huntington patients
0.30595517.15525658.html.plaintext.txt	13	Like animal models patients impaired orexin function R62 mice narcoleptic
0.30595517.15525658.html.plaintext.txt	14	Both number orexin neurons lateral hypothalamus levels orexin cerebrospinal fluid reduced 72 end stage R62 mice compared wild type littermates suggesting orexin could used biomarker reflecting neurodegeneration
0.30595517.15525658.html.plaintext.txt	15	Our results show loss orexin novel potentially important pathology HD
0.30595517.15525658.html.plaintext.txt	16	INTRODUCTION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS SUPPLEMENTARY MATERIAL REFERENCES Huntingtons disease HD hereditary neurodegenerative disorder characterized personality changes motor disturbances cognitive decline weight loss 1
0.30595517.15525658.html.plaintext.txt	17	It caused CAG triplet repeat expansion gene encoding huntingtin 2 protein unclear function albeit essential cell survival development 3 adult life 4
0.30595517.15525658.html.plaintext.txt	18	Descriptions neuropathology emphasize neurodegeneration neostriatum cerebral cortex appearance intraneuronal aggregates misfolded huntingtin 56
0.30595517.15525658.html.plaintext.txt	19	In addition significant neuronal death also described tuber nucleus lateral hypothalamus 78
0.30595517.15525658.html.plaintext.txt	20	The studied animal model HD R62 mouse expresses exon 1 human mutant HD gene 150 CAG repeats 9
0.30595517.15525658.html.plaintext.txt	21	In advanced stages mice display several clinical features reminiscent HD
0.30595517.15525658.html.plaintext.txt	22	These include impaired motor coordination tremor changes open field behavior progressive weight loss increased incidence epileptic seizures 10
0.30595517.15525658.html.plaintext.txt	23	For unclear reasons die prematurely age 12 15 weeks
0.30595517.15525658.html.plaintext.txt	24	Their brains exhibit high frequency intraneuronal nuclear inclusions polyglutamine containing protein
0.30595517.15525658.html.plaintext.txt	25	So far relatively little cell death scattered neurons undergoing dark degeneration described 1112
0.30595517.15525658.html.plaintext.txt	26	Neuropathological studies end stage HD patients demonstrated 90 neuronal loss tuber nucleus lateral hypothalamus 78
0.30595517.15525658.html.plaintext.txt	27	In humans region particularly enriched NMDA receptors 13
0.30595517.15525658.html.plaintext.txt	28	This implicates involvement excitotoxic cell death repeatedly suggested play role pathogenesis HD brain regions 114
0.30595517.15525658.html.plaintext.txt	29	Interestingly recent study showed slice cultures rat lateral hypothalamus neurons containing peptide orexin also known hypocretin particularly susceptible excitotoxic damage 15
0.30595517.15525658.html.plaintext.txt	30	Orexin A B synthesized precursor gene expressed neurons cell bodies concentrated lateral hypothalamus 1617
0.30595517.15525658.html.plaintext.txt	31	These neurons project widely throughout central nervous system particular dense projections monoaminergic centers
0.30595517.15525658.html.plaintext.txt	32	They thought interact autonomic neuroendocrine arousal systems excitatory effects orexin reviewed 18
0.30595517.15525658.html.plaintext.txt	33	Importantly studies mice null mutation gene orexin 19 one receptors 20 well transgenic mice targeted ablation orexin neurons 21 revealed severe disturbances sleep wakefulness similar narcoleptic symptoms humans 22
0.30595517.15525658.html.plaintext.txt	34	Subsequent studies shown human narcolepsy patients reduced levels orexin cerebrospinal fluid CSF 23 cases number orexin neurons lateral hypothalamus reduced 24
0.30595517.15525658.html.plaintext.txt	35	Taken together findings strongly implicate orexin system sleep regulation
0.30595517.15525658.html.plaintext.txt	36	Here describe first time progressive loss orexin neurons ultrastructural signs neurodegeneration lateral hypothalamus R62 mice
0.30595517.15525658.html.plaintext.txt	37	Importantly also observed significant reduction number orexin positive neurons well significant atrophy remaining orexin neurons lateral hypothalamus HD patients
0.30595517.15525658.html.plaintext.txt	38	We also report significant reduction orexin levels R62 mouse CSF suggests measuring CSF levels orexin HD patients could novel means assess disease progression potential effect novel therapies
0.30595517.15525658.html.plaintext.txt	39	RESULTS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS SUPPLEMENTARY MATERIAL REFERENCES Orexin loss R62 mice We quantified progressive reduction number orexin containing neurons lateral hypothalamus R62 compared wild type mice Fig
0.30595517.15525658.html.plaintext.txt	40	The reduction apparent 3
0.30595517.15525658.html.plaintext.txt	41	5 weeks age progressed significantly time Fig
0.30595517.15525658.html.plaintext.txt	42	The remaining orexin neurons significantly atrophied R62 mice compared wild type assessed measuring cross sectional surface area cell bodies Fig
0.30595517.15525658.html.plaintext.txt	43	5 weeks age 7 neurons lateral hypothalamus orexin immunoreactive wild type mice compared 2 R62 mice
0.30595517.15525658.html.plaintext.txt	44	To confirm cell loss lateral hypothalamus reduced orexin surviving cells adjacent sections processed cresyl violet NeuN immunohistochemistry
0.30595517.15525658.html.plaintext.txt	45	5 weeks age found significant reduction number cresyl violet stained cells 4381 plus minus 345mm2 versus 5363 plus minus 193mm2 Students test P 0
0.30595517.15525658.html.plaintext.txt	46	05 NeuN immunopositive neurons 3138 plus minus 167mm2 versus 3704 plus minus 143mm2 Students test P 0
0.30595517.15525658.html.plaintext.txt	47	05 R62 mice compared wild type controls
0.30595517.15525658.html.plaintext.txt	48	Interestingly percentage cells lost lateral hypothalamus 12
0.30595517.15525658.html.plaintext.txt	49	5 week old R62 compared age matched wild type mice 15 cells immunopositive neuron specific marker NeuN 72 orexin neurons
0.30595517.15525658.html.plaintext.txt	50	Using transmission electron microscopy observed frequent ultrastructural signs neurodegeneration lateral hypothalamus R62 mice neurons displaying dark neuron degeneration Fig
0.30595517.15525658.html.plaintext.txt	51	2 previously described brain regions R62 mice 11
0.30595517.15525658.html.plaintext.txt	52	5 weeks age R62 mice assessed hypothalamic sections processed glial fibrillary acidic protein GFAP immunohistochemistry data shown
0.30595517.15525658.html.plaintext.txt	53	View larger version 104K Figure 1
0.30595517.15525658.html.plaintext.txt	54	Progressive loss atrophy orexin neurons R62 mice
0.30595517.15525658.html.plaintext.txt	55	Sections lateral hypothalamus processed orexin A immunohistochemistry wild type A C R62 B D mice 12
0.30595517.15525658.html.plaintext.txt	56	Scale bar 200 microm A 20 microm C
0.30595517.15525658.html.plaintext.txt	57	Progressive reduction density orexin immunopositive neurons E n4 9 per genotype per age two factor ANOVA genotype P 0
0.30595517.15525658.html.plaintext.txt	58	12 cross sectional surface area somata orexin positive neurons F n4 per genotype R62 mice compared wild type littermates F two factor ANOVA genotype P 0
0.30595517.15525658.html.plaintext.txt	59	Values represent mean plus minus SEM
0.30595517.15525658.html.plaintext.txt	60	View larger version 127K Figure 2
0.30595517.15525658.html.plaintext.txt	61	Dark neuron degeneration R62 lateral hypothalamus
0.30595517.15525658.html.plaintext.txt	62	Transmission electron micrographs lateral hypothalamus 12 week old wild type mouse A R62 mouse B showing examples dark degenerating nerve cell bodies R62 mouse
0.30595517.15525658.html.plaintext.txt	63	We also studied frequency huntingtin inclusions orexin immunopositive neurons R62 mice
0.30595517.15525658.html.plaintext.txt	64	5 week old R62 mice none orexin neurons lateral hypothalamus contained EM48 immunopositive inclusions whereas 7
0.30595517.15525658.html.plaintext.txt	65	5 weeks 50 plus minus 6 orexin positive neurons EM48 positive
0.30595517.15525658.html.plaintext.txt	66	5 plus minus 5 NeuN immunopositive neurons 12
0.30595517.15525658.html.plaintext.txt	67	5 week old R62 lateral hypothalamus displayed EM48 immunoreactive inclusions whereas 57 plus minus 5 remaining orexin positive neurons contained inclusions Students test P 0
0.30595517.15525658.html.plaintext.txt	68	Using radioimmunoassay RIA found significant reduction orexin A B levels R62 compared wild type mice 12
0.30595517.15525658.html.plaintext.txt	69	5 weeks age hypothalamus remaining brain tissue Students test P 0
0.30595517.15525658.html.plaintext.txt	70	The latter result indicates projections orexin neurons throughout CNS affected
0.30595517.15525658.html.plaintext.txt	71	Importantly found severe loss orexin immunoreactive fibers around third ventricle subcommisural organ region comprising pineal gland 25 12
0.30595517.15525658.html.plaintext.txt	72	We also examined whether orexin levels measured mouse CSF could used biomarker disease compartment readily monitored living patients
0.30595517.15525658.html.plaintext.txt	73	Indeed found marked reduction orexin CSF 12 week old R62 mice 586 plus minus 174 pgml n4 compared wild type littermates 2078 plus minus 130 pgml n4 Students test P0
0.30595517.15525658.html.plaintext.txt	74	Loss orexin fibers R62 pineal region
0.30595517.15525658.html.plaintext.txt	75	Photomicrographs pineal region around third ventricle 12 week old wild type mouse A R62 B mouse showing loss orexin fibers R62 mouse
0.30595517.15525658.html.plaintext.txt	76	PC posterior commisure SCO subcommisural organ 3V third ventricle
0.30595517.15525658.html.plaintext.txt	77	Narcoleptic episodes R62 mice We performed infrared video recordings mice different ages first 4 h dark cycle analyze whether orexin loss R62 mice would result appearance narcoleptic episodes 19
0.30595517.15525658.html.plaintext.txt	78	5 weeks age R62 mice indistinguishable wild type controls periods hyperactivity intense exploratory behavior intercalated prolonged periods rest normal sleeping Fig
0.30595517.15525658.html.plaintext.txt	79	5 weeks age observed several periods brief behavioral arrest R62 mice 1 8 episodes per mouse group median6 n5 Fig
0.30595517.15525658.html.plaintext.txt	80	These episodes characterized sudden interruption purposeful motor activity associated change posture maintained throughout episode
0.30595517.15525658.html.plaintext.txt	81	This closely resembled narcoleptic episodes described orexin knockout mice 19
0.30595517.15525658.html.plaintext.txt	82	5 weeks episodes became even frequent 4 h observed 11 14 group median11 n3 10 14 episodes behavioral arrest per mouse group median13 n3 respectively Fig
0.30595517.15525658.html.plaintext.txt	83	5 weeks age episodes occurred first third hours dark phase duration varied 3 214 group average62 n3 example distribution episodes one R62 mouse illustrated Fig
0.30595517.15525658.html.plaintext.txt	84	View larger version 27K Figure 4
0.30595517.15525658.html.plaintext.txt	85	Characterization narcoleptic episodes R62 mice
0.30595517.15525658.html.plaintext.txt	86	All analyses narcoleptic episodes performed first 4 h dark phase active period mice
0.30595517.15525658.html.plaintext.txt	87	A The total number narcoleptic episodes increases age R62 mice
0.30595517.15525658.html.plaintext.txt	88	Different mice used time point
0.30595517.15525658.html.plaintext.txt	89	B The duration narcoleptic episodes one 12
0.30595517.15525658.html.plaintext.txt	90	5 week old R62 mouse time occurred illustrated vertical lines
0.30595517.15525658.html.plaintext.txt	91	C The total number narcoleptic episodes per mouse divided three different categories 12
0.30595517.15525658.html.plaintext.txt	92	Insert table shows mean duration different categories narcoleptic episodes
0.30595517.15525658.html.plaintext.txt	93	D Typical EEGEMG recording narcoleptic episode 12
0.30595517.15525658.html.plaintext.txt	94	5 week old R62 mouse showing reduced EMG activity epileptic activity EEG
0.30595517.15525658.html.plaintext.txt	95	Arrows indicate beginning end narcoleptic episode
0.30595517.15525658.html.plaintext.txt	96	In contrast EEGEMG recording resting wild type mice display continued low level EMG activity even mouse ambulatory
0.30595517.15525658.html.plaintext.txt	97	Arrow indicates beginning period
0.30595517.15525658.html.plaintext.txt	98	To analyze behavior end stage mice 12
0.30595517.15525658.html.plaintext.txt	99	5 weeks divided episodes behavioral arrest three different categories according severity 1 periods movement 2 periods movement abruptsudden change posture beginning episode 3 episodes involving loss muscular tone andor sudden collapse head neck occasionally causing mouse fall completely onto side
0.30595517.15525658.html.plaintext.txt	100	All R62 mice studied n3 showed episodes movement 5 9 episodes per mouse group median7
0.30595517.15525658.html.plaintext.txt	101	Two animals also exhibited abrupt sudden changes posture interestingly three mice displayed interpreted narcoleptic episodes complete falls onto side 4 5 falls per mouse group median4 Fig
0.30595517.15525658.html.plaintext.txt	102	These episodes followed sudden bouts locomotion typically hyperactive compared wild type control mice
0.30595517.15525658.html.plaintext.txt	103	5 week old R62 mouse displaying severe narcoleptic episode viewed online Supplementary Material
0.30595517.15525658.html.plaintext.txt	104	We also evaluated behavior 12 week old R62 mice daytime mice normally largely spend sleeping
0.30595517.15525658.html.plaintext.txt	105	Interestingly light phase diurnal cycle R62 mice generally spent less time sleeping wild type mice exhibited repeated sudden episodes behavioral arrest sometimes associated abrupt change posture
0.30595517.15525658.html.plaintext.txt	106	Those episodes never seen wild type littermate controls data shown
0.30595517.15525658.html.plaintext.txt	107	As R62 mice known seizure prone 9 subjected different group 12
0.30595517.15525658.html.plaintext.txt	108	5 week old R62 n4 wild type n2 mice EEGEMG recordings order confirm observed episodes behavioral arrest interpreted narcolepsy caused epileptiform brain activity
0.30595517.15525658.html.plaintext.txt	109	Mice videorecorded EEGEMG activities assessed episodes behavioral arrest scored
0.30595517.15525658.html.plaintext.txt	110	Our video EEG recordings revealed epileptiform electrographic activity type episodes motor arrest
0.30595517.15525658.html.plaintext.txt	111	Rather EEG characterized small amplitude theta activity reduced EMG signal neck muscles Fig
0.30595517.15525658.html.plaintext.txt	112	In contrast wild type mice occasionally paused movements EMG activity decreased Fig
0.30595517.15525658.html.plaintext.txt	113	Orexin loss human HD brains To ensure loss orexin containing neurons also relevant human HD examined lateral hypothalamus HD affected individuals
0.30595517.15525658.html.plaintext.txt	114	The average number orexin positive neurons per square millimeter section showing highest density orexin positive neurons subject given Table 2
0.30595517.15525658.html.plaintext.txt	115	In control brains healthy individuals average number orexin positive neurons per square millimeter estimated 62 plus minus 4 neurons
0.30595517.15525658.html.plaintext.txt	116	In corresponding areas brains HD affected individuals grade II IV average number orexin positive neurons 45 plus minus 1mm2 Students test P 0
0.30595517.15525658.html.plaintext.txt	117	There also significant neuronal atrophy detected reduction average cross sectional surface area orexin cell bodies HD patients 230 plus minus 33 microm2 compared controls 363 plus minus 8 microm2 Students test P 0
0.30595517.15525658.html.plaintext.txt	118	Reduction orexin neurons HD patients
0.30595517.15525658.html.plaintext.txt	119	Representative photographs orexin A immunopositive neurons lateral hypothalamus control individual A HD patient B
0.30595517.15525658.html.plaintext.txt	120	The illustration shows atrophy individual neurons reduction orexin immunopositive neurons HD patient brain compared control brain
0.30595517.15525658.html.plaintext.txt	121	DISCUSSION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS SUPPLEMENTARY MATERIAL REFERENCES In HD neuronal death select brain regions
0.30595517.15525658.html.plaintext.txt	122	Transgenic HD mouse models provided insight possible disease mechanisms part reproduced extent specific patterns cell death occur HD
0.30595517.15525658.html.plaintext.txt	123	This also true R62 mouse reported exhibit minor cell loss neostriatum cerebral cortex 1112 besides loss retinal cells 26
0.30595517.15525658.html.plaintext.txt	124	The paucity intracerebral neuronal death R62 mice suggests mouse model poor analogy HD patients
0.30595517.15525658.html.plaintext.txt	125	Consequently clinical relevance R62 mouse questioned
0.30595517.15525658.html.plaintext.txt	126	Nevertheless currently widely used mouse model HD research 20 published reports testing novel therapies model 27
0.30595517.15525658.html.plaintext.txt	127	Now first time demonstrate progressive neuronal loss brains R62 mice
0.30595517.15525658.html.plaintext.txt	128	The neuronal population located lateral hypothalamus contains orexin
0.30595517.15525658.html.plaintext.txt	129	We also found significant depletion orexin hypothalamic tissue samples cell bodies located parts brain receive orexin projections including pineal region
0.30595517.15525658.html.plaintext.txt	130	Importantly also significant loss atrophy orexin immunostained neurons lateral hypothalamus HD patients extending earlier reports loss unidentified neurons structure HD 7
0.30595517.15525658.html.plaintext.txt	131	In small number HD brains examined study obvious correlation Vonsattel grade loss orexin neurons
0.30595517.15525658.html.plaintext.txt	132	The Vonsattel scale neuropathological changes based cell loss striatum 28 given degenerative changes hypothalamus follow similar time course
0.30595517.15525658.html.plaintext.txt	133	Whether hypothalamic cell death including orexin loss occurs early human disease whether correlated motor cognitive sleep weight loss symptoms remain studied
0.30595517.15525658.html.plaintext.txt	134	What connections narcoleptic like episodes loss orexin neurons lateral hypothalamus R62 mice Deficits orexin neurotransmission known result behavior reminiscent narcolepsy mice dogs 19 2129
0.30595517.15525658.html.plaintext.txt	135	Interestingly frequency duration general appearance narcoleptic episodes seen R62 mice similar observed genetically modified mice lacking orexin carrying mutant orexin receptors 19 21
0.30595517.15525658.html.plaintext.txt	136	Furthermore correlation progressive loss orexin neurons gradual onset narcoleptic phenotype R62 mice
0.30595517.15525658.html.plaintext.txt	137	Taken together striking motor arrests R62 mice likely direct consequence observed loss orexin neurons
0.30595517.15525658.html.plaintext.txt	138	Why loss hypothalamic orexin containing neurons HD R62 mouse model Clearly sensitive expression expanded polyglutamine protein mouse rat models expressing ataxin 3 construct increased number CAG repeats control orexin promoter exhibited adult onset degeneration hypothalamic orexin neurons 2130
0.30595517.15525658.html.plaintext.txt	139	Possibly expanded polyglutamine stretches disturb functions crucial interacting proteins
0.30595517.15525658.html.plaintext.txt	140	Thus huntingtin associated protein 1 HAP 1 partner huntingtin unknown function enriched hypothalamus null mutant mice HAP 1 die early owing impaired feeding exhibit hypothalamic degeneration 31
0.30595517.15525658.html.plaintext.txt	141	In study transgenic mouse model expressing first 171 amino acids huntingtin 82 glutamines N171 82Q mice also showed HAP 1 depletion degeneration neurons hypothalamus
0.30595517.15525658.html.plaintext.txt	142	Although transmitter identity dying neurons models established degenerative phenomena included lateral hypothalamus
0.30595517.15525658.html.plaintext.txt	143	Another explanation selective vulnerability hypothalamic orexin containing neurons may related expression NMDA receptors
0.30595517.15525658.html.plaintext.txt	144	Recently shown exposure rat hypothalamic cultures excitotoxicity resulted specific loss orexin neurons 15
0.30595517.15525658.html.plaintext.txt	145	Excitotoxicity widely regarded likely contributor cell death HD 114
0.30595517.15525658.html.plaintext.txt	146	There evidence functional changes glutamatergic pathways R62 mice several levels release transmitter inactivation receptor composition intracellular signaling neurons receiving glutamatergic input 32 37
0.30595517.15525658.html.plaintext.txt	147	Despite little cell death striatum R62 mice
0.30595517.15525658.html.plaintext.txt	148	Possibly striatal neurons gradually develop resistance damage due protracted low grade excitotoxic stress 38
0.30595517.15525658.html.plaintext.txt	149	The resistance acute excitotoxic damage correlated number neurons exhibiting intranuclear inclusions R62 striatum 35 proportion generally lower lateral hypothalamus 57 study compared striatum 95 39
0.30595517.15525658.html.plaintext.txt	150	What implications findings Characterization death orexin neurons may shed light cellular events leading neuronal death HD
0.30595517.15525658.html.plaintext.txt	151	In addition monitoring loss orexin containing neurons lateral hypothalamus may also important index measure therapeutic efficacy novel drugs R62 mice
0.30595517.15525658.html.plaintext.txt	152	Changes sleep behavior occurrence narcoleptic episodes constitute functional outcome parameter follow
0.30595517.15525658.html.plaintext.txt	153	Although studies showing HD patients actually suffer symptoms similar narcolepsy reported far sleep patterns disturbed 40
0.30595517.15525658.html.plaintext.txt	154	Indeed HD patients abnormal sleepwake cycle R62 mice exhibit progressive disruption circadian rhythms caused dysregulation circadian rhythm genes suprachiasmatic nucleus hypothalamus J
0.30595517.15525658.html.plaintext.txt	155	Morton personal communication
0.30595517.15525658.html.plaintext.txt	156	Importantly found orexin fibers lost R62 pineal region involved regulating circadian rhythm via connections suprachiasmatic nucleus
0.30595517.15525658.html.plaintext.txt	157	In HD state biomarkers available
0.30595517.15525658.html.plaintext.txt	158	As plasma CSF measurements substances secreted sites neuropathology hypothalamus feasible identification affected neuronal subpopulation opens new possibilities identify marker
0.30595517.15525658.html.plaintext.txt	159	In end stage R62 mice number orexin neurons lateral hypothalamus levels orexin CSF reduced 72 compared wild type littermates
0.30595517.15525658.html.plaintext.txt	160	This suggests orexin could used biomarker reflecting hypothalamic neurodegeneration
0.30595517.15525658.html.plaintext.txt	161	Considering substantial loss atrophy orexin also human condition hypothesize symptomatic HD patients reduced CSF orexin levels levels considered diagnostic narcolepsy
0.30595517.15525658.html.plaintext.txt	162	In healthy individuals normal orexin values CSF 200 pgml
0.30595517.15525658.html.plaintext.txt	163	Orexin levels 110 pgml diagnostic narcolepsy 41
0.30595517.15525658.html.plaintext.txt	164	Can one predict similar decrease HD patients Our study shows HD patients Vonsattel grade II III around 43 CAG repeats
0.30595517.15525658.html.plaintext.txt	165	mild moderate cases completely lost 30 orexin neurons
0.30595517.15525658.html.plaintext.txt	166	The remaining 70 neurons undergone atrophy neuronal cross sectional area 40 representing even greater percentage loss volume cell taken together suggest reduction total cell volume atrophy cell death considered would lead reduction CSF levels orexin diagnostic levels narcolepsy
0.30595517.15525658.html.plaintext.txt	167	Considering scenario CSF orexin levels could constitute novel biomarker assess disease progression effectiveness therapeutic interventions HD
0.30595517.15525658.html.plaintext.txt	168	Currently biomarker lacking HD
0.30595517.15525658.html.plaintext.txt	169	MATERIALS AND METHODS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS SUPPLEMENTARY MATERIAL REFERENCES Transgenic animals We used transgenic HD mice R62 line wild type littermates Jackson Laboratories Bar Harbor ME USA
0.30595517.15525658.html.plaintext.txt	170	They obtained crossing transgenic males females background strain CBAxC57BL6
0.30595517.15525658.html.plaintext.txt	171	The genotype assessed using polymerase chain reaction assay 9
0.30595517.15525658.html.plaintext.txt	172	The mice housed groups ad libitum access food water 12 h lightdark cycle
0.30595517.15525658.html.plaintext.txt	173	The experimental procedures approved Regional Ethical Committee Lund Sweden
0.30595517.15525658.html.plaintext.txt	174	Human HD brains We evaluated formalin fixed brains five HD patients age 69 plus minus 6 years four controls age 64 plus minus 10 years Leiden University Hospital Brain Bank Table 2
0.30595517.15525658.html.plaintext.txt	175	Immunohistochemistry R62 mice wild type littermates 3
0.30595517.15525658.html.plaintext.txt	176	5 weeks age perfused 4 paraformaldehyde
0.30595517.15525658.html.plaintext.txt	177	Coronal sections 30 microm cut six series throughout brains using microtome
0.30595517.15525658.html.plaintext.txt	178	Tissue wild typecontrols R62HD subjects processed parallel immunohistochemistry control staining intensity times
0.30595517.15525658.html.plaintext.txt	179	We processed free floating mouse sections primary antibodies following markers orexin A diluted 1 700 mouse tissue Phoenix Pharm
0.30595517.15525658.html.plaintext.txt	180	Belmont CA USA NeuN diluted 1 1000 Chemicon Temecula CA USA GFAP 1 700 Dako Nissl stain cresyl violet ICN Biomedicals Inc
0.30595517.15525658.html.plaintext.txt	181	For double labeling employed mouse anti EM48 antibody 1 500 Chemicon shown specific also mouse tissue 42 anti orexin A antibody
0.30595517.15525658.html.plaintext.txt	182	Paraffin embedded human brain sections 15 microm immunohistochemically processed orexin A 1 5000 human tissue Phoenix Pharm
0.30595517.15525658.html.plaintext.txt	183	Cell measurements All morphological analyses performed blind coded slides using Olympus CAST Grid system Olympus Danmark AS Albertslund Denmark composed Olympus BH2 microscope X Y step motor run IBM personal computer
0.30595517.15525658.html.plaintext.txt	184	The density orexin neurons lateral hypothalamus assessed three sections largest number orexin immunopositive neurons per mouse ages n4 9 per genotype per age
0.30595517.15525658.html.plaintext.txt	185	The outer borders areas orexin immunopositive neurons first delineated area assessed Olympus CAST Grid system
0.30595517.15525658.html.plaintext.txt	186	Using systematic random sampling technique number profiles assessed 25 areas
0.30595517.15525658.html.plaintext.txt	187	The technique used mice
0.30595517.15525658.html.plaintext.txt	188	Profiles characterized intense dark staining throughout cell body counted included independently size shape soma cells atrophied see Results
0.30595517.15525658.html.plaintext.txt	189	The average density orexin positive neurons three sections mouse used statistical analysis
0.30595517.15525658.html.plaintext.txt	190	The cross sectional soma area orexin neurons assessed 30 randomly selected orexin immunopositive neurons three sections four mice per genotype age using Olympus CAST Grid system
0.30595517.15525658.html.plaintext.txt	191	In areas total number cells neurons EM48 positive neurons analyzed 12
0.30595517.15525658.html.plaintext.txt	192	The presence EM48 immunopositive inclusions orexin neurons analyzed 100 randomly selected orexin neurons three mentioned sections four mice per genotype ages 3
0.30595517.15525658.html.plaintext.txt	193	In human brains compared sections containing orexin A positive cells individual selected section estimated show highest density orexin A positive cells
0.30595517.15525658.html.plaintext.txt	194	In section orexin A positive cells counted four different fields delineated 1 mm2 ocular grid
0.30595517.15525658.html.plaintext.txt	195	We measured cross sectional soma area orexin cell bodies 20 orexin A positive neuronsindividual using Olympus CAST Grid system
0.30595517.15525658.html.plaintext.txt	196	Radioimmunoassay Hypothalami dissected 12
0.30595517.15525658.html.plaintext.txt	197	5 week old mice n7 per genotype CSF withdrawn cisterna magna 12 week old mice n4 per genotype used peptide extraction
0.30595517.15525658.html.plaintext.txt	198	Using commercially available 125I RIA kits Phoenix Pharm
0.30595517.15525658.html.plaintext.txt	199	orexin A CSF brain tissue orexin B brain tissue measured
0.30595517.15525658.html.plaintext.txt	200	Duplicate samples assayed levels determined known standard
0.30595517.15525658.html.plaintext.txt	201	Electron microscopy Mice 12 weeks age n2 per genotype perfused 0
0.30595517.15525658.html.plaintext.txt	202	075 M Sorensen buffer containing 3 parafomaldehyde 1 glutaraldehyde
0.30595517.15525658.html.plaintext.txt	203	Hypothalami dissected fixed overnight fixative rinsed Sorensen buffer post fixed 1 h 1 OsO4 buffer dehydrated acetone embedded Polybed 812
0.30595517.15525658.html.plaintext.txt	204	Ultrathin sections cut placed copper grids contrasted 0
0.30595517.15525658.html.plaintext.txt	205	5 lead citrate 4 uranyl acetate
0.30595517.15525658.html.plaintext.txt	206	Specimens examined Philips CM10 transmission electron microscope
0.30595517.15525658.html.plaintext.txt	207	Scoring narcoleptic episodes We videorecorded scored narcoleptic episodes 19 R62 wild type mice following ages 3
0.30595517.15525658.html.plaintext.txt	208	Different mice used age
0.30595517.15525658.html.plaintext.txt	209	Briefly mice habituated 3 h individual glass cylinders covered bedding material recorded first 4 h dark cycle Sony CCD infrared videocamera
0.30595517.15525658.html.plaintext.txt	210	For behavioral experiment one R62 mouse one wild type mouse videorecorded simultaneously
0.30595517.15525658.html.plaintext.txt	211	The scoring episodes carried two investigators blinded mouse genotype
0.30595517.15525658.html.plaintext.txt	212	The protocol used evaluate behavior 12 week old R62 mice n4 light phase diurnal cycle
0.30595517.15525658.html.plaintext.txt	213	EEGEMG recordings At 10 weeks age mice n4 R62 n2 wild type implanted recording electrodes
0.30595517.15525658.html.plaintext.txt	214	One cortical screw electrode attached right parietal bone record EEG wire electrode insulated copper 250 microm diameter tip exposed 1
0.30595517.15525658.html.plaintext.txt	215	5 mm Belden St Louis MI USA attached occipital bone neck muscles record EMG
0.30595517.15525658.html.plaintext.txt	216	Both electrodes referred ground frontal screw electrode
0.30595517.15525658.html.plaintext.txt	217	Two additional anchor screws attached onto left parietal frontal bones three way connector Plastic One Roanoke VA USA fixed screws dental acrylic cement
0.30595517.15525658.html.plaintext.txt	218	At 12 15 days following electrode implantation pairs mice wild type R62 videotaped EEGEMG recorded continuously Chart 3
0.30595517.15525658.html.plaintext.txt	219	3 PowerLabMacLab ADInstruments Arhus Denmark first 4 h dark cycle
0.30595517.15525658.html.plaintext.txt	220	Videotapes scored narcoleptic episodes EEG parameters analyzed Chart 3
0.30595517.15525658.html.plaintext.txt	221	Statistics The data analyzed one two factor ANOVA appropriate un paired Students tests using Statview 5
0.30595517.15525658.html.plaintext.txt	222	4 package Abacus concepts Berkeley CA USA
0.30595517.15525658.html.plaintext.txt	223	Data presented mean median plus minus SEM
0.30595517.15525658.html.plaintext.txt	224	SUPPLEMENTARY MATERIAL TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS SUPPLEMENTARY MATERIAL REFERENCES Supplementary Material available HMG Online
0.30595517.15525658.html.plaintext.txt	225	ACKNOWLEDGEMENTS We grateful Birgit Haraldsson Britt Lindberg Elsy Ling Bengt Mattsson Paul Mohapel Britt Marie Nilsson Laurent Roybon excellent technical assistance
0.30595517.15525658.html.plaintext.txt	226	supported Swedish Brain Foundation National Board Health Welfare Sweden
0.30595517.15525658.html.plaintext.txt	227	fellowship Foundation Science Technology FCT Portugal SFRHBD60682001
0.30595517.15525658.html.plaintext.txt	228	supported short term fellowship Federation European Biochemical Societies FEBS
0.30595517.15525658.html.plaintext.txt	229	supported Cure HD Initiative Swedish Research Council F
0.30595517.15525658.html.plaintext.txt	230	Swedish Research Council
0.30595517.15525658.html.plaintext.txt	231	supported grant Biodegradable controlled drug delivery systems treatment brain diseases BCDDS QLRT 2000 02226 RTD EU project Quality Life Management Living Resources
0.30595517.15525658.html.plaintext.txt	232	supported Swedish Research Council Hereditary Disease Foundation The European Union concerted action consortium Early pathogenetic markers Slow Neurodegenerative Diseases EPSND QLK6 CT 2000 00384
0.30595517.15525658.html.plaintext.txt	233	FOOTNOTES The authors wish known opinion first two authors regarded joint First Authors
0.30595517.15525658.html.plaintext.txt	234	REFERENCES TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS SUPPLEMENTARY MATERIAL REFERENCES Petersen A
0.30595517.15525658.html.plaintext.txt	235	2002 Huntingtons disease mystery unfolds Int
0.30595517.15525658.html.plaintext.txt	236	The Huntingtons Disease Collaborative Research Group
0.30595517.15525658.html.plaintext.txt	237	1993 A novel gene containing trinucleotide repeat expanded unstable Huntingtons disease chromosomes
0.30595517.15525658.html.plaintext.txt	238	2003 Wild type huntingtin plays role brain development neuronal survival
0.30595517.15525658.html.plaintext.txt	239	2001 Loss normal huntingtin function new developments Huntingtons disease research
0.30595517.15525658.html.plaintext.txt	240	1997 Aggregation huntingtin neuronal intranuclear inclusions dystrophic neurites brain
0.30595517.15525658.html.plaintext.txt	241	1999 Distribution inclusions neuronal nuclei dystrophic neurites Huntington disease brain
0.30595517.15525658.html.plaintext.txt	242	1990 Atrophy hypothalamic lateral tuberal nucleus Huntingtons disease
0.30595517.15525658.html.plaintext.txt	243	1991 The hypothalamic lateral tuberal nucleus characteristics neuronal loss Huntingtons disease
0.30595517.15525658.html.plaintext.txt	244	1996 Exon 1 HD gene expanded CAG repeat sufficient cause progressive neurological phenotype transgenic mice
0.30595517.15525658.html.plaintext.txt	245	2002 Mouse models Huntingtons disease
0.30595517.15525658.html.plaintext.txt	246	2000 Nonapoptotic neurodegeneration transgenic mouse model Huntingtons disease
0.30595517.15525658.html.plaintext.txt	247	2000 Early alterations gene expression cell morphology mouse model Huntingtons disease
0.30595517.15525658.html.plaintext.txt	248	1993 AMPA NMDA binding sites hypothalamic lateral tuberal nucleus implications Huntingtons disease
0.30595517.15525658.html.plaintext.txt	249	2000 Energetics pathogenesis neurodegenerative diseases
0.30595517.15525658.html.plaintext.txt	250	2004 Excitotoxic degeneration hypothalamic orexin neurons slice culture
0.30595517.15525658.html.plaintext.txt	251	1998 The hypocretins hypothalamus specific peptides neuroexcitatory activity
0.30595517.15525658.html.plaintext.txt	252	1998 Orexins orexin receptors family hypothalamic neuropeptides G protein coupled receptors regulate feeding behavior
0.30595517.15525658.html.plaintext.txt	253	2004 Hypocretin orexin role normal behavior neuropathology
0.30595517.15525658.html.plaintext.txt	254	1999 Narcolepsy orexin knockout mice molecular genetics sleep regulation
0.30595517.15525658.html.plaintext.txt	255	2003 Distinct narcolepsy syndromes orexin receptor 2 orexin null mice molecular genetic dissection non REM REM sleep regulatory processes
0.30595517.15525658.html.plaintext.txt	256	2001 Genetic ablation orexin neurons mice results narcolepsy hypophagia obesity
0.30595517.15525658.html.plaintext.txt	257	1999 Narcolepsy key role hypocretins orexins
0.30595517.15525658.html.plaintext.txt	258	2001 CSF hypocretinorexin levels narcolepsy neurological conditions
0.30595517.15525658.html.plaintext.txt	259	2000 A mutation case early onset narcolepsy generalized absence hypocretin peptides human narcoleptic brains
0.30595517.15525658.html.plaintext.txt	260	2001 Hypocretin orexin rat pineal gland central transmitter effects noradrenaline induced release melatonin
0.30595517.15525658.html.plaintext.txt	261	2002 Progressive retinal degeneration dysfunction R6 Huntingtons disease mice
0.30595517.15525658.html.plaintext.txt	262	2004 Experimental therapeutics transgenic mouse models Huntingtons disease
0.30595517.15525658.html.plaintext.txt	263	Jr 1985 Neuropathological classification Huntingtons disease
0.30595517.15525658.html.plaintext.txt	264	1999 The sleep disorder canine narcolepsy caused mutation hypocretin orexin receptor 2 gene
0.30595517.15525658.html.plaintext.txt	265	2004 Expression poly glutamine ataxin 3 transgene orexin neurons induces narcolepsy cataplexy rat
0.30595517.15525658.html.plaintext.txt	266	2003 Lack huntingtin associated protein 1 causes neuronal death resembling hypothalamic degeneration Huntingtons disease
0.30595517.15525658.html.plaintext.txt	267	2003 Transient progressive electrophysiological alterations corticostriatal pathway mouse model Huntingtons disease
0.30595517.15525658.html.plaintext.txt	268	2001 Impaired glutamate uptake R6 huntingtons disease transgenic mice
0.30595517.15525658.html.plaintext.txt	269	2001 Altered striatal amino acid neurotransmitter release monitored using microdialysis R61 Huntington transgenic mice
0.30595517.15525658.html.plaintext.txt	270	2001 Resistance NMDA toxicity correlates appearance nuclear inclusions behavioural deficits changes calcium homeostasis mice transgenic exon 1 huntington gene
0.30595517.15525658.html.plaintext.txt	271	2003 Abnormal association mutant huntingtin synaptic vesicles inhibits glutamate release
0.30595517.15525658.html.plaintext.txt	272	2002 Impaired glutamate transport glutamate glutamine cycling downstream effects Huntington mutation
0.30595517.15525658.html.plaintext.txt	273	1999 Transgenic mice expressing Huntingtons disease mutation resistant quinolinic acid induced striatal excitotoxicity
0.30595517.15525658.html.plaintext.txt	274	2000 Progressive formation inclusions striatum hippocampus mice transgenic human Huntingtons disease mutation
0.30595517.15525658.html.plaintext.txt	275	2004 Sleep quantitative EEG neurodegenerative disorders
0.30595517.15525658.html.plaintext.txt	276	2002 The role cerebrospinal fluid hypocretin measurement diagnosis narcolepsy hypersomnias
0.30595517.15525658.html.plaintext.txt	277	2002 Huntingtin inclusions deplete polyglutamine containing transcription factors HD mice
0.095306225.11416103.html.plaintext.txt	0	NEWS Cancer Fatigue One Drug Fails But More Are Pipeline Caroline McNeil
0.095306225.11416103.html.plaintext.txt	1	The hypothesis made sense drug promising
0.095306225.11416103.html.plaintext.txt	2	The hypothesis reducing depression could also reduce fatigue cancer patients based widespread observation two often coexist
0.095306225.11416103.html.plaintext.txt	3	The drug paroxetine Paxil feasible biologic model showing serotonin might play role cancer related fatigue
0.095306225.11416103.html.plaintext.txt	4	It made perfect sense said Gary Morrow Ph
0.095306225.11416103.html.plaintext.txt	5	University Rochester N
0.095306225.11416103.html.plaintext.txt	6	led large randomized trial test hypothesis
0.095306225.11416103.html.plaintext.txt	7	It seemed fit lot observed lot know
0.095306225.11416103.html.plaintext.txt	8	It happened accurate
0.095306225.11416103.html.plaintext.txt	9	View larger version 146K Dr
0.095306225.11416103.html.plaintext.txt	10	The patients took Paxil Community Clinical Oncology Program trial significantly less depression took placebo neither group reduction fatigue
0.095306225.11416103.html.plaintext.txt	11	Morrow reported finding May meeting American Society Clinical Oncology San Francisco concluded appears unlikely serotonin involved common mechanism fatigue depression
0.095306225.11416103.html.plaintext.txt	12	The question said probably worth study
0.095306225.11416103.html.plaintext.txt	13	The surprising disappointing outcome Paxil trial leaves clinicians little offer patients common debilitating aspect cancer treatment
0.095306225.11416103.html.plaintext.txt	14	Other drugs pipeline however trials planned oncologists increasingly recognize impact fatigue patients
0.095306225.11416103.html.plaintext.txt	15	Fatigue affects majority cancer patients treatment according various estimates
0.095306225.11416103.html.plaintext.txt	16	For example one recent survey 300 chemotherapy patients Greg Curt M
0.095306225.11416103.html.plaintext.txt	17	National Cancer Institute found 76 cancer patients reported fatigue chemotherapy 30 reported experienced fatigue daily
0.095306225.11416103.html.plaintext.txt	18	Among patients worked 75 change employment status fatigue
0.095306225.11416103.html.plaintext.txt	19	Despite widespread occurrence fatigue seldom addressed clinical practice
0.095306225.11416103.html.plaintext.txt	20	And try address problem field potential treatments still limited
0.095306225.11416103.html.plaintext.txt	21	It nausea emesis 15 years ago said Morrow
0.095306225.11416103.html.plaintext.txt	22	Of current candidates managing fatigue studied methylphenidate Ritalin psychostimulant used widely attention deficit disorder
0.095306225.11416103.html.plaintext.txt	23	A phase III trial Eastern Cooperative Oncology Group comparing methylphenidate placebo patients taking interferon
0.095306225.11416103.html.plaintext.txt	24	Originally designed test drug patients melanoma taking high dose interferon trial recently modified include cancer patient taking interferon dose said principal investigator Paul Hutson Pharm
0.095306225.11416103.html.plaintext.txt	25	University Wisconsin Madison
0.095306225.11416103.html.plaintext.txt	26	So far accrual trial slower hoped Hutson said
0.095306225.11416103.html.plaintext.txt	27	One reason may Ritalin controlled substance states oncologists must obtain permission state officials use trial
0.095306225.11416103.html.plaintext.txt	28	Another large randomized methylphenidate trial still review test psychostimulant chemotherapy interferon patients said Morrow also lead second CCOP trial
0.095306225.11416103.html.plaintext.txt	29	This study compare drug placebo 700 patients could open early fall Morrow said
0.095306225.11416103.html.plaintext.txt	30	The frequently mentioned approach managing fatigue use low dose steroids dexamethasone prednisone
0.095306225.11416103.html.plaintext.txt	31	chairman Department Pain Medicine Palliative Care Beth Israel Medical Center New York said large clinical experience drugs cancer fatigue among oncologists address fatigue use could called conventional medical practice
0.095306225.11416103.html.plaintext.txt	32	However never evaluated clinical trial fatigue primary end point
0.095306225.11416103.html.plaintext.txt	33	Portenoy said necessity investing randomized controlled trial steroids recognized investigators exploring possibility
0.095306225.11416103.html.plaintext.txt	34	chair ECOG quality life committee said June meeting cooperative group would consider trial dexamethasone Decadron among candidates managing fatigue
0.095306225.11416103.html.plaintext.txt	35	He added group plans begin enrolling patients least one trial fatigue reduction end point end year
0.095306225.11416103.html.plaintext.txt	36	While methylphenidate low dose steroids two drugs frequently mentioned others could way
0.095306225.11416103.html.plaintext.txt	37	A new psychostimulant called modafinil Provigil approved narcolepsy anecdotally seems effect cancer fatigue
0.095306225.11416103.html.plaintext.txt	38	It getting lot favorable reviews Portenoy said
0.095306225.11416103.html.plaintext.txt	39	company makes drug plans evaluate effect fatigue trial according spokesperson
0.095306225.11416103.html.plaintext.txt	40	However ECOG consider trial modafinil June meeting Cella said
0.095306225.11416103.html.plaintext.txt	41	Erythropoietin also considered outside standard use patients anemia
0.095306225.11416103.html.plaintext.txt	42	At Beth Israel several institutions trial patients brain irradiation begin Portenoy said see whether erythropoietin alleviate fatigue associated treatment
0.095306225.11416103.html.plaintext.txt	43	The hypothesis based animal studies showing erythropoietin reduces injury ischemia concussion types brain injury
0.095306225.11416103.html.plaintext.txt	44	In support idea study reported September issue Proceedings National Academy Sciences demonstrated rat brain capillaries receptors erythropoietin enabling drug cross blood brain barrier
0.095306225.11416103.html.plaintext.txt	45	Erythropoietin treat fatigue patients slightly lowered hemoglobin levels
0.095306225.11416103.html.plaintext.txt	46	lower 12 gdL lower 10 gdL also possibility trial
0.095306225.11416103.html.plaintext.txt	47	It one concepts ECOG consider Cella said
0.095306225.11416103.html.plaintext.txt	48	Another new approach fatigue based preliminary data use antihistamines
0.095306225.11416103.html.plaintext.txt	49	In poster session ASCO annual meeting Eddie Reed M
0.095306225.11416103.html.plaintext.txt	50	West Virginia University Morgantown reported tricyclic antihistamine loratidine Claritin appeared reduce fatigue among ovarian cancer patients treated irofulven
0.095306225.11416103.html.plaintext.txt	51	The finding suggests said treatment regimens may induce fatigue cytokine release mediated H 1 histamine receptor
0.095306225.11416103.html.plaintext.txt	52	Reed said trial loratidine fatigue would end point consideration
0.095306225.11416103.html.plaintext.txt	53	Nonpharmacologic approaches cancer fatigue also study
0.095306225.11416103.html.plaintext.txt	54	Exercise shown help small studies among selected patients
0.095306225.11416103.html.plaintext.txt	55	Other investigators interested nutrition alternative therapies little evidence effectiveness published date
0.095306225.11416103.html.plaintext.txt	56	Cella said addition pharmacologic treatments ECOG meeting consider exercise lifestyle interventions
0.095306225.11416103.html.plaintext.txt	57	All symptoms pain nausea fatigue others psychological well physiologic components Morrow said one frontiers fatigue research examination behavioral biological factors may interact
0.095306225.11416103.html.plaintext.txt	58	The crossroads psyche soma worthwhile place research said
0.095306225.11416103.html.plaintext.txt	59	Copyright 2001 Oxford University Press unless otherwise stated Oxford University Press Privacy Policy Legal Statement Search All Search JNCI Search Journals Search Cancer Statistics Search PDQ Search PDR Search Calendar
0.18766233.15687100.html.plaintext.txt	0	Food deprivation differentially modulates orexin receptor expression signaling rat hypothalamus adrenal cortex Emmanouil Karteris1 Rachel J
0.18766233.15687100.html.plaintext.txt	1	Machado1 Jing Chen1 Sevasti Zervou1 Edward W
0.18766233.15687100.html.plaintext.txt	2	1Biomedical Research Institute Department Biological Sciences 2Warwick Medical School University Warwick Coventry 3The Deans Office The Medical School University Leeds Leeds United Kingdom
0.18766233.15687100.html.plaintext.txt	3	Submitted 2 August 2004 accepted final form 10 January 2005
0.18766233.15687100.html.plaintext.txt	4	ABSTRACT TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES Although starvation induced biochemical metabolic changes perceived hypothalamus adrenal gland plays key role integration metabolic activity energy balance implicating feeding major synchronizer rhythms hypothalamic pituitary adrenal HPA axis
0.18766233.15687100.html.plaintext.txt	5	Given orexins involved regulating food intake activating HPA axis hypothesized food deprivation acute challenge systems regulate energy balance elicit changes orexin receptor signaling hypothalamic adrenal levels
0.18766233.15687100.html.plaintext.txt	6	Food deprivation induced orexin type 1 OX1R 2 OX2R receptors mRNA protein levels hypothalamus addition fivefold increase prepro orexin mRNA
0.18766233.15687100.html.plaintext.txt	7	Cleaved peptides OR A OR B also elevated protein level
0.18766233.15687100.html.plaintext.txt	8	Interestingly adrenal OX1R OX2R levels significantly reduced food deprived animals whereas expression prepro orexin adrenal gland either state
0.18766233.15687100.html.plaintext.txt	9	Food deprivation exerted differential effect OXR G protein coupling
0.18766233.15687100.html.plaintext.txt	10	In hypothalamus food deprived rats compared controls significant increase coupling orexin receptors Gq Gs Go demonstrated whereas coupling Gi relatively less
0.18766233.15687100.html.plaintext.txt	11	However adrenal cortex food deprived animal decreased coupling orexin receptors Gs Go Gq increased coupling Gi
0.18766233.15687100.html.plaintext.txt	12	Subsequent second messenger studies cAMPIP3 supported findings
0.18766233.15687100.html.plaintext.txt	13	Our data indicate food deprivation differential effects orexin receptor expression signaling characteristics hypothalamic adrenocortical levels
0.18766233.15687100.html.plaintext.txt	14	These findings suggest orexins potential metabolic regulators within HPA axis centrally peripherally
0.18766233.15687100.html.plaintext.txt	15	STARVATION INDUCED BIOCHEMICAL metabolic changes perceived hypothalamus turn coordinates behavioral autonomic neuroendocrine responses stimuli 1
0.18766233.15687100.html.plaintext.txt	16	Studies rodents shown food deprivation induces marked ACTH corticosterone responses implicating feeding major synchronizer rhythms hypothalamic pituitary adrenal HPA axis 2 3
0.18766233.15687100.html.plaintext.txt	17	Besides nutritional states neuropeptides corticotropin releasing hormone neuropeptide Y NPY known regulate HPA system feeding behavior several signals known regulate HPA system
0.18766233.15687100.html.plaintext.txt	18	Hypoglycemia potent activator HPA axis reflecting strong functional relationship hypothalamic feeding centers HPA axis 4 leptin whose concentrations governed nutritional status inhibitory effect plasma corticosterone rats 5
0.18766233.15687100.html.plaintext.txt	19	More recently orexin A OR A orexin B OR B produced neurons localized lateral dorsal hypothalamic area perifornical hypothalamus 6 implicated central regulation feeding energy homeostasis 7
0.18766233.15687100.html.plaintext.txt	20	Both OR A 33 residue peptide OR B 28 residue peptide proteolytically cleaved common precursor prepro orexin share 46 amino acid sequence homology
0.18766233.15687100.html.plaintext.txt	21	Besides playing role regulation feeding energy homeostasis orexins reported exert divergent physiological actions 8 12
0.18766233.15687100.html.plaintext.txt	22	Orexins orchestrate actions binding activating two types G protein coupled receptors orexin 1 receptor OX1R orexin 2 receptor OX2R display 64 homology amino acid sequence 6
0.18766233.15687100.html.plaintext.txt	23	The OX1R preferentially binds OR A whereas OX2R binds OR A OR B apparently similar affinity 6
0.18766233.15687100.html.plaintext.txt	24	In hypothalamus levels prepro orexin messenger RNA regulated several nutritional states signals
0.18766233.15687100.html.plaintext.txt	25	Fasting 6 insulin induced hypoglycemia 13 14 increase prepro orexin mRNA rat lateral hypothalamic area whereas leptin converse effect 15
0.18766233.15687100.html.plaintext.txt	26	Interestingly fasting leptin also regulate hypothalamic expression orexin receptors 15 16
0.18766233.15687100.html.plaintext.txt	27	These findings observation intracerebroventricular administration OR A OR B stimulates food consumption rats 6 suggests physiological role neuropeptides mediators regulation feeding particularly response energy deprivation
0.18766233.15687100.html.plaintext.txt	28	Although hypothalamus considered cornerstone maintenance energy homeostasis adrenal gland plays role integration metabolic activity energy balance
0.18766233.15687100.html.plaintext.txt	29	For example studies food deprived rats suggested HPA axis integral larger hypothalamic system mediates energy flow 2 animals catabolic activity quickly predominates reinforced elevated corticosterone driven hypothalamic control ACTH implicating adrenal activity metabolic regulator 3
0.18766233.15687100.html.plaintext.txt	30	In addition hypothalamic effects nutritional signals leptin NPY direct action adrenal level via receptors including modulation corticosteroid secretion 17 18
0.18766233.15687100.html.plaintext.txt	31	Of interest rat adrenals express orexin receptors 19 orexins stimulate corticosterone secretion rat adrenocortical cells activation adenylyl cyclase dependent signaling cascade 20
0.18766233.15687100.html.plaintext.txt	32	The expression orexin receptors rat human adrenals well documented
0.18766233.15687100.html.plaintext.txt	33	In rat receptors expressed adrenal cortex
0.18766233.15687100.html.plaintext.txt	34	Interestingly highest amount OX2R mRNA found adrenal gland male rats four times higher brain OX2R mRNA levels 19
0.18766233.15687100.html.plaintext.txt	35	In situ hybridization revealed OX2R mRNA localized primarily zona glomerulosa zona reticularis whereas expression adrenal medulla 19
0.18766233.15687100.html.plaintext.txt	36	In view findings observation changes orexin levels closely related nutritional status rather state hunger satiety 21 hypothesizsed activation orexin receptors adrenal level may explain ACTH independent rise corticosterone seen starved rats
0.18766233.15687100.html.plaintext.txt	37	We sought investigate hypothalamus adrenal gland 1 whether levels orexins receptors OX1R OX2R differ fed food deprived rats assessing expression mRNA protein level 2 elucidate whether nutritional status elicits functional changes OX1R OX2R studying G protein coupling subsequent activation second messenger pathways
0.18766233.15687100.html.plaintext.txt	38	MATERIALS AND METHODS TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES Animal Preparation
0.18766233.15687100.html.plaintext.txt	39	The University Warwick UK ethics committee use care animals approved procedures described
0.18766233.15687100.html.plaintext.txt	40	Adult male initially 250 g Wistar rats housed groups two n 6 group environmentally controlled conditions 22 plus minus 2 degrees C humidity 40 60 1212 h light dark schedule lights 0600
0.18766233.15687100.html.plaintext.txt	41	Rats allowed unrestricted access standard laboratory pellet rodent diet 13
0.18766233.15687100.html.plaintext.txt	42	1 kcalg CRM Biosure Cambridge UK access tap water subjected study
0.18766233.15687100.html.plaintext.txt	43	After week habituation conditions rats randomly distributed two groups
0.18766233.15687100.html.plaintext.txt	44	The first group allowed eat freelyad libitum
0.18766233.15687100.html.plaintext.txt	45	The second group food deprived 24 h beginning onset dark cycle lights 1800 groups animals killed CO2 inhalation cervical dislocation following day 1800
0.18766233.15687100.html.plaintext.txt	46	Hypothalamic Adrenal Dissection
0.18766233.15687100.html.plaintext.txt	47	To isolate hypothalamus animals decapitated brains removed rapidly
0.18766233.15687100.html.plaintext.txt	48	The hypothalamus defined posterior margin optic chiasm anterior margin mamillary bodies depth 2 3 mm dissected
0.18766233.15687100.html.plaintext.txt	49	Adrenal cortex fractions freed adipose tissue separated inner adrenomedullary tissue pressure glass plates
0.18766233.15687100.html.plaintext.txt	50	Upon removal tissues immediately snap frozen liquid nitrogen
0.18766233.15687100.html.plaintext.txt	51	Samples stored 70 degrees C use
0.18766233.15687100.html.plaintext.txt	52	Assay Plasma Corticosterone Concentration
0.18766233.15687100.html.plaintext.txt	53	Plasma corticosterone levels fed n 6 group
0.18766233.15687100.html.plaintext.txt	54	CO2cervical dislocation food deprived rats n 6 group measured radioimmunoassay Amersham Life Sciences Buckinghamshire UK
0.18766233.15687100.html.plaintext.txt	55	The range radioimmunoassay specific corticosterone 0
0.18766233.15687100.html.plaintext.txt	56	Total RNA Extraction cDNA Synthesis
0.18766233.15687100.html.plaintext.txt	57	Total RNA prepared individual samples using RNeasy Total RNA Kit Qiagen Crawley UK according manufacturers guidelines
0.18766233.15687100.html.plaintext.txt	58	First strand cDNA synthesis performed using RNase reverse transcriptase GIBCO BRL Paisley UK according manufacturers recommendation
0.18766233.15687100.html.plaintext.txt	59	Quantitative PCR performed Roche Light Cycler system Roche Molecular Biochemicals Manheim Germany
0.18766233.15687100.html.plaintext.txt	60	PCR reactions carried reaction mixture consisting 5
0.18766233.15687100.html.plaintext.txt	61	0 microl reaction buffer 2
0.18766233.15687100.html.plaintext.txt	62	0 mM MgCl2 Biogene Kimbolton UK 1
0.18766233.15687100.html.plaintext.txt	63	0 microl primer 1 ng microl 2
0.18766233.15687100.html.plaintext.txt	64	5 microl Light Cycler SYBR Gold Biogene
0.18766233.15687100.html.plaintext.txt	65	Protocol conditions consisted denaturation 95 degrees C 15 followed 40 cycles 94 degrees C 1 58 degrees C 5 72 degrees C 12 followed melting curve analysis
0.18766233.15687100.html.plaintext.txt	66	For analysis quantitative amounts genes interest standardized housekeeping gene actin
0.18766233.15687100.html.plaintext.txt	67	As negative control reactions preparations lacking RNA reverse transcriptase used place cDNA
0.18766233.15687100.html.plaintext.txt	68	For quantitative analysis cDNAs six fed six food deprived rats used
0.18766233.15687100.html.plaintext.txt	69	Serial dilutions hypothalamic adrenal cDNAs provided template line best fit plotted used standard curve demonstrate accuracy reproducibility analysis
0.18766233.15687100.html.plaintext.txt	70	Quantification data analyzed using Light Cycler analysis software
0.18766233.15687100.html.plaintext.txt	71	The RNA levels expressed ratio using delta delta method comparing relative expression results treatments real time PCR 22
0.18766233.15687100.html.plaintext.txt	72	The resultant PCR products sequenced automated DNA sequencer sequence data analyzed using BLAST nucleic acid database searches National Center Biotechnology Information
0.18766233.15687100.html.plaintext.txt	73	Preparation Hypothalamic Adrenocortical Membranes
0.18766233.15687100.html.plaintext.txt	74	Rat hypothalami adrenal cortex obtained food deprived control male Wistar rats described
0.18766233.15687100.html.plaintext.txt	75	Tissues homogenized Dulbeccos phosphate buffered saline containing 10 mM MgCl2 2 mM EGTA 1
0.18766233.15687100.html.plaintext.txt	76	5 gl bovine serum albumin BSA wtvol 0
0.18766233.15687100.html.plaintext.txt	77	15 mM bacitracin 1 mM phenylmethylsulfonyl fluoride PMSF pH 7
0.18766233.15687100.html.plaintext.txt	78	2 extraction buffer 22 degrees C
0.18766233.15687100.html.plaintext.txt	79	The homogenate centrifuged 800 g 30 min 4 degrees C
0.18766233.15687100.html.plaintext.txt	80	The pellet discarded supernatant spun 45000 g 60 min 4 degrees C
0.18766233.15687100.html.plaintext.txt	81	The resultant pellet washed resuspended extraction buffer spun 45000 g 60 min 4 degrees C
0.18766233.15687100.html.plaintext.txt	82	The final pellet resuspended 5 ml extraction buffer use homogenizer
0.18766233.15687100.html.plaintext.txt	83	The protein concentration membrane suspension determined using bicinchoninic acid method BSA standard 23
0.18766233.15687100.html.plaintext.txt	84	Hypothalamic n 6 group
0.18766233.15687100.html.plaintext.txt	85	fed food deprived 100 microg adrenocortical membranes n 6 group 100 microg centrifuged 15000 g 15 min 4 degrees C
0.18766233.15687100.html.plaintext.txt	86	The supernatant discarded resultant pellets solubilized Laemmli buffer 5 M urea 0
0.18766233.15687100.html.plaintext.txt	87	17 M sodium dodecyl sulfate SDS 0
0.18766233.15687100.html.plaintext.txt	88	4 M dithiothreitol DTT 50 mM Tris HCl pH 8
0.18766233.15687100.html.plaintext.txt	89	0 mixed placed boiling water bath 5 min allowed cool room temperature
0.18766233.15687100.html.plaintext.txt	90	Samples separated 12 SDS polyacrylamide gel proteins electrophoretically transferred nitrocellulose membrane 250 mA 1 h transfer buffer containing 20 mM Tris 150 mM glycine 20 methanol
0.18766233.15687100.html.plaintext.txt	91	The filter blocked PBS containing 0
0.18766233.15687100.html.plaintext.txt	92	1 Tween 20 5 milk powder wtvol 2 h room temperature
0.18766233.15687100.html.plaintext.txt	93	1 Tween nitrocellulose membranes incubated primary antibody OX1R OX2R Santa Cruz Biotechnology Santa Cruz CA
0.18766233.15687100.html.plaintext.txt	94	The primary antisera used 11000 dilution PBS 0
0.18766233.15687100.html.plaintext.txt	95	1 Tween 1 h room temperature
0.18766233.15687100.html.plaintext.txt	96	The filters washed thoroughly 30 min PBS 0
0.18766233.15687100.html.plaintext.txt	97	1 Tween incubation secondary anti rabbit horseradish peroxidase conjugated immunoglobulin 12000 1 h room temperature washing 30 min PBS 0
0.18766233.15687100.html.plaintext.txt	98	Antibody complexes visualized previously described 24
0.18766233.15687100.html.plaintext.txt	99	To ensure specificity also performed preabsorption OX1R OX2R blocking peptides Santa Cruz Biotechnology prior Western blotting
0.18766233.15687100.html.plaintext.txt	100	For detection OR A OR B similar procedures followed using specific non cross reactive antibodies Phoenix Peptides Belmont MA total hypothalamic adrenal lysate
0.18766233.15687100.html.plaintext.txt	101	To ensure protein amount loaded samples used Western blotting used antibodies housekeeping gene actin Santa Cruz Biotechnology
0.18766233.15687100.html.plaintext.txt	102	Treatment Membranes Pertussis Cholera Toxins
0.18766233.15687100.html.plaintext.txt	103	Both pertussis 50 microgml cholera 150 microgml toxin preactivated 0
0.18766233.15687100.html.plaintext.txt	104	5 containing 20 mM DTT 50 mM glycine 45 min 37 degrees C final volume 50 microl cooled ice 20 min
0.18766233.15687100.html.plaintext.txt	105	Hypothalamic adrenal membranes n 3 group 100 microg incubated 20 mM Tris pH 7
0.18766233.15687100.html.plaintext.txt	106	5 containing 1 mM EDTA 1 mM DTT 1 mM ATP 1 mM GTP 5 mM MgCl2 10 mM thymidine 10 microM NAD 5 microCi 32PNAD together preactivated toxins
0.18766233.15687100.html.plaintext.txt	107	All reactions carried 37 degrees C 30 min incubations terminated 0
0.18766233.15687100.html.plaintext.txt	108	7 ml ice cold 20 mM Tris buffer pH 7
0.18766233.15687100.html.plaintext.txt	109	Control samples prepared incubating membranes medium absence toxin
0.18766233.15687100.html.plaintext.txt	110	After termination samples centrifuged 13000 rpm 20 min pellets washed respun three times
0.18766233.15687100.html.plaintext.txt	111	The resultant pellets resuspended 100 microl 2 SDS 320 microl buffer containing 1 volvol Triton X 100 1 deoxycholate 0
0.18766233.15687100.html.plaintext.txt	112	5 wtvol SDS 150 mM NaCl 10 mM Tris HCl pH 7
0.18766233.15687100.html.plaintext.txt	113	2 mM PMSF 10 microgml aprotinin
0.18766233.15687100.html.plaintext.txt	114	Resuspended samples centrifuged 11000 rpm 10 min room temperature resulting supernatants equally aliquoted 200 microl
0.18766233.15687100.html.plaintext.txt	115	Into aliquots 10 microl Gi Gs antisera New England Nuclear DuPont Boston MA added left continuous agitation 2 h followed addition 60 microl protein Sepharose A per tube agitation overnight 4 degrees C
0.18766233.15687100.html.plaintext.txt	116	The samples centrifuged 12000 rpm 10 min pellets solubilized Laemmli buffer mixed placed boiling water bath 5 min cooling room temperature
0.18766233.15687100.html.plaintext.txt	117	Each sample loaded onto SDS 12 polyacrylamide gel electrophoresis gels dried autoradiographed using Kodak X ray film assess extent ADP ribosylation
0.18766233.15687100.html.plaintext.txt	118	Synthesis 32PGTP Azidoanilide Photoaffinity Labeling G Subunits
0.18766233.15687100.html.plaintext.txt	119	GTP azidoanilide GTP AA synthesized using method previously described 23
0.18766233.15687100.html.plaintext.txt	120	Hypothalamic adrenocortical membranes n 3 group 150 microg incubated 3 min 30 degrees C OR A 100 nM buffer A 50 mM HEPES 30 mM KCl 10 mM MgCl2 1 mM benzamidine 0
0.18766233.15687100.html.plaintext.txt	121	1 mM EDTA followed addition 5 microM GDP 6 microCi GTP AA
0.18766233.15687100.html.plaintext.txt	122	After incubation 3 min 30 degrees C darkened room membranes placed ice collected centrifugation 15000 g 15 min 4 degrees C
0.18766233.15687100.html.plaintext.txt	123	The supernatant carefully removed membrane pellet resuspended 120 microlL modified buffer A 1
0.18766233.15687100.html.plaintext.txt	124	Samples vortexed irradiated 5 min 4 degrees C ultraviolet light 254 nm distance 5 cm cross link GTP AA G proteins
0.18766233.15687100.html.plaintext.txt	125	Immunoprecipitation using 10 microl undiluted G protein antisera New England Nuclear DuPont subunit carried previously described 24
0.18766233.15687100.html.plaintext.txt	126	Samples subjected gel electrophoresis using discontinuous SDS PAGE slab gels 10 running 5 stacking
0.18766233.15687100.html.plaintext.txt	127	The gels stained Coomassie blue dried using slab gel dryer exposed Fuji X ray film 70 degrees C 2 5 days intensifying screens
0.18766233.15687100.html.plaintext.txt	128	cAMP Inositol Triphosphate Second Messenger Studies
0.18766233.15687100.html.plaintext.txt	129	For cAMP studies using commercially available kit New England Nuclear DuPont hypothalamic adrenocortical membrane suspensions n 3 group 100 microg incubated increasing concentrations OR A amount cAMP incubate determined radioimmunoassay previously described 25
0.18766233.15687100.html.plaintext.txt	130	Standard cAMP concentrations covering range 0
0.18766233.15687100.html.plaintext.txt	131	138 100 pmolml used determination standard curve radioimmunoassay
0.18766233.15687100.html.plaintext.txt	132	The interassay coefficient variation 8
0.18766233.15687100.html.plaintext.txt	133	CAMP assay buffer without membrane preparations used negative control
0.18766233.15687100.html.plaintext.txt	134	For inositol triphosphate IP3 assay Amersham Pharmacia Biotech Little Chalfont UK hypothalamic adrenocortical membranes incubated increasing concentrations OR A followed addition 200 microl IP3 generation buffer previously described 24
0.18766233.15687100.html.plaintext.txt	135	Membranes incubated 3 min 37 degrees C reaction terminated addition 1 M ice cold trichloroacetic acid followed extraction inositol phosphates neutralization
0.18766233.15687100.html.plaintext.txt	136	IP3 levels estimated radioimmunoassay basis displacement 3HIP3 specific bovine adrenocortical IP3 binding proteins
0.18766233.15687100.html.plaintext.txt	137	The interassay coefficient variation 8
0.18766233.15687100.html.plaintext.txt	138	Data shown means plus minus SD measurement
0.18766233.15687100.html.plaintext.txt	139	For real time PCR measurements photoaffinity labeling Western immunoblotting results evaluated groups using two tailed Students test significance determined level P 0
0.18766233.15687100.html.plaintext.txt	140	For Western immunoblotting photoaffinity labeling experiments densities measured using scanning densitometer coupled scanning software ImageQuant Molecular Dynamics Amersham Pharmacia Little Chalfont UK
0.18766233.15687100.html.plaintext.txt	141	For second messenger measurements one way analysis variance used followed Dunnetts test compare treatment dose
0.18766233.15687100.html.plaintext.txt	142	RESULTS TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES Effect Food Deprivation Corticosterone Level
0.18766233.15687100.html.plaintext.txt	143	Plasma corticosterone levels almost twofold higher P 0
0.18766233.15687100.html.plaintext.txt	144	01 food deprived rats 51 plus minus 2
0.18766233.15687100.html.plaintext.txt	145	9 ngml compared fed ones 28 plus minus 2
0.18766233.15687100.html.plaintext.txt	146	7 ngml measured radioimmunoassay Fig
0.18766233.15687100.html.plaintext.txt	147	Given rats killed CO2 inhalation corticosterone levels rats killed cervical dislocation also measured
0.18766233.15687100.html.plaintext.txt	148	After two subgroups compared appeared apparent differences two different methods killing animals thus suggesting model CO2 inhalation constitute additional stress factor Fig
0.18766233.15687100.html.plaintext.txt	149	View larger version 26K Fig
0.18766233.15687100.html.plaintext.txt	150	A significant upregulation P 0
0.18766233.15687100.html.plaintext.txt	151	01 corticosterone production food deprived rats n 6 compared fed ones n 6
0.18766233.15687100.html.plaintext.txt	152	The method sacrificing exert effects corticosterone levels 2 groups
0.18766233.15687100.html.plaintext.txt	153	B significant increase prepro orexin mRNA levels food deprived hypothalamus rat n 6
0.18766233.15687100.html.plaintext.txt	154	These differences mRNA expression seen large difference amplification efficiency demonstrated delay amplification intercept cycle fed rat sample
0.18766233.15687100.html.plaintext.txt	155	C Western blot analysis OR A OR B rat hypothalamic lysates
0.18766233.15687100.html.plaintext.txt	156	Lane 1 corresponds positive control OR A OR B lane 2 corresponds fed hypothalamus lane 3 corresponds food deprived hypothalamic lysates
0.18766233.15687100.html.plaintext.txt	157	Quantification immunocomplexes revealed significant increase protein expression OR A OR B food deprivation conditions n 6
0.18766233.15687100.html.plaintext.txt	158	Effect Food Deprivation Peptide Receptor Expression Hypothalamus
0.18766233.15687100.html.plaintext.txt	159	Serial dilutions hypothalamic cDNA provided template line best fit plotted used standard curve demonstrate accuracy reproducibility analysis
0.18766233.15687100.html.plaintext.txt	160	Melting curve analysis PCR products presented fluorescence time dFdT temperature T degrees C
0.18766233.15687100.html.plaintext.txt	161	The melting curve analysis showed single melting maximum 89
0.18766233.15687100.html.plaintext.txt	162	20 degrees C prepro orexin gene single melting maximum 90
0.18766233.15687100.html.plaintext.txt	163	30 degrees C actin gene thus confirming product specificity data shown
0.18766233.15687100.html.plaintext.txt	164	There fivefold increase prepro orexin message P 0
0.18766233.15687100.html.plaintext.txt	165	01 hypothalami food deprived animals Fig
0.18766233.15687100.html.plaintext.txt	166	These mRNA changes prepro orexin peptide also confirmed immunoblotting analysis protein expression OR A OR B significantly P 0
0.18766233.15687100.html.plaintext.txt	167	05 respectively increased food deprivation Fig
0.18766233.15687100.html.plaintext.txt	168	Compared controls OXR1 OXR2 mRNA significantly P 0
0.18766233.15687100.html.plaintext.txt	169	05 increased hypothalamus food deprived rat Fig
0.18766233.15687100.html.plaintext.txt	170	The increases similar forms orexin receptors 2
0.18766233.15687100.html.plaintext.txt	171	5 fold increase OX1R 2 fold increase OX2R
0.18766233.15687100.html.plaintext.txt	172	Protein expression OXR1 OXR2 confirmed immunoblotting using specific goat polyclonal antibodies Fig
0.18766233.15687100.html.plaintext.txt	173	The OXR1 antibody raised peptide mapping carboxy terminus OXR1 rat origin whereas OXR2 antibody raised peptide mapping amino terminus OX2R human origin rat cross reactive
0.18766233.15687100.html.plaintext.txt	174	The detected protein OX1R apparent molecular mass 50 kDa whereas OX2R detected 40 kDa peptide
0.18766233.15687100.html.plaintext.txt	175	The specificity response confirmed preincubation OX1R OX2R antibodies blocking peptides Fig
0.18766233.15687100.html.plaintext.txt	176	Protein expression reflected mRNA data Fig
0.18766233.15687100.html.plaintext.txt	177	2A significant increase P 0
0.18766233.15687100.html.plaintext.txt	178	01 receptors food deprived animals Fig
0.18766233.15687100.html.plaintext.txt	179	View larger version 33K Fig
0.18766233.15687100.html.plaintext.txt	180	A significant upregulation OX1R OX2R mRNA levels food deprived hypothalamus n 6 rat compared fed ones n 6 assessed real time PCR
0.18766233.15687100.html.plaintext.txt	181	B Western blot analysis membrane protein extracts rat adrenal lane 3 hypothalamus lane 4 demonstrate antibody orexin 1 receptor OX1R recognized band apparent molecular mass 50 kDa
0.18766233.15687100.html.plaintext.txt	182	Similarly specific OX2R antibody used recognized single band apparent molecular mass 40 kDa
0.18766233.15687100.html.plaintext.txt	183	Both bands appeared specific orexin receptors antibodies preabsorbed respective blocking peptides lanes 1 2 rat adrenal hypothalamus respectively apparent immunodetection
0.18766233.15687100.html.plaintext.txt	184	C Western blot analysis OX1R OX2R hypothalamic membranes fed n 6 food deprived rats n 6
0.18766233.15687100.html.plaintext.txt	185	Quantification immunocomplexes revealed significant increase protein expression orexin receptors food deprivation conditions whereas protein levels housekeeping gene actin appeared unaltered
0.18766233.15687100.html.plaintext.txt	186	Effect Food Deprivation Orexin Receptor Expression Adrenal Cortex
0.18766233.15687100.html.plaintext.txt	187	Interestingly findings adrenal cortex marked contrast observed hypothalamus
0.18766233.15687100.html.plaintext.txt	188	Quantitative analysis PCR products rat adrenal cortex showed OX1R OX2R levels significantly P 0
0.18766233.15687100.html.plaintext.txt	189	01 respectively reduced food deprived animals compared controls Fig
0.18766233.15687100.html.plaintext.txt	190	The decrease profound OX2R 4 fold whereas OX1R demonstrated twofold decrease Fig
0.18766233.15687100.html.plaintext.txt	191	Similarly OX1R OX2R protein levels significantly decreased P 0
0.18766233.15687100.html.plaintext.txt	192	01 respectively adrenal cortex food deprived animals compared controls
0.18766233.15687100.html.plaintext.txt	193	Again decrease pronounced OXR2
0.18766233.15687100.html.plaintext.txt	194	In groups studied protein levels actin remained unaltered Fig
0.18766233.15687100.html.plaintext.txt	195	View larger version 36K Fig
0.18766233.15687100.html.plaintext.txt	196	A significant updownregulation OX1R OX2R mRNA levels food deprived rat adrenal cortex n 6 compared fed adrenals assessed real time PCR
0.18766233.15687100.html.plaintext.txt	197	These changes mRNA expression shown differences amplification efficiency demonstrated delay amplification intercept cycle food deprived cDNAs
0.18766233.15687100.html.plaintext.txt	198	B Western blot analysis OX1R OX2R adrenal membranes fed n 6 food deprived n 6 rats
0.18766233.15687100.html.plaintext.txt	199	Quantification immunocomplexes revealed significant decrease protein expression orexin receptors food deprivation conditions whereas protein levels house keeping gene actin appeared unaltered
0.18766233.15687100.html.plaintext.txt	200	These changes agreement mRNA data
0.18766233.15687100.html.plaintext.txt	201	Incubating membranes cholera toxin resulted incorporation 32PADP ribose two bands 45 47 kDa hypothalamic adrenal membranes
0.18766233.15687100.html.plaintext.txt	202	There apparent differences incorporation probe fed food deprived preparations tissues Fig
0.18766233.15687100.html.plaintext.txt	203	View larger version 25K Fig
0.18766233.15687100.html.plaintext.txt	204	A ADP ribosylation cholera toxin CTx hypothalamic H n 3 adrenal A n 3 membrane Gs subunits
0.18766233.15687100.html.plaintext.txt	205	Both membranes incubated 150 microgml CTx
0.18766233.15687100.html.plaintext.txt	206	After protein precipitation samples denatured applied 12 SDS polyacrylamide gel
0.18766233.15687100.html.plaintext.txt	207	Incorporation label resulted detection 2 bands 45 47 kDa hypothalamic adrenal membranes respectively
0.18766233.15687100.html.plaintext.txt	208	There apparent difference fed food deprived samples
0.18766233.15687100.html.plaintext.txt	209	B ADP ribosylation pertussis toxin PTx hypothalamic n 3 adrenal n 3 membrane Gi subunits
0.18766233.15687100.html.plaintext.txt	210	After protein precipitation samples denatured applied 12 SDS polyacrylamide gel
0.18766233.15687100.html.plaintext.txt	211	Incorporation label resulted detection single band 41 kDa hypothalamic adrenal membranes
0.18766233.15687100.html.plaintext.txt	212	There apparent difference fed food deprived samples
0.18766233.15687100.html.plaintext.txt	213	C autoradiograph OR A induced photolabeling 32PGTP azidoanilide 32PGTP AA Gs subunits rat hypothalamic adrenal membranes
0.18766233.15687100.html.plaintext.txt	214	Membranes incubated 32PGTP AA different concentrations OR A 10 11 10 7M followed UV cross linking immunoprecipitation Gs specific antibody
0.18766233.15687100.html.plaintext.txt	215	Proteins resolved SDS PAGE gels followed autoradiography
0.18766233.15687100.html.plaintext.txt	216	Immunodetected bands quantified scanning densitometric analysis
0.18766233.15687100.html.plaintext.txt	217	Identical results obtained 3 independent experiments means plus minus SD
0.18766233.15687100.html.plaintext.txt	218	Treatment hypothalamic adrenal membranes pertussis toxin resulted incorporation 32PADP ribose single band apparent molecular masses 41 kDa Fig
0.18766233.15687100.html.plaintext.txt	219	No incorporation label seen either hypothalamic adrenal tissues absence pertussis toxin
0.18766233.15687100.html.plaintext.txt	220	Similarly detectable differences fed food deprived Gi subunits
0.18766233.15687100.html.plaintext.txt	221	These data confirm functional integrity G protein subunits also reveal nutritional status interfere expression signaling proteins
0.18766233.15687100.html.plaintext.txt	222	Functional Analysis G Protein Activation OR A Effects Food Deprivation
0.18766233.15687100.html.plaintext.txt	223	To determine G proteins coupled orexin receptors food deprived fed state hypothalamic adrenocortical membranes labeled GTP AA presence absence OR A followed immunoprecipitation specific G subunit antibodies Gs Gi Gq Go
0.18766233.15687100.html.plaintext.txt	224	Optimal labeling G subunits GTP AA requires receptor activation heterotrimeric G proteins release bound GDP
0.18766233.15687100.html.plaintext.txt	225	The binding GTP AA dependent GDP concentration GTP affinity G subunit agonist incubation time 26
0.18766233.15687100.html.plaintext.txt	226	Therefore conditions labeling G subunits established empirically
0.18766233.15687100.html.plaintext.txt	227	We demonstrated optimum labeling obtained presence 5 microm GDP data shown
0.18766233.15687100.html.plaintext.txt	228	OR A induced labeling GTP AA time dependent optimal incubation time 3 min data shown
0.18766233.15687100.html.plaintext.txt	229	Using Gs subunit paradigm able demonstrate coupling orexin receptors upon challenge OR A dose dependent maximal activation concentration 100 nM Fig
0.18766233.15687100.html.plaintext.txt	230	The specificity immunoprecipitating properties Gs antibody assessed comparing migration positions orexin induced GTP AA photoaffinity labeled G proteins ADP ribosylated using 32PNAD cholera toxin demonstrate protein band radiolabeled immunoprecipitated specific antibody
0.18766233.15687100.html.plaintext.txt	231	Surprisingly photoaffinity 32PGTP AA experiment indicated orexin receptors hypothalamus adrenal cortex preferentially activate 45 kDa form Gs protein
0.18766233.15687100.html.plaintext.txt	232	This observation requires investigation
0.18766233.15687100.html.plaintext.txt	233	Treatment hypothalamic membranes OR A 100 nM revealed orexin receptors coupled multiple G proteins including Go Gi Gs lesser extent Gq control group Fig
0.18766233.15687100.html.plaintext.txt	234	In food deprived rats however change profile G protein activation
0.18766233.15687100.html.plaintext.txt	235	Compared controls significant increase coupling orexin receptors Gq Gs Go whereas less coupling orexin receptors Gi Fig
0.18766233.15687100.html.plaintext.txt	236	Quantification immunocomplexes shown Fig
0.18766233.15687100.html.plaintext.txt	237	View larger version 37K Fig
0.18766233.15687100.html.plaintext.txt	238	A autoradiograph agonist induced photolabeling G protein subunits GTP AA
0.18766233.15687100.html.plaintext.txt	239	Hypothalamic adrenal cortex membranes fed rats n 3 group incubated GTP AA OR A 100 nM
0.18766233.15687100.html.plaintext.txt	240	The experiment repeated food deprived rats n 3 group
0.18766233.15687100.html.plaintext.txt	241	After UV cross linking G protein subunits immunoprecipitated specific antisera Gs Gq Gi Go resolved 12 SDS polyacrylamide gels
0.18766233.15687100.html.plaintext.txt	242	Immunodetected bands quantified scanning densitometric analysis
0.18766233.15687100.html.plaintext.txt	243	Data expressed means plus minus SD
0.18766233.15687100.html.plaintext.txt	244	Optical density OD units expressed ratio treated untreated membranes rat hypothalamus B rat adrenal cortex C
0.18766233.15687100.html.plaintext.txt	245	Treatment adrenocortical membranes OR A 100 nM revealed similar promiscuity G protein profile adrenal orexin receptors
0.18766233.15687100.html.plaintext.txt	246	In control group fed rats OR A increased labeling Gs Gq Go Gi Fig
0.18766233.15687100.html.plaintext.txt	247	As hypothalamus food deprivation modulated G protein activation profile
0.18766233.15687100.html.plaintext.txt	248	Interestingly food deprived animal OR A decreased coupling orexin receptors Gs Go increased Gi whereas coupling toward Gq Fig
0.18766233.15687100.html.plaintext.txt	249	Quantification immunocomplexes shown Fig
0.18766233.15687100.html.plaintext.txt	250	Functional Analysis Intracellular Second Messenger Generation OR A Effects Food Deprivation
0.18766233.15687100.html.plaintext.txt	251	In addition G protein data dissected signaling characteristics orexin receptors hypothalamus adrenal cortex measuring second messengers cAMP IP3 controls food deprived animals upon stimulation different concentrations OR A
0.18766233.15687100.html.plaintext.txt	252	To test OR A ability activate hypothalamic adenylyl cyclase determined effect OR A cAMP production
0.18766233.15687100.html.plaintext.txt	253	When hypothalamic membranes fed rats incubated OR A 10 pM 100 nM 30 min 25 degrees C significant increase cAMP production
0.18766233.15687100.html.plaintext.txt	254	This increase found dose dependent whereas maximal response 55 plus minus 5 basal observed concentration 100 nM Fig
0.18766233.15687100.html.plaintext.txt	255	The response amplified food deprived rat 100 nM treatment induced cAMP response 95 plus minus 5 basal Fig
0.18766233.15687100.html.plaintext.txt	256	View larger version 18K Fig
0.18766233.15687100.html.plaintext.txt	257	cAMP A inositol triphosphate IP3 B accumulation rat hypothalamic membranes 100 microg protein presence different concentrations OR A
0.18766233.15687100.html.plaintext.txt	258	Results expressed means plus minus SD 3 independent experiments
0.18766233.15687100.html.plaintext.txt	259	cAMP C IP3 D accumulation rat adrenal cortex membranes 100 microg protein presence different concentrations orexin A
0.18766233.15687100.html.plaintext.txt	260	Results expressed means plus minus SD 3 independent experiments
0.18766233.15687100.html.plaintext.txt	261	control treatments hypothalamus adrenal cortex
0.18766233.15687100.html.plaintext.txt	262	Similarly found OR A treatment hypothalamic membranes induced rapid IP3 turnover dose dependent manner
0.18766233.15687100.html.plaintext.txt	263	This OR A effect threshold 1 nM maximum response 100 nM 30 plus minus 4 basal Fig
0.18766233.15687100.html.plaintext.txt	264	Consistent G protein labeling studies significant P 0
0.18766233.15687100.html.plaintext.txt	265	01 increase IP3 production hypothalami food deprived rats compared controls 70 plus minus 7 basal Fig
0.18766233.15687100.html.plaintext.txt	266	Similarly rat adrenocortical membranes fed rats incubated OR A 0
0.18766233.15687100.html.plaintext.txt	267	01 nM 100 nM significant increase cAMP IP3 production Fig
0.18766233.15687100.html.plaintext.txt	268	These increases appeared dose dependent maximum response 100 nM cAMP 78 plus minus 8 basal 10 nM IP3 50 plus minus 7 basal
0.18766233.15687100.html.plaintext.txt	269	However food deprived animals compared controls treatment adrenocortical membranes OR A induced modest response toward cAMP production significant 100 nM apparent effect toward IP3 turnover Fig
0.18766233.15687100.html.plaintext.txt	270	Again findings keeping photoaffinity labeling experiments
0.18766233.15687100.html.plaintext.txt	271	DISCUSSION TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES In present study demonstrate effects food deprivation 24 h orexins orexin receptor expression rat hypothalamus adrenal cortex mRNA protein levels
0.18766233.15687100.html.plaintext.txt	272	In addition present differential effects stressful nutritional stimulus signaling characteristics orexin receptors tissues
0.18766233.15687100.html.plaintext.txt	273	The hypothalamus plays major role regulation food intake energy balance integrating multiple anorexigenic orexigenic signals including elicited orexins 21 27
0.18766233.15687100.html.plaintext.txt	274	A similar role adrenal gland possible given expresses receptors leptin NPY 28 orexin 19 29 regulators energy homeostasis
0.18766233.15687100.html.plaintext.txt	275	In agreement previous studies 6 15 able show levels prepro orexin mRNA influenced nutritional status upregulated upon fasting hypothalamus
0.18766233.15687100.html.plaintext.txt	276	Detailed analysis protein level confirmed cleaved bioactive peptides OR A OR B upregulated food deprivation
0.18766233.15687100.html.plaintext.txt	277	Previous studies fasted lactating rats demonstrated hypothalamic OR B levels raised 10 fold controls nonfasted whereas OR A showed change 30
0.18766233.15687100.html.plaintext.txt	278	These differences due rodent strain used sex metabolic status duration food deprivation
0.18766233.15687100.html.plaintext.txt	279	Food deprivation leads changes activity HPA axis within 3 h increase corticosterone 3
0.18766233.15687100.html.plaintext.txt	280	These findings interest given orexins stimulate HPA axis administered centrally 31
0.18766233.15687100.html.plaintext.txt	281	Furthermore orexin neurons sensitive nutritional signals insulin glucose alter food deprivation 3 hypothalamic orexin neurons express leptin receptors
0.18766233.15687100.html.plaintext.txt	282	As prepro orexin expression fasting leptin also regulate hypothalamic expression orexin receptors 15 16 32
0.18766233.15687100.html.plaintext.txt	283	Numerous studies mapped detail expression orexin orexin receptors hypothalamic level
0.18766233.15687100.html.plaintext.txt	284	33 demonstrated within hypothalamus OX1R mRNA abundant ventromedial hypothalamic nucleus whereas OX2R predominantly expressed paraventricular nucleus
0.18766233.15687100.html.plaintext.txt	285	In another study shown 20 h fasting levels rat OX1R mRNA significantly increased ventromedial hypothalamic nuclei medial division amygdala whereas levels OX2R mRNA augmented arcuate nucleus remained unchanged dorsomedial hypothalamic nucleus paraventricular hypothalamic nucleus amygdala following fasting 16
0.18766233.15687100.html.plaintext.txt	286	Three different studies 34 13 15 indicated prepro orexin upregulated hypothalamus upon food deprivation lateral hypothalamic area rat
0.18766233.15687100.html.plaintext.txt	287	In agreement studies noted fasting hypothalamic OX1R OX2R gene expression induced
0.18766233.15687100.html.plaintext.txt	288	Given detailed analysis studies provided shifted interest expression protein level
0.18766233.15687100.html.plaintext.txt	289	Here provide new evidence changes also mirrored protein level assessed semiquantitative Western blotting analysis
0.18766233.15687100.html.plaintext.txt	290	Previous studies 3 4 shown food deprivation switches feeding responses adrenocortical responses time food presentation appears potent synchronizer phase plasma corticosteroid levels light dark cycle 35
0.18766233.15687100.html.plaintext.txt	291	These observations interest given orexins circadian dependent actions orexins known increase corticosterone production rats 20 cortisol human adrenocortical cells 36
0.18766233.15687100.html.plaintext.txt	292	However view data conclude adrenal orexin receptors influence mediate rise corticosterone levels seen food deprivation conditions
0.18766233.15687100.html.plaintext.txt	293	It well documented food deprivation induces multiple metabolic changes may directly influence orexin receptor expression adrenal gland
0.18766233.15687100.html.plaintext.txt	294	For example negative correlation testosterone levels fasting 37
0.18766233.15687100.html.plaintext.txt	295	Studies laboratory shown testosterone levels also decrease following 24 h food deprivation unpublished observations
0.18766233.15687100.html.plaintext.txt	296	Interestingly gonadectomized rats significant downregulation adrenal OX2R effect reversed upon testosterone replacement 38
0.18766233.15687100.html.plaintext.txt	297	Although regulation adrenal orexin receptors gonadal steroids directly relevant findings suggests changes orexin receptor expression may secondary phenomenon following initial food deprivation induced alterations
0.18766233.15687100.html.plaintext.txt	298	Future studies concentrate elucidating central peripheral actions orexins
0.18766233.15687100.html.plaintext.txt	299	This done systematically deleting OX1R andor OX2R tissue specific fashion using Cre loxP system
0.18766233.15687100.html.plaintext.txt	300	By use approach model generated bearing neuronal adrenal specific deletions orexin receptors
0.18766233.15687100.html.plaintext.txt	301	Our data indicate orexin signaling may enhanced response energy deficit sensed hypothalamus possibly predominantly via OX1R time decreased adrenal cortex
0.18766233.15687100.html.plaintext.txt	302	Orexins act two distinct G protein coupled receptors transduce intracellular signals activating heterotrimeric G proteins
0.18766233.15687100.html.plaintext.txt	303	It likely multiple second messenger systems involved orexins shown increase intracellular calcium influx 6 39 40 41
0.18766233.15687100.html.plaintext.txt	304	There also suggestion OX2R coupled inhibitory Gi protein 42
0.18766233.15687100.html.plaintext.txt	305	We shown first time native orexin receptors hypothalamus activate four types G proteins namely Gs Gq Go Gi response OR A
0.18766233.15687100.html.plaintext.txt	306	Although Gi Go two major inhibitory signaling pathways rat brain previously shown multiple subtypes G proteins couple G protein coupled receptor systems 43
0.18766233.15687100.html.plaintext.txt	307	Food deprivation altered G protein coupling profile
0.18766233.15687100.html.plaintext.txt	308	Our findings supported functional assays cAMP IP3 assays reflecting G protein coupling status
0.18766233.15687100.html.plaintext.txt	309	Further research needed investigate whether subunits implicated activating second messengers also assess effects OR B G protein signaling
0.18766233.15687100.html.plaintext.txt	310	Although demonstrated functional orexin receptors human fetal adult adrenal glands 23 44 first report G proteins coupling orexin receptors rat adrenal cortex
0.18766233.15687100.html.plaintext.txt	311	Interestingly note downregulation G proteins apart Gi response OR A upon food deprivation
0.18766233.15687100.html.plaintext.txt	312	Second messenger studies confirmed findings minimal response toward cAMP production none IP3 adrenal cortex food deprived rat
0.18766233.15687100.html.plaintext.txt	313	Our findings support observations rat adrenocortical cells OR A stimulates corticosterone release via cAMP pathway 20
0.18766233.15687100.html.plaintext.txt	314	Despite demonstrating first time rat orexin receptors couple differentially several G protein subunits activate multiple second messengers caution exercised interpret changes
0.18766233.15687100.html.plaintext.txt	315	Given plethora different cell types reside within hypothalamus adrenal gland distinctions made specific subpopulations brain regions adrenal zones data
0.18766233.15687100.html.plaintext.txt	316	Here provide evidence signaling characteristics orexin receptors food deprivation total hypothalamic adrenal preparations
0.18766233.15687100.html.plaintext.txt	317	In conclusion study indicates nutritional changes like food deprivation exert differential effects orexin receptor expression signaling characteristics hypothalamic adrenocortical levels
0.18766233.15687100.html.plaintext.txt	318	However significance novel findings particular differential expression G protein activation upon food deprivation hypothalamus adrenal cortex needs elucidation
0.18766233.15687100.html.plaintext.txt	319	GRANTS TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES This work supported Research Grants H
0.18766233.15687100.html.plaintext.txt	320	Randeva The General Charities Coventry The Research Teaching Development Fund University Warwick The Clinical Endocrinology Trust UK
0.18766233.15687100.html.plaintext.txt	321	FOOTNOTES Address reprint requests correspondence E
0.18766233.15687100.html.plaintext.txt	322	Karteris Biomedical Research Institute Univ
0.18766233.15687100.html.plaintext.txt	323	Coventry CV4 7AL UK E mail e
0.18766233.15687100.html.plaintext.txt	324	The costs publication article defrayed part payment page charges
0.18766233.15687100.html.plaintext.txt	325	The article must therefore hereby marked advertisement accordance 18 U
0.18766233.15687100.html.plaintext.txt	326	Section 1734 solely indicate fact
0.18766233.15687100.html.plaintext.txt	327	Machado contributed equally study
0.18766233.15687100.html.plaintext.txt	328	REFERENCES TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES Schwartz MW Dallman MF Woods SC
0.18766233.15687100.html.plaintext.txt	329	The hypothalamus response starvation implications study wasting disorders
0.18766233.15687100.html.plaintext.txt	330	Am J Physiol Regul Integr Comp Physiol 269 R949 R957 1995
0.18766233.15687100.html.plaintext.txt	331	AbstractFree Full Text Akana SF Strack AM Hanson ES Dallman MF
0.18766233.15687100.html.plaintext.txt	332	Regulation activity hypothalamic pituitary adrenal axis integral larger hypothalamic system determines caloric flow
0.18766233.15687100.html.plaintext.txt	333	Endocrinology 135 1125 1134 1994
0.18766233.15687100.html.plaintext.txt	334	Abstract Dallman MF Akana SF Bhatnagar S Bell ME Choi S Chu A Horsley C Levin N Meijer O Soriano LR Strack AM Viau V
0.18766233.15687100.html.plaintext.txt	335	Starvation early signals sensors sequelae
0.18766233.15687100.html.plaintext.txt	336	Endocrinology 140 4015 4023 1999
0.18766233.15687100.html.plaintext.txt	337	AbstractFree Full Text Guillaume V Grino M Conte Devlox B Boudouresque F Oliver C
0.18766233.15687100.html.plaintext.txt	338	Corticotropin releasing factor secretion increases rat hypophyseal portal blood insulin induced hypoglycaemia
0.18766233.15687100.html.plaintext.txt	339	Neuroendocrinology 49 676 679 1989
0.18766233.15687100.html.plaintext.txt	340	ISIMedline Ahima RS Prabakaran D Mantzoros C Qu D Lowell B Maratos Flier E Flier JS
0.18766233.15687100.html.plaintext.txt	341	Role leptin neuroendocrine response fasting
0.18766233.15687100.html.plaintext.txt	342	CrossRefISIMedline Sakurai T Amemiya A Ishii M Matsuzaki I Chemelli RM Tanaka H Williams SC Richardson JA Kozlowski GP Wilson S Arch JR Buckingham RE Haynes AC Carr SA Annan RS McNulty DE Liu WS Terrett JA Elshourbagy NA Bergsma DJ Yanagisawa M
0.18766233.15687100.html.plaintext.txt	343	Orexins orexin receptors family hypothalamic neuropeptides G protein coupled receptors regulate feeding behaviour
0.18766233.15687100.html.plaintext.txt	344	CrossRefISIMedline Kalra SP Dube MG Pu S Xu B Horvath TL Kalra PS
0.18766233.15687100.html.plaintext.txt	345	Interacting appetite regulating pathways hypothalamic regulation body weight
0.18766233.15687100.html.plaintext.txt	346	Endocr Rev 20 68 100 1999
0.18766233.15687100.html.plaintext.txt	347	AbstractFree Full Text Ida T Nakahara K Katayama T Murakami N Nakazato M
0.18766233.15687100.html.plaintext.txt	348	Effect lateral cerebroventricular injection appetite stimulating neuropeptide orexin neurpeptide Y various behavioural aspects rats
0.18766233.15687100.html.plaintext.txt	349	Brain Res 821 526 529 1999
0.18766233.15687100.html.plaintext.txt	350	CrossRefISIMedline Samson WK Gosnell B Chang JK Resch ZT Murphy TC
0.18766233.15687100.html.plaintext.txt	351	Cardiovascular regulatory actions hypocretins brain
0.18766233.15687100.html.plaintext.txt	352	Brain Res 831 248 253 1999
0.18766233.15687100.html.plaintext.txt	353	CrossRefISIMedline Takahashi N Okumura T Yamada H Kohgo Y
0.18766233.15687100.html.plaintext.txt	354	Stimulation gastric acid secretion centrally administered orexin A conscious rats
0.18766233.15687100.html.plaintext.txt	355	Biochem Biophys Res Commun 254 623 627 1999
0.18766233.15687100.html.plaintext.txt	356	CrossRefISIMedline Pu S Jain MR Kalra PS Kalra SP
0.18766233.15687100.html.plaintext.txt	357	Orexins novel family hypothalamic neuropeptides modulate pituitary luteinising hormone secretion ovarian steroid dependent manner
0.18766233.15687100.html.plaintext.txt	358	Regul Pept 78 133 136 1998
0.18766233.15687100.html.plaintext.txt	359	CrossRefISIMedline Lin L Faraco J Li R Kadotani H Rogers W Lin X Qiu X de Jong PJ Nishino S Mignot E
0.18766233.15687100.html.plaintext.txt	360	The sleep disorder canine narcolepsy caused mutation hypocretin orexin receptor 2 gene
0.18766233.15687100.html.plaintext.txt	361	CrossRefISIMedline Cai XJ Widdowson PS Harrold J Wilson S Buckingham RE Arch JR Tadayyon M Clapham JC Wilding J Williams G
0.18766233.15687100.html.plaintext.txt	362	Hypothalamic orexin expression modulation blood glucose feeding
0.18766233.15687100.html.plaintext.txt	363	Diabetes 48 2132 2137 1999
0.18766233.15687100.html.plaintext.txt	364	Abstract Griffond B Risold PY Jacquemard C Colard C Fellman D
0.18766233.15687100.html.plaintext.txt	365	Insulin induced hypoglycaemia increases preprohypocretin orexin mRNA rat lateral hypothalamic area
0.18766233.15687100.html.plaintext.txt	366	Neurosci Lett 262 77 80 1999
0.18766233.15687100.html.plaintext.txt	367	CrossRefISIMedline Lopez M Seoane L Garcia MC Lago F Casanueva FF Senaris R Dieguez C
0.18766233.15687100.html.plaintext.txt	368	Leptin regulation prepro orexin orexin receptor mRNA levels hypothalamus
0.18766233.15687100.html.plaintext.txt	369	Biochem Biophys Res Commun 269 41 45 2000
0.18766233.15687100.html.plaintext.txt	370	CrossRefISIMedline Lu XY Bagnol D Burke S Akil H Watson SJ
0.18766233.15687100.html.plaintext.txt	371	Differential distribution regulation OX1 OX2 orexinhypocretin receptor messenger RNA brain upon fasting
0.18766233.15687100.html.plaintext.txt	372	Horm Behav 37 335 344 2000
0.18766233.15687100.html.plaintext.txt	373	CrossRefISIMedline Bornstein SR Uhlmann K Haidan A Ehrhart Bornstein M Scherbaum WA
0.18766233.15687100.html.plaintext.txt	374	Evidence novel peripheral action leptin metabolic signal adrenal gland
0.18766233.15687100.html.plaintext.txt	375	Leptin inhibits cortisol release directly
0.18766233.15687100.html.plaintext.txt	376	Diabetes 46 1235 1238 1997
0.18766233.15687100.html.plaintext.txt	377	Abstract Nussdorfer GG Gottardo G
0.18766233.15687100.html.plaintext.txt	378	Neuropeptide Y family peptides autocrine regulation adrenocortical function
0.18766233.15687100.html.plaintext.txt	379	Horm Metab Res 30 368 373 1998
0.18766233.15687100.html.plaintext.txt	380	ISIMedline Johren O Neidert SJ Kummer M Dendorfer A Dominiak P
0.18766233.15687100.html.plaintext.txt	381	Prepro orexin orexin receptor mRNAs differentially expressed peripheral tissues male female rats
0.18766233.15687100.html.plaintext.txt	382	Endocrinology 142 3324 3331 2001
0.18766233.15687100.html.plaintext.txt	383	AbstractFree Full Text Malendowicz LK Tortorella C Nussdorfer GG
0.18766233.15687100.html.plaintext.txt	384	Orexins stimulate corticosterone secretion rat adrenocortical cells activation adenylate cyclase dependent signaling cascade
0.18766233.15687100.html.plaintext.txt	385	J Steroid Biochem Mol Biol 70 185 188 1999
0.18766233.15687100.html.plaintext.txt	386	CrossRefISIMedline Lubkin M Stricker Krongrad A
0.18766233.15687100.html.plaintext.txt	387	Independent feeding metabolic actions orexins mice
0.18766233.15687100.html.plaintext.txt	388	Biochem Biophys Res Commun 253 241 245 1998
0.18766233.15687100.html.plaintext.txt	389	CrossRefISIMedline Pfaffl MW
0.18766233.15687100.html.plaintext.txt	390	A new mathematical model relative quantification real time RT PCR
0.18766233.15687100.html.plaintext.txt	391	Nucleic Acids Res 1 e45 2000
0.18766233.15687100.html.plaintext.txt	392	CrossRef Smith PK Krohn RI Hermanson GT Mallia AK Gartner FH Provenzano MD Fujimoto EK Goeke NM Olson BJ Klenk DC
0.18766233.15687100.html.plaintext.txt	393	Measurement protein using bicinchoninic acid
0.18766233.15687100.html.plaintext.txt	394	Anal Biochem 15076 85 1985
0.18766233.15687100.html.plaintext.txt	395	CrossRefISIMedline Randeva HS Karteris E Grammatopoulos D Hillhouse EW
0.18766233.15687100.html.plaintext.txt	396	Expression orexin A functional orexin type 2 receptors human adult adrenals implications adrenal function energy homeostasis
0.18766233.15687100.html.plaintext.txt	397	J Clin Endocrinol Metab 86 4808 4813 2001
0.18766233.15687100.html.plaintext.txt	398	AbstractFree Full Text Karteris E Papadopoulou N Grammatopoulos DK Hillhouse EW
0.18766233.15687100.html.plaintext.txt	399	Expression signalling characteristics corticotrophin releasing hormone receptors implantation phase human endometrium
0.18766233.15687100.html.plaintext.txt	400	J Mol Endocrinol 32 21 32 2004
0.18766233.15687100.html.plaintext.txt	401	AbstractFree Full Text Offermanns S Schultz G Rosenthal W
0.18766233.15687100.html.plaintext.txt	402	Identification receptor activated G proteins photoreactive GTP analog alpha 32PGTP azidoanilide
0.18766233.15687100.html.plaintext.txt	403	Methods Enzymol 195 286 301 1991
0.18766233.15687100.html.plaintext.txt	404	ISIMedline Balasko M Szelenyi Z Szekely M
0.18766233.15687100.html.plaintext.txt	405	Central thermoregulatory effects neuropeptide Y orexin A rats
0.18766233.15687100.html.plaintext.txt	406	Acta Physiol Hung 86 219 222 1999
0.18766233.15687100.html.plaintext.txt	407	Medline Cao GY Considine RV Lynn RB
0.18766233.15687100.html.plaintext.txt	408	Leptin receptors adrenal medulla rat
0.18766233.15687100.html.plaintext.txt	409	Am J Physiol Endocrinol Metab 273 E448 E452 1997
0.18766233.15687100.html.plaintext.txt	410	AbstractFree Full Text Nanmoku T Isobe K Sakurai T Yamanaka A Takekoshi K Kawakami Y Ishii K Goto K Nakai T
0.18766233.15687100.html.plaintext.txt	411	Orexins suppress catecholamine synthesis secretion cultured PC12 cells
0.18766233.15687100.html.plaintext.txt	412	Biochem Biophys Res Commun 274 310 315 2000
0.18766233.15687100.html.plaintext.txt	413	CrossRefISIMedline Cai XJ Denis R Vernon RG Clapham JC Wilson S Arch JR Williams G
0.18766233.15687100.html.plaintext.txt	414	Food restriction selectively increases hypothalamic orexin B levels lactating rats
0.18766233.15687100.html.plaintext.txt	415	Regul Pept 97 163 168 2001
0.18766233.15687100.html.plaintext.txt	416	CrossRefISIMedline Kuru M Ueta Y Serino R Nakazato M Yamamoto Y Shibuya I Yamashita H
0.18766233.15687100.html.plaintext.txt	417	Centrally administered orexinhypocretin activates HPA axis rats
0.18766233.15687100.html.plaintext.txt	418	Neuroreport 11 1977 1980 2000
0.18766233.15687100.html.plaintext.txt	419	ISIMedline Yamanaka A Beuckmann CT Willie JT Hara J Tsujino N Mieda M Tominaga M Yagami K Sugiyama F Goto K Yanagisawa M Sakurai T
0.18766233.15687100.html.plaintext.txt	420	Hypothalamic orexin neurons regulate arousal according energy balance mice
0.18766233.15687100.html.plaintext.txt	421	CrossRefISIMedline Trivedi P Yu H MacNeil DJ Van der Ploeg LH Guan XM
0.18766233.15687100.html.plaintext.txt	422	Distribution orexin receptor mRNA rat brain
0.18766233.15687100.html.plaintext.txt	423	CrossRefISIMedline Lopez M Seoane L Senaris RM Dieguez C
0.18766233.15687100.html.plaintext.txt	424	Prepro orexin mRNA levels rat hypothalamus orexin receptors mRNA levels rat hypothalamus adrenal gland influenced thyroid status
0.18766233.15687100.html.plaintext.txt	425	Neurosci Lett 300 171 175 2001
0.18766233.15687100.html.plaintext.txt	426	CrossRefISIMedline Krieger DT Hauser H
0.18766233.15687100.html.plaintext.txt	427	Comparison synchronisation circadian corticosteroid rhythms photoperiod food
0.18766233.15687100.html.plaintext.txt	428	Proc Natl Acad Sci USA 75 1577 1581 1978
0.18766233.15687100.html.plaintext.txt	429	Abstract Mazzocchi G Malendowicz LK Gottardo L Aragona F Nussdorfer GG
0.18766233.15687100.html.plaintext.txt	430	Orexin A stimulates cortisol secretion human adrenocortical cells activation adenylate cyclase dependent signaling cascade
0.18766233.15687100.html.plaintext.txt	431	J Clin Endocrinol Metab 86 778 782 2001
0.18766233.15687100.html.plaintext.txt	432	AbstractFree Full Text Bergendahl M Perheentupa A Huhtaniemi I
0.18766233.15687100.html.plaintext.txt	433	Effect short term starvation reproductive hormone gene expression secretion receptor levels male rats
0.18766233.15687100.html.plaintext.txt	434	J Endocrinol 121 409 417 1989
0.18766233.15687100.html.plaintext.txt	435	Abstract Johren O Bruggemann N Dendorfer A Dominiak P
0.18766233.15687100.html.plaintext.txt	436	Gonadal steroids differentially regulate messenger ribonucleic acid expression pituitary orexin type 1 receptors adrenal orexin type 2 receptors
0.18766233.15687100.html.plaintext.txt	437	Endocrinology 144 1219 1225 2003
0.18766233.15687100.html.plaintext.txt	438	AbstractFree Full Text Eriksson KS Sergeeva O Brown RE Haas HL
0.18766233.15687100.html.plaintext.txt	439	Orexinhypocretin excites histaminergic neurons tuberomammillary nucleus
0.18766233.15687100.html.plaintext.txt	440	J Neurosci 21 9273 9279 2001
0.18766233.15687100.html.plaintext.txt	441	AbstractFree Full Text Lund PE Shariatmadari R Uustare A Detheux M Parmentier M Kukkonen JP Akerman KE
0.18766233.15687100.html.plaintext.txt	442	The orexin OX1 receptor activates novel Ca2 influx pathway necessary coupling phospholipase C
0.18766233.15687100.html.plaintext.txt	443	J Biol Chem 275 30806 30812 2000
0.18766233.15687100.html.plaintext.txt	444	AbstractFree Full Text Van den Pol AN Gao XB Obrietan K Kilduff TS Belousov AB
0.18766233.15687100.html.plaintext.txt	445	Presynaptic postsynaptic actions modulation neuroendocrine neurons new hypothalamic peptide hypocretinorexin
0.18766233.15687100.html.plaintext.txt	446	J Neurosci 18 7962 7971 1998
0.18766233.15687100.html.plaintext.txt	447	AbstractFree Full Text Martin G Fabre V Siggins GR de Lecea L
0.18766233.15687100.html.plaintext.txt	448	Interaction hypocretins neurotransmitters nucleus accumbens
0.18766233.15687100.html.plaintext.txt	449	Regul Pept 104 111 117 2002
0.18766233.15687100.html.plaintext.txt	450	CrossRefISIMedline Grammatopoulos DK Randeva HS Levine MA Kanellopoulou KA Hillhouse EW
0.18766233.15687100.html.plaintext.txt	451	Rat cerebral cortex corticotropin releasing hormone receptors evidence receptor coupling multiple G proteins
0.18766233.15687100.html.plaintext.txt	452	J Neurochem 2 509 519 2001
0.18766233.15687100.html.plaintext.txt	453	Karteris E Randeva HS Grammatopoulos DK Jaffe RB Hillhouse EW
0.18766233.15687100.html.plaintext.txt	454	Expression coupling characteristics CRH orexin type 2 receptors human fetal adrenals
0.18766233.15687100.html.plaintext.txt	455	J Clin Endocrinol Metab 86 4512 4519 2001
0.18766233.15687100.html.plaintext.txt	456	AbstractFree Full Text This Article Abstract Full Text PDF All Versions Article 2886E1089 recent 00351
0.18766233.15687100.html.plaintext.txt	457	2004v1 Alert article cited Alert correction posted Citation Map Services Email article friend Similar articles journal Similar articles ISI Web Science Similar articles PubMed Alert new issues journal Download citation manager Search citing articles ISI Web Science 3 Google Scholar Articles Karteris E
0.18766233.15687100.html.plaintext.txt	458	Articles citing Article PubMed PubMed Citation Articles Karteris E
0.18766233.15687100.html.plaintext.txt	459	HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS Visit Other APS Journals Online Copyright 2005 American Physiological Society
0.103533715.11181518.html.plaintext.txt	0	Immediate Prolonged Patterns Agouti Related Peptide 83 132 Induced c Fos Activation Hypothalamic Extrahypothalamic Sites1 Mary M
0.103533715.11181518.html.plaintext.txt	1	University Alabama Birmingham Alabama 35294 1170 Department Psychiatry University Cincinnati Medical Center S
0.103533715.11181518.html.plaintext.txt	2	Address correspondence requests reprints Mary M
0.103533715.11181518.html.plaintext.txt	3	415 Campbell Hall Department Psychology University Alabama Birmingham Alabama 35294 1170
0.103533715.11181518.html.plaintext.txt	4	Abstract Top Abstract Introduction Materials Methods Results Discussion References Several lines evidence substantiate important role central nervous system melanocortin 3 4 receptor MC34 R system control food intake energy balance
0.103533715.11181518.html.plaintext.txt	5	Agouti related peptide AgRP endogenous antagonist receptors produces robust unique pattern increased food intake lasts 7 days single injection
0.103533715.11181518.html.plaintext.txt	6	Little known brain regions may mediate powerful effect AgRP food intake
0.103533715.11181518.html.plaintext.txt	7	To end compared c Fos like immunoreactivity c FLI several brain sites rats injected intracerebroventricularly 1 nmol AgRP 83 132 2 24 h death compared c FLI patterns induced another potent orexigenic peptide neuropeptide Y NPY
0.103533715.11181518.html.plaintext.txt	8	Although NPY AgRP induced c FLI hypothalamic areas AgRP also produced increased c FLI accumbens shell lateral septum
0.103533715.11181518.html.plaintext.txt	9	Although NPY elicited changes c FLI 24 h administration AgRP induced c FLI accumbens shell nucleus solitary tract central amygdala lateral hypothalamus
0.103533715.11181518.html.plaintext.txt	10	These results indicate NPY like hypothalamic circuit mediates short term effects AgRP unique sustained effect AgRP food intake involves complex circuit key extrahypothalamic reward feeding regulatory nuclei
0.103533715.11181518.html.plaintext.txt	11	Introduction Top Abstract Introduction Materials Methods Results Discussion References MUCH EVIDENCE establishes central melanocortin MC system important regulator food intake energy balance 1 2 3 4 5
0.103533715.11181518.html.plaintext.txt	12	The endogenous melanocortin MSH binds MC3 MC4 receptors MC34 R agonist actions limit food intake
0.103533715.11181518.html.plaintext.txt	13	Central injection MSH 6 7 synthetic agonists 1 8 9 10 reduces feeding
0.103533715.11181518.html.plaintext.txt	14	MSH appears critical regard blockade endogenous MSH using synthetic MC34 R antagonist SHU9119 reverses natural hypophagia animals overfed gain weight 2 SHU9119 potently stimulates feeding sated animals 1 9
0.103533715.11181518.html.plaintext.txt	15	Interestingly endogenous antagonist MC34 R termed Agouti related peptide AgRP
0.103533715.11181518.html.plaintext.txt	16	AgRP synthesized exclusively arcuate nucleus hypothalamus projecting hypothalamic extrahypothalamic sites 11 12 13
0.103533715.11181518.html.plaintext.txt	17	Central administration fragment AgRP 83 132 14 increases food intake 15
0.103533715.11181518.html.plaintext.txt	18	States energy deficiency increase AgRP expression 16 17 transgenic mice overexpressing AgRP hyperphagic obese 18
0.103533715.11181518.html.plaintext.txt	19	We recently found AgRP 83 132 induces long lasting increase food intake 168 h single third ventricular injection 100 pmol rats
0.103533715.11181518.html.plaintext.txt	20	AgRP short term hyperphagia involves competitive MC34 R antagonism whereas persistent effects engage alternate yet unknown mechanisms 19 20
0.103533715.11181518.html.plaintext.txt	21	Our goal study begin elucidate central nervous system CNS circuits subserve AgRP potent remarkably sustained increase food intake
0.103533715.11181518.html.plaintext.txt	22	We measured changes neuronal activation induced AgRP using immunohistochemistry protein associated immediate early gene c fos 21
0.103533715.11181518.html.plaintext.txt	23	We compared areas activated AgRP 2 h administration areas activated full 24 h administration
0.103533715.11181518.html.plaintext.txt	24	Additionally compared pattern AgRP induced neuronal activation elicited another potent stimulator food intake neuropeptide Y NPY
0.103533715.11181518.html.plaintext.txt	25	Given NPY extensively colocalized AgRP 16 22 hypothesis two peptides might engage similar circuits short term
0.103533715.11181518.html.plaintext.txt	26	However given NPY stimulate intake long periods like AgRP hypothesized circuits engaged NPY AgRP would different 24 h
0.103533715.11181518.html.plaintext.txt	27	Materials Methods Top Abstract Introduction Materials Methods Results Discussion References Animals housing Male Long Evans rats 350 390 g time surgery maintained individual cages 12 h light 12 h dark cycle lights 1300 h implanted cannula aimed third cerebral ventricle i3vt
0.103533715.11181518.html.plaintext.txt	28	2 mm posterior bregma 7
0.103533715.11181518.html.plaintext.txt	29	A minimum 10 day recovery period followed confirmation cannula placement i3vt infusion 10 ng angiotensin II saline
0.103533715.11181518.html.plaintext.txt	30	Only animals drinking excess 5 ml 1 h AII infusion included study n 26
0.103533715.11181518.html.plaintext.txt	31	This protocol approved University Cincinnati animal care committee
0.103533715.11181518.html.plaintext.txt	32	Peptide infusions The animals assigned six groups matched body weight baseline food intake infused 1
0.103533715.11181518.html.plaintext.txt	33	0 nmol AgRP 83 132 gift Merck Co
0.103533715.11181518.html.plaintext.txt	34	Rahway NJ purchased Phoenix Pharmaceuticals Inc
0.103533715.11181518.html.plaintext.txt	35	Mountain View CA 5 microg NPY American Peptide Co
0.103533715.11181518.html.plaintext.txt	36	Sunnyvale CA physiological saline vehicle equal volume 2 microl
0.103533715.11181518.html.plaintext.txt	37	Groups infused AgRP NPY saline killed 2 h 2 h 24 h 24 h injection
0.103533715.11181518.html.plaintext.txt	38	The possibility feeding could influence AgRP induced c Fos like immunoreactivity c FLI patterns minimized removing food period 6 h time death animals killed 2 24 h periods
0.103533715.11181518.html.plaintext.txt	39	Although cannot completely rule possible influence AgRP induced food intake c FLI patterns rats killed 24 h injection 18 h access food removed 6 h feeding effect unlikely feeding induced Fos patterns observed others 24 differed observed AgRP
0.103533715.11181518.html.plaintext.txt	40	The selected doses NPY AgRP lie within ranges elicit similar magnitude increased food intake 2 h injected intraventricularly rats 15 19 25
0.103533715.11181518.html.plaintext.txt	41	Water available times
0.103533715.11181518.html.plaintext.txt	42	In counterbalanced order drug received rats infused 0900 1100 h killed either 2 24 h later corresponding minute infusion
0.103533715.11181518.html.plaintext.txt	43	Tissue processing c Fos like immunohistochemistry At time death animals anesthetized 60 mgkg sodium pentobarbital intracardially infused 0
0.103533715.11181518.html.plaintext.txt	44	Brains postfixed least 4 h stored 30 sucrose PBS minimum 2 weeks
0.103533715.11181518.html.plaintext.txt	45	Forebrains frozen sectioned 40 microm thickness coronal plane hindbrains sectioned horizontal plane visualize sites interest
0.103533715.11181518.html.plaintext.txt	46	For 12 sites examined one section selected representing plane care taken closely match plane across rats
0.103533715.11181518.html.plaintext.txt	47	The sections chosen experimenter blind group treatments
0.103533715.11181518.html.plaintext.txt	48	The procedure followed sections taken 24 h injection
0.103533715.11181518.html.plaintext.txt	49	With exception two rats contributing sections forebrain regions 24 h NPY condition sections taken total three rats 2 h saline four rats 24 h saline three rats 2 h NPY four rats 24 h NPY four rats 2 h AgRP five rats 24 h AgRP condition
0.103533715.11181518.html.plaintext.txt	50	Immunohistochemical procedures conducted quantified previously described 8
0.103533715.11181518.html.plaintext.txt	51	Bilateral sections quantified brain site interest except accumbens shell counted unilaterally
0.103533715.11181518.html.plaintext.txt	52	Neuroanatomical boundaries 23 given Table 1
0.103533715.11181518.html.plaintext.txt	53	Rat atlas coordinates Bregma millimeters centermost area neuroanatomical sites quantified c Fos like immunoreactivity 23
0.103533715.11181518.html.plaintext.txt	54	Comparisons time points conducted two time points differed proximity injection procedure
0.103533715.11181518.html.plaintext.txt	55	Rather compared time point saline injected control determine changes c FLI associated treatment
0.103533715.11181518.html.plaintext.txt	56	Therefore data analyzed one way ANOVAs specifically examine differences treatment groups saline vs
0.103533715.11181518.html.plaintext.txt	57	AgRP injected brain site time point 2 24 h postinfusion
0.103533715.11181518.html.plaintext.txt	58	Significant main effects analyzed using either Bonferroni least significant difference post hoc tests significance set P 0
0.103533715.11181518.html.plaintext.txt	59	Results Top Abstract Introduction Materials Methods Results Discussion References Distribution comparison c Fos like immunoreactivity induced 2 h NPY AgRP infusions As depicted Fig
0.103533715.11181518.html.plaintext.txt	60	1A saline induced c FLI notable hypothalamic regions
0.103533715.11181518.html.plaintext.txt	61	Increased NPY induced c FLI relative saline occurred caudal accumbens shell lateral septum paraventricular nucleus hypothalamus PVN dorsal region dorsomedial nucleus DMN nucleus solitary tract NTS commissural NTS c FLI 300 590 460 240 1500 360 saline induced levels respectively Fig
0.103533715.11181518.html.plaintext.txt	62	However PVN NPY induced c FLI statistically different saline induced levels
0.103533715.11181518.html.plaintext.txt	63	AgRP elicited similar c FLI pattern NPY Table 2 except AgRP elicited higher c FLI rostral accumbens shell DMN 300 180 greater NPY induced c FLI respectively lower c FLI NPY commissural NTS NTS proper
0.103533715.11181518.html.plaintext.txt	64	The statistically significant differences NPY AgRP provoked c FLI occurred commissural NTS Fig
0.103533715.11181518.html.plaintext.txt	65	Comparisons NPY AgRP induced c FLI could made amygdala lateral hypothalamus due artifact slicing process disrupted morphological integrity sections prevented accurate orientation sites match taken brains
0.103533715.11181518.html.plaintext.txt	66	Previous studies led us predict NPY like AgRP would evoke increased c FLI expression areas 26 27
0.103533715.11181518.html.plaintext.txt	67	Representative examples c FLI expression saline NPY AgRP treated animals 2 h injection depicted Fig
0.103533715.11181518.html.plaintext.txt	68	View larger version 27K Figure 1
0.103533715.11181518.html.plaintext.txt	69	Mean c Fos like immunoreactive nuclei brain sites rats injected third ventricle saline NPY AgRP 2 h death A 24 h death B
0.103533715.11181518.html.plaintext.txt	70	Different saline P 0
0.103533715.11181518.html.plaintext.txt	71	001 marginally different saline d P 0
0.103533715.11181518.html.plaintext.txt	72	057 different NPY e P 0
0.103533715.11181518.html.plaintext.txt	73	In B NPY induced c FLI included area numbers saline treated levels
0.103533715.11181518.html.plaintext.txt	74	Density distribution central AgRP NPY induced c FLI relative saline induced expression 2 24 h postinfusion
0.103533715.11181518.html.plaintext.txt	75	View larger version 124K Figure 2
0.103533715.11181518.html.plaintext.txt	76	Representative photomicrographs illustrating c Fos like immunoreactive cells 2 h injection saline left column NPY middle column AgRP right column caudal accumbens shell A paraventricular nucleus B dorsal region DMN C hypothalamus
0.103533715.11181518.html.plaintext.txt	77	Surrounding structures aca anterior area anterior commissure ACC nucleus accumbens core AH central region anterior hypothalamus 3vt third cerebroventricle
0.103533715.11181518.html.plaintext.txt	78	Magnification images x10
0.103533715.11181518.html.plaintext.txt	79	Distribution comparison c Fos like immunoreactivity induced 24 h NPY AgRP infusions Patterns c FLI observed 2 h NPY injection reverted saline like levels 24 h injection
0.103533715.11181518.html.plaintext.txt	80	However AgRP injection elicited sustained elevations c FLI several brain sites Table 2
0.103533715.11181518.html.plaintext.txt	81	In fact c FLI rostral caudal accumbens shell lateral septum central amygdala basolateral amygdala lateral hypothalamus NTS greater delayed time point shortly AgRP injection Table 2
0.103533715.11181518.html.plaintext.txt	82	1B c FLI rostral caudal accumbens shell remained elevated 24 h 1550 2400 control value respectively albeit lesser degree observed 2 h point
0.103533715.11181518.html.plaintext.txt	83	c FLI NTS considerably elevated 426 control value compared c FLI expression 2 h whereas significant c FLI changes observed central amygdala lateral hypothalamus 2 h AgRP 24 h areas displayed 14 128 fold increased c FLI saline treatment respectively
0.103533715.11181518.html.plaintext.txt	84	Representative brain regions depicting salient c FLI differences AgRP saline treatment 24 h injection presented Fig
0.103533715.11181518.html.plaintext.txt	85	View larger version 85K Figure 3
0.103533715.11181518.html.plaintext.txt	86	Representative photomicrographs illustrating c Fos like immunoreactive cells 24 h injection saline left column AgRP right column caudal accumbens shell A central amygdala B lateral hypothalamus C nucleus solitary tract D
0.103533715.11181518.html.plaintext.txt	87	Surrounding structures aca anterior area anterior commissure ACC nucleus accumbens core 4vt fourth cerebroventricle
0.103533715.11181518.html.plaintext.txt	88	Magnification images x10
0.103533715.11181518.html.plaintext.txt	89	Discussion Top Abstract Introduction Materials Methods Results Discussion References AgRP distinct naturally occurring antagonist brain binding MC34 R presumably inhibit melanocortin ligand MSH 4 18
0.103533715.11181518.html.plaintext.txt	90	Also unique AgRP ability stimulate food intake rats prolonged interval 7 days single central picomolar dose 19
0.103533715.11181518.html.plaintext.txt	91	We observed whereas acute increase intake seen AgRP involves intrinsic action MC34 R sustained hyperphagia relies alternate unique mechanisms 19
0.103533715.11181518.html.plaintext.txt	92	The present study conducted begin elucidating CNS mechanisms engaged AgRP mediate effect food intake
0.103533715.11181518.html.plaintext.txt	93	c FLI used identify neuroanatomical sites activated acutely 24 h AgRP
0.103533715.11181518.html.plaintext.txt	94	Two hours AgRP injection time point reflecting acute induction food intake largest c FLI response occurred hypothalamic PVN DMN accumbens shell lateral septum outside hypothalamus
0.103533715.11181518.html.plaintext.txt	95	In PVN DMN sites dense MC34 R 28 c FLI probably due competitive binding MC34 R
0.103533715.11181518.html.plaintext.txt	96	PVN injection MTII MC34 R agonist suppresses intake fasted rats effect reversible SHU9119 MC34 R antagonist 29
0.103533715.11181518.html.plaintext.txt	97	AgRP acts inhibitory manner decreasing MSH induced cAMP activation 4 11 15 MC34 R agonists potentiate aminobutyric acid GABA mediated inhibition postsynaptic PVN neurons 29
0.103533715.11181518.html.plaintext.txt	98	Because c FLI induced transcriptional level extracellular stimulation inhibition 21 c FLI observed PVN may reflect AgRP inhibition GABA release PVN neurons inhibitory signals
0.103533715.11181518.html.plaintext.txt	99	To understand AgRP actions compared c FLI pattern induced NPY
0.103533715.11181518.html.plaintext.txt	100	Both peptides induce potent hyperphagia animals 5 30 31 extensively coexpressed colocalized arcuate nucleus 16 22
0.103533715.11181518.html.plaintext.txt	101	AgRP NPY activated common neuroanatomical targets 2 h infusion including ACSh lateral septum PVN anterior hypothalamic area DMN NTS
0.103533715.11181518.html.plaintext.txt	102	The largest c FLI response occurred PVN AgRP NPY
0.103533715.11181518.html.plaintext.txt	103	The PVN critical regulating energy intake metabolism NPY mediates many actions 31 32
0.103533715.11181518.html.plaintext.txt	104	The colocalization density NPY melanocortin receptors PVN 28 suggest AgRP like NPY perhaps concert NPY prominent role control energy homeostasis
0.103533715.11181518.html.plaintext.txt	105	The DMN also high levels c FLI AgRP NPY injection
0.103533715.11181518.html.plaintext.txt	106	Morphologically linked PVN DMN also important energy regulation 33
0.103533715.11181518.html.plaintext.txt	107	DMN lesioned rats hypophagic 33 high level NPY expression specifically DMN associated obesity MC4 R deficient mice 34
0.103533715.11181518.html.plaintext.txt	108	Given NPY AgRP impact activity DMN current results implicate DMN one area NPY AgRP may interact coordinating response negative energy balance
0.103533715.11181518.html.plaintext.txt	109	Like AgRP NPY also inhibitory peptide stimulation receptors promotes inhibition adenylate cyclase 35
0.103533715.11181518.html.plaintext.txt	110	Hence expression c FLI observed NPY injection nuclei probably reflects NPY inhibition catabolic signals produced peptides known interact NPY leptin MSH 1 17 29
0.103533715.11181518.html.plaintext.txt	111	Outside hypothalamus AgRP evoked c FLI accumbens shell lateral septum
0.103533715.11181518.html.plaintext.txt	112	Similar c FLI increases observed lateral septum lateral ventricular injection NDP MSH MC34 R agonist 36
0.103533715.11181518.html.plaintext.txt	113	The nucleus accumbens contains MC4 R AgRP containing fibers whereas lateral septum moderately innervated AgRP fibers 22
0.103533715.11181518.html.plaintext.txt	114	The accumbens shell innervated viscero endocrine circuits integrates reward signals lateral hypothalamus food intake 37
0.103533715.11181518.html.plaintext.txt	115	The accumbens largely innervated GABA neurons enkephalin terminals abundant shell 38
0.103533715.11181518.html.plaintext.txt	116	Inhibition accumbens shell neurons GABA agonists elicits powerful lateral hypothalamus stimulation like feeding response 37
0.103533715.11181518.html.plaintext.txt	117	The lateral hypothalamus also nonsignificant 8 fold increases c FLI AgRP relative saline treatment
0.103533715.11181518.html.plaintext.txt	118	It tempting speculate AgRP may activate opioid reward regulatory circuit elicits feeding possibly via interaction MC34 R may inhibit accumbens GABA neurons proposed AgRP action PVN 29
0.103533715.11181518.html.plaintext.txt	119	Consistent observation NPY induced hyperphagia suppressed opioid antagonist 39 recently found opioid antagonist suppresses hyperphagia induced injection AgRP 40
0.103533715.11181518.html.plaintext.txt	120	Activation accumbens opioid system however one potential mediator AgRP hyperphagia
0.103533715.11181518.html.plaintext.txt	121	In hindbrain NPY AgRP increased c FLI NTS
0.103533715.11181518.html.plaintext.txt	122	Others reported increased c FLI medial areas NTS fourth ventricular injection NPY absence food 41 neuronal activation NTS generally associated feeding 27 41
0.103533715.11181518.html.plaintext.txt	123	Although powerful tool c FLI data limited cannot describe neurochemical phenotype neurons activated critical connections nuclei affect feeding
0.103533715.11181518.html.plaintext.txt	124	Fos data also limited cannot identify neurons inhibited treatment
0.103533715.11181518.html.plaintext.txt	125	Furthermore absence c FLI expression nuclei mean activated brain cells express c FLI stimulated
0.103533715.11181518.html.plaintext.txt	126	Therefore future dual labeling studies warranted identify neurochemical phenotype activated neurons example serotonin glutamate dopamine possible candidates accumbens shell neurons 37 38
0.103533715.11181518.html.plaintext.txt	127	Another limitation current study ventricular injection expected distribute NPY AgRP pattern identical endogenous secretion peptides
0.103533715.11181518.html.plaintext.txt	128	Hence data indicate circuits recruited peptides rather determine exactly ones engaged endogenous secretion
0.103533715.11181518.html.plaintext.txt	129	Complementary studies using peptide injection discrete sites help determine neuroanatomical origin observed effect c FLI expression possibly elucidate divergent patterns
0.103533715.11181518.html.plaintext.txt	130	As AgRP produces hyperphagia long 7 days injection 20 also future interest observe whether c FLI patterns produced AgRP beyond 24 h injection recapitulated different patterns observed 24 h injection
0.103533715.11181518.html.plaintext.txt	131	The intriguing aspect AgRP effect behavior ability stimulate increased intake 7 days single picomolar injection 19 behavior observed NPY
0.103533715.11181518.html.plaintext.txt	132	Based previous data suggesting mechanisms competitive binding MC34 R mediate AgRP long term effects 19 discovery AgRP elicits hyperphagia MC4 R deficient mice 42 hypothesized AgRP would recruit additional neuroanatomical substrates 24 h injection
0.103533715.11181518.html.plaintext.txt	133	At site examined c FLI increased 24 h NPY injection
0.103533715.11181518.html.plaintext.txt	134	However extended CNS actions AgRP evident increased c FLI 10 12 sites studied compared saline treatment
0.103533715.11181518.html.plaintext.txt	135	Accumbens shell activation even greater observed 2 h whereas activity PVN anterior hypothalamus dorsomedial nucleus decreased returned control levels
0.103533715.11181518.html.plaintext.txt	136	Nonsignificant c FLI elevations central amygdala lateral hypothalamus NTS 2 h became significant 24 h
0.103533715.11181518.html.plaintext.txt	137	It unlikely AgRP stimulated feeding 6 h fast induced patterns others found opposite patterns c Fos expression dorsomedial nucleus NTS response ingestion 24
0.103533715.11181518.html.plaintext.txt	138	A functional link accumbens shell lateral hypothalamus control feeding well established 37 43
0.103533715.11181518.html.plaintext.txt	139	Both accumbens lateral hypothalamus innervated functionally interconnected amygdala 44
0.103533715.11181518.html.plaintext.txt	140	The central amygdala key role integrating food intake learned hedonic emotional inputs 45 46
0.103533715.11181518.html.plaintext.txt	141	Projections central amygdala NTS 44 47 implicated control food intake 48 49
0.103533715.11181518.html.plaintext.txt	142	In summary strong c FLI expression evoked AgRP ACSh lateral hypothalamus central amygdala NTS 24 h injection suggests nuclei form functional circuit AgRP may mediate long lasting changes food intake
0.103533715.11181518.html.plaintext.txt	143	These long lasting orexigenic effects may involve modulation release expression orexigenic peptides localized within nuclei hypocretin melanin concentrating hormone
0.103533715.11181518.html.plaintext.txt	144	AgRP may stimulate hypocretin release contained lateral hypothalamus surrounded AgRP containing cell bodies 22 elicits extrahypothalamic c FLI pattern similar induced AgRP injected lateral hypothalamus 49
0.103533715.11181518.html.plaintext.txt	145	AgRP may similar effects melanin concentrating hormone also contained lateral hypothalamus expressed extrahypothalamic sites c Fos reactive AgRP 50
0.103533715.11181518.html.plaintext.txt	146	AgRP may also induce transcriptional changes leading altered synaptic efficacy hypothalamic extrahypothalamic proteins involved regulation energy balance
0.103533715.11181518.html.plaintext.txt	147	Depletion organism caloric stores results strong behavioral changes find ingest calories
0.103533715.11181518.html.plaintext.txt	148	Consistent survival function AgRP elicits long lasting effect increase food intake acute pharmacological manipulation CNS
0.103533715.11181518.html.plaintext.txt	149	AgRP apparently accomplishes recruitment anatomical sites inside outside hypothalamus sites integrate relay gustatory sensory reward properties food
0.103533715.11181518.html.plaintext.txt	150	Footnotes 1 This work supported several grants NIH DK 54080 DK 54890 DK 17844
0.103533715.11181518.html.plaintext.txt	151	References Top Abstract Introduction Materials Methods Results Discussion References Fan W Boston B Kesterson R Hruby V Cone R 1997 Role melanocortinergic neurons feeding agouti obesity syndrome
0.103533715.11181518.html.plaintext.txt	152	Nature 385165 168CrossRefMedline Hagan M Rushing P Schwartz M Yagaloff K Burn P Woods S Seeley R 1999 Role CNS melanocortin system response overfeeding
0.103533715.11181518.html.plaintext.txt	153	J Neurosci 192362 2367AbstractFree Full Text Huszar D Lynch C Fairchild Huntress V Dunmore JH Fang Q Berkemeier LR Gu W Kesterson RA Boston BA Cone RD Smith FJ Campfield LA Burn P Lee F 1997 Targeted disruption melanocortin 4 receptor results obesity mice
0.103533715.11181518.html.plaintext.txt	154	Cell 88131 141CrossRefMedline Ollmann M Wilson B Yang Y Kerns J Chen Y Gantz I Barsh G 1997 Antagonism central melanocortin receptors vitro vivo agouti related protein
0.103533715.11181518.html.plaintext.txt	155	Science 278135 138AbstractFree Full Text Seeley R Yagaloff K Fisher S Burn P Thiele T van DG Baskin D Schwartz M 1997 Melanocortin receptors leptin effects
0.103533715.11181518.html.plaintext.txt	156	Nature 390349CrossRefMedline Poggioli R Vergoni AV Bertolini A 1986 ACTH 1 24 alpha MSH antagonize feeding behavior stimulated opiate agonists
0.103533715.11181518.html.plaintext.txt	157	Peptides 7843 848CrossRefMedline Tsujii S Bray GA 1989 Acetylation alters feeding response MSH endorphin
0.103533715.11181518.html.plaintext.txt	158	Brain Res Bull 23165 169CrossRefMedline Benoit SC Schwartz MW Lachey JL Hagan MM Rushing PA Blake KA Yagaloff KA Kurylko G Franco L Danhoo W Seeley RJ 2000 A novel selective melanocortin 4 receptor agonist reduces food intake rats mice without producing aversive consequences
0.103533715.11181518.html.plaintext.txt	159	J Neurosci 203442 3448AbstractFree Full Text Grill HJ Ginsberg AB Seeley RJ Kaplan JM 1998 Brainstem application melanocortin receptor ligands produces long lasting effects feeding body weight
0.103533715.11181518.html.plaintext.txt	160	J Neurosci 1810128 10135AbstractFree Full Text Thiele T van DG Yagaloff K Fisher S Schwartz M Burn P Seeley R 1998 Central infusion melanocortin agonist MTII rats assessment c Fos expression taste aversion
0.103533715.11181518.html.plaintext.txt	161	Am J Physiol 274R248 R254 Lu D Willard D Patel I Kadwell S Overton L Kost T Luther M Chen W Woychik R Wilkison W Cone RD 1994 Agouti protein antagonist melanocyte stimulating hormone receptor
0.103533715.11181518.html.plaintext.txt	162	Nature 371799 802CrossRefMedline Bagnol T Lu XY Kaelin CB Day HE Ollmann M Gantz I Akil H Barsh GS Watson SJ 1999 The anatomy endogenous antagonist relationship agouti related protein proopiomelanocortin brain
0.103533715.11181518.html.plaintext.txt	163	J Neurosci 19RC26 Haskell Luevano C Chen P Li C Chang K Smith MS Cameron JL Cone RD 1999 Characterization neuroanatomical distribution agouti related protein immunoreactivity rhesus monkey rat
0.103533715.11181518.html.plaintext.txt	164	Endocrinology 1401408 1415AbstractFree Full Text Quillan JM Sadee W Wei ET Jimenez C Ji L Chang JK 1998 A synthetic human Agouti related protein 83 132 NH2 fragment potent inhibitor melanocortin receptor function
0.103533715.11181518.html.plaintext.txt	165	FEBS Lett 42859 62CrossRefMedline Rossi M Kim M Morgan D Small C Edwards C Sunter D Abusnana S Goldstone A Russell S Stanley S Smith D Yagaloff K Ghatei M Bloom S 1998 A C terminal fragment Agouti related protein increases feeding antagonizes effect melanocyte stimulating hormone vivo
0.103533715.11181518.html.plaintext.txt	166	Endocrinology 1394428 4431AbstractFree Full Text Hahn TM Breininger JF Baskin DG Schwartz MW 1998 Coexpression Agrp NPY fasting activated hypothalamic neurons
0.103533715.11181518.html.plaintext.txt	167	Nat Neurosci 1271 272CrossRefMedline Mizuno TM Mobbs CV 1999 Hypothalamic agouti related protein messenger ribonucleic acid inhibited leptin stimulated fasting
0.103533715.11181518.html.plaintext.txt	168	Endocrinology 140814 817AbstractFree Full Text Graham M Shutter JR Sarmiento U Sarosi I Stark KL 1997 Overexpression Agrt leads obesity transgenic mice
0.103533715.11181518.html.plaintext.txt	169	Nat Genet 17273 275Medline Hagan MM Rushing PA Pritchard LM Schwartz MW Strack AM Van der Ploeg HT Woods SC Seeley RJ 2000 Long term orexigenic effects AgRP83 132 involve mechanisms melanocortin receptor blockade
0.103533715.11181518.html.plaintext.txt	170	Am J Physiol 279R47 R52 Marsh D Hollopeter G Huszar D Laufer R Yagaloff K Fisher S Burn P Palmiter R 1999 Response melanocortin 4 receptor deficient mice anorectic orexigenic peptides
0.103533715.11181518.html.plaintext.txt	171	Nat Genet 21119 122CrossRefMedline Sheng M Greenberg ME 1990 The regulation function c fos immediate early genes nervous system
0.103533715.11181518.html.plaintext.txt	172	Neuron 4477 485Medline Broberger C Johansen J Johansson C Schalling M Hokfelt T 1998 The neuropeptide Yagouti gene related protein AGRP brain circuitry normal anorectic monosodium glutamate treated mice
0.103533715.11181518.html.plaintext.txt	173	Proc Natl Acad Sci USA 9515043 15048AbstractFree Full Text Paxinos G Watson C 1986 The Rat Brain Stereotaxic Coordinates Ed 2
0.103533715.11181518.html.plaintext.txt	174	Academic Press Orlando Emond MH Weingarten HP 1995 Fos like immunoreactivity vagal hypoglossal nuclei different feeding states quantitative study
0.103533715.11181518.html.plaintext.txt	175	Physiol Behav 58459 465CrossRefMedline Clark JT Kalra PS Crowley WR Kalra SP 1984 Neuropeptide Y human pancreatic polypeptide stimulate feeding behavior rats
0.103533715.11181518.html.plaintext.txt	176	Endocrinology 115427 429Abstract Lambert PD Phillips PJ Wilding JPH Bloom SR Herbert J 1995 c fos expression paraventricular nucleus hypothalamus following intracerebroventricular infusions neuropeptide Y
0.103533715.11181518.html.plaintext.txt	177	Brain Res 67059 65CrossRefMedline Pomonis JD Levine AS Billington CJ 1997 Interaction hypothalamic paraventricular nucleus central nucleus amygdala naloxone blockade neuropeptide Y induced feeding revealed c fos expression
0.103533715.11181518.html.plaintext.txt	178	J Neurosci 175175 5182AbstractFree Full Text Mountjoy K Mortrud M Low M Simerly R Cone R 1994 Localization melanocortin 4 receptor MC4 R neuroendocrine autonomic control circuits brain
0.103533715.11181518.html.plaintext.txt	179	Mol Endocrinol 81298 1308Abstract Cowley MA Pronchuk N Fan W Dinulescu DM Colmers WF Cone RD 1999 Integration NPY AGRP melanocortin signals hypothalamic paraventricular nucleus evidence cellular basis adipostat
0.103533715.11181518.html.plaintext.txt	180	Neuron 24155 163CrossRefMedline Giraudo SQ Billington CJ Levine AS 1998 Feeding effects hypothalamic injection melanocortin 4 receptor ligands
0.103533715.11181518.html.plaintext.txt	181	Brain Res 809302 306CrossRefMedline Stanley BG 1993 Neuropeptide Y multiple hypothalamic sites controls eating behavior endocrine autonomic systems energy balance
0.103533715.11181518.html.plaintext.txt	182	In Colmers WF Wahlestedt C eds The Biology Neuropeptide Y Related Peptides
0.103533715.11181518.html.plaintext.txt	183	Humana Press Totowa pp 457 509 Billington CJ Briggs JE Harker S Grace M Levine AS 1994 Neuropeptide Y hypothalamic paraventricular nucleus center coordinating energy metabolism
0.103533715.11181518.html.plaintext.txt	184	Am J Physiol 266R1765 R1770 Bellinger LL Bernardis LL 1999 Effect dorsomedial hypothalamic nuclei knife cuts ingestive behavior
0.103533715.11181518.html.plaintext.txt	185	Am J Physiol 276R1772 R1779 Kesterson R Huszar D Lynch C Simerly R Cone R 1997 Induction neuropeptide Y gene expression dorsal medial hypothalamic nucleus two models agouti obesity syndrome
0.103533715.11181518.html.plaintext.txt	186	Mol Endocrinol 11630 739AbstractFree Full Text Harfstrand A Fredholm B Fuxe K 1987 Inhibitory effects neuropeptide Y cyclic AMP accumulation slices nucleus tractus solitarius region rat
0.103533715.11181518.html.plaintext.txt	187	Neurosci Lett 76185 190CrossRefMedline Brown KS Gentry RM Rowland NE 1998 Central injection rats melanocyte stimulating hormone analog effects food intake brain Fos
0.103533715.11181518.html.plaintext.txt	188	Regul Pept 7889 94CrossRefMedline Stratford TR Kelley AE 1999 Evidence functional relationship nucleus accumbens shell lateral hypothalamus subserving control feeding behavior
0.103533715.11181518.html.plaintext.txt	189	J Neurosci 1911040 11048AbstractFree Full Text Meredith GE 1999 The synaptic framework chemical signaling nucleus accumbens
0.103533715.11181518.html.plaintext.txt	190	Ann NY Acad Sci 877140 156AbstractFree Full Text Levine AS Grace M Billington CJ 1990 The effect centrally administered naloxone deprivation drug induced feeding
0.103533715.11181518.html.plaintext.txt	191	Pharmacol Biochem Behav 36409 412CrossRefMedline Hagan MM Rushing PA Benoit SC Woods SC Seeley RJ Opioid receptor involvement effect AgRP83 132 food intake food selection
0.103533715.11181518.html.plaintext.txt	192	Am J Physiol press Xu B Li B H Rowland NE Kalra SP 1995 Neuropeptide Y injection fourth cerebroventricle stimulates c Fos expression paraventricular nucleus nuclei forebrain effect food consumption
0.103533715.11181518.html.plaintext.txt	193	Brain Res 698227 231CrossRefMedline Marsh DJ Miura GI Yagaloff KA Schwartz MW Barsh GS R DP 1999 Effects neuropeptide Y deficiency hypothalamic agouti related protein expression responsiveness melanocortin analogues
0.103533715.11181518.html.plaintext.txt	194	Brain Res 84866 77CrossRefMedline Kelley AE 1999a Functional specificity ventral striatal compartments appetitive behaviors
0.103533715.11181518.html.plaintext.txt	195	Ann NY Acad Sci 87771 90 Zahm DS Jensen SL Williams ES Martin JRI 1999 Direct comparison projections central amygdaloid nucleus accumbens shell
0.103533715.11181518.html.plaintext.txt	196	Eur J Neurosci 111119 1126CrossRefMedline Glass MJ Billington CJ Levine AS 1999 Opioids food intake distributed functional neuronal pathways Neuropeptides 33360 368CrossRefMedline Roozendaal B Oldenbeurger WP Strubbe JH Koolhaas JM Bohus B 1990 The central amygdala involved conditioned meal induced cephalic insulin response rat
0.103533715.11181518.html.plaintext.txt	197	Neurosci Lett 116210 215CrossRefMedline Halsell CB 1998 Differential distribution amygdoloid input across rostral solitary nucleus subdivisions rat
0.103533715.11181518.html.plaintext.txt	198	Ann NY Acad Sci 855482 485AbstractFree Full Text Giraudo SQ Kotz CM Billington CJ Levine AS 1998 Association amygdala nucleus solitary tract micro opioid induced feeding rat
0.103533715.11181518.html.plaintext.txt	199	Brain Res 802184 185CrossRefMedline Mullett MA Billington CJ Levine AS Kotz CM 2000 Hypocretin I lateral hypothalamus activates key feeding regulatory brain sites motivation emotion feeding drinking
0.103533715.11181518.html.plaintext.txt	200	Neuroreport 11103 108Medline Bittencourt JC Presse F Arias C Peto C Vaughan J Nahon JL Vale W Sawchenco PE 1992 The melanin concentrating hormone system rat brain immuno hybridization histochemical characterization
0.103533715.11181518.html.plaintext.txt	201	J Comp Neurol 319218 245CrossRefMedline
0.119480975.15905320.html.plaintext.txt	0	Sex Difference Response Melanin Concentrating Hormone Neurons Lateral Hypothalamic Area Glucose Revealed Expression Phosphorylated Cyclic Adenosine 35 Monophosphate Response Element Binding Protein Kazutaka Mogi Toshiya Funabashi Dai Mitsushima Hiroko Hagiwara Fukuko Kimura
0.119480975.15905320.html.plaintext.txt	1	Department Neuroendocrinology K
0.119480975.15905320.html.plaintext.txt	2	Yokohama City University Graduate School Medicine Kanazawa ku Yokohama 236 0004 International University Health Welfare F
0.119480975.15905320.html.plaintext.txt	3	Amity Nogizaka Minamiaoyama Minato ku Tokyo 107 0062 Japan
0.119480975.15905320.html.plaintext.txt	4	Address correspondence requests reprints Dr
0.119480975.15905320.html.plaintext.txt	5	Toshiya Funabashi Department Neuroendocrinology Yokohama City University Graduate School Medicine 3 9 Fukuura Kanazawa ku Yokohama 236 0004 Japan
0.119480975.15905320.html.plaintext.txt	6	Abstract Top Abstract Introduction Materials Methods Results Discussion References Because sex differences feeding behavior rats looked possible sex difference response glucose melanin concentrating hormone MCH neurons lateral hypothalamic area using phosphorylated cAMP response element binding protein pCREB marker neural activity
0.119480975.15905320.html.plaintext.txt	7	Intact male rats female rats diestrus 2 proestrus estrus fed normally fasted 48 h injected saline glucose 400 mgkg
0.119480975.15905320.html.plaintext.txt	8	Thereafter preparations subjected immunohistochemical processing double staining MCH pCREB
0.119480975.15905320.html.plaintext.txt	9	Fasting increased ratio MCH neurons pCREB double stained cells male female rats
0.119480975.15905320.html.plaintext.txt	10	In fasted rats glucose injection decreased ratio double stained cells promptly females males
0.119480975.15905320.html.plaintext.txt	11	The magnitude decrease caused glucose greater proestrus estrus diestrus 2
0.119480975.15905320.html.plaintext.txt	12	Gonadectomy males enhanced females attenuated response MCH neurons glucose
0.119480975.15905320.html.plaintext.txt	13	Testosterone estrogen replacement males females respectively restored response MCH neurons glucose
0.119480975.15905320.html.plaintext.txt	14	The demonstrated sex differences response MCH neurons glucose correlated well gonadal steroid milieu thus MCH neurons may play important role sex differences feeding behavior
0.119480975.15905320.html.plaintext.txt	15	Introduction Top Abstract Introduction Materials Methods Results Discussion References SEX DIFFERENCES IN feeding behavior long recognized many species
0.119480975.15905320.html.plaintext.txt	16	For example analyses spontaneous patterns feeding shown size single meal smaller females males total volume daily food intake also smaller females males 1 2
0.119480975.15905320.html.plaintext.txt	17	In addition size single meal varies estrous cycle decreasing around time ovulation females including humans 1 3 4
0.119480975.15905320.html.plaintext.txt	18	Although sex differences attributable gonadal steroid hormones testosterone andor estrogen 5 6 7 8 9 neural mechanism still unclear
0.119480975.15905320.html.plaintext.txt	19	For example although cholecystokinin reported involved estrogen induced decrease food intake 10 still controversy whether cholecystokinin mediates estrogen induced anorexia 11 12
0.119480975.15905320.html.plaintext.txt	20	It also known whether cholecystokinin mediates testosterone induced hyperphagia
0.119480975.15905320.html.plaintext.txt	21	Recent studies identified distinct neurons lateral hypothalamic area LHA containing melanin concentrating hormone MCH neurons 13 generate hunger 14 15
0.119480975.15905320.html.plaintext.txt	22	Neuropeptide Y NPY produced neurons arcuate nucleus hypothalamus 16 another neuropeptide prominently induces feeding 17 18
0.119480975.15905320.html.plaintext.txt	23	The hypothalamic circuit LHA arcuate nucleus thus important component central system controlling feeding behavior 19
0.119480975.15905320.html.plaintext.txt	24	In circuit judging studies genetically disrupted orexigenic neuropeptides MCH neurons LHA play key role
0.119480975.15905320.html.plaintext.txt	25	Mice lacking gene encoding MCH lean 20 whereas mice overexpressing MCH gene susceptible obesity 21
0.119480975.15905320.html.plaintext.txt	26	It also suggested MCH neurons involved glucosensing system hypothalamic MCH mRNA levels increased hypoglycemic conditions fasting insulin injection 2 deoxy D glucose treatment 14 22 23
0.119480975.15905320.html.plaintext.txt	27	In contrast MCH mice lacking gene encoding prepro orexin NPY display normal growth 24 25 26
0.119480975.15905320.html.plaintext.txt	28	It probable sex differences feeding behavior least part attributable sex differences neurons involved feeding behavior
0.119480975.15905320.html.plaintext.txt	29	Because MCH neurons LHA play important role regulation feeding behavior hypothesized might sex difference activity MCH neurons LHA fasting andor glucose injection
0.119480975.15905320.html.plaintext.txt	30	In support view hypothalamic MCH neurons suggested involved estrogen induced weight loss male rats 27
0.119480975.15905320.html.plaintext.txt	31	We therefore examined response MCH neurons iv injection glucose 48 h fasting adult male female rats using expression phosphorylated cAMP response element binding protein pCREB immunoreactivity marker neural activity
0.119480975.15905320.html.plaintext.txt	32	On assumption sex difference MCH neurons existed also examined whether could affected gonadal steroid hormones testosterone andor estrogen
0.119480975.15905320.html.plaintext.txt	33	In present study used pCREB marker neural activity increased generally used c Fos increase expression c Fos needs transcription andor translation occur 28 takes long time see changes would difficult examine acute changes response glucose
0.119480975.15905320.html.plaintext.txt	34	In contrast CREB constitutively expressed transcription factor immediately activated phosphorylation via cAMP calcium dependent cascade 29 30
0.119480975.15905320.html.plaintext.txt	35	Thus thought pCREB suitable marker examine neural activity changes within short period response dynamic changes blood glucose concentrations
0.119480975.15905320.html.plaintext.txt	36	Materials Methods Top Abstract Introduction Materials Methods Results Discussion References Animals Adult male female Wistar rats Charles River Laboratories Yokohama Japan maintained constant temperature 24 26 C controlled lighting conditions lights 0500 1900 h food water available ad libitum
0.119480975.15905320.html.plaintext.txt	37	Daily vaginal smears taken female rats exhibiting two consecutive 4 d estrous cycles used experiments 1 2
0.119480975.15905320.html.plaintext.txt	38	Forty eight hours saline glucose injection silicone cannula iv injection implanted right atrium rats ether anesthesia
0.119480975.15905320.html.plaintext.txt	39	This procedure interfere estrous cycle
0.119480975.15905320.html.plaintext.txt	40	The number rats used group indicated figures
0.119480975.15905320.html.plaintext.txt	41	All animal housing surgical procedures accord guidelines laid institutional animal care use committee Yokohama City University School Medicine
0.119480975.15905320.html.plaintext.txt	42	Determination blood glucose insulin concentrations To determine changes blood glucose insulin concentrations glucose injection 400 mgkg intact males orchidectomized ORX males females proestrus diestrus 2 ovariectomized OVX females implanted silicone cannula right atrium ether anesthesia
0.119480975.15905320.html.plaintext.txt	43	Male female rats castrated 4 wk experiment
0.119480975.15905320.html.plaintext.txt	44	After cannula implantation fasted 48 h injected 400 mgkg glucose dissolved 200 microl saline first blood sampling 100 microl
0.119480975.15905320.html.plaintext.txt	45	Control rats injected volume saline
0.119480975.15905320.html.plaintext.txt	46	Thereafter blood sampled 5 10 15 30 60 120 min injection though cannula
0.119480975.15905320.html.plaintext.txt	47	An equal volume heparinized saline 2 IUml injected sampling
0.119480975.15905320.html.plaintext.txt	48	As another control blood samples obtained intact males ORX males females proestrus OVX females fasted
0.119480975.15905320.html.plaintext.txt	49	Blood glucose concentrations determined instant blood glucose assay apparatus ACCU CHEK Comfort Roche Tokyo Japan
0.119480975.15905320.html.plaintext.txt	50	Serum insulin concentrations measured ELISA kit Morinaga Institute Biological Sciences Yokohama Japan
0.119480975.15905320.html.plaintext.txt	51	Experiment 1 sex difference activity MCH neurons To determine whether sex difference activity MCH neurons male female rats fed normally injected iv 200 microl saline FedSaline group male female rats fasted 48 h given iv injection 200 microl saline FastSaline group glucose FastGlucose group 400 mgkg dissolved 200 microl saline 1000 1200 h
0.119480975.15905320.html.plaintext.txt	52	The injection made silicon cannula right atrium described
0.119480975.15905320.html.plaintext.txt	53	The dose glucose used present study based previous study showed treatment could reverse inhibition pulsatile LH secretion caused insulin induced hypoglycemia 31
0.119480975.15905320.html.plaintext.txt	54	For females three groups composed rats diestrus 2 D2 group proestrus P group estrus E group prepared check effect stage estrous cycle
0.119480975.15905320.html.plaintext.txt	55	The rats D2 group fasted day estrus P group fasted day last diestrus 1 E group fasted day last diestrus 2
0.119480975.15905320.html.plaintext.txt	56	Thus 12 groups rats four groups containing three treatment groups prepared processed blindly immunohistochemistry
0.119480975.15905320.html.plaintext.txt	57	In groups rats killed 5 min saline glucose injection iv injection overdose pentobarbital 100 mgkg
0.119480975.15905320.html.plaintext.txt	58	Perfusion cardiac ventricle quickly started 2 paraformaldehyde 4 acrolein phosphate buffer PB pH 7
0.119480975.15905320.html.plaintext.txt	59	After perfusion brains removed cranium fixed overnight 4 C PB containing 2 paraformaldehyde incubated overnight 4 C 30 sucrose PB
0.119480975.15905320.html.plaintext.txt	60	The brains frozen powdered dry ice stored 70 C immunohistochemical processing
0.119480975.15905320.html.plaintext.txt	61	Experiment 2 time dependent changes activity MCH neurons glucose injection To examine time dependent changes activity MCH neurons iv glucose injection male rats fasted 48 h injected iv glucose 400 mgkg dissolved 200 microl saline 1000 1200 h
0.119480975.15905320.html.plaintext.txt	62	Rats killed 15 30 60 min glucose injection FastGlucose 15 min group FastGlucose 30 min group FastGlucose 60 min group iv injection overdose pentobarbital
0.119480975.15905320.html.plaintext.txt	63	Female rats diestrus 2 fasted 48 h day estrus similarly killed
0.119480975.15905320.html.plaintext.txt	64	All subsequent procedures obtain brains described experiment 1
0.119480975.15905320.html.plaintext.txt	65	Experiment 3 effects testosterone estrogen response MCH neurons glucose To determine whether gonadal steroid hormones affected response MCH neurons glucose male female rats castrated ether anesthesia used experiment 4 wk later
0.119480975.15905320.html.plaintext.txt	66	ORX OVX rats implanted sc silicone tube inside diameter 2
0.119480975.15905320.html.plaintext.txt	67	0 mm length 30 mm containing 100 testosterone crystals ORXT group OVXT group silicone tube inside diameter 2
0.119480975.15905320.html.plaintext.txt	68	0 mm length 15 mm containing 20 17ss estradiol crystals ORXE2 group OVXE2 group silicone tube inside diameter 2
0.119480975.15905320.html.plaintext.txt	69	0 mm length 30 mm containing cholesterol alone ORX group OVX group control
0.119480975.15905320.html.plaintext.txt	70	All silicone tubes previously soaked saline 24 h facilitate rapid hormone release
0.119480975.15905320.html.plaintext.txt	71	It shown previously tube containing dose 17ss estradiol produced serum 17ss estradiol concentration equivalent observed proestrus intact female rats 32 tube containing testosterone produced serum testosterone concentration equivalent observed intact male rats 33
0.119480975.15905320.html.plaintext.txt	72	After implantation tubes rats fed normally rats fasted 48 h
0.119480975.15905320.html.plaintext.txt	73	Normally fed rats injected iv 200 microl saline FedSaline group fasted rats injected iv 200 microl saline FastSaline group glucose FastGlucose group 400 mgkg dissolved 200 microl saline 1000 1200 h
0.119480975.15905320.html.plaintext.txt	74	All rats killed 5 min iv injection
0.119480975.15905320.html.plaintext.txt	75	Thus total 18 groups rats six groups containing three treatment groups ORX ORXT ORXE2 OVX OVXT OVXE2 groups x FedSaline FastSaline FastGlucose groups prepared
0.119480975.15905320.html.plaintext.txt	76	All subsequent procedures obtain brains described experiment 1
0.119480975.15905320.html.plaintext.txt	77	Immunohistochemistry Thirty micrometer frozen coronal sections cut Bright cryostat Jencons Ltd
0.119480975.15905320.html.plaintext.txt	78	Leighton Buzzard UK every fourth section used study
0.119480975.15905320.html.plaintext.txt	79	The sections incubated 1 sodium borohydride PBS 0
0.119480975.15905320.html.plaintext.txt	80	They incubated overnight rabbit polyclonal antibody pCREB diluted 1900 Cell Signaling Technology Beverly MA PBS containing 1
0.119480975.15905320.html.plaintext.txt	81	The next day incubated biotinylated antirabbit IgG diluted 1200 PBS containing 1
0.119480975.15905320.html.plaintext.txt	82	05 Triton X 100 thereafter incubated streptavidin biotin peroxidase complex Vectastain Elite ABC Kit Vector Laboratories Inc
0.119480975.15905320.html.plaintext.txt	83	Bound peroxidase visualized incubating sections 30 min 0
0.119480975.15905320.html.plaintext.txt	84	05 33 diaminobenzidine H2O2
0.119480975.15905320.html.plaintext.txt	85	For double staining sections incubated overnight rabbit polyclonal antibody MCH diluted 11800 Phoenix Pharmaceuticals Belmont CA PBS containing 1
0.119480975.15905320.html.plaintext.txt	86	They additionally incubated biotinylated antirabbit IgG diluted 1200 PBS containing 1
0.119480975.15905320.html.plaintext.txt	87	05 Triton X 100 Cy3 labeled streptavidin Amersham Biosciences Little Chalfont UK
0.119480975.15905320.html.plaintext.txt	88	Finally mounted glass slides dehydrated graded alcohol cleared xylene coverslipped Permount Fisher Scientific Fairlawn NJ
0.119480975.15905320.html.plaintext.txt	89	A total eight series immunohistochemical procedures performed incubation time 33 diaminobenzidine staining experimental conditions checked carefully reproducibility
0.119480975.15905320.html.plaintext.txt	90	Histological analysis The counting performed investigator blind experimental conditions expectations
0.119480975.15905320.html.plaintext.txt	91	We initially used every fourth section LHA thus approximately 10 sectionsrat stained MCH pCREB antibodies
0.119480975.15905320.html.plaintext.txt	92	Using fluorescence microscope five sections per rat finally selected counting MCH immunoreactive cells MCH neurons pCREB immunoreactive cells pCREB cells dorsolateral hypothalamic group LHA distribution MCH neurons varies anterior posterior diencepalon group LHA comprises numerically predominant grouping MCH expressing cells diencephalon 13
0.119480975.15905320.html.plaintext.txt	93	Sections carefully matched across animals experimental groups
0.119480975.15905320.html.plaintext.txt	94	The number MCH neurons LHA square region 1
0.119480975.15905320.html.plaintext.txt	95	0 mm counted bilaterally fluorescence microscope 20 x 10 magnification
0.119480975.15905320.html.plaintext.txt	96	MCH cells nucleus clearly visible surrounded fluorescent cytoplasmic staining counted
0.119480975.15905320.html.plaintext.txt	97	In sections pCREB cells also observed number MCH neurons expressing pCREB immunoreactive nuclei double stained neurons Fig
0.119480975.15905320.html.plaintext.txt	98	Cells defined double stained MCH pCREB blue black nucleus surrounded fluorescent cytoplasm 20 x 10 magnification
0.119480975.15905320.html.plaintext.txt	99	Then average ratio percentage number double stained neurons number MCH neurons rat calculated
0.119480975.15905320.html.plaintext.txt	100	Both average number MCH neurons per section rat average percentage double stained neurons per section rat used statistical analysis
0.119480975.15905320.html.plaintext.txt	101	In male rats female rats P group experiment 1 counted number pCREB cells LHA
0.119480975.15905320.html.plaintext.txt	102	View larger version 96K FIG
0.119480975.15905320.html.plaintext.txt	103	Representative photographs double stained neurons LHA
0.119480975.15905320.html.plaintext.txt	104	Fluorescent MCH immunoreactive neurons top arrowheads pCREB immunoreactive nuclei bottom arrowheads tissue section magnification x400 FastSaline group left panels FastGlucose group right panels male female P rats experiment 1 shown
0.119480975.15905320.html.plaintext.txt	105	Data analyzed one way ANOVA followed Fisher protected least significant difference post hoc test comparisons treatment groups animal group
0.119480975.15905320.html.plaintext.txt	106	Differences considered significant P 0
0.119480975.15905320.html.plaintext.txt	107	Results Top Abstract Introduction Materials Methods Results Discussion References In control
0.119480975.15905320.html.plaintext.txt	108	fasted intact males ORX males females proestrus OVX females blood glucose insulin levels 103
0.119480975.15905320.html.plaintext.txt	109	5 mgdl n 4 1273 plus minus 54 pgml 107
0.119480975.15905320.html.plaintext.txt	110	4 n 5 mgdl 1433 plus minus 121 pgml 101
0.119480975.15905320.html.plaintext.txt	111	4 mgdl n 4 1306 plus minus 113 pgml 105
0.119480975.15905320.html.plaintext.txt	112	7 mgdl n 4 1323 plus minus 143 pgml respectively
0.119480975.15905320.html.plaintext.txt	113	No significant differences glucose F313 0
0.119480975.15905320.html.plaintext.txt	114	As shown Table 1 one way ANOVA saline injected group showed significant effect saline injection blood glucose concentrations male group F621 0
0.119480975.15905320.html.plaintext.txt	115	1 OVX group F628 2
0.119480975.15905320.html.plaintext.txt	116	05 suggesting control procedure used present study affect blood glucose concentrations
0.119480975.15905320.html.plaintext.txt	117	However blood glucose concentrations significantly increased glucose injection groups
0.119480975.15905320.html.plaintext.txt	118	One way ANOVA time point showed significant difference blood glucose concentrations among groups Table 2
0.119480975.15905320.html.plaintext.txt	119	In addition area curve AUC calculated rat significantly different among groups F419 0
0.119480975.15905320.html.plaintext.txt	120	This suggests changes blood glucose concentrations glucose injection uniform among groups
0.119480975.15905320.html.plaintext.txt	121	Insulin concentrations also significantly increased glucose injection groups one way ANOVA time point showed significant difference insulin concentrations among groups Table 2
0.119480975.15905320.html.plaintext.txt	122	That insulin concentrations intact male ORX groups significantly higher D2 P OVX groups time points glucose injection
0.119480975.15905320.html.plaintext.txt	123	In fact AUC insulin significantly different among groups F419 9
0.119480975.15905320.html.plaintext.txt	124	Post hoc comparison showed AUC intact male ORX groups significantly greater D2 P OVX groups P 0
0.119480975.15905320.html.plaintext.txt	125	This result suggested insulin secretion response glucose male rats greater female rats good accord previous reports sex difference glucose tolerance 34 35
0.119480975.15905320.html.plaintext.txt	126	Changes blood glucose concentrations milligrams per deciliter saline injection
0.119480975.15905320.html.plaintext.txt	127	Changes blood glucose insulin concentrations 400 mgkg glucose injection
0.119480975.15905320.html.plaintext.txt	128	In rats overall distribution MCH neurons red fluorescent cytoplasm good accord previous report 13 experiments
0.119480975.15905320.html.plaintext.txt	129	The average number MCH neurons per section approximately 500 groups number vary experiment data shown
0.119480975.15905320.html.plaintext.txt	130	In intact male P groups number pCREB expressing cells slightly larger MCH neurons expressing pCREB Table 3 changes number pCREB cells similar MCH neurons expressing pCREB indicated
0.119480975.15905320.html.plaintext.txt	131	These results suggest MCH neurons population cells expressing pCREB LHA
0.119480975.15905320.html.plaintext.txt	132	Changes number pCREB expressing cells lateral hypothalamic area male rats female rats proestrus
0.119480975.15905320.html.plaintext.txt	133	Experiment 1 All female rats E D2 groups exhibited regular 4 d estrous cycle monitored vaginal smear experiments
0.119480975.15905320.html.plaintext.txt	134	Almost 40 female rats fasted 48 h P group however diestrus like vaginal smear day supposed proestrus
0.119480975.15905320.html.plaintext.txt	135	Data rats showing perturbed cycle discarded rats showing proestrous vaginal smear included P group
0.119480975.15905320.html.plaintext.txt	136	In FedSaline groups pCREB cells blue black nuclei scattered LHA arcuate nucleus hypothalamus data shown ratio double stained neurons approximately 10 Fig
0.119480975.15905320.html.plaintext.txt	137	View larger version 33K FIG
0.119480975.15905320.html.plaintext.txt	138	Effects 48 h fasting glucose injection 48 h fasting ratio percentage MCH immunoreactive neurons expressing pCREB immunoreactive nuclei experiment 1
0.119480975.15905320.html.plaintext.txt	139	In groups rats examined 5 min saline glucose injection
0.119480975.15905320.html.plaintext.txt	140	Columns vertical lines indicate mean SEM respectively
0.119480975.15905320.html.plaintext.txt	141	Numbers parentheses refer number rats
0.119480975.15905320.html.plaintext.txt	142	Numbers columns body weights mean plus minus SEM time testing
0.119480975.15905320.html.plaintext.txt	143	See text details statistics
0.119480975.15905320.html.plaintext.txt	144	D2 Diestrus 2 P proestrus E estrus
0.119480975.15905320.html.plaintext.txt	145	In FastSaline groups large number pCREB cells observed LHA arcuate nucleus hypothalamus data shown ratio double stained neurons approximately 40 Fig
0.119480975.15905320.html.plaintext.txt	146	One way ANOVA showed significant effect treatment ratio double stained neurons animal group intact male group F212 7
0.119480975.15905320.html.plaintext.txt	147	05 D2 group F211 11
0.119480975.15905320.html.plaintext.txt	148	In groups post hoc comparison showed significantly greater ratio double stained neurons FastSaline group FedSaline group Fig
0.119480975.15905320.html.plaintext.txt	149	These results indicated 48 h fasting significantly increased ratio double stained neurons animal groups
0.119480975.15905320.html.plaintext.txt	150	In FastGlucose group number pCREB cells LHA varied among animal groups data shown
0.119480975.15905320.html.plaintext.txt	151	Post hoc comparison male group showed significantly greater ratio double stained neurons FastGlucose group FedSaline group P 0
0.119480975.15905320.html.plaintext.txt	152	05 significant difference FastGlucose group FastSaline group indicating glucose injection affect increase ratio double stained neurons caused fasting intact male rats Fig
0.119480975.15905320.html.plaintext.txt	153	In contrast pCREB cells relatively LHA female groups glucose injection data shown
0.119480975.15905320.html.plaintext.txt	154	Post hoc comparisons female groups showed significantly smaller ratio double stained neurons FastGlucose group FastSaline group Fig
0.119480975.15905320.html.plaintext.txt	155	In P E groups ratio double stained neurons differ FastGlucose group FedSaline group indicating glucose injection completely blocked fasting induced increase ratio double stained neurons Fig
0.119480975.15905320.html.plaintext.txt	156	In D2 group contrast ratio double stained neurons significantly greater FastGlucose group FedSaline group Fig
0.119480975.15905320.html.plaintext.txt	157	05 indicating 48 h fasting glucose injection less effective D2 group P E groups
0.119480975.15905320.html.plaintext.txt	158	Experiment 2 The data experiment 2 analyzed data experiment 1 FastSaline FastGlucose groups intact male rats D2 group female rats Fig
0.119480975.15905320.html.plaintext.txt	159	View larger version 22K FIG
0.119480975.15905320.html.plaintext.txt	160	Time dependent changes ratio percentage MCH immunoreactive cells expressing pCREB immunoreactive nuclei FastSaline FastGlucose groups male female D2 rats experiment 2
0.119480975.15905320.html.plaintext.txt	161	In groups rats fasted 48 h examined 5 min saline injection 15 30 60 min glucose injection
0.119480975.15905320.html.plaintext.txt	162	Columns vertical lines indicate mean SEM respectively
0.119480975.15905320.html.plaintext.txt	163	Numbers parentheses refer number rats
0.119480975.15905320.html.plaintext.txt	164	Numbers columns body weights mean plus minus SEM time testing
0.119480975.15905320.html.plaintext.txt	165	In intact male rats pCREB cells LHA FastGlucose 15 min group FastGlucose 30 min group ratio double stained neurons less 10 Fig
0.119480975.15905320.html.plaintext.txt	166	The number pCREB cells relatively large FastGlucose 60 min group
0.119480975.15905320.html.plaintext.txt	167	One way ANOVA showed significant effect treatment ratio double stained neurons intact male rats F420 5
0.119480975.15905320.html.plaintext.txt	168	Post hoc comparison intact male rats showed significantly smaller ratio double stained neurons FastGlucose 15 min group FastGlucose 30 min group FastSaline group P 0
0.119480975.15905320.html.plaintext.txt	169	These results indicated glucose injection significantly decreased ratio double stained neurons 15 30 min injection intact male rats effect disappeared 60 min injection
0.119480975.15905320.html.plaintext.txt	170	In D2 group female rats pCREB cells LHA FastGlucose 15 min group ratio double stained neurons approximately 10 Fig
0.119480975.15905320.html.plaintext.txt	171	The number pCREB cells relatively large FastGlucose 30 min group FastGlucose 60 min group
0.119480975.15905320.html.plaintext.txt	172	One way ANOVA showed significant effect treatment ratio double stained neurons D2 group F419 11
0.119480975.15905320.html.plaintext.txt	173	Post hoc comparison D2 group showed significantly smaller ratio double stained neurons FastGlucose 5 min group FastGlucose 15 min group FastSaline group P 0
0.119480975.15905320.html.plaintext.txt	174	These results indicated glucose injection significantly decreased ratio double stained neurons 5 15 min injection female rats effect disappeared 30 min injection
0.119480975.15905320.html.plaintext.txt	175	Experiment 3 In FedSaline groups FastSaline groups ratios double stained neurons approximately 10 40 respectively Fig
0.119480975.15905320.html.plaintext.txt	176	One way ANOVA showed significant effect treatment ratio double stained neurons animal group ORX group F210 15
0.119480975.15905320.html.plaintext.txt	177	001 ORXT group F210 4
0.119480975.15905320.html.plaintext.txt	178	05 ORXE2 group F212 38
0.119480975.15905320.html.plaintext.txt	179	05 OVXT group F211 11
0.119480975.15905320.html.plaintext.txt	180	005 OVXE2 group F29 6
0.119480975.15905320.html.plaintext.txt	181	In animal groups post hoc comparison showed significantly greater ratio double stained neurons FastSaline group FedSaline group Fig
0.119480975.15905320.html.plaintext.txt	182	Because ratio double stained neurons FedSaline groups FastSaline groups experiment 3 comparable experiment 1 results indicated 48 h fasting significantly increased ratio double stained neurons regardless presence absence gonadal steroid hormones
0.119480975.15905320.html.plaintext.txt	183	View larger version 24K FIG
0.119480975.15905320.html.plaintext.txt	184	Effects testosterone estrogen ratio percentage MCH immunoreactive neurons expressing pCREB immunoreactive nuclei FedSaline FastSaline FastGlucose groups experiment 3
0.119480975.15905320.html.plaintext.txt	185	In groups rats examined 5 min saline glucose injection
0.119480975.15905320.html.plaintext.txt	186	Columns vertical lines indicate mean SEM respectively
0.119480975.15905320.html.plaintext.txt	187	Numbers parentheses refer number rats
0.119480975.15905320.html.plaintext.txt	188	Numbers columns body weights mean plus minus SEM time testing
0.119480975.15905320.html.plaintext.txt	189	See text details statistics
0.119480975.15905320.html.plaintext.txt	190	E2 Implantation 17ss estradiol crystals T implantation testosterone crystals
0.119480975.15905320.html.plaintext.txt	191	Effects glucose injection varied among groups
0.119480975.15905320.html.plaintext.txt	192	In ORX ORXE2 groups post hoc comparisons showed ratio double stained neurons FastGlucose group significantly smaller FastSaline group P 0
0.119480975.15905320.html.plaintext.txt	193	001 ratio double stained neurons FastGlucose group different FedSaline group P 0
0.119480975.15905320.html.plaintext.txt	194	In ORXT groups post hoc comparison showed ratio double stained neurons FastGlucose group different FastSaline group FedSaline group P 0
0.119480975.15905320.html.plaintext.txt	195	These results indicated orchidectomy estrogen replacement decreased ratio double stained neurons 5 min glucose injection testosterone replacement blocked orchidectomy induced decrease ratio double stained neurons male rats
0.119480975.15905320.html.plaintext.txt	196	In OVXT OVXE2 groups post hoc comparisons showed ratio double stained neurons FastGlucose group significantly smaller FastSaline group P 0
0.119480975.15905320.html.plaintext.txt	197	05 ratio double stained neurons FastGlucose group different FedSaline group P 0
0.119480975.15905320.html.plaintext.txt	198	In OVX groups post hoc comparison showed ratio double stained neurons FastGlucose group different FastSaline group P 0
0.119480975.15905320.html.plaintext.txt	199	5 ratio double stained neurons FastGlucose group significantly larger FedSaline group P 0
0.119480975.15905320.html.plaintext.txt	200	These results indicated ovariectomy increased ratio double stained neurons 5 min glucose injection testosterone estrogen replacement blocked ovariectomy induced increase ratio double stained neurons female rats
0.119480975.15905320.html.plaintext.txt	201	Discussion Top Abstract Introduction Materials Methods Results Discussion References The present study demonstrated sex differences response MCH neurons glucose using expression pCREB marker neural activity
0.119480975.15905320.html.plaintext.txt	202	Fasting 48 h activated MCH neurons similar manner male female rats inactivation MCH neurons glucose 48 h fasting occurred rapidly female rats male rats
0.119480975.15905320.html.plaintext.txt	203	These sex differences could attributed gonadal steroid hormones including testosterone estrogen
0.119480975.15905320.html.plaintext.txt	204	Taking account orexigenic effect MCH 14 15 glucostatic theory feeding 36 findings provide molecularneurotransmitter basis neurons controlled glucose LHA suggest MCH neurons LHA play important role sex differences feeding behavior acting CREB pathway 29 30
0.119480975.15905320.html.plaintext.txt	205	Although hypoglycemia caused treatments fasting insulin injection 2 deoxy D glucose injection increases expression hypothalamic MCH mRNA 14 22 23 little information second messenger system would stimulated hypoglycemic conditions
0.119480975.15905320.html.plaintext.txt	206	For example Fos expression increased LHA insulin induced hypoglycemia MCH neurons expressed Fos protein 22 37
0.119480975.15905320.html.plaintext.txt	207	Thus unclear whether Fos proteins involved control expression MCH mRNA LHA hypoglycemia
0.119480975.15905320.html.plaintext.txt	208	In experiment 1 showed normal feeding conditions male female rats stages estrous cycle examined approximately 10 MCH neurons expressed pCREB immunoreactive nuclei LHA indicating small population MCH neurons active LHA
0.119480975.15905320.html.plaintext.txt	209	However found fasting 48 h increased ratio double stained neurons approximately 40 sexes
0.119480975.15905320.html.plaintext.txt	210	Furthermore showed fasting induced increase independent presence testosterone estrogen
0.119480975.15905320.html.plaintext.txt	211	This first demonstration MCH neurons express pCREB nuclei response fasting good accord results previous study showing fasting 48 h increased pCREB levels nuclear extracts rat hypothalamus although neurons expressed pCREB shown 38
0.119480975.15905320.html.plaintext.txt	212	An analog cAMP agents increase levels endogenous cAMP promote phosphorylation CREB 29 reported elicit vigorous feeding response microinjected LHA 39
0.119480975.15905320.html.plaintext.txt	213	Thus pCREB reliable marker activation MCH neurons 48 h fasting phosphorylation CREB probably promoted increase cAMP may contribute least part orexigenic activity MCH neurons
0.119480975.15905320.html.plaintext.txt	214	We thus suggest sex difference fasting induced activation MCH neurons
0.119480975.15905320.html.plaintext.txt	215	We also examined changes activity MCH neurons glucose injection 48 h fasted rats experiment 1 found significant decrease ratio double stained neurons induced 5 min female rats stages estrous cycle examined
0.119480975.15905320.html.plaintext.txt	216	In contrast female rats MCH neurons male rats failed respond glucose within 5 min
0.119480975.15905320.html.plaintext.txt	217	Additional time course studies experiment 2 demonstrated MCH neurons male rats responded glucose 15 30 min glucose injection whereas female rats stage insensitive glucose MCH neurons responded 5 15 min
0.119480975.15905320.html.plaintext.txt	218	In study found clear sex difference response MCH neurons glucose response MCH neurons glucose delayed male rats compared female rats
0.119480975.15905320.html.plaintext.txt	219	This due differences blood glucose concentrations sex difference blood glucose concentrations glucose injection intact male female rats
0.119480975.15905320.html.plaintext.txt	220	Furthermore due sex differences insulin secretion response glucose sex difference effect castration insulin secretion thus could explain results experiment 3
0.119480975.15905320.html.plaintext.txt	221	One possible reason delay decrease pCREB may sensitivity MCH neurons glucose male rats less female rats thus MCH neurons respond increase glucose concentrations blood resulting delay decrease pCREB
0.119480975.15905320.html.plaintext.txt	222	According glucostatic theory increase glucose blood signal meal termination 33 dietary glucose may inactivate orexigenic activity MCH neurons induce meal termination rapidly female rats male rats
0.119480975.15905320.html.plaintext.txt	223	This may account sex difference meal size smaller females males 1 2
0.119480975.15905320.html.plaintext.txt	224	Although glucose sensing neurons may respond physiological changes blood glucose regulate integrative metabolic functions counterregulatory responses food intake metabolic rate 40 glucostatic theory sufficient explain complex regulation feeding behavior 41
0.119480975.15905320.html.plaintext.txt	225	Glucose obviously one several peripheral metabolic signals involved regulation feeding behavior physiological conditions 42
0.119480975.15905320.html.plaintext.txt	226	Hence speculate inactivation MCH neurons metabolic signals feeding faster females males
0.119480975.15905320.html.plaintext.txt	227	We currently know glucose acts MCH neurons
0.119480975.15905320.html.plaintext.txt	228	However judging electrophysiological study showing neurons LHA respond changes glucose concentration vitro 43 direct effect glucose MCH neurons likely
0.119480975.15905320.html.plaintext.txt	229	Effects afferent signals glucose sensors localized different central peripheral structures also likely 41 44
0.119480975.15905320.html.plaintext.txt	230	In hypothalamus NPY neurons arcuate nucleus shown glucose sensitive neurons vitro electrophysiological study 45
0.119480975.15905320.html.plaintext.txt	231	Considering hypothalamic circuit involving LHA arcuate nucleus 19 probable glucose affects MCH neurons indirectly via NPY neurons arcuate nucleus
0.119480975.15905320.html.plaintext.txt	232	We also found present study response MCH neurons glucose varied depending stage estrous cycle
0.119480975.15905320.html.plaintext.txt	233	magnitude decrease number double stained neurons glucose injection greater proestrus estrus diestrus 2
0.119480975.15905320.html.plaintext.txt	234	An additional time course study confirmed ratio double stained neurons diestrus 2 decreased 15 min glucose injection approximately 10 similar levels proestrus estrus 5 min glucose injection indicating response MCH neurons glucose diestrus 2 delayed
0.119480975.15905320.html.plaintext.txt	235	As discussed decrease activity MCH neurons related meal termination follows meal termination occurs rapidly proestrus estrus diestrus 2
0.119480975.15905320.html.plaintext.txt	236	In support meal size smaller proestrus estrus diestrus 2 4
0.119480975.15905320.html.plaintext.txt	237	Therefore MCH neurons may also participate fluctuation feeding behavior estrous cycle
0.119480975.15905320.html.plaintext.txt	238	Our findings experiment 3 indicate sex difference MCH neurons least part attributable presence gonadal steroid hormones adults
0.119480975.15905320.html.plaintext.txt	239	That presence testosterone males estrogen females critical male female type responses MCH neurons glucose
0.119480975.15905320.html.plaintext.txt	240	In male rats found orchidectomy significantly enhanced response MCH neurons glucose testosterone replacement attenuated effect
0.119480975.15905320.html.plaintext.txt	241	Because orchidectomy decreased food intake 46 effect reversed testosterone replacement ORX rats 7 47 48 speculate testosterone attenuates response MCH neurons metabolic signals increases food intake males
0.119480975.15905320.html.plaintext.txt	242	In contrast estrogen replacement cause significant effect orchidectomy induced enhancement response glucose male rats
0.119480975.15905320.html.plaintext.txt	243	This result good accord report food intake ORX rats relatively insensitive influence estrogen compared OVX rats 8
0.119480975.15905320.html.plaintext.txt	244	The results present study male rats therefore suggest estrogen could longer enhance response MCH neurons glucose orchidectomy caused response reach maximum
0.119480975.15905320.html.plaintext.txt	245	In female rats ovariectomy attenuated response MCH neurons glucose estrogen replacement prevented ovariectomy induced attenuation response
0.119480975.15905320.html.plaintext.txt	246	These results good accord previous studies ovariectomy adult female rats increased food intake 7 46 effect reversed estrogen replacement 6
0.119480975.15905320.html.plaintext.txt	247	Thus easily hypothesized estrogen enhances response MCH neurons metabolic signals females causes decreases food intake body weight
0.119480975.15905320.html.plaintext.txt	248	In support estrogen inhibited expression MCH mRNA LHA female 49 male 27 rats
0.119480975.15905320.html.plaintext.txt	249	In contrast effect testosterone ORX rats testosterone enhanced response MCH neurons OVX rats estrogen
0.119480975.15905320.html.plaintext.txt	250	This effect testosterone OVX rats could explained postulating testosterone enhances response MCH neurons converted estrogen
0.119480975.15905320.html.plaintext.txt	251	In support speculation suggested male rats reduced food intake weight gain seen high dose testosterone treatment due aromatization testosterone estrogen 8
0.119480975.15905320.html.plaintext.txt	252	In light previous reports females sensitive effect estrogen food intake males 8 50 males sensitive effect testosterone food intake 47 50 present study indicates dominant effect testosterone response MCH neurons females testosterone induced attenuation estrogen induced enhancement
0.119480975.15905320.html.plaintext.txt	253	In males contrast dominant effect testosterone response MCH neurons estrogen induced enhancement testosterone induced attenuation
0.119480975.15905320.html.plaintext.txt	254	Hence present study may provide neural basis sex difference feeding behavior although mechanisms action estrogen testosterone need determined future studies
0.119480975.15905320.html.plaintext.txt	255	Recent reports demonstrating estrogen attenuates neuroendocrine responses hypoglycemia women 51 female rats 52 suggest estrogen enhances effects glucose brain
0.119480975.15905320.html.plaintext.txt	256	In light results present study estrogen may enhance glucose transport metabolism brain 53 54 55
0.119480975.15905320.html.plaintext.txt	257	This suggests one mechanism estrogen exerts widely reported protective effects brain 56 enhancing glucose transport metabolism
0.119480975.15905320.html.plaintext.txt	258	Footnotes This work supported part grant Yokohama Foundation Advancement Medical Science K
0.119480975.15905320.html.plaintext.txt	259	First Published Online May 19 2005
0.119480975.15905320.html.plaintext.txt	260	Abbreviations AUC Area curve LHA lateral hypothalamic area MCH melanin concentrating hormone NPY neuropeptide Y ORX orchidectomized OVX ovariectomized PB phosphate buffer pCREB phosphorylated cAMP response element binding protein
0.119480975.15905320.html.plaintext.txt	261	Accepted publication May 10 2005
0.119480975.15905320.html.plaintext.txt	262	References Top Abstract Introduction Materials Methods Results Discussion References de Castro JM 1987 Circadian rhythms spontaneous meal pattern macronutrient intake mood humans
0.119480975.15905320.html.plaintext.txt	263	Physiol Behav 40437 446CrossRefMedline Laviano A Meguid MM Gleason JR Yang ZJ Renvyle T 1996 Comparison long term feeding pattern male female Fischer 344 rats influence estrous cycle
0.119480975.15905320.html.plaintext.txt	264	Am J Physiol 270R413 R419 Dye L Blundell JE 1997 Menstrual cycle appetite control implications weight regulation
0.119480975.15905320.html.plaintext.txt	265	Hum Reprod 121142 1151CrossRefMedline Eckel LA Houpt TA Geary N 2000 Spontaneous meal patterns female rats without access running wheels
0.119480975.15905320.html.plaintext.txt	266	Physiol Behav 70397 405CrossRefMedline Bell DD Zucker I 1971 Sex differences body weight eating organization activation gonadal hormones rat
0.119480975.15905320.html.plaintext.txt	267	Physiol Behav 727 34CrossRefMedline Blaustein JD Wade GN 1976 Ovarian influences meal patterns female rats
0.119480975.15905320.html.plaintext.txt	268	Physiol Behav 17201 208CrossRefMedline Gentry RT Wade GN 1976 Androgenic control food intake body weight male rats
0.119480975.15905320.html.plaintext.txt	269	J Comp Physiol Psychol 9018 25Medline Gentry RT Wade GN 1976 Sex differences sensitivity food intake body weight running wheel activity ovarian steroids rats
0.119480975.15905320.html.plaintext.txt	270	J Comp Physiol Psychol 90747 754Medline Varma M Chai JK Meguid MM Laviano A Gleason JR Yang ZJ Blaha V 1999 Effect estradiol progesterone daily rhythm food intake feeding patterns Fischer rats
0.119480975.15905320.html.plaintext.txt	271	Physiol Behav 6899 107CrossRefMedline Geary N 1999 Estradiol CCK satiation
0.119480975.15905320.html.plaintext.txt	272	Peptides 221251 1263CrossRef Wager Srdar SA Gannon M Levine AS 1987 The effect cholecystokinin food intake gonadectomized intact rats influence sex hormones
0.119480975.15905320.html.plaintext.txt	273	Physiol Behav 4025 28CrossRefMedline Flanagan Cato LM King JL Blechman JG O Brien MP 1998 Estrogen reduces cholecystokinin induced c Fos expression rat brain
0.119480975.15905320.html.plaintext.txt	274	Neuroenedocrinology 67384 391CrossRef Bittencourt JC Presse F Arias C Peto C Vaughan J Nahon JL Vale W Sawchenko PE 1992 The melanin concentrating hormone system rat brain immuno hybridization histochemical characterization
0.119480975.15905320.html.plaintext.txt	275	J Comp Neurol 319218 245CrossRefMedline Qu D Ludwig DS Gammeltoft S Piper M Pelleymounter MA Cullen MJ Mathes WF Przypek R Kanarek R Maratos Flier E 1996 A role melanin concentrating hormone central regulation feeding behaviour
0.119480975.15905320.html.plaintext.txt	276	Nature 380243 247CrossRefMedline Rossi M Choi SJ O Shea D Miyoshi T Ghatei MA Bloom SR 1997 Melanin concentrating hormone acutely stimulates feeding chronic administration effect body weight
0.119480975.15905320.html.plaintext.txt	277	Endocrinology 138351 355AbstractFree Full Text Allen YS Adrian TE Allen JM Tatemoto K Crow TJ Bloom SR Polak JM 1983 Neuropeptide Y distribution rat brain
0.119480975.15905320.html.plaintext.txt	278	Science 221877 879Medline Clark JT Kalra PS Crowley WR Kalra SP 1984 Neuropeptide Y human pancreatic polypeptide stimulate feeding behavior rats
0.119480975.15905320.html.plaintext.txt	279	Endocrinology 115427 429Abstract Stanley BG Magdalin W Seirafi A Thomas WJ Leibowitz SF 1993 The perifornical area major focus patchily distributed hypothalamic neuropeptide Y sensitive feeding systems
0.119480975.15905320.html.plaintext.txt	280	Brain Res 604304 317CrossRefMedline Schwartz MW Woods SC Porte Jr D Seeley RJ Baskin DG 2000 Central nervous system control food intake
0.119480975.15905320.html.plaintext.txt	281	Nature 404661 671Medline Shimada M Tritos NA Lowell BB Flier JS Maratos Flier E 1998 Mice lacking melanin concentrating hormone hypophagic lean
0.119480975.15905320.html.plaintext.txt	282	Nature 396670 674CrossRefMedline Ludwig DS Tritos NA Mastaitis JW Kulkarni R Kokkotou E Elmquist J Lowell B Flier JS Maratos Flier E 2001 Melanin concentrating hormone overexpression transgenic mice leads obesity insulin resistance
0.119480975.15905320.html.plaintext.txt	283	J Clin Invest 107379 386AbstractFree Full Text Bahjaoui Bouhaddi M Fellmann D Griffond B Bugnon C 1994 Insulin treatment stimulates rat melanin concentrating hormone producing neurons
0.119480975.15905320.html.plaintext.txt	284	Neuropeptides 27251 258CrossRefMedline Sergeyev V Broberger C Gorbatyuk O Hokfelt T 2000 Effect 2 mercaptoacetate 2 deoxy D glucose administration expression NPY AGRP POMC MCH hypocretinorexin rat hypothalamus
0.119480975.15905320.html.plaintext.txt	285	Neuroreport 11117 121Medline Erickson JC Clegg KE Palmiter RD 1996 Sensitivity leptin susceptibility seizures mice lacking neuropeptide Y
0.119480975.15905320.html.plaintext.txt	286	Nature 381415 421CrossRefMedline Chemelli RM Willie JT Sinton CM Elmquist JK Scammell T Lee C Richardson JA Williams SC Xiong Y Kisanuki Y Fitch TE Nakazato M Hammer RE Saper CB Yanagisawa M 1999 Narcolepsy orexin knockout mice molecular genetics sleep regulation
0.119480975.15905320.html.plaintext.txt	287	Cell 98437 451CrossRefMedline Willie JT Chemelli RM Sinton CM Yanagisawa M 2001 To eat sleep Orexin regulation feeding wakefulness
0.119480975.15905320.html.plaintext.txt	288	Annu Rev Neurosci 24429 458CrossRefMedline Mystkowski P Seeley RJ Hahn TM Baskin DG Havel PJ Matsumoto AM Wilkinson CW Peacock Kinzig K Blake KA Schwartz MW 2000 Hypothalamic melanin concentrating hormone estrogen induced weight loss
0.119480975.15905320.html.plaintext.txt	289	J Neurosci 208637 8642AbstractFree Full Text Ji RR Rupp F 1997 Phosphorylation transcription factor CREB rat spinal cord formalin induced hyperalgesia relationship c fos induction
0.119480975.15905320.html.plaintext.txt	290	J Neurosci 171776 1178AbstractFree Full Text Montminy MR Bilezikjian L 1987 Binding nuclear protein cyclic AMP response element somatostatin gene
0.119480975.15905320.html.plaintext.txt	291	Nature 328175 178CrossRefMedline Dash PK Karl KA Colicos MA Prywes R Kandel ER 1991 cAMP response element binding protein activated Ca2calmodulin well cAMP dependent protein kinase
0.119480975.15905320.html.plaintext.txt	292	Proc Natl Acad Sci USA 885061 5065AbstractFree Full Text He D Funabashi T Sano A Uemura T Minaguchi H Kimura F 1999 Effects glucose related substrates recovery electrical activity gonadotropin releasing hormone pulse generator decreased insulin induced hypoglycemia estrogen primed ovariectomized rat
0.119480975.15905320.html.plaintext.txt	293	Brain Res 82071 76CrossRefMedline Mitsushima D Tin Tin Win Shwe Kimura F 2003 Sexual dimorphism GABAergic control gonadotropin release intact rats
0.119480975.15905320.html.plaintext.txt	294	Neurosci Res 46399 405CrossRefMedline Steiner RA Bremner WJ Clifton DK 1982 Regulation luteinizing hormone pulse frequency amplitude testosterone adult male rat
0.119480975.15905320.html.plaintext.txt	295	Endocrinology 1112055 2061Abstract Crace CJ Swenne I Milner RDG 1989 Long term follow early protein calorie malnutrition young rats sex difference glucose tolerance serum insulin levels
0.119480975.15905320.html.plaintext.txt	296	Metabolism 38933 938CrossRefMedline Galipeau DM Yao L McNeill JH 2002 Relationship among hyperinsulinemia insulin resistance hypertension dependent sex
0.119480975.15905320.html.plaintext.txt	297	Am J Phyisol 283H562 H567 Mayer J 1953 Glucostatic mechanism regulation food intake
0.119480975.15905320.html.plaintext.txt	298	N Engl J Med 24913 16Medline Bahjaoui Bouhaddi M Fellmann D Bugnon C 1994 Induction Fos immunoreactivity prolactin like containing neurons rat lateral hypothalamus insulin treatment
0.119480975.15905320.html.plaintext.txt	299	Neurosci Lett 16811 15CrossRefMedline Sheriff S Chance WT Fischer JE Balasubramaniam A 1997 Neuropeptide Y treatment food deprivation increase cyclic AMP response element binding rat hypothalamus
0.119480975.15905320.html.plaintext.txt	300	Mol Pharmacol 51597 604AbstractFree Full Text Gillard ER Khan AM Grewal RS Mouradi B Wolfsohn SD Stanley BG 1998 The second messenger cAMP elicits eating anatomically specific action perifornical hypothalamus
0.119480975.15905320.html.plaintext.txt	301	J Neurosci 182646 2652AbstractFree Full Text Yang X J Funabashi T Kow L M Mobbs CV 2004 A glucokinaseAP 1 glucose transduction mechanism ventromedial hypothalamic satiety center
0.119480975.15905320.html.plaintext.txt	302	In Matschinsky FM Magnuson MA eds
0.119480975.15905320.html.plaintext.txt	303	Basel Karger 313 326 Levin BE Dunn Meynell AA Routh VH 1999 Brain glucose sensing body energy homeostasis role obesity diabetes
0.119480975.15905320.html.plaintext.txt	304	Am J Physiol 276R1223 R1231 Havel PJ 2001 Peripheral signals conveying metabolic information brain short term long term regulation food intake energy homeostasis
0.119480975.15905320.html.plaintext.txt	305	Exp Biol Med 226963 977AbstractFree Full Text Orsini JC Armstrong DL Wayner MJ 1992 Responses lateral hypothalamic neurons recorded vitro moderate changes glucose concentration
0.119480975.15905320.html.plaintext.txt	306	Brain Res Bull 29503 505CrossRefMedline Niijima A 1986 Neural control blood glucose level
0.119480975.15905320.html.plaintext.txt	307	Jpn J Physiol 36827 841Medline Muroya S Yada T Shioda S Takigawa M 1999 Glucose sensitive neurons rat arcuate nucleus contain neuropeptide Y
0.119480975.15905320.html.plaintext.txt	308	Neurosci Lett 264113 116CrossRefMedline Kakolewski JW Cox VC Valenstein ES 1968 Sex differences body weight changes following gonadectomy rats
0.119480975.15905320.html.plaintext.txt	309	Psychol Rep 22547 554Medline Rowland DL Perrings TS Thommes JA 1980 Comparison androgenic effects food intake body weight adult rats
0.119480975.15905320.html.plaintext.txt	310	Physiol Behav 24205 209CrossRefMedline Chai J K Blaha V Meguid MM Laviano A Yang Z J Varma M 1999 Use orchidectomy testosterone replacement explore number meal size relationship male rats
0.119480975.15905320.html.plaintext.txt	311	Am J Physiol 276R1366 R1373 Murray JF Baker BI Levy A Wilson CA 2000 The influence gonadal steroids pre pro melanin concentrating hormone mRNA female rats
0.119480975.15905320.html.plaintext.txt	312	J Neuroendocrinol 1253 59CrossRefMedline Czaja JA 1984 Sex differences activational effects gonadal hormones food intake body weight
0.119480975.15905320.html.plaintext.txt	313	Physiol Behav 33553 558CrossRefMedline Sandoval DA Ertl AC Richardson A Tate DB Davis SN 2003 Estrogen blunts neuroendocrine metabolic responses hypoglycemia
0.119480975.15905320.html.plaintext.txt	314	Diabetes 521749 1755AbstractFree Full Text Adams JM Legan SJ Ott CE Jackson BA 2005 Modulation hypoglycemia induced increases plasma epinephrine estrogen female rat
0.119480975.15905320.html.plaintext.txt	315	J Neurosci Res 79360 367CrossRefMedline Shi J Zhang YQ Simpkins JW 1997 Effects 17b estradiol glucose transporter 1 expression endothelial cell survival following focal ischemia rats
0.119480975.15905320.html.plaintext.txt	316	Exp Brain Res 117200 206CrossRefMedline Luine VN Khylchevskaya RI McEwen BS 1975 Effect gonadal hormones enzyme activities brain pituitary male female rats
0.119480975.15905320.html.plaintext.txt	317	Brain Res 86283 292CrossRefMedline Hamba H Sokoloff L 1984 Acute administration high doses estrogen increases glucose utilization throughout brain
0.119480975.15905320.html.plaintext.txt	318	Brain Res 291391 394CrossRefMedline Wise PM 2003 Estrogens protective risk factors brain function Prog Neurobiol 69181 191CrossRefMedline This Article Abstract Full Text PDF All Versions Article 14683325 recent Author Manuscript PDF Purchase Article View Shopping Cart Alert article cited Alert correction posted Citation Map Services Email article friend Similar articles journal Similar articles PubMed Alert new issues journal Download citation manager Request Copyright Permission Google Scholar Articles Mogi K
0.119480975.15905320.html.plaintext.txt	319	Articles citing Article PubMed PubMed Citation Articles Mogi K
0.119480975.15905320.html.plaintext.txt	320	HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS Endocrinology Endocrine Reviews J
0.119480975.15905320.html.plaintext.txt	321	Molecular Endocrinology Recent Prog
0.20854747.15870393.html.plaintext.txt	0	Genetic modifiers interact Cpefat affect body weight adiposity hyperglycemia Gayle B
0.20854747.15870393.html.plaintext.txt	1	Maddatu1 aunak Sen12 Jurgen K
0.20854747.15870393.html.plaintext.txt	2	1 The Jackson Laboratory Bar Harbor Maine 2 Department Epidemiology Biostatistics University California San Francisco California
0.20854747.15870393.html.plaintext.txt	3	ABSTRACT TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES Obesity Type II diabetes complex diseases human population
0.20854747.15870393.html.plaintext.txt	4	The existence large number contributing loci gene gene well gene environment interactions make difficult identify disease genes underlying complex traits
0.20854747.15870393.html.plaintext.txt	5	In mouse models obesity Type II diabetes murine fat mutation genetic crosses used dissect genetic complexity influencing observed phenotypes
0.20854747.15870393.html.plaintext.txt	6	The underlying defect fat mutant Ser202Pro change carboxypeptidase E CPE enzyme responsible final proteolytic processing step prohormone intermediates
0.20854747.15870393.html.plaintext.txt	7	On HRSJ HRS inbred strain background mice homozygous fat mutation exhibit early onset hyperinsulinemia followed postpubertal moderate obesity without hyperglycemia
0.20854747.15870393.html.plaintext.txt	8	In contrast C57BLKSJ BKS genetic background fatfat mice become severely obese hyperinsulinemic hyperglycemic
0.20854747.15870393.html.plaintext.txt	9	Therefore Cpefat genetic model fat mutation necessary sufficient development obesity Type II diabetes related metabolic disorders
0.20854747.15870393.html.plaintext.txt	10	To dissect susceptibility loci responsible modifying obesity diabetes associated traits characterized genetically phenotypically fatfat male progeny large intercross BKS
0.20854747.15870393.html.plaintext.txt	11	Four major loci mapped including locus body weight body weight 1 chromosome 14 locus hyperglycemia fat induced diabetes 1 chromosome 19 locus hyperglycemia hyperinsulinemia hypercholesterolemia fat induced diabetes 2 chromosome 5 locus adiposity body weight fat induced adiposity 1 chromosome 11
0.20854747.15870393.html.plaintext.txt	12	The identification interacting genetic determinants obesity Type II diabetes may allow better definition obesitydiabetes related hormone signaling pathways ultimately may provide new insights pathogenesis complex diseases
0.20854747.15870393.html.plaintext.txt	13	quantitative trait loci Type II diabetes
0.20854747.15870393.html.plaintext.txt	14	INTRODUCTION TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES OBESITY AND RELATED METABOLIC DISORDERS insulin resistance Type II diabetes major health problems human population
0.20854747.15870393.html.plaintext.txt	15	Presumably genetic dissection complex traits humans difficult polygenic nature genetic heterogeneity gene gene gene environmental interactions disease traits 4 7 23
0.20854747.15870393.html.plaintext.txt	16	For reason genetic studies obesity diabetes extended use mouse models
0.20854747.15870393.html.plaintext.txt	17	The mouse constitutes useful model system large number animals bred controlling genetic environmental influences
0.20854747.15870393.html.plaintext.txt	18	These advantages necessary study epistatic effects mutated genes susceptibility loci
0.20854747.15870393.html.plaintext.txt	19	Five single gene mutations result obese phenotype identified mice one fat mutation
0.20854747.15870393.html.plaintext.txt	20	The fat mutation single nucleotide change carboxypeptidase E CPE gene resulting 202Ser Pro change CPE protein fat mice 22
0.20854747.15870393.html.plaintext.txt	21	The CPE gene Cpe encodes enzyme responsible processing hormones insulin proopiomelanocortin
0.20854747.15870393.html.plaintext.txt	22	CPE present high concentrations secretory granules pancreatic islets required excision residual dibasic residues remaining carboxy terminal end propeptides processing endolytic prohormone convertases PCSK1 PCSK2 10
0.20854747.15870393.html.plaintext.txt	23	The mutation Cpefat renders enzyme unstable ultimately degraded endoplasmic reticulum
0.20854747.15870393.html.plaintext.txt	24	The reduction CPE activity turn leads decrease biologically active hormones insulin
0.20854747.15870393.html.plaintext.txt	25	CPE defects also observed tissues including hypothalamus suggests number additional prohormones may implicated obesity phenotype neuropeptides melanin stimulating hormone 3 melanin concentrating hormone 25
0.20854747.15870393.html.plaintext.txt	26	The fat mutation initially arose inbred HRSJ HRS strain 7
0.20854747.15870393.html.plaintext.txt	27	HRS fatfat mice exhibit early chronic hyperinsulinemia followed mature onset obesity without hyperglycemia
0.20854747.15870393.html.plaintext.txt	28	When fat mutation transferred C57BLKSJ BKS background male mice harboring mutation homozygous state became hyperglycemic sixth backcross generation N6
0.20854747.15870393.html.plaintext.txt	29	In addition BKS fatfat mice exhibit elevated plasma triglyceride high density lipoprotein HDL total cholesterol levels
0.20854747.15870393.html.plaintext.txt	30	As background strain difference respect diabetes development demonstrates Cpefat necessary sufficient development diabesity obesitydiabetes Cpefat model
0.20854747.15870393.html.plaintext.txt	31	Other susceptibility loci must interact fat produce hyperglycemia metabolic phenotypes observed BKS fatfat mice
0.20854747.15870393.html.plaintext.txt	32	To dissect susceptibility loci interacting Cpefat performed genetic analysis male mice homozygous Cpefat mutation large BKS x HRShr F1 Cpefat intercross inbred HRS strain also carries mutation hairless gene hr
0.20854747.15870393.html.plaintext.txt	33	For temporal phenotypes body weight plasma glucose constructed sets derived phenotypes capture key aspects longitudinal measurements rate flux severity phenotype
0.20854747.15870393.html.plaintext.txt	34	Here present outcome genome wide screen susceptibility loci interact Cpefat development obesity diabetes related disorders
0.20854747.15870393.html.plaintext.txt	35	MATERIALS AND METHODS TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES Mice Mice study ad libitum fed NIH31 diet 6 fat PMI Feeds St
0.20854747.15870393.html.plaintext.txt	36	Louis MO provided unlimited access water HCl acidified pH 2
0.20854747.15870393.html.plaintext.txt	37	2 temperature humidity controlled setting 1212 h light dark cycle
0.20854747.15870393.html.plaintext.txt	38	Because fatfat mice difficulty breeding ovaries hyperglycemic female insipient congenic BKS
0.20854747.15870393.html.plaintext.txt	39	HRS CpefatCpefat mice BKS fatfat cohorts I II backcross N6 cohort III backcross N10 transplanted NOD
0.20854747.15870393.html.plaintext.txt	40	CB17 PrkdascidJ homozygous female mice recipients mated HRShr male mice HRS stock maintained The Jackson Laboratory hr x hr matings
0.20854747.15870393.html.plaintext.txt	41	F1 offspring intercrossed produce total 2838 F2 mice 3 cohorts
0.20854747.15870393.html.plaintext.txt	42	Although obesity observed male female BKS fatfat mice hyperglycemia females rare
0.20854747.15870393.html.plaintext.txt	43	Therefore selected F2 fatfat male progeny quantitative trait loci QTL analysis
0.20854747.15870393.html.plaintext.txt	44	Phenotypic Measurements Body weights
0.20854747.15870393.html.plaintext.txt	45	Mice weighed monthly termination 24 cohorts II III 30 wk cohort I age
0.20854747.15870393.html.plaintext.txt	46	See Table 1 schedule phenotypic measurements
0.20854747.15870393.html.plaintext.txt	47	Schedule phenotypic measurements F2 intercross progeny
0.20854747.15870393.html.plaintext.txt	48	Whole blood collected via orbital sinus biweekly 7 10 AM using EDTA coated capillary tube
0.20854747.15870393.html.plaintext.txt	49	Samples centrifuged plasma used biochemical assays
0.20854747.15870393.html.plaintext.txt	50	Plasma glucose cholesterol triglyceride levels measured using commercial colorimetric assays Sigma St
0.20854747.15870393.html.plaintext.txt	51	Louis MO Roche Indianapolis IN
0.20854747.15870393.html.plaintext.txt	52	To determine HDL cholesterol levels low density low density lipoprotein particles precipitated polyethylene glycol 15
0.20854747.15870393.html.plaintext.txt	53	To determine plasma triglyceride levels free glycerol subtracted total glycerol content
0.20854747.15870393.html.plaintext.txt	54	Plasma insulin levels measured using radioimmunoassay kit Linco St
0.20854747.15870393.html.plaintext.txt	55	Plasma glucose levels monitored biweekly whereas lipid insulin levels determined 16 wk age termination
0.20854747.15870393.html.plaintext.txt	56	Subcutaneous rostral caudal retroperitoneal epididymal fat pads isolated weighed termination
0.20854747.15870393.html.plaintext.txt	57	Total fat pad weights defined sum fat pads described
0.20854747.15870393.html.plaintext.txt	58	Adiposity indexes calculated dividing total fat pad weight carcass weight multiplying 100
0.20854747.15870393.html.plaintext.txt	59	In addition fat pad weights body lengths nose tail girths animals measured
0.20854747.15870393.html.plaintext.txt	60	DNA isolated tail tissue using proteinase K digestion salt precipitation 28
0.20854747.15870393.html.plaintext.txt	61	Because Cpefat hr segregating F2 intercross progeny DNAs PCR amplified allele specific primers determine genotypes loci
0.20854747.15870393.html.plaintext.txt	62	PCR conditions Cpe primers previously described 19
0.20854747.15870393.html.plaintext.txt	63	Cycling conditions PCR amplification hr follows 94 degrees C 2 min followed 49 cycles 94 degrees C 20 50 degrees C 30 72 degrees C 30
0.20854747.15870393.html.plaintext.txt	64	A final extension done 72 degrees C 7 min
0.20854747.15870393.html.plaintext.txt	65	PCRs done 10 microl volume containing 1x PCR buffer Roche 100 ng genomic DNA 1
0.20854747.15870393.html.plaintext.txt	66	2 microM primer F1 5 agggaggtcagagcctctg 3 0
0.20854747.15870393.html.plaintext.txt	67	1 microM primer R15 ggtcctcctgtttgcttgg 3 0
0.20854747.15870393.html.plaintext.txt	68	1 microM primer F2 5 gccactccttgaacctgtg 3
0.20854747.15870393.html.plaintext.txt	69	DNAs separated 3 metaphor 1 agarose gel BMA Rockland ME stained ethidium bromide examined ultraviolet light
0.20854747.15870393.html.plaintext.txt	70	DNA heterozygous hr animals yielded two fragments 910 581 bps respectively
0.20854747.15870393.html.plaintext.txt	71	To identify polymorphic regions BKS HRS strains across genome DNA parental BKS fatfat N6 BKS fatfat N10 HRS mice typed single stranded length polymorphism SSLP markers Research Genetics using PCR assays previously described 14
0.20854747.15870393.html.plaintext.txt	72	Initially total 87 SSLP markers average spacing 20 cM tested genome scan largest gap 47 cM markers D1Mit26 D1Mit17 marker information available upon request
0.20854747.15870393.html.plaintext.txt	73	Additional markers tested chromosomal regions showing significant linkage
0.20854747.15870393.html.plaintext.txt	74	At resolution detected 187 markers tested scan region chromosome 17 differed BKS fatfat N6 N10 animals
0.20854747.15870393.html.plaintext.txt	75	N6 animals HRS genotype D17Mit142 whereas N10 animals segregating HRS BKS alleles
0.20854747.15870393.html.plaintext.txt	76	Because areas HRS contaminated regions may exist 2 genome 2 BKS modifying QTL may missed
0.20854747.15870393.html.plaintext.txt	77	Of 2838 F2 mice generated intercross DNA 282 fatfat F2 male progeny PCR amplified
0.20854747.15870393.html.plaintext.txt	78	Only 10 fatfat male mice instead expected 12
0.20854747.15870393.html.plaintext.txt	79	5 available mice died early lost completion study
0.20854747.15870393.html.plaintext.txt	80	Approximately 83 possible genotypes complete
0.20854747.15870393.html.plaintext.txt	81	To determine whether QTL modified trait absence Cpe defect genome scan performed DNA 48 F2 fat 24 F2 mice
0.20854747.15870393.html.plaintext.txt	82	Statistical Analysis Before data analysis data thoroughly examined mice exhibiting spontaneous extraneous ailments malocclusions
0.20854747.15870393.html.plaintext.txt	83	These animals removed data set analysis
0.20854747.15870393.html.plaintext.txt	84	The phenotypic profiles F2 progeny obtained using one way ANOVA
0.20854747.15870393.html.plaintext.txt	85	In examining longitudinal data male F2 fatfat mice noted different patterns disease progression
0.20854747.15870393.html.plaintext.txt	86	For example mice became hyperglycemic early sustained hyperglycemia others transiently hyperglycemic others showed slow moderate rise plasma glucose levels
0.20854747.15870393.html.plaintext.txt	87	To address longitudinal nature phenotypes created derived phenotypes body weight plasma glucose
0.20854747.15870393.html.plaintext.txt	88	This allowed us obtain results clear biological interpretation
0.20854747.15870393.html.plaintext.txt	89	detect modifiers act early late disease process change affect rate disease progression curvature affect disease severity final remain constitutively expressed throughout time course average
0.20854747.15870393.html.plaintext.txt	90	This also makes results comparable future studies may measure body weight progression different time points even irregular time intervals
0.20854747.15870393.html.plaintext.txt	91	We constructed following sets derived phenotypes
0.20854747.15870393.html.plaintext.txt	92	Let bi log body weight week
0.20854747.15870393.html.plaintext.txt	93	Let gi log plasma glucose level mouse week
0.20854747.15870393.html.plaintext.txt	94	Termination age time necropsies performed differed cohorts 24 30 wk age
0.20854747.15870393.html.plaintext.txt	95	We statistically examined whether difference mean values necropsies done 24 versus 30 wk
0.20854747.15870393.html.plaintext.txt	96	The adiposity indexes measured 24 30 wk age significantly different P 0
0.20854747.15870393.html.plaintext.txt	97	Therefore genome scan analysis combined adiposity data cohorts increase power detect linkage
0.20854747.15870393.html.plaintext.txt	98	To adjust included additive effect cohort analyses adiposity
0.20854747.15870393.html.plaintext.txt	99	View larger version 18K Fig
0.20854747.15870393.html.plaintext.txt	100	Schematic showing derived phenotypes body weight BW A plasma glucose PG B
0.20854747.15870393.html.plaintext.txt	101	The multiple imputation method Sen Churchill 26 used perform one dimensional two dimensional genome scans derived phenotypes adiposity
0.20854747.15870393.html.plaintext.txt	102	A one dimensional genome scan also commonly referred genome scan survey single locus models explaining phenotype
0.20854747.15870393.html.plaintext.txt	103	This amounts performing ANOVA every locus complete genotype information available
0.20854747.15870393.html.plaintext.txt	104	We examine much phenotypic variation explained genetic variation every locus summarize statistical evidence locus affects phenotype LOD score
0.20854747.15870393.html.plaintext.txt	105	A two dimensional genome scan survey two locus models explaining phenotype
0.20854747.15870393.html.plaintext.txt	106	Here examined much phenotypic variation explained genetic variation every pair loci genome
0.20854747.15870393.html.plaintext.txt	107	For one dimensional two dimensional scans included additive cohort effect three cohorts mice
0.20854747.15870393.html.plaintext.txt	108	This method analysis able combine overall evidence favor locus three cohorts respecting differences
0.20854747.15870393.html.plaintext.txt	109	The rationale combining crosses previously reported used studies 1 8 17 31
0.20854747.15870393.html.plaintext.txt	110	Genotypes chromosome 8 linked fat mutation distal chromosome 17 cohort I II animals HRS genotype hence excluded genome analysis
0.20854747.15870393.html.plaintext.txt	111	After genome scans two stage model selection procedure followed
0.20854747.15870393.html.plaintext.txt	112	Locus locus pair selection previously described 29
0.20854747.15870393.html.plaintext.txt	113	All loci cleared 5 permutation test threshold one dimensional scans selected
0.20854747.15870393.html.plaintext.txt	114	We selected locus pairs follows
0.20854747.15870393.html.plaintext.txt	115	All pairs cleared 5 permutation test threshold two dimensional scan full two locus model subjected secondary tests
0.20854747.15870393.html.plaintext.txt	116	To determine whether loci pair acting additively compared two locus additive model single locus models dropping locus turn
0.20854747.15870393.html.plaintext.txt	117	For comparison used nominal P value 0
0.20854747.15870393.html.plaintext.txt	118	This corresponds approximately 5 permutation test threshold one dimensional genome scan
0.20854747.15870393.html.plaintext.txt	119	We tested interaction component two locus model using nominal P value 0
0.20854747.15870393.html.plaintext.txt	120	This corresponds 5 permutation test threshold interaction test
0.20854747.15870393.html.plaintext.txt	121	Backward elimination previously described 5
0.20854747.15870393.html.plaintext.txt	122	All loci locus pairs selected previous stage put together multiple QTL model
0.20854747.15870393.html.plaintext.txt	123	The additive cohort effect always included multiple QTL model
0.20854747.15870393.html.plaintext.txt	124	The multiple QTL model formed selecting marker closest locus
0.20854747.15870393.html.plaintext.txt	125	If genotypes missing markers multiple imputation method 26 used account missing genotypes
0.20854747.15870393.html.plaintext.txt	126	The basic idea missing genotypes probabilistically inferred genotypes nearby markers
0.20854747.15870393.html.plaintext.txt	127	This done simulating missing genotype marker conditional flanking typed markers
0.20854747.15870393.html.plaintext.txt	128	To account uncertainty knowledge true genotypes number imputations 26 used
0.20854747.15870393.html.plaintext.txt	129	Each term model including cohort effect dropped change LOD score noted
0.20854747.15870393.html.plaintext.txt	130	This corresponds type III ANOVA
0.20854747.15870393.html.plaintext.txt	131	If nominal P value change LOD score 0
0.20854747.15870393.html.plaintext.txt	132	002 main effects 0
0.20854747.15870393.html.plaintext.txt	133	0001 interactions term dropped
0.20854747.15870393.html.plaintext.txt	134	This procedure continued term could dropped
0.20854747.15870393.html.plaintext.txt	135	To test whether major QTLs specific fatfat animals performed ANOVA test fatfat non fatfat male progeny
0.20854747.15870393.html.plaintext.txt	136	We selected nearest typed marker fatfat non fatfat progeny
0.20854747.15870393.html.plaintext.txt	137	0 cM initial plasma glucose fat induced diabetes 1 find1 D5Mit95 68
0.20854747.15870393.html.plaintext.txt	138	0 cM average plasma glucose find2 D11Mit35 47
0.20854747.15870393.html.plaintext.txt	139	6 cM adiposity index fat induced adiposity 1 fina1 D14Mit5 22
0.20854747.15870393.html.plaintext.txt	140	5 cM final body weight body weight 1 bwt1
0.20854747.15870393.html.plaintext.txt	141	Because plasma glucose measured 20 wk non fatfat mice redefined average glucose measurement animals average plasma glucose levels 4 8 12 16 24 wk test
0.20854747.15870393.html.plaintext.txt	142	The phenotype definitions three phenotypes left unchanged
0.20854747.15870393.html.plaintext.txt	143	Individuals missing phenotypes genotypes discarded
0.20854747.15870393.html.plaintext.txt	144	ANOVAs performed QTL marker genotype separately fatfat non fatfat animals
0.20854747.15870393.html.plaintext.txt	145	Mutation Analysis Total RNA prepared whole brain C57BLKSJ HRSJ mouse
0.20854747.15870393.html.plaintext.txt	146	Tissues homogenized RNA isolated treatment TRIzol Life Technologies according manufacturers protocol
0.20854747.15870393.html.plaintext.txt	147	cDNA generated using Superscript One Step RT PCR kit Life Technologies Gaithersburg MD
0.20854747.15870393.html.plaintext.txt	148	PCR primers mutation analysis orexinhypocretin Hcrt carboxypeptidase D genes Cpd designed sequences public database National Center Biotechnology Information
0.20854747.15870393.html.plaintext.txt	149	PCR amplification cDNA performed using Expand Template system Roche
0.20854747.15870393.html.plaintext.txt	150	Amplified products separated 1 1
0.20854747.15870393.html.plaintext.txt	151	2 gel excised purified using Nucleospin columns Clontech Palo Alto CA sequenced ABI Prism 3700 using forward reverse primers
0.20854747.15870393.html.plaintext.txt	152	RESULTS TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES Segregation Traits F2 Male Progeny To investigate effects Cpefat mutation traits phenotypic data 76 fatfat 48 fat 61 intercross progeny cohort I collected means compared different genotypic groups
0.20854747.15870393.html.plaintext.txt	153	Table 2 summarizes mean values metabolic features examined F2 progeny cohort I
0.20854747.15870393.html.plaintext.txt	154	Increased adiposity hyperglycemia hyperinsulinemia hypercholesteremia observed fatfat homozygotes compared fat heterozygous wild type mice
0.20854747.15870393.html.plaintext.txt	155	The significant difference means physiological parameters observed F2 fatfat fat progeny large variation F2 fatfat progeny suggest background genes playing important role modifying trait phenotypes
0.20854747.15870393.html.plaintext.txt	156	In addition fact HRS fatfat mice exhibit elevated plasma glucose 7 supports idea Cpefat necessary sufficient development diabesity mouse models carrying Cpe defect
0.20854747.15870393.html.plaintext.txt	157	Phenotypic profiles parental BKS fatfat N10 N6 HRS fatfat F2 fatfat fat mice cohort I
0.20854747.15870393.html.plaintext.txt	158	In general fatfat mice significantly higher body weights fat mice
0.20854747.15870393.html.plaintext.txt	159	A heterozygous effect body weight fat mice evident time period examined
0.20854747.15870393.html.plaintext.txt	160	As expected adiposity indexes fatfat mutant mice much higher nonobese controls
0.20854747.15870393.html.plaintext.txt	161	Whereas fat mice tended toward higher adiposity levels significantly different normal littermates
0.20854747.15870393.html.plaintext.txt	162	Interestingly significant differences body length girth also observed three subgroups
0.20854747.15870393.html.plaintext.txt	163	All F2 fat mice normoglycemic
0.20854747.15870393.html.plaintext.txt	164	Of total 282 F2 fatfat males cohorts I III monitored plasma glucose levels 253 abnormal levels plasma glucose 225 mgdl
0.20854747.15870393.html.plaintext.txt	165	Fifty eight percent defined diabetic chronically diabetic plasma glucose 300 mgdl 2 timepoints termination
0.20854747.15870393.html.plaintext.txt	166	Plasma glucose levels ranged 61 1020 mgdl mean 312
0.20854747.15870393.html.plaintext.txt	167	Different forms diabetes onset observed F2 generation mice transiently diabetic early whereas others became diabetic later life
0.20854747.15870393.html.plaintext.txt	168	Hyperlipidemia hyperinsulinemia
0.20854747.15870393.html.plaintext.txt	169	F2 fatfat mice developed chronic hyperinsulinemia plasma insulin 5 ngml mild moderate hyperlipidemia
0.20854747.15870393.html.plaintext.txt	170	At 30 wk age plasma insulin levels elevated 30 fold total cholesterol levels nearly doubled F2 fatfat mice compared nonobese littermates
0.20854747.15870393.html.plaintext.txt	171	QTL Mapping Loci Interacting Cpefat Genome Scan Analysis For QTL analysis data logarithmically transformed stabilize variance
0.20854747.15870393.html.plaintext.txt	172	The resulting phenotypic distributions much symmetric shown Fig
0.20854747.15870393.html.plaintext.txt	173	The frequency distribution body weight varies age whereas frequency distribution plasma glucose remains homogenous 8 24 wk age
0.20854747.15870393.html.plaintext.txt	174	When disease progressions examined animals individually different patterns observed body weight plasma glucose
0.20854747.15870393.html.plaintext.txt	175	To make observations biologically meaningful derived data phenotype different categories detect modifiers affecting rate flux severity disease progression see MATERIALS AND METHODS
0.20854747.15870393.html.plaintext.txt	176	View larger version 25K Fig
0.20854747.15870393.html.plaintext.txt	177	Frequency distributions BWs A PG levels B F2 fatfat male mice biweekly time intervals
0.20854747.15870393.html.plaintext.txt	178	The length horizontal lines corresponds number observations
0.20854747.15870393.html.plaintext.txt	179	A total 87 SSLP markers used genotype total 282 fatfat male progeny
0.20854747.15870393.html.plaintext.txt	180	The results one two dimensional scans shown Fig
0.20854747.15870393.html.plaintext.txt	181	In Table 3 summary major QTLs positions presented whereas Table 4 type III ANOVA table corresponding multiple QTL model selected trait shown
0.20854747.15870393.html.plaintext.txt	182	View larger version 32K Fig
0.20854747.15870393.html.plaintext.txt	183	A genome scan plots one dimensional traits
0.20854747.15870393.html.plaintext.txt	184	Chromosomes containing significant markers shown bold
0.20854747.15870393.html.plaintext.txt	185	B allelic plots significant quanitative trait loci QTL adiposity BW PG plasma insulin total cholesterol derived phenotypes
0.20854747.15870393.html.plaintext.txt	186	C allelic plot significant interactive QTL BW two dimensional scan
0.20854747.15870393.html.plaintext.txt	187	Summary major QTL adiposity body weight PG plasma insulin blood cholesterol detected F2 BKS x HRS fatfat mice
0.20854747.15870393.html.plaintext.txt	188	Multiple QTL models type III ANOVA traits
0.20854747.15870393.html.plaintext.txt	189	A major QTL Cpefat induced adiposity fina1 identified chromosome 11 F2 fatfat male progeny peak LOD score D11Mit242
0.20854747.15870393.html.plaintext.txt	190	QTL analysis individual fat pad weights detected QTLs rostral caudal epididymal fat pads region chromosome 11
0.20854747.15870393.html.plaintext.txt	191	Mice homozygous BKS derived allele D11Mit242 significantly higher fat depot weights Fig
0.20854747.15870393.html.plaintext.txt	192	In F2 male progeny major locus body weight bwt1 identified chromosome 14 tightly linked hr
0.20854747.15870393.html.plaintext.txt	193	To determine effects hr various traits F2 intercross progeny fatfat fat mice genotyped allele specific primers hr mutation mean values traits compared Table 5
0.20854747.15870393.html.plaintext.txt	194	In three genetic subgroups mice homozygous hr mutation significantly reduced body weight measurements suggests bwt1 acting independently fat body weight
0.20854747.15870393.html.plaintext.txt	195	In addition fatfat fat hr mice lowered total cholesterol plasma insulin levels shown
0.20854747.15870393.html.plaintext.txt	196	Body weight BKS x HRS F2 fatfat fat mice segregated hr
0.20854747.15870393.html.plaintext.txt	197	We identified locus chromosome 18 interacts bwt1 lower body weight intra allelic interaction heterosis
0.20854747.15870393.html.plaintext.txt	198	That heterozygosity chromosome 18 strongest epistatic effect body weight mice homozygous HRS derived allele bwt1 Fig
0.20854747.15870393.html.plaintext.txt	199	The chromosome 18 locus showed significant effect body weights interacting bwt1 independent effect body weight measurements
0.20854747.15870393.html.plaintext.txt	200	A major locus weight gain maximum LOD score 5
0.20854747.15870393.html.plaintext.txt	201	0 D11Mit23 overlapped adiposity locus fina1 also detected
0.20854747.15870393.html.plaintext.txt	202	Mice homozygous BKS derived alleles BB largest weight gains compared heterozygous BH homozygous HH HRS littermates Fig
0.20854747.15870393.html.plaintext.txt	203	Hyperglycemia hyperinsulinemia hypercholesterolemia
0.20854747.15870393.html.plaintext.txt	204	Two loci Cpefat induced diabetes find1 find2 detected chromosomes 19 5 respectively Fig
0.20854747.15870393.html.plaintext.txt	205	For find2 mice homozygous BKS derived alleles BB exhibited higher plasma glucose levels BH homozygous HH littermates whereas find1 presence HRS allele resulted elevated plasma glucose levels
0.20854747.15870393.html.plaintext.txt	206	The find2 locus found affect metabolic features besides plasma glucose insulin total cholesterol levels
0.20854747.15870393.html.plaintext.txt	207	With use backward elimination multiple QTL model locus including find2 identified interaction find1
0.20854747.15870393.html.plaintext.txt	208	The fact significant interaction detected find1 surprising HRS fatfat mice become diabetic
0.20854747.15870393.html.plaintext.txt	209	Because hr segregated crosses hypothesized find1 effect plasma glucose may dependent hr genotype chromosome 14
0.20854747.15870393.html.plaintext.txt	210	We compared plasma glucose means mice homozygous HRS derived allele find1 two genotypic cohorts BB HH D14Mit115 marker tightly linked hr locus Table 6
0.20854747.15870393.html.plaintext.txt	211	As suspected mice homozygous HRS derived allele find1 homozygous BKS derived allele D14Mit115 significantly higher plasma glucose levels mice homozygous HRS derived alleles find1 D14Mit115
0.20854747.15870393.html.plaintext.txt	212	Comparison PG levels BB HH genotypes D14Mit115
0.20854747.15870393.html.plaintext.txt	213	Significant loci plasma insulin 24 wk total cholesterol 16 wk detected chromosome 5 find2 Fig
0.20854747.15870393.html.plaintext.txt	214	F2 mice homozygous BKS derived allele D5Mit95 significantly higher total cholesterol levels lower plasma insulin levels
0.20854747.15870393.html.plaintext.txt	215	Evaluation Major QTL Fat Progeny To determine whether major QTL identified acted modifiers Cpefat mutation performed ANOVAs QTL marker genotype separately fatfat non fatfat male intercross progeny Table 7
0.20854747.15870393.html.plaintext.txt	216	As fatfat mice significant effect also observed bwt1 fat mice D14Mit5 marker linked hr locus
0.20854747.15870393.html.plaintext.txt	217	However none QTLs find1 find2 fina1 showed strong effect non fatfat male progeny consistent modifier hypothesis
0.20854747.15870393.html.plaintext.txt	218	ANOVA results major QTL effects CpefatCpefat Cpefat Cpe mice
0.20854747.15870393.html.plaintext.txt	219	Evaluation Candidate Genes The region spanning fina1 includes attractive biological candidates Hcrt Cpd
0.20854747.15870393.html.plaintext.txt	220	Orexin positive neurons localized lateral hypothalamus project throughout brain
0.20854747.15870393.html.plaintext.txt	221	Orexin knockout mice exhibit narcoleptic phenotype suggests orexin may function regulation arousal sleep wake cycle 6
0.20854747.15870393.html.plaintext.txt	222	However intraventricular injection orexin peptide increases feeding C57BL6J mice 18
0.20854747.15870393.html.plaintext.txt	223	Carboxypeptidase D similar enzymatic activity CPE might functionally complement CPE deficit cell types
0.20854747.15870393.html.plaintext.txt	224	Mutation analysis coding regions Hcrt Cpd mRNA HRS BKS mice detected sequence differences
0.20854747.15870393.html.plaintext.txt	225	Although promotor regions examined mRNA abundance differ judged amount ethidium bromide stained RT PCR product obtained two strains
0.20854747.15870393.html.plaintext.txt	226	DISCUSSION TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES Obesity complex multifactorial disease human population often associated increased susceptibility comorbidities Type II diabetes atherosclerosis hypertension 30
0.20854747.15870393.html.plaintext.txt	227	HRS fatfat mice resistance HRS fatfat mice Type II diabetes make mutant fat mouse useful model study gene interactions development diabesity
0.20854747.15870393.html.plaintext.txt	228	In study two major loci hyperglycemia find2 find1 identified chromosomes 5 19 respectively
0.20854747.15870393.html.plaintext.txt	229	F2 fatfat mice homozygous BKS derived allele find2 increased susceptibility mice homozygous HRS derived allele resistant hyperglycemia
0.20854747.15870393.html.plaintext.txt	230	Hence hypothesize find2 may locus protects HRS fatfat mice developing diabetes
0.20854747.15870393.html.plaintext.txt	231	It known previously BKS genetic background diabetogenic 7
0.20854747.15870393.html.plaintext.txt	232	In C57BLKSJ x C57BL6J LeprdbLeprdb intercross two putative loci hyperglycemia identified chromosomes 8 17 QTL detected chromosome 5 21
0.20854747.15870393.html.plaintext.txt	233	This disparity may due differences db fat mutations interacting BKS background
0.20854747.15870393.html.plaintext.txt	234	Alternatively chromosome 8 locus may lie close Cpe locus BKS
0.20854747.15870393.html.plaintext.txt	235	HRS mice used may carry
0.20854747.15870393.html.plaintext.txt	236	In addition subset mice analyzed BKS x B6 intercross 20 highest plasma glucose lowest plasma glucose levels thus find2 locus chromosome 5 locus may missed
0.20854747.15870393.html.plaintext.txt	237	BKS x HRS F2 fatfat mice homozygous HRS allele find1 elevated plasma glucose levels
0.20854747.15870393.html.plaintext.txt	238	Because HRS fatfat mice become hyperglycemic implies find1 interacting additional loci BKS background
0.20854747.15870393.html.plaintext.txt	239	Our multiple QTL model detect locus interacting find1 however observe association plasma glucose levels mice homozygous HH find1 genotype near hr locus chromosome 14
0.20854747.15870393.html.plaintext.txt	240	This suggests hr gene closely linked gene may effect find1 expression
0.20854747.15870393.html.plaintext.txt	241	In addition loci closely linked Cpe locus chromosome 8 cannot ruled mice analyzed homozygous Cpefat
0.20854747.15870393.html.plaintext.txt	242	Diabetes susceptibility loci found interval find1 distal mouse chromosome 19 several rodent experiments 11 12 16 27
0.20854747.15870393.html.plaintext.txt	243	Whether loci due mutations gene remains determined
0.20854747.15870393.html.plaintext.txt	244	A major QTL body weight bwt1 identified chromosome 14
0.20854747.15870393.html.plaintext.txt	245	The LOD peak bwt1 close vicinity hr making hr plausible candidate
0.20854747.15870393.html.plaintext.txt	246	Allele typing hr allele F2 progeny showed hrhr mutant mice significantly lower mean body weight values haired mice
0.20854747.15870393.html.plaintext.txt	247	Hairless HRS mice HRS hrhr mice also lower mean adipose depot body weights normally haired albino HRS littermates 20
0.20854747.15870393.html.plaintext.txt	248	It previously shown hairless mice higher metabolic rate normally haired albino mice 9
0.20854747.15870393.html.plaintext.txt	249	This attributed greater energy requirement thermoregulation mice lacking body hair
0.20854747.15870393.html.plaintext.txt	250	However recently discovered hr gene product acts corepressor thyroid hormone receptor 24 hr mutation might therefore mimic effects thyroid hormone energy metabolism
0.20854747.15870393.html.plaintext.txt	251	Altogether data suggest hr responsible lowered body weight HRS hrhr mice hr gene explains variance observed F2 fatfat males acts independently fat locus
0.20854747.15870393.html.plaintext.txt	252	There currently published reports adiposity human patients congenital alopecia artrichia carrying mutations Hr gene unclear whether hr mutations effect metabolism humans mice
0.20854747.15870393.html.plaintext.txt	253	A major locus fina1 chromosome 11 strongly associated adiposity genome scan F2 fatfat mice
0.20854747.15870393.html.plaintext.txt	254	The fact fina1 observed lean controls implies fina1 locus epistatically interacting fat thereby masking effects hr adipose depot distribution F2 fatfat mutant mice
0.20854747.15870393.html.plaintext.txt	255	The interval fina1 still fairly large includes intriguing candidates Hcrt Cpd
0.20854747.15870393.html.plaintext.txt	256	Although sequence variations observed coding regions genes possibility promoter defects needs exploration
0.20854747.15870393.html.plaintext.txt	257	In study carried genetic analysis complex phenotype caused prohormone processing defect fat mutant mice
0.20854747.15870393.html.plaintext.txt	258	We use novel method analyzing modifier genes involved different patterns disease progression rate fluctuation severity
0.20854747.15870393.html.plaintext.txt	259	We also show many phenotypes observed fat mice ameliorated action major modifier genes
0.20854747.15870393.html.plaintext.txt	260	Because obesity often associated alterations neuropeptide levels identification diabesity associated modifier QTL also lead better understanding biological pathways neuropeptides may involved common forms obesity
0.20854747.15870393.html.plaintext.txt	261	GRANTS TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES This study supported National Institute Diabetes Digestive Kidney Diseases Grants DK 46977 DK 53278
0.20854747.15870393.html.plaintext.txt	262	Institutional shared services supported National Cancer Institute Cancer Center Support Grant CA 34196
0.20854747.15870393.html.plaintext.txt	263	ACKNOWLEDGMENTS We gratefully acknowledge technical assistance Theolyn Gilley Jay Young
0.20854747.15870393.html.plaintext.txt	264	FOOTNOTES Article published online print
0.20854747.15870393.html.plaintext.txt	265	See web site date publication httpphysiolgenomics
0.20854747.15870393.html.plaintext.txt	266	Address reprint requests correspondence J
0.20854747.15870393.html.plaintext.txt	267	Naggert The Jackson Laboratory 600 Main St
0.20854747.15870393.html.plaintext.txt	268	Bar Harbor ME 04609 E mail jknatjax
0.20854747.15870393.html.plaintext.txt	269	Maddatu contributed equally work
0.20854747.15870393.html.plaintext.txt	270	REFERENCES TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES Almind K Kulkarni RN Lannon SM Kahn CR
0.20854747.15870393.html.plaintext.txt	271	Identification interactive loci linked insulin leptin mice genetic resistance
0.20854747.15870393.html.plaintext.txt	272	Diabetes 52 1535 1543 2003
0.20854747.15870393.html.plaintext.txt	273	AbstractFree Full Text Bailey D
0.20854747.15870393.html.plaintext.txt	274	How pure inbred strains mice Immunol Today 3 210 214 1982
0.20854747.15870393.html.plaintext.txt	275	CrossRefISI Berman Y Mzhavia N Polonskaia A Devi LA
0.20854747.15870393.html.plaintext.txt	276	Impaired prohormone convertases CpefatCpefat mice
0.20854747.15870393.html.plaintext.txt	277	J Biol Chem 276 1466 1473 2001
0.20854747.15870393.html.plaintext.txt	278	AbstractFree Full Text Brockmann GA Bevova MR
0.20854747.15870393.html.plaintext.txt	279	Using mouse models dissect genetics obesity
0.20854747.15870393.html.plaintext.txt	280	Trends Genet 18 367 376 2002
0.20854747.15870393.html.plaintext.txt	281	CrossRefISIMedline Broman KW Speed TP
0.20854747.15870393.html.plaintext.txt	282	A model selection approach identification quantitative trait loci experimental crosses
0.20854747.15870393.html.plaintext.txt	283	J Royal Stat Soc B 64 641 656 731 775 2002
0.20854747.15870393.html.plaintext.txt	284	CrossRefISI Chemelli RM Willie JT Sinton CM Elmquist JK Scamell T Lee C Richardson JA Williams SC Xiong Y
0.20854747.15870393.html.plaintext.txt	285	Narcolepsy orexin knockout mice molecular genetics sleep regulation
0.20854747.15870393.html.plaintext.txt	286	CrossRefISIMedline Coleman DL Eicher EM
0.20854747.15870393.html.plaintext.txt	287	Fat fat tubby tub two autosomal recessive mutations causing obesity syndromes mouse
0.20854747.15870393.html.plaintext.txt	288	ISIMedline DiPetrillo K Tsaih SW Sheehan S Johns C Kelmenson P Gavras H Churchill GA Paigen B
0.20854747.15870393.html.plaintext.txt	289	Genetic analysis blood pressure C3HHeJ SWRJ mice
0.20854747.15870393.html.plaintext.txt	290	Physiol Genomics 17 215 220 2004
0.20854747.15870393.html.plaintext.txt	291	AbstractFree Full Text Donnelly HT
0.20854747.15870393.html.plaintext.txt	292	Oxygen consumption activity body fat normal hairless mice
0.20854747.15870393.html.plaintext.txt	293	ISIMedline Fricker LD Berman YL Leiter EL Devi LA
0.20854747.15870393.html.plaintext.txt	294	Carboxypeptidase E activity deficient mice fat mutation
0.20854747.15870393.html.plaintext.txt	295	J Biol Chem 271 30619 30624 1996
0.20854747.15870393.html.plaintext.txt	296	AbstractFree Full Text Galli J Li LS Glasser A Ostenson CG Jiao H Fakhrai rad H Jacob HJ Lander ES Lutherman H
0.20854747.15870393.html.plaintext.txt	297	Genetic analysis non insulin dependent diabetes mellitus GK rat
0.20854747.15870393.html.plaintext.txt	298	CrossRefISIMedline Gauguier D Froguel P Oarent V Bernard C Bihoreau MT Portha B James MR Penicaud L Lathrop M Ktorza A
0.20854747.15870393.html.plaintext.txt	299	Chromosomal mapping genetic loci associated non insulin dependent diabetes GK rat
0.20854747.15870393.html.plaintext.txt	300	CrossRefISIMedline Gloyn AL McCarthy MI
0.20854747.15870393.html.plaintext.txt	301	The genetics type 2 diabetes
0.20854747.15870393.html.plaintext.txt	302	Best Pract Res Clin Endocrinol Metab 15 293 308 2001
0.20854747.15870393.html.plaintext.txt	303	CrossRefISIMedline Ikeda A Zheng QY Rosenstiel P Maddatu T Zuberi AR Roopenian DC North MA Naggert JK Johnson KR Nishina PM
0.20854747.15870393.html.plaintext.txt	304	Genetic modification hearing tubby mice evidence existence major gene moth1 protects tubby mice hearing loss
0.20854747.15870393.html.plaintext.txt	305	Hum Mol Genet 8 1761 1767 1999
0.20854747.15870393.html.plaintext.txt	306	AbstractFree Full Text Izzo C Grillo F Murador E
0.20854747.15870393.html.plaintext.txt	307	Improved method determination high density lipoprotein cholesterol
0.20854747.15870393.html.plaintext.txt	308	Isolationof high density lipoproteins use polyethylene glycol 6000
0.20854747.15870393.html.plaintext.txt	309	Clin Chem 27 371 374 1981
0.20854747.15870393.html.plaintext.txt	310	AbstractFree Full Text Kim JH Sen S Avery CS Simpson E Chandler P Nishina PM Churchill GA Naggert JK
0.20854747.15870393.html.plaintext.txt	311	Genetic analysis new mouse model non insulin dependent diabetes
0.20854747.15870393.html.plaintext.txt	312	CrossRefISIMedline Li R Lyons MA Wittenburg H Paigen B Churchill GA
0.20854747.15870393.html.plaintext.txt	313	Combining data multiple inbred line crosses improves power resolution quantitative trait loci mapping
0.20854747.15870393.html.plaintext.txt	314	Genetics 169 1699 1709 2005
0.20854747.15870393.html.plaintext.txt	315	AbstractFree Full Text Lubkin M Stricker Krongrad A
0.20854747.15870393.html.plaintext.txt	316	Independent feeding metabolic actions orexins mice
0.20854747.15870393.html.plaintext.txt	317	Biochem Biophys Res Commun 253 241 245 1998
0.20854747.15870393.html.plaintext.txt	318	CrossRefISIMedline Maddatu TP Naggert JK
0.20854747.15870393.html.plaintext.txt	319	Allele specific PCR assays tub cpefat mutations
0.20854747.15870393.html.plaintext.txt	320	Mamm Genome 8 857 858 1997
0.20854747.15870393.html.plaintext.txt	321	CrossRefISIMedline Mount LE
0.20854747.15870393.html.plaintext.txt	322	Metabolic rate thermal insulation albino hairless mice
0.20854747.15870393.html.plaintext.txt	323	J Physiol 217 315 326 1971
0.20854747.15870393.html.plaintext.txt	324	ISIMedline Mu JL Naggert JK Svenson KL Collin GB Kim JH McFarland C Nishina PM Levine DM Williams KJ Paigen B
0.20854747.15870393.html.plaintext.txt	325	Quantitative trait loci analysis differences susceptibility atherosclerosis diabetes inbred mouse strains C57BL6J C57BLKSJ
0.20854747.15870393.html.plaintext.txt	326	J Lipid Res 40 1328 1335 1999
0.20854747.15870393.html.plaintext.txt	327	AbstractFree Full Text Naggert JK Fricker LD Varlamov O Nishina PM Rouille Y Steiner DF Carroll RJ Paigen BJ Leiter EH
0.20854747.15870393.html.plaintext.txt	328	Hyperproinsulinaemia obese fatfat mice associated carboxypeptidase E mutation reduces enzyme activity
0.20854747.15870393.html.plaintext.txt	329	Nat Genet 10 135 142 1995
0.20854747.15870393.html.plaintext.txt	330	Genetic dissection obesity polygenic animal models
0.20854747.15870393.html.plaintext.txt	331	Behav Genet 27 285 306 1997
0.20854747.15870393.html.plaintext.txt	332	CrossRefISIMedline Potter GB Beaudoin IIIGMJ DeRenzo CL Zarach JM Chen SH Thompson CC
0.20854747.15870393.html.plaintext.txt	333	The hairless gene mutated congenital hair loss disorders encodes novel nuclear receptor corepressor
0.20854747.15870393.html.plaintext.txt	334	Genes Dev 15 2687 2701 2001
0.20854747.15870393.html.plaintext.txt	335	AbstractFree Full Text Rovere C Viale A Nahon J Kitabgi P
0.20854747.15870393.html.plaintext.txt	336	Impaired processing brain proneurotensin promelanin concentrating hormone obese fatfat mice
0.20854747.15870393.html.plaintext.txt	337	Endocrinology 137 2954 2958 1996
0.20854747.15870393.html.plaintext.txt	338	Abstract Sen S Churchill GA
0.20854747.15870393.html.plaintext.txt	339	A statistical framework quantitative trait mapping
0.20854747.15870393.html.plaintext.txt	340	Genetics 159 371 387 2001
0.20854747.15870393.html.plaintext.txt	341	AbstractFree Full Text Stoehr JP Nadler ST Schueler KL Rabaglia ME Yandell BS Metz SA Attie AD
0.20854747.15870393.html.plaintext.txt	342	Genetic obesity unmasks nonlinear interactions murine type 2 diabetes susceptibility loci
0.20854747.15870393.html.plaintext.txt	343	Diabetes 49 1946 1954 2000
0.20854747.15870393.html.plaintext.txt	344	Preparation genomic DNA mammalian tissue
0.20854747.15870393.html.plaintext.txt	345	In Current Protocols Molecular Biology
0.20854747.15870393.html.plaintext.txt	346	Sugiyama F Churchill GA Higgins DC Johns C Makaritsis KP Gavras H Paigen B
0.20854747.15870393.html.plaintext.txt	347	Concordance murine quantitative trait loci salt induced hypertension rat human loci
0.20854747.15870393.html.plaintext.txt	348	CrossRefISIMedline Watkins PJ
0.20854747.15870393.html.plaintext.txt	349	Cardiovascular disease hypertension lipids
0.20854747.15870393.html.plaintext.txt	350	Free Full Text Zou F Yandell BS Fine JP
0.20854747.15870393.html.plaintext.txt	351	Statistical issues analysis quantitative traits combined crosses
0.20854747.15870393.html.plaintext.txt	352	Genetics 158 1339 1346 2001
0.18866605.11796701.html.plaintext.txt	0	HIGHLIGHTED TOPICS Functional Genomics Sleep Circadian Rhythm Invited Review Integration human sleep wake regulation circadian rhythmicity Derk Jan Dijk1 Steven W
0.18866605.11796701.html.plaintext.txt	1	1 Centre Chronobiology School Biomedical Life Sciences University Surrey Guildford GU27XH United Kingdom 2 Division Sleep Medicine Brigham Womens Hospital Harvard Medical School Boston Massachusetts 02115
0.18866605.11796701.html.plaintext.txt	2	ABSTRACT TOP ABSTRACT INTRODUCTION SEPARATION OF CIRCADIAN AND
0.18866605.11796701.html.plaintext.txt	3	CIRCADIAN SLEEP WAKE PROPENSITY
0.18866605.11796701.html.plaintext.txt	4	DIURNAL PREFERENCE ADVANCED AND DELAYED SLEEP
0.18866605.11796701.html.plaintext.txt	5	CONCLUSION AND PERSPECTIVES REFERENCES
0.18866605.11796701.html.plaintext.txt	6	The human sleep wake cycle generated circadian process originating suprachiasmatic nuclei interaction separate oscillatory process sleep homeostat
0.18866605.11796701.html.plaintext.txt	7	The sleep wake cycle normally timed occur specific phase relative external cycle light dark exposure
0.18866605.11796701.html.plaintext.txt	8	It also timed specific phase relative internal circadian rhythms pineal melatonin rhythm circadian sleep wake propensity rhythm rhythm responsiveness circadian pacemaker light
0.18866605.11796701.html.plaintext.txt	9	Variations internal external phase relationships occur blindness aging morning evening advanced delayed sleep phase syndrome lead sleep disruptions complaints
0.18866605.11796701.html.plaintext.txt	10	Changes ocular circadian photoreception interindividual variation near 24 h intrinsic period circadian pacemaker sleep homeostasis contribute variations external internal phase
0.18866605.11796701.html.plaintext.txt	11	Recent findings physiological molecular genetic correlates circadian sleep disorders suggest timing sleep wake cycle circadian rhythms closely integrated part regulated differentially
0.18866605.11796701.html.plaintext.txt	12	sleep homeostasis entrainment clock genes blindness aging
0.18866605.11796701.html.plaintext.txt	13	INTRODUCTION TOP ABSTRACT INTRODUCTION SEPARATION OF CIRCADIAN AND
0.18866605.11796701.html.plaintext.txt	14	CIRCADIAN SLEEP WAKE PROPENSITY
0.18866605.11796701.html.plaintext.txt	15	DIURNAL PREFERENCE ADVANCED AND DELAYED SLEEP
0.18866605.11796701.html.plaintext.txt	16	CONCLUSION AND PERSPECTIVES REFERENCES
0.18866605.11796701.html.plaintext.txt	17	WE ARE ALL CONSCIOUS OF BEDTIME wake time subjective quality sleep
0.18866605.11796701.html.plaintext.txt	18	Our appreciation importance sleep wake cycle enhanced confronted consequences disruption
0.18866605.11796701.html.plaintext.txt	19	Disturbance timing sleep cycles occurs example response shift work jet lag long work hours social family demands leads decrements quality life performance health
0.18866605.11796701.html.plaintext.txt	20	Disorders daily sleep patterns also observed blind individuals older people sighted young individuals suffering circadian sleep disorders
0.18866605.11796701.html.plaintext.txt	21	Such disorders often lead use sleep aids hypnotics among commonly prescribed medications
0.18866605.11796701.html.plaintext.txt	22	Biological circadian clocks thought play important role regulation sleep wake cycles disorders
0.18866605.11796701.html.plaintext.txt	23	Recently remarkable progress made understanding functions mechanisms circadian clocks various model systems levels description ranging intact organism clock gene expression vitro
0.18866605.11796701.html.plaintext.txt	24	Progress also made understanding regulation timing human sleep wake cycle integration timing endogenous circadian rhythms endocrinology physiology
0.18866605.11796701.html.plaintext.txt	25	The human sleep wake cycle simply driven circadian pacemaker located suprachiasmatic nuclei SCN instead generated interactions circadian rhythmicity sleep wake oscillatory process sleep homeostasis circadian photoreception well feedback sleep wake cycle onto processes see Fig
0.18866605.11796701.html.plaintext.txt	26	Alterations processes interactions may lead sleep wakefulness occurring abnormal clock times altered external timing andor phase endogenous circadian rhythms altered internal timing
0.18866605.11796701.html.plaintext.txt	27	Here describe recent developments related circadian sleep propensity rhythm sleep homeostasis circadian photoreception
0.18866605.11796701.html.plaintext.txt	28	View larger version 16K Fig
0.18866605.11796701.html.plaintext.txt	29	A circadian pacemaker clock presumably located suprachiasmatic nuclei SCN sleep homeostat presumably located outside SCN two major determinants timing human sleep wake cycle sleep structure
0.18866605.11796701.html.plaintext.txt	30	The oscillation sleep homeostat strongly maybe exclusively determined sleep wake cycle arrow 1
0.18866605.11796701.html.plaintext.txt	31	Light input circadian clock mediated circadian photoreception
0.18866605.11796701.html.plaintext.txt	32	The sleep wake cycle major determinant light input clock arrow 2
0.18866605.11796701.html.plaintext.txt	33	SEPARATION OF CIRCADIAN AND SLEEP HOMEOSTATIC PROCESSES TOP ABSTRACT INTRODUCTION SEPARATION OF CIRCADIAN AND
0.18866605.11796701.html.plaintext.txt	34	CIRCADIAN SLEEP WAKE PROPENSITY
0.18866605.11796701.html.plaintext.txt	35	DIURNAL PREFERENCE ADVANCED AND DELAYED SLEEP
0.18866605.11796701.html.plaintext.txt	36	CONCLUSION AND PERSPECTIVES REFERENCES
0.18866605.11796701.html.plaintext.txt	37	It long recognized adequate description phenomenology sleep wake timing approximate daily time basis two separate interacting oscillatory processes need postulated strong circadian oscillator sleep wake oscillatory process sleep homeostat reviews see Refs
0.18866605.11796701.html.plaintext.txt	38	Early key evidence existence two processes included observation spontaneous desynchrony sleep wake cycle circadian rhythm body temperature classical temporal isolation studies 6 30 circadian variation sleep duration experimentally displaced sleep 8
0.18866605.11796701.html.plaintext.txt	39	These data summarized mathematical conceptual models sleep wake cycle contribution two oscillatory processes sleep timing defined 13 32 63
0.18866605.11796701.html.plaintext.txt	40	Experimental human animal work past two decades confirmed dual regulation sleep timing circadian process relaxation type sleep wake oscillatory process
0.18866605.11796701.html.plaintext.txt	41	The latter process also referred sleep homeostat functional perspective oscillatory process regulates average level sleep debt
0.18866605.11796701.html.plaintext.txt	42	Sleep debt increases wakefulness dissipates sleep
0.18866605.11796701.html.plaintext.txt	43	More recently quantification relative contribution processes forced desynchrony sleep wake cycle circadian process shown processes contribute equally sleep consolidation waking performance 36 98
0.18866605.11796701.html.plaintext.txt	44	The relative contribution two processes sleep structure aspects electroencephalogram EEG non rapid eye movement NREM rapid eye movement REM sleep varies widely 37 41
0.18866605.11796701.html.plaintext.txt	45	CIRCADIAN SLEEP WAKE PROPENSITY SIGNAL TOP ABSTRACT INTRODUCTION SEPARATION OF CIRCADIAN AND
0.18866605.11796701.html.plaintext.txt	46	CIRCADIAN SLEEP WAKE PROPENSITY
0.18866605.11796701.html.plaintext.txt	47	DIURNAL PREFERENCE ADVANCED AND DELAYED SLEEP
0.18866605.11796701.html.plaintext.txt	48	CONCLUSION AND PERSPECTIVES REFERENCES
0.18866605.11796701.html.plaintext.txt	49	Lesions SCN animals clinical cases hypothalamic areas close SCN damaged demonstrated strong circadian process affecting sleep timing sleep structure generated SCN 27 46 87
0.18866605.11796701.html.plaintext.txt	50	1 In humans SCN thought generate wake arousal signal increases strength throughout biological day
0.18866605.11796701.html.plaintext.txt	51	habitual wake episode peaking evening hours 2200 h
0.18866605.11796701.html.plaintext.txt	52	The strength signal declines biological night
0.18866605.11796701.html.plaintext.txt	53	habitual sleep episode 36 48 reach minimum 0600 h coincides temperature nadir 36
0.18866605.11796701.html.plaintext.txt	54	In absence circadian arousal signal sleep wake consolidation lost monophasic sleep wake cycle replaced polyphasic sleep wake cycle presumably dictated primarily sleep homeostasis
0.18866605.11796701.html.plaintext.txt	55	Thus circadian pacemaker maintains timing sleep wake cycle consolidation sleep wake behavior opposing increase homeostatic sleep need associated sustained wakefulness
0.18866605.11796701.html.plaintext.txt	56	Experiments sleep scheduled occur many circadian phases demonstrated consolidated 8 h episode sleep obtained one specific phase relationship sleep wake cycle endogenous circadian rhythmicity
0.18866605.11796701.html.plaintext.txt	57	Only sleep initiated 6 h temperature nadir
0.18866605.11796701.html.plaintext.txt	58	shortly crest wake propensity rhythm sleep remain virtually uninterrupted 8 h see Fig
0.18866605.11796701.html.plaintext.txt	59	View larger version 44K Fig
0.18866605.11796701.html.plaintext.txt	60	Wakefulness scheduled sleep episodes simultaneous function time since start sleep episode circadian phase core body temperature rhythm
0.18866605.11796701.html.plaintext.txt	61	Consolidation sleep 8 h observed sleep initiated 6 8 h temperature nadir dashed line
0.18866605.11796701.html.plaintext.txt	62	The circadian sleep wake propensity rhythm could generated circadian modulation wake propensity circadian modulation sleep propensity circadian modulation
0.18866605.11796701.html.plaintext.txt	63	Evidence circadian pacemaker primarily affects wake propensity derived studies squirrel monkeys
0.18866605.11796701.html.plaintext.txt	64	SCN lesions lead increase total sleep time per 24 h conjunction loss circadian sleep timing 48
0.18866605.11796701.html.plaintext.txt	65	Such increase total sleep time suggests promotion wakefulness absent absence SCN
0.18866605.11796701.html.plaintext.txt	66	On hand SCN lesion studies animals forced desynchrony studies young older healthy people support view SCN also actively promotes sleep particular second half normal sleep episode 40 97
0.18866605.11796701.html.plaintext.txt	67	Thus intact squirrel monkey wakefulness second half subjective night lowest levels well percentage wakefulness observed SCN lesioned animal 48
0.18866605.11796701.html.plaintext.txt	68	Comparisons REM sleep rebound REM sleep deprivation control SCN lesioned rats demonstrated major rest phase SCN actively promotes entry REM sleep 97
0.18866605.11796701.html.plaintext.txt	69	In humans sleep spindle activity highest biological night
0.18866605.11796701.html.plaintext.txt	70	Furthermore sleep latencies older people longer young people around temperature nadir circadian phases suggesting active promotion sleep SCN diminished circadian phase older people 40
0.18866605.11796701.html.plaintext.txt	71	The waveform endogenously generated circadian sleep wake propensity rhythm may change response variations day length photoperiod prolonged exposure long dark episodes internal biological night extended 94 95
0.18866605.11796701.html.plaintext.txt	72	The circadian arousal andor circadian hypnotic signals could humoral andor neural
0.18866605.11796701.html.plaintext.txt	73	The circadian variation sleep propensity closely associated circadian rhythm plasma melatonin 35 68
0.18866605.11796701.html.plaintext.txt	74	Recent functional neuroanatomic studies identified pathways SCN may transmit circadian information sleep arousal centers rat
0.18866605.11796701.html.plaintext.txt	75	Efferents SCN modulate numerous systems including adrenergic serotonergic histaminergic orexin systems 1 7 73 75 79
0.18866605.11796701.html.plaintext.txt	76	Deficiencies orexin system implicated sleep disorder narcolepsy 81 82
0.18866605.11796701.html.plaintext.txt	77	Narcoleptic patients experience excessive daytime sleepiness multiple sleep attacks day though unable maintain wakefulness
0.18866605.11796701.html.plaintext.txt	78	Edgar colleagues 33 demonstrated whereas timing circadian modulation sleep propensity normal strength signal
0.18866605.11796701.html.plaintext.txt	79	promotion wakefulness appears markedly attenuated narcoleptics
0.18866605.11796701.html.plaintext.txt	80	The recent insights derived studies orexin system narcoleptic patients suggest orexin may part circadian effector system
0.18866605.11796701.html.plaintext.txt	81	MEDIATORS AND MARKERS OF SLEEP HOMEOSTASIS TOP ABSTRACT INTRODUCTION SEPARATION OF CIRCADIAN AND
0.18866605.11796701.html.plaintext.txt	82	CIRCADIAN SLEEP WAKE PROPENSITY
0.18866605.11796701.html.plaintext.txt	83	DIURNAL PREFERENCE ADVANCED AND DELAYED SLEEP
0.18866605.11796701.html.plaintext.txt	84	CONCLUSION AND PERSPECTIVES REFERENCES
0.18866605.11796701.html.plaintext.txt	85	Slow wave sleep SWS EEG slow wave activity SWA NREM sleep classical markers sleep homeostatic process
0.18866605.11796701.html.plaintext.txt	86	Increases SWA visually scored SWS sleep deprivation obliterated SCN lesioned rodents 90
0.18866605.11796701.html.plaintext.txt	87	In humans SWS SWA decline sleep independent circadian phase sleep occurs
0.18866605.11796701.html.plaintext.txt	88	Furthermore duration wakefulness predicts much SWS SWA occur sleep circadian phases 9 34
0.18866605.11796701.html.plaintext.txt	89	Thus localization sleep homeostat likely distinct SCN could diffuse
0.18866605.11796701.html.plaintext.txt	90	There convincing evidence time course sleep homeostatic process also monitored wakefulness humans
0.18866605.11796701.html.plaintext.txt	91	Low frequency components EEG increase duration wakefulness progresses circadian phases 3 19 21 49
0.18866605.11796701.html.plaintext.txt	92	Scheduling multiple naps day attenuates increase low frequency activity wakefulness 22
0.18866605.11796701.html.plaintext.txt	93	This similar previously observed reduction SWA sleep following daytime naps 96
0.18866605.11796701.html.plaintext.txt	94	It thus appears low frequency components EEG wakefulness closely associated sleep homeostasis
0.18866605.11796701.html.plaintext.txt	95	Interestingly effects wakefulness sleep wake EEG pronounced frontal cortical areas brain 20 21 49 50
0.18866605.11796701.html.plaintext.txt	96	Whether local changes EEG related circadian sleep wake dependent modulation performance remains established
0.18866605.11796701.html.plaintext.txt	97	A number hypotheses neurochemical basis sleep homeostasis put forward review see Ref
0.18866605.11796701.html.plaintext.txt	98	There substantial evidence role neuromodulator adenosine mediating sleep homeostatic signals
0.18866605.11796701.html.plaintext.txt	99	Levels adenosine basal forebrain areas increase sustained wakefulness administration adenosine brain areas leads sleep 11
0.18866605.11796701.html.plaintext.txt	100	Such role adenosine would consistent popular use adenosine antagonist caffeine combat sleepiness
0.18866605.11796701.html.plaintext.txt	101	The kinetics sleep homeostatic process mice indexed EEG SWA shown strong genetic control
0.18866605.11796701.html.plaintext.txt	102	Quantitative trait loci analysis identified genomic regions contribute genetic control contain genes regulate adenosine levels 52
0.18866605.11796701.html.plaintext.txt	103	The concept circadian sleep homeostatic processes functionally anatomically distinct investigated studying sleep timing structure responses challenges sleep homeostat mammals altered clock genes 99
0.18866605.11796701.html.plaintext.txt	104	The first studies indicated sleep duration response sleep loss may affected mutations murine Clock gene
0.18866605.11796701.html.plaintext.txt	105	Interestingly REM sleep sleep stage strongly regulated circadian processes modified Clock mutant mice 80
0.18866605.11796701.html.plaintext.txt	106	Some people suffering human familial form advanced sleep phase syndrome ASPS shown carry altered hPer2 gene 91 one key clock genes
0.18866605.11796701.html.plaintext.txt	107	It appears patients suffering disorder sleep structure within normal range 55 84
0.18866605.11796701.html.plaintext.txt	108	Clock genes may involved generation sleep wake oscillatory processes
0.18866605.11796701.html.plaintext.txt	109	During pharmacologically induced desynchrony rest activity cycles circadian rhythms rats entrained 24 h light dark cycles clock genes rPer1 rPer2 rBmal1 rClock parietal cortex caudate putamen oscillate synchrony rest activity cycle
0.18866605.11796701.html.plaintext.txt	110	In contrast clock gene expression SCN remained phase locked light dark cycle rhythm pineal melatonin 78
0.18866605.11796701.html.plaintext.txt	111	Alternatively extra SCN rhythms clock gene expression could driven rest activity cycle
0.18866605.11796701.html.plaintext.txt	112	CIRCADIAN PHOTORECEPTION IN HUMANS TOP ABSTRACT INTRODUCTION SEPARATION OF CIRCADIAN AND
0.18866605.11796701.html.plaintext.txt	113	CIRCADIAN SLEEP WAKE PROPENSITY
0.18866605.11796701.html.plaintext.txt	114	DIURNAL PREFERENCE ADVANCED AND DELAYED SLEEP
0.18866605.11796701.html.plaintext.txt	115	CONCLUSION AND PERSPECTIVES REFERENCES
0.18866605.11796701.html.plaintext.txt	116	Although thought light major synchronizer human circadian rhythms shown multiple rhythms driven SCN including rhythms sleep propensity pineal melatonin shifted scheduled ocular light exposure 31
0.18866605.11796701.html.plaintext.txt	117	Current estimates sensitivity human circadian pacemaker light indicate ordinary room light exerts effect 50 maximal effect induced bright indoor light 100
0.18866605.11796701.html.plaintext.txt	118	Similar high sensitivities obtained dose response studies direct effects light melatonin suppression subjective alertness EEG electrooculogram correlates alertness 23
0.18866605.11796701.html.plaintext.txt	119	Such studies indicate range illuminances expressed lux light exerts differential effect spans two three log units
0.18866605.11796701.html.plaintext.txt	120	Such small dynamic range previously observed circadian responses animal studies accordance hypothesis effects light circadian timing system mediated photoreceptive system distinct system mediating vision 77
0.18866605.11796701.html.plaintext.txt	121	Quantitative aspects circadian photoreception relationship duration intensity light phase shifting effects intense investigation shown first minutes light exposure effective 85
0.18866605.11796701.html.plaintext.txt	122	In mice circadian phase shifting neuroendocrine pupillary responses light elicited absence rods cones suggesting another ocular photoreceptor involved mediating effects 53 76
0.18866605.11796701.html.plaintext.txt	123	In humans spectral sensitivity circadian photoreceptive system investigated using light induced melatonin suppression dependent variable
0.18866605.11796701.html.plaintext.txt	124	The assessment relative efficacy different wavelengths light varying 420 600 nm suppression melatonin demonstrated short wavelengths blue light effective suppressing melatonin 18
0.18866605.11796701.html.plaintext.txt	125	A detailed analysis data suggested neither rods cones primarily mediate light induced neuroendocrine response 17 89
0.18866605.11796701.html.plaintext.txt	126	This neuroendocrine response often used proxy circadian phase shifting effects light remains established whether spectral sensitivity phase shifting similar observed melatonin suppression
0.18866605.11796701.html.plaintext.txt	127	Nevertheless data first compelling evidence human circadian photoreceptive system distinct photoreceptive system involved image formation
0.18866605.11796701.html.plaintext.txt	128	It hypothesized melanopsin located ganglion cells human inner retina photopigment mediating circadian light responses 83
0.18866605.11796701.html.plaintext.txt	129	The question spectral sensitivity human circadian system related entrainment natural light dark cycle remains investigated
0.18866605.11796701.html.plaintext.txt	130	Phase shifts endogenous circadian rhythms including sleep propensity rhythm induced broad spectrum light exposure even sleep wake cycle kept constant 31
0.18866605.11796701.html.plaintext.txt	131	Thus effects light circadian pacemaker necessarily mediated sleep wake oscillator likely mediated direct projection retinal ganglion cells SCN retinohypothalamic tract
0.18866605.11796701.html.plaintext.txt	132	The sleep wake cycle nevertheless plays important role regulating light input pacemaker close eyes sleep open eyes awake see Fig
0.18866605.11796701.html.plaintext.txt	133	Consideration interaction sleep wake behavior light input light sensitive pacemaker may important understanding synchronization human circadian system
0.18866605.11796701.html.plaintext.txt	134	Previously postulated effects light circadian pacemaker part mediated sleep wake oscillator turn would affect circadian oscillator
0.18866605.11796701.html.plaintext.txt	135	Currently mechanisms light could exert direct effects sleep wake oscillatory process unknown
0.18866605.11796701.html.plaintext.txt	136	Direct projections retina extra SCN hypothalamic areas ventrolateral preoptic area known contain sleep active neurons 74 may play role mediating effects light
0.18866605.11796701.html.plaintext.txt	137	This view entrainment light via sleep wake oscillator also implies sleep wake cycle exerts influence circadian pacemaker
0.18866605.11796701.html.plaintext.txt	138	Experiments sleep wake cycle inverted shown conditions feedback effects small 44
0.18866605.11796701.html.plaintext.txt	139	However growing evidence animal human studies feedback sleep wake cycle onto SCN could nevertheless significant particular maintenance entrainment 5 54 62 96a
0.18866605.11796701.html.plaintext.txt	140	DETERMINANTS OF PHASE RELATIONSHIPS BETWEEN THE SLEEP WAKE CYCLE ENDOGENOUS CIRCADIAN RHYTHMS AND THE ENVIRONMENT TOP ABSTRACT INTRODUCTION SEPARATION OF CIRCADIAN AND
0.18866605.11796701.html.plaintext.txt	141	CIRCADIAN SLEEP WAKE PROPENSITY
0.18866605.11796701.html.plaintext.txt	142	DIURNAL PREFERENCE ADVANCED AND DELAYED SLEEP
0.18866605.11796701.html.plaintext.txt	143	CONCLUSION AND PERSPECTIVES REFERENCES
0.18866605.11796701.html.plaintext.txt	144	In young healthy individuals without abnormalities sleep timing sleep occurs melatonin secretion trough endogenous circadian component temperature cycle
0.18866605.11796701.html.plaintext.txt	145	Sleep begins maximal circadian wake propensity ends maximal circadian sleep propensity
0.18866605.11796701.html.plaintext.txt	146	Sleep also occurs specific phase relative circadian rhythm response light largest shifts circadian rhythmicity response ocular light exposure induced near transition wakefulness sleep vice versa see Fig
0.18866605.11796701.html.plaintext.txt	147	Determinants internal external phase relationships circadian rhythms sleep wake cycle external world include exposure responsiveness light intrinsic period human circadian pacemaker rate homeostatic sleep need builds wakefulness dissipates sleep
0.18866605.11796701.html.plaintext.txt	148	View larger version 30K Fig
0.18866605.11796701.html.plaintext.txt	149	Schematic representation timing habitual sleep episode young adults relative circadian rhythm core body temperature plasma melatonin wake propensity responsiveness light
0.18866605.11796701.html.plaintext.txt	150	The circadian variation responsiveness light schematic representation see Refs
0.18866605.11796701.html.plaintext.txt	151	Note maximum melatonin rhythm located 2 h nadir circadian temperature rhythm
0.18866605.11796701.html.plaintext.txt	152	Sleep disruption wakefulness within scheduled sleep episodes maximal sleep scheduled rise melatonin
0.18866605.11796701.html.plaintext.txt	153	Based data published Ref
0.18866605.11796701.html.plaintext.txt	154	Can variation phenomenology sleep wake timing explained variations intrinsic period circadian pacemaker circadian photoreception responsiveness circadian pacemaker light changes sleep homeostatic process
0.18866605.11796701.html.plaintext.txt	155	INTRINSIC PERIOD OF THE HUMAN CIRCADIAN PACEMAKER ASSOCIATION WITH INTERNAL AND EXTERNAL PHASE RELATIONSHIPS TOP ABSTRACT INTRODUCTION SEPARATION OF CIRCADIAN AND
0.18866605.11796701.html.plaintext.txt	156	CIRCADIAN SLEEP WAKE PROPENSITY
0.18866605.11796701.html.plaintext.txt	157	DIURNAL PREFERENCE ADVANCED AND DELAYED SLEEP
0.18866605.11796701.html.plaintext.txt	158	CONCLUSION AND PERSPECTIVES REFERENCES
0.18866605.11796701.html.plaintext.txt	159	The notion intrinsic period human circadian pacemaker near 25 h recently challenged
0.18866605.11796701.html.plaintext.txt	160	It recognized exquisite sensitivity human circadian pacemaker room levels light may affected period estimate classical free running experiments estimate 25 h derived 60
0.18866605.11796701.html.plaintext.txt	161	During past decade number laboratories investigated aspect human circadian rhythmicity assessing intrinsic periodicity conditions confounding effects room light exposure controlled
0.18866605.11796701.html.plaintext.txt	162	Such experiments sighted subjects young older adolescent blind adult subjects circadian system entrained yielded estimates intrinsic period close 24 h see Refs
0.18866605.11796701.html.plaintext.txt	163	26 28 38 57 69 references therein
0.18866605.11796701.html.plaintext.txt	164	Relatively minor discrepancies estimates populations sighted blind subjects may related selection subjects included population average aftereffects entrainment light observed period study methodology differential control potential nonphotic time cues 28
0.18866605.11796701.html.plaintext.txt	165	Experiments confounding effects light carefully controlled shown young subjects phase angle entrainment correlated intrinsic period circadian pacemaker
0.18866605.11796701.html.plaintext.txt	166	One estimate intrinsic period human circadian pacemaker conditions 24 h 11 min remarkably small variation SD 8 min 28
0.18866605.11796701.html.plaintext.txt	167	This small variation nevertheless associated entrained phase 6 min difference intrinsic period leads approximately 1 h difference entrained phase 45
0.18866605.11796701.html.plaintext.txt	168	In healthy older people without sleep complaints without sleep disorders circadian rhythms melatonin core body temperature cortisol occur earlier clock time young adults 25 43 45a
0.18866605.11796701.html.plaintext.txt	169	In older people habitual wake time shown also occur earlier relative core body temperature plasma melatonin rhythms
0.18866605.11796701.html.plaintext.txt	170	This internal circadian phase advance wake time also observed forced desynchrony sleep wake cycle endogenous circadian rhythm plasma melatonin core body temperature 40 43 45a
0.18866605.11796701.html.plaintext.txt	171	Therefore age related change interaction sleep wake oscillator endogenous circadian rhythmicity wake time advanced respect clock time altered external timing also advanced relative internal circadian rhythms altered internal timing
0.18866605.11796701.html.plaintext.txt	172	Although advance entrained phase external timing could theoretically explained age related reduction intrinsic period simultaneous advance wake time relative endogenous circadian rhythms could
0.18866605.11796701.html.plaintext.txt	173	A plot internal external phase relationships two categories compared theoretical changes internal phase relationships due changes period illustrates point see Fig
0.18866605.11796701.html.plaintext.txt	174	In addition empirical assessments intrinsic period young older people yielded identical estimates 28
0.18866605.11796701.html.plaintext.txt	175	Thus age related 1 h difference timing core body temperature melatonin rhythm young older people cannot currently accounted age related reduction intrinsic period 28 57 suggesting changes period circadian system primarily responsible age related changes sleep timing
0.18866605.11796701.html.plaintext.txt	176	However may worthwhile point according observed association entrained phase intrinsic period young subjects age related difference intrinsic period 6 min would required account age related difference entrained phase 45
0.18866605.11796701.html.plaintext.txt	177	View larger version 13K Fig
0.18866605.11796701.html.plaintext.txt	178	Schematic representation differences internal phase relationship wake time circadian rhythm core body temperature owls larks young older people compared theoretical phase relationships could expected individuals relatively longer shorter intrinsic periods circadian pacemaker
0.18866605.11796701.html.plaintext.txt	179	Tmin circadian phase marker core body temperature minimum
0.18866605.11796701.html.plaintext.txt	180	Note relationship Tmin wake time constant
0.18866605.11796701.html.plaintext.txt	181	short thus demonstrating changes internal phase relationships circadian sleep rhythms
0.18866605.11796701.html.plaintext.txt	182	DIURNAL PREFERENCE TOP ABSTRACT INTRODUCTION SEPARATION OF CIRCADIAN AND
0.18866605.11796701.html.plaintext.txt	183	CIRCADIAN SLEEP WAKE PROPENSITY
0.18866605.11796701.html.plaintext.txt	184	DIURNAL PREFERENCE ADVANCED AND DELAYED SLEEP
0.18866605.11796701.html.plaintext.txt	185	CONCLUSION AND PERSPECTIVES REFERENCES
0.18866605.11796701.html.plaintext.txt	186	People vary diurnal preference timing activity sleep preference paralleled physiology
0.18866605.11796701.html.plaintext.txt	187	In morning types wake time temperature nadir plasma melatonin rhythm occur earlier clock times evening types 10 42 58 59
0.18866605.11796701.html.plaintext.txt	188	Sleep deprivation studies indicated homeostatic aspect sleep regulation markedly different morning evening types 64
0.18866605.11796701.html.plaintext.txt	189	Furthermore differences timing circadian melatonin core body temperature rhythms persist constant routine conditions absence sleep wake cycle demonstrating differences direct consequence altered sleep wake timing
0.18866605.11796701.html.plaintext.txt	190	Examinations internal phase relationships sleep wake cycle endogenous circadian rhythms led somewhat paradoxical conclusion morning types wake earlier clock time wake later relative circadian cycle temperature melatonin 42
0.18866605.11796701.html.plaintext.txt	191	The opposite true evening types
0.18866605.11796701.html.plaintext.txt	192	As previously discussed young subjects small variations intrinsic period correlated variations diurnal preference
0.18866605.11796701.html.plaintext.txt	193	A 6 min difference intrinsic period correlated change Horne Ostberg rating measure diurnal preference 5 10 points 70 point range 45
0.18866605.11796701.html.plaintext.txt	194	These data indicate differences intrinsic period magnitude smaller associated clock mutants rodents significant consequences sleep wake timing diurnal preference humans
0.18866605.11796701.html.plaintext.txt	195	In fact association diurnal preference polymorphism human Clock gene described 56
0.18866605.11796701.html.plaintext.txt	196	ADVANCED AND DELAYED SLEEP PHASE SYNDROMES TOP ABSTRACT INTRODUCTION SEPARATION OF CIRCADIAN AND
0.18866605.11796701.html.plaintext.txt	197	CIRCADIAN SLEEP WAKE PROPENSITY
0.18866605.11796701.html.plaintext.txt	198	DIURNAL PREFERENCE ADVANCED AND DELAYED SLEEP
0.18866605.11796701.html.plaintext.txt	199	CONCLUSION AND PERSPECTIVES REFERENCES
0.18866605.11796701.html.plaintext.txt	200	ASPS delayed sleep phase syndromes DSPS often thought associated advanced delayed timing endogenous circadian rhythms temperature melatonin
0.18866605.11796701.html.plaintext.txt	201	Surprisingly studies carefully characterized circadian physiology sleep disorders
0.18866605.11796701.html.plaintext.txt	202	In examination internal external phase relationships DSPS patients delayed bedtime delayed wake time later clock time onset peak melatonin rhythm reported 88 92
0.18866605.11796701.html.plaintext.txt	203	In addition bedtime wake time reportedly delayed relative melatonin rhythm
0.18866605.11796701.html.plaintext.txt	204	Therefore DSPS patients appear wake later clock time also later phase endogenous rhythm melatonin temperature
0.18866605.11796701.html.plaintext.txt	205	The observation contrast evening types wake earlier endogenous circadian cycle
0.18866605.11796701.html.plaintext.txt	206	An association DSPS polymorphisms clock gene hPer3 reported suggesting circadian processes may contribute condition 47
0.18866605.11796701.html.plaintext.txt	207	The timing sleep circadian rhythms temperature melatonin individuals suffering familial forms ASPS described
0.18866605.11796701.html.plaintext.txt	208	As may expected timing sleep endogenous circadian rhythms advanced much 4 h 55 84
0.18866605.11796701.html.plaintext.txt	209	The internal phase relationships sleep circadian rhythms melatonin temperature appeared normal patients
0.18866605.11796701.html.plaintext.txt	210	SWS REM sleep expressed percentage total sleep time also appeared normal suggesting primary change patients associated sleep homeostatic facet sleep wake regulation rather circadian aspect
0.18866605.11796701.html.plaintext.txt	211	So far assessments intrinsic period absence confounding effects light available patients
0.18866605.11796701.html.plaintext.txt	212	The free running period assessed classical free running paradigm reported rather short one patient 55
0.18866605.11796701.html.plaintext.txt	213	This may related change hPer2 phosphorylation site reported separate study ASPS patients 91
0.18866605.11796701.html.plaintext.txt	214	CHANGES IN CIRCADIAN PHOTORECEPTION IN AGING AND IN BLIND INDIVIDUALS TOP ABSTRACT INTRODUCTION SEPARATION OF CIRCADIAN AND
0.18866605.11796701.html.plaintext.txt	215	CIRCADIAN SLEEP WAKE PROPENSITY
0.18866605.11796701.html.plaintext.txt	216	DIURNAL PREFERENCE ADVANCED AND DELAYED SLEEP
0.18866605.11796701.html.plaintext.txt	217	CONCLUSION AND PERSPECTIVES REFERENCES
0.18866605.11796701.html.plaintext.txt	218	Changes circadian photoreception changes responsiveness circadian pacemaker light due changes downstream circadian photoreceptors may contribute variations entrained phase
0.18866605.11796701.html.plaintext.txt	219	Initial comparisons responsiveness light young older healthy volunteers suggested older people somewhat less sensitive light phase advance portion phase response curve PRC
0.18866605.11796701.html.plaintext.txt	220	The responsiveness light phase delay portion PRC significantly different 61
0.18866605.11796701.html.plaintext.txt	221	These findings inconsistent hypothesis changes responsiveness pacemaker light underlie observed phase advance
0.18866605.11796701.html.plaintext.txt	222	The phase advance older people may mediated observed internal phase advance wake time
0.18866605.11796701.html.plaintext.txt	223	As result would increase light exposure phase advance region PRC would thereby contribute advance endogenous circadian rhythms 43
0.18866605.11796701.html.plaintext.txt	224	This hypothesis highlights potential role sleep wake behavior changes internal phase relationship sleep circadian rhythms determination entrained phase
0.18866605.11796701.html.plaintext.txt	225	Alteration light input responsiveness oscillator light indirectly examined studies circadian rhythms blind subjects
0.18866605.11796701.html.plaintext.txt	226	Despite massive loss visual function majority blind individuals degree light perception maintain normal circadian rhythmicity 29 69 72
0.18866605.11796701.html.plaintext.txt	227	Similar observations reported rodless mice 51
0.18866605.11796701.html.plaintext.txt	228	No significant associations observed circadian rhythm abnormalities specific retinal abnormalities
0.18866605.11796701.html.plaintext.txt	229	In fact within totally blind subjects best predictor circadian rhythm disorders appears lack intact eyes 69 observation consistent distinct nature circadian photoreceptive system
0.18866605.11796701.html.plaintext.txt	230	The report several blind individuals despite conscious light perception sensitive light induced suppression melatonin 29 consistent functional circadian photoreceptive system
0.18866605.11796701.html.plaintext.txt	231	These subjects reported cyclic sleep disorders presumably photically entrained circadian rhythms despite visual function
0.18866605.11796701.html.plaintext.txt	232	Alternatively lack association retinal abnormalities entrainment may explained effects nonphotic time cues regular sleep wake cycle societal constraints etc exerting sufficient drive onto pacemaker maintain entrainment 62
0.18866605.11796701.html.plaintext.txt	233	A variety abnormal sleep wake patterns well internal external phase relationships reported totally blind subjects
0.18866605.11796701.html.plaintext.txt	234	Approximately 25 normally timed hormonal rhythms relative light dark cycle clock time sleep wake cycle
0.18866605.11796701.html.plaintext.txt	235	A 25 hormonal rhythms entrained abnormal clock time maintain less normal sleep timing
0.18866605.11796701.html.plaintext.txt	236	The remainder nonentrained non 24 h hormonal rhythms non 24 h sleep wake cycles
0.18866605.11796701.html.plaintext.txt	237	These subjects attempt maintain normal internal phase relationship often unsuccessful conflict internal circadian timing external 24 h time cues 70
0.18866605.11796701.html.plaintext.txt	238	Thus totally blind subjects observe abnormal phase relationships endogenous circadian rhythms relative clock time altered external timing also highly abnormal internal external phase relationships respect sleep timing altered internal timing
0.18866605.11796701.html.plaintext.txt	239	Such observations represent extreme example consequences altering phase angle sleep internal circadian system
0.18866605.11796701.html.plaintext.txt	240	Exogenous melatonin administration 5 10 mgday used successfully treat non 24 h sleep wake disorder 71 86 appropriately timed realign abnormal internal phase relationships relationship circadian system external 24 h social day
0.18866605.11796701.html.plaintext.txt	241	ALTERATIONS IN SLEEP HOMEOSTASIS TOP ABSTRACT INTRODUCTION SEPARATION OF CIRCADIAN AND
0.18866605.11796701.html.plaintext.txt	242	CIRCADIAN SLEEP WAKE PROPENSITY
0.18866605.11796701.html.plaintext.txt	243	DIURNAL PREFERENCE ADVANCED AND DELAYED SLEEP
0.18866605.11796701.html.plaintext.txt	244	CONCLUSION AND PERSPECTIVES REFERENCES
0.18866605.11796701.html.plaintext.txt	245	Self reported sleep need sleep duration found vary individuals
0.18866605.11796701.html.plaintext.txt	246	First sleep regulation habitual short long sleepers studied context circadian homeostatic regulation sleep
0.18866605.11796701.html.plaintext.txt	247	Analyses sleep EEG waking EEG indicate short sleepers live higher homeostatic sleep pressure 2 4
0.18866605.11796701.html.plaintext.txt	248	Second sleep duration declines across life span
0.18866605.11796701.html.plaintext.txt	249	It well documented SWS SWA decline age 24 93
0.18866605.11796701.html.plaintext.txt	250	These findings suggest sleep need may decline age
0.18866605.11796701.html.plaintext.txt	251	The age related reduction SWS sleep duration observed circadian phases even older subjects scheduled rest activity cycle similar young subjects 40 see Fig
0.18866605.11796701.html.plaintext.txt	252	Thus major differences activity daytime napping cannot primary cause changes
0.18866605.11796701.html.plaintext.txt	253	Analyses awakenings young older subjects shown primarily consolidation NREM sleep impaired older subjects 39
0.18866605.11796701.html.plaintext.txt	254	Quantitative analyses EEG young older subjects demonstrated age related changes spectral composition EEG near mirror image changes induced increase homeostatic sleep pressure sleep deprivation 24 67 opposite effects major inhibitory neurotransmitter GABA EEG 65
0.18866605.11796701.html.plaintext.txt	255	In addition age related changes EEG appear prominent frontal cortical areas 66
0.18866605.11796701.html.plaintext.txt	256	These data consistent hypothesis major aspect age related changes human sleep related extra SCN sleep process
0.18866605.11796701.html.plaintext.txt	257	Whether change reflects age related reduction sleep need age related changes ability maintain sleep remains unclear
0.18866605.11796701.html.plaintext.txt	258	Age related changes circadian aspect sleep regulation appear limited reduction active promotion sleep early morning 40
0.18866605.11796701.html.plaintext.txt	259	View larger version 42K Fig
0.18866605.11796701.html.plaintext.txt	260	Comparison time course slow wave sleep SWS top wakefulness bottom sleep episodes scheduled many circadian phases young left older right people
0.18866605.11796701.html.plaintext.txt	261	Note older people wakefulness less SWS within scheduled sleep episodes present circadian phases
0.18866605.11796701.html.plaintext.txt	262	38 permission based data published Ref
0.18866605.11796701.html.plaintext.txt	263	CONCLUSION AND PERSPECTIVES TOP ABSTRACT INTRODUCTION SEPARATION OF CIRCADIAN AND
0.18866605.11796701.html.plaintext.txt	264	CIRCADIAN SLEEP WAKE PROPENSITY
0.18866605.11796701.html.plaintext.txt	265	DIURNAL PREFERENCE ADVANCED AND DELAYED SLEEP
0.18866605.11796701.html.plaintext.txt	266	CONCLUSION AND PERSPECTIVES REFERENCES
0.18866605.11796701.html.plaintext.txt	267	Human sleep wake timing circadian rhythmicity closely interrelated part separable mediated distinct processes
0.18866605.11796701.html.plaintext.txt	268	Consideration external internal sleep timing may provide new parameters quantify phenomenology normal abnormal sleep regulation
0.18866605.11796701.html.plaintext.txt	269	Detailed description controlled examination internal external phase relationships comprehensive description sleep circadian physiology could clarify contribution circadian processes sleep homeostasis circadian photoreception molecular genetic basis phenomenology sleep timing
0.18866605.11796701.html.plaintext.txt	270	Examination impact specific genotypes affecting sleep phenomenology sleep physiology circadian physiology well circadian photoreception undoubtedly lead discovery new postgenomic physiology
0.18866605.11796701.html.plaintext.txt	271	This turn may lead us revise abandon current concepts necessitate design new conceptual frameworks therapeutic approaches human sleep timing disorders
0.18866605.11796701.html.plaintext.txt	272	Shantha Rajaratnam constructive comments manuscript
0.18866605.11796701.html.plaintext.txt	273	Skene University Surrey Dr
0.18866605.11796701.html.plaintext.txt	274	Czeisler Brigham Womens Hospital continued support
0.18866605.11796701.html.plaintext.txt	275	Lockley supported Wellcome Trust Grant 060018Z99Z
0.18866605.11796701.html.plaintext.txt	276	Address reprint requests correspondence D
0.18866605.11796701.html.plaintext.txt	277	Dijk Centre Chronobiology School Biomedical Life Sciences Univ
0.18866605.11796701.html.plaintext.txt	278	Surrey Guildford GU2 7XH UK E mail d
0.18866605.11796701.html.plaintext.txt	279	1 We use term circadian process general context paper mean signals affect sleep propensity sleep structure originate circadian pacemaker presumably located SCN
0.18866605.11796701.html.plaintext.txt	280	REFERENCES TOP ABSTRACT INTRODUCTION SEPARATION OF CIRCADIAN AND
0.18866605.11796701.html.plaintext.txt	281	CIRCADIAN SLEEP WAKE PROPENSITY
0.18866605.11796701.html.plaintext.txt	282	DIURNAL PREFERENCE ADVANCED AND DELAYED SLEEP
0.18866605.11796701.html.plaintext.txt	283	CONCLUSION AND PERSPECTIVES REFERENCES
0.18866605.11796701.html.plaintext.txt	284	Abrahamson EE Leak RK Moore RY
0.18866605.11796701.html.plaintext.txt	285	The suprachiasmatic nucleus projects posterior hypothalamic arousal systems
0.18866605.11796701.html.plaintext.txt	286	Neuroreport 12 435 440 2001ISIMedline
0.18866605.11796701.html.plaintext.txt	287	Aeschbach D Cajochen C Landolt HP Borbely AA
0.18866605.11796701.html.plaintext.txt	288	Homeostatic sleep regulation habitual short sleepers long sleepers
0.18866605.11796701.html.plaintext.txt	289	Am J Physiol Regulatory Integrative Comp Physiol 270 R41 R53 1996AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	290	Aeschbach D Matthews JR Postolache TT Jackson MA Giesen HA Wehr TA
0.18866605.11796701.html.plaintext.txt	291	Dynamics human EEG prolonged wakefulness evidence frequency specific circadian homeostatic influences
0.18866605.11796701.html.plaintext.txt	292	Neurosci Lett 239 121 124 1997ISIMedline
0.18866605.11796701.html.plaintext.txt	293	Aeschbach D Postolache TT Sher L Matthews JR Jackson MA Wehr TA
0.18866605.11796701.html.plaintext.txt	294	Evidence waking electroencephalogram short sleepers live higher homeostatic sleep pressure long sleepers
0.18866605.11796701.html.plaintext.txt	295	Neuroscience 102 493 502 2001ISIMedline
0.18866605.11796701.html.plaintext.txt	296	Antle MC Mistlberger RE
0.18866605.11796701.html.plaintext.txt	297	Circadian clock resetting sleep deprivation without exercise Syrian hamster
0.18866605.11796701.html.plaintext.txt	298	J Neurosci 20 9326 9332 2000AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	299	Aschoff J Gerecke U Wever R
0.18866605.11796701.html.plaintext.txt	300	Desynchronization human circadian rhythms
0.18866605.11796701.html.plaintext.txt	301	Jpn J Physiol 17 450 457 1967ISIMedline
0.18866605.11796701.html.plaintext.txt	302	Aston Jones GS Chen S Zhu Y Oshinsky ML
0.18866605.11796701.html.plaintext.txt	303	A neural circuit circadian regulation arousal
0.18866605.11796701.html.plaintext.txt	304	Nat Neurosci 4 732 738 2001ISIMedline
0.18866605.11796701.html.plaintext.txt	305	Akerstedt T Gillberg M
0.18866605.11796701.html.plaintext.txt	306	The circadian variation experimentally displaced sleep
0.18866605.11796701.html.plaintext.txt	307	Sleep 4 159 169 1981ISIMedline
0.18866605.11796701.html.plaintext.txt	308	Akerstedt T Hume K Minors D Waterhouse J
0.18866605.11796701.html.plaintext.txt	309	Experimental separation time day homeostatic influences sleep
0.18866605.11796701.html.plaintext.txt	310	Am J Physiol Regulatory Integrative Comp Physiol 274 R1162 R1168 1998AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	311	Baehr EK Revelle W Eastman CI
0.18866605.11796701.html.plaintext.txt	312	Individual differences phase amplitude human circadian temperature rhythm emphasis morningness eveningness
0.18866605.11796701.html.plaintext.txt	313	J Sleep Res 9 117 127 2000ISIMedline
0.18866605.11796701.html.plaintext.txt	314	Basheer R Porkka Heiskanen T Strecker RE Thakkar MM McCarley RW
0.18866605.11796701.html.plaintext.txt	315	Adenosine biological signal mediating sleepiness following prolonged wakefulness
0.18866605.11796701.html.plaintext.txt	316	Biol Signals Recept 9 319 327 2000ISIMedline
0.18866605.11796701.html.plaintext.txt	317	Beersma DGM Models human sleep regulation
0.18866605.11796701.html.plaintext.txt	318	Sleep Med Rev 2 31 43 1998Medline
0.18866605.11796701.html.plaintext.txt	319	A two process model sleep regulation
0.18866605.11796701.html.plaintext.txt	320	Hum Neurobiol 1 195 204 1982Medline
0.18866605.11796701.html.plaintext.txt	321	Process underlying sleep regulation
0.18866605.11796701.html.plaintext.txt	322	Horm Res 49 114 117 1998ISIMedline
0.18866605.11796701.html.plaintext.txt	323	Borbely AA Achermann P
0.18866605.11796701.html.plaintext.txt	324	Sleep homeostasis models sleep regulation
0.18866605.11796701.html.plaintext.txt	325	J Biol Rhythms 14 557 568 1999AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	326	Endogenous sleep promoting substances sleep regulation
0.18866605.11796701.html.plaintext.txt	327	Physiol Rev 69 605 670 1989Free Full Text
0.18866605.11796701.html.plaintext.txt	328	Brainard GC Hanifin JP Greeson JM Byrne B Glickman G Gerner E Rollag MD
0.18866605.11796701.html.plaintext.txt	329	Action spectrum melatonin regulation humans evidence novel circadian photoreceptor
0.18866605.11796701.html.plaintext.txt	330	J Neurosci 21 6405 6412 2001AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	331	Brainard GC Hanifin JP Rollag MD Greeson J Byrne B Glickman G Gerner E Sanford B
0.18866605.11796701.html.plaintext.txt	332	Human melatonin regulation mediated three cone photopic visual system
0.18866605.11796701.html.plaintext.txt	333	J Clin Endocrinol Metab 86 433 436 2001AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	334	Cajochen C Brunner DP Krauchi K Graw P Wirz Justice A
0.18866605.11796701.html.plaintext.txt	335	Power density thetaalpha frequencies waking EEG progressively increases sustained wakefulness
0.18866605.11796701.html.plaintext.txt	336	Sleep 18 890 894 1995ISIMedline
0.18866605.11796701.html.plaintext.txt	337	Cajochen C Foy R Dijk DJ
0.18866605.11796701.html.plaintext.txt	338	Frontal predominance relative increase sleep delta theta EEG activity sleep loss humans
0.18866605.11796701.html.plaintext.txt	339	Sleep Res Online 2 65 69 1999Medline
0.18866605.11796701.html.plaintext.txt	340	Cajochen C Khalsa SBS Wyatt JK Czeisler CA Dijk DJ
0.18866605.11796701.html.plaintext.txt	341	EEG ocular correlates circadian melatonin phase human performance decrements sleep loss
0.18866605.11796701.html.plaintext.txt	342	Am J Physiol Regulatory Integrative Comp Physiol 277 R640 R649 1999AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	343	Cajochen C Knoblauch V Krauchi K Renz C Wirz Justice A
0.18866605.11796701.html.plaintext.txt	344	Dynamics frontal EEG activity sleepiness body temperature high low sleep pressure
0.18866605.11796701.html.plaintext.txt	345	Neuroreport 12 2277 2281 2001ISIMedline
0.18866605.11796701.html.plaintext.txt	346	Cajochen C Zeitzer JM Czeisler CA Dijk DJ
0.18866605.11796701.html.plaintext.txt	347	Dose response relationship light intensity ocular electroencephalographic correlates human alertness
0.18866605.11796701.html.plaintext.txt	348	Behav Brain Res 115 75 83 2000ISIMedline
0.18866605.11796701.html.plaintext.txt	349	Carrier J Land S Buysse DJ Kupfer DJ Monk TH
0.18866605.11796701.html.plaintext.txt	350	The effects age gender sleep EEG power spectral density middle years life age 20 60 years old
0.18866605.11796701.html.plaintext.txt	351	Psychophysiology 38 232 242 2001ISIMedline
0.18866605.11796701.html.plaintext.txt	352	Carrier J Monk TH Buysse DJ Kupfer DJ
0.18866605.11796701.html.plaintext.txt	353	Sleep morningness eveningness middle years life 20 59y
0.18866605.11796701.html.plaintext.txt	354	J Sleep Res 6 230 237 1997ISIMedline
0.18866605.11796701.html.plaintext.txt	355	Carskadon MA Labyak SE Acebo C Seifer R
0.18866605.11796701.html.plaintext.txt	356	Intrinsic circadian period adolescent humans measured conditions forced desynchrony
0.18866605.11796701.html.plaintext.txt	357	Neurosci Lett 260 129 132 1999ISIMedline
0.18866605.11796701.html.plaintext.txt	358	Disruption human circadian cognitive regulation following discrete hypothalamic lesion case study
0.18866605.11796701.html.plaintext.txt	359	Neurology 41 726 729 1991Abstract
0.18866605.11796701.html.plaintext.txt	360	Czeisler CA Duffy JF Shanahan TL Brown EN Mitchell JF Rimmer DW Ronda JM Silva EJ Allan JS Emens JS Dijk DJ Kronauer RE
0.18866605.11796701.html.plaintext.txt	361	Stability precision near 24 hour period human circadian pacemaker
0.18866605.11796701.html.plaintext.txt	362	Science 284 2177 2181 1999AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	363	Czeisler CA Shanahan TL Klerman EB Martens H Brotman DJ Emens JS Klein T Rizzo IIIJF Suppression melatonin secretion blind patients exposure bright light
0.18866605.11796701.html.plaintext.txt	364	N Engl J Med 332 6 11 1995AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	365	Czeisler CA Weitzman ED Moore Ede MC Zimmerman JC Knauer RS
0.18866605.11796701.html.plaintext.txt	366	Human sleep duration organization depend circadian phase
0.18866605.11796701.html.plaintext.txt	367	Science 210 1264 1267 1980Medline
0.18866605.11796701.html.plaintext.txt	368	Czeisler CA Wright KP Jr
0.18866605.11796701.html.plaintext.txt	369	Influence light circadian rhythmicity humans
0.18866605.11796701.html.plaintext.txt	370	In Regulation Sleep Circadian Rhythms edited Turek FW Zee PC
0.18866605.11796701.html.plaintext.txt	371	New York Marcel Dekker 1999 p
0.18866605.11796701.html.plaintext.txt	372	Daan S Beersma DGM Borbely AA
0.18866605.11796701.html.plaintext.txt	373	Timing human sleep recovery process gated circadian pacemaker
0.18866605.11796701.html.plaintext.txt	374	Am J Physiol Regulatory Integrative Comp Physiol 246 R161 R183 1984AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	375	Dantz B Edgar DM Dement WC
0.18866605.11796701.html.plaintext.txt	376	Circadian rhythms narcolepsy studies 90 minute day
0.18866605.11796701.html.plaintext.txt	377	Electroencephalogr Clin Neurophysiol 90 24 35 1994ISIMedline
0.18866605.11796701.html.plaintext.txt	378	Dijk DJ Beersma DGM Daan S
0.18866605.11796701.html.plaintext.txt	379	EEG power density nap sleep reflection hourglass measuring duration prior wakefulness
0.18866605.11796701.html.plaintext.txt	380	J Biol Rhythms 2 207 219 1987Medline
0.18866605.11796701.html.plaintext.txt	381	Melatonin circadian regulation sleep initiation consolidation structure sleep EEG
0.18866605.11796701.html.plaintext.txt	382	J Biol Rhythms 12 627 635 1997ISIMedline
0.18866605.11796701.html.plaintext.txt	383	Paradoxical timing circadian rhythm sleep propensity serves consolidate sleep wakefulness humans
0.18866605.11796701.html.plaintext.txt	384	Neurosci Lett 166 63 68 1994ISIMedline
0.18866605.11796701.html.plaintext.txt	385	Contribution circadian pacemaker sleep homeostat sleep propensity sleep structure electroencephalographic slow waves sleep spindle activity humans
0.18866605.11796701.html.plaintext.txt	386	J Neurosci 15 3526 3538 1995Abstract
0.18866605.11796701.html.plaintext.txt	387	Dijk DJ Duffy JF Czeisler CA
0.18866605.11796701.html.plaintext.txt	388	Contribution circadian physiology sleep homeostasis age related changes human sleep
0.18866605.11796701.html.plaintext.txt	389	Chronobiol Int 17 285 311 2000ISIMedline
0.18866605.11796701.html.plaintext.txt	390	Dijk DJ Duffy JF Czeisler CA
0.18866605.11796701.html.plaintext.txt	391	Age related increase awakenings impaired consolidation nonREM sleep circadian phases
0.18866605.11796701.html.plaintext.txt	392	Sleep 24 565 577 2001ISIMedline
0.18866605.11796701.html.plaintext.txt	393	Dijk DJ Duffy JF Riel E Shanahan TL Czeisler CA
0.18866605.11796701.html.plaintext.txt	394	Ageing circadian homeostatic regulation human sleep forced desynchrony rest melatonin temperature rhythms
0.18866605.11796701.html.plaintext.txt	395	J Physiol Lond 516 611 627 1999AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	396	Dijk DJ Shanahan TL Duffy JF Ronda JM Czeisler CA
0.18866605.11796701.html.plaintext.txt	397	Variation electroencephalographic activity non rapid eye movement rapid eye movement sleep phase circadian melatonin rhythm humans
0.18866605.11796701.html.plaintext.txt	398	J Physiol Lond 505 851 858 1997Abstract
0.18866605.11796701.html.plaintext.txt	399	Duffy JF Dijk DJ Hall EF Czeisler CA
0.18866605.11796701.html.plaintext.txt	400	Relationship endogenous circadian melatonin temperature rhythms self reported preference morning evening activity young older people
0.18866605.11796701.html.plaintext.txt	401	J Investig Med 47 141 150 1999ISIMedline
0.18866605.11796701.html.plaintext.txt	402	Duffy JF Dijk DJ Klerman EB Czeisler CA
0.18866605.11796701.html.plaintext.txt	403	Later endogenous circadian temperature nadir relative earlier waketime older people
0.18866605.11796701.html.plaintext.txt	404	Am J Physiol Regulatory Integrative Comp Physiol 275 R1478 R1487 1998AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	405	Duffy JF Kronauer RE Czeisler CA
0.18866605.11796701.html.plaintext.txt	406	Phase shifting human circadian rhythms influence sleep timing social contact light exposure
0.18866605.11796701.html.plaintext.txt	407	J Physiol Lond 495 289 297 1996Abstract
0.18866605.11796701.html.plaintext.txt	408	Duffy JF Rimmer DW Czeisler CA
0.18866605.11796701.html.plaintext.txt	409	Association intrinsic circadian period morningness eveningness usual wake time circadian phase
0.18866605.11796701.html.plaintext.txt	410	Behav Neurosci 115 895 899 2001ISIMedline
0.18866605.11796701.html.plaintext.txt	411	Duffy JE Zeitzer JM Rimmer DW Klerman EB Dijk D J Czeisler CA
0.18866605.11796701.html.plaintext.txt	412	Peak circadian melatonin rhythm occurs later within sleep older subjects
0.18866605.11796701.html.plaintext.txt	413	Am J Physiol Endocrinol Metab Physiol In press
0.18866605.11796701.html.plaintext.txt	414	Eastman CI Mistlberger RE Rechtschaffen A
0.18866605.11796701.html.plaintext.txt	415	Suprachiasmatic nuclei lesions eliminate circadian temperature sleep rhythms rat
0.18866605.11796701.html.plaintext.txt	416	Physiol Behav 32 357 368 1984ISIMedline
0.18866605.11796701.html.plaintext.txt	417	Ebisawa T Uchiyama M Kajimura N Mishima K Kamei Y Katoh M Watanabe T Sekimoto M Shibui K Kim K Kudo Y Ozeki Y Sugishita M Toyoshima R Inoue Y Yamada N Nagase T Ozaki N Ohara O Ishida N Okawa M Takahashi K Yamauchi T
0.18866605.11796701.html.plaintext.txt	418	Association structural polymorphisms human period3 gene delayed sleep phase syndrome
0.18866605.11796701.html.plaintext.txt	419	EMBO Rep 2 342 346 2001AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	420	Edgar DM Dement WC Fuller CA
0.18866605.11796701.html.plaintext.txt	421	Effect SCN lesions sleep squirrel monkeys evidence opponent processes sleep wake regulation
0.18866605.11796701.html.plaintext.txt	422	J Neurosci 13 1065 1079 1993Abstract
0.18866605.11796701.html.plaintext.txt	423	Finelli LA Baumann H Borbely AA Achermann P
0.18866605.11796701.html.plaintext.txt	424	Dual electroencephalogram markers human sleep homeostasis correlation theta activity waking slow wave activity sleep
0.18866605.11796701.html.plaintext.txt	425	Neuroscience 101 523 529 2000ISIMedline
0.18866605.11796701.html.plaintext.txt	426	Finelli LA Borbely AA Achermann P
0.18866605.11796701.html.plaintext.txt	427	Functional topography human nonREM sleep electroencephalogram
0.18866605.11796701.html.plaintext.txt	428	Eur J Neurosci 13 2282 2290 2001ISIMedline
0.18866605.11796701.html.plaintext.txt	429	Foster RG Provencio I Hudson D Fiske S De Grip W Menaker M
0.18866605.11796701.html.plaintext.txt	430	Circadian photoreception retinally degenerate mouse rdrd
0.18866605.11796701.html.plaintext.txt	431	J Comp Physiol A 169 39 50 1991ISIMedline
0.18866605.11796701.html.plaintext.txt	432	Franken P Chollet D Tafti M
0.18866605.11796701.html.plaintext.txt	433	The homeostatic regulation sleep need genetic control
0.18866605.11796701.html.plaintext.txt	434	J Neurosci 21 2610 2621 2001AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	435	Freedman MS Lucas RJ Soni B von Schantz M Munoz M David Gray Z Foster R
0.18866605.11796701.html.plaintext.txt	436	Regulation mammalian circadian behavior non rod non cone ocular photoreceptors
0.18866605.11796701.html.plaintext.txt	437	Science 284 502 504 1999AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	438	Gordijn MC Beersma DG Korte HJ van den Hoofdakker RH
0.18866605.11796701.html.plaintext.txt	439	Effects light exposure sleep displacement dim light melatonin onset
0.18866605.11796701.html.plaintext.txt	440	J Sleep Res 8 163 174 1999ISIMedline
0.18866605.11796701.html.plaintext.txt	441	Jones CR Campbell SS Zone SE Cooper F DeSano A Murphy PJ Jones B Czajkowski L Ptacek LJ
0.18866605.11796701.html.plaintext.txt	442	Familial advanced sleep phase syndrome short period circadian rhythm variant humans
0.18866605.11796701.html.plaintext.txt	443	Nat Med 5 1062 1065 1999ISIMedline
0.18866605.11796701.html.plaintext.txt	444	Katzenberg D Young T Finn L Lin L King DP Takahashi JS Mignot E
0.18866605.11796701.html.plaintext.txt	445	A CLOCK polymorphism associated human diurnal preference
0.18866605.11796701.html.plaintext.txt	446	Sleep 21 569 576 1998ISIMedline
0.18866605.11796701.html.plaintext.txt	447	Kendall AR Lewy AJ Sack RL
0.18866605.11796701.html.plaintext.txt	448	Effects aging intrinsic circadian period totally blind humans
0.18866605.11796701.html.plaintext.txt	449	J Biol Rhythms 16 87 95 2001AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	450	Inter individual differences human circadian system review
0.18866605.11796701.html.plaintext.txt	451	Biol Psychol 20 83 112 1985ISIMedline
0.18866605.11796701.html.plaintext.txt	452	Kerkhof GA van Dongen HPA Morning type evening type individuals differ phase position endogenous circadian oscillator
0.18866605.11796701.html.plaintext.txt	453	Neurosci Lett 218 153 156 1996ISIMedline
0.18866605.11796701.html.plaintext.txt	454	Klerman EB Dijk DJ Kronauer RE Czeisler CA
0.18866605.11796701.html.plaintext.txt	455	Simulations light effects human circadian pacemaker implications assessment intrinsic period
0.18866605.11796701.html.plaintext.txt	456	Am J Physiol Regulatory Integrative Comp Physiol 270 R271 R282 1996AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	457	Klerman EB Duffy JF Dijk DJ Czeisler CA
0.18866605.11796701.html.plaintext.txt	458	Circadian phase resetting older people ocular bright light exposure
0.18866605.11796701.html.plaintext.txt	459	J Investig Med 49 30 40 2001ISIMedline
0.18866605.11796701.html.plaintext.txt	460	Klerman EB Rimmer DW Dijk DJ Kronauer RE Rizzo IIIJF Czeisler CA
0.18866605.11796701.html.plaintext.txt	461	Nonphotic entrainment human circadian pacemaker
0.18866605.11796701.html.plaintext.txt	462	Am J Physiol Regulatory Integrative Comp Physiol 274 R991 R996 1998AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	463	Kronauer RE Czeisler CA Pilato SF Moore Ede MC Weitzman ED
0.18866605.11796701.html.plaintext.txt	464	Mathematical model human circadian system two interacting oscillators
0.18866605.11796701.html.plaintext.txt	465	Am J Physiol Regulatory Integrative Comp Physiol 242 R3 R17 1982AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	466	Sleep structure EEG power density morning types evening types simulated day night shift
0.18866605.11796701.html.plaintext.txt	467	Physiol Behav 49 1195 1201 1991ISIMedline
0.18866605.11796701.html.plaintext.txt	468	Lancel M Wetter TC Steiger A Mathias S
0.18866605.11796701.html.plaintext.txt	469	Effect GABAA agonist gaboxadol nocturnal sleep hormone secretion healthy elderly subjects
0.18866605.11796701.html.plaintext.txt	470	Am J Physiol Endocrinol Metab 281 E130 E137 2001AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	471	Age dependent changes sleep EEG topography
0.18866605.11796701.html.plaintext.txt	472	Clin Neurophysiol 112 369 377 2001ISIMedline
0.18866605.11796701.html.plaintext.txt	473	Landolt HP Dijk DJ Achermann P Borbely AA
0.18866605.11796701.html.plaintext.txt	474	Effect age sleep EEG slow wave activity spindle frequency activity young middle aged men
0.18866605.11796701.html.plaintext.txt	475	Brain Res 738 205 212 1996ISIMedline
0.18866605.11796701.html.plaintext.txt	476	Melatonin role gating nocturnal rise sleep propensity
0.18866605.11796701.html.plaintext.txt	477	J Biol Rhythms 12 657 665 1997ISIMedline
0.18866605.11796701.html.plaintext.txt	478	Lockley SW Skene DJ Arendt J Tabandeh H Bird AC Defrance R
0.18866605.11796701.html.plaintext.txt	479	Relationship melatonin rhythms visual loss blind
0.18866605.11796701.html.plaintext.txt	480	J Clin Endocrinol Metab 82 3763 3770 1997AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	481	Lockley SW Skene DJ Butler LJ Arendt J
0.18866605.11796701.html.plaintext.txt	482	Sleep activity rhythms related circadian phase blind
0.18866605.11796701.html.plaintext.txt	483	Sleep 22 616 623 1999ISIMedline
0.18866605.11796701.html.plaintext.txt	484	Lockley SW Skene DJ James K Thapan K Wright J Arendt J
0.18866605.11796701.html.plaintext.txt	485	Melatonin administration entrain free running circadian system blind subjects
0.18866605.11796701.html.plaintext.txt	486	J Endocrinol 164 R1 R6 2000Abstract
0.18866605.11796701.html.plaintext.txt	487	Lockley SW Skene DJ Tabandeh H Bird AC Defrance R Arendt J
0.18866605.11796701.html.plaintext.txt	488	Relationship napping melatonin blind
0.18866605.11796701.html.plaintext.txt	489	J Biol Rhythms 12 16 25 1997ISIMedline
0.18866605.11796701.html.plaintext.txt	490	Lu J Greco MA Shiromani P Saper CB
0.18866605.11796701.html.plaintext.txt	491	Effect lesions ventrolateral preoptic nucleus NREM REM sleep
0.18866605.11796701.html.plaintext.txt	492	J Neurosci 20 3830 3842 2000AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	493	Lu J Shiromani P Saper CB
0.18866605.11796701.html.plaintext.txt	494	Retinal input sleep active ventrolateral preoptic nucleus rat
0.18866605.11796701.html.plaintext.txt	495	Neuroscience 93 209 214 1999ISIMedline
0.18866605.11796701.html.plaintext.txt	496	Lu J Zhang YH Chou TC Gaus SE Elmquist JK Shiromani P Saper CB
0.18866605.11796701.html.plaintext.txt	497	Contrasting effects ibotenate lesions paraventricular nucleus subparaventricular zone sleep wake cycle temperature regulation
0.18866605.11796701.html.plaintext.txt	498	J Neurosci 21 4864 4874 2001AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	499	Lucas RJ Douglas RH Foster RG
0.18866605.11796701.html.plaintext.txt	500	Characterization ocular photopigment capable driving pupillary constriction mice
0.18866605.11796701.html.plaintext.txt	501	Nat Neurosci 4 621 626 2001ISIMedline
0.18866605.11796701.html.plaintext.txt	502	Lucas RJ Freedman MS Munoz M Garcia Fernandez JM Foster RG
0.18866605.11796701.html.plaintext.txt	503	Regulation mammalian pineal non rod non cone ocular photoreceptors
0.18866605.11796701.html.plaintext.txt	504	Science 284 505 507 1999AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	505	Masubuchi S Honma S Abe H Ishizaki K Namihira M Ikeda M Honma K
0.18866605.11796701.html.plaintext.txt	506	Clock genes outside suprachiasmatic nucleus involved manifestation locomotor activity rhythm rats
0.18866605.11796701.html.plaintext.txt	507	Eur J Neurosci 12 4206 4214 2000ISIMedline
0.18866605.11796701.html.plaintext.txt	508	Moore RY Abrahamson EA Van Den Pol A
0.18866605.11796701.html.plaintext.txt	509	The hypocretin neuron system arousal system human brain
0.18866605.11796701.html.plaintext.txt	510	Arch Ital Biol 139 195 205 2001ISIMedline
0.18866605.11796701.html.plaintext.txt	511	Naylor E Bergmann BM Krauski K Zee PC Takahashi JS Vitaterna MH Turek FW
0.18866605.11796701.html.plaintext.txt	512	The circadian clock mutation alters sleep homeostasis mouse
0.18866605.11796701.html.plaintext.txt	513	J Neurosci 20 8138 8143 2000AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	514	Overeem S Mignot E van Dijk GJ Lammers GJ
0.18866605.11796701.html.plaintext.txt	515	Narcolepsy clinical features new pathophysiologic insights future perspectives
0.18866605.11796701.html.plaintext.txt	516	J Clin Neurophysiol 18 78 105 2001ISIMedline
0.18866605.11796701.html.plaintext.txt	517	Peyron C Faraco J Rogers W Ripley B Overeem S Charnay Y Nevsimalova S Aldrich M Reynolds D Albin R Li R Hungs M Pedrazzoli M Padigaru M Kucherlapati M Fan J Maki R Lammers GJ Bouras C Kucherlapati R Nishino S Mignot E
0.18866605.11796701.html.plaintext.txt	518	A mutation case early onset narcolepsy generalized absence hypocretin peptides human narcoleptic brains
0.18866605.11796701.html.plaintext.txt	519	Nat Med 6 991 997 2000ISIMedline
0.18866605.11796701.html.plaintext.txt	520	Provencio I Rodriguez IR Jiang G Hayes WP Moreira EF Rollag MD
0.18866605.11796701.html.plaintext.txt	521	A novel human opsin inner retina
0.18866605.11796701.html.plaintext.txt	522	J Neurosci 20 600 605 2000AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	523	Reid KJ Chang AM Dubocovich ML Turek FW Takahashi JS Zee PC
0.18866605.11796701.html.plaintext.txt	524	Familial advanced sleep phase syndrome
0.18866605.11796701.html.plaintext.txt	525	Arch Neurol 58 1089 1094 2001AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	526	Rimmer DW Boivin DB Shanahan TL Kronauer RE Duffy JF Czeisler CA
0.18866605.11796701.html.plaintext.txt	527	Dynamic resetting human circadian pacemaker intermittent bright light
0.18866605.11796701.html.plaintext.txt	528	Am J Physiol Regulatory Integrative Comp Physiol 279 R1574 R1579 2000AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	529	Sack RL Brandes RW Kendall AR Lewy AJ
0.18866605.11796701.html.plaintext.txt	530	Entrainment free running circadian rhythms melatonin blind people
0.18866605.11796701.html.plaintext.txt	531	N Engl J Med 343 1070 1077 2000AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	532	Schwartz WJ Busis NA Hedley Whyte ET
0.18866605.11796701.html.plaintext.txt	533	A discrete lesion ventral hypothalamus optic chiasm disturbed daily temperature rhythm
0.18866605.11796701.html.plaintext.txt	534	J Neurol 233 1 4 1986ISIMedline
0.18866605.11796701.html.plaintext.txt	535	Shibui K Uchiyama M Okawa M
0.18866605.11796701.html.plaintext.txt	536	Melatonin rhythms delayed sleep phase syndrome
0.18866605.11796701.html.plaintext.txt	537	J Biol Rhythms 14 72 76 1999AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	538	Thapan K Arendt J Skene DJ
0.18866605.11796701.html.plaintext.txt	539	An action spectrum melatonin suppression evidence novel non rod non cone photoreceptor system humans
0.18866605.11796701.html.plaintext.txt	540	J Physiol Lond 535 261 267 2001AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	541	Tobler I Borbely AA Groos G
0.18866605.11796701.html.plaintext.txt	542	The effect sleep deprivation sleep rats suprachiasmatic lesions
0.18866605.11796701.html.plaintext.txt	543	Neurosci Lett 42 49 54 1983ISIMedline
0.18866605.11796701.html.plaintext.txt	544	Toh KL Jones CR He Y Eide EJ Hinz WA Virshup DM Ptacek LJ Fu YH
0.18866605.11796701.html.plaintext.txt	545	An hPer2 phosphorylation site mutation familial advanced sleep phase syndrome
0.18866605.11796701.html.plaintext.txt	546	Science 291 1040 1043 2001AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	547	Uchiyama M Okawa M Shibui K Kim K Tagaya H Kudo Y Kamei Y Hayakawa T Urata J Takahashi K
0.18866605.11796701.html.plaintext.txt	548	Altered phase relation sleep timing core body temperature rhythm delayed sleep phase syndrome non 24 hour sleep wake syndrome humans
0.18866605.11796701.html.plaintext.txt	549	Neurosci Lett 294 101 104 2000ISIMedline
0.18866605.11796701.html.plaintext.txt	550	Van Cauter E Leproult R Plat L
0.18866605.11796701.html.plaintext.txt	551	Age related changes slow wave sleep REM sleep relationship growth hormone cortisol levels healthy men
0.18866605.11796701.html.plaintext.txt	552	JAMA 284 861 868 2000AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	553	A clock seasons human brain
0.18866605.11796701.html.plaintext.txt	554	Prog Brain Res 111 321 342 1996ISIMedline
0.18866605.11796701.html.plaintext.txt	555	Wehr TA Aeschbach D Duncan WC Jr
0.18866605.11796701.html.plaintext.txt	556	Evidence biological dawn dusk human circadian timing system
0.18866605.11796701.html.plaintext.txt	557	J Physiol Lond 535 937 951 2001AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	558	Werth E Dijk DJ Achermann P Borbely AA
0.18866605.11796701.html.plaintext.txt	559	Dynamics sleep EEG early evening nap Experimental data simulations
0.18866605.11796701.html.plaintext.txt	560	Am J Physiol Regulatory Integrative Comp Physiol 271 R501 R510 1996AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	561	Wright KP Jr Hughes RJ Kronauer RE Dijk D J Czeisler CA
0.18866605.11796701.html.plaintext.txt	562	Intrinsic near 24 hour pacemaker period determines limits circadian entrainment weak synchronizer humans
0.18866605.11796701.html.plaintext.txt	563	Proc Natl Acad Sci USA 98 14027 14032 2001AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	564	Circadian homeostatic control rapid eye movement REM sleep promotion REM tendency suprachiasmatic nucleus
0.18866605.11796701.html.plaintext.txt	565	J Neurosci 20 4300 4310 2000AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	566	Wyatt JK Ritz De Cecco A Czeisler CA Dijk DJ
0.18866605.11796701.html.plaintext.txt	567	Circadian temperature melatonin rhythms sleep neurobehavioral function humans living 20 h day
0.18866605.11796701.html.plaintext.txt	568	Am J Physiol Regulatory Integrative Comp Physiol 277 R1152 R1163 1999AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	569	Time zones comparative genetics circadian clocks
0.18866605.11796701.html.plaintext.txt	570	Nat Rev Genet 2 702 715 2001ISIMedline
0.18866605.11796701.html.plaintext.txt	571	Zeitzer JM Dijk DJ Kronauer RE Brown EN Czeisler CA
0.18866605.11796701.html.plaintext.txt	572	Sensitivity human circadian pacemaker nocturnal light melatonin phase resetting suppression
0.18866605.11796701.html.plaintext.txt	573	J Physiol Lond 526 695 702 2000AbstractFree Full Text
0.18866605.11796701.html.plaintext.txt	574	J APPL PHYSIOL 922852 862 8750 758702 5
0.18866605.11796701.html.plaintext.txt	575	00 Copyright 2002 American Physiological Society
0.5774776.12453828.html.plaintext.txt	0	Somatotropic axis hypocretin deficient narcoleptic humans altered circadian distribution GH secretory events Sebastiaan Overeem1 Simon W
0.5774776.12453828.html.plaintext.txt	1	Kok2 Gert Jan Lammers1 Alla A
0.5774776.12453828.html.plaintext.txt	2	Vein1 Marijke Frolich2 Arend E
0.5774776.12453828.html.plaintext.txt	3	Meinders2 Ferdinand Roelfsema3 Hanno Pijl2
0.5774776.12453828.html.plaintext.txt	4	1 Department Neurology Clinical Neurophysiology 2 Department General Internal Medicine 3 Department Endocrinology Leiden University Medical Center 2300 RC Leiden The Netherlands
0.5774776.12453828.html.plaintext.txt	5	ABSTRACT TOP ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES
0.5774776.12453828.html.plaintext.txt	6	Narcolepsy sleep disorder caused impaired hypocretin orexin neurotransmission
0.5774776.12453828.html.plaintext.txt	7	Growth hormone GH secretion may altered narcolepsy various reasons
0.5774776.12453828.html.plaintext.txt	8	Slow wave sleep episodes closely associated GH secretory events randomly dispersed 24 h narcoleptics
0.5774776.12453828.html.plaintext.txt	9	Furthermore hypocretins may inhibit pituitary GH release
0.5774776.12453828.html.plaintext.txt	10	We assessed function somatotropic axis narcolepsy deconvolving 24 h 10 min sampling interval plasma GH concentration profiles seven hypocretin deficient narcoleptic patients seven healthy controls matched age sex body weight
0.5774776.12453828.html.plaintext.txt	11	Both basal pulsatile GH secretion rate secretagogue induced GH release similar patients controls
0.5774776.12453828.html.plaintext.txt	12	However narcoleptics secreted 50 total production daytime whereas controls secreted 25 day
0.5774776.12453828.html.plaintext.txt	13	Also GH output pattern narcoleptics significantly less regular
0.5774776.12453828.html.plaintext.txt	14	We propose hypocretin deficiency disrupts circadian distribution hypothalamic GH releasing hormone release narcoleptic patients simultaneously cause daytime GH release promote propensity fall asleep day
0.5774776.12453828.html.plaintext.txt	15	INTRODUCTION TOP ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES
0.5774776.12453828.html.plaintext.txt	16	NARCOLEPSY PRIMARILY AFFECTS organization regulation sleep wakefulness
0.5774776.12453828.html.plaintext.txt	17	Its main symptoms excessive daytime sleepiness cataplexy fragmented nocturnal sleep 20
0.5774776.12453828.html.plaintext.txt	18	Narcolepsy caused disruption hypocretin orexin mediated neurotransmission 7 16 21
0.5774776.12453828.html.plaintext.txt	19	The vast majority human patients lack hypocretin cerebrospinal fluid CSF 17 18 28
0.5774776.12453828.html.plaintext.txt	20	An autoimmune mediated destruction hypocretin neurons currently presumed principal cause narcolepsy humans 21 30
0.5774776.12453828.html.plaintext.txt	21	Sleep activity somatotropic axis intimately related 33
0.5774776.12453828.html.plaintext.txt	22	In particular slow wave sleep SWS associated pituitary growth hormone GH release
0.5774776.12453828.html.plaintext.txt	23	In healthy individuals major GH secretory event occurs often shortly sleep onset close temporal association first period SWS
0.5774776.12453828.html.plaintext.txt	24	Conversely sleep deprivation consistently associated reduction circulating GH levels age related decline SWS accompanied marked decrease GH secretion 32
0.5774776.12453828.html.plaintext.txt	25	Because SWS episodes randomly distributed 24 h narcoleptic patients healthy subjects 5 6 circadian distribution GH secretory events may altered hypocretin deficient narcoleptic humans
0.5774776.12453828.html.plaintext.txt	26	Moreover intracerebroventricular injection hypocretin 1 causes dose dependent reduction plasma GH rats 13 hypocretin deficiency may exert direct excitatory effect GH release narcoleptics
0.5774776.12453828.html.plaintext.txt	27	Only limited number studies assessed status somatotropic axis narcoleptic humans
0.5774776.12453828.html.plaintext.txt	28	In general studies suggested rise plasma GH concentrations around sleep onset markedly dampened even absent narcolepsy 2 8 15
0.5774776.12453828.html.plaintext.txt	29	It hypothesized intrinsic disturbance SWS andor frequent occurrence sleep onset rapid eye movement REM periods underlies alterations GH secretion narcoleptic humans 33
0.5774776.12453828.html.plaintext.txt	30	However interpretation data obtained early studies hampered methodological imperfections particularly respect selection control subjects e
0.5774776.12453828.html.plaintext.txt	31	matched age andor body mass index BMI
0.5774776.12453828.html.plaintext.txt	32	Moreover course time novel analytical techniques deconvolution approximate entropy ApEn developed allow estimation pituitary GH secretion rate quantification orderliness release process basis frequently sampled plasma GH concentration time series 24 34 38
0.5774776.12453828.html.plaintext.txt	33	To evaluate impact disturbance circadian slow wave sleep distribution andor hypocretin deficiency various features pulsatile GH secretion humans deconvolved 24 h plasma GH concentration profiles narcoleptic patients healthy controls matched age sex BMI
0.5774776.12453828.html.plaintext.txt	34	We specifically hypothesized circadian distribution peaks troughs plasma GH concentrations would disrupted total daily GH production would increased narcoleptic patients
0.5774776.12453828.html.plaintext.txt	35	METHODS TOP ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES
0.5774776.12453828.html.plaintext.txt	36	We included seven male patients outpatient clinic Department Neurology
0.5774776.12453828.html.plaintext.txt	37	A physician experienced narcolepsy G
0.5774776.12453828.html.plaintext.txt	38	Lammers made clinical diagnosis narcolepsy cataplexy
0.5774776.12453828.html.plaintext.txt	39	The diagnosis confirmed Multiple Sleep Latency Testing showed results typical narcolepsy 1
0.5774776.12453828.html.plaintext.txt	40	All patients HLA DQB10602 positive
0.5774776.12453828.html.plaintext.txt	41	We confirmed patients hypocretin deficient hypocretin 1 undetectable CSF direct radioimmunoassay RIA previously described 28
0.5774776.12453828.html.plaintext.txt	42	The subjects except three two using psychostimulants one using clomipramine discontinued medication 2 wk study free medication
0.5774776.12453828.html.plaintext.txt	43	Weight height subjects measured well waist hip circumference waist halfway lowest rib crista iliaca hip maximum circumference standing position
0.5774776.12453828.html.plaintext.txt	44	The waist hip ratio WHR used relative measure abdominal fat mass
0.5774776.12453828.html.plaintext.txt	45	Total body fat mass determined dual energy X ray absorptiometry Hologic QDR4500 Waltham MA 3
0.5774776.12453828.html.plaintext.txt	46	We recruited seven male control subjects advertisements local newspapers
0.5774776.12453828.html.plaintext.txt	47	Controls matched age BMI total fat mass WHR
0.5774776.12453828.html.plaintext.txt	48	Controls take medication history sleep disorders
0.5774776.12453828.html.plaintext.txt	49	Subjects eligible study exclusion hypertension defined repeated blood pressure measurement showing systolic pressure 140 mmHg diastolic pressure 90 mmHg known history endocrine disease recent weight change 3 kg weight gain loss within last 3 mo fasting blood glucose 7
0.5774776.12453828.html.plaintext.txt	50	The study protocol approved Medical Ethics Committee Leiden University Medical Center
0.5774776.12453828.html.plaintext.txt	51	All subjects gave written informed consent participate
0.5774776.12453828.html.plaintext.txt	52	All investigations performed Clinical Research Center CRC Department General Internal Medicine
0.5774776.12453828.html.plaintext.txt	53	Subjects admitted CRC prepared sleep registration
0.5774776.12453828.html.plaintext.txt	54	During 24 h study occasion three standardized meals served 0900 1300 1800 Nutridrink 1
0.5774776.12453828.html.plaintext.txt	55	5 kcalml 1500 1800 kcalday macronutrient composition per 100 ml 5 g protein 6
0.5774776.12453828.html.plaintext.txt	56	9 g carbohydrate Nutricia Zoetermeer Netherlands
0.5774776.12453828.html.plaintext.txt	57	Subjects remained sedentary throughout study except bathroom visits
0.5774776.12453828.html.plaintext.txt	58	Lights switched 2300
0.5774776.12453828.html.plaintext.txt	59	An intravenous cannula inserted antecubital vein 1 h start blood sampling
0.5774776.12453828.html.plaintext.txt	60	Blood samples taken three way stopcock attached extended line prevent sleep disturbances manipulations investigators
0.5774776.12453828.html.plaintext.txt	61	The catheter kept patent 0
0.5774776.12453828.html.plaintext.txt	62	9 NaCl heparin 1 Uml drip 500 ml24 h
0.5774776.12453828.html.plaintext.txt	63	Blood collected S monovetten tubes Sarstedt Etten Leur Netherlands 10 min intervals 24 h allowed clot centrifuged 4 degrees C 20 min within hour collection serum frozen 20 degrees C assays performed
0.5774776.12453828.html.plaintext.txt	64	Serum IGF I IGF binding protein 3 IGFBP 3 concentrations measured early morning sample
0.5774776.12453828.html.plaintext.txt	65	After 24 h sampling procedure 0900 next morning 50 microg GH releasing hormone GHRH given intravenous bolus serum GH concentrations measured blood samples taken every 10 min 90 min bolus injection 31
0.5774776.12453828.html.plaintext.txt	66	Serum GH concentrations measured using sensitive time resolved immunofluorometric assay Wallac Turku Finland
0.5774776.12453828.html.plaintext.txt	67	The assay specific 22 kDa GH isoform
0.5774776.12453828.html.plaintext.txt	68	Human biosynthetic GH Pharmacia Uppsala Sweden diluted bovine calf serum used standard calibrated World Health Organization First International Reference Preparation 80 505 1 microg 2
0.5774776.12453828.html.plaintext.txt	69	The detection limit assay defined value 2 SD mean value zero standard 0
0.5774776.12453828.html.plaintext.txt	70	The interassay coefficients variation varied 2
0.5774776.12453828.html.plaintext.txt	71	2 GH concentration range 0
0.5774776.12453828.html.plaintext.txt	72	All samples one subject measured assay
0.5774776.12453828.html.plaintext.txt	73	Total serum IGF I IGFBP 3 concentrations measured RIA previously described 23
0.5774776.12453828.html.plaintext.txt	74	During 24 h sampling procedure sleep recorded polygraphically using Porti 5 ambulant electroencephalogram recording system Twente Medical Systems International Enschede Netherlands scored EEG 2100 review software Nihon Kohden Tokyo Japan
0.5774776.12453828.html.plaintext.txt	75	An experienced technician blinded subject study visually scored sleep recordings 30 epochs means standardized criteria 27
0.5774776.12453828.html.plaintext.txt	76	Nocturnal sleep onset identified first epoch stages II III IV REM sleep lights provided subsequent interval scored wake
0.5774776.12453828.html.plaintext.txt	77	The sleep period defined time sleep onset final awakening morning
0.5774776.12453828.html.plaintext.txt	78	Sleep efficiency calculated percentage sleep period actually spent asleep
0.5774776.12453828.html.plaintext.txt	79	For GH time series used multiple parameter deconvolution analysis estimate various specific measures pulsatile secretion half life basis simultaneous consideration serum hormone concentrations dose dependent intrasample variances 35 37
0.5774776.12453828.html.plaintext.txt	80	Results expressed milliunits per liter distribution volume mUlD
0.5774776.12453828.html.plaintext.txt	81	The following parameters estimated GH series number secretory bursts secretory burst half duration duration half maximal amplitude burst amplitude mean mass secreted per burst hormone half life pulsatile secretion rate basal secretion rate total secretion per 24 h
0.5774776.12453828.html.plaintext.txt	82	Furthermore quantified amount GH secreted 0900 2300 2300 0900 3 h sleep onset first secretory burst sleep onset
0.5774776.12453828.html.plaintext.txt	83	We quantified minute minute regularity serial orderliness GH secretion use ApEn statistic scale model independent metric 24
0.5774776.12453828.html.plaintext.txt	84	ApEn estimates regularity subordinate nonpulsatile patterns data yields information complementary deconvolution techniques 25 39
0.5774776.12453828.html.plaintext.txt	85	Greater regularity yields smaller ApEn values whereas greater independence among sequential values time series yields larger ApEn values
0.5774776.12453828.html.plaintext.txt	86	We applied normalized ApEn parameters m 1 r 20 intraseries SD previously validated GH series length 26
0.5774776.12453828.html.plaintext.txt	87	The ApEn ratio delineates orderliness concentration time series compared ApEn score associated maximal randomness time series estimated computer simulation
0.5774776.12453828.html.plaintext.txt	88	Thus ApEn ratio equal 1 reflects maximal randomness time series study smaller ApEn ratios denote greater regularity
0.5774776.12453828.html.plaintext.txt	89	GH release response GHRH injection determined using deconvolution analysis see
0.5774776.12453828.html.plaintext.txt	90	Unless otherwise stated results expressed means plus minus SE
0.5774776.12453828.html.plaintext.txt	91	Median values shown parentheses
0.5774776.12453828.html.plaintext.txt	92	Comparisons made using unpaired two tailed Students test log transformation GH concentrationsecretion data
0.5774776.12453828.html.plaintext.txt	93	Differences groups considered significant P 0
0.5774776.12453828.html.plaintext.txt	94	Statistical calculations performed using SPSS Windows release 9
0.5774776.12453828.html.plaintext.txt	95	0 Systat release 10 SPSS Chicago IL
0.5774776.12453828.html.plaintext.txt	96	RESULTS TOP ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES
0.5774776.12453828.html.plaintext.txt	97	The clinical characteristics subjects study shown Table 1
0.5774776.12453828.html.plaintext.txt	98	Note mean BMI subjects overweight range
0.5774776.12453828.html.plaintext.txt	99	25 30 kgm2 expected narcoleptic patients 8
0.5774776.12453828.html.plaintext.txt	100	All participants well matched anthropometric variables potentially influencing GH secretion including BMI body composition
0.5774776.12453828.html.plaintext.txt	101	View table Table 1
0.5774776.12453828.html.plaintext.txt	102	Clinical characteristics study subjects
0.5774776.12453828.html.plaintext.txt	103	The duration sleep period differ patients 405 plus minus 30 min controls 383 plus minus 41 min P 0
0.5774776.12453828.html.plaintext.txt	104	Both groups relatively low sleep efficiency narcolepsy 64 plus minus 6
0.5774776.12453828.html.plaintext.txt	105	4 controls 72 plus minus 4
0.5774776.12453828.html.plaintext.txt	106	41 resulting 263 plus minus 32 min nocturnal sleep patients 274 plus minus 36 min controls P 0
0.5774776.12453828.html.plaintext.txt	107	However relative amount nocturnal stage I sleep 50 higher narcoleptics 21
0.5774776.12453828.html.plaintext.txt	108	04 suggests fragmented nocturnal sleep
0.5774776.12453828.html.plaintext.txt	109	The amount SWS night differ patients controls 25
0.5774776.12453828.html.plaintext.txt	110	None control subjects slept daytime
0.5774776.12453828.html.plaintext.txt	111	In contrast narcoleptics took least two daytime naps average 3
0.5774776.12453828.html.plaintext.txt	112	1 min daytime sleep episodes spent SWS 40
0.5774776.12453828.html.plaintext.txt	113	Figure 1 illustrates 24 h sleep pattern patient individual control together concomitant serum GH concentration profiles deconvolution based estimates GH secretion rates
0.5774776.12453828.html.plaintext.txt	114	The 24 h mean serum concentration GH significantly different narcoleptic patients controls 1
0.5774776.12453828.html.plaintext.txt	115	Likewise serum IGF I IGFBP 3 concentrations differ groups data shown
0.5774776.12453828.html.plaintext.txt	116	View larger version 19K Fig
0.5774776.12453828.html.plaintext.txt	117	Example 24 h growth hormone GH profiles narcoleptic patient 31 yr old A individual control 33 yr old B
0.5774776.12453828.html.plaintext.txt	118	Plotted top bottom hypnogram pattern wakefulness sleep stages serum GH concentration conc
0.5774776.12453828.html.plaintext.txt	119	mUl 10 min intervals GH secretory rate secr
0.5774776.12453828.html.plaintext.txt	120	mU l1 min1 estimated multiparameter deconvolution
0.5774776.12453828.html.plaintext.txt	121	Note occurrence 3 daytime naps patient
0.5774776.12453828.html.plaintext.txt	122	The deconvolution derived 24 h GH secretion parameters summarized Table 2
0.5774776.12453828.html.plaintext.txt	123	Patients narcolepsy differ controls respect basal secretion rate total number GH peaks peak amplitude area
0.5774776.12453828.html.plaintext.txt	124	Consequently total production GH different two groups Fig
0.5774776.12453828.html.plaintext.txt	125	However distribution GH secretory events 24 h differed considerably groups
0.5774776.12453828.html.plaintext.txt	126	Narcoleptics secreted almost one half total pulsatile production day whereas controls produced one quarter day pulsatile release daytime fraction total pulsatile release 0
0.5774776.12453828.html.plaintext.txt	127	View table Table 2
0.5774776.12453828.html.plaintext.txt	128	Secretory parameters 24 h serum GH narcolepsy patients controls
0.5774776.12453828.html.plaintext.txt	129	View larger version 9K Fig
0.5774776.12453828.html.plaintext.txt	130	Total 24 h GH secretion patients controls
0.5774776.12453828.html.plaintext.txt	131	lD liter distribution volume
0.5774776.12453828.html.plaintext.txt	132	Individual levels shown together mean value
0.5774776.12453828.html.plaintext.txt	133	Sleep onset GH secretion assessed determination GH production first 3 h sleep quantifying first GH pulse sleep onset
0.5774776.12453828.html.plaintext.txt	134	Both narcoleptics controls secreted approximately one third total 24 h GH production first 3 h sleep 29
0.5774776.12453828.html.plaintext.txt	135	The amount secreted first secretory event sleep onset also similar groups 10
0.5774776.12453828.html.plaintext.txt	136	The total amount GH released per day strongly correlated total 24 h amount SWS controls r2 0
0.5774776.12453828.html.plaintext.txt	137	This relationship remained intact narcoleptics r2 0
0.5774776.12453828.html.plaintext.txt	138	In contrast GH release correlated total amount REM sleep either group r2 0
0.5774776.12453828.html.plaintext.txt	139	1 narcoleptics controls respectively
0.5774776.12453828.html.plaintext.txt	140	View larger version 19K Fig
0.5774776.12453828.html.plaintext.txt	141	Correlation total amount slow wave sleep 24 h total GH secretion patients controls groups combined
0.5774776.12453828.html.plaintext.txt	142	The slopes regression lines significantly different groups
0.5774776.12453828.html.plaintext.txt	143	The GH secretion pattern less orderly narcoleptic patients may reflect disruption GHRH feedforward inputs see DISCUSSION
0.5774776.12453828.html.plaintext.txt	144	Both ApEn120 values 0
0.5774776.12453828.html.plaintext.txt	145	03 increased patient group reflecting decrease serial orderliness GH secretion
0.5774776.12453828.html.plaintext.txt	146	The narcoleptic patients responded GHRH injection secreting amounts GH similar control subjects
0.5774776.12453828.html.plaintext.txt	147	With use multiparameter deconvolution GH secretion GHRH injection calculated 56
0.5774776.12453828.html.plaintext.txt	148	9 mUlD patients controls respectively P 0
0.5774776.12453828.html.plaintext.txt	149	DISCUSSION TOP ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES
0.5774776.12453828.html.plaintext.txt	150	We assessed 24 h sleep patterns GH secretion profiles conjointly well defined group narcoleptic patients controls matched various confounding variables
0.5774776.12453828.html.plaintext.txt	151	The patients several daytime naps including SWS episodes whereas sleep confined nighttime controls
0.5774776.12453828.html.plaintext.txt	152	Total daily GH production strongly correlated total time SWS narcoleptic patients controls alike Fig
0.5774776.12453828.html.plaintext.txt	153	As result dispersion GH secretory events slow wave sleep epochs 24 h altered concomitantly narcoleptics secreted larger fraction total GH production day 48 vs
0.5774776.12453828.html.plaintext.txt	154	The GH output pattern significantly less regular narcoleptic patients
0.5774776.12453828.html.plaintext.txt	155	Against expectations basal pulsatile GH production secretagogue induced GH release similar patients controls Fig
0.5774776.12453828.html.plaintext.txt	156	Only previous studies examined plasma GH concentrations patients narcolepsy
0.5774776.12453828.html.plaintext.txt	157	The results studies generally suggested GH release spontaneous 24 h secretagogue induced blunted narcoleptics 2 8 15
0.5774776.12453828.html.plaintext.txt	158	However interpretation data obtained studies hampered potential imperfections regarding selection control subjects
0.5774776.12453828.html.plaintext.txt	159	For example two studies 2 15 body weight participants reported third study 8 include healthy control subjects
0.5774776.12453828.html.plaintext.txt	160	We know narcoleptic patients tend obese 9 GH production profoundly reduced abdominally obese humans 23 36
0.5774776.12453828.html.plaintext.txt	161	Also age reported two studies 2 15
0.5774776.12453828.html.plaintext.txt	162	In one 15 narcoleptic patients 10 yr older controls 32 vs
0.5774776.12453828.html.plaintext.txt	163	24 yr may also biased results 32
0.5774776.12453828.html.plaintext.txt	164	In present study control subjects carefully matched respect age sex BMI body fat distribution preclude analogous bias
0.5774776.12453828.html.plaintext.txt	165	Therefore believe data presented present paper conclusive previous study whether narcolepsy per se impacts GH secretion
0.5774776.12453828.html.plaintext.txt	166	Moreover narcoleptic patients present study confirmed hypocretin deficient possible determine previous studies hypocretin peptides unknown time
0.5774776.12453828.html.plaintext.txt	167	Thus present data pertain specifically hypocretin deficient narcoleptic humans
0.5774776.12453828.html.plaintext.txt	168	Our results clearly argue reduction spontaneous secretagogue induced GH secretion human narcolepsy
0.5774776.12453828.html.plaintext.txt	169	What learn regulation GH secretion sleep results study First onset nocturnal sleep remains important correlate GH release even numerous naps interrupted daytime wakefulness
0.5774776.12453828.html.plaintext.txt	170	Both narcoleptics controls 30 total daily GH secretion occurred 3 h nocturnal sleep onset
0.5774776.12453828.html.plaintext.txt	171	Second relationship SWS GH release remains robust even sleep fragmented randomly dispersed 24 h
0.5774776.12453828.html.plaintext.txt	172	A strong positive highly significant correlation variables observed narcoleptics controls
0.5774776.12453828.html.plaintext.txt	173	Third dispersion GH secretory events sleep epochs 24 h appears altered analogously narcoleptic patients slow wave sleep time GH secretion day
0.5774776.12453828.html.plaintext.txt	174	Finally endogenous hypocretins significantly impact amount GH produced daily humans
0.5774776.12453828.html.plaintext.txt	175	The hypocretin peptides hypocretin 1 2 also known orexin A B produced exclusively small number neurons located perifornical area hypothalamus 10 29
0.5774776.12453828.html.plaintext.txt	176	Hypocretin neurons connect nuclei within hypothalamus including arcuate nucleus pituitary 22 explain impact energy balance several neuroendocrine ensembles reviews see Refs
0.5774776.12453828.html.plaintext.txt	177	Intracerebroventricular administration hypocretin 1 causes dose dependent decrease plasma GH rats 13
0.5774776.12453828.html.plaintext.txt	178	Furthermore recently reported somatotropic cells human pituitary express hypocretin receptor 1 4
0.5774776.12453828.html.plaintext.txt	179	These data suggest hypocretins directly blunt GH secretion
0.5774776.12453828.html.plaintext.txt	180	We therefore hypothesized hypocretin deficiency would enhance total daily GH production narcoleptic humans
0.5774776.12453828.html.plaintext.txt	181	Our results support contention narcoleptic patients produced normal total amounts GH Fig
0.5774776.12453828.html.plaintext.txt	182	However believe data support thesis hypocretin deficiency disrupts circadian dispersion hypothalamic GHRH release normally confines sleep GH secretion night
0.5774776.12453828.html.plaintext.txt	183	Sleep activity somatotropic axis intimately related 33
0.5774776.12453828.html.plaintext.txt	184	The reproducible GH secretory event humans occurs around nocturnal sleep onset close temporal association first epoch SWS see Ref
0.5774776.12453828.html.plaintext.txt	185	The secretion GH controlled mainly two hypothalamic peptides GHRH somatostatin 12 14
0.5774776.12453828.html.plaintext.txt	186	A large body evidence suggests GHRH simultaneously promotes sleep GH release explain consistent association sleep GH secretion see Ref
0.5774776.12453828.html.plaintext.txt	187	The present study shows dual regulatory effect GHRH probably intact narcoleptics SWS GH release remain closely associated patients Fig
0.5774776.12453828.html.plaintext.txt	188	This inference may imply circadian distribution hypothalamic GHRH release disrupted narcolepsy simultaneously cause diurnal GH secretion enhance daytime sleepiness
0.5774776.12453828.html.plaintext.txt	189	Specifically hypocretin system particularly active day 11 may normally inhibit hypothalamic GHRH secretion promote arousal reduce pituitary GH output
0.5774776.12453828.html.plaintext.txt	190	Conversely diminution hypocretin tonus night 11 may relax inhibitory restraint GHRH release dampen arousal increase GH output
0.5774776.12453828.html.plaintext.txt	191	In scenario hypocretin deficiency particularly enhances GHRH release day system normally peak activity concurrently promote daytime GH secretion compromise daytime wakefulness narcoleptic patients
0.5774776.12453828.html.plaintext.txt	192	The irregular GH output pattern found narcoleptics also supports notion hypothalamic GHRH release may enhanced disorder
0.5774776.12453828.html.plaintext.txt	193	The serial orderliness pulsatile GH release determined ApEn statistic reflects balance feedforward feedback inputs somatotropic neuroendocrine ensemble 40
0.5774776.12453828.html.plaintext.txt	194	In present study GH output irregular narcoleptic patients healthy controls suggests negative feedback restraint somatotropic activity muted andor positive feedforward inputs enhanced narcolepsy 40
0.5774776.12453828.html.plaintext.txt	195	In conclusion study documents irregular release normal amounts GH hypocretin deficient narcoleptic humans
0.5774776.12453828.html.plaintext.txt	196	In addition circadian dispersion GH secretory events altered narcoleptics relatively large fraction total production occurs daytime
0.5774776.12453828.html.plaintext.txt	197	We propose altered circadian distribution GHRH release brought hypocretin deficiency simultaneously causes increased daytime GH secretion enhanced daytime sleepiness narcolepsy
0.5774776.12453828.html.plaintext.txt	198	We thank following efforts completion study E
0.5774776.12453828.html.plaintext.txt	199	Sierat van der Steen technical support study occasions M
0.5774776.12453828.html.plaintext.txt	200	Haasnoot van der Bent performing GH measurements P
0.5774776.12453828.html.plaintext.txt	201	Reijntjes technical assistance analysis visualization parts data
0.5774776.12453828.html.plaintext.txt	202	Address reprint requests correspondence H
0.5774776.12453828.html.plaintext.txt	203	General Internal Medicine C1 R39 P
0.5774776.12453828.html.plaintext.txt	204	Box 9600 2300 RC Leiden The Netherlands E mail h
0.5774776.12453828.html.plaintext.txt	205	The costs publication article defrayed part payment page charges
0.5774776.12453828.html.plaintext.txt	206	The article must therefore hereby marked advertisement accordance 18 U
0.5774776.12453828.html.plaintext.txt	207	Section 1734 solely indicate fact
0.5774776.12453828.html.plaintext.txt	208	First published November 26 200210
0.5774776.12453828.html.plaintext.txt	209	Received 1 October 2002 accepted final form 22 November 2002
0.5774776.12453828.html.plaintext.txt	210	REFERENCES TOP ABSTRACT INTRODUCTION METHODS RESULTS DISCUSSION REFERENCES
0.5774776.12453828.html.plaintext.txt	211	American Sleep Disorders Association
0.5774776.12453828.html.plaintext.txt	212	International Classification Sleep Disorders
0.5774776.12453828.html.plaintext.txt	213	Diagnostic Coding Manual Revised
0.5774776.12453828.html.plaintext.txt	214	Rochester MN American Sleep Disorders Association 1997
0.5774776.12453828.html.plaintext.txt	215	Besset A Bonardet A Billiard M Descomps B de Paulet AC Passouant P
0.5774776.12453828.html.plaintext.txt	216	Circadian patterns growth hormone cortisol secretions narcoleptic patients
0.5774776.12453828.html.plaintext.txt	217	Chronobiologia 6 19 31 1979ISIMedline
0.5774776.12453828.html.plaintext.txt	218	Technical principles dual energy x ray absorptiometry
0.5774776.12453828.html.plaintext.txt	219	Semin Nucl Med 27 210 228 1997ISIMedline
0.5774776.12453828.html.plaintext.txt	220	Blanco M Lopez M Garcia Caballero T Gallego R Vazquez Boquete A Morel G Senaris R Casanueva F Dieguez C Beiras A
0.5774776.12453828.html.plaintext.txt	221	Cellular localization orexin receptors human pituitary
0.5774776.12453828.html.plaintext.txt	222	J Clin Endocrinol Metab 86 1616 1619 2001AbstractFree Full Text
0.5774776.12453828.html.plaintext.txt	223	Broughton R Dunham W Newman J Lutley K Duschesne P Rivers M
0.5774776.12453828.html.plaintext.txt	224	Ambulatory 24 hour sleep wake monitoring narcolepsy cataplexy compared matched controls
0.5774776.12453828.html.plaintext.txt	225	Electroencephalogr Clin Neurophysiol 70 473 481 1988ISIMedline
0.5774776.12453828.html.plaintext.txt	226	Broughton R Krupa S Boucher B Rivers M Mullington J
0.5774776.12453828.html.plaintext.txt	227	Impaired circadian waking arousal narcolepsy cataplexy
0.5774776.12453828.html.plaintext.txt	228	Online Sleep Res 1 159 165 1998
0.5774776.12453828.html.plaintext.txt	229	Chemelli RM Willie JT Sinton CM Elmquist JK Scammell T Lee C Richardson JA Williams SC Xiong Y Kisanuki Y Fitch TE Nakazato M Hammer RE Saper CB Yanagisawa M
0.5774776.12453828.html.plaintext.txt	230	Narcolepsy orexin knockout mice molecular genetics sleep regulation
0.5774776.12453828.html.plaintext.txt	231	Cell 98 437 451 1999ISIMedline
0.5774776.12453828.html.plaintext.txt	232	Clark RW Schmidt HS Malarkey WB
0.5774776.12453828.html.plaintext.txt	233	Disordered growth hormone prolactin secretion primary disorders sleep
0.5774776.12453828.html.plaintext.txt	234	Neurology 29 855 861 1979Abstract
0.5774776.12453828.html.plaintext.txt	235	Dahmen N Bierbrauer J Kasten M
0.5774776.12453828.html.plaintext.txt	236	Increased prevalence obesity narcoleptic patients relatives
0.5774776.12453828.html.plaintext.txt	237	Eur Arch Psychiatry Clin Neurosci 251 85 89 2001ISIMedline
0.5774776.12453828.html.plaintext.txt	238	De Lecea L Kilduff TS Peyron C Gao X Foye PE Danielson PE Fukuhara C Battenberg EL Gautvik VT Bartlett FS Frankel WN Den Pol AN Bloom FE Gautvik KM Sutcliffe JG
0.5774776.12453828.html.plaintext.txt	239	The hypocretins hypothalamus specific peptides neuroexcitatory activity
0.5774776.12453828.html.plaintext.txt	240	Proc Natl Acad Sci USA 95 322 327 1998AbstractFree Full Text
0.5774776.12453828.html.plaintext.txt	241	Fujiki N Yoshida Y Ripley B Honda K Mignot E Nishino S
0.5774776.12453828.html.plaintext.txt	242	Changes CSF hypocretin 1 orexin A levels rats across 24 hours response food deprivation
0.5774776.12453828.html.plaintext.txt	243	Neuroreport 12 993 997 2001ISIMedline
0.5774776.12453828.html.plaintext.txt	244	Giustina A Veldhuis JD
0.5774776.12453828.html.plaintext.txt	245	Pathophysiology neuroregulation growth hormone secretion experimental animals human
0.5774776.12453828.html.plaintext.txt	246	Endocr Rev 19 717 797 1998AbstractFree Full Text
0.5774776.12453828.html.plaintext.txt	247	Hagan JJ Leslie RA Patel S Evans ML Wattam TA Holmes S Benham CD Taylor SG Routledge C Hemmati P Munton RP Ashmeade TE Shah AS Hatcher JP Hatcher PD Jones DN Smith MI Piper DC Hunter AJ Porter RA Upton N
0.5774776.12453828.html.plaintext.txt	248	Orexin A activates locus coeruleus cell firing increases arousal rat
0.5774776.12453828.html.plaintext.txt	249	Proc Natl Acad Sci USA 96 10911 10916 1999AbstractFree Full Text
0.5774776.12453828.html.plaintext.txt	250	Hartman ML Veldhuis JD Thorner MO
0.5774776.12453828.html.plaintext.txt	251	Normal control growth hormone secretion
0.5774776.12453828.html.plaintext.txt	252	Horm Res 40 37 47 1993ISIMedline
0.5774776.12453828.html.plaintext.txt	253	Higuchi T Takahashi Y Takahashi K Niimi Y Miyasita A
0.5774776.12453828.html.plaintext.txt	254	Twenty four hour secretory patterns growth hormone prolactin cortisol narcolepsy
0.5774776.12453828.html.plaintext.txt	255	J Clin Endocrinol Metab 49 197 204 1979Abstract
0.5774776.12453828.html.plaintext.txt	256	Lin L Faraco J Li R Kadotani H Rogers W Lin X Qiu X de Jong PJ Nishino S Mignot E
0.5774776.12453828.html.plaintext.txt	257	The sleep disorder canine narcolepsy caused mutation hypocretin orexin receptor 2 gene
0.5774776.12453828.html.plaintext.txt	258	Cell 98 365 376 1999ISIMedline
0.5774776.12453828.html.plaintext.txt	259	Nishino S Ripley B Overeem S Lammers GJ Mignot E
0.5774776.12453828.html.plaintext.txt	260	Hypocretin orexin deficiency human narcolepsy
0.5774776.12453828.html.plaintext.txt	261	Lancet 355 39 40 2000ISIMedline
0.5774776.12453828.html.plaintext.txt	262	Nishino S Ripley B Overeem S Nevsimalova S Lammers GJ Vankova J Okun M Rogers W Brooks S Mignot E
0.5774776.12453828.html.plaintext.txt	263	Low cerebrospinal fluid hypocretin orexin altered energy homeostasis human narcolepsy
0.5774776.12453828.html.plaintext.txt	264	Ann Neurol 50 381 388 2001ISIMedline
0.5774776.12453828.html.plaintext.txt	265	Obal F Jr Fang J Taishi P Kacsoh B Gardi J Krueger JM
0.5774776.12453828.html.plaintext.txt	266	Deficiency growth hormone releasing hormone signaling associated sleep alterations dwarf rat
0.5774776.12453828.html.plaintext.txt	267	J Neurosci 21 2912 2918 2001AbstractFree Full Text
0.5774776.12453828.html.plaintext.txt	268	Overeem S Mignot E van Dijk JG Lammers GJ
0.5774776.12453828.html.plaintext.txt	269	Narcolepsy clinical features new pathophysiologic insights future perspectives
0.5774776.12453828.html.plaintext.txt	270	J Clin Neurophysiol 18 78 105 2001ISIMedline
0.5774776.12453828.html.plaintext.txt	271	Peyron C Faraco J Rogers W Ripley B Overeem S Charnay Y Nevsimalova S Aldrich M Reynolds D Albin R Li R Hungs M Pedrazzoli M Padigaru M Kucherlapati M Fan J Maki R Lammers GJ Bouras C Kucherlapati R Nishino S Mignot E
0.5774776.12453828.html.plaintext.txt	272	A mutation case early onset narcolepsy generalized absence hypocretin peptides human narcoleptic brains
0.5774776.12453828.html.plaintext.txt	273	Nat Med 6 991 997 2000ISIMedline
0.5774776.12453828.html.plaintext.txt	274	Peyron C Tighe DK Den Pol AN de Lecea L Heller HC Sutcliffe JG Kilduff TS
0.5774776.12453828.html.plaintext.txt	275	Neurons containing hypocretin orexin project multiple neuronal systems
0.5774776.12453828.html.plaintext.txt	276	J Neurosci 18 9996 10015 1998AbstractFree Full Text
0.5774776.12453828.html.plaintext.txt	277	Pijl H Langendonk JG Burggraaf J Frolich M Cohen AF Veldhuis JD Meinders AE
0.5774776.12453828.html.plaintext.txt	278	Altered neuroregulation GH secretion viscerally obese premenopausal women
0.5774776.12453828.html.plaintext.txt	279	J Clin Endocrinol Metab 86 5509 5515 2001AbstractFree Full Text
0.5774776.12453828.html.plaintext.txt	280	Approximate entropy measure system complexity
0.5774776.12453828.html.plaintext.txt	281	Proc Natl Acad Sci USA 88 2297 2301 1991Abstract
0.5774776.12453828.html.plaintext.txt	282	Pincus SM Gevers EF Robinson IC van den BG Roelfsema F Hartman ML Veldhuis JD
0.5774776.12453828.html.plaintext.txt	283	Females secrete growth hormone process irregularity males humans rats
0.5774776.12453828.html.plaintext.txt	284	Am J Physiol Endocrinol Metab 270 E107 E115 1996AbstractFree Full Text
0.5774776.12453828.html.plaintext.txt	285	Pincus SM Hartman ML Roelfsema F Thorner MO Veldhuis JD
0.5774776.12453828.html.plaintext.txt	286	Hormone pulsatility discrimination via coarse short time sampling
0.5774776.12453828.html.plaintext.txt	287	Am J Physiol Endocrinol Metab 277 E948 E957 1999AbstractFree Full Text
0.5774776.12453828.html.plaintext.txt	288	Rechtschaffen A Kales A
0.5774776.12453828.html.plaintext.txt	289	A Manual Standardized Terminology Techniques Scoring System Sleep Stages Human Subjects
0.5774776.12453828.html.plaintext.txt	290	Los Angeles CA UCLA Brain Information ServiceBrain Research Institute 1968
0.5774776.12453828.html.plaintext.txt	291	Ripley B Overeem S Fujiki N Nevsimalova S Uchino M Yesavage J Di Monte D Dohi K Melberg A Lammers GJ Nishida Y Roelandse FW Hungs M Mignot E Nishino S
0.5774776.12453828.html.plaintext.txt	292	CSF hypocretinorexin levels narcolepsy neurological conditions
0.5774776.12453828.html.plaintext.txt	293	Neurology 57 2253 2258 2001AbstractFree Full Text
0.5774776.12453828.html.plaintext.txt	294	Sakurai T Amemiya A Ishii M Matsuzaki I Chemelli RM Tanaka H Williams SC Richardson JA Kozlowski GP Wilson S Arch JR Buckingham RE Haynes AC Carr SA Annan RS McNulty DE Liu WS Terrett JA Elshourbagy NA Bergsma DJ Yanagisawa M
0.5774776.12453828.html.plaintext.txt	295	Orexins orexin receptors family hypothalamic neuropeptides G protein coupled receptors regulate feeding behavior
0.5774776.12453828.html.plaintext.txt	296	Cell 92 573 585 1998ISIMedline
0.5774776.12453828.html.plaintext.txt	297	Thannickal TC Moore RY Nienhuis R Ramanathan L Gulyani S Aldrich M Cornford M Siegel JM
0.5774776.12453828.html.plaintext.txt	298	Reduced number hypocretin neurons human narcolepsy
0.5774776.12453828.html.plaintext.txt	299	Neuron 27 469 474 2000ISIMedline
0.5774776.12453828.html.plaintext.txt	300	Thorner MO Vance ML Evans WS Rogol AD Rivier J Vale W Blizzard RM
0.5774776.12453828.html.plaintext.txt	301	Clinical studies GHRH man
0.5774776.12453828.html.plaintext.txt	302	Horm Res 24 91 98 1986ISIMedline
0.5774776.12453828.html.plaintext.txt	303	Van Cauter E Leproult R Plat L
0.5774776.12453828.html.plaintext.txt	304	Age related changes slow wave sleep REM sleep relationship growth hormone cortisol levels healthy men
0.5774776.12453828.html.plaintext.txt	305	JAMA 284 861 868 2000AbstractFree Full Text
0.5774776.12453828.html.plaintext.txt	306	Van Cauter E Plat L Copinschi G
0.5774776.12453828.html.plaintext.txt	307	Interrelations sleep somatotropic axis
0.5774776.12453828.html.plaintext.txt	308	Sleep 21 553 566 1998ISIMedline
0.5774776.12453828.html.plaintext.txt	309	New modalities understanding dynamic regulation somatotropic GH axis explication gender differences GH neuroregulation human
0.5774776.12453828.html.plaintext.txt	310	J Pediatr Endocrinol Metab 9 Suppl3 237 253 1996ISIMedline
0.5774776.12453828.html.plaintext.txt	311	Veldhuis JD Carlson ML Johnson ML
0.5774776.12453828.html.plaintext.txt	312	The pituitary gland secretes bursts appraising nature glandular secretory impulses simultaneous multiple parameter deconvolution plasma hormone concentrations
0.5774776.12453828.html.plaintext.txt	313	Proc Natl Acad Sci USA 84 7686 7690 1987Abstract
0.5774776.12453828.html.plaintext.txt	314	Veldhuis JD Iranmanesh A Ho KK Waters MJ Johnson ML Lizarralde G
0.5774776.12453828.html.plaintext.txt	315	Dual defects pulsatile growth hormone secretion clearance subserve hyposomatotropism obesity man
0.5774776.12453828.html.plaintext.txt	316	J Clin Endocrinol Metab 72 51 59 1991Abstract
0.5774776.12453828.html.plaintext.txt	317	Veldhuis JD Johnson ML
0.5774776.12453828.html.plaintext.txt	318	Deconvolution analysis hormone data
0.5774776.12453828.html.plaintext.txt	319	Methods Enzymol 210 539 575 1992ISIMedline
0.5774776.12453828.html.plaintext.txt	320	Veldhuis JD Johnson ML
0.5774776.12453828.html.plaintext.txt	321	Analytical methods evaluating episodic secretory activity within neuroendocrine axes
0.5774776.12453828.html.plaintext.txt	322	Neurosci Biobehav Rev 18 605 612 1994ISIMedline
0.5774776.12453828.html.plaintext.txt	323	Orderliness hormone release patterns complementary measure conventional pulsatile circadian analyses
0.5774776.12453828.html.plaintext.txt	324	Eur J Endocrinol 138 358 362 1998ISIMedline
0.5774776.12453828.html.plaintext.txt	325	Veldhuis JD Straume M Iranmanesh A Mulligan T Jaffe C Barkan A Johnson ML Pincus S
0.5774776.12453828.html.plaintext.txt	326	Secretory process regularity monitors neuroendocrine feedback feedforward signaling strength humans
0.5774776.12453828.html.plaintext.txt	327	Am J Physiol Regul Integr Comp Physiol 280 R721 R729 2001AbstractFree Full Text
0.5774776.12453828.html.plaintext.txt	328	Willie JT Chemelli RM Sinton CM Yanagisawa M
0.5774776.12453828.html.plaintext.txt	329	To eat sleep Orexin regulation feeding wakefulness
0.5774776.12453828.html.plaintext.txt	330	Annu Rev Neurosci 24 429 458 2001ISIMedline
0.5774776.12453828.html.plaintext.txt	331	Am J Physiol Endocrinol Metab 2843E641 E647 0193 184903 5
0.5774776.12453828.html.plaintext.txt	332	00 Copyright 2003 American Physiological Society
0.22697699.15746258.html.plaintext.txt	0	Dual Regulatory Effects Orexins Sympathetic Nerve Activity Innervating Brown Adipose Tissue Rats Tohru Yasuda Takayuki Masaki Tetsuya Kakuma Masahide Hara Tomoko Nawata Isao Katsuragi Hironobu Yoshimatsu
0.22697699.15746258.html.plaintext.txt	1	Department Internal Medicine I Faculty Medicine Oita University Hasama Oita 879 5593 Japan
0.22697699.15746258.html.plaintext.txt	2	Address correspondence requests reprints Professor Hironobu Yoshimatsu M
0.22697699.15746258.html.plaintext.txt	3	Department Internal Medicine I Faculty Medicine Oita University 1 1 Idaigaoka Hasama Oita 879 5593 Japan
0.22697699.15746258.html.plaintext.txt	4	Abstract Top Abstract Introduction Materials Methods Results Discussion References This study examined orexin regulates activity sympathetic nerves innervate brown adipose tissue BAT rats
0.22697699.15746258.html.plaintext.txt	5	Infusion orexin A dose 0
0.22697699.15746258.html.plaintext.txt	6	3 nmol third cerebral ventricle decreased BAT sympathetic nerve activity compared effect PBS P 0
0.22697699.15746258.html.plaintext.txt	7	05 whereas infusion orexin B dose caused significant increase P 0
0.22697699.15746258.html.plaintext.txt	8	Pretreatment third cerebral ventricle injection 2
0.22697699.15746258.html.plaintext.txt	9	24 micromolkg fluoromethylhistidine irreversible inhibitor histamine synthesizing enzyme histidine decarboxylase attenuated orexin B induced response BAT sympathetic nerve activity induced orexin A
0.22697699.15746258.html.plaintext.txt	10	These results indicate orexins may regulate BAT energy expenditure thermogenesis dual effects sympathetic nerve activity
0.22697699.15746258.html.plaintext.txt	11	In particular orexin B regulates BAT sympathetic nerve activity via neuronal histamine hypothalamus
0.22697699.15746258.html.plaintext.txt	12	Introduction Top Abstract Introduction Materials Methods Results Discussion References OREXIN A AND OREXIN B hypothalamic neuropeptides derived 130 amino acid precursor prepro orexin potent agonists orexin 1 OX1 orexin 2 OX2 receptors
0.22697699.15746258.html.plaintext.txt	13	Orexin neurons located lateral hypothalamic area LHA innervate almost regions brain except cerebellum 1 2
0.22697699.15746258.html.plaintext.txt	14	Especially dense projections observed specific regions thalamus limbic system aminergic nuclei noradrenergic locus coeruleus LC serotonergic raphe nucleus histaminergic tuberomammillary nucleus TMN 3 4
0.22697699.15746258.html.plaintext.txt	15	Concomitantly presence orexin receptors identified nuclei namely OX1R LC OX2R TMN 5
0.22697699.15746258.html.plaintext.txt	16	Hypothalamic histamine neurons cell bodies TMN shown involved regulation variety physiological functions feeding behavior drinking behavior thermoregulation well autonomic nervous neuroendocrine systems 6
0.22697699.15746258.html.plaintext.txt	17	The orexin histamine signaling pathway plays important role regulation sleep wakefulness cycle although involvement hypothalamic functions remains unclear 7
0.22697699.15746258.html.plaintext.txt	18	Brown adipose tissue BAT plays major role energy expenditure thermogenesis via function uncoupling protein 1
0.22697699.15746258.html.plaintext.txt	19	The regulation energy expenditure BAT control sympathetic nervous system higher brain structures
0.22697699.15746258.html.plaintext.txt	20	Discrete hypothalamic nuclei various orexigenic anorexigenic neuropeptides regulate BAT metabolism affecting efferent sympathetic nerve activity 8 9 10 11
0.22697699.15746258.html.plaintext.txt	21	Hypothalamic neuronal histamine anorexigenic substance increases BAT sympathetic nerve activity 12
0.22697699.15746258.html.plaintext.txt	22	Orexins affect energy balance thermoregulation
0.22697699.15746258.html.plaintext.txt	23	Orexin A shown induce hypothermia food intake orexins increase renal sympathetic nerve activity 13 14 15 16
0.22697699.15746258.html.plaintext.txt	24	Therefore highly probable orexins regulate BAT energy expenditure thermogenesis influencing sympathetic nerve activity
0.22697699.15746258.html.plaintext.txt	25	We thus hypothesized hypothalamic neuronal histamine may mediate orexin signals sympathetic nerves innervate BAT close relationship two systems recognized anatomically functionally 17 18
0.22697699.15746258.html.plaintext.txt	26	This study therefore examined effects central administration orexins electrophysiological sympathetic nerve activity BAT modulation responses neuronal histamine
0.22697699.15746258.html.plaintext.txt	27	Materials Methods Top Abstract Introduction Materials Methods Results Discussion References Animals Mature male Sprague Dawley rats 8 10 wk old Seac Yoshitomi Fukuoka Japan maintained 12 h light 12 h dark photoperiod lights 0700 h room controlled temperature 21 plus minus 1 C humidity 55 plus minus 5
0.22697699.15746258.html.plaintext.txt	28	The rats allowed free access food pelleted rodent chow
0.22697699.15746258.html.plaintext.txt	29	CE 2 Clea Japan Tokyo Japan water
0.22697699.15746258.html.plaintext.txt	30	All studies conducted accordance Oita Medical University Guidelines based National Institutes Health Guide Care Use Laboratory Animals
0.22697699.15746258.html.plaintext.txt	31	Reagents Orexin A orexin B fluoromethylhistidine FMH purchased Sigma Chemical Co
0.22697699.15746258.html.plaintext.txt	32	Louis MO dissolved PBS final concentrations 30 microM 30 microM 67 mM respectively
0.22697699.15746258.html.plaintext.txt	33	Each solution freshly prepared day use
0.22697699.15746258.html.plaintext.txt	34	The pH solution adjusted 6
0.22697699.15746258.html.plaintext.txt	35	Cerebroventricular cannula implantation Each rat fixed stereotaxic apparatus Narishige Tokyo Japan sodium pentobarbital anesthesia 45 mgkg ip stainless steel guide cannula 23 gauge surgically implanted third cerebral ventricle i3vt
0.22697699.15746258.html.plaintext.txt	36	A stainless steel wire stylet 29 gauge left place guide cannula maintain patency prevent leakage cerebrospinal fluid
0.22697699.15746258.html.plaintext.txt	37	Surgery carried least 1 wk infusion test solutions details surgical procedure described elsewhere 19
0.22697699.15746258.html.plaintext.txt	38	Measurement sympathetic nerve activity Electrophysiological recordings made anesthesia urethane 0
0.22697699.15746258.html.plaintext.txt	39	8 gkg chloralose 80 mgkg using 20 cannulated rats
0.22697699.15746258.html.plaintext.txt	40	After dissection fine branches sympathetic nerves innervate interscapular BAT nerves transected entered BAT
0.22697699.15746258.html.plaintext.txt	41	Nerve activity measured using pair silver wire electrodes immersed mixture liquid paraffin white petroleum jelly prevent dehydration nerve tissue
0.22697699.15746258.html.plaintext.txt	42	The action potentials amplified filtered low high frequency cutoffs
0.22697699.15746258.html.plaintext.txt	43	The nerve signal distinguished background noise using window discriminator
0.22697699.15746258.html.plaintext.txt	44	All nerve activity analyzed based values obtained conversion raw data standard pulses using analog digital converter
0.22697699.15746258.html.plaintext.txt	45	Impulses integrated rate meter reset time 5 sec recorded using chart recorder
0.22697699.15746258.html.plaintext.txt	46	Details nerve recording technique described elsewhere 8 20
0.22697699.15746258.html.plaintext.txt	47	After determination background firing rate sympathetic nerves changes nerve activity measured 60 min bolus i3vt infusion orexin A 0 3 nmolrat 1
0.22697699.15746258.html.plaintext.txt	48	0 microlmin 10 min orexin B 0 3 nmolrat 1
0.22697699.15746258.html.plaintext.txt	49	0 microlmin 10 min FMH 0 3 micromolkg 1
0.22697699.15746258.html.plaintext.txt	50	0 microlmin 10 min PBS n 4 treatment
0.22697699.15746258.html.plaintext.txt	51	The doses orexins FMH determined previous studies 21 22 preliminary study
0.22697699.15746258.html.plaintext.txt	52	Infusions orexins performed 2 h pretreatment FMH 1300 h
0.22697699.15746258.html.plaintext.txt	53	Nerve activity measured 10 min intervals beginning 20 min continuing 60 min administration test solution
0.22697699.15746258.html.plaintext.txt	54	Nerve activity values recorded administration test solution expressed percentage difference baseline value 0 min
0.22697699.15746258.html.plaintext.txt	55	The baseline 100 figures signifies 60 min averages score BAT sympathetic nerve activity orexin treatment
0.22697699.15746258.html.plaintext.txt	56	For analysis dose dependence orexins intracerebroventricular icv PBS icv infusion performed sympathetic nerve activity BAT recorded 20 40 min infusion
0.22697699.15746258.html.plaintext.txt	57	Statistical analysis Differences among groups assessed using two way ANOVA post hoc Fisher protected least significant difference test
0.22697699.15746258.html.plaintext.txt	58	A two sided P value less 0
0.22697699.15746258.html.plaintext.txt	59	05 considered statistically significant
0.22697699.15746258.html.plaintext.txt	60	The statistical analysis dose dependence assessed Spearman correlation coefficient rank
0.22697699.15746258.html.plaintext.txt	61	Results Top Abstract Introduction Materials Methods Results Discussion References Dose dependent effects orexins BAT sympathetic nerve activity We observed dose dependent effects orexin A orexin B
0.22697699.15746258.html.plaintext.txt	62	The BAT sympathetic nerve activity changes dependent doses orexins given icv orexin A 0 nmol 100
0.22697699.15746258.html.plaintext.txt	63	Dose dependent effects orexin A orexin B BAT sympathetic nerve activity
0.22697699.15746258.html.plaintext.txt	64	The effect i3vt infusion orexin A BAT sympathetic nerve activity Figure 1A shows typical response BAT sympathetic nerve activity infusion orexin A i3vt
0.22697699.15746258.html.plaintext.txt	65	Sympathetic nerve activity rapidly decreased central administration orexin A
0.22697699.15746258.html.plaintext.txt	66	The changes sympathetic nerve activity response orexin A treatment differed significantly induced PBS P 0
0.22697699.15746258.html.plaintext.txt	67	View larger version 20K FIG
0.22697699.15746258.html.plaintext.txt	68	A Rate meter plots BAT sympathetic nerve activity infusion orexin A 0
0.22697699.15746258.html.plaintext.txt	69	Vertical axis shows nerve impulses per 5 sec
0.22697699.15746258.html.plaintext.txt	70	Horizontal bars 10 min time scale bold horizontal bar orexin A infusion
0.22697699.15746258.html.plaintext.txt	71	B Percentage differences sympathetic nerve activity baseline 100 i3vt infusion orexin A 0
0.22697699.15746258.html.plaintext.txt	72	The baseline 100 signifies 60 min averages score BAT sympathetic nerve activity orexin treatment
0.22697699.15746258.html.plaintext.txt	73	All data means plus minus SEM n 4 per group
0.22697699.15746258.html.plaintext.txt	74	Orexin A treated animals control
0.22697699.15746258.html.plaintext.txt	75	The effect pretreatment FMH changes BAT sympathetic nerve activity induced orexin A Figure 2A shows typical responses BAT sympathetic nerve activity infusion orexin A rats pretreated infusion FMH i3vt
0.22697699.15746258.html.plaintext.txt	76	The mean changes sympathetic nerve activity induced orexin A pretreatment FMH shown Fig
0.22697699.15746258.html.plaintext.txt	77	Sympathetic nerve activity decreased rapidly central administration orexin A pretreated rats changes differed significantly induced PBS P 0
0.22697699.15746258.html.plaintext.txt	78	05 differ significantly induced orexin A rats pretreated PBS P 0
0.22697699.15746258.html.plaintext.txt	79	View larger version 22K FIG
0.22697699.15746258.html.plaintext.txt	80	A Rate meter plots BAT sympathetic nerve activity i3vt injection orexin A 0
0.22697699.15746258.html.plaintext.txt	81	3 nmol 2 h pretreatment FMH 0
0.22697699.15746258.html.plaintext.txt	82	Vertical axis shows nerve impulses per 5 sec
0.22697699.15746258.html.plaintext.txt	83	Horizontal bars 10 min time scale bold bar orexin A infusion
0.22697699.15746258.html.plaintext.txt	84	B Percentage differences sympathetic nerve activity baseline i3vt injection orexin A 0
0.22697699.15746258.html.plaintext.txt	85	67 micromol pretreatment PBS control
0.22697699.15746258.html.plaintext.txt	86	The baseline 100 signifies 60 min averages score BAT sympathetic nerve activity orexin treatment
0.22697699.15746258.html.plaintext.txt	87	All data means plus minus SEM n 4 per group
0.22697699.15746258.html.plaintext.txt	88	Orexin A treated animals orexin A treated animals FMH pretreatment control
0.22697699.15746258.html.plaintext.txt	89	The effect i3vt infusion orexin B BAT sympathetic nerve activity A typical response BAT sympathetic nerve activity i3vt infusion orexin B shown Fig
0.22697699.15746258.html.plaintext.txt	90	Sympathetic nerve activity gradually increased central administration orexin B
0.22697699.15746258.html.plaintext.txt	91	The mean change sympathetic nerve activity response orexin B treatment statistically significant compared induced PBS P 0
0.22697699.15746258.html.plaintext.txt	92	View larger version 17K FIG
0.22697699.15746258.html.plaintext.txt	93	A Rate meter plots BAT sympathetic nerve activity infusion orexin B 0
0.22697699.15746258.html.plaintext.txt	94	Vertical axis shows nerve impulses per 5 sec
0.22697699.15746258.html.plaintext.txt	95	Horizontal bars 10 min time scale bold horizontal bar orexin B infusion
0.22697699.15746258.html.plaintext.txt	96	B Percentage differences sympathetic nerve activity baseline i3vt infusion orexin B 0
0.22697699.15746258.html.plaintext.txt	97	The baseline 100 signifies 60 min averages score BAT sympathetic nerve activity orexin treatment
0.22697699.15746258.html.plaintext.txt	98	All data means plus minus SEM n 4 per group
0.22697699.15746258.html.plaintext.txt	99	Orexin B treated animals control
0.22697699.15746258.html.plaintext.txt	100	The effect pretreatment FMH changes BAT sympathetic nerve activity induced orexin B Figure 4A shows typical responses BAT sympathetic nerve activity infusion orexin B rats pretreated infusion FMH i3vt
0.22697699.15746258.html.plaintext.txt	101	Sympathetic nerve activity gradually increased central administration orexin B rats pretreated FMH
0.22697699.15746258.html.plaintext.txt	102	The changes sympathetic nerve activity response orexin B significantly attenuated pretreated rats compared induced orexin B rats pretreated PBS P 0
0.22697699.15746258.html.plaintext.txt	103	View larger version 20K FIG
0.22697699.15746258.html.plaintext.txt	104	A Rate meter plots BAT sympathetic nerve activity i3vt injection orexin B 0
0.22697699.15746258.html.plaintext.txt	105	3 nmol 2 h pretreatment FMH 0
0.22697699.15746258.html.plaintext.txt	106	Vertical axis shows nerve impulses per 5 sec
0.22697699.15746258.html.plaintext.txt	107	Horizontal bars 10 min time scale bold bar orexin B infusion
0.22697699.15746258.html.plaintext.txt	108	B Percentage differences sympathetic nerve activity baseline 100 i3vt injection orexin B 0
0.22697699.15746258.html.plaintext.txt	109	67 micromol pretreatment PBS control
0.22697699.15746258.html.plaintext.txt	110	All data means plus minus SEM n 4 per group
0.22697699.15746258.html.plaintext.txt	111	Orexin B treated animals orexin B treated animals FMH pretreatment control
0.22697699.15746258.html.plaintext.txt	112	Discussion Top Abstract Introduction Materials Methods Results Discussion References This study demonstrated i3vt infusion orexin A orexin B dose dependently decreased increased BAT sympathetic nerve activity anesthetized rats respectively
0.22697699.15746258.html.plaintext.txt	113	Depletion neuronal histamine pretreatment FMH attenuated sympathetic nerve responses induced orexin B induced orexin A indicating action orexin B mediated neuronal histamine
0.22697699.15746258.html.plaintext.txt	114	Thus likely dual effects orexin BAT sympathetic nerve may depend differences peptide subtype andor target neuronal substance
0.22697699.15746258.html.plaintext.txt	115	We present discussion orexin differentiates actions sympathetic nerves well effects neuronal histamine
0.22697699.15746258.html.plaintext.txt	116	The actions orexins mediated via two G protein coupled receptors OX1R OX2R 1 2
0.22697699.15746258.html.plaintext.txt	117	The receptor binding affinity orexin A 10 100 times greater orexin B OX1R whereas orexins equipotent OX2R 2 23 24 25
0.22697699.15746258.html.plaintext.txt	118	Distinct expression patterns two receptor subtypes identified throughout brain 5
0.22697699.15746258.html.plaintext.txt	119	Considering i3vt infusion site used study target site binding orexin receptors may either hypothalamus brain stem
0.22697699.15746258.html.plaintext.txt	120	From standpoint ventromedial hypothalamic nucleus A5 cell group LC express high levels OX1R mRNA may candidates targets orexin A nuclei identified central origins efferent pathways BAT 26
0.22697699.15746258.html.plaintext.txt	121	On hand high density expression OX2R observed arcuate nucleus ARC LHA paraventricular nucleus PVN ventral premammillary nucleus TMN moderate expression levels found medial preoptic area dorsal motor nucleus vagus 5
0.22697699.15746258.html.plaintext.txt	122	The PVN medial preoptic area identified major hypothalamic origins efferent pathways BAT neuroanatomical study 26
0.22697699.15746258.html.plaintext.txt	123	In fact chemical stimulation nuclei increased BAT sympathetic nerve activity 8
0.22697699.15746258.html.plaintext.txt	124	From ARC LHA especially orexin neurons PVN direct neuronal projections intermediolateral cell column spinal cord location sympathetic preganglionic neurons identified 27 28
0.22697699.15746258.html.plaintext.txt	125	Among nuclei cumulative evidence indicates importance LHA ARC orexin A OX2R signaling suppress BAT sympathetic nerve activity
0.22697699.15746258.html.plaintext.txt	126	Electrophysiological studies demonstrated excitatory effect orexin A LHA neuronal activity inhibitory influence area BAT sympathetic nerve activity 8 indicating LHA target site orexin A regulation sympathetic innervation BAT
0.22697699.15746258.html.plaintext.txt	127	In contrast suppressive effects orexin A central administration orexin B present study increased BAT sympathetic nerve activity
0.22697699.15746258.html.plaintext.txt	128	In addition orexin B induced response attenuated histamine depletion caused pretreatment FMH
0.22697699.15746258.html.plaintext.txt	129	As described presence orexin neurons well orexin receptor OXR2 identified TMN site origin histamine neurons 29
0.22697699.15746258.html.plaintext.txt	130	It demonstrated neuronal histamine mediates orexin signaling regulation sleep wakefulness cycle 30
0.22697699.15746258.html.plaintext.txt	131	Finally central administration histamine shown increase BAT sympathetic nerve activity 12
0.22697699.15746258.html.plaintext.txt	132	Taken together evidence suggests highly probable orexin B regulates BAT sympathetic nerve activity excitatory manner OX2R TMN
0.22697699.15746258.html.plaintext.txt	133	Our unpublished observation demonstrated FMH treatment neuropeptide Y antagonist influenced orexin B induced feeding andor sympathetic nerve activity
0.22697699.15746258.html.plaintext.txt	134	The results suggested neuronal histamine neuropeptide Y might closely involved orexin B induced feeding behavior sympathetic nerve activity
0.22697699.15746258.html.plaintext.txt	135	Further study necessary clarify details mechanism
0.22697699.15746258.html.plaintext.txt	136	Considering present previous studies results suggest OXR hypothalamus brain stem may mediate orexin induced effect BAT sympathetic nerve activity
0.22697699.15746258.html.plaintext.txt	137	In addition modulation OXR outside hypothalamus cerebral cortex spinal cord cisterna magna also possible
0.22697699.15746258.html.plaintext.txt	138	Previous studies demonstrated orexin could direct effects level sympathetic preganglionic neurons 31
0.22697699.15746258.html.plaintext.txt	139	Beyond BAT sympathetic nerve activity studies examine sympathetic nerve activity renal lumber nerves may merited
0.22697699.15746258.html.plaintext.txt	140	Functional studies recently demonstrated central administration orexin A orexin B induces hypothermia hyperthermia respectively 14 15
0.22697699.15746258.html.plaintext.txt	141	These results consistent present study time course BAT thermogenesis assessed local BAT temperature similar observed BAT sympathetic nerve activity 32
0.22697699.15746258.html.plaintext.txt	142	On hand previous studies demonstrated orexin A induced hyperthermic response unanesthetized animals 33 34
0.22697699.15746258.html.plaintext.txt	143	It well known arousal state muscle movement affect body temperature unanesthetized condition administration orexin A induced increase arousal level consequent arbitrary movements may elevate body temperature
0.22697699.15746258.html.plaintext.txt	144	There possibility anesthesia might modulate BAT sympathetic nerve activity thermogenesis anesthesia factor sole mechanism regulating arousal state body temperature
0.22697699.15746258.html.plaintext.txt	145	Because present study limited acute phase orexins effects anesthetized rats possible differences state arousal may determine effect orexins body temperature
0.22697699.15746258.html.plaintext.txt	146	In addition timing infusion might influence orexin induced sympathetic nerve activity effects orexins clearly dependent sleep wake cycle 30
0.22697699.15746258.html.plaintext.txt	147	In summary demonstrated central administration orexins induces dual effects BAT sympathetic nerve activity inhibition orexin A stimulation orexin B
0.22697699.15746258.html.plaintext.txt	148	Hypothalamic neuronal histamine involved latter response BAT sympathetic nerve activity
0.22697699.15746258.html.plaintext.txt	149	Footnotes This work supported Grants Aid 136770067 Japanese Ministry Education Science Culture Research Grants Intractable Diseases Japanese Ministry Health Welfare 2001 2002
0.22697699.15746258.html.plaintext.txt	150	This work also supported part grant Smoking Research Foundation Venture Business Laboratory Oita University Grants 16922171 Japan Society Promotion Science
0.22697699.15746258.html.plaintext.txt	151	First Published Online March 3 2005
0.22697699.15746258.html.plaintext.txt	152	Abbreviations ARC Arcuate nucleus BAT brown adipose tissue FMH fluoromethylhistidine i3vt third cerebral ventricle icv intracerebroventricular LC locus coeruleus LHA lateral hypothalamic area OX1 orexin 1 OX2 orexin 2 OX1R OX1 receptor OX2R OX2 receptor PVN paraventricular nucleus TMN tuberomammillary nucleus
0.22697699.15746258.html.plaintext.txt	153	Accepted publication February 16 2005
0.22697699.15746258.html.plaintext.txt	154	References Top Abstract Introduction Materials Methods Results Discussion References de Lecea L Kilduff TS Peyron C Gao X Foye PE Danielson PE Fukuhara C Battenberg EL Gautvik VT Bartlett 2nd FS Frankel WN van den Pol AN Bloom FE Gautvik KM Sutcliffe JG 1998 The hypocretins hypothalamus specific peptides neuroexcitatory activity
0.22697699.15746258.html.plaintext.txt	155	Proc Natl Acad Sci USA 95322 327AbstractFree Full Text Sakurai T Amemiya A Ishii M Matsuzaki I Chemelli RM Tanaka H Williams SC Richardson JA Kozlowski GP Wilson S Arch JR Buckingham RE Haynes AC Carr SA Annan RS McNulty DE Liu WS Terrett JA Elshourbagy NA Bergsma DJ Yanagisawa M 1998 Orexins orexin receptors family hypothalamic neuropeptides G protein coupled receptors regulate feeding behavior
0.22697699.15746258.html.plaintext.txt	156	Cell 92573 585CrossRefMedline Peyron C Tighe DK van den Pol AN de Lecea L Heller HC Sutcliffe JG Kilduff TS 1998 Neurons containing hypocretin orexin project multiple neuronal systems
0.22697699.15746258.html.plaintext.txt	157	J Neurosci 189996 10015AbstractFree Full Text Nambu T Sakurai T Mizukami K Hosoya Y Yanagisawa M Goto K 1999 Distribution orexin neurons adult rat brain
0.22697699.15746258.html.plaintext.txt	158	Brain Res 827243 260CrossRefMedline Marcus JN Aschkenasi CJ Lee CE Chemelli RM Saper CB Yanagisawa M Elmquist JK 2001 Differential expression orexin receptors 1 2 rat brain
0.22697699.15746258.html.plaintext.txt	159	J Comp Neurol 4356 25CrossRefMedline Wada H Inagaki N Itowi N Yamatodani A 1991 Histaminergic neuron system morphological features possible functions
0.22697699.15746258.html.plaintext.txt	160	Agents Actions Suppl 3311 27Medline Huang ZL Qu WM Li WD Mochizuki T Eguchi N Watanabe T Urade Y Hayaishi O 2001 Arousal effect orexin A depends activation histaminergic system
0.22697699.15746258.html.plaintext.txt	161	Proc Natl Acad Sci USA 989965 9970AbstractFree Full Text Yoshimatsu H Egawa M Bray GA 1993 Sympathetic nerve activity discrete hypothalamic injections L glutamate
0.22697699.15746258.html.plaintext.txt	162	Brain Res 601121 128CrossRefMedline Yoshimatsu H Egawa M Bray GA 1992 Effects cholecystokinin sympathetic activity interscapular brown adipose tissue
0.22697699.15746258.html.plaintext.txt	163	Brain Res 597298 303CrossRefMedline Egawa M Yoshimatsu H Bray GA 1991 Neuropeptide Y suppresses sympathetic activity interscapular brown adipose tissue rats
0.22697699.15746258.html.plaintext.txt	164	Am J Physiol 260R328 R334 Egawa M Yoshimatsu H Bray GA 1990 Preoptic area injection corticotropin releasing hormone stimulates sympathetic activity
0.22697699.15746258.html.plaintext.txt	165	Am J Physiol 259R799 R806 Yasuda T Masaki T Sakata T Yoshimatsu H 2004 Hypothalamic neuronal histamine regulates sympathetic nerve activity expression uncoupling protein 1 mRNA brown adipose tissue rats
0.22697699.15746258.html.plaintext.txt	166	Neuroscience 125535 540CrossRefMedline Date Y Ueta Y Yamashita H Yamaguchi H Matsukura S Kangawa K Sakurai T Yanagisawa M Nakazato M 1999 Orexins orexigenic hypothalamic peptides interact autonomic neuroendocrine neuroregulatory systems
0.22697699.15746258.html.plaintext.txt	167	Proc Natl Acad Sci USA 96748 753AbstractFree Full Text Szekely M Petervari E Balasko M Hernadi I Uzsoki B 2002 Effects orexins energy balance thermoregulation
0.22697699.15746258.html.plaintext.txt	168	Regul Pept 10447 53CrossRefMedline Jaszberenyi M Bujdoso E Kiss E Pataki I Telegdy G 2002 The role NPY mediation orexin induced hypothermia
0.22697699.15746258.html.plaintext.txt	169	Regul Pept 10455 59CrossRefMedline Shirasaka T Nakazato M Matsukura S Takasaki M Kannan H 1999 Sympathetic cardiovascular actions orexins conscious rats
0.22697699.15746258.html.plaintext.txt	170	Am J Physiol 277R1780 R1785 Yamanaka A Tsujino N Funahashi H Honda K Guan JL Wang QP Tominaga M Goto K Shioda S Sakurai T 2002 Orexins activate histaminergic neurons via orexin 2 receptor
0.22697699.15746258.html.plaintext.txt	171	Biochem Biophys Res Commun 2901237 1245CrossRefMedline Ishizuka T Yamamoto Y Yamatodani A 2002 The effect orexin A B histamine release anterior hypothalamus rats
0.22697699.15746258.html.plaintext.txt	172	Neurosci Lett 32393 96CrossRefMedline Sakata T Tsutsui K Fukushima M Arase K Kita H Oomura Y Ohki K Nicolaidis S 1981 Feeding hyperglycemia induced 15 anhydroglucitol rat
0.22697699.15746258.html.plaintext.txt	173	Physiol Behav 27401 405CrossRefMedline Niijima A 1989 Nervous regulation metabolism
0.22697699.15746258.html.plaintext.txt	174	Prog Neurobiol 33135 147CrossRefMedline Russell SH Small CJ Sunter D Morgan I Dakin CL Cohen MA Bloom SR 2002 Chronic intraparaventricular nuclear administration orexin A male rats alter thyroid axis uncoupling protein 1 brown adipose tissue
0.22697699.15746258.html.plaintext.txt	175	Regul Pept 10461 68CrossRefMedline Yoshimatsu H Itateyama E Kondou S Hidaka S Tajima D Kurokawa M Sakata T 1999 Hypothalamic neuronal histamine target leptin action feeding behavior central nervous system
0.22697699.15746258.html.plaintext.txt	176	Diabetes 481342 1346 Okumura T Takeuchi S Motomura W Yamada H Egashira Si S Asahi S Kanatani A Ihara M Kohgo Y 2001 Requirement intact disulfide bonds orexin A induced stimulation gastric acid secretion mediated OX1 receptor activation
0.22697699.15746258.html.plaintext.txt	177	Biochem Biophys Res Commun 280976 981CrossRefMedline Holmqvist T Akerman KE Kukkonen JP 2002 Orexin signaling recombinant neuron like cells
0.22697699.15746258.html.plaintext.txt	178	FEBS Lett 52611 14CrossRefMedline Smart D 1999 Orexins new family neuropeptides
0.22697699.15746258.html.plaintext.txt	179	Br J Anaesth 83695 697Free Full Text Bamshad M Song CK Bartness TJ 1999 CNS origins sympathetic nervous system outflow brown adipose tissue
0.22697699.15746258.html.plaintext.txt	180	Am J Physiol 276R1569 R1578 Elias CF Lee C Kelly J Aschkenasi C Ahima RS Couceyro PR Kuhar MJ Saper CB Elmquist JK 1998 Leptin activates hypothalamic CART neurons projecting spinal cord
0.22697699.15746258.html.plaintext.txt	181	Neuron 211375 1385CrossRefMedline van den Pol AN 1999 Hypothalamic hypocretin orexin robust innervation spinal cord
0.22697699.15746258.html.plaintext.txt	182	J Neurosci 193171 3182AbstractFree Full Text Inagaki N Yamatodani A Ando Yamamoto M Tohyama M Watanabe T Wada HJ 1988 Organization histaminergic fibers rat brain
0.22697699.15746258.html.plaintext.txt	183	Comp Neurol 273283 300Medline Lin L Faraco J Li R Kadotani H Rogers W Lin X Qiu X de Jong PJ Nishino S Mignot E 1999 The sleep disorder canine narcolepsy caused mutation hypocretin orexin receptor 2 gene
0.22697699.15746258.html.plaintext.txt	184	Cell 98365 376CrossRefMedline van den Pol AN Gao XB Obrietan K Kilduff TS Belousov AB 1998 Presynaptic postsynaptic actions modulation neuroendocrine neurons new hypothalamic peptide hypocretinorexin
0.22697699.15746258.html.plaintext.txt	185	J Neurosci 187962 7971AbstractFree Full Text Yasuda T Masaki T Kakuma T Yoshimatsu H 2003 Centrally administered ghrelin suppresses sympathetic nerve activity brown adipose tissue rats
0.22697699.15746258.html.plaintext.txt	186	Neurosci Lett 34975 78CrossRefMedline Yoshimichi G Yoshimatsu H Masaki T Sakata T 2001 Orexin A regulates body temperature coordination arousal status
0.22697699.15746258.html.plaintext.txt	187	Exp Biol Med Maywood 226468 476AbstractFree Full Text Monda M Viggiano A De Luca V 2003 Paradoxical effect orexin A hypophagia induced hyperthermia
0.22697699.15746258.html.plaintext.txt	188	Brain Res 961220 228CrossRefMedline
0.17783286.11751609.html.plaintext.txt	0	The Feeding Response Melanin Concentrating Hormone Is Attenuated Antagonism NPY Y1 Receptor Rat Christine L
0.17783286.11751609.html.plaintext.txt	1	Department Pharmacology University Melbourne Melbourne Victoria 3010 Australia
0.17783286.11751609.html.plaintext.txt	2	Address correspondence requests reprints Dr
0.17783286.11751609.html.plaintext.txt	3	Margaret Morris Department Pharmacology University Melbourne Melbourne Victoria 3010 Australia
0.17783286.11751609.html.plaintext.txt	4	Abstract Top Abstract Introduction Materials Methods Results Discussion References Melanin concentrating hormone MCH NPY orexigenic peptides localized lateral hypothalamic area arcuate nucleus respectively
0.17783286.11751609.html.plaintext.txt	5	Although NPY MCH containing fibers innervate areas hypothalamus implicated feeding extent regulation appetite dependent interactions peptides unknown
0.17783286.11751609.html.plaintext.txt	6	Daytime feeding responses 2 nmol MCH 1 nmol NPY vehicle investigated male Sprague Dawley rats previously implanted intracerebroventricular cannulas
0.17783286.11751609.html.plaintext.txt	7	The effects prior administration Y1 receptor antagonists BIBO 3304 20 nmol GR231118 5 nmol responses examined
0.17783286.11751609.html.plaintext.txt	8	NPY MCH stimulated food intake relative vehicle 4 h intake 5
0.17783286.11751609.html.plaintext.txt	9	BIBO 3304 GR231118 significantly inhibited MCH induced feeding 73 P 0
0.17783286.11751609.html.plaintext.txt	10	Coadministration NPY MCH increase food intake response NPY alone however prior administration BIBO 3304 resulted less marked inhibition feeding P 0
0.17783286.11751609.html.plaintext.txt	11	Inhibition MCH induced feeding two structurally different NPY Y1 receptor antagonists provides strong evidence orexigenic action MCH involves Y1 receptor
0.17783286.11751609.html.plaintext.txt	12	Introduction Top Abstract Introduction Materials Methods Results Discussion References THE REGULATION OF appetite highly integrated system involving numerous central peripheral regulators reflecting complex nature energy homeostasis
0.17783286.11751609.html.plaintext.txt	13	The hypothalamus key feeding center within central nervous system CNS many hypothalamic neuropeptides NPY melanin concentrating hormone MCH play pivotal role regulation food intake 1
0.17783286.11751609.html.plaintext.txt	14	Due intricate network neuropeptide signaling pathways involved mechanisms underlying regulation food intake energy expenditure completely understood
0.17783286.11751609.html.plaintext.txt	15	NPY potent endogenous stimulator feeding known intracerebroventricular icv administration nanomole quantities eliciting eating satiated rats 2
0.17783286.11751609.html.plaintext.txt	16	Furthermore chronic administration NPY causes hyperphagia increase body weight resulting obesity 3
0.17783286.11751609.html.plaintext.txt	17	NPY mRNA markedly increased hypothalamus genetically obese animals 4
0.17783286.11751609.html.plaintext.txt	18	Thus factors regulating potent feeding stimulator may important implications therapeutic management obesity
0.17783286.11751609.html.plaintext.txt	19	NPY containing fibers widely distributed throughout CNS within hypothalamus NPY particularly abundant paraventricular nucleus PVN 5 area important control eating behavior receives dense NPY containing projection arcuate nucleus 6
0.17783286.11751609.html.plaintext.txt	20	Studies vivo demonstrated NPY release PVN strongly associated increased appetite 7 central administration NPY increases c fos expression region 8
0.17783286.11751609.html.plaintext.txt	21	NPY exerts effects G protein coupled receptors GPCR five subtypes cloned 9
0.17783286.11751609.html.plaintext.txt	22	NPY Y1 Y2 Y5 receptors expressed hypothalamic areas implicated feeding actions NPY 10
0.17783286.11751609.html.plaintext.txt	23	Early studies showed Y1 agonist Leu31Pro34NPY stimulates food intake 11 whereas Y1 selective antagonist reduces food intake evoked NPY food deprivation 12
0.17783286.11751609.html.plaintext.txt	24	The recently characterized Y5 receptor also implicated feeding behavior Y5 selective agonist PYY 3 36 stimulates feeding rats 13
0.17783286.11751609.html.plaintext.txt	25	More modest effects food intake observed response stimulation Y2 receptor Y2 selective agonist NPY 13 36 14
0.17783286.11751609.html.plaintext.txt	26	The NPY knockout mouse however shown normal body weight normal hyperphagic response fasting 15 suggesting neuropeptides able compensate loss
0.17783286.11751609.html.plaintext.txt	27	As previously noted many hypothalamic neuropeptides involved feeding
0.17783286.11751609.html.plaintext.txt	28	Of particular interest current study orexigenic neuropeptide MCH first noted ability induce melanosome aggregation teleost fish thus antagonizing melanin dispersing action MSH 16
0.17783286.11751609.html.plaintext.txt	29	MCH isolated rat hypothalamus 17 identified cyclic 19 amino acid neuropeptide human rat 18
0.17783286.11751609.html.plaintext.txt	30	MCH like immunoreactive ir perikarya found abundant lateral hypothalamic area LHA subzona incerta perifornical area fibers distributed widely throughout rat brain 19
0.17783286.11751609.html.plaintext.txt	31	MCH ir also found PVN arcuate nucleus median eminence 20
0.17783286.11751609.html.plaintext.txt	32	A similar regional distribution MCH peptide described human brain highest concentrations hypothalamus 21
0.17783286.11751609.html.plaintext.txt	33	The LHA another nucleus within hypothalamus important regulation feeding lesions area result profound hypophagia 22
0.17783286.11751609.html.plaintext.txt	34	Cells region contain orexin addition MCH separate populations neurons review see Ref
0.17783286.11751609.html.plaintext.txt	35	Both neuropeptides shown stimulate feeding
0.17783286.11751609.html.plaintext.txt	36	Several observations pointed role MCH stimulating feeding including antagonistic effects actions MSH potent anorexigenic peptide 24 elevated levels MCH mRNA hypothalamus genetically obese obob mice 25
0.17783286.11751609.html.plaintext.txt	37	Low doses MCH administered icv stimulate feeding 25 26
0.17783286.11751609.html.plaintext.txt	38	Furthermore MCH mRNA increased fasting normal obese animals 25
0.17783286.11751609.html.plaintext.txt	39	Recently mice carrying targeted deletion MCH gene reported reduced body weight hypoadiposity due hypophagia inappropriately increased metabolic rate 27
0.17783286.11751609.html.plaintext.txt	40	Hence MCH appears play pivotal role stimulation appetite
0.17783286.11751609.html.plaintext.txt	41	Controversy surrounding nature receptor responsible actions MCH recently resolved demonstration somatostatin like receptor 1 SLC 1 orphan GPCR specific MCH receptor 28
0.17783286.11751609.html.plaintext.txt	42	Consistent wide distribution MCH ir terminals CNS SLC 1 mRNA protein located rat cerebral cortex caudate putamen hippocampal formation amygdala hypothalamus thalamus 29
0.17783286.11751609.html.plaintext.txt	43	Binding studies show similar distribution MCH binding sites human brain highest concentration hypothalamus 30
0.17783286.11751609.html.plaintext.txt	44	Both NPY MCH containing fibers project areas hypothalamus regulate appetite
0.17783286.11751609.html.plaintext.txt	45	Although orexigenic peptides NPY MCH operate regionally discrete pathways recent anatomical studies provide evidence link
0.17783286.11751609.html.plaintext.txt	46	Reciprocal projections exist arcuate nucleus LHA 31 NPY ir fibers shown directly innervate MCH fibers LHA 32
0.17783286.11751609.html.plaintext.txt	47	The observation feeding effects LHA peptide orexin influenced antagonist NPY 33 suggests important interactions may arise different orexigenic peptides regions
0.17783286.11751609.html.plaintext.txt	48	However extent NPY MCH interact regulate feeding remains unclear
0.17783286.11751609.html.plaintext.txt	49	Therefore study examined whether selective NPY Y1 receptor antagonists BIBO 3304 GR231118 inhibit feeding induced MCH rat vivo
0.17783286.11751609.html.plaintext.txt	50	We hypothesized feeding response elicited MCH involved NPY Y1 antagonist might modulate MCH induced food intake
0.17783286.11751609.html.plaintext.txt	51	Materials Methods Top Abstract Introduction Materials Methods Results Discussion References Animals Adult male Sprague Dawley rats 250 300 g maintained individual cages controlled temperature 20 plus minus 2 C light 12 h light 12 h dark cycle lights 0600 h ad libitum access standard laboratory chow GR2 Barastoc St
0.17783286.11751609.html.plaintext.txt	52	All animal procedures approved animal experimentation ethics committee University Melbourne
0.17783286.11751609.html.plaintext.txt	53	Intracerebroventricular cannulation injections Rats anesthetized pentobarbitone sodium 60 mgkg BW ip Nembutal administered analgesic buprenorphine 0
0.17783286.11751609.html.plaintext.txt	54	15 mgkg sc Temgesic placed stereotaxic frame Narishige SR 6N Tokyo Japan
0.17783286.11751609.html.plaintext.txt	55	A permanent 9 mm 22 gauge stainless steel cannula Plastics One Roanoke VA inserted right lateral ventricle 0
0.17783286.11751609.html.plaintext.txt	56	5 mm lateral midline 3
0.17783286.11751609.html.plaintext.txt	57	5 mm surface brain 34
0.17783286.11751609.html.plaintext.txt	58	The cannula secured dental cement Paladur Wehrheim Germany jeweler screws
0.17783286.11751609.html.plaintext.txt	59	A 28 gauge stainless steel dummy cannula Plastics One inserted occlude guide cannula use
0.17783286.11751609.html.plaintext.txt	60	After surgery rats housed individual cages high top lids allow social interaction
0.17783286.11751609.html.plaintext.txt	61	To minimize nonspecific stress rats handled daily acclimatized experimental conditions 7 d commencement study
0.17783286.11751609.html.plaintext.txt	62	All substances administered volume 2 microl using 10 microl Hamilton syringe Hamilton Reno NV attached polyethylene tubing id 0
0.17783286.11751609.html.plaintext.txt	63	61 mm stainless steel injection cannula Plastics One extending 0
0.17783286.11751609.html.plaintext.txt	64	At end study period animals killed decapitation anesthetic overdose
0.17783286.11751609.html.plaintext.txt	65	Cannula placement verified removal brain visual inspection coronal brain slices
0.17783286.11751609.html.plaintext.txt	66	Effects NPY andor MCH food intake presence absence NPY Y1 receptor antagonists In initial study food intake response daytime icv administration vehicle 1 nmol NPY 2 nmol MCH coadministration 1 nmol NPY 2 nmol MCH examined group icv cannulated rats n 9 beginning light phase
0.17783286.11751609.html.plaintext.txt	67	NPY MCH dissolved 0
0.17783286.11751609.html.plaintext.txt	68	On day experiment rats acclimatized experimental room 1 h ad libitum access food water
0.17783286.11751609.html.plaintext.txt	69	A 28 gauge injection cannula used deliver substances volume 2 microl period 10 sec
0.17783286.11751609.html.plaintext.txt	70	Each experiment consisted two injections administered 10 min apart
0.17783286.11751609.html.plaintext.txt	71	When effect one agonist alone investigated animals received prior dose appropriate vehicle
0.17783286.11751609.html.plaintext.txt	72	Preweighed food placed cage food intake measured 0
0.17783286.11751609.html.plaintext.txt	73	All combinations injections performed randomized order took place 0930 1030 h
0.17783286.11751609.html.plaintext.txt	74	Each combination injections repeated animal possible minimum 48 h experiments
0.17783286.11751609.html.plaintext.txt	75	In second group animals effects synthetic Y1 selective receptor antagonist BIBO 3304 food intake response 1 nmol NPY 2 nmol MCH coadministration 1 nmol NPY 2 nmol MCH examined
0.17783286.11751609.html.plaintext.txt	76	BIBO 3304 20 nmol dissolved dimethylsulfoxide 25 saline
0.17783286.11751609.html.plaintext.txt	77	To make within group comparisons responses combinations injections used previous study repeated animals appropriate vehicle
0.17783286.11751609.html.plaintext.txt	78	Food intake measured 0
0.17783286.11751609.html.plaintext.txt	79	Again combinations injections performed randomized order
0.17783286.11751609.html.plaintext.txt	80	Using similar protocol responses Y1 selective peptide antagonist GR231118 whose structure based C terminal end NPY molecule 12 investigated new experimental series
0.17783286.11751609.html.plaintext.txt	81	In addition Y1 antagonist properties agent Y4 agonist activity 35
0.17783286.11751609.html.plaintext.txt	82	GR231118 5 nmol dissolved 0
0.17783286.11751609.html.plaintext.txt	83	9 saline administered 1 nmol NPY 2 nmol MCH effects food intake examined
0.17783286.11751609.html.plaintext.txt	84	Again feeding responses NPY MCH appropriate vehicle measured group animals
0.17783286.11751609.html.plaintext.txt	85	Drugs MCH humanrat purchased Auspep Melbourne Australia
0.17783286.11751609.html.plaintext.txt	86	James Angus Department Pharmacology University Melbourne donated NPY porcine GR231118
0.17783286.11751609.html.plaintext.txt	87	BIBO 3304 gift Boehringer Ingelheim GmbH Biberach Germany
0.17783286.11751609.html.plaintext.txt	88	Pentobarbitone sodium buprenorphine purchased Rhone Merieux Pinkenba Australia Reckitt Colman Hull UK respectively
0.17783286.11751609.html.plaintext.txt	89	Statistical analysis Food intake expressed mean plus minus SEM
0.17783286.11751609.html.plaintext.txt	90	Results feeding studies analyzed one way ANOVA repeated measures followed post hoc least significant difference test pairwise comparisons required
0.17783286.11751609.html.plaintext.txt	91	05 considered statistically significant
0.17783286.11751609.html.plaintext.txt	92	Results Top Abstract Introduction Materials Methods Results Discussion References Effects NPY MCH food intake Cumulative food intake response single icv doses 1 nmol NPY 2 nmol MCH vehicle compared group rats 4 h Fig
0.17783286.11751609.html.plaintext.txt	93	Vehicle treated rats consumed 0
0.17783286.11751609.html.plaintext.txt	94	The injection either NPY MCH significantly stimulated food intake relative vehicle time points examined Fig
0.17783286.11751609.html.plaintext.txt	95	Food intake response NPY administration occurred rapid onset rats eaten 3
0.17783286.11751609.html.plaintext.txt	96	4 g first 30 min 5
0.17783286.11751609.html.plaintext.txt	97	Administration near maximal dose MCH 26 resulted 4 h food intake 3
0.17783286.11751609.html.plaintext.txt	98	Thus stimulation food intake MCH significantly less observed NPY time points examined P 0
0.17783286.11751609.html.plaintext.txt	99	View larger version 17K Figure 1
0.17783286.11751609.html.plaintext.txt	100	The effects daytime icv administration 1 nmol NPY 2 nmol MCH vehicle food intake 4 h male Sprague Dawley rats n 8group
0.17783286.11751609.html.plaintext.txt	101	Data expressed mean plus minus SEM analyzed using repeated measures ANOVA followed post hoc least significant difference test
0.17783286.11751609.html.plaintext.txt	102	001 significantly different NPY MCH
0.17783286.11751609.html.plaintext.txt	103	001 significantly different MCH
0.17783286.11751609.html.plaintext.txt	104	Effect BIBO 3304 MCH induced feeding Interestingly prior administration synthetic Y1 receptor selective antagonist BIBO 3304 20 nmol significantly reduced feeding induced 2 nmol MCH time points examined Fig
0.17783286.11751609.html.plaintext.txt	105	This inhibition occurred immediately reduction food intake 1
0.17783286.11751609.html.plaintext.txt	106	Inhibition MCH induced feeding sustained throughout experiment reaching maximum 73 2 h post injection corrected food intake vehicle administration vehicle MCH 3
0.17783286.11751609.html.plaintext.txt	107	3 g n 9 BIBO 3304 MCH 1
0.17783286.11751609.html.plaintext.txt	108	3 g n 9 vehicle vehicle 0
0.17783286.11751609.html.plaintext.txt	109	After BIBO 3304 administration MCH induced food intake significantly different vehicle group first 2 h experiment Fig
0.17783286.11751609.html.plaintext.txt	110	View larger version 14K Figure 2
0.17783286.11751609.html.plaintext.txt	111	Effect BIBO 3304 feeding responses MCH NPY
0.17783286.11751609.html.plaintext.txt	112	Food intake determined 0
0.17783286.11751609.html.plaintext.txt	113	5 1 2 4 h post MCH A NPY B injection
0.17783286.11751609.html.plaintext.txt	114	MCH NPY significantly stimulated food intake relative saline vehicle P 0
0.17783286.11751609.html.plaintext.txt	115	A The effect icv administration 2 nmol MCH absence presence 20 nmol BIBO 3304 daytime food intake male Sprague Dawley rats n 9group
0.17783286.11751609.html.plaintext.txt	116	B Effect icv administration 1 nmol NPY daytime food intake absence presence 20 nmol BIBO 3304 male Sprague Dawley rats n 8group
0.17783286.11751609.html.plaintext.txt	117	Data expressed mean plus minus SEM analyzed using repeated measures ANOVA followed post hoc least significant difference test
0.17783286.11751609.html.plaintext.txt	118	01 significant effect BIBO 3304 MCH
0.17783286.11751609.html.plaintext.txt	119	001 significant effect BIBO 3304 NPY
0.17783286.11751609.html.plaintext.txt	120	05 significantly different saline
0.17783286.11751609.html.plaintext.txt	121	Effect BIBO 3304 NPY induced feeding At dose 20 nmol BIBO 3304 significantly inhibited feeding response icv administration 1 nmol NPY Fig
0.17783286.11751609.html.plaintext.txt	122	This inhibition rapid onset NPY induced food intake reduced 3
0.17783286.11751609.html.plaintext.txt	123	4 g 30 min representing 71 reduction
0.17783286.11751609.html.plaintext.txt	124	BIBO 3304 provided sustained inhibition feeding response NPY duration experiment 63 reduction still evident 4 h Fig
0.17783286.11751609.html.plaintext.txt	125	This dose BIBO 3304 completely abolish NPY induced feeding Fig
0.17783286.11751609.html.plaintext.txt	126	Effect GR231118 MCH induced feeding In separate group rats effect 5 nmol GR231118 structurally unrelated BIBO 3304 MCH induced feeding investigated Fig
0.17783286.11751609.html.plaintext.txt	127	Prior administration GR231118 significantly reduced food intake response 2 nmol MCH time points examined n 8 P 0
0.17783286.11751609.html.plaintext.txt	128	The inhibition rapid onset food intake reduced 86 2 h vehicle MCH 2
0.17783286.11751609.html.plaintext.txt	129	4 g n 10 GR231118 MCH 0
0.17783286.11751609.html.plaintext.txt	130	1 g n 8 vehicle vehicle 0
0.17783286.11751609.html.plaintext.txt	131	After 4 h MCH induced food intake remained inhibited 50 presence GR231118
0.17783286.11751609.html.plaintext.txt	132	As observed BIBO 3304 response GR231118 MCH induced food intake significantly different vehicle group first 2 h experiment Fig
0.17783286.11751609.html.plaintext.txt	133	View larger version 14K Figure 3
0.17783286.11751609.html.plaintext.txt	134	Effect GR231118 feeding responses MCH NPY
0.17783286.11751609.html.plaintext.txt	135	5 1 2 4 h MCH A NPY B injection
0.17783286.11751609.html.plaintext.txt	136	The response saline vehicle also shown group rats
0.17783286.11751609.html.plaintext.txt	137	A Food intake response daytime icv administration 2 nmol MCH absence presence 5 nmol GR231118 male Sprague Dawley rats n 8
0.17783286.11751609.html.plaintext.txt	138	B Effect icv administration 1 nmol NPY daytime food intake absence presence 5 nmol GR231118 male Sprague Dawley rats n 4
0.17783286.11751609.html.plaintext.txt	139	Data expressed mean plus minus SEM analyzed using repeated measures ANOVA followed post hoc least significant difference test
0.17783286.11751609.html.plaintext.txt	140	01 significant effect GR231118 MCH
0.17783286.11751609.html.plaintext.txt	141	001 significant effect GR231118 NPY
0.17783286.11751609.html.plaintext.txt	142	05 significantly different saline
0.17783286.11751609.html.plaintext.txt	143	Effect GR231118 NPY induced feeding The effect 5 nmol GR231118 NPY induced feeding also examined
0.17783286.11751609.html.plaintext.txt	144	At dose GR231118 significantly reduced food intake response NPY Fig
0.17783286.11751609.html.plaintext.txt	145	The administration GR231118 abolished feeding response 1 nmol NPY first 2 h experiment
0.17783286.11751609.html.plaintext.txt	146	Moreover administration GR231118 led sustained reduction NPY induced food intake 77 inhibition still evident 4 h vehicle NPY 6
0.17783286.11751609.html.plaintext.txt	147	1 g n 4 vehicle vehicle 0
0.17783286.11751609.html.plaintext.txt	148	Effect BIBO 3304 NPY MCH coadministration To investigate possible additive effects responses icv coadministration 1 nmol NPY 2 nmol MCH food intake compared 1 nmol NPY alone
0.17783286.11751609.html.plaintext.txt	149	Feeding induced coadministration agonists closely resembled feeding response 1 nmol NPY
0.17783286.11751609.html.plaintext.txt	150	7 g n 8 response coadministration agonists compared 5
0.17783286.11751609.html.plaintext.txt	151	In separate group animals effects 20 nmol BIBO 3304 dose previously inhibited NPY MCH induced food intake feeding response coadministration 1 nmol NPY 2 nmol MCH examined Fig
0.17783286.11751609.html.plaintext.txt	152	Prior administration BIBO 3304 significantly reduced food intake response coadministration agonists 30 min 3
0.17783286.11751609.html.plaintext.txt	153	05 however food intake longer different 1 h
0.17783286.11751609.html.plaintext.txt	154	Although food intake response combined NPY MCH administration remained slightly lower presence BIBO 3304 significant difference time point examined
0.17783286.11751609.html.plaintext.txt	155	8 g n 8 absence presence antagonist respectively
0.17783286.11751609.html.plaintext.txt	156	Food intake response coadministration 1 nmol NPY 2 nmol MCH different response administration 1 nmol NPY alone consistent results earlier series
0.17783286.11751609.html.plaintext.txt	157	View larger version 17K Figure 4
0.17783286.11751609.html.plaintext.txt	158	Daytime effects icv administration 1 nmol NPY coadministration 1 nmol NPY 2 nmol MCH absence presence 20 nmol BIBO 3304 male Sprague Dawley rats n 8 13 8 respectively
0.17783286.11751609.html.plaintext.txt	159	Food intake measured 4 h period
0.17783286.11751609.html.plaintext.txt	160	Data expressed mean plus minus SEM analyzed using repeated measures ANOVA followed post hoc least significant difference test
0.17783286.11751609.html.plaintext.txt	161	05 significant effect BIBO 3304 coadministration NPY MCH 30 min
0.17783286.11751609.html.plaintext.txt	162	A higher dose 40 nmol BIBO 3304 also administered coadministration 1 nmol NPY 2 nmol MCH
0.17783286.11751609.html.plaintext.txt	163	However due adverse effect torpor observed dose experiments continued
0.17783286.11751609.html.plaintext.txt	164	Activation Y1 receptor MCH To test hypothesis MCH stimulate feeding directly activating Y1 receptor effect MCH examined well characterized Y1 receptor system rat mesenteric artery
0.17783286.11751609.html.plaintext.txt	165	Mesenteric artery tone examined using Mulvaney myograph previously described 36
0.17783286.11751609.html.plaintext.txt	166	In four experiments constrictor responses Leu31Pro34NPY evaluated concentration range 10 10 10 6 M
0.17783286.11751609.html.plaintext.txt	167	Robust constrictor responses Leu31Pro34NPY observed resulting EC50 value 8
0.17783286.11751609.html.plaintext.txt	168	1 BIBO 3304 inhibited constrictor activity dose dependent manner
0.17783286.11751609.html.plaintext.txt	169	However evidence constrictor activity response MCH 3 x 10 9 3 x 10 5 M found vessels animals
0.17783286.11751609.html.plaintext.txt	170	Moreover presence 10 5 M MCH Leu31Pro34NPY still able elicit normal constrictor response
0.17783286.11751609.html.plaintext.txt	171	Discussion Top Abstract Introduction Materials Methods Results Discussion References The results study confirm previously reported orexigenic actions NPY MCH 2 25 26
0.17783286.11751609.html.plaintext.txt	172	Although peptides stimulated food intake lower feeding response near maximal dose MCH 26 demonstrates NPY potent appetite stimulant
0.17783286.11751609.html.plaintext.txt	173	This study aimed investigate possible interaction two peptides feeding
0.17783286.11751609.html.plaintext.txt	174	Immunohistochemical studies show reciprocal connections NPY MCH containing fibers arcuate nucleus LHA fibers project areas hypothalamus implicated feeding 31 32
0.17783286.11751609.html.plaintext.txt	175	Recent reports confirm MCH activates receptor distinct NPY known mediate feeding effects 28
0.17783286.11751609.html.plaintext.txt	176	We investigated possible interaction two orexigenic peptides assessing effects Y1 receptor blockade stimulation food intake induced MCH
0.17783286.11751609.html.plaintext.txt	177	The present study shown first time food intake induced MCH significantly inhibited BIBO 3304
0.17783286.11751609.html.plaintext.txt	178	BIBO 3304 recently available synthetic nonpeptide molecule competes high affinity IC50 0
0.17783286.11751609.html.plaintext.txt	179	2 nM rat Y1 receptor displays micromolar affinity Y2 Y4 Y5 receptors 37
0.17783286.11751609.html.plaintext.txt	180	These results suggest feeding response elicited MCH mediated part activation Y1 receptor
0.17783286.11751609.html.plaintext.txt	181	This could achieved via indirect mechanism MCH causes NPY release thus stimulates food intake perhaps direct activation Y1 receptor MCH see Fig
0.17783286.11751609.html.plaintext.txt	182	As reported previously PVN administration 38 study icv BIBO 3304 significantly inhibited feeding induced central administration NPY
0.17783286.11751609.html.plaintext.txt	183	We also demonstrated administration BIBO 3304 alone affect daytime feeding relative vehicle
0.17783286.11751609.html.plaintext.txt	184	Therefore unlikely reduction MCH induced food intake due nonspecific side effects BIBO 3304
0.17783286.11751609.html.plaintext.txt	185	View larger version 19K Figure 5
0.17783286.11751609.html.plaintext.txt	186	Schematic representation possible mechanisms underlying interaction NPY MCH
0.17783286.11751609.html.plaintext.txt	187	Top MCH increase feeding causing release NPY effect blocked Y1 antagonists
0.17783286.11751609.html.plaintext.txt	188	Middle MCH may stimulate feeding acting Y1 agonist
0.17783286.11751609.html.plaintext.txt	189	Note however observations mesenteric artery support possibility
0.17783286.11751609.html.plaintext.txt	190	Alternatively MCH may activate SLC 1 receptors Y1 receptor expressing neurons altering neuronal responsivity shown
0.17783286.11751609.html.plaintext.txt	191	Bottom Y1 antagonists might block MCH receptor SLC 1
0.17783286.11751609.html.plaintext.txt	192	Consistent inhibition MCH induced feeding BIBO 3304 structurally distinct Y1 selective peptide antagonist GR231118 also able inhibit food intake induced MCH
0.17783286.11751609.html.plaintext.txt	193	Reports show GR231118 binds high affinity Ki 0
0.17783286.11751609.html.plaintext.txt	194	16 nM rat Y1 receptor 39 autoradiographic studies demonstrate 125IGR231118 binding fully inhibited BIBO 3304 areas rat brain 40
0.17783286.11751609.html.plaintext.txt	195	The present study confirms dose administered GR231118 significantly inhibits NPY induced food intake
0.17783286.11751609.html.plaintext.txt	196	Apart observed inhibition NPY induced feeding Y1 antagonists 12 38 39 41 earlier observation Y1 selective analog Leu31Pro34NPY stimulated feeding pointed role Y1 receptor mediating NPY induced food intake 11 41 42
0.17783286.11751609.html.plaintext.txt	197	Although argued recently Leu31Pro34NPY also activates Y5 receptor stimulate feeding 13 extent inhibition feeding observed presence two different Y1 receptor antagonists confirms importance receptor mediating feeding effects NPY
0.17783286.11751609.html.plaintext.txt	198	Other studies shown food intake induced icv administration NPY remarkably reduced Y1 knockout preserved Y5 knockout mouse 43
0.17783286.11751609.html.plaintext.txt	199	Although GR231118 also agonist human NPY Y4 receptor 35 comparatively low levels Y4 receptor expression areas known stimulate food intake rat 10 thus unlikely Y4 effects contributed responses observed
0.17783286.11751609.html.plaintext.txt	200	Moreover previous work group others shown administration GR231118 stimulate food intake 12 41
0.17783286.11751609.html.plaintext.txt	201	Taken together actions GR231118 feeding paradigm appear Y1 mediated effect
0.17783286.11751609.html.plaintext.txt	202	The extent inhibition MCH induced food intake BIBO 3304 GR231118 similar 73 86 inhibition 2 h respectively
0.17783286.11751609.html.plaintext.txt	203	The slight difference degree inhibition two antagonists may arise variation two groups animals used
0.17783286.11751609.html.plaintext.txt	204	Although administration higher dose BIBO 3304 40 nmol investigated presence adverse reactions precluded investigation
0.17783286.11751609.html.plaintext.txt	205	The time course inhibitory effects BIBO 3304 GR231118 MCH similar marked effect first 2 h
0.17783286.11751609.html.plaintext.txt	206	This study also investigated effects coadministration NPY MCH food intake
0.17783286.11751609.html.plaintext.txt	207	If agonists stimulate feeding independent mechanisms operating parallel one might expected additive effect food intake achieved response agonist alone
0.17783286.11751609.html.plaintext.txt	208	However coadministration NPY MCH increase food intake achieved NPY alone
0.17783286.11751609.html.plaintext.txt	209	These results may surprising dose NPY approached maximally effective stimulating food intake
0.17783286.11751609.html.plaintext.txt	210	The doses NPY MCH chosen gave reproducible effects know parallel studies using NPY different mediator Hansen M
0.17783286.11751609.html.plaintext.txt	211	Morris unpublished observations possible elicit 9 10 g food intake identical conditions
0.17783286.11751609.html.plaintext.txt	212	Therefore believe mediators acting entirely independent manner larger response would observed
0.17783286.11751609.html.plaintext.txt	213	Further work needed test particularly effect BIBO 3304 feeding responses lower doses NPY MCH coadministration
0.17783286.11751609.html.plaintext.txt	214	In support interaction results demonstrating 20 nmol BIBO 3304 less able inhibit food intake response combination agonists NPY alone suggest antagonism Y1 receptor less effective presence MCH
0.17783286.11751609.html.plaintext.txt	215	This may arise due competition MCH Y1 receptor
0.17783286.11751609.html.plaintext.txt	216	Alternatively MCH may stimulate NPY release leading increased amount NPY Y1 receptor
0.17783286.11751609.html.plaintext.txt	217	This possibility could tested using techniques measure vivo NPY release
0.17783286.11751609.html.plaintext.txt	218	Finally relatively weaker antagonism agonist induced feeding BIBO 3304 presence MCH NPY may reflect summation non Y1 receptor mediated effects agonists via Y5 receptorSLC 1 receptor
0.17783286.11751609.html.plaintext.txt	219	The fact two selective Y1 receptor antagonists able block feeding induced MCH also suggests MCH may act part directly Y1 receptor
0.17783286.11751609.html.plaintext.txt	220	Another possibility MCH may act via SLC 1 receptors Y1 receptor expressing neurons altering neuronal responsivity
0.17783286.11751609.html.plaintext.txt	221	To knowledge ability MCH bind Y1 receptor previously examined however observed lack constrictor activity MCH well characterized Y1 receptor model mesenteric blood vessels suggests unlikely case
0.17783286.11751609.html.plaintext.txt	222	We found response MCH mesenteric arteries contracted Leu31Pro34NPY MCH affect ability Leu31Pro34NPY cause contraction suggesting MCH compete Y1 receptor least preparation
0.17783286.11751609.html.plaintext.txt	223	If MCH activate Y1 receptor might expected feeding response MCH Y1 knockout would attenuated
0.17783286.11751609.html.plaintext.txt	224	The Y5 receptor may make contribution feeding action MCH question examined present study
0.17783286.11751609.html.plaintext.txt	225	The possibility SLC 1 might another NPY receptor appears unlikely peptides screened identification cognate ligand SLC 1 obtained whole rat brain extracts MCH truncated version MCH yielded high agonist activity 44
0.17783286.11751609.html.plaintext.txt	226	An SLC 1 receptor antagonist would help characterize mechanism action MCH
0.17783286.11751609.html.plaintext.txt	227	MCH displays nanomolar affinity receptor SLC 1 28
0.17783286.11751609.html.plaintext.txt	228	As MCH induced food intake inhibited two Y1 receptor antagonists possibility MCH acts via receptor cause NPY release thereby stimulate food intake seems quite feasible
0.17783286.11751609.html.plaintext.txt	229	The anatomical distribution fibers supports hypothesis
0.17783286.11751609.html.plaintext.txt	230	MCH ir fibers SLC 1 mRNA immunoreactivity found hypothalamic areas implicated NPY induced feeding including PVN 29 31
0.17783286.11751609.html.plaintext.txt	231	MCH ir terminals also found arcuate nucleus 31 site major arcuo PVN NPY ergic projection
0.17783286.11751609.html.plaintext.txt	232	The site putative MCH induced NPY release cannot determined results study using exogenous icv administration orexigenic peptides
0.17783286.11751609.html.plaintext.txt	233	From results present study cannot exclude possibility GR231118 BIBO 3304 antagonists SLC 1 receptor Fig
0.17783286.11751609.html.plaintext.txt	234	5 although similar degree inhibition NPY MCH effects observed well characterized molecules support Y1 receptor mechanism
0.17783286.11751609.html.plaintext.txt	235	Interestingly recent reports detail existence second GPCR MCH MCH R2 45 46 areas implicated regulation body weight 46
0.17783286.11751609.html.plaintext.txt	236	The role MCH regulation food intake influence feeding mediators particularly intriguing cell specific lesions LHA produce hypophagia 23 47
0.17783286.11751609.html.plaintext.txt	237	MCH cell bodies localized LHA separate spatially overlapping cell bodies within LHA orexins newly recognized peptides also stimulate food intake upon icv administration 48
0.17783286.11751609.html.plaintext.txt	238	The feeding effects orexin recently shown involve NPY receptors suggesting interaction two mediators 33
0.17783286.11751609.html.plaintext.txt	239	Targeted deletion MCH gene results decreased food intake body weight 27 closely resembling phenotype rats LHA lesions whereas targeted deletion orexin gene induces narcolepsy 49
0.17783286.11751609.html.plaintext.txt	240	The recent observation transgenic mice overexpress MCH hyperphagic display obese phenotype 50 confirms fundamental role MCH plays regulation food intake
0.17783286.11751609.html.plaintext.txt	241	This study demonstrates two structurally distinct Y1 selective antagonists able significantly inhibit feeding response evoked MCH
0.17783286.11751609.html.plaintext.txt	242	With overlapping distribution MCH NPY containing fibers receptors new evidence supports hypothesis responses two important orexigenic peptides integrated
0.17783286.11751609.html.plaintext.txt	243	Although generally considered arcuate NPY cells may make contact LHA MCH ir neurons 23 leading MCH release one interpretation finding MCH may elicit hyperphagia part stimulating NPY release subsequent activation SLC 1 receptor
0.17783286.11751609.html.plaintext.txt	244	It also possible MCH able stimulate food intake directly acting Y1 receptor although vitro findings support possibility
0.17783286.11751609.html.plaintext.txt	245	Although work needed delineate mechanism MCH may interact NPY stimulate food intake present study provides evidence feeding response elicited MCH mediated activation NPY Y1 receptor probably regulating NPY release
0.17783286.11751609.html.plaintext.txt	246	Acknowledgments We indebted Prof
0.17783286.11751609.html.plaintext.txt	247	Peter Coles performing myograph experiments
0.17783286.11751609.html.plaintext.txt	248	BIBO 3304 kindly provided Dr Henri Doods Boehringer Ingelheim GmbH
0.17783286.11751609.html.plaintext.txt	249	Footnotes This work supported Grant 970374 National Health Medical Research Council Australia
0.17783286.11751609.html.plaintext.txt	250	Presented abstract form 34th Meeting Australian Society Clinical Experimental Pharmacologists Toxicologists 2000
0.17783286.11751609.html.plaintext.txt	251	Abbreviations CNS Central nervous system GPCR G protein coupled receptors icv intracerebroventricular ir immunoreactive LHA lateral hypothalamic area MCH melanin concentrating hormone PVN paraventricular nucleus SLC 1 somatostatin like receptor 1
0.17783286.11751609.html.plaintext.txt	252	Accepted publication September 10 2001
0.17783286.11751609.html.plaintext.txt	253	References Top Abstract Introduction Materials Methods Results Discussion References Schwartz MW Woods SC Porte DJ Seeley RJ Baskin DG 2000 Central nervous system control food intake
0.17783286.11751609.html.plaintext.txt	254	Nature 404661 671Medline Clark JT Kalra PS Crowley WR Kalra SP 1984 Neuropeptide Y human pancreatic polypeptide stimulate feeding behavior rats
0.17783286.11751609.html.plaintext.txt	255	Endocrinology 115427 429Abstract Stanley BG Kyrkouli SE Lampert S Leibowitz SF 1986 Neuropeptide Y chronically injected hypothalamus powerful neurochemical inducer hyperphagia obesity
0.17783286.11751609.html.plaintext.txt	256	Peptides 71189 1192CrossRefMedline Sanacora G Kershaw M Ginkelstein JA White JD 1990 Increased hypothalamic content preproneuropeptide Y messenger ribonucleic acid genetically obese zucker rats regulation food deprivation
0.17783286.11751609.html.plaintext.txt	257	Endocrinology 127730 737Abstract Chronwall BM Dimaggio DA Massari VJ Pickel VM Ruggiero DA O Donahue TL 1985 The anatomy neuropeptide Y containing neurons rat brain
0.17783286.11751609.html.plaintext.txt	258	Neuroscience 151159 1181CrossRefMedline Bai FL Yamano M Shiotani Y Emson PC Smith AD Powess JF Tohyama M 1985 An arcuato paraventricular dorsomedial hypothalamic neuropeptide Y containing system lacks noradrenaline rat
0.17783286.11751609.html.plaintext.txt	259	Brain Res 331172 175CrossRefMedline Kalra SP Dube MG Sahu A Phelps CP Kalra PS 1991 Neuropeptide Y secretion increases paraventricular nucleus association increased appetite food
0.17783286.11751609.html.plaintext.txt	260	Proc Natl Acad Sci USA 8810931 10935Abstract Li BH Xu B Rowland NE Kalra SP 1994 c fos Expression rat brain following central administration neuropeptide Y effects food consumption
0.17783286.11751609.html.plaintext.txt	261	Brain Res 665277 284CrossRefMedline Blomqvist AG Herzog H 1997 Y receptor subtypes many Trends Neurosci 20294 298CrossRefMedline Parker RM Herzog H 1999 Regional distribution Y receptor subtype mRNAs rat brain
0.17783286.11751609.html.plaintext.txt	262	Eur J Neurosci 111431 1448CrossRefMedline Stanley BG Magdalin W Seirafi A Nguyen MM Leibowitz SF 1992 Evidence neuropeptide Y mediation eating produced food deprivation variant Y1 receptor mediating peptide effect
0.17783286.11751609.html.plaintext.txt	263	Peptides 13581 587CrossRefMedline Kanatani A Ishihara A Asahi S Tanaka T Ozaki S Ihara M 1996 Potent neuropeptide Y Y1 receptor antagonist 1229U91 blockade neuropeptide Y induced physiological food intake
0.17783286.11751609.html.plaintext.txt	264	Endocrinology 1373177 3182Abstract Gerald C Walker MW Criscione L Gustafson EL Batzl Hartmann C Smith KE Vaysse P Durkin MM Laz TM Linemeyer DL Schaffhauser AO Whitebread S Hofbauer KG Taber RI Branchek TA Weinshank RL 1996 A receptor subtype involved neuropeptide Y induced food intake
0.17783286.11751609.html.plaintext.txt	265	Nature 382168 171CrossRefMedline O Shea D Morgan DGA Meerans K Edwards CM Turton MD Choi SJ Heath MM Gunn I Taylor GM Howard JK Bloom CI Small CJ Haddo O Ma JJ Callinan W Smith DM Ghatei MA Bloom SR 1997 Neuropeptide Y induced feeding rat mediated novel receptor
0.17783286.11751609.html.plaintext.txt	266	Endocrinology 138196 202AbstractFree Full Text Erickson JC Clegg KE Palmiter RD 1996 Sensitivity leptin susceptibility seizures mice lacking neuropeptide Y
0.17783286.11751609.html.plaintext.txt	267	Nature 381451 421Medline Rance TA Baker BI 1979 The teleost melanin concentrating hormone pituitary hormone hypothalamic origin
0.17783286.11751609.html.plaintext.txt	268	Gen Comp Endocrinol 3764 73Medline Vaughan JM Fischer WH Hoeger C Rivier J Vale W 1989 Characterization melanin concentrating hormone rat hypothalamus
0.17783286.11751609.html.plaintext.txt	269	Endocrinology 1231660 1665Abstract Presse F Nahon JL Fisher WH Vale W 1990 Structure human melanin concentrating hormone mRNA
0.17783286.11751609.html.plaintext.txt	270	Mol Endocrinol 4632 637Abstract Skofitsch G Jacobowitz DM Zamir N 1985 Immunohistochemical localization melanin concentrating hormone like peptide rat brain
0.17783286.11751609.html.plaintext.txt	271	Brain Res Bull 15635 649CrossRefMedline Zamir N Skoftsch G Jacobowitz DM 1986 Distribution immunoreactive melanin concentrating hormone central nervous system rat
0.17783286.11751609.html.plaintext.txt	272	Brain Res 373240 245CrossRefMedline Sekiya K Ghatei MA Lacoumenta S Burnet PW Zamir N Burrin JM Polak JM Bloom SR 1988 The distribution melanin concentrating hormone like immunoreactivity central nervous system rat guinea pig pig man
0.17783286.11751609.html.plaintext.txt	273	Neuroscience 25925 930CrossRefMedline Hetherington AW Ranson SW 1940 Hypothalamic lesions adiposity rat
0.17783286.11751609.html.plaintext.txt	274	Anat Rec 78149 172 Elmquist JK Elias CF Saper CB 1999 From lesions leptin hypothalamic control food intake body weight
0.17783286.11751609.html.plaintext.txt	275	Neuron 22221 32Medline Grill HJ Ginsberg AB Seeley RJ Kaplan JM 1998 Brainstem application melanocortin receptor ligands produces long lasting effects feeding body weight
0.17783286.11751609.html.plaintext.txt	276	J Neurosci 1810128 10135AbstractFree Full Text Qu D Ludwig DS Gammeltoft S Piper M Pelleymounter MA Cullen MJ Mathes WF Przypek R Kanarek R Maratos Flier E 1996 A role melanin concentrating hormone regulation feeding behaviour
0.17783286.11751609.html.plaintext.txt	277	Nature 380243 247CrossRefMedline Rossi M Choi SJ O Shea D Miyoshi T Ghatei MA Bloom SR 1997 Melanin concentrating hormone acutely stimulates feeding chronic administration effect body weight
0.17783286.11751609.html.plaintext.txt	278	Endocrinology 138351 355AbstractFree Full Text Shimada M Tritos NA Lowell BB Flier JS Maratos Flier E 1998 Mice lacking melanin concentrating hormone hypophagic lean
0.17783286.11751609.html.plaintext.txt	279	Nature 396670 674CrossRefMedline Chambers J Ames RS Bergsma D Muir A Fitzgerald LR Hervieu G Dytko GM Foley JJ Martin J Liu WS Park J Ellis C Ganguly S Konchar S Cluderay J Leslie R Wilson S Sarau HM 1999 Melanin concentrating hormone cognate ligand orphan G protein coupled receptor SLC 1
0.17783286.11751609.html.plaintext.txt	280	Nature 400261 265CrossRefMedline Hervieu GJ Cluderay JE Harrison D Meakin J Maycox P Nasir S Leslie RA 2000 The distribution mRNA protein products melanin concentrating hormone MCH receptor gene SLC 1 central nervous system rat
0.17783286.11751609.html.plaintext.txt	281	Eur J Neurosci 121194 1216CrossRefMedline Sone M Takahashi K Murakami O Totsune K Arihara Z Satoh F Sasano H Ito H Mouri T 2000 Binding sites melanin concentrating hormone human brain
0.17783286.11751609.html.plaintext.txt	282	Peptides 21245 250CrossRefMedline Broberger C De Lecea L Sutcliffe JG Hokfelt T 1998 Hypocretinorexin melanin concentrating hormone expressing cells form distinct populations rodent lateral hypothalamus relationship neuropeptide Y agouti gene related protein systems
0.17783286.11751609.html.plaintext.txt	283	CO2 R 24CrossRefMedline Paxinos G Watson C 1986 The rat brain stereotaxic coordinates
0.17783286.11751609.html.plaintext.txt	284	Sydney Australia Academic Press Parker EM Babij CK Balasubramaniam A Burrier RE Guzzi M Hamud F Mukhopadhyay G Rudinski MS Tao Z Tice M Xia L Mullins DE Salisbury BG 1998 GR23118 1229U91 analogues c terminus neuropeptide Y potent neuropeptide Y Y1 receptor antagonists neuropeptide Y Y4 receptor agonists
0.17783286.11751609.html.plaintext.txt	285	Eur J Pharmacol 34997 105CrossRefMedline Lew MJ Murphy R Angus JA 1996 Synthesis characterization selective peptide antagonist neuropeptide Y vascular postsynaptic receptors
0.17783286.11751609.html.plaintext.txt	286	Br J Pharmacol 1171768 1772Abstract Dumont Y Cadieux A Doods H Fournier A Quirion R 2000 Potent selective tools investigate neuropeptide Y receptors central peripheral nervous systems BIBO 3304 Y1 CGP71683A Y5
0.17783286.11751609.html.plaintext.txt	287	Can J Physiol Pharmacol 781116 1125 Wieland HA Engel W Rudolf K Doods HN 1998 Subtype selectivity novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 effects feeding rodents
0.17783286.11751609.html.plaintext.txt	288	Br J Pharmacol 125549 555Abstract Kanatani A Ito J Ishihara A Iwaasa H Fukuroda T Fukami T MacNeil DJ Van der Ploeg LH Ihara M 1998 NPY induced feeding involves action Y1 like receptor rodents
0.17783286.11751609.html.plaintext.txt	289	Regul Pept 75 76409 415 Dumont Y Quirion R 2000 125I GR231118 high affinity radioligand investigate neuropeptide Y Y1 Y4 receptors
0.17783286.11751609.html.plaintext.txt	290	Br J Pharmacol 12937 46AbstractFree Full Text Tortelli CF Morris MJ 1997 Multiple NPY receptors involved food intake agonist antagonist studies rat
0.17783286.11751609.html.plaintext.txt	291	Aust Soc Study Obes 639 Abstract Leibowitz SF Alexander JT 1991 Analysis neuropeptide Y induced feeding dissociation Y1 Y2 receptor effects natural meal patterns
0.17783286.11751609.html.plaintext.txt	292	Peptides 121251 1260CrossRefMedline Kanatani A Mashiko S Murai N et al 2000 Role Y1 receptor regulation neuropeptide Y mediated feeding comparison wild type Y1 receptor deficient Y5 receptor deficient mice
0.17783286.11751609.html.plaintext.txt	293	Endocrinology 1411011 1016AbstractFree Full Text Bachner D Kreienkamp H J Weisem C Buck F Richter D 1999 Identification melanin concentrating hormone MCH natural ligand orphan somatostatin like receptor SLC 1
0.17783286.11751609.html.plaintext.txt	294	FEBS Lett 457522 524CrossRefMedline An S Cutler G Zhao JJ Huang SG Tian H Li W Liang L Rich M Bakleh A Du J Chen JL Dai K 2001 Identification characterization melanin concentrating hormone receptor
0.17783286.11751609.html.plaintext.txt	295	Proc Natl Acad Sci USA 987576 7581AbstractFree Full Text Sailer AW Sano H Zeng Z McDonald TP Pan J Pong SS Feighner SD Tan CP Fukami T Iwaasa H Hreniuk DL Morin NR Sadowski SJ Ito M Bansal A Ky B Figueroa DJ Jiang Q Austin CP MacNeil DJ Ishihara A Ihara M Kanatani A Van der Ploeg LH Howard AD Liu Q 2001 Identification characterization second melanin concentrating hormone receptor MCH 2R
0.17783286.11751609.html.plaintext.txt	296	Proc Natl Acad Sci USA 987564 7569AbstractFree Full Text Grossman SP Dacey D Halaris AE Colier T Routtenberg A 1978 Aphagia adipsia preferential destruction nerve cell bodies hypothalamus
0.17783286.11751609.html.plaintext.txt	297	Science 202537 539Medline Sakurai T Amemiya A Ishii M Matsuzaki I Chemelli RM Tanaka H Williams SC Richarson JA Kozlowski GP Wilson S Arch JR Buckingham RE Haynes AC Carr SA Annan RS McNulty DE Liu WS Terrett JA Elshourbagy NA Bergsma DJ Yanagisawa M 1998 Orexins orexin receptors family hypothalamic neuropeptides G protein coupled receptors regulate feeding behavior
0.17783286.11751609.html.plaintext.txt	298	Cell 92573 585Medline Chemelli R 1999 Narcolepsy orexin knockout mice molecular genetics sleep regulation
0.17783286.11751609.html.plaintext.txt	299	Cell 98437 451Medline Ludwig DS Tritos NA Mastaitis JW Kulkarni R Kokkotou E Elmquist J Lowell B Flier JS Maratos Flier E 2001 Melanin concentrating hormone overexpression transgenic mice leads obesity insulin resistance
0.17783286.11751609.html.plaintext.txt	300	J Clin Invest 107379 386AbstractFree Full Text
0.16537316.15829503.html.plaintext.txt	0	SINE exonic insertion PTPLA gene leads multiple splicing defects segregates autosomal recessive centronuclear myopathy dogs Manuel Pele1 Laurent Tiret1 Jean Louis Kessler1 Stephane Blot23 Jean Jacques Panthier1
0.16537316.15829503.html.plaintext.txt	1	1UMR 955 INRA ENVA de Genetique Moleculaire et Cellulaire 2Laboratoire de Neurobiologie Ecole Nationale Veterinaire dAlfort 7 avenue du General de Gaulle 94704 Maisons Alfort cedex France 3INSERM EMI E00 11 94000 Creteil France
0.16537316.15829503.html.plaintext.txt	2	To correspondence addressed
0.16537316.15829503.html.plaintext.txt	3	Tel 33 143967275 Fax 33 143967169 Email ltiretatvet alfort
0.16537316.15829503.html.plaintext.txt	4	Received February 8 2005 Revised March 30 2005 Accepted April 6 2005
0.16537316.15829503.html.plaintext.txt	5	ABSTRACT TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS SUPPLEMENTARY MATERIAL REFERENCES Human centronuclear myotubular myopathies belong genetically heterogeneous nosological group clinical variability ranging fatal disorder mild weakness
0.16537316.15829503.html.plaintext.txt	6	The severe X linked form attributed 200 different mutations myotubularin encoding gene MTM1
0.16537316.15829503.html.plaintext.txt	7	In contrast reports regarding molecular etiology linkage studies autosomal forms disease
0.16537316.15829503.html.plaintext.txt	8	Labrador retrievers affected spontaneous centronuclear myopathy cnm clinical histological features human disorder represent first model recessive autosomal centronuclear myopathy
0.16537316.15829503.html.plaintext.txt	9	We previously mapped cnm locus centromeric region canine chromosome 2
0.16537316.15829503.html.plaintext.txt	10	No gene MTM1 family maps human homologous chromosomal region
0.16537316.15829503.html.plaintext.txt	11	Described herein disease associated insertion within PTPLA exon 2 found alleles affected Labradors single allele obligate carriers
0.16537316.15829503.html.plaintext.txt	12	The inserted tRNA derived short interspersed repeat element SINE striking effect maturation PTPLA mRNA whereby spliced partially exonized involved multiple exon skipping
0.16537316.15829503.html.plaintext.txt	13	As result amount wild type transcripts falls 1 affected muscles
0.16537316.15829503.html.plaintext.txt	14	This example therefore recapitulates cumulative SINE associated transcriptional defects previously described exclusive consequences independent mutations
0.16537316.15829503.html.plaintext.txt	15	Although function PTPLA metazoa remains unknown characterization hypomorphic mutation Labradors centronuclear myopathy provides new clues molecular complexity skeletal myofiber homeostasis
0.16537316.15829503.html.plaintext.txt	16	These results also suggest impaired PTPLA signaling might implicated human myopathies
0.16537316.15829503.html.plaintext.txt	17	INTRODUCTION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS SUPPLEMENTARY MATERIAL REFERENCES The nosological group human centronuclear myopathy OMIM
0.16537316.15829503.html.plaintext.txt	18	160150 defined heterogeneous forms inherited muscular disorders share common clinical histological features
0.16537316.15829503.html.plaintext.txt	19	Hallmarks disease include generalized muscle weakness ptosis ophthalmoplegia externa areflexia muscular atrophy affecting predominantly type 1 myofibers nuclei centralization pale central zones variably staining granules 1 3
0.16537316.15829503.html.plaintext.txt	20	Genetic heterogeneity correlated onset severity disease
0.16537316.15829503.html.plaintext.txt	21	A significant proportion infants affected severe X linked form called myotubular myopathy XLMTM OMIM
0.16537316.15829503.html.plaintext.txt	22	310400 die months age following respiratory failure 45
0.16537316.15829503.html.plaintext.txt	23	Eighty percent survivors become dependent artificial ventilation suffer medical complications 5
0.16537316.15829503.html.plaintext.txt	24	Autosomal dominant recessive forms OMIM
0.16537316.15829503.html.plaintext.txt	25	255200 run milder course recessive form intermediate X linked dominant forms 26
0.16537316.15829503.html.plaintext.txt	26	The XLMTM locus initially mapped Xq28 7 mutations Myotubularin MTM1 gene associated disease 8
0.16537316.15829503.html.plaintext.txt	27	To date spectrum 200 disease associated mutations MTM1 account severe mild phenotype observed XLMTM patients 9
0.16537316.15829503.html.plaintext.txt	28	MTM1 encodes myotubularin contains consensus sequence tyrosine phosphatase catalytic site 8
0.16537316.15829503.html.plaintext.txt	29	However protein seems essentially act muscles phosphoinositide phosphatase specifically dephosphorylates lipid second messengers phosphatidylinositol 3 phosphate PtdIns3P 10 12 phosphatidylinositol 35 bisphosphate PtdIns35P2 1314
0.16537316.15829503.html.plaintext.txt	30	Myotubularin first identified member large protein family comprises 13 known members human named myotubularin related 1 13 MTMR1 MTMR13
0.16537316.15829503.html.plaintext.txt	31	Mutations MTMR2 MTMR13 associated Charcot Marie Tooth demyelinating diseases 15 17 reinforce central role phosphoinositides neuromuscular homeostasis reviewed 18
0.16537316.15829503.html.plaintext.txt	32	The MTM1 protein family encompasses active inactive members recent reports suggested functional cooperation two groups 18 23
0.16537316.15829503.html.plaintext.txt	33	Besides characterized etiology XLMTM significant molecular data autosomal forms reported far
0.16537316.15829503.html.plaintext.txt	34	Spontaneous cases Labrador retrievers suffering congenital form hereditary myopathy hereditary myopathy Labrador retriever HMLR first described USA 1976 24 later groups across world 25 29
0.16537316.15829503.html.plaintext.txt	35	The myopathy transmitted autosomal recessive disease 28 30
0.16537316.15829503.html.plaintext.txt	36	Clinical features male female pups include hypotonia generalized muscle weakness abnormal postures stiff hopping gait exercise intolerance increased collapse exposed cold see movie published Supplementary Material HMG Online
0.16537316.15829503.html.plaintext.txt	37	On examination evidence skeletal muscle atrophy particularly involving muscles head tendinous areflexia
0.16537316.15829503.html.plaintext.txt	38	Metabolic shape remodeling muscles observed type 2 fibers deficiency predominance atrophic hypertrophic type 1 fibers 24252829
0.16537316.15829503.html.plaintext.txt	39	In reported cases histopathological evaluation muscle biopsies demonstrated characteristic centralization myonuclei often located areas devoid myofibrils mitochondrial aggregation
0.16537316.15829503.html.plaintext.txt	40	Centronuclear myopathy cnm therefore proposed alternative name HMLR 29 knowledge spontaneous animal model human autosomal centronuclear myopathies
0.16537316.15829503.html.plaintext.txt	41	We previously described experimental pedigree Labrador retrievers segregating centronuclear myopathy
0.16537316.15829503.html.plaintext.txt	42	The cnm locus mapped highly significant LOD score 9
0.16537316.15829503.html.plaintext.txt	43	1 cM segment centromeric region canine chromosome 2 CFA2 29 region forms shuffled block synteny human chromosome segment 10p15 10p11
0.16537316.15829503.html.plaintext.txt	44	Interestingly gene MTM1 family maps human chromosome 10p 12
0.16537316.15829503.html.plaintext.txt	45	The purpose study identify plausible candidate genes within cnm interval characterize disease causing mutation one genes
0.16537316.15829503.html.plaintext.txt	46	We report mutation gene encoding protein tyrosine phosphatase like member A PTPLA perfectly segregates cnm Labrador retrievers experimental pedigree
0.16537316.15829503.html.plaintext.txt	47	Indeed tRNA like short interspersed repeat element SINE insertion identified exon 2 PTPLA leads multiple transcriptional alterations SINE containing PTPLA allele
0.16537316.15829503.html.plaintext.txt	48	Moreover disclose original complex disease associated mutation multiple transcriptional defects arising tRNA like SINE insertion
0.16537316.15829503.html.plaintext.txt	49	RESULTS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS SUPPLEMENTARY MATERIAL REFERENCES Candidate gene selection Using human genome resources NCBI Map Viewer identified 208 genes within cnm region data shown
0.16537316.15829503.html.plaintext.txt	50	None member MTM1 family
0.16537316.15829503.html.plaintext.txt	51	Hence focused genes expressed skeletal muscles temporal window compatible early postnatal symptoms diagnosed affected dogs
0.16537316.15829503.html.plaintext.txt	52	Among genes PTPLA shown expressed embryogenesis murine myogenic precursors 32 adult skeletal muscles mouse human 3233
0.16537316.15829503.html.plaintext.txt	53	Furthermore PTPLA annotated phosphatase coding gene PTPLA protein contains putative phosphatase like domain proline instead arginine catalytic site
0.16537316.15829503.html.plaintext.txt	54	The motif characteristics similar myotubularin mutated responsible human XLMTM
0.16537316.15829503.html.plaintext.txt	55	Mutation identification segregation experimental pedigree The detailed structure canine PTPLA gene phylogenetic analysis PTPLA family members described elsewhere Pele et al
0.16537316.15829503.html.plaintext.txt	56	The following data taken consideration designing experiments detailed subsequently
0.16537316.15829503.html.plaintext.txt	57	Canine PTPLA spans 20 kb contains seven exons Fig
0.16537316.15829503.html.plaintext.txt	58	1A structure shared human 33 murine orthologs see Ensembl Gene ID ENSMUSG00000063275
0.16537316.15829503.html.plaintext.txt	59	In dog skeletal muscles PTPLA transcripts exist two isoforms Fig
0.16537316.15829503.html.plaintext.txt	60	1B differing retention PTPLAfl full length EMBL accession
0.16537316.15829503.html.plaintext.txt	61	AJ876904 exclusion exon 5 PTPLAd5 deleted exon 5 EMBL accession
0.16537316.15829503.html.plaintext.txt	62	PTPLAfl transcript encodes putative protein 249 amino acids contains four transmembrane domains putative tyrosine phosphatase like HCX2GX2P catalytic site Fig
0.16537316.15829503.html.plaintext.txt	63	Exon 5 skipping PTPLAd5 transcript leads frame disruption premature translation termination
0.16537316.15829503.html.plaintext.txt	64	The resulting predicted PTPLAD5 protein contains two transmembrane domains putative tyrosine phosphatase like HCX2GX2P catalytic site
0.16537316.15829503.html.plaintext.txt	65	PTPLAFL PTPLAD5 proteins share common 125 amino acids N terminus domain differ C terminus regions 124 amino acids 11 amino acids length respectively Fig
0.16537316.15829503.html.plaintext.txt	66	View larger version 30K Figure 1
0.16537316.15829503.html.plaintext.txt	67	A The structure gene drawn follows seven exons indicated vertical bars
0.16537316.15829503.html.plaintext.txt	68	The size individual exons introns indicated horizontal bar respectively
0.16537316.15829503.html.plaintext.txt	69	B In skeletal muscle PTPLA transcripts exist two isoforms differing retention PTPLAfl full length exclusion PTPLAd5 exon 5 deleted isoform exon 5
0.16537316.15829503.html.plaintext.txt	70	Each box represents exon number indicated
0.16537316.15829503.html.plaintext.txt	71	The probe used Southern spans seven exons gene covers 69 full length cDNA
0.16537316.15829503.html.plaintext.txt	72	C Sequences PTPLAFL PTPLAD5 proteins inferred corresponding mRNAs
0.16537316.15829503.html.plaintext.txt	73	The predicted transmembrane domains indicated drawings
0.16537316.15829503.html.plaintext.txt	74	The Prosite bar indicates putative protein tyrosine phosphatase like site
0.16537316.15829503.html.plaintext.txt	75	In gene searched specific polymorphism would segregate disease experimental pedigree
0.16537316.15829503.html.plaintext.txt	76	Genomic DNA wild type wt cnm healthy carriers cnm affected cnm Labradors digested hybridized probe encompassing PTPLA cDNA shown Fig
0.16537316.15829503.html.plaintext.txt	77	A BamHI restriction fragment length polymorphism RFLP detected DNA samples cnm cnm dogs seen DNA samples cnm dogs
0.16537316.15829503.html.plaintext.txt	78	Furthermore RFLP perfectly segregated disease data shown
0.16537316.15829503.html.plaintext.txt	79	Using PCR RT PCR amplified individual exons PTPLA genomic DNA RNAs skeletal muscles
0.16537316.15829503.html.plaintext.txt	80	PCR RT PCR amplifications carried samples healthy carrier cnm affected cnm dog
0.16537316.15829503.html.plaintext.txt	81	Figure 2 illustrates results obtained exons 1 2
0.16537316.15829503.html.plaintext.txt	82	PCR RT PCR amplifications exon 1 using Ex1F1 Ex1R1 primers Fig
0.16537316.15829503.html.plaintext.txt	83	2A led single 123 bp fragment corresponding exon 1 Fig
0.16537316.15829503.html.plaintext.txt	84	The 123 bp signal weaker RNAs cnm muscles used template RT PCR reaction compared RNAs cnm muscles Fig
0.16537316.15829503.html.plaintext.txt	85	PCR amplification exon 2 using genomic DNA cnm dog template Ex2F1 Ex2R1 primers yielded two products 105 341 bp respectively Fig
0.16537316.15829503.html.plaintext.txt	86	The 105 bp product normal size exon 2 fragment expected primers
0.16537316.15829503.html.plaintext.txt	87	This 105 bp fragment also obtained RNAs cnm muscles used template RT PCR reaction detected RNAs cnm muscles used Fig
0.16537316.15829503.html.plaintext.txt	88	2B lanes 6 7 respectively
0.16537316.15829503.html.plaintext.txt	89	View larger version 60K Figure 2
0.16537316.15829503.html.plaintext.txt	90	Mutation analysis PTPLA segregation cnm pedigree
0.16537316.15829503.html.plaintext.txt	91	A Location PCR primers indicated black arrows
0.16537316.15829503.html.plaintext.txt	92	B The size marker lane 1 100 bp ladder
0.16537316.15829503.html.plaintext.txt	93	PCR genomic DNA lanes 2 5 RT PCR muscular mRNAs lanes 3 4 6 7 healthy carrier cnm affected dog cnm using Ex1F1Ex1R1 lanes 2 4 Ex2F1Ex2R1 lanes 5 7 primer pairs
0.16537316.15829503.html.plaintext.txt	94	An insertion within exon 2 PTPLA seen cnm dog genomic samples
0.16537316.15829503.html.plaintext.txt	95	C PCR amplification genomic DNA representative panel healthy unrelated Labradors cnm lanes 2 4 healthy carriers cnm lanes 5 7 affected Labradors cnm lanes 8 10 cnm pedigree using Ex2F2 Ex3R1 primers
0.16537316.15829503.html.plaintext.txt	96	The size marker lanes 1 11 100 bp ladder
0.16537316.15829503.html.plaintext.txt	97	To characterize 341 bp fragment PCR amplifications exon 2 intron 2 using Ex2F2 Ex3R1 primers performed genomic DNA 61 individuals six generation experimental pedigree 29 three unrelated healthy cnm Labradors
0.16537316.15829503.html.plaintext.txt	98	A representative panel resulting PCR products presented Fig
0.16537316.15829503.html.plaintext.txt	99	2C complete amplifications 46 animals among 22 affected dogs provided Supplementary Material Fig
0.16537316.15829503.html.plaintext.txt	100	PCR using DNA wt cnm dogs template yielded single 282 bp product lanes 2 4
0.16537316.15829503.html.plaintext.txt	101	PCR performed affected cnm dogs DNA contained single 518 bp product lanes 8 10
0.16537316.15829503.html.plaintext.txt	102	Finally PCR using cnm dogs DNA yielded 282 518 bp products lanes 5 7
0.16537316.15829503.html.plaintext.txt	103	To explain size shift seen genomic DNA cnm cnm dogs used templates cloned sequenced 518 bp product
0.16537316.15829503.html.plaintext.txt	104	It contained 236 bp antisense canine tRNA like SINE EMBL accession
0.16537316.15829503.html.plaintext.txt	105	AJ876906 flanked sides 13 bp direct duplication insertion site Fig
0.16537316.15829503.html.plaintext.txt	106	After comparison RepeatMasker libraries known vertebrate carnivore specific repeat elements SINE sequence found within PTPLA best aligned SINECCf repeats SINELys subfamily first described Minnick et al
0.16537316.15829503.html.plaintext.txt	107	Using tRNAScan identified glutamine anticodon within tRNA like sequence SINE
0.16537316.15829503.html.plaintext.txt	108	Finally sequence analysis revealed BamHI restriction site within insertion explained RFLP previously described
0.16537316.15829503.html.plaintext.txt	109	View larger version 30K Figure 3
0.16537316.15829503.html.plaintext.txt	110	Structure inserted SINE
0.16537316.15829503.html.plaintext.txt	111	The nucleotide sequence tRNA like SINE depicted large black letters
0.16537316.15829503.html.plaintext.txt	112	Small grey letters correspond PTPLA exon 2 sequence
0.16537316.15829503.html.plaintext.txt	113	The 13 bp direct duplication insertion site underlined
0.16537316.15829503.html.plaintext.txt	114	The BamHI restriction site GGATCC detected Southern blots shown bold characters
0.16537316.15829503.html.plaintext.txt	115	Grey boxes indicate repeated splicing donors acceptors allow proper splicing SINE
0.16537316.15829503.html.plaintext.txt	116	Circles highlight cryptic splicing sites leading variant v1 synthesis Fig
0.16537316.15829503.html.plaintext.txt	117	To strengthen causative link insertion centronuclear myopathy 18 dogs 14 breeds 20 mongrels six additional unrelated healthy French Labradors screened presence SINE
0.16537316.15829503.html.plaintext.txt	118	All 44 tested dogs lacked insertion data shown
0.16537316.15829503.html.plaintext.txt	119	Finally BLAST analysis conducted Boxer genome assembly httpwww
0.16537316.15829503.html.plaintext.txt	120	No SINE inserted within PTPLA exon 2 genome
0.16537316.15829503.html.plaintext.txt	121	Hence SINE insertion seemed highly specific Labrador retriever pedigree segregating centronuclear myopathy developed Alfort School Veterinary Medicine
0.16537316.15829503.html.plaintext.txt	122	Using standard nomenclature system human mutations 35 PTPLA corresponding genomic sequence Boxer genome assembly mutation called PTPLA g9459 9460ins236
0.16537316.15829503.html.plaintext.txt	123	It hereafter referred PTPLAalf
0.16537316.15829503.html.plaintext.txt	124	SINE insertion leads aberrant splicing pattern skeletal muscles Alu insertions frequently associated human diseases
0.16537316.15829503.html.plaintext.txt	125	Most insertions occurred within introns causing either close hand exon skipping e
0.16537316.15829503.html.plaintext.txt	126	36 39 incorporation Alu sequences mature mRNA splicing mediated process called exonization 36
0.16537316.15829503.html.plaintext.txt	127	Few SINE insertions within coding sequences reported
0.16537316.15829503.html.plaintext.txt	128	They may lead specific skipping mutated exon e
0.16537316.15829503.html.plaintext.txt	129	3640 frame disruption premature translation termination signal e
0.16537316.15829503.html.plaintext.txt	130	To test putative transcriptional defects resulting SINE insertion within PTPLA exon 2 PTPLA transcripts amplified RT PCR using sequences exon 1 exon 7 primers RNAs skeletal muscles cnm cnm cnm dogs templates
0.16537316.15829503.html.plaintext.txt	131	Both PTPLAfl PTPLAd5 transcripts amplified cnm cnm samples Fig
0.16537316.15829503.html.plaintext.txt	132	In contrast ladder like profile seven RT PCR products obtained cnm samples Fig
0.16537316.15829503.html.plaintext.txt	133	All seven amplicons cloned sequenced precisely determine acceptor donor splicing sites used synthesis corresponding transcripts cnm muscles Fig
0.16537316.15829503.html.plaintext.txt	134	Figure 4C proposes classification PTPLA transcripts based splicing profile predicted proteins
0.16537316.15829503.html.plaintext.txt	135	As far cnm dogs concerned RT PCR products corresponding PTPLAfl PTPLAd5 wt isoforms observed indicates SINE occasionally spliced
0.16537316.15829503.html.plaintext.txt	136	Furthermore point mutation could detected transcripts indicating wt cnm associated PTPLA alleles differ SINE insertion
0.16537316.15829503.html.plaintext.txt	137	RT PCR product v1 corresponds splicing variant carried partial 25 bp deletion PTPLA exon 2 well 154 bp exonization 3 region inserted SINE
0.16537316.15829503.html.plaintext.txt	138	Further analysis SINE sequence confirmed presence cryptic splicing donor acceptor sites could lead either proper splicing insertion transcripts PTPLAfl PTPLAd5 variant v1 Fig
0.16537316.15829503.html.plaintext.txt	139	The remaining variants v2 v5 lacked internal exons
0.16537316.15829503.html.plaintext.txt	140	These variants arose exon skipping involving respectively exon 2 v2 exons 2 3 v3 exons 2 3 4 v4 exons 2 3 4 5 v5 Fig
0.16537316.15829503.html.plaintext.txt	141	View larger version 34K Figure 4
0.16537316.15829503.html.plaintext.txt	142	Splicing alterations PTPLAalf mutated allele
0.16537316.15829503.html.plaintext.txt	143	A RT PCR amplification PTPLA using mRNA skeletal muscle cnm lane 1 cnm lane 2 cnm lane 3 dogs primers depicted B
0.16537316.15829503.html.plaintext.txt	144	B Schematic representation transcripts SINE containing PTPLAalf allele skeletal muscles affected dogs A lane 3
0.16537316.15829503.html.plaintext.txt	145	The dashed lines represent inferred splicing profiles transcript
0.16537316.15829503.html.plaintext.txt	146	C Classification seven splicing variants fl d5 v1 v2 v3 v4 v5 according splicing profiles predicted proteins
0.16537316.15829503.html.plaintext.txt	147	Darts indicate positions premature stop condons
0.16537316.15829503.html.plaintext.txt	148	To assess biological impact SINE induced splicing defects amino acid sequences inferred transcript
0.16537316.15829503.html.plaintext.txt	149	PTPLAFL PTPLAD5 proteins deduced transcripts PTPLAfl PTPLAd5 respectively
0.16537316.15829503.html.plaintext.txt	150	Frameshift mutations found variants v1 v2 v3 v4 hence leading truncated forms PTPLA
0.16537316.15829503.html.plaintext.txt	151	Finally exons 1 6 frame variant v5 sequence encodes small truncated protein lacking PTPL site Fig
0.16537316.15829503.html.plaintext.txt	152	The SINE insertion within PTPLA PTPLAalf allele strongly affected splicing mechanisms
0.16537316.15829503.html.plaintext.txt	153	However quite surprisingly AGGT sequence contained within 13 bp repeats flanking insertion Fig
0.16537316.15829503.html.plaintext.txt	154	3 allowed proper splicing SINE thus leading wt transcripts
0.16537316.15829503.html.plaintext.txt	155	tRNA like SINE sufficient alter splicing To test whether SINE responsible characterized splicing defects performed ex vivo analyses using exon trapping experiments
0.16537316.15829503.html.plaintext.txt	156	Two PTPLA genomic fragments spanning intron 1 intron 4 differed absence presence SINE insertion cloned pSPL3 exon trapping vector Fig
0.16537316.15829503.html.plaintext.txt	157	Both plasmids termed pCOS cnm pCOS wt respectively transfected COS 7 cells resulting transcripts analyzed RT PCR
0.16537316.15829503.html.plaintext.txt	158	When pCOS wt plasmid used RT PCR nested PCR products corresponded properly spliced transcript containing PTPLA exons 2 3 4 flanked two 5 3 ss globin exons vector Fig
0.16537316.15829503.html.plaintext.txt	159	SacI digestion confirmed presence PTPLA exon 4 Fig
0.16537316.15829503.html.plaintext.txt	160	In contrast smaller products observed RT PCR nested PCR total RNAs COS 7 cells transfected SINE containing plasmid pCOS cnm used template
0.16537316.15829503.html.plaintext.txt	161	SacI digestion suggested PTPLA exon 4 present products Fig
0.16537316.15829503.html.plaintext.txt	162	This hypothesis confirmed sequence analysis
0.16537316.15829503.html.plaintext.txt	163	Indeed smaller size transcripts resulted absence PTPLA exon 2
0.16537316.15829503.html.plaintext.txt	164	Additional RT PCR experiments revealed low level wt transcript containing PTPLA exons 2 3 4 data shown
0.16537316.15829503.html.plaintext.txt	165	View larger version 37K Figure 5
0.16537316.15829503.html.plaintext.txt	166	SINE induced splicing defects transfected COS 7 cells
0.16537316.15829503.html.plaintext.txt	167	A pSPL3 vector sequence genomic structure wt pCOS wt insert SINE containing pCOS cnm insert sequences depicted
0.16537316.15829503.html.plaintext.txt	168	Full lines correspond intronic plasmidic sequences
0.16537316.15829503.html.plaintext.txt	169	White black vertical arrow heads indicate locations splicing donor acceptor sites respectively
0.16537316.15829503.html.plaintext.txt	170	B RT PCR amplification total RNAs pCOS wt pCOS cnm transfected cells using SD6SA2 primer pair followed nested PCR using SD2SA4 primer pair
0.16537316.15829503.html.plaintext.txt	171	SD6 SA2 SD2 SA4 primers depicted A
0.16537316.15829503.html.plaintext.txt	172	PCR products digested SacI loaded onto agarose gel
0.16537316.15829503.html.plaintext.txt	173	Thus precise splicing SINE inserted sequence skipping mutated exon 2 induced ex vivo using 1
0.16537316.15829503.html.plaintext.txt	174	5 kb mini PTPLAalf allele recapitulating splicing defects seen complete PTPLAalf allele transcribed muscle cells vivo
0.16537316.15829503.html.plaintext.txt	175	Quantification PTPLA transcripts affected dogs muscles Seven splicing variants resulting transcription PTPLAalf allele detected cnm muscles two wt isoforms PTPLAfl PTPLAd5
0.16537316.15829503.html.plaintext.txt	176	To determine total amount PTPLA transcripts proportion wt PTPLA transcripts cnm muscles performed quantitative analyses using real time RT PCR
0.16537316.15829503.html.plaintext.txt	177	All PTPLA transcripts identified cnm cnm muscles contained exons 6 7 Fig
0.16537316.15829503.html.plaintext.txt	178	Hence specific primer pair encompassing sequences exons 6 7 designed quantify total amount PTPLA transcripts Fig
0.16537316.15829503.html.plaintext.txt	179	In contrast exon 2 either deleted partially skipped aberrant PTPLA transcripts cnm Fig
0.16537316.15829503.html.plaintext.txt	180	Hence specific forward primer designed 25 bp exon 2 fragment specific wt transcripts used combination reverse primer located within exon 4 quantify amount wt transcripts Fig
0.16537316.15829503.html.plaintext.txt	181	View larger version 21K Figure 6
0.16537316.15829503.html.plaintext.txt	182	Quantitative analysis PTPLA expression skeletal muscles affected Labradors
0.16537316.15829503.html.plaintext.txt	183	A The genomic structure SINE containing PTPLAalf allele reminded
0.16537316.15829503.html.plaintext.txt	184	Black arrows indicate location primers used RT PCR amplification wt PTPLAfl PTPLAd5 isoforms wt
0.16537316.15829503.html.plaintext.txt	185	Empty arrows indicate primer pair used RT PCR amplification PTPLA transcripts
0.16537316.15829503.html.plaintext.txt	186	Histograms show normalized proportion PTPLA wt isoforms B PTPLA transcripts C calculated quantitative real time RT PCR experiments using mRNAs skeletal muscles cnm cnm Labradors
0.16537316.15829503.html.plaintext.txt	187	Five healthy cnm controls five affected cnm dogs included analysis
0.16537316.15829503.html.plaintext.txt	188	Amounts PTPLA transcript normalized TATA box binding protein TBP muscular phosphofructo kinase MPFK housekeeping gene transcripts
0.16537316.15829503.html.plaintext.txt	189	Amounts PTPLA transcripts cnm cnm muscles compared histograms summarizing results presented Fig
0.16537316.15829503.html.plaintext.txt	190	PTPLA transcripts detected muscles cnm dogs represented 35 34
0.16537316.15829503.html.plaintext.txt	191	4 amount PTPLA transcripts found muscles cnm dogs
0.16537316.15829503.html.plaintext.txt	192	Furthermore PTPLAfl PTPLAd5 transcripts cnm muscles represented 1 0
0.16537316.15829503.html.plaintext.txt	193	03 PTPLAfl PTPLAd5 transcripts expressed cnm muscles
0.16537316.15829503.html.plaintext.txt	194	Statistical analysis based pair wise fixed reallocation randomization tests 43 confirmed observed differences highly significant P0
0.16537316.15829503.html.plaintext.txt	195	In conclusion PTPLAalf allele transcribed cnm affected muscles rather low efficiency 35 total transcripts compared healthy cnm muscles
0.16537316.15829503.html.plaintext.txt	196	Furthermore transcription mainly led abnormal transcripts either premature stop codons codons encoding truncated protein
0.16537316.15829503.html.plaintext.txt	197	Finally transcription PTPLAalf allele also led normal wt transcripts although low level 1
0.16537316.15829503.html.plaintext.txt	198	DISCUSSION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS SUPPLEMENTARY MATERIAL REFERENCES Labrador retriever centronuclear myopathy perfectly mimics clinical histological features human autosomal dominant recessive forms centronuclear myopathy
0.16537316.15829503.html.plaintext.txt	199	To date neither genetic linkage molecular data available two forms human disease
0.16537316.15829503.html.plaintext.txt	200	To best knowledge canine centronuclear myopathy Labrador retrievers spontaneous animal model disease described far
0.16537316.15829503.html.plaintext.txt	201	We previously mapped canine cnm locus 18
0.16537316.15829503.html.plaintext.txt	202	1 cM interval within centromeric region CFA2
0.16537316.15829503.html.plaintext.txt	203	Here report identification canine gene PTPLA likely plays critical role pathogenesis centronuclear myopathy seen Labrador retrievers
0.16537316.15829503.html.plaintext.txt	204	PTPLA shown expressed early myogenic precursors mouse embryogenesis 32 afterwards adult skeletal muscles mouse 32 human 33
0.16537316.15829503.html.plaintext.txt	205	In experiments PTPLA expressed canine skeletal muscles tested stages birth adulthood data shown
0.16537316.15829503.html.plaintext.txt	206	This temporal expression pattern compatible clinical histological evolution disease affected dogs
0.16537316.15829503.html.plaintext.txt	207	Furthermore observed homozygous tRNA like SINE insertion within PTPLA exon 2 affected dogs
0.16537316.15829503.html.plaintext.txt	208	In human genome Alu elements abundant SINEs numerous Alu insertions genes associated hereditary disorders 36
0.16537316.15829503.html.plaintext.txt	209	Not cases demonstrated directly causative disease lack detectable mutation rarity Alu insertions strongly suggest likely candidate
0.16537316.15829503.html.plaintext.txt	210	In case Labrador retriever centronuclear myopathy two lines reasoning suggest SINE exonic insertion responsible disease
0.16537316.15829503.html.plaintext.txt	211	First SINE insertion identified pedigree Labrador retriever perfectly segregates disease
0.16537316.15829503.html.plaintext.txt	212	We sampled 47 healthy dogs 15 pure mixed breeds failed detect insertion
0.16537316.15829503.html.plaintext.txt	213	In particular SINE insertion found nine healthy French Labrador retrievers unrelated experimental pedigree
0.16537316.15829503.html.plaintext.txt	214	The presence retroposed SINE within PTPLA therefore highly correlated segregation centronuclear myopathy French Labrador retrievers
0.16537316.15829503.html.plaintext.txt	215	Second compellingly show repeat element insertion severely affects splicing corresponding SINE containing PTPLAalf allele
0.16537316.15829503.html.plaintext.txt	216	We provide strong evidence tRNA like SINE responsible cumulative transcriptional abnormalities based four following features SINE properly spliced although low level 1 ii partial exonization SINE iii exon skipping involving several exons iv total amount PTPLA transcripts markedly reduced
0.16537316.15829503.html.plaintext.txt	217	Taken together observations show exonic SINE insertion within PTPLA gene cnm dogs acts hypomorphic mutation
0.16537316.15829503.html.plaintext.txt	218	Existing data ongoing experiments help us confirm SINE insertion within PTPLA causative event leading canine centronuclear myopathy
0.16537316.15829503.html.plaintext.txt	219	First experimental pedigree established two affected Labradors unrelated 11 generations 29
0.16537316.15829503.html.plaintext.txt	220	We found dogs homozygotes insertion within PTPLA exon 2
0.16537316.15829503.html.plaintext.txt	221	Genotyping additional affected Labradors coming Alfort clinics allow us reinforce association SINE insertion cnm
0.16537316.15829503.html.plaintext.txt	222	We also believe close clinical histopathological relationships exist centronuclear myopathy found French Labrador retrievers HMLR identified dogs countries 29
0.16537316.15829503.html.plaintext.txt	223	Although precisely determined yet number generations common ancestors affected Labradors USA France higher affected French dogs
0.16537316.15829503.html.plaintext.txt	224	Amplifying SINE insertion affected Labrador retrievers USA country reinforce SINE insertion causative disease mutation founder effect
0.16537316.15829503.html.plaintext.txt	225	Finally characterization mutations PTPLA similar phenotype either transgenic mice human patients affected autosomal recessive cnm would provide strong evidence PTPLA plays central role etiology centronuclear myopathy
0.16537316.15829503.html.plaintext.txt	226	In human related X linked myotubular myopathy attributed truncating missense mutations MTM1 gene encoding myotubularin 8944
0.16537316.15829503.html.plaintext.txt	227	Classical tissue specific gene targeting inactivation Mtm1 mouse confirmed absence muscular expression Mtm1 affect myogenesis induces lethal degeneration skeletal muscles 4 weeks age 45
0.16537316.15829503.html.plaintext.txt	228	Myotubularin phosphatase dual activity specifically dephosphorylates subpools phosphatidylinositols PIs 10111314
0.16537316.15829503.html.plaintext.txt	229	PIs implicated number physiological processes including cell proliferation death motility cytoskeletal regulation intracellular vesicle trafficking 46
0.16537316.15829503.html.plaintext.txt	230	Ptpla first annotated mouse human basis putative protein tyrosine phosphatase like catalytic site proline replacing arginine consensus HCX26X2R sequence 3233
0.16537316.15829503.html.plaintext.txt	231	PTPLA protein shares sequence homology MTM1 protein family data shown quite surprisingly canine cnm associated histopathological features closely resemble observed human murine XLMTM
0.16537316.15829503.html.plaintext.txt	232	Hence PTPLA protein may involved PI dependent functional signaling pathway MTM1 least skeletal muscle
0.16537316.15829503.html.plaintext.txt	233	This hypothesis addressed testing putative PTPLA phosphatase activity andor investigating functional interactions PTPLA MTM1 proteins analyzing example subcellular localization MTM1 muscles affected Labrador subcellular localization PTPLA muscles Mtm1 mice
0.16537316.15829503.html.plaintext.txt	234	In work presented show SINE insertion detected within PTPLA exon 2 associated various transcriptional features
0.16537316.15829503.html.plaintext.txt	235	First SINE insertion flanked direct duplication insertion site characteristic retroposition mechanism SINEs
0.16537316.15829503.html.plaintext.txt	236	As duplicated sequence contains AGGT tetranucleotide SINE acquired uncommon intron like status 5 splicing donor site GT 3 splicing acceptor site AG allowing proper excision
0.16537316.15829503.html.plaintext.txt	237	Although generates complete normal mature PTPLA transcripts mechanism seems poorly efficient 1 wt PTPLA transcripts detected muscles affected cnm Labradors compared healthy cnm dogs
0.16537316.15829503.html.plaintext.txt	238	Precise elimination SINE observed vivo reproduced ex vivo
0.16537316.15829503.html.plaintext.txt	239	In addition exceptionally fine removal parasitic sequence repeat element insertion deleterious consequences transcription SINE containing PTPLAalf allele
0.16537316.15829503.html.plaintext.txt	240	Indeed provide evidence splicing machinery recognizes cryptic splice sites within SINE exon 2 sequences yields mature elongated transcript containing partially exonized SINE sequence
0.16537316.15829503.html.plaintext.txt	241	Concomitantly exon skipping involving either exon 2 alone combination exons results several PTPLA truncated transcripts
0.16537316.15829503.html.plaintext.txt	242	Again PTPLAalf associated aberrant exon skipping could undoubtedly attributed SINE sequence reproduced ex vivo splicing experiments
0.16537316.15829503.html.plaintext.txt	243	Alu insertions associated diseases 36 394247
0.16537316.15829503.html.plaintext.txt	244	These insertions either associated exonization repeat element sequences specific exon skipping
0.16537316.15829503.html.plaintext.txt	245	Strikingly work presented highlights two mutational mechanisms previously reported independent defects necessarily mutually exclusive
0.16537316.15829503.html.plaintext.txt	246	The systematic dichotomy observed exonization exon skipping mechanisms may depend splicing regulatory elements either contained inserted Alu sequence located genomic vicinity
0.16537316.15829503.html.plaintext.txt	247	Alternatively technical limitations might prevented identification concomittant subtle transcriptional aberrations previously reported studies
0.16537316.15829503.html.plaintext.txt	248	Owing transcriptional defects associated SINE insertion PTPLA tempting speculate repeat element contains splicing regulatory motifs strong enough drive exonization exon skipping
0.16537316.15829503.html.plaintext.txt	249	Furthermore SINE associated exon skipping previously reported refer skipping single exon
0.16537316.15829503.html.plaintext.txt	250	For example Alu insertion exon 22 human BCRA2 gene induces alternative skipping exon may play role development breast cancer 48
0.16537316.15829503.html.plaintext.txt	251	Surprisingly Labradors affected centronuclear myopathy SINE targeted exon 2 also exons 3 4 5 abnormally skipped muscular transcripts
0.16537316.15829503.html.plaintext.txt	252	Introns 2 3 canine PTPLA 183 76 bp length respectively
0.16537316.15829503.html.plaintext.txt	253	We may thus assume SINE hampers spliceosome machinery recognize normal consensus splicing sites modifying spatial conformation transcripts andor specific interaction RNA regulatory proteins
0.16537316.15829503.html.plaintext.txt	254	Abnormal skipping exons 3 4 would thus result closeness SINE
0.16537316.15829503.html.plaintext.txt	255	Finally one PTPLA abnormal transcripts bear disruption reading frame
0.16537316.15829503.html.plaintext.txt	256	Princeps studies yeast human paved way nonsense mediated mRNA decay NMD surveillance mechanism eliminates transcripts containing premature termination codons 4950
0.16537316.15829503.html.plaintext.txt	257	The reduced total amount 35 PTPLA transcripts detected muscles cnm dogs using real time RT PCR analyses could therefore result NMD leading degradation PTPLA abnormal transcripts
0.16537316.15829503.html.plaintext.txt	258	Deleterious effects repeat elements already reported dogs
0.16537316.15829503.html.plaintext.txt	259	For example intronic SINE insertion within Hypocretin receptor 2 Doberman pinschers induces exon skipping leading narcolepsy 51
0.16537316.15829503.html.plaintext.txt	260	To date relatively canine diseases characterized genomic level
0.16537316.15829503.html.plaintext.txt	261	With examples narcolepsy hemophilia centronuclear myopathy diseases associated insertion repeat elements seem well represented
0.16537316.15829503.html.plaintext.txt	262	The low average divergence SINECCf repeats dogs high percentage bimorphic loci respect presence absence SINE insertion 6
0.16537316.15829503.html.plaintext.txt	263	5 dogs different breed indicate expansion SINEs recent still active process 52 Ewen Kirkness personal communication
0.16537316.15829503.html.plaintext.txt	264	The high incidence disease associated insertions dogs may explained recent expansion repeat sequences represent 31 canine genome 52
0.16537316.15829503.html.plaintext.txt	265	By comparison finding 406 gross insertion duplication mutations Human Genetic Mutation Database contains 44 090 characterized human mutations suggests Alu insertions occur lower rate hardly contribute 0
0.16537316.15829503.html.plaintext.txt	266	Besides deleterious consequences gene expression insertions SINEs dogs observed bimorphism may contribute interbreed intrabreed modulation gene expression accompanying physiological phenotypic diversity 52
0.16537316.15829503.html.plaintext.txt	267	The functional effects PTPLA mutation reported present paper disclose rare example single SINE insertion several modifications RNA processing provides molecular basis dynamic evolutionary mechanism gene control mobile elements reviewed 53
0.16537316.15829503.html.plaintext.txt	268	In conclusion work presented shows exonic SINE insertion within PTPLA gene cnm dogs acts hypomorphic mutation recapitulates SINE dependent mutational molecular mechanisms
0.16537316.15829503.html.plaintext.txt	269	These results also illustrate relevance canine model genetic studies
0.16537316.15829503.html.plaintext.txt	270	Indeed major advances development canine genomic genetic resources reported recently soon available integrated 4249 marker FISHRH map 31 ii publication 1
0.16537316.15829503.html.plaintext.txt	271	5x Poodle genome 52 iii partial annotation 7
0.16537316.15829503.html.plaintext.txt	272	6x canine genome assembly identification 500 000 SNPs Kerstin Lindblad Toh personal communication iv 10 000 gene map canine genome help assembly sequence useful comparative mapping Christophe Hitte personal communication
0.16537316.15829503.html.plaintext.txt	273	These resources provide long awaited means mapping genes underlying striking diversity among breeds morphology behavior well canine disease genes
0.16537316.15829503.html.plaintext.txt	274	MATERIALS AND METHODS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS SUPPLEMENTARY MATERIAL REFERENCES mRNA extraction biceps femoris cDNA synthesis Frozen muscular biopsies 150 mg grinded mortar containing liquid nitrogen
0.16537316.15829503.html.plaintext.txt	275	The resulting powder resuspended 1 ml Dynabeads mRNA direct kit lysingbinding buffer DYNAL incubated 55 degrees C proteinase K 2 h
0.16537316.15829503.html.plaintext.txt	276	Crude extracts centrifuged 5000g 5 min polyA mRNA isolation supernatant performed using Dynabeads mRNA direct kit DYNAL
0.16537316.15829503.html.plaintext.txt	277	First strand cDNA generated 200 ng polyA mRNAs using Superscript II reverse transcriptase 200 U Invitrogen anchored oligodT25 1
0.16537316.15829503.html.plaintext.txt	278	6 microM Q Biogen RNase inhibitor 40 U RNaseOUT Invitrogen
0.16537316.15829503.html.plaintext.txt	279	Synthesis cDNA performed 55 degrees C 90 min followed 20 min RNase H treatment 4 U Invitrogen
0.16537316.15829503.html.plaintext.txt	280	Mutation screening PTPLA locus segregation analysis centronuclear myopathic canines Primers designed 5 3 ends PTPLA exons 1 2 used amplify exons healthy carriers cnm affected dogs cnm samples
0.16537316.15829503.html.plaintext.txt	281	PCR RT PCR performed genomic DNA polyA mRNAs respectively using following primer pairs exon1 Ex1F1 5 GACGAGGACGGCACCAAC 3Ex1R1 5 GGTCATGGCATGTTGTAGA 3 exon 2 Ex2F1 5 GCTATTGCCATGGTACGTTTT 3Ex2R1 5 AAGCAAGGCAAATGTTTGGA 3
0.16537316.15829503.html.plaintext.txt	282	Cycling conditions 94 degrees C 2 min 35 cycles 94 degrees C 30 60 degrees C exon 1 50 degrees C exon 2 30 72 degrees C 1 min 72 degrees C 5 min
0.16537316.15829503.html.plaintext.txt	283	After initial detection SINE insertion new primers specific exon 2 Ex2F2 5 GGAAAAAGGAACACACAAAGG 3 exon 3 Ex3R1 5 ACCAATTAAACAGTGGACTAT 3 designed detect SINE insertion following PCR amplification genomic DNA
0.16537316.15829503.html.plaintext.txt	284	PCR conditions 94 degrees C 3 min two cycles 94 degrees C 30 57 degrees C 30 72 degrees C 2 min two cycles 94 degrees C 30 55 degrees C 30 72 degrees C 2 min two cycles 94 degrees C 30 53 degrees C 30 72 degrees C 2 min 29 cycles 94 degrees C 30 50 degrees C 30 72 degrees C 2 min 72 degrees C 5 min
0.16537316.15829503.html.plaintext.txt	285	Cloning sequencing SINE insertion PCR products extracted 1 Seakem GTG agarose TEBU gels using NucleoSpin Extract II Macherey Nagel ligated pCR4 TOPO plasmid Invitrogen following manufacturers recommendations
0.16537316.15829503.html.plaintext.txt	286	Inserts sequenced using T3 T7 primers
0.16537316.15829503.html.plaintext.txt	287	Splicing pattern analysis PTPLAalf allele PTPLA transcripts amplified RT PCR using muscular polyA mRNAs samples cnm cnm cnm dogs template Ex1F2 5 CTACAACATCGCCATGACC 3 Ex7R 5 CACCTCTCCATGAAGCACCT 3 primers
0.16537316.15829503.html.plaintext.txt	288	PCR conditions 94 degrees C 2 min two cycles 94 degrees C 20 62 degrees C 30 72 degrees C 2 min three cycles 94 degrees C 20 60 degrees C 30 72 degrees C 2 min 35 cycles 94 degrees C 20 58 degrees C 30 72 degrees C 2 min 72 degrees C 5 min
0.16537316.15829503.html.plaintext.txt	289	RT PCR products either visualized using standard electrophoresis techniques distinct fragments purified cloned sequenced described earlier
0.16537316.15829503.html.plaintext.txt	290	Ex vivo splicing experiments Primers containing EcoRI NotI restriction sites designed 3 end PTPLA intron 1 Int1F 5 CGGAATTCCGCAGATGCTCAACCACCCAG 3 5 end PTPLA intron 4 Int4R 5 TTGCGGCCGCAACCCTTCCAACTTTTCATTTAGTCTT 3
0.16537316.15829503.html.plaintext.txt	291	They used amplify wt SINE containing cnm genomic inserts
0.16537316.15829503.html.plaintext.txt	292	Amplified fragments checked size ligated pSPL3 vector using standard EcoRINotI double digestion ligation protocol
0.16537316.15829503.html.plaintext.txt	293	The resulting pCOS wt pCOS cnm plasmids transfected COS 7 cells follows cells grown 37 degrees C 8 CO2 DMEM medium Gibco supplemented 10 fetal calf serum D
0.16537316.15829503.html.plaintext.txt	294	Deutscher penicilin 100 Uml Invitrogen streptomycin 100 microgml Invitrogen
0.16537316.15829503.html.plaintext.txt	295	At 80 confluence cells trypsinated centrifuged resuspended final concentration 1x107 cellsml
0.16537316.15829503.html.plaintext.txt	296	Cells incubated ice 10 min 2 microg plasmids electroporation 200 25 microF 1
0.16537316.15829503.html.plaintext.txt	297	4 mm cuvettes using Biorad GenePulser
0.16537316.15829503.html.plaintext.txt	298	Electroporated cells grown using standard cell culture conditions 48 h 37 degrees C 8 CO2
0.16537316.15829503.html.plaintext.txt	299	Total RNA extraction transfected COS 7 cells done using Trizol Reagent Invitrogen according manufacturers recommendation first strand cDNA synthesis performed described earlier
0.16537316.15829503.html.plaintext.txt	300	Amplification performed using SA2 5 ATCTCAGTGGTATTTGTGAGC 3 SD6 5 TCTGAGTCACCTGGACAACC 3 primers
0.16537316.15829503.html.plaintext.txt	301	A 300 fold dilution first PCR used template nested PCR using SA4 5 CACCTGAGGAGTGAATTGGTCG 3 SD2 5 GTGACCTGCACTGTGACAAGC 3 primer pair
0.16537316.15829503.html.plaintext.txt	302	PCR conditions 94 degrees C 2 min 20 cycles 94 degrees C 1 min 60 degrees C first PCR 63 degrees C nested PCR 1 min 72 degrees C 2 min 72 degrees C 5 min
0.16537316.15829503.html.plaintext.txt	303	Real time RT PCR analyses Prior first strand cDNA synthesis genomic DNA removed 200 ng mRNA samples using DNA free kit Ambion
0.16537316.15829503.html.plaintext.txt	304	Three independent cDNA samples skeletal muscle healthy Golden retriever cnm used internal calibrator normalize data independent reactions
0.16537316.15829503.html.plaintext.txt	305	Primer pair sequences MgCl2 final concentrations used presented Supplementary Material Table S1
0.16537316.15829503.html.plaintext.txt	306	Annealing temperature 64 degrees C samples
0.16537316.15829503.html.plaintext.txt	307	Real time PCR reactions performed LightCycler ROCHE using cDNA dilutions specific primers 0
0.16537316.15829503.html.plaintext.txt	308	4 microM LC FastStart DNA Master SYBR Green I kit according manufacturers recommendations
0.16537316.15829503.html.plaintext.txt	309	For sample evaluated crossing points Cp automatically calculated using second derivative maximum method LightCycler Software
0.16537316.15829503.html.plaintext.txt	310	Standard curves primer pair generated using duplicated 4 fold dilution series calibrator sample
0.16537316.15829503.html.plaintext.txt	311	The corresponding PCR efficiencies indicated Supplementary Material Table S1
0.16537316.15829503.html.plaintext.txt	312	Five healthy Labradors cnm five affected Labradors cnm samples tested duplicates
0.16537316.15829503.html.plaintext.txt	313	Each experiment included calibrator based internal controls used normalize calculated Cp value sample Supplementary Material Table S2
0.16537316.15829503.html.plaintext.txt	314	Relative expression analyses efficiency correction performed using REST software described Pfaffl et al
0.16537316.15829503.html.plaintext.txt	315	As TBP MPFK expression levels significantly different healthy carriers cnm affected dogs cnm used references
0.16537316.15829503.html.plaintext.txt	316	Expression ratios calculated target using healthy carriers controls affected dogs samples
0.16537316.15829503.html.plaintext.txt	317	Two thousands randomization tests performed assess statistical significance observed differences transcript amounts control cnm affected dog samples
0.16537316.15829503.html.plaintext.txt	318	Bioinformatics All primers designed using Primer3 software httpfrodo
0.16537316.15829503.html.plaintext.txt	319	educgi binprimer3primer3www
0.16537316.15829503.html.plaintext.txt	320	BLAST searches human genome canine genome assemblies performed NBCI BLAST page httpwww
0.16537316.15829503.html.plaintext.txt	321	Sequence alignments performed using CAP dialign2 softwares freely available Infobiogen services home page httpwww
0.16537316.15829503.html.plaintext.txt	322	Canine TBP MPFK sequences retrieved SRS database httpsrs
0.16537316.15829503.html.plaintext.txt	323	Quantitative expression analysis REST Software downloaded Gene quantification Academic Industrial Information Platform qPCR httpwww
0.16537316.15829503.html.plaintext.txt	324	SUPPLEMENTARY MATERIAL TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS SUPPLEMENTARY MATERIAL REFERENCES Supplementary Material available HMG Online
0.16537316.15829503.html.plaintext.txt	325	ACKNOWLEDGEMENTS We thank Denis Houzelstein UMR 7592 Institut Jacques Monod helpful discussions real time PCR analysis Stephanie Le Bras technical expertise exon trapping experiments members UMR 955 assistance molecular techniques Kelly Rogers Pasteur Institute Ewen Kirkness The Institute Genome Research improving manuscript
0.16537316.15829503.html.plaintext.txt	326	We also thank Jean Laurent Thibaud Nicolas Granger UETM medical expertise Xavier Cauchois Stephanie Le Mevel Ingrid Gruyer Serge Kouame taking care animals
0.16537316.15829503.html.plaintext.txt	327	This work received financial support Association Francaise contre les Myopathies AFM
0.16537316.15829503.html.plaintext.txt	328	REFERENCES TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS SUPPLEMENTARY MATERIAL REFERENCES Karpati G
0.16537316.15829503.html.plaintext.txt	329	1970 Type I muscle fibre atrophy central nuclei
0.16537316.15829503.html.plaintext.txt	330	A rare familial neuromuscular disease
0.16537316.15829503.html.plaintext.txt	331	1995 The myotubular myopathies differential diagnosis X linked recessive autosomal dominant autosomal recessive forms present state DNA studies
0.16537316.15829503.html.plaintext.txt	332	2004 Clinical histologic findings autosomal centronuclear myopathy
0.16537316.15829503.html.plaintext.txt	333	1974 Familial neuromuscular disease myotubes
0.16537316.15829503.html.plaintext.txt	334	1999 Medical complications long term survivors X linked myotubular myopathy
0.16537316.15829503.html.plaintext.txt	335	1995 The myotubular myopathies differential diagnosis X linked recessive autosomal dominant autosomal recessive forms present state DNA studies
0.16537316.15829503.html.plaintext.txt	336	1998 Myotubular myopathy morphological immunohistochemical clinical variation
0.16537316.15829503.html.plaintext.txt	337	1996 X linked myotubular myopathy refinement gene 280 kb region new highly informative microsatellite markers
0.16537316.15829503.html.plaintext.txt	338	1996 A gene mutated X linked myotubular myopathy defines new putative tyrosine phosphatase family conserved yeast
0.16537316.15829503.html.plaintext.txt	339	2003 Characterisation mutations 77 patients X linked myotubular myopathy including family mild phenotype
0.16537316.15829503.html.plaintext.txt	340	2000 Myotubularin phosphatase deficient myotubular myopathy acts phosphatidylinositol 3 kinase phosphatidylinositol 3 phosphate pathway
0.16537316.15829503.html.plaintext.txt	341	2000 Inaugural article myotubularin protein tyrosine phosphatase mutated myotubular myopathy dephosphorylates lipid second messenger phosphatidylinositol 3 phosphate
0.16537316.15829503.html.plaintext.txt	342	2001 The myotubularin family genetic disease phosphoinositide metabolism
0.16537316.15829503.html.plaintext.txt	343	2003 Phosphatidylinositol 5 phosphate activation conserved substrate specificity myotubularin phosphatidylinositol 3 phosphatases
0.16537316.15829503.html.plaintext.txt	344	2004 Production phosphatidylinositol 5 phosphate phosphoinositide 3 phosphatase myotubularin mammalian cells
0.16537316.15829503.html.plaintext.txt	345	2000 Charcot Marie Tooth type 4B caused mutations gene encoding myotubularin related protein 2
0.16537316.15829503.html.plaintext.txt	346	2003 Mutations MTMR13 new pseudophosphatase homologue MTMR2 Sbf1 two families autosomal recessive demyelinating form Charcot Marie Tooth disease associated early onset glaucoma
0.16537316.15829503.html.plaintext.txt	347	2003 Mutation SBF2 gene encoding novel member myotubularin family Charcot Marie Tooth neuropathy type 4B211p15
0.16537316.15829503.html.plaintext.txt	348	2003 Myotubularins large disease associated family cooperating catalytically active inactive phosphoinositides phosphatases
0.16537316.15829503.html.plaintext.txt	349	2001 Characterization adapter subunit phosphatidylinositol 3P 3 phosphatase identification myotubularin related protein lacking catalytic activity
0.16537316.15829503.html.plaintext.txt	350	2002 The myotubularin family novel phosphoinositide regulators
0.16537316.15829503.html.plaintext.txt	351	2003 Regulation myotubularin related MTMR2 phosphatidylinositol phosphatase MTMR5 catalytically inactive phosphatase
0.16537316.15829503.html.plaintext.txt	352	2003 Characterization myotubularin related protein 7 binding partner myotubularin related protein 9
0.16537316.15829503.html.plaintext.txt	353	2003 Identification myotubularin lipid phosphatase catalytic subunit associated 3 phosphatase adapter protein 3 PAP
0.16537316.15829503.html.plaintext.txt	354	1976 A muscle disorder Labrador retrievers characterized deficiency type II muscle fibers
0.16537316.15829503.html.plaintext.txt	355	1986 Hereditary myopathy Labrador retrievers morphologic study
0.16537316.15829503.html.plaintext.txt	356	1988 Myopathy Labrador retriever
0.16537316.15829503.html.plaintext.txt	357	1996 Inherited myopathy litter Labrador retrievers
0.16537316.15829503.html.plaintext.txt	358	2002 Genetic aspects Labrador Retriever myopathy
0.16537316.15829503.html.plaintext.txt	359	2003 The cnm locus canine homologue human autosomal forms centronuclear myopathy maps chromosome 2
0.16537316.15829503.html.plaintext.txt	360	1981 Inheritance neuromuscular disorder Labrador retriever dogs
0.16537316.15829503.html.plaintext.txt	361	2004 An integrated 4249 marker FISHRH map canine genome
0.16537316.15829503.html.plaintext.txt	362	1999 Molecular cloning chromosomal mapping developmental expression novel protein tyrosine phosphatase like gene
0.16537316.15829503.html.plaintext.txt	363	2000 Human protein tyrosine phosphatase like gene expression profile genomic structure mutation analysis families ARVD
0.16537316.15829503.html.plaintext.txt	364	1992 A highly repetitive DNA sequence possibly unique canids
0.16537316.15829503.html.plaintext.txt	365	1998 Recommendations nomenclature system human gene mutations
0.16537316.15829503.html.plaintext.txt	366	CO2 OlinktypeDOI CrossRefISIMedline
0.16537316.15829503.html.plaintext.txt	367	1999 Alu repeats human disease
0.16537316.15829503.html.plaintext.txt	368	2002 Inactivation Fas gene Alu insertion retrotransposition intron causing splicing variation autoimmune lymphoproliferative syndrome
0.16537316.15829503.html.plaintext.txt	369	2003 Exon skipping caused intronic insertion young Alu Yb9 element leads severe hemophilia A
0.16537316.15829503.html.plaintext.txt	370	2003 An Alu mediated rearrangement cause exon skipping Hunter disease
0.16537316.15829503.html.plaintext.txt	371	2002 Alu containing exons alternatively spliced
0.16537316.15829503.html.plaintext.txt	372	1999 Insertion Alu element responsible acute intermittent porphyria
0.16537316.15829503.html.plaintext.txt	373	CO2 PlinktypeDOI CrossRefISIMedline
0.16537316.15829503.html.plaintext.txt	374	2003 De novo insertion Alu sequence coding region CLCN5 gene results Dents disease
0.16537316.15829503.html.plaintext.txt	375	2002 Relative expression software tool REST group wise comparison statistical analysis relative expression results real time PCR
0.16537316.15829503.html.plaintext.txt	376	2000 MTM1 mutations X linked myotubular myopathy
0.16537316.15829503.html.plaintext.txt	377	CO2 RlinktypeDOI CrossRefISIMedline
0.16537316.15829503.html.plaintext.txt	378	2002 The lipid phosphatase myotubularin essential skeletal muscle maintenance myogenesis mice
0.16537316.15829503.html.plaintext.txt	379	2002 Phosphoinositides signal transduction
0.16537316.15829503.html.plaintext.txt	380	1999 De novo alu element insertions FGFR2 identify distinct pathological basis Apert syndrome
0.16537316.15829503.html.plaintext.txt	381	1996 Mutation analysis BRCA2 gene primary breast cancers
0.16537316.15829503.html.plaintext.txt	382	1999 A perfect message RNA surveillance nonsense mediated decay
0.16537316.15829503.html.plaintext.txt	383	2002 Listening silence understanding nonsense exonic mutations affect splicing
0.16537316.15829503.html.plaintext.txt	384	1999 The sleep disorder canine narcolepsy caused mutation hypocretin orexin receptor 2 gene
0.16537316.15829503.html.plaintext.txt	385	2003 The dog genome survey sequencing comparative analysis
0.16537316.15829503.html.plaintext.txt	386	1996 DNA sequence insertion evolutionary variation gene regulation
0.08808324.12130565.html.plaintext.txt	0	Eating Elicited Orexin A But Not Melanin Concentrating Hormone Is Opioid Mediated Deborah J
0.08808324.12130565.html.plaintext.txt	1	Department Psychiatry University Cincinnati Medical Center D
0.08808324.12130565.html.plaintext.txt	2	Cincinnati Ohio 45267 0559 Departments Biomedical Sciences Cell Biology Neurobiology Anatomy University Cincinnati Medical Center E
0.08808324.12130565.html.plaintext.txt	3	Address correspondence requests reprints Deborah J
0.08808324.12130565.html.plaintext.txt	4	Department Psychiatry University Cincinnati Medical Center P
0.08808324.12130565.html.plaintext.txt	5	Box 670559 Cincinnati Ohio 45267 0559
0.08808324.12130565.html.plaintext.txt	6	Abstract Top Abstract Introduction Materials Methods Results Discussion References Melanin concentrating hormone MCH orexin A orexigenic peptidergic neurotransmitters produced primarily lateral hypothalamus
0.08808324.12130565.html.plaintext.txt	7	Because two hypothalamic peptides neuropeptide Y agouti related peptide increase food intake mechanism depends activation opioid receptors assessed whether MCH orexin A also elicits food intake via opioid receptor activation
0.08808324.12130565.html.plaintext.txt	8	3 mgkg ip effect reduced acute orexigenic effect third ventricular i3vt orexin A 3 ngrat
0.08808324.12130565.html.plaintext.txt	9	However dose naloxone effect i3vt MCH 5 micrograt induced hyperphagia
0.08808324.12130565.html.plaintext.txt	10	Because opioid system also linked food selection investigated whether MCH orexin A alters food choice rats simultaneous access two diets differing relative amounts fat carbohydrate
0.08808324.12130565.html.plaintext.txt	11	Whereas i3vt MCH stimulated intake diets alter food choice i3vt orexin A stimulated intake high fat diet
0.08808324.12130565.html.plaintext.txt	12	These data indicate despite several similarities MCH orexin A two lateral hypothalamic area peptides stimulate food intake recruiting different neural circuits exert different effects food choice
0.08808324.12130565.html.plaintext.txt	13	Introduction Top Abstract Introduction Materials Methods Results Discussion References IN MAMMALS neurons located lateral hypothalamic area LHA important controllers feeding behavioral arousal
0.08808324.12130565.html.plaintext.txt	14	Animals lesions LHA exhibit hypophagia increased metabolic rate decreased arousal extreme weight loss 1 2 3 4 5
0.08808324.12130565.html.plaintext.txt	15	They also fail respond appropriate adaptive behavioral physiological responses homeostatic challenges fasting 6
0.08808324.12130565.html.plaintext.txt	16	Because electrical stimulation LHA results vigorous feeding response well see review Ref
0.08808324.12130565.html.plaintext.txt	17	2 LHA historically regarded hypothalamic feeding center considered important integrating site somatic autonomic controls ingestion
0.08808324.12130565.html.plaintext.txt	18	Related functional observations LHA extensive anatomical projections within hypothalamus well throughout entire neuroaxis facilitating coordination metabolic motivational motor autonomic arousal processes important energy homeostasis 6
0.08808324.12130565.html.plaintext.txt	19	Neurons LHA synthesize peptidergic transmitters stimulate feeding behavior specifically melanin concentrating hormone MCH 7 orexins A B also termed hypocretins 8 9
0.08808324.12130565.html.plaintext.txt	20	MCH expressed predominately LHA 10 11 several lines investigation implicate key regulator food intake body weight 7 12 13 14
0.08808324.12130565.html.plaintext.txt	21	First MCH gene expression influenced changes energy balance
0.08808324.12130565.html.plaintext.txt	22	The adipocyte hormone leptin inhibits MCH gene expression food restriction increases MCH gene expression 15
0.08808324.12130565.html.plaintext.txt	23	Second intracerebroventricular administration exogenous MCH stimulates food intake 7 13 14 mice overexpress MCH obese insulin resistant 13
0.08808324.12130565.html.plaintext.txt	24	Finally mice targeted disruption MCH gene reduced food intake body weight accompanied increased metabolic rate resulting little body fat 15
0.08808324.12130565.html.plaintext.txt	25	The orexin hypocretin system 8 9 comprised two peptides termed orexin A orexin B two associated receptors
0.08808324.12130565.html.plaintext.txt	26	Intraventricular administration neutralizing antiorexin antibody suppresses spontaneous feeding fasted rats 16 intraventricular administration orexin A dose dependently stimulates food consumption 9 16 17 18
0.08808324.12130565.html.plaintext.txt	27	Changes feeding administration orexin B inconsistent 9 17 18 stronger case made role orexin A energy homeostasis
0.08808324.12130565.html.plaintext.txt	28	Although orexin MCH expressing neurons made within different neurons LHA 19 20 peptides increase energy intake
0.08808324.12130565.html.plaintext.txt	29	In regard similar agouti related protein AgRP neuropeptide Y NPY peptides made population neurons within arcuate nucleus
0.08808324.12130565.html.plaintext.txt	30	Both NPY AgRP administered exogenously increase food intake 21 22 23 24 25 26
0.08808324.12130565.html.plaintext.txt	31	As axons LHA project medial hypothalamus including arcuate AgRPNPY neurons arcuate project LHA 27 28 29 understanding functional interactions among peptides important
0.08808324.12130565.html.plaintext.txt	32	NPY AgRP induced increases food intake dependent opioid receptor activation action blocked nonspecific opioid receptor antagonist naloxone 30 31
0.08808324.12130565.html.plaintext.txt	33	Activation opioid system turn associated increased intake preferred high fat containing diets 32
0.08808324.12130565.html.plaintext.txt	34	Consistent found AgRP selectively increases intake high fat diet rats simultaneous access two diets differing relative amounts carbohydrate fat 31
0.08808324.12130565.html.plaintext.txt	35	On hand administration NPY reportedly increases consumption high carbohydrate diets 33 34 although attributed stimulation whichever diet individual rat prefers 35 36
0.08808324.12130565.html.plaintext.txt	36	The purpose present experiments determine whether orexigenic action MCH orexin A depends upon activity opioid receptors whether peptides influence diet selection
0.08808324.12130565.html.plaintext.txt	37	Materials Methods Top Abstract Introduction Materials Methods Results Discussion References Animals Male Long Evans rats Harlan Sprague Dawley Indianapolis IN weighing 380 440 g onset experiments individually housed Plexiglas tubs maintained 12 h light 12 h dark cycle temperature controlled American Association Accedidation Laboratory Animal Care accredited vivarium procedures approved internal animal care use committee University Cincinnati
0.08808324.12130565.html.plaintext.txt	38	The rats maintained ad libitum pelleted food tap water unless otherwise noted
0.08808324.12130565.html.plaintext.txt	39	Each rat implanted cannula aimed third cerebral ventricle i3vt
0.08808324.12130565.html.plaintext.txt	40	Coordinates cannula placement midline 2
0.08808324.12130565.html.plaintext.txt	41	2 mm posterior bregma 7
0.08808324.12130565.html.plaintext.txt	42	5 mm ventral dura bregma vertical coordinate 37
0.08808324.12130565.html.plaintext.txt	43	After 10 d recovery accuracy cannula placement verified i3vt infusion 10 ng angiotensin II 1 microl physiological saline
0.08808324.12130565.html.plaintext.txt	44	Only animals drank least 5 ml water within 1 h used experiments
0.08808324.12130565.html.plaintext.txt	45	Drugs AgRP 83 132 orexin A MCH purchased Phoenix Pharmaceuticals Inc
0.08808324.12130565.html.plaintext.txt	46	Naloxone hydrochloride NALX purchased Sigma St
0.08808324.12130565.html.plaintext.txt	47	All substances dissolved physiological saline also served control solution
0.08808324.12130565.html.plaintext.txt	48	AgRP 83 132 orexin A MCH saline administered i3vt 2 microl volume NALX control saline injected ip volume 0
0.08808324.12130565.html.plaintext.txt	49	Diets Animals maintained pelleted rat chow Harlan Teklad Indianapolis IN experiments 1 4
0.08808324.12130565.html.plaintext.txt	50	High fat HF low fat LF pelleted diets prepared Dyets Bethlehem PA used experiments 5 6
0.08808324.12130565.html.plaintext.txt	51	The macronutrient compositions diets given Table 1
0.08808324.12130565.html.plaintext.txt	52	Macronutrient composition low fat high fat regular chow diets kilocalories per gram percentage total kilocalories
0.08808324.12130565.html.plaintext.txt	53	We previously determined 0
0.08808324.12130565.html.plaintext.txt	54	3 mgkg NALX ip effect food intake
0.08808324.12130565.html.plaintext.txt	55	dose subthreshold 31
0.08808324.12130565.html.plaintext.txt	56	However dose administered conjunction i3vt AgRP reliably reduced increase food intake elicited AgRP 31
0.08808324.12130565.html.plaintext.txt	57	Experiment 1 replication experiment confirm 0
0.08808324.12130565.html.plaintext.txt	58	3 mgkg NALX ip fact subthreshold cohort rats reconfirm attenuates AgRP induced overeating
0.08808324.12130565.html.plaintext.txt	59	Rats assigned one four treatment groups n 8 9group matched preexperimental body weight food intake
0.08808324.12130565.html.plaintext.txt	60	On test day food removed 2 h lights
0.08808324.12130565.html.plaintext.txt	61	Thirty minutes lights rats two groups received ip injection 0
0.08808324.12130565.html.plaintext.txt	62	3 mgkg NALX rats two groups received equal volume saline
0.08808324.12130565.html.plaintext.txt	63	Ten minutes later one naloxone one saline group received i3vt injection 1 nmol AgRP2 microl two groups received saline 2 microl
0.08808324.12130565.html.plaintext.txt	64	This dose AgRP elicits reliable long lasting increase food intake 25 26 38
0.08808324.12130565.html.plaintext.txt	65	Five minutes lights food returned cages intake measured 1 2 3 4 24 h
0.08808324.12130565.html.plaintext.txt	66	Water available times
0.08808324.12130565.html.plaintext.txt	67	This experiment paralleled experiment 1 except MCH used instead AgRP
0.08808324.12130565.html.plaintext.txt	68	Body weight matched rats assigned one four treatment groups n 8 9group
0.08808324.12130565.html.plaintext.txt	69	On test day half rats received ip injection 0
0.08808324.12130565.html.plaintext.txt	70	3 mgkg NALX half received saline 10 min later half group received i3vt injection MCH saline 5 microg 2 microl vol saline 2 microl vol
0.08808324.12130565.html.plaintext.txt	71	Because observed MCH effective increasing food intake light dark period 14 experiment 2 repeated animals 10 d later except first injection occurred 7 h light phase
0.08808324.12130565.html.plaintext.txt	72	The animals counterbalanced previous treatment reassigned one four new groups ip NALX saline i3vt MCH saline
0.08808324.12130565.html.plaintext.txt	73	Because orexin A effective increasing food intake light dark period 18 experiment paralleled experiment 2 every way except orexin A 3 ng2 microlrat substituted MCH
0.08808324.12130565.html.plaintext.txt	74	A group rats n 20 adapted two diets HF LF simultaneously available ad libitum separate food hoppers cages 1 month
0.08808324.12130565.html.plaintext.txt	75	They matched average daily food intake body weight assigned one two groups receiving either saline 5 microg MCH i3vt 2 microl injection volume following paradigm described experiment 3
0.08808324.12130565.html.plaintext.txt	76	This experiment paralleled experiment 5 except rats received either saline 3 ng orexin A i3vt 2 microl
0.08808324.12130565.html.plaintext.txt	77	On test day procedure identical described experiment 5 followed
0.08808324.12130565.html.plaintext.txt	78	Intake diet recorded 30 60 90 120 min
0.08808324.12130565.html.plaintext.txt	79	Data analysis The data analyzed parametric statistics repeated measures ANOVA time repeated measure followed Tukey HSD post hoc tests
0.08808324.12130565.html.plaintext.txt	80	Significance set P 0
0.08808324.12130565.html.plaintext.txt	81	Results Top Abstract Introduction Materials Methods Results Discussion References Experiment 1 As depicted Fig
0.08808324.12130565.html.plaintext.txt	82	3 mgkg NALX ip alter food intake
0.08808324.12130565.html.plaintext.txt	83	As others observed i3vt AgRP increased food intake 85 relative saline trend continued 24 h data depicted
0.08808324.12130565.html.plaintext.txt	84	NALX significantly reduced AgRP induced eating beginning first hour
0.08808324.12130565.html.plaintext.txt	85	Two way repeated measures ANOVA yielded reliable interaction drug time F13 12
0.08808324.12130565.html.plaintext.txt	86	Tukey post hoc tests confirmed food intake AgRP plus NALX AgRP plus saline significantly different higher intake saline plus saline saline plus NALX P 0
0.08808324.12130565.html.plaintext.txt	87	The anorectic effect NALX AgRP induced eating gone 4 h data shown
0.08808324.12130565.html.plaintext.txt	88	View larger version 12K Figure 1
0.08808324.12130565.html.plaintext.txt	89	3 mgkg NALX ip saline injected association i3vt injection saline 1 nmol AgRP chow intake 1 h
0.08808324.12130565.html.plaintext.txt	90	Different saline plus saline P 0
0.08808324.12130565.html.plaintext.txt	91	05 different AgRP plus saline P 0
0.08808324.12130565.html.plaintext.txt	92	Experiment 2 MCH 5 microg potently stimulated food intake level 70 greater produced saline dark
0.08808324.12130565.html.plaintext.txt	93	3 mgkg NALX affect food intake
0.08808324.12130565.html.plaintext.txt	94	Further NALX reduce MCH induced eating
0.08808324.12130565.html.plaintext.txt	95	Two way repeated measures ANOVA yielded reliable main effect drug F33 36
0.08808324.12130565.html.plaintext.txt	96	Tukey post hoc tests confirmed food intake MCH plus NALX MCH alone significantly higher saline saline plus NALX P 0
0.08808324.12130565.html.plaintext.txt	97	View larger version 13K Figure 2
0.08808324.12130565.html.plaintext.txt	98	3 mgkg NALX ip saline administered association i3vt injection saline 5 microg MCH chow intake 1 h
0.08808324.12130565.html.plaintext.txt	99	Injections given 30 min onset dark phase
0.08808324.12130565.html.plaintext.txt	100	Different saline plus saline P 0
0.08808324.12130565.html.plaintext.txt	101	Experiment 3 During light period MCH stimulated food intake level 85 greater saline
0.08808324.12130565.html.plaintext.txt	102	As occurred beginning dark phase NALX neither suppressed food intake reduced MCH induced hyperphagia Fig
0.08808324.12130565.html.plaintext.txt	103	Two way repeated measures ANOVA yielded reliable interaction drug time F39 5
0.08808324.12130565.html.plaintext.txt	104	Tukey post hoc tests confirmed food intakes MCH plus NALX MCH alone significantly higher intake saline saline plus NALX P 0
0.08808324.12130565.html.plaintext.txt	105	View larger version 13K Figure 3
0.08808324.12130565.html.plaintext.txt	106	3 mgkg NALX ip saline administered association i3vt injection saline 5 microg MCH chow intake 1 h
0.08808324.12130565.html.plaintext.txt	107	Injections given light phase
0.08808324.12130565.html.plaintext.txt	108	Different saline plus saline P 0
0.08808324.12130565.html.plaintext.txt	109	Experiment 4 Orexin A increased intake 85 relative saline NALX significantly reduced orexin A induced eating second hour P 0
0.08808324.12130565.html.plaintext.txt	110	Two way repeated measures ANOVA yielded reliable interaction drug time F39 4
0.08808324.12130565.html.plaintext.txt	111	Tukey post hoc tests confirmed food intake orexin A plus saline orexin A plus NALX different significantly higher intake saline saline plus NALX P 0
0.08808324.12130565.html.plaintext.txt	112	View larger version 11K Figure 4
0.08808324.12130565.html.plaintext.txt	113	3 mgkg NALX ip saline administered association i3vt injection saline 3 ng orexin A chow intake 1 h
0.08808324.12130565.html.plaintext.txt	114	Injections given light phase
0.08808324.12130565.html.plaintext.txt	115	Different saline plus saline P 0
0.08808324.12130565.html.plaintext.txt	116	05 different orexin A plus saline P 0
0.08808324.12130565.html.plaintext.txt	117	Experiment 5 On day test day animals preferred HF diet LF diet consuming average 84 intake weight HF diet
0.08808324.12130565.html.plaintext.txt	118	5 MCH increased total food intake well total caloric intake manifest significant increase diets
0.08808324.12130565.html.plaintext.txt	119	Hence food intake food choice altered i3vt MCH
0.08808324.12130565.html.plaintext.txt	120	View larger version 13K Figure 5
0.08808324.12130565.html.plaintext.txt	121	Intake HF LF diets 1 h light phase 5 microg MCH i3vt saline
0.08808324.12130565.html.plaintext.txt	122	Experiment 6 On day test day animals preferred HF diet LF diet consuming average 90 HF diet
0.08808324.12130565.html.plaintext.txt	123	6 orexin A stimulated intake HF diet level 176 saline control intake significantly greater extent intake LF diet P 0
0.08808324.12130565.html.plaintext.txt	124	Therefore total caloric intake increased well proportion calories derived HF diet
0.08808324.12130565.html.plaintext.txt	125	View larger version 13K Figure 6
0.08808324.12130565.html.plaintext.txt	126	Intake HF LF diets 1 h light phase 3 ng orexin A i3vt saline
0.08808324.12130565.html.plaintext.txt	127	Discussion Top Abstract Introduction Materials Methods Results Discussion References The current results indicate although subthreshold dose naloxone nonselective opioid antagonist attenuate potent effects AgRP orexin A increase food intake dose alter effect MCH stimulate food intake
0.08808324.12130565.html.plaintext.txt	128	These data consistent hypothesis orexigenic effect orexin A critically depends activation opioid receptors downstream receptor whereas orexigenic action MCH
0.08808324.12130565.html.plaintext.txt	129	The data also indicate although orexin A MCH increase food intake effects food choice quite distinct
0.08808324.12130565.html.plaintext.txt	130	Although orexin A selectively stimulates consumption HF diet MCH stimulates intake diet comparably
0.08808324.12130565.html.plaintext.txt	131	Thus MCH increases caloric intake without altering source calories whereas orexin A alters caloric intake diet selection
0.08808324.12130565.html.plaintext.txt	132	These results consistent hypothesis regard energy homeostasis AgRP orexin A share common underlying mechanism whereas MCH acts different mechanism
0.08808324.12130565.html.plaintext.txt	133	The opioid system long implicated regulation food intake increased opioid activity brain leading increased caloric consumption 30 39 40 41
0.08808324.12130565.html.plaintext.txt	134	In particular opioids modulate incentive value food opioid agonists increasing opioid antagonists decreasing 30 40 42
0.08808324.12130565.html.plaintext.txt	135	Consistent opioids alter relative selection preference specific foods
0.08808324.12130565.html.plaintext.txt	136	ss Endorphin example increases intake preferred HF diet 43 44
0.08808324.12130565.html.plaintext.txt	137	Likewise present experiments orexin A selectively increased consumption preferred HF diet orexin A stimulated intake pelleted chow attenuated prior administration naloxone
0.08808324.12130565.html.plaintext.txt	138	Hence conclude orexin A like AgRP uses opioid mediated circuits orexigenic action
0.08808324.12130565.html.plaintext.txt	139	In contrast comparably orexigenic dose MCH alter diet selection MCH elicited increase pelleted chow influenced naloxone
0.08808324.12130565.html.plaintext.txt	140	We therefore conclude opioid system downstream mediator MCH orexigenic action
0.08808324.12130565.html.plaintext.txt	141	Considerable controversy surrounds contention macronutrient intake selectively regulated different central nervous system systems 45 including opioids 42 46 47
0.08808324.12130565.html.plaintext.txt	142	As example drug treatment given cannot easily ascertained whether increase decrease one particular food choice relative another reflects preference aversion specific macronutrient e
0.08808324.12130565.html.plaintext.txt	143	carbohydrate whether reflects magnified minimized preexisting preference based upon palatability 48
0.08808324.12130565.html.plaintext.txt	144	Regardless actual mechanism critical observation orexin A MCH influence food intake via distinct mechanisms dissociated use opioid antagonists andor considering food selection
0.08808324.12130565.html.plaintext.txt	145	Because AgRP orexigenic action also reduced naloxone AgRP selectively increases intake preferred HF diet 31 conclude orexin A AgRP act common mechanism
0.08808324.12130565.html.plaintext.txt	146	Recent data laboratory 49 50 others 51 indicate orexigenic dose AgRP increases Fos activity LHA dual label immunohistochemistry indicates increased activity orexin A producing neurons
0.08808324.12130565.html.plaintext.txt	147	Importantly AgRP increase Fos activity MCH producing neurons 50 51
0.08808324.12130565.html.plaintext.txt	148	Hence functional anatomical data consistent pharmacological behavioral data
0.08808324.12130565.html.plaintext.txt	149	AgRP endogenous antagonist melanocortin 3 4 receptors 27 found LHA well projection sites NPYAgRP neurons arcuate nucleus 20 29
0.08808324.12130565.html.plaintext.txt	150	The present data allow determination whether AgRP stimulates orexin A neurons turn stimulate food intake acting via opioid receptors
0.08808324.12130565.html.plaintext.txt	151	Additionally data determine whether pathway orexin A AgRP opioid circuits whether relay sites involved integrate information AgRP orexin A inputs
0.08808324.12130565.html.plaintext.txt	152	Added facts AgRP neurons arcuate cosynthesize NPY NPY elicited food intake also naloxone dependent
0.08808324.12130565.html.plaintext.txt	153	Hence NPY AgRP orexin A appear share common circuit point
0.08808324.12130565.html.plaintext.txt	154	Over last several years number identified peptides involved control food intake energy balance grown enormously
0.08808324.12130565.html.plaintext.txt	155	Much growth fueled application sophisticated molecular biological approaches pressing clinical need treat exponential growth obesity
0.08808324.12130565.html.plaintext.txt	156	To develop appropriate therapeutic strategies however alphabet soup peptides transmitters need organized functional circuits
0.08808324.12130565.html.plaintext.txt	157	The identification functional circuits depend intensive efforts delineate neuroanatomical relationship among systems well functional interactions
0.08808324.12130565.html.plaintext.txt	158	The present results demonstrate two peptides located within single hypothalamic subarea peptides appear regulated similarly energy balance stimulate food intake act via distinct behavioral neural mechanisms
0.08808324.12130565.html.plaintext.txt	159	Such results point complexity homeostatic system designed much regulate intake rat ad libitum access single caloric source
0.08808324.12130565.html.plaintext.txt	160	Rather existence two LHA subsystems influence food intake different ways emphasizes system great flexibility respond myriad environmental physiological challenges
0.08808324.12130565.html.plaintext.txt	161	Footnotes This work supported NIH Grants DK 17844 DK 56863 DK 54080 American Diabetes Association Physician Scientist Training Award E
0.08808324.12130565.html.plaintext.txt	162	The Obesity Research Center University Cincinnati supported part Procter Gamble Co
0.08808324.12130565.html.plaintext.txt	163	Abbreviations AgRP Agouti related peptide HF high fat i3vt administered third ventricular LF low fat LHA lateral hypothalamic area MCH melanin concentrating hormone NALX naloxone hydrochloride NPY neuropeptide Y
0.08808324.12130565.html.plaintext.txt	164	Accepted publication April 23 2002
0.08808324.12130565.html.plaintext.txt	165	References Top Abstract Introduction Materials Methods Results Discussion References Anand BK Brobeck JR 1951 Hypothalamic control food intake rats cats
0.08808324.12130565.html.plaintext.txt	166	Yale J Biol Med 24123 140 Smith OAJ 1961 Food intake hypothalamic stimulation
0.08808324.12130565.html.plaintext.txt	167	Electrical stimulation brain
0.08808324.12130565.html.plaintext.txt	168	Austin University Texas Press 367 370 Teitelbaum P Epstein AN 1962 The lateral hypothalamic syndrome recovery feeding drinking hypothalamic lesions
0.08808324.12130565.html.plaintext.txt	169	Psychol Rev 6974 90 Teitelbaum P Cheng MF Rozin P 1969 Stages recovery development lateral hypothalamic control food water intake
0.08808324.12130565.html.plaintext.txt	170	Ann NY Acad Sci 157849 860Medline Teitelbaum P Stellar E 1954 Recovery failure eat produced hypothalamic lesions
0.08808324.12130565.html.plaintext.txt	171	Science 120894 895 Bernardis LL Bellinger LL 1996 The lateral hypothalamic area revisited ingestive behavior
0.08808324.12130565.html.plaintext.txt	172	Neurosci Biobehav Rev 20189 287CrossRefMedline Qu D Ludwig DS Gammeltoft S Piper M Pelleymounter MA Cullen MJ Mathes WF Przypek R Kanarek R Maratos Flier E 1996 A role melanin concentrating hormone central regulation feeding behaviour
0.08808324.12130565.html.plaintext.txt	173	Nature 380243 247CrossRefMedline de Lecea L Kilduff TS Peyron C Gao X Foye PE Danielson PE Fukuhara C Battenberg EL Gautvik VT Bartlett FS Frankel WN van den Pol AN Bloom FE Gautvik KM Sutcliffe JG 1998 The hypocretins hypothalamus specific peptides neuroexcitatory activity
0.08808324.12130565.html.plaintext.txt	174	Proc Natl Acad Sci USA 95322 327AbstractFree Full Text Sakurai T Amemiya A Ishii M Matsuzaki I Chemelli RM Tanaka H Williams SC Richardson JA Kozlowski GP Wilson S Arch JR Buckingham RE Haynes AC Carr SA Annan RS McNulty DE Liu WS Terrett JA Elshourbagy NA Bergsma DJ Yanagisawa M 1998 Orexins orexin receptors family hypothalamic neuropeptides G protein coupled receptors regulate feeding behavior
0.08808324.12130565.html.plaintext.txt	175	Cell 92573 585Medline Bittencourt JC Presse F Arias C Peto C Vaughan J Nahon JL Vale W Sawchenko PE 1992 The melanin concentrating hormone system rat brain immuno hybridization histochemical characterization
0.08808324.12130565.html.plaintext.txt	176	J Comp Neurol 319218 245Medline Skofitsch G Jacobowitz DM 1985 Immunohistochemical mapping galanin like neurons rat central nervous system
0.08808324.12130565.html.plaintext.txt	177	Peptides 6509 546CrossRefMedline Tritos NA Maratos Flier E 1999 Two important systems energy homeostasis melanocortins melanin concentrating hormone
0.08808324.12130565.html.plaintext.txt	178	Neuropeptides 33339 349CrossRefMedline Ludwig D Mountjoy K Tatro J Gillette J Frederich R Flier J Maratos Flier E 1998 Melanin concentrating hormone functional melanocortin antagonist hypothalamus
0.08808324.12130565.html.plaintext.txt	179	Am J Physiol 274E627 E633 Rossi M Choi SJ O Shea D Miyoshi T Ghatei MA Bloom SR 1997 Melanin concentrating hormone acutely stimulates feeding chronic administration effect body weight
0.08808324.12130565.html.plaintext.txt	180	Endocrinology 138351 355AbstractFree Full Text Shimada M Tritos N Lowell B Flier J Maratos Flier E 1998 Mice lacking melanin concentrating hormone hypophagic lean
0.08808324.12130565.html.plaintext.txt	181	Nature 396670 674CrossRefMedline Yamanaka A Kunii K Nambu T Tsujino N Sakai A Matsuzaki I Miwa Y Goto K Sakurai T 2000 Orexin induced food intake involves neuropeptide Y pathway
0.08808324.12130565.html.plaintext.txt	182	Brain Res 859404 409CrossRefMedline Edwards CM Abusnana S Sunter D Murphy KG Ghatei MA Bloom SR 1999 The effect orexins food intake comparison neuropeptide Y melanin concentrating hormone galanin
0.08808324.12130565.html.plaintext.txt	183	J Endocrinol 160R7 R12 Haynes AC Jackson B Overend P Buckingham RE Wilson S Tadayyon M Arch JR 1999 Effects single chronic intracerebroventricular administration orexins feeding rat
0.08808324.12130565.html.plaintext.txt	184	Peptides 201099 1105CrossRefMedline Broberger C De Lecea L Sutcliffe JG Hokfelt T 1998 Hypocretinorexin melanin concentrating hormone expressing cells form distinct populations rodent lateral hypothalamus relationship neuropeptide Y agouti gene related protein systems
0.08808324.12130565.html.plaintext.txt	185	CO2 R 3943 Stanley BG 1993 Neuropeptide Y multiple hypothalamic sites controls eating behavior endocrine autonomic systems energy balance
0.08808324.12130565.html.plaintext.txt	186	In Colmers WF Wahlestedt C eds
0.08808324.12130565.html.plaintext.txt	187	The biology neuropeptide Y related peptides
0.08808324.12130565.html.plaintext.txt	188	Totowa Humana Press 457 509 Clark JT Kalra PS Crowley WR Kalra SP 1984 Neuropeptide Y human pancreatic polypeptide stimulate feeding behavior rats
0.08808324.12130565.html.plaintext.txt	189	Endocrinology 115427 429Abstract Billington CJ Briggs JE Grace M Levine AS 1991 Effects intracerebroventricular injection neuropeptide Y energy metabolism
0.08808324.12130565.html.plaintext.txt	190	Am J Physiol 260R321 R327 Rossi M Kim M Morgan D Small C Edwards C Sunter D Abusnana S Goldstone A Russell S Stanley S Smith D Yagaloff K Ghatei M Bloom S 1998 A C terminal fragment agouti related protein increases feeding antagonizes effect melanocyte stimulating hormone vivo
0.08808324.12130565.html.plaintext.txt	191	Endocrinology 1394428 4431AbstractFree Full Text Hagan MM Rushing PA Pritchard LM Schwartz MW Strack AM Van der Ploeg HT Woods SC Seeley RJ 2000 Long term orexigenic effects AgRP 83 132 involve mechanisms melanocortin receptor blockade
0.08808324.12130565.html.plaintext.txt	192	Am J Physiol 279R47 R52 Ollmann M Wilson B Yang Y Kerns J Chen Y Gantz I Barsh G 1997 Antagonism central melanocortin receptors vitro vivo agouti related protein
0.08808324.12130565.html.plaintext.txt	193	Science 278135 138AbstractFree Full Text Hahn TM Breininger JF Baskin DG Schwartz MW 1998 Coexpression Agrp NPY fasting activated hypothalamic neurons
0.08808324.12130565.html.plaintext.txt	194	Nat Neurosci 1271 272CrossRefMedline Cowley MA Pronchuk N Fan W Dinulescu DM Colmers WF Cone RD 1999 Integration NPY AGRP melanocortin signals hypothalamic paraventricular nucleus evidence cellular basis adipostat
0.08808324.12130565.html.plaintext.txt	195	Neuron 24155 163Medline Kotz CM Grace MK Briggs J Levine AS Billington CJ 1995 Effects opioid antagonists naloxone naltrexone neuropeptide Y induced feeding brown fat thermogenesis rat
0.08808324.12130565.html.plaintext.txt	196	J Clin Invest 96163 170Medline Hagan MM Rushing PA Benoit SC Woods SC Seeley RJ 2001 Opioid receptor involvement effect AgRP 83 132 food intake food selection
0.08808324.12130565.html.plaintext.txt	197	Am J Physiol 280R814 R821 Zhang M Gosnell BA Kelley AE 1998 Intake high fat food selectively enhanced mu opioid receptor stimulation within nucleus accumbens
0.08808324.12130565.html.plaintext.txt	198	J Pharmacol Exp Ther 285908 914AbstractFree Full Text Wang J Akabayashi A Dourmashkin J Yu HJ Alexander JT Chae HJ Leibowitz SF 1998 Neuropeptide Y relation carbohydrate intake corticosterone dietary obesity
0.08808324.12130565.html.plaintext.txt	199	Brain Res 80275 88CrossRefMedline Stanley BG Daniel DR Chin AS Leibowitz SF 1985 Paraventricular nucleus injections peptide YY neuropeptide Y preferentially enhance carbohydrate ingestion
0.08808324.12130565.html.plaintext.txt	200	Peptides 61205 1211CrossRefMedline Morley JE Levine AS Gosnell BA Kneip J Grace M 1987 Effect neuropeptide Y ingestive behaviors rat
0.08808324.12130565.html.plaintext.txt	201	Am J Physiol 252R599 R609 Brown CM Coscina DV Fletcher PJ 2000 The rewarding properties neuropeptide Y perifornical hypothalamus versus nucleus accumbens
0.08808324.12130565.html.plaintext.txt	202	Peptides 211279 1287CrossRefMedline Chavez M Kaiyala K Madden LJ Schwartz MW Woods SC 1995 Intraventricular insulin level maintained body weight rats
0.08808324.12130565.html.plaintext.txt	203	Behav Neurosci 109528 531CrossRefMedline Wirth MM Giraudo SQ 2001 Effect agouti related protein delivered dorsomedial nucleus hypothalamus intake preferred versus non preferred diet
0.08808324.12130565.html.plaintext.txt	204	Brain Res 897169 174CrossRefMedline Rudski JM Grace M Kuskowski MA Billington CJ Levine AS 1996 Behavioral effects naloxone neuropeptide Y induced feeding
0.08808324.12130565.html.plaintext.txt	205	Pharmacol Biochem Behav 54771 777CrossRefMedline Kotz CM Billington CJ Levine AS 1997 Opioids nucleus solitary tract involved feeding rat
0.08808324.12130565.html.plaintext.txt	206	Am J Physiol 272R1028 R1032 Levine AS Grace M Billington CJ 1990 The effect centrally administered naloxone deprivation drug induced feeding
0.08808324.12130565.html.plaintext.txt	207	Pharmacol Biochem Behav 36409 412CrossRefMedline Glass MJ Billington CJ Levine AS 1999 Opioids food intake distributed functional neuronal pathways Neuropeptides 33360 368CrossRefMedline Silva RM Hadjimarkou MM Rossi GC Pasternak GW Bodnar RJ 2001 ss Endorphin induced feeding pharmacological characterization using selective opioid antagonists antisense probes rats
0.08808324.12130565.html.plaintext.txt	208	J Pharmacol Exp Ther 297590 596AbstractFree Full Text McKay LD Kenney NJ Edens NK Williams RH Woods SC 1981 Intracerebroventricular ss endorphin increases food intake rats
0.08808324.12130565.html.plaintext.txt	209	Life Sci 291429 1434CrossRefMedline Seeley RJ Berthoud HR 2000 Neural control macronutrient selection consensus controversy
0.08808324.12130565.html.plaintext.txt	210	In Neural metabolic control macronutrient selection
0.08808324.12130565.html.plaintext.txt	211	Boca Raton FL CRC Press 489 496 Islam AK Bodnar RJ 1990 Selective opioid receptor antagonist effects upon intake high fat diet rats
0.08808324.12130565.html.plaintext.txt	212	Brain Res 508293 296CrossRefMedline Ookuma K Barton C York DA Bray GA 1997 Effect enterostatin opioids macronutrient selection consumption
0.08808324.12130565.html.plaintext.txt	213	Peptides 18785 791CrossRefMedline Glass MJ Billington CJ Levine AS 2000 Opioids food reward macronutrient selection
0.08808324.12130565.html.plaintext.txt	214	In Berthoud HR Seeley RJ eds
0.08808324.12130565.html.plaintext.txt	215	Neural metabolic control macronutrient intake
0.08808324.12130565.html.plaintext.txt	216	Danvers CRC Press vol 1407 423 Hagan MM Benoit SC Rushing PA Pritchard LM Woods SC Seeley RJ 2001 Immediate prolonged patterns agouti related peptide 83 132 induced c Fos activation hypothalamic extrahypothalamic sites
0.08808324.12130565.html.plaintext.txt	217	Endocrinology 1421050 1056AbstractFree Full Text Jackman A Reed JA Clegg DJ Woods SC Seeley RJ Interactions melanin concentrating hormone MCH c fos agouti related protein AgRP administration
0.08808324.12130565.html.plaintext.txt	218	Society Study Ingestive Behaviors Philadelphia PA 2001 p 60 Abstract Zheng H Corkern MM Crousillac SM Patterson LM Phifer CB Berthoud HR 2002 Neurochemical phenotype hypothalamic neurons showing Fos expression 23 h intracranial AgRP
0.08808324.12130565.html.plaintext.txt	219	Am J Physiol Regul Integr Comp Physiol 282R1773 R1781
0.09531622.15591134.html.plaintext.txt	0	Expression Class II Major Histocompatibility Complex Molecules Thyrocytes Does Not Cause Spontaneous Thyroiditis Mildly Increases Its Severity Immunization Hiroaki Kimura Miho Kimura Shey Cherng Tzou Yen Chun Chen Koichi Suzuki Noel R
0.09531622.15591134.html.plaintext.txt	1	The Johns Hopkins Medical Institutions Baltimore Maryland 21205 Department Microbiology K
0.09531622.15591134.html.plaintext.txt	2	Leprosy Research Center National Institute Infectious Diseases Tokyo 189 0002 Japan
0.09531622.15591134.html.plaintext.txt	3	Address correspondence requests reprints Patrizio Caturegli M
0.09531622.15591134.html.plaintext.txt	4	Johns Hopkins Medical Institutions Department Pathology Ross Building Room 656 720 Rutland Avenue Baltimore Maryland 21205
0.09531622.15591134.html.plaintext.txt	5	Abstract Top Abstract Introduction Materials Methods Results Discussion References Class II major histocompatibility complex MHC molecules classically expressed antigen presenting cells hematopoietic lineage also described epithelial cells association autoimmunity
0.09531622.15591134.html.plaintext.txt	6	In context however remains debatable whether class II MHC molecules initiating event rather consequence autoimmune attack
0.09531622.15591134.html.plaintext.txt	7	In addition role epithelial class II expression autoimmune attack begun unknown
0.09531622.15591134.html.plaintext.txt	8	We generated transgenic mice expressing thyroid follicular cells class II transactivator master regulator genes class II MHC pathway
0.09531622.15591134.html.plaintext.txt	9	The study used cohort 245 CBAJ mice 127 wild type 118 transgenic basal conditions n 63 different time points immunization mouse thyroglobulin n 182
0.09531622.15591134.html.plaintext.txt	10	In basal conditions transgenic mice similar wild type controls develop spontaneous autoimmune thyroiditis despite aberrant expression class II MHC molecules thyrocytes
0.09531622.15591134.html.plaintext.txt	11	After immunization thyroiditis 8 severe transgenics controls 95 confidence interval 1
0.09531622.15591134.html.plaintext.txt	12	033 especially florid stages disease
0.09531622.15591134.html.plaintext.txt	13	These findings suggest expression class II MHC molecules epithelial cells sufficient initiate autoimmunity mildly modulates already established autoimmune attack target organ
0.09531622.15591134.html.plaintext.txt	14	Introduction Top Abstract Introduction Materials Methods Results Discussion References AUTOIMMUNE DISEASES OF thyroid gland represented Graves disease Hashimoto thyroiditis collectively referred autoimmune thyroiditis common autoimmune diseases 1 excellent model organ specific autoimmunity 2
0.09531622.15591134.html.plaintext.txt	15	They chronic conditions initiated loss immunological tolerance thyroid restricted self antigens TSH receptor thyroperoxidase thyroglobulin loss leads thyroid dysfunction via immune mediated inflammation ultimately clinical phenotype
0.09531622.15591134.html.plaintext.txt	16	The loss tolerance considered result combined effect environmental factors iodine gene variants
0.09531622.15591134.html.plaintext.txt	17	For example individuals A G polymorphism noncoding 3 region cytotoxic T lymphocyte antigen 4 gene 2
0.09531622.15591134.html.plaintext.txt	18	45 fold increased risk developing Graves disease Hashimoto thyroiditis respectively 3
0.09531622.15591134.html.plaintext.txt	19	The first described potent genetic influence known affect susceptibility autoimmune thyroiditis however major histocompatibility complex MHC
0.09531622.15591134.html.plaintext.txt	20	The association MHC autoimmunity originally reported 1971 first patients systemic lupus erythematosus 4 mice experimental autoimmune thyroiditis 5
0.09531622.15591134.html.plaintext.txt	21	The MHC located short arm human chromosome 6 spanning 3
0.09531622.15591134.html.plaintext.txt	22	6 megabases complete annotated DNA sequence 6
0.09531622.15591134.html.plaintext.txt	23	Its main functions guide intracellular processing antigens display antigenic peptides plasma membrane recognition T lymphocytes 7
0.09531622.15591134.html.plaintext.txt	24	It gene dense region genome containing 224 loci 96 pseudogenes 128 expressed genes grouped three classes
0.09531622.15591134.html.plaintext.txt	25	Class II MHC genes constitutively expressed hematopoietic cells involved antigen presentation dendritic cells macrophages B lymphocytes cortical thymic epithelial cells induced inflammatory stimuli many cell types endothelial cells hepatocytes ss cells pancreas thyrocytes
0.09531622.15591134.html.plaintext.txt	26	Little known biological significance observation although implicated allograft rejection 8 subsequently autoimmunity
0.09531622.15591134.html.plaintext.txt	27	In field Bottazzo Feldman hypothesized class II MHC molecules aberrantly expressed epithelial cells confer antigen presenting functions favoring initiation autoimmune diseases 9 10
0.09531622.15591134.html.plaintext.txt	28	The MHC also region associated greatest number human diseases ranging narcolepsy 11 primary immunodeficiencies 12 autoimmune conditions 13 14
0.09531622.15591134.html.plaintext.txt	29	The strength association classically measured relative risks RR odds ratios varies low RR 2
0.09531622.15591134.html.plaintext.txt	30	5 myasthenia gravis person carrying DR3 allele 15 medium RR 30 DQ8 type 1 diabetes 16 high RR 109 A29 birdshot retinochoroidopathy 17
0.09531622.15591134.html.plaintext.txt	31	For Graves disease MHC DR3 association mild RRs ranging 1
0.09531622.15591134.html.plaintext.txt	32	For Hashimoto thyroiditis contribution MHC haplotypes disease less definitive although may play role familial clustering thyroiditis diabetes 19
0.09531622.15591134.html.plaintext.txt	33	Given biological plausibility replication findings strength many associations MHC molecules considered causal pathway leads autoimmune disease
0.09531622.15591134.html.plaintext.txt	34	There however important factors could confound described association
0.09531622.15591134.html.plaintext.txt	35	First MHC loci found together frequencies much higher would expected random combination frequencies population
0.09531622.15591134.html.plaintext.txt	36	It thus possible genes causing disease MHC genes per se rather genes travel MHC
0.09531622.15591134.html.plaintext.txt	37	For example polymorphisms LMP2 LMP7 genes embedded within class II region associated ankylosing spondylitis 20
0.09531622.15591134.html.plaintext.txt	38	In addition allele associated particular disease also common normal unaffected population actually majority patients susceptible allele develop autoimmune disease
0.09531622.15591134.html.plaintext.txt	39	Finally unknown whether initiate autoimmunity MHC molecules expressed professional antigen presenting cells within secondary lymphoid organs rather nonhematopoietic cells target organ thyroid follicular cell case autoimmune thyroiditis
0.09531622.15591134.html.plaintext.txt	40	To investigate whether MHC class II molecules expressed thyrocytes play causal role autoimmune thyroiditis developed transgenic mice express specifically thyroid gland MHC class II transactivator CIITA master regulator MHC class II pathway 21 22
0.09531622.15591134.html.plaintext.txt	41	In experimental model temporal relationship exposure
0.09531622.15591134.html.plaintext.txt	42	expression class II MHC molecules thyrocytes disease
0.09531622.15591134.html.plaintext.txt	43	autoimmune thyroiditis clear defined ab initio
0.09531622.15591134.html.plaintext.txt	44	Materials Methods Top Abstract Introduction Materials Methods Results Discussion References Construction screening thyr CIITA transgenic mice The thyr CIITA transgene made joining rat thyroglobulin promoter rat CIITA type IV cDNA jellyfish green fluorescent protein GFP part human GH gene source introns polyadenylation signal Fig
0.09531622.15591134.html.plaintext.txt	45	GFP linked bicistronically CIITA using internal ribosomal entry site IRES allow easier detection transgene expression
0.09531622.15591134.html.plaintext.txt	46	5 kb transgene excised ClaI SacII digestion purified electroelution resuspended 10 ng microl 10 mM Tris0
0.09531622.15591134.html.plaintext.txt	47	The transgene injected fertilized eggs CBA x C57BL6 F1 females maintained hemizygous mating wild type CBAJ mice Jackson Laboratory Bar Harbor ME
0.09531622.15591134.html.plaintext.txt	48	View larger version 53K FIG
0.09531622.15591134.html.plaintext.txt	49	Construction screening thyr CIITA transgenic mice
0.09531622.15591134.html.plaintext.txt	50	The rat thyroglobulin promoter rat type IV CIITA internal ribosomal entry site IRES jellyfish GFP part human GH source splice donor acceptor sequences indicated rectangles different shades
0.09531622.15591134.html.plaintext.txt	51	Primers used screening indicated arrows
0.09531622.15591134.html.plaintext.txt	52	B PCR screening using primers CIITA region top GFP region bottom positive plasmid control lane 1 100 bp DNA marker lane 2 water control lane 3 wild type littermate lane 4 line C line D thyr CIITA transgenic lanes 5 6
0.09531622.15591134.html.plaintext.txt	53	C Southern blot screening HindIII DNA marker lane 1 positive plasmid control lane 2 wild type littermate lane 3 line C CIITA transgenic lane 4 line D CIITA transgenic lane 5
0.09531622.15591134.html.plaintext.txt	54	Founders identified Southern hybridization
0.09531622.15591134.html.plaintext.txt	55	Eight micrograms tail genomic DNA digested BamHI separated overnight electrophoresis transferred onto Hybond N membranes Amersham Piscataway NJ
0.09531622.15591134.html.plaintext.txt	56	A 305 bp DNA fragment GFP gene used generate 32P labeled probe using random priming labeling kit InVitrogen Carlsbad CA
0.09531622.15591134.html.plaintext.txt	57	Hybridization carried overnight 60 C 0
0.09531622.15591134.html.plaintext.txt	58	2 supplemented 7 SDS 5 dextran sulfate containing 1
0.09531622.15591134.html.plaintext.txt	59	5 x 106 trichloroacetic acid precipitable counts per minute probe per milliliter hybridization buffer
0.09531622.15591134.html.plaintext.txt	60	Blots washed twice 2x standard saline citrate SSC 1x SSC 0
0.09531622.15591134.html.plaintext.txt	61	015 M sodium citrate washed 30 min 42 C 2x SSC0
0.09531622.15591134.html.plaintext.txt	62	1 SDS 30 min room temperature 0
0.09531622.15591134.html.plaintext.txt	63	Blots wrapped plastic exposed overnight 70 C BioMax MS autoradiographic films Eastman Kodak Rochester NY
0.09531622.15591134.html.plaintext.txt	64	After establishment transgenic lines mice screened PCR tail genomic DNA using one primer pair CIITA region one GFP region
0.09531622.15591134.html.plaintext.txt	65	The primer sequences follows CIITA forward primer 5 GTCAAGTGTTCTTGAACAGTAG 3 CIITA reverse primer 5 AGTATGGCCTTGCAGGTAAG 3 GFP forward primer 5 TGAACCGCATCGAGCTGAAG 3 GFP reverse primer 5 TCCAGCAGGACCATGTGATC 3
0.09531622.15591134.html.plaintext.txt	66	PCR products fractionated electrophoresis 1
0.09531622.15591134.html.plaintext.txt	67	Mice contained CIITA amplicon 451 bp GFP amplicon 305 bp labeled transgenic
0.09531622.15591134.html.plaintext.txt	68	Analysis thyr CIITA transgene expression Thyroid specific expression CIITA assessed fluorescent microscopy detect GFP RT PCR immunohistochemistry detect MCH class II
0.09531622.15591134.html.plaintext.txt	69	GFP expression measured freezing thyroids cutting 10 microm sections microtome observing directly green fluorescence Zeiss UV microscope
0.09531622.15591134.html.plaintext.txt	70	Messenger RNA extracted thyroid lobes using oligodT magnetic beads Dynal Lake Success NY treated RNase free DNase I Invitrogen reverse transcribed Superscript II Invitrogen cDNA
0.09531622.15591134.html.plaintext.txt	71	cDNA amplified PCR forward 5 GACATTGAGGCCGACCACGTAG 3 reverse 5 ATTGGTAGCTGGGGTGGAATTTG 3 primers I A locus mouse H 2 complex
0.09531622.15591134.html.plaintext.txt	72	Primers glyceraldehyde 3 phosphate dehydrogenase forward 5 GCATCTTGGGCTACACTGAG 3 reverse 5 TCTCTTGCTCAGTGTCCTTG 3 used adjust amount loading
0.09531622.15591134.html.plaintext.txt	73	Immunohistochemistry performed zinc fixed paraffin embedded thyroid specimens
0.09531622.15591134.html.plaintext.txt	74	Five micrometer sections cut mounted onto SuperFrost plus slides Fisher Scientific Pittsburgh PA deparaffinized rehydrated
0.09531622.15591134.html.plaintext.txt	75	After blocking antibody nonspecific binding 1 h 2 normal goat serum sections incubated overnight humid chamber 4 C biotin conjugated monoclonal antibody recognizing I Ak clone 10 3
0.09531622.15591134.html.plaintext.txt	76	6 PharMingen San Diego CA
0.09531622.15591134.html.plaintext.txt	77	Sections washed PBS incubated 3 hydrogen peroxide 5 min block endogenous peroxidase peroxidase conjugated streptavidin Dako Carpinteria CA 30 min humid chamber
0.09531622.15591134.html.plaintext.txt	78	Reactions visualized addition diaminobenzidine substrate Sigma Chemical Co
0.09531622.15591134.html.plaintext.txt	79	Finally sections rinsed distilled water counterstained Mayer hematoxylin Polyscientific Bay Shore NY washed running tap water dehydrated increasing concentrations ethanol mounted Cytoseal Richard Allan Scientific Kalamazoo MI
0.09531622.15591134.html.plaintext.txt	80	Induction experimental autoimmune thyroiditis evaluation thyroid pathology The study population included total 245 mice CBAJ background 127 wild type 81 females 46 males 118 thyr CIITA transgenic 51 females 67 males
0.09531622.15591134.html.plaintext.txt	81	Sixty three mice 30 wild type 33 transgenic analyzed different time points 2 18 months age basal conditions without immunization d 0 Table 1
0.09531622.15591134.html.plaintext.txt	82	The remaining 182 mice 97 wild type 85 transgenic immunized twice d 0 7 via sc injection gel purified murine thyroglobulin 75 microg emulsified complete Freund adjuvant contains 5 mgml Mycobacterium tuberculosis strain H37 Ra Difco Laboratories Detroit MI
0.09531622.15591134.html.plaintext.txt	83	Mice killed different time points immunization indicated Table 1
0.09531622.15591134.html.plaintext.txt	84	After euthanasia tracheas attached thyroids removed fixed 2 3 d zinc based Beckstead solution 23
0.09531622.15591134.html.plaintext.txt	85	After processing embedding paraffin six eight nonsequential sections cut specimen stained hematoxylin eosin
0.09531622.15591134.html.plaintext.txt	86	The section greatest surface area selected digital imaging performed described 2
0.09531622.15591134.html.plaintext.txt	87	Briefly acquisition images SPOT RT video camera mounted Zeiss Axioplot microscope images analyzed Carnoy software
0.09531622.15591134.html.plaintext.txt	88	The area corresponding entire thyroid gland marked measured used denominator b
0.09531622.15591134.html.plaintext.txt	89	The areas mononuclear cell infiltration marked summed used numerator
0.09531622.15591134.html.plaintext.txt	90	The thyroid histopathology score expressed percentage total thyroid area infiltrated mononuclear cells ab x 100
0.09531622.15591134.html.plaintext.txt	91	All experimental protocols conformed Johns Hopkins Animal Care Use Committee guidelines
0.09531622.15591134.html.plaintext.txt	92	Distribution mouse numbers wild type thyr CIITA transgenic mice according day killing immunization mouse thyroglobulin
0.09531622.15591134.html.plaintext.txt	93	Measurement mouse thyroglobulin specific IgG antibodies Mice bled retroorbital venous plexus beginning immunization 10 14 21 28 35 70 100 d first immunization
0.09531622.15591134.html.plaintext.txt	94	Sera diluted PBS 1100 1400 incubated overnight Immulon2 ELISA plates Dynex Technologies Chantilly VA precoated mouse thyroglobulin 100 ngwell
0.09531622.15591134.html.plaintext.txt	95	After proper washing mouse thyroglobulin specific IgG subclasses detected using secondary antibodies IgG1 IgG2a IgG2b conjugated alkaline phosphatase
0.09531622.15591134.html.plaintext.txt	96	The color change p nitrophenol phosphate measured 405 nm using Emax microplate reader Molecular Devices Sunnyvale CA
0.09531622.15591134.html.plaintext.txt	97	Each plate included homemade standard curve derived serial dilutions pool serum known mouse thyroglobulin antibodies
0.09531622.15591134.html.plaintext.txt	98	The standard curve allowed us express results arbitrary units rather absorbance thus adjusting intra interassay variability
0.09531622.15591134.html.plaintext.txt	99	Flow cytometry analysis draining cervical lymph nodes Cervical lymph nodes isolated mechanically disrupted prepare single cell suspension
0.09531622.15591134.html.plaintext.txt	100	After 15 min Fc block 4 C lymphoid cells stained 30 min 4 C following monoclonal antibodies PharMingen San Diego CA fluorescein isothiocyanate conjugated anti B220 anti CD69 anti CD8 phycoerythrin conjugated anti CD19 anti CD44 cy chrome conjugated anti CD4 anti CD3
0.09531622.15591134.html.plaintext.txt	101	Data collected FACScalibur cytometer Becton Dickinson San Diego CA gated first forward side scatter CD4 compensated displayed using CellQuest software Becton Dickinson
0.09531622.15591134.html.plaintext.txt	102	Assessment thyroid function total T4 TSH levels Total T4 level measured commercial competitive RIA GammaCoat 125IT4 Diasorin Stillwater MN
0.09531622.15591134.html.plaintext.txt	103	Mouse TSH measured highly sensitive double antibody RIA developed A
0.09531622.15591134.html.plaintext.txt	104	Briefly assay employs highly purified rat TSH AFP11542B iodinated ligand selected guinea pig antimouse TSH AFP98991 primary antibody partially purified extract mouse pituitary containing TSH AFP5171
0.09531622.15591134.html.plaintext.txt	105	8MP reference preparation
0.09531622.15591134.html.plaintext.txt	106	Cross reactivity either highly purified mouse FSH mouse LH mouse TSH RIA less 1
0.09531622.15591134.html.plaintext.txt	107	Statistical analysis Statistical analysis performed two phases
0.09531622.15591134.html.plaintext.txt	108	The first phase analyzed cross sectionally whether mean severity thyroid lesions thyroid histopathology score differed wild type thyr CIITA transgenic mice
0.09531622.15591134.html.plaintext.txt	109	The crude unadjusted effect covariate genotype outcome thyroid histopathology score calculated simple linear regression ignoring effect covariates
0.09531622.15591134.html.plaintext.txt	110	Then net adjusted effect genotype thyroid histopathology score holding covariates fixed calculated multiple linear regression
0.09531622.15591134.html.plaintext.txt	111	The covariates relating thyroid histopathology score considered inclusion model addition genotype sex transgenic line day killing first immunization total T4 d 0 TSH d 0 thyroglobulin specific antibodies d 0
0.09531622.15591134.html.plaintext.txt	112	Day killing immunization treated dummy variable d 0 chosen reference category
0.09531622.15591134.html.plaintext.txt	113	Using stepwise backward selection removed sex total T4 d 0 TSH d 0 thyroglobulin specific antibodies d 0 based P values greater 0
0.09531622.15591134.html.plaintext.txt	114	The final multiple linear regression model therefore included genotype transgenic line day killing covariates used estimate mean thyroid histopathology score
0.09531622.15591134.html.plaintext.txt	115	Analysis residuals fitting regression model indicated nonnormality heteroscedasticity
0.09531622.15591134.html.plaintext.txt	116	We thus used bootstrapping 2000 replications estimate SE around regression coefficient perform valid hypothesis testing regression analysis nonnormal thyroid histopathology scores
0.09531622.15591134.html.plaintext.txt	117	We also analyzed cumulative incidence thyroiditis transgenic controls labeling thyroiditis cases mice thyroid histopathology score greater 2
0.09531622.15591134.html.plaintext.txt	118	RRs time point immunization expressed ratio incidence thyroiditis transgenic incidence wild type mice
0.09531622.15591134.html.plaintext.txt	119	Confidence intervals around RRs calculated logarithmic scale results exponentiated
0.09531622.15591134.html.plaintext.txt	120	Fisher exact test used test null hypothesis RRs equal 1
0.09531622.15591134.html.plaintext.txt	121	The second phase used multiple linear regression generalized estimating equations GEE 25 analyze longitudinally thyroid function assessed total T4 TSH thyroglobulin antibodies evolved immunization thyr CIITA transgenic controls
0.09531622.15591134.html.plaintext.txt	122	GEE allows analysis multiple values T4 TSH mouse corrects fact characteristics single animal time likely correlated one another
0.09531622.15591134.html.plaintext.txt	123	In GEE analyses repeated measures participant clustered
0.09531622.15591134.html.plaintext.txt	124	Furthermore GEE analysis takes account status changing value covariates time point
0.09531622.15591134.html.plaintext.txt	125	The outcomes used GEE analysis total T4 TSH IgG1 IgG2a IgG2b thyroglobulin specific antibodies covariates addition genotype sex transgenic line day killing
0.09531622.15591134.html.plaintext.txt	126	Statistical analyses performed using Stata 8 Stata Corp
0.09531622.15591134.html.plaintext.txt	127	Results Top Abstract Introduction Materials Methods Results Discussion References Transgene expression baseline phenotype The CIITA transgene expressed control rat thyroglobulin promoter 26 shown support transcription specifically thyroid follicular cells
0.09531622.15591134.html.plaintext.txt	128	Four 76 injected mice transgene integrated genome passed progeny
0.09531622.15591134.html.plaintext.txt	129	Two four founders named thyr CIITA transgenic lines C D Fig
0.09531622.15591134.html.plaintext.txt	130	1C maintained hemizygous expanded mating normal CBAJ mice form cohort described present study
0.09531622.15591134.html.plaintext.txt	131	Specific expression transgene thyroid gland assessed fluorescent microscopy showed characteristic green positivity GFP specifically within thyroid follicular cells Fig
0.09531622.15591134.html.plaintext.txt	132	RT PCR revealed aberrant expression class II MHC transcripts thyrocytes thyr CIITA transgenic thyrocytes wild type littermates Fig
0.09531622.15591134.html.plaintext.txt	133	Immunohistochemistry confirmed protein level expression class II MHC molecules transgenic thyrocytes Fig
0.09531622.15591134.html.plaintext.txt	134	2D wild type thyrocytes Fig
0.09531622.15591134.html.plaintext.txt	135	View larger version 120K FIG
0.09531622.15591134.html.plaintext.txt	136	Thyroid expression function thyr CIITA transgene
0.09531622.15591134.html.plaintext.txt	137	A Frozen section thyr CIITA transgenic thyroid observed UV microscope direct green fluorescence x25 magnification 1 min exposure
0.09531622.15591134.html.plaintext.txt	138	The inset represents background autofluorescence wild type thyroid x25 magnification 5 min exposure
0.09531622.15591134.html.plaintext.txt	139	B Specific expression MHC class II I Ak mRNA transgenic thyroids assessed RT PCR
0.09531622.15591134.html.plaintext.txt	140	C Control gel expression common housekeeping gene glyceraldehyde 3 phosphate dehydrogenase
0.09531622.15591134.html.plaintext.txt	141	In B C gels minus sign indicates RT reaction performed absence reverse transcriptase control possible genomic DNA contamination RNA samples
0.09531622.15591134.html.plaintext.txt	142	Lane 1 100 bp DNA marker lane 2 water control lanes 3 4 wild type littermate lanes 5 6 line C thyr CIITA transgenic lanes 7 8 line D thyr CIITA transgenic
0.09531622.15591134.html.plaintext.txt	143	D Specific expression MHC class II I Ak protein transgenic thyroids assessed immunohistochemistry
0.09531622.15591134.html.plaintext.txt	144	Note diffuse cytosolic plasma membrane brown staining epithelial cells lining thyroid follicles thyr CIITA transgenics
0.09531622.15591134.html.plaintext.txt	145	Nuclei negative colored blue hematoxylin counterstain
0.09531622.15591134.html.plaintext.txt	146	E Wild type control shown comparison
0.09531622.15591134.html.plaintext.txt	147	Thyr CIITA transgenic mice developed normally normal litter size life span T4 levels 4
0.09531622.15591134.html.plaintext.txt	148	15 microgdl plus minus 1
0.09531622.15591134.html.plaintext.txt	149	None 63 mice 30 wild type 33 transgenic analyzed histologically d 0 showed signs thyroid pathology Fig
0.09531622.15591134.html.plaintext.txt	150	3A developed antibodies mouse thyroglobulin Fig
0.09531622.15591134.html.plaintext.txt	151	Thus basal conditions thyr CIITA transgenic mice despite ectopic expression MHC class II molecules thyrocytes different wild type littermates develop spontaneous autoimmune thyroiditis
0.09531622.15591134.html.plaintext.txt	152	View larger version 85K FIG
0.09531622.15591134.html.plaintext.txt	153	Thyroid histopathology different time points immunization mouse thyroglobulin
0.09531622.15591134.html.plaintext.txt	154	A D Thyroids CIITA transgenic mice d 0 A 10 B 14 C 21 D E F d 35 thyroids wild type E CIITA transgenic F G H thyroids CIITA transgenic mice d 70 G 100 H
0.09531622.15591134.html.plaintext.txt	155	View larger version 16K FIG
0.09531622.15591134.html.plaintext.txt	156	Time series thyroglobulin specific antibodies immunization
0.09531622.15591134.html.plaintext.txt	157	A IgG2a isotype B IgG2b C IgG1
0.09531622.15591134.html.plaintext.txt	158	There difference antibody levels wild type transgenics therefore data represent pooled mean plus minus SE genotypes
0.09531622.15591134.html.plaintext.txt	159	The numbers graph represent mice analyzed time point
0.09531622.15591134.html.plaintext.txt	160	Thyroid histopathology immunization mouse thyroglobulin We immunized 182 mice 97 wild type 85 transgenic mouse thyroglobulin assessed severity thyroid lesions thyroid histopathology score different time points thereafter
0.09531622.15591134.html.plaintext.txt	161	In groups mice thyroid lesions already present although minimal 12 total thyroid area d 10 post immunization Fig
0.09531622.15591134.html.plaintext.txt	162	They increased 65 d 14 reached peak 90 d 21 Figs
0.09531622.15591134.html.plaintext.txt	163	In wild type mice thyroid histopathology score decreased approximately 45 remained around value d 100 Fig
0.09531622.15591134.html.plaintext.txt	164	In thyr CIITA transgenic instead score remained higher became significantly higher controls d 35
0.09531622.15591134.html.plaintext.txt	165	Simple linear regression assessing crude effect genotype score revealed transgenic mice tended severe disease average score 5 higher seen wild type although difference marked P 0
0.09531622.15591134.html.plaintext.txt	166	Multiple linear regression showed holding transgenic line day killing constant thyr CIITA transgenic mice average thyroid histopathology score 8 higher seen wild type 95 confidence interval 1
0.09531622.15591134.html.plaintext.txt	167	Overall results indicate thyr CIITA transgenics developed thyroiditis moderately severe wild type controls
0.09531622.15591134.html.plaintext.txt	168	The pronounced separation transgenic wild type seen d 35 Figs
0.09531622.15591134.html.plaintext.txt	169	3 E F 5B transgenics average thyroid histopathology score 80 compared wild type score 55 P 0
0.09531622.15591134.html.plaintext.txt	170	In groups mice scores observed d 14 28 35 70 100 significantly higher observed d 0 10 Figs
0.09531622.15591134.html.plaintext.txt	171	0001 comparing d 14 28 35 70 100 d 10 0
0.09531622.15591134.html.plaintext.txt	172	View larger version 22K FIG
0.09531622.15591134.html.plaintext.txt	173	A Distribution mean scores thyr CIITA transgenic wild type littermates d 0 several time points immunization B individual scores thyr CIITA transgenic wild type littermates d 35 immunization
0.09531622.15591134.html.plaintext.txt	174	In addition severity also incidence thyroiditis tended greater thyr CIITA transgenic mice although time point difference reach statistical significance Table 2
0.09531622.15591134.html.plaintext.txt	175	Incidence experimental autoimmune thyroiditis wild type thyr CIITA transgenic mice immunization mouse thyroglobulin
0.09531622.15591134.html.plaintext.txt	176	Antibody response thyroglobulin immunization mouse thyroglobulin Longitudinal data regression analysis demonstrated IgG1 IgG2b isotypes specific mouse thyroglobulin followed similar pattern reached similar levels thyr CIITA transgenic controls
0.09531622.15591134.html.plaintext.txt	177	They began increase d 14 post immunization became significantly higher d 21 reached peak d 28 P 0
0.09531622.15591134.html.plaintext.txt	178	IgG1 IgG2b gradually decreased d 35 70 100 still remaining significantly higher d 0
0.09531622.15591134.html.plaintext.txt	179	The IgG2a isotype attained higher levels IgG1 IgG2b isotypes showed different trend
0.09531622.15591134.html.plaintext.txt	180	It also reached peak d 21 continued stay high d 70
0.09531622.15591134.html.plaintext.txt	181	No significant difference observed d 21 28 35 70 although mean value looked higher d 70 Fig
0.09531622.15591134.html.plaintext.txt	182	IgG2a levels decreased d 100 still remaining significantly higher d 0 P 0
0.09531622.15591134.html.plaintext.txt	183	IgG2a levels differ thyr CIITA transgenic controls
0.09531622.15591134.html.plaintext.txt	184	Lymphocyte activation draining cervical lymph nodes immunization mouse thyroglobulin It shown experimental models type 1 diabetes mellitus activation islet specific CD4 T cells precedes onset diabetes occurs draining pancreatic lymph nodes within islets 27
0.09531622.15591134.html.plaintext.txt	185	These observations also confirmed primate experimental allergic encephalomyelitis human multiple sclerosis 28
0.09531622.15591134.html.plaintext.txt	186	We therefore looked CD4 T cell activation markers increased expression CD69 CD44 diminished display CD62L cervical lymph nodes draining thyroid gland
0.09531622.15591134.html.plaintext.txt	187	Before immunization mouse thyroglobulin d 0 activated CD4 T cells Fig
0.09531622.15591134.html.plaintext.txt	188	6A thyr CIITA transgenic wild type littermates
0.09531622.15591134.html.plaintext.txt	189	At d 35 immunization significant increase d 0 P 0
0.09531622.15591134.html.plaintext.txt	190	001 percentage activated CD4 T cells Fig
0.09531622.15591134.html.plaintext.txt	191	6B difference however transgenic wild type
0.09531622.15591134.html.plaintext.txt	192	View larger version 25K FIG
0.09531622.15591134.html.plaintext.txt	193	Flow cytometry analysis draining cervical lymph nodes markers T cell activation
0.09531622.15591134.html.plaintext.txt	194	Expression CD69 CD44 gated CD4 T cells A 35 d B immunization mouse thyroglobulin
0.09531622.15591134.html.plaintext.txt	195	Four six lymph nodes collected mouse pooled analysis performed 11 thyr CIITA transgenic mice seven wild type controls
0.09531622.15591134.html.plaintext.txt	196	Thyroid function immunization mouse thyroglobulin Longitudinal regression analysis showed total T4 significantly decreased average 4
0.09531622.15591134.html.plaintext.txt	197	1 microgdl d 0 average 2
0.09531622.15591134.html.plaintext.txt	198	T4 remained significantly low d 35 difference among d 14 21 28 35 increased normal levels d 70 P 0
0.09531622.15591134.html.plaintext.txt	199	Holding covariates constant transgenic line sex days killing thyroglobulin specific antibodies difference thyr CIITA transgenic wild type total T4 levels
0.09531622.15591134.html.plaintext.txt	200	Total T4 poor predictor thyroid histopathology score P 0
0.09531622.15591134.html.plaintext.txt	201	842 multiple linear regression analysis
0.09531622.15591134.html.plaintext.txt	202	The decrease total T4 d 14 present rise TSH suggesting decrease represents recovery phase euthyroid sick syndrome induced immunization procedure
0.09531622.15591134.html.plaintext.txt	203	View larger version 19K FIG
0.09531622.15591134.html.plaintext.txt	204	Total T4 levels A TSH levels B CIITA transgenic wild type littermates several time points immunization mouse thyroglobulin
0.09531622.15591134.html.plaintext.txt	205	Dotted lines indicate normal reference range CBAJ mice 5th 95th percentile
0.09531622.15591134.html.plaintext.txt	206	99 microgdl T4 63 182 Uml TSH
0.09531622.15591134.html.plaintext.txt	207	TSH began increase 21 d immunization became significantly higher d 0 d 35 P 0
0.09531622.15591134.html.plaintext.txt	208	031 returned normal levels d 100 Fig
0.09531622.15591134.html.plaintext.txt	209	Holding covariates constant thyr CIITA transgenic tended higher TSH levels although difference reach statistical significance P 0
0.09531622.15591134.html.plaintext.txt	210	Similarly observed thyroid pathology greatest distinction wild type thyr CIITA transgenic observed d 35 post immunization Fig
0.09531622.15591134.html.plaintext.txt	211	Among humoral predictors measured study total T4 TSH IgG1 IgG2a IgG2b thyroglobulin antibodies TSH best predictor thyroid histopathology score
0.09531622.15591134.html.plaintext.txt	212	Multiple linear regression showed every 100 U increase serum TSH score increased 6
0.09531622.15591134.html.plaintext.txt	213	Discussion Top Abstract Introduction Materials Methods Results Discussion References MHC molecules undoubtedly associated autoimmune diseases 13
0.09531622.15591134.html.plaintext.txt	214	In cases ankylosing spondylitis 29 birdshot retinochoroidopathy 30 strength association high
0.09531622.15591134.html.plaintext.txt	215	RRs around 100 little doubt causative role MHC molecules pathway leading autoimmunity
0.09531622.15591134.html.plaintext.txt	216	Trowsdale case argued particular MHC allele necessary sufficient cause autoimmune disease 31
0.09531622.15591134.html.plaintext.txt	217	Also unknown importance location whether MHC molecules play causal role expressed secondary lymphoid organs rather parenchymal cells organ targeted autoimmune attack 32
0.09531622.15591134.html.plaintext.txt	218	We focused class II MHC molecules used experimental autoimmune thyroiditis classical model organ specific autoimmunity
0.09531622.15591134.html.plaintext.txt	219	Class II molecules primarily expressed antigen presenting cells hematopoietic lineage also induced endothelial epithelial cells
0.09531622.15591134.html.plaintext.txt	220	This observation raised question whether nonhematopoietic parenchymal cells function antigen presenting cells whether required damage target organ
0.09531622.15591134.html.plaintext.txt	221	Much work comes transplantation field generated conflicting results
0.09531622.15591134.html.plaintext.txt	222	33 found mice lacking secondary lymphoid organs spleen lymph nodes mucosa associated lymphoid tissues incapable rejecting either skin allografts primarily vascularized cardiac allografts suggesting secondary lymphoid organs required initiating immune response
0.09531622.15591134.html.plaintext.txt	223	34 using model graft vs
0.09531622.15591134.html.plaintext.txt	224	host disease bone marrow chimeras expressing MHC molecules antigen presenting cells epithelial endothelial cells found graft capable inducing epithelial damage target organs skin gut liver host expressed MHC molecules host antigen presenting cells host target epithelium
0.09531622.15591134.html.plaintext.txt	225	These studies consistent recent direct visual evidence immune response indicating naive T cells constantly roam secondary lymphoid organs encounter antigen presenting cells taken antigen target organs brought lymphoid organs 35 36 37 38
0.09531622.15591134.html.plaintext.txt	226	These studies also consistent notion naive T cells possess receptors necessary homing secondary lymphoid organs rather nonlymphoid organs notion nonprofessional antigen presenting cells usually lack costimulatory molecules required complete T cell activation
0.09531622.15591134.html.plaintext.txt	227	On side however Kreisel et al
0.09531622.15591134.html.plaintext.txt	228	39 showed naive CD8 T cells indeed activated vitro vivo nonprofessional antigen presenting cells likely endothelial cells lead prompt rejection cardiac allograft suggesting endothelial expression MHC molecules direct pathogenic immune responses independently expression MHC molecules professional antigen presenting cells
0.09531622.15591134.html.plaintext.txt	229	We expressed via transgenesis transcriptional regulator CIITA specifically nonprofessional antigen presenting cell thyrocyte
0.09531622.15591134.html.plaintext.txt	230	CIITA transcription factor defective causes severe primary immunodeficiency called bare lymphocyte syndrome 22 entirely attributable absence class II MHC expression
0.09531622.15591134.html.plaintext.txt	231	CIITA true coactivator bind directly DNA mediates function class II MHC promoter interaction proteins 40
0.09531622.15591134.html.plaintext.txt	232	It considered master regulator necessary sufficient expression genes MHC class II pathway 21 although recently shown control genes outside MHC 41
0.09531622.15591134.html.plaintext.txt	233	CIITA three different isoforms synthesized different cell specific promoters 42 promoter 1 used dendritic cells promoter 3 B lymphocytes promoter 4 nonhematopoietic cells
0.09531622.15591134.html.plaintext.txt	234	We previously shown vitro promoter 4 mediates interferon induced transcription CIITA thyrocytes 43 thus used type 4 isoform CIITA present study
0.09531622.15591134.html.plaintext.txt	235	Under basal conditions CIITA transgenic mice differ wild type littermates
0.09531622.15591134.html.plaintext.txt	236	They develop spontaneously autoimmune thyroiditis despite aberrant expression class II MHC molecules thyrocytes
0.09531622.15591134.html.plaintext.txt	237	These findings agreement recent report Li et al
0.09531622.15591134.html.plaintext.txt	238	44 shows thyroidal expression class II molecules driven TSH receptor promoter lead apparent thyroid autoimmunity
0.09531622.15591134.html.plaintext.txt	239	The phenomenon seem limited thyroid gland
0.09531622.15591134.html.plaintext.txt	240	45 expressed CIITA fact specifically central nervous system using promoter glial fibrillary protein Herkel et al
0.09531622.15591134.html.plaintext.txt	241	46 expressed liver using C reactive protein promoter
0.09531622.15591134.html.plaintext.txt	242	In cases despite aberrant expression class II MHC molecules astrocytes hepatocytes mice develop spontaneous autoimmunity
0.09531622.15591134.html.plaintext.txt	243	Taken together observations strongly suggest expression class II MHC molecules nonprofessional antigen presenting cells sufficient initiate autoimmune disease
0.09531622.15591134.html.plaintext.txt	244	We postulate expression likely results inflammatory stimuli interferon lipopolysaccharide released immune cells infiltrate target organ rather initiating event recruits immune cells target organ
0.09531622.15591134.html.plaintext.txt	245	In addition basal conditions also interested analyzing role class II molecules thyrocytes autoimmune response
0.09531622.15591134.html.plaintext.txt	246	Upon immunization thyr CIITA transgenic mice developed thyroiditis moderately severe greater incidence observed wild type littermates
0.09531622.15591134.html.plaintext.txt	247	The difference severity although higher transgenics time points became significantly higher d 35 immunization
0.09531622.15591134.html.plaintext.txt	248	These results suggest thyrocytes expressing class II MHC molecules play secondary role initiation phase serve better targets facilitate greater immunopathology process already begun
0.09531622.15591134.html.plaintext.txt	249	Lack significant difference thyroiditis severity earlier time points d 10 28 explained fact immunization protocol used effective inducing thyroid lesions majority mice incidence comprised 86 95 wild type 100 transgenic
0.09531622.15591134.html.plaintext.txt	250	The notion class II MHC molecules epithelial cells modulatory role autoimmune attack begun intriguing may possible relevance Hashimoto thyroiditis Graves disease 47
0.09531622.15591134.html.plaintext.txt	251	In diseases fact collectively referred autoimmune thyroiditis expression class II molecules may indicate particularly severe stage disease
0.09531622.15591134.html.plaintext.txt	252	This question difficult assess humans use mouse model essential allows us analyze disease period time rather single time point
0.09531622.15591134.html.plaintext.txt	253	The greater severity thyroid lesions displayed thyr CIITA transgenic result greater number function activated T cells considering CD4 T cells cervical lymph nodes expressed similar levels activation markers wild type transgenics
0.09531622.15591134.html.plaintext.txt	254	The difference likely explained fact thyrocytes expressing class II MHC molecules better recognized autoreactive CD4 T cells T cells already expanded
0.09531622.15591134.html.plaintext.txt	255	In words thyrocytes may serve endogenous immunogens potentiate expand reactivity T cells initially selected thyroglobulin immunization protocol
0.09531622.15591134.html.plaintext.txt	256	It well established T cell activation requires formation specialized cell cell junction antigen presenting cell called immunological synapse facilitates outcome immune recognition 48
0.09531622.15591134.html.plaintext.txt	257	The center synapse occupied T cell receptorCD3 complexes CD4 coreceptors T cell side MHCpeptide complexes antigen presenting side
0.09531622.15591134.html.plaintext.txt	258	Also center costimulatory molecules CD28 CD40 ligand T cells B7 CD40 antigen presenting cells
0.09531622.15591134.html.plaintext.txt	259	The periphery synapse instead occupied integrins lymphocyte function associated antigen 1 CD2 T cells intercellular adhesion molecule 1 CD58 antigen presenting cells
0.09531622.15591134.html.plaintext.txt	260	To function efficiently antigen presenting cell thyrocytes aberrantly express MHC class II molecules also express costimulatory molecules integrins
0.09531622.15591134.html.plaintext.txt	261	Thyrocytes patients Graves disease Hashimoto thyroiditis shown express integrins intercellular adhesion molecule 1 CD58 49 50 costimulator CD40 51 52
0.09531622.15591134.html.plaintext.txt	262	The expression thyrocytes B7 probably potent costimulator less firmly established although reported Hashimoto thyroiditis 53 differentiated thyroid tumors 54
0.09531622.15591134.html.plaintext.txt	263	B7 costimulation could also supplied trans professional antigen presenting cells parenchymal cells 55
0.09531622.15591134.html.plaintext.txt	264	Thus theory thyrocytes aberrantly expressing class II MHC molecules possess signal transduction circuitry necessary full T cell activation although unknown whether individual components associate supramolecular activation complex
0.09531622.15591134.html.plaintext.txt	265	Here show expression thyrocytes class II MHC insufficient initiate autoimmune thyroiditis
0.09531622.15591134.html.plaintext.txt	266	These results emphasize importance location initiation immune response location likely requires interaction autoreactive T cell antigen presenting cells within secondary lymphoid organs
0.09531622.15591134.html.plaintext.txt	267	In conclusion study reports expression class II MHC molecules epithelial thyroid cells required initiation autoimmune attack thyroid
0.09531622.15591134.html.plaintext.txt	268	The initiation seems mainly mediated professional antigen presenting cells secondary lymphoid organs
0.09531622.15591134.html.plaintext.txt	269	Once immune recognition begun however aberrant expression class II nonprofessional antigen presenting cells facilitate disease progression yields severe disease
0.09531622.15591134.html.plaintext.txt	270	Additional studies required fully explain intriguing association MHC molecules autoimmune diseases
0.09531622.15591134.html.plaintext.txt	271	Acknowledgments We grateful Drs
0.09531622.15591134.html.plaintext.txt	272	Baldwin James Tonascia critical revisions manuscript
0.09531622.15591134.html.plaintext.txt	273	Footnotes This work supported National Institutes Health Grant DK55670 P
0.09531622.15591134.html.plaintext.txt	274	First Published Online December 9 2004
0.09531622.15591134.html.plaintext.txt	275	Abbreviations CIITA Class II transactivator GEE generalized estimating equations GFP green fluorescent protein MHC major histocompatibility complex RR relative risk
0.09531622.15591134.html.plaintext.txt	276	Accepted publication December 2 2004
0.09531622.15591134.html.plaintext.txt	277	References Top Abstract Introduction Materials Methods Results Discussion References Jacobson DL Gange SJ Rose N Graham NMH 1997 Epidemiology estimated population burden selected autoimmune diseases United States
0.09531622.15591134.html.plaintext.txt	278	Clin Immunol Immunopathol 84223 243CrossRefMedline Caturegli P Rose NR Kimura M Kimura H Tzou SC 2003 Studies murine thyroiditis new insights organ flow cytometry
0.09531622.15591134.html.plaintext.txt	279	Thyroid 13419 426CrossRefMedline Ueda H Howson JM Esposito L Heward J Snook H Chamberlain G Rainbow DB Hunter KM Smith AN Di Genova G Herr MH Dahlman I Payne F Smyth D Lowe C Twells RC Howlett S Healy B Nutland S Rance HE Everett V Smink LJ Lam AC Cordell HJ Walker NM et al
0.09531622.15591134.html.plaintext.txt	280	2003 Association T cell regulatory gene CTLA4 susceptibility autoimmune disease
0.09531622.15591134.html.plaintext.txt	281	Nature 423506 511CrossRefMedline Grumet FC Coukell A Bodmer JG Bodmer WF McDevitt HO 1971 Histocompatibility HL A antigens associated systemic lupus erythematosus possible genetic predisposition disease
0.09531622.15591134.html.plaintext.txt	282	N Engl J Med 285193 196Medline Vladutiu AO Rose NR 1971 Autoimmune murine thyroiditis relation histocompatibility H 2 type
0.09531622.15591134.html.plaintext.txt	283	Science 1741137 1139Medline Mungall AJ Palmer SA Sims SK Edwards CA Ashurst JL Wilming L Jones MC Horton R Hunt SE Scott CE Gilbert JG Clamp ME Bethel G Milne S Ainscough R Almeida JP Ambrose KD Andrews TD Ashwell RI Babbage AK Bagguley CL Bailey J Banerjee R Barker DJ Barlow KF et al
0.09531622.15591134.html.plaintext.txt	284	2003 The DNA sequence analysis human chromosome 6
0.09531622.15591134.html.plaintext.txt	285	Nature 425805 811CrossRefMedline Kumanovics A Takada T Lindahl KF 2003 Genomic organization mammalian MHC
0.09531622.15591134.html.plaintext.txt	286	Annu Rev Immunol 21629 657CrossRefMedline Dallman MJ Mason DW 1983 Induction Ia antigens murine epidermal cells rejection skin allografts
0.09531622.15591134.html.plaintext.txt	287	Transplantation 36222 224Medline Bottazzo GF Pujol Borrell R Hanafusa T Feldmann M 1983 Role aberrant HLA DR expression antigen presentation induction endocrine autoimmunity
0.09531622.15591134.html.plaintext.txt	288	Lancet 21115 1119Medline Mirakian R Hammond LJ Bottazzo GF 1998 Pathogenesis thyroid autoimmunity Bottazzo Feldmann hypothesis
0.09531622.15591134.html.plaintext.txt	289	Immunol Today 1997 98CrossRefMedline Lin L Hungs M Mignot E 2001 Narcolepsy HLA region
0.09531622.15591134.html.plaintext.txt	290	J Neuroimmunol 1179 20CrossRefMedline Kralovicova J Hammarstrom L Plebani A Webster AD Vorechovsky I 2003 Fine scale mapping IGAD1 genome wide genetic linkage analysis implicate HLA DQDR major susceptibility locus selective IgA deficiency common variable immunodeficiency
0.09531622.15591134.html.plaintext.txt	291	J Immunol 1702765 2775AbstractFree Full Text Price P Witt C Allcock R Sayer D Garlepp M Kok CC French M Mallal S Christiansen F 1999 The genetic basis association 8
0.09531622.15591134.html.plaintext.txt	292	1 ancestral haplotype A1 B8 DR3 multiple immunopathological diseases
0.09531622.15591134.html.plaintext.txt	293	Immunol Rev 167257 274Medline Klein J Sato A 2000 The HLA system second two parts
0.09531622.15591134.html.plaintext.txt	294	N Engl J Med 343782 786Free Full Text Carlsson B Wallin J Pirskanen R Matell G Smith CI 1990 Different HLA DR DQ associations subgroups idiopathic myasthenia gravis
0.09531622.15591134.html.plaintext.txt	295	Immunogenetics 31285 290Medline Pociot F McDermott MF 2002 Genetics type 1 diabetes mellitus
0.09531622.15591134.html.plaintext.txt	296	Genes Immun 3235 249CrossRefMedline Levinson RD Gonzales CR 2002 Birdshot retinochoroidopathy immunopathogenesis evaluation treatment
0.09531622.15591134.html.plaintext.txt	297	Ophthalmol Clin North Am 15343 350 viiMedline Tomer Y Davies TF 2003 Searching autoimmune thyroid disease susceptibility genes gene mapping gene function
0.09531622.15591134.html.plaintext.txt	298	Endocr Rev 24694 717AbstractFree Full Text Levin L Ban Y Concepcion E Davies TF Greenberg DA Tomer Y 2004 Analysis HLA genes families autoimmune diabetes thyroiditis
0.09531622.15591134.html.plaintext.txt	299	Hum Immunol 65640 647CrossRefMedline Maksymowych WP Tao S Vaile J Suarez Almazor M Ramos Remus C Russell AS 2000 LMP2 polymorphism associated extraspinal disease HLA B27 negative Caucasian Mexican Mestizo patients ankylosing spondylitis
0.09531622.15591134.html.plaintext.txt	300	J Rheumatol 27183 189Medline Mach B 1999 Perspectives immunology
0.09531622.15591134.html.plaintext.txt	301	Science 2851367Free Full Text Reith W Mach B 2001 The bare lymphocyte syndrome regulation MHC expression
0.09531622.15591134.html.plaintext.txt	302	Annu Rev Immunol 19331 373CrossRefMedline Beckstead JH 1995 A simple technique preservation fixation sensitive antigens paraffin embedded tissues addendum
0.09531622.15591134.html.plaintext.txt	303	J Histochem Cytochem 43345Free Full Text Schneider MJ Fiering SN Pallud SE Parlow AF St Germain DL Galton VA 2001 Targeted disruption type 2 selenodeiodinase gene DIO2 results phenotype pituitary resistance T4
0.09531622.15591134.html.plaintext.txt	304	Mol Endocrinol 152137 2148AbstractFree Full Text Diggle PJ Liang KY Zeger SL 1995 Analysis longitudinal data
0.09531622.15591134.html.plaintext.txt	305	Oxford UK Clarendon Press Musti AM Ursini VM Avvedimento EV Zimarino V Di Lauro R 1987 A cell type specific factor recognizes rat thyroglobulin promoter
0.09531622.15591134.html.plaintext.txt	306	Nucleic Acids Res 158149 8166Abstract Hoglund P Mintern J Waltzinger C Heath W Benoist C Mathis D 1999 Initiation autoimmune diabetes developmentally regulated presentation islet cell antigens pancreatic lymph nodes
0.09531622.15591134.html.plaintext.txt	307	J Exp Med 189331 339AbstractFree Full Text de Vos AF van Meurs M Brok HP Boven LA Hintzen RQ van der Valk P Ravid R Rensing S Boon L Hart BA Laman JD 2002 Transfer central nervous system autoantigens presentation secondary lymphoid organs
0.09531622.15591134.html.plaintext.txt	308	J Immunol 1695415 5423AbstractFree Full Text Sims AM Wordsworth BP Brown MA 2004 Genetic susceptibility ankylosing spondylitis
0.09531622.15591134.html.plaintext.txt	309	Curr Mol Med 413 20Medline LeHoang P Ozdemir N Benhamou A Tabary T Edelson C Betuel H Semiglia R Cohen JH 1992 HLA A29
0.09531622.15591134.html.plaintext.txt	310	2 subtype associated birdshot retinochoroidopathy
0.09531622.15591134.html.plaintext.txt	311	Am J Ophthalmol 11333 35Medline Beck S Trowsdale J 2000 The human major histocompatability complex lessons DNA sequence
0.09531622.15591134.html.plaintext.txt	312	Annu Rev Genomics Hum Genet 1117 137CrossRefMedline Lakkis FG 2003 Where alloimmune response initiated Am J Transplant 3241 242CrossRefMedline Lakkis FG Arakelov A Konieczny BT Inoue Y 2000 Immunologic ignorance vascularized organ transplants absence secondary lymphoid tissue
0.09531622.15591134.html.plaintext.txt	313	Nat Med 6686 688CrossRefMedline Teshima T Ordemann R Reddy P Gagin S Liu C Cooke KR Ferrara JL 2002 Acute graft versus host disease require alloantigen expression host epithelium
0.09531622.15591134.html.plaintext.txt	314	Nat Med Erratum 2002 81039 8575 581CrossRef Monks CR Freiberg BA Kupfer H Sciaky N Kupfer A 1998 Three dimensional segregation supramolecular activation clusters T cells
0.09531622.15591134.html.plaintext.txt	315	Nature 39582 86CrossRefMedline Wulfing C Davis MM 1998 A receptorcytoskeletal movement triggered costimulation T cell activation
0.09531622.15591134.html.plaintext.txt	316	Science 2822266 2269AbstractFree Full Text Grakoui A Bromley SK Sumen C Davis MM Shaw AS Allen PM Dustin ML 1999 The immunological synapse molecular machine controlling T cell activation
0.09531622.15591134.html.plaintext.txt	317	Science 285221 227AbstractFree Full Text Itano AA Jenkins MK 2003 Antigen presentation naive CD4 T cells lymph node
0.09531622.15591134.html.plaintext.txt	318	Nat Immunol 4733 739CrossRefMedline Kreisel D Krupnick AS Gelman AE Engels FH Popma SH Krasinskas AM Balsara KR Szeto WY Turka LA Rosengard BR 2002 Non hematopoietic allograft cells directly activate CD8 T cells trigger acute rejection alternative mechanism allorecognition
0.09531622.15591134.html.plaintext.txt	319	Nat Med 8233 239CrossRefMedline Ting JP Trowsdale J 2002 Genetic control MHC class II expression
0.09531622.15591134.html.plaintext.txt	320	Cell 109SupplS21 S33 Reith W 2003 ComPLEXIN new targets CIITA
0.09531622.15591134.html.plaintext.txt	321	Nat Immunol 4819 820CrossRefMedline Muhlethaler Mottet A Otten LA Steimle V Mach B 1997 Expression MHC class II molecules different cellular functional compartments controlled differential usage multiple promoters transactivator CIITA
0.09531622.15591134.html.plaintext.txt	322	EMBO J 162851 2860AbstractFree Full Text Mori Aoki A Pietrarelli M Nakazato M Caturegli P Kohn LD Suzuki K 2000 Class II transactivator suppresses transcription thyroid specific genes
0.09531622.15591134.html.plaintext.txt	323	Biochem Biophys Res Commun 27858 62CrossRefMedline Li YS Kanamoto N Hataya Y Moriyama K Hiratani H Nakao K Akamizu T 2004 Transgenic mice producing major histocompatibility complex class II molecules thyroid cells develop apparent autoimmune thyroid diseases
0.09531622.15591134.html.plaintext.txt	324	Endocrinology 1452524 2530AbstractFree Full Text Stuve O Youssef S Slavin AJ King CL Patarroyo JC Hirschberg DL Brickey WJ Soos JM Piskurich JF Chapman HA Zamvil SS 2002 The role MHC class II transactivator class II expression antigen presentation astrocytes susceptibility central nervous system autoimmune disease
0.09531622.15591134.html.plaintext.txt	325	J Immunol 1696720 6732AbstractFree Full Text Herkel J Jagemann B Wiegard C Lazaro JF Lueth S Kanzler S Blessing M Schmitt E Lohse AW 2003 MHC class II expressing hepatocytes function antigen presenting cells activate specific CD4 T lymphocytes
0.09531622.15591134.html.plaintext.txt	326	Hepatology 371079 1085CrossRefMedline Weetman AP 2003 Autoimmune thyroid disease propagation progression
0.09531622.15591134.html.plaintext.txt	327	Eur J Endocrinol 1481 9AbstractFree Full Text Dustin ML 2002 The immunological synapse
0.09531622.15591134.html.plaintext.txt	328	Arthritis Res 4Suppl 3S119 S125 Zheng RQ Abney ER Grubeck Loebenstein B Dayan C Maini RN Feldmann M 1990 Expression intercellular adhesion molecule 1 lymphocyte function associated antigen 3 human thyroid epithelial cells Graves Hashimoto diseases
0.09531622.15591134.html.plaintext.txt	329	J Autoimmun 3727 736Medline Bonita RE Rose NR Rasooly L Caturegli P Burek CL 2002 Adhesion molecules susceptibility factors spontaneous autoimmune thyroiditis NOD H2h4 mouse
0.09531622.15591134.html.plaintext.txt	330	Exp Mol Pathol 73155 163CrossRefMedline Faure GC Bensoussan Lejzerowicz D Bene MC Aubert V Leclere J 1997 Coexpression CD40 class II antigen HLA DR Graves disease thyroid epithelial cells
0.09531622.15591134.html.plaintext.txt	331	Clin Immunol Immunopathol 84212 215CrossRefMedline Metcalfe RA McIntosh RS Marelli Berg F Lombardi G Lechler R Weetman AP 1998 Detection CD40 human thyroid follicular cells analysis expression function
0.09531622.15591134.html.plaintext.txt	332	J Clin Endocrinol Metab 831268 1274AbstractFree Full Text Battifora M Pesce G Paolieri F Fiorino N Giordano C Riccio AM Torre G Olive D Bagnasco M 1998 B7
0.09531622.15591134.html.plaintext.txt	333	1 costimulatory molecule expressed thyroid follicular cells Hashimoto thyroiditis Graves disease
0.09531622.15591134.html.plaintext.txt	334	J Clin Endocrinol Metab 834130 4139AbstractFree Full Text Shah R Banks K Patel A Dogra S Terrell R Powers PA Fenton C Dinauer CA Tuttle RM Francis GL 2002 Intense expression B7 2 antigen presentation coactivator unfavorable prognostic indicator differentiated thyroid carcinoma children adolescents
0.09531622.15591134.html.plaintext.txt	335	J Clin Endocrinol Metab 874391 4397AbstractFree Full Text Mandelbrot DA Kishimoto K Auchincloss Jr H Sharpe AH Sayegh MH 2001 Rejection mouse cardiac allografts costimulation trans
0.09531622.15591134.html.plaintext.txt	336	J Immunol 1671174 1178AbstractFree Full Text This Article Abstract Full Text PDF All Versions Article 14631154 recent Author Manuscript PDF Purchase Article View Shopping Cart Alert article cited Alert correction posted Citation Map Services Email article friend Similar articles journal Similar articles PubMed Alert new issues journal Download citation manager Request Copyright Permission Google Scholar Articles Kimura H
0.09531622.15591134.html.plaintext.txt	337	Articles citing Article PubMed PubMed Citation Articles Kimura H
0.09531622.15591134.html.plaintext.txt	338	HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS Endocrinology Endocrine Reviews J
0.09531622.15591134.html.plaintext.txt	339	Molecular Endocrinology Recent Prog
0.358711.12485808.html.plaintext.txt	0	MINIREVIEW The side orexins endocrine metabolic actions Meghan M
0.358711.12485808.html.plaintext.txt	1	Pharmacological Physiological Science St
0.358711.12485808.html.plaintext.txt	2	Louis University School Medicine St
0.358711.12485808.html.plaintext.txt	3	ABSTRACT TOP ABSTRACT INTRODUCTION BIOLOGICAL ACTIONS OF THE
0.358711.12485808.html.plaintext.txt	4	Although clear orexinhypocretin peptides significant physiologically relevant role sleepwakefulness broader picture emerged indicating metabolic actions may depend upon neural endocrine mechanisms manifestation
0.358711.12485808.html.plaintext.txt	5	The ability exogenous peptide activate sympathetic tone increase locomotor activity alter feeding behavior together observed alterations functions knockout animals strongly suggests important neural actions endogenous orexinshypocretins
0.358711.12485808.html.plaintext.txt	6	Likewise action exogenously administered peptides alter endocrine function particular corticotropin release mirrored potential endocrinopathies knockout animals
0.358711.12485808.html.plaintext.txt	7	Thus pluripotent peptides hold great potential treatment human narcolepsy also provide insight coordinated regulation multiple physiological systems
0.358711.12485808.html.plaintext.txt	8	food intake autonomic nervous system narcolepsy corticotropin corticosterone
0.358711.12485808.html.plaintext.txt	9	INTRODUCTION TOP ABSTRACT INTRODUCTION BIOLOGICAL ACTIONS OF THE
0.358711.12485808.html.plaintext.txt	10	A REMARKABLE CONVERGENCE independent efforts occurred early 1998 La Jolla Dallas groups simultaneously reported predicted 6 elucidated 29 structures two peptides would become named hypocretins 6 alternatively orexins 29
0.358711.12485808.html.plaintext.txt	11	These peptides known processed prohormone recognized produced brain remarkably circumscribed location lateral hypothalamusperifornical area region known important feeding behavior 29
0.358711.12485808.html.plaintext.txt	12	Axonal projections multiple brain sites 4 6 21 25 29 38 predicted diversity biological actions clear beginning peptides exerted membrane effects similar recognized neurotransmitters 6 8 42 might significant role central nervous system CNS regulation feeding behavior 13 29 31
0.358711.12485808.html.plaintext.txt	13	For simplicity peptides referred orexins
0.358711.12485808.html.plaintext.txt	14	Orexin A hypocretin 1 33 amino acid peptide two internal disulfide linkages pyroglutamyl residue NH2 terminus amidated COOH terminus
0.358711.12485808.html.plaintext.txt	15	Orexin B hypocretin 2 28 amino acids length lacks internal disulfide bonds similarly amidated COOH terminus
0.358711.12485808.html.plaintext.txt	16	In initial description orexins Yanigisawas group Sakurai et al
0.358711.12485808.html.plaintext.txt	17	29 also identified two orexin receptors OX1R OX2R
0.358711.12485808.html.plaintext.txt	18	Although G protein coupled receptors OX1R appears couple via Gq11 subclass heteromeric receptors OX2R may couple either Gq11 Gio subclasses 29 42
0.358711.12485808.html.plaintext.txt	19	It clear OX1R prefers orexin A ligand whereas OX2R binds orexin A orexin B similar affinities 29
0.358711.12485808.html.plaintext.txt	20	Finally recognized addition broad projection field originating orexin producing neurons lateral hypothalamicperifornical area unique distributions OX1R OX2R subtypes exist 17 19 29 41 establishing potential development pharmacological agents interact uniquely single subclass orexin receptor therefore act selective agonists antagonists specific biological actions endogenous peptides
0.358711.12485808.html.plaintext.txt	21	BIOLOGICAL ACTIONS OF THE OREXINSHYPOCRETINS TOP ABSTRACT INTRODUCTION BIOLOGICAL ACTIONS OF THE
0.358711.12485808.html.plaintext.txt	22	Although agreed exogenously applied orexin stimulate feeding orexin production determined metabolic state animal see review Mieda Yanagisawa Ref
0.358711.12485808.html.plaintext.txt	23	20 investigators recognize effects orexins less potent neuropeptide Y NPY see review Smart et al
0.358711.12485808.html.plaintext.txt	24	However must recognized multiple peptide systems interact control feeding response hierarchy within systems clearly established
0.358711.12485808.html.plaintext.txt	25	Pretreatment NPY antagonists significantly decreased feeding response exogenously administered orexin 7 44 suggesting NPY neurons located downstream wiring diagram however evidence exist potential opposite true
0.358711.12485808.html.plaintext.txt	26	orexin neurons located farther downstream NPY series circuit controlling feeding 22
0.358711.12485808.html.plaintext.txt	27	There strong evidence innervation NPY neurons orexin terminals arcuate nucleus hypothalamus 5 11 central administration dose orexin stimulated feeding significantly increased NPY mRNA nuclear group well 16
0.358711.12485808.html.plaintext.txt	28	Convincing evidence physiologically relevant role endogenous orexins CNS control feeding comes passive immunoneutralization studies compromise bioactivity endogenous orexin 22 43 neutralizing antibodies reduced feeding response overnight fast
0.358711.12485808.html.plaintext.txt	29	At least one group access compound observed decreased feeding response exogenously applied orexin fast induced feeding administration relatively selective nonpeptide OX1R antagonist SB 334867 27
0.358711.12485808.html.plaintext.txt	30	Orexin knockout mice preprohormone gene deletion ate less wild type littermates 2 suggesting physiologically relevant role endogenous orexin regulation appetite
0.358711.12485808.html.plaintext.txt	31	However mice grew normally thus determinant growth body weight must compensate decreased feeding
0.358711.12485808.html.plaintext.txt	32	There two excellent possibilities motor activity metabolic state
0.358711.12485808.html.plaintext.txt	33	Early recognized orexins stimulated motor activity apparently increased arousal state 8 30
0.358711.12485808.html.plaintext.txt	34	The peptides also stimulate sympathetic nervous system activity 3 30 34 36 thought increase feeding might actually secondary increased arousal state metabolic demand 18
0.358711.12485808.html.plaintext.txt	35	It clear locomotor activity time spent awake state increased animals administered orexin 8
0.358711.12485808.html.plaintext.txt	36	Thus addition stimulating feeding peptides stimulated energy expenditure 45
0.358711.12485808.html.plaintext.txt	37	Things became much clearer Yanagisawa colleagues Chemelli et al
0.358711.12485808.html.plaintext.txt	38	2 demonstrated technical expertise developing orexin gene knockout mouse
0.358711.12485808.html.plaintext.txt	39	This model proved importance endogenous orexin system sleepwakefulness time cast doubt physiological relevance observed effects peptides feeding behavior metabolism
0.358711.12485808.html.plaintext.txt	40	These mice displayed behavioral phenotype quite similar human canine models narcolepsy 2 15 25 distinct periods behavioral arrest intrusion rapid eye movement REM sleep normal waking state
0.358711.12485808.html.plaintext.txt	41	If primary function orexins control feeding metabolic rate pharmacological studies suggested animals would expected display phenotypic changes reflective loss activities
0.358711.12485808.html.plaintext.txt	42	However mice reported otherwise phenotypically normal general metabolic state mirrored serum electrolytes glucose levels similar wild type littermates 14 15 wk age
0.358711.12485808.html.plaintext.txt	43	In addition mice fertile thus pharmacological effects previously reported reproductive hormone 8 26 28 39 growth hormone 8 secretion appear physiological expression animals times studied
0.358711.12485808.html.plaintext.txt	44	DEVELOPMENT OF THE OREXIN NEURON DROPOUT MODEL REVEALS THE POTENTIAL PHYSIOLOGICAL RELEVANCE OF ENDOCRINE AND METABOLIC ACTION OF THE OREXINSHYPOCRETINS TOP ABSTRACT INTRODUCTION BIOLOGICAL ACTIONS OF THE
0.358711.12485808.html.plaintext.txt	45	Although embryonic orexin gene knockout mice provided key evidence pharmacological effects orexin sleepwakefulness potential physiological relevance drew attention investigators away endocrine metabolic effects peptides model entirely recapitulate pathology human narcolepsy 2
0.358711.12485808.html.plaintext.txt	46	On contrary recognized human narcolepsy almost cases frank lack orexin gene expression throughout life instead gradual loss orexin producing neurons hypothalamus aging 24 40
0.358711.12485808.html.plaintext.txt	47	Thus faithfully recreate mouse equivalent human model Yanagisawa colleagues Hara et al
0.358711.12485808.html.plaintext.txt	48	9 yet another brilliant series experiments created mice harboring toxic ataxin 3 gene attached orexin promotor
0.358711.12485808.html.plaintext.txt	49	The ataxin 3 gene encodes protein extended polyglutamine repeats caused apoptosis expressed transfected cells vitro 46
0.358711.12485808.html.plaintext.txt	50	Already 2 wk age expression transgene could detected orexin producing neurons 4 8 wk age majority orexin producing neurons eliminated
0.358711.12485808.html.plaintext.txt	51	Similarly 8 wk age ataxin 3 transgenic mice preproorexin mRNA could detected whereas expression two peptides known involved control feeding NPY melanin concentrating hormone appeared normal 9
0.358711.12485808.html.plaintext.txt	52	By 6 wk age orexinataxin 3 mice 9 observed display periods behavioral arrest similar previously reported investigators orexin knockout animals 2
0.358711.12485808.html.plaintext.txt	53	Fragmentation sleepwakefulness characteristic orexin knockout animals also observed orexinataxin 3 mice
0.358711.12485808.html.plaintext.txt	54	This included increased frequency entry duration REM sleep
0.358711.12485808.html.plaintext.txt	55	Thus mice delayed onset compromise orexin producing neurons faithfully mirrored situation human narcolepsy characterized slowly progressive disease due dropping orexin neurons lateral hypothalamus 40
0.358711.12485808.html.plaintext.txt	56	The appearance alterations sleepwakefulness mice predictable however additional observations made group investigators surprises provide important insight potential endocrine metabolic actions endogenous orexins
0.358711.12485808.html.plaintext.txt	57	One might expected orexinataxin 3 mice aged would lose weight compared wild type controls due loss orexigenic action peptides
0.358711.12485808.html.plaintext.txt	58	Instead even predicted decrease food intake became obese 9
0.358711.12485808.html.plaintext.txt	59	The obese phenotype might due fact orexinataxin 3 mice displayed decreased spontaneous motor activity dark phase compared controls thus energy expenditure might possibly less leading obesity
0.358711.12485808.html.plaintext.txt	60	This would suggest ability exogenous peptide stimulate arousal sympathetic nervous system locomotor activity 3 8 30 36 earlier pharmacological studies physiological correlates
0.358711.12485808.html.plaintext.txt	61	A intriguing finding reported Hara et al
0.358711.12485808.html.plaintext.txt	62	9 orexinataxin 3 mice developed along obesity appeared late onset diabetes type 2 diabetes
0.358711.12485808.html.plaintext.txt	63	Earlier work preproorexin gene knockout animals suggested alterations glucose homeostasis reports direct effects orexin insulin secretion isolated pancreatic islets cells
0.358711.12485808.html.plaintext.txt	64	There one report intravenous administration orexin elevates circulating insulin glucose levels rats orexin A stimulates insulin release vitro isolated perfused pancreas preparations 23 doses higher present gland circulation
0.358711.12485808.html.plaintext.txt	65	The observed phenotype obesity diabetes orexinataxin 3 mice resembles situation human narcoleptic patients 10 35
0.358711.12485808.html.plaintext.txt	66	It also mirrors situation cortisol excess obesity result combination fat redistribution due altered insulin sensitivity increased appetite
0.358711.12485808.html.plaintext.txt	67	It hypothesis orexinataxin 3 mice represent exactly pathology
0.358711.12485808.html.plaintext.txt	68	Central administration orexin conscious rats resulted behavioral response similar stress response 8 30
0.358711.12485808.html.plaintext.txt	69	This included increased grooming motor activity e
0.358711.12485808.html.plaintext.txt	70	These injections also resulted increased sympathetic nervous system tone reflected increased heart rate blood pressure 3 30 36
0.358711.12485808.html.plaintext.txt	71	It known whether orexinataxin 3 mice display reset depressed autonomic system important examine possibility
0.358711.12485808.html.plaintext.txt	72	Similarly central administration orexin stimulated corticotropin ACTH corticosterone release 8 12 14 34 vivo action blocked pretreatment animals corticotropin releasing factor CRF antagonist 12 34
0.358711.12485808.html.plaintext.txt	73	CRF recognized anorexigenicanxiogenic peptide 8 loss orexin neurons might predict decrease CRF release hypothalamo pituitary portal vessels response stress also loss potential stimulatory action orexin CRF neurons important shut feeding cues
0.358711.12485808.html.plaintext.txt	74	Thus absence orexin less CRF would released basal stimulated conditions animal addition feeding longer periods would become corticosterone deficient
0.358711.12485808.html.plaintext.txt	75	Instead quite opposite observed
0.358711.12485808.html.plaintext.txt	76	The animals ate less appeared experience corticosterone excess
0.358711.12485808.html.plaintext.txt	77	The decreased feeding observed clearly might due loss orexigenic drive provided endogenous peptide might explain apparent corticosterone excess
0.358711.12485808.html.plaintext.txt	78	We thought ability centrally administered orexin stimulate ACTH corticosterone release vivo 8 12 14 34 reflection generalized stress effect exogenous peptide 30 36 indication role endogenous orexin day day control hypothalamo pituitary adrenal axis
0.358711.12485808.html.plaintext.txt	79	Instead identified direct anterior pituitary effects orexinshypocretins 32 potentially explain metabolic phenotype orexinataxin 3 mice 9
0.358711.12485808.html.plaintext.txt	80	Orexin immunopositive nerve terminals exist external lamina median eminence 4 site diffusion neuroendocrine factors hypophysial portal vessels connecting hypothalamus anterior lobe pituitary gland
0.358711.12485808.html.plaintext.txt	81	In addition OX1R OX2R subtypes exist anterior lobe OX1R localized corticotrophs human gland 1
0.358711.12485808.html.plaintext.txt	82	We demonstrated significant inhibitory effect orexins CRF stimulated ACTH release cultured anterior pituitary cells 32
0.358711.12485808.html.plaintext.txt	83	The effect appeared mediated OX1R subtype PKC dependent mechanism suggesting activation Gq initiated signaling pathway 32
0.358711.12485808.html.plaintext.txt	84	More recently demonstrated orexin stimulated transient elevations intracellular inositol trisphosphate levels 33 Ferguson Samson A
0.358711.12485808.html.plaintext.txt	85	Samson unpublished observations observed calcium transients fura 2 labeled CRF responsive pituitary cells vitro A
0.358711.12485808.html.plaintext.txt	86	Samson unpublished observations
0.358711.12485808.html.plaintext.txt	87	This would suggest binding orexin OX1R corticotrophs results activation phospholipase C subsequent formation inositol trisphosphate diacylglycerol DAG
0.358711.12485808.html.plaintext.txt	88	Because blocked inhibitory action orexin CRF induced ACTH release PKC inhibitor calphostin C hypothesize formation DAG results activation potassium channel resulting hyperpolarization corticotroph right shift CRF concentration response curve
0.358711.12485808.html.plaintext.txt	89	This hypothesis supported demonstration pretreatment cells concentration potassium channel inhibitor glyburide alter basal CRF stimulated hormone release resulted complete reversal inhibitory effects orexin 33
0.358711.12485808.html.plaintext.txt	90	Thus hypothesize significant physiologically relevant effect orexin hypothalamo pituitary adrenal axis exerted pituitary hypothalamic level
0.358711.12485808.html.plaintext.txt	91	The loss physiologically relevant inhibitory effect peptide time orexin neurons degenerate would lead increased sensitivity corticotrophs CRF resultant resetting corticosteroid release apparent corticosteroid excess
0.358711.12485808.html.plaintext.txt	92	This might explain appearance diabetes reality situation decreased insulin sensitivity caused corticosterone excess
0.358711.12485808.html.plaintext.txt	93	Certainly obese appearance mice would support hypothesis
0.358711.12485808.html.plaintext.txt	94	CONCLUSIONS TOP ABSTRACT INTRODUCTION BIOLOGICAL ACTIONS OF THE
0.358711.12485808.html.plaintext.txt	95	The absence readily available selective OX1R OX2R antagonists inherent problems encountered passive immunoneutralization approaches resulted slow progress toward goal establishing physiological relevance described pharmacological actions orexins endocrine systems metabolism
0.358711.12485808.html.plaintext.txt	96	However observations study preproorexin gene knockout mice suggested several observed endocrine actions pharmacologically administered orexin likelihood without physiological correlate
0.358711.12485808.html.plaintext.txt	97	Those mice fertile apparently grew normally exception decreased activity food intakes addition alterations sleepwakefulness
0.358711.12485808.html.plaintext.txt	98	Thus previously described effects exogenous peptide reproductive hormone growth hormone secretion reflected knockout mice 2
0.358711.12485808.html.plaintext.txt	99	Metabolic alterations recognized however
0.358711.12485808.html.plaintext.txt	100	When animals expressing orexinataxin 3 gene product followed adulthood clearer picture physiological relevance pharmacological effects exogenously administered orexin began appear
0.358711.12485808.html.plaintext.txt	101	These mice narcoleptic display decreased motor activity 9
0.358711.12485808.html.plaintext.txt	102	In addition obese diabetic
0.358711.12485808.html.plaintext.txt	103	The model certainly provide additional insight control sleepwakefulness even importantly may provide information genesis forms insulin resistant diabetes particular associated excess corticosteroid production e
0.358711.12485808.html.plaintext.txt	104	This may also stimulate clinical researchers examine possibility subset human narcoleptic individuals cushingoid
0.358711.12485808.html.plaintext.txt	105	Finally mice provide model examine unique concordant actions peptides feeding energy utilization case orexin unlike orexigenic peptides 9 18 positive food intake energy expenditure
0.358711.12485808.html.plaintext.txt	106	We acknowledge financial support Dean St
0.358711.12485808.html.plaintext.txt	107	Louis University School Medicine W
0.358711.12485808.html.plaintext.txt	108	Samson Chairman Department Pharmacological Physiological Science M
0.358711.12485808.html.plaintext.txt	109	Taylor Predoctoral Fellow supported grant Heartland Affiliate American Heart Association
0.358711.12485808.html.plaintext.txt	110	Address reprint requests correspondence W
0.358711.12485808.html.plaintext.txt	111	Samson Pharmacological Physiological Science St
0.358711.12485808.html.plaintext.txt	112	School Medicine 1406 South Grand Blvd
0.358711.12485808.html.plaintext.txt	113	Louis MO 63104 E mail samsonwkatslu
0.358711.12485808.html.plaintext.txt	114	The costs publication article defrayed part payment page charges
0.358711.12485808.html.plaintext.txt	115	The article must therefore hereby marked advertisement accordance 18 U
0.358711.12485808.html.plaintext.txt	116	Section 1734 solely indicate fact
0.358711.12485808.html.plaintext.txt	117	REFERENCES TOP ABSTRACT INTRODUCTION BIOLOGICAL ACTIONS OF THE
0.358711.12485808.html.plaintext.txt	118	Blanco M Lopez M Garcia Caballero T Gallego R Vazquez Boquete A Morel G Senaris R Casaneuva F Dieguez C Beiras A
0.358711.12485808.html.plaintext.txt	119	Cellular localization orexin receptors human pituitary
0.358711.12485808.html.plaintext.txt	120	J Clin Endocrinol Metab 86 1616 1619 2001AbstractFree Full Text
0.358711.12485808.html.plaintext.txt	121	Chemelli RM Willie JT Sinton CM Elmquist JK Scammell T Lee C Richardson JA Williams SC Xiong X Kisanuki Y Fitch TE Nakazato M Hammer RE Saper CB Yanagisawa M
0.358711.12485808.html.plaintext.txt	122	Narcolepsy orexin knockout mice molecular genetics sleep regulation
0.358711.12485808.html.plaintext.txt	123	Cell 98 437 451 1999ISIMedline
0.358711.12485808.html.plaintext.txt	124	Chen CT Hwang LL Chang JK Dunn NJ
0.358711.12485808.html.plaintext.txt	125	Pressor effects orexins injected intracisternally rostral ventrolateral medulla anesthetized rats
0.358711.12485808.html.plaintext.txt	126	Am J Physiol Regul Integr Comp Physiol 278 R692 R697 2000AbstractFree Full Text
0.358711.12485808.html.plaintext.txt	127	Date Y Mondal MS Matsukura S Ueta Y Yamashita H Kaiya H Kangawa K Nakazato M
0.358711.12485808.html.plaintext.txt	128	Distribution orexinhypocretin rat median eminence pituitary
0.358711.12485808.html.plaintext.txt	129	Mol Brain Res 76 1 6 2000ISIMedline
0.358711.12485808.html.plaintext.txt	130	Date Y Ueta Y Yamashita H Yamaguchi H Matsukura S Kangawa K Sakurai Yanagisawa M Nakazato M
0.358711.12485808.html.plaintext.txt	131	Orexins orexigenic hypothalamic peptides interact autonomic neuroendocrine neuroregulatory systems
0.358711.12485808.html.plaintext.txt	132	Proc Natl Acad Sci USA 96 748 753 1999AbstractFree Full Text
0.358711.12485808.html.plaintext.txt	133	De Lecea L Kilduff TS Peyron C Gao XB Foye PE Danielson PE Fukuhara C Battenberg ELF Gautvik VT Bartlett FS Frankel WN van den Pol AN Bloom FE Gautvik KM Sutcliffe JG
0.358711.12485808.html.plaintext.txt	134	The hypocretins hypothalamus specific peptides neuroexcitatory activity
0.358711.12485808.html.plaintext.txt	135	Proc Natl Acad Sci USA 95 322 327 1998AbstractFree Full Text
0.358711.12485808.html.plaintext.txt	136	Dube MG Horvath TL Kalra PS Kalra SP
0.358711.12485808.html.plaintext.txt	137	Evidence neuropeptide Y Y5 receptor involvement food intake elicited orexin A sated rats
0.358711.12485808.html.plaintext.txt	138	Peptides 21 1557 1560 2001ISI
0.358711.12485808.html.plaintext.txt	139	Hagan JJ Leslie RA Patel S Evans ML Wattam TA Holmes S Benham CD Taylor SG Routledge C Hemmati P Munton RP Ashmeade TE Shah AJ Hatcher JP Hatcher PD Jones DN Smith MI Piper DC Hunter AJ Porter RA Upton N
0.358711.12485808.html.plaintext.txt	140	Orexin A activates locus coeruleus cell firing increases arousal rat
0.358711.12485808.html.plaintext.txt	141	Proc Natl Acad Sci USA 96 10911 10916 1999AbstractFree Full Text
0.358711.12485808.html.plaintext.txt	142	Hara J Beuckmann CT Nambu T Willie JT Chemelli RM Sinton CM Sugiyama F Yagami K Goto K Yanagisawa M Sakurai T
0.358711.12485808.html.plaintext.txt	143	Genetic ablation orexin neurons mice results narcolepsy hypophagia obesity
0.358711.12485808.html.plaintext.txt	144	Neuron 30 345 354 2001ISIMedline
0.358711.12485808.html.plaintext.txt	145	Honda Y Doi Y Nimomiya R Ninomiya C
0.358711.12485808.html.plaintext.txt	146	Increased frequency non insulin diabetes mellitus among narcoleptic patients
0.358711.12485808.html.plaintext.txt	147	Sleep 9 254 259 1986ISIMedline
0.358711.12485808.html.plaintext.txt	148	Horvath TL Diano S van den Pol A
0.358711.12485808.html.plaintext.txt	149	Synaptic interaction hypocretin orexin neuropeptide Y cells rodent primate hypothalamus novel circuit implicated metabolic endocrine regulations
0.358711.12485808.html.plaintext.txt	150	J Neurosci 19 1072 1087 1999AbstractFree Full Text
0.358711.12485808.html.plaintext.txt	151	Jasberenyi M Bujdoso E Pataki I Telegdy G
0.358711.12485808.html.plaintext.txt	152	Effects orexin hypothalamic pituitary adrenal system
0.358711.12485808.html.plaintext.txt	153	J Neuroendocrinol 12 1174 1178 2000ISIMedline
0.358711.12485808.html.plaintext.txt	154	The hypocretinorexin ligand receptor system implications sleep sleep disorders
0.358711.12485808.html.plaintext.txt	155	Trends Neurosci 23 359 365 2000ISIMedline
0.358711.12485808.html.plaintext.txt	156	Kuru M Ueta Y Serino R Nakazato M Yamamoto Y Shibuya I Yamashita H
0.358711.12485808.html.plaintext.txt	157	Centrally administered orexinhypocretin activates HPA axis rats
0.358711.12485808.html.plaintext.txt	158	Neuroreport 11 1977 1980 2000ISIMedline
0.358711.12485808.html.plaintext.txt	159	Lin L Faraco J Li R Kadotani H Rogers W Lin X Qiu X de Jong PJ Nishino S Mignot E
0.358711.12485808.html.plaintext.txt	160	The sleep disorder canine narcolepsy caused mutation hypocretin orexin receptor 2 gene
0.358711.12485808.html.plaintext.txt	161	Cell 98 365 376 1999ISIMedline
0.358711.12485808.html.plaintext.txt	162	Lopez M Seoane LM del Carmen Garcia M Dieguez C Senaris R
0.358711.12485808.html.plaintext.txt	163	Neuropeptide Y agouti related peptide melanin concentrating hormone target peptide orexin A feeding actions rat hypothalamus
0.358711.12485808.html.plaintext.txt	164	Neuroendocrinology 75 34 44 2002ISIMedline
0.358711.12485808.html.plaintext.txt	165	Lu XY Bagnol D Burke S Akil H Watson SJ
0.358711.12485808.html.plaintext.txt	166	Differential distribution OX1 OX2 orexinhypocretin receptor messenger RNA brain upon fasting
0.358711.12485808.html.plaintext.txt	167	Horm Behav 37 335 344 2000ISIMedline
0.358711.12485808.html.plaintext.txt	168	Lubkin M Stricker Krongrad A
0.358711.12485808.html.plaintext.txt	169	Independent feeding metabolic actions orexins mice
0.358711.12485808.html.plaintext.txt	170	Biochem Biophys Res Commun 253 241 245 1998ISIMedline
0.358711.12485808.html.plaintext.txt	171	Marcus JN Aschkenasi CJ Lee CE Chemelli RM Saper CB Yanagisawa M Elmquist JK
0.358711.12485808.html.plaintext.txt	172	Differential expression orexin receptors 1 2 rat brain
0.358711.12485808.html.plaintext.txt	173	J Comp Neurol 435 6 25 2001ISIMedline
0.358711.12485808.html.plaintext.txt	174	Sleep feeding neuropeptides roles orexins orexin receptors
0.358711.12485808.html.plaintext.txt	175	Curr Opin Neurobiol 12 339 346 2002ISIMedline
0.358711.12485808.html.plaintext.txt	176	Nambu T Sakurai T Mizukami K Hosoya Y Yanagisawa M Goto K
0.358711.12485808.html.plaintext.txt	177	Distribution orexin neurons adult rat brain
0.358711.12485808.html.plaintext.txt	178	Brain Res 827 243 260 1999ISIMedline
0.358711.12485808.html.plaintext.txt	179	Niimi M Sato M Taminato T
0.358711.12485808.html.plaintext.txt	180	Neuropeptide Y central control feeding interactions orexin leptin
0.358711.12485808.html.plaintext.txt	181	Endocrine 14 269 273 2001ISIMedline
0.358711.12485808.html.plaintext.txt	182	Nowak KW Mackowiak P Switonska MM Fabis M Malendowicz LK
0.358711.12485808.html.plaintext.txt	183	Acute orexin effects insulin secretion rat vivo vitro studies
0.358711.12485808.html.plaintext.txt	184	Life Sci 66 449 454 2000ISIMedline
0.358711.12485808.html.plaintext.txt	185	Peyron C Faraco J Rogers W Ripley B Overeem S Charnay Y Nevismalov S Aldrich M Reynolds D Albin R Li R Hungs M Pedrazzoli M Padigaru M Kucherlapati M Fan J Maki R Lammers GJ Bouras C Kucherlapati R Nishino S Mignot E
0.358711.12485808.html.plaintext.txt	186	A mutation case early onset narcolepsy generalized absence hypocretin peptides human narcoleptic brains
0.358711.12485808.html.plaintext.txt	187	Nature Med 6 991 997 2000ISIMedline
0.358711.12485808.html.plaintext.txt	188	Peyron C Tighe DK van den Pol AN De Lecea L Heller HC Sutcliffe JG Kilduff TS
0.358711.12485808.html.plaintext.txt	189	Neurons containing hypocretin orexin project multiple neuronal systems
0.358711.12485808.html.plaintext.txt	190	J Neurosci 18 9996 10015 1998AbstractFree Full Text
0.358711.12485808.html.plaintext.txt	191	Pu S Jain MR Kalra PS Kalra SP
0.358711.12485808.html.plaintext.txt	192	Orexins novel family hypothalamic neuropeptides modulate pituitary luteinizing hormone secretion ovarian steroid dependent manner
0.358711.12485808.html.plaintext.txt	193	Regul Pept 78 133 136 1998ISIMedline
0.358711.12485808.html.plaintext.txt	194	Rodgers RJ Halford JC Nunes de Souza RL Canto de Souza AL Piper DC Arch JR Upton N Porter RA Johns A Blundell JE
0.358711.12485808.html.plaintext.txt	195	SB 334867 selective orexin 1 receptor antagonist enhances behavioural satiety blocks hyperphagic effect orexin A rats
0.358711.12485808.html.plaintext.txt	196	Eur J Neurosci 13 1444 1452 2001ISIMedline
0.358711.12485808.html.plaintext.txt	197	Russell SH Kim MS Small CJ Abbott CR Morgan DGA Taheri S Murphy KG Todd JF Ghatei MA Bloom SR
0.358711.12485808.html.plaintext.txt	198	Central administration orexin A suppresses basal domperidone stimulated plasma prolactin
0.358711.12485808.html.plaintext.txt	199	J Neuroendocrinol 12 1213 1218 2000ISIMedline
0.358711.12485808.html.plaintext.txt	200	Sakurai T Amemiya A Ishii M Matsuzaki I Chemelli RM Tanaka H Williams SC Richardson JA Kozlowski GP Wilson S Arch JRS Buckingham RE Haynes AC Carr SA Annan RS McNulty DE Liu WS Terrett JA Elshourbagy NA Bergsma DJ Yanagisawa M
0.358711.12485808.html.plaintext.txt	201	Orexins orexin receptors family hypothalamic neuropeptides G protein coupled receptors regulate feeding behavior
0.358711.12485808.html.plaintext.txt	202	Cell 92 573 585 1998ISIMedline
0.358711.12485808.html.plaintext.txt	203	Samson WK Gosnell B Chang JK Resch ZT Murphy TC
0.358711.12485808.html.plaintext.txt	204	Cardiovascular regulatory actions hypocretins brain
0.358711.12485808.html.plaintext.txt	205	Brain Res 831 248 253 1999ISIMedline
0.358711.12485808.html.plaintext.txt	206	Trends Endocrinol Metab 11 257 262 2000ISIMedline
0.358711.12485808.html.plaintext.txt	207	Hypocretinorexin suppresses corticotroph responsiveness vitro
0.358711.12485808.html.plaintext.txt	208	Am J Physiol Regul Integr Comp Physiol 281 R1140 R1145 2001AbstractFree Full Text
0.358711.12485808.html.plaintext.txt	209	Samson WK Taylor MM Anderson JW Ferguson AV
0.358711.12485808.html.plaintext.txt	210	Orexin inhibition CRH stimulated ACTH secretion possible role potassium channel activation Abstract
0.358711.12485808.html.plaintext.txt	211	Samson WK Taylor MM Folwell M Ferguson AV
0.358711.12485808.html.plaintext.txt	212	Orexin actions hypothalamic paraventricular nucleus physiological consequences cellular correlates
0.358711.12485808.html.plaintext.txt	213	Regul Pept 104 97 103 2002ISIMedline
0.358711.12485808.html.plaintext.txt	214	Schuld A Hebebrand J Geller F Pollmaecher T
0.358711.12485808.html.plaintext.txt	215	Increased body mass index patients narcolepsy
0.358711.12485808.html.plaintext.txt	216	Lancet 355 1274 1275 2000ISIMedline
0.358711.12485808.html.plaintext.txt	217	Shirasaka T Nakazato M Matsukura S Takasaki M Kannan H
0.358711.12485808.html.plaintext.txt	218	Sympathetic cardiovascular actions orexins conscious rats
0.358711.12485808.html.plaintext.txt	219	Am J Physiol Regul Integr Comp Physiol 277 R1780 R1785 1999AbstractFree Full Text
0.358711.12485808.html.plaintext.txt	220	Smart D Haynes AC Williams G Arch JRS Orexins treatment obesity
0.358711.12485808.html.plaintext.txt	221	Eur J Pharmacol 440 199 212 2002ISIMedline
0.358711.12485808.html.plaintext.txt	222	Taheri S Mahmoodi SM Opacka Juffry J Ghatei MA Bloom SR
0.358711.12485808.html.plaintext.txt	223	Distribution quantification immunoreactive orexin A rat tissues
0.358711.12485808.html.plaintext.txt	224	FEBS Lett 457 157 161 1999ISIMedline
0.358711.12485808.html.plaintext.txt	225	Tamura T Irahara M Tezuka M Kiyokawa M Aono T
0.358711.12485808.html.plaintext.txt	226	Orexins orexigenic hypothalamic neuropeptides suppress pulsatile secretion luteinizing hormone ovariectomized female rats
0.358711.12485808.html.plaintext.txt	227	Biochem Biophys Res Commun 264 759 762 1999ISIMedline
0.358711.12485808.html.plaintext.txt	228	Thannickal TC Moore RY Nienhuis R Ramanathan L Gukyani S Aldrich M Comford M Siegel JM
0.358711.12485808.html.plaintext.txt	229	Reduced number hypocretin neurons human narcolepsy
0.358711.12485808.html.plaintext.txt	230	Neuron 27 469 474 2000ISIMedline
0.358711.12485808.html.plaintext.txt	231	Trivedi P Yu H MacNeil DJ Van der Ploeg LHT Guan XM
0.358711.12485808.html.plaintext.txt	232	Distribution orexin receptor mRNA rat brain
0.358711.12485808.html.plaintext.txt	233	FEBS Lett 438 71 75 1998ISIMedline
0.358711.12485808.html.plaintext.txt	234	Van den Pol A Gao XB Obrietan K Kilduff TS Belousov AB
0.358711.12485808.html.plaintext.txt	235	Presynaptic postsynaptic actions modulation neuroendocrine neurons new hypothalamic peptide hypocretinorexin
0.358711.12485808.html.plaintext.txt	236	J Neurosci 18 7962 7971 1998AbstractFree Full Text
0.358711.12485808.html.plaintext.txt	237	Yamada H Okumura T Motomuran W Kobayashi Y Kohgo Y
0.358711.12485808.html.plaintext.txt	238	Inhibition food intake central injection anti orexin antibody fasted rats
0.358711.12485808.html.plaintext.txt	239	Biochem Biophys Res Commun 267 527 531 2000ISIMedline
0.358711.12485808.html.plaintext.txt	240	Yamanaka A Kunii K Nambu T Tsujino N Sakai A Matsuzaki I Miwa Y Goto K Sakurai T
0.358711.12485808.html.plaintext.txt	241	Orexin induced food intake involves neuropeptide Y pathway
0.358711.12485808.html.plaintext.txt	242	Brain Res 859 404 409 2000ISIMedline
0.358711.12485808.html.plaintext.txt	243	Yoshimichi G Yoshimatsu H Masaki T Sakata T
0.358711.12485808.html.plaintext.txt	244	Orexin A regulates body temperature coordination arousal status
0.358711.12485808.html.plaintext.txt	245	Exp Biol Med 226 468 476 2001AbstractFree Full Text
0.358711.12485808.html.plaintext.txt	246	Yoshizawa T Yamagishi Y Koseki N Goto J Yoshida H Shibasaki F Shoji S Kanazawa I
0.358711.12485808.html.plaintext.txt	247	Cell cycle arrest enhances vitro toxicity truncated Machado Joseph disease gene product expanded pyroglutamine stretch
0.358711.12485808.html.plaintext.txt	248	Hum Mol Genet 9 69 78 2000AbstractFree Full Text
0.358711.12485808.html.plaintext.txt	249	Am J Physiol Endocrinol Metab 2841E13 E17 0193 184903 5
0.358711.12485808.html.plaintext.txt	250	00 Copyright 2003 American Physiological Society
0.099135764.12639939.html.plaintext.txt	0	Gonadotropin Releasing Hormone Neurons Coexpress Orexin 1 Receptor Immunoreactivity Receive Direct Contacts Orexin Fibers Rebecca E
0.099135764.12639939.html.plaintext.txt	1	Oregon National Primate Research Center Beaverton Oregon 97006 Department Physiology Pharmacology R
0.099135764.12639939.html.plaintext.txt	2	Oregon Health Science University Portland Oregon 97239
0.099135764.12639939.html.plaintext.txt	3	Address correspondence requests reprints Dr
0.099135764.12639939.html.plaintext.txt	4	Susan Smith Oregon National Primate Research Center Oregon Health Science University Beaverton Oregon 97006
0.099135764.12639939.html.plaintext.txt	5	Abstract Top Abstract Introduction Materials Methods Results Discussion References The orexins produced neurons lateral hypothalamic area implicated regulation feeding reproductive function
0.099135764.12639939.html.plaintext.txt	6	Orexins stimulate LH secretion steroid primed ovariectomized female rats suppress LH secretion nonprimed ovariectomized rats
0.099135764.12639939.html.plaintext.txt	7	The aim present study characterize neuroanatomical pathway orexin might modulate LH secretion rat
0.099135764.12639939.html.plaintext.txt	8	Using double triple label immunofluorescence coupled confocal microscopy found 75 85 GnRH neurons contacted orexin fibers triple labeling synaptophysin provided additional confirmation close contacts
0.099135764.12639939.html.plaintext.txt	9	Furthermore 85 GnRH neurons colocalized orexin receptor 1 OX R1 OX R1 expressing GnRH neurons contacted orexin terminals providing basis functional neuroanatomical pathway
0.099135764.12639939.html.plaintext.txt	10	GnRH nerve terminals median eminence however express OX R1
0.099135764.12639939.html.plaintext.txt	11	An additional study investigated coexpression neuropeptide Y Y4 like receptors orexin fibers relation GnRH neurons
0.099135764.12639939.html.plaintext.txt	12	There evidence Y4 receptor stimulation results LH release studies laboratory show Y4 like immunoreactivity majority orexin cell bodies lateral hypothalamic area orexin fibers scattered throughout hypothalamus
0.099135764.12639939.html.plaintext.txt	13	The present study found although Y4 positive orexin fibers present area GnRH neurons never come close contact GnRH neurons
0.099135764.12639939.html.plaintext.txt	14	Together data suggest Y4 receptor modulation LH release likely indirect orexin cell bodies orexin modulates GnRH neurons directly via OX R1
0.099135764.12639939.html.plaintext.txt	15	Introduction Top Abstract Introduction Materials Methods Results Discussion References THE NEUROPEPTIDES OREXIN A orexin B also known hypocretin 1 hypocretin 2 recently characterized 1 2 implicated regulation arousal states energy metabolism neuroendocrine reproductive function reviews see Refs
0.099135764.12639939.html.plaintext.txt	16	The peptides derived common precursor expression identified neuronal cell bodies lateral hypothalamic area LHA
0.099135764.12639939.html.plaintext.txt	17	Although orexin expressing cell bodies restricted area send widespread projections throughout brain spinal cord
0.099135764.12639939.html.plaintext.txt	18	Orexin actions mediated via G protein coupled receptors two different subtypes OX R1 OX R2
0.099135764.12639939.html.plaintext.txt	19	OX R2 nonselective receptor binds orexin A B OX R1 highly selective orexin A 2
0.099135764.12639939.html.plaintext.txt	20	Complementary widespread projections orexin fibers 6 OX R1 OX R2 mRNA protein found widely expressed brain 7 8 9 10
0.099135764.12639939.html.plaintext.txt	21	Recent physiological neuroanatomical studies suggest orexin A may play important role control hypothalamo pituitary gonadal axis
0.099135764.12639939.html.plaintext.txt	22	For example shown central administration orexin A stimulates LH secretion 11
0.099135764.12639939.html.plaintext.txt	23	However similar orexigenic peptides neuropeptide Y NPY orexin shown bimodal effects LH secretion orexin stimulating LH secretion steroid primed ovariectomized rats inhibiting LH secretion absence ovarian steroids 11 12
0.099135764.12639939.html.plaintext.txt	24	It also demonstrated immunoneutralization orexin A brain completely abolishes LH PRL surges icv administration orexin leads dose dependent recovery fasting suppressed LH surges 13
0.099135764.12639939.html.plaintext.txt	25	In addition tissue explant studies shown orexin A stimulates GnRH release hypothalamus intact male rats female rats proestrus 14
0.099135764.12639939.html.plaintext.txt	26	Recently study employing low dose estrogen replacement ovariectomized rats resulting serum levels similar observed diestrus demonstrated low dose estrogen potentiates suppressive effects centrally administered orexin A LH secretion 15 suggesting orexin A inhibitory diestrus low estrogen states excitatory surge conditions
0.099135764.12639939.html.plaintext.txt	27	Although orexin clearly implicated regulation GnRHLH secretion neuroanatomical pathway orexin may mediating effects rat remains determined
0.099135764.12639939.html.plaintext.txt	28	The first aim present study investigate whether orexin fibers project come close contact GnRH neurons whether GnRH neurons express OX R1 rat
0.099135764.12639939.html.plaintext.txt	29	Similar orexin NPY found elicit bimodal effects LH release likely acting Y1 16 17 18 Y4 17 19 20 21 Y5 22 23 receptor subtypes
0.099135764.12639939.html.plaintext.txt	30	Recently laboratory reported majority orexin cell bodies LHA expressed Y4 like immunoreactivity Y4 ir orexin fibers also positive Y4 ir 19
0.099135764.12639939.html.plaintext.txt	31	Others shown activation Y4 receptors Y4 agonist 1229U91 high affinity ligand Y4 receptor rat pancreatic polypeptide rPP stimulates GnRH neurons turn LH release intact male rats 20 important basal release LH female rat 17
0.099135764.12639939.html.plaintext.txt	32	Conversely infertile leptin deficient obob mouse crossed Y4 knockout mouse fertility partially restored suggesting Y4 receptor involved suppressing reproductive function 21
0.099135764.12639939.html.plaintext.txt	33	Taken together data suggest effects Y4 activation LH release may mediated via orexin
0.099135764.12639939.html.plaintext.txt	34	Therefore second aim present study characterize neuroanatomical relationship Y4 positive orexin fibers GnRH neurons
0.099135764.12639939.html.plaintext.txt	35	Materials Methods Top Abstract Introduction Materials Methods Results Discussion References Animals tissue Male virgin cycling female rats Simonsen Laboratories Gilroy CA housed individually maintained 12 h light 12 h dark cycle lights 0700 h constant temperature 23 plus minus 2 C
0.099135764.12639939.html.plaintext.txt	36	Food water available ad libitum
0.099135764.12639939.html.plaintext.txt	37	All animal procedures approved Oregon National Primate Research Center Institutional Animal Care Use Committee
0.099135764.12639939.html.plaintext.txt	38	For immunocytochemical studies animals n 4 5 male female rats used experiment killed pentobarbital anesthesia cardiac infusion ice cold PBS followed ice cold paraformaldehyde NaPO4 buffer pH 7
0.099135764.12639939.html.plaintext.txt	39	The brains removed saturated 25 sucrose frozen cooled isopentane stored 80 C sectioning microtome
0.099135764.12639939.html.plaintext.txt	40	A one six series tissue sections 25 microm collected animal
0.099135764.12639939.html.plaintext.txt	41	Double triple label immunofluorescence IF All immunofluorescent labeling previously reported 18 22 performed floating sections
0.099135764.12639939.html.plaintext.txt	42	Double triple label IF orexin GnRH one synaptophysin OX R1 Y4 performed using cocktail primary antibodies
0.099135764.12639939.html.plaintext.txt	43	The goat polyclonal orexin antibody Santa Cruz Biotechnology Santa Cruz CA used concentration 110000 19
0.099135764.12639939.html.plaintext.txt	44	The mouse monoclonal GnRH antibody kind gift H
0.099135764.12639939.html.plaintext.txt	45	Urbanski Oregon National Primate Research Center Beaverton OR used concentration 1500 22
0.099135764.12639939.html.plaintext.txt	46	The rabbit polyclonal synaptophysin antibody DAKO Corp
0.099135764.12639939.html.plaintext.txt	47	Carpinteria CA used concentration 1200
0.099135764.12639939.html.plaintext.txt	48	The rabbit polyclonal OX R1 antibody kind gift G
0.099135764.12639939.html.plaintext.txt	49	Hervieu SmithKline Beecham Foods International Harlow Essex UK used concentration 1500 9 24
0.099135764.12639939.html.plaintext.txt	50	The OX R1 antibody extensively characterized shown specific evidenced agreement patterns receptor mRNA protein expression 9 specific detection receptor cell line transfected OX R1 9 loss specific staining following preabsorption antiserum immunogen peptide 24
0.099135764.12639939.html.plaintext.txt	51	The rabbit polyclonal Y4 antibody kind gift J
0.099135764.12639939.html.plaintext.txt	52	ffrench Mullen used 110000 concentration 19
0.099135764.12639939.html.plaintext.txt	53	The specificity antibody confirmed showing similar expression patterns mRNA protein determined Western blot IF
0.099135764.12639939.html.plaintext.txt	54	For combination double triple labeling primary antibodies titrated establish maximum dilutions provided robust signals minimum nonspecific staining
0.099135764.12639939.html.plaintext.txt	55	First double labeling orexin GnRH performed
0.099135764.12639939.html.plaintext.txt	56	Briefly floating tissue sections removed cryoprotectant washed 0
0.099135764.12639939.html.plaintext.txt	57	Tissue incubated blocking buffer KPBS 0
0.099135764.12639939.html.plaintext.txt	58	4 Triton X 100 2 normal donkey serum 20 min reduce background incubated cocktail orexin GnRH primary antibodies 48 h 4 C
0.099135764.12639939.html.plaintext.txt	59	Following washes KPBS tissue incubated 1 h cocktail fluorescent secondary antibodies
0.099135764.12639939.html.plaintext.txt	60	Orexin visualized tetramethyl rhodamine isothiocyanate TRITC conjugated donkey antigoat antibody 1200 Jackson ImmunoResearch Laboratories Inc
0.099135764.12639939.html.plaintext.txt	61	West Grove PA GnRH visualized fluorescein isothiocyanate FITC conjugated donkey antimouse antibody 1200 Jackson ImmunoResearch Laboratories Inc
0.099135764.12639939.html.plaintext.txt	62	Subsequently double labeling GnRH OX R1 performed
0.099135764.12639939.html.plaintext.txt	63	As previous experiment GnRH visualized FITC conjugated donkey antimouse antibody 1200 OX R1 visualized TRITC conjugated donkey antirabbit antibody 1200 Jackson ImmunoResearch Laboratories Inc
0.099135764.12639939.html.plaintext.txt	64	Triple label experiments GnRHorexinsynaptophysin GnRHOX R1orexin GnRHorexinY4 carried similar manner
0.099135764.12639939.html.plaintext.txt	65	In triple label experiment GnRH visualized FITC conjugated donkey antimouse antibody 1200
0.099135764.12639939.html.plaintext.txt	66	In first triple label experiment orexin visualized TRITC conjugated donkey antigoat antibody 1200 synaptophysin visualized Cy5 conjugated donkey antirabbit antibody 1200 Jackson ImmunoResearch Laboratories Inc
0.099135764.12639939.html.plaintext.txt	67	In second triple label experiment OX R1 visualized TRITC conjugated donkey antirabbit antibody 1200 orexin visualized Cy5 conjugated donkey antigoat antibody 1200
0.099135764.12639939.html.plaintext.txt	68	The final triple label experiment used Cy5 conjugated donkey antirabbit antibody 1200 visualize Y4 TRITC conjugated donkey antigoat antibody 1200 visualize orexin
0.099135764.12639939.html.plaintext.txt	69	To enhance signal Y4 ir BLAST technique biotinylated tyramide enhancement used reported previously 18 19
0.099135764.12639939.html.plaintext.txt	70	Sections experiments mounted onto subbed slides cover slipped glycerol sealed
0.099135764.12639939.html.plaintext.txt	71	Confocal laser microscopy Confocal laser microscopy previously described 18 22 used analyze double triple label IF images colocalization close contacts
0.099135764.12639939.html.plaintext.txt	72	The TSC SP confocal system Leica Corp
0.099135764.12639939.html.plaintext.txt	73	Germany consisting RBE inverted microscope Leica Corp
0.099135764.12639939.html.plaintext.txt	74	Ar laser producing light 488 nm visualization FITC Kr laser producing light 568 nm visualizing TRITC HeNe laser producing light 647 nm visualization Cy5 used scan images
0.099135764.12639939.html.plaintext.txt	75	Various objectives x25 numerical aperture 0
0.099135764.12639939.html.plaintext.txt	76	75 x40 numerical aperture 1
0.099135764.12639939.html.plaintext.txt	77	25 used scan capture images
0.099135764.12639939.html.plaintext.txt	78	For experiment fluorophore signals checked individually bleed apposing detector
0.099135764.12639939.html.plaintext.txt	79	All bleed eliminated adjusting laser intensity detector window width
0.099135764.12639939.html.plaintext.txt	80	To assess colocalization two signals series continuous optical sections 0
0.099135764.12639939.html.plaintext.txt	81	5 microm intervals along z axis tissue section scanned fluorescent signal
0.099135764.12639939.html.plaintext.txt	82	The signals obtained fluorophore one series optical sections stored separately series 512 x 512 pixel images
0.099135764.12639939.html.plaintext.txt	83	The stacks individual optical slices 0
0.099135764.12639939.html.plaintext.txt	84	5 microm resolution analyzed using MetaMorph imaging system Universal Imaging Corp
0.099135764.12639939.html.plaintext.txt	85	West Chester PA determine colocalization contacts
0.099135764.12639939.html.plaintext.txt	86	The confocal images presented projections stacks optical images individual slices indicated
0.099135764.12639939.html.plaintext.txt	87	The brightness contrast images adjusted Photoshop match microscope visualization Adobe Systems Inc
0.099135764.12639939.html.plaintext.txt	88	Data analysis In double label IF studies GnRHorexin GnRHOX R1 one series tissue sections 10 12 sections 150 microm interval sections used animal n 4 5 animals
0.099135764.12639939.html.plaintext.txt	89	GnRH neurons analyzed entire cell body including proximal dendritic processes visible section
0.099135764.12639939.html.plaintext.txt	90	For triple label IF studies representative sections several animals examined
0.099135764.12639939.html.plaintext.txt	91	These studies performed primarily proof principle
0.099135764.12639939.html.plaintext.txt	92	GnRH neurons expressing OX R1 contacted orexin fibers GnRHOX R1orexin orexin contacts observed GnRH neurons represent potential synaptic contacts GnRHorexinsynaptophysin
0.099135764.12639939.html.plaintext.txt	93	In triple label IF GnRHorexinY4 scattered Y4 positive orexin fibers area GnRH neurons
0.099135764.12639939.html.plaintext.txt	94	Results Top Abstract Introduction Materials Methods Results Discussion References Double label IF studies showed orexin fibers red surrounded GnRH neurons green made close contact yellow color indicates colocalization Fig
0.099135764.12639939.html.plaintext.txt	95	Sections four brains analyzed 500 GnRH neurons results showed 75 85 GnRH neurons brain contacted orexin fibers differences observed male female animals
0.099135764.12639939.html.plaintext.txt	96	Using synaptophysin protein localized synaptic vesicles marker synaptic contacts orexin fiber butons colocalized synaptophysin associated GnRH neurons Fig
0.099135764.12639939.html.plaintext.txt	97	Shown stack images D individual optical slices 0
0.099135764.12639939.html.plaintext.txt	98	25 microm resolution E F spine orexin fiber red colocalized synaptophsyin blue makes close contact GnRH neuron white represents triple labeling
0.099135764.12639939.html.plaintext.txt	99	Additional double label studies showed GnRH neurons colocalized OX R1 ir indicated yellow color low high power examples Fig
0.099135764.12639939.html.plaintext.txt	100	Consistent robust innervation GnRH neurons orexin OX R1 ir colocalized 85 plus minus 2 GnRH neurons examined 485 neurons five brains
0.099135764.12639939.html.plaintext.txt	101	Triple label IF confirmed orexin fibers shown blue made contacts onto GnRH neurons expressing OX R1 ir Fig
0.099135764.12639939.html.plaintext.txt	102	View larger version 56K Figure 1
0.099135764.12639939.html.plaintext.txt	103	Orexin fibers come close contact GnRH neurons
0.099135764.12639939.html.plaintext.txt	104	A A low power fluorescent photomicrograph demonstrating GnRH neurons green surrounded orexin fibers red
0.099135764.12639939.html.plaintext.txt	105	Higher power examples individual GnRH neurons B C show orexin fibers making close contact
0.099135764.12639939.html.plaintext.txt	106	Arrowheads indicate apparent close contacts B C colocalization pixels results yellow color
0.099135764.12639939.html.plaintext.txt	107	D An example orexin fiber red spine arrowhead colocalized synaptophysin blue makes close contact GnRH cell body green
0.099135764.12639939.html.plaintext.txt	108	The white pixels indicate triple label overlap yellow pixels indicate colocalization red green pixels
0.099135764.12639939.html.plaintext.txt	109	25 microm resolution optical slices demonstrating triple labeling arrowhead
0.099135764.12639939.html.plaintext.txt	110	White scale bars A 50 microm B E 25 microm
0.099135764.12639939.html.plaintext.txt	111	View larger version 69K Figure 2
0.099135764.12639939.html.plaintext.txt	112	GnRH neurons express OX R1 ir receive close contacts orexin fibers
0.099135764.12639939.html.plaintext.txt	113	A A low power example double label IF GnRH neurons green OX R1 expressing neurons red medial preoptic area hypothalamus
0.099135764.12639939.html.plaintext.txt	114	The yellow color indicates colocalization
0.099135764.12639939.html.plaintext.txt	115	B A higher power example OX R1 expressing GnRH greenyellow neuron single labeled OX R1 neuron red shown
0.099135764.12639939.html.plaintext.txt	116	C D Two representative examples triple label IF GnRH neurons green expressing OX R1 ir single label red colocalization GnRH yellow
0.099135764.12639939.html.plaintext.txt	117	Orexin fibers blue make apparent close contacts OX R1 expressing regions GnRH neurons indicated white arrows
0.099135764.12639939.html.plaintext.txt	118	The yellow arrow indicates orexin fiber contact onto single label OX R1 neuron red
0.099135764.12639939.html.plaintext.txt	119	White scale bars A 50 microm B D 25 microm
0.099135764.12639939.html.plaintext.txt	120	OX R1 expression orexin innervation also investigated region GnRH terminals median eminence ME
0.099135764.12639939.html.plaintext.txt	121	3 although OX R1 expression red region orexin fibers appear innervate dorsolateral ME blue coexpression OX R1 GnRH green little interaction orexin fibers GnRH nerve terminals
0.099135764.12639939.html.plaintext.txt	122	View larger version 77K Figure 3
0.099135764.12639939.html.plaintext.txt	123	GnRH nerve terminals median eminence express OX R1
0.099135764.12639939.html.plaintext.txt	124	A B Two representative images triple label IF GnRH fibers green OX R1 red orexin fibers blue ME
0.099135764.12639939.html.plaintext.txt	125	No colocalization OX R1 GnRH fibers apparent orexin fibers minimal interaction GnRH nerve terminals
0.099135764.12639939.html.plaintext.txt	126	An additional triple label study carried investigate whether Y4 positive orexin fibers make close contacts GnRH neurons
0.099135764.12639939.html.plaintext.txt	127	Only scattered Y4 positive orexin fibers observed vicinity GnRH cell bodies
0.099135764.12639939.html.plaintext.txt	128	Figure 4 depicts three GnRH cell bodies surrounded orexin fibers
0.099135764.12639939.html.plaintext.txt	129	The white arrows indicate two fibers Y4orexin positive
0.099135764.12639939.html.plaintext.txt	130	The yellow arrows indicate orexin positive fibers identified coming close contact GnRH neurons
0.099135764.12639939.html.plaintext.txt	131	Although multiple close contacts orexin fibers GnRH shown previously Fig
0.099135764.12639939.html.plaintext.txt	132	1 Y4 positive orexin fibers never came close contact GnRH neurons
0.099135764.12639939.html.plaintext.txt	133	View larger version 46K Figure 4
0.099135764.12639939.html.plaintext.txt	134	Y4 positive orexin ir fibers near GnRH neurons make close contacts
0.099135764.12639939.html.plaintext.txt	135	Triple label IF demonstrates GnRH neurons green surrounded orexin fibers red Y4 positive orexin double label fibers white indicated white arrows
0.099135764.12639939.html.plaintext.txt	136	It noted Y4 expression orexin fibers changed original color magenta white make visible photographs
0.099135764.12639939.html.plaintext.txt	137	The beaded appearance Y4 positive orexin neurons may exaggerated BLAST technique enhance Y4 staining although similar appearance also observed single label orexin fibers see Figs
0.099135764.12639939.html.plaintext.txt	138	Orexin single label fibers coming close contact GnRH neurons indicated double label yellow pixels marked yellow arrows
0.099135764.12639939.html.plaintext.txt	139	Discussion Top Abstract Introduction Materials Methods Results Discussion References The present study provides evidence functional neuroanatomical pathway orexin system GnRH neurons rat GnRH neurons express OX R1 contacted orexin fibers Figs
0.099135764.12639939.html.plaintext.txt	140	There appears interaction orexin fibers GnRH nerve terminals ME Fig
0.099135764.12639939.html.plaintext.txt	141	The immunoreactivity orexin fibers OX R1 presented present study confirms previous findings demonstrating orexin A immunoreactive fibers 6 OX R1 mRNA 7 immunoreactivity 9 present septal medial preoptic regions GnRH neurons located
0.099135764.12639939.html.plaintext.txt	142	Our data support previously reported findings ovine hypothalamus orexin fibers originating LHA found close contact GnRH neurons 25
0.099135764.12639939.html.plaintext.txt	143	However although present study found 75 85 GnRH neurons contacted orexin fibers approximately 85 GnRH neurons expressed OX R1 previous study found contacts 30 GnRH neurons
0.099135764.12639939.html.plaintext.txt	144	This discrepancy two studies may due several things including species differences rodent sheep
0.099135764.12639939.html.plaintext.txt	145	If case important investigate orexin innervation GnRH neurons species especially primate
0.099135764.12639939.html.plaintext.txt	146	Another discrepancy may due differences sensitivity antibodies used two studies obtained different sources
0.099135764.12639939.html.plaintext.txt	147	The present study shows dense networks fine immunoreactive fibers Figs
0.099135764.12639939.html.plaintext.txt	148	1A 4 orexin fibers demonstrated ovine hypothalamus 25 much less dense
0.099135764.12639939.html.plaintext.txt	149	Yet another discrepancy might due differences sensitivity confocal microscopy analysis
0.099135764.12639939.html.plaintext.txt	150	It generally accepted although confocal microscopy provide good approximation synaptic interactions limitations technique preclude degree certainty obtained using electron microscopy
0.099135764.12639939.html.plaintext.txt	151	Several lines evidence support contention orexin A modulates neuroendocrine function
0.099135764.12639939.html.plaintext.txt	152	In addition number studies indicating steroid dependent effects central orexin administration LH release 11 12 15 studies using vitro explants indicate stimulatory effects orexin hypothalamic level 14
0.099135764.12639939.html.plaintext.txt	153	It also reported orexin A stimulates GnRH release hypothalamic explants collected male rats female rats proestrus
0.099135764.12639939.html.plaintext.txt	154	These data suggest stimulatory effects orexin LH release via direct stimulation GnRH secretion
0.099135764.12639939.html.plaintext.txt	155	Indeed present findings provide functional neuroanatomical pathway orexin may stimulate GnRH neurons subsequent LH release via direct contact OX R1 GnRH cell bodies nerve terminals within ME
0.099135764.12639939.html.plaintext.txt	156	OX R1 exclusively coupled Gq11 subtype G proteins 5 26 suggesting orexin action via OX R1 GnRH neurons excitatory
0.099135764.12639939.html.plaintext.txt	157	However orexin also shown inhibit LH secretion absence gonadal steroids 12 although mechanism gonadal steroids modulate orexin effects LH secretion remains determined
0.099135764.12639939.html.plaintext.txt	158	It possible inhibitory actions orexin GnRH neurons indirect involving activation neurons within preoptic area also express OX R1 Fig
0.099135764.12639939.html.plaintext.txt	159	2 turn may inhibitory actions GnRH neurons
0.099135764.12639939.html.plaintext.txt	160	As name implies orexin activity necessary normal feeding behavior
0.099135764.12639939.html.plaintext.txt	161	The central injection orexin A stimulates food intake satiated rats 27 28 whereas neutralization orexin antiorexin antibody dose dependently suppresses spontaneous feeding fasted rats 29
0.099135764.12639939.html.plaintext.txt	162	Furthermore orexin mRNA increased fasting 2
0.099135764.12639939.html.plaintext.txt	163	These data suggest orexin neurons able sense nutritional state animal
0.099135764.12639939.html.plaintext.txt	164	It shown repeatedly changes metabolic status animal tightly linked changes reproductive function
0.099135764.12639939.html.plaintext.txt	165	Therefore ability orexin modulate feeding behavior reproductive function along present neuroanatomical findings suggests orexin system key position serve integrating signal energy balance reproductive function
0.099135764.12639939.html.plaintext.txt	166	In addition orexin neurons known coexpress long form leptin receptor Ob Rb rat 30 sheep 25
0.099135764.12639939.html.plaintext.txt	167	Leptin peripheral metabolic signal released adipocytes important denoting adiposity energy balance brain
0.099135764.12639939.html.plaintext.txt	168	Also leptin shown play role regulating reproductive function
0.099135764.12639939.html.plaintext.txt	169	Administration leptin restores fasting induced suppression LH secretion sheep primates 31 32 33
0.099135764.12639939.html.plaintext.txt	170	However GnRH neurons express Ob Rb
0.099135764.12639939.html.plaintext.txt	171	As previously suggested similar findings ovine hypothalamus 25 direct projections Ob Rb expressing orexin neurons GnRH neurons may provide one potential neuroanatomical circuit leptin regulates GnRH activity
0.099135764.12639939.html.plaintext.txt	172	NPY another neuropeptide system may important integrating signal energy balancefood intake reproductive function 34
0.099135764.12639939.html.plaintext.txt	173	Similar effects orexin NPY also elicits steroid dependent effects LH secretion 35
0.099135764.12639939.html.plaintext.txt	174	Orexin neurons LHA receive direct synaptic contacts NPY neurons projecting arcuate nucleus turn send reciprocal projections arcuate nucleus NPY neurons 36
0.099135764.12639939.html.plaintext.txt	175	Currently evidence implicating Y1 16 17 18 Y4 17 19 20 21 Y5 22 23 receptor subtypes NPY modulation neuroendocrine reproductive function
0.099135764.12639939.html.plaintext.txt	176	Of direct relevance Y4 ir mRNA colocalized orexin neurons LHA 19
0.099135764.12639939.html.plaintext.txt	177	These data coupled present findings GnRH neurons express OX R1 contacted orexin fibers demonstrate unique potential neuronal circuit whereby NPY acting Y4 receptor exert effects LH release via modulation orexin
0.099135764.12639939.html.plaintext.txt	178	Because present study also showed Y4 positive orexin fibers never observed close contact GnRH neurons major actions Y4 receptor appear postsynaptic effects orexin cell bodies within LHA
0.099135764.12639939.html.plaintext.txt	179	Taken together data suggest orexin neurons receiving critical input via Y4 leptin receptors may provide important link regulation energy balance reproductive function
0.099135764.12639939.html.plaintext.txt	180	A number questions remain concerning modulatory effects Y4 orexin system GnRH neurons
0.099135764.12639939.html.plaintext.txt	181	First endogenous ligand brain Y4 receptor clear
0.099135764.12639939.html.plaintext.txt	182	Is NPY much lower affinity Y4 receptor 37 pancreatic polypeptide family ligands Our recent study characterizing expression Y4 ir orexin neurons also found administration rPP endogenous ligand Y4 receptor induced robust cFos activation orexin neurons 19
0.099135764.12639939.html.plaintext.txt	183	Furthermore rPP stimulated modest increase food intake robust drinking response 19 similar responses orexin
0.099135764.12639939.html.plaintext.txt	184	These data suggest stimulation Y4 receptor rPP excitatory orexin neurons
0.099135764.12639939.html.plaintext.txt	185	However effects Y4 reproductive function shown stimulatory 17 20 inhibitory 21
0.099135764.12639939.html.plaintext.txt	186	Similarly effects orexin reported stimulatory inhibitory reproductive function 11 12 13 14 15
0.099135764.12639939.html.plaintext.txt	187	Therefore possible actions Y4 receptor GnRHLH axis mediated via orexin system
0.099135764.12639939.html.plaintext.txt	188	In summary data provide neuroanatomical evidence direct link orexin system GnRH neurons
0.099135764.12639939.html.plaintext.txt	189	These findings suggest orexin plays direct role neuroendocrine control reproduction may also uniquely positioned integrate signals associated energy balance regulation
0.099135764.12639939.html.plaintext.txt	190	Additional studies necessary establish relative importance novel neuronal circuitry regulation reproductive function normal cyclicity well metabolic changes
0.099135764.12639939.html.plaintext.txt	191	Footnotes This work supported NIH Grants HD 14643 HD 18185 RR 00163
0.099135764.12639939.html.plaintext.txt	192	Abbreviations FITC Fluorescein isothiocyanate IF immunofluorescence KPBS potassium PBS LHA lateral hypothalamic area ME median eminence NPY neuropeptide Y OX R orexin receptor rPP rat pancreatic polypeptide TRITC tetramethyl rhodamine isothiocyanate Y4 ir Y4 like immunoreactivity
0.099135764.12639939.html.plaintext.txt	193	Accepted publication January 6 2003
0.099135764.12639939.html.plaintext.txt	194	References Top Abstract Introduction Materials Methods Results Discussion References De Lecea L Kilduff TS Peyron C Gao X Foye PE Danielson PE Fukuhara C Battenberg EL Gautvik VT Bartlett 2nd FS Frankel WN van den Pol AN Bloom FE Gautvik KM Sutcliffe JG 1998 The hypocretins hypothalamus specific peptides neuroexcitatory activity
0.099135764.12639939.html.plaintext.txt	195	Proc Natl Acad Sci USA 95322 327AbstractFree Full Text Sakurai T Amemiya A Ishii M Matsuzaki I Chemelli RM Tanaka H Williams SC Richardson JA Kozlowski GP Wilson S Arch JR Buckingham RE Haynes AC Carr SA Annan RS McNulty DE Liu WS Terrett JA Elshourbagy NA Bergsma DJ Yanagisawa M 1998 Orexins orexin receptors family hypothalamic neuropeptides G protein coupled receptors regulate feeding behavior
0.099135764.12639939.html.plaintext.txt	196	Cell 92573 585Medline Sakurai T 2002 Roles orexins regulation feeding wakefulness
0.099135764.12639939.html.plaintext.txt	197	Neuroreport 13987 995Medline Sutcliffe JG de Lecea L 2002 The hypocretins setting arousal threshold
0.099135764.12639939.html.plaintext.txt	198	Nat Rev Neurosci 3339 349CrossRefMedline Beuckmann CT Yanagisawa M 2002 Orexins neuropeptides energy homeostasis sleepwake regulation
0.099135764.12639939.html.plaintext.txt	199	J Mol Med 80329 342CrossRefMedline Peyron C Tighe DK van den Pol AN de Lecea L Heller HC Sutcliffe JG Kilduff TS 1998 Neurons containing hypocretin orexin project multiple neuronal systems
0.099135764.12639939.html.plaintext.txt	200	J Neurosci 189996 10015AbstractFree Full Text Trivedi P Yu H MacNeil DJ Van der Ploeg LH Guan XM 1998 Distribution orexin receptor mRNA rat brain
0.099135764.12639939.html.plaintext.txt	201	FEBS Lett 43871 75CrossRefMedline Marcus JN Aschkenasi CJ Lee CE Chemelli RM Saper CB Yanagisawa M Elmquist JK 2001 Differential expression orexin receptors 1 2 rat brain
0.099135764.12639939.html.plaintext.txt	202	J Comp Neurol 4356 25CrossRefMedline Hervieu GJ Cluderay JE Harrison DC Roberts JC Leslie RA 2001 Gene expression protein distribution orexin 1 receptor rat brain spinal cord
0.099135764.12639939.html.plaintext.txt	203	Neuroscience 103777 797CrossRefMedline Cluderay JE Harrison DC Hervieu GJ 2002 Protein distribution orexin 2 receptor rat central nervous system
0.099135764.12639939.html.plaintext.txt	204	Regul Pept 104131 144CrossRefMedline Pu S Jain MR Kalra PS Kalra SP 1998 Orexins novel family hypothalamic neuropeptides modulate pituitary luteinizing hormone secretion ovarian steroid dependent manner
0.099135764.12639939.html.plaintext.txt	205	Regul Pept 78133 136CrossRefMedline Tamura T Irahara M Tezuka M Kiyokawa M Aono T 1999 Orexins orexigenic hypothalamic neuropeptides suppress pulsatile secretion luteinizing hormone ovariectomized female rats
0.099135764.12639939.html.plaintext.txt	206	Biochem Biophys Res Commun 264759 762CrossRefMedline Kohsaka A Watanobe H Kakizaki Y Suda T Schioth HB 2001 A significant participation orexin A potent orexigenic peptide preovulatory luteinizing hormone prolactin surges rat
0.099135764.12639939.html.plaintext.txt	207	Brain Res 898166 170CrossRefMedline Russell SH Small CJ Kennedy AR Stanley SA Seth A Murphy KG Taheri S Ghatei MA Bloom SR 2001 Orexin A interactions hypothalamo pituitary gonadal axis
0.099135764.12639939.html.plaintext.txt	208	Endocrinology 1425294 5302AbstractFree Full Text Furuta M Funabashi T Kimura F 2002 Suppressive action orexin A pulsatile luteinizing hormone secretion potentiated low dose estrogen ovariectomized rats
0.099135764.12639939.html.plaintext.txt	209	Neuroendocrinology 75151 155CrossRefMedline Leupen SM Besecke LM Levine JE 1997 Neuropeptide Y Y1 receptor stimulation required physiological amplification preovulatory luteinizing hormone surges
0.099135764.12639939.html.plaintext.txt	210	Endocrinology 1382735 2739AbstractFree Full Text Jain MR Pu S Kalra PS Kalra SP 1999 Evidence stimulation two modalities pituitary luteinizing hormone release ovarian steroid primed ovariectomized rats may involve neuropeptide Y Y1 Y4 receptors
0.099135764.12639939.html.plaintext.txt	211	Endocrinology 1405171 5177AbstractFree Full Text Li C Chen P Smith MS 1999 Morphological evidence direct interaction arcuate nucleus neuropeptide Y NPY neurons gonadotropin releasing hormone neurons possible involvement NPY Y1 receptors
0.099135764.12639939.html.plaintext.txt	212	Endocrinology 1405382 5390AbstractFree Full Text Campbell RE Smith MS Allen SE Grayson BE ffrench Mullen J Grove KL Orexin neurons lateral hypothalamic area express Neuropeptide Y Y4 receptor activated rat pancreatic polypeptide rPP
0.099135764.12639939.html.plaintext.txt	213	J Neurosci press Raposinho PD Broqua P Hayward A Akinsanya K Galyean R Schteingart C Junien J Aubert ML 2000 Stimulation gonadotropic axis neuropeptide Y receptor Y1 antagonistY4 agonist 1229U91 male rat
0.099135764.12639939.html.plaintext.txt	214	Neuroendocrinology 712 7CrossRefMedline Sainsbury A Schwarzer C Couzens M Jenkins A Oakes SR Ormandy CJ Herzog H 2002 Y4 receptor knockout rescues fertility obob mice
0.099135764.12639939.html.plaintext.txt	215	Genes Dev 161077 1088AbstractFree Full Text Campbell RE ffrench Mullen JM Cowley MA Smith MS Grove KL 2001 Hypothalamic circuitry neuropeptide Y regulation neuroendocrine function food intake via Y5 receptor subtype
0.099135764.12639939.html.plaintext.txt	216	Neuroendocrinology 74106 119CrossRefMedline Raposinho PD Broqua P Pierroz DD Hayward A Dumont Y Quirion R Junien JL Aubert ML 1999 Evidence inhibition luteinizing hormone secretion central administration neuropeptide Y NPY rat predominantly mediated NPY Y5 receptor subtype
0.099135764.12639939.html.plaintext.txt	217	Endocrinology 1404046 4055AbstractFree Full Text Backberg M Hervieu G Wilson S Meister B 2002 Orexin receptor 1 OX R1 immunoreactivity chemically identified neurons hypothalamus focus orexin targets involved control food water intake
0.099135764.12639939.html.plaintext.txt	218	Eur J Neurosci 15315 328CrossRefMedline Iqbal J Pompolo S Sakurai T Clarke IJ 2001 Evidence orexin containing neurones provide direct input gonadotropin releasing hormone neurones ovine hypothalamus
0.099135764.12639939.html.plaintext.txt	219	J Neuroendocrinol 131033 1041CrossRefMedline Van den Pol AN Gao XB Obrietan K Kilduff TS Belousov AB 1998 Presynaptic postsynaptic actions modulation neuroendocrine neurons new hypothalamic peptide hypocretinorexin
0.099135764.12639939.html.plaintext.txt	220	J Neurosci 187962 7971AbstractFree Full Text Ida T Nakahara K Katayama T Murakami N Nakazato M 1999 Effect lateral cerebroventricular injection appetite stimulating neuropeptide orexin neuropeptide Y various behavioral activities rats
0.099135764.12639939.html.plaintext.txt	221	Brain Res 821526 529CrossRefMedline Haynes AC Jackson B Overend P Buckingham RE Wilson S Tadayyon M Arch JR 1999 Effects single chronic intracerebroventricular administration orexins feeding rat
0.099135764.12639939.html.plaintext.txt	222	Peptides 201099 1105CrossRefMedline Yamada H Okumura T Motomura W Kobayashi Y Kohgo Y 2000 Inhibition food intake central injection anti orexin antibody fasted rats
0.099135764.12639939.html.plaintext.txt	223	Biochem Biophys Res Commun 267527 531CrossRefMedline Hakansson M de Lecea L Sutcliffe JG Yanagisawa M Meister B 1999 Leptin receptor STAT3 immunoreactivities hypocretinorexin neurones lateral hypothalamus
0.099135764.12639939.html.plaintext.txt	224	J Neuroendocrinol 11653 663CrossRefMedline Finn PD Cunningham MJ Pau KY Spies HG Clifton DK Steiner RA 1998 The stimulatory effect leptin neuroendocrine reproductive axis monkey
0.099135764.12639939.html.plaintext.txt	225	Endocrinology 1394652 4662AbstractFree Full Text Nagatani S Guthikonda P Thompson RC Tsukamura H Maeda KI Foster DL 1998 Evidence GnRH regulation leptin leptin administration prevents reduced pulsatile LH secretion fasting
0.099135764.12639939.html.plaintext.txt	226	Neuroendocrinology 67370 376CrossRefMedline Nagatani S Zeng Y Keisler DH Foster DL Jaffe CA 2000 Leptin regulates pulsatile luteinizing hormone growth hormone secretion sheep
0.099135764.12639939.html.plaintext.txt	227	Endocrinology 1413965 3975AbstractFree Full Text Smith MS Grove KL 2002 Integration regulation reproductive function energy balance lactation model
0.099135764.12639939.html.plaintext.txt	228	Front Neuroendocrinol 23225 256CrossRefMedline Kalra SP Dube MG Pu S Horvath TL Kalra PS 1999 Interacting appetite regulating pathways hypothalamic regulation body weight
0.099135764.12639939.html.plaintext.txt	229	Endocr Rev 2068 100AbstractFree Full Text Horvath TL Diano S van den Pol AN 1999 Synaptic interaction hypocretin orexin neuropeptide Y cells rodent primate hypothalamus novel circuit implicated metabolic endocrine regulations
0.099135764.12639939.html.plaintext.txt	230	J Neurosci 191072 1087AbstractFree Full Text Bard JA Walker MW Branchek TA Weinshank RL 1995 Cloning functional expression human Y4 subtype receptor pancreatic polypeptide neuropeptide Y peptide YY
0.099135764.12639939.html.plaintext.txt	231	J Biol Chem 27026762 26765AbstractFree Full Text
0.29009572.11459774.html.plaintext.txt	0	Prepro Orexin Orexin Receptor mRNAs Are Differentially Expressed Peripheral Tissues Male Female Rats Olaf Johren Steffi J
0.29009572.11459774.html.plaintext.txt	1	Neidert Marco Kummer Andreas Dendorfer Peter Dominiak
0.29009572.11459774.html.plaintext.txt	2	Institute Experimental Clinical Pharmacology Toxicology Medical University Lubeck D 23538 Lubeck Germany
0.29009572.11459774.html.plaintext.txt	3	Address correspondence requests reprints Olaf Johren Ph
0.29009572.11459774.html.plaintext.txt	4	Institute Experimental Clinical Pharmacology Toxicology Medical University Lubeck Ratzeburger Allee 160 D 23538 Lubeck Germany
0.29009572.11459774.html.plaintext.txt	5	Abstract Top Abstract Introduction Materials Methods Results Discussion References Orexins produced specifically neurons located lateral hypothalamus
0.29009572.11459774.html.plaintext.txt	6	Recent results suggested peripheral actions orexins
0.29009572.11459774.html.plaintext.txt	7	Therefore analyzed mRNA expression prepro orexin orexin receptor subtypes OX1 OX2 peripheral rat tissues
0.29009572.11459774.html.plaintext.txt	8	Using real time quantitative RT PCR detected significant amounts prepro orexin mRNA testis ovaries
0.29009572.11459774.html.plaintext.txt	9	OX1 receptor mRNA highly expressed brain lower levels pituitary gland
0.29009572.11459774.html.plaintext.txt	10	Only small amounts OX1 receptor mRNA found tissues kidney adrenal thyroid testis ovaries jejunum
0.29009572.11459774.html.plaintext.txt	11	Very high levels OX2 receptor mRNA 4 fold higher brain found adrenal glands male rats
0.29009572.11459774.html.plaintext.txt	12	Low amounts OX2 receptor mRNA present lung pituitary
0.29009572.11459774.html.plaintext.txt	13	In adrenal glands OX2 receptor mRNA localized zona glomerulosa reticularis situ hybridization indicating role adrenal steroid synthesis andor release
0.29009572.11459774.html.plaintext.txt	14	OX1 receptor mRNA pituitary OX2 receptor mRNA adrenal gland much higher male female rats
0.29009572.11459774.html.plaintext.txt	15	In hypothalamus OX1 receptor mRNA slightly elevated female rats
0.29009572.11459774.html.plaintext.txt	16	The differential mRNA expression orexin receptor subtypes peripheral organs indicates discrete peripheral effects orexins existence peripheral orexin system
0.29009572.11459774.html.plaintext.txt	17	This supported detection orexin A rat plasma
0.29009572.11459774.html.plaintext.txt	18	Moreover sexually dimorphic expression OX1 OX2 receptors hypothalamus pituitary adrenal glands suggests gender specific roles orexins control endocrine functions
0.29009572.11459774.html.plaintext.txt	19	Introduction Top Abstract Introduction Materials Methods Results Discussion References THE NEUROPEPTIDES OREXIN A orexin B identified endogenous ligands orphan seven transmembrane receptor shown stimulate food intake injected brain ventricle 1
0.29009572.11459774.html.plaintext.txt	20	Orexin A B derive precursor prepro orexin selectively expressed lateral hypothalamic area region involved control feeding behavior
0.29009572.11459774.html.plaintext.txt	21	Prepro orexin identical prepro hypocretin identified independently directional tag PCR subtraction mRNA species specifically expressed rat hypothalamus 2 3
0.29009572.11459774.html.plaintext.txt	22	Orexin hypocretin immunoreactive fibers project various brain regions cerebral cortex limbic system locus coeruleus brainstem spinal chord 4 5 6 7
0.29009572.11459774.html.plaintext.txt	23	The orexin receptor subtypes OX1 OX2 also widely expressed rat brain expression patterns good agreement distribution orexin immunoreactive fibers 8
0.29009572.11459774.html.plaintext.txt	24	Based widespread projections orexinergic neurons functional considerations innervated brain areas involvement orexins control functions feeding behavior proposed including control neuroendocrine systems autonomic nervous system
0.29009572.11459774.html.plaintext.txt	25	Subsequently orexins shown increase plasma ACTH corticosterone levels reduce plasma PRL GH levels injected intracerebroventricularly icv 9 10 11
0.29009572.11459774.html.plaintext.txt	26	Furthermore icv injected orexin increased reduced plasma LH levels female rats depending status ovarian steroids 12 13
0.29009572.11459774.html.plaintext.txt	27	In addition icv intracisternally injected orexin increased mean arterial blood pressure heart rate renal sympathetic nerve activity plasma catecholamine levels 14 15 16
0.29009572.11459774.html.plaintext.txt	28	Moreover dogs mice humans orexin system seems closely associated pathogenesis narcolepsy 17 18 19
0.29009572.11459774.html.plaintext.txt	29	To date orexins considered exclusively synthesized brain 20
0.29009572.11459774.html.plaintext.txt	30	However recent results indicated endocrine effects peripheral administration orexins 21 22 23
0.29009572.11459774.html.plaintext.txt	31	On hand iv injected orexin A able cross blood brain barrier 24 sites peripheral orexin generation distribution orexin receptor subtypes yet established
0.29009572.11459774.html.plaintext.txt	32	Therefore analyzed expression prepro orexin well OX1 OX2 receptor mRNA various tissues adult male female rats
0.29009572.11459774.html.plaintext.txt	33	Materials Methods Top Abstract Introduction Materials Methods Results Discussion References Animals tissue preparation Wistar rats 250 300 g purchased Charles River Sulzfeld Germany
0.29009572.11459774.html.plaintext.txt	34	A total four male rats anesthetized pentobarbital 100 mgkg ip killed decapitation
0.29009572.11459774.html.plaintext.txt	35	Brain pituitary gland thyroid adrenals lung heart kidneys spleen liver stomach pancreas jejunum duodenum aorta adipose tissue muscle testis removed immediately
0.29009572.11459774.html.plaintext.txt	36	Tissues frozen quickly isopentane 30 C stored 80 C use
0.29009572.11459774.html.plaintext.txt	37	To analyze gender differences brain pituitary adrenals prepared eight male eight female rats 250 300 g
0.29009572.11459774.html.plaintext.txt	38	The hypothalamus dissected according method described Palkovits Brownstein 25
0.29009572.11459774.html.plaintext.txt	39	Trunk blood collected polypropylene tubes containing EDTA 15 mg aprotinin 0
0.29009572.11459774.html.plaintext.txt	40	7 mg 0 C centrifuged 1600 x g 15 min 0 C
0.29009572.11459774.html.plaintext.txt	41	Plasma stored use 70 C
0.29009572.11459774.html.plaintext.txt	42	For situ hybridization immunohistochemistry tissues obtained extra set animals n 3 sections 16 microm cut 20 C cryostat
0.29009572.11459774.html.plaintext.txt	43	The sections mounted aminoalkylsilane coated glass slides Sigma St
0.29009572.11459774.html.plaintext.txt	44	Louis MO stored 80 C
0.29009572.11459774.html.plaintext.txt	45	Every 10th section stained hematoxylineosin
0.29009572.11459774.html.plaintext.txt	46	RNA isolation cDNA synthesis Tissue samples homogenized presence guanidinium isothiocyanate total RNA isolated using silica gel based spin columns RNeasy Kit QIAGEN Hilden Germany
0.29009572.11459774.html.plaintext.txt	47	Genomic DNA digested thorough treatment deoxyribonuclease I QIAGEN
0.29009572.11459774.html.plaintext.txt	48	First strand cDNA synthesized 1 microg total RNA volume 20 microl containing 5 mM MgCl2 10 mM Tris HCl pH 9
0.29009572.11459774.html.plaintext.txt	49	1 Triton X 100 1 mM deoxy NTPs 1U microl RNasin 0
0.29009572.11459774.html.plaintext.txt	50	5 microg oligodeoxythymidine15 primer 15 U AMV reverse transcriptase Promega Corp
0.29009572.11459774.html.plaintext.txt	51	For template control samples RNA replaced H2O
0.29009572.11459774.html.plaintext.txt	52	Possible contamination RNA samples genomic DNA monitored omission reverse transcriptase synthesis first strand cDNA
0.29009572.11459774.html.plaintext.txt	53	No genomic DNA detected conditions
0.29009572.11459774.html.plaintext.txt	54	PCR cDNA cloning Prepro orexin OX1 OX2 receptors ss actin specific sense antisense oligonucleotide primers designed based published cDNA sequences 1 26 using Primer3 software developed S
0.29009572.11459774.html.plaintext.txt	55	Skaletsky code available httpwww genome
0.29009572.11459774.html.plaintext.txt	56	edugenomesoftwareotherprimer3
0.29009572.11459774.html.plaintext.txt	57	Oligonucleotides obtained Live Technologies Karlsruhe Germany
0.29009572.11459774.html.plaintext.txt	58	The oligonucleotide sequence product size primer pair used shown Table 1
0.29009572.11459774.html.plaintext.txt	59	Nucleotide sequences PCR primer
0.29009572.11459774.html.plaintext.txt	60	PCR performed 5 microl first strand cDNA reaction presence 10 mM Tris HCl pH 9
0.29009572.11459774.html.plaintext.txt	61	5 microM sense antisense primers 1
0.29009572.11459774.html.plaintext.txt	62	2 U DNA polymerase DyNAzyme II Biometra Gottingen Germany final volume 50 microl
0.29009572.11459774.html.plaintext.txt	63	The PCR conditions initial denaturation 5 min 94 C followed 35 cycles denaturation 30 sec 94 C annealing 30 sec 56 C extension 60 sec 72 C
0.29009572.11459774.html.plaintext.txt	64	After final extension 5 min 72 C amplification products stored 20 C
0.29009572.11459774.html.plaintext.txt	65	ss Actin mRNA levels analyzed positive control cDNA synthesis dilution first strand cDNA 1100
0.29009572.11459774.html.plaintext.txt	66	PCR products size fractionated electrophoresis 2
0.29009572.11459774.html.plaintext.txt	67	0 agarose gels presence ethidium bromide
0.29009572.11459774.html.plaintext.txt	68	The amplified prepro orexin OX1 OX2 receptor cDNA fragments subcloned pCR II vector using TA cloning kit Invitrogen Groningen The Netherlands
0.29009572.11459774.html.plaintext.txt	69	The identity cloned cDNAs confirmed nucleotide sequencing MWG Biotech Ebersberg Germany
0.29009572.11459774.html.plaintext.txt	70	Real time quantitative RT PCR Real time quantitative RT PCR performed GeneAmp 5700 sequence detection system PE Applied Biosystems Weiterstadt Germany using SYBR green I reaction system Eurogentec SA Seraing Belgium
0.29009572.11459774.html.plaintext.txt	71	Sense antisense primers identical described Table 1
0.29009572.11459774.html.plaintext.txt	72	Each sample analyzed triplicate along standards template controls
0.29009572.11459774.html.plaintext.txt	73	The reaction contained 100 ng cDNA 0
0.29009572.11459774.html.plaintext.txt	74	3 microM primers 10 mM Tris HCl 50 mM KCl 3 mM MgCl2 0
0.29009572.11459774.html.plaintext.txt	75	25 U Hot GoldStar DNA Polymerase Eurogentec Cologne Germany final volume 50 microl
0.29009572.11459774.html.plaintext.txt	76	After denaturation 95 C 10 min cDNA products amplified 40 cycles cycle consisting denaturation 95 C 15 sec annealing 56 C 30 sec extension 60 C 30 sec
0.29009572.11459774.html.plaintext.txt	77	Product purity confirmed dissociation curve agarose gel analysis
0.29009572.11459774.html.plaintext.txt	78	Copy number calculations based cycle threshold method 27
0.29009572.11459774.html.plaintext.txt	79	Serial dilutions known amounts cloned prepro orexin OX1 OX2 receptor cDNA fragments used generate standard curves
0.29009572.11459774.html.plaintext.txt	80	The threshold cycle number sample calculated using GeneAmp 5700 sequence detection system software automatic baseline setting fluorescence threshold Rn 0
0.29009572.11459774.html.plaintext.txt	81	No template control samples typically surpass Rn 0
0.29009572.11459774.html.plaintext.txt	82	Only case OX1 receptor mRNA amplification template controls reach Rn value 0
0.29009572.11459774.html.plaintext.txt	83	Therefore copy numbers mRNA generally considered nonsignificant threshold cycle number exceeded 35 cycles
0.29009572.11459774.html.plaintext.txt	84	The value corresponds detection limit 20 mRNA copies100 ng cDNA
0.29009572.11459774.html.plaintext.txt	85	For comparison male female rats copy numbers OX1 OX2 receptor mRNA normalized ss actin mRNA levels
0.29009572.11459774.html.plaintext.txt	86	View larger version 28K Figure 3
0.29009572.11459774.html.plaintext.txt	87	Real time quantitative PCR demonstrating presence prepro orexin A B OX1 C D OX2 E F receptor mRNA rat brain peripheral tissues
0.29009572.11459774.html.plaintext.txt	88	For template controls mRNA replaced H2O A C D
0.29009572.11459774.html.plaintext.txt	89	In situ hybridization histochemistry Antisense oligonucleotides obtained Live Technologies
0.29009572.11459774.html.plaintext.txt	90	These probes shown previously hybridize specifically OX1 OX2 receptor mRNA 8
0.29009572.11459774.html.plaintext.txt	91	To enhance hybridization signal three different antisense oligonucleotides directed different parts receptor subtype mRNAs used simultaneously detection receptor mRNA 8
0.29009572.11459774.html.plaintext.txt	92	The sequences OX1 receptor antisense oligonucleotides 5 TCC TCA TAG TCT GGA GGC AGG TGG AAG GGT TCC CCA CTG CTA GTG 3 5 AAG GCT ATG AGA AAC ACG GCC ACG TAG GCC GCG ATG AGA ACC CAC 3 5 TGC TGA GCT TCC AGT TGC TCT GAG GGT CGC TTC CAG TTC CGC ACC 3
0.29009572.11459774.html.plaintext.txt	93	The sequences OX2 receptor antisense oligonucleotides 5 AGT TGC GAC GAG GGA GGG AAT CCT CCA ATT TGG TGC TGG ACA TCA 3 5 AGA GCC ACG ACG AAC ACG ATG ATA TAC CCT GCG ATC AGG ACC CAC 3 5 CAA AGT TGC TGA TCT GAG TAG TCA GGG ACT TCC TGC TCT CTG TAC 3
0.29009572.11459774.html.plaintext.txt	94	Ten picomoles antisense oligonucleotide 3 end labeled specific activity 104 Cimmol incubation 60 min 37 C 50 pmol 33Pdeoxy ATP Amersham Pharmacia Biotech Freiburg Germany terminal deoxynucleotidyl transferase Amersham Pharmacia Biotech
0.29009572.11459774.html.plaintext.txt	95	The labeled oligonucleotides purified Sephadex G 25 columns Amersham Pharmacia Biotech
0.29009572.11459774.html.plaintext.txt	96	Sections fixed 10 min 4 paraformaldehyde PBS 0
0.29009572.11459774.html.plaintext.txt	97	4 followed two washes PBS
0.29009572.11459774.html.plaintext.txt	98	The sections dehydrated 70 2 min 95 2 min ethanol air dried
0.29009572.11459774.html.plaintext.txt	99	Sections hybridized 16 18 h 42 C 1 2 pmolml labeled oligonucleotides hybridization buffer containing 50 formamide 10 dextran sulfate 1 x Denhardt solution 20 mM Tris pH 7
0.29009572.11459774.html.plaintext.txt	100	3 M NaCl 1 mM EDTA 150 mM dithiothreitol 0
0.29009572.11459774.html.plaintext.txt	101	2 SDS 100 microgml salmon sperm DNA 250 microgml yeast tRNA
0.29009572.11459774.html.plaintext.txt	102	After hybridization sections washed several times 1 x NaCl sodium citrate SSC room temperature followed high stringency washing 1 x SSC 55 C 30 min
0.29009572.11459774.html.plaintext.txt	103	After washing 1 x SSC 0
0.29009572.11459774.html.plaintext.txt	104	1 x SSC 1 min room temperature sections dehydrated series ethanols containing 300 mM ammonium acetate air dried exposed Hyperfilm 3H Amersham Pharmacia Biotech 1 2 wk
0.29009572.11459774.html.plaintext.txt	105	The specificity hybridization signal assessed hybridization 33P labeled antisense oligonucleotides presence 100 fold molar excess respective unlabeled oligonucleotide
0.29009572.11459774.html.plaintext.txt	106	Immunohistochemistry To distinguish area adrenal OX2 receptor expression obtained situ hybridization immunohistochemically stained adrenal medulla adjacent sections using monoclonal antibody tyrosine hydroxylase clone TH 2 Sigma Deisenhofen Germany
0.29009572.11459774.html.plaintext.txt	107	This antibody shown previously specifically stain catecholaminergic neurons 28
0.29009572.11459774.html.plaintext.txt	108	After fixation sections ice cold acetone 10 min sections incubated primary antibody 12000 dilution 60 min 37 degrees C Tris buffered saline pH 7
0.29009572.11459774.html.plaintext.txt	109	Positive staining detected avidin biotin complex method 29 biotinylated secondary antibody peroxidase conjugated streptavidin using LSAB kit DAKO Corp
0.29009572.11459774.html.plaintext.txt	110	Hamburg Germany according manufacturer protocol
0.29009572.11459774.html.plaintext.txt	111	The chromogen 33 diaminobenzidine tetrahydrochloride Sigma
0.29009572.11459774.html.plaintext.txt	112	As negative control sections processed immunostaining absence first antibody
0.29009572.11459774.html.plaintext.txt	113	In control experiments staining observed
0.29009572.11459774.html.plaintext.txt	114	RIA Orexin A extracted plasma samples adsorption phenyl silica Isolute SPE International Sorbent Technology Mid Glamorgan UK
0.29009572.11459774.html.plaintext.txt	115	After elution 60 acetonitrile 1 trifluoroacetic acid samples concentrated lyophilization
0.29009572.11459774.html.plaintext.txt	116	The recovery 125Iorexin A procedure 90
0.29009572.11459774.html.plaintext.txt	117	Orexin A concentrations determined reconstituted samples specific RIA according instructions manufacturer Peninsula Laboratories Inc
0.29009572.11459774.html.plaintext.txt	118	The detection limit assay based amount orexin A produced least 10 tracer displacement 3 pgtube
0.29009572.11459774.html.plaintext.txt	119	All samples analyzed within assay intraassay variability 9 calculated
0.29009572.11459774.html.plaintext.txt	120	Statistical analysis Data presented mean plus minus SEM
0.29009572.11459774.html.plaintext.txt	121	Differences male female rats evaluated test
0.29009572.11459774.html.plaintext.txt	122	05 considered statistically significant
0.29009572.11459774.html.plaintext.txt	123	Results Top Abstract Introduction Materials Methods Results Discussion References Expression prepro orexin OX1 OX2 receptor mRNA peripheral tissues RT PCR The mRNA expression prepro orexin orexin receptor subtypes analyzed various peripheral tissues adult male rats RT PCR Fig
0.29009572.11459774.html.plaintext.txt	124	Brain samples used positive controls mRNAs prepro orexin well orexin receptor subtypes OX1 OX2 present rat brain 1 3 8
0.29009572.11459774.html.plaintext.txt	125	View larger version 78K Figure 1
0.29009572.11459774.html.plaintext.txt	126	Expression prepro orexin B OX1 C OX2 receptor mRNA D peripheral rat tissues
0.29009572.11459774.html.plaintext.txt	127	No amplification product detected reverse transcriptase omitted cDNA synthesis A
0.29009572.11459774.html.plaintext.txt	128	ss Actin specific DNA fragments detected samples analyzed E
0.29009572.11459774.html.plaintext.txt	129	RT PCR prepro orexin mRNA resulted amplification specific DNA fragments 303 bp rat brain testis Fig
0.29009572.11459774.html.plaintext.txt	130	In one case detected low levels prepro orexin mRNA heart
0.29009572.11459774.html.plaintext.txt	131	No prepro orexin mRNA detected pituitary adrenal kidney stomach duodenum jejunum pancreas liver spleen aorta lung thyroid adipose tissue muscle male rats Fig
0.29009572.11459774.html.plaintext.txt	132	1B prepro orexin detected ovaries Fig
0.29009572.11459774.html.plaintext.txt	133	Using real time quantitative PCR confirmed high mRNA levels prepro orexin rat brain 300000 copies100 ng cDNA presence prepro orexin mRNA testes Fig
0.29009572.11459774.html.plaintext.txt	134	In ovary heart amplification threshold value 0
0.29009572.11459774.html.plaintext.txt	135	3 occurred cycle numbers higher 35 considered nonsignificant
0.29009572.11459774.html.plaintext.txt	136	View larger version 36K Figure 2
0.29009572.11459774.html.plaintext.txt	137	Prepro orexin mRNA expressed testis ovaries
0.29009572.11459774.html.plaintext.txt	138	cDNA samples obtained ovaries testis four individual male female rats amplified using prepro orexin specific primer A
0.29009572.11459774.html.plaintext.txt	139	The integrity RNA verified amplification ss actin specific DNA fragments samples B
0.29009572.11459774.html.plaintext.txt	140	OX1 receptor specific DNA fragments 260 bp amplified RNA rat brain pituitary adrenal thyroid kidney jejunum testis ovaries Fig
0.29009572.11459774.html.plaintext.txt	141	OX1 receptor mRNA levels highest brain followed lower levels pituitary low levels kidney thyroid gland testes ovaries adrenals Fig
0.29009572.11459774.html.plaintext.txt	142	OX2 receptor specific DNA fragments 314 bp amplified RNA rat brain lung adrenal pituitary Fig
0.29009572.11459774.html.plaintext.txt	143	The highest amounts OX2 receptor mRNA found adrenal 4 times higher brain OX2 receptor mRNA levels Fig
0.29009572.11459774.html.plaintext.txt	144	In lung pituitary significant low levels OX2 receptor mRNA present Fig
0.29009572.11459774.html.plaintext.txt	145	No significant amounts OX1 OX2 receptor mRNA detected stomach duodenum pancreas liver spleen heart aorta adipose tissue muscle
0.29009572.11459774.html.plaintext.txt	146	The specificity RT PCR verified restriction analysis Fig
0.29009572.11459774.html.plaintext.txt	147	Restriction amplified prepro orexin fragments PvuII resulted expected cleavage two discrete fragments Fig
0.29009572.11459774.html.plaintext.txt	148	4A predicted rat cDNA sequence 1
0.29009572.11459774.html.plaintext.txt	149	The specificity OX1 OX2 receptor mRNA amplification confirmed restriction AluI Fig
0.29009572.11459774.html.plaintext.txt	150	For final proof RT PCR specificity nucleotide sequences subcloned amplification fragments prepro orexin OX1 OX2 receptor cDNA determined sequence analysis found identical corresponding prepro orexin OX1 OX2 receptor cDNA sequences 1
0.29009572.11459774.html.plaintext.txt	151	View larger version 68K Figure 4
0.29009572.11459774.html.plaintext.txt	152	Restriction analysis amplified RT PCR DNA fragments
0.29009572.11459774.html.plaintext.txt	153	A PvuII cuts amplified prepro orexin DNA fragments two fragments 136 167 bp
0.29009572.11459774.html.plaintext.txt	154	B AluI cuts amplified OX2 receptor DNA fragments two fragments 89 225 bp
0.29009572.11459774.html.plaintext.txt	155	C AluI cuts amplified OX1 receptor DNA fragments four fragments 20 visible 51 59 130 bp
0.29009572.11459774.html.plaintext.txt	156	For template controls mRNA replaced H2O monitor contamination D
0.29009572.11459774.html.plaintext.txt	157	Amplification products ss actin 380 bp detected samples showing integrity RNA Fig
0.29009572.11459774.html.plaintext.txt	158	No amplification product detected reverse transcriptase omitted cDNA synthesis Fig
0.29009572.11459774.html.plaintext.txt	159	Moreover control reactions without cDNA samples run parallel PCR assays resulted low background fluorescence Fig
0.29009572.11459774.html.plaintext.txt	160	Therefore presence genomic DNA samples DNA contaminations reactions sources excluded
0.29009572.11459774.html.plaintext.txt	161	Localization OX2 receptor mRNA adrenal gland situ hybridization To explore high levels OX2 receptor mRNA rat adrenal used radiolabeled antisense oligonucleotides localize mRNA expression situ hybridization
0.29009572.11459774.html.plaintext.txt	162	As orexins shown regulate tyrosine hydroxylase mRNA rate limiting enzyme catecholamine synthesis rat pheochromocytoma cells 30 specifically immunostained adrenal medulla using antibody tyrosine hydroxylase distinguish OX2 receptor mRNA expression medulla adjacent zona reticularis Fig
0.29009572.11459774.html.plaintext.txt	163	However OX2 receptor mRNA detected adrenal medulla Fig
0.29009572.11459774.html.plaintext.txt	164	5D tyrosine hydroxylase like immunoreactivity present adjacent sections Fig
0.29009572.11459774.html.plaintext.txt	165	Conversely high levels OX2 receptor mRNA found zona glomerulosa reticularis zona fasciculata adrenal cortex Fig
0.29009572.11459774.html.plaintext.txt	166	The specificity hybridization signals shown absence hybridization signals presence excessive unlabeled antisense oligonucleotides Fig
0.29009572.11459774.html.plaintext.txt	167	No significant levels OX1 receptor mRNA detected adrenal gland Fig
0.29009572.11459774.html.plaintext.txt	168	5C although strong signal obtained locus coeruleus simultaneously hybridized brain sections served positive controls shown
0.29009572.11459774.html.plaintext.txt	169	Possibly due low expression levels could detect OX1 OX2 receptor mRNA situ hybridization antisense oligonucleotide probes peripheral tissues pituitary kidney testes shown
0.29009572.11459774.html.plaintext.txt	170	View larger version 140K Figure 5
0.29009572.11459774.html.plaintext.txt	171	Film autoradiographs showing localization OX2 receptor mRNA male adrenal glands
0.29009572.11459774.html.plaintext.txt	172	Consecutive sections stained hematoxylineosin A tyrosine hydroxylase antibodies B hybridized 33P labeled OX1 C OX2 receptor D antisense oligonucleotide probes
0.29009572.11459774.html.plaintext.txt	173	No signal detected hybridization 33P labeled OX1 E OX2 receptor F antisense probes presence excessive amount respective unlabeled receptor probes
0.29009572.11459774.html.plaintext.txt	174	Scale bar F 1 mm applies panels
0.29009572.11459774.html.plaintext.txt	175	ZG Zona glomerulosa ZF zona fasciculata ZR zona reticularis M medulla
0.29009572.11459774.html.plaintext.txt	176	Comparison OX1 OX2 receptor mRNA expression male female rats Because peripheral expression OX1 OX2 receptor mRNA highest pituitary adrenal respectively compared OX1 OX2 receptor mRNA levels hypothalamic pituitary adrenal axis male female rats using real time quantitative PCR
0.29009572.11459774.html.plaintext.txt	177	In hypothalamus OX1 receptor mRNA levels slightly significantly higher female rats male rats Fig
0.29009572.11459774.html.plaintext.txt	178	No differences male female rats found amounts hypothalamic OX2 receptor mRNA Fig
0.29009572.11459774.html.plaintext.txt	179	In male rats OX1 receptor mRNA levels pituitary Fig
0.29009572.11459774.html.plaintext.txt	180	6B OX2 receptor mRNA levels adrenal Fig
0.29009572.11459774.html.plaintext.txt	181	6C 5 fold higher compared female rats
0.29009572.11459774.html.plaintext.txt	182	In situ hybridization radiolabeled OX2 receptor antisense oligonucleotides confirmed comparatively low OX2 receptor expression rat female adrenal gland Fig
0.29009572.11459774.html.plaintext.txt	183	View larger version 16K Figure 6
0.29009572.11459774.html.plaintext.txt	184	Expression OX1 OX2 receptor mRNA hypothalamus A pituitary B adrenal C male female rats real time quantitative PCR
0.29009572.11459774.html.plaintext.txt	185	View larger version 62K Figure 7
0.29009572.11459774.html.plaintext.txt	186	Film autoradiographs showing expression OX2 receptor mRNA adrenal glands male A female rats B situ hybridization using 33P labeled OX2 receptor antisense oligonucleotide probes
0.29009572.11459774.html.plaintext.txt	187	ZG Zona glomerulosa ZF zona fasciculata ZR zona reticularis M medulla
0.29009572.11459774.html.plaintext.txt	188	Plasma orexin A levels Plasma orexin A levels determined using commercially available RIA kit 11
0.29009572.11459774.html.plaintext.txt	189	There significant difference male female rats
0.29009572.11459774.html.plaintext.txt	190	Discussion Top Abstract Introduction Materials Methods Results Discussion References Our present data demonstrate first time expression OX1 receptor mRNA thyroid jejunum gonads kidney OX2 receptors lung
0.29009572.11459774.html.plaintext.txt	191	In addition confirmed recent results showing presence OX1 OX2 receptor mRNA pituitary adrenal 31 32 rats
0.29009572.11459774.html.plaintext.txt	192	Using real time quantitative PCR found highest peripheral OX1 receptor mRNA expression pituitary highest OX2 receptor mRNA expression adrenal 4 fold higher brain
0.29009572.11459774.html.plaintext.txt	193	Furthermore detected profound differences male female rats tissues
0.29009572.11459774.html.plaintext.txt	194	The expression OX1 OX2 receptors pituitary adrenal indicates possible role orexins regulation endocrine systems particular hypothalamic pituitary adrenal axis
0.29009572.11459774.html.plaintext.txt	195	The effects icv injected orexins plasma levels ACTH corticosterone shown previously 9 10 11
0.29009572.11459774.html.plaintext.txt	196	Our present results indicate orexins may also regulate pituitary adrenal hormones direct action organs
0.29009572.11459774.html.plaintext.txt	197	The localization OX2 receptor mRNA zona glomerulosa reticularis adrenal cortex supports finding Malendowitz et al
0.29009572.11459774.html.plaintext.txt	198	22 increased plasma corticosterone levels sc injection orexins enhanced corticosterone secretion dispersed rat adrenocortical cells orexins
0.29009572.11459774.html.plaintext.txt	199	Recent results also demonstrated stimulatory effect orexin release cortisol human adrenal glands 33
0.29009572.11459774.html.plaintext.txt	200	As found high levels OX2 receptor mRNA could detect OX1 receptor mRNA rat adrenal gland situ hybridization low OX1 receptor mRNA levels highly sensitive real time PCR effects orexins corticosterone synthesis release rats might mediated mainly via OX2 receptor
0.29009572.11459774.html.plaintext.txt	201	Orexins shown decrease tyrosine hydroxylase mRNA levels dopamine release PC12 rat pheochromocytoma cell line 30 OX1 well OX2 receptor like immunoreactivity found adrenal medulla rats 31
0.29009572.11459774.html.plaintext.txt	202	In contrast could detect orexin receptor mRNA adrenal medulla situ hybridization
0.29009572.11459774.html.plaintext.txt	203	However may low levels orexin receptor mRNA adrenal medulla beside stimulation corticosterone release orexins may influence adrenal catecholamine synthesis release
0.29009572.11459774.html.plaintext.txt	204	The described effects orexins plasma levels pituitary hormones ACTH GH PRL LH occurred injection orexins brain ventricles effects likely mediated via corresponding releasing hormones 9 11 12 13
0.29009572.11459774.html.plaintext.txt	205	Plasma TSH levels decreased iv injection orexin 34
0.29009572.11459774.html.plaintext.txt	206	However effect may direct effect pituitary appears arise inhibition TRH secretion hypothalamus 34
0.29009572.11459774.html.plaintext.txt	207	Thus physiological roles orexin receptors tissues pituitary thyroid well lung kidney remain unclear series experiments needed address local effects orexins tissues
0.29009572.11459774.html.plaintext.txt	208	Interestingly found much higher levels OX1 receptor mRNA pituitary OX2 receptor mRNA adrenal male compared female rats
0.29009572.11459774.html.plaintext.txt	209	Conversely hypothalamic OX1 receptor mRNA levels higher female rats
0.29009572.11459774.html.plaintext.txt	210	Hypothalamic orexin A content higher female rats 35 effect orexins LH release depends estrogens 12 13
0.29009572.11459774.html.plaintext.txt	211	Thus sex steroids affect content actions orexin also may differentially regulate expression orexin receptors
0.29009572.11459774.html.plaintext.txt	212	We also show expression prepro orexin mRNA rat testis
0.29009572.11459774.html.plaintext.txt	213	indicated existence prepro orexin rat testis 1
0.29009572.11459774.html.plaintext.txt	214	Beside occurrence rat brain orexin A found tissue extracts rat testis peripheral tissues 36
0.29009572.11459774.html.plaintext.txt	215	Other groups however unable detect prepro orexin prepro hypocretin orexin A peripheral rat tissues including testis 3 35
0.29009572.11459774.html.plaintext.txt	216	These discrepancies may explained different sensitivities assays used
0.29009572.11459774.html.plaintext.txt	217	Using highly sensitive RT PCR able detect prepro orexin mRNA rat testis
0.29009572.11459774.html.plaintext.txt	218	Interestingly find prepro orexin mRNA rat ovaries
0.29009572.11459774.html.plaintext.txt	219	Thus peripheral tissues orexins appear synthesized exclusively testis
0.29009572.11459774.html.plaintext.txt	220	On hand compared brain prepro orexin levels testis low situ hybridization experiments using oligonucleotide antisense probes failed reveal significant amounts prepro orexin testis unpublished observation
0.29009572.11459774.html.plaintext.txt	221	Thus functional relevance testicular prepro orexin synthesis remains clarified
0.29009572.11459774.html.plaintext.txt	222	Prepro orexin mRNA found peripheral tissues expressing orexin receptors
0.29009572.11459774.html.plaintext.txt	223	Therefore unlikely organs orexins act autocrineparacrine manner
0.29009572.11459774.html.plaintext.txt	224	The presence orexin A human plasma 37 recently described also detected comparable concentrations orexin A rat plasma
0.29009572.11459774.html.plaintext.txt	225	Thus circulating orexin may activate orexin receptors peripheral tissues
0.29009572.11459774.html.plaintext.txt	226	The source plasma orexin remains unclear
0.29009572.11459774.html.plaintext.txt	227	As find differences male female rats plasma orexin A levels uncertain whether plasma orexins originate testis
0.29009572.11459774.html.plaintext.txt	228	On hand orexin containing neurons project median eminence pituitary 32 orexin may released circulation pituitary
0.29009572.11459774.html.plaintext.txt	229	As orexin A relatively slowly metabolized iv injection 24 low rate secretion sufficient contribute substantial plasma concentrations orexin
0.29009572.11459774.html.plaintext.txt	230	The lack gender differences plasma orexin levels comparatively low prepro orexin mRNA expression testis indicate predominant role hypothalamic orexin production
0.29009572.11459774.html.plaintext.txt	231	Another possibility stimulate peripheral orexin receptors could action peptides orexin
0.29009572.11459774.html.plaintext.txt	232	NPY example shown act cloned orexin receptor 38 NPY locally produced adrenal gland 39
0.29009572.11459774.html.plaintext.txt	233	In summary shown sexually dimorphic expression prepro orexin orexin receptor subtypes various peripheral tissues propose existence peripheral orexin system
0.29009572.11459774.html.plaintext.txt	234	Such system may involved regulation endocrine physiological functions remain determined
0.29009572.11459774.html.plaintext.txt	235	The localization OX2 receptor mRNA rat adrenal cortex indicates role adrenal steroid synthesis andor release
0.29009572.11459774.html.plaintext.txt	236	Our results represent basis physiological studies addressing possible peripheral orexin effects
0.29009572.11459774.html.plaintext.txt	237	Acknowledgments The authors thank Constanze V
0.29009572.11459774.html.plaintext.txt	238	Siggel Gudrun Vierke expert technical assistance
0.29009572.11459774.html.plaintext.txt	239	Footnotes Abbreviations icv Intracerebroventricularly Rn fluorescence threshold
0.29009572.11459774.html.plaintext.txt	240	Accepted publication April 3 2001
0.29009572.11459774.html.plaintext.txt	241	References Top Abstract Introduction Materials Methods Results Discussion References Sakurai T Amemiya A Ishii M et al
0.29009572.11459774.html.plaintext.txt	242	1998 Orexins orexin receptors family hypothalamic neuropeptides G protein coupled receptors regulate feeding behavior
0.29009572.11459774.html.plaintext.txt	243	Cell 92573 585Medline Gautvik KM de Lecea L Gautvik VT et al
0.29009572.11459774.html.plaintext.txt	244	1996 Overview prevalent hypothalamus specific mRNAs identified directional tag PCR subtraction
0.29009572.11459774.html.plaintext.txt	245	Proc Natl Acad Sci USA 938733 8738AbstractFree Full Text de Lecea L Kilduff TS Peyron C et al
0.29009572.11459774.html.plaintext.txt	246	1998 The hypocretins hypothalamus specific peptides neuroexcitatory activity
0.29009572.11459774.html.plaintext.txt	247	Proc Natl Acad Sci USA 95322 327AbstractFree Full Text Peyron C Tighe DK van Den Pol AN et al
0.29009572.11459774.html.plaintext.txt	248	1998 Neurons containing hypocretin orexin project multiple neuronal systems
0.29009572.11459774.html.plaintext.txt	249	J Neurosci 189996 10015AbstractFree Full Text Date Y Ueta Y Yamashita H et al
0.29009572.11459774.html.plaintext.txt	250	1999 Orexins orexigenic hypothalamic peptides interact autonomic neuroendocrine neuroregulatory systems
0.29009572.11459774.html.plaintext.txt	251	Proc Natl Acad Sci USA 96748 753AbstractFree Full Text van Den Pol AN 1999 Hypothalamic hypocretin orexin robust innervation spinal cord
0.29009572.11459774.html.plaintext.txt	252	J Neurosci 193171 3182AbstractFree Full Text Harrison TA Chen CT Dun NJ Chang JK 1999 Hypothalamic orexin A immunoreactive neurons project rat dorsal medulla
0.29009572.11459774.html.plaintext.txt	253	Neurosci Lett 27317 20CrossRefMedline Trivedi P Yu H MacNeil DJ Van der Ploeg LH Guan XM 1998 Distribution orexin receptor mRNA rat brain
0.29009572.11459774.html.plaintext.txt	254	FEBS Lett 43871 75CrossRefMedline Hagan JJ Leslie RA Patel S et al
0.29009572.11459774.html.plaintext.txt	255	1999 Orexin A activates locus coeruleus cell firing increases arousal rat
0.29009572.11459774.html.plaintext.txt	256	Proc Natl Acad Sci USA 9610911 10916AbstractFree Full Text Ida T Nakahara K Murakami T Hanada R Nakazato M Murakami N 2000 Possible involvement orexin stress reaction rats
0.29009572.11459774.html.plaintext.txt	257	Biochem Biophys Res Commun 270318 323CrossRefMedline Kuru M Ueta Y Serino R Nakazato M Yamamoto Y Shibuya I Yamashita H 2000 Centrally administered orexinhypocretin activates HPA axis rats
0.29009572.11459774.html.plaintext.txt	258	NeuroReport 111977 1980Medline Pu S Jain MR Kalra PS Kalra SP 1998 Orexins novel family hypothalamic neuropeptides modulate pituitary luteinizing hormone secretion ovarian steroid dependent manner
0.29009572.11459774.html.plaintext.txt	259	Regul Pept 78133 136CrossRefMedline Tamura T Irahara M Tezuka M Kiyokawa M Aono T 1999 Orexins orexigenic hypothalamic neuropeptides suppress pulsatile secretion luteinizing hormone ovariectomized female rats
0.29009572.11459774.html.plaintext.txt	260	Biochem Biophys Res Commun 264759 762CrossRefMedline Samson WK Gosnell B Chang JK Resch ZT Murphy TC 1999 Cardiovascular regulatory actions hypocretins brain
0.29009572.11459774.html.plaintext.txt	261	Brain Res 831248 253CrossRefMedline Shirasaka T Nakazato M Matsukura S Takasaki M Kannan H 1999 Sympathetic cardiovascular actions orexins conscious rats
0.29009572.11459774.html.plaintext.txt	262	Am J Physiol 277R1780 R1785 Chen CT Hwang LL Chang JK Dun NJ 2000 Pressor effects orexins injected intracisternally rostral ventrolateral medulla anesthetized rats
0.29009572.11459774.html.plaintext.txt	263	Am J Physiol Regul Integr Comp Physiol 278R692 R697 Lin L Faraco J Li R et al
0.29009572.11459774.html.plaintext.txt	264	1999 The sleep disorder canine narcolepsy caused mutation hypocretin orexin receptor 2 gene
0.29009572.11459774.html.plaintext.txt	265	Cell 98365 376Medline Chemelli RM Willie JT Sinton CM et al
0.29009572.11459774.html.plaintext.txt	266	1999 Narcolepsy orexin knockout mice molecular genetics sleep regulation
0.29009572.11459774.html.plaintext.txt	267	Cell 98437 451Medline Nishino S Ripley B Overeem S Lammers GJ Mignot E 2000 Hypocretin orexin deficiency human narcolepsy
0.29009572.11459774.html.plaintext.txt	268	Lancet 35539 40CrossRefMedline Kilduff TS Peyron C 2000 The hypocretinorexin ligand receptor system implications sleep sleep disorders
0.29009572.11459774.html.plaintext.txt	269	Trends Neurosci 23359 365CrossRefMedline Kirchgessner AL Liu M 1999 Orexin synthesis response gut
0.29009572.11459774.html.plaintext.txt	270	Neuron 24941 951Medline Malendowicz LK Tortorella C Nussdorfer GG 1999 Orexins stimulate corticosterone secretion rat adrenocortical cells activation adenylate cyclase dependent signaling cascade
0.29009572.11459774.html.plaintext.txt	271	J Steroid Biochem Mol Biol 70185 188CrossRefMedline Nowak KW Mackowiak P Switonska MM Fabis M Malendowicz LK 2000 Acute orexin effects insulin secretion rat vivo vitro studies
0.29009572.11459774.html.plaintext.txt	272	Life Sci 66449 454CrossRefMedline Kastin AJ Akerstrom V 1999 Orexin A orexin B rapidly enters brain blood simple diffusion
0.29009572.11459774.html.plaintext.txt	273	J Pharmacol Exp Ther 289219 223AbstractFree Full Text Palkovits M Brownstein MJ 1988 Maps guide microdissection rat brain
0.29009572.11459774.html.plaintext.txt	274	Elsevier New York Nudel U Zakut R Shani M Neuman S Levy Z Yaffe D 1983 The nucleotide sequence rat cytoplasmic beta actin gene
0.29009572.11459774.html.plaintext.txt	275	Nucleic Acids Res 111759 1771Abstract Higuchi R Fockler C Dollinger G Watson R 1993 Kinetic PCR analysis real time monitoring DNA amplification reactions
0.29009572.11459774.html.plaintext.txt	276	BioTechnology 111026 1030Medline Johren O Sanvitto GL Egidy G Saavedra JM 1997 Angiotensin II AT1A receptor mRNA expression induced estrogen progesterone dopaminergic neurons female rat arcuate nucleus
0.29009572.11459774.html.plaintext.txt	277	J Neurosci 178283 8292AbstractFree Full Text Hsu SM Raine L Fanger H 1981 Use avidin biotin peroxidase complex ABC immunoperoxidase techniques comparison ABC unlabeled antibody PAP procedures
0.29009572.11459774.html.plaintext.txt	278	J Histochem Cytochem 29577 580Abstract Nanmoku T Isobe K Sakurai T et al
0.29009572.11459774.html.plaintext.txt	279	2000 Orexins suppress catecholamine synthesis secretion cultured PC12 cells
0.29009572.11459774.html.plaintext.txt	280	Biochem Biophys Res Commun 274310 315CrossRefMedline Lopez M Senaris R Gallego R et al
0.29009572.11459774.html.plaintext.txt	281	1999 Orexin receptors expressed adrenal medulla rat
0.29009572.11459774.html.plaintext.txt	282	Endocrinology 1405991 5994AbstractFree Full Text Date Y Mondal MS Matsukura S et al
0.29009572.11459774.html.plaintext.txt	283	2000 Distribution orexinhypocretin rat median eminence pituitary
0.29009572.11459774.html.plaintext.txt	284	Mol Brain Res 761 6Medline Mazzocchi G Malendowicz LK Gottardo L Aragona F Nussdorfer GG 2001 Orexin A stimulates cortisol secretion human adrenocortical cells activation adenylate cyclase dependent signaling cascade
0.29009572.11459774.html.plaintext.txt	285	J Clin Endocrinol Metab 86778 782AbstractFree Full Text Mitsuma T Hirooka Y Mori Y et al
0.29009572.11459774.html.plaintext.txt	286	1999 Effects orexin A thyrotropin releasing hormone thyrotropin secretion rats
0.29009572.11459774.html.plaintext.txt	287	Horm Metab Res 31606 609Medline Taheri S Mahmoodi M Opacka Juffry J Ghatei MA Bloom SR 1999 Distribution quantification immunoreactive orexin A rat tissues
0.29009572.11459774.html.plaintext.txt	288	FEBS Lett 457157 161CrossRefMedline Mitsuma T Hirooka Y Kayama M et al
0.29009572.11459774.html.plaintext.txt	289	2000 Radioimmunoassay orexin A
0.29009572.11459774.html.plaintext.txt	290	Life Sci 66897 904CrossRefMedline Arihara Z Takahashi K Murakami O et al
0.29009572.11459774.html.plaintext.txt	291	2001 Immunoreactive orexin A human plasma
0.29009572.11459774.html.plaintext.txt	292	Peptides 22139 142CrossRefMedline Kane JK Tanaka H Parker SL Yanagisawa M Li MD 2000 Sensitivity orexin A binding phospholipase C inhibitors neuropeptide Y secretin
0.29009572.11459774.html.plaintext.txt	293	Biochem Biophys Res Commun 272959 965CrossRefMedline Ehrhart Bornstein M Hinson JP Bornstein SR Scherbaum WA Vinson GP 1998 Intraadrenal interactions regulation adrenocortical steroidogenesis
0.29009572.11459774.html.plaintext.txt	294	Endocr Rev 19101 143AbstractFree Full Text
0.14836259.11809725.html.plaintext.txt	0	Identification new copper metabolism gene positional cloning purebred dog population Bart van de Sluis Jan Rothuizen1 Peter L
0.14836259.11809725.html.plaintext.txt	1	Department Medical Genetics KC04
0.14836259.11809725.html.plaintext.txt	2	2 University Medical Centre Utrecht WKZ Lundlaan 6 3584 EA Utrecht The Netherlands 1Department Clinical Sciences Companion Animals Faculty Veterinary Medicine Utrecht University Utrecht The Netherlands
0.14836259.11809725.html.plaintext.txt	3	Received September 21 2001 Revised Accepted November 12 2001
0.14836259.11809725.html.plaintext.txt	4	DDBJEMBLGenBank accession nos AY047597 AY047600
0.14836259.11809725.html.plaintext.txt	5	ABSTRACT TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES Domesticated animal species dogs cats many different characteristics breed specific diseases close relationship shared environment humans potentially rich source identification genetic contribution human biology disease
0.14836259.11809725.html.plaintext.txt	6	Copper toxicosis Bedlington terriers genetic disease occurring high prevalence worldwide unique breed
0.14836259.11809725.html.plaintext.txt	7	Copper homeostasis appears well regulated mammals
0.14836259.11809725.html.plaintext.txt	8	Two copper carrier proteins identified man rodents dysfunctional cause either copper deficiency Menkes disease copper accumulation various tissues Wilson disease
0.14836259.11809725.html.plaintext.txt	9	However proteins primarily involved biliary excretion copper
0.14836259.11809725.html.plaintext.txt	10	Bedlington terriers high prevalence copper toxicosis well documented biliary excretion copper impaired
0.14836259.11809725.html.plaintext.txt	11	This disease direct relevance understanding copper metabolism mammals
0.14836259.11809725.html.plaintext.txt	12	Previously mapped copper toxicosis gene dog chromosome region 10q26
0.14836259.11809725.html.plaintext.txt	13	Based DNA samples obtained privately owned dogs able confine localization copper toxicosis gene region 500 kb linkage disequilibrium mapping
0.14836259.11809725.html.plaintext.txt	14	While screening genes expressed sequence tags region mutations found exon 2 MURR1 gene deleted alleles affected Bedlington terriers single alleles obligate carriers
0.14836259.11809725.html.plaintext.txt	15	Although function MURR1 gene still unknown discovery mutated MURR1 gene Bedlington terriers copper toxicosis provides new lead disentangling complexities copper metabolism mammals
0.14836259.11809725.html.plaintext.txt	16	INTRODUCTION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES Naturally occurring canine genetic diseases useful models study pathophysiology genetics treatment homologous diseases humans 1
0.14836259.11809725.html.plaintext.txt	17	In general genetic diseases dogs resemble human diseases faithfully rodent counterparts
0.14836259.11809725.html.plaintext.txt	18	This surprising given closer evolutionary relationship higher degree DNA sequence identity humans dogs humans rodents
0.14836259.11809725.html.plaintext.txt	19	Dogs receive high degree medical scrutiny nearly comparable applied human medicine diagnostic procedures used humans dogs
0.14836259.11809725.html.plaintext.txt	20	The positional cloning canine homologs human disease genes largely depended establishment maintenance breeding colonies 2 6
0.14836259.11809725.html.plaintext.txt	21	However captured diseases represent small portion available canine disease models might utilized advance knowledge mammalian genetic diseases
0.14836259.11809725.html.plaintext.txt	22	Purebred dogs bred dedicated dog breeders offer unique source pedigrees elucidate molecular basis simple complex genetic diseases traits
0.14836259.11809725.html.plaintext.txt	23	The unusual useful feature dog breeds makes particularly amenable genetic analysis breed represents isolated inbred population 7 9
0.14836259.11809725.html.plaintext.txt	24	Copper one essential heavy metals man life although highly toxic excess certain threshold 10
0.14836259.11809725.html.plaintext.txt	25	Therefore well regulated copper metabolism required ensure cellular copper homeostasis
0.14836259.11809725.html.plaintext.txt	26	Yeast indispensable model understanding genes involved eukaryotic copper metabolism homeostasis
0.14836259.11809725.html.plaintext.txt	27	Two copper carrier proteins identified man rodents dysfunctional cause either copper deficiency Menkes disease MIM 277900 copper accumulation various tissues Wilson disease MIM 309400
0.14836259.11809725.html.plaintext.txt	28	Copper toxicosis CT Bedlington terriers first described Hardy 11 autosomal recessive disorder 1213
0.14836259.11809725.html.plaintext.txt	29	It characterized inefficient excretion copper via bile 11 resulting accumulation copper liver leading chronic hepatitis finally cirrhosis 14
0.14836259.11809725.html.plaintext.txt	30	An anonymous microsatellite marker C04107 15 shown genetically closely linked CT locus Bedlington terriers
0.14836259.11809725.html.plaintext.txt	31	Moreover tight linkage disequilibrium LD observed allele 2 marker C04107 CT locus
0.14836259.11809725.html.plaintext.txt	32	Although marker available since 1995 molecular basis disorder yet reported
0.14836259.11809725.html.plaintext.txt	33	In 1999 reported localization CT locus canine chromosome region CFA10q26 16 region homologous human chromosome region HSA2p13 21
0.14836259.11809725.html.plaintext.txt	34	This localization able rule candidate gene known time 16 18
0.14836259.11809725.html.plaintext.txt	35	Since CT mutation present Bedlington terrier breed least 20 30 generations recently able refine CT region homozygosity mapping region 42
0.14836259.11809725.html.plaintext.txt	36	3 cR3000 corresponds region 9 Mb 19
0.14836259.11809725.html.plaintext.txt	37	The purpose study isolate CT gene positional cloning
0.14836259.11809725.html.plaintext.txt	38	We employed homozygosity LD mapping refine CT candidate gene region even region 500 kb
0.14836259.11809725.html.plaintext.txt	39	A physical map bacterial artificial chromosomes BACs constructed covering region
0.14836259.11809725.html.plaintext.txt	40	Comparative mapping sample sequencing used construct transcription map region
0.14836259.11809725.html.plaintext.txt	41	Several genes expressed sequence tags ESTs putative transcripts identified
0.14836259.11809725.html.plaintext.txt	42	Mutation analysis revealed genomic deletion MURR1 gene leading predicted truncated protein 94 amino acids conserved mammals far unknown function
0.14836259.11809725.html.plaintext.txt	43	RESULTS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES Homozygosity mapping In previous study using homozygosity mapping showed CT locus mapped markers FH2523 C10
0.14836259.11809725.html.plaintext.txt	44	602 recombinants observed indicating CT candidate region could refined even
0.14836259.11809725.html.plaintext.txt	45	However time one marker present within interval namely C04107
0.14836259.11809725.html.plaintext.txt	46	All affected Bedlington terriers included study homozygous allele 2 marker C04107
0.14836259.11809725.html.plaintext.txt	47	Therefore partial BAC contig covering 4
0.14836259.11809725.html.plaintext.txt	48	6 cM CT region described used isolate new polymorphic microsatellite markers
0.14836259.11809725.html.plaintext.txt	49	In addition new marker DTR10
0.14836259.11809725.html.plaintext.txt	50	5 reported literature 20
0.14836259.11809725.html.plaintext.txt	51	These 11 new markers subjected panel Bedlington terriers
0.14836259.11809725.html.plaintext.txt	52	Haplotypes Belgian Bedlington terrier pedigree members created using individual genotypes 14 polymorphic markers
0.14836259.11809725.html.plaintext.txt	53	In addition genotypes determined 10 single Belgian Bedlington terriers unrelated large Belgian pedigree three English Bedlington terriers
0.14836259.11809725.html.plaintext.txt	54	Although lack additional family members dogs prohibited construction phase known haplotypes majority haplotypes could reconstructed easily animals shared homozygosity majority marker alleles consecutive markers Table 1
0.14836259.11809725.html.plaintext.txt	55	In addition haplotypes obligate carriers unaffected dogs shown comparison Table 1
0.14836259.11809725.html.plaintext.txt	56	A complete list haplotypes 22 affected dogs 14 obligate carriers seven unaffected dogs found httphumgen
0.14836259.11809725.html.plaintext.txt	57	Haplotypes selected number affected obligate carriers unaffected Bedlington terriers The region homozygous affected Bedlington terriers comprises markers CF10B17 C04107 Table 1 300 kb flanked markers CF10B18 CF10B19
0.14836259.11809725.html.plaintext.txt	58	Although marker CF10B19 repeatedly showed 23 genotype Bedlington terrier UTB10 cannot exclude allele 3 result mutation event instead recombination event
0.14836259.11809725.html.plaintext.txt	59	Hence included CF10B19 part CT candidate region considered region flanked markers CF10B18 CF10B23 CT candidate region
0.14836259.11809725.html.plaintext.txt	60	This candidate region completely covered five BAC clones Fig
0.14836259.11809725.html.plaintext.txt	61	1 cover region 500 kb
0.14836259.11809725.html.plaintext.txt	62	View larger version 13K Figure 1
0.14836259.11809725.html.plaintext.txt	63	Physical map canine CT region
0.14836259.11809725.html.plaintext.txt	64	Mapped genes EST CT region shown upper part putative transcripts shown BAC clones middle part microsatellite markers
0.14836259.11809725.html.plaintext.txt	65	The refined CT candidate region 500 kb indicated arrow
0.14836259.11809725.html.plaintext.txt	66	Construction BAC contig covering CT region Previously CT region confined 42
0.14836259.11809725.html.plaintext.txt	67	3 cR3000 interval FH2523 C10
0.14836259.11809725.html.plaintext.txt	68	Based partial BAC contig constructed time estimated one cR3000 equivalent 210 kb implying CT candidate region 9 Mb
0.14836259.11809725.html.plaintext.txt	69	This 9 Mb region saturated using EST clones genes corresponding homologous region human genome described
0.14836259.11809725.html.plaintext.txt	70	Canine BAC clones isolated many human genes ESTs order multiple starting points construction BAC contig covering CT region
0.14836259.11809725.html.plaintext.txt	71	ESTs KIAA0903 AB020710 KIAA0570 AB011142 DKFZp586J101 HSM800548 clone 24963 AF131737 genes PEX13 AB022192 MHD1 XM049272 used help constructing BAC contig
0.14836259.11809725.html.plaintext.txt	72	This resulted three independent BAC contigs minimum tiling paths eight 10 14 clones estimated cover 3 Mb DNA
0.14836259.11809725.html.plaintext.txt	73	Fortunately sequence flanking canine marker DTR10
0.14836259.11809725.html.plaintext.txt	74	5 conserved man showed homology one YAC clones covering human 2p13 p16 region
0.14836259.11809725.html.plaintext.txt	75	Detailed information canine BAC comparative human YAC contig found httphumgen
0.14836259.11809725.html.plaintext.txt	76	The C04107 marker initially isolated BAC clone N21 27 16
0.14836259.11809725.html.plaintext.txt	77	Starting BAC clone walk initiated directions
0.14836259.11809725.html.plaintext.txt	78	Marker FH2523 determining proximal boundary CT candidate region cloned BAC J20 135 within four BAC clones C04107
0.14836259.11809725.html.plaintext.txt	79	The C04107 BAC contig consists minimum tiling path nine BAC clones Fig
0.14836259.11809725.html.plaintext.txt	80	Since contig contains markers CF10B18 CF10B23 covers entire CT candidate region
0.14836259.11809725.html.plaintext.txt	81	For remainder results refer contig CT contig
0.14836259.11809725.html.plaintext.txt	82	Comparative mapping construction transcription map CT region It anticipated completion human genome sequence would aid constructing transcription map candidate CT region
0.14836259.11809725.html.plaintext.txt	83	However examining NCBI httpwww
0.14836259.11809725.html.plaintext.txt	84	org databases revealed sequence information human 2p13 p16 region represented public databases May 2001
0.14836259.11809725.html.plaintext.txt	85	Nevertheless 40 ESTs genes predicted transcripts identified region genes VRK2 XM002687 MDH1 XM049272
0.14836259.11809725.html.plaintext.txt	86	However every new update sequence showed large changes comparison previous one respect genes present
0.14836259.11809725.html.plaintext.txt	87	Because large fluctuations decided focus attention primarily transcripts could mapped back onto CT contig either PCR Southern blot analysis
0.14836259.11809725.html.plaintext.txt	88	A total seven ESTsgenes human genome sequence could localized onto CT contig namely CRM1 XM002691 ys77h10
0.14836259.11809725.html.plaintext.txt	89	s1 H93765 SHGC 34371 G28276 nh35c12
0.14836259.11809725.html.plaintext.txt	90	s1 AA524967 FLJ13305 AK023367 CCT4 AF026291 MURR1 D85433
0.14836259.11809725.html.plaintext.txt	91	In addition individual BAC clones CT contig subjected sample sequencing subsequent BLAST analysis
0.14836259.11809725.html.plaintext.txt	92	Seventeen putative transcripts identified CT region three represented known genes data shown
0.14836259.11809725.html.plaintext.txt	93	Full length canine mRNA sequences MURR1 FLJ13305 CCT4 nh35c12
0.14836259.11809725.html.plaintext.txt	94	s1 obtained 5 3 RACE PCR liver mRNA derived unaffected Beagle
0.14836259.11809725.html.plaintext.txt	95	Mutation analysis We subjected cDNA FLJ13305 CCT4 MURR1 nh35c12
0.14836259.11809725.html.plaintext.txt	96	s1 mutation analysis using liver mRNA Bedlington terriers CT
0.14836259.11809725.html.plaintext.txt	97	After amplification part MURR1 gene liver RNA Bedlington terriers using primers Murr1 3 Murr1 5 deletion fragment 187 bp identified MURR1 mRNA 22 affected Bedlington terriers included study
0.14836259.11809725.html.plaintext.txt	98	In contrast unaffected Bedlington terriers showed expected 469 bp fragment whereas obligate carriers heterozygous 187 469 bp fragment Fig
0.14836259.11809725.html.plaintext.txt	99	Sequence analysis 187 469 bp fragment revealed homozygous deletion exon 2 Fig
0.14836259.11809725.html.plaintext.txt	100	View larger version 49K Figure 2
0.14836259.11809725.html.plaintext.txt	101	Mutation analysis MURR1 gene
0.14836259.11809725.html.plaintext.txt	102	A RT PCR liver cDNA unaffected U affected A carrier C H2O negative control RT PCR
0.14836259.11809725.html.plaintext.txt	103	Locations RT PCR primers used F R indicated D
0.14836259.11809725.html.plaintext.txt	104	The size marker indicated M 50 bp ladder
0.14836259.11809725.html.plaintext.txt	105	B Deletion exon 2 liver cDNA affected Bedlington terrier CT
0.14836259.11809725.html.plaintext.txt	106	C Southern blot analysis genomic dog DNA digested EcoRI E BamHI B hybridized exon 2 exon 3
0.14836259.11809725.html.plaintext.txt	107	Equal amounts genomic dog DNA loaded onto gels data shown
0.14836259.11809725.html.plaintext.txt	108	D Genomic organization canine MURR1 gene
0.14836259.11809725.html.plaintext.txt	109	The EcoRI E BamHI B restriction fragments present genomic DNA indicated lines
0.14836259.11809725.html.plaintext.txt	110	A dotted line indicates exact location distance restriction site yet known
0.14836259.11809725.html.plaintext.txt	111	Southern blot analysis genomic DNA affected Bedlington terriers confirmed exon 2 deleted 22 affected dogs showed homozygous deletion 1
0.14836259.11809725.html.plaintext.txt	112	5 kb EcoRI fragment obligate carriers one copy the1
0.14836259.11809725.html.plaintext.txt	113	The location EcoRI sites confirmed sequencing flanking intronic sequences exon 2 accession
0.14836259.11809725.html.plaintext.txt	114	In addition hybridization exon 3 showed BamHI junction fragment 6
0.14836259.11809725.html.plaintext.txt	115	7 kb affected dogs 6 kb BamHI fragment unaffected dogs Fig
0.14836259.11809725.html.plaintext.txt	116	The fragmentary genomic information accumulated genomic structure MURR1 gene indicates genomic deletion least 10 kb Fig
0.14836259.11809725.html.plaintext.txt	117	The distal breakpoint localized 500 bp BamHI EcoRI fragment intron 2 data shown
0.14836259.11809725.html.plaintext.txt	118	The proximal breakpoint remains determined intron 1 since exon 1 present animals studied
0.14836259.11809725.html.plaintext.txt	119	Intron 1 estimated 40 kb data shown
0.14836259.11809725.html.plaintext.txt	120	Notably mapped C04107 marker within intron 1 MURR1 gene
0.14836259.11809725.html.plaintext.txt	121	MURR1 gene The canine full length mRNA sequence MURR1 accession
0.14836259.11809725.html.plaintext.txt	122	AY047597 spans 1518 bp including open reading frame 564 bp encodes predicted protein consisting 188 amino acid residues
0.14836259.11809725.html.plaintext.txt	123	Direct BAC sequencing BAC clone N21 27 E6 166 derived normal dog revealed normal canine MURR1 gene consists three exons total accession nos AY047598 AY047600
0.14836259.11809725.html.plaintext.txt	124	The translation start codon present exon 1 including kozak consensus sequence 21
0.14836259.11809725.html.plaintext.txt	125	The translation stop codon TAG present exon 3 polyadenylation site AATAAA seen 877 bp downstream TAG termination codon
0.14836259.11809725.html.plaintext.txt	126	An expression profile MURR1 gene different tissues performed hybridization human multiple tissue blot using MURR1 cDNA probe
0.14836259.11809725.html.plaintext.txt	127	Northern blot analysis revealed human transcript expected size 710 bp accession
0.14836259.11809725.html.plaintext.txt	128	AX060277 clearly showed highest expression MURR1 liver Fig
0.14836259.11809725.html.plaintext.txt	129	Low expression MURR1 identified human heart skeleton muscle kidney placenta correction GAPDH expression Fig
0.14836259.11809725.html.plaintext.txt	130	Although obvious MURR1 expression X ray film exposure 3 days seen human brain colon thymus spleen small intestine lung RT PCR could identify expression MURR1 gene canine kidney kidney medulla bile bladder thalamus fibroblasts brain pancreas spleen peripheral blood leukocytes liver Fig
0.14836259.11809725.html.plaintext.txt	131	Northern blot analysis showed additional unidentified transcript 1
0.14836259.11809725.html.plaintext.txt	132	7 kb human liver kidney placenta data shown longer X ray film exposure
0.14836259.11809725.html.plaintext.txt	133	The nature cross hybridizing transcript human RNA needs investigated
0.14836259.11809725.html.plaintext.txt	134	View larger version 20K Figure 3
0.14836259.11809725.html.plaintext.txt	135	Expression profile MURR1 gene
0.14836259.11809725.html.plaintext.txt	136	A Northern blot analysis human poly A RNA brain 1 heart 2 skeletal muscle 3 colon 4 thymus 5 spleen 6 kidney 7 liver 8 small intestine 9 placenta 10 lung 11 peripheral blood leukocytes 12 hybridized canine cDNA MURR1 probe rehybridized GAPDH cDNA probe control
0.14836259.11809725.html.plaintext.txt	137	B RT PCR single stranded cDNA canine liver 1 peripheral blood leukocytes 2 fibroblast 3 pancreas 4 kidney 5 kidney medulla 6 bile bladder 7 thalamus 8 testis 9 brain 10 genomic canine DNA 11 H2O 12 negative control RT PCR
0.14836259.11809725.html.plaintext.txt	138	The size marker indicated M 50 bp ladder
0.14836259.11809725.html.plaintext.txt	139	The canine MURR1 protein shows high homology human accession
0.14836259.11809725.html.plaintext.txt	140	CAC24864 mouse Murr1 proteins accession
0.14836259.11809725.html.plaintext.txt	141	CAC24865 87 86 amino acid identity respectively Fig
0.14836259.11809725.html.plaintext.txt	142	The MURR1 gene first discovered Nabetani et al
0.14836259.11809725.html.plaintext.txt	143	22 named gene Murr1 mouse MURR1 human explanation
0.14836259.11809725.html.plaintext.txt	144	In mouse Murr1 gene harbors imprinted gene U2af1 rs1 present human gene 22
0.14836259.11809725.html.plaintext.txt	145	Database searches also identified MURR1 orthologs pig accession
0.14836259.11809725.html.plaintext.txt	146	BE682977 rat accession
0.14836259.11809725.html.plaintext.txt	147	BF404829 detectable homologs present Saccharomyces cerevisiae Drosophila melanogaster Caenorhabditis elegans Fugu rubripe Danio rerio
0.14836259.11809725.html.plaintext.txt	148	View larger version 47K Figure 4
0.14836259.11809725.html.plaintext.txt	149	Alignment deduced amino acid sequence MURR1 dog human mouse Bedlington terriers copper toxicosis
0.14836259.11809725.html.plaintext.txt	150	Amino acid residues identical least two sequences bold
0.14836259.11809725.html.plaintext.txt	151	Conserved predicted helix structure marked alignment sequences H conserved sheet structure marked E
0.14836259.11809725.html.plaintext.txt	152	The conserved protein kinase C phosphorylation site indicated casein kinase II phosphorylation site indicated N myristoylation site indicated
0.14836259.11809725.html.plaintext.txt	153	No homology protein identifiable domains could identified indicate putative function protein
0.14836259.11809725.html.plaintext.txt	154	According different structural prediction programs seems secondary structure MURR1 protein conserved dog human mouse
0.14836259.11809725.html.plaintext.txt	155	It contains least seven helixes three sheets Fig
0.14836259.11809725.html.plaintext.txt	156	In addition predicted sites protein kinase C phosphorylation site casein kinase II phosphorylation site N myristoylation site conserved dog human mouse MURR1 protein Fig
0.14836259.11809725.html.plaintext.txt	157	DISCUSSION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES We describe first example exploiting one 300 isolated canine populations worldwide discover new gene 1
0.14836259.11809725.html.plaintext.txt	158	When gene identified mutated Bedlington terrier affected CT therefore likely gene involved copper homeostasis mammals
0.14836259.11809725.html.plaintext.txt	159	CT Bedlington terriers long interested researchers phenotypic similarities human copper related diseases Wilson disease Indian non Indian childhood cirrhosis
0.14836259.11809725.html.plaintext.txt	160	The cloning Wilson disease gene ATP7B presence genetic marker linked CT locus Bedlington terriers allowed us exclude ATP7B gene candidate gene CT based map location 16
0.14836259.11809725.html.plaintext.txt	161	Soon additional genes known involved copper metabolism also excluded candidates CT 16 18
0.14836259.11809725.html.plaintext.txt	162	Although CT locus linked marker C04107 recombination events CT locus marker C04107 2324 suggested C04107 still certain distance CT gene
0.14836259.11809725.html.plaintext.txt	163	We identified recombinant event cohort CT affected dogs nevertheless based strategy observations
0.14836259.11809725.html.plaintext.txt	164	We initially set refine CT candidate region LD mapping affected dogs would result identical regions homozygosity encompassing CT locus
0.14836259.11809725.html.plaintext.txt	165	Although Ostrander Kruglyak 9 advocated approach also suggested extensive inbreeding could result rather large regions LD thereby hampering fine mapping disease locus
0.14836259.11809725.html.plaintext.txt	166	However since CT mutation existed Bedlington terrier breed 20 30 generations regions LD around disease mutation shared Belgian British Bedlington terriers fairly small
0.14836259.11809725.html.plaintext.txt	167	Nevertheless surprised find cohort 22 affected dogs come one Belgian pedigree CT region could refined region small 500 kb
0.14836259.11809725.html.plaintext.txt	168	The region shared homozygous form affected dogs isolated BAC clones
0.14836259.11809725.html.plaintext.txt	169	The conservative CT contig consisted nine overlapping BAC clones region refined 500 kb flanked markers CF10B18 CF10B23
0.14836259.11809725.html.plaintext.txt	170	The 500 kb region covered five BAC clones
0.14836259.11809725.html.plaintext.txt	171	A transcription map generated region using combination human genome sequence data sample sequencing canine BAC clones
0.14836259.11809725.html.plaintext.txt	172	The human sequence revealed six different transcripts combined approach revealed 16 putative transcripts region
0.14836259.11809725.html.plaintext.txt	173	Since identity transcripts region yet determined focused attention known genes
0.14836259.11809725.html.plaintext.txt	174	One genes MURR1 revealed deletion exon 2 resulting frame deletion production predicted truncated protein 94 amino acid residues instead 188 amino acid residues
0.14836259.11809725.html.plaintext.txt	175	Southern blot analysis PCR analysis using intronic primers clearly demonstrated presence genomic deletion spans least 10 kb encompasses exon 2
0.14836259.11809725.html.plaintext.txt	176	The presence deletion exon 2 MURR1 gene affected Bedlington terriers homozygous state suggests MURR1 disease causing gene CT Bedlington terriers
0.14836259.11809725.html.plaintext.txt	177	Interestingly however C04107 marker located within intron 1 MURR1
0.14836259.11809725.html.plaintext.txt	178	This would make C04107 excellent predictive marker CT especially given extensive LD allele 2 marker CT locus
0.14836259.11809725.html.plaintext.txt	179	Nevertheless localization C04107 within MURR1 gene also raises intriguing question explain recombinants described previously
0.14836259.11809725.html.plaintext.txt	180	It cannot excluded recombination C04107 site deletion associated CT lead uncoupling allele 2 C04107 CT mutation
0.14836259.11809725.html.plaintext.txt	181	Therefore would interesting test recombinant dogs presence CT mutation
0.14836259.11809725.html.plaintext.txt	182	Alternatively different mutations may present MURR1 gene associated different C04107 alleles although unlikely several mutations would occur purebred dog
0.14836259.11809725.html.plaintext.txt	183	However incorrect diagnosis disease may also provide logical explanation observed discrepancy
0.14836259.11809725.html.plaintext.txt	184	In cohort Bedlington terriers CT affection status determined hepatic copper concentrations 1000 microgg dry weight liver
0.14836259.11809725.html.plaintext.txt	185	24 considered dogs affected CT hepatic copper concentrations exceeded 400 microgg dry weight liver
0.14836259.11809725.html.plaintext.txt	186	Normal liver copper concentrations dogs vary widely even healthy dogs may exceed 400 microgg dry weight liver 25
0.14836259.11809725.html.plaintext.txt	187	An extensive survey much larger panel Bedlington terriers would resolve issue
0.14836259.11809725.html.plaintext.txt	188	The large genomic deletion causing truncated MURR1 protein 94 amino acids suggests loss function mutation would lead complete loss protein function
0.14836259.11809725.html.plaintext.txt	189	The function MURR1 protein remains elucidated since protein completely unknown shows homology protein identifiable motifs
0.14836259.11809725.html.plaintext.txt	190	The MURR1 gene seems restricted vertebrates perhaps mammals detectable homologs present S
0.14836259.11809725.html.plaintext.txt	191	In addition results structural site predictions limited indicate putative function protein
0.14836259.11809725.html.plaintext.txt	192	We know affected Bedlington terriers copper stored lysosomes due inefficient excretion copper via bile 26
0.14836259.11809725.html.plaintext.txt	193	Recently knowledge copper uptake cell cellular copper transport different proteins increased substantially 10
0.14836259.11809725.html.plaintext.txt	194	However knowledge cellular processes acting downstream Wilson disease protein ATP7B involving copper excretion bile limited
0.14836259.11809725.html.plaintext.txt	195	It known ATP7B redistributes vesicular structures apical vacuoles reminiscent bile canaliculi high copper levels 27
0.14836259.11809725.html.plaintext.txt	196	Therefore tempting speculate accumulation copper lysosomes associated defect lysosomal vesicles transport bile canalicular membrane excretion bile
0.14836259.11809725.html.plaintext.txt	197	An 84 copper level reduction bile affected Bedlington terriers seen H
0.14836259.11809725.html.plaintext.txt	198	Roelofsen personal communication confirming speculations
0.14836259.11809725.html.plaintext.txt	199	Although exact role MURR1 still needs elucidated ubiquitous expression pattern gene consistent general function protein vesicle transport
0.14836259.11809725.html.plaintext.txt	200	The fact copper retained liver 28 copper excreted body explains tissues affected Bedlington terriers show copper accumulation
0.14836259.11809725.html.plaintext.txt	201	In addition high level expression MURR1 liver adds importance MURR1 copper excretion liver
0.14836259.11809725.html.plaintext.txt	202	The function MURR1 copper homeostasis mammalian cells investigated future
0.14836259.11809725.html.plaintext.txt	203	Moreover MURR1 becomes good candidate gene human copper storage disorders still need elucidated including Indian childhood cirrhosis 29 non Indian childhood cirrhosis 30 well copper toxicosis disorders seen dog breeds sheep 2531
0.14836259.11809725.html.plaintext.txt	204	MATERIALS AND METHODS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES Animals samples DNA isolation Blood collected 23 related Bedlington terriers Belgian origin nine affected 12 carriers two unaffected 10 unrelated affected Bedlington terriers 19
0.14836259.11809725.html.plaintext.txt	205	The pedigree Belgian Bedlington terriers depicted van de Sluis 19
0.14836259.11809725.html.plaintext.txt	206	DNA isolated according Miller et al
0.14836259.11809725.html.plaintext.txt	207	Diagnostic criteria described results copper analysis published Rothuizen et al
0.14836259.11809725.html.plaintext.txt	208	In addition DNA three affected English Bedlington terriers kindly provided Dr Nigel Holmes Centre Preventive Medicine Animal Health Trust Suffolk UK
0.14836259.11809725.html.plaintext.txt	209	DNA probes comparative mapping The probes ys77h10
0.14836259.11809725.html.plaintext.txt	210	s1pr SHGC 34371pr FLJ13305pr nh35c12
0.14836259.11809725.html.plaintext.txt	211	s1pr cct4pr crm1pr pex13pr mdh1pr KIAA0903pr KIAA0570pr DKFZp586J101pr 24963pr correspond human ESTsgenes ys77h10
0.14836259.11809725.html.plaintext.txt	212	s1 H93765 SHGC 34371 G28276 FLJ13305 AK023367 nh35c12
0.14836259.11809725.html.plaintext.txt	213	s1 AA524967 CCT4 AF026291 CRM1 XM002691 PEX13 AB022192 MDH1 XM049272 KIAA0903 AB020710 KIAA0570 AB011142 DKFZp586J101pr HSM800548 clone 24963 AF131737 respectively
0.14836259.11809725.html.plaintext.txt	214	These probes obtained PCR amplification human genomic DNA human placenta cDNA
0.14836259.11809725.html.plaintext.txt	215	Primers sequence information found httphumgen
0.14836259.11809725.html.plaintext.txt	216	nlresearchcoppersluis2001 selected coding regions
0.14836259.11809725.html.plaintext.txt	217	PCR reactions performed GeneAmp PCR system 9700 Perkin Elmer 20 microl volume containing 50 ng template DNA cDNA 50 ng oligonucleotide primer 200 mM dNTP 0
0.14836259.11809725.html.plaintext.txt	218	5 U Amplitaq Gold Perkin Elmer 1x PCR buffer II 2
0.14836259.11809725.html.plaintext.txt	219	DNA initially denaturated 95 degrees C 10 min subjected 35 cycles 95 degrees C 30 annealing 30 temperatures see httphumgen
0.14836259.11809725.html.plaintext.txt	220	nlresearchcoppersluis2001 72 degrees C 1 min followed final extension step 4 min 72 degrees C
0.14836259.11809725.html.plaintext.txt	221	The identity probes confirmed sequence analysis
0.14836259.11809725.html.plaintext.txt	222	Construction BAC contig Overlapping BAC clones isolated screening total canine BAC library 34 colony hybridization 32PdATP 32PdCTP labeled overgos 35
0.14836259.11809725.html.plaintext.txt	223	The overgos generated BAC end sequences determined previously described van de Sluis et al
0.14836259.11809725.html.plaintext.txt	224	The verification overlapping BAC clones determined PCR using PCR primers generated BAC end sequences
0.14836259.11809725.html.plaintext.txt	225	BAC clones isolated total BAC library colony hybridization 32PdATP labeled probes crm1pr pex13pr mdh1pr KIAA0903pr KIAA0570pr DKFZp586J101pr 24963pr
0.14836259.11809725.html.plaintext.txt	226	The hybridization procedure verification positive BAC clones performed described van de Sluis et al
0.14836259.11809725.html.plaintext.txt	227	Comparative mapping BAC DNA isolated alkaline lysis method described BacPac website httpbacpac
0.14836259.11809725.html.plaintext.txt	228	BAC DNA digested EcoRI BamHI EcoRI BamHI separated 0
0.14836259.11809725.html.plaintext.txt	229	7 agarose gel transferred Hybond N Amersham hybridized 65 degrees C ys77h10
0.14836259.11809725.html.plaintext.txt	230	s1pr SHGC 34371pr FLJ13305pr nh35c12
0.14836259.11809725.html.plaintext.txt	231	Construction microsatellite enriched library BAC clones BAC DNA BAC clones comprising CT contig Results isolated alkaline lysis method
0.14836259.11809725.html.plaintext.txt	232	500 ng BAC DNA digested Sau3AI Roche adapters ligated end restriction fragments restriction fragments amplified using adapter specific primers described 37
0.14836259.11809725.html.plaintext.txt	233	The amplified product enrichment CA GAAA repeats performed previously described Korstanje et al
0.14836259.11809725.html.plaintext.txt	234	38 using 3 biotinylated CA22 3 biotinylated GAAA7 oligos
0.14836259.11809725.html.plaintext.txt	235	The enriched fragments amplified PCR using adapter specific primers described previously 37
0.14836259.11809725.html.plaintext.txt	236	The PCR products cloned pCR 2
0.14836259.11809725.html.plaintext.txt	237	1 cloning vector using TA cloning kit Invitrogen
0.14836259.11809725.html.plaintext.txt	238	Positive clones identified colony hybridization identity determined sequence analysis using BigDye Terminator cycle sequencing Applied Biosystems followed separation ABI Prism 3700 DNA analyzer Applied Biosystems
0.14836259.11809725.html.plaintext.txt	239	Thereafter specific primers generated amplify microsatellite repeat sequences
0.14836259.11809725.html.plaintext.txt	240	Primer sequences listed httphumgen
0.14836259.11809725.html.plaintext.txt	241	The approximate localization order microsatellite markers determined PCR analysis individual BAC clones comprising CT contig
0.14836259.11809725.html.plaintext.txt	242	Sample sequencing CT contig BAC DNA BAC clones J20 135 G6 181 E6 166 N21 27 L3 237 M22 353 D17 109 isolated described
0.14836259.11809725.html.plaintext.txt	243	500 ng BAC DNA partially digested Sau3AI Roche obtain DNA fragments 400 2000 bp using 0
0.14836259.11809725.html.plaintext.txt	244	5 U enzyme reaction volume 50 microl
0.14836259.11809725.html.plaintext.txt	245	The resulting digests ligated pBluescript SK Stratagene digested BamHI transformed plated LB agar plates 50 microgml ampicillin
0.14836259.11809725.html.plaintext.txt	246	Subclones randomly selected sequence analysis using M13 forward 21M13F reverse M13 R 2 primers
0.14836259.11809725.html.plaintext.txt	247	DNA marker analysis Dog DNA amplified 10 newly isolated canine microsatellite markers marker DTR10
0.14836259.11809725.html.plaintext.txt	248	Markers FH2422 FH2523 C04107 genotyped previously 19
0.14836259.11809725.html.plaintext.txt	249	The forward primer marker labeled HEX TET FITC fluorescent dyes allowed separation marker alleles automated ABI377 DNA sequencer
0.14836259.11809725.html.plaintext.txt	250	The markers analyzed described Wijmenga et al
0.14836259.11809725.html.plaintext.txt	251	Homozygosity mapping For canine microsatellite marker determined whether dogs heterozygous homozygous
0.14836259.11809725.html.plaintext.txt	252	If additional family members available haplotypes constructed determine identity descent mutant chromosome
0.14836259.11809725.html.plaintext.txt	253	The haplotypes typed dogs available online resource httphumgen
0.14836259.11809725.html.plaintext.txt	254	5 3 RACE PCR MURR1 gene Full length mRNA sequence MURR1 obtained 5 3 RACE using Marathon cDNA Amplification kit Clontech following primers 5 primer GATCTGAACTACTGAGAAAGTTGGG 3 primer CCCAACTTTCTCAGTAGTTCAGATC
0.14836259.11809725.html.plaintext.txt	255	The RACE PCR products subsequently cloned analyzed sequence analysis
0.14836259.11809725.html.plaintext.txt	256	Mutation analysis Mutation analysis MURR1 mRNA sequence performed using primer combination Murr1 3 CCCAGGAAGCTTTCCACGG Murr1 5 GTTGACTGACCTTGACTTCATC Murr1 4 CTGTTGCCATAATGGAGCTGG Murr1 2 CCTCAACCCCAAGATCAAGAG
0.14836259.11809725.html.plaintext.txt	257	The PCR performed described instead genomic DNA cDNA affected Bedlington terrier Beagle used
0.14836259.11809725.html.plaintext.txt	258	PCR products separated 1
0.14836259.11809725.html.plaintext.txt	259	5 agarose gel analyzed sequence analysis
0.14836259.11809725.html.plaintext.txt	260	Bioinformatics Sequences obtained sample sequencing analyzed Basic BLAST search httpwww
0.14836259.11809725.html.plaintext.txt	261	Database searches find MURR1 orthologs species performed using available databases available NCBI httpwww
0.14836259.11809725.html.plaintext.txt	262	gov fugu zebra fish database httpfugu
0.14836259.11809725.html.plaintext.txt	263	The presence domains structural motifs within MURR1 protein analyzed using different prediction programs httpwww
0.14836259.11809725.html.plaintext.txt	264	RT PCR Total RNA different tissues Beagle used synthesize single stranded cDNA using Reverse Transcription System Promega
0.14836259.11809725.html.plaintext.txt	265	The reverse transcriptase reaction performed according manufacturer specifications Promega
0.14836259.11809725.html.plaintext.txt	266	MURR1 expression performed using primer combination Murr1 3 Murr1 5
0.14836259.11809725.html.plaintext.txt	267	The PCR reaction performed described
0.14836259.11809725.html.plaintext.txt	268	PCR products separated 2 agarose gel
0.14836259.11809725.html.plaintext.txt	269	Northern blot analysis Human 12 lane multiple tissue northern MTNTM blot hybridized 32PdCTP labeled cDNA dog MURR1 probe containing exon 2 exon 3 according manufacturer specifications Clontech
0.14836259.11809725.html.plaintext.txt	270	The northern blot rehybridized 32PdCTP labeled cDNA GAPDH probe control
0.14836259.11809725.html.plaintext.txt	271	ACKNOWLEDGEMENTS We thank Nigel Holmes Animal Health Trust New Market UK collecting DNA samples Bedlington terriers UK Martin Wapenaar critical review Ellen van Binsbergen Monique van Wolferen technical assistance Harm van Bakel bioinformatic assistance Jackie Senior improving manuscript
0.14836259.11809725.html.plaintext.txt	272	We thank British Bedlington terrier club financial support
0.14836259.11809725.html.plaintext.txt	273	This work also received financial support International Copper Association TPT0551 98 Netherlands Organization Scientific Research NWO 902 23 254
0.14836259.11809725.html.plaintext.txt	274	FOOTNOTES To correspondence addressed
0.14836259.11809725.html.plaintext.txt	275	Tel 31 30 250 4286 Fax 31 30 250 5301 Email
0.14836259.11809725.html.plaintext.txt	276	REFERENCES TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES 1 PattersonD
0.14836259.11809725.html.plaintext.txt	277	2002 Canine Genetic Disease Information System
0.14836259.11809725.html.plaintext.txt	278	Mosby Harcourt Health Science St Louis MO
0.14836259.11809725.html.plaintext.txt	279	1998 Genetic markers linked neuronal ceroid lipofuscinosis English setter dogs
0.14836259.11809725.html.plaintext.txt	280	1998 Linkage analysis comparative mapping canine progressive rod cone degeneration prcd establishes potential locus homology retinitis pigmentosa RP17 humans
0.14836259.11809725.html.plaintext.txt	281	1999 A novel retinal degeneration locus identified linkage comparative mapping canine early retinal degeneration
0.14836259.11809725.html.plaintext.txt	282	1999 The sleep disorder canine narcolepsy caused mutation hypocretin orexin receptor 2 gene
0.14836259.11809725.html.plaintext.txt	283	2000 Genetic mapping naturally occurring hereditary renal cancer syndrome dogs
0.14836259.11809725.html.plaintext.txt	284	1997 Semper fidelis man best friend teach us human biology disease
0.14836259.11809725.html.plaintext.txt	285	2000 Canine genetics comes age
0.14836259.11809725.html.plaintext.txt	286	2000 Unleashing canine genome
0.14836259.11809725.html.plaintext.txt	287	1999 A delicate balance homeostatic control copper uptake distribution
0.14836259.11809725.html.plaintext.txt	288	1975 Chronic progressive hepatitis Bedlington terriers associated elevated liver copper concentrations
0.14836259.11809725.html.plaintext.txt	289	Minnesota Veterinarian 15 13 24
0.14836259.11809725.html.plaintext.txt	290	1980 Inheritance copper toxicosis Bedlington terriers
0.14836259.11809725.html.plaintext.txt	291	1982 Inherited copper toxicosis Bedlington terriers Wilson disease hepatolenticular degeneration
0.14836259.11809725.html.plaintext.txt	292	1979 Clinical morphologic chemical studies copper toxicosis Bedlington terriers
0.14836259.11809725.html.plaintext.txt	293	1997 Linkage microsatellite marker canine copper toxicosis locus Bedlington terriers
0.14836259.11809725.html.plaintext.txt	294	1999 Genetic mapping copper toxicosis locus Bedlington terriers dog chromosome 10 region syntenic human chromosome region 2p13 p16
0.14836259.11809725.html.plaintext.txt	295	1999 The copper chaperone Atox1 canine copper toxicosis Bedlington terriers
0.14836259.11809725.html.plaintext.txt	296	1999 The canine copper toxicosis locus syntenic ATP7B ATX1 maps region showing homology human 2p21
0.14836259.11809725.html.plaintext.txt	297	2000 Refined genetic comparative physical mapping canine copper toxicosis locus
0.14836259.11809725.html.plaintext.txt	298	2000 Assignation highly polymorphic markers canine purebred pedigree
0.14836259.11809725.html.plaintext.txt	299	1987 An analysis 5 noncoding sequences 699 vertebrate messenger RNAs
0.14836259.11809725.html.plaintext.txt	300	1997 Mouse U2af1 rs1 neomorphic imprinted gene
0.14836259.11809725.html.plaintext.txt	301	1998 DNA marker C04107 copper toxicosis population Bedlington terriers United Kingdom
0.14836259.11809725.html.plaintext.txt	302	2001 Copper toxicosis Bedlington terrier diagnostic dilemma
0.14836259.11809725.html.plaintext.txt	303	2000 A perspective copper liver disease dog
0.14836259.11809725.html.plaintext.txt	304	1981 Hepatic lysosomal copper protein dogs inherited copper toxicosis
0.14836259.11809725.html.plaintext.txt	305	2000 Copper induced apical trafficking ATP7B polarized hepatoma cells provides mechanism biliary copper excretion
0.14836259.11809725.html.plaintext.txt	306	Gastroenterology 119 782 793
0.14836259.11809725.html.plaintext.txt	307	1998 Role copper Indian childhood cirrhosis
0.14836259.11809725.html.plaintext.txt	308	1996 Endemic Tyrolean infantile cirrhosis ecogenetic disorder
0.14836259.11809725.html.plaintext.txt	309	1982 Copper toxicosis sheep
0.14836259.11809725.html.plaintext.txt	310	1988 A simple salting procedure extracting DNA human nucleated cells
0.14836259.11809725.html.plaintext.txt	311	1999 Diagnostic value microsatellite DNA marker copper toxicosis west European Bedlington terriers incidence disease
0.14836259.11809725.html.plaintext.txt	312	1999 Construction characterization eightfold redundant dog genomic bacterial artificial chromosome library
0.14836259.11809725.html.plaintext.txt	313	2000 Construction BAC contig map chromosome 16q two dimensional overgo hybridization
0.14836259.11809725.html.plaintext.txt	314	1998 Identification fragments human transcripts defined chromosomal region representational difference analysis somatic cell hybrids
0.14836259.11809725.html.plaintext.txt	315	2001 Mapping Rabbit chromosome 1 markers generated microsatellite enriched chromosome specific library
0.14836259.11809725.html.plaintext.txt	316	1998 Localization ICF syndrome chromosome 20 homozygosity mapping
0.10528083.15870395.html.plaintext.txt	0	Genome wide analysis gene transcription hypothalamus Jocelyn M
0.10528083.15870395.html.plaintext.txt	1	Department Medical Genetics University Alberta Edmonton Alberta Canada
0.10528083.15870395.html.plaintext.txt	2	ABSTRACT TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES As genomic regions containing loci predisposing obesity related traits mapped human population screens mouse genetic studies identification susceptibility genes increasingly facilitated bioinformatic methods
0.10528083.15870395.html.plaintext.txt	3	We hypothesized candidate genes prioritized expression levels tissues central importance obesity
0.10528083.15870395.html.plaintext.txt	4	Our objective develop combined bioinformatics molecular paradigm identify novel genes candidates murine human obesity genetic modifiers based differential expression patterns hypothalamus compared murine tissues
0.10528083.15870395.html.plaintext.txt	5	We used bioinformatics tools search publicly available gene expression databases using criteria designed identify novel genes differentially expressed hypothalamus
0.10528083.15870395.html.plaintext.txt	6	We used RNA methods determine expression sites levels expression hypothalamus murine brain
0.10528083.15870395.html.plaintext.txt	7	We identified chromosomal location novel genes mice humans compared locations genetic loci predisposing obesity related traits
0.10528083.15870395.html.plaintext.txt	8	We developed search strategy correctly identified set genes known important hypothalamic function well candidate gene Prader Willi syndrome previously identified differentially expressed hypothalamus
0.10528083.15870395.html.plaintext.txt	9	Using strategy identified characterized set 11 genes previously known differentially expressed murine hypothalamus
0.10528083.15870395.html.plaintext.txt	10	Our results demonstrate feasibility combined bioinformatics molecular approaches identification genes candidates obesity related disorders humans mice
0.10528083.15870395.html.plaintext.txt	11	hypothalamus candidate genes bioinformatics gene expression microarray
0.10528083.15870395.html.plaintext.txt	12	INTRODUCTION TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES OBESITY major health issue facing developed nations today
0.10528083.15870395.html.plaintext.txt	13	Despite years population studies genetic determinants healthy body weight poorly understood 1
0.10528083.15870395.html.plaintext.txt	14	Likewise although increased understanding role hypothalamic pituitary adrenal axis obesity proteins implicated development andor function organ system identified characterized
0.10528083.15870395.html.plaintext.txt	15	Specific proteins hormones receptors responsible control appetite long term maintenance body weight 18 24
0.10528083.15870395.html.plaintext.txt	16	An increasing number studies rely mapping obesity modifier loci mice humans choosing candidate genes within mapped region study 11a 20
0.10528083.15870395.html.plaintext.txt	17	Still studies examine changes gene expression mice undergoing dietary challenges obesity gene knockout versus wild type mice
0.10528083.15870395.html.plaintext.txt	18	Yet reliability effective choice candidate genes depends prior knowledge gene expression function searchable databases
0.10528083.15870395.html.plaintext.txt	19	Often knowledge exists readily available researchers unfamiliar complexities bioinformatic databases
0.10528083.15870395.html.plaintext.txt	20	To search obesity candidate genes used combined bioinformatic molecular biology approach identify novel genes important function hypothalamus
0.10528083.15870395.html.plaintext.txt	21	The hypothalamus complex region brain involved homeostatic processes including limited energy balance
0.10528083.15870395.html.plaintext.txt	22	We identified set genes already known important hypothalamic function set genes previously associated hypothalamus
0.10528083.15870395.html.plaintext.txt	23	We propose genes may important function hypothalamus may provide new source hypothalamus specific regulatory elements may important disorders hypothalamic function obesity
0.10528083.15870395.html.plaintext.txt	24	Furthermore genes identified search candidate genes obesity related traits genetically mapped chromosomal intervals reside
0.10528083.15870395.html.plaintext.txt	25	MATERIALS AND METHODS TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES Bioinformatics
0.10528083.15870395.html.plaintext.txt	26	The Genomics Institute Novartis Research Foundation GNF murine gene expression atlas updated GNF SymAtlas version 1
0.10528083.15870395.html.plaintext.txt	27	3 originally developed tool high throughput analysis transcriptional activity biological samples 25 26
0.10528083.15870395.html.plaintext.txt	28	The expression specific genes within 45 diverse murine tissues including hypothalamus quantified hybridization Affymetrix mouse U74A high density oligonucleotide arrays made available searchable line database
0.10528083.15870395.html.plaintext.txt	29	We filtered murine dataset select genes levels expression median hypothalamus moderately high level expression median five tissues
0.10528083.15870395.html.plaintext.txt	30	According GNF SymAtlas database duplicate samples andor duplicate hybridizations performed tissue values integrated error bars measurement
0.10528083.15870395.html.plaintext.txt	31	Because configuration database possible generate estimates statistical significance rather search criteria left deliberately broad risk including genes fact show much specificity hypothalamic expression analyzed might expected database search alone
0.10528083.15870395.html.plaintext.txt	32	The median defined specific gene across tissues bias genes low moderate levels gene expression overall
0.10528083.15870395.html.plaintext.txt	33	This first search performed GeneAtlas Version 1 Dataset 25
0.10528083.15870395.html.plaintext.txt	34	A second search performed GeneAtlas Version 2 Dataset Mouse GeneAtlas GNF1M 26
0.10528083.15870395.html.plaintext.txt	35	In data set correlation search performed identify genes high value hypothalamus set 400 value nonbrain tissues low value set 1 regions brain correlation 0
0.10528083.15870395.html.plaintext.txt	36	Because preoptic region part hypothalamus allowed value expression preoptic area well
0.10528083.15870395.html.plaintext.txt	37	Genome localization selected murine hypothalamic genes identified May 2004 mouse Mus musculus draft genome data build 33 assembly National Center Biotechnology Information NCBI
0.10528083.15870395.html.plaintext.txt	38	The genomic localization human orthologs deduced using NCBI database UniGene Gene
0.10528083.15870395.html.plaintext.txt	39	RNA situ hybridization performed using digoxigenin labeled antisense RNA probes 20 microm cryosections embryonic day 18
0.10528083.15870395.html.plaintext.txt	40	5 mouse embryos previously described 16
0.10528083.15870395.html.plaintext.txt	41	Probes Hcrt A26100 Dscr1l2 Impact Pnck derived PCR fragments amplified reverse transcribed adult mouse hypothalamus mRNA recombinant Taq DNA polymerase Invitrogen cloned pBluescript vector Invitrogen
0.10528083.15870395.html.plaintext.txt	42	The Hcrt probe includes positions 7 573 hypocretin Hcrt mRNA NM010410
0.10528083.15870395.html.plaintext.txt	43	The A26100 probe includes positions 432 1004 RIKEN cDNA 2610042L04 gene 2610042L04Rik mRNA NM025940
0.10528083.15870395.html.plaintext.txt	44	The Dscr1l2 probe includes positions 177 638 Down syndrome critical region gene 1 like 2 Dscr1l2 mRNA NM022980
0.10528083.15870395.html.plaintext.txt	45	The Impact probe includes positions 504 955 imprinted ancient Impact mRNA NM008378
0.10528083.15870395.html.plaintext.txt	46	The Pnck probe includes positions 697 1252 pregnancy upregulated nonubiquitously expressed Ca2calmodulin kinase Pnck mRNA NM012040
0.10528083.15870395.html.plaintext.txt	47	The Magel2 probe includes positions 984 1754 Genbank accession number NM013779 previously described 16
0.10528083.15870395.html.plaintext.txt	48	All studies involving animals performed according guidelines use care laboratory animals University Alberta
0.10528083.15870395.html.plaintext.txt	49	RESULTS TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES A major goal Human Genome Project identify expressed sequences expressed sequence tags ESTs RNA isolated tissues cell lines
0.10528083.15870395.html.plaintext.txt	50	By clustering ESTs groups UniGene clusters sequence identity resulting UniGene database could queried gene name discover tissues gene expressed
0.10528083.15870395.html.plaintext.txt	51	Until recently public databases allowed investigators perform converse query discover expression levels transcripts particular tissue respect expression levels tissues
0.10528083.15870395.html.plaintext.txt	52	However results two large scale gene array experiments documenting expression levels genes wide range mouse tissues including hypothalamus recently published
0.10528083.15870395.html.plaintext.txt	53	Specifically labeled cDNA mouse tissue hybridized Affymetrix Genechip microarrays profile expression levels 36000 genes tissues
0.10528083.15870395.html.plaintext.txt	54	In study multitissue comparisons performed normalize expression levels input searchable gene expression database GNF database made available Novartis Research Foundation 8 25
0.10528083.15870395.html.plaintext.txt	55	The major advantage previous studies used subtractive methods derive hypothalamic cDNAs levels expression compared tissues parts brain genes expressed highly specifically hypothalamus easily identified
0.10528083.15870395.html.plaintext.txt	56	We queried database identify genes differentially expressed murine adult hypothalamus
0.10528083.15870395.html.plaintext.txt	57	Strategy identification hypothalamic transcripts
0.10528083.15870395.html.plaintext.txt	58	We reasoned genes important hypothalamic development function likely transcribed hypothalamic precursor tissues mature hypothalamus
0.10528083.15870395.html.plaintext.txt	59	The laboratory mouse model particularly amenable studies brain function similarities anatomy human hypothalamus widespread use obesity studies
0.10528083.15870395.html.plaintext.txt	60	We performed three searches using different criteria query GNF expression database genes highly expressed postnatal murine hypothalamus
0.10528083.15870395.html.plaintext.txt	61	Our first search GNF database used low specificity criteria required high expression hypothalamus least 8 times median expression level 45 mouse tissues
0.10528083.15870395.html.plaintext.txt	62	This search identified set genes already studied role hypothalamic function pro opiomelanocortin POMC Hcrt also identified many genes broadly expressed nervous system microtubule associated protein
0.10528083.15870395.html.plaintext.txt	63	Notably genes important obesity andor hypothalamic function identified conditions e
0.10528083.15870395.html.plaintext.txt	64	Our second search GNF database used high specificity criteria first search high expression hypothalamus least eight times median expression tissues
0.10528083.15870395.html.plaintext.txt	65	In addition second search required low expression 3 times median least 40 tissues
0.10528083.15870395.html.plaintext.txt	66	This second search identified five genes including arginine vasopressin POMC Hcrt oxytocin major roles endocrine regulation hypothalamus
0.10528083.15870395.html.plaintext.txt	67	Significantly high specificity search also identified Magel2 developmentally regulated inactivated genetic obesity disorder Prader Willi syndrome
0.10528083.15870395.html.plaintext.txt	68	We formulated third search intermediate specificity expression hypothalamus eight times median level tissues fewer five tissues three times median level expression
0.10528083.15870395.html.plaintext.txt	69	The third search GNF database identified set 15 genes highly expressed hypothalamus moderately highly expressed 5 murine tissues Table 1 screen 1
0.10528083.15870395.html.plaintext.txt	70	We repeated third search using updated database 2004 version mouse Geneatlas
0.10528083.15870395.html.plaintext.txt	71	As third search GNF database search Geneatlas 2004 identified genes high expression hypothalamus low expression elsewhere brain
0.10528083.15870395.html.plaintext.txt	72	We used correlation function searchable Symatlas database within Geneatlas
0.10528083.15870395.html.plaintext.txt	73	The Symatlas search refined allow either high low expression preoptic region functionally overlaps hypothalamus
0.10528083.15870395.html.plaintext.txt	74	This last search still using intermediate specificity criteria identified 7 genes 3 identified GNF intermediate specificity search Table 1 screen 2 total 19 genes
0.10528083.15870395.html.plaintext.txt	75	Intermediate search GNF Gene Expression Atlas detect genes highly expressed hypothalamus expressed low levels tissues
0.10528083.15870395.html.plaintext.txt	76	Selection novel hypothalamic genes
0.10528083.15870395.html.plaintext.txt	77	Of 19 genes two searches GNF databases 3 genes identified searches Table 1
0.10528083.15870395.html.plaintext.txt	78	Because nature search engine provided GNF changed 2002 release 2004 release two search criteria directly comparable
0.10528083.15870395.html.plaintext.txt	79	In common two searches requirement high expression hypothalamus low expression regions brain
0.10528083.15870395.html.plaintext.txt	80	Because interested identifying genes known important hypothalamus first set aside genes whose role hypothalamic function well described
0.10528083.15870395.html.plaintext.txt	81	These included genes encoding neuropeptide signaling molecules Hcrtorexin pro opiomelanocortin oxytocin agouti related protein arginine vasopressin 4
0.10528083.15870395.html.plaintext.txt	82	A neuroendocrine role calcitonin calcitonin receptor growth hormone secretion hypothalamuspituitary previously suggested 17
0.10528083.15870395.html.plaintext.txt	83	We previously identified Magel2 specifically expressed developing murine hypothalamus although function tissue yet known 16
0.10528083.15870395.html.plaintext.txt	84	Magel2 particular interest human ortholog MAGEL2 one set genes inactivated genetic obesity disorder Prader Willi syndrome 9 15
0.10528083.15870395.html.plaintext.txt	85	Finally mutations Patched Ptch1 result holoprosencephaly developmental delay humans alternatively cause basal cell nervous syndrome homozygously inactivated somatic cells
0.10528083.15870395.html.plaintext.txt	86	Ptch1 antagonist signaling molecule hedgehog functions patterning neural tube known specific role hypothalamus
0.10528083.15870395.html.plaintext.txt	87	The remaining 11 genes fell 2 categories 1 novel genes function predicted sequence similarity known genes 2 novel genes known function limited similarity known genes Table 2
0.10528083.15870395.html.plaintext.txt	88	We examined UniGene clusters associated novel genes
0.10528083.15870395.html.plaintext.txt	89	Because EST sets made hypothalamus RNA represented mouse EST databases expected see representation hypothalamic cDNAs within Unigene clusters corresponding genes
0.10528083.15870395.html.plaintext.txt	90	Indeed 11 genes corresponding ESTs derived whole brain specifically including hypothalamus 4 diencephalon 2 Table 2
0.10528083.15870395.html.plaintext.txt	91	The information UniGene clusters point genes particularly hypothalamus specific contrast Unigene cluster arginine vasopressin example 12 19 ESTs derived hypothalamus
0.10528083.15870395.html.plaintext.txt	92	We used EST ProfileViewer function Unigene test whether expression profile derived ESTs overlapped derived Geneatlas databases
0.10528083.15870395.html.plaintext.txt	93	Seven eleven novel genes major contribution ESTs brain pituitary gland hypothalamus included brain sample EST Profile viewer
0.10528083.15870395.html.plaintext.txt	94	In one case Itih3 majority UniGene ESTs derived liver small minority brain
0.10528083.15870395.html.plaintext.txt	95	This consistent Geneatlas distribution shows highest expression Itih3 liver remaining expression preoptic hypothalamus samples
0.10528083.15870395.html.plaintext.txt	96	In one case Dscr1l2 UniGene ESTs distribute tissue specific pattern although examination developmental timing expression also using function Unigene demonstrated vast majority ESTs derived egg opposed preimplantation embryos postimplantation embryonic stage
0.10528083.15870395.html.plaintext.txt	97	This contrast GeneAtlas 2004 expression profile shows little tissue specificity Dscr1l2 transcript also contrasts GeneAtlas 2002 expression profile showed specific expression hypothalamus
0.10528083.15870395.html.plaintext.txt	98	Similarly Pitpnm1 showed conflicting expression profiles GeneAtlas 2002 GeneAtlas 2004 EST ProfileViewer one commonality expression eye
0.10528083.15870395.html.plaintext.txt	99	EST expression profile murine gene targeting studies
0.10528083.15870395.html.plaintext.txt	100	In cases preliminary expression patterns novel genes determined RNA protein based methods already published
0.10528083.15870395.html.plaintext.txt	101	This information readily available JAX bioinformatics server references original publications
0.10528083.15870395.html.plaintext.txt	102	It proposed Igsf1 also known InhBPp120 may involved pituitary function male female mice mutant Igsf1 viable fertile 3
0.10528083.15870395.html.plaintext.txt	103	The insulin receptor substrates including Irs4 function insulin signaling
0.10528083.15870395.html.plaintext.txt	104	Absence Irs4 causes mild defects growth reproduction glucose homeostasis Irs4 null mutant mouse line 5
0.10528083.15870395.html.plaintext.txt	105	On basis mouse knockout model Ptprz shown role oligodendrocyte survival recovery demyelinating disease 11
0.10528083.15870395.html.plaintext.txt	106	Pnck 6 Nsg1 21 Ptpro 2 suggested roles developing nervous system whereas function Itih3 studied liver function predicted brain 2
0.10528083.15870395.html.plaintext.txt	107	No function predicted Impact although human ortholog IMPACT suggested candidate gene bipolar affective disorder 10 14
0.10528083.15870395.html.plaintext.txt	108	There also information putative function gene represented Unigene cluster Mm
0.10528083.15870395.html.plaintext.txt	109	We first verified 11 selected genes indeed expressed murine hypothalamus RT PCR RNA samples adult mouse hypothalamus data shown
0.10528083.15870395.html.plaintext.txt	110	We localized expression specific hypothalamic nuclei RNA situ hybridization using standard mouse atlas label sections 13
0.10528083.15870395.html.plaintext.txt	111	A probe Hcrt displayed strong signal lateral anterior hypothalamus consistent known abundance RNA transcripts region brain Fig
0.10528083.15870395.html.plaintext.txt	112	Consistent earlier embryonic expression Magel2 suprachiasmatic nucleus 16 detected Magel2 transcripts anterior hypothalamus suprachiasmatic nucleus Fig
0.10528083.15870395.html.plaintext.txt	113	We selected four genes emerged bioinformatic analysis little else known
0.10528083.15870395.html.plaintext.txt	114	All four genes displayed high levels expression hypothalamus compared surrounding brain tissue RNA situ hybridization Fig
0.10528083.15870395.html.plaintext.txt	115	Probes A2610042L04 Pnck detected abundant expression anterior hypothalamus whereas probe Dscr1l2 detected strongest expressions dorsal medial hypothalamus ventromedial hypothalamus arcuate nucleus probe Impact detected highest expression arcuate nucleus
0.10528083.15870395.html.plaintext.txt	116	View larger version 194K Fig
0.10528083.15870395.html.plaintext.txt	117	Expression candidate genes late embryonic hypothalamus
0.10528083.15870395.html.plaintext.txt	118	Cryosections embryonic day 18
0.10528083.15870395.html.plaintext.txt	119	5 mouse brain hybridized digoxigenin labeled antisense RNA situ hybridization probes Hcrt Magel2 Dscr1l2 Impact A2610042L04 Pnck
0.10528083.15870395.html.plaintext.txt	120	Hybridization signals detected anterior hypothalamus AH arcuate nucleus Arc dorsomedial hypothalamus Dmh suprachiasmatic nucleus Scn ventromedial hypothalamus Vmh
0.10528083.15870395.html.plaintext.txt	121	3V third ventricle If infidibular recess Oc optic chiasm
0.10528083.15870395.html.plaintext.txt	122	All sections oriented ventral aspect bottom
0.10528083.15870395.html.plaintext.txt	123	We used NCBI databases map 11 selected genes chromosomal regions mouse genome NCBI build 33 human genome NCBI build 35 Table 3
0.10528083.15870395.html.plaintext.txt	124	We correlated map positions selected genes genomic positions published loci influencing obesity related traits either human mammals 23 Table 3 updated published line The Obesity Gene Map Database 11a
0.10528083.15870395.html.plaintext.txt	125	We identified eight traits body mass index fat mass percent body fat mapped chromosomal regions selected genes human studies weight gain obesity
0.10528083.15870395.html.plaintext.txt	126	We identified cases obesity traits identified mapping within mouse rat pig chromosomal region homologous human chromosome bands containing selected genes
0.10528083.15870395.html.plaintext.txt	127	We include traits mapped interval contained three chromosome bands would contain large number candidate genes
0.10528083.15870395.html.plaintext.txt	128	In way identified 13 obesity related traits mouse 11 rat 1 pig 1 correlated map positions 6 11 selected genes traits related obesity weight gain
0.10528083.15870395.html.plaintext.txt	129	Except A2610042L04 poorly characterized predicted mouse gene chromosome 14 selected genes regions mammalian genome genetic evidence obesity related trait exists
0.10528083.15870395.html.plaintext.txt	130	Obesity traits near candidate genes
0.10528083.15870395.html.plaintext.txt	131	DISCUSSION TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES The use microarray based systems accelerated high throughput gene expression profiling tissues interest disease processes
0.10528083.15870395.html.plaintext.txt	132	Previous studies designed identify cDNAs enriched hypothalamus used subtractive hybridization 7 EST cataloguing 12
0.10528083.15870395.html.plaintext.txt	133	Although methods identify genes expressed hypothalamus intrinsic biases toward highly expressed genes methods subtractive hybridization methodologies also intrinsic sequence specific biases
0.10528083.15870395.html.plaintext.txt	134	In contrast high throughput gene expression profiling provides robust unbiased searchable resource freely available research community
0.10528083.15870395.html.plaintext.txt	135	We examined relative expression levels estimated 30000 genes murine hypothalamus determined Affymetrix microarray technology made available Novartis Research Foundation 8
0.10528083.15870395.html.plaintext.txt	136	From identified set genes previously recognized important hypothalamic function highly preferentially expressed murine hypothalamus
0.10528083.15870395.html.plaintext.txt	137	It exciting think database available time cloned Magel2 1999 analysis could facilitated selection human MAGEL2 candidate gene extreme obesity seen Prader Willi syndrome
0.10528083.15870395.html.plaintext.txt	138	We identified 11 genes whose expression enriched hypothalamus previously associated development hypothalamus function
0.10528083.15870395.html.plaintext.txt	139	The candidate genes could involved number interrelated processes partially mediated hypothalamus besides energy fluid balance circadian rhythm reproduction stress responses temperature regulation 1
0.10528083.15870395.html.plaintext.txt	140	The definitive proof involvement obesity rather functions hypothalamus would come demonstration gene dysregulation various models obesity including genetic diet induced obesity
0.10528083.15870395.html.plaintext.txt	141	We concentrated obesity large number studies providing genetically mapped obesity related traits genes identified could equally well roles disorders hypothalamic function
0.10528083.15870395.html.plaintext.txt	142	Other regions brain including cortex hindbrain important roles food intake 22 major roles neurological functions
0.10528083.15870395.html.plaintext.txt	143	The gut liver pancreas adipose tissues also major roles appetite parallel studies could reveal novel obesity susceptibility genes highly specifically expressed tissues expressed brain hypothalamus
0.10528083.15870395.html.plaintext.txt	144	Because susceptibility obesity part genetically determined variations genes may contribute familial obesity
0.10528083.15870395.html.plaintext.txt	145	The information available cellular physiological function proteins encoded genes however highly variable
0.10528083.15870395.html.plaintext.txt	146	Furthermore size intervals obesity traits mapped also highly variable
0.10528083.15870395.html.plaintext.txt	147	Further genetic molecular studies would clarify possible roles candidate genes obesity
0.10528083.15870395.html.plaintext.txt	148	For example candidate gene located within region specific mouse strains human subjects shown genetic predisposition obesity could sequenced coding regulatory sequence variants
0.10528083.15870395.html.plaintext.txt	149	These variants could tested larger populations association obesity related traits including traits genetically mapped chromosomal intervals genes reside
0.10528083.15870395.html.plaintext.txt	150	Finally investigations physiological cellular functions proteins identified bioinformatic screens may elucidate role specific genes gene products hypothalamic function genetic predisposition obesity
0.10528083.15870395.html.plaintext.txt	151	GRANTS TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES This research performed support Canadian Institutes Health Research Pilot Project Grant Obesity Healthy Body Weight Request Applications R
0.10528083.15870395.html.plaintext.txt	152	Wevrick Senior Scholar Alberta Heritage Foundation Medical Research
0.10528083.15870395.html.plaintext.txt	153	ACKNOWLEDGMENTS We acknowledge Sharee Kuny Megan ONeill helpful discussions
0.10528083.15870395.html.plaintext.txt	154	FOOTNOTES Article published online print
0.10528083.15870395.html.plaintext.txt	155	See web site date publication httpphysiolgenomics
0.10528083.15870395.html.plaintext.txt	156	Address reprint requests correspondence R
0.10528083.15870395.html.plaintext.txt	157	Medical Genetics 8 42 Medical Sciences Bldg
0.10528083.15870395.html.plaintext.txt	158	Alberta Edmonton Alberta Canada T6G 2H7 E mail rachel
0.10528083.15870395.html.plaintext.txt	159	REFERENCES TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES Barsh GS Farooqi IS ORahilly S
0.10528083.15870395.html.plaintext.txt	160	Genetics body weight regulation
0.10528083.15870395.html.plaintext.txt	161	CrossRefISIMedline Beltran PJ Bixby JL Masters BA
0.10528083.15870395.html.plaintext.txt	162	Expression PTPRO mouse development suggests involvement axonogenesis differentiation NT 3 NGF dependent neurons
0.10528083.15870395.html.plaintext.txt	163	J Comp Neurol 456 384 395 2003
0.10528083.15870395.html.plaintext.txt	164	CrossRefISIMedline Bernard DJ Burns KH Haupt B Matzuk MM Woodruff TK
0.10528083.15870395.html.plaintext.txt	165	Normal reproductive function InhBPp120 deficient mice
0.10528083.15870395.html.plaintext.txt	166	Mol Cell Biol 23 4882 4891 2003
0.10528083.15870395.html.plaintext.txt	167	AbstractFree Full Text Ellacott KL Cone RD
0.10528083.15870395.html.plaintext.txt	168	The central melanocortin system integration short long term regulators energy homeostasis
0.10528083.15870395.html.plaintext.txt	169	Recent Prog Horm Res 59 395 408 2004
0.10528083.15870395.html.plaintext.txt	170	AbstractFree Full Text Fantin VR Wang Q Lienhard GE Keller SR
0.10528083.15870395.html.plaintext.txt	171	Mice lacking insulin receptor substrate 4 exhibit mild defects growth reproduction glucose homeostasis
0.10528083.15870395.html.plaintext.txt	172	Am J Physiol Endocrinol Metab 278 E127 E133 2000
0.10528083.15870395.html.plaintext.txt	173	AbstractFree Full Text Gardner HP Rajan JV Ha SI Copeland NG Gilbert DJ Jenkins NA Marquis ST Chodosh LA
0.10528083.15870395.html.plaintext.txt	174	Cloning characterization chromosomal localization Pnck Ca2calmodulin dependent protein kinase
0.10528083.15870395.html.plaintext.txt	175	CrossRefISIMedline Gautvik KM de Lecea L Gautvik VT Danielson PE Tranque P Dopazo A Bloom FE Sutcliffe JG
0.10528083.15870395.html.plaintext.txt	176	Overview prevalent hypothalamus specific mRNAs identified directional tag PCR subtraction
0.10528083.15870395.html.plaintext.txt	177	Proc Natl Acad Sci USA 93 8733 8738 1996
0.10528083.15870395.html.plaintext.txt	178	AbstractFree Full Text Genomics Institute Novartis Research Foundation Gene Expression Atlas
0.10528083.15870395.html.plaintext.txt	179	Prader Willi syndrome advances genetics pathophysiology treatment
0.10528083.15870395.html.plaintext.txt	180	Trends Endocrinol Metab 15 12 20 2004
0.10528083.15870395.html.plaintext.txt	181	CrossRefISIMedline Hagiwara Y Hirai M Nishiyama K Kanazawa I Ueda T Sakaki Y Ito T
0.10528083.15870395.html.plaintext.txt	182	Screening imprinted genes allelic message display identification paternally expressed gene impact mouse chromosome 18
0.10528083.15870395.html.plaintext.txt	183	Proc Natl Acad Sci USA 94 9249 9254 1997
0.10528083.15870395.html.plaintext.txt	184	AbstractFree Full Text Harroch S Furtado GC Brueck W Rosenbluth J Lafaille J Chao M Buxbaum JD Schlessinger J
0.10528083.15870395.html.plaintext.txt	185	A critical role protein tyrosine phosphatase receptor type Z functional recovery demyelinating lesions
0.10528083.15870395.html.plaintext.txt	186	Nat Genet 32 411 414 2002
0.10528083.15870395.html.plaintext.txt	187	CrossRefISIMedline Human Genetics Laboratory
0.10528083.15870395.html.plaintext.txt	188	Hu RM Han ZG Song HD Peng YD Huang QH Ren SX Gu YJ Huang CH Li YB Jiang CL Fu G Zhang QH Gu BW Dai M Mao YF Gao GF Rong R Ye M Zhou J Xu SH Gu J Shi JX Jin WR Zhang CK Wu TM Huang GY Chen Z Chen MD Chen JL
0.10528083.15870395.html.plaintext.txt	189	Gene expression profiling human hypothalamus pituitary adrenal axis full length cDNA cloning
0.10528083.15870395.html.plaintext.txt	190	Proc Natl Acad Sci USA 97 9543 9548 2000
0.10528083.15870395.html.plaintext.txt	191	AbstractFree Full Text Jacobowitz DM Abbott LC
0.10528083.15870395.html.plaintext.txt	192	Chemoarchitectonic Atlas Developing Mouse Brain
0.10528083.15870395.html.plaintext.txt	193	Kosaki K Suzuki T Kosaki R Yoshihashi H Itoh M Goto Y Matsuo N
0.10528083.15870395.html.plaintext.txt	194	Human homolog mouse imprinted gene Impact resides pericentric region chromosome 18 within critical region bipolar affective disorder
0.10528083.15870395.html.plaintext.txt	195	Mol Psychiatry 6 87 91 2001
0.10528083.15870395.html.plaintext.txt	196	CrossRefISIMedline Lee S Kozlov S Hernandez L Chamberlain SJ Brannan CI Stewart CL Wevrick R
0.10528083.15870395.html.plaintext.txt	197	Expression imprinting MAGEL2 suggest role Prader Willi syndrome homologous murine imprinting phenotype
0.10528083.15870395.html.plaintext.txt	198	Hum Mol Genet 9 1813 1819 2000
0.10528083.15870395.html.plaintext.txt	199	AbstractFree Full Text Lee S Walker CL Wevrick R
0.10528083.15870395.html.plaintext.txt	200	Prader Willi syndrome transcripts expressed phenotypically significant regions developing mouse brain
0.10528083.15870395.html.plaintext.txt	201	Gene Expr Patterns 3 599 609 2003
0.10528083.15870395.html.plaintext.txt	202	CrossRefISIMedline Lengyel AM Toledo AL Czepielewski MA Vieira JG Chacra AR
0.10528083.15870395.html.plaintext.txt	203	Calcitonin suppresses growth hormone GH response growth hormone releasing hormone GHRH man
0.10528083.15870395.html.plaintext.txt	204	J Endocrinol Invest 12 25 29 1989
0.10528083.15870395.html.plaintext.txt	205	The developmental program hypothalamus disorders
0.10528083.15870395.html.plaintext.txt	206	Clin Genet 60 255 263 2001
0.10528083.15870395.html.plaintext.txt	207	CrossRefISIMedline Rankinen T Perusse L Weisnagel SJ Snyder EE Chagnon YC Bouchard C
0.10528083.15870395.html.plaintext.txt	208	The human obesity gene map 2001 update
0.10528083.15870395.html.plaintext.txt	209	AbstractFree Full Text Saberan Djoneidi D Picart R Escalier D Gelman M Barret A Tougard C Glowinski J Levi Strauss M
0.10528083.15870395.html.plaintext.txt	210	A 21 kDa polypeptide belonging new family proteins expressed Golgi apparatus neural germ cells
0.10528083.15870395.html.plaintext.txt	211	J Biol Chem 273 3909 3914 1998
0.10528083.15870395.html.plaintext.txt	212	AbstractFree Full Text Schwartz GJ
0.10528083.15870395.html.plaintext.txt	213	Biology eating behavior obesity
0.10528083.15870395.html.plaintext.txt	214	Obes Res 12 Suppl 2 102S 106S 2004
0.10528083.15870395.html.plaintext.txt	215	AbstractFree Full Text Snyder EE Walts B Perusse L Chagnon YC Weisnagel SJ Rankinen T Bouchard C
0.10528083.15870395.html.plaintext.txt	216	The human obesity gene map 2003 update
0.10528083.15870395.html.plaintext.txt	217	AbstractFree Full Text Spiegelman BM Flier JS
0.10528083.15870395.html.plaintext.txt	218	Obesity regulation energy balance
0.10528083.15870395.html.plaintext.txt	219	CrossRefISIMedline Su AI Cooke MP Ching KA Hakak Y Walker JR Wiltshire T Orth AP Vega RG Sapinoso LM Moqrich A Patapoutian A Hampton GM Schultz PG Hogenesch JB
0.10528083.15870395.html.plaintext.txt	220	Large scale analysis human mouse transcriptomes
0.10528083.15870395.html.plaintext.txt	221	Proc Natl Acad Sci USA 99 4465 4470 2002
0.10528083.15870395.html.plaintext.txt	222	AbstractFree Full Text Su AI Wiltshire T Batalov S Lapp H Ching KA Block D Zhang J Soden R Hayakawa M Kreiman G Cooke MP Walker JR Hogenesch JB
0.10528083.15870395.html.plaintext.txt	223	A gene atlas mouse human protein encoding transcriptomes
0.10528083.15870395.html.plaintext.txt	224	Proc Natl Acad Sci USA 101 6062 6067 2004
0.10528083.15870395.html.plaintext.txt	225	AbstractFree Full Text Van Den Pol AN Patrylo PR Ghosh PK Gao XB
0.10528083.15870395.html.plaintext.txt	226	Lateral hypothalamus early developmental expression response hypocretin orexin
0.10528083.15870395.html.plaintext.txt	227	J Comp Neurol 433 349 363 2001
0.27228677.10767319.html.plaintext.txt	0	Dissection behavior psychiatric disorders using mouse model Lisa Tarantino1 Maja Bucan12
0.27228677.10767319.html.plaintext.txt	1	1Center Neurobiology Behavior Department Psychiatry 2Department Genetics University Pennsylvania CRB 415 Curie Boulevard Philadelphia PA 19104 USA
0.27228677.10767319.html.plaintext.txt	2	Received 28 January 2000 Revised Accepted 8 February 2000
0.27228677.10767319.html.plaintext.txt	3	ABSTRACT TOP ABSTRACT MOUSE MODELS FOR HUMAN
0.27228677.10767319.html.plaintext.txt	4	REFERENCES Mouse genetic models played important role elucidation molecular pathways underlying human disease
0.27228677.10767319.html.plaintext.txt	5	This approach becoming increasingly popular way study genetic underpinning psychiatric disorders
0.27228677.10767319.html.plaintext.txt	6	Genes within candidate regions susceptibility psychiatric illness evaluated phenotypic assessment mutants mapped corresponding regions mouse genome
0.27228677.10767319.html.plaintext.txt	7	Alternatively one search mouse mutants displaying characteristics might correspond physiological behavioral markers psychiatric disorder sometimes referred endophenotypes
0.27228677.10767319.html.plaintext.txt	8	Mice anomalies traits generated targeted mutagenesis known genes gene based mutagenesis reverse genetics identified among progeny mice random mutagenesis screen phenotype based mutagenesis forward genetics
0.27228677.10767319.html.plaintext.txt	9	In review discuss recently generated behavioral mutants mouse
0.27228677.10767319.html.plaintext.txt	10	We also give overview several robust commonly used behavioral phenotypes relevance human disease lessons learned recent successes mouse behavioral genetics
0.27228677.10767319.html.plaintext.txt	11	MOUSE MODELS FOR HUMAN BEHAVIORAL AND PSYCHIATRIC DISORDERS TOP ABSTRACT MOUSE MODELS FOR HUMAN
0.27228677.10767319.html.plaintext.txt	12	REFERENCES The burgeoning interest genetics complex traits including behavior generated variety new approaches uncovering genetic basis neuropsychiatric diseases schizophrenia bipolar disorder 1
0.27228677.10767319.html.plaintext.txt	13	Recent efforts localize susceptibility genes linkage strategies including genome wide searches provided evidence possible linkage schizophrenia chromosome regions 6p24 8p 13q32 18p11
0.27228677.10767319.html.plaintext.txt	14	2 22q11 2 7 confirmed susceptibility loci bipolar disorder chromosomes 4p16 18p11
0.27228677.10767319.html.plaintext.txt	15	2 12q24 13q32 21q21 22q11 13 Xq26 8 15
0.27228677.10767319.html.plaintext.txt	16	The observed overlap susceptibility loci bipolar disorder schizophrenia several chromosomes e
0.27228677.10767319.html.plaintext.txt	17	2 22q11 represents intriguing finding considering overlap diagnosis schizoaffective disorders recurrent unipolar illness relatives individuals either bipolar disorder schizophrenia 16 18
0.27228677.10767319.html.plaintext.txt	18	Despite successes genomic localization susceptibility loci several common psychiatric illnesses genome scans generally power assigning disease susceptibility loci narrow critical regions implying analysis candidate genes critical step identification genes underlying syndrome
0.27228677.10767319.html.plaintext.txt	19	Promising candidate genes corresponding proteins routinely identified physiological pharmacological properties functional studies gene model organisms Fig
0.27228677.10767319.html.plaintext.txt	20	Genetic approaches currently available mouse make model organism particularly powerful functional analysis candidate genes defining molecular pathways underlying pathogenesis human disease
0.27228677.10767319.html.plaintext.txt	21	For example functional analysis genes velocardiofacial syndrome region 22q11 region shared susceptibility bipolar disorder schizophrenia involves behavioral studies mice mutations genes within region 1920
0.27228677.10767319.html.plaintext.txt	22	View larger version 16K Figure 1
0.27228677.10767319.html.plaintext.txt	23	The use mouse model functional analysis candidate genes psychiatric disorders
0.27228677.10767319.html.plaintext.txt	24	An alternative approach identification genes may contribute psychiatric illness involves genetic dissection complex phenotypes components called endophenotypes may amenable genetic studies fully expressed psychiatric manifestation disease Fig
0.27228677.10767319.html.plaintext.txt	25	For example schizophrenia abnormalities social interaction attention sensorimotor gating olfactory cognitive dysfunction suggested useful endophenotypes 21 25
0.27228677.10767319.html.plaintext.txt	26	These neurobiological physiological characteristics apparently polygenic illness may occur result single gene effects might useful additional perhaps easily measured robust phenotypes genetic linkage analysis 26 28
0.27228677.10767319.html.plaintext.txt	27	View larger version 25K Figure 2
0.27228677.10767319.html.plaintext.txt	28	An example use mouse model endophenotype approach identify genes underlying psychiatric disorder case schizophrenia
0.27228677.10767319.html.plaintext.txt	29	In review suggest physiological neurobiological endophenotypes monitored measured animal model organism
0.27228677.10767319.html.plaintext.txt	30	We also review discuss current efforts identify single gene mutations mouse alter traits
0.27228677.10767319.html.plaintext.txt	31	Genetic mapping mutant loci predictions map location human genome based syntenic regions mouse may provide candidate genes susceptibility loci human disease
0.27228677.10767319.html.plaintext.txt	32	Even cases single gene mutations may still valuable providing entry point important genetic pathways underlying human physiology behavior
0.27228677.10767319.html.plaintext.txt	33	In field obesity research point illustrated example single gene mutations leptin leptin receptor genes cause obesity mouse 29 31
0.27228677.10767319.html.plaintext.txt	34	Although genome scans human families segregating obesity identify loci major effect majority families 32 36 studies mice provided important information basic physiology regulation body weight humans rodents 3738
0.27228677.10767319.html.plaintext.txt	35	A number strategies currently employed generate identify single gene behavioral mutants mouse
0.27228677.10767319.html.plaintext.txt	36	A collection mice targeted null mutations known genes increasingly used tools defining vivo function molecules
0.27228677.10767319.html.plaintext.txt	37	These targeted null mutations continue provide rich source behavioral phenotypes Table 1
0.27228677.10767319.html.plaintext.txt	38	In addition recent employment sophisticated tools generation conditional mutants exhibiting gene loss temporally spatially restricted manner proving particularly useful understanding behavior 3940
0.27228677.10767319.html.plaintext.txt	39	In general phenotypic changes conditional mutants specific subtle loss function mutations gene therefore allow better understanding underlying behavioral neuropathological physiological consequences
0.27228677.10767319.html.plaintext.txt	40	Conditional mutations also allow appropriate controls dissect components behavior acquisition consolidation retention performance studies learning memory 4142
0.27228677.10767319.html.plaintext.txt	41	In case genes play role development behavior conditional induced mutations permit studies behavior apart role disrupted gene plays course pre postnatal development
0.27228677.10767319.html.plaintext.txt	42	For example later review describe specific behavioral electrophysiological defects conditional knockout neurotrophin tyrosine kinase receptor TrkB 43 whereas complete loss function gene associated postnatal lethality likely due respiratory failure 44
0.27228677.10767319.html.plaintext.txt	43	Targeted mutants displaying behavioral phenotypes subset reported since 1998 In contrast gene based approaches also called reverse genetics forward genetics animal model begins phenotype
0.27228677.10767319.html.plaintext.txt	44	There two approaches commonly used forward genetics identification altered phenotype due point mutations induced mutagen N ethyl N nitrosourea ENU observation natural phenotypic variation genetic cross two inbred strains identify quantitative trait loci QTL 45
0.27228677.10767319.html.plaintext.txt	45	The intended outcome identification positional cloning altered influential gene
0.27228677.10767319.html.plaintext.txt	46	The QTL approach represents powerful tool behavioral genetics extensively reviewed elsewhere 4647
0.27228677.10767319.html.plaintext.txt	47	To increase resources necessary forward genetics strategies generate single gene mutants displaying behavioral anomalies several phenotype based mutagenesis programs initiated
0.27228677.10767319.html.plaintext.txt	48	48 issue Justice et al
0.27228677.10767319.html.plaintext.txt	49	49 describe list ongoing mutagenesis efforts detail discuss efforts context psychiatric genetics behavioral genetic studies targeted mutations
0.27228677.10767319.html.plaintext.txt	50	In addition provide overview critical issues identification mouse models psychiatric disorders definition relevant phenotypes problems involved characterization novel behavioral mutants identified random mutagenesis screens
0.27228677.10767319.html.plaintext.txt	51	GOOD GENETICS NEEDS GOOD PHENOTYPES 26 TOP ABSTRACT MOUSE MODELS FOR HUMAN
0.27228677.10767319.html.plaintext.txt	52	REFERENCES The first priority search behavioral mutants mouse identification definition phenotypes
0.27228677.10767319.html.plaintext.txt	53	A subset impressive collection targeted mutants behavioral phenotypes reported last 2 years listed Table 1
0.27228677.10767319.html.plaintext.txt	54	A limitation studies inability directly compare mutants correlate studies performed different laboratories primarily due differences experimental procedures behavioral paradigms differing genetic backgrounds novel mutations
0.27228677.10767319.html.plaintext.txt	55	These concerns recently confirmed observation differing behavioral profiles observed different laboratories using inbred mutant lines mice even strictly controlling environmental variables experimental procedures 50
0.27228677.10767319.html.plaintext.txt	56	Although finding discouraging study Crabbe et al
0.27228677.10767319.html.plaintext.txt	57	also promising results genetic variance relatively high behaviors tested large differences strains shown robust unlikely influenced specific laboratory environments 50
0.27228677.10767319.html.plaintext.txt	58	Rather providing reason perform behavioral analysis study Crabbe et al
0.27228677.10767319.html.plaintext.txt	59	provides guidelines regarding variables need addressed behavior studies kind 50
0.27228677.10767319.html.plaintext.txt	60	For example address problem replication uniformity behavioral phenotyping analysis novel behavioral mutants performed using standard battery tests provide strong consistent phenotypes
0.27228677.10767319.html.plaintext.txt	61	It also recommended behavioral differences observed mutant animals replicated multiple laboratories using multiple tests behavioral domain 50
0.27228677.10767319.html.plaintext.txt	62	This course implies behavioral mutants shared among investigators interest confirming altered behaviors observed laboratories
0.27228677.10767319.html.plaintext.txt	63	In addition suggest behavioral assessment one two inbred strains example C57BL6 DBA2 also conducted along wild type littermates provide running baseline compare results given timepoint 51
0.27228677.10767319.html.plaintext.txt	64	This information allow calibration behavioral physiological parameters novel mutations existing generally available inbred strains well provide better basis comparison findings experimental conditions one laboratory
0.27228677.10767319.html.plaintext.txt	65	Finally considerable thought given controlling genetic background mutation generated maintained 5253
0.27228677.10767319.html.plaintext.txt	66	A major challenge analysis rodent phenotypes identification traits correspond endophenotypes human disease
0.27228677.10767319.html.plaintext.txt	67	Based recent studies number relatively simple robust behaviors selected amenable forward genetic approaches
0.27228677.10767319.html.plaintext.txt	68	Sensorimotor gating Deficiencies attention information processing long noted patients schizophrenia psychiatric illnesses 5455
0.27228677.10767319.html.plaintext.txt	69	It believed inability filter extraneous stimuli process information presented fairly rapid succession accounts tendency schizophrenics suffer fragmentation normal cognitive processes 56 functions vital maintenance cognitive function 57
0.27228677.10767319.html.plaintext.txt	70	Some attentional deficiencies may due impairments sensory gating 58
0.27228677.10767319.html.plaintext.txt	71	Sensory gating measured level attenuation startle response either acoustic tactile upon presentation non startle inducing prepulse stimulus commonly called prepulse inhibition
0.27228677.10767319.html.plaintext.txt	72	Prepulse inhibition startle response PPI one easily transferred behavioral tests humans mice
0.27228677.10767319.html.plaintext.txt	73	In humans startle response measured eyeblink response P50 event related potential suppression whereas mice generally measured whole body response using commercially available startle chambers
0.27228677.10767319.html.plaintext.txt	74	Multiple studies conducted using inbred strains mice show substantial genetic influence startle response PPI
0.27228677.10767319.html.plaintext.txt	75	In general inbred strains vary response acoustic tactile startle stimuli display wide range variability prepulse inhibition 515960
0.27228677.10767319.html.plaintext.txt	76	Several single gene mutations show alterations prepulse inhibition Table 1
0.27228677.10767319.html.plaintext.txt	77	One example particular shows power animal models investigate possible candidate genes human disorders
0.27228677.10767319.html.plaintext.txt	78	Prodh mice deficient gene encodes proline dehydrogenase show significantly lower levels PPI comparison wild type controls along elevated levels proline brain 20
0.27228677.10767319.html.plaintext.txt	79	Prodh mouse homolog Drosophila slgA sluggish A gene
0.27228677.10767319.html.plaintext.txt	80	The human homolog lies chromosome 22q11 region associated psychiatric illness cases deleted psychiatric patients 61 63
0.27228677.10767319.html.plaintext.txt	81	In addition elevated levels proline reported patient 22q11 deletion 64
0.27228677.10767319.html.plaintext.txt	82	Mice deficient neural cell adhesion molecule NCAM 180 also display decreased PPI well increased lateral ventricle size 65
0.27228677.10767319.html.plaintext.txt	83	NCAM involved neural migration previous study shown markedly reduced hippocampus schizophrenic brains 66
0.27228677.10767319.html.plaintext.txt	84	This study particularly important lends evidence widely held belief schizophrenia results abnormalities brain development 6768
0.27228677.10767319.html.plaintext.txt	85	Learning memory The use rodent models study genetics learning memory began 1940s selective breeding maze dull maze bright rats 69
0.27228677.10767319.html.plaintext.txt	86	For several decades much work genetic analysis learning memory consisted basic behavior quantitative genetic analysis using experimental models Drosophila Phormia regina blowfly
0.27228677.10767319.html.plaintext.txt	87	However use Mendelian crosses perform genetic analysis limited providing information genetic architecture learning memory revealing cases genetics complex attributable many genes
0.27228677.10767319.html.plaintext.txt	88	In late 1960s Seymour Benzer proposed forward genetic approach using chemical mutagens disrupt single genes screening lines mutagenized flies observe abnormal behaviors 70
0.27228677.10767319.html.plaintext.txt	89	Using method multitude genes learning memory identified Drosophila 71
0.27228677.10767319.html.plaintext.txt	90	There several commonly used tasks study learning memory mice
0.27228677.10767319.html.plaintext.txt	91	The hidden platform version Morris water maze test spatial learning animals trained escape pool water 72
0.27228677.10767319.html.plaintext.txt	92	Mice given multiple training sessions learn placement platform using visual cues room
0.27228677.10767319.html.plaintext.txt	93	The platform removed search pattern animal recorded
0.27228677.10767319.html.plaintext.txt	94	Animals learned location platform spend time area previously contained platform make crosses platform site
0.27228677.10767319.html.plaintext.txt	95	Different configurations water maze measure different forms learning utilize different brain systems
0.27228677.10767319.html.plaintext.txt	96	A second commonly used paradigm studying learning memory conditioned fear test
0.27228677.10767319.html.plaintext.txt	97	The direct measure freezing behavior response discrete conditioned stimuli tones lights measure learning first conducted Bouton Bolles 73
0.27228677.10767319.html.plaintext.txt	98	Fear conditioning evaluate two discrete forms learning cued contextual evidence different neural substrates support two forms learning 74
0.27228677.10767319.html.plaintext.txt	99	Genetic manipulations including gene targeting utilized extensively test role genes learning memory Table 1 4142
0.27228677.10767319.html.plaintext.txt	100	These studies initiated genes proteins shown previously pharmacological studies involved synaptic plasticity
0.27228677.10767319.html.plaintext.txt	101	For example null mutations calcium calmodulin kinase II 7576 CREB 7778 PKC 7980 NMDA receptor 1 subunit 81 adenylate cyclase 8283 mGluR5 84 revealed anomalies different forms synaptic plasticity learning memory
0.27228677.10767319.html.plaintext.txt	102	The relationship long term potentiation LTP behavioral affects learning memory particularly intriguing recently generated hypermorphic conditional mutants
0.27228677.10767319.html.plaintext.txt	103	For example reported mice overexpressing NMDA receptor 2B Grin2b forebrain show enhanced learning memory variety behavioral tasks including Morris water maze conditioned fear novel object recognition fear extinction also exhibit enhanced LTP thought underlie forms learning memory 85
0.27228677.10767319.html.plaintext.txt	104	Deficits learning memory apparent conditional knockouts neurotrophin tyrosine kinase receptor TrkB 43
0.27228677.10767319.html.plaintext.txt	105	Trkb conditional knockout mice knockout restricted forebrain occurs postnatal development learn Morris water maze perform poorly radial maze task show reduced LTP hippocampus 43
0.27228677.10767319.html.plaintext.txt	106	Despite recent examples linking LTP learning also growing evidence dissociation two 86 88
0.27228677.10767319.html.plaintext.txt	107	In recent example mutant mice lacking L amino 3 hydroxy 5 methylisoxazole 4 propionate receptor subunit GluR A GluR A showed absence LTP hippocampus exhibited deficits spatial learning 89
0.27228677.10767319.html.plaintext.txt	108	A significant outcome studies described many biochemical components common molecular mechanisms underlie learning memory invertebrate vertebrate systems review see ref
0.27228677.10767319.html.plaintext.txt	109	Systematic assessment learning memory targeted mutations well mutants random mutagenesis screens reveal differences pathways facilitate identification genetic components specific mammalian system including factors involved human disease
0.27228677.10767319.html.plaintext.txt	110	Anxiety The manifestation anxiety number psychiatric disorders including panic disorder generalized anxiety disorder specific social phobias obsessive compulsive disorder depression post traumatic stress disorder highlights importance gaining better understanding genetic etiology
0.27228677.10767319.html.plaintext.txt	111	The use animal models study anxiety related behaviors long history 9091
0.27228677.10767319.html.plaintext.txt	112	The commonly used assay testing anxiety rats mice historically brightly lit open field 90
0.27228677.10767319.html.plaintext.txt	113	Other assays also developed widely used including elevated plus maze 9293 zero maze 94
0.27228677.10767319.html.plaintext.txt	114	Both tests take advantage fact rodents fearful bright andor open spaces yet also tendency explore novel environments
0.27228677.10767319.html.plaintext.txt	115	All tests allow measurement variety anxious non anxious behaviors including time spent closed dark areas versus open lighted areas wall seeking tendency thigmotaxis defecation exploratory activity
0.27228677.10767319.html.plaintext.txt	116	The hallmark relevant animal assay anxiety course ability either anxiolytics anxiogenics reverse animal behavior test many paradigms listed developed study efficacy various anxiolytic drugs
0.27228677.10767319.html.plaintext.txt	117	The validation relating rodent anxiety human anxiety proven numerous times using behaviors 95 97
0.27228677.10767319.html.plaintext.txt	118	There numerous examples mice null mutations variety genes express abnormal behavior several different assays anxiety Table 1
0.27228677.10767319.html.plaintext.txt	119	Some notable examples include serotonin gene knockouts Htr1a Htr1b tested multiple groups consistently shown elevated Htr1a reduced Htr1b anxiety 98 103
0.27228677.10767319.html.plaintext.txt	120	In addition three different studies investigated anxiety related behaviors knockouts corticotropin releasing hormone Crhr1 gene 104 106 three studies showed reduced anxiety null mutants
0.27228677.10767319.html.plaintext.txt	121	The consensus behaviors observed different laboratories serotonin Crhr knockouts validates conclusion Crabbe et al
0.27228677.10767319.html.plaintext.txt	122	50 differences seen genetically engineered mice cannot stand replicated validated different behavioral paradigms across different laboratories
0.27228677.10767319.html.plaintext.txt	123	Sleep circadian rhythms Deficits sleep circadian rhythms part symptomatology variety psychiatric disorders including bipolar disorder depression
0.27228677.10767319.html.plaintext.txt	124	The earliest understanding genetic nature circadian rhythms came identification circadian mutations Drosophila period 107 Neurospora frequency 108
0.27228677.10767319.html.plaintext.txt	125	Genetic studies identified additional genes circadian system gene interactions provide one best characterized evolutionarily conserved molecular genetic pathways underlying behavior review see ref
0.27228677.10767319.html.plaintext.txt	126	Single gene mutations mouse played important role dissection circadian pathway
0.27228677.10767319.html.plaintext.txt	127	Several years ago identification Clock gene starting ENU induced mutation provided first transcription factor circadian feedback loop 110111
0.27228677.10767319.html.plaintext.txt	128	Recently null mutations components clock generated
0.27228677.10767319.html.plaintext.txt	129	Mutants lacking Period2 gene mPer2 one among three known homologs Drosophila period per gene display shorter circadian period loss circadian rhythmicity total darkness 112
0.27228677.10767319.html.plaintext.txt	130	Studies Arabidopsis thaliana identified cryptochromes blue light receptors 113
0.27228677.10767319.html.plaintext.txt	131	Targeted null mutations mouse homologs Cry1 Cry2 showed genes essential maintenance circadian rhythmicity rather entrainment light cues 114 116
0.27228677.10767319.html.plaintext.txt	132	Cryptochrome 1 knockouts Cry1 shortened circadian period 1 h 114116 Cryptochrome 2 Cry2 knockouts lengthened circadian period 1 h 114115
0.27228677.10767319.html.plaintext.txt	133	In total darkness double knockouts Cry1 Cry2 Cry1 Cry2 display complete arrythmicity indicating longer internal circadian clock two genes partially overlapping function 114116
0.27228677.10767319.html.plaintext.txt	134	A fascinating finding field genetics sleep reported last year discovered null mutation orexin also known hypocretin Hcrt gene resulted narcolepsy like behavior changes electroencephalographic EEG pattern mice 117
0.27228677.10767319.html.plaintext.txt	135	Furthermore also reported modafinil anti narcoleptic drug activates orexin containing neurons
0.27228677.10767319.html.plaintext.txt	136	This finding conjunction behavioral EEG observations led authors conclude knockout mice model human narcolepsy
0.27228677.10767319.html.plaintext.txt	137	Another landmark discovery identification orexin receptor 2 gene disrupted dog model narcolepsy 118
0.27228677.10767319.html.plaintext.txt	138	In general studies represent powerful example marriage reverse forward genetic approaches identification components important neurobiological physiological pathway
0.27228677.10767319.html.plaintext.txt	139	IDENTIFICATION OF BEHAVIORAL MUTANTS IN PHENOTYPE BASED MUTAGENESIS SCREENS TOP ABSTRACT MOUSE MODELS FOR HUMAN
0.27228677.10767319.html.plaintext.txt	140	REFERENCES Recently number random chromosomal region specific mutagenesis programs initiated take advantage power single gene mutations developing understanding complex disorders
0.27228677.10767319.html.plaintext.txt	141	Many efforts focusing wide range phenotypes including physiological assays developmental phenotypes well neurological behavioral traits 49119 121
0.27228677.10767319.html.plaintext.txt	142	In section discuss insights nature behavioral anomalies drawn studies mice targeted mutations known genes consideration issues designing random mutagenesis screen
0.27228677.10767319.html.plaintext.txt	143	Ongoing mutagenesis efforts already identified array novel mutants httpwww
0.27228677.10767319.html.plaintext.txt	144	html including behavioral phenotypes
0.27228677.10767319.html.plaintext.txt	145	Novel mutants anomalies circadian behavior rest activity patterns sensorimotor gating anxiety learning memory reported phenotypic characterization genetic mapping mutations progress reported 13th International Mouse Genome Conference Philadelphia PA Mouse Molecular Genetics meeting Heidelberg Germany
0.27228677.10767319.html.plaintext.txt	146	Characterization mutations may take course differ characterization mutations visible phenotypes obvious neurological symptoms
0.27228677.10767319.html.plaintext.txt	147	Some caution persistence patience necessary search mutations based exclusively abnormal behavioral phenotypes well identification genes defined loci
0.27228677.10767319.html.plaintext.txt	148	In general reduced penetrance variable expressivity sensitivity genetic background well influences environmental factors hamper characterization mutants identified random mutagenesis screens
0.27228677.10767319.html.plaintext.txt	149	The Clock mutation represents published behavioral mutation identified random mutagenesis screen
0.27228677.10767319.html.plaintext.txt	150	Future studies show many behavioral mutants robust phenotype Clock
0.27228677.10767319.html.plaintext.txt	151	Although identification cloning Clock mutation illustrated value efficacy dominant screen important broaden extend screens potential uncovering recessive mutations
0.27228677.10767319.html.plaintext.txt	152	With dominant screen large number genes may missed
0.27228677.10767319.html.plaintext.txt	153	For example among targeted behavioral mutants small number lines show dominant semidominant phenotypes 43122
0.27228677.10767319.html.plaintext.txt	154	Future studies show whether attributed fact majority genes abnormal phenotypes present one copy whether mutations dominant behavioral phenotypes indeed rare
0.27228677.10767319.html.plaintext.txt	155	Sophisticated electrophysiological neuropathological neurobiochemical assessments novel mutations may uncover subtle anomalies heterozygotes would missed routine behavioral observation
0.27228677.10767319.html.plaintext.txt	156	This point illustrated recently reported Trkb conditional knockouts 43
0.27228677.10767319.html.plaintext.txt	157	Whereas homozygotes impaired LTP hippocampal synapses accompanied impaired learning heterozygotes partial reduction LTP detected apparent behavioral anomalies observed currently utilized learning memory tasks
0.27228677.10767319.html.plaintext.txt	158	This suggests presence absence dominant phenotype absolute finding may depend hard one looks phenotype
0.27228677.10767319.html.plaintext.txt	159	Another important question remains many dominant behavioral mutations associated developmental visible anomalies homozygotes conversely many embryonic lethal mutations dominant behavioral phenotypes
0.27228677.10767319.html.plaintext.txt	160	From human genetics standpoint important question genes role development could also considered candidate genes susceptibility psychiatric disorders
0.27228677.10767319.html.plaintext.txt	161	For example mutations Presenilin 1 Pre1 cause early onset familial Alzheimer disease 123
0.27228677.10767319.html.plaintext.txt	162	A targeted null mutation gene mice associated embryonic lethality due defects somite segmentation 124
0.27228677.10767319.html.plaintext.txt	163	It interesting examine behavior neuropathology Pre1 heterozygotes await behavioral analysis mice spectrum point mutations seen human Alzheimer disease
0.27228677.10767319.html.plaintext.txt	164	Over last years field targeted mutagenesis provided several examples mutations strong phenotypes combined mutations although single gene mutations exhibit anomalies least weak phenotypes 114125126
0.27228677.10767319.html.plaintext.txt	165	These findings provide important clue search novel behavioral mutants using random mutagenesis
0.27228677.10767319.html.plaintext.txt	166	Mutations phenotypes weak show incomplete penetrance may tested combination double mutant analysis available mutants
0.27228677.10767319.html.plaintext.txt	167	Moreover random mutagenesis screens novel phenotypes existing mutations generated targeted mutagenesis called sensitized screens may particularly useful identification genes molecular genetic pathway
0.27228677.10767319.html.plaintext.txt	168	The use sensitized screens behavioral phenotypes combine random mutagenesis pharmacological manipulations may yield mutations affect defined neurochemical pathway
0.27228677.10767319.html.plaintext.txt	169	A mutagenesis screen currently performed laboratory involves examination G1 progeny ENU treated mice battery behavioral paradigms zero maze rotarod acoustic startle response olfaction analysis wheel running activity patterns lightdark constant dark conditions L
0.27228677.10767319.html.plaintext.txt	170	This experimental paradigm allows us evaluate prior testing inheritance specific pleiotropic behavioral anomalies identified phenotypic deviants
0.27228677.10767319.html.plaintext.txt	171	Whereas mutants specific phenotypes may particular value combinations phenotypes single gene mutations may even informative search models psychiatric disorders
0.27228677.10767319.html.plaintext.txt	172	Epidemiological evidence indicates comorbidity may rule rather exception behavioral disorders humans
0.27228677.10767319.html.plaintext.txt	173	For example co occurrence anxiety disorders substance abuse recurrent unipolar disorder documented repeatedly 127128
0.27228677.10767319.html.plaintext.txt	174	Therefore single gene mutants mouse generated either forward reverse genetic experiments examined variety phenotypic traits
0.27228677.10767319.html.plaintext.txt	175	Combinations phenotypes found together human syndrome particular importance
0.27228677.10767319.html.plaintext.txt	176	The impending elucidation complete sequence mouse human genomes along ability perform expression profiling large number genes compare mutant wild type animals increase value generated mutations facilitate positional cloning mutant gene aid understanding molecular pathways affected mutations
0.27228677.10767319.html.plaintext.txt	177	ACKNOWLEDGEMENTS The authors would like thank colleagues Center Neurobiology Behavior numerous discussions Drs Ted Abel Wade Berrettini Margit Burmeister Thomas Gould Steve Kanes Robert Lenox Dani Reed comments manuscript
0.27228677.10767319.html.plaintext.txt	178	This research supported NIH grants MH57855 M
0.27228677.10767319.html.plaintext.txt	179	partially supported NIMH Training Grant MH19112
0.27228677.10767319.html.plaintext.txt	180	FOOTNOTES Present address Genomics Institute Novartis Research Foundation 3115 Merryfield Row San Diego CA 92121 USA
0.27228677.10767319.html.plaintext.txt	181	To correspondence addressed
0.27228677.10767319.html.plaintext.txt	182	Tel 1 215 898 0020 Fax 1 215 573 2041 Email bucanpobox
0.27228677.10767319.html.plaintext.txt	183	REFERENCES TOP ABSTRACT MOUSE MODELS FOR HUMAN
0.27228677.10767319.html.plaintext.txt	184	2000 Recent progress psychiatric genetics hope hype
0.27228677.10767319.html.plaintext.txt	185	1995 A potential vulnerability locus schizophrenia chromosome 6p24 22 evidence genetic heterogeneity
0.27228677.10767319.html.plaintext.txt	186	1995 Evaluation susceptibility gene schizophrenia chromosome 6p multipoint affected sib pair linkage analysis
0.27228677.10767319.html.plaintext.txt	187	1998 Schizophrenia susceptibility loci chromosomes 13q32 8p21
0.27228677.10767319.html.plaintext.txt	188	1997 Suggestive evidence linkage schizophrenia markers chromosome 13 Caucasian Oriental populations
0.27228677.10767319.html.plaintext.txt	189	1998 Support chromosome 18p locus conferring susceptibility functional psychoses families schizophrenia association linkage analysis
0.27228677.10767319.html.plaintext.txt	190	1994 Sequential strategy identify susceptibility gene schizophrenia report potential linkage chromosome 22q12 q13
0.27228677.10767319.html.plaintext.txt	191	1996 A locus bipolar affective disorder chromosome 4p
0.27228677.10767319.html.plaintext.txt	192	1999 A high density genome scan detects evidence bipolar disorder susceptibility locus 13q32 potential loci 1q32 18p11
0.27228677.10767319.html.plaintext.txt	193	1994 Chromosome 18 DNA markers manic depressive illness evidence susceptibility gene
0.27228677.10767319.html.plaintext.txt	194	1996 An approach investigating linkage bipolar disorder using large Costa Rican pedigrees
0.27228677.10767319.html.plaintext.txt	195	1999 A comprehensive linkage analysis chromosome 21q22 supports prior evidence putative bipolar affective disorder locus
0.27228677.10767319.html.plaintext.txt	196	1994 A possible vulnerability locus bipolar affective disorder chromosome 21q22
0.27228677.10767319.html.plaintext.txt	197	1996 Bipolar spectrum disorders patients diagnosed velo cardio facial syndrome hemizygous deletion chromosome 22q11 result bipolar affective disorder Am
0.27228677.10767319.html.plaintext.txt	198	1995 Evidence predisposing locus bipolar disorder Xq24 q27
0.27228677.10767319.html.plaintext.txt	199	1 extended Finnish pedigree
0.27228677.10767319.html.plaintext.txt	200	1988 A controlled family study chronic psychoses
0.27228677.10767319.html.plaintext.txt	201	Schizophrenia schizoaffective disorder
0.27228677.10767319.html.plaintext.txt	202	1993 Continuity discontinuity affective disorders schizophrenia
0.27228677.10767319.html.plaintext.txt	203	Results controlled family study
0.27228677.10767319.html.plaintext.txt	204	2000 Susceptibility loci bipolar disorder overlap inherited vulnerability schizophrenia
0.27228677.10767319.html.plaintext.txt	205	1998 Catechol O methyltransferase deficient mice exhibit sexually dimorphic changes catecholamine levels behavior
0.27228677.10767319.html.plaintext.txt	206	1999 The gene encoding proline dehydrogenase modulates sensorimotor gating mice
0.27228677.10767319.html.plaintext.txt	207	1997 Linkage neurophysiological deficit schizophrenia chromosome 15 locus
0.27228677.10767319.html.plaintext.txt	208	1997 Olfactory identification deficits schizophrenia correlation duration illness
0.27228677.10767319.html.plaintext.txt	209	1998 P50 abnormalities schizophrenia relationship clinical neuropsychological indices attention
0.27228677.10767319.html.plaintext.txt	210	1999 Phencyclidine social interaction test animal model schizophrenia face predictive validity
0.27228677.10767319.html.plaintext.txt	211	1999 Cognitive behavioral precursors schizophrenia
0.27228677.10767319.html.plaintext.txt	212	1988 Splitting schizophrenia
0.27228677.10767319.html.plaintext.txt	213	1998 Psychiatric genetics search phenotypes
0.27228677.10767319.html.plaintext.txt	214	1999 Mouse models madness
0.27228677.10767319.html.plaintext.txt	215	1978 Obese diabetes two mutant genes causing diabetes obesity syndromes mice
0.27228677.10767319.html.plaintext.txt	216	1994 Positional cloning mouse obese gene human homologue
0.27228677.10767319.html.plaintext.txt	217	1995 Identification expression cloning leptin receptor OB R
0.27228677.10767319.html.plaintext.txt	218	1997 A major quantitative trait locus determining serum leptin levels fat mass located human chromosome 2
0.27228677.10767319.html.plaintext.txt	219	1998 A genome wide scan human obesity genes reveals major susceptibility locus chromosome 10
0.27228677.10767319.html.plaintext.txt	220	1997 Recessive inheritance obesity familial non insulin dependent diabetes mellitus lack linkage nine candidate genes
0.27228677.10767319.html.plaintext.txt	221	1999 Genome scan human obesity linkage markers 20q13
0.27228677.10767319.html.plaintext.txt	222	1998 Autosomal genomic scan loci linked obesity energy metabolism Pima Indians
0.27228677.10767319.html.plaintext.txt	223	1999 Rodent mutant models obesity correlations human obesity
0.27228677.10767319.html.plaintext.txt	224	1998 Leptin regulation body weight mammals
0.27228677.10767319.html.plaintext.txt	225	1995 Inducible gene targeting mice
0.27228677.10767319.html.plaintext.txt	226	1998 Inducible gene targeting mice using Crelox system
0.27228677.10767319.html.plaintext.txt	227	1999 Genetic approaches memory storage
0.27228677.10767319.html.plaintext.txt	228	1998 Gene targeting novel window biology learning memory
0.27228677.10767319.html.plaintext.txt	229	eds Neurobiology Learning Memory
0.27228677.10767319.html.plaintext.txt	230	Academic Press New York NY pp
0.27228677.10767319.html.plaintext.txt	231	1999 Essential role TrkB receptors hippocampus mediated learning
0.27228677.10767319.html.plaintext.txt	232	1996 Mice lacking brain derived neurotrophic factor exhibit visceral sensory neuron losses distinct mice lacking NT4 display severe developmental deficit control breathing
0.27228677.10767319.html.plaintext.txt	233	1994 Forward reverse genetic approaches behavior mouse
0.27228677.10767319.html.plaintext.txt	234	1992 Mapping quantitative trait loci behavioral traits mouse
0.27228677.10767319.html.plaintext.txt	235	1997 Mapping quantitative trait loci behavioral traits mouse
0.27228677.10767319.html.plaintext.txt	236	eds Handbook Psychiatric Genetics
0.27228677.10767319.html.plaintext.txt	237	2000 Towards new models disease physiology neurosciences role induced naturally occurring mutations
0.27228677.10767319.html.plaintext.txt	238	1999 Genetics mouse behavior interactions laboratory environment
0.27228677.10767319.html.plaintext.txt	239	2000 Behavior mutagenesis screens importance baseline analysis inbred strains
0.27228677.10767319.html.plaintext.txt	240	1997 Behavioral phenotypes inbred mouse strains implications recommendations molecular studies
0.27228677.10767319.html.plaintext.txt	241	Psychopharmacology 132 107 124
0.27228677.10767319.html.plaintext.txt	242	1997 Mutant mice neuroscience recommendations concerning genetic background
0.27228677.10767319.html.plaintext.txt	243	Scholar Facsimiles Reprints Delmar NY translated A
0.27228677.10767319.html.plaintext.txt	244	Dover Publications New York NY translated A
0.27228677.10767319.html.plaintext.txt	245	1990 Startle response models sensorimotor gating habituation deficits schizophrenia
0.27228677.10767319.html.plaintext.txt	246	1992 Gating habituation startle reflex schizophrenic patients
0.27228677.10767319.html.plaintext.txt	247	1990 Sensorimotor gating schizophrenia
0.27228677.10767319.html.plaintext.txt	248	Human animal model studies
0.27228677.10767319.html.plaintext.txt	249	1997 Inbred strain differences prepulse inhibition mouse startle response
0.27228677.10767319.html.plaintext.txt	250	Psychopharmacology 132 169 180
0.27228677.10767319.html.plaintext.txt	251	1997 Assessment locomotor activity acoustic tactile startle prepulse inhibition startle inbred mouse strains F1 hybrids implications genetic background single gene quantitative trait loci analyses
0.27228677.10767319.html.plaintext.txt	252	Neuroscience 80 1075 1086
0.27228677.10767319.html.plaintext.txt	253	1995 Schizophrenia susceptibility associated interstitial deletions chromosome 22q11
0.27228677.10767319.html.plaintext.txt	254	1998 22q11 deletion syndrome adults schizophrenia
0.27228677.10767319.html.plaintext.txt	255	2 interstitial deletions among childhood onset schizophrenics multidimensionally impaired
0.27228677.10767319.html.plaintext.txt	256	1996 Association hyperprolinaemia type 1 heparin cofactor II deficiency CATCH 22 syndrome evidence contiguous gene syndrome locating proline oxidase gene
0.27228677.10767319.html.plaintext.txt	257	1998 NCAM 180 knockout mice display increased lateral ventricle size reduced prepulse inhibition startle
0.27228677.10767319.html.plaintext.txt	258	1995 Decreased expression embryonic form neural cell adhesion molecule schizophrenic brains
0.27228677.10767319.html.plaintext.txt	259	1997 Workshop schizophrenia
0.27228677.10767319.html.plaintext.txt	260	1998 A candidate molecule approach defining developmental pathology schizophrenia
0.27228677.10767319.html.plaintext.txt	261	1940 Genetic differences maze learning rats
0.27228677.10767319.html.plaintext.txt	262	1969 Behavioral mutants Drosophila isolated countercurrent distribution
0.27228677.10767319.html.plaintext.txt	263	1998 Gene discovery Drosophila new insights learning memory
0.27228677.10767319.html.plaintext.txt	264	1981 Spatial localisation depend presence local cues
0.27228677.10767319.html.plaintext.txt	265	1980 Conditioned fear assessed freezing suppression three different baselines
0.27228677.10767319.html.plaintext.txt	266	1997 Hippocampal lesions cause learning deficits inbred mice Morris water maze conditioned fear task
0.27228677.10767319.html.plaintext.txt	267	1992 Impaired spatial learning alpha calcium calmodulin kinase II mutant mice
0.27228677.10767319.html.plaintext.txt	268	1992 Deficient hippocampal long term potentiation alpha calcium calmodulin kinase II mutant mice
0.27228677.10767319.html.plaintext.txt	269	1994 Targeted mutation CREB gene compensation within CREBATF family transcription factors
0.27228677.10767319.html.plaintext.txt	270	1994 Deficient long term memory mice targeted mutation cAMP responsive element binding protein
0.27228677.10767319.html.plaintext.txt	271	1993 Modified hippocampal long term potentiation PKC gamma mutant mice
0.27228677.10767319.html.plaintext.txt	272	1993 PKC gamma mutant mice exhibit mild deficits spatial contextual learning
0.27228677.10767319.html.plaintext.txt	273	1995 Reduced hippocampal LTP spatial learning mice lacking NMDA receptor epsilon 1 subunit
0.27228677.10767319.html.plaintext.txt	274	1995 Altered behavior long term potentiation type I adenylyl cyclase mutant mice
0.27228677.10767319.html.plaintext.txt	275	1998 Impaired cerebellar long term potentiation type I adenylyl cyclase mutant mice
0.27228677.10767319.html.plaintext.txt	276	1997 Mice lacking metabotropic glutamate receptor 5 show impaired learning reduced CA1 long term potentiation LTP normal CA3 LTP
0.27228677.10767319.html.plaintext.txt	277	1999 Genetic enhancement learning memory mice
0.27228677.10767319.html.plaintext.txt	278	1998 Memory long term potentiation LTP dissociated normal spatial memory despite CA1 LTP elimination Kv1
0.27228677.10767319.html.plaintext.txt	279	1997 Impaired long term potentiation induction dentate gyrus calretinin deficient mice
0.27228677.10767319.html.plaintext.txt	280	1995 A genetic test effects mutations PKA mossy fiber LTP relation spatial contextual learning
0.27228677.10767319.html.plaintext.txt	281	1999 Importance AMPA receptors hippocampal synaptic plasticity spatial learning
0.27228677.10767319.html.plaintext.txt	282	1934 Emotional behavior rat
0.27228677.10767319.html.plaintext.txt	283	Defaecation urination measures individual differences emotionality
0.27228677.10767319.html.plaintext.txt	284	1973 Tests emotionality rats mice review
0.27228677.10767319.html.plaintext.txt	285	1955 The relation fear induced novel stimulation exploratory behaviour
0.27228677.10767319.html.plaintext.txt	286	1987 The use plus maze measure anxiety mouse
0.27228677.10767319.html.plaintext.txt	287	Psychopharmacology 92 180 185
0.27228677.10767319.html.plaintext.txt	288	1994 Behavioural pharmacological characterisation elevated zero maze animal model anxiety
0.27228677.10767319.html.plaintext.txt	289	Psychopharmacology 116 56 64
0.27228677.10767319.html.plaintext.txt	290	1996 Do animal models place genetic analysis quantitative human behavioural traits J
0.27228677.10767319.html.plaintext.txt	291	1995 Genetic analysis anxiety related behaviors responses benzodiazepine related drugs AXB BXA recombinant inbred mouse strains
0.27228677.10767319.html.plaintext.txt	292	1997 The effects cholecystokinin A B receptor antagonists exploratory behaviour elevated zero maze rat
0.27228677.10767319.html.plaintext.txt	293	Neuropharmacology 36 389 396
0.27228677.10767319.html.plaintext.txt	294	1998 Elevated anxiety antidepressant like responses serotonin 5 HT1A receptor mutant mice
0.27228677.10767319.html.plaintext.txt	295	1998 Serotonin receptor 1A knockout animal model anxiety related disorder
0.27228677.10767319.html.plaintext.txt	296	1998 Increased anxiety mice lacking serotonin 1A receptor
0.27228677.10767319.html.plaintext.txt	297	1999 Altered emotional states knockout mice lacking 5 HT1A 5 HT1B receptors
0.27228677.10767319.html.plaintext.txt	298	Neuropsychopharmacology 21 52S 60S
0.27228677.10767319.html.plaintext.txt	299	1999 5 HT1B receptor knock mice exhibit increased exploratory activity enhanced spatial memory performance Morris water maze
0.27228677.10767319.html.plaintext.txt	300	1999 Anxiety motor activation maternal infant interactions 5HT1B knockout mice
0.27228677.10767319.html.plaintext.txt	301	1998 Corticotropin releasing factor receptor 1 deficient mice display decreased anxiety impaired stress response aberrant neuroendocrine development
0.27228677.10767319.html.plaintext.txt	302	1998 Impaired stress response reduced anxiety mice lacking functional corticotropin releasing hormone receptor
0.27228677.10767319.html.plaintext.txt	303	1999 Reduced anxiety like cognitive performance mice lacking corticotropin releasing factor receptor 1
0.27228677.10767319.html.plaintext.txt	304	1971 Clock mutants Drosophila melanogaster
0.27228677.10767319.html.plaintext.txt	305	1973 Isolation circadian clock mutants Neurospora crassa
0.27228677.10767319.html.plaintext.txt	306	1999 Molecular bases circadian clocks
0.27228677.10767319.html.plaintext.txt	307	1994 Mutagenesis mapping mouse gene Clock essential circadian behavior
0.27228677.10767319.html.plaintext.txt	308	1997 Positional cloning mouse circadian clock gene
0.27228677.10767319.html.plaintext.txt	309	1999 The mPer2 gene encodes functional component mammalian circadian clock
0.27228677.10767319.html.plaintext.txt	310	thaliana encodes protein characteristics blue light photoreceptor
0.27228677.10767319.html.plaintext.txt	311	1999 Mammalian Cry1 Cry2 essential maintenance circadian rhythms
0.27228677.10767319.html.plaintext.txt	312	1998 Role mouse cryptochrome blue light photoreceptor circadian responses
0.27228677.10767319.html.plaintext.txt	313	1999 Differential regulation mammalian period genes circadian rhythmicity cryptochromes 1 2
0.27228677.10767319.html.plaintext.txt	314	1999 Narcolepsy orexin knockout mice molecular genetics sleep regulation
0.27228677.10767319.html.plaintext.txt	315	1999 The sleep disorder canine narcolepsy caused mutation hypocretin orexin receptor 2 gene
0.27228677.10767319.html.plaintext.txt	316	1998 Functional genomics mouse phenotype based mutagenesis screens
0.27228677.10767319.html.plaintext.txt	317	1998 Mouse mutagenesis systematic studies mammalian gene function
0.27228677.10767319.html.plaintext.txt	318	1998 Large scale ENU screens mouse genetics meets genomics
0.27228677.10767319.html.plaintext.txt	319	1999 Decreased GABAA receptor clustering results enhanced anxiety bias threat cues
0.27228677.10767319.html.plaintext.txt	320	1995 Cloning gene bearing missense mutations early onset familial Alzheimer disease
0.27228677.10767319.html.plaintext.txt	321	1997 Presenilin 1 required Notch1 DII1 expression paraxial mesoderm
0.27228677.10767319.html.plaintext.txt	322	1999 Id1 Id3 required neurogenesis angiogenesis vascularization tumour xenografts
0.27228677.10767319.html.plaintext.txt	323	1999 Mice lacking presenelin genes exhibit early embryonic paterning defects
0.27228677.10767319.html.plaintext.txt	324	1998 Comorbidity fundamental feature generalized anxiety disorders results National Comorbidity Study NCS
0.27228677.10767319.html.plaintext.txt	325	1998 Comorbidity substance use disorders mood anxiety disorders results International Consortium Psychiatric Epidemiology
0.27228677.10767319.html.plaintext.txt	326	1999 Anxiety like behavior mice lacking angiotensin II type 2 receptor
0.27228677.10767319.html.plaintext.txt	327	1999 Behavioral characterization mdx3cv mice deficient C terminal dystrophins
0.27228677.10767319.html.plaintext.txt	328	1999 Dopamine D4 receptor knockout mice exhibit reduced exploration novel stimuli
0.27228677.10767319.html.plaintext.txt	329	1999 Increased anxiety altered responses anxiolytics mice deficient 65 kDa isoform glutamic acid decarboxylase
0.27228677.10767319.html.plaintext.txt	330	1999 Disruption glucocorticoid receptor gene nervous system results reduced anxiety
0.27228677.10767319.html.plaintext.txt	331	1998 Behavioural characterization amounts brain monoamines metabolites mice lacking histamine H1 receptors
0.27228677.10767319.html.plaintext.txt	332	1998 The influence targeted deletion IFNgamma gene emotional behaviors
0.27228677.10767319.html.plaintext.txt	333	1998 IL 6 deficiency leads increased emotionality mice evidence transgenic mice carrying null mutation IL 6
0.27228677.10767319.html.plaintext.txt	334	1998 Sustained long term potentiation anxiety mice lacking Mas protooncogene
0.27228677.10767319.html.plaintext.txt	335	1998 Disruption midkine gene Mdk resulted altered expression calcium binding protein hippocampus infant mice abnormal behaviour
0.27228677.10767319.html.plaintext.txt	336	1999 Anxiety increased 5 HT1A receptor response NCAM null mutant mice
0.27228677.10767319.html.plaintext.txt	337	1999 Increased anxiety impaired pain response puromycin sensitive aminopeptidase gene deficient mice obtained mouse gene trap method
0.27228677.10767319.html.plaintext.txt	338	1999 Increased neurodegeneration ageing mice lacking high affinity nicotine receptors
0.27228677.10767319.html.plaintext.txt	339	1998 Alpha2C adrenoceptor overexpressing mice impaired executing nonspatial spatial escape strategies
0.27228677.10767319.html.plaintext.txt	340	1999 No hippocampal neuron synaptic bouton loss learning impaired aged beta amyloid precursor protein null mice
0.27228677.10767319.html.plaintext.txt	341	Neuroscience 90 1207 1216
0.27228677.10767319.html.plaintext.txt	342	1998 Neurobehavioral development adult openfield exploration swimming navigation learning mice modified beta amyloid precursor protein gene
0.27228677.10767319.html.plaintext.txt	343	1998 Autophosphorylation Thr286 calcium calmodulin kinase II LTP learning
0.27228677.10767319.html.plaintext.txt	344	1998 Selectively enhanced contextual fear conditioning mice lacking transcriptional regulator CCAATenhancer binding protein delta
0.27228677.10767319.html.plaintext.txt	345	1998 Deficits memory tasks mice CREB mutations depend gene dosage
0.27228677.10767319.html.plaintext.txt	346	1998 Mice lacking beta3 subunit GABAA receptor epilepsy phenotype many behavioral characteristics Angelman syndrome
0.27228677.10767319.html.plaintext.txt	347	1998 Importance intracellular domain NR2 subunits NMDA receptor function vivo
0.27228677.10767319.html.plaintext.txt	348	1998 Multiple behavioral anomalies GluR2 mutant mice exhibiting enhanced LTP
0.27228677.10767319.html.plaintext.txt	349	1998 Altered spatial learning memory mice lacking mGluR4 subtype metabotropic glutamate receptor
0.27228677.10767319.html.plaintext.txt	350	1998 Perturbed dentate gyrus function serotonin 5 HT2C receptor mutant mice
0.27228677.10767319.html.plaintext.txt	351	1999 Impaired learning memory altered hippocampal neurodevelopment resulting interleukin 2 gene deletion
0.27228677.10767319.html.plaintext.txt	352	1999 Impaired memory retention decreased long term potentiation integrin associated protein deficient mice
0.27228677.10767319.html.plaintext.txt	353	1998 Reduced K channel inactivation spike broadening hyperpolarization Kvss1
0.27228677.10767319.html.plaintext.txt	354	1 deficient mice impaired learning
0.27228677.10767319.html.plaintext.txt	355	1999 Central neuronal loss behavioral impairment mice lacking neurotrophin receptor p75
0.27228677.10767319.html.plaintext.txt	356	1998 Enhancement spatial attention nociceptinorphanin FQ receptor knockout mice
0.27228677.10767319.html.plaintext.txt	357	1998 Facilitation long term potentiation memory mice lacking nociceptin receptors
0.27228677.10767319.html.plaintext.txt	358	1999 Cognitive deficits genetic mouse model common biochemical cause human mental retardation
0.27228677.10767319.html.plaintext.txt	359	1998 Genetic pharmacological evidence novel intermediate phase long term potentiation suppressed calcineurin
0.27228677.10767319.html.plaintext.txt	360	1998 Restricted regulated overexpression reveals calcineurin key component transition short term long term memory
0.27228677.10767319.html.plaintext.txt	361	1999 Deletion ryanodine receptor type 3 RyR3 impairs forms synaptic plasticity spatial learning
0.27228677.10767319.html.plaintext.txt	362	1998 Mice lacking ataxin 1 display learning deficits decreased hippocampal paired pulse facilitation
0.27228677.10767319.html.plaintext.txt	363	1998 Motor learning dysfunction postnatal development mice defective dopamine neuronal transmission
0.27228677.10767319.html.plaintext.txt	364	1998 Mutation Angelman ubiquitin ligase mice causes increase cytoplasmic p53 deficits contextual learning long term potentiation
0.27228677.10767319.html.plaintext.txt	365	1998 Disruption retinoid related orphan receptor beta changes circadian behavior causes retinal degeneration leads vacillans phenotype mice
0.27228677.10767319.html.plaintext.txt	366	1999 Reduction depressive like behavior mice lacking angiotensinogen
0.27228677.10767319.html.plaintext.txt	367	1999 Mice reduced NMDA receptor expression display behaviors related schizophrenia
0.27228677.10767319.html.plaintext.txt	368	1999 Metabotropic glutamate receptor subtype 7 ablation causes deficit fear response conditioned taste aversion
0.27228677.10767319.html.plaintext.txt	369	1999 Increased exploratory activity altered response LSD mice lacking 5 HT 5A receptor
0.27228677.10767319.html.plaintext.txt	370	1998 Behavioural characterization interleukin 6 overexpressing deficient mice agonistic encounters
0.11059638.15044362.html.plaintext.txt	0	Differential Effects Adrenalectomy Melanin Concentrating Hormone Orexin A Deborah L
0.11059638.15044362.html.plaintext.txt	1	Genome Research Institute University Cincinnati Cincinnati Ohio 45237 Department Cell Biology L
0.11059638.15044362.html.plaintext.txt	2	Neurobiology Anatomy University Cincinnati Cincinnati Ohio 45267
0.11059638.15044362.html.plaintext.txt	3	Address correspondence requests reprints Deborah L
0.11059638.15044362.html.plaintext.txt	4	Drazen Genome Research Institute University Cincinnati 2170 East Galbraith Road Building 43 Third Floor Cincinnati Ohio 45237
0.11059638.15044362.html.plaintext.txt	5	Abstract Top Abstract Introduction Materials Methods Results Discussion References Removal glucocorticoids adrenalectomy ADX reduces food intake body weight rodents prevents excessive weight gain many genetic dietary models obesity
0.11059638.15044362.html.plaintext.txt	6	Glucocorticoids play key role promote positive energy balance normal pathological conditions least part altering sensitivity hypothalamic peptides
0.11059638.15044362.html.plaintext.txt	7	The hyperphagia central neuropeptide Y administration example attenuated ADX evidence glucocorticoids influence MCH orexin A activity
0.11059638.15044362.html.plaintext.txt	8	In present study feeding responses third ventricular MCH orexin A measured rats bilateral ADX sham surgery
0.11059638.15044362.html.plaintext.txt	9	ADX rats significantly less sensitive orexigenic action third ventricular MCH whereas orexin A induced hyperphagia unaffected
0.11059638.15044362.html.plaintext.txt	10	Replacement corticosterone drinking water ADX rats reversed effects ADX MCH sensitivity
0.11059638.15044362.html.plaintext.txt	11	Although found significant populations glucocorticoid receptors lateral hypothalamus none colocalized either MCH orexin A containing cell bodies
0.11059638.15044362.html.plaintext.txt	12	Furthermore whereas ADX significantly reduced hypothalamic MCH orexin gene expression could restored glucocorticoids drinking water
0.11059638.15044362.html.plaintext.txt	13	Collectively present data suggest glucocorticoids may promote food intake part potentiating orexigenic actions MCH without affecting actions orexin A glucocorticoids act indirectly influence effects MCH food intake
0.11059638.15044362.html.plaintext.txt	14	Introduction Top Abstract Introduction Materials Methods Results Discussion References OBESITY IS A MAJOR risk factor many diseases including diabetes mellitus hypertension cardiovascular disease cancers 1
0.11059638.15044362.html.plaintext.txt	15	Among myriad factors mediating regulation food intake body weight glucocorticoid cortisol corticosterone rats secreted adrenal cortex
0.11059638.15044362.html.plaintext.txt	16	Glucocorticoids lipophilic molecules freely cross blood brain barrier interact receptors distributed throughout central nervous system including nuclei hypothalamus critical energy balance regulation 2
0.11059638.15044362.html.plaintext.txt	17	Glucocorticoids long term effects food intake obesity 3 rodents forms genetic obesity associated increased glucocorticoid levels whereas lack glucocorticoids linked hypophagia reduced body weight 4
0.11059638.15044362.html.plaintext.txt	18	The central infusion glucocorticoids also leads increase food intake body weight 5
0.11059638.15044362.html.plaintext.txt	19	In humans change glucocorticoid status also alter body weight
0.11059638.15044362.html.plaintext.txt	20	For example individuals Addison disease exhibit anorexia weight loss due adrenal insufficiency whereas patients Cushing disease glucocorticoid excess syndromes increased food intake visceral adiposity reviewed Ref
0.11059638.15044362.html.plaintext.txt	21	In rodents adrenalectomy ADX reverses many forms obesity whereas glucocorticoid replacement restores obese state 4 6 glucocorticoid administration adrenal intact animals increases food intake weight gain 4 7
0.11059638.15044362.html.plaintext.txt	22	In addition important metabolic effects periphery glucocorticoids act several hypothalamic nuclei associated control energy balance
0.11059638.15044362.html.plaintext.txt	23	Several studies elucidated actions glucocorticoids activity paraventricular arcuate nuclei ARC 8
0.11059638.15044362.html.plaintext.txt	24	Less explored whether glucocorticoids also act upon neuropeptide systems within lateral hypothalamus LH
0.11059638.15044362.html.plaintext.txt	25	Because long known activity LH associated increased food intake weight gain one reasonable hypothesis powerful effects glucocorticoids stimulate positive energy balance act part stimulating neuropeptide systems within LH
0.11059638.15044362.html.plaintext.txt	26	The first neuropeptide systems LH melanin concentrating hormone MCH 19 amino acid polypeptide originally isolated salmon pituitaries 9
0.11059638.15044362.html.plaintext.txt	27	Neuroanatomical studies rats demonstrate MCH gene expression limited LH zona incerta extensive fiber projections throughout brain 10
0.11059638.15044362.html.plaintext.txt	28	MCH produced prepro MCH along two putative peptides neuropeptides EI GE 11
0.11059638.15044362.html.plaintext.txt	29	The known MCH receptor rats SLC 1 G coupled protein receptor present throughout brain periphery 12 13
0.11059638.15044362.html.plaintext.txt	30	Central MCH involved many different physiological functions including reproduction stress activity importantly energy balance reviewed Ref
0.11059638.15044362.html.plaintext.txt	31	Food restriction increases MCH expression central injection MCH promotes feeding 15
0.11059638.15044362.html.plaintext.txt	32	In addition MCH deficient mice reduced body weight lean due hypophagia increase metabolic rate 16
0.11059638.15044362.html.plaintext.txt	33	The central administration MCH also elicits increase water intake independent food intake 17
0.11059638.15044362.html.plaintext.txt	34	The second peptide system contained LH orexins also known hypocretins originate prepro orexin prepro hypocretin reviewed Ref
0.11059638.15044362.html.plaintext.txt	35	Orexin influences variety endocrine autonomic metabolic functions including control food intake wakefulness motor activity metabolic rate blood pressure 19
0.11059638.15044362.html.plaintext.txt	36	Orexin A 33 amino acid peptide increases food intake body weight dose dependent manner injected brain 20
0.11059638.15044362.html.plaintext.txt	37	Conversely administration orexin receptor antibody reduces food intake fasted rats 21
0.11059638.15044362.html.plaintext.txt	38	Similar MCH fasting regulates orexin mRNA expression 22
0.11059638.15044362.html.plaintext.txt	39	Orexin containing neurons project widely central nervous system hypothalamic nuclei important control feeding orexin receptors located ventromedial hypothalamus VMN LH ARC paraventricular nucleus PVN reviewed Ref
0.11059638.15044362.html.plaintext.txt	40	Given profound effects glucocorticoids feeding orexigenic hypothalamic peptides goal present study assess potential role glucocorticoids influence effects MCH orexin A food intake
0.11059638.15044362.html.plaintext.txt	41	We tested hypothesis glucocorticoids promote actions peptides lateral hypothalamus part complex hypothalamic system regulates energy balance
0.11059638.15044362.html.plaintext.txt	42	As result present study first investigated effects third ventricular i3vt administration MCH orexin A food intake ADX rats sham operated controls
0.11059638.15044362.html.plaintext.txt	43	Next examined influence glucocorticoids expression MCH orexin mRNA using semiquantitative PCR
0.11059638.15044362.html.plaintext.txt	44	Because ADX causes deficiency circulating hormones addition glucocorticoids also examined whether glucocorticoid replacement could reverse effects observed ADX
0.11059638.15044362.html.plaintext.txt	45	Finally assessed potential colocalization MCH orexin protein glucocorticoid receptors within LH determine whether glucocorticoids may act directly neuronal populations
0.11059638.15044362.html.plaintext.txt	46	Materials Methods Top Abstract Introduction Materials Methods Results Discussion References Animals Male Long Evans rats weighing 267 329 g obtained Harlan Harlan Indianapolis IN housed University Cincinnati
0.11059638.15044362.html.plaintext.txt	47	Rats housed individually clear plastic cages ad libitum access pelleted rat chow water unless otherwise specified temperature controlled vivarium 12 h light 12 h dark schedule
0.11059638.15044362.html.plaintext.txt	48	After ADX sham surgery animals access 0
0.11059638.15044362.html.plaintext.txt	49	9 NaCl solution addition tap water
0.11059638.15044362.html.plaintext.txt	50	The research animals studies presented conducted Association Assessment Accreditation Laboratory Animal Care International approved facilities conducted approval Institutional Animal Care Use Committee
0.11059638.15044362.html.plaintext.txt	51	Procedures Third ventricular cannulation
0.11059638.15044362.html.plaintext.txt	52	Animals surgically implanted 22 gauge Plastics One Roanoke VA cannula tip third ventricle described previously 23
0.11059638.15044362.html.plaintext.txt	53	Rats anesthetized ketamine 86 mgkg ipxylazine 12
0.11059638.15044362.html.plaintext.txt	54	Verification cannula placement accomplished i3vt injection 10 ng angiotensin II 1 microl 0
0.11059638.15044362.html.plaintext.txt	55	Animals drink 5 ml water within 60 min treatment included experiments
0.11059638.15044362.html.plaintext.txt	56	A short incision made skin rostral kidney
0.11059638.15044362.html.plaintext.txt	57	The perirenal fat located prominent adrenal veins located adrenals isolated surrounding fat capsule removed
0.11059638.15044362.html.plaintext.txt	58	Animals allowed recover least 10 d experiments began
0.11059638.15044362.html.plaintext.txt	59	Because ADX also removes mineralocorticoids necessary sodium retention ADX animals access isotonic 0
0.11059638.15044362.html.plaintext.txt	60	9 saline addition tap water
0.11059638.15044362.html.plaintext.txt	61	To maintain balanced design sham animals also access fluids
0.11059638.15044362.html.plaintext.txt	62	ADX verified measuring plasma corticosterone levels RIA
0.11059638.15044362.html.plaintext.txt	63	Tail blood sampled completion behavioral testing 1 h lights 100 microl tip tail determination plasma corticosterone levels
0.11059638.15044362.html.plaintext.txt	64	Animals plasma levels 1 microldl removed study
0.11059638.15044362.html.plaintext.txt	65	Plasma corticosterone levels determined RIA using rabbit antiserum raised corticosterone 21 hemisuccinate B3 163 Endocrine Sciences Tarzana CA
0.11059638.15044362.html.plaintext.txt	66	5 microldl intraassay coefficient variation 2 5 experiments
0.11059638.15044362.html.plaintext.txt	67	Experiment 1 effect ADX feeding response MCH Behavioral procedures
0.11059638.15044362.html.plaintext.txt	68	Rats sham n 10 ADX n 9 adapted schedule food water saline removed cages 5 h end light cycle
0.11059638.15044362.html.plaintext.txt	69	On experimental days 1 h food fluid removed animals received i3vt infusion 2 microl either MCH American Peptide Co
0.11059638.15044362.html.plaintext.txt	70	Sunnyvale CA dissolved 0
0.11059638.15044362.html.plaintext.txt	71	9 saline saline alone via Hamilton syringe
0.11059638.15044362.html.plaintext.txt	72	Food returned immediately injection food fluid weighed 30 min 2 h
0.11059638.15044362.html.plaintext.txt	73	Each animal received three doses MCH 2
0.11059638.15044362.html.plaintext.txt	74	5 5 10 microg vehicle alone order counterbalanced across subjects using Latin square procedure
0.11059638.15044362.html.plaintext.txt	75	Animals allowed least 3 d without injections experimental days
0.11059638.15044362.html.plaintext.txt	76	Experiment 2 effect ADX response MCH corticosterone replaced rats ADX animals saline drinking fluid replaced solution 0
0.11059638.15044362.html.plaintext.txt	77	9 saline 40 microgml corticosterone CORT 0
0.11059638.15044362.html.plaintext.txt	78	5 alcohol keep corticosterone solution
0.11059638.15044362.html.plaintext.txt	79	Providing ADX rats corticosterone solution results plasma corticosterone levels comparable sham operated controls 24
0.11059638.15044362.html.plaintext.txt	80	Rats access solution 5 d behavioral testing
0.11059638.15044362.html.plaintext.txt	81	Food intake subsequently determined 30 min 2 h groups rats sham n 10 ADX CORT n 8 i3vt administration either 5
0.11059638.15044362.html.plaintext.txt	82	0 microg MCH saline order treatments counterbalanced across subjects
0.11059638.15044362.html.plaintext.txt	83	Tail blood sampled completion behavioral testing 1 h lights 100 microl tip tail determination plasma corticosterone levels
0.11059638.15044362.html.plaintext.txt	84	Experiment 3 effect ADX feeding response orexin A Procedures
0.11059638.15044362.html.plaintext.txt	85	Surgical procedures verifications performed described experiment 1
0.11059638.15044362.html.plaintext.txt	86	All ADX animals maintained plasma corticosterone levels less 1 microldl
0.11059638.15044362.html.plaintext.txt	87	Rats sham n 10 ADX n 9 adapted schedule food water saline removed cages 5 h end light cycle
0.11059638.15044362.html.plaintext.txt	88	On experimental days 1 h food removed animals received i3vt infusion 2 microl either orexin A Phoenix Pharmaceuticals Inc
0.11059638.15044362.html.plaintext.txt	89	Mountain View CA dissolved 0
0.11059638.15044362.html.plaintext.txt	90	9 saline saline alone via Hamilton syringe
0.11059638.15044362.html.plaintext.txt	91	Food returned immediately injection food fluid weighed 1 2 h
0.11059638.15044362.html.plaintext.txt	92	Each animal received three doses orexin A 1
0.11059638.15044362.html.plaintext.txt	93	0 nmol saline alone order counterbalanced across subjects using Latin square procedure
0.11059638.15044362.html.plaintext.txt	94	Animals allowed least 3 d without injections experimental days
0.11059638.15044362.html.plaintext.txt	95	Experiment 4 effect ADX corticosterone replacement hypothalamic MCH orexin expression Procedures
0.11059638.15044362.html.plaintext.txt	96	Half group ADX animals 0
0.11059638.15044362.html.plaintext.txt	97	9 saline solution replaced corticosterone solution 5 d drinking water see three groups rats semiquantitative PCR analysis sham n 13 ADX n 7 ADX CORT n 9
0.11059638.15044362.html.plaintext.txt	98	All animals killed 1 h lights brief exposure CO2 followed rapid decapitation removal fresh brain tissue
0.11059638.15044362.html.plaintext.txt	99	RNA isolation cDNA synthesis
0.11059638.15044362.html.plaintext.txt	100	Brains rapidly removed decapitation placed RNA Later Ambion Austin TX stored 4 C 24 h
0.11059638.15044362.html.plaintext.txt	101	They stored 80 C use gene measurement
0.11059638.15044362.html.plaintext.txt	102	Mediobasal hypothalami dissected total RNA extracted using TRI Reagent Molecular Research Center Cincinnati OH
0.11059638.15044362.html.plaintext.txt	103	All RNA samples deoxyribonuclease treated using deoxyribonuclease free Ambion Austin TX
0.11059638.15044362.html.plaintext.txt	104	The Superscript III first strand synthesis system Invitrogen Life Technologies Carlsbad CA used synthesize cDNA 5 microg total RNA
0.11059638.15044362.html.plaintext.txt	105	Semiquantitative expression MCH orexin A mRNA real time PCR
0.11059638.15044362.html.plaintext.txt	106	Primers designed amplify portion rat MCH orexin genes using Primer3 primer design software 25
0.11059638.15044362.html.plaintext.txt	107	Primer sequences 5 3 forward ATATGAGCCTCTCTTAC reverse GTCGTCTTCTACGTTCCTGA MCH forward TTCCTTCTACAAAGGTTCCCT reverse TAGCAGCAGCAGCAGCGTCA orexin
0.11059638.15044362.html.plaintext.txt	108	The constitutively expressed ribosomal protein L32 used obtain relative quantification gene
0.11059638.15044362.html.plaintext.txt	109	The primer sequences L32 forward CATCGTAGAAAGAGCAGCAC reverse GCACACAAGCCATCTATTCAT
0.11059638.15044362.html.plaintext.txt	110	A master mix including cDNA prepared 5 microg total RNA see using Superscript III first strand synthesis kit Invitrogen Life Technologies 10 microM primer Bio Rad SYBR green supermix used PCRs
0.11059638.15044362.html.plaintext.txt	111	All PCRs performed using Bio Rad iCycler Richmond CA final volume 25 microl
0.11059638.15044362.html.plaintext.txt	112	The PCR conditions measurements L32 orexin consisted two step reaction annealing temperature 58 C extension time 30 sec 40 cycles
0.11059638.15044362.html.plaintext.txt	113	PCR conditions measurements MCH 60 C 30 sec 40 cycles
0.11059638.15044362.html.plaintext.txt	114	A standard curve genes performed using dilution series spanning 7 orders magnitude dilution factor 5
0.11059638.15044362.html.plaintext.txt	115	The PCR efficiencies L32 MCH orexin 95 100
0.11059638.15044362.html.plaintext.txt	116	Correlation coefficients standard curves 0
0.11059638.15044362.html.plaintext.txt	117	Standard curves calculated slope plot threshold cycle vs
0.11059638.15044362.html.plaintext.txt	118	Samples run triplicate normalized constitutively expressed ribosomal protein L32
0.11059638.15044362.html.plaintext.txt	119	Data expressed mean plus minus SEM MCH orexin relative L32 using Ct method Applied Biosystems Foster City CA User Bulletin No
0.11059638.15044362.html.plaintext.txt	120	Experiment 5 visualization glucocorticoid receptor MCH orexin A Tissue preparation
0.11059638.15044362.html.plaintext.txt	121	Adult male rats n 4 deeply anesthetized using pentobarbital 200 mgkg perfused transcardially 100 ml 0
0.11059638.15044362.html.plaintext.txt	122	9 NaCl followed 500 ml 4 paraformaldehyde 0
0.11059638.15044362.html.plaintext.txt	123	The brains removed postfixed 1 h room temperature fixative placed 20 sucrose 0
0.11059638.15044362.html.plaintext.txt	124	Coronal sections 35 microm cut freezing microtome Richard Allen Kalamazoo MI collected four parallel series cryoprotectant solution 30 sucrose 30 ethylene glycol 0
0.11059638.15044362.html.plaintext.txt	125	1 M PB 26 stored 20 C processing
0.11059638.15044362.html.plaintext.txt	126	All incubations performed room temperature gentle agitation
0.11059638.15044362.html.plaintext.txt	127	Free floating sections washed extensively 0
0.11059638.15044362.html.plaintext.txt	128	Sections incubated 10 min 1 H2O2 blocked 1 h incubation solution PBS containing 0
0.11059638.15044362.html.plaintext.txt	129	All primary antibody incubations performed incubation solution overnight room temperature
0.11059638.15044362.html.plaintext.txt	130	After staining sections washed thoroughly 0
0.11059638.15044362.html.plaintext.txt	131	1 M PB mounted onto glass slides 0
0.11059638.15044362.html.plaintext.txt	132	3 gelatin ddH2O coverslipped DPX Electron Microscopy Sciences Fort Washington PA
0.11059638.15044362.html.plaintext.txt	133	Immunocytochemical controls included omission primary antibodies
0.11059638.15044362.html.plaintext.txt	134	Sections containing hypothalamus incubated overnight rabbit polyclonal antibody recognizing glucocorticoid receptor 1200 PA1 511A Affinity Bioreagents Golden CO followed 1 h incubations biotinylated goat antirabbit IgG 1600 Vector Laboratories Burlingame CA avidin horseradish peroxidase complex 11000 ABC Elite Kit Vector Laboratories Burlingame CA
0.11059638.15044362.html.plaintext.txt	135	Finally sections incubated 10 min 0
0.11059638.15044362.html.plaintext.txt	136	02 diaminobenzidine Sigma Aldrich St
0.11059638.15044362.html.plaintext.txt	137	08 nickel sulfate resulting blue black reaction product
0.11059638.15044362.html.plaintext.txt	138	Next sections incubated overnight rabbit polyclonal antibody orexin 11000 Phoenix Pharmaceuticals Belmont CA rabbit anti MCH 1150000 Phoenix Pharmaceuticals biotinylated goat antirabbit IgG 1600 Vector Laboratories Burlingame CA ABC described
0.11059638.15044362.html.plaintext.txt	139	Finally sections incubated 10 min 0
0.11059638.15044362.html.plaintext.txt	140	012 hydrogen peroxide resulting reddish brown reaction product
0.11059638.15044362.html.plaintext.txt	141	Data analysis Food intake data experiments 1 3 analyzed using mixed model ANOVA
0.11059638.15044362.html.plaintext.txt	142	Experiment 2 analyzed using one way ANOVA experiment 5 analyzed using two tailed tests
0.11059638.15044362.html.plaintext.txt	143	All pair wise comparisons mean differences conducted using Tukey honestly significant difference post hoc comparisons
0.11059638.15044362.html.plaintext.txt	144	Differences group means considered statistically significant P 0
0.11059638.15044362.html.plaintext.txt	145	For experiment 5 MCH orexin positive cells examined coexpression glucocorticoid receptor throughout hypothalamus
0.11059638.15044362.html.plaintext.txt	146	Digital images immunostained sections captured using digital camera Magnafire Optronics Goleta CA attached Leica microscope Leica Microsystems Wetzlar Germany
0.11059638.15044362.html.plaintext.txt	147	Images imported Adobe Photoshop 7
0.11059638.15044362.html.plaintext.txt	148	0 Adobe Systems San Jose CA compose figures
0.11059638.15044362.html.plaintext.txt	149	Images adjusted altered way except occasional adjustment brightness
0.11059638.15044362.html.plaintext.txt	150	Results Top Abstract Introduction Materials Methods Results Discussion References Experiment 1 In set rats percent body weight change mean plus minus SEM presurgery time experiments performed 39
0.11059638.15044362.html.plaintext.txt	151	4 ADX weight gain significantly less ADX sham P 0
0.11059638.15044362.html.plaintext.txt	152	MCH significantly increased food intake 5 10 microg sham animals 30 min 2 h P 0
0.11059638.15044362.html.plaintext.txt	153	05 cases whereas ADX animals MCH increased food intake 10 microg dose 2 h P 0
0.11059638.15044362.html.plaintext.txt	154	MCH increased food intake 5 10 microg greater extent sham compared ADX animals 30 min 2 h P 0
0.11059638.15044362.html.plaintext.txt	155	When assessed absolute change food intake animals injected vehicle food intake significantly greater sham compared ADX animals 5 10 microg 30 min 2 h P 0
0.11059638.15044362.html.plaintext.txt	156	9 NaCl solution significantly increased 5 10 microg MCH sham animals 30 min 2 h 10 microg ADX animals 30 min 2 h P 0
0.11059638.15044362.html.plaintext.txt	157	Ten micrograms MCH increased fluid intake greater extent sham animals compared ADX animals time points P 0
0.11059638.15044362.html.plaintext.txt	158	Mean plus minus SEM 30 min 2 h food intake g rats treated i3vt MCH
0.11059638.15044362.html.plaintext.txt	159	View larger version 10K FIG
0.11059638.15044362.html.plaintext.txt	160	Mean plus minus SEM A 30 min B 2 h food intake rats received either bilateral ADX surgery sham surgery treated i3vt MCH vehicle
0.11059638.15044362.html.plaintext.txt	161	Data represented absolute change animals injected vehicle
0.11059638.15044362.html.plaintext.txt	162	Significantly different paired sham P 0
0.11059638.15044362.html.plaintext.txt	163	Mean plus minus SEM 30 min 2 h total fluid water 0
0.11059638.15044362.html.plaintext.txt	164	9 NaCl solution intake ml rats treated i3vt MCH
0.11059638.15044362.html.plaintext.txt	165	Experiment 2 Plasma corticosterone concentrations significantly reduced undetectable levels ADX compared sham animals 11
0.11059638.15044362.html.plaintext.txt	166	7 microgdl assessed 1 h lights P 0
0.11059638.15044362.html.plaintext.txt	167	ADX CORT animals plasma corticosterone concentrations similar sham animals 8
0.11059638.15044362.html.plaintext.txt	168	Administration 5 microg MCH significantly increased food intake sham ADX CORT animals P 0
0.11059638.15044362.html.plaintext.txt	169	MCH increased food intake similar extent sham ADX CORT animals 30 min see Fig
0.11059638.15044362.html.plaintext.txt	170	2 2 h data shown P 0
0.11059638.15044362.html.plaintext.txt	171	View larger version 12K FIG
0.11059638.15044362.html.plaintext.txt	172	Mean plus minus SEM 30 min food intake rats received either sham surgery ADX surgery consecutive 5 d corticosterone drinking water 2
0.11059638.15044362.html.plaintext.txt	173	7 mgml treated i3vt 5 microg MCH vehicle
0.11059638.15044362.html.plaintext.txt	174	Significantly different saline treated rats P 0
0.11059638.15044362.html.plaintext.txt	175	Experiment 3 In set rats percent body weight change mean plus minus SEM presurgery time experiments performed 51
0.11059638.15044362.html.plaintext.txt	176	3 ADX weight gain significantly less ADX sham P 0
0.11059638.15044362.html.plaintext.txt	177	Orexin A 3 nmol significantly increased food intake P 0
0.11059638.15044362.html.plaintext.txt	178	05 extent P 0
0.11059638.15044362.html.plaintext.txt	179	05 sham ADX animals 1 2 h see Table 3
0.11059638.15044362.html.plaintext.txt	180	When assessed absolute change food intake animals injected vehicle 1 h 2 h food intake similar sham ADX animals 3
0.11059638.15044362.html.plaintext.txt	181	Mean plus minus SEM 1 2 h food intake g rats treated i3vt orexin A
0.11059638.15044362.html.plaintext.txt	182	View larger version 12K FIG
0.11059638.15044362.html.plaintext.txt	183	Mean plus minus SEM A 1 h B 2 h food intake rats received either ADX sham surgery treated i3vt orexin A vehicle
0.11059638.15044362.html.plaintext.txt	184	Data represented absolute change animals injected vehicle
0.11059638.15044362.html.plaintext.txt	185	Experiment 4 Hypothalamic mRNA expression MCH relative L32 control significantly reduced ADX ADX CORT animals compared sham animals P 0
0.11059638.15044362.html.plaintext.txt	186	Hypothalamic expression orexin relative L32 control also significantly reduced ADX ADX CORT animals compared sham animals P 0
0.11059638.15044362.html.plaintext.txt	187	View larger version 15K FIG
0.11059638.15044362.html.plaintext.txt	188	Hypothalamic expression A MCH B orexin mRNA relative L32 control data represented percentage sham expression
0.11059638.15044362.html.plaintext.txt	189	Significantly different sham animals P 0
0.11059638.15044362.html.plaintext.txt	190	Experiment 5 Expression glucocorticoid receptor GR MCH orexin similar distributions previously described 10 18 27
0.11059638.15044362.html.plaintext.txt	191	Although GR observed neurons close vicinity neurons expressing orexin MCH observed colocalization GR orexin GR MCH LH see Fig
0.11059638.15044362.html.plaintext.txt	192	View larger version 176K FIG
0.11059638.15044362.html.plaintext.txt	193	Lack colocalization GR orexin A B MCH C D
0.11059638.15044362.html.plaintext.txt	194	GR observed neurons close vicinity neurons expressing orexin MCH indicated arrows
0.11059638.15044362.html.plaintext.txt	195	Discussion Top Abstract Introduction Materials Methods Results Discussion References The results present study suggest well established orexigenic actions MCH influenced glucocorticoid status whereas orexin A another lateral hypothalamic orexigenic peptide
0.11059638.15044362.html.plaintext.txt	196	More specifically whereas ADX attenuated orexigenic actions MCH actions orexin A unaffected
0.11059638.15044362.html.plaintext.txt	197	The effect ADX sensitivity MCH reversed corticosterone replacement suggesting effect specific glucocorticoid deficiency associated ADX
0.11059638.15044362.html.plaintext.txt	198	In addition examining effect glucocorticoids hyperphagic actions MCH orexin A examined actions glucocorticoids alter mRNA expression MCH orexin
0.11059638.15044362.html.plaintext.txt	199	In accord previous data ADX reduced hypothalamic MCH mRNA orexin mRNA 28 29
0.11059638.15044362.html.plaintext.txt	200	However reductions observed MCH orexin restored 5 d corticosterone replacement drinking water despite regimen achieving glucocorticoid levels comparable sham operated animals
0.11059638.15044362.html.plaintext.txt	201	These data suggest gene expression changes lateral hypothalamic peptides glucocorticoid dependent depend nonglucocorticoid aspects ADX
0.11059638.15044362.html.plaintext.txt	202	Previous reports described MCH mRNA increased sham controls ADX rats treated dexamethasone 28
0.11059638.15044362.html.plaintext.txt	203	Similarly dexamethasone administration restored orexin mRNA ADX 29
0.11059638.15044362.html.plaintext.txt	204	Although commonly used dexamethasone binding properties glucocorticoids 30 makes much harder assess whether physiological levels glucocorticoid replacement achieved
0.11059638.15044362.html.plaintext.txt	205	Further work necessary address whether methodological differences underlie differences current data reports groups
0.11059638.15044362.html.plaintext.txt	206	Nevertheless tempting speculate mineralocorticoids may significant effects lateral hypothalamus
0.11059638.15044362.html.plaintext.txt	207	This particularly true case MCH reported MCH potent rapid effect increase water intake even absence available food 17 making possible osmoregulatory aspects mineralocorticoids may influence fluid ingestion via actions MCH
0.11059638.15044362.html.plaintext.txt	208	Glucocorticoid receptors present regions hypothalamus important regulation food intake body weight including ARC PVN LH 27 suggesting glucocorticoids may directly influence activity responsiveness numerous neuropeptide systems regulating feeding
0.11059638.15044362.html.plaintext.txt	209	Despite fact large population glucocorticoid receptor positive cells within LH evidence located either MCH orexin containing neurons
0.11059638.15044362.html.plaintext.txt	210	This consistent data gene expression experiments changes MCH orexin expression appeared tied glucocorticoid action
0.11059638.15044362.html.plaintext.txt	211	Collectively data make several interesting points
0.11059638.15044362.html.plaintext.txt	212	First data provide another dissociation MCH orexin systems LH
0.11059638.15044362.html.plaintext.txt	213	Although systems cell bodies almost exclusively LH act regulate food intake appear separate neural circuits
0.11059638.15044362.html.plaintext.txt	214	These data indicate actions MCH stimulate food intake glucocorticoid dependent whereas actions orexin A
0.11059638.15044362.html.plaintext.txt	215	In addition MCH added extensive list regulatory peptides whose effects altered glucocorticoids
0.11059638.15044362.html.plaintext.txt	216	Thus appears glucocorticoids broad effects number central nervous system circuits linked control food intake
0.11059638.15044362.html.plaintext.txt	217	The present data also allow speculation glucocorticoids influence actions MCH increase food intake
0.11059638.15044362.html.plaintext.txt	218	MCH projections many brain regions important regulation energy balance 10
0.11059638.15044362.html.plaintext.txt	219	For example SLC 1 first identified MCH receptor rodents mRNA immunoreactivity observed ARC PVN LH VMN 13
0.11059638.15044362.html.plaintext.txt	220	It possible glucocorticoids exert effects MCH food intake system acting target cells MCH
0.11059638.15044362.html.plaintext.txt	221	For example strong signals SLC 1 GR observed PVN making potential candidate site action glucocorticoids reduce MCH ability increase food intake 13 27
0.11059638.15044362.html.plaintext.txt	222	There data indicating melanocortin system antagonizes MCH system
0.11059638.15044362.html.plaintext.txt	223	Consistent MCH MSH exert opposing antagonistic effects food intake 31
0.11059638.15044362.html.plaintext.txt	224	Other studies demonstrate administration either agouti related protein AgRP SHU9119 increases MCH mRNA orexin mRNA 32
0.11059638.15044362.html.plaintext.txt	225	Because ADX increases melanocortin tone rodent models 33 34 possible speculate increase melanocortin tone may antagonize orexigenic effects MCH leading present effects ADX MCH orexin
0.11059638.15044362.html.plaintext.txt	226	Another possibility MCH exerts effects via actions ARC alter release neuropeptide Y NPY andor AgRP
0.11059638.15044362.html.plaintext.txt	227	Glucocorticoid receptors found neurons 35 potent orexigenic effects NPY AgRP blocked glucocorticoid deficiency 34 36
0.11059638.15044362.html.plaintext.txt	228	Recent reports indicate ARC potent site MCH increase food intake hypothalamic explants administration MCH increases release NPY suggesting MCH may act activation NPY neurons affect feeding 37
0.11059638.15044362.html.plaintext.txt	229	These data lead hypothesis reduced action MCH glucocorticoid deficiency could due decreased actions NPY andor AgRP
0.11059638.15044362.html.plaintext.txt	230	The reverse may also true proposed NPY andor AgRP exert effects via recruiting MCH neurons LH 38
0.11059638.15044362.html.plaintext.txt	231	Double label immunohistochemistry demonstrates MCH neurons receive innervation NPY immunoreactive fibers 39 data also suggest MCH neurons may express NPY receptors 40
0.11059638.15044362.html.plaintext.txt	232	Such evidence encourages hypothesis effect ADX reduce orexigenic actions MCH may responsible alteration NPY actions ADX
0.11059638.15044362.html.plaintext.txt	233	Future research identify glucocorticoid receptor populations responsible ability glucocorticoids dramatically alter effects variety neuropeptides MCH NPY MSH AgRP
0.11059638.15044362.html.plaintext.txt	234	Acknowledgments We grateful Jennifer Schurdak Jennifer Adelman expert technical assistance
0.11059638.15044362.html.plaintext.txt	235	Randall Sakai measurements corticosterone
0.11059638.15044362.html.plaintext.txt	236	Footnotes This work supported several grants National Institutes Health DK54080 DK17844 Procter Gamble Co
0.11059638.15044362.html.plaintext.txt	237	Abbreviations ADX Adrenalectomy AgRP agouti related protein ARC arcuate nucleus CORT corticosterone GR glucocorticoid receptor i3vt third ventricular LH lateral hypothalamus MCH melanin concentrating hormone NPY neuropeptide Y PB phosphate buffer PVN paraventricular nucleus VMN ventromedial nucleus
0.11059638.15044362.html.plaintext.txt	238	Accepted publication March 15 2004
0.11059638.15044362.html.plaintext.txt	239	References Top Abstract Introduction Materials Methods Results Discussion References Bray GA 2003 Risks obesity
0.11059638.15044362.html.plaintext.txt	240	Prim Care 30281 299Medline Visser DT Hu Z Pasterkamp RJ Morimoto M Kawatam M 1996 The alteration glucocorticoid receptor immunoreactivity rat forebrain following short term long term adrenalectomy
0.11059638.15044362.html.plaintext.txt	241	Brain Res 729216 222CrossRefMedline Strack AM Sebastian RJ Schwartz MW Dallman MF 1995 Glucocorticoids insulin reciprocal signals energy balance
0.11059638.15044362.html.plaintext.txt	242	Am J Physiol 268142 149 Zakrzewska KE Cusin I Sainsbury A Rohner Jeanrenaud F Jeanrenaud B 1997 Glucocorticoids counterregulatory hormones leptin
0.11059638.15044362.html.plaintext.txt	243	Diabetes 46717 719Abstract Zakrzewska KE Cusin I Stricker Krongrad A Boss O Ricquier D Jeanrenaud B Rohner Jeanrenaud F 1999 Induction obesity hyperleptinemia central glucocorticoid infusion rat
0.11059638.15044362.html.plaintext.txt	244	Diabetes 48365 370AbstractFree Full Text Freedman MR Horowitz BA Stern JS 1986 Effect adrenalectomy glucocorticoid replacement development obesity
0.11059638.15044362.html.plaintext.txt	245	Am J Physiol 250R595 R607 Green PK Wilkinson CW Woods SC 1992 Intraventricular corticosterone increases rate body weight gain underweight adrenalectomized rats
0.11059638.15044362.html.plaintext.txt	246	Endocrinology 130269 275Abstract Dallman MF Strack AM Akana SF Bradbury MJ Hanson ES Scribner KA Smith M 1993 Feast famine critical role glucocorticoids insulin daily energy flow
0.11059638.15044362.html.plaintext.txt	247	Front Neuroendocrinol 14303 347CrossRefMedline Kawauchi H Kawazoe I Tsubokawa M Kishida M Baker BI 1983 Characterization melanin concentrating hormone chum salmon pituitaries
0.11059638.15044362.html.plaintext.txt	248	Nature 305321 323Medline Bittencourt JC Presse F Arias C Peto C Vaughan J Nahon JL Vale W Sawchenko PE 1992 The melanin concentrating hormone system rat brain immuno hybridization histochemical characterization
0.11059638.15044362.html.plaintext.txt	249	J Comp Neurol 319218 245Medline Nahon JL Presse F Bittencourt JC Sawchenko PE Vale W 1989 The rat melanin concentrating hormone messenger ribonucleic acid encodes multiple putative neuropeptides coexpressed dorsolateral hypothalamus
0.11059638.15044362.html.plaintext.txt	250	Endocrinology 1252056 2065Abstract Chambers J Ames RS Bergsma D Muir A Fitzgerald LR Hervieu G Dytko GM Foley JJ Martin J Liu WS Park J Ellis C Ganguly S Konchar S Cluderay J Leslie R Wilson S Sarau HM 1999 Melanin concentrating hormone cognate ligand orphan G protein coupled receptor SLC 1
0.11059638.15044362.html.plaintext.txt	251	Nature 400261 265CrossRefMedline Hervieu GJ Cluderay JE Harrison D Meakin J Maycox P Nasir S Leslie RA 2000 The distribution mRNA protein products melanin concentrating hormone MCH receptor gene slc 1 central nervous system rat
0.11059638.15044362.html.plaintext.txt	252	Eur J Neurosci 121194 1216CrossRefMedline Griffond B Baker BI 2002 Cell molecular cell biology melanin concentrating hormone
0.11059638.15044362.html.plaintext.txt	253	Int Rev Cytol 213233 277Medline Qu D Ludwig DS Gammeltoft S Piper M Pelleymounter MA Cullen MJ Mathes WF Przypek R Kanarek R Maratos Flier E 1996 A role melanin concentrating hormone central regulation feeding behaviour
0.11059638.15044362.html.plaintext.txt	254	Nature 380243 247CrossRefMedline Shimada M Tritos NA Lowell BB Flier JS Maratos Flier E 1998 Mice lacking melanin concentrating hormone hypophagic lean
0.11059638.15044362.html.plaintext.txt	255	Nature 396670 674CrossRefMedline Clegg DJ Air EL Benoit SC Sakai RS Seeley RJ Woods SC 2003 Intraventricular melanin concentrating hormone stimulates water intake independent food intake
0.11059638.15044362.html.plaintext.txt	256	Effects intraduodenal glucose fructose antropyloric motility appetite healthy humans 284R494 R499 Kirchgessner AL 2002 Orexins brain gut axis
0.11059638.15044362.html.plaintext.txt	257	Endocr Rev 231 15AbstractFree Full Text Preti A 2002 Orexins hypocretins role appetite arousal
0.11059638.15044362.html.plaintext.txt	258	Orexins hypocretins role appetite arousal 31199 1206 Dube MG Kalra SP Kalra PS 1999 Food intake elicited central administration orexinshypocretins identification hypothalamic sites action
0.11059638.15044362.html.plaintext.txt	259	Brain Res 842473 477CrossRefMedline Yamada H Okumura T Motomura W Kobayashi Y Kohgo Y 2000 Inhibition food intake central injection anti orexin antibody fasted rats
0.11059638.15044362.html.plaintext.txt	260	Biochem Biophys Res Commun 267527 531CrossRefMedline Sakurai T Amemiya A Ishii M Matsuzaki I Chemelli RM Tanaka H Williams SC Richardson JA Kozlowski GP Wilson S Arch JR Buckingham RE Haynes AC Carr SA Annan RS McNulty DE Liu WS Terrett JA Elshourbagy NA Bergsma DJ Yanagisawa M 1998 Orexins orexin receptors family hypothalamic neuropeptides G protein coupled receptors regulate feeding behavior
0.11059638.15044362.html.plaintext.txt	261	Cell 92573 585Medline Chavez M Seeley RJ Woods SC 1995 A comparison effects intraventricular insulin intraperitoneal LiCl three measures sensitive emetic agents
0.11059638.15044362.html.plaintext.txt	262	Behav Neurosci 109547 550CrossRefMedline Wilkinson CW Engeland WC Shinsako J Dallman MF 1981 Nonsteroidal adrenal feedback demarcates two types pathways CRF ACTH release
0.11059638.15044362.html.plaintext.txt	263	Am J Physiol 240E136 E145 Rozen S Skaletsky HJ 2000 Primer3 WWW general users biologist programmers
0.11059638.15044362.html.plaintext.txt	264	Bioinformatics methods protocols methods molecular biology
0.11059638.15044362.html.plaintext.txt	265	Totowa NJ Humana Press 365 386 Watson Jr RE Wiegand SJ Clough RW Hoffman GE 1986 Use cryoprotectant maintain long term peptide immunoreactivity tissue morphology
0.11059638.15044362.html.plaintext.txt	266	Peptides 7155 159CrossRefMedline Morimoto M Morita N Ozawa H Yokoyama K Kawata M 1996 Distribution glucocorticoid receptor immunoreactivity mRNA rat brain immunohistochemical situ hybridization study
0.11059638.15044362.html.plaintext.txt	267	Neurosci Res 26235 269CrossRefMedline Presse F Hervieu G Imaki T Sawchenko PE Vale W Nahon JL 1992 Rat melanin concentrating hormone messenger ribonucleic acid expression marked changes development stress glucocorticoid stimuli
0.11059638.15044362.html.plaintext.txt	268	Endocrinology 1311241 1250Abstract Stricker Krongrad A Beck B 2002 Modulation hypothalamic hypocretinorexin mRNA expression glucocorticoids
0.11059638.15044362.html.plaintext.txt	269	Biochem Biophys Res Commun 296129 133CrossRefMedline Spencer RL Young EA Choo PH McEwen BS 1990 Adrenal steroid type I type II receptor binding estimates vivo receptor number occupancy activation varying level steroid
0.11059638.15044362.html.plaintext.txt	270	Brain Res 51437 48CrossRefMedline Ludwig D Mountjoy K Tatro J Gillette J Frederich R Flier J Maratos Flier E 1998 Melanin concentrating hormone functional melanocortin antagonist hypothalamus
0.11059638.15044362.html.plaintext.txt	271	Am J Physiol 274E627 E633 Hanada R Nakazato M Matsukura S Murakami N Yoshimatsu H Sakata T 2000 Differential regulation melanin concentrating hormone orexin genes agouti related proteinmelanocortin 4 receptor system
0.11059638.15044362.html.plaintext.txt	272	Biochem Biophys Res Commun 26888 91CrossRefMedline Makimura H Mizuno TM Roberts J Silverstein J Beasley J Mobbs CV 2000 Adrenalectomy reverses obese phenotype restores hypothalamic melanocortin tone leptin deficient obob mice
0.11059638.15044362.html.plaintext.txt	273	Diabetes 491917 1923Abstract Drazen DL Wortman MD Schwartz MW Clegg DJ van Dijk G Woods SC Seeley RJ 2003 Adrenalectomy alters sensitivity central nervous system melanocortin system
0.11059638.15044362.html.plaintext.txt	274	Diabetes 522928 2934AbstractFree Full Text Harfstrand A Cintra A Fuxe K Aronsson M Wikstrom AC Okret S Gustafsson JA Agnati LF 1989 Regional differences glucocorticoid receptor immunoreactivity among neuropeptide Y immunoreactive neurons rat brain
0.11059638.15044362.html.plaintext.txt	275	Acta Physiol Scand 1353 9Medline Stanley BG 1989 Suppression neuropeptide Y elicited eating adrenalectomy hypophysectomy reversal corticosterone
0.11059638.15044362.html.plaintext.txt	276	Brain Res 50132 36CrossRefMedline Abbott CR Kennedy AR Wren AM Rossi M Murphy KG Seal LJ Todd JF Ghatei MA Small CJ Bloom SR 2003 Identification hypothalamic nuclei involved orexigenic effect melanin concentrating hormone
0.11059638.15044362.html.plaintext.txt	277	Endocrinology 1443943 3949AbstractFree Full Text Schwartz MW Gelling RW 2002 Rats lighten MCH antagonist
0.11059638.15044362.html.plaintext.txt	278	Nat Med 8779 781CrossRefMedline Elias CF Saper CB Maratos Flier E Tritos NA Lee C Kelly J Tatro JB Hoffman GE Ollmann MM Barsh GS Sakurai T Yanagisawa M Elmquist JK 1998 Chemically defined projections linking mediobasal hypothalamus lateral hypothalamic area
0.11059638.15044362.html.plaintext.txt	279	CO2 R 3985AbstractFree Full Text
0.27402496.12639903.html.plaintext.txt	0	Gonadal Steroids Differentially Regulate Messenger Ribonucleic Acid Expression Pituitary Orexin Type 1 Receptors Adrenal Orexin Type 2 Receptors Olaf Johren Norbert Bruggemann Andreas Dendorfer Peter Dominiak
0.27402496.12639903.html.plaintext.txt	1	Institute Experimental Clinical Pharmacology Toxicology University Clinic Lubeck D 23538 Lubeck Germany
0.27402496.12639903.html.plaintext.txt	2	Address correspondence requests reprints Olaf Johren Ph
0.27402496.12639903.html.plaintext.txt	3	Institute Experimental Clinical Pharmacology Toxicology University Clinic Lubeck Ratzeburger Allee 160 D 23538 Lubeck Germany
0.27402496.12639903.html.plaintext.txt	4	Abstract Top Abstract Introduction Materials Methods Results Discussion References Hypothalamic prepro orexin well pituitary adrenal orexin receptors gender specifically expressed
0.27402496.12639903.html.plaintext.txt	5	To assess regulation gonadal steroids investigated effect 17ss estradiol female testosterone male rats prepro orexin orexin receptor mRNA expression
0.27402496.12639903.html.plaintext.txt	6	Rats either sham operated gonadectomized subsequently treated placebo 17ss estradiol testosterone 21 d
0.27402496.12639903.html.plaintext.txt	7	Tissue mRNA levels prepro orexin orexin type 1 OX1 orexin type 2 OX2 receptors measured using quantitative real time RT PCR
0.27402496.12639903.html.plaintext.txt	8	In female rats pituitary OX1 receptor mRNA levels increased 12 fold ovariectomy compared sham operated rats
0.27402496.12639903.html.plaintext.txt	9	The increase pituitary OX1 receptor mRNA inhibited treatment 17ss estradiol
0.27402496.12639903.html.plaintext.txt	10	Adrenal mRNA levels OX2 receptors ovariectomized rats increased 2 fold compared sham operated rats also reduced treatment 17ss estradiol
0.27402496.12639903.html.plaintext.txt	11	In male rats orchidectomy increased mRNA levels pituitary OX1 receptors compared sham operated rats
0.27402496.12639903.html.plaintext.txt	12	In contrast adrenal OX2 receptor mRNA reduced orchidectomy
0.27402496.12639903.html.plaintext.txt	13	Testosterone treatment reversed effect orchidectomy pituitary OX1 adrenal OX2 receptors
0.27402496.12639903.html.plaintext.txt	14	In hypothalamus differences found mRNA levels prepro orexin OX1 OX2 receptors sham operated placebo treated steroid treated female male rats
0.27402496.12639903.html.plaintext.txt	15	Our results indicate gonadal steroids differentially regulate pituitary OX1 receptors adrenal OX2 receptors male female rats may contribute specific sex dependent neuroendocrine endocrine actions orexins
0.27402496.12639903.html.plaintext.txt	16	Introduction Top Abstract Introduction Materials Methods Results Discussion References OREXIN A AND OREXIN B isolated endogenous ligands orphan G protein coupled receptor 1
0.27402496.12639903.html.plaintext.txt	17	Both peptides derive common precursor prepro orexin identical independently cloned prepro hypocretin 2
0.27402496.12639903.html.plaintext.txt	18	Prepro orexin selectively expressed lateral hypothalamic area region involved control feeding behavior 1 2
0.27402496.12639903.html.plaintext.txt	19	Consequently orexins shown stimulate food intake rats injected brain ventricles prepro orexin mRNA regulated lateral hypothalamus fasting 1
0.27402496.12639903.html.plaintext.txt	20	Orexin hypocretin containing neurons project numerous areas throughout brain spinal cord suggesting involvement orexins regulation multiple physiological functions besides effect feeding behavior 3 4 5 6 7
0.27402496.12639903.html.plaintext.txt	21	These areas include cerebral cortex limbic system locus coeruleus brain stem regions also hypothalamus
0.27402496.12639903.html.plaintext.txt	22	Accordingly orexins shown regulate autonomic functions like heart rate blood pressure 8 9 sleep wake behavior arousal 10 11 12 various neuroendocrine systems 13 14 15 16
0.27402496.12639903.html.plaintext.txt	23	Two subtypes orexin receptors namely OX1 OX2 receptors cloned 1
0.27402496.12639903.html.plaintext.txt	24	Their expression patterns rat brain good agreement widespread projections orexin immunoreactive neurons 17 18
0.27402496.12639903.html.plaintext.txt	25	Within hypothalamus OX1 receptor mRNA detected areas like medial preoptic nucleus anterior hypothalamic nucleus ventromedial nucleus whereas OX2 receptor mRNA found regions paraventricular arcuate nucleus 18
0.27402496.12639903.html.plaintext.txt	26	Therefore effects intracerebroventricularly icv injected orexins plasma hormones ACTH prolactin LH GH 13 14 15 16 may mediated affecting synthesis andor liberation releasing hormones
0.27402496.12639903.html.plaintext.txt	27	In addition orexins may directly influence pituitary hormones orexinergic nerve fibers present median eminence pituitary gland orexin receptors detected pituitary gland 4 19 20
0.27402496.12639903.html.plaintext.txt	28	Indeed orexins shown stimulate CRH GnRH release hypothalamus 21 also inhibit releasing hormone stimulated ACTH LH release pituitary 22 23
0.27402496.12639903.html.plaintext.txt	29	The inhibitory action orexin GnRH stimulated pituitary LH release observed proestrous female rats male rats 22
0.27402496.12639903.html.plaintext.txt	30	Moreover female rats effect icv injected orexins dependent status ovarian steroids 16
0.27402496.12639903.html.plaintext.txt	31	Furthermore whereas ovariectomized OVX rats treated 17ss estradiol E2 progesterone icv orexin increased plasma LH levels untreated OVX rats orexin decreased plasma LH levels 16
0.27402496.12639903.html.plaintext.txt	32	One explanation bimodal action orexins LH release possible regulation orexin receptors estrogens
0.27402496.12639903.html.plaintext.txt	33	Interestingly recently detected sexually dimorphic expression peripheral orexin receptors higher mRNA levels OX1 receptors pituitary OX2 receptors adrenal glands male rats compared female rats 20
0.27402496.12639903.html.plaintext.txt	34	To clarify effect gonadal steroids orexin system analyzed mRNA expression prepro orexin well OX1 OX2 receptors hypothalamus pituitary adrenal glands sham operated gonadectomized male female rats influence subsequent E2 T treatment using quantitative real time PCR
0.27402496.12639903.html.plaintext.txt	35	Materials Methods Top Abstract Introduction Materials Methods Results Discussion References Animals treatments OVX sham operated female Wistar rats 8 wk old well orchidectomized ORX sham operated male rats 8 wk old purchased Charles River Sulzfeld Germany operated facilities supplier
0.27402496.12639903.html.plaintext.txt	36	Rats kept controlled conditions 12 h dark 12 h light cycle free access standard diet water
0.27402496.12639903.html.plaintext.txt	37	One week surgery rats anesthetized pentobarbital 40 mg kg 1 ip implanted sc 21 d release hormone pellets Innovative Research America Sarasota FL
0.27402496.12639903.html.plaintext.txt	38	Sham operated rats received placebo Plac pellets Sham Plac n 8
0.27402496.12639903.html.plaintext.txt	39	OVX female rats received either Plac pellets OVX Plac n 8 E2 pellets OVX E2 n 8 concentrations 0
0.27402496.12639903.html.plaintext.txt	40	ORX male rats received either Plac pellets ORX Plac n 8 testosterone T pellets ORX T n 8 concentrations 5
0.27402496.12639903.html.plaintext.txt	41	Three weeks pellet implantation rats weighed killed decapitation
0.27402496.12639903.html.plaintext.txt	42	Trunk blood collected ice serum processed blood aliquoted stored 20 C assayed orexin A E2 T levels
0.27402496.12639903.html.plaintext.txt	43	Brains pituitaries adrenal glands isolated frozen immediately isopentane 30 C stored 80 C use
0.27402496.12639903.html.plaintext.txt	44	The hypothalami dissected according Palkovits Brownstein 24
0.27402496.12639903.html.plaintext.txt	45	All animal protocols complied NIH Guide Care Use Laboratory Animals approved Ministerium fur Umwelt Natur und Forsten Schleswig Holstein Germany Animal Protocol No
0.27402496.12639903.html.plaintext.txt	46	RNA isolation cDNA synthesis Total RNA isolated tissue homogenates guanidinium isothiocyanate method purified using silica gel based spin columns RNeasy Kit QIAGEN GmbH Hilden Germany digestion genomic DNA treatment deoxyribonuclease I QIAGEN
0.27402496.12639903.html.plaintext.txt	47	First strand cDNA synthesized 1 microg total RNA presence 5 mM MgCl2 10 mM Tris HCl pH 9
0.27402496.12639903.html.plaintext.txt	48	1 Triton X 100 1 mM deoxy NTPs 1 U microl RNasin 0
0.27402496.12639903.html.plaintext.txt	49	5 microg oligo deoxythymidine15 primer 15 U avian myeloblastosis virus reverse transcriptase Promega GmbH Mannheim Germany
0.27402496.12639903.html.plaintext.txt	50	To validate successful deoxyribonuclease I treatment reverse transcriptase omitted control reactions
0.27402496.12639903.html.plaintext.txt	51	The absence PCR amplified DNA fragments samples indicated isolation RNA free genomic DNA
0.27402496.12639903.html.plaintext.txt	52	Quantitative real time PCR To amplify prepro orexin OX1 OX2 receptor glyceraldehyde 3 phosphate dehydrogenase GAPDH cDNA sense antisense oligonucleotide primers designed based published cDNA sequences 1 25 using Primer3 software S
0.27402496.12639903.html.plaintext.txt	53	Skaletsky code available httpwww genome
0.27402496.12639903.html.plaintext.txt	54	edugenome softwareotherprimer3
0.27402496.12639903.html.plaintext.txt	55	Oligonucleotides obtained Invitrogen GmbH Karlsruhe Germany
0.27402496.12639903.html.plaintext.txt	56	The sequences primers follows 5 GCC GTC TCT ACG AAC TGT TG 3 prepro orexin sense 5 CGA GGA GAG GGG AAA GTT AG 3 prepro orexin antisense 5 CCC TCA ACT CCA GTC CTA GC 3 OX1 sense 5 CAG GGA GGG CCT ATA ATT GA 3 OX1 antisense 5 CAA TGT TGT TGG GGT GCT TA 3 OX2 sense 5 TCC CCC TCT CAT AAA CTT GG 3 OX2 antisense 5 CTC CCT CAA GAT TGT CAG CA 3 GAPDH sense 5 GTT CAG CTC TGG GAT GAC CT 3 GAPDH antisense
0.27402496.12639903.html.plaintext.txt	57	Quantitative measurement prepro orexin OX1 OX2 receptor GAPDH cDNA performed kinetic PCR using SYBR green I fluorescent dye Eurogentec SA Seraing Belgium described previously 20
0.27402496.12639903.html.plaintext.txt	58	Each sample analyzed triplicate GeneAmp 5700 sequence detection system PE Applied Biosystems Weiterstadt Germany along specific standards template controls monitor contaminating DNA
0.27402496.12639903.html.plaintext.txt	59	Each reaction consisted 100 ng cDNA 0
0.27402496.12639903.html.plaintext.txt	60	3 microM primers 10 mM Tris HCl 50 mM KCl 3 mM MgCl2 0
0.27402496.12639903.html.plaintext.txt	61	25 U Hot GoldStar DNA Polymerase Eurogentec final volume 50 microl
0.27402496.12639903.html.plaintext.txt	62	After denaturation 95 C 10 min cDNA products amplified 40 cycles cycle consisting denaturation 95 C 30 sec annealing extension 60 C 60 sec
0.27402496.12639903.html.plaintext.txt	63	The accumulating DNA products monitored GeneAmp 5700 sequence detection system data stored continuously reaction
0.27402496.12639903.html.plaintext.txt	64	Product purity confirmed dissociation curve analysis agarose gel electrophoresis presence ethidium bromide
0.27402496.12639903.html.plaintext.txt	65	The identity amplified cDNA fragments confirmed restriction analysis
0.27402496.12639903.html.plaintext.txt	66	Furthermore amplified prepro orexin OX1 OX2 receptor GAPDH cDNA fragments cloned using TA cloning kit Invitrogen identities nucleotide sequences confirmed
0.27402496.12639903.html.plaintext.txt	67	The calculations initial mRNA copy numbers sample made according cycle threshold CT method 26
0.27402496.12639903.html.plaintext.txt	68	Dilutions known amounts cloned prepro orexin OX1 OX2 receptor cDNA fragments used generate standard curves 20
0.27402496.12639903.html.plaintext.txt	69	The CT sample calculated fluorescence threshold Rn 0
0.27402496.12639903.html.plaintext.txt	70	3 using GeneAmp 5700 sequence detection system software automatic baseline setting
0.27402496.12639903.html.plaintext.txt	71	The detection limit gene interest 20 copies per 100 ng cDNA
0.27402496.12639903.html.plaintext.txt	72	The copy numbers prepro orexin OX1 OX2 receptor mRNA normalized using GAPDH mRNA levels
0.27402496.12639903.html.plaintext.txt	73	No differences observed treatment groups GAPDH mRNA levels
0.27402496.12639903.html.plaintext.txt	74	RIAs Concentrations plasma E2 T measured using 125I RIA kits ICN Biomedicals Inc
0.27402496.12639903.html.plaintext.txt	75	After two extractions 200 microl serum 1 ml ether evaporation sample reconstituted 100 microl RIA buffer 25 microl samples assayed duplicate according manufacturer instructions
0.27402496.12639903.html.plaintext.txt	76	Intraassay interassay variations less 6 10 respectively
0.27402496.12639903.html.plaintext.txt	77	Plasma orexin A extracted adsorption phenyl silica Isolute SPE International Sorbent Technology Mid Glamorgan UK
0.27402496.12639903.html.plaintext.txt	78	After elution 60 acetonitrile 1 trifluoroacetic acid samples concentrated lyophilization
0.27402496.12639903.html.plaintext.txt	79	Orexin A concentrations determined specific RIA according manufacturer instructions Peninsula Laboratories Inc
0.27402496.12639903.html.plaintext.txt	80	The detection limit assay 3 pgtube based amount orexin A produced least 10 tracer displacement
0.27402496.12639903.html.plaintext.txt	81	All samples analyzed within assay
0.27402496.12639903.html.plaintext.txt	82	The intraassay variability less 10
0.27402496.12639903.html.plaintext.txt	83	Statistics Data presented mean plus minus SEM
0.27402496.12639903.html.plaintext.txt	84	Differences treatment groups estimated one way variance analysis ANOVA followed Bonferroni posttest using GraphPad Software Inc
0.27402496.12639903.html.plaintext.txt	85	San Diego CA Prism Software
0.27402496.12639903.html.plaintext.txt	86	05 indicated statistically significant differences
0.27402496.12639903.html.plaintext.txt	87	Results Top Abstract Introduction Materials Methods Results Discussion References Specific amplification prepro orexin OX1 OX2 receptor mRNA hypothalamus pituitary adrenal axis real time PCR Amplification cDNA hypothalamus male female rats prepro orexin OX1 OX2 receptor specific primers resulted PCR products expected size Fig
0.27402496.12639903.html.plaintext.txt	88	No amplification products observed template controls H2O analyzed simultaneously assays indicating absence contaminating DNA Fig
0.27402496.12639903.html.plaintext.txt	89	Restriction analysis amplified cDNA fragments confirmed identity published cDNA clones prepro orexin OX1 OX2 receptors Fig
0.27402496.12639903.html.plaintext.txt	90	The size restriction pattern amplified cDNA OX1 OX2 receptors also confirmed pituitary adrenal glands shown
0.27402496.12639903.html.plaintext.txt	91	Amplification prepro orexin OX1 OX2 receptors hypothalamus pituitary adrenal gland achieved within exponential phase PCR Fig
0.27402496.12639903.html.plaintext.txt	92	Background fluorescence template control samples typically surpass Rn value 0
0.27402496.12639903.html.plaintext.txt	93	View larger version 27K Figure 1
0.27402496.12639903.html.plaintext.txt	94	Amplification restriction analysis cDNA fragments expected size 303 bp prepro orexin A 260 bp OX1 receptor B 314 bp OX2 receptor C
0.27402496.12639903.html.plaintext.txt	95	PvuII cuts prepro orexin cDNA fragments 136 167 bp fragments A
0.27402496.12639903.html.plaintext.txt	96	Alu I cuts OX1 receptor cDNA fragments four fragments 20 bp visible gel 51 bp 59 bp 130 bp B OX2 receptor cDNA fragments two fragments size 89 bp 225 bp C
0.27402496.12639903.html.plaintext.txt	97	Treatment restriction enzyme
0.27402496.12639903.html.plaintext.txt	98	M DNA size marker indicated base pairs left
0.27402496.12639903.html.plaintext.txt	99	View larger version 17K Figure 2
0.27402496.12639903.html.plaintext.txt	100	Amplification plots prepro orexin A OX1 receptor mRNA B OX2 receptor mRNA C hypothalamus pituitary adrenal gland male rats n 8
0.27402496.12639903.html.plaintext.txt	101	Fluorescence measured PCR every cycle using GeneAmp 5700 sequence detection system
0.27402496.12639903.html.plaintext.txt	102	For sample CT determined automatically Rn 0
0.27402496.12639903.html.plaintext.txt	103	No template controls H2O used estimate background amplification
0.27402496.12639903.html.plaintext.txt	104	Because pituitary adrenal significant amounts prepro orexin mRNA previously detected 20 real time PCR prepro orexin performed organs
0.27402496.12639903.html.plaintext.txt	105	Expression prepro orexin mRNA hypothalamus male female rats effect gonadectomy hormone treatment Very high mRNA levels prepro orexin found hypothalamus female Fig
0.27402496.12639903.html.plaintext.txt	106	3B rats quantitative real time PCR using CT method
0.27402496.12639903.html.plaintext.txt	107	No differences detected mRNA levels hypothalamic prepro orexin sham operated control rats gonadectomized rats treated Plac steroid treated female male rats Fig
0.27402496.12639903.html.plaintext.txt	108	View larger version 18K Figure 3
0.27402496.12639903.html.plaintext.txt	109	Effects OVX E2 treatment A ORX T treatment B hypothalamic prepro orexin mRNA levels
0.27402496.12639903.html.plaintext.txt	110	Shown means plus minus SEM n 8
0.27402496.12639903.html.plaintext.txt	111	Expression OX1 OX2 receptor mRNA female rats effect ovariectomy E2 treatment High mRNA levels OX1 OX2 receptors found hypothalamus female rats Fig
0.27402496.12639903.html.plaintext.txt	112	In pituitary gland sham operated female rats significant amounts OX1 receptor mRNA present Fig
0.27402496.12639903.html.plaintext.txt	113	4A whereas low mRNA levels OX2 receptors detected Fig
0.27402496.12639903.html.plaintext.txt	114	In adrenal gland female rats found low mRNA levels OX1 receptors high mRNA levels OX2 receptors Fig
0.27402496.12639903.html.plaintext.txt	115	View larger version 32K Figure 4
0.27402496.12639903.html.plaintext.txt	116	Effects OVX E2 treatment hypothalamic pituitary adrenal OX1 OX2 receptor mRNA levels female rats
0.27402496.12639903.html.plaintext.txt	117	Shown means plus minus SEM n 8
0.27402496.12639903.html.plaintext.txt	118	In hypothalamus female rats differences detected mRNA levels OX1 OX2 receptors sham operated control rats OVX rats OVX rats treated E2 21 d Fig
0.27402496.12639903.html.plaintext.txt	119	In pituitary gland Plac treated OVX rats OX1 receptor mRNA levels significantly higher compared Plac treated sham operated rats Fig
0.27402496.12639903.html.plaintext.txt	120	Treatment OVX rats E2 completely reversed OVX induced increase mRNA levels pituitary OX1 receptors Fig
0.27402496.12639903.html.plaintext.txt	121	As control rats low amounts OX2 receptor mRNA found pituitary glands Plac E2 treated OVX rats Fig
0.27402496.12639903.html.plaintext.txt	122	In adrenal glands substantial differences mRNA levels OX1 receptors treatment groups Fig
0.27402496.12639903.html.plaintext.txt	123	However OX2 receptor mRNA levels significantly higher Plac treated OVX rats compared Plac treated sham operated rats significantly reduced E2 treatment OVX rats Fig
0.27402496.12639903.html.plaintext.txt	124	Expression OX1 OX2 receptor mRNA male rats effect ORX T treatment OX1 OX2 receptor mRNA detected high levels hypothalamus male rats Fig
0.27402496.12639903.html.plaintext.txt	125	In pituitary gland high mRNA levels OX1 receptors low mRNA levels OX2 receptors present male rats Fig
0.27402496.12639903.html.plaintext.txt	126	In contrast low levels adrenal OX1 receptor mRNA Fig
0.27402496.12639903.html.plaintext.txt	127	5A high mRNA levels OX2 receptors detected adrenal gland male rats Fig
0.27402496.12639903.html.plaintext.txt	128	View larger version 31K Figure 5
0.27402496.12639903.html.plaintext.txt	129	Effects ORX T treatment hypothalamic pituitary adrenal OX1 OX2 receptor mRNA levels male rats
0.27402496.12639903.html.plaintext.txt	130	Shown means plus minus SEM n 8
0.27402496.12639903.html.plaintext.txt	131	No differences detected amounts OX1 OX2 receptor mRNA hypothalamus male sham operated control rats ORX rats ORX rats treated T 21 d Fig
0.27402496.12639903.html.plaintext.txt	132	Pituitary mRNA levels OX1 receptors significantly regulated mRNA levels adrenal OX2 receptors significantly regulated Plac treated ORX rats compared sham operated rats Fig
0.27402496.12639903.html.plaintext.txt	133	The effects orchidectomy pituitary adrenal glands reversed treatment ORX rats T Fig
0.27402496.12639903.html.plaintext.txt	134	No differences observed low amounts pituitary OX2 adrenal OX1 receptor mRNA treatment groups male rats Fig
0.27402496.12639903.html.plaintext.txt	135	Effect gonadectomy hormone treatment plasma hormones body weight Ovariectomy reduced subsequent treatment OVX rats E2 significantly increased plasma E2 levels Table 1
0.27402496.12639903.html.plaintext.txt	136	Plasma T levels undetectable orchidectomy restored treatment T Table 2
0.27402496.12639903.html.plaintext.txt	137	No differences plasma orexin A levels observed sham operated OVX E2 treated female rats Table 1
0.27402496.12639903.html.plaintext.txt	138	Male rats showed slight significant reduction plasma orexin A levels ORX compared sham operated rats
0.27402496.12639903.html.plaintext.txt	139	Treatment ORX rats T restored plasma orexin A levels Table 2
0.27402496.12639903.html.plaintext.txt	140	Plasma E2 concentrations plasma orexin A concentrations body weights sham operated OVX female rats treated placebo E2
0.27402496.12639903.html.plaintext.txt	141	Plasma T concentrations plasma orexin A concentrations body weights sham operated ORX male rats treated placebo T
0.27402496.12639903.html.plaintext.txt	142	Body weight significantly increased female rats ovariectomy whereas treatment E2 21 d suppressed weight gain Table 1
0.27402496.12639903.html.plaintext.txt	143	No differences body weight observed male sham operated control rats ORX rats ORX rats treated T 21 d Table 2
0.27402496.12639903.html.plaintext.txt	144	Discussion Top Abstract Introduction Materials Methods Results Discussion References We recently found profound differences mRNA levels pituitary OX1 adrenal OX2 receptors male female rats 20
0.27402496.12639903.html.plaintext.txt	145	In addition mRNA expression hypothalamic prepro orexin higher female rats 27
0.27402496.12639903.html.plaintext.txt	146	Our present results confirm expression OX1 receptors pituitary OX2 receptors adrenal gland 20 28 29 30 31
0.27402496.12639903.html.plaintext.txt	147	Furthermore show first time gonadal steroids affect mRNA expression OX1 OX2 receptors pituitary adrenal glands
0.27402496.12639903.html.plaintext.txt	148	The regulation ovariectomy regulation E2 pituitary OX1 adrenal OX2 receptors female rats accordance much lower mRNA levels receptors intact female rats compared male rats 20
0.27402496.12639903.html.plaintext.txt	149	In addition T regulated adrenal OX2 receptor mRNA male rats whereas pituitary OX1 receptor mRNA regulated
0.27402496.12639903.html.plaintext.txt	150	Thus lower pituitary OX1 receptor mRNA levels female rats 20 may explained inhibitory actions E2 female rats
0.27402496.12639903.html.plaintext.txt	151	In adrenal inhibitory actions E2 female rats stimulatory actions T male rats may contribute differences OX2 receptor mRNA levels female male rats 20
0.27402496.12639903.html.plaintext.txt	152	In addition effects energy homeostasis considerable evidence orexins regulate activity hypothalamo pituitary gonadal axis 16 22 32 33 34
0.27402496.12639903.html.plaintext.txt	153	Icv injected orexins increased plasma LH concentrations ovarian steroid treated female rats whereas untreated OVX rats plasma LH reduced initially shown Pu et al
0.27402496.12639903.html.plaintext.txt	154	This bimodal response appears part mediated GnRH orexin stimulates GnRH release hypothalamic explants male proestrous female rats 21 22
0.27402496.12639903.html.plaintext.txt	155	In addition orexin containing neurons project several hypothalamic nuclei including areas involved regulation GnRH orexin receptors present 3 4 35 36
0.27402496.12639903.html.plaintext.txt	156	However orexin receptors also present pituitary gland direct effect orexins assumed
0.27402496.12639903.html.plaintext.txt	157	In ovarian steroid treated rats stimulatory effect icv orexins pituitary LH release observed already low doses whereas high dose orexin necessary suppress release LH absence ovarian steroids 16 32
0.27402496.12639903.html.plaintext.txt	158	It could possible orexins injected icv high doses reach pituitary gland diffusion portal circulation stimulate pituitary OX1 receptors regulated absence ovarian steroids shown results
0.27402496.12639903.html.plaintext.txt	159	Although significant effect orexin basal LH release dispersed pituitary cells orexin inhibited GnRH induced release LH isolated pituitary cells proestrous female rats 22
0.27402496.12639903.html.plaintext.txt	160	Thus orexins may differentially regulate activity hypothalamo pituitary gonadal axis exerting contrary effects hypothalamus pituitary gland
0.27402496.12639903.html.plaintext.txt	161	These estrogen dependent bimodal actions orexins LH release female rats may caused regulation OX1 receptors low E2 levels
0.27402496.12639903.html.plaintext.txt	162	Such receptor dependent regulation hormone release well established peptides angiotensin II 37 38
0.27402496.12639903.html.plaintext.txt	163	In addition effect GnRH induced LH release direct actions orexin pituitary gland possible
0.27402496.12639903.html.plaintext.txt	164	Although effects orexins basal ACTH observed male female rats Samson Taylor 23 reported inhibitory effect orexins CRH stimulated ACTH release vitro
0.27402496.12639903.html.plaintext.txt	165	This finding supported localization orexin receptors human corticotrope pituitary cells 30
0.27402496.12639903.html.plaintext.txt	166	Interestingly ACTH response stress depends gonadal steroids male female rats 39 40
0.27402496.12639903.html.plaintext.txt	167	The role orexins responses remains unclear
0.27402496.12639903.html.plaintext.txt	168	However findings strong regulation pituitary OX1 receptors E2 lesser degree T imply far undefined hormonal regulation orexin actions pituitary gland male female rats
0.27402496.12639903.html.plaintext.txt	169	In adrenal gland found high mRNA levels OX2 receptors accordance previous findings also showed much higher amounts OX2 receptor mRNA male rats compared female rats 20
0.27402496.12639903.html.plaintext.txt	170	Interestingly gonadal hormones differentially affected mRNA levels adrenal OX2 receptors
0.27402496.12639903.html.plaintext.txt	171	E2 reduced mRNA levels OX2 receptors whereas T increased mRNA levels OX2 receptors
0.27402496.12639903.html.plaintext.txt	172	Therefore E2 female rats T male rats may contribute observed sex differences adrenal OX2 receptor mRNA expression
0.27402496.12639903.html.plaintext.txt	173	Inconsistent data exist regarding localization adrenal orexin receptors
0.27402496.12639903.html.plaintext.txt	174	In rats OX1 OX2 receptor like immunoreactivity found adrenal medulla cortex 28
0.27402496.12639903.html.plaintext.txt	175	In contrast quantitative PCR showed much higher levels OX2 receptor mRNA selectively localized adrenal cortex rat situ hybridization 20
0.27402496.12639903.html.plaintext.txt	176	These results supported findings Randeva et al
0.27402496.12639903.html.plaintext.txt	177	31 found OX2 receptors OX1 receptors selectively cortex human adrenals using RT PCR situ hybridization immunostaining
0.27402496.12639903.html.plaintext.txt	178	Others however described OX1 receptors cortex OX2 receptors medulla human adrenal 41
0.27402496.12639903.html.plaintext.txt	179	Because orexins stimulate adrenal glucocorticoid release rats humans 42 43 glucocorticoids play unique role energy homeostasis intriguing speculate male rats orexins may regulate glucose metabolism via regulation glucocorticoids
0.27402496.12639903.html.plaintext.txt	180	Interestingly found increased levels plasma orexin A T male rats contrast female rats plasma orexin A levels unchanged E2
0.27402496.12639903.html.plaintext.txt	181	Further experiments needed clarify possible T dependent functions adrenal orexin system
0.27402496.12639903.html.plaintext.txt	182	Thus far unclear whether rats adrenal OX2 receptors stimulated circulating orexins whether orexins locally produced adrenal gland described Randeva et al
0.27402496.12639903.html.plaintext.txt	183	The presence orexin plasma described rats humans circulating orexins may activate adrenal orexin receptors 20 44
0.27402496.12639903.html.plaintext.txt	184	Although source plasma orexins currently uncertain orexin producing neurons project median eminence may therefore contribute plasma orexins 29
0.27402496.12639903.html.plaintext.txt	185	In contrast lower mRNA levels orexin receptors pituitary adrenal glands female rats compared male rats prepro orexin OX1 receptor mRNA levels elevated hypothalamus female rats 20 27
0.27402496.12639903.html.plaintext.txt	186	In present study could reveal changes hypothalamic prepro orexin orexin receptor mRNA gonadectomy hormonal treatment male female rats
0.27402496.12639903.html.plaintext.txt	187	Our results female rats accordance findings Russell et al
0.27402496.12639903.html.plaintext.txt	188	22 showing effect estrogens hypothalamic prepro orexin mRNA female rats
0.27402496.12639903.html.plaintext.txt	189	In addition male sheep E2 affect prepro orexin mRNA levels 45
0.27402496.12639903.html.plaintext.txt	190	Thus factors may responsible observed differences male female rats may concluded central hypothalamic expression prepro orexin orexin receptors control ovarian steroids
0.27402496.12639903.html.plaintext.txt	191	However orexin receptor subtypes distinctively expressed hypothalamic nuclei 18 discrete changes orexin receptor mRNA levels specific hypothalamic nuclei might detectable analyzing whole hypothalamic extracts using RT PCR cannot completely ruled results
0.27402496.12639903.html.plaintext.txt	192	Estrogens T divergent effects food intake energy expenditure body weight plasma levels estrogens correlate positively whereas plasma levels T correlate negatively body fat mass 46
0.27402496.12639903.html.plaintext.txt	193	Our findings weight gain ovariectomy accordance previous observations 47
0.27402496.12639903.html.plaintext.txt	194	The reduced weight female rats E2 replacement may attributed somewhat higher plasma E2 levels E2 treated female rats comparison sham operated female rats 47
0.27402496.12639903.html.plaintext.txt	195	48 showed OVX could influence body weight independently food intake separately central mechanisms
0.27402496.12639903.html.plaintext.txt	196	In study regulation orexin receptors gonadal steroids appears limited peripheral organs
0.27402496.12639903.html.plaintext.txt	197	Thus peripheral orexin system particularly adrenal OX2 receptors may contribute sex specific regulations energy homeostasis
0.27402496.12639903.html.plaintext.txt	198	In summary results show E2 T differentially regulate mRNA expression pituitary OX1 adrenal OX2 receptors female male rats
0.27402496.12639903.html.plaintext.txt	199	Thus addition ability orexins regulate reproductive system sex steroids may affect actions orexins
0.27402496.12639903.html.plaintext.txt	200	Like peptides regulating energy homeostasis reproductive functions 49 orexins may play important role coordinating systems may also sex dependently influence orexin related functions like autonomic system sleeping behavior
0.27402496.12639903.html.plaintext.txt	201	Acknowledgments The authors wish thank C
0.27402496.12639903.html.plaintext.txt	202	Eichholz real time PCR assistance G
0.27402496.12639903.html.plaintext.txt	203	Footnotes Abbreviations CT Cycle threshold E2 17ss estradiol GAPDH glyceraldehyde 3 phosphate dehydrogenase icv intracerebroventricular ORX orchidectomized OVX ovariectomized OX1 orexin type 1 OX2 orexin type 2 Plac placebo Rn fluorescence threshold T testosterone
0.27402496.12639903.html.plaintext.txt	204	Accepted publication December 18 2002
0.27402496.12639903.html.plaintext.txt	205	References Top Abstract Introduction Materials Methods Results Discussion References Sakurai T Amemiya A Ishii M Matsuzaki I Chemelli RM Tanaka H Williams SC Richardson JA Kozlowski GP Wilson S Arch JR Buckingham RE Haynes AC Carr SA Annan RS McNulty DE Liu WS Terrett JA Elshourbagy NA Bergsma DJ Yanagisawa M 1998 Orexins orexin receptors family hypothalamic neuropeptides G protein coupled receptors regulate feeding behavior
0.27402496.12639903.html.plaintext.txt	206	Cell 92573 585Medline de Lecea L Kilduff TS Peyron C Gao X Foye PE Danielson PE Fukuhara C Battenberg EL Gautvik VT Bartlett FS Frankel WN van den Pol AN Bloom FE Gautvik KM Sutcliffe JG 1998 The hypocretins hypothalamus specific peptides neuroexcitatory activity
0.27402496.12639903.html.plaintext.txt	207	Proc Natl Acad Sci USA 95322 327AbstractFree Full Text Peyron C Tighe DK van den Pol AN de Lecea L Heller HC Sutcliffe JG Kilduff TS 1998 Neurons containing hypocretin orexin project multiple neuronal systems
0.27402496.12639903.html.plaintext.txt	208	J Neurosci 189996 10015AbstractFree Full Text Date Y Ueta Y Yamashita H Yamaguchi H Matsukura S Kangawa K Sakurai T Yanagisawa M Nakazato M 1999 Orexins orexigenic hypothalamic peptides interact autonomic neuroendocrine neuroregulatory systems
0.27402496.12639903.html.plaintext.txt	209	Proc Natl Acad Sci USA 96748 753AbstractFree Full Text van den Pol AN 1999 Hypothalamic hypocretin orexin robust innervation spinal cord
0.27402496.12639903.html.plaintext.txt	210	J Neurosci 193171 3182AbstractFree Full Text Harrison TA Chen CT Dun NJ Chang JK 1999 Hypothalamic orexin A immunoreactive neurons project rat dorsal medulla
0.27402496.12639903.html.plaintext.txt	211	Neurosci Lett 27317 20CrossRefMedline Cutler DJ Morris R Sheridhar V Wattam TA Holmes S Patel S Arch JR Wilson S Buckingham RE Evans ML Leslie RA Williams G 1999 Differential distribution orexin A orexin B immunoreactivity rat brain spinal cord
0.27402496.12639903.html.plaintext.txt	212	Peptides 201455 1470CrossRefMedline Samson WK Gosnell B Chang JK Resch ZT Murphy TC 1999 Cardiovascular regulatory actions hypocretins brain
0.27402496.12639903.html.plaintext.txt	213	Brain Res 831248 253CrossRefMedline Shirasaka T Nakazato M Matsukura S Takasaki M Kannan H 1999 Sympathetic cardiovascular actions orexins conscious rats
0.27402496.12639903.html.plaintext.txt	214	Am J Physiol 277R1780 R1785 Lin L Faraco J Li R Kadotani H Rogers W Lin X Qiu X de Jong PJ Nishino S Mignot E 1999 The sleep disorder canine narcolepsy caused mutation hypocretin orexin receptor 2 gene
0.27402496.12639903.html.plaintext.txt	215	Cell 98365 376Medline Chemelli RM Willie JT Sinton CM Elmquist JK Scammell T Lee C Richardson JA Williams SC Xiong Y Kisanuki Y Fitch TE Nakazato M Hammer RE Saper CB Yanagisawa M 1999 Narcolepsy orexin knockout mice molecular genetics sleep regulation
0.27402496.12639903.html.plaintext.txt	216	Cell 98437 451Medline Peyron C Faraco J Rogers W Ripley B Overeem S Charnay Y Nevsimalova S Aldrich M Reynolds D Albin R Li R Hungs M Pedrazzoli M Padigaru M Kucherlapati M Fan J Maki R Lammers GJ Bouras C Kucherlapati R Nishino S Mignot E 2000 A mutation case early onset narcolepsy generalized absence hypocretin peptides human narcoleptic brains
0.27402496.12639903.html.plaintext.txt	217	Nat Med 6991 997CrossRefMedline Hagan JJ Leslie RA Patel S Evans ML Wattam TA Holmes S Benham CD Taylor SG Routledge C Hemmati P Munton RP Ashmeade TE Shah AS Hatcher JP Hatcher PD Jones DN Smith MI Piper DC Hunter AJ Porter RA Upton N 1999 Orexin A activates locus coeruleus cell firing increases arousal rat
0.27402496.12639903.html.plaintext.txt	218	Proc Natl Acad Sci USA 9610911 10916AbstractFree Full Text Ida T Nakahara K Murakami T Hanada R Nakazato M Murakami N 2000 Possible involvement orexin stress reaction rats
0.27402496.12639903.html.plaintext.txt	219	Biochem Biophys Res Commun 270318 323CrossRefMedline Kuru M Ueta Y Serino R Nakazato M Yamamoto Y Shibuya I Yamashita H 2000 Centrally administered orexinhypocretin activates HPA axis rats
0.27402496.12639903.html.plaintext.txt	220	Neuroreport 111977 1980Medline Pu S Jain MR Kalra PS Kalra SP 1998 Orexins novel family hypothalamic neuropeptides modulate pituitary luteinizing hormone secretion ovarian steroid dependent manner
0.27402496.12639903.html.plaintext.txt	221	Regul Pept 78133 136CrossRefMedline Trivedi P Yu H MacNeil DJ Van der Ploeg LH Guan XM 1998 Distribution orexin receptor mRNA rat brain
0.27402496.12639903.html.plaintext.txt	222	FEBS Lett 43871 75CrossRefMedline Marcus JN Aschkenasi CJ Lee CE Chemelli RM Saper CB Yanagisawa M Elmquist JK 2001 Differential expression orexin receptors 1 2 rat brain
0.27402496.12639903.html.plaintext.txt	223	J Comp Neurol 4356 25CrossRefMedline Nambu T Sakurai T Mizukami K Hosoya Y Yanagisawa M Goto K 1999 Distribution orexin neurons adult rat brain
0.27402496.12639903.html.plaintext.txt	224	Brain Res 827243 260CrossRefMedline Johren O Neidert SJ Kummer M Dendorfer A Dominiak P 2001 Prepro orexin orexin receptor mRNAs differentially expressed peripheral tissues male female rats
0.27402496.12639903.html.plaintext.txt	225	Endocrinology 1423324 3331AbstractFree Full Text Russell SH Kim MS Small CJ Abbott CR Morgan DG Taheri S Murphy KG Todd JF Ghatei MA Bloom SR 2000 Central administration orexin A suppresses basal domperidone stimulated plasma prolactin
0.27402496.12639903.html.plaintext.txt	226	J Neuroendocrinol 121213 1218CrossRefMedline Russell SH Small CJ Kennedy AR Stanley SA Seth A Murphy KG Taheri S Ghatei MA Bloom SR 2001 Orexin A interactions hypothalamo pituitary gonadal axis
0.27402496.12639903.html.plaintext.txt	227	Endocrinology 1425294 5302AbstractFree Full Text Samson WK Taylor MM 2001 Hypocretinorexin suppresses corticotroph responsiveness vitro
0.27402496.12639903.html.plaintext.txt	228	Am J Physiol Regul Integr Comp Physiol 281R1140 R1145 Palkovits M Brownstein MJ 1988 Maps guide microdissection rat brain
0.27402496.12639903.html.plaintext.txt	229	New York Elsevier Tso JY Sun XH Kao TH Reece KS Wu R 1985 Isolation characterization rat human glyceraldehyde 3 phosphate dehydrogenase cDNAs genomic complexity molecular evolution gene
0.27402496.12639903.html.plaintext.txt	230	Nucleic Acids Res 132485 2502Abstract Higuchi R Fockler C Dollinger G Watson R 1993 Kinetic PCR analysis real time monitoring DNA amplification reactions
0.27402496.12639903.html.plaintext.txt	231	Biotechnology 111026 1030Medline Johren O Neidert SJ Kummer M Dominiak P 2002 Sexually dimorphic expression prepro orexin mRNA rat hypothalamus
0.27402496.12639903.html.plaintext.txt	232	Peptides 231177 1180CrossRefMedline Lopez M Senaris R Gallego R Garcia Caballero T Lago F Seoane L Casanueva F Dieguez C 1999 Orexin receptors expressed adrenal medulla rat
0.27402496.12639903.html.plaintext.txt	233	Endocrinology 1405991 5994AbstractFree Full Text Date Y Mondal MS Matsukura S Ueta Y Yamashita H Kaiya H Kangawa K Nakazato M 2000 Distribution orexinhypocretin rat median eminence pituitary
0.27402496.12639903.html.plaintext.txt	234	Brain Res Mol Brain Res 761 6Medline Blanco M Lopez M Garcia Caballero T Gallego R Vazquez Boquete A Morel G Senaris R Casanueva F Dieguez C Beiras A 2001 Cellular localization orexin receptors human pituitary
0.27402496.12639903.html.plaintext.txt	235	J Clin Endocrinol Metab 861616 1619AbstractFree Full Text Randeva HS Karteris E Grammatopoulos D Hillhouse EW 2001 Expression orexin A functional orexin type 2 receptors human adult adrenals implications adrenal function energy homeostasis
0.27402496.12639903.html.plaintext.txt	236	J Clin Endocrinol Metab 864808 4813AbstractFree Full Text Tamura T Irahara M Tezuka M Kiyokawa M Aono T 1999 Orexins orexigenic hypothalamic neuropeptides suppress pulsatile secretion luteinizing hormone ovariectomized female rats
0.27402496.12639903.html.plaintext.txt	237	Biochem Biophys Res Commun 264759 762CrossRefMedline Kohsaka A Watanobe H Kakizaki Y Suda T Schioth HB 2001 A significant participation orexin A potent orexigenic peptide preovulatory luteinizing hormone prolactin surges rat
0.27402496.12639903.html.plaintext.txt	238	Brain Res 898166 170CrossRefMedline Furuta M Funabashi T Kimura F 2002 Suppressive action orexin A pulsatile luteinizing hormone secretion potentiated low dose estrogen ovariectomized rats
0.27402496.12639903.html.plaintext.txt	239	Neuroendocrinology 75151 157CrossRefMedline van den Pol AN Gao XB Obrietan K Kilduff TS Belousov AB 1998 Presynaptic postsynaptic actions modulation neuroendocrine neurons new hypothalamic peptide hypocretinorexin
0.27402496.12639903.html.plaintext.txt	240	J Neurosci 187962 7971AbstractFree Full Text Iqbal J Pompolo S Sakurai T Clarke IJ 2001 Evidence orexin containing neurones provide direct input gonadotropin releasing hormone neurones ovine hypothalamus
0.27402496.12639903.html.plaintext.txt	241	J Neuroendocrinol 131033 1041CrossRefMedline Steele MK McCann SM Negro Vilar A 1982 Modulation dopamine estradiol central effects angiotensin II anterior pituitary hormone release
0.27402496.12639903.html.plaintext.txt	242	Endocrinology 111722 729Medline Johren O Sanvitto GL Egidy G Saavedra JM 1997 Angiotensin II AT1A receptor mRNA expression induced estrogen progesterone dopaminergic neurons female rat arcuate nucleus
0.27402496.12639903.html.plaintext.txt	243	J Neurosci 178283 8292AbstractFree Full Text Viau V Meaney MJ 1991 Variations hypothalamic pituitary adrenal response stress estrous cycle rat
0.27402496.12639903.html.plaintext.txt	244	Endocrinology 1292503 2511Abstract Handa RJ Nunley KM Lorens SA Louie JP McGivern RF Bollnow MR 1994 Androgen regulation adrenocorticotropin corticosterone secretion male rat following novelty foot shock stressors
0.27402496.12639903.html.plaintext.txt	245	Physiol Behav 55117 124CrossRefMedline Blanco M Garcia Caballero T Fraga M Gallego R Cuevas J Forteza J Beiras A Dieguez C 2002 Cellular localization orexin receptors human adrenal gland adrenocortical adenomas pheochromocytomas
0.27402496.12639903.html.plaintext.txt	246	Regul Pept 104161 165CrossRefMedline Malendowicz LK Tortorella C Nussdorfer GG 1999 Orexins stimulate corticosterone secretion rat adrenocortical cells activation adenylate cyclase dependent signaling cascade
0.27402496.12639903.html.plaintext.txt	247	J Steroid Biochem Mol Biol 70185 188CrossRefMedline Mazzocchi G Malendowicz LK Gottardo L Aragona F Nussdorfer GG 2001 Orexin A stimulates cortisol secretion human adrenocortical cells activation adenylate cyclase dependent signaling cascade
0.27402496.12639903.html.plaintext.txt	248	J Clin Endocrinol Metab 86778 782AbstractFree Full Text Arihara Z Takahashi K Murakami O Totsune K Sone M Satoh F Ito S Mouri T 2001 Immunoreactive orexin A human plasma
0.27402496.12639903.html.plaintext.txt	249	Peptides 22139 142CrossRefMedline Archer ZA Findlay PA Rhind SM Mercer JG Adam CL 2002 Orexin gene expression regulation photoperiod sheep hypothalamus
0.27402496.12639903.html.plaintext.txt	250	Regul Pept 10441 45CrossRefMedline Mystkowski P Schwartz MW 2000 Gonadal steroids energy homeostasis leptin era
0.27402496.12639903.html.plaintext.txt	251	Nutrition 16937 946CrossRefMedline Wade GN 1975 Some effects ovarian hormones food intake body weight female rats
0.27402496.12639903.html.plaintext.txt	252	J Comp Physiol Psychol 88183 193Medline Bernardis LL Bellinger LL Goldman JK MacKenzie R 1981 Dorsomedial hypothalamic lesions weaning ovariectomy maturity somatic metabolic changes
0.27402496.12639903.html.plaintext.txt	253	Physiol Behav 2691 98CrossRefMedline Kalra SP Kalra PS 1996 Nutritional infertility role interconnected hypothalamic neuropeptide Y galanin opioid network
0.27402496.12639903.html.plaintext.txt	254	Front Neuroendocrinol 17371 401CrossRefMedline
0.20402655.11147774.html.plaintext.txt	0	Hypoglycemia Activates Orexin Neurons Selectively Increases Hypothalamic Orexin B Levels Responses Inhibited Feeding Possibly Mediated Nucleus Solitary Tract Xue J
0.20402655.11147774.html.plaintext.txt	1	Arch Shelagh Wilson Gareth Williams
0.20402655.11147774.html.plaintext.txt	2	From Diabetes Endocrinology Research Group X
0.20402655.11147774.html.plaintext.txt	3	University Liverpool Liverpool Divisions Neuroscience M
0.20402655.11147774.html.plaintext.txt	4	SmithKline Beecham Pharmaceuticals Harlow U
0.20402655.11147774.html.plaintext.txt	5	Address correspondence reprint requests Dr
0.20402655.11147774.html.plaintext.txt	6	Xue J Cai Diabetes Endocrinology Research Unit University Liverpool Liverpool L69 3GA U
0.20402655.11147774.html.plaintext.txt	7	ABSTRACT TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES Orexins novel appetite stimulating peptides expressed lateral hypothalamic area LHA expression stimulated hypoglycemia fasted rats
0.20402655.11147774.html.plaintext.txt	8	We investigated activation orexin neurons insulin induced hypoglycemia using immediate early gene product Fos
0.20402655.11147774.html.plaintext.txt	9	Insulin 50 Ukg lowered plasma glucose 50 5 h stimulated feeding sixfold compared saline injected controls
0.20402655.11147774.html.plaintext.txt	10	Hypoglycemic rats allowed feed normoglycemic controls showed sparse Fos positive Fos neurons LHA paraventricular nucleus PVN arcuate nucleus ARC showed none nucleus solitary tract NTS relays visceral feeding signals LHA
0.20402655.11147774.html.plaintext.txt	11	In LHA total numbers Fos neurons comparable fed hypoglycemic control groups 60 plus minus 6 vs
0.20402655.11147774.html.plaintext.txt	12	52 plus minus 4 cellsmm2 P 0
0.20402655.11147774.html.plaintext.txt	13	05 Fos neurons immunoreactive orexin 1
0.20402655.11147774.html.plaintext.txt	14	By contrast hypoglycemic rats fasted showed significantly Fos nuclei LHA 96 plus minus 10 cellsmm2 P 0
0.20402655.11147774.html.plaintext.txt	15	groups Fos orexin neurons 8
0.20402655.11147774.html.plaintext.txt	16	They also showed two threefold Fos nuclei P 0
0.20402655.11147774.html.plaintext.txt	17	001 PVN ARC fed hypoglycemic rats controls showed strikingly abundant Fos neurons NTS dorsal motor nucleus vagus
0.20402655.11147774.html.plaintext.txt	18	In parallel studies whole hypothalamic orexin A levels changed hypoglycemic rats whether fasted freely fed whereas orexin B levels 10 fold higher hypoglycemic fasted rats control hypoglycemic fed groups
0.20402655.11147774.html.plaintext.txt	19	These data support hypothesis orexin neurons stimulated falling glucose levels readily inhibited signals related nutrient ingestion suggest may functionally link neuronal activity NTS
0.20402655.11147774.html.plaintext.txt	20	Orexin A B may play specific roles behavioral neuroendocrine responses hypoglycemia
0.20402655.11147774.html.plaintext.txt	21	INTRODUCTION TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES The lateral hypothalamic area LHA important overall regulation feeding behavior body weight 1
0.20402655.11147774.html.plaintext.txt	22	Specifically crucial intense hunger caused hypoglycemia
0.20402655.11147774.html.plaintext.txt	23	Eating one component concerted metabolic response mounted restore normal blood glucose levels
0.20402655.11147774.html.plaintext.txt	24	Lesions LHA abolish hyperphagic response hypoglycemia induced insulin 2 also neuroglycopenia caused 2 deoxyglucose 3
0.20402655.11147774.html.plaintext.txt	25	The neurochemical identities LHA neurons pathways mediate hypoglycemia induced hyperphagia remain uncertain
0.20402655.11147774.html.plaintext.txt	26	The LHA contains glucose sensitive neurons stimulated hypoglycemia account 25 LHA neurons 45
0.20402655.11147774.html.plaintext.txt	27	Hypoglycemia mainly activates LHA glucose sensitive neurons indirectly 6 pathways ascending brainstem thought particularly important
0.20402655.11147774.html.plaintext.txt	28	These include projection nucleus solitary tract NTS 78 relays information vagal afferents including glucoreceptors gut liver 9
0.20402655.11147774.html.plaintext.txt	29	About 75 recorded NTS neurons respond altered electrical activity blood glucose fluctuations within physiological range 10
0.20402655.11147774.html.plaintext.txt	30	Recent evidence suggests LHA neurons respond hypoglycemia express peptides known orexins 11 hypocretins 12
0.20402655.11147774.html.plaintext.txt	31	The hypocretins sequences similar longer orexins
0.20402655.11147774.html.plaintext.txt	32	Hypocretin 1 includes orexin A sequence five extra amino acids NH2 terminus one COOH terminus whereas hypocretin 2 one extra residue COOH terminus orexin B sequence 12
0.20402655.11147774.html.plaintext.txt	33	Orexin A B 33 28 residue peptides respectively derived prepro orexin 13 named ability stimulate feeding injected intracerebroventricularly LHA 13141516171819
0.20402655.11147774.html.plaintext.txt	34	Orexins expressed solely neuronal population restricted perifornical LHA zona incerta 2021222324
0.20402655.11147774.html.plaintext.txt	35	This region reciprocal connections numerous hypothalamic extrahypothalamic structures involved feeding behavior including hypothalamic paraventricular nucleus PVN arcuate nucleus ARC NTS 2024
0.20402655.11147774.html.plaintext.txt	36	We others previously showed hypothalamic pre pro orexin mRNA levels increased prolonged fasting insulin induced hypoglycemia food available 1325
0.20402655.11147774.html.plaintext.txt	37	We suggested orexin neurons stimulated falling blood glucose levels inhibited food ingestion might participate regulation short term feeding behavior 25
0.20402655.11147774.html.plaintext.txt	38	It clear orexin neurons previously identified containing prolactin like immunoreactivity known activated hypoglycemia 26
0.20402655.11147774.html.plaintext.txt	39	Here explored relationship hypoglycemia food intake orexin neuronal activation possible mediatory role NTS
0.20402655.11147774.html.plaintext.txt	40	We induced acute 5 h hypoglycemia insulin groups rats either allowed eat freely fasted throughout
0.20402655.11147774.html.plaintext.txt	41	We first used early response gene marker Fos map neuronal activation LHA PVN ARC NTS together immunohistochemical identification orexin neurons
0.20402655.11147774.html.plaintext.txt	42	In parallel experiment used specific radioimmunoassays measure changes whole hypothalamic orexin A B concentrations experimental conditions
0.20402655.11147774.html.plaintext.txt	43	RESEARCH DESIGN AND METHODS TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES Experiment 1
0.20402655.11147774.html.plaintext.txt	44	Eighteen adult male Wistar rats housed singly environmentally controlled conditions 22 plus minus 2 degrees C humidity 40 60 12 h lightdark cycle lights 0800 habituated 1 week frequent handling daily weighing food intake measurements
0.20402655.11147774.html.plaintext.txt	45	They allowed free access standard laboratory pelleted rodent diet CRM Biosure Cambridge U
0.20402655.11147774.html.plaintext.txt	46	except 5 h experimental period described tap water freely available throughout
0.20402655.11147774.html.plaintext.txt	47	Each rat received saline injection 0
0.20402655.11147774.html.plaintext.txt	48	2 ml intraperitoneally 0900 daily 3 days study
0.20402655.11147774.html.plaintext.txt	49	Two groups n 6 given intermediate duration insulin 50 Ukg Insulatard intraperitoneally 0900 induce hypoglycemia previous study 25
0.20402655.11147774.html.plaintext.txt	50	One hypoglycemic group allowed feed freely whereas food deprived
0.20402655.11147774.html.plaintext.txt	51	The third group euglycemic controls received volume saline intraperitoneally allowed eat freely n 6
0.20402655.11147774.html.plaintext.txt	52	The study terminated 5 h injection food intake measured rats allowed eat
0.20402655.11147774.html.plaintext.txt	53	The rats killed tissue prepared immunohistochemistry
0.20402655.11147774.html.plaintext.txt	54	The rats deeply anesthetized lethal dose HypnormHypnovel 3 mgkg blood collected centrifuged
0.20402655.11147774.html.plaintext.txt	55	Plasma stored assayed plasma glucose using autoanalyzer glucose oxidase method Yellow Springs Instruments Yellow Springs OH
0.20402655.11147774.html.plaintext.txt	56	The rats perfused transcardially 0
0.20402655.11147774.html.plaintext.txt	57	9 saline containing heparin 20 Uml followed ice cold fixative solution containing 4 paraformaldehyde 0
0.20402655.11147774.html.plaintext.txt	58	01 moll phosphate buffered saline PBS
0.20402655.11147774.html.plaintext.txt	59	Brains removed post fixed overnight immersion fixative cryoprotected 0
0.20402655.11147774.html.plaintext.txt	60	5 moll sucrose 24 h 4 degrees C
0.20402655.11147774.html.plaintext.txt	61	Brains rapidly frozen dry ice cooled isopentane sliced 50 microm coronal sections cryostat 23 degrees C
0.20402655.11147774.html.plaintext.txt	62	Free floating sections rinsed several times stored immunobuffer 0
0.20402655.11147774.html.plaintext.txt	63	A preliminary study using chromogenic double labeling detection Fos orexin immunoreactivities
0.20402655.11147774.html.plaintext.txt	64	avidin biotin complex plus diaminobenzidine Fos Vector blue alkaline phosphatase detection orexin cases allow us determine whether Fos positive Fos nuclear profiles lay within orexin containing cells especially cell bodies strongly orexin positive
0.20402655.11147774.html.plaintext.txt	65	To overcome difficulty developed fluorescent double labeling protocol similar used others study colocalization receptors Fos neurons 27
0.20402655.11147774.html.plaintext.txt	66	This technique demonstrated patterns Fos orexin immunoreactivities identical obtained using chromogenic detection similar previous reports 2829
0.20402655.11147774.html.plaintext.txt	67	The fluorescence method combination confocal analysis proved powerful histochemical detection methods revealed greater subcellular three dimensional 3 D detail
0.20402655.11147774.html.plaintext.txt	68	In particular could interrogate confocal 3 D volume cases association Fos orexin ambiguous see Image analysis
0.20402655.11147774.html.plaintext.txt	69	Fluorescence double labeling performed every fifth frontal section hypothalamic region contained orexin neurons every tenth frontal section medulla level NTS
0.20402655.11147774.html.plaintext.txt	70	Sections rinsed three times immunobuffer incubation avidin D solution followed biotin solution Vector Laboratories Burlingame CA block endogenous biotin binding sites
0.20402655.11147774.html.plaintext.txt	71	The sections incubated overnight polyclonal sheep anti Fos antibody 13000 Genosys Cambridge U
0.20402655.11147774.html.plaintext.txt	72	2 h biotin SP conjugated donkey anti sheep IgG 1500 Jackson ImmunoResearch West Grove PA followed Alexa 488 conjugated NeutrAvidin 11000 Molecular Probes Eugene OR 2 h
0.20402655.11147774.html.plaintext.txt	73	Sections next incubated overnight rabbit polyclonal antibody partial sequence amino acids 14 33 orexin A 11000 raised house SmithKline Beecham reported 29 followed Cy5 conjugated donkey anti rabbit IgG 1400 Jackson ImmunoResearch 2 h
0.20402655.11147774.html.plaintext.txt	74	Before incubation sections washed thoroughly three times 10 min immunobuffer
0.20402655.11147774.html.plaintext.txt	75	All incubations room temperature
0.20402655.11147774.html.plaintext.txt	76	Finally sections mounted cover slips Citifluor Citifluor London U
0.20402655.11147774.html.plaintext.txt	77	sealed stored 4 degrees C
0.20402655.11147774.html.plaintext.txt	78	The specificity anti orexin serum tested preincubating primary antiserum excess synthetic orexin A 50 microgml 2 h use omitting primary antiserum incubation steps
0.20402655.11147774.html.plaintext.txt	79	In cases selective staining cell profiles abolished 29
0.20402655.11147774.html.plaintext.txt	80	To test specificity Fos antiserum primary antiserum omitted incubation procedure resulted selective immunostaining
0.20402655.11147774.html.plaintext.txt	81	Fluorescence double labeling visualized using laser scanning confocal microscope Leica TCS SP Leica Heidelberg Germany
0.20402655.11147774.html.plaintext.txt	82	Alexa 488 excited 488 nm laser line emitted light collected 540 plus minus 35 nm reveal Fos immunoreactivity
0.20402655.11147774.html.plaintext.txt	83	Cy5 excited using 633 nm laser line emitted light collected 675 plus minus 35 nm reveal orexin immunoreactivity
0.20402655.11147774.html.plaintext.txt	84	With arrangement cross talk observed detection channels scanning detection Alexa 488 Cy5 performed simultaneously
0.20402655.11147774.html.plaintext.txt	85	For region analyzed series 8 12 optical sections intervals 1
0.20402655.11147774.html.plaintext.txt	86	2 microm examined generate brightest point projection single image containing Fos orexin immunoreactivity
0.20402655.11147774.html.plaintext.txt	87	For LHA Fos nuclei counted categorized whether lay within orexin containing neuronal cell body cases coincidence ambiguous 3 D volume image constructed rotated clarify relationship
0.20402655.11147774.html.plaintext.txt	88	Counts expressed number nuclei per 500 x 500 microm square field bounded medially fornix extending laterally toward internal capsule dorsally toward zona incerta
0.20402655.11147774.html.plaintext.txt	89	For PVN dorsomedial hypothalamic nucleus DMN ARC sections similarly imaged Fos nuclei counted identified anatomical areas contained within 1000 x 1000 microm square field
0.20402655.11147774.html.plaintext.txt	90	Results expressed means plus minus SE nucleimm2 bilaterally 8 10 sections animal
0.20402655.11147774.html.plaintext.txt	91	Brainstem sections examined dark field using dissecting microscope Leica FL3 determine rostrocaudal level relative Bregma according atlas Paxinos Watson 30
0.20402655.11147774.html.plaintext.txt	92	Sections first viewed using differential interference contrast Leica DMR Leica Heidelberg Germany identify neuroanatomical boundaries viewed fluorescence mode count Fos nuclei
0.20402655.11147774.html.plaintext.txt	93	Using DIC boundary NTS dorsal motor nucleus vagus DMNX identified larger cell bodies DMNX
0.20402655.11147774.html.plaintext.txt	94	Separate counts made DMNX NTS expressed total numbers smaller areas
0.20402655.11147774.html.plaintext.txt	95	Three groups Sprague Dawley rats n 8 given treatment experiment 1 killed 6 h injection
0.20402655.11147774.html.plaintext.txt	96	The hypothalamus immediately dissected en bloc binocular microscope frontal slice fresh unfixed brain tissue optic chiasm mammillary bodies cutting horizontally anterior commissure vertically perihypothalamic sulci 31
0.20402655.11147774.html.plaintext.txt	97	The hypothalamus boiled 0
0.20402655.11147774.html.plaintext.txt	98	1 moll hydrochloric acid 10 min extract peptides supernatant kept 80 degrees C assayed protein concentrations BCA protein assay kit Pierce Rockford IL orexins
0.20402655.11147774.html.plaintext.txt	99	Hypothalamic orexin A B levels measured using commercially available radioimmunoassay kits Peninsula Laboratories San Carlos CA
0.20402655.11147774.html.plaintext.txt	100	Neither orexin A B assay significant cross reactivity neuropeptide Y NPY melanocyte stimulating hormone major neuropeptides orexin A B assays significant cross reactivity
0.20402655.11147774.html.plaintext.txt	101	The orexin A antiserum cross react mouse hypocretin 1 whereas cross reactivity orexin B anti serum mouse hypocretin 2 100
0.20402655.11147774.html.plaintext.txt	102	The within assay coefficient variation orexin A 5
0.20402655.11147774.html.plaintext.txt	103	Data expressed means plus minus SE analyzed two way analysis variance followed Students test
0.20402655.11147774.html.plaintext.txt	104	RESULTS TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES Hypoglycemia hyperphagia
0.20402655.11147774.html.plaintext.txt	105	Saline treated controls terminal blood glucose concentrations 9
0.20402655.11147774.html.plaintext.txt	106	5 mmoll whereas insulin injection induced profound hypoglycemia severe insulin treated rats allowed feed Table 1
0.20402655.11147774.html.plaintext.txt	107	Hypoglycemia markedly stimulated feeding sixfold 5 h period P 0
0.20402655.11147774.html.plaintext.txt	108	Orexin Fos immunoreactivities LHA neurons
0.20402655.11147774.html.plaintext.txt	109	Orexin immunoreactive cell bodies seen LHA confined peri subfornical distribution previously reported 2021222324
0.20402655.11147774.html.plaintext.txt	110	The cell bodies spheroidal elongated orexin immunoreactive fibers found PVN LHA ARC median eminence
0.20402655.11147774.html.plaintext.txt	111	Numbers cell bodies immunoreactive orexin different among euglycemic rats hypoglycemic rats either fasted freely fed Fig
0.20402655.11147774.html.plaintext.txt	112	View larger version 91K FIG
0.20402655.11147774.html.plaintext.txt	113	Photomicrographs showing Fos orexin neurons LHA saline control A insulin treated rats either hypoglycemic freely fed B hypoglycemic fasted C
0.20402655.11147774.html.plaintext.txt	114	Fos appears green fluorescence nucleus whereas orexin A appears red fluorescence cytoplasm
0.20402655.11147774.html.plaintext.txt	115	Arrows indicate representative neurons coincident Fos orexin labeling
0.20402655.11147774.html.plaintext.txt	116	Fos distribution induced hypoglycemia previous report 28
0.20402655.11147774.html.plaintext.txt	117	In euglycemic rats Fos immunoreactivity confined nucleus seen occasional cells thalamus hypothalamus notably PVN LHA DMN ARC Fig
0.20402655.11147774.html.plaintext.txt	118	In hypoglycemic fed rats numbers Fos immunoreactive neurons LHA slightly significantly higher vehicle treated controls whereas hypoglycemic fasted rats significantly Fos nuclei groups nearly twice many controls P 0
0.20402655.11147774.html.plaintext.txt	119	View larger version 210K FIG
0.20402655.11147774.html.plaintext.txt	120	Photomicrographs Fos staining hypothalamic areas hypoglycemic rats fasted 5 h
0.20402655.11147774.html.plaintext.txt	121	A Lateral hypothalamus area LH B paraventricular hypothalamic nucleus PVN C ARC D dorsal medial hypothalamic nucleus DMN 3V third ventricle f fornix
0.20402655.11147774.html.plaintext.txt	122	View table TABLE 2
0.20402655.11147774.html.plaintext.txt	123	Double labeling showed sparse Fos nuclei belonged orexin neurons controls hypoglycemic fed rats 1
0.20402655.11147774.html.plaintext.txt	124	1 Fos nuclei respectively 0
0.20402655.11147774.html.plaintext.txt	125	7 orexin cells control hypoglycemic fed rats included Fos nucleus
0.20402655.11147774.html.plaintext.txt	126	However coincidence Fos orexin significantly increased hypoglycemic rats allowed eat compared control freely fed hypoglycemic rats Table 2 Fig
0.20402655.11147774.html.plaintext.txt	127	8 Fos nuclei belonged orexin neurons whereas 13
0.20402655.11147774.html.plaintext.txt	128	Controls fed hypoglycemic rats comparable low numbers Fos cells ARC Table 2
0.20402655.11147774.html.plaintext.txt	129	In hypoglycemic rats fasted numbers Fos nuclei ARC significantly increased 2 fold 1
0.20402655.11147774.html.plaintext.txt	130	5 fold compared controls hypoglycemic fed rats respectively P 0
0.20402655.11147774.html.plaintext.txt	131	Similarly Fos cells PVN increased 1
0.20402655.11147774.html.plaintext.txt	132	5 fold 2 fold respectively P 0
0.20402655.11147774.html.plaintext.txt	133	0001 hypoglycemic fasted rats compared control hypoglycemic fed groups Table 2
0.20402655.11147774.html.plaintext.txt	134	Neither euglycemic controls freely fed hypoglycemic rats showed Fos neurons NTS whereas hypoglycemic fasted rats abundant Fos cells NTS
0.20402655.11147774.html.plaintext.txt	135	Fos nuclei observed several subregions NTS including region C2 adrenergic cell complex ventral portion commissural NTS sparser distribution near border area postrema
0.20402655.11147774.html.plaintext.txt	136	Fos nuclei also strikingly abundant dorsal motor nucleus vagus DMNX area adjacent NTS rostro caudal level extending 12
0.20402655.11147774.html.plaintext.txt	137	Labeled cell counts brain stem shown Table 3 Fig
0.20402655.11147774.html.plaintext.txt	138	View larger version 109K FIG
0.20402655.11147774.html.plaintext.txt	139	Photomicrographs showing Fos expression NTS DMNX saline control A hypoglycemic rats freely fed B food deprived C F
0.20402655.11147774.html.plaintext.txt	140	Images A B C taken levels approximating Bregma 12
0.20402655.11147774.html.plaintext.txt	141	Images D E F taken levels approximating Bregma 12
0.20402655.11147774.html.plaintext.txt	142	4V fourth ventricle CC central canal
0.20402655.11147774.html.plaintext.txt	143	View table TABLE 3
0.20402655.11147774.html.plaintext.txt	144	Orexin A B concentrations hypothalamus
0.20402655.11147774.html.plaintext.txt	145	Orexin A B detected hypothalamic extracts rats
0.20402655.11147774.html.plaintext.txt	146	In controls orexin A levels approximately twice high orexin B levels P 0
0.20402655.11147774.html.plaintext.txt	147	Compared euglycemic rats orexin A levels changed hypoglycemic rats whether freely fed fasted throughout Fig
0.20402655.11147774.html.plaintext.txt	148	Orexin B concentrations hypoglycemic freely fed rats comparable controls
0.20402655.11147774.html.plaintext.txt	149	Notably however hypothalamic orexin B concentrations raised fasted hypoglycemic rats 10 fold higher groups P 0
0.20402655.11147774.html.plaintext.txt	150	View larger version 17K FIG
0.20402655.11147774.html.plaintext.txt	151	Hypothalamic orexin A B saline treated controls insulin treated rats
0.20402655.11147774.html.plaintext.txt	152	Data means plus minus SE
0.20402655.11147774.html.plaintext.txt	153	DISCUSSION TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES The LHA one several brain regions cooperates control energy homeostasis previously regarded feeding center lesions cause sustained decrease food intake profound weight loss 1
0.20402655.11147774.html.plaintext.txt	154	The LHA contains distinct neuronal populations express specific appetite stimulating neurotransmitters including orexins melanin concentrating hormone MCH 32 also site projection neurons release orexigenic neurotransmitters notably NPY neurons ARC 33
0.20402655.11147774.html.plaintext.txt	155	The LHA appears crucial mediating intense hyperphagia induced blood glucose levels fall hypoglycemic range LHA lesions abolish selectively without impairing hyperphagic response conditions fasting 2
0.20402655.11147774.html.plaintext.txt	156	Previous studies group others 112534 indicate prepro orexin expression LHA neurons stimulated profound hypoglycemia suggesting increased release appetite stimulating orexin A could contribute hypoglycemia induced hyperphagia
0.20402655.11147774.html.plaintext.txt	157	Interestingly prepro orexin expression increase hypoglycemic rats either free access food 25 given glucose infusion maintain euglycemia 34
0.20402655.11147774.html.plaintext.txt	158	Prepro orexin expression also increased rats fasted 48 h others food restricted several days produce weight loss comparable 48 h starvation several conditions increased hunger including insulin deficient diabetes provision highly palatable diet 25
0.20402655.11147774.html.plaintext.txt	159	Here demonstrated activation orexin neurons significantly increased 5 h insulin injection profoundly hypoglycemic rats allowed eat whereas increases found hypoglycemic rats allowed free access food
0.20402655.11147774.html.plaintext.txt	160	These findings parallel previous studies prepro orexin expression support suggestion orexin neurons stimulated falling glucose inhibited feeding related signals 25
0.20402655.11147774.html.plaintext.txt	161	Prandial signals hypoglycemic rats ate could include presence food gut e
0.20402655.11147774.html.plaintext.txt	162	gastric stretch receptors increases glucose nutrients hepatic portal circulation
0.20402655.11147774.html.plaintext.txt	163	However clear whether orexin neurons respond directly changes local glucose availability case certain neurons ventromedial hypothalamus NTS 1035 whether modulating signals relayed indirectly LHA 6
0.20402655.11147774.html.plaintext.txt	164	One well established indirect pathway projection ascending NTS receives input visceral glucoreceptors vagal afferents 36
0.20402655.11147774.html.plaintext.txt	165	The NTS contains neurons stimulated falling glucose systemic portal circulations inhibited rising systemic portal glucose gastric distension 1037 neurons therefore potential integrate various feeding related signals
0.20402655.11147774.html.plaintext.txt	166	We found significantly increased numbers activated orexin nonorexin LHA neurons fasted hypoglycemic rats
0.20402655.11147774.html.plaintext.txt	167	Neuronal activation LHA accompanied appearance Fos neurons NTS adjacent DMNX responses entirely absent euglycemic controls fed hypoglycemic rats
0.20402655.11147774.html.plaintext.txt	168	The DMNX intimately linked NTS controls gut motility secretory responses particularly important feeding behaviors 38
0.20402655.11147774.html.plaintext.txt	169	The strikingly similar pattern NTS LHA leads us believe signals triggered orexin neurons may relayed via NTS major projection LHA 8
0.20402655.11147774.html.plaintext.txt	170	Interestingly orexin neurons accounted numerically one quarter additional number LHA neurons activated fasted hypoglycemic rats Table 2
0.20402655.11147774.html.plaintext.txt	171	The neurochemical identities Fos neurons clear
0.20402655.11147774.html.plaintext.txt	172	The activation neurons ARC PVN sites involved regulation feeding suggests neurons areas may contribute hypoglycemia induced hyperphagia
0.20402655.11147774.html.plaintext.txt	173	Prolonged 24 h fasting known activate neurons areas 3940 however brief 5 h fast light phase normoglycemic rats ate 1 g unlikely affected Fos expression per se hypoglycemic food deprived group
0.20402655.11147774.html.plaintext.txt	174	An obvious candidate NPY potent appetite stimulating peptide known produced ARC released sites including PVN LHA 32
0.20402655.11147774.html.plaintext.txt	175	However hypothalamic NPY gene expression NPY levels affected hypoglycemia rats allowed eat 4142 although NPY reported fasted hypoglycemic rats
0.20402655.11147774.html.plaintext.txt	176	MCH produced separate population LHA neurons 32 stimulates feeding experimentally may regulate energy homeostasis MCH deficient mice hypophagic lean 43
0.20402655.11147774.html.plaintext.txt	177	MCH expression increased insulin induced hypoglycemia MCH neurons show Fos immunoreactivity hypoglycemia 44
0.20402655.11147774.html.plaintext.txt	178	There extensive synaptic connections NPY proopiomelanocortin MCH orexin neurons 2245 functional interactions among may drive hyperphagia hypoglycemia
0.20402655.11147774.html.plaintext.txt	179	We found 14 orexin neurons Fos lower proportion reported others 11
0.20402655.11147774.html.plaintext.txt	180	This finding may reflect difference time course hypoglycemia methodology used demonstrate localize Fos immunoreactivity
0.20402655.11147774.html.plaintext.txt	181	Using dose intermediate acting insulin selected consistent ability stimulate feeding plasma glucose dropped rapidly remained low 2 h insulin administration hypoglycemia profound rats fasted throughout rats freely fed 25
0.20402655.11147774.html.plaintext.txt	182	As immunohistochemical methods double fluorescence technique may sensitive enough detect activated orexin neurons although false positive results less likely using approach
0.20402655.11147774.html.plaintext.txt	183	The Fos method widely used identify map neuronal activation across relatively large brain areas acknowledge may miss neuronal activation via pathways Fos may case MCH 11
0.20402655.11147774.html.plaintext.txt	184	We previously reported prepro orexin mRNA levels increased twofold 6 h hypoglycemia fasting conditions activated orexin neurons LHA neurons NTSDMNX
0.20402655.11147774.html.plaintext.txt	185	In study found whole hypothalamic concentrations orexin B markedly raised 10 fold controls hypoglycemic fasted group levels unchanged fed hypoglycemic rats orexin A showed changes either hypoglycemic group
0.20402655.11147774.html.plaintext.txt	186	The increase orexin B levels specifically accompanied indexes orexin neuronal activation magnitude rise dissociation unchanged orexin A levels difficult explain relate physiological behavioral effects hypoglycemia
0.20402655.11147774.html.plaintext.txt	187	Increased prepro orexin expression equally increase production orexin A B derived common precursor
0.20402655.11147774.html.plaintext.txt	188	Because orexin A levels increased possible orexin A release enhanced parallel gene expression increased synaptic availability orexin A would predicted stimulate feeding 13 could contribute hyperphagia hypoglycemia
0.20402655.11147774.html.plaintext.txt	189	The increase orexin B concentrations could explained selective decrease release causing peptide accumulate within orexin neurons terminals
0.20402655.11147774.html.plaintext.txt	190	Orexin B little effect feeding 16 instead may act preferentially OX 2 receptor concerned arousal mutation OX 2 causes narcolepsy dogs 46 whereas orexin knockout mice causes disturbed arousal sleep patterns 47
0.20402655.11147774.html.plaintext.txt	191	We therefore speculate orexin B release may blocked severe hypoglycemia leading accumulation hypothalamus may contribute somnolence ultimately coma induced hypoglycemia
0.20402655.11147774.html.plaintext.txt	192	This discrepancy orexin A B may indicate orexin neurons functionally heterogeneous one subpopulation may involved mediating feeding via orexin A release whereas another releasing orexin B may regulate sleep arousal
0.20402655.11147774.html.plaintext.txt	193	This explanation must remain speculative orexin A B release measured separately vivo key hypothalamus regions also locus coeruleus receives dense orexinergic projection controls sleep wake cycle 48
0.20402655.11147774.html.plaintext.txt	194	In conclusion found striking activation orexin LHA neurons hypoglycemic rats allowed eat food freely available
0.20402655.11147774.html.plaintext.txt	195	Increased activation orexin neurons accompanied emergence Fos neurons NTS DMNX indicating projection NTS LHA may important regulator orexin neurons responses changes glucose availability prandial signals
0.20402655.11147774.html.plaintext.txt	196	These findings support suggestions orexin neurons glucose sensitive neurons LHA regulated visceral signals relayed via NTS
0.20402655.11147774.html.plaintext.txt	197	As may involved triggering hunger eating response hypoglycemia perhaps terminating feeding episodes
0.20402655.11147774.html.plaintext.txt	198	Orexins may involved various aspects hypothalamic responses hypoglycemia precise roles deserve clarification
0.20402655.11147774.html.plaintext.txt	199	ACKNOWLEDGMENTS We would like thank Committee Vice Chancellors Principals U
0.20402655.11147774.html.plaintext.txt	200	Overseas Research Scholarship SmithKline Beecham Medical Research Council financial support Collaborative Achievement Science Engineering Award
0.20402655.11147774.html.plaintext.txt	201	David Cutler valuable discussion input
0.20402655.11147774.html.plaintext.txt	202	received consulting fees lecture fees research funding SmithKline Beecham
0.20402655.11147774.html.plaintext.txt	203	3 D three dimensional ARC arcuate nucleus DMN dorsomedial hypothalamic nucleus DMNX dorsal motor nucleus vagus LHA lateral hypothalamic area MCH melanin concentrating hormone NPY neuropeptide Y NTS nucleus solitary tract PBS phosphate buffered saline PVN paraventricular nucleus
0.20402655.11147774.html.plaintext.txt	204	Received publication February 14 2000 accepted revised form September 8 2000
0.20402655.11147774.html.plaintext.txt	205	REFERENCES TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES Bernardis LL Bellinger LL The lateral hypothalamic area revisited ingestive behavior
0.20402655.11147774.html.plaintext.txt	206	Neurosci Biobehav Rev20 189 2871996Medline Epstein AN Teitelbaum P Specific loss hypoglycemic control feeding recovered lateral rats
0.20402655.11147774.html.plaintext.txt	207	Am J Physiol213 1159 11671967Medline Stricker EM Friedman MI Zigmond MJ Gluco regulatory feeding rats intraventricular 6 hydroxy dopamine lateral hypothalamic lesions
0.20402655.11147774.html.plaintext.txt	208	Science 189895 897 1975Medline Oomura Y Onyama H Sugimori M Nakemura T Yamada Y Glucose inhibition glucose sensitive neurons rat lateral hypothalamus
0.20402655.11147774.html.plaintext.txt	209	Nature 247284 286 1974Medline Orsini JC Armstrong DL Wayner MJ Responses lateral hypothalamic neurons recorded vitro moderate changes glucose concentration
0.20402655.11147774.html.plaintext.txt	210	Brain Res Bull29 503 5051992Medline Orsini JC Himmi T Wiser AK Perrin J Local versus indirect action glucose lateral hypothalamic neurons sensitive glycemic level
0.20402655.11147774.html.plaintext.txt	211	Brain Res Bull 2549 53 1990Medline Ricardo JA Koh ET Anatomical evidence direct projections nucleus solitary tract hypothalamus amygdala forebrain structure rat
0.20402655.11147774.html.plaintext.txt	212	Brain Res153 1 261978Medline Horst GJT de Boer P Luiten PGM van Willigen JD Ascending projections solitary tract nucleus hypothalamus phaseolus velgaris lectin tracing study rat
0.20402655.11147774.html.plaintext.txt	213	Neuroscience 31785 797 1989Medline Paton JFR Li YW Deuchars J Kasparov S Properties solitary tract neurons receiving inputs sub diaphragmatic vagus nerve
0.20402655.11147774.html.plaintext.txt	214	Neuroscience 95141 153 1999 Yettefti K Orsini JC Perrin J Characteristics glycemia sensitive neurons nucleus tractus solitarii possible involvement nutritional regulation
0.20402655.11147774.html.plaintext.txt	215	Physiol Behav61 93 1001997Medline Moriguchi T Sakurai T Nambu T Yanagisawa M Goto K Neurons containing orexin lateral hypothalamic area adult rat brain activated insulin induced acute hypoglycemia
0.20402655.11147774.html.plaintext.txt	216	Neurosci Lett 264101 104 1999Medline De Lecea L Kilduff TS Peyron C Gao XB Foye PE Danielson PE Fukuhara C Battenberg ELF Gautvik KM Bartlett FS Frankel WN van den Pol AN Bloom FE Gautvik VT Sutcliff JG The hypocretins hypothalamic specific peptides neuroexcitatory activity
0.20402655.11147774.html.plaintext.txt	217	Proc Natl Acad Sci U S A 95 322 3271998AbstractFree Full Text Sakurai T Amemiya A Ishii M Matsuzaki I Chemelli RM Tanaka H Williams SC Richardson JA Kozlowski GP Wilson S Arch JS Buckingham RE Haynes AC Carr SA Annan RS Mcnulty DE Liu WS Terrett JA Elshourbagy NA Bergsma DJ Yanagisawa M Orexins orexin receptors family hypothalamic neuropeptides G protein coupled receptors regulate feeding behavior
0.20402655.11147774.html.plaintext.txt	218	Cell 92573 585 1998Medline Sweet DC Levine AS Billington CJ Kotz CM Feeding response central orexins
0.20402655.11147774.html.plaintext.txt	219	Brain Res 821535 538 1999Medline Ida T Nakahara K Katayama T Murakami N Nakazato M Effect lateral cerebroventricular injection appetite stimulating neuropeptide orexin neuropeptide Y various behavioral activities rats
0.20402655.11147774.html.plaintext.txt	220	Brain Res 821526 529 1999Medline Edwards CB Abusnana S Sunter D Murphy KG Ghatei MA Bloom SR The effect orexins food intake comparison neuropeptide Y melaninconcentrating hormone galanin
0.20402655.11147774.html.plaintext.txt	221	J Endocrinol160 R7 R121999Abstract Haynes A Jackson B Overend P Buckingham R Wilson S Tadayyon M Arch JS Effects single chronic intracerebroventricular administration orexins feeding rat
0.20402655.11147774.html.plaintext.txt	222	Peptides20 1099 11051999Medline Dube MG Kalra SP Kalra PS Food intake elicited central administration orexinshypocretins identification hypothalamic sites action
0.20402655.11147774.html.plaintext.txt	223	Brain Res 842473 477 1999Medline Yamanaka A Sakurai T Katsumoto T Yanagisawa M Goto K Chronic intracerebroventricular administration orexin A rats increases food intake daytime effect body weight
0.20402655.11147774.html.plaintext.txt	224	Brain Res 849 248 2521999Medline Peyron C Tighe DK Vandenpol AN Delecea L Heller HC Sutcliffe JG Kilduff TS Neurons containing hypocretin orexin project multiple neuronal systems
0.20402655.11147774.html.plaintext.txt	225	J Neurosci18 9996 100151998AbstractFree Full Text Date Y Ueta Y Yamashita H Yamaguchi H Matsukura S Kangawa K Sakurai T Yanagisawa M Nakazato M Orexins orexigenic hypothalamic peptides interact autonomic neuroendocrine neuroregulatory systems
0.20402655.11147774.html.plaintext.txt	226	Proc Natl Acad Sci U S A 96748 753 1999AbstractFree Full Text Horvath TL Diano S van den Pol AN Synaptic interaction hypocretin orexin neuropeptide Y cells rodent primate hypothalamus novel circuit implicated metabolic endocrine regulations
0.20402655.11147774.html.plaintext.txt	227	J Neurosci19 1072 10871999AbstractFree Full Text Chen CT Dun SL Kwok EH Dun NJ Chang JK Orexin A like immunoreactivity rat brain
0.20402655.11147774.html.plaintext.txt	228	Neurosci Lett260 161 1641999Medline Harrison TA Chen CT Dun NJ Chang JK Hypothalamic orexin A immunoreactive neurons project rat dorsal medulla
0.20402655.11147774.html.plaintext.txt	229	Neurosci Lett 27317 20 1999Medline Cai XJ Widdowson P Harrold J Wilson S Buckingham R Arch J Tadayyon M Clapham JC Wilding J Williams G Hypothalamic orexin expression modulation blood glucose feeding
0.20402655.11147774.html.plaintext.txt	230	Diabetes48 2132 21371999Abstract Risold PY Griffond B Kilduff TS Sutcliffe JG Fellmann D Preprohypocretin orexin prolactin like immunoreactivity coexpressed neurons rat lateral hypothalamic area
0.20402655.11147774.html.plaintext.txt	231	Neurosci Lett 259153 156 1999Medline Greco B Edwards DA Michael RP Zumpe D Clancy AN Colocalization androgen receptors mating induced FOS immunoreactivity neurons project central tegmental field male rats
0.20402655.11147774.html.plaintext.txt	232	J Comp Neurol 408220 236 1999Medline Niimi M Sato M Tamaki M Wada Y Takahara J Kawanishi K Induction Fos protein rat hypothalamus elicited insulin induced hypoglycemia
0.20402655.11147774.html.plaintext.txt	233	Neurosci Res 23361 364 1995Medline Cutler DJ Morris R Sheridhar V Wattam TAK Holmes S Patel S Arch JRS Wilson S Buckingham RE Evans ML Leslie SA Williams G Differential distribution orexin A orexin B immunoreactivity rat brain spinal cord
0.20402655.11147774.html.plaintext.txt	234	Peptides20 1455 14701999Medline Paxinos G Watson C The Rat Brain Stereotaxic Coordinates
0.20402655.11147774.html.plaintext.txt	235	San Diego CA Academic Press1986 Williams G Steel JH Cardoso H Ghatei MA Lee YC Gill JS Burrin JM Polak JM Bloom SR Increased hypothalamic neuropeptide Y concentrations streptozotocin diabetic rat
0.20402655.11147774.html.plaintext.txt	236	Diabetes37 763 7721988Abstract Broberger C De Lecea L Sutcliffe JG Hokfelt T Hypocretinorexin melanin concentrating hormone expressing cells form distinct populations rodent lateral hypothalamus relationship neuropeptide Y Agouti gene related protein systems
0.20402655.11147774.html.plaintext.txt	237	J Comp Neurol 402460 474 1998Medline Jhanwar Uniyal M Beck B Jhanwar YS Burlet C Leibowitz SF Neuropeptide Y projection arcuate nucleus parvocellular division paraventricular nucleus specific relation ingestion carbohydrate
0.20402655.11147774.html.plaintext.txt	238	Brain Res 63197 106 1993Medline Griffond B Risold PY Jacquemard C Colard C Fellmann D Insulin induced hypoglycemia increases preprohypocretin orexin mRNA rat lateral hypothalamic area
0.20402655.11147774.html.plaintext.txt	239	Neurosci Lett262 77 801999Medline Oomura Y Yoshimatsu H Neural network glucose monitoring system
0.20402655.11147774.html.plaintext.txt	240	J Auton Nerv Syst 10359 372 1984Medline Altschuler SM Bao XM Bieger D Hopkin DA Miselis RR Viscerotopic representation upper alimentary tract rat sensory ganglia nuclei solitary spinal trigeminal tracts
0.20402655.11147774.html.plaintext.txt	241	J Comp Neurol 283248 268 1989Medline Chambert G Kobashi M Adachi A Convergence gastric hepatic information brain stem neurons rat
0.20402655.11147774.html.plaintext.txt	242	Brain Res Bull 32 525 5291993Medline Powley TL Vagal circuitry mediating cephalic phase responses food
0.20402655.11147774.html.plaintext.txt	243	Appetite 34184 188 2000Medline Lin S Huang XF Altered hypothalamic c Fos like immunoreactivity diet induced obese mice
0.20402655.11147774.html.plaintext.txt	244	Brain Res Bull49 215 2191999Medline Wang L Martines V Barrachina MD Tache Y Fos expression brain induced peripheral injection CCK leptin plus CCK fasted lean mice
0.20402655.11147774.html.plaintext.txt	245	Brain Res 791157 166 1998Medline Dryden S Pickavance L Henderson L Williams G Hyperphagia induced hypoglycemia rats independent leptin hypothalamic neuropeptide Y NPY
0.20402655.11147774.html.plaintext.txt	246	Peptides19 1549 15551998Medline Corrin SE McCarthy HD McKibbin PE Williams G Unchanged hypothalamic neuropeptide Y concentrations hyperphagic hypoglycemic rats evidence specific metabolic regulation hypothalamic NPY
0.20402655.11147774.html.plaintext.txt	247	Peptides 12425 430 1991Medline Shimada M Tritos NA Lowell BB Flier LS Maratos Flier E Mice lacking melanin concentrating hormone hypophagic lean
0.20402655.11147774.html.plaintext.txt	248	Nature 396670 674 1998Medline Bahjaoui Bouhaddi M Fellmann D Griffond B Bugnon C Insulin treatment stimulates rat melanin concentrating hormone producing neurons
0.20402655.11147774.html.plaintext.txt	249	Neuropeptides 27251 258 1994Medline Elias CF Saper CB Maratos Flier E Tritos NA Lee C Kelly J Tatro JB Hoffman GE Ollmann MM Barsh GS Sakurai T Yanagisawa M Elmquist JK Chemically defined projections linking mediobasal hypothalamus lateral hypothalamic area
0.20402655.11147774.html.plaintext.txt	250	J Comp Neurol402 442 4591998Medline Lin L Faraco J Li R Kadotani H Roger W Lin X Qiu X de Jong PJ Nishino S Mignot E The sleep disorder canine narcolepsy caused mutation hypocretin orexin receptor 2 gene
0.20402655.11147774.html.plaintext.txt	251	Cell 98365 376 1999Medline Chemelli RM Willie JT Sinton CM Elmquist JK Scammell T Lee C Richardson JA Williams SC Xiong Y Kisanuki Y Fitch TE Nakazato M Hammer RE Saper CB Yanagisawa M Narcolepsy orexin knockout mice molecular genetics sleep regulation
0.20402655.11147774.html.plaintext.txt	252	Cell98 437 4511999Medline Hagan JJ Leslie RA Patel S Evans ML Wattam TA Holmes S Benham CD Taylor SG Routledge C Hemmati P Munton RP Ashmeade TE Shah AS Hatcher JP Hatcher PD Jones DNC Smith MI Piper DC Hunter AJ Porter RA Upton N Orexin A activates locus coeruleus cell firing increases arousal rat
0.20402655.11147774.html.plaintext.txt	253	Proc Natl Acad Sci U S A96 10911 109161999AbstractFree Full Text
0.08830947.11796488.html.plaintext.txt	0	PRL Releasing Peptide Interacts Leptin Reduce Food Intake Body Weight Kate L
0.08830947.11796488.html.plaintext.txt	1	School Biological Sciences University Manchester Manchester M13 9PT United Kingdom
0.08830947.11796488.html.plaintext.txt	2	Address correspondence requests reprints Dr
0.08830947.11796488.html.plaintext.txt	3	124 Stopford Building School Biological Sciences University Manchester Oxford Road Manchester M13 9PT United Kingdom
0.08830947.11796488.html.plaintext.txt	4	Abstract Top Abstract Introduction Materials Methods Results Discussion References PRL releasing peptide PrRP novel anorexigen reduces food intake body weight gain rats
0.08830947.11796488.html.plaintext.txt	5	In common anorexigens PrRP mRNA expression reduced states negative energy balance
0.08830947.11796488.html.plaintext.txt	6	lactation fasting female rats
0.08830947.11796488.html.plaintext.txt	7	In study examined interaction PrRP adiposity signal leptin interacts number peptidergic systems brain regulate energy homeostasis
0.08830947.11796488.html.plaintext.txt	8	Intracerebroventricular coadministration 4 nmol PrRP 1 microg leptin rats resulted additive reductions nocturnal food intake body weight gain increase core body temperature compared peptide alone
0.08830947.11796488.html.plaintext.txt	9	We show also quantitative situ hybridization PrRP mRNA reduced fasted male rats obese Zucker rats indicating PrRP mRNA expression like anorexigens may regulated leptin
0.08830947.11796488.html.plaintext.txt	10	Finally show using immunohistochemistry greater 90 PrRP neurons regions PrRP expressed contain leptin receptors
0.08830947.11796488.html.plaintext.txt	11	Thus provide evidence PrRP neurons forming part leptin sensitive brain circuitry involved regulation food intake energy homeostasis
0.08830947.11796488.html.plaintext.txt	12	Introduction Top Abstract Introduction Materials Methods Results Discussion References PRL RELEASING PEPTIDE PrRP identified 1998 endogenous ligand orphan GPR10hGR3 receptor 1
0.08830947.11796488.html.plaintext.txt	13	Although shown cause PRL release cultured pituitary cells 1 lack immunoreactive fibers external region median eminence suggested act typical hypophysiotrophic hormone 2 3 4 5 6
0.08830947.11796488.html.plaintext.txt	14	These findings reinforced number studies question PrRP role modulation PRL release vivo vitro 6 7 8 9
0.08830947.11796488.html.plaintext.txt	15	PrRP neurons located dorsal medial hypothalamus DMH nucleus tractus solitarius NTS ventrolateral medulla VLM 2 10 11 regions known involved regulation food intake reviews see Refs
0.08830947.11796488.html.plaintext.txt	16	This suggested us alternative role regulation energy balance
0.08830947.11796488.html.plaintext.txt	17	This confirmed showed intracerebroventricular icv administration PrRP reduces normal nocturnal fast induced feeding accompanied reduction body weight gain without causing taste aversion disrupting normal feeding behavior 14 15
0.08830947.11796488.html.plaintext.txt	18	Furthermore PrRP mRNA regulated two states negative energy balance female rats fasting lactation 14
0.08830947.11796488.html.plaintext.txt	19	Leptin adiposity signal encoded obesity ob gene 16
0.08830947.11796488.html.plaintext.txt	20	It produced primarily adipose tissue also expressed gastric parietal 17 skeletal muscle 18 placental cells 19 20
0.08830947.11796488.html.plaintext.txt	21	Leptin regulates food intake energy expenditure interaction receptors brain review see Ref
0.08830947.11796488.html.plaintext.txt	22	There six known isoforms leptin receptor Ob Ra e long form receptor Ob Rb possesses necessary intracellular domain enable signaling transcriptional pathways
0.08830947.11796488.html.plaintext.txt	23	There two rodent models defective leptin signaling Zucker rat dbdb mouse obese due defects Ob Rb severely reduces ability respond leptin 22 23 24
0.08830947.11796488.html.plaintext.txt	24	Ob R transcripts immunoreactivity widely distributed rodent brain
0.08830947.11796488.html.plaintext.txt	25	In hypothalamus strong expression Ob R seen arcuate nucleus ARC DMH ventromedial nucleus premammillary nucleus supraoptic nucleus paraventricular nucleus PVN lateral hypothalamus periventricular nucleus 25 26 27
0.08830947.11796488.html.plaintext.txt	26	In brainstem Ob R mRNA found NTS medullary reticular nucleus lateral parabrachial nucleus 25 28
0.08830947.11796488.html.plaintext.txt	27	Ob R expressed neurons contain peptides known involved regulation food intake
0.08830947.11796488.html.plaintext.txt	28	In hypothalamus Ob R coexpressed NPY 29 agouti related peptide 30 POMC 31 cocaine amphetamine regulated transcript 32 orexinhypocretin 33 34 thus providing morphological evidence action leptin neurons containing orexigenic anorexigenic peptides
0.08830947.11796488.html.plaintext.txt	29	Leptin also shown interact number peptides vivo modulate food intake mRNA expression 32 35 36 37 38 39
0.08830947.11796488.html.plaintext.txt	30	In study examined interaction PrRP leptin vivo examination effect nocturnal food intake body weight gain core body temperature following coadministration
0.08830947.11796488.html.plaintext.txt	31	We looked distribution PrRP Ob R tyrosine hydroxlase TH using double fluorescence immunohistochemistry DMH NTS VLM ascertain whether morphological basis interaction
0.08830947.11796488.html.plaintext.txt	32	Also acute chronic model energy imbalance fasted rat obese Zucker rat used examine regulation PrRP gene expression
0.08830947.11796488.html.plaintext.txt	33	Materials Methods Top Abstract Introduction Materials Methods Results Discussion References Animals materials Unless stated otherwise experiments performed adult male Sprague Dawley rats 250 300 g Charles River Laboratories Inc
0.08830947.11796488.html.plaintext.txt	34	Adult male obese fafa 415 480 g lean fa 280 350 g Zucker rats kind gift AstraZeneca Plc Alderley Park UK
0.08830947.11796488.html.plaintext.txt	35	Animals kept 12 h light 12 h dark cycle lights 0800 2000 h 21 C plus minus 1 C 45 plus minus 10 humidity ad libitum access food water
0.08830947.11796488.html.plaintext.txt	36	All experiments performed accordance UK Animals Scientific Procedures Act 1986
0.08830947.11796488.html.plaintext.txt	37	Unless otherwise stated chemicals obtained Sigma Aldrich Corp
0.08830947.11796488.html.plaintext.txt	38	Coadministration leptin PrRP Animals lateral ventricular cannulae inserted 0
0.08830947.11796488.html.plaintext.txt	39	5 halothane AstraZeneca Plc Macclesfield UK anesthesia
0.08830947.11796488.html.plaintext.txt	40	During anesthesia precalibrated remote radiotelemetry transmitters TA10TA F40 Data Sciences International Minneapolis MN implanted peritoneal cavity
0.08830947.11796488.html.plaintext.txt	41	The animals allowed recover experiments performed 1 wk later
0.08830947.11796488.html.plaintext.txt	42	They housed individually 1000 h left acclimatize
0.08830947.11796488.html.plaintext.txt	43	During hour lights 2000 h conscious unrestrained animals received one following treatments icv 4 nmol PrRP 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 2 microl sterile water Peptide Inc
0.08830947.11796488.html.plaintext.txt	44	Osaka Japan 2 microl isotonic saline leptin vehicle 1 microg recombinant murine leptin kind gift AstraZeneca Plc 2 microl isotonic saline 2 microl sterile water PrRP vehicle 4 nmol PrRP 2 microl 1 microg leptin 2 microl together 2 microl vehicle
0.08830947.11796488.html.plaintext.txt	45	Total injection volume 4 microl n 5 6 per group
0.08830947.11796488.html.plaintext.txt	46	Core body temperature measured continuously throughout 12 h dark period
0.08830947.11796488.html.plaintext.txt	47	Food water intake body weights measured 12 h treatments
0.08830947.11796488.html.plaintext.txt	48	In situ hybridization Animals allowed free access food except fasted group killed cervical dislocation decapitation n 6 per group fedfasted experiment n 8 per group leanobese Zucker experiment
0.08830947.11796488.html.plaintext.txt	49	The fasted group first food withheld 48 h
0.08830947.11796488.html.plaintext.txt	50	Coronal brain sections 15 microm DMH bregma 3
0.08830947.11796488.html.plaintext.txt	51	16 mm 40 NTSVLM bregma 13
0.08830947.11796488.html.plaintext.txt	52	60 mm 40 collected onto Polysine slides BDH Poole UK
0.08830947.11796488.html.plaintext.txt	53	Oligonucleotide probes PrRP 11 mixture 5 tag cag cag caa gca cag aag cca cgt ctt cag ggc 3 5 tta tcc acg ctg aga gaa ctt ggt gcg tcc atc cag 3 NPY 5 gga gta gta tct ggc cat gtc ctc tgc tgg 3 labeled 35S deoxy ATP NEN Life Science Products Boston MA
0.08830947.11796488.html.plaintext.txt	54	Following hybridization slides washed final stringency 1x SSC 55 C developed photographic emulsion Ilford Imaging Ltd
0.08830947.11796488.html.plaintext.txt	55	The resulting silver grains quantified using computer based analysis system Northern Eclipse Empix Imaging Inc
0.08830947.11796488.html.plaintext.txt	56	A minimum four sections per animal DMH four six sections NTSVLM analyzed
0.08830947.11796488.html.plaintext.txt	57	Cells deemed PrRP positive contained greater three times background number silver grains determined negative control slides hybridized excess unlabeled probe
0.08830947.11796488.html.plaintext.txt	58	Double fluorescence immunohistochemistry Animals deeply anesthetized using sodium pentabarbitone Sagatal 100 mgkg Rhone Merieux Harlow UK undergoing transcardial perfusion heparinized 100 kUliter isotonic saline 0
0.08830947.11796488.html.plaintext.txt	59	9 NaCl followed 4 paraformaldehyde 0
0.08830947.11796488.html.plaintext.txt	60	The brains postfixed 4 paraformaldehyde 0
0.08830947.11796488.html.plaintext.txt	61	1 M phosphate buffer 2 h cryoprotection 30 sucrose
0.08830947.11796488.html.plaintext.txt	62	Twenty micrometer coronal brain sections incubated rabbit polyclonal antibody raised human PrRP sequence 11000 Phoenix Pharmaceuticals Inc
0.08830947.11796488.html.plaintext.txt	63	Belmont CA followed fluorescein isothiocyanate labeled donkey antirabbit IgG complex 1200 Jackson ImmunoResearch Laboratories Inc
0.08830947.11796488.html.plaintext.txt	64	The sections underwent incubation goat anti leptin receptor antibody 1500 M 18 Santa Cruz Biotechnology Inc
0.08830947.11796488.html.plaintext.txt	65	Santa Cruz CA Texas Red labeled donkey antigoat IgG complex 1500 Jackson Immunoresearch Laboratories Inc
0.08830947.11796488.html.plaintext.txt	66	The primary antibody recognizes long short forms leptin receptor
0.08830947.11796488.html.plaintext.txt	67	For TH PrRP double immunohistochemistry procedure repeated Ob R antibody replaced mouse anti TH 14000 Mab 318 Chemicon International Inc
0.08830947.11796488.html.plaintext.txt	68	Harrow UK horse antimouse biotinylated IgG 1200 2
0.08830947.11796488.html.plaintext.txt	69	6 microlml streptavidin Texas Red complex Vector Laboratories Inc
0.08830947.11796488.html.plaintext.txt	70	The specificities primary antibodies tested commercial producers cellular distributions staining brain correspond situ hybridization data
0.08830947.11796488.html.plaintext.txt	71	In addition staining leptin receptor antibody completely abolished following liquid phase preabsorption peptide immunogen sc1834P Santa Cruz Biotechnology Inc
0.08830947.11796488.html.plaintext.txt	72	Double immunohistochemistry assessed scoring number cells per section showed specific immunoreactivity PrRP without Ob R TH number neurons displayed immunoreactivity
0.08830947.11796488.html.plaintext.txt	73	Only sections PrRP neurons found included analysis
0.08830947.11796488.html.plaintext.txt	74	Statistical analyses All data expressed mean plus minus SEM
0.08830947.11796488.html.plaintext.txt	75	Food intake body weight measurements analyzed using one way ANOVA followed Tukey post hoc test
0.08830947.11796488.html.plaintext.txt	76	Core body temperature data analyzed using area curve AUC 2 h 12 h AUC degrees Celsius Ch followed one way ANOVA Dunnett multiple comparisons post hoc test
0.08830947.11796488.html.plaintext.txt	77	Analysis core body temperature performed 2 h avoid transient hypothermia occurs following administration PrRP 14
0.08830947.11796488.html.plaintext.txt	78	In situ hybridization data analyzed using Mann Whitney U test
0.08830947.11796488.html.plaintext.txt	79	Results Top Abstract Introduction Materials Methods Results Discussion References The effect coadministration PrRP leptin nocturnal food intake body weight Administration PrRP 4 nmol icv alone caused 24 reduction food intake 12 h dark period Fig
0.08830947.11796488.html.plaintext.txt	80	This reduction food intake accompanied 56 reduction overnight body weight gain Fig
0.08830947.11796488.html.plaintext.txt	81	Rats injected leptin 1 microg icv ate 18 less food control group quite reach statistical significance post hoc test
0.08830947.11796488.html.plaintext.txt	82	However leptin produce significant 55 reduction overnight body weight gain Fig
0.08830947.11796488.html.plaintext.txt	83	Coadministration PrRP leptin caused 54 reduction food intake indicating additive effect two peptides Fig
0.08830947.11796488.html.plaintext.txt	84	001 compared vehicle P 0
0.08830947.11796488.html.plaintext.txt	85	01 compared leptin alone P 0
0.08830947.11796488.html.plaintext.txt	86	This also reflected data body weight gain animals received PrRP leptin showed net loss body weight period Fig
0.08830947.11796488.html.plaintext.txt	87	001 compared vehicle P 0
0.08830947.11796488.html.plaintext.txt	88	05 compared leptin alone significantly different compared PrRP alone
0.08830947.11796488.html.plaintext.txt	89	View larger version 18K Figure 1
0.08830947.11796488.html.plaintext.txt	90	The effect coadministration PrRP leptin A food intake B body weight gain 12 h dark period adult male Sprague Dawley rats
0.08830947.11796488.html.plaintext.txt	91	05 compared vehicle P 0
0.08830947.11796488.html.plaintext.txt	92	001 compared vehicle P 0
0.08830947.11796488.html.plaintext.txt	93	05 compared PrRP alone P 0
0.08830947.11796488.html.plaintext.txt	94	05 compared leptin alone P 0
0.08830947.11796488.html.plaintext.txt	95	01 compared leptin alone one way ANOVA
0.08830947.11796488.html.plaintext.txt	96	Data expressed mean plus minus SEM n 5 6
0.08830947.11796488.html.plaintext.txt	97	The effect coadministration PrRP leptin nocturnal core body temperature Remote radiotelemetry used measure core body temperature continuously dark period animals used feeding study values 30 min intervals plotted Fig
0.08830947.11796488.html.plaintext.txt	98	Injections made lights thus normal nocturnal rise core body temperature seen vehicle hormone treated animals
0.08830947.11796488.html.plaintext.txt	99	Administration leptin alone caused slight hyperthermic response duration dark phase compared vehicle treated controls although statistically significant experiment Fig
0.08830947.11796488.html.plaintext.txt	100	Administration PrRP caused initial rapid hypothermic response characteristic PrRP 14 reached nadir 30 min time animals displayed small significant hyperthermia Fig
0.08830947.11796488.html.plaintext.txt	101	05 compared vehicle treated animals
0.08830947.11796488.html.plaintext.txt	102	Animals received PrRP leptin showed hypothermic response followed elevation core body temperature compared vehicle treated animals greater administration either PrRP leptin alone Fig
0.08830947.11796488.html.plaintext.txt	103	View larger version 24K Figure 2
0.08830947.11796488.html.plaintext.txt	104	The effect A leptin B PrRP C leptin PrRP nocturnal changes core body temperature adult male Sprague Dawley rats
0.08830947.11796488.html.plaintext.txt	105	Core body temperature C recorded continuously remote radiotelemetry temperature change basal values calculated 30 min intervals plotted 12 h dark phase
0.08830947.11796488.html.plaintext.txt	106	For ease comparison trace control group included panel one treatment group mean plus minus SEM n 5 6 group
0.08830947.11796488.html.plaintext.txt	107	See text details statistical analysis
0.08830947.11796488.html.plaintext.txt	108	The expression PrRP mRNA fasted Zucker rats In brain PrRP mRNA expressed exclusively DMH NTS VLM fed fasted male rats
0.08830947.11796488.html.plaintext.txt	109	The negative control excess unlabeled PrRP probe addition radiolabeled probe resulted background levels silver grains indicating signal due specific binding PrRP probe results shown
0.08830947.11796488.html.plaintext.txt	110	These data indicate absolute numbers PrRP mRNA transcripts number silver grains represent relative abundance
0.08830947.11796488.html.plaintext.txt	111	In brain region PrRP mRNA detected fasted animals showed reduction number silver grains per cell compared ad libitum fed controls see Table 1A Fig
0.08830947.11796488.html.plaintext.txt	112	DMH 32 reduction NTS 34 reduction VLM 55 reduction though reduction statistically significant case DMH P 0
0.08830947.11796488.html.plaintext.txt	113	Fasted animals also showed significantly reduced number detectable cells per section expressing PrRP mRNA compared ad libitum fed control animals area Table 1A DMH 58 reduction P 0
0.08830947.11796488.html.plaintext.txt	114	Expression mRNA orexigen NPY ARC used positive control
0.08830947.11796488.html.plaintext.txt	115	In agreement literature 41 fasted animals showed increased level NPY mRNA respect number grains per cell fed 49 plus minus 5 grains per cell fasted 69 plus minus 4 grains per cell P 0
0.08830947.11796488.html.plaintext.txt	116	05 number detectable cells per section fed 61 plus minus 5 cells per section fasted 112 plus minus 10 cells per section P 0
0.08830947.11796488.html.plaintext.txt	117	01 compared ad libitum fed animals
0.08830947.11796488.html.plaintext.txt	118	PrRP mRNA expression male rats
0.08830947.11796488.html.plaintext.txt	119	View larger version 94K Figure 3
0.08830947.11796488.html.plaintext.txt	120	An example radioactive situ hybridization PrRP mRNA NTS fed A fasted B adult male Sprague Dawley rats lean C obese D Zucker rats
0.08830947.11796488.html.plaintext.txt	121	Insets higher magnification micrographs show silver grains individual cells
0.08830947.11796488.html.plaintext.txt	122	In obese Zucker rats reduction number silver grains per cell regions examined Table 1B Fig
0.08830947.11796488.html.plaintext.txt	123	001 VLM 68 reduction P 0
0.08830947.11796488.html.plaintext.txt	124	There also reduction number detectable PrRP cells per section obese compared lean animals Table 1B DMH 59 reduction P 0
0.08830947.11796488.html.plaintext.txt	125	Expression ARC NPY mRNA used positive control agreement literature 42 showed increased level NPY mRNA respect amount per cell lean 35 plus minus 3 grains per cell obese 50 plus minus 3 grains per cell P 0
0.08830947.11796488.html.plaintext.txt	126	001 number detectable cells per section lean 39 plus minus 3 cells per section obese 56 plus minus 6 cells per section P 0
0.08830947.11796488.html.plaintext.txt	127	05 obese compared lean animals
0.08830947.11796488.html.plaintext.txt	128	PrRP leptin receptor Ob R localization double fluorescence immunohistochemistry In agreement situ hybridization studies PrRP immunoreactive neurons identified exclusively DMH NTS VLM
0.08830947.11796488.html.plaintext.txt	129	Figure 4 shows localization Ob R visualized using Texas Red labeled secondary antibody PrRP visualized using fluorescein isothiocyanate labeled secondary antibody
0.08830947.11796488.html.plaintext.txt	130	In DMH large number cells expressing Ob R relatively expressing PrRP
0.08830947.11796488.html.plaintext.txt	131	Almost PrRP neurons region contained Ob R whereas PrRP neurons accounted less one percent leptin receptive neurons see Table 2
0.08830947.11796488.html.plaintext.txt	132	View larger version 109K Figure 4
0.08830947.11796488.html.plaintext.txt	133	Examples double fluorescence immunohistochemistry Ob R PrRP DMH A B NTS C D VLM E F
0.08830947.11796488.html.plaintext.txt	134	Ob R shown upper panels A C E PrRP lower panels B D F
0.08830947.11796488.html.plaintext.txt	135	White arrows indicate examples neurons show colocalization
0.08830947.11796488.html.plaintext.txt	136	The gray arrow indicates example PrRP positive neuron show colocalization Ob R
0.08830947.11796488.html.plaintext.txt	137	cc Central canal 3V third ventricle
0.08830947.11796488.html.plaintext.txt	138	PrRP Ob R immunoreactivity rat brain sections
0.08830947.11796488.html.plaintext.txt	139	In brainstem PrRP neurons found level area postrema caudally
0.08830947.11796488.html.plaintext.txt	140	No PrRP immunopositive neurons found rostral area postrema
0.08830947.11796488.html.plaintext.txt	141	Ob R expressing neurons abundant PrRP expressing neurons particularly around level area postrema
0.08830947.11796488.html.plaintext.txt	142	Overall majority PrRP immunopositive neurons NTS contained Ob R immunoreactivity see Table 2 Fig
0.08830947.11796488.html.plaintext.txt	143	Conversely fifth Ob R containing neurons sections also contained PrRP immunoreactivity
0.08830947.11796488.html.plaintext.txt	144	In VLM nearly PrRP neurons expressed Ob R
0.08830947.11796488.html.plaintext.txt	145	In sections Ob R expression less widespread approximately half Ob R expressing neurons found contain PrRP immunoreactivity
0.08830947.11796488.html.plaintext.txt	146	Single immunocytochemsitry studies performed regions demonstrated colocalization seen due antibody cross reactivity data shown
0.08830947.11796488.html.plaintext.txt	147	PrRP TH localization double fluorescence immunohistochemistry PrRP neurons NTS VLM also express TH immunoreactivity 3 10 43 44 45
0.08830947.11796488.html.plaintext.txt	148	In present study majority PrRP neurons NTS VLM contained TH immunoreactivity see Table 3 Fig
0.08830947.11796488.html.plaintext.txt	149	In sections NTS VLM level PrRP immunoreactive neurons approximately two thirds TH positive neurons also contained PrRP immunoreactivity
0.08830947.11796488.html.plaintext.txt	150	PrRP TH immunoreactivity rat brain sections
0.08830947.11796488.html.plaintext.txt	151	View larger version 129K Figure 5
0.08830947.11796488.html.plaintext.txt	152	Examples double fluorescence immunohistochemistry PrRP TH NTS A B VLM C D
0.08830947.11796488.html.plaintext.txt	153	The left panels show TH A C right panels PrRP B D
0.08830947.11796488.html.plaintext.txt	154	White arrows indicate examples neurons show colocalization
0.08830947.11796488.html.plaintext.txt	155	Discussion Top Abstract Introduction Materials Methods Results Discussion References The results study indicate similarity actions acutely administered PrRP leptin provides evidence interaction two peptides
0.08830947.11796488.html.plaintext.txt	156	Studies vivo show coadministration PrRP leptin caused additive effect reductions food intake body weight Fig
0.08830947.11796488.html.plaintext.txt	157	We demonstrated previously using pair feeding experiments reduction body weight caused PrRP cannot explained solely reduction food intake likely include effect energy expenditure 14
0.08830947.11796488.html.plaintext.txt	158	Here show hyperthermic responses PrRP leptin indirect measure increased energy expenditure also additive Fig
0.08830947.11796488.html.plaintext.txt	159	The interaction peptides appears additive rather synergistic effect induced coadministration two peptides equivalent sum peptides administered alone
0.08830947.11796488.html.plaintext.txt	160	This additivity demonstrates effects one peptide mediated define level interaction
0.08830947.11796488.html.plaintext.txt	161	At present time known antagonists GPR10hGR3 leptin receptors would enable clarification interaction
0.08830947.11796488.html.plaintext.txt	162	The reduction PrRP mRNA expression fasted male rats provides evidence PrRP anorexigen
0.08830947.11796488.html.plaintext.txt	163	This confirms previous result fasted female rats 14 removes complication hormonal fluctuations studies report variations PrRP mRNA levels according stage estrous cycle 46
0.08830947.11796488.html.plaintext.txt	164	We report also PrRP mRNA reduced obese Zucker rats three areas brain PrRP expressed
0.08830947.11796488.html.plaintext.txt	165	This phenomenon reported number anorexigenic peptides including cocaine amphetamine regulated transcript 32 POMC 47 CRH 48
0.08830947.11796488.html.plaintext.txt	166	The reduction PrRP mRNA models energy imbalance used study may indicate PrRP mRNA expression regulated leptin
0.08830947.11796488.html.plaintext.txt	167	We localized leptin receptor immunoreactivity PrRP neurons demonstrates regulation PrRP mRNA could achieved direct action leptin PrRP neurons
0.08830947.11796488.html.plaintext.txt	168	In addition containing Ob R PrRP neurons NTS VLM also contain TH shown previously others 3 10 43 44 45
0.08830947.11796488.html.plaintext.txt	169	The location PrRP neurons mainly caudal brainstem makes likely noradrenergic rather adrenergic neurons
0.08830947.11796488.html.plaintext.txt	170	It reported recently almost TH positive cells A1 A2 regions express Ob R immunoreactivity 49
0.08830947.11796488.html.plaintext.txt	171	This combined findings indicating high levels colocalization PrRP Ob R TH suggests presence subpopulation noradrenergic neurons express PrRP Ob R
0.08830947.11796488.html.plaintext.txt	172	Retrograde tracing studies shown PrRP neurons NTS VLM project hypothalamic PVN 44 PrRP immunoreactive fibers detected 2
0.08830947.11796488.html.plaintext.txt	173	The PVN contains major population neurons containing anorexigen CRH reported mediate effects leptin 50 51
0.08830947.11796488.html.plaintext.txt	174	Thus CRH neurons PVN may act point convergence various leptin sensitive systems
0.08830947.11796488.html.plaintext.txt	175	We shown peripheral satiety signal cholecystokinin CCK activates PrRP neurons brainstem 15
0.08830947.11796488.html.plaintext.txt	176	Recent interest focused ability leptin enhance effects CCK vice versa 52 53 54
0.08830947.11796488.html.plaintext.txt	177	Although cooperativity occurs level gut 55 56 results suggest PrRP neurons brainstem may another point interaction leptin CCK mediated satiety pathway
0.08830947.11796488.html.plaintext.txt	178	In summary studies suggest PrRP interacts leptin regulation food intake metabolism
0.08830947.11796488.html.plaintext.txt	179	The expression PrRP mRNA reduced obese Zucker rats fasted rats indicating leptin may regulating PrRP expression
0.08830947.11796488.html.plaintext.txt	180	In addition leptin receptors present PrRP neurons DMH NTS VLM providing morphological evidence direct interaction
0.08830947.11796488.html.plaintext.txt	181	As PrRP number peptides coexpressed Ob R hypothalamic neurons shown also interact leptin 29 30 31 32 33 34
0.08830947.11796488.html.plaintext.txt	182	Together data support notion leptin acts throughout entire brain circuitry involved appetite body weight regulation
0.08830947.11796488.html.plaintext.txt	183	Footnotes This work supported Biotechnology Biological Sciences Research Council AstraZeneca Plc K
0.08830947.11796488.html.plaintext.txt	184	Medical Research Council Industrial Collaborative Student
0.08830947.11796488.html.plaintext.txt	185	Abbreviations ARC Arcuate nucleus AUC area curve CCK cholecystokinin DMH dorsal medial hypothalamus icv intracerebrovintricularly NTS nucleus tractus solitarius PrRP PRL related peptide PVN paraventricular nucleus TH tyrosine hydroxlase VLM ventrolateral medulla
0.08830947.11796488.html.plaintext.txt	186	Accepted publication October 5 2001
0.08830947.11796488.html.plaintext.txt	187	References Top Abstract Introduction Materials Methods Results Discussion References Hinuma S Habata Y Fujii R Kawamata Y Hosoya M Fukusumi S Kitada C Masuo Y Asano T Matsumoto H Sekiguchi M Kurokawa T Nishimura O Onda H Fujino M 1998 A prolactin releasing peptide brain
0.08830947.11796488.html.plaintext.txt	188	Nature 393272 276CrossRefMedline Maruyama M Matsumoto H Fujiwara K Kitada C Hinuma S Onda H Fujino M Inoue K 1999 Immunocytochemical localization prolactin releasing peptide rat brain
0.08830947.11796488.html.plaintext.txt	189	Endocrinology 1402326 2333AbstractFree Full Text Iijima N Kataoka Y Kakihara K Bamba H Tamada Y Hayashi S Matsuda T Tanaka M Honjyo H Hosoya M Hinuma S Ibata Y 1999 Cytochemical study prolactin releasing peptide PrRP rat brain
0.08830947.11796488.html.plaintext.txt	190	Neuroreport 101713 1716Medline Yamakawa K Kudo K Kanba S Arita J 1999 Distribution prolactin releasing peptide immunoreactive neurons rat hypothalamus
0.08830947.11796488.html.plaintext.txt	191	Neurosci Lett 267113 116CrossRefMedline Matsumoto H Murakami Y Horikoshi Y Noguchi J Habata Y Kitada C Hinuma S Onda H Fujino M 1999 Distribution characterization immunoreactive prolactin releasing peptide rat tissue plasma
0.08830947.11796488.html.plaintext.txt	192	Biochem Biophys Res Commun 257264 268CrossRefMedline Jarry H Heuer H Schomburg L Bauer K 2000 Prolactin releasing peptides stimulate prolactin release vivo
0.08830947.11796488.html.plaintext.txt	193	Neuroendocrinology 71262 267CrossRefMedline Watanobe H Schioth HB Wikberg JE Suda T 2000 Evaluation role prolactin releasing peptide prolactin secretion induced ether stress suckling rat comparison vasoactive intestinal peptide
0.08830947.11796488.html.plaintext.txt	194	Brain Res 86591 96CrossRefMedline Samson WK Resch ZT Murphy TC Chang JK 1998 Gender biased activity novel prolactin releasing peptides comparison thyrotropin releasing hormone reveals pharmacologic effects
0.08830947.11796488.html.plaintext.txt	195	Endocrine 9289 291Medline Takahashi K Abe T Matsumoto K Tomita M 2000 Does prolactin releasing peptide receptor regulate prolactin secretion human pituitary adenomas Neurosci Lett 291159 162CrossRefMedline Chen C Dun SL Dun NJ Chang JK 1999 Prolactin releasing peptide immunoreactivity A1 A2 noradrenergic neurons rat medulla
0.08830947.11796488.html.plaintext.txt	196	Brain Res 822276 279CrossRefMedline Lee Y Yang SP Soares MJ Voogt JL 2000 Distribution prolactin releasing peptide mRNA rat brain
0.08830947.11796488.html.plaintext.txt	197	Brain Res Bull 51171 176CrossRefMedline Elmquist JK Elias CF Saper CB 1999 From lesions leptin hypothalamic control food intake body weight
0.08830947.11796488.html.plaintext.txt	198	Neuron 22221 232Medline Kalra SP Dube MG Pu S Xu B Horvath TL Kalra PS 1999 Interacting appetite regulating pathways hypothalamic regulation body weight
0.08830947.11796488.html.plaintext.txt	199	Endocr Rev 2068 100AbstractFree Full Text Lawrence CB Celsi F Brennand J Luckman SM 2000 Alternative role prolactin releasing peptide regulation food intake
0.08830947.11796488.html.plaintext.txt	200	Nat Neurosci 3645 646CrossRefMedline Lawrence CB Ellacott KLJ Luckman SM 2002 PRL releasing peptide reduces food intake may mediate satiety signaling
0.08830947.11796488.html.plaintext.txt	201	Endocrinology 143360 367AbstractFree Full Text Zhang Y Proenca R Maffei M Barone M Leopold L Friedman JM 1994 Positional cloning mouse obese gene human homologue
0.08830947.11796488.html.plaintext.txt	202	Nature 372425 432CrossRefMedline Bado A Levasseur S Attoub S Kermorgant S Laigneau JP Bortoluzzi MN Moizo L Lehy T Guerre Millo M Marchand Brustel Y Lewin MJ 1998 The stomach source leptin
0.08830947.11796488.html.plaintext.txt	203	Nature 394790 793CrossRefMedline Wang J Liu R Hawkins M Barzilai N Rossetti L 1998 A nutrient sensing pathway regulates leptin gene expression muscle fat
0.08830947.11796488.html.plaintext.txt	204	Nature 393684 688CrossRefMedline Masuzaki H Ogawa Y Sagawa N Hosoda K Matsumoto T Mise H Nishimura H Yoshimasa Y Tanaka I Mori T Nakao K 1997 Nonadipose tissue production leptin leptin novel placenta derived hormone humans
0.08830947.11796488.html.plaintext.txt	205	Nat Med 31029 1033Medline Hoggard N Hunter L Duncan JS Williams LM Trayhurn P Mercer JG 1997 Leptin leptin receptor mRNA protein expression murine fetus placenta
0.08830947.11796488.html.plaintext.txt	206	Proc Natl Acad Sci USA 9411073 11078AbstractFree Full Text Ahima RS Flier JS 2000 Leptin
0.08830947.11796488.html.plaintext.txt	207	Annu Rev Physiol 62413 437CrossRefMedline Phillips MS Liu Q Hammond HA Dugan V Hey PJ Caskey CJ Hess JF 1996 Leptin receptor missense mutation fatty Zucker rat
0.08830947.11796488.html.plaintext.txt	208	Nat Genet 1318 19Medline Seeley RJ van Dijk G Campfield LA Smith FJ Burn P Nelligan JA Bell SM Baskin DG Woods SC Schwartz MW 1996 Intraventricular leptin reduces food intake body weight lean rats obese Zucker rats
0.08830947.11796488.html.plaintext.txt	209	Horm Metab Res 28664 668Medline Chen H Charlat O Tartaglia LA Woolf EA Weng X Ellis SJ Lakey ND Culpepper J Moore KJ Breitbart RE Duyk GM Tepper RI Morgenstern JP 1996 Evidence diabetes gene encodes leptin receptor identification mutation leptin receptor gene dbdb mice
0.08830947.11796488.html.plaintext.txt	210	Cell 84491 495Medline Mercer JG Hoggard N Williams LM Lawrence CB Hannah LT Trayhurn P 1996 Localization leptin receptor mRNA long form splice variant Ob Rb mouse hypothalamus adjacent brain regions situ hybridization
0.08830947.11796488.html.plaintext.txt	211	FEBS Lett 387113 116CrossRefMedline Elmquist JK Bjorbaek C Ahima RS Flier JS Saper CB 1998 Distributions leptin receptor mRNA isoforms rat brain
0.08830947.11796488.html.plaintext.txt	212	CO2 2 572AbstractFree Full Text Mercer JG Moar KM Hoggard N 1998 Localization leptin receptor Ob R messenger ribonucleic acid rodent hindbrain
0.08830947.11796488.html.plaintext.txt	213	Endocrinology 13929 34AbstractFree Full Text Mercer JG Hoggard N Williams LM Lawrence CB Hannah LT Morgan PJ Trayhurn P 1996 Coexpression leptin receptor preproneuropeptide Y mRNA arcuate nucleus mouse hypothalamus
0.08830947.11796488.html.plaintext.txt	214	J Neuroendocrinol 8733 735Medline Wilson BD Bagnol D Kaelin CB Ollmann MM Gantz I Watson SJ Barsh GS 1999 Physiological anatomical circuitry Agouti related protein leptin signaling
0.08830947.11796488.html.plaintext.txt	215	Endocrinology 1402387 2397AbstractFree Full Text Cheung CC Clifton DK Steiner RA 1997 Proopiomelanocortin neurons direct targets leptin hypothalamus
0.08830947.11796488.html.plaintext.txt	216	Endocrinology 1384489 4492AbstractFree Full Text Kristensen P Judge ME Thim L Ribel U Christjansen KN Wulff BS Clausen JT Jensen PB Madsen OD Vrang N Larsen PJ Hastrup S 1998 Hypothalamic CART new anorectic peptide regulated leptin
0.08830947.11796488.html.plaintext.txt	217	Nature 39372 76CrossRefMedline Hakansson M L de Lecea L Sutcliffe JG Yanagisawa M Meister B 1999 Leptin receptor STAT3 immunoreactivities hypocretinorexin neurons lateral hypothalamus
0.08830947.11796488.html.plaintext.txt	218	J Neuroendocrinol 11653 663CrossRefMedline Funahashi H Hori T Shimoda Y Mizushima H Ryushi T Katoh S Shioda S 2000 Morphological evidence neural interactions leptin orexin hypothalamus
0.08830947.11796488.html.plaintext.txt	219	Regul Pept 9231 35CrossRefMedline Stephens TW Basinski M Bristow PK Bue Valleskey JM Burgett SG Craft L Hale J Hoffmann J Hsiung HM Kriauciunas A 1995 The role neuropeptide Y antiobesity action obese gene product
0.08830947.11796488.html.plaintext.txt	220	Nature 377530 532CrossRefMedline Schwartz MW Seeley RJ Woods SC Weigle DS Campfield LA Burn P Baskin DG 1997 Leptin increases hypothalamic pro opiomelanocortin mRNA expression rostral arcuate nucleus
0.08830947.11796488.html.plaintext.txt	221	Diabetes 462119 2123Abstract Sahu A 1998 Leptin decreases food intake induced melanin concentrating hormone MCH galanin GAL neuropeptide Y NPY rat
0.08830947.11796488.html.plaintext.txt	222	Endocrinology 1394739 4742AbstractFree Full Text Beck B Richy S 1999 Hypothalamic hypocretinorexin neuropeptide Y divergent interaction energy depletion leptin
0.08830947.11796488.html.plaintext.txt	223	Biochem Biophys Res Commun 258119 122CrossRefMedline Sahu A Carraway RE Wang YP 2001 Evidence neurotensin mediates central effect leptin food intake rat
0.08830947.11796488.html.plaintext.txt	224	Brain Res 888343 347CrossRefMedline Paxinos G Watson C 1986 The rat brain stereotaxic coordinates
0.08830947.11796488.html.plaintext.txt	225	San Diego Academic Press Brady LS Smith MA Gold PW Herkenham M 1990 Altered expression hypothalamic neuropeptide mRNAs food restricted food deprived rats
0.08830947.11796488.html.plaintext.txt	226	Neuroendocrinology 52441 447Medline Beck B Burlet A Nicolas JP Burlet C 1990 Hyperphagia obesity associated central peptidergic dysregulation rats
0.08830947.11796488.html.plaintext.txt	227	J Nutr 120806 811Medline Roland BL Sutton SW Wilson SJ Luo L Pyati J Huvar R Erlander MG Lovenberg TW 1999 Anatomical distribution prolactin releasing peptide receptor suggests additional functions central nervous system periphery
0.08830947.11796488.html.plaintext.txt	228	Endocrinology 1405736 5745AbstractFree Full Text Morales T Hinuma S Sawchenko PE 2000 Prolactin releasing peptide expressed afferents endocrine hypothalamus neurosecretory neurones
0.08830947.11796488.html.plaintext.txt	229	J Neuroendocrinol 12131 140CrossRefMedline Maruyama M Matsumoto H Fujiwara K Noguchi J Kitada C Fujino M Inoue K 2001 Prolactin releasing peptide novel stress mediator central nervous system
0.08830947.11796488.html.plaintext.txt	230	Endocrinology 1422032 2038AbstractFree Full Text Kataoka Y Iijima N Yano T Kakihara K Hayashi S Hinuma S Honjo H Hayashi S Tanaka M Ibata Y 2001 Gonadal regulation PrRP mRNA expression nucleus tractus solitarius ventral lateral reticular nuclei rat
0.08830947.11796488.html.plaintext.txt	231	Mol Brain Res 8742 47Medline Kim EM O Hare E Grace MK Welch CC Billington CJ Levine AS 2000 ARC POMC mRNA PVN MSH lower obese relative lean zucker rats
0.08830947.11796488.html.plaintext.txt	232	Brain Res 86211 16CrossRefMedline Richard D Rivest R Naimi N Timofeeva E Rivest S 1996 Expression corticotropin releasing factor receptors brain lean obese Zucker rats
0.08830947.11796488.html.plaintext.txt	233	Endocrinology 1374786 4795Abstract Hay Schmidt A Helboe L Larsen PJ 2001 Leptin receptor immunoreactivity present ascending serotonergic catecholaminergic neurons rat
0.08830947.11796488.html.plaintext.txt	234	Neuroendocrinology 73215 226CrossRefMedline Huang Q Rivest R Richard D 1998 Effects leptin corticotropin releasing factor CRF synthesis CRF neuron activation paraventricular hypothalamic nucleus obese obob mice
0.08830947.11796488.html.plaintext.txt	235	Endocrinology 1391524 1532AbstractFree Full Text Gardner JD Rothwell NJ Luheshi GN 1998 Leptin affects food intake via CRF receptor mediated pathways
0.08830947.11796488.html.plaintext.txt	236	Nat Neurosci 1103CrossRefMedline Barrachina MD Martinez V Wang L Wei JY Tache Y 1997 Synergistic interaction leptin cholecystokinin reduce short term food intake lean mice
0.08830947.11796488.html.plaintext.txt	237	Proc Natl Acad Sci USA 9410455 10460AbstractFree Full Text Matson CA Wiater MF Kuijper JL Weigle DS 1997 Synergy leptin cholecystokinin CCK control daily caloric intake
0.08830947.11796488.html.plaintext.txt	238	Peptides 181275 1278CrossRefMedline Emond M Schwartz GJ Ladenheim EE Moran TH 1999 Central leptin modulates behavioral neural responsivity CCK
0.08830947.11796488.html.plaintext.txt	239	Am J Physiol 276R1545 R1549 Wang YH Tache Y Sheibel AB Go VL Wei JY 1997 Two types leptin responsive gastric vagal afferent terminals vitro single unit study rats
0.08830947.11796488.html.plaintext.txt	240	Am J Physiol 273R833 R837 Yuan CS Attele AS Dey L Xie JT 2000 Gastric effects cholecystokinin interaction leptin brainstem neuronal activity neonatal rats
0.08830947.11796488.html.plaintext.txt	241	J Pharmacol Exp Ther 295177 182AbstractFree Full Text
0.14533791.15976062.html.plaintext.txt	0	Orexin A Modulates Mitral Cell Activity Rat Olfactory Bulb Patch Clamp Study Slices Immunocytochemical Localization Orexin Receptors Alexandre B
0.14533791.15976062.html.plaintext.txt	1	Hardy Josiane Aioun Christine Baly Karyn A
0.14533791.15976062.html.plaintext.txt	2	Julliard Monique Caillol Roland Salesse Patricia Duchamp Viret
0.14533791.15976062.html.plaintext.txt	3	Laboratoire de Neurosciences et Systemes Sensoriels A
0.14533791.15976062.html.plaintext.txt	4	Centre National de la Recherche Scientifique Unite Mixte de Recherche 5020 Universite Claude Bernard 69366 Lyon cedex 07 Laboratoire Neurobiologie de l Olfaction et Prise Alimentaire J
0.14533791.15976062.html.plaintext.txt	5	Equipe Recepteurs et Communication Chimique Institut National de la Recherche Agronomique 78352 Jouy en Josas France
0.14533791.15976062.html.plaintext.txt	6	Address correspondence requests reprints Patricia Duchamp Viret Laboratoire de Neurosciences et Systemes Sensoriels Centre National de la Recherche Scientifique Unite Mixte de Recherche 5020 Universite Claude Bernard 50 Avenue Tony Garnier 69366 Lyon cedex 07 France
0.14533791.15976062.html.plaintext.txt	7	Abstract Top Abstract Introduction Materials Methods Results Discussion References Orexin A B involved feeding behaviors recently fibers containing peptides found rat olfactory bulb
0.14533791.15976062.html.plaintext.txt	8	These fibers originate lateral posterior hypothalamus perifornical area distributed glomerular mitral cell granule cell layers
0.14533791.15976062.html.plaintext.txt	9	Orexin receptors mainly expressed mitral cells
0.14533791.15976062.html.plaintext.txt	10	In present study RT PCR experiments done determine orexin receptor expression early postnatal life rats immunocytochemical experiments performed clarify structural ultrastructural localization orexin receptors olfactory bulb
0.14533791.15976062.html.plaintext.txt	11	Furthermore functional electrophysiological approach examined action orexin A mitral cell excitability spontaneous activity using vitro patch clamp techniques
0.14533791.15976062.html.plaintext.txt	12	RT PCR results show mRNA two type receptors type 1 orexin receptors type 2 orexin receptors expressed olfactory bulb rat 10 d adult stage
0.14533791.15976062.html.plaintext.txt	13	At ages immunocytochemical data show orexin 1 receptors localized cell bodies periglomerular mitraltufted granule cells
0.14533791.15976062.html.plaintext.txt	14	Immunoreactivity also demonstrated mitraltufted cell dendrites arborizing glomerulus mitraltufted granule cell processes running external plexiform layer
0.14533791.15976062.html.plaintext.txt	15	Functionally orexin A produced either direct tetrodotoxin insensitive depolarization one group mitral cells 7 another group 30 indirect tetrodotoxin sensitive hyperpolarization
0.14533791.15976062.html.plaintext.txt	16	Both actions mediated type 1 orexin receptors response antagonized SB 334867 A selective antagonist
0.14533791.15976062.html.plaintext.txt	17	Mitral cell recordings performed bicuculline aminobutyric acid GABAA receptor antagonist indicate orexin induced indirect hyperpolarization partly mediated GABAA receptors
0.14533791.15976062.html.plaintext.txt	18	Because granule cells periglomerular cells express orexin receptors GABAergic cells could involved hyperpolarization
0.14533791.15976062.html.plaintext.txt	19	Other mechanisms could support indirect hyperpolarization mitral cells dopamine interneuron solicitation proposed
0.14533791.15976062.html.plaintext.txt	20	Our results provide data allow us better understand neural communication regulation mechanisms hypothalamic feeding centers olfactory bulb
0.14533791.15976062.html.plaintext.txt	21	Introduction Top Abstract Introduction Materials Methods Results Discussion References MANY ANIMAL BEHAVIORS triggered odorant cues environment particular food odors among major determinants food choice food learning
0.14533791.15976062.html.plaintext.txt	22	It clear several years olfactory system involved feeding behavior
0.14533791.15976062.html.plaintext.txt	23	The nutritional status animal shown influence reactivity food odors mitral cells main output neurons olfactory bulb 1 2 3 4 5
0.14533791.15976062.html.plaintext.txt	24	For example demonstrated fasted rats 70 mitral cells stimulated food odor stimulation vs
0.14533791.15976062.html.plaintext.txt	25	12 nonfood odor whereas fed animals 11 responded food odors 6
0.14533791.15976062.html.plaintext.txt	26	Conversely shown odors regulate food intake behavior
0.14533791.15976062.html.plaintext.txt	27	Indeed Le Magnen 7 showed rats increased food intake satiated presented differently odorized foods
0.14533791.15976062.html.plaintext.txt	28	Moreover everyday experience humans animals food odors attractive feeding whereas stimuli may become neutral even aversive feeding
0.14533791.15976062.html.plaintext.txt	29	Sensory olfactory inputs thus crucial nutrition behavior humans animals
0.14533791.15976062.html.plaintext.txt	30	Olfactory system involvement begins food search step olfactory sensitivity levels provide signal detection allows animals follow concentration gradient toward food source
0.14533791.15976062.html.plaintext.txt	31	Then olfactory system contributes palatability analysis food appetence animal food defined internal physiological status
0.14533791.15976062.html.plaintext.txt	32	Hypothalamic feeding centers 8 analyze metabolic cues turn regulate appetite
0.14533791.15976062.html.plaintext.txt	33	These centers send direct specific projections olfactory structures especially olfactory bulb OB first integrative relay system 9 10 11 12 13
0.14533791.15976062.html.plaintext.txt	34	The discovery orexin A OXA B OXB hypocretin I II 11 13 two peptides derived prepropeptide contained neurons localized lateral hypothalamus perifornical area provided new insights regulation mechanisms feeding
0.14533791.15976062.html.plaintext.txt	35	Orexin OX neurons lateral hypothalamus perifornical area controlled changes circulating nutriment activated natural hypoglycemic conditions 14 insulin induced ones 15 whereas inhibited glucose signals related ingestion food 15 16 17 18 19
0.14533791.15976062.html.plaintext.txt	36	These data led classification OX neurons lateral hypothalamus perifornical area glucose sensitive neurons 20
0.14533791.15976062.html.plaintext.txt	37	Furthermore OX neurons stimulated increase circulating lipids
0.14533791.15976062.html.plaintext.txt	38	Thus OX neurons negatively related glucose level inversely related circulating fat 21 latter relation suggesting role peptide increased activity associated high fat diet 22 23
0.14533791.15976062.html.plaintext.txt	39	The majority physiological studies reviews see Refs
0.14533791.15976062.html.plaintext.txt	40	24 25 indicate orexins potent stimulators food intake 26 27 OXA effective OXB
0.14533791.15976062.html.plaintext.txt	41	Moreover peptides interact various neuronal pathways potentiate apparently divergent functions review see Ref
0.14533791.15976062.html.plaintext.txt	42	Currently two closely related G protein coupled receptor types termed type 1 orexin receptors ORX1 type 2 orexin receptors ORX2 identified
0.14533791.15976062.html.plaintext.txt	43	Although OXA affinity ORX1 ORX2 OXB 10 fold greater affinity ORX2 13 29 30
0.14533791.15976062.html.plaintext.txt	44	31 demonstrated OB immunoreactive OXA varicose fibers mainly around glomeruli mitral cell granule cell layers
0.14533791.15976062.html.plaintext.txt	45	Glomeruli spherical neuropiles lying OB periphery primary axons synapse mitral cells delimited GABAergic interneurons called periglomerular cells
0.14533791.15976062.html.plaintext.txt	46	Granule cells deep GABAergic inhibitory interneurons
0.14533791.15976062.html.plaintext.txt	47	The localization OXB labeling paralleled OXA
0.14533791.15976062.html.plaintext.txt	48	However immunoreactivity ORX1 ORX2 detected mitraltufted cell bodies ORX2 labeling faint 31
0.14533791.15976062.html.plaintext.txt	49	This localization may support least partly data reporting OB mitral cell reactivity odors modulated according hunger satiation states rats 3
0.14533791.15976062.html.plaintext.txt	50	Our exploration OX actions OB network provide better understanding cross talk olfactory metabolic cues brain basis nutritional behavior
0.14533791.15976062.html.plaintext.txt	51	This study analyzed specifically OX action mitral cells putative cell targets OB 31 vitro patch clamp study
0.14533791.15976062.html.plaintext.txt	52	To actions OXA SB 334867 A ORX1 antagonist GlaxoSmithKline Harlow Essex UK tested spontaneous activity excitability mitral cells
0.14533791.15976062.html.plaintext.txt	53	Furthermore immunocytochemical study done clarify cellular subcellular localizations ORX1 expressed orexin receptor OB
0.14533791.15976062.html.plaintext.txt	54	In addition data available early ontogenetic development orexin innervation orexin receptors OB electrophysiological studies slices performed 10 25 d old rats presence ORX1 evaluated RT PCR experiments rats adults 10 25 postnatal days P old
0.14533791.15976062.html.plaintext.txt	55	Altogether data expected provide enlightenment neurochemical modulatory effect OXA OB activity reveal cell types bulbar network targets orexin innervations
0.14533791.15976062.html.plaintext.txt	56	Furthermore first functional study expected give rise preliminary hypotheses dealing role olfactory system regulation food intake processes
0.14533791.15976062.html.plaintext.txt	57	Materials Methods Top Abstract Introduction Materials Methods Results Discussion References All experiments done according European Communities Council Directive 24 November 1986 86609EEC
0.14533791.15976062.html.plaintext.txt	58	RT PCR analysis orexin receptor expression hypothalamus HYPO OB Animals tissue preparation
0.14533791.15976062.html.plaintext.txt	59	Experimental procedures carried minimize animal suffering number rats used
0.14533791.15976062.html.plaintext.txt	60	Male Wistar rats breeding stock housed 12 h light 12 h dark cycles free access food water
0.14533791.15976062.html.plaintext.txt	61	A total three animals killed decapitation 10 d 25 d P10 P25 2 months adults
0.14533791.15976062.html.plaintext.txt	62	Before weaning P21 young kept dam
0.14533791.15976062.html.plaintext.txt	63	The brain quickly removed HYPO OB dissected ice
0.14533791.15976062.html.plaintext.txt	64	Total RNA isolation RT PCR analysis
0.14533791.15976062.html.plaintext.txt	65	Total RNA isolated HYPO OB using guanidium thiocyanate phenol chloroform extraction method 32 DNase I treated Roche Molecular Biochemicals Meylan France cDNA reverse transcribed 3 microg total RNA 50 U Superscript II reverse transcriptase according manufacturer procedures Life Technologies Inc
0.14533791.15976062.html.plaintext.txt	66	A control reaction omitting enzyme systematically included confirm absence genomic contamination
0.14533791.15976062.html.plaintext.txt	67	An internal standard using glyceraldehyde 3 phophate dehydrogenase GAPDH referent housekeeping gene systematically included
0.14533791.15976062.html.plaintext.txt	68	For PCR amplification 1 microl reverse transcription aliquot added 20 microl reaction mixture containing pair primers GAPDH primers 5 AAACCCATCACCATCTTCCA 1057 1077 NM017008 low 5 AGGGGCCATCCACAGTCTTCT 1417 1397 ORX1 primers 5 CCTGCCTCCAGACTATGAGGA 631 651 NM013064 low 5 ATCTTAGGGTAGAGTTCATCT 1206 1186 ORX2 primers 5 GATTCCCTCCCTCGTCGCAA 81 100 NM013074
0.14533791.15976062.html.plaintext.txt	69	1 low 5 CAGCGTTCATCGCAGACTGTA 700 681
0.14533791.15976062.html.plaintext.txt	70	PCRs done according standard procedures using 0
0.14533791.15976062.html.plaintext.txt	71	5U Taq DNA polymerase Promega Charbonnieres France
0.14533791.15976062.html.plaintext.txt	72	A thermal cycler apparatus used following conditions 45 sec 94 C 45 sec 57 C 45 sec 72 C 23 GAPDH 35 cycles ORX1 ORX2
0.14533791.15976062.html.plaintext.txt	73	PCR products 3 microl aliquot resolved 1
0.14533791.15976062.html.plaintext.txt	74	5 agarose gel 1x TAE Tris acetate EDTA buffer containing 1 microgml ethidium bromide
0.14533791.15976062.html.plaintext.txt	75	A molecular weight marker systematically included 1 kb DNA ladder Life Technologies Inc
0.14533791.15976062.html.plaintext.txt	76	InVitrogen Cergy Pontoise France
0.14533791.15976062.html.plaintext.txt	77	Gels photographed UV light
0.14533791.15976062.html.plaintext.txt	78	OB PCR products 25 d old rats sequenced Genome Express Paris France analyzed using BLAST programs
0.14533791.15976062.html.plaintext.txt	79	Structural ultrastructural immunocytochemical study Seven male Wistar rats used light microscopy three adults rats 2 month old body weight 300 g two P10 two P25
0.14533791.15976062.html.plaintext.txt	80	Animals deeply anesthetized pentobarbital 60 mgkg body weight ip Sanofi Paris France perfused transcardially 100 ml saline 150 ml freshly prepared fixative solution 4 paraformaldehyde 0
0.14533791.15976062.html.plaintext.txt	81	The olfactory bulbs carefully dissected postfixed fixative 3 h room temperature cryoprotected saccharose 30 cut cryostat serial coronal sections 14 microm thick
0.14533791.15976062.html.plaintext.txt	82	Sections first treated 30 min 4 C 0
0.14533791.15976062.html.plaintext.txt	83	5 H2O2 PBS eliminate endogenous peroxidases carefully washed
0.14533791.15976062.html.plaintext.txt	84	A 1 h immersion solution 10 normal goat serum PBS room temperature RT used block nonspecific sites
0.14533791.15976062.html.plaintext.txt	85	Sections incubated 4 C 3 d primary antibody diluted 12000 PBS containing 1 normal goat serum 0
0.14533791.15976062.html.plaintext.txt	86	1 BSA rabbit antiserum directed rathuman ORX1 Alpha Diagnostic International Cortec France
0.14533791.15976062.html.plaintext.txt	87	As controls sections incubated without primary antibody
0.14533791.15976062.html.plaintext.txt	88	After several washings PBS containing 1 nonfat freeze dried milk sections incubated biotinylated goat antirabbit IgG Vectastain Elite kit Vector Laboratories Burlingame CA buffer 1 2 h RT
0.14533791.15976062.html.plaintext.txt	89	All sections rinsed PBS incubated 1 h RT either avidin biotin peroxidase complex Vectastain Elite kit labeling visualized using 3 3 diaminobenzidine tetrahydrochloride solution intensified nickel peroxidase substrate kit Vector Laboratories streptavidin fluorescein 11000 Vector Laboratories 46 diamino 2 phenylindole DAPI added 10 min 110000 PBS achieve nuclear counterstaining
0.14533791.15976062.html.plaintext.txt	90	Electron microscopy done three adult male Wistar rats deeply anesthetized described
0.14533791.15976062.html.plaintext.txt	91	They transcardially perfused 200 ml saline followed 300 ml freshly prepared fixative solution paraformaldehyde 4 picric acid 0
0.14533791.15976062.html.plaintext.txt	92	The brains dissected postfixed overnight 4 C fixative
0.14533791.15976062.html.plaintext.txt	93	Serial coronal sections 50 microm obtained vibratome VT1000S Leica Nussloch Germany collected phosphate buffer
0.14533791.15976062.html.plaintext.txt	94	The immunocytochemical study performed free floating sections PBS using preembedding protocol previously described except Triton X 100 omitted sections immersed 1 sodium borohydride NaBH4 Sigma Aldrich Saint Quentin Fallavier France PBS quench free aldehydic sites blocking nonspecific sites
0.14533791.15976062.html.plaintext.txt	95	The ORX1 visualized using diaminobenzidine DAB method adapted electron microscopy
0.14533791.15976062.html.plaintext.txt	96	05 M sucrosed Tris buffer pH 7
0.14533791.15976062.html.plaintext.txt	97	05 DAB substrate presence H2O2
0.14533791.15976062.html.plaintext.txt	98	The reaction conducted stereomicroscope stopped immersion sections Tris buffer
0.14533791.15976062.html.plaintext.txt	99	The immunostained sections selected osmicated 1 OsO4 solution stained en bloc 1 uranyl acetate dehydrated graded series ethanol embedded Epoxy resin LX112 Ladd Research Industries Inland Europe ConflansLanterne France
0.14533791.15976062.html.plaintext.txt	100	Semithin sections 1 2 microm obtained resin embedded material stained toluidine blue
0.14533791.15976062.html.plaintext.txt	101	Ultrathin sections 50 100 nm collected copper grids contrasted lead citrate observed Philips Suresne France CM12 electron microscope 80 kV accelerating voltage
0.14533791.15976062.html.plaintext.txt	102	Patch clamp recording experiments Slice preparation
0.14533791.15976062.html.plaintext.txt	103	Experiments performed 10 25 d old rats Wistar
0.14533791.15976062.html.plaintext.txt	104	Animals killed decapitation head quickly immersed ice cold artificial cerebrospinal fluid ACSF 2 4 C containing millimoles 125 NaCl 4 KCl 25 NaHCO3 2 CaCl2 1
0.14533791.15976062.html.plaintext.txt	105	3 bubbled mixture 95 O2 5 CO2 osmolarity adjusted 320 mOsm glucose
0.14533791.15976062.html.plaintext.txt	106	The OB removed previously detailed 33 cut sagittal horizontal slices 250 350 microm thick using vibratome
0.14533791.15976062.html.plaintext.txt	107	Slices incubated Gibb chamber 30 C 1 h stored RT
0.14533791.15976062.html.plaintext.txt	108	For electrophysiological recordings slices transferred experimental chamber 2 ml mounted upright microscope Axioscope FS Zeiss Gottingen Germany
0.14533791.15976062.html.plaintext.txt	109	During recordings slices continuously perfused oxygenated 30 C ACSF 2
0.14533791.15976062.html.plaintext.txt	110	Neurons visualized using water immersion x40 objective differential interference contrast optics Nomarski Edgewater NJ infrared illumination Hamamatsu camera Hamamatsu Photonics France Massy France
0.14533791.15976062.html.plaintext.txt	111	Electrophysiological recordings
0.14533791.15976062.html.plaintext.txt	112	The whole cell recording technique used
0.14533791.15976062.html.plaintext.txt	113	Patch pipettes pulled borosilicate glass outer diameter 1
0.14533791.15976062.html.plaintext.txt	114	17 mm Clark electromedical instrument Phymep Paris France without internal filament fired polished
0.14533791.15976062.html.plaintext.txt	115	Recording pipettes tip resistance 2 4 M
0.14533791.15976062.html.plaintext.txt	116	Seal resistance always greater 3 G
0.14533791.15976062.html.plaintext.txt	117	The recording pipette solution contained millimoles 121
0.14533791.15976062.html.plaintext.txt	118	1 GTPNa 10 HEPES 1 MgCl2 pH set 7
0.14533791.15976062.html.plaintext.txt	119	4 NaOH osmolarity 310 mOsmol glucose
0.14533791.15976062.html.plaintext.txt	120	For experiments reported values membrane potential values correction junction potential
0.14533791.15976062.html.plaintext.txt	121	A bipolar concentric electrode placed olfactory nerve layer near recorded mitraltufted cell stimulate olfactory nerve
0.14533791.15976062.html.plaintext.txt	122	Monophasic square pulses delivered stimulus isolation unit
0.14533791.15976062.html.plaintext.txt	123	Voltage current measurements neuron activity performed axoclamp 2B amplifier Axon Instruments Foster City CA
0.14533791.15976062.html.plaintext.txt	124	All experiments controlled PC pentium III computer using 12 bit AD DA converters digidata 1200B Axon Instruments sampling frequency 30 KHz clampex software version 8
0.14533791.15976062.html.plaintext.txt	125	All data presented mean plus minus SD
0.14533791.15976062.html.plaintext.txt	126	OXA Bachem Voisins le Brettoneux France aliquoted stored 20 C
0.14533791.15976062.html.plaintext.txt	127	OXA action mitral cells tested switching ACSF solution 1 min one containing OXA 10 200 nM see Refs
0.14533791.15976062.html.plaintext.txt	128	All solutions perfused tissue 2
0.14533791.15976062.html.plaintext.txt	129	Some experiments performed presence tetrodotoxin TTX 1 microM Tocris Fisher Bioblock Scientific Illkirch France blocks voltage gated sodium channels
0.14533791.15976062.html.plaintext.txt	130	Picrotoxin 50 microM Sigma bicuculline 10 microM Sigma also used block chloride conductance GABAA receptors respectively
0.14533791.15976062.html.plaintext.txt	131	ORX1 blocked SB 334867 A 10 microM GlaxoSmithKline see Refs
0.14533791.15976062.html.plaintext.txt	132	Results Top Abstract Introduction Materials Methods Results Discussion References RT PCR analysis orexin receptor expression OB RT PCR OB samples revealed single band expected size sequence ORX1 556 bp ORX2 620 bp mRNAs attesting presence mRNAs OB rats aged 10 25 d 2 months Fig
0.14533791.15976062.html.plaintext.txt	133	The relative abundance ORX1 ORX2 mRNAs seemed lower OB compared HYPO GAPDH gene equally amplified 361 bp fragment tissues
0.14533791.15976062.html.plaintext.txt	134	Albeit nonquantitative levels receptors mRNA dramatically change development
0.14533791.15976062.html.plaintext.txt	135	View larger version 47K FIG
0.14533791.15976062.html.plaintext.txt	136	Detection different orexin receptors mRNA RT PCR analysis HYPO OB tissues
0.14533791.15976062.html.plaintext.txt	137	PCR products GAPDH ORX1 ORX2 obtained HYPO OB samples 10 25 d old 10 25 adult rats ad run ethidium bromide stained 1
0.14533791.15976062.html.plaintext.txt	138	Products expected size controlled sequencing PCR products derived OB25 samples
0.14533791.15976062.html.plaintext.txt	139	O Control without DNA matrix MWM molecular weight marker 1 kb DNA ladder 512506 bp band specified
0.14533791.15976062.html.plaintext.txt	140	Only one representative rat experimental point shown n 3
0.14533791.15976062.html.plaintext.txt	141	Structural ultrastructural immunocytochemical study Light microscopic localization ORX1 immunoreactivity OB
0.14533791.15976062.html.plaintext.txt	142	31 showed ORX1 seems expressed higher levels ORX2 protein level present study focused ORX1
0.14533791.15976062.html.plaintext.txt	143	Our observations confirmed refined previous description ORX1 localization OB 31
0.14533791.15976062.html.plaintext.txt	144	At light microscopic level ORX1 immunoreactive cells identified dark staining due presence DAB nickel reaction product green fluorescence cytoplasm Fig
0.14533791.15976062.html.plaintext.txt	145	In P10 P25 adult rats ORX1 distributed laminar pattern
0.14533791.15976062.html.plaintext.txt	146	ORX1 immunoreactivity obvious cell bodies glomerular Fig
0.14533791.15976062.html.plaintext.txt	147	2 A B E mitral cell granule cell layers Fig
0.14533791.15976062.html.plaintext.txt	148	The immunolabeling homogeneous along mitral cell layer immunoreactive mitral cells clustered patches
0.14533791.15976062.html.plaintext.txt	149	In way glomeruli ORX1 immunoreactive whereas others devoid immunolabeling
0.14533791.15976062.html.plaintext.txt	150	Most often ORX1 immunoreactive glomeruli located immunoreactive zones mitral cell layer
0.14533791.15976062.html.plaintext.txt	151	In glomerular layer immunoreactive cell bodies found base glomerulus external plexiform layer
0.14533791.15976062.html.plaintext.txt	152	Some neurons rather elongated shape whereas others slightly smaller round
0.14533791.15976062.html.plaintext.txt	153	Some round neurons also observed around glomerulus
0.14533791.15976062.html.plaintext.txt	154	According location neurons could correspond external tufted cells periglomerular cells PGs respectively
0.14533791.15976062.html.plaintext.txt	155	In semifine sections brown dots probably corresponding mitral cell dendrites appeared dispersed external plexiform layer EPL inside glomeruli
0.14533791.15976062.html.plaintext.txt	156	In sections primary antiserum omitted immunolabeling observed
0.14533791.15976062.html.plaintext.txt	157	View larger version 122K FIG
0.14533791.15976062.html.plaintext.txt	158	Light microscopic localization ORX1 immunoreactivity OB
0.14533791.15976062.html.plaintext.txt	159	The presence ORX1 OB checked semithin sections obtained 50 microm sections embedded epoxy resin adults A D thin sections 14 microm P10 rat E P25 rat F
0.14533791.15976062.html.plaintext.txt	160	The semithin sections observed either stained Toluidine blue 1 microm thick A C without counterstaining 2 microm thick B D
0.14533791.15976062.html.plaintext.txt	161	The presence ORX1 visualized dark DAB A D DAB nickel staining spread cytoplasm immunoreactive ir cells E green fluorescence F blue staining 46 diamino 2 phenylindole nuclear coloration
0.14533791.15976062.html.plaintext.txt	162	ORX1 ir cell bodies identified layers except olfactory nerve layer
0.14533791.15976062.html.plaintext.txt	163	In glomerular layer A B x40 immersion ir cell bodies observed around glomeruli
0.14533791.15976062.html.plaintext.txt	164	Large elongated cell bodies mostly located basis glomeruli could external tufted cell large arrows whereas small round cell bodies border could identified PG cells thin arrows
0.14533791.15976062.html.plaintext.txt	165	Inside glomeruli brown dots likely mitral cells dendrites arrowheads
0.14533791.15976062.html.plaintext.txt	166	In mitral cell layer cytoplasm mitral cells highly ir large arrows C D x40 immersion
0.14533791.15976062.html.plaintext.txt	167	Some mitral cells express ORX1 arrowheads C D
0.14533791.15976062.html.plaintext.txt	168	In sections mitral cell nucleus apparent devoid immunolabeling C D
0.14533791.15976062.html.plaintext.txt	169	Some granule cells ORX1 ir E F
0.14533791.15976062.html.plaintext.txt	170	In EPL punctiform DAB labeling thin arrows 2D corresponded presumably mitral cell dendrites
0.14533791.15976062.html.plaintext.txt	171	bc Blood capillary GCL granular cell layer GL glomeruli MCL mitral cell layer n nucleus
0.14533791.15976062.html.plaintext.txt	172	Ultrastructural localization ORX1 immunoreactivity OB
0.14533791.15976062.html.plaintext.txt	173	Electron microscopy observations confirmed light microscopy observations
0.14533791.15976062.html.plaintext.txt	174	At ultrastrutural level presence ORX1 visualized electron dense DAB deposits
0.14533791.15976062.html.plaintext.txt	175	The identification immunoreactive elements based descriptions Pinching Powell 39 40 Price Powell 41
0.14533791.15976062.html.plaintext.txt	176	Deep OB ORX1 expressed granule cell bodies localized cytoplasm neighborhood plasma membrane Fig
0.14533791.15976062.html.plaintext.txt	177	In mitral cell layer rather mitral cell bodies characterized typical abundant stacks rough endoplasmic reticulum ORX1 labeled
0.14533791.15976062.html.plaintext.txt	178	However ORX1 immunoreactive mitral cells labeling obvious consisted numerous patches localized cisternae endoplasmic reticulum neighborhood plasma membrane indicating ORX1 locally synthesized folded membrane Fig
0.14533791.15976062.html.plaintext.txt	179	In EPL immunolabeling shown mitral cell granule cell dendrites Fig 3C reciprocal synapses ORX1 immunoreactive mitral cells granule cell dendrites could observed Fig
0.14533791.15976062.html.plaintext.txt	180	3D accumulation labeling near synapse noted
0.14533791.15976062.html.plaintext.txt	181	View larger version 164K FIG
0.14533791.15976062.html.plaintext.txt	182	Ultrastructural localization ORX1 granule cell layer mitral cell layer EPL OB
0.14533791.15976062.html.plaintext.txt	183	At ultrastructural level presence ORX1 visualized electron dense DAB deposits arrows
0.14533791.15976062.html.plaintext.txt	184	In granule cell layer A x10500 ORX1 immunoreactivity identified numerous granule cell bodies
0.14533791.15976062.html.plaintext.txt	185	Labeling either cytoplasmic close plasma membrane
0.14533791.15976062.html.plaintext.txt	186	In mitral cell layer B x11000 mitral cells exhibited punctuated labeling also cytoplasmic close plasma membrane
0.14533791.15976062.html.plaintext.txt	187	In EPL C x7000 ORX1 immunoreactivity found mitral cell granule cell dendrites
0.14533791.15976062.html.plaintext.txt	188	In cases D x17500 ORX1 immunoreactive gemmules granule cell observed establishing synaptic contact mitral cell dendrites reciprocal synapses arrowheads
0.14533791.15976062.html.plaintext.txt	189	rer Rough endoplasmic reticulum GCg gemmule granule cell GC granule cell m mitochondria MCd mitral cell dendrite MC mitral cell GCd granule cell dendrite v synaptic vesicle
0.14533791.15976062.html.plaintext.txt	190	In glomerular layer immunolabeling found cell bodies processes
0.14533791.15976062.html.plaintext.txt	191	Some ORX1 immunoreactive neurons observed periphery glomeruli small round cells almost completely filled nuclei surrounded thin rim cytoplasm Fig
0.14533791.15976062.html.plaintext.txt	192	These ultrastructural features corresponded PGs
0.14533791.15976062.html.plaintext.txt	193	At base glomerulus infraglomerular area immunoreactive neurons identified
0.14533791.15976062.html.plaintext.txt	194	They slightly larger PGs cytoplasm abundant showed well developed granular endoplasmic reticulum Fig
0.14533791.15976062.html.plaintext.txt	195	On basis description Pinching Powell 40 neurons identified external tufted cells
0.14533791.15976062.html.plaintext.txt	196	The glomerular neuropil showed numerous ORX1 immunoreactive processes
0.14533791.15976062.html.plaintext.txt	197	Strongly immunoreactive dendritic shafts observed
0.14533791.15976062.html.plaintext.txt	198	Given regular arrangement neurotubules identified main dendritic shafts tufted cells shown
0.14533791.15976062.html.plaintext.txt	199	Numerous dendrites mitraltufted cells surrounded olfactory neurons terminals ORX1 immunoreactive Fig
0.14533791.15976062.html.plaintext.txt	200	Some gemmules PG also ORX1 immunoreactive Fig
0.14533791.15976062.html.plaintext.txt	201	In glomerular neuropil terminals olfactory axons never ORX1 immunoreactive
0.14533791.15976062.html.plaintext.txt	202	View larger version 166K FIG
0.14533791.15976062.html.plaintext.txt	203	Ultrastructural localization ORX1 glomerular layer OB
0.14533791.15976062.html.plaintext.txt	204	At ultrastructural level presence ORX1 visualized electron dense DAB deposits arrows
0.14533791.15976062.html.plaintext.txt	205	In glomerular layer A x12000 DAB electron dense deposits arrows found small cells exhibiting large nucleus surrounded thin rim cytoplasm
0.14533791.15976062.html.plaintext.txt	206	These cells located around glomeruli identified PGs
0.14533791.15976062.html.plaintext.txt	207	At basis glomeruli infraglomerular layer area B x19000 larger cells characterized stacks rer also ORX1 immunoreactive
0.14533791.15976062.html.plaintext.txt	208	These ultrastructural characteristics correspond external tuft cell
0.14533791.15976062.html.plaintext.txt	209	In glomerular neuropile C x28000 D x29000 ORX1 immunoreactive dendrites mitraltufted cells numerous surrounded ORN terminals showing synaptic contacts C curved arrows
0.14533791.15976062.html.plaintext.txt	210	Some gemmules kind typical varicosities termed OB anatomists see Ref
0.14533791.15976062.html.plaintext.txt	211	39 PGs also ORX1 immunoreactive E x17000
0.14533791.15976062.html.plaintext.txt	212	ETC External tufted cell G glomerulus m mitochondria MTCd mitraltufted cell dendrite ORN olfactory receptor neuron rer rough endoplasmic reticulum v synaptic vesicles PGg gemmule periglomerular cell
0.14533791.15976062.html.plaintext.txt	213	Patch clamp recording experiments Whole cell recordings obtained 204 mitral cells strictly located mitral cell layer
0.14533791.15976062.html.plaintext.txt	214	Cell identification based location electrophysiological properties morphology size
0.14533791.15976062.html.plaintext.txt	215	Mitral cells showed average resting potential 60 plus minus 4 mV mean input resistance 74 plus minus 38 M
0.14533791.15976062.html.plaintext.txt	216	Among 204 mitral cells 61 30 responsive OXA
0.14533791.15976062.html.plaintext.txt	217	In current clamp mode bath application OXA induced hyperpolarization n 46 23 depolarization n 15 7 mitral cells two types response observed two distinct subsets
0.14533791.15976062.html.plaintext.txt	218	OXA induced hyperpolarizations long lasting small amplitudes
0.14533791.15976062.html.plaintext.txt	219	At 100 nM hyperpolarizations 3 plus minus 2 mV mean amplitude occurred 30 plus minus 9
0.14533791.15976062.html.plaintext.txt	220	5 sec delay lasted 95 plus minus 57 sec
0.14533791.15976062.html.plaintext.txt	221	In spontaneously active cells n 12 hyperpolarizations caused complete cessation spontaneous spikes excitatory postsynaptic potentials EPSP Fig
0.14533791.15976062.html.plaintext.txt	222	View larger version 39K FIG
0.14533791.15976062.html.plaintext.txt	223	Inhibitory action OXA mitral cells
0.14533791.15976062.html.plaintext.txt	224	A 20 nM OXA horizontal bar totally abolished mitral cell spontaneous activity control activity recovered rinsing period 120 sec
0.14533791.15976062.html.plaintext.txt	225	B Mitral cell showing spontaneous activity composed spikes EPSPs abolished OXA 10 nM
0.14533791.15976062.html.plaintext.txt	226	B1 B3 Enlargement 2 sec periods focusing EPSPs
0.14533791.15976062.html.plaintext.txt	227	B1 Spontaneous EPSPs control
0.14533791.15976062.html.plaintext.txt	228	B2 Disappearance EPSPs OXA
0.14533791.15976062.html.plaintext.txt	229	B3 Recovery spontaneous EPSPs rinsing
0.14533791.15976062.html.plaintext.txt	230	MP Resting membrane potential beginning recording
0.14533791.15976062.html.plaintext.txt	231	OXA induced hyperpolarizations reproducible cells tested successive applications n 3 data shown abolished TTX fast Na channel blocker added ACSF n 2 Fig
0.14533791.15976062.html.plaintext.txt	232	6 C D seen OXA caused cessation spontaneous firing control whereas presence bicuculline slowed spontaneous firing
0.14533791.15976062.html.plaintext.txt	233	Bicuculline decreased amplitude OXA hyperpolarizing responses 17 75 n 14
0.14533791.15976062.html.plaintext.txt	234	Picrotoxin n 5 similar effects bicuculline data shown
0.14533791.15976062.html.plaintext.txt	235	When ACSF perfusion contained SB 334867 A ORX1 antagonist hyperpolarizing responses completely blocked n 4 Fig
0.14533791.15976062.html.plaintext.txt	236	Altogether results indicate hyperpolarizing effect OXA indirect effect
0.14533791.15976062.html.plaintext.txt	237	OXA may act ORX1 GABAergic neurons would act turn mitral cell GABAA receptors
0.14533791.15976062.html.plaintext.txt	238	Consistent hypothesis bicuculline decreased OXA hyperpolarizing effect mitral cells
0.14533791.15976062.html.plaintext.txt	239	View larger version 22K FIG
0.14533791.15976062.html.plaintext.txt	240	Inhibitory action OXA may indirect
0.14533791.15976062.html.plaintext.txt	241	A OXA 200 nM hyperpolarized silent mitral cell
0.14533791.15976062.html.plaintext.txt	242	B The hyperpolarizing effect OXA abolished TTX 1 microM
0.14533791.15976062.html.plaintext.txt	243	C OXA 20 nM hyperpolarized spontaneously active mitral cell 1
0.14533791.15976062.html.plaintext.txt	244	5 mV horizontal scale bar 20 sec vertical scale bar 5 mV
0.14533791.15976062.html.plaintext.txt	245	D The hyperpolarizing effect OXA maintained bicuculline 10 microM reduced 0
0.14533791.15976062.html.plaintext.txt	246	MP Resting membrane potential beginning recording
0.14533791.15976062.html.plaintext.txt	247	View larger version 27K FIG
0.14533791.15976062.html.plaintext.txt	248	Characterization orexin receptor type involved mitral cell hyperpolarizing responses
0.14533791.15976062.html.plaintext.txt	249	A OXA 200 nM hyperpolarized mitral cell control condition
0.14533791.15976062.html.plaintext.txt	250	B SB 334867 ORX1 antagonist 10 microM blocked completely OXA induced hyperpolarization
0.14533791.15976062.html.plaintext.txt	251	MP Resting membrane potential beginning recording
0.14533791.15976062.html.plaintext.txt	252	In distinct set 14 mitral cells bath application OXA induced long lasting small amplitude depolarizations Fig
0.14533791.15976062.html.plaintext.txt	253	At 25 nM OXA depolarizations 2 plus minus 0
0.14533791.15976062.html.plaintext.txt	254	6 mV mean amplitude occurred 33 plus minus 18 sec delay lasted 241 plus minus 84 sec
0.14533791.15976062.html.plaintext.txt	255	Orexin depolarizations insensitive TTX n 2 Fig
0.14533791.15976062.html.plaintext.txt	256	To examine depolarizing effect detail subsequent experiments conducted voltage clamp conditions
0.14533791.15976062.html.plaintext.txt	257	When membrane potential voltage clamped near resting level OXA produced inward current whose delay duration matched OXA induced depolarizations Fig
0.14533791.15976062.html.plaintext.txt	258	This inward current blocked SB 334867 A n 3 Fig
0.14533791.15976062.html.plaintext.txt	259	These experiments indicate OXA depolarizing action mitral cells direct mediated ORX1
0.14533791.15976062.html.plaintext.txt	260	View larger version 30K FIG
0.14533791.15976062.html.plaintext.txt	261	A OXA 25 nM depolarized mitral cell 4 mV
0.14533791.15976062.html.plaintext.txt	262	B This depolarization prevented TTX
0.14533791.15976062.html.plaintext.txt	263	MP Resting membrane potential beginning recording
0.14533791.15976062.html.plaintext.txt	264	View larger version 28K FIG
0.14533791.15976062.html.plaintext.txt	265	ORX1 involved OXA induced inward current
0.14533791.15976062.html.plaintext.txt	266	A OXA induced slow inward current
0.14533791.15976062.html.plaintext.txt	267	B SB 334867 10 microM abolished current
0.14533791.15976062.html.plaintext.txt	268	Vh Holding potential MP resting membrane potential beginning recording
0.14533791.15976062.html.plaintext.txt	269	Among 46 mitral cells hyperpolarized OXA 42 submitted electrical stimulation applied olfactory nerves complete protocol described Ref
0.14533791.15976062.html.plaintext.txt	270	33 21 mitral cells responsive stimulation
0.14533791.15976062.html.plaintext.txt	271	For recorded cell excitation threshold determined control condition stimulation intensity adjusted elicit one spike per shock stable latency
0.14533791.15976062.html.plaintext.txt	272	Then OXA perfused recording chamber effect mitral cell response parameters threshold latency number spikes analyzed function time
0.14533791.15976062.html.plaintext.txt	273	In four mitral cells olfactory nerve stimulation excitability decreased OXA Fig
0.14533791.15976062.html.plaintext.txt	274	10 although affected 17
0.14533791.15976062.html.plaintext.txt	275	View larger version 9K FIG
0.14533791.15976062.html.plaintext.txt	276	Effect OXA mitral cell responses evoked olfactory nerve stimulation
0.14533791.15976062.html.plaintext.txt	277	A Three superimposed control responses olfactory nerve stimulation one spike per stimulation
0.14533791.15976062.html.plaintext.txt	278	B Five minutes perfusion 100 nM OXA solution hyperpolarized cell 69 mV stimulations failed induce action potential
0.14533791.15976062.html.plaintext.txt	279	C Partial recovery control excitability two spikes three stimulations obtained rinsing period 10 min
0.14533791.15976062.html.plaintext.txt	280	MP Resting membrane potential beginning recording
0.14533791.15976062.html.plaintext.txt	281	Discussion Top Abstract Introduction Materials Methods Results Discussion References Past studies shown orexin fibers receptors adult rat OB 9 10 11 12 13 31
0.14533791.15976062.html.plaintext.txt	282	However data development orexin innervation orexin receptor expression available tissue
0.14533791.15976062.html.plaintext.txt	283	Through RT PCR experiments present information orexin receptor mRNA OB early postnatal development
0.14533791.15976062.html.plaintext.txt	284	Our results indicate ORX1 ORX2 expressed early 10 d birth P10 presence shown adult stage control tissues HYPO OB
0.14533791.15976062.html.plaintext.txt	285	Although quantitative RT PCR could lead us definitive conclusion study suggests ORX1 ORX2 expressed lower level OB compared HYPO
0.14533791.15976062.html.plaintext.txt	286	Noteworthy results show stable level ORX1 expression weaning well adults
0.14533791.15976062.html.plaintext.txt	287	Other brain tissues hypoglossal neurons 42 hypothalamus 43 show higher expression levels P20 25 stable level thereafter
0.14533791.15976062.html.plaintext.txt	288	From functional point view Van den Pol et al
0.14533791.15976062.html.plaintext.txt	289	44 report orexin system functional early brain development show P10 orexin induces robust synaptic activity hypothalamic neurons
0.14533791.15976062.html.plaintext.txt	290	Altogether results hypothalamic structures convinced us perform electrophysiological recordings P10 25 rats
0.14533791.15976062.html.plaintext.txt	291	Furthermore anatomical results appears cellular localization ORX1 similar preweaning adult rats
0.14533791.15976062.html.plaintext.txt	292	At light microscopic level immunocytochemical study confirms localization ORX1 mitraltufted cell bodies reported Caillol et al
0.14533791.15976062.html.plaintext.txt	293	At ultrastructural level localization orexin receptors widely studied one recent publication arcuate nucleus 45
0.14533791.15976062.html.plaintext.txt	294	Our results agreement study showing ORX1 localized cell bodies well pre postsynaptic levels
0.14533791.15976062.html.plaintext.txt	295	In study part labeling localized rough endoplasmic reticulum suggesting local synthesis ORX1
0.14533791.15976062.html.plaintext.txt	296	ORX1 immunoreactivity also shown mitraltufted cell dendrites running EPL bodies processes external tuft cells periglomerular granule cells
0.14533791.15976062.html.plaintext.txt	297	Thus ORX1 seems expressed OB cell categories systematic homogeneous way
0.14533791.15976062.html.plaintext.txt	298	Indeed ORX1 labeling homogeneously distributed neither along mitral cell layer glomerular layer
0.14533791.15976062.html.plaintext.txt	299	Interestingly ORX1 immunoreactive mitral cell bodies found cases adjacent ORX1 immunoreactive glomeruli
0.14533791.15976062.html.plaintext.txt	300	Although observation needs documented may suggest columnar organization orexin receptive cells OB
0.14533791.15976062.html.plaintext.txt	301	To optimize vitro neuron survival electrophysiological recordings performed 10 25 d old rats period surrounding weaning
0.14533791.15976062.html.plaintext.txt	302	During period ingestive behavior evolves type food changes liquid diet full fat solid diet less fat
0.14533791.15976062.html.plaintext.txt	303	However experimental conditions observed weaning progressive developing rats suck mothers nipples eat solid food available ad libitum dam
0.14533791.15976062.html.plaintext.txt	304	Furthermore recordings 75 made 20 25 d old rats obvious variability due different ages rats observed mitral cell reactivity OXA
0.14533791.15976062.html.plaintext.txt	305	Our results show OXA modulates mitral cell activity
0.14533791.15976062.html.plaintext.txt	306	Only 61 mitral cells 30 shown modulated OXA 7 23 depolarized hyperpolarized respectively
0.14533791.15976062.html.plaintext.txt	307	These results agreement immunocytochemical observations indicate rather mitral cells ORX1 immunoreactive
0.14533791.15976062.html.plaintext.txt	308	OXA shown exert two opposite effects two distinct sets mitral cells either direct depolarizing effect inducing TTX insensitive inward current indirect hyperpolarizing effect
0.14533791.15976062.html.plaintext.txt	309	However OXA effects blocked SB 334867 A demonstrated involvement ORX1 Fig
0.14533791.15976062.html.plaintext.txt	310	View larger version 34K FIG
0.14533791.15976062.html.plaintext.txt	311	OXA action mitral cells rat OB network
0.14533791.15976062.html.plaintext.txt	312	From olfactory mucosa olfactory receptor neurons ORN send axons OB terminating glomeruli GLO spherical neuropiles lying OB periphery
0.14533791.15976062.html.plaintext.txt	313	Within glomeruli axons synapse primary dendrites pd mitral cells MC
0.14533791.15976062.html.plaintext.txt	314	Mitral cells make reciprocal dendrodendritic synapses two categories GABAergic inhibitory interneurons pd PGs secondary dendrites sd granule cells GC
0.14533791.15976062.html.plaintext.txt	315	So mitral cell activity modulated double GABAergic control sending axon olfactory cortex
0.14533791.15976062.html.plaintext.txt	316	ORX1 found expressed subsets MC PG GC cells dark gray tufted cells Tc light gray receptors localized soma processes neurons
0.14533791.15976062.html.plaintext.txt	317	Left The diagram schematizes indirect hyperpolarizing action OXA MC OXA acting ORX1 hypothesized depolarize GABAergic inhibitory interneurons PGs GCs dark gray turn would inhibit MCs white via GABA release acting GABAA receptors localized MC
0.14533791.15976062.html.plaintext.txt	318	Within glomeruli part OXA indirect hyperpolarizing action also ascribed action GABA released PGs GABAB receptors localized ORN axons MCs pd
0.14533791.15976062.html.plaintext.txt	319	Right The diagram schematizes direct depolarizing action OXA MC OXA acting ORX1 expressed subset mitral cells hypothesized depolarize MC dark gray
0.14533791.15976062.html.plaintext.txt	320	The hyperpolarizing action OXA sufficient completely shut mitral cell spontaneous activity antagonized voltage gated Na channel blocker TTX
0.14533791.15976062.html.plaintext.txt	321	The latter observation supports OXA action indirect
0.14533791.15976062.html.plaintext.txt	322	Such OXA indirect effects reported brain area like substantia nigra 34 laterodorsal tegmental nucleus 46 HYPO 47 raphe nucleus 43
0.14533791.15976062.html.plaintext.txt	323	These OXA effects either excitatory inhibitory
0.14533791.15976062.html.plaintext.txt	324	We show OXA hyperpolarizing response partly antagonized GABAA receptor antagonist bicuculline
0.14533791.15976062.html.plaintext.txt	325	This result indicates GABAergic interneurons involved OXA induced hyperpolarization mitral cells
0.14533791.15976062.html.plaintext.txt	326	Our immunocytochemical observations PG granule cell bodies express ORX1 support GABAergic interneurons could contacted orexin fibers localized mainly glomerular layer feebly granule cell layer 31
0.14533791.15976062.html.plaintext.txt	327	Indeed PG granule cells main interneurons two layers mainly GABAergic 49 50 shown inhibit mitral cells activation GABAA receptors 51 52
0.14533791.15976062.html.plaintext.txt	328	Along line GABAergic interneurons excited OXA may act metabotropic GABAB receptors
0.14533791.15976062.html.plaintext.txt	329	Indeed GABAB receptor activation reported elsewhere abolish completely spontaneous activity mitral cells decrease mitral cell excitability electrical shocks applied olfactory nerve layer 33 53 54
0.14533791.15976062.html.plaintext.txt	330	In present study OXA also observed decrease mitral cell excitability electrical shocks
0.14533791.15976062.html.plaintext.txt	331	For effect OXA induced GABA release may act extrasynaptic presynaptic GABAB receptors located primary afferent axons 55 56 strongly suspected act depressing neurotransmitter release 54 57 58 59 60
0.14533791.15976062.html.plaintext.txt	332	On hand decreasing mitral cell spontaneous activity OXA induced GABA release may act GABAB receptors located either soma dendritic intraglomerular tuft rat mitral cells 55 56
0.14533791.15976062.html.plaintext.txt	333	One mechanisms GABAB would silence spontaneous activity may GABAB would slightly hyperpolarize mitral cells rest shifting cell polarization state state latter signaling steady silent state 61
0.14533791.15976062.html.plaintext.txt	334	Because dopamine GABA colocalized PG interneurons 62 63 64 dopamine also would good candidate support OXA indirect inhibition mitral cells
0.14533791.15976062.html.plaintext.txt	335	Consistent hypothesis frog OB dopamine found inhibit mitral cell spontaneous activity 65
0.14533791.15976062.html.plaintext.txt	336	A coaction GABA dopamine cannot ruled
0.14533791.15976062.html.plaintext.txt	337	An especially interesting fact electrophysiological results fully consistent vivo study 48
0.14533791.15976062.html.plaintext.txt	338	The authors recorded unit extracellular activity mitral cells anesthetized rats whereas applied OXA directly OB surface lateral ventricle
0.14533791.15976062.html.plaintext.txt	339	Both types applications shown induce decrease spontaneous rate cells increase others distinct cells
0.14533791.15976062.html.plaintext.txt	340	Noteworthy vivo vitro studies OXA induces two types opposite actions mitral cell spontaneous activity
0.14533791.15976062.html.plaintext.txt	341	As conclusion study brings information ontogenetic expression orexin receptors rat OB clarifies ORX1 structural ultrastructural localization within network
0.14533791.15976062.html.plaintext.txt	342	In addition vitro recordings demonstrate OXA acts mitral cells directly indirectly inducing apparently opposite effects
0.14533791.15976062.html.plaintext.txt	343	The direct depolarizing effect could mediated ORX1 located mitral cell bodies dendrites
0.14533791.15976062.html.plaintext.txt	344	ORX1 located PG granular cells could responsible indirect hyperpolarizing action OXA via GABA induced release
0.14533791.15976062.html.plaintext.txt	345	Altogether data provide new insights apprehending mechanisms olfactory system involved regulation food intake behavior
0.14533791.15976062.html.plaintext.txt	346	In hungry animals hypothalamic OX neurons stimulated hypoglycemia 14 probably increase release centrifugal pathways
0.14533791.15976062.html.plaintext.txt	347	Our electrophysiological data detail OX action OB
0.14533791.15976062.html.plaintext.txt	348	Indeed acting directly increasing output neuron background activity indirectly inhibitory interneuron networks OX depress excite mitral cells
0.14533791.15976062.html.plaintext.txt	349	These two opposite actions shown occur two distinct mitral cell sets
0.14533791.15976062.html.plaintext.txt	350	OX may provide selective dual actions olfactory information processing favoring mitral cells involved food odor processing silencing others involved
0.14533791.15976062.html.plaintext.txt	351	This duality action could result increasing signal noise ratio may increase olfactory detection power
0.14533791.15976062.html.plaintext.txt	352	This hypothesis fully agrees behavioral experiments progress research team
0.14533791.15976062.html.plaintext.txt	353	Indeed preliminary results indicate olfactory detection thresholds rats enhanced OXA intracerebral injection
0.14533791.15976062.html.plaintext.txt	354	Acknowledgments We thank GlaxoSmithKline Harlow Essex UK generous gift SB 334867 A Professor Edwin Griff University Cincinnati Cincinnati OH careful reading English
0.14533791.15976062.html.plaintext.txt	355	Footnotes First Published Online June 23 2005
0.14533791.15976062.html.plaintext.txt	356	Abbreviations ACSF Artificial cerebrospinal fluid DAB diaminobenzidine EPL external plexiform layer EPSP excitatory postsynaptic potential GABA aminobutyric acid GABAergic neurons use GABA neurotransmitter GAPDH glyceraldehyde 3 phophate dehydrogenase HYPO hypothalamus OB olfactory bulb ORX1 orexin receptor 1 ORX2 orexin receptor 2 OX orexin OXA orexin A OXB orexin B P postnatal day PG periglomerular cell RT room temperature TTX tetrodotoxin
0.14533791.15976062.html.plaintext.txt	357	Accepted publication June 8 2005
0.14533791.15976062.html.plaintext.txt	358	References Top Abstract Introduction Materials Methods Results Discussion References Chaput M Holley A 1976 Olfactory bulb responsiveness food odour stomach distension rat
0.14533791.15976062.html.plaintext.txt	359	Chem Senses 2198 201 Pager J 1974 A selective modulation olfactory input suppressed lesions anterior limb anterior commisure
0.14533791.15976062.html.plaintext.txt	360	Physiol Behav 13523 526CrossRefMedline Pager J 1974 A selective modulation olfactory bulb electrical activity relation learning palatability hungry satiated rats
0.14533791.15976062.html.plaintext.txt	361	Physiol Behav 12189 195CrossRefMedline Pager J 1978 Ascending olfactory information centrifugal influxes contributing nutritional modification rat mitral cell responses
0.14533791.15976062.html.plaintext.txt	362	Brain Res 140251 271CrossRefMedline Pager J Giachetti I Holley A Le Magnen J 1972 A selective control olfactory bulb electrical activity relation food deprivation satiety rats
0.14533791.15976062.html.plaintext.txt	363	Physiol Behav 9573 579CrossRefMedline Giachetti I Mac Leod P Le Magnen J 1970 Influence hunger satiety states responses olfactory bulb rats
0.14533791.15976062.html.plaintext.txt	364	J Physiol Paris 62Suppl 2280 281 Le Magnen J 1999 Increased food intake induced rats changes satiating sensory input food first published French 1956
0.14533791.15976062.html.plaintext.txt	365	Appetite 3333 35CrossRefMedline Bernardis LL Bellinger LL 1996 The lateral hypothalamic area revisited ingestive behavior
0.14533791.15976062.html.plaintext.txt	366	Neurosci Biobehav Rev 20189 287CrossRefMedline Chemelli RM Willie JT Sinton CM Elmquist JK Scammell T Lee C Richardson JA Williams SC Xiong Y Kisanuki Y Fitch TE Nakazato M Hammer RE Saper CB Yanagisawa M 1999 Narcolepsy orexin knockout mice molecular genetics sleep regulation
0.14533791.15976062.html.plaintext.txt	367	Cell 98437 451CrossRefMedline Date Y Ueta Y Yamashita H Yamaguchi H Matsukara S Kangawa K Sakurai T Yanagisawa M Nakazato M 1999 Orexins orexigenic hypothalamic peptides interact autonomic neuroendocrine neuroregulatory systems
0.14533791.15976062.html.plaintext.txt	368	Proc Natl Acad Sci USA 96748 753AbstractFree Full Text De Lecea L Kilduff TS Peyron C Gao X Foye PE Danielson PE Fukuhara C Battenberg EL Gautvik VT Bartlett 2nd FS Frankel WN van den Pol AN Bloom FE Gautvik KM Sutcliffe JG 1998 The hypocretins hypothalamus specific peptides neuroexcitatory activity
0.14533791.15976062.html.plaintext.txt	369	Proc Natl Acad Sci USA 95322 327AbstractFree Full Text Peyron C Tighe D Vanden Pol AN De Lecea L Heller HC Sutcliffe JG Kilduff TS 1998 Neurons containing hypocretin orexin project multiple neuronal systems
0.14533791.15976062.html.plaintext.txt	370	J Neurosci 189996 10015AbstractFree Full Text Sakurai T Amemiya A Ishii M Matsuzaki I Chemelli RM Tanaka H Williams SC Richarson JA Kozlowski GP Wilson S Arch JR Buckingham RE Haynes AC Carr SA Annan RS McNulty DE Liu WS Terrett JA Elshourbagy NA Bergsma DJ Yanagisawa M 1998 Orexins orexin receptors family hypothalamic neuropeptides G protein coupled receptors regulate feeding behavior
0.14533791.15976062.html.plaintext.txt	371	Cell 92696 Moriguchi T Sakurai T Nambu T Yanagisawa M Goto K 1999 Neurons containing orexin lateral hypothalamic area adult rat brain activated insulin induced acute hypoglycemia
0.14533791.15976062.html.plaintext.txt	372	Neurosci Lett 264101 104CrossRefMedline Griffond B Risold PY Jacquemard C Colard C Fellmann D 1999 Insulin induced hypoglycemia increases preprohypocretin orexin mRNA rat lateral hypothalamic area
0.14533791.15976062.html.plaintext.txt	373	Neurosci Lett 26277 80CrossRefMedline Briski KP Sylvester PW 2001 Hypothalamic orexin A immunopositive neurons express Fos response central glucopenia
0.14533791.15976062.html.plaintext.txt	374	Neuroreport 12531 534CrossRefMedline Cai XJ Denis R Vernon RG Clapham JC Wilson S Arch JR Williams G 2001 Food restriction selectively increases hypothalamic orexin B levels lactating rats
0.14533791.15976062.html.plaintext.txt	375	Regul Pept 97163 168CrossRefMedline Cai XJ Widdowson PS Harrold J Wilson S Buckingham RE Arch JR Tadayyon M Clapham JC Wilding J Williams G 1999 Hypothalamic orexin expression modulation blood glucose feeding
0.14533791.15976062.html.plaintext.txt	376	Diabetes 482132 2137Abstract Yamanaka A Muraki Y Tsujino N Goto K Sakurai T 2003 Regulation orexin neurons monoaminergic cholinergic systems
0.14533791.15976062.html.plaintext.txt	377	Biochem Biophys Res Commun 303120 129CrossRefMedline Bahjaoui Bouhaddi M Fellmann D Griffond B Bugnon C 1994 Insulin treatment stimulates rat melanin concentrating hormone producing neurons
0.14533791.15976062.html.plaintext.txt	378	Neuropeptides 27251 258CrossRefMedline Wortley KE Chang GQ Davydova Z Leibowitz SF 2003 Peptides regulate food intake orexin gene expression increased states hypertriglyceridemia
0.14533791.15976062.html.plaintext.txt	379	Am J Physiol Regul Integr Comp Physiol 284R1454 R1465 Hagan JJ Leslie RA Patel S Evans ML Wattam TA Holmes S Benham CD Taylor SG Routledge C Hemmati P Munton RP Ashmeade TE Shah AS Hatcher JP Hatcher PD Jones DN Smith MI Piper DC Hunter AJ Porter RA Upton N 1999 Orexin A activates locus coeruleus cell firing increases arousal rat
0.14533791.15976062.html.plaintext.txt	380	Proc Natl Acad Sci USA 9610911 10916AbstractFree Full Text Ida T Nakahara K Katayama T Murakami N Nakazato M 1999 Effect lateral cerebroventricular injection appetite stimulating neuropeptide orexin neuropeptide Y various behavioral activities rats
0.14533791.15976062.html.plaintext.txt	381	Brain Res 821526 529CrossRefMedline Leibowitz SF Wortley KE 2004 Hypothalamic control energy balance different peptides different functions
0.14533791.15976062.html.plaintext.txt	382	Peptides 25473 504CrossRefMedline Rodgers RJ Ishii Y Halford JC Blundell JE 2002 Orexins appetite regulation
0.14533791.15976062.html.plaintext.txt	383	Neuropeptides 36303 325CrossRefMedline Edwards CM Abusnana S Sunter D Murphy KG Ghatei MA Bloom SR 1999 The effect orexins food intake comparison neuropeptide Y melanin concentrating hormone galanin
0.14533791.15976062.html.plaintext.txt	384	J Endocrinol 160R7 R12 Lubkin M Stricker Krongrad A 1998 Independent feeding metabolic actions orexins mice
0.14533791.15976062.html.plaintext.txt	385	Biochem Biophys Res Commun 253241 245CrossRefMedline Mondal MS Nakazato M Matsukura S 2000 Orexins hypocretins novel hypothalamic peptides divergent functions
0.14533791.15976062.html.plaintext.txt	386	Biochem Cell Biol 78299 305CrossRefMedline Smart D Jerman JC Brough SJ Neville WA Jewitt F Porter RA 2000 The hypocretins weak agonists recombinant human orexin 1 orexin 2 receptors
0.14533791.15976062.html.plaintext.txt	387	Br J Pharmacol 1291289 1291CrossRefMedline Smart D Jerman JC Brough SJ Rushton SL Murdock PR Jewitt F Elshourbagy NA Ellis CE Middlemiss DN Brown F 1999 Characterization recombinant human orexin receptor pharmacology Chinese hamster ovary cell line using FLIPR
0.14533791.15976062.html.plaintext.txt	388	Br J Pharmacol 1281 3CrossRefMedline Caillol M Aioun J Baly C Persuy MA Salesse R 2003 Localization orexins receptors rat olfactory system possible modulation olfactory perception neuropeptide synthetized centrally locally
0.14533791.15976062.html.plaintext.txt	389	Brain Res 96048 61CrossRefMedline Chomczynski P Sacchi N 1987 Single step method RNA isolation acid guanidinium thiocyanate phenol chloroform extraction
0.14533791.15976062.html.plaintext.txt	390	Anal Biochem 162156 159CrossRefMedline Palouzier Paulignan B Duchamp Viret P Hardy AB Duchamp A 2002 GABAB mediated inhibition mitral cell activity rat olfactory bulb whole cell patch clamp study vitro
0.14533791.15976062.html.plaintext.txt	391	Neuroscience 111241 250CrossRefMedline Korotkova TM Eriksson KS Haas HL Brown RE 2002 Selective excitation GABAergic neurons substantia nigra rat orexinhypocretin vitro
0.14533791.15976062.html.plaintext.txt	392	Regul Pept 10483 89CrossRefMedline Korotkova TM Sergeeva OA Eriksson KS Haas HL Brown RE 2003 Excitation ventral tegmental area dopaminergic nondopaminergic neurons orexinshypocretins
0.14533791.15976062.html.plaintext.txt	393	J Neurosci 237 11AbstractFree Full Text Yang B Ferguson AV 2002 Orexin A depolarizes dissociated rat area postrema neurons activation nonselective cationic conductance
0.14533791.15976062.html.plaintext.txt	394	J Neurosci 226303 6308AbstractFree Full Text Soffin EM Evans ML Gill CH Harries MH Benham CD Davies CH 2002 SB 334867 A antagonises orexin mediated excitation locus coeruleus
0.14533791.15976062.html.plaintext.txt	395	Neuropharmacology 42127 133CrossRefMedline Matsuo K Kaibara M Uezono Y Hayashi H Taniyama K Nakane Y 2002 Involvement cholinergic neurons orexin induced contraction guinea pig ileum
0.14533791.15976062.html.plaintext.txt	396	Eur J Pharmacol 452105 109CrossRefMedline Pinching AJ Powell TPS 1971 The neuron types glomerular layer olfactory bulb
0.14533791.15976062.html.plaintext.txt	397	J Cell Sci 9305 345Medline Pinching AJ Powell TPS 1971 The neuropil periglomerular region olfactory bulb
0.14533791.15976062.html.plaintext.txt	398	J Cell Sci 9379 409Medline Price JL Powell TPS 1970 The synaptology granule cells olfactory bulb
0.14533791.15976062.html.plaintext.txt	399	J Cell Sci 7125 155Medline Volgin DV Saghir M Kubin L 2002 Developmental changes orexin 2 receptor mRNA hypoglossal motoneurons
0.14533791.15976062.html.plaintext.txt	400	Neuroreport 13433 436CrossRefMedline Liu RJ van den Pol AN Aghajanian GK 2002 Hypocretins orexins regulate serotonin neurons dorsal raphe nucleus excitatory direct inhibitory indirect actions
0.14533791.15976062.html.plaintext.txt	401	J Neurosci 229453 9464AbstractFree Full Text Van den Pol AN Patrylo PR Ghosh PK Gao XB 2001 Lateral hypothalamus early developmental expression response hypocretin orexin
0.14533791.15976062.html.plaintext.txt	402	J Comp Neurol 433349 363CrossRefMedline Guan XB Suzuki R Funahashi H Wang QP Kageyama H Uehara K Yamada S Tsurugano S Shioda S 2002 Ultrastructural localization orexin 1 receptor pre post synaptic neurones rat arcuate nucleus
0.14533791.15976062.html.plaintext.txt	403	Neurosci Lett 329209 212CrossRefMedline Burlet S Tyler CJ Leonard CS 2002 Direct indirect excitation laterodorsal tegmental neurons hypocretinorexin peptides implications wakefulness narcolepsy
0.14533791.15976062.html.plaintext.txt	404	J Neurosci 222862 2872AbstractFree Full Text Follwell MJ Ferguson AV 2002 Cellular mechanisms orexin actions paraventricular nucleus neurones rat hypothalamus
0.14533791.15976062.html.plaintext.txt	405	J Physiol 545855 867AbstractFree Full Text Apelbaum A Perrut A Chaput M 2005 Orexin A effects olfactory bulb spontaneous activity odor responsiveness freely breathing rats
0.14533791.15976062.html.plaintext.txt	406	Regul Pept 12949 61CrossRefMedline Mugnaini E Oertel WH Wouterlood FF 1984 Immunocytochemical localization GABA neurons dopamine neurons rat main accessory olfactory bulbs
0.14533791.15976062.html.plaintext.txt	407	Neurosci Lett 47221 226CrossRefMedline Ribak CE Vaughn JE Saito K Barber B Roberts E 1977 Glutamate decarboxylase localization neurons olfactory bulb
0.14533791.15976062.html.plaintext.txt	408	Brain Res 1261 18CrossRefMedline Duchamp Viret P Duchamp A Chaput M 1993 GABAergic control odor induced activity frog olfactory bulb electrophysiological study picrotoxin bicuculline
0.14533791.15976062.html.plaintext.txt	409	Neuroscience 53111 120CrossRefMedline Jahr CE Nicoll RA 1982 An intracellular analysis dendrodendritic inhibition turtle vitro olfactory bulb
0.14533791.15976062.html.plaintext.txt	410	J Physiol 326213 234Medline Duchamp Viret P Delaleu JC Duchamp A
0.14533791.15976062.html.plaintext.txt	411	2000 GABAB mediated action frog olfactory bulb makes odor responses salient
0.14533791.15976062.html.plaintext.txt	412	Neuroscience 97771 777CrossRefMedline Nickell WT Behbehani MM Shipley MT 1994 Evidence GABAB mediated inhibition transmission olfactory nerve mitral cells rat olfactory bulb
0.14533791.15976062.html.plaintext.txt	413	Brain Res Bull 35119 123CrossRefMedline Bonino M Cantino D Sassoe Pognetto M 1999 Cellular subcellular localization aminobutyric acid B receptors rat olfactory bulb
0.14533791.15976062.html.plaintext.txt	414	Neuroscience Letters 274195 198CrossRefMedline Margeta Mitrovic M Mitrovic I Riley RC Jan LY Basbaum AI 1999 Immunohistochemical localization GABAB receptors rat central nervous system
0.14533791.15976062.html.plaintext.txt	415	CO2 6 1203AbstractFree Full Text Potapov AA 1985 Baclofen inhibition synaptic transmission frog olfactory glomeruli
0.14533791.15976062.html.plaintext.txt	416	Neirofiziologiya 17834 837 Potapov AA Trepakov VV 1986 Two types GABA receptors intact olfactory bulb primordial hippocampus frog pharmacological data
0.14533791.15976062.html.plaintext.txt	417	Bull Exp Biol Med 101323 326CrossRef Wachowiak M Cohen LB 1999 Presynaptic inhibition primary olfactory afferents mediated different mechanisms lobster turtle
0.14533791.15976062.html.plaintext.txt	418	J Neurosci 198808 8817AbstractFree Full Text Heyward P Ennis M Keller A Shipley MT 2001 Membrane bistability olfactory bulb mitral cells
0.14533791.15976062.html.plaintext.txt	419	J Neurosci 215311 5320AbstractFree Full Text Gall C Hendry SHC Seroogy KB Jones EG Haycock JW 1987 Evidence coexistence GABA dopamine neurons rat olfactory bulb
0.14533791.15976062.html.plaintext.txt	420	J Comp Neurol 266307 318CrossRefMedline Kosaka K Toida K Margolis FL Kosaka T 1997 Chemically defined neuron groups subpopulations glomerular layer rat main olfactory bulb
0.14533791.15976062.html.plaintext.txt	421	Prominent differences intraglomerular dendritic arborization relationship olfactory nerve terminals
0.14533791.15976062.html.plaintext.txt	422	Neuroscience 76775 786CrossRefMedline Kosaka T Hataguchi Y Hama K Nagatsu I Wu JY 1985 Coexistence immunoreactivities glutamate decarboxylase tyrosine hydroxylase neurons periglomerular region rat main olfactory bulb possible coexistence aminobutyric acid GABA dopamine
0.14533791.15976062.html.plaintext.txt	423	Brain Res 343166 171CrossRefMedline Duchamp Viret P Coronas V Delaleu JC Moyse E Duchamp A 1997 Dopaminergic modulation mitral cell activity frog olfactory bulb combined radioligand binding electrophysiological study
0.14533791.15976062.html.plaintext.txt	424	Neuroscience 79203 216CrossRefMedline This Article Abstract Full Text PDF All Versions Article 14694042 recent Author Manuscript PDF Purchase Article View Shopping Cart Alert article cited Alert correction posted Citation Map Services Email article friend Similar articles journal Similar articles PubMed Alert new issues journal Download citation manager Request Copyright Permission Google Scholar Articles Hardy A
0.14533791.15976062.html.plaintext.txt	425	Articles citing Article PubMed PubMed Citation Articles Hardy A
0.14533791.15976062.html.plaintext.txt	426	HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS Endocrinology Endocrine Reviews J
0.14533791.15976062.html.plaintext.txt	427	Molecular Endocrinology Recent Prog
0.12693419.14871884.html.plaintext.txt	0	Sleep enhances nocturnal plasma ghrelin levels healthy subjects Andrea Dzaja Mira A
0.12693419.14871884.html.plaintext.txt	1	Dalal Hubertus Himmerich Manfred Uhr Thomas Pollmacher Andreas Schuld
0.12693419.14871884.html.plaintext.txt	2	Max Planck Institute Psychiatry 80804 Munich Germany
0.12693419.14871884.html.plaintext.txt	3	Submitted 18 November 2003 accepted final form 5 February 2004
0.12693419.14871884.html.plaintext.txt	4	ABSTRACT TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Ghrelin endogenous ligand growth hormone secretagogue receptor shown promote slow wave sleep SWS non REM sleep stages 3 4
0.12693419.14871884.html.plaintext.txt	5	Plasma levels ghrelin dependent food intake increase sleeping subjects early part night
0.12693419.14871884.html.plaintext.txt	6	It unknown whether sleep affects ghrelin levels whether circadian networks involved
0.12693419.14871884.html.plaintext.txt	7	Therefore studied effect sleep deprivation nocturnal ghrelin secretion
0.12693419.14871884.html.plaintext.txt	8	In healthy male volunteers plasma levels ghrelin cortisol human growth hormone hGH measured two experimental sessions 24 h subjects allowed sleep 2300 0700 kept awake throughout night
0.12693419.14871884.html.plaintext.txt	9	During sleep ghrelin levels increased early part night decreased morning
0.12693419.14871884.html.plaintext.txt	10	This nocturnal increase blunted sleep deprivation ghrelin levels increased slightly early morning
0.12693419.14871884.html.plaintext.txt	11	Ghrelin secretion first hours sleep correlated positively peak hGH concentrations
0.12693419.14871884.html.plaintext.txt	12	We conclude nocturnal increase ghrelin levels likely caused sleep associated processes circadian influences
0.12693419.14871884.html.plaintext.txt	13	During first hours sleep ghrelin might promote sleep associated hGH secretion contribute promotion SWS
0.12693419.14871884.html.plaintext.txt	14	growth hormone cortisol circadian rhythm slow wave sleep sleep deprivation
0.12693419.14871884.html.plaintext.txt	15	GHRELIN IS A 28 AMINO ACID POLYPEPTIDE discovered endogenous ligand growth hormone secretagogue receptor 11
0.12693419.14871884.html.plaintext.txt	16	Ghrelin synthesized mainly stomach endocrine cells also identified tissues including hypothalamus 7 10 12
0.12693419.14871884.html.plaintext.txt	17	Ghrelin stimulates growth hormone secretion increases food intake appetite promotes body weight gain 17 37 38
0.12693419.14871884.html.plaintext.txt	18	Recent findings suggest ghrelin might involved regulation sleep humans promoting slow wave sleep SWS 35
0.12693419.14871884.html.plaintext.txt	19	Plasma ghrelin levels increase fasting decline within 1 h food intake 4
0.12693419.14871884.html.plaintext.txt	20	Furthermore ghrelin levels observed increase night sleeping subjects decrease morning hours awakening thus breakfast 4
0.12693419.14871884.html.plaintext.txt	21	This time course sleeping subjects suggests existence mechanism regulating ghrelin production dependent food intake
0.12693419.14871884.html.plaintext.txt	22	Possible candidates circadian rhythms regulating numerous endocrine networks example secretion cortisol leptin 5 13 turn related insulin blood glucose levels 27
0.12693419.14871884.html.plaintext.txt	23	Alternatively sleep might directly influence ghrelin production demonstrated example secretion growth hormone pituitary 28
0.12693419.14871884.html.plaintext.txt	24	To dissect diurnal variations sleep related influences ghrelin production performed study 24 h pattern ghrelin secretion healthy males
0.12693419.14871884.html.plaintext.txt	25	During two experimental sessions 0900 1000 following morning subjects allowed sleep sleep deprived balanced order
0.12693419.14871884.html.plaintext.txt	26	Nocturnal ghrelin secretion compared two conditions using within subjects design
0.12693419.14871884.html.plaintext.txt	27	MATERIALS AND METHODS TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Experimental subjects
0.12693419.14871884.html.plaintext.txt	28	We investigated 10 healthy nonobese male volunteers age 28 plus minus 3
0.12693419.14871884.html.plaintext.txt	29	5 kgm2 sleep sleep deprivation conditions
0.12693419.14871884.html.plaintext.txt	30	Written informed consent obtained participants inclusion study approved independent ethics committee
0.12693419.14871884.html.plaintext.txt	31	The subjects underwent detailed medical history evaluation sleeping habits physical examination laboratory investigations electroencephalogram EEG electrocardiogram exclude acute chronic diseases
0.12693419.14871884.html.plaintext.txt	32	Subjects personal family history psychiatric disorders history symptoms sleep disorder use medication alcohol substance abuse dependence included
0.12693419.14871884.html.plaintext.txt	33	Furthermore excluded subjects history recent irregular sleep wake schedules e
0.12693419.14871884.html.plaintext.txt	34	shift work intercontinental flights within previous 4 wk
0.12693419.14871884.html.plaintext.txt	35	To control regular sleep wake behavior subjects kept sleep log week experimental sessions
0.12693419.14871884.html.plaintext.txt	36	The study performed using balanced randomized within subject design
0.12693419.14871884.html.plaintext.txt	37	Every subject participated two 24 h experiments
0.12693419.14871884.html.plaintext.txt	38	Once subjects totally sleep deprived time allowed sleep 2300 0700
0.12693419.14871884.html.plaintext.txt	39	The time interval two sessions BORDER02 wk
0.12693419.14871884.html.plaintext.txt	40	To adjust experimental settings subjects spent night session 2300 0700 sleep laboratory
0.12693419.14871884.html.plaintext.txt	41	At 0800 electrodes EEG electromyogram electrooculogram recordings placed according standardized criteria 20
0.12693419.14871884.html.plaintext.txt	42	The subjects remained semirecumbent position received standardized meals four different time points
0.12693419.14871884.html.plaintext.txt	43	The subjects received standardized diet hospital kitchen 1800 kcal24 h containing 30 fat 60 carbohydrates 10 protein
0.12693419.14871884.html.plaintext.txt	44	The subjects allowed eat additional food
0.12693419.14871884.html.plaintext.txt	45	Measurements started 0900
0.12693419.14871884.html.plaintext.txt	46	Subjects stayed bed 25 h 1000 next morning
0.12693419.14871884.html.plaintext.txt	47	Artificial light intensity always 200 lux
0.12693419.14871884.html.plaintext.txt	48	Lights turned subjects allowed sleep 2300 0700 sleep condition
0.12693419.14871884.html.plaintext.txt	49	During sleep deprivation another person stayed continuously room subject prevent lapses sleep
0.12693419.14871884.html.plaintext.txt	50	Standardized meals served 0800 1200 1900 0800 next morning
0.12693419.14871884.html.plaintext.txt	51	Water freely available whole experimental session
0.12693419.14871884.html.plaintext.txt	52	Blood samples taken hourly via intravenous catheter placed antecubital vein kept patent continuous 0
0.12693419.14871884.html.plaintext.txt	53	9 saline infusion containing 400 IU Na heparinl rate 30 mlh
0.12693419.14871884.html.plaintext.txt	54	To minimize disturbances sleep continuity blood sampling done wall via long line room adjacent sleep laboratory
0.12693419.14871884.html.plaintext.txt	55	Blood collected tubes stored ice contained Na EDTA 1 mgml blood aprotinin 300 kallikrein inhibitor unitsml blood
0.12693419.14871884.html.plaintext.txt	56	Immediately withdrawal blood centrifuged 2600 g 7 min 4 degrees C plasma aliquoted frozen 20 degrees C various assays performed
0.12693419.14871884.html.plaintext.txt	57	To ensure sleep deprivation successful polygraphic recordings obtained throughout 24 h
0.12693419.14871884.html.plaintext.txt	58	All records visually scored 30 epochs standardized criteria 20 experienced person blind experimental condition
0.12693419.14871884.html.plaintext.txt	59	During sleep deprivation none subjects displayed rapid eye movement REM sleep non REM sleep stages 2 4
0.12693419.14871884.html.plaintext.txt	60	The sleep parameters sleep phase sleep condition shown Table 1
0.12693419.14871884.html.plaintext.txt	61	Sleep quality distribution different sleep stages comparable data studies healthy male volunteers underwent sleep recordings intermittent blood sampling 15 19 26 Table 1
0.12693419.14871884.html.plaintext.txt	62	Sleep parameters sleep condition
0.12693419.14871884.html.plaintext.txt	63	Determination ghrelin human growth hormone cortisol plasma levels
0.12693419.14871884.html.plaintext.txt	64	Total plasma ghrelin levels determined radioimmunoassay Phoenix Pharmaceuticals Mountain View CA
0.12693419.14871884.html.plaintext.txt	65	The limit detection 80 pgml
0.12693419.14871884.html.plaintext.txt	66	The intra interassay coefficients variation 13
0.12693419.14871884.html.plaintext.txt	67	Human growth hormone hGH plasma levels determined using radioimmunoassays purchased Nichols Institute Diagnostics San Juan Capistrano CA
0.12693419.14871884.html.plaintext.txt	68	5 ngml intra interassay coefficients variation 7
0.12693419.14871884.html.plaintext.txt	69	Plasma cortisol levels determined means radioimmunoassay ICN Biomedicals Carson CA
0.12693419.14871884.html.plaintext.txt	70	2 ngml intra interassay coefficients variation 7
0.12693419.14871884.html.plaintext.txt	71	To compare nocturnal hormone plasma levels sleep condition sleep deprivation condition ANOVA repeated measures performed time condition sleep vs
0.12693419.14871884.html.plaintext.txt	72	sleep deprivation within subject factors
0.12693419.14871884.html.plaintext.txt	73	To avoid many posteriori tests would imply strong reduction level significance five time points 2300 0700 included 2300 0100 0300 0500 0700 ANOVA
0.12693419.14871884.html.plaintext.txt	74	For hormone averages measured plasma concentrations sleep period considered baseline values conditions tested significance separate ANOVA
0.12693419.14871884.html.plaintext.txt	75	If hormone baseline plasma concentrations differed significantly two conditions corresponding values sleep period normed baseline values ANOVA application
0.12693419.14871884.html.plaintext.txt	76	Additionally ghrelin levels compared conditions recently developed methodology comparison stability hormone concentration curves 36
0.12693419.14871884.html.plaintext.txt	77	Finally peak level hGH 2300 0300 determined associated ghrelin concentrations 2300 0300 area curve interval well using Pearsons correlation coefficient
0.12693419.14871884.html.plaintext.txt	78	The level statistical significance set 0
0.12693419.14871884.html.plaintext.txt	79	One subject excluded statistical analysis blood samples available 2300 0500 sleep condition due technical reasons
0.12693419.14871884.html.plaintext.txt	80	In figures data depicted means plus minus SE table data given means plus minus SD
0.12693419.14871884.html.plaintext.txt	81	RESULTS TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Condition reveal significant effect baseline values considered hormones
0.12693419.14871884.html.plaintext.txt	82	In sleep condition ghrelin levels rose sharply around midnight slowly declined next morning
0.12693419.14871884.html.plaintext.txt	83	In contrast subjects sleep deprived ghrelin levels increased steadily plateau early morning hours declined breakfast Fig
0.12693419.14871884.html.plaintext.txt	84	ANOVA repeated measures revealed significant difference conditions respect nocturnal 2300 0700 ghrelin secretion F432 6
0.12693419.14871884.html.plaintext.txt	85	This confirmed Z score 2
0.12693419.14871884.html.plaintext.txt	86	05 comparison hormone curves sleep sleep deprivation aforementioned stability testing 36
0.12693419.14871884.html.plaintext.txt	87	View larger version 19K Fig
0.12693419.14871884.html.plaintext.txt	88	Plasma levels ghrelin human growth hormone hGH cortisol 9 healthy subjects sleep sleep deprivation
0.12693419.14871884.html.plaintext.txt	89	Arrows indicate food intake black bar indicates time subjects allowed sleep kept awake respectively
0.12693419.14871884.html.plaintext.txt	90	ANOVA also revealed significant difference nocturnal hGH secretion conditions F432 8
0.12693419.14871884.html.plaintext.txt	91	01 confirming well established hGH peak around sleep onset strong attenuation sleep deprivation Fig
0.12693419.14871884.html.plaintext.txt	92	The peak hGH level night sleep positively correlated ghrelin secretion first 4 h sleep r 0
0.12693419.14871884.html.plaintext.txt	93	A similar nonsignificant NS relationship r 0
0.12693419.14871884.html.plaintext.txt	94	433 NS obvious hGH ghrelin levels suppressed sleep deprivation
0.12693419.14871884.html.plaintext.txt	95	During day ghrelin hGH plasma levels increased meals declined thereafter Fig
0.12693419.14871884.html.plaintext.txt	96	View larger version 11K Fig
0.12693419.14871884.html.plaintext.txt	97	area curve AUC ghrelin secretion 2300 0300 sleep 9 healthy subjects
0.12693419.14871884.html.plaintext.txt	98	Pearsons correlation coefficient revealed significant positive correlation r 0
0.12693419.14871884.html.plaintext.txt	99	Cortisol levels across 24 h experimental period showed well known circadian variability maximum morning nadir night
0.12693419.14871884.html.plaintext.txt	100	ANOVA repeated measures revealed significant differences two conditions F432 2
0.12693419.14871884.html.plaintext.txt	101	DISCUSSION TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES In present study investigated influence nocturnal sleep compared sleep deprivation ghrelin plasma levels healthy volunteers
0.12693419.14871884.html.plaintext.txt	102	We confirmed finding Cummings et al
0.12693419.14871884.html.plaintext.txt	103	4 sleeping subjects ghrelin levels rise early part night decline morning breakfast
0.12693419.14871884.html.plaintext.txt	104	We discovered however increase blunted sleep deprivation
0.12693419.14871884.html.plaintext.txt	105	When subjects stayed awake ghrelin levels rose slowly steadily reach plateau early morning decrease breakfast
0.12693419.14871884.html.plaintext.txt	106	This relative increase 25 nocturnal wakefulness similar effects 12 h fast observed day 1
0.12693419.14871884.html.plaintext.txt	107	The suppressive effect sleep deprivation ghrelin levels suggests bell shaped time course observed sleep might due influence circadian rhythms rather might related sleep
0.12693419.14871884.html.plaintext.txt	108	Hence nocturnal ghrelin secretion shows similarities hGH production promoted sleep well particularly sleep onset 3
0.12693419.14871884.html.plaintext.txt	109	In addition peak hGH levels correlated positively ghrelin secretion first hours sleep Fig
0.12693419.14871884.html.plaintext.txt	110	2 supporting idea tight interaction
0.12693419.14871884.html.plaintext.txt	111	Sleep related growth hormone secretion probably caused increased production hypothalamic growth hormone releasing hormone GHRH acting pituitary 28
0.12693419.14871884.html.plaintext.txt	112	Ghrelin contrast produced mainly stomach splanchnic organs 1 14
0.12693419.14871884.html.plaintext.txt	113	Small quantities might also produced hypothalamus review see Ref
0.12693419.14871884.html.plaintext.txt	114	9 unlikely contribute systemic levels 34
0.12693419.14871884.html.plaintext.txt	115	Hence almost certain increased ghrelin levels found sleeping subjects due peripheral production
0.12693419.14871884.html.plaintext.txt	116	Yet unclear present brain might act ghrelin producing cells
0.12693419.14871884.html.plaintext.txt	117	Despite positive correlation ghrelin hGH secretion causative role hGH unlikely number studies demonstrated hGH administration affect ghrelin levels 2 8 16 30
0.12693419.14871884.html.plaintext.txt	118	Studies investigating interaction ghrelin production feeding suggest influence vagal cholinergic efferents ghrelin production transmission ghrelin signal brain vagal afferents 29 30
0.12693419.14871884.html.plaintext.txt	119	These studies indicate negative influence vagus ghrelin secretion
0.12693419.14871884.html.plaintext.txt	120	Therefore increased parasympathetic tone occurring sleep 30 unlikely explain increased ghrelin secretion opposite would rather expected
0.12693419.14871884.html.plaintext.txt	121	Hence although present results clearly demonstrate increased ghrelin levels sleep question remains solved sleeping brain stimulates ghrelin secretion
0.12693419.14871884.html.plaintext.txt	122	At first glance easy understand production appetite stimulating hormone increased sleep
0.12693419.14871884.html.plaintext.txt	123	However interaction among metabolic endocrine sleep regulating networks complex ghrelin numerous functions
0.12693419.14871884.html.plaintext.txt	124	Ghrelin recently shown increase SWS effect probably dependent GHRH receptor 33 35
0.12693419.14871884.html.plaintext.txt	125	Therefore ghrelin might represent peripheral feed forward signal support SWS initiation andor maintenance first hours night sleep concert central SWS promoting actions GHRH 18
0.12693419.14871884.html.plaintext.txt	126	Similarly ghrelin potent growth hormone secretagogue 11 might reinforce central GHRH signal enhanced hGH production
0.12693419.14871884.html.plaintext.txt	127	This idea supported correlation hGH ghrelin production shown Fig
0.12693419.14871884.html.plaintext.txt	128	Studies interactions sleep neuroendocrine factors date back late 1960s e
0.12693419.14871884.html.plaintext.txt	129	31 recently particularly intriguing link sleep regulation appetite became evident
0.12693419.14871884.html.plaintext.txt	130	Orexins hypothalamic peptides initially thought mainly regulate food intake also potent arousing properties 21 play crucial role pathophysiology narcolepsy
0.12693419.14871884.html.plaintext.txt	131	Narcolepsy characterized excessive daytime sleepiness cataplexy sudden short lasting loss muscle tone triggered emotions acquired complete loss hypothalamic orexin production hypothalamus patients 21
0.12693419.14871884.html.plaintext.txt	132	In addition sleep related symptoms patients display various endocrine metabolic abnormalities obesity hypoleptinemia 23 25
0.12693419.14871884.html.plaintext.txt	133	Like ghrelin plasma levels orexin cerebrospinal fluid levels increased night 6 ghrelin induced food intake mediated orexinergic pathways 22
0.12693419.14871884.html.plaintext.txt	134	Therefore might great interest investigate ghrelin baseline conditions association sleep sleep deprivation association meals narcoleptic patients
0.12693419.14871884.html.plaintext.txt	135	To conclude ghrelin production enhanced night sleep healthy humans correlates increased release hGH occurring parallel
0.12693419.14871884.html.plaintext.txt	136	Although underlying mechanisms remain elucidated present study supports idea ghrelin novel important player within sleep neuroendocrine interplay
0.12693419.14871884.html.plaintext.txt	137	ACKNOWLEDGMENTS We gratefully acknowledge statistical advice Dr
0.12693419.14871884.html.plaintext.txt	138	Alexander Yassouridis helpful comments Dr
0.12693419.14871884.html.plaintext.txt	139	Furthermore thank Gabriele Kohl expert technical assistance Dorothea Skottke assistance preparing manuscript
0.12693419.14871884.html.plaintext.txt	140	FOOTNOTES Address reprint requests correspondence A
0.12693419.14871884.html.plaintext.txt	141	Schuld Max Planck Institute Psychiatry Kraepelinstrasse 10 80804 Munich Germany E mail schuldatmpipsykl
0.12693419.14871884.html.plaintext.txt	142	The costs publication article defrayed part payment page charges
0.12693419.14871884.html.plaintext.txt	143	The article must therefore hereby marked advertisement accordance 18 U
0.12693419.14871884.html.plaintext.txt	144	Section 1734 solely indicate fact
0.12693419.14871884.html.plaintext.txt	145	REFERENCES TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES Ariyasu H Takaya K Tagami T Ogawa Y Hosoda K Akamizu T Suda M Koh T Natsui K Toyooka S Shirakami G Usui T Shimatsu A Doi K Hosoda H Kojima M Kangawa K Nakao K
0.12693419.14871884.html.plaintext.txt	146	Stomach major source circulating ghrelin feeding state determines plasma ghrelin like immunoreactivity levels humans
0.12693419.14871884.html.plaintext.txt	147	J Clin Endocrinol Metab 86 4753 4758 2001
0.12693419.14871884.html.plaintext.txt	148	AbstractFree Full Text Barkan AL Dimaraki EV Jessup SK Symons KV Ermolenko M Jaffe CA
0.12693419.14871884.html.plaintext.txt	149	Ghrelin secretion humans sexually dimorphic suppressed somatostatin affected ambient growth hormone levels
0.12693419.14871884.html.plaintext.txt	150	J Clin Endocrinol Metab 88 2180 2184 2003
0.12693419.14871884.html.plaintext.txt	151	AbstractFree Full Text Born J Muth S Fehm HL
0.12693419.14871884.html.plaintext.txt	152	The significance sleep onset slow wave sleep nocturnal release growth hormone GH cortisol
0.12693419.14871884.html.plaintext.txt	153	Psychoneuroendocrinology 13 233 423 1988
0.12693419.14871884.html.plaintext.txt	154	CrossRefISIMedline Cummings DE Purnell JQ Frayo RS Schmidova K Wisse BE Weigle DS
0.12693419.14871884.html.plaintext.txt	155	A preprandial rise plasma ghrelin levels suggests role meal initiation humans
0.12693419.14871884.html.plaintext.txt	156	Diabetes 50 1714 1719 2001
0.12693419.14871884.html.plaintext.txt	157	AbstractFree Full Text Czeisler CA Klerman EB
0.12693419.14871884.html.plaintext.txt	158	Circadian sleep dependent regulation hormone release humans
0.12693419.14871884.html.plaintext.txt	159	Recent Prog Horm Res 54 97 130 1999
0.12693419.14871884.html.plaintext.txt	160	Medline Dalal MA Schuld A Haack M Uhr M Geisler P Eisensehr I Noachtar S Pollmacher T
0.12693419.14871884.html.plaintext.txt	161	Normal plasma levels orexin A hypocretin 1 narcoleptic patients
0.12693419.14871884.html.plaintext.txt	162	Neurology 56 1749 1751 2001
0.12693419.14871884.html.plaintext.txt	163	AbstractFree Full Text Date Y Kojima M Hosoda H Sawaguchi A Mondal MS Suganuma T Matsukura S Kangawa K Nakazato M
0.12693419.14871884.html.plaintext.txt	164	Ghrelin novel growth hormone releasing acylated peptide synthesized distinct endocrine cell type gastrointestinal tracts rats humans
0.12693419.14871884.html.plaintext.txt	165	Endocrinology 141 4255 4261 2000
0.12693419.14871884.html.plaintext.txt	166	AbstractFree Full Text Hansen TK Dall R Hosoda H Kojima M Kangawa K Christiansen JS Jorgensen JOL
0.12693419.14871884.html.plaintext.txt	167	Weight loss increases circulating levels ghrelin human obesity
0.12693419.14871884.html.plaintext.txt	168	Clin Endocrinol Oxf 56 203 206 2002
0.12693419.14871884.html.plaintext.txt	169	CrossRefISIMedline Horvath TL Diano S Sotonyi P Heiman M Tschop M
0.12693419.14871884.html.plaintext.txt	170	Minireview ghrelin regulation energy balance hypothalamic perspective
0.12693419.14871884.html.plaintext.txt	171	Endocrinology 142 4163 4169 2001
0.12693419.14871884.html.plaintext.txt	172	AbstractFree Full Text Kojima M Hosoda H Date Y Nakazato M Matsuo H Kangawa K
0.12693419.14871884.html.plaintext.txt	173	Ghrelin growth hormone releasing acylated peptide stomach
0.12693419.14871884.html.plaintext.txt	174	CrossRefISIMedline Kojima M Hosoda H Matsuo H Kangawa K
0.12693419.14871884.html.plaintext.txt	175	Ghrelin discovery natural endogenous ligand growth hormone secretagogue receptor
0.12693419.14871884.html.plaintext.txt	176	Trends Endocrinol Metab 12 118 122 2001
0.12693419.14871884.html.plaintext.txt	177	CrossRefISIMedline Korbonits M Bustin SA Kojima M Jordan S Adams EF Lowe DG Kangawa K Grossman AB
0.12693419.14871884.html.plaintext.txt	178	The expression growth hormone secretagogue receptor ligand ghrelin normal abnormal human pituitary neuroendocrine tumors
0.12693419.14871884.html.plaintext.txt	179	J Clin Endocrinol Metab 86 881 887 2001
0.12693419.14871884.html.plaintext.txt	180	AbstractFree Full Text Licinio J Mantzoros C Negrao AB Cizza G Wong ML Bongiorno PB Chrousos GP Karp B Allen C Flier JS Gold PW
0.12693419.14871884.html.plaintext.txt	181	Human leptin levels pulsatile inversely related pituitary adrenal function
0.12693419.14871884.html.plaintext.txt	182	ISIMedline Moller N Nygren J Hansen TK Oslashrskov H Frystyk J Nair KS
0.12693419.14871884.html.plaintext.txt	183	Splanchnic release ghrelin humans
0.12693419.14871884.html.plaintext.txt	184	J Clin Endocrinol Metab 88 850 852 2003
0.12693419.14871884.html.plaintext.txt	185	AbstractFree Full Text Mullington J Korth C Hermann DM Orth A Galanos C Holsboer F Pollmacher T
0.12693419.14871884.html.plaintext.txt	186	Dose dependent effects endotoxin human sleep
0.12693419.14871884.html.plaintext.txt	187	Am J Physiol Regul Integr Comp Physiol 278 R947 R955 2000
0.12693419.14871884.html.plaintext.txt	188	AbstractFree Full Text Murdolo G Lucidi P Di Loreto C Parlanti N De Cicco A Fanelli C Perriello G Mughetti D Pippi R Brozzetti A Santeusanio F De Feo P
0.12693419.14871884.html.plaintext.txt	189	Circulating ghrelin levels visceral obese men modified short term treatment low doses GH replacement
0.12693419.14871884.html.plaintext.txt	190	J Endocrinol Invest 26 244 249 2003
0.12693419.14871884.html.plaintext.txt	191	ISIMedline Nakazato M Murakami N Date Y Kojima M Matsuo H Kangawa K Matsukura S
0.12693419.14871884.html.plaintext.txt	192	A role ghrelin central regulation feeding
0.12693419.14871884.html.plaintext.txt	193	CrossRefISIMedline Obal F Alt J Taishi P Gardi J Krueger JM
0.12693419.14871884.html.plaintext.txt	194	Sleep mice nonfunctional growth hormone releasing hormone receptors
0.12693419.14871884.html.plaintext.txt	195	Am J Physiol Regul Integr Comp Physiol 284 R131 R139 2003
0.12693419.14871884.html.plaintext.txt	196	AbstractFree Full Text Pollmacher T Schuld A Kraus T Haack M Hinze Selch D Mullington J
0.12693419.14871884.html.plaintext.txt	197	Experimental immunomodulation sleep sleepiness humans
0.12693419.14871884.html.plaintext.txt	198	Ann NY Acad Sci 917 488 499 2000
0.12693419.14871884.html.plaintext.txt	199	AbstractFree Full Text Rechtschaffen A Kales A
0.12693419.14871884.html.plaintext.txt	200	A Manual Standardized Terminology Techniques Scoring System Sleep Stages Human Subjects
0.12693419.14871884.html.plaintext.txt	201	Neurological Diseases Blindness 1968
0.12693419.14871884.html.plaintext.txt	202	Orexin link energy homeostasis adaptive behaviour
0.12693419.14871884.html.plaintext.txt	203	Curr Opin Clin Nutr Metab Care 6 353 360 2003
0.12693419.14871884.html.plaintext.txt	204	CrossRefISIMedline Salomon RM Ripley B Kennedy JS Johnson B Schmidt D Zeitzer JM Nishino S Mignot E
0.12693419.14871884.html.plaintext.txt	205	Diurnal variation cerebrospinal fluid hypocretin 1 Orexin A levels control depressed subjects
0.12693419.14871884.html.plaintext.txt	206	Biol Psychiatry 54 96 104 2003
0.12693419.14871884.html.plaintext.txt	207	CrossRefISIMedline Scammell TE
0.12693419.14871884.html.plaintext.txt	208	The neurobiology diagnosis treatment narcolepsy
0.12693419.14871884.html.plaintext.txt	209	Ann Neurol 53 154 166 2003
0.12693419.14871884.html.plaintext.txt	210	CrossRefISIMedline Schuld A Blum WF Uhr M Haack M Kraus T Holsboer F Pollmacher T
0.12693419.14871884.html.plaintext.txt	211	Reduced leptin levels human narcolepsy
0.12693419.14871884.html.plaintext.txt	212	Neuroendocrinology 72 195 198 2000
0.12693419.14871884.html.plaintext.txt	213	CrossRefISIMedline Schuld A Hebebrand J Geller F Pollmacher T
0.12693419.14871884.html.plaintext.txt	214	Increased body mass index patients narcolepsy
0.12693419.14871884.html.plaintext.txt	215	Lancet 355 1274 1275 2000
0.12693419.14871884.html.plaintext.txt	216	ISIMedline Schuld A Mullington J Hermann D Hinze Selch D Fenzel T Holsboer F Pollmacher T
0.12693419.14871884.html.plaintext.txt	217	Effects granulocyte colony stimulating factor night sleep humans
0.12693419.14871884.html.plaintext.txt	218	Am J Physiol Regul Integr Comp Physiol 276 R1149 R1155 1999
0.12693419.14871884.html.plaintext.txt	219	AbstractFree Full Text Simon C Gronfier C Schlienger JL Brandenberger G
0.12693419.14871884.html.plaintext.txt	220	Circadian ultradian variations leptin normal man continuous enteral nutrition relationship sleep body temperature
0.12693419.14871884.html.plaintext.txt	221	J Clin Endocrinol Metab 83 1893 1899 1998
0.12693419.14871884.html.plaintext.txt	222	AbstractFree Full Text Steiger A
0.12693419.14871884.html.plaintext.txt	223	Sleep endocrine regulation
0.12693419.14871884.html.plaintext.txt	224	Front Biosci 8 S358 S376 2003
0.12693419.14871884.html.plaintext.txt	225	ISIMedline Sugino T Hasegawa Y Kikkawa Y Yamaura J Yamagishi M Kurose Y Kojima M Kangawa K Terashima Y
0.12693419.14871884.html.plaintext.txt	226	A transient ghrelin surge occurs feeding scheduled meal fed sheep
0.12693419.14871884.html.plaintext.txt	227	Biochem Biophys Res Commun 295 255 260 2002
0.12693419.14871884.html.plaintext.txt	228	CrossRefISIMedline Sugino T Yamaura J Yamagishi M Kurose Y Kojima M Kangawa K Hasegawa Y Terashima Y
0.12693419.14871884.html.plaintext.txt	229	Involvement cholinergic neurons regulation ghrelin secretory response feeding sheep
0.12693419.14871884.html.plaintext.txt	230	Biochem Biophys Res Commun 304 308 312 2003
0.12693419.14871884.html.plaintext.txt	231	CrossRefISIMedline Takahashi Y Kipnis DM Daughaday WH
0.12693419.14871884.html.plaintext.txt	232	Growth hormone secretion sleep
0.12693419.14871884.html.plaintext.txt	233	J Clin Invest 47 2079 2090 1968
0.12693419.14871884.html.plaintext.txt	234	ISIMedline Toshinai K Date Y Murakami N Shimada M Mondal MS Shimbara T Guan JL Wang QP Funahashi H Sakurai T Shioda S Matsukura S Kangawa K Nakazato M
0.12693419.14871884.html.plaintext.txt	235	Ghrelin induced food intake mediated via orexin pathway
0.12693419.14871884.html.plaintext.txt	236	Endocrinology 144 1506 1512 2003
0.12693419.14871884.html.plaintext.txt	237	AbstractFree Full Text Trinder J Kleiman J Carrington M Smith S Breen S Tan N Kim Y
0.12693419.14871884.html.plaintext.txt	238	Autonomic activity human sleep function time sleep stage
0.12693419.14871884.html.plaintext.txt	239	J Sleep Res 10 253 264 2001
0.12693419.14871884.html.plaintext.txt	240	CrossRefISIMedline Van der Toorn FM Janssen JAMJ de Herder WW Broglio F Ghigo E van der Lely AJ
0.12693419.14871884.html.plaintext.txt	241	Central ghrelin production substantially contribute systemic ghrelin concentrations study two subjects active acromegaly
0.12693419.14871884.html.plaintext.txt	242	Eur J Endocrinol 147 195 199 2002
0.12693419.14871884.html.plaintext.txt	243	ISIMedline Weikel JC Wichniak A Ising M Brunner H Friess E Held K Mathias S Schmid DA Uhr M Steiger A
0.12693419.14871884.html.plaintext.txt	244	Ghrelin promotes slow wave sleep humans
0.12693419.14871884.html.plaintext.txt	245	Am J Physiol Endocrinol Metab 284 E407 E415 2003
0.12693419.14871884.html.plaintext.txt	246	AbstractFree Full Text Wiedemann K Jahn H Yassouridis A Kellner M
0.12693419.14871884.html.plaintext.txt	247	Anxiolytic like effects atrial natriuretic peptide cholecystokinin tetrapeptide induced panic attacks preliminary findings
0.12693419.14871884.html.plaintext.txt	248	Arch Gen Psychiatry 58 371 377 2001
0.12693419.14871884.html.plaintext.txt	249	AbstractFree Full Text Wren AM Seal LJ Cohen MA Brynes AE Frost GS Murphy KG Dhillo WS Ghatei MA Bloom SR
0.12693419.14871884.html.plaintext.txt	250	Ghrelin enhances appetite increases food intake humans
0.12693419.14871884.html.plaintext.txt	251	J Clin Endocrinol Metab 86 5992 5995 2001
0.12693419.14871884.html.plaintext.txt	252	AbstractFree Full Text Wren AM Small CJ Ward HL Murphy KG Dakin CL Taheri S Kennedy AR Roberts GH Morgan DGA Ghatei MA Bloom SR
0.12693419.14871884.html.plaintext.txt	253	The novel hypothalamic peptide ghrelin stimulates food intake growth hormone secretion
0.12693419.14871884.html.plaintext.txt	254	Endocrinology 141 4325 4328 2000
0.09719374.15994572.html.plaintext.txt	0	Modafinil modulates anterior cingulate function chronic schizophrenia SEAN A
0.09719374.15994572.html.plaintext.txt	1	SPENCE MRCPsych RUSSELL D
0.09719374.15994572.html.plaintext.txt	2	Sheffield Cognition Neuroimaging Laboratory SCANLab Academic Clinical Psychiatry Division Genomic Medicine University Sheffield
0.09719374.15994572.html.plaintext.txt	3	Academic Unit Radiology University Sheffield
0.09719374.15994572.html.plaintext.txt	4	SCANLab Academic Clinical Psychiatry Division Genomic Medicine University Sheffield Sheffield UK
0.09719374.15994572.html.plaintext.txt	5	Spence Sheffield Cognition Neuroimaging SCANLab Academic Clinical Psychiatry Division Genomic Medicine University Sheffield The Longley Centre Norwood Grange Drive Sheffield S5 7JT UK
0.09719374.15994572.html.plaintext.txt	6	Tel 44 0 114 22 61519 Fax 44 0 114 22 61522 E mail
0.09719374.15994572.html.plaintext.txt	7	Declaration interest This study supported investigator led award S
0.09719374.15994572.html.plaintext.txt	8	supported Wellcome Trust UK
0.09719374.15994572.html.plaintext.txt	9	ABSTRACT TOP ABSTRACT INTRODUCTION METHOD RESULTS DISCUSSION Clinical Implications
0.09719374.15994572.html.plaintext.txt	10	ACKNOWLEDGMENTS REFERENCES Background Schizophrenia associated widespread cognitive deficits impact social function
0.09719374.15994572.html.plaintext.txt	11	Modafinil promotes wakefulness reported enhance cognition
0.09719374.15994572.html.plaintext.txt	12	Aims To study acute effects modafinil administration upon brain activity cognitive performance people chronic schizophrenia
0.09719374.15994572.html.plaintext.txt	13	Method In randomised double blind placebo controlled crossover design 19 patients received either modafinil 100 mg placebo prior undertaking working memory task functional magnetic resonance imaging
0.09719374.15994572.html.plaintext.txt	14	Results Seventeen patients completed study another underwent acute relapse 4 days post drug
0.09719374.15994572.html.plaintext.txt	15	Modafinil administration associated significantly greater activation anterior cingulate cortex working memory task
0.09719374.15994572.html.plaintext.txt	16	The anterior cingulate cortex signal correlated cognitive performance although subset patients exhibited enhancement
0.09719374.15994572.html.plaintext.txt	17	Conclusions Modafinil modulates anterior cingulate cortex function chronic schizophrenia beneficial cognitive effects may restricted subset patients requiring characterisation
0.09719374.15994572.html.plaintext.txt	18	INTRODUCTION TOP ABSTRACT INTRODUCTION METHOD RESULTS DISCUSSION Clinical Implications
0.09719374.15994572.html.plaintext.txt	19	ACKNOWLEDGMENTS REFERENCES Schizophrenia associated widespread cognitive impairments affecting memory vigilance impact upon independent living Velligan et al 1997
0.09719374.15994572.html.plaintext.txt	20	Amelioration impairments might improve quality life therefore studied effects putative cognitive enhancer modafinil upon prefrontal function people chronic schizophrenia
0.09719374.15994572.html.plaintext.txt	21	Modafinil 2 diphenylmethylsulphinyl acetamide novel agent promotes wakefulness licensed UK USA treatment narcolepsy Cephalon 1999 US Modafinil Narcolepsy Multicenter Study Group 2000 British Medical Association 2004
0.09719374.15994572.html.plaintext.txt	22	Its precise mode action uncertain although animal models shown elicit early gene expression anterior hypothalamus Lin et al 1996 anterior cingulate cortex Scammell et al 2000 findings congruent properties
0.09719374.15994572.html.plaintext.txt	23	Very recently modafinil reported enhance short term verbal memory people schizophrenia Turner et al 2004
0.09719374.15994572.html.plaintext.txt	24	METHOD TOP ABSTRACT INTRODUCTION METHOD RESULTS DISCUSSION Clinical Implications
0.09719374.15994572.html.plaintext.txt	25	ACKNOWLEDGMENTS REFERENCES On basis animal studies chose probe cognitive functions would engage higher executive regions particularly anterior cingulate cortex implicated vigilance
0.09719374.15994572.html.plaintext.txt	26	However view uncertain mechanism action modafinil emerging evidence possible risk psychosis exacerbation Narendran et al 2002 utilised relatively small dose drug
0.09719374.15994572.html.plaintext.txt	27	Our study conducted 28 August 2002 4 July 2003
0.09719374.15994572.html.plaintext.txt	28	Participants Right handed males aged 18 60 years premorbid IQ 70 National Adult Reading Test NART Nelson OConnell 1978 DSM IV American Psychiatric Association 1994 diagnosis schizophrenia prominent negative symptomatology rating 3 least one item Scale Assessment Negative Symptoms SANS Andreasen 1983 included
0.09719374.15994572.html.plaintext.txt	29	Exclusion criteria prominent positive symptomatology marked delusions andor hallucinations recent history mental state instability changes psychotropic medication admission hospital within 3 months assessment significant history neurological endocrine cardiovascular disorder hypersensitivity modafinil concurrent prescription stimulant medication concurrent substance misuse contraindications magnetic resonance imaging scanning metallic implants foreign bodies claustrophobia
0.09719374.15994572.html.plaintext.txt	30	Thirty two patients approached 21 agreed participate following full explanation study
0.09719374.15994572.html.plaintext.txt	31	Nineteen satisfied detailed assessment inclusion exclusion criteria
0.09719374.15994572.html.plaintext.txt	32	Participants underwent psychiatric Brief Psychiatric Rating Scale Overall Gorham 1962 SANS Scale Assessment Positive Symptoms Andreasen 1984 Beck Depression Inventory Beck et al 1961 Mini Mental State Examination Folstein et al 1975 physical including electrocardiogram neuropsychological assessment Simpson Angus Scale Simpson Angus 1970 Abnormal Involuntary Movements Scale Guy 1976 Barnes Akathisia Scale Barnes 1989
0.09719374.15994572.html.plaintext.txt	33	Written informed consent obtained patient
0.09719374.15994572.html.plaintext.txt	34	The study approved North South Sheffield Research Ethics Committees also Rotherham Doncaster South Humber Research Ethics Committees
0.09719374.15994572.html.plaintext.txt	35	Because study funded investigator led award company sponsored trial research indemnity provided Sheffield Care Trust reciprocally participating National Health Service trusts clinical trial insurance provided University Sheffield
0.09719374.15994572.html.plaintext.txt	36	Procedures We utilised randomised double blind placebo controlled crossover design
0.09719374.15994572.html.plaintext.txt	37	Patients studied 2 days 1 week apart
0.09719374.15994572.html.plaintext.txt	38	On day patients received oral modafinil 100 mg placebo 2 h prior functional magnetic resonance imaging fMRI scanning
0.09719374.15994572.html.plaintext.txt	39	Administration scanning times predicated drugs pharmacokinetics humans peak plasma levels occur 2 4 h post acute oral dosing Cephalon 1999 Robertson Hellriegel 2003
0.09719374.15994572.html.plaintext.txt	40	Randomisation performed pharmacist member research team achieved drawing labelled counters ensured approximately equivalent numbers patients received modafinil placebo day 1 vice versa day 2
0.09719374.15994572.html.plaintext.txt	41	Patients required smoke consume caffeine prior scanning
0.09719374.15994572.html.plaintext.txt	42	They admitted 24 h observation scanning procedure
0.09719374.15994572.html.plaintext.txt	43	The outcome measures difference fMRI signal working memory task modafinil placebo conditions difference behavioural performance accuracy intra scanner task modafinil placebo conditions patient wise bivariate correlation first two measures
0.09719374.15994572.html.plaintext.txt	44	Psychological paradigm Inside scanner patients performed standard working memory task 2 back Callicott et al 1998
0.09719374.15994572.html.plaintext.txt	45	This difficult task required subjects monitor update temporally tag contents working memory Manoach 2003
0.09719374.15994572.html.plaintext.txt	46	A series numbers 1 4 presented visually pseudo random order one every 2
0.09719374.15994572.html.plaintext.txt	47	Colour coding stimuli cued patients indicate pressing button either number currently presented screen 0 back baseline condition number presented two trials earlier
0.09719374.15994572.html.plaintext.txt	48	2 back active condition
0.09719374.15994572.html.plaintext.txt	49	Stimuli delivered using Presentation Neurobehavioral Systems Inc California USA software running personal computer via video projector mirror located inside scanner bore
0.09719374.15994572.html.plaintext.txt	50	Patients responded pressing one four buttons intra scanner box optically connected computer system via interface New Micros Inc Texas USA
0.09719374.15994572.html.plaintext.txt	51	In alternating blocked 0 back2 back design 15 consecutive 0 back stimuli lasting 30 followed 15 consecutive 2 back stimuli also lasting 30
0.09719374.15994572.html.plaintext.txt	52	This sequence repeated six times hence functional scans lasted 6 min total
0.09719374.15994572.html.plaintext.txt	53	Patients practised task prior entering scanner three times order minimise automation procedure
0.09719374.15994572.html.plaintext.txt	54	Different performance levels permitted previous studies
0.09719374.15994572.html.plaintext.txt	55	Some incorporated wide range accuracy among patients schizophrenia Callicott et al 1998 performance relatively poor Meyer Lindenberg et al 2001 Bertolino et al 2003 whereas others set stringent thresholds Callicott et al 2000 2003
0.09719374.15994572.html.plaintext.txt	56	Comparison healthy control group necessarily requires comparable levels performance across groups study wished compare patients performances modafinil
0.09719374.15994572.html.plaintext.txt	57	Hence allowed range performance accuracy
0.09719374.15994572.html.plaintext.txt	58	This partly pragmatic given deliberately studying people chronic schizophrenia prominent negative symptomatology likely recipients putative cognitive enhancers also design led required range performance across group detect changes performance within subjects exposed modafinil hence avoiding ceiling effects allow post hoc correlations performance per se Manoach et al 1999 Callicott et al 2000 2003
0.09719374.15994572.html.plaintext.txt	59	Functional image acquisition analysis At 120 functional imaging time points 3264 mm contiguous T2 weighted slices acquired using echo planar imaging 1
0.09719374.15994572.html.plaintext.txt	60	5 T system Eclipse Philips Ohio Sheffield University repetition time3 echo time40 ms field view 240 mm plane matrix128 x 128
0.09719374.15994572.html.plaintext.txt	61	Images analysed using SPM99 httpwww
0.09719374.15994572.html.plaintext.txt	62	The blood oxygenation level dependent BOLD response measured fMRI thought represent vascular marker neuronal activation Logothetis et al 2001
0.09719374.15994572.html.plaintext.txt	63	Following timing movement correction spatial normalisation smoothing Gaussian kernel 6 mm full width half maximum Friston et al 1995 used boxcar wave convolved synthetic haemodynamic response function model BOLD response
0.09719374.15994572.html.plaintext.txt	64	Each patient two fMRI data sets modafinil placebo individual data set first level voxel wise contrast activation working memory v
0.09719374.15994572.html.plaintext.txt	65	This generated contrast images used second order random effects group analysis
0.09719374.15994572.html.plaintext.txt	66	Random effects analyses allow quantitative inferences drawn regarding average behaviour population patients selected across different scanning sessions
0.09719374.15994572.html.plaintext.txt	67	Such analysis mandatory psychopharmacological designs main effect interest exists distinct scanning sessions
0.09719374.15994572.html.plaintext.txt	68	Individual contrast images entered data points whole group analysis covariance ANCOVA compared brain activation working memory v
0.09719374.15994572.html.plaintext.txt	69	baseline conditions modafinil activation working memory v
0.09719374.15994572.html.plaintext.txt	70	Order scanning whether modafinil received day 1 day 2 comprised nuisance covariate
0.09719374.15994572.html.plaintext.txt	71	This produced group parametric brain map statistics stereotactic space Montreal Neurological Institute MNI Evans et al 1993 showing brain areas activated working memory baseline conditions modafinil compared placebo
0.09719374.15994572.html.plaintext.txt	72	We emphasise intra session effects working memory v
0.09719374.15994572.html.plaintext.txt	73	baseline modelled first level main inter session effect modafinil v
0.09719374.15994572.html.plaintext.txt	74	placebo modelled second level random effects analysis
0.09719374.15994572.html.plaintext.txt	75	We also produced two subsidiary brain maps demonstrating brain areas activated working memory baseline placebo modafinil using two single group ANCOVAs scanning order nuisance covariate
0.09719374.15994572.html.plaintext.txt	76	Hence able ensure expected pattern cortical activation obtained 2 back irrespective drugplacebo condition
0.09719374.15994572.html.plaintext.txt	77	Because study hypothesis driven set significance threshold P 0
0.09719374.15994572.html.plaintext.txt	78	01 uncorrected height extent activation
0.09719374.15994572.html.plaintext.txt	79	We also designated small volume sphere diameter 10 mm could used correct multiple comparisons family wise error method activation priori region interest anterior cingulate cortex observed uncorrected threshold
0.09719374.15994572.html.plaintext.txt	80	For purposes reporting neuroanatomical labelling stereotactic coordinates activated areas transformed MNI space system Talairach Tournoux 1988
0.09719374.15994572.html.plaintext.txt	81	Brain activationbehavioural performance correlations For patient calculated measure performance percentage accuracy working memory task study days hence difference score modafinil placebo conditions
0.09719374.15994572.html.plaintext.txt	82	Taking anterior cingulate cortex region interest also estimated magnitude fMRI signal change derived beta parameters SPM99 working memory task v
0.09719374.15994572.html.plaintext.txt	83	For patient allowed us calculate difference anterior cingulate cortex signal change working memory task modafinil placebo conditions
0.09719374.15994572.html.plaintext.txt	84	We ran patient wise bivariate correlations difference behavioural performance modafinil v
0.09719374.15994572.html.plaintext.txt	85	placebo difference anterior cingulate cortex signal change modafinil v
0.09719374.15994572.html.plaintext.txt	86	RESULTS TOP ABSTRACT INTRODUCTION METHOD RESULTS DISCUSSION Clinical Implications
0.09719374.15994572.html.plaintext.txt	87	ACKNOWLEDGMENTS REFERENCES Adverse events image quality We analysed data 17 19 patients entering study
0.09719374.15994572.html.plaintext.txt	88	One patient complete study due relapse acute psychosis 4 days first scanning day
0.09719374.15994572.html.plaintext.txt	89	Ethical considerations required disclosure randomisation status revealing received modafinil
0.09719374.15994572.html.plaintext.txt	90	This clinically significant adverse event occurred study
0.09719374.15994572.html.plaintext.txt	91	Data another patient could analysed technical problems second session fMRI images
0.09719374.15994572.html.plaintext.txt	92	Demographic data Patients predominantly middle aged males ill approximately 15 years Table 1
0.09719374.15994572.html.plaintext.txt	93	Sixteen single none paid employment five performed voluntary work 16 received maximum disability living allowance eight lived accommodation three parents two supported group projects four rehabilitation units
0.09719374.15994572.html.plaintext.txt	94	Most patients receiving oral antipsychotics n13 atypical one case
0.09719374.15994572.html.plaintext.txt	95	Four patients received intramuscular typical depot medication
0.09719374.15994572.html.plaintext.txt	96	Of 17 patients none changed medication study period
0.09719374.15994572.html.plaintext.txt	97	Nine patients received modafinil day 1 placebo day 2 eight received reverse
0.09719374.15994572.html.plaintext.txt	98	View table Table 1 Demographic clinical characteristics included patients
0.09719374.15994572.html.plaintext.txt	99	Behavioural measures Statistical comparisons prespecified except indicated
0.09719374.15994572.html.plaintext.txt	100	We used non parametric tests analyse group behavioural accuracy data working memory task placebo modafinil conditions normally distributed
0.09719374.15994572.html.plaintext.txt	101	Under placebo conditions response accuracy control 0 back condition 19 88 median 71 differ significantly modafinil range 11 99 median 71 Wilcoxon signed rank test Z0
0.09719374.15994572.html.plaintext.txt	102	Under placebo conditions response accuracy 2 back task 5 85 median 26 differ significantly modafinil range 4 79 median 22 Wilcoxon signed rank test Z0
0.09719374.15994572.html.plaintext.txt	103	Brain activations Functional image analysis showed modafinil placebo days patients exhibited activations 2 back condition relative 0 back predicted brain regions Tables 2 3 specifically prefrontal anterior cingulate parietal cortices Callicott et al 2000 2003 Meyer Lindenberg et al 2001
0.09719374.15994572.html.plaintext.txt	104	View table Table 2 Brain areas exhibiting greater activation working memory baseline placebo condition
0.09719374.15994572.html.plaintext.txt	105	View table Table 3 Brain areas exhibiting greater activation working memory baseline modafinil condition
0.09719374.15994572.html.plaintext.txt	106	View larger version 74K Fig
0.09719374.15994572.html.plaintext.txt	107	1 The brain area anterior cingulate cortex exhibited greater activation working memory task modafinil placebo
0.09719374.15994572.html.plaintext.txt	108	Group data displayed canonical T1 weighted image upper panels supra threshold voxels shown yellow P50
0.09719374.15994572.html.plaintext.txt	109	In order demonstrate regional specificity finding data also displayed statistical threshold within glass brain lower panels
0.09719374.15994572.html.plaintext.txt	110	Functional image analysis comparing modafinil placebo condition revealed working memory task performance associated significantly greater activation solely anterior cingulate cortex Fig
0.09719374.15994572.html.plaintext.txt	111	1 Talairach coordinates x6 mm y38 mm z15 mm 131 supra threshold voxels peak Z score3
0.09719374.15994572.html.plaintext.txt	112	01 uncorrected height extent activation
0.09719374.15994572.html.plaintext.txt	113	This activation remained significant correction multiple comparisons within defined region interest P 0
0.09719374.15994572.html.plaintext.txt	114	Examining separate modafinil placebo brain maps working memory v
0.09719374.15994572.html.plaintext.txt	115	baseline contrast confirmed focal difference due greater anterior cingulate cortex activation working memory baseline performance modafinil x6 mm y38 mm z18 mm 50 voxels Z3
0.09719374.15994572.html.plaintext.txt	116	01 uncorrected height activation converse namely greater activation baseline working memory placebo
0.09719374.15994572.html.plaintext.txt	117	Patient wise differences anterior cingulate cortex activation Fig
0.09719374.15994572.html.plaintext.txt	118	1 behavioural performance modafinil placebo conditions positively significantly correlated Fig
0.09719374.15994572.html.plaintext.txt	119	However correlation reflect straightforward relationship improved activation improved performance
0.09719374.15994572.html.plaintext.txt	120	Rather reflected increased fMRI signal majority patients modafinil session concomitant improvement memory performance half decreased signal minority patients response modafinil exhibited reduced performance drug Fig
0.09719374.15994572.html.plaintext.txt	121	Hence patient group whole relationship degree anterior cingulate cortex activation memory task modulated increaseddecreased drug level cognitive performance
0.09719374.15994572.html.plaintext.txt	122	Although subgroup patients exhibited enhanced cognition association increased anterior cingulate cortex activation patient exhibiting reduced anterior cingulate cortex activity improved cognitively
0.09719374.15994572.html.plaintext.txt	123	View larger version 8K Fig
0.09719374.15994572.html.plaintext.txt	124	placebo working memory task correlation difference anterior cingulate activation behavioural performance
0.09719374.15994572.html.plaintext.txt	125	For patient n17 x axis shows difference accuracy intra scanner working memory task modafinil placebo conditions y axis shows corresponding difference estimated functional magnetic resonance imaging fMRI signal change
0.09719374.15994572.html.plaintext.txt	126	Positive values indicate greater accuracygreater fMRI signal change modafinil placebo
0.09719374.15994572.html.plaintext.txt	127	Post hoc examination data revealed five patients exhibiting improvements anterior cingulate cortex fMRI signal 2 back performance four receiving typical neuroleptics depot sulpiride one receiving olanzapine
0.09719374.15994572.html.plaintext.txt	128	That five patients received typicals majority responded positively modafinil physiologically cognitively
0.09719374.15994572.html.plaintext.txt	129	Conversely 12 patients receiving atypicals one exhibited pattern
0.09719374.15994572.html.plaintext.txt	130	Moreover post hoc analysis confirmed positive correlation anterior cingulate cortex signal performance change significant five patients receiving typical antipsychotics Spearmans 1
0.09719374.15994572.html.plaintext.txt	131	Conversely patients excluded group analysis latter longer significant 12 patients receiving atypicals 0
0.09719374.15994572.html.plaintext.txt	132	Exclusion subjects whose performance level chance placebo led exclusion three four subjects receiving depots reduction anterior cingulate cortexperformance correlation trend significance 0
0.09719374.15994572.html.plaintext.txt	133	Hence possible receiving depot medication derived greatest benefit modafinil perhaps consequence greater initial deficit contributed findings
0.09719374.15994572.html.plaintext.txt	134	We investigated post hoc deficitbenefit hypothesis found exhibiting improved working memory performance modafinil demonstrated significantly worse performance verbal fluency task initial assessment compared patients
0.09719374.15994572.html.plaintext.txt	135	Responders generated 7 18 words 1 min median 10 non responders generated 4 25 words median 11
0.09719374.15994572.html.plaintext.txt	136	There correlations intra scanner working memory task performance specific symptom ratings
0.09719374.15994572.html.plaintext.txt	137	Finally way validating sample described successive reports repeatedly described positive correlations 2 back accuracy right dorsolateral prefrontal cortex activity people schizophrenia compared normals Callicott et al 1999 2000 examined correlates performance per se 2 back task
0.09719374.15994572.html.plaintext.txt	138	We found right dorsolateral prefrontal cortex implicated conditions placebo x44 mm y41 mm z9 mm 21 voxels Z2
0.09719374.15994572.html.plaintext.txt	139	01 uncorrected height activation modafinil x44 mm y49 mm z18 mm 62 voxels Z3
0.09719374.15994572.html.plaintext.txt	140	01 uncorrected height activation
0.09719374.15994572.html.plaintext.txt	141	DISCUSSION TOP ABSTRACT INTRODUCTION METHOD RESULTS DISCUSSION Clinical Implications
0.09719374.15994572.html.plaintext.txt	142	ACKNOWLEDGMENTS REFERENCES Neural response We administered single low dose modafinil people chronic schizophrenia assessed working memory fMRI
0.09719374.15994572.html.plaintext.txt	143	Our data reveal specific effect drug upon area frontal lobe called anterior cingulate cortex
0.09719374.15994572.html.plaintext.txt	144	Importantly effect specific active memory condition baseline state
0.09719374.15994572.html.plaintext.txt	145	Anterior cingulate cortex involved wide range executive functions Bush et al 2000 activated working memory protocols previous studies Callicott et al 2000 2003 Meyer Lindenberg et al 2001
0.09719374.15994572.html.plaintext.txt	146	Its activation people chronic schizophrenia appears enhanced modafinil Fig
0.09719374.15994572.html.plaintext.txt	147	Cognitive response Despite enhanced anterior cingulate cortex activation group level working memory performance patients exhibit enhanced cognition
0.09719374.15994572.html.plaintext.txt	148	For group whole effect modafinil upon working memory protocol
0.09719374.15994572.html.plaintext.txt	149	Therefore might posited increased anterior cingulate cortex activation either unrelated cognition indicative reduced efficiency cognitive processing Callicott et al 2000 Manoach 2003
0.09719374.15994572.html.plaintext.txt	150	If greater anterior cingulate cortex activation occurs without increase cognitive performance brain function might said less efficient presence modafinil
0.09719374.15994572.html.plaintext.txt	151	However important note cognitive function improve minority patients although might posited expected statistically merely manifestation variation around mean feature data runs counter interpretation
0.09719374.15994572.html.plaintext.txt	152	This positive correlation anterior cingulate cortex activation cognitive improvement Fig
0.09719374.15994572.html.plaintext.txt	153	If modafinil simply made anterior cingulate cortex function less efficient expect correlation negative
0.09719374.15994572.html.plaintext.txt	154	The positive correlation implies magnitude anterior cingulate cortex activation cognitive performance indeed related context modafinil exposure exhibiting greater anterior cingulate cortex response also exhibit greater cognitive enhancement working memory
0.09719374.15994572.html.plaintext.txt	155	Accounting responders It interest exhibiting greater physiological cognitive response modafinil tended receiving typical neuroleptic medications depots sulpiride
0.09719374.15994572.html.plaintext.txt	156	The numbers small may rationale finding
0.09719374.15994572.html.plaintext.txt	157	The neurotransmitter systems implicated promotion wakefulness modafinil include dopaminergic serotonergic systems
0.09719374.15994572.html.plaintext.txt	158	Although antipsychotics share antagonism dopaminergic system especially D2 receptor typicals atypicals differ affinities receptors particularly 5HT2A Keefe et al 1999
0.09719374.15994572.html.plaintext.txt	159	In animal models modafinils effect increasing alertness attenuated 5HT2A antagonism Shelton et al 1995 hence possible atypical antipsychotic treatment antagonising 5HT2A might constrain cognotropic effects modafinil hypothesis deserving study
0.09719374.15994572.html.plaintext.txt	160	Alternatively ability atypicals enhance cognition albeit limited extent Keefe et al 1999 might curtail improvement modafinil
0.09719374.15994572.html.plaintext.txt	161	Safety There number caveats study findings
0.09719374.15994572.html.plaintext.txt	162	First reasons described deliberately utilised relatively low dose modafinil
0.09719374.15994572.html.plaintext.txt	163	This may sub optimal
0.09719374.15994572.html.plaintext.txt	164	Nevertheless one participants underwent psychotic relapse 4 days post drug
0.09719374.15994572.html.plaintext.txt	165	We cannot determine whether modafinil responsible
0.09719374.15994572.html.plaintext.txt	166	Although covert non adherence concurrent medication cannot excluded receiving oral antipsychotic must wary seeking exculpate test medication
0.09719374.15994572.html.plaintext.txt	167	However psychotic reaction single dose modafinil unprecedented knowledge although cases psychosis emerging de novo receiving multiple doses
0.09719374.15994572.html.plaintext.txt	168	The manufacturers prescribing information reports one healthy male volunteer developed ideas reference paranoid delusions auditory hallucinations association multiple daily 600 mg doses modafinil sleep deprivation
0.09719374.15994572.html.plaintext.txt	169	There evidence psychosis 36 hours drug discontinuation
0.09719374.15994572.html.plaintext.txt	170	The British National Formulary mention psychosis either contraindication consequence modafinil exposure
0.09719374.15994572.html.plaintext.txt	171	In recent study 20 patients schizophrenia exposed single dose 200 mg modafinil drug elicited exacerbation psychosis Turner et al 2004
0.09719374.15994572.html.plaintext.txt	172	However anecdotal accounts schizophrenic relapse following repeated dosing Narendran et al 2002 Rosenthal Bryant 2003
0.09719374.15994572.html.plaintext.txt	173	Further multi dosing studies centres may help clarify magnitude putative risk
0.09719374.15994572.html.plaintext.txt	174	Clinical Implications Limitations TOP ABSTRACT INTRODUCTION METHOD RESULTS DISCUSSION Clinical Implications
0.09719374.15994572.html.plaintext.txt	175	ACKNOWLEDGMENTS REFERENCES CLINICAL IMPLICATIONS Schizophrenia associated cognitive impairments impact upon social function cognitive enhancer modafinil might reduce impairments
0.09719374.15994572.html.plaintext.txt	176	Patients chronic schizophrenia exhibited increased anterior cingulate activation response modafinil performing working memory protocol also exhibited improved memory performance
0.09719374.15994572.html.plaintext.txt	177	Of patients exhibiting improved memory performance modafinil receiving concomitant typical antipsychotic medication
0.09719374.15994572.html.plaintext.txt	178	LIMITATIONS As many neuroimaging studies number subjects examined relatively small
0.09719374.15994572.html.plaintext.txt	179	The impact memory improvement upon day day function outside scanner remains demonstrated
0.09719374.15994572.html.plaintext.txt	180	Those patients may derive cognitive benefit modafinil require characterisation
0.09719374.15994572.html.plaintext.txt	181	ACKNOWLEDGMENTS TOP ABSTRACT INTRODUCTION METHOD RESULTS DISCUSSION Clinical Implications
0.09719374.15994572.html.plaintext.txt	182	ACKNOWLEDGMENTS REFERENCES We thank patients participated study Dr C
0.09719374.15994572.html.plaintext.txt	183	Lawson radiography colleagues Royal Hallamshire Hospital Ms Anne Connors pharmacist nursing staff Rowan Ward Clinical Academic Unit Ms Karen Roy initial advice
0.09719374.15994572.html.plaintext.txt	184	The sponsor involved scientific discussions regarding study design role data collection data analysis data interpretation writing report decision submit paper publication
0.09719374.15994572.html.plaintext.txt	185	We grateful University Sheffield Sheffield Care Trust insurance indemnification study
0.09719374.15994572.html.plaintext.txt	186	REFERENCES TOP ABSTRACT INTRODUCTION METHOD RESULTS DISCUSSION Clinical Implications
0.09719374.15994572.html.plaintext.txt	187	ACKNOWLEDGMENTS REFERENCES American Psychiatric Association 1994 Diagnostic Statistical Manual Mental Disorders 4th edn DSM IV
0.09719374.15994572.html.plaintext.txt	188	1983 Scale Assessment Negative Symptoms SANS
0.09719374.15994572.html.plaintext.txt	189	1984 Scale Assessment Positive Symptoms SAPS
0.09719374.15994572.html.plaintext.txt	190	1989 A rating scale drug induced akathisia
0.09719374.15994572.html.plaintext.txt	191	British Journal Psychiatry 154 672 676
0.09719374.15994572.html.plaintext.txt	192	et al 1961 An inventory measuring depression
0.09719374.15994572.html.plaintext.txt	193	Archives General Psychiatry 4 561 571
0.09719374.15994572.html.plaintext.txt	194	et al 2003 Working memory deficits levels N acetylaspartate patients schizophreniform disorder
0.09719374.15994572.html.plaintext.txt	195	American Journal Psychiatry 160 483 489
0.09719374.15994572.html.plaintext.txt	196	British Medical Association 2004 British National Formulary
0.09719374.15994572.html.plaintext.txt	197	London British Medical AssociationRoyal Pharmaceutical Society Great Britain
0.09719374.15994572.html.plaintext.txt	198	2000 Cognitive emotional influences anterior cingulate cortex
0.09719374.15994572.html.plaintext.txt	199	Trends Cognitive Sciences 4 215 222
0.09719374.15994572.html.plaintext.txt	200	et al 1998 Functional magnetic resonance brain mapping psychiatry methodological issues illustrated study working memory schizophrenia
0.09719374.15994572.html.plaintext.txt	201	Neuropsychopharmacology 18 186 196
0.09719374.15994572.html.plaintext.txt	202	et al 1999 Physiological characteristics capacity constraints working memory revealed functional MRI
0.09719374.15994572.html.plaintext.txt	203	et al 2000 Physiological dysfunction dorsolateral prefrontal cortex schizophrenia revisited
0.09719374.15994572.html.plaintext.txt	204	Cerebral Cortex 10 1078 1092
0.09719374.15994572.html.plaintext.txt	205	et al 2003 Abnormal fMRI response dorsolateral prefrontal cortex cognitively intact siblings patients schizophrenia
0.09719374.15994572.html.plaintext.txt	206	American Journal Psychiatry 160 709 719
0.09719374.15994572.html.plaintext.txt	207	Cephalon 1999 Prescribing Information Provigil Modafinil Tablets
0.09719374.15994572.html.plaintext.txt	208	West Chester PA Cephalon Inc
0.09719374.15994572.html.plaintext.txt	209	et al 1993 3D statistical neuroanatomical models 305 MRI volumes
0.09719374.15994572.html.plaintext.txt	210	IEEE Nuclear Science Symposium Medical Imaging Conference Proceedings 108 1877 1878
0.09719374.15994572.html.plaintext.txt	211	1975 Mini Mental State practical method grading cognitive state patients clinician
0.09719374.15994572.html.plaintext.txt	212	Journal Psychiatric Research 12 189 198
0.09719374.15994572.html.plaintext.txt	213	et al 1995 Spatial registration normalisation images
0.09719374.15994572.html.plaintext.txt	214	Human Brain Mapping 2 165 169
0.09719374.15994572.html.plaintext.txt	215	1999 How many subjects constitute study NeuroImage 10 1 5
0.09719374.15994572.html.plaintext.txt	216	1976 Early Clinical Drug Evaluation Unit Assessment Manual Psychopharmacology Revised Edition
0.09719374.15994572.html.plaintext.txt	217	Washington DC Department Health Education Welfare
0.09719374.15994572.html.plaintext.txt	218	et al 1999 The effects atypical antipsychotic drugs neurocognitive impairment schizophrenia review meta analysis
0.09719374.15994572.html.plaintext.txt	219	Schizophrenia Bulletin 25 201 222
0.09719374.15994572.html.plaintext.txt	220	1996 Potential brain neuronal targets amphetamine methylphenidate modafinil induced wakefulness evidenced c fos immunocytochemistry cat
0.09719374.15994572.html.plaintext.txt	221	Proceedings National Academy Sciences USA 93 14128 14133
0.09719374.15994572.html.plaintext.txt	222	et al 2001 Neurophysiological investigation basis fMRI signal
0.09719374.15994572.html.plaintext.txt	223	2003 Prefrontal cortex dysfunction working memory performance schizophrenia reconciling discrepant findings
0.09719374.15994572.html.plaintext.txt	224	Schizophrenia Research 60 285 298
0.09719374.15994572.html.plaintext.txt	225	et al 1999 1999 Schizophrenic subjects activate dorsolateral prefrontal cortex working memory task measured fMRI
0.09719374.15994572.html.plaintext.txt	226	Biological Psychiatry 45 1128 1137
0.09719374.15994572.html.plaintext.txt	227	et al 2001 Evidence abnormal cortical functional connectivity working memory schizophrenia
0.09719374.15994572.html.plaintext.txt	228	American Journal Psychiatry 158 1809 1817
0.09719374.15994572.html.plaintext.txt	229	et al 2002 Is psychosis exacerbated modafinil Archives General Psychiatry 59 292 293
0.09719374.15994572.html.plaintext.txt	230	1978 Dementia estimation premorbid intelligence levels using National Adult Reading Test
0.09719374.15994572.html.plaintext.txt	231	1962 The Brief Psychiatric Rating Scale
0.09719374.15994572.html.plaintext.txt	232	Psychological Reports 10 799 812
0.09719374.15994572.html.plaintext.txt	233	2003 Clinical pharmacokinetic profile modafinil
0.09719374.15994572.html.plaintext.txt	234	Clinical Pharmacokinetics 42 123 137
0.09719374.15994572.html.plaintext.txt	235	2003 Benefits adjunct modafinil open label pilot study patients schizophrenia
0.09719374.15994572.html.plaintext.txt	236	Schizophrenia Research 60 301
0.09719374.15994572.html.plaintext.txt	237	et al 2000 Hypothalamic arousal regions activated modafinil induced wakefulness
0.09719374.15994572.html.plaintext.txt	238	Journal Neuroscience 20 8620 8628
0.09719374.15994572.html.plaintext.txt	239	et al 1995 Comparative effects modafinil amphetamine daytime sleepiness cataplexy narcoleptic dogs
0.09719374.15994572.html.plaintext.txt	240	1970 A rating scale extrapyramidal side effects
0.09719374.15994572.html.plaintext.txt	241	Acta Psychiatrica Scandinavica 212 suppl
0.09719374.15994572.html.plaintext.txt	242	1988 A Stereotactic Co planar Atlas Human Brain
0.09719374.15994572.html.plaintext.txt	243	et al 2004 Modafinil improves cognition attentional set shifting people schizophrenia
0.09719374.15994572.html.plaintext.txt	244	Neuropsychopharmacology 29 1363 1373
0.09719374.15994572.html.plaintext.txt	245	US Modafinil Narcolepsy Multicenter Study Group 2000 Randomised trial modafinil treatment excessive daytime somnolence narcolepsy
0.09719374.15994572.html.plaintext.txt	246	et al 1997 The functional significance symptomatology cognitive function schizophrenia
0.09719374.15994572.html.plaintext.txt	247	Schizophrenia Research 25 21 31
0.09719374.15994572.html.plaintext.txt	248	Received publication May 18 2004
0.09719374.15994572.html.plaintext.txt	249	Revision received October 19 2004
0.09719374.15994572.html.plaintext.txt	250	Accepted publication October 21 2004
0.09719374.15994572.html.plaintext.txt	251	This Article Abstract Full Text PDF Submit response Alert article cited Alert eLetters posted Alert correction posted Citation Map Services Email article friend Similar articles journal Similar articles PubMed Alert new issues journal Download citation manager Google Scholar Articles SPENCE S
0.09719374.15994572.html.plaintext.txt	252	Articles citing Article PubMed PubMed Citation Articles SPENCE S
0.09719374.15994572.html.plaintext.txt	253	HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS Psychiatric Bulletin Advances Psychiatric Treatment All RCPsych Journals
0.20187694.15557013.html.plaintext.txt	0	Orexin stimulates breathing via medullary spinal pathways John K
0.20187694.15557013.html.plaintext.txt	1	Young1 Mingfei Wu1 Kebreten F
0.20187694.15557013.html.plaintext.txt	2	1Howard University Specialized Neuroscience Research Program Departments Physiology Anatomy Washington District Columbia 2Departments Pediatrics Anatomy Case Western University Cleveland Ohio
0.20187694.15557013.html.plaintext.txt	3	Submitted 20 August 2004 accepted final form 10 November 2004
0.20187694.15557013.html.plaintext.txt	4	ABSTRACT TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES A central neuronal network regulates respiration may include hypothalamic neurons produce orexin peptide influences sleep arousal
0.20187694.15557013.html.plaintext.txt	5	In experiments investigated 1 projections orexin containing neurons pre Botzinger region rostral ventrolateral medulla regulates rhythmic breathing phrenic motoneurons innervate diaphragm 2 presence orexin A receptors pre Botzinger region phrenic motoneurons 3 physiological effects orexin administered pre Botzinger region phrenic nuclei C3 C4 levels
0.20187694.15557013.html.plaintext.txt	6	We found orexin containing fibers within pre Botzinger complex
0.20187694.15557013.html.plaintext.txt	7	5 orexin containing neurons projected pre Botzinger region whereas 2
0.20187694.15557013.html.plaintext.txt	8	9 orexin containing neurons innervated phrenic nucleus
0.20187694.15557013.html.plaintext.txt	9	Neurons pre Botzinger region phrenic nucleus stained orexin receptors activation orexin receptors microperfusion orexin either site produced dose dependent significant P 0
0.20187694.15557013.html.plaintext.txt	10	05 increase diaphragm electromyographic activity
0.20187694.15557013.html.plaintext.txt	11	These data indicate orexin regulates respiratory activity may role pathophysiology sleep related respiratory disorders
0.20187694.15557013.html.plaintext.txt	12	hypothalamus pre Botzinger region phrenic motor neurons orexin 1 receptors sleep apnea
0.20187694.15557013.html.plaintext.txt	13	BREATHING IS AN ACTIVE NEURALLY controlled process regulated neural mechanisms adjust respiratory related drive behavioral state metabolic demands organism
0.20187694.15557013.html.plaintext.txt	14	Hypothalamic neurons part controlling system play important role regulation breathing rate depth 14 26
0.20187694.15557013.html.plaintext.txt	15	Neurons lateral hypothalamus synthesize orexin A orexin B also called hypocretin 1 hcrt 1 hypocretin 2 hcrt 2
0.20187694.15557013.html.plaintext.txt	16	These peptide neurotransmitters processed common precursor prepro orexin encoded gene localized human chromosome 17q2
0.20187694.15557013.html.plaintext.txt	17	Orexin containing neurons affect autonomic neuroendocrine sleep wakefulness neuroregulatory systems turn could potentially influence breathing 9 13 16 19
0.20187694.15557013.html.plaintext.txt	18	The orexins stimulate target cells via two orexin G protein coupled receptors orexin R1 orexin R2 40
0.20187694.15557013.html.plaintext.txt	19	It proposed orexin containing neurons promote wakefulness excitation cholinergic neurons basal forebrain release acetylcholine thereby contribute cortical activation wakefulness
0.20187694.15557013.html.plaintext.txt	20	However causality associations remains determined wakefulness often accompanied behavioral activation
0.20187694.15557013.html.plaintext.txt	21	Suppression rapid eye movement sleep occurs inhibition cholinergic neurons laterodorsal tegmental pedunculopontine nuclei 49
0.20187694.15557013.html.plaintext.txt	22	In central nervous system orexin containing neurons innervate multiple sites including cell groups brain stem spinal cord involved regulation cardiovascular functions 10 19 25 43 45
0.20187694.15557013.html.plaintext.txt	23	However information projections orexin containing neurons respiratory related brain stem regions spinal cord motoneurons innervate respiratory muscles diaphragm
0.20187694.15557013.html.plaintext.txt	24	Furthermore known whether brain stem region involved generation inspiratory rhythmic activity pre Botzinger complex ventrolateral medulla andor inspiratory motoneurons phrenic motor neurons express orexin receptors 42
0.20187694.15557013.html.plaintext.txt	25	We hypothesized orexin containing neurons involved arousal also participate respiratory control via direct projections pre Botzinger complex phrenic motor neurons
0.20187694.15557013.html.plaintext.txt	26	MATERIALS AND METHODS TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES Animals
0.20187694.15557013.html.plaintext.txt	27	Experimental protocols approved Howard University Institutional Animal Care Use Committee
0.20187694.15557013.html.plaintext.txt	28	All experiments performed male Sprague Dawley rats Harlan Indianapolis IN 300 350 g according National Institutes Health Guide Care Use Laboratory Animals
0.20187694.15557013.html.plaintext.txt	29	Male rats chosen reduce potential effects hormonal cycling females
0.20187694.15557013.html.plaintext.txt	30	In present study distribution neurons express orexin 1 receptors within rostral ventrolateral medulla cervical spinal cord determined
0.20187694.15557013.html.plaintext.txt	31	To define whether phrenic motor neurons express orexin receptors animals n 3 rats anesthetized pentobarbital sodium 40 mgkg retrograde tracer cholera toxin B subunit 0
0.20187694.15557013.html.plaintext.txt	32	1 CTB List Biological Laboratories Campbell CA injected costal region diaphragm 10 sites 300 nlsite
0.20187694.15557013.html.plaintext.txt	33	This procedure specifically identifies phrenic motoneurons project diaphragm
0.20187694.15557013.html.plaintext.txt	34	Seven days CTB injections animals deeply anesthetized 50 mgkg ip pentobarbital rapidly perfused transcardially 0
0.20187694.15557013.html.plaintext.txt	35	9 buffered saline followed 4 paraformaldehyde 0
0.20187694.15557013.html.plaintext.txt	36	The perfused brains removed animals postfixed 4 paraformaldehyde 0
0.20187694.15557013.html.plaintext.txt	37	After cryoprotection immersion 30 sucrose 0
0.20187694.15557013.html.plaintext.txt	38	1 M PBS 4 degrees C 48 h 40 microm thick frozen sections brains prepared using Leitz microtome
0.20187694.15557013.html.plaintext.txt	39	In experiments immunostaining procedures orexin receptors performed sequentially rather simultaneously previous studies laboratory demonstrated approach provides better specificity lower background staining 26
0.20187694.15557013.html.plaintext.txt	40	Briefly enhance immunoreactivity free floating sections brain stem cervical spinal cord C3 C5 region washed PBS incubated 10 mM citric acid 37 degrees C 1 h followed three washes PBS incubation 30 min PBS Triton solution containing 1 normal serum block nonspecific binding sites
0.20187694.15557013.html.plaintext.txt	41	After wash sections incubated 24 h 4 degrees C PBS Triton solution containing rabbit anti orexin 1 receptor antibody Chemicon International 1400 dilution
0.20187694.15557013.html.plaintext.txt	42	The sections rinsed incubated 2 h 1200 dilution goat anti rabbit IgG conjugated Alexa Fluro 488 fluorescein isothiocyanate FITC Molecular Probes Eugene OR
0.20187694.15557013.html.plaintext.txt	43	Briefly second step sections rinsed PBS stained CTB
0.20187694.15557013.html.plaintext.txt	44	Sections placed primary polyclonal antibody solution 120 000 dilution goat anti CTB PBS Triton List Biological Laboratories 48 h 4 degrees C
0.20187694.15557013.html.plaintext.txt	45	The sections washed twice PBS incubated 2 h 1200 solution donkey anti goat IgG conjugated Alexa Fluro 594 Texas red Molecular Probes
0.20187694.15557013.html.plaintext.txt	46	The sections washed mounted gelatinalum coated glass slides
0.20187694.15557013.html.plaintext.txt	47	A drop Vecta Shield Vector Laboratories Burlingame CA applied air dried sections slides coverslipped
0.20187694.15557013.html.plaintext.txt	48	Selected sections medulla oblongata also stained orexin 1 receptors peroxidase labeled antibody diaminobenzidine chromogen ABC technique described
0.20187694.15557013.html.plaintext.txt	49	Control experiments experiment done determine whether primary secondary antibodies produced false positive results
0.20187694.15557013.html.plaintext.txt	50	In experiments sections stained possible combinations primary secondary antibodies single immunoprobe omitted
0.20187694.15557013.html.plaintext.txt	51	Omission primary secondary antibodies resulted absence labeling demonstrating false positive results obtained reagents
0.20187694.15557013.html.plaintext.txt	52	Slides viewed bright field fluorescence microscope Olympus AX70 Olympus America equipped adequate filter systems observe Texas red green FITC fluorescence
0.20187694.15557013.html.plaintext.txt	53	Colocalization CTB orexin 1 receptors identified alternating filters view Texas red FITC fluorescence analyzing merged images exact sites
0.20187694.15557013.html.plaintext.txt	54	In qualitative approach problem attempt quantitatively estimate total numbers identifiable phrenic motor neurons C3 C5 percentage phrenic motor neurons stained positively orexin receptors
0.20187694.15557013.html.plaintext.txt	55	In second set experiments orexin containing lateral hypothalamic cells project phrenic nucleus identified neuroanatomic tracing
0.20187694.15557013.html.plaintext.txt	56	In anesthetized animals n 3 rats CTB unilaterally injected ventral horn cervical spinal cord extending C3 C5 total 300 nl 0
0.20187694.15557013.html.plaintext.txt	57	1 solution previously described 26
0.20187694.15557013.html.plaintext.txt	58	Injections made glass micropipette 40 60 microm diameter 0
0.20187694.15557013.html.plaintext.txt	59	4 mm dorsal surface spinal cord
0.20187694.15557013.html.plaintext.txt	60	Seven days CTB injections animals perfused brains prepared outlined
0.20187694.15557013.html.plaintext.txt	61	In third set experiments three experimental subjects projections orexin containing neurons pre Botzinger complex determined unilateral microinjection CTB 12
0.20187694.15557013.html.plaintext.txt	62	8 mm dorsal ventral surface ventrolateral medulla oblongata right site 100 nl 0
0.20187694.15557013.html.plaintext.txt	63	These coordinates used previous studies laboratory examine respiration regulating neurons possessing neurokinin 1 receptors within called pre Botzinger complex region 26 42
0.20187694.15557013.html.plaintext.txt	64	These coordinates later utilized microinjection either orexin toluidine blue marker dye see
0.20187694.15557013.html.plaintext.txt	65	Histological inspection sections confirmed injection site caudal facial nuclei rostral level hypoglossal nuclei within anatomic borders pre Botzinger complex see also Fig
0.20187694.15557013.html.plaintext.txt	66	Seven days injection animals deeply anesthetized perfused described brains removed processed immunohistochemically CTB orexin labeling
0.20187694.15557013.html.plaintext.txt	67	Transverse sections whole brain animal cut 40 microm
0.20187694.15557013.html.plaintext.txt	68	The immunohistochemical procedures used previously described 26 staining tissue sections hypothalamus
0.20187694.15557013.html.plaintext.txt	69	Briefly free floating sections washed PBS containing 0
0.20187694.15557013.html.plaintext.txt	70	3 Triton X 100 1 5 series tissue sections exposed 30 min PBS Triton solution containing 1 BSA block nonspecific binding sites
0.20187694.15557013.html.plaintext.txt	71	After wash tissue placed overnight 4 degrees C primary polyclonal antibody solution 12000 dilution rabbit anti orexin A 1 normal goat serum PBS Triton Oncogene Research Products 48 h 4 degrees C
0.20187694.15557013.html.plaintext.txt	72	The sections washed twice PBS incubated 2 h solution biotinylated goat anti rabbit secondary antibody Vector Laboratories
0.20187694.15557013.html.plaintext.txt	73	The sections washed PBS incubated 60 min avidin biotin peroxidase complex recommended supplier
0.20187694.15557013.html.plaintext.txt	74	View larger version 116K Fig
0.20187694.15557013.html.plaintext.txt	75	A schematic diagram area medulla investigated 12
0.20187694.15557013.html.plaintext.txt	76	3 mm posterior bregma 37 paired section showing distribution toluidine blue dye microperfused using coordinates volume used infuse orexin
0.20187694.15557013.html.plaintext.txt	77	Boxed region shows area examined higher magnifications B C D
0.20187694.15557013.html.plaintext.txt	78	Amb ambiguus PrBo pre Botzinger complex sol solitary tract ml medial lemniscus py pyramid sp5 spinal tract 5
0.20187694.15557013.html.plaintext.txt	79	B orexin immunoreactive beaded axons present within region pre Botzinger complex
0.20187694.15557013.html.plaintext.txt	80	C low magnification view medulla showing orexin A receptor immunoreactivity brown nucleus ambiguus subjacent neurons pre Botzinger complex section counterstained thionin
0.20187694.15557013.html.plaintext.txt	81	D higher magnification view neurons nucleus ambiguus immunoreactive orexin receptors
0.20187694.15557013.html.plaintext.txt	82	To identify retrogradely labeled neurons within lateral hypothalamus produce orexin labeled orexin sections washed PBS placed primary polyclonal antibody solution 120000 dilution goat anti CTB PBS Triton 48 h 4 degrees C
0.20187694.15557013.html.plaintext.txt	83	The sections washed twice PBS incubated 2 h 1200 solution donkey anti goat IgG conjugated Alexa Fluro 594 Texas red Molecular Probes
0.20187694.15557013.html.plaintext.txt	84	The sections washed mounted gelatinalum coated glass slides
0.20187694.15557013.html.plaintext.txt	85	A drop Vecta Shield Vector Laboratories applied air dried sections slides coverslipped
0.20187694.15557013.html.plaintext.txt	86	Sections viewed either bright field microscopy orexin immunoreactivity brown diaminobenzidine precipitate fluorescence microscopy CTB immunoreactivity red fluorescence
0.20187694.15557013.html.plaintext.txt	87	Digitized bright field images merged fluorescence images using imaging software detect double labeled cells Sigma Scan Pro SPSS Chicago IL
0.20187694.15557013.html.plaintext.txt	88	Rats anesthetized urethane 1
0.20187694.15557013.html.plaintext.txt	89	2 gkg carotid artery external jugular vein catheterized recording blood pressure heart rate administering fluid anesthetic one tenth initial concentration per hour
0.20187694.15557013.html.plaintext.txt	90	After bilateral vagotomy tracheotomy rats placed stereotaxic apparatus prone position
0.20187694.15557013.html.plaintext.txt	91	Diaphragm electromyographic activity DEMG recorded via bipolar electrodes placed costal diaphragm
0.20187694.15557013.html.plaintext.txt	92	Animals ventilated O2 pump rate provided 30 total ventilatory activity obtained 7 CO2 O2 previously described 14 26
0.20187694.15557013.html.plaintext.txt	93	To investigate effects orexin phrenic motoneurons cervical spinal cord segment C3 C5 exposed laminectomy dura opened retracted n 5 rats
0.20187694.15557013.html.plaintext.txt	94	After control values recorded spinal cord segment microperfused 5 microl saline orexin A dissolved saline applied surface cord respiratory variables recorded 5 min solution
0.20187694.15557013.html.plaintext.txt	95	Respiratory cardiovascular responses three doses orexin 4 40 200 microgml sterile saline studied
0.20187694.15557013.html.plaintext.txt	96	These doses corresponded doses proven effective stimulating neuronal firing andor arousal studies e
0.20187694.15557013.html.plaintext.txt	97	To examine medullary effects orexin 200 nl either saline three doses orexin microinjected pre Botzinger complex additional five rats via Hamilton syringe coordinates described
0.20187694.15557013.html.plaintext.txt	98	Respiratory variables recorded described
0.20187694.15557013.html.plaintext.txt	99	Finally end physiological experiments three five rats microinjected medullary stereotaxic coordinates 200 nl 1 toluidine blue mark anatomic location perfusion site
0.20187694.15557013.html.plaintext.txt	100	These rats perfused brains sectioned medullary sections dried onto slides counterstained 0
0.20187694.15557013.html.plaintext.txt	101	1 basic fuchsin mounted Vecta Shield without exposure slides alcohol
0.20187694.15557013.html.plaintext.txt	102	This procedure avoided elution marker dye toluidine blue sections alcohol
0.20187694.15557013.html.plaintext.txt	103	Moving average DEMG used determine amplitude well frequency inspiratory bursts
0.20187694.15557013.html.plaintext.txt	104	Respiratory responses quantified averaging parameters control period 10 consecutive breaths 10 breaths peak response microperfusion saline increasing concentrations orexin A
0.20187694.15557013.html.plaintext.txt	105	Blood pressure heart rate measured control period peak changes occurred orexin A administration
0.20187694.15557013.html.plaintext.txt	106	Average values means plus minus SD analyzed variables compared analysis variance repeated measures Tukeys protected tests
0.20187694.15557013.html.plaintext.txt	107	Statistical significance considered achieved P 0
0.20187694.15557013.html.plaintext.txt	108	RESULTS TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES Neuroanatomic Experiments
0.20187694.15557013.html.plaintext.txt	109	Connectivity orexin ir neurons phrenic motor nucleus spinal cord
0.20187694.15557013.html.plaintext.txt	110	After CTB injection spinal phrenic nucleus retrogradely labeled cells abundant lateral hypothalamus dorsal fornix
0.20187694.15557013.html.plaintext.txt	111	This distribution showed considerable overlap distribution orexin immunoreactive ir neurons lateral hypothalamus
0.20187694.15557013.html.plaintext.txt	112	In rats 386 orexin ir cells 173 CTB labeled cells examined total 11 double labeled cells mainly concentrated portion orexin ir neurons dorsolateral fornix found Fig
0.20187694.15557013.html.plaintext.txt	113	View larger version 97K Fig
0.20187694.15557013.html.plaintext.txt	114	A Schematic diagram area hypothalamus investigated 2
0.20187694.15557013.html.plaintext.txt	115	Boxed region shows location orexin immunoreactive neurons
0.20187694.15557013.html.plaintext.txt	116	B bright field microscopy lateral hypothalamus showing orexin immunoreactive neurons brown labeled diaminobenzidine
0.20187694.15557013.html.plaintext.txt	117	C field B viewed fluorescence microscopy show neurons retrogradely labeled CTB rhodamine labeled antibody infused phrenic motor nucleus
0.20187694.15557013.html.plaintext.txt	118	Neurons labeled CTB appear white whereas orexin immunoreactive neuron also labeled CTB appears red arrow
0.20187694.15557013.html.plaintext.txt	119	Calibration bar 100 microm F fornix
0.20187694.15557013.html.plaintext.txt	120	Connectivity orexin ir neurons pre Botzinger complex
0.20187694.15557013.html.plaintext.txt	121	After CTB injection pre Botzinger complex labeled cells tended located somewhat closer third ventricle cells projecting phrenic motor nucleus
0.20187694.15557013.html.plaintext.txt	122	In hypothalamic area 227 orexin ir cells 362 CTB labeled cells examined one cell double labeled
0.20187694.15557013.html.plaintext.txt	123	However orexin containing fibers observed pre Botzinger complex region rostral ventrolateral medulla Fig
0.20187694.15557013.html.plaintext.txt	124	Detection orexin 1 receptors
0.20187694.15557013.html.plaintext.txt	125	Immunoreactivity present neurons nucleus ambiguus nearby areas ventrolateral medulla roughly corresponding pre Botzinger complex Fig
0.20187694.15557013.html.plaintext.txt	126	This area precisely corresponds region recently reported contain unusually dense accumulation orexin ir fibers 12
0.20187694.15557013.html.plaintext.txt	127	Immunocytochemistry orexin receptor protein showed positive staining neurons phrenic motor nucleus identified retrograde transport CTB diaphragm Fig
0.20187694.15557013.html.plaintext.txt	128	View larger version 67K Fig
0.20187694.15557013.html.plaintext.txt	129	A diagram location phrenic motor neurons boxed region segment C4 spinal cord 32
0.20187694.15557013.html.plaintext.txt	130	B phrenic motor neurons ventral horn spinal cord retrogradely labeled CTB infused diaphragm green FITC labeled secondary antibody
0.20187694.15557013.html.plaintext.txt	131	C view B displaying section showing red fluorescence rhodamine labeled secondary antibody sites orexin A receptor immunoreactivity
0.20187694.15557013.html.plaintext.txt	132	Double labeled cells demonstrate phrenic motor neurons possess orexin receptors
0.20187694.15557013.html.plaintext.txt	133	Physiological effect orexin A receptor activation respiratory drive
0.20187694.15557013.html.plaintext.txt	134	To analyze effects microinjection orexin pre Botzinger complex changes induced orexin expressed percentage baseline discharge compared Fig
0.20187694.15557013.html.plaintext.txt	135	This analysis showed two higher doses orexin elicited statistically significant changes peak DEMG compared response saline P 0
0.20187694.15557013.html.plaintext.txt	136	05 40 microgml 200 microgml Tukeys protected test analysis variance
0.20187694.15557013.html.plaintext.txt	137	Toluidine blue dye infusion confirmed anatomic position infusion site within pre Botzinger complex Fig
0.20187694.15557013.html.plaintext.txt	138	A close inspection infusion site microscope showed intense color dye confined area diameter 200 microm dye could detected farther 500 microm away center infusion site
0.20187694.15557013.html.plaintext.txt	139	View larger version 18K Fig
0.20187694.15557013.html.plaintext.txt	140	A mean peak integrated respiratory diaphragmatic voltages expressed percent deviations electromyographic values observed baseline recording diaphragm
0.20187694.15557013.html.plaintext.txt	141	The respiratory responses microperfusion 40 200 microg orexin ventrolateral medulla significantly different responses saline 4 microgml orexin P 0
0.20187694.15557013.html.plaintext.txt	142	B breathing rates 5 treatment conditions
0.20187694.15557013.html.plaintext.txt	143	Heart rates blood pressure values rats study 5 higher previous experiences slightly elevated typical values reported others e
0.20187694.15557013.html.plaintext.txt	144	We exact explanation although values may related specific experimental conditions employed
0.20187694.15557013.html.plaintext.txt	145	multiple vascular cannulae vagotomy tracheal cannula etc
0.20187694.15557013.html.plaintext.txt	146	No statistically significant effects orexin heart rate blood pressure detected Table 1
0.20187694.15557013.html.plaintext.txt	147	A recording single rat representative group differences treatment conditions shown Fig
0.20187694.15557013.html.plaintext.txt	148	Cardiovascular variables following microperfusion test solutions pre Botzinger complex rostral ventrolateral medulla
0.20187694.15557013.html.plaintext.txt	149	View larger version 28K Fig
0.20187694.15557013.html.plaintext.txt	150	Respiratory activity rat 13 microperfusion saline ventrolateral medulla A application 40 microgml orexin medulla B
0.20187694.15557013.html.plaintext.txt	151	DEMG integrated electromyographic activity diaphragm
0.20187694.15557013.html.plaintext.txt	152	Similarly microperfusion two higher doses orexin onto spinal cord elicited statistically significant changes peak DEMG compared response saline P 0
0.20187694.15557013.html.plaintext.txt	153	05 40 microgml P 0
0.20187694.15557013.html.plaintext.txt	154	No statistically significant changes P 0
0.20187694.15557013.html.plaintext.txt	155	05 breathing rate treatment conditions detected Fig
0.20187694.15557013.html.plaintext.txt	156	Orexin produced slight statistically significant increase heart rate P 0
0.20187694.15557013.html.plaintext.txt	157	05 4 40 microgml P 0
0.20187694.15557013.html.plaintext.txt	158	01 200 microgml orexin Table 2
0.20187694.15557013.html.plaintext.txt	159	A recording single rat representative mean results shown Fig
0.20187694.15557013.html.plaintext.txt	160	View larger version 20K Fig
0.20187694.15557013.html.plaintext.txt	161	A mean peak integrated respiratory diaphragmatic voltages expressed percent changes electromyographic values observed baseline recording diaphragm
0.20187694.15557013.html.plaintext.txt	162	Respiratory responses application 40 200 microgml orexin onto spinal cord significantly different responses saline 4 microgml orexin P 0
0.20187694.15557013.html.plaintext.txt	163	B breathing rates 5 treatment conditions
0.20187694.15557013.html.plaintext.txt	164	Cardiovascular variables following microperfusion test solutions phrenic motor nucleus spinal cord
0.20187694.15557013.html.plaintext.txt	165	View larger version 33K Fig
0.20187694.15557013.html.plaintext.txt	166	Respiratory activity rat 5 application saline spinal cord A application 200 microgml orexin spinal cord B
0.20187694.15557013.html.plaintext.txt	167	DISCUSSION TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES Hypothalamic Orexin Producing Neurons Brain Stem Spinal Cord Respiratory Related Network
0.20187694.15557013.html.plaintext.txt	168	The results study showed first time discrete population orexin ir neurons lateral hypothalamus projects ventrolateral medulla phrenic nuclei
0.20187694.15557013.html.plaintext.txt	169	These findings extend previous reports demonstrating long descending orexin containing axonal projections innervate spinal cord 13 24
0.20187694.15557013.html.plaintext.txt	170	However results suggest direct synaptic contact pre Botzinger neurons orexin ir neurons infrequent despite presence numerous orexin containing fibers region
0.20187694.15557013.html.plaintext.txt	171	Conceivably apparent projection subset lateral hypothalamic orexin containing neurons pre Botzinger neurons phrenic nuclei could partly due nonspecific labeling produced diffusion retrograde tracer regions contain nonrespiratory related cells andor uptake tracer descending fibers orexin neurons innervate intermediate cell column thoracolumbar portion spinal cord 24
0.20187694.15557013.html.plaintext.txt	172	In addition CTB may also taken fibers passage
0.20187694.15557013.html.plaintext.txt	173	However CTB continues regarded useful retrograde tracer even recent neuroanatomic studies 11
0.20187694.15557013.html.plaintext.txt	174	Furthermore results accord reports transsynaptic transport pseudorabies virus diaphragm lateral hypothalamus 18 21 27
0.20187694.15557013.html.plaintext.txt	175	Considerable numbers orexin containing fibers present within rostral ventrolateral medulla rat
0.20187694.15557013.html.plaintext.txt	176	This finding accordance recent data orexin containing neurons innervate vagal preganglionic cells within nucleus ambiguus 12
0.20187694.15557013.html.plaintext.txt	177	However found little retrograde transport CTB infused area hypothalamic orexin ir neurons CTB labeled cells mostly located medial orexin ir neurons
0.20187694.15557013.html.plaintext.txt	178	Because CTB taken synaptic vesicles possibility exists synapses pre Botzinger complex neurons orexinergic fibers passage may sparse
0.20187694.15557013.html.plaintext.txt	179	It may orexin released passing fibers nonsynaptically activates receptors orexin circulating within cerebrospinal fluid may activate neurons contain orexin receptors volume transmission analogy effects endogenously released catecholamines region 2 23
0.20187694.15557013.html.plaintext.txt	180	Medullary neurons ventral compact portion nucleus ambiguus study also immunoreactive orexin A receptors may belong external loose portion nucleus ambiguus
0.20187694.15557013.html.plaintext.txt	181	Such vagal preganglionic neurons may contribute control respiration pre Botzinger complex else may directly involved control respiratory timing
0.20187694.15557013.html.plaintext.txt	182	A diversity function orexin sensitive neurons medulla may explain stimulatory effects orexin respiratory amplitude apparent lack effect respiratory timing
0.20187694.15557013.html.plaintext.txt	183	Orexin Receptor Expression Brain Stem Spinal Cord Respiratory Related Neurons
0.20187694.15557013.html.plaintext.txt	184	The results present study showed neurons within rostral ventrolateral medullary region corresponding pre Botzinger complex stain positively orexin A receptors
0.20187694.15557013.html.plaintext.txt	185	This finding accord numerous studies orexin receptors found throughout brain stem rostral brain regions 6 7 15 19 28 46
0.20187694.15557013.html.plaintext.txt	186	Furthermore findings first time indicate identified phrenic motor neurons express orexin receptors
0.20187694.15557013.html.plaintext.txt	187	Respiratory Effects Orexin Activation
0.20187694.15557013.html.plaintext.txt	188	Orexin microinjected pre Botzinger region administered topically cervical spinal cord increased DEMG without affecting discharge frequency bilaterally vagotomized rats
0.20187694.15557013.html.plaintext.txt	189	An increase peak integrated moving average activity diaphragm without changes respiratory timing indicates neurons involved regulation tidal volume activity inspiratory pumping muscles independent frequency discharge
0.20187694.15557013.html.plaintext.txt	190	However results exclude critical role inspiratory rhythm generating cells pre Botzinger complex control respiratory timing 17
0.20187694.15557013.html.plaintext.txt	191	Orexin may also affect respiration via projections sites e
0.20187694.15557013.html.plaintext.txt	192	may cause increase respiratory drive via activation hypothalamic neurons project pre Botzinger complex phrenic nuclei 14 26 29 41 50
0.20187694.15557013.html.plaintext.txt	193	Furthermore activity upper airway dilating muscles genioglossus muscle could affected via direct projections orexin containing neurons hypoglossal motoneurons activation orexin 1 receptors expressed hypoglossal motor cells innervate muscle 48
0.20187694.15557013.html.plaintext.txt	194	In addition dense orexinergic projections innervate intermediolateral cell column spinal cord majority sympathetic preganglionic neuronal cell bodies reside 13 46
0.20187694.15557013.html.plaintext.txt	195	This indicates lateral hypothalamic orexinergic neurons may act directly different brain stem spinal cord cell groups providing parallel control cardiovascular respiratory related output neurons behavioral state control defensive responses energy homeostasis 22 42
0.20187694.15557013.html.plaintext.txt	196	Orexin topically applied spinal cord slight significant effects heart rate
0.20187694.15557013.html.plaintext.txt	197	These findings accord data showing intracisternal intrathecal injections orexin A B provoke dose related increase heart rate sympathetic neuronal activity urethane anesthetized rats
0.20187694.15557013.html.plaintext.txt	198	Orexin given routes could activate multiple central nervous system spinal orexin sensitive sites including excitatory brain stem neurons spinal cord sympathetic preganglionic neurons 3 10
0.20187694.15557013.html.plaintext.txt	199	We observed effects medullary infusions orexin heart rate possibly rats vagotomized 12
0.20187694.15557013.html.plaintext.txt	200	The physiological effects observed study showed reliable dose response curve obtained using relatively high concentrations orexin
0.20187694.15557013.html.plaintext.txt	201	Possibly responses could part pharmacological
0.20187694.15557013.html.plaintext.txt	202	A blockade results pretreatment orexin antagonist e
0.20187694.15557013.html.plaintext.txt	203	SB 334867 would required completely eliminate possibility could partly non orexin receptor mediated 5
0.20187694.15557013.html.plaintext.txt	204	Physiological Relevance These Findings
0.20187694.15557013.html.plaintext.txt	205	Orexin neurons provide link central nervous system mechanisms coordinate sleep wakefulness states central nervous system control autonomic functions via multiple projections 38
0.20187694.15557013.html.plaintext.txt	206	These neurons also shown present study involved regulation breathing activity via projections brain stem spinal cord respiratory related network presumably orexin R1 signaling pathway
0.20187694.15557013.html.plaintext.txt	207	This accord recent report stimulation perifornical lateral hypothalamus elicits increases respiratory activity response diminished mice genetically engineered lack orexin 25
0.20187694.15557013.html.plaintext.txt	208	If humans orexin proves stimulate respiration deficit orexin action may contribute decrease respiratory drive sleeping review see Ref
0.20187694.15557013.html.plaintext.txt	209	This assumption consistent recent findings indicating orexin plays important role maintenance wakefulness reviews see Refs
0.20187694.15557013.html.plaintext.txt	210	A decreased influence orexin brain regions regulate sleep breathing could cause simultaneous decreases arousal respiratory drive
0.20187694.15557013.html.plaintext.txt	211	Recently reported patients sleep apnea decreased blood levels orexin relative controls 34
0.20187694.15557013.html.plaintext.txt	212	The mechanisms could produce decreased production orexin unknown may related apparent link obesity sleep apnea
0.20187694.15557013.html.plaintext.txt	213	It well known obesity prominent risk factor sleep apnea 30 56
0.20187694.15557013.html.plaintext.txt	214	Diabetes mellitus hyperglycemia also appear provoke sleep apnea 47
0.20187694.15557013.html.plaintext.txt	215	It seems likely metabolic alterations provoked obesity possibly elevations circulating nutrient molecules could partly explain association obesity sleep apnea
0.20187694.15557013.html.plaintext.txt	216	In genetic diet induced obesity rodents blood concentrations number circulating molecules elevated
0.20187694.15557013.html.plaintext.txt	217	An increased effect glucose free fatty acids leptin hypothalamic function could provoke altered activity orexin containing neurons 1 4 8 20 35 36 39 51 52 54 55
0.20187694.15557013.html.plaintext.txt	218	Thus orexin containing neurons may key component connection obesity sleep apnea
0.20187694.15557013.html.plaintext.txt	219	Further study required investigate hypothesis
0.20187694.15557013.html.plaintext.txt	220	In summary hypothalamic orexin containing neurons part brain stem spinal cord respiratory related network
0.20187694.15557013.html.plaintext.txt	221	Orexin acting via orexin R1 expressed pre Botzinger neurons phrenic nuclei increases respiratory drive
0.20187694.15557013.html.plaintext.txt	222	This indicates orexin orexin R1 pathway may play important role linking central nervous system nuclei involved regulation sleep wakefulness states central nervous system control respiration
0.20187694.15557013.html.plaintext.txt	223	Alterations regulatory system could lead autonomic dysfunctions sleep related respiratory disorders
0.20187694.15557013.html.plaintext.txt	224	GRANTS TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES A preliminary account findings appeared abstract form 53
0.20187694.15557013.html.plaintext.txt	225	This study supported National Institutes Health Grants NINDS 1 U54 NS39407 NCRR HL 5027 M
0.20187694.15557013.html.plaintext.txt	226	Mack Howard University Mordecai W
0.20187694.15557013.html.plaintext.txt	227	Johnson Research Support Grant J
0.20187694.15557013.html.plaintext.txt	228	FOOTNOTES Address reprint requests correspondence J
0.20187694.15557013.html.plaintext.txt	229	NW Washington DC 20059 E mail jyoungathoward
0.20187694.15557013.html.plaintext.txt	230	The costs publication article defrayed part payment page charges
0.20187694.15557013.html.plaintext.txt	231	The article must therefore hereby marked advertisement accordance 18 U
0.20187694.15557013.html.plaintext.txt	232	Section 1734 solely indicate fact
0.20187694.15557013.html.plaintext.txt	233	REFERENCES TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES Adam JA Menheere PP van Dielen FM Soeters PB Buurman WA Greve JW
0.20187694.15557013.html.plaintext.txt	234	Decreased plasma orexin A levels obese individuals
0.20187694.15557013.html.plaintext.txt	235	Int J Obes Relat Metab Disord 26 274 276 2002
0.20187694.15557013.html.plaintext.txt	236	CrossRefMedline Angati LF Zoli M Stromberg I Fuxe K
0.20187694.15557013.html.plaintext.txt	237	Intercellular communication brain wiring versus volume transmission
0.20187694.15557013.html.plaintext.txt	238	Neuroscience 69 711 726 1995
0.20187694.15557013.html.plaintext.txt	239	CrossRefISIMedline Antunes VR Brailoiu GC Kwok EH Scruggs P Dun NJ
0.20187694.15557013.html.plaintext.txt	240	Orexinhypocretins excite rat sympathetic preganglionic neurons vivo vitro
0.20187694.15557013.html.plaintext.txt	241	Am J Physiol Regul Integr Comp Physiol 281 R1801 R1807 2001
0.20187694.15557013.html.plaintext.txt	242	AbstractFree Full Text Beck B Richy S
0.20187694.15557013.html.plaintext.txt	243	Hypothalamic hypocretinorexin neuropeptide Y divergent interaction energy depletion leptin
0.20187694.15557013.html.plaintext.txt	244	Biochem Biophys Res Commun 258 119 122 1999
0.20187694.15557013.html.plaintext.txt	245	CrossRefISIMedline Bernard R Lydic R Baghdoyan HA
0.20187694.15557013.html.plaintext.txt	246	Hypocretin 1 causes G protein activation increases ACh release rat pons
0.20187694.15557013.html.plaintext.txt	247	Eur J Neurosci 18 1775 1785 2003
0.20187694.15557013.html.plaintext.txt	248	CrossRefISIMedline Bourgin P Huitron Resendiz S Spier AD Fabre V Morte B Criado JR Sutcliffe JG Henriksen SJ de Lecea L
0.20187694.15557013.html.plaintext.txt	249	Hypocretin 1 modulates rapid eye movement sleep activation locus coeruleus neurons
0.20187694.15557013.html.plaintext.txt	250	J Neurosci 20 7760 7765 2000
0.20187694.15557013.html.plaintext.txt	251	AbstractFree Full Text Brown RE Sergeeva OA Eriksson KS Haas HL
0.20187694.15557013.html.plaintext.txt	252	Convergent excitation dorsal raphe serotonin neurons multiple arousal systems orexinhypocretin histamine noradrenaline
0.20187694.15557013.html.plaintext.txt	253	J Neurosci 22 8850 8859 2002
0.20187694.15557013.html.plaintext.txt	254	AbstractFree Full Text Cai XJ Evans ML Lister CA Leslie RA Arch JR Wilson S Williams G
0.20187694.15557013.html.plaintext.txt	255	Hypoglycemia activates orexin neurons selectively increases hypothalamic orexin B levels responses inhibited feeding possibly mediated nucleus solitary tract
0.20187694.15557013.html.plaintext.txt	256	AbstractFree Full Text Chemelli RM Willie JT Sinton CM Elmquist JK Scammell T Lee C Richardson JA Williams SC Xiong Y Kisanuki Y Fitch TE Nakazato M Hammer RE Saper CB Yanagisawa M
0.20187694.15557013.html.plaintext.txt	257	Narcolepsy orexin knockout mice molecular genetics sleep regulation
0.20187694.15557013.html.plaintext.txt	258	CrossRefISIMedline Chen CT Hwang LL Chang JK Dun NJ
0.20187694.15557013.html.plaintext.txt	259	Pressor effects orexins injected intracisternally rostral ventrolateral medulla anesthetized rats
0.20187694.15557013.html.plaintext.txt	260	Am J Physiol Regul Integr Comp Physiol 278 R692 R697 2000
0.20187694.15557013.html.plaintext.txt	261	AbstractFree Full Text Chen S Aston Jones G
0.20187694.15557013.html.plaintext.txt	262	Axonal collateral collateral transport tract tracers brain neurons false anterograde labeling useful tool
0.20187694.15557013.html.plaintext.txt	263	Neuroscience 82 1151 1163 1998
0.20187694.15557013.html.plaintext.txt	264	CrossRefISIMedline Ciriello J de Oliveira CVR
0.20187694.15557013.html.plaintext.txt	265	Cardiac effects hypocretin 1 nucleus ambiguus
0.20187694.15557013.html.plaintext.txt	266	Am J Physiol Regul Integr Comp Physiol 284 R1611 R1620 2003
0.20187694.15557013.html.plaintext.txt	267	AbstractFree Full Text Date Y Mondal MS Matsukura S Nakazato M
0.20187694.15557013.html.plaintext.txt	268	Distribution orexin A orexin B hypocretins rat spinal cord
0.20187694.15557013.html.plaintext.txt	269	Neurosci Lett 288 87 90 2000
0.20187694.15557013.html.plaintext.txt	270	CrossRefISIMedline Dreshaj IA Haxhiu MA Martin RJ Young JK
0.20187694.15557013.html.plaintext.txt	271	The basomedial hypothalamus modulates ventilatory response hypoxia neonatal rats
0.20187694.15557013.html.plaintext.txt	272	Pediatr Res 53 945 949 2003
0.20187694.15557013.html.plaintext.txt	273	AbstractFree Full Text Eriksson KS Sergeeva O Brown RE Haas HL
0.20187694.15557013.html.plaintext.txt	274	Orexinhypocretin excites histaminergic neurons tuberomammillary nucleus
0.20187694.15557013.html.plaintext.txt	275	J Neurosci 21 9273 9279 2001
0.20187694.15557013.html.plaintext.txt	276	AbstractFree Full Text Espana RA Baldo BA Kelley AE Berridge CW
0.20187694.15557013.html.plaintext.txt	277	Wake promoting sleep suppressing actions hypocretin orexin basal forebrain sites action
0.20187694.15557013.html.plaintext.txt	278	Neuroscience 106 699 715 2001
0.20187694.15557013.html.plaintext.txt	279	CrossRefISIMedline Feldman JL Mitchell GS Nattie EE
0.20187694.15557013.html.plaintext.txt	280	Breathing rhythmicity plasticity chemosensitivity
0.20187694.15557013.html.plaintext.txt	281	Annu Rev Neurosci 26 239 266 2003
0.20187694.15557013.html.plaintext.txt	282	CrossRefISIMedline Gaytan SP Pasaro R Coulon P Bevengut M Hilaire G
0.20187694.15557013.html.plaintext.txt	283	Identification central nervous system neurons innervating respiratory muscles mouse transneuronal tracing study
0.20187694.15557013.html.plaintext.txt	284	Brain Res Bull 57 335 339 2002
0.20187694.15557013.html.plaintext.txt	285	CrossRefISIMedline Hagan JJ Leslie RA Patel S Evans ML Wattam TA Holmes S Benham CD Taylor SG Routledge C Hemmati P Munton RP Ashmeade TE Shah AS Hatcher JP Hatcher PD Jones DNC Smith MI Piper DC Hunter AJ Porter RA Upton N
0.20187694.15557013.html.plaintext.txt	286	Orexin A activates locus coeruleus cell firing increases arousal rat
0.20187694.15557013.html.plaintext.txt	287	Proc Natl Acad Sci USA 96 10911 10916 1999
0.20187694.15557013.html.plaintext.txt	288	AbstractFree Full Text Hakansson M de Lecea L Sutcliffe JG Yanagisawa M Meister B
0.20187694.15557013.html.plaintext.txt	289	Leptin receptor STAT3 immunoreactivities hypocretinorexin neurones lateral hypothalamus
0.20187694.15557013.html.plaintext.txt	290	J Neuroendocrinol 11 653 663 1999
0.20187694.15557013.html.plaintext.txt	291	CrossRefISIMedline Haxhiu MA Jansen AS Cherniack NS Loewy AD
0.20187694.15557013.html.plaintext.txt	292	CNS innervation airway related parasympathetic preganglionic neurons transneuronal labeling study using pseudorabies virus
0.20187694.15557013.html.plaintext.txt	293	Brain Res 618 115 134 1993
0.20187694.15557013.html.plaintext.txt	294	CrossRefISIMedline Haxhiu MA Mack SO Wilson CG Feng P Strohl KP
0.20187694.15557013.html.plaintext.txt	295	Sleep networks anatomic physiologic connections respiratory control
0.20187694.15557013.html.plaintext.txt	296	Front Biosci 8 946 962 2003
0.20187694.15557013.html.plaintext.txt	297	Haxhiu MA Neziri B Yamamoto BK Ferguson DG Massari VJ
0.20187694.15557013.html.plaintext.txt	298	Catecholaminergic microcircuitry controlling output airway related vagal preganglionic neurons
0.20187694.15557013.html.plaintext.txt	299	J Appl Physiol 94 1999 2009 2003
0.20187694.15557013.html.plaintext.txt	300	AbstractFree Full Text Hervieu GJ Cluderay JE Harrison DC Roberts JC Leslie RA
0.20187694.15557013.html.plaintext.txt	301	Gene expression protein distribution orexin 1 receptor rat brain spinal cord
0.20187694.15557013.html.plaintext.txt	302	Neuroscience 103 777 797 2001
0.20187694.15557013.html.plaintext.txt	303	CrossRefISIMedline Kayaba Y Nakamura A Kasuya Y Ohuchi T Yanagisawa M Komuro I Fukuda Y Kuwaki T
0.20187694.15557013.html.plaintext.txt	304	Attenuated defense response low basal blood pressure orexin knockout mice
0.20187694.15557013.html.plaintext.txt	305	Am J Physiol Regul Integr Comp Physiol 285 R581 R593 2003
0.20187694.15557013.html.plaintext.txt	306	AbstractFree Full Text Kc P Haxhiu MA Tolentino Silva FP Wu M Trouth CO Mack SO
0.20187694.15557013.html.plaintext.txt	307	Paraventricular vasopressin containing neurons project brain stem spinal cord respiratory related sites
0.20187694.15557013.html.plaintext.txt	308	Respir Physiol Neurobiol 133 75 88 2002
0.20187694.15557013.html.plaintext.txt	309	CrossRefISIMedline Krout KE Mettenleiter TC Loewy AD
0.20187694.15557013.html.plaintext.txt	310	Single CNS neurons link central motor cardiosympathetic systems double virus tracing study
0.20187694.15557013.html.plaintext.txt	311	Neuroscience 118 853 866 2003
0.20187694.15557013.html.plaintext.txt	312	CrossRefISIMedline Kukkonen JP Holmqvist T Ammoun S Akerman KE
0.20187694.15557013.html.plaintext.txt	313	Functions orexinergichypocretinergic system
0.20187694.15557013.html.plaintext.txt	314	Am J Physiol Cell Physiol 283 C1567 C1591 2002
0.20187694.15557013.html.plaintext.txt	315	AbstractFree Full Text Mack SO Kc P Wu M Coleman BR Tolentino Silva FP Haxhiu MA
0.20187694.15557013.html.plaintext.txt	316	Paraventricular oxytocin neurons involved neural modulation breathing
0.20187694.15557013.html.plaintext.txt	317	J Appl Physiol 92 826 834 2002
0.20187694.15557013.html.plaintext.txt	318	AbstractFree Full Text Manzella D Parillo M Razzino T Gnasso P Buonanno S Gargiulo A Caputi M Paolisso G
0.20187694.15557013.html.plaintext.txt	319	Soluble leptin receptor insulin resistance determinant sleep apnea
0.20187694.15557013.html.plaintext.txt	320	Int J Obes Relat Metab Disord 26 370 375 2002
0.20187694.15557013.html.plaintext.txt	321	CrossRefMedline Matsumura K Tsuchihashi T Abe I
0.20187694.15557013.html.plaintext.txt	322	Central orexin A augments sympathoadrenal outflow conscious rabbits
0.20187694.15557013.html.plaintext.txt	323	Hypertension 37 1382 1387 2001
0.20187694.15557013.html.plaintext.txt	324	AbstractFree Full Text Molander C Grant G
0.20187694.15557013.html.plaintext.txt	325	In The Rat Nervous System edited Paxinos G
0.20187694.15557013.html.plaintext.txt	326	San Diego CA Academic 1995 Fig
0.20187694.15557013.html.plaintext.txt	327	Nambu T Sakurai T Mizukami K Hosoya Y Yanagisawa M Goto K
0.20187694.15557013.html.plaintext.txt	328	Distribution orexin neurons adult rat brain
0.20187694.15557013.html.plaintext.txt	329	Brain Res 827 243 260 1999
0.20187694.15557013.html.plaintext.txt	330	CrossRefISIMedline Nishijima T Sakurai S Arihara A Takahashi K
0.20187694.15557013.html.plaintext.txt	331	Plasma orexin like immunoreactivity patients sleep apnea hypopnea syndrome
0.20187694.15557013.html.plaintext.txt	332	CrossRefISIMedline ODonnell CP Tankersley CG Polotsky VP Schwartz AR Smith PL
0.20187694.15557013.html.plaintext.txt	333	Leptin obesity respiratory function
0.20187694.15557013.html.plaintext.txt	334	Respir Physiol 119 163 170 2000
0.20187694.15557013.html.plaintext.txt	335	CrossRefISIMedline Ouedraogo R Naslund E Kirchgessner AL
0.20187694.15557013.html.plaintext.txt	336	Glucose regulates release orexin A endocrine pancreas
0.20187694.15557013.html.plaintext.txt	337	AbstractFree Full Text Paxinos G Watson C
0.20187694.15557013.html.plaintext.txt	338	The Rat Brain Stereotaxic Coordinates
0.20187694.15557013.html.plaintext.txt	339	San Diego CA Academic 1998 Fig
0.20187694.15557013.html.plaintext.txt	340	Peyron C Tighe DK van den Pol AN de Lecea L Heller HC Sutcliffe JG Kilduff TS
0.20187694.15557013.html.plaintext.txt	341	Neurons containing hypocretin orexin project multiple neuronal systems
0.20187694.15557013.html.plaintext.txt	342	J Neurosci 18 9996 10015 1998
0.20187694.15557013.html.plaintext.txt	343	AbstractFree Full Text Powis JE Bains JS Ferguson AV
0.20187694.15557013.html.plaintext.txt	344	Leptin depolarizes rat hypothalamic paraventricular nucleus neurons
0.20187694.15557013.html.plaintext.txt	345	Am J Physiol Regul Integr Comp Physiol 274 R1468 R1472 1998
0.20187694.15557013.html.plaintext.txt	346	AbstractFree Full Text Sakurai T Amemiya A Ishii M Matsuzaki I Chemelli RM Tanaka H Williams SC Richardson JA Kozlowski GP Wilson S Arch JR Buckingham RE Haynes AC Carr SA Annan RS McNulty DE Liu WS Terrett JA Elshourbagy NA Bergsma DJ Yanagisawa M
0.20187694.15557013.html.plaintext.txt	347	Orexins orexin receptors family hypothalamic neuropeptides G protein coupled receptors regulate feeding behavior
0.20187694.15557013.html.plaintext.txt	348	CrossRefISIMedline Samson WK Taylor MM Follwell M Ferguson AV
0.20187694.15557013.html.plaintext.txt	349	Orexin actions hypothalamic paraventricular nucleus physiological consequences cellular correlates
0.20187694.15557013.html.plaintext.txt	350	Regul Pept 104 97 103 2002
0.20187694.15557013.html.plaintext.txt	351	CrossRefISIMedline Smith JC Ellenberger HH Ballanyi K Richter DW Feldman JL
0.20187694.15557013.html.plaintext.txt	352	Pre Botzinger complex brainstem region may generate respiratory rhythm mammals
0.20187694.15557013.html.plaintext.txt	353	ISIMedline Sunter D Morgan I Edwards CMB Dakin CL Murphy KG Gardiner J Taheri S Rayes E Bloom SR
0.20187694.15557013.html.plaintext.txt	354	Orexins effects behavior localisation orexin receptor 2 messenger ribonucleic acid rat brainstem
0.20187694.15557013.html.plaintext.txt	355	CrossRefISIMedline Sutcliffe JG de Lecea L
0.20187694.15557013.html.plaintext.txt	356	CrossRefISIMedline Takahashi N Okumura T Hiroto Y Kohgo Y
0.20187694.15557013.html.plaintext.txt	357	Stimulation gastric acid secretion centrally administered orexin A conscious rats
0.20187694.15557013.html.plaintext.txt	358	Biochem Biophys Res Commun 254 623 627 1999
0.20187694.15557013.html.plaintext.txt	359	CrossRefISIMedline Van den Pol AN Ghosh PK Liu RJ Li Y Aghajanian GK Gao XB
0.20187694.15557013.html.plaintext.txt	360	Hypocretin orexin enhances neuron activity cell synchrony developing mouse GFP expressing locus coeruleus
0.20187694.15557013.html.plaintext.txt	361	J Physiol 541 169 185 2002
0.20187694.15557013.html.plaintext.txt	362	AbstractFree Full Text Villa MP Multari G Montesano M Pagani J Cervoni M Midulla F Ceror E Ronchetti R
0.20187694.15557013.html.plaintext.txt	363	Sleep apnoea children diabetes mellitus effect glycaemic control
0.20187694.15557013.html.plaintext.txt	364	Diabetologia 43 696 702 2000
0.20187694.15557013.html.plaintext.txt	365	CrossRefISIMedline Volgin DV Saghir M Kubin L
0.20187694.15557013.html.plaintext.txt	366	Developmental changes orexin 2 receptor mRNA hypoglossal motoneurons
0.20187694.15557013.html.plaintext.txt	367	Neuroreport 13 433 436 2002
0.20187694.15557013.html.plaintext.txt	368	CrossRefISIMedline Xi MC Morales FR Chase MH
0.20187694.15557013.html.plaintext.txt	369	Effects sleep wakefulness injection hypocretin 1 orexin A laterodorsal tegmental nucleus cat
0.20187694.15557013.html.plaintext.txt	370	Brain Res 901 259 264 2001
0.20187694.15557013.html.plaintext.txt	371	CrossRefISIMedline Yeh ER Erokwu B LaManna JC Haxhiu MA
0.20187694.15557013.html.plaintext.txt	372	The paraventricular nucleus hypothalamus influences respiratory timing activity rat
0.20187694.15557013.html.plaintext.txt	373	Neurosci Lett 232 63 66 1997
0.20187694.15557013.html.plaintext.txt	374	CrossRefISIMedline Young JK
0.20187694.15557013.html.plaintext.txt	375	Anatomical relationship specialized astrocytes leptin sensitive neurons
0.20187694.15557013.html.plaintext.txt	376	CrossRefISIMedline Young JK Grizard J
0.20187694.15557013.html.plaintext.txt	377	Sensitivity satiating taste qualities glucose obese Zucker rats
0.20187694.15557013.html.plaintext.txt	378	Physiol Behav 34 415 421 1985
0.20187694.15557013.html.plaintext.txt	379	CrossRefISIMedline Young JK Haxhiu MA Allard J Zaidi SIA Manaye KF
0.20187694.15557013.html.plaintext.txt	380	Projections orexin ir neurons respiratory control regions
0.20187694.15557013.html.plaintext.txt	381	GLUT2 immunoreactivity Gomori positive astrocytes hypothalamus
0.20187694.15557013.html.plaintext.txt	382	J Histochem Cytochem 52 1519 1524 2004
0.20187694.15557013.html.plaintext.txt	383	AbstractFree Full Text Young JK Nance DM Gorski RA
0.20187694.15557013.html.plaintext.txt	384	Effects diet upon hypothalamic vulnerability goldthioglucose male mice
0.20187694.15557013.html.plaintext.txt	385	Brain Res Bull 4 69 74 1978
0.20187694.15557013.html.plaintext.txt	386	CrossRefISI Young T Peppard PE Gottlieb DJ
0.20187694.15557013.html.plaintext.txt	387	Epidemiology obstructive sleep apnea population health perspective
0.20187694.15557013.html.plaintext.txt	388	Am J Respir Crit Care Med 165 1217 1239 2002
0.39352274.11796702.html.plaintext.txt	0	HIGHLIGHTED TOPICS Functional Genomics Sleep Circadian Rhythm Invited Review Molecular genetic studies sleep wake regulation special emphasis prostaglandin D2 system Osamu Hayaishi
0.39352274.11796702.html.plaintext.txt	1	Osaka Bioscience Institute Suita Osaka 565 0874 Japan
0.39352274.11796702.html.plaintext.txt	2	ABSTRACT TOP ABSTRACT INTRODUCTION HOMEOSTATIC REGULATION OF NREM
0.39352274.11796702.html.plaintext.txt	3	FOS EXPERIMENTS AND PGD2 H1R GENE AND THE
0.39352274.11796702.html.plaintext.txt	4	SUMMARY AND CONCLUSIONS REFERENCES
0.39352274.11796702.html.plaintext.txt	5	To elucidate exact role PGD2 system sleep wake regulation vivo sleep behavior knockout mice generated authors laboratories examined lipocalin type PGD synthase L PGDS PGD receptor adenosine A2A receptor histamine H1 receptor transgenic mice overexpressing human L PGDS gene generated authors laboratory also examined
0.39352274.11796702.html.plaintext.txt	6	The circadian profiles sleep patterns wild type genetically manipulated mice essentially identical indicating possibility deficiency one system may effectively compensated systems development
0.39352274.11796702.html.plaintext.txt	7	Available evidence indicated PGD2 system involved homeostatic regulation non rapid eye movement sleep arousal effect orexin A mediated histamine H1 receptor system
0.39352274.11796702.html.plaintext.txt	8	knockout mice transgenic mice adenosine histamine
0.39352274.11796702.html.plaintext.txt	9	INTRODUCTION TOP ABSTRACT INTRODUCTION HOMEOSTATIC REGULATION OF NREM
0.39352274.11796702.html.plaintext.txt	10	FOS EXPERIMENTS AND PGD2 H1R GENE AND THE
0.39352274.11796702.html.plaintext.txt	11	SUMMARY AND CONCLUSIONS REFERENCES
0.39352274.11796702.html.plaintext.txt	12	DURING THE LAST SEVERAL DECADES molecular genetic approaches become increasingly popular powerful tool study molecular mechanisms underlying sleep wake regulation
0.39352274.11796702.html.plaintext.txt	13	The fruits investigations subject extensive reviews recent years
0.39352274.11796702.html.plaintext.txt	14	For example special issue Journal Sleep Research entitled Genetic approaches Sleep Sleep Disorders 10 contributors presented state art reviews mid 1999 36
0.39352274.11796702.html.plaintext.txt	15	A symposium entitled Genetics Sleep held Third International Congress World Federation Sleep Research Societies Dresden October 1999 38
0.39352274.11796702.html.plaintext.txt	16	Because orexinhypocretin system suggested role cause narcolepsy subject also reviewed depth 19
0.39352274.11796702.html.plaintext.txt	17	In present article therefore focus placed mainly ongoing recent experimental studies laboratory related molecular genetics sleep wakefulness special emphasis PGD2 related systems
0.39352274.11796702.html.plaintext.txt	18	In addition possible involvement phosphatidylinositol 45 bisphosphate another lipid mediator brain function rapid eye movement REM non rapid eye movement NREM sleep studied phospholipase C PLC 4 knockout KO mice 17
0.39352274.11796702.html.plaintext.txt	19	HOMEOSTATIC REGULATION OF NREM SLEEP BY THE L PGDS GENE TOP ABSTRACT INTRODUCTION HOMEOSTATIC REGULATION OF NREM
0.39352274.11796702.html.plaintext.txt	20	FOS EXPERIMENTS AND PGD2 H1R GENE AND THE
0.39352274.11796702.html.plaintext.txt	21	SUMMARY AND CONCLUSIONS REFERENCES
0.39352274.11796702.html.plaintext.txt	22	PGD2 implicated physiological regulator sleep PGD2 major prostanoid mammalian brain intracerobroventricular infusion femtomolar amounts per minute PGD2 induced NREM REM sleep rats mice monkeys
0.39352274.11796702.html.plaintext.txt	23	Sleep promoted PGD2 indistinguishable natural sleep judged several electrophysiological behavioral criteria whereas sleep induced hypnotic drugs manifested differently natural PGD2 induced sleep
0.39352274.11796702.html.plaintext.txt	24	Lipocalin type PGD synthase L PGDS enzyme produces PGD2 PGH2 brain monomeric glycoprotein molecular weight 26000
0.39352274.11796702.html.plaintext.txt	25	The enzyme purified brains rats frogs humans crystal structure well catalytic properties determined
0.39352274.11796702.html.plaintext.txt	26	When selenium chloride potent specific reversible inhibitor L PGDS infused third ventricle rat daylight hour slow wave sleep REM sleep inhibited time dose dependently
0.39352274.11796702.html.plaintext.txt	27	After 2 h start infusion slow wave sleep REM sleep almost completely reversibly inhibited indicating L PGDS plays crucial role sleep regulation
0.39352274.11796702.html.plaintext.txt	28	These earlier studies 1999 reviewed previously 10 13 37
0.39352274.11796702.html.plaintext.txt	29	Whereas studies mainly carried rats monkeys Roberts co workers 28 reported 1980 endogenous production PGD2 increased 150 fold patients systemic mastocytosis deep sleep episodes
0.39352274.11796702.html.plaintext.txt	30	Subsequently PGD2 concentration shown elevated progressively selectively 1000 fold cerebrospinal fluid CSF patients African sleeping sickness 25
0.39352274.11796702.html.plaintext.txt	31	These clinical observations consistent concept excessive endogenous production PGD2 responsible sleep also humans certain pathological conditions
0.39352274.11796702.html.plaintext.txt	32	However experiments verify assumption yet carried animals
0.39352274.11796702.html.plaintext.txt	33	To examine L PGDS gene endogenously produced PGD2 function vivo generated transgenic TG mice incorporating human L PGDS gene mice 26
0.39352274.11796702.html.plaintext.txt	34	Northern blot analyses clearly revealed human L PGDS mRNA overexpressed almost tissues including brain TG mice
0.39352274.11796702.html.plaintext.txt	35	The TG mice therefore expected sleep time
0.39352274.11796702.html.plaintext.txt	36	However contrary expectations animals appeared quite healthy grow sleep normally
0.39352274.11796702.html.plaintext.txt	37	In fact significant difference overall sleep pattern wild type WT TG mice
0.39352274.11796702.html.plaintext.txt	38	However tails mice clipped DNA sampling 800 PM amount NREM sleep REM sleep TG mice increased sharply significantly
0.39352274.11796702.html.plaintext.txt	39	This effect seemed last several hours amount NREM sleep returned control level 5 6 h
0.39352274.11796702.html.plaintext.txt	40	The maximum increment almost high maximum amount sleep daytime
0.39352274.11796702.html.plaintext.txt	41	However sleep pattern WT mice essentially unaffected tail clipping
0.39352274.11796702.html.plaintext.txt	42	These somewhat unexpected results may explained assuming L PGDS rate limiting enzyme arachidonic cascade system rate limiting enzyme located upstream L PGDS catalyzed step may induced activated noxious stimulus tail clipping
0.39352274.11796702.html.plaintext.txt	43	In fact enzyme cyclooxygenase called COX generally believed rate limiting enzyme rather individual synthases
0.39352274.11796702.html.plaintext.txt	44	If case sleep patterns WT TG mice would essentially identical
0.39352274.11796702.html.plaintext.txt	45	It possible however pain stimulus activated COX produced excessive amount PGH2 substrate L PGDS
0.39352274.11796702.html.plaintext.txt	46	The L PGDS step would become rate limiting step conditions thus leading production quantity PGD2 larger TG mice WT mice ultimately increased amount NREM sleep TG mice
0.39352274.11796702.html.plaintext.txt	47	To test validity interpretation amount PGD2 produced brains WT TG mice measured tail clipping
0.39352274.11796702.html.plaintext.txt	48	As expected amount PGD2 brains WT TG mice tail clipping essentially identical even though amount L PGDS brains TG mice far greater WT mice
0.39352274.11796702.html.plaintext.txt	49	The amount PGD2 brains TG mice increased sharply significantly 3 h tail clipping started decrease thereafter
0.39352274.11796702.html.plaintext.txt	50	These changes almost exactly paralleled time course changes NREM sleep
0.39352274.11796702.html.plaintext.txt	51	In contrast PGD2 content brains WT controls remained essentially
0.39352274.11796702.html.plaintext.txt	52	Thus seems reasonable conclude increase NREM sleep TG mice tail clipping probably due inflicted pain causing induction COX possibly rate limiting enzymes upstream L PGDS step resulting increased level PGH2 brain prostanoid converted large amount PGD2 excessive amount PGDS TG mice
0.39352274.11796702.html.plaintext.txt	53	L PGDS KO mice also generated
0.39352274.11796702.html.plaintext.txt	54	Circadian profiles NREM REM sleep WT L PGDS KO mice almost identical suggesting absence L PGDS affect basal sleep patterns 8
0.39352274.11796702.html.plaintext.txt	55	Sleep regulated function prior wakefulness sleep propensities increase waking sleep deprivation SD
0.39352274.11796702.html.plaintext.txt	56	8 investigated effect 6 h SD amounts NREM REM sleep WT L PGDS KO mice
0.39352274.11796702.html.plaintext.txt	57	In WT mice SD amount NREM sleep increased twofold compared SD indicating strong rebound NREM sleep occurred recovery period
0.39352274.11796702.html.plaintext.txt	58	However KO mice amount NREM sleep SD almost SD indicating NREM rebound occur SD
0.39352274.11796702.html.plaintext.txt	59	In contrast REM sleep rebound SD observed WT mice well KO mice
0.39352274.11796702.html.plaintext.txt	60	8 analyzed electroencephalogram EEG power spectra type sleep
0.39352274.11796702.html.plaintext.txt	61	The spectrum distribution pattern NREM sleep almost WT KO mice SD also SD
0.39352274.11796702.html.plaintext.txt	62	The spectrum distribution pattern REM sleep also identical WT KO mice SD
0.39352274.11796702.html.plaintext.txt	63	These results showed SD affect distribution pattern EEG power spectrum either type sleep KO WT mice
0.39352274.11796702.html.plaintext.txt	64	The PGD2 content brains WT mice SD approximately twofold higher SD whereas amount PGD2 brains KO mice unchanged SD
0.39352274.11796702.html.plaintext.txt	65	These results indicate deficiency L PGDS increase sleep propensity NREM sleep SD endogenous PGD2 probably involved homeostatic regulation NREM sleep 8
0.39352274.11796702.html.plaintext.txt	66	These results taken together indicate 1 PGD2 endogenous sleep promoting substance brain mammals 2 L PGDS plays crucial role sleep regulation 3 PGDS gene first gene shown involved homeostatic control NREM sleep
0.39352274.11796702.html.plaintext.txt	67	INVOLVEMENT OF PGD RECEPTOR GENE AND ADENOSINE A2A RECEPTOR GENE IN NREM SLEEP REGULATION TOP ABSTRACT INTRODUCTION HOMEOSTATIC REGULATION OF NREM
0.39352274.11796702.html.plaintext.txt	68	FOS EXPERIMENTS AND PGD2 H1R GENE AND THE
0.39352274.11796702.html.plaintext.txt	69	SUMMARY AND CONCLUSIONS REFERENCES
0.39352274.11796702.html.plaintext.txt	70	L PGDS mainly located membrane system surrounding brain rather brain parenchyma leptomeninges choroid plexus except oligodendrocytes secreted CSF become trace protein 37
0.39352274.11796702.html.plaintext.txt	71	Trace originally discovered Clausen 1961 second abundant CSF protein next albumin
0.39352274.11796702.html.plaintext.txt	72	PGD2 produced L PGDS also circulates CSF exhibits circadian fluctuation parallel sleep wake cycle
0.39352274.11796702.html.plaintext.txt	73	The infusion PGD2 via microdialysis probe showed PGD2 induce sleep parts brain parenchyma effectively promote sleep infused subarachnoid space underlying rostral basal forebrain rats called PGD2 sensitive zone indicating presence cluster PGD receptors DPR area 23
0.39352274.11796702.html.plaintext.txt	74	The DPR gene originally cloned characterized Hirata et al
0.39352274.11796702.html.plaintext.txt	75	15 thereafter DPR deficient mice generated 22
0.39352274.11796702.html.plaintext.txt	76	Immunofluorescence staining adult mouse brain revealed DPR immunoreactivity IR mainly localized leptomeninges basal forebrain electron microscopic observation indicated DPR IR particles predominantly located plasma membranes arachnoid trabecular cells leptomeninges 23
0.39352274.11796702.html.plaintext.txt	77	To find DPR mediated signal transmitted brain parenchyma number neurotransmitters peptides hormones applied PGD2 sensitive zone
0.39352274.11796702.html.plaintext.txt	78	Adenosine especially A2A agonists A1 agonists found compound could mimic somnogenic activity PGD2 30
0.39352274.11796702.html.plaintext.txt	79	Administration CGS 21680 specific adenosine A2A agonist agonist A1 subtype subarachnoid space induced sleep suggesting PGD2 induced sleep may mediated adenosine adenosine A2A receptor A2AR system
0.39352274.11796702.html.plaintext.txt	80	Both CGS 21680 PGD2 induced sleep attenuated pretreatment rats KF 17837 A2AR antagonist dose dependent manner
0.39352274.11796702.html.plaintext.txt	81	When PGD2 applied area amount adenosine extracellular space increased time dose dependently
0.39352274.11796702.html.plaintext.txt	82	However DPR deficient mice amount NREM sleep increase PGD2 infusion extracellular adenosine level also unchanged subarachnoid space rostral basal forebrain 27
0.39352274.11796702.html.plaintext.txt	83	Therefore DPR expressing cells considered important production release adenosine subarachnoid space rostral basal forebrain mice results sleep induction
0.39352274.11796702.html.plaintext.txt	84	Because baseline sleep wake patterns WT DPR deficient mice essentially identical results also indicate DPR PGD2 involved homeostatic regulation NREM sleep
0.39352274.11796702.html.plaintext.txt	85	Quite recently another type receptor PGD2 CRTH2 discovered T helper type 2 cells eosinophils basophils humans mice 1 14
0.39352274.11796702.html.plaintext.txt	86	The CRTH2 receptor involved chemotactic activity PGD2 toward cells also expressed mouse brain
0.39352274.11796702.html.plaintext.txt	87	However expression level mRNA CRTH2 brain essentially unchanged WT DPR deficient mice suggesting CRTH2 may unrelated PGD2 induced sleep adenosine release
0.39352274.11796702.html.plaintext.txt	88	My group also employed A2AR KO mice confirm hypothesis PGD2 induced sleep mediated A2AR system
0.39352274.11796702.html.plaintext.txt	89	Preliminary evidence indicated PGD2 exerted somnogenic effects manner least partially dependent A2AR system 27 somewhat analogous interaction A2AR D2 dopamine receptor 7
0.39352274.11796702.html.plaintext.txt	90	FOS EXPERIMENTS AND PGD2 TOP ABSTRACT INTRODUCTION HOMEOSTATIC REGULATION OF NREM
0.39352274.11796702.html.plaintext.txt	91	FOS EXPERIMENTS AND PGD2 H1R GENE AND THE
0.39352274.11796702.html.plaintext.txt	92	SUMMARY AND CONCLUSIONS REFERENCES
0.39352274.11796702.html.plaintext.txt	93	Wakefulness REM sleep NREM sleep driven highly complicated patterns neuronal humoral activities specific wake sleep generating systems target cells usually difficult identify vivo experiments
0.39352274.11796702.html.plaintext.txt	94	The immediate early gene product Fos useful marker neuronal activation facilitated identification wake sleep active neurons
0.39352274.11796702.html.plaintext.txt	95	Using Fos immunohistochemistry Sherin co workers 35 recently identified discrete cluster neurons within ventrolateral preoptic area VLPO may play critical role generation sleep
0.39352274.11796702.html.plaintext.txt	96	The VLPO sends specific GABAergic galaninergic efferents core tuberomammillary nucleus TMN 34 source ascending histaminergic arousal system area considered wake center
0.39352274.11796702.html.plaintext.txt	97	To determine neural regions involved response PGD2 adenosine Fos immunohistochemistry used identify neurons activated infusion PGD2 A2A agonist subarachnoid space collaboration Scammell co workers 31
0.39352274.11796702.html.plaintext.txt	98	PGD2 increased NREM sleep induced striking expressions Fos VLPO basal leptomeninges several brain regions may related sleep 31
0.39352274.11796702.html.plaintext.txt	99	31 found infusion PGD2 subarachnoid space anterior preoptic area induced Fos IR VLPO association increase NREM sleep
0.39352274.11796702.html.plaintext.txt	100	This neuronal activation accompanied decrease Fos level putative wake active neurons TMN
0.39352274.11796702.html.plaintext.txt	101	These observations suggest PGD2 may induce sleep via meningeal DPR probably adenosine A2AR subsequent activation VLPO
0.39352274.11796702.html.plaintext.txt	102	PGD2 promote sleep infused posterior hypothalamus thus unlikely wake promoting neurons TMN directly inhibited PGD2
0.39352274.11796702.html.plaintext.txt	103	PGD2 induces sleep effectively infused subarachnoid space anterior preoptic area PGD2 increase firing rates sleep active preoptic neurons
0.39352274.11796702.html.plaintext.txt	104	Within preoptic area sleep active neurons abundant VLPO region
0.39352274.11796702.html.plaintext.txt	105	showed PGD2 induces Fos IR VLPO proportion production sleep
0.39352274.11796702.html.plaintext.txt	106	Considered together observations indicate PGD2 may stimulate sleep active VLPO neurons
0.39352274.11796702.html.plaintext.txt	107	The VLPO may induce sleep inhibition wake promoting TMN neurons 34
0.39352274.11796702.html.plaintext.txt	108	The VLPO projects heavily proximal dendrites soma TMN neurons axons contain GABA galanin
0.39352274.11796702.html.plaintext.txt	109	Neurons TMN tonically active waking state less active NREM sleep cease firing REM sleep
0.39352274.11796702.html.plaintext.txt	110	GABA levels elevated posterior hypothalamus sleep electrical stimulation lateral preoptic area elicit GABAA mediated inhibitory postsynaptic potentials TMN neurons
0.39352274.11796702.html.plaintext.txt	111	Galanin also hyperpolarizes decreases firing rate TMN neurons
0.39352274.11796702.html.plaintext.txt	112	Furthermore insomnia caused preoptic neuron lesions reversed muscimol injection posterior hypothalamus cat 29
0.39352274.11796702.html.plaintext.txt	113	The highly sensitive Fos antiserum used Scammell et al
0.39352274.11796702.html.plaintext.txt	114	study 31 permitted anatomic identification wake active TMN neurons demonstration inverse relationship Fos IR VLPO TMN
0.39352274.11796702.html.plaintext.txt	115	These findings indicate VLPO neuronal activity increased TMN neurons decreased supporting hypothesis GABAergic galaninergic projections VLPO contribute inhibition TMN thus generating NREM sleep flip flop mechanism
0.39352274.11796702.html.plaintext.txt	116	Although experiments needed work detailed mechanisms laboratorys current tentative conclusion summarized scheme given Fig
0.39352274.11796702.html.plaintext.txt	117	PGD2 produced trabecular cells arachnoid membrane choroid plexus circulates CSF promotes sleep inducing meningeal cells release paracrine signaling molecules adenosine subsequently excite nearby sleep active neurons via A2AR expressing neurons projected VLPO
0.39352274.11796702.html.plaintext.txt	118	These cells send inhibitory signals downregulate neuronal activity involved maintenance wakefulness TMN contributes arousal histamine H1 receptor H1R
0.39352274.11796702.html.plaintext.txt	119	View larger version 19K Fig
0.39352274.11796702.html.plaintext.txt	120	Schematic representation molecular mechanisms sleep wake regulation PGD2
0.39352274.11796702.html.plaintext.txt	121	Solid horizontal arrow represents excitatory open horizontal arrow represents inhibitory
0.39352274.11796702.html.plaintext.txt	122	H1R GENE AND THE OREXIN SYSTEM TOP ABSTRACT INTRODUCTION HOMEOSTATIC REGULATION OF NREM
0.39352274.11796702.html.plaintext.txt	123	FOS EXPERIMENTS AND PGD2 H1R GENE AND THE
0.39352274.11796702.html.plaintext.txt	124	SUMMARY AND CONCLUSIONS REFERENCES
0.39352274.11796702.html.plaintext.txt	125	Narcolepsy unique neurological disorder characterized persistent daytime sleepiness abnormal REM sleep
0.39352274.11796702.html.plaintext.txt	126	Dysfunction orexinhypocretin system narcoleptic dogs mice humans suggests system plays important role aetiology narcolepsy 19
0.39352274.11796702.html.plaintext.txt	127	For example mice lacking orexin peptide display increased propensity REM also NREM sleep decrease awake time active period normal rodents 5
0.39352274.11796702.html.plaintext.txt	128	Canine narcolepsy caused mutation orexin 2 receptor OX2R gene 21
0.39352274.11796702.html.plaintext.txt	129	Furthermore human narcolepsy associated deficiency orexin system
0.39352274.11796702.html.plaintext.txt	130	These findings indicate orexin OX2R interaction involved pathological sleep regulation humans animals
0.39352274.11796702.html.plaintext.txt	131	However role orexin physiological sleep mechanisms involved vigilance control still unknown
0.39352274.11796702.html.plaintext.txt	132	The orexin neurons exclusively localized lateral hypothalamus project fibers aminergic nuclei including histaminergic TMN OX2R abundant
0.39352274.11796702.html.plaintext.txt	133	It well known activation histaminergic system promotes wakefulness activation H1R 4 20 24
0.39352274.11796702.html.plaintext.txt	134	Furthermore administration modafinil increasingly popular wake promoting drug used treatment narcolepsy produces wakefulness rats association activation TMN 32
0.39352274.11796702.html.plaintext.txt	135	These findings suggest histaminergic system may play role orexin system narcolepsy
0.39352274.11796702.html.plaintext.txt	136	16 demonstrated infusion orexin A third ventricle WT mice increased arousal second 2 h onward significantly change sleep stage distribution first 2 h infusion
0.39352274.11796702.html.plaintext.txt	137	A similar delay 1 h also observed rats intracerobroventricular administration orexin A
0.39352274.11796702.html.plaintext.txt	138	Because TMN recently shown putative wake center investigators used microdialysis probe directly deliver orexin A TMN rats
0.39352274.11796702.html.plaintext.txt	139	Orexin A 5 25 pmolmin promptly increased wakefulness start perfusion arousal effect prolonged 1 h perfusion ended clearly showing TMN vicinity direct action site arousal effect orexin A 16
0.39352274.11796702.html.plaintext.txt	140	The histaminergic neurons located TMN dense distribution orexin A IR processes OX2R expression observed
0.39352274.11796702.html.plaintext.txt	141	Histamine promotes cortical wakefulness probably either direct cortical projections tonic control sleep generating mechanisms preopticanterior hypothalamus
0.39352274.11796702.html.plaintext.txt	142	To examine whether orexin activates histaminergic system employed vivo microdialysis method found perfusion orexin A TMN rats increased histamine release medial preoptic area frontal cortex implicated arousal effect histamine suggesting application orexin A TMN activated histaminergic system brain
0.39352274.11796702.html.plaintext.txt	143	The duration increase histamine release medial preoptic area frontal cortex almost paralleled arousal effect
0.39352274.11796702.html.plaintext.txt	144	These results supported observation orexin A markedly increased basal firing rate histaminergic neurons vitro suggest activation histaminergic system involved orexin A induced wakefulness
0.39352274.11796702.html.plaintext.txt	145	Histamine reported promote wakefulness activation H1R
0.39352274.11796702.html.plaintext.txt	146	H1R KO mice provided valuable tool study role histaminergic system orexin A induced arousal
0.39352274.11796702.html.plaintext.txt	147	H1R KO mice initially generated Inoue et al
0.39352274.11796702.html.plaintext.txt	148	1996 18 behavior neuropharmacological characteristics investigated detail
0.39352274.11796702.html.plaintext.txt	149	Although authors reported mice lacking H1R showed significant decrease ambulation open field activity wheel electrophysiological studies carried far
0.39352274.11796702.html.plaintext.txt	150	Results laboratory 16 showed mice genotype displayed essentially amounts sleep wakefulness basal conditions yet orexin A infusion TMN significantly increased wakefulness WT mice H1R KO mice clearly indicating H1R plays crucial role mediating orexin A induced arousal
0.39352274.11796702.html.plaintext.txt	151	Nevertheless contrary narcoleptic symptoms manifested orexin KO mice symptoms detected H1R KO mice examined judged either electrophysiological criteria results infrared video recordings
0.39352274.11796702.html.plaintext.txt	152	The detailed mechanisms underlying interaction orexinergic histaminergic systems currently investigation
0.39352274.11796702.html.plaintext.txt	153	POSSIBLE INVOLVEMENT OF PLC 4 GENE IN REM SLEEP TOP ABSTRACT INTRODUCTION HOMEOSTATIC REGULATION OF NREM
0.39352274.11796702.html.plaintext.txt	154	FOS EXPERIMENTS AND PGD2 H1R GENE AND THE
0.39352274.11796702.html.plaintext.txt	155	SUMMARY AND CONCLUSIONS REFERENCES
0.39352274.11796702.html.plaintext.txt	156	PLC catalyzes formation two second messengers inositol trisphosphate diacylglycerol phosphatidylinositol 45 bisphosphate
0.39352274.11796702.html.plaintext.txt	157	Inositol trisphosphate mobilizes intracellular Ca2 diacylglycerol activates protein kinase C
0.39352274.11796702.html.plaintext.txt	158	Because phosphatidylinositol 45 bisphosphate another lipid mediator involved signal transduction brain Ca2 recently implicated sleep regulation 2 group decided study sleep behavior mutant mice lacking PLC 4
0.39352274.11796702.html.plaintext.txt	159	PLC 4 KO mice generated found show arrhythmic REM sleep unusual REMwake repeats faster thetalike EEG wave REM sleep
0.39352274.11796702.html.plaintext.txt	160	These changes appear rather specific REM sleep NREM sleep KO mice essentially identical WT mice 17
0.39352274.11796702.html.plaintext.txt	161	To date gene KO mice used demonstrate involvement orexin 5 serotonin 1 receptor 3 albumin D binding protein 9 REM sleep
0.39352274.11796702.html.plaintext.txt	162	Respective roles compounds REM sleep regulation possible interaction need investigation
0.39352274.11796702.html.plaintext.txt	163	SUMMARY AND CONCLUSIONS TOP ABSTRACT INTRODUCTION HOMEOSTATIC REGULATION OF NREM
0.39352274.11796702.html.plaintext.txt	164	FOS EXPERIMENTS AND PGD2 H1R GENE AND THE
0.39352274.11796702.html.plaintext.txt	165	SUMMARY AND CONCLUSIONS REFERENCES
0.39352274.11796702.html.plaintext.txt	166	Although molecular genetic approach sleep research become increasingly powerful tool yielded numerous interesting sometimes unexpected experimental results molecular mechanisms underlying phenotypes yet clear instances
0.39352274.11796702.html.plaintext.txt	167	It somewhat surprising genetically manipulated mice circadian sleep patterns usually essentially unchanged
0.39352274.11796702.html.plaintext.txt	168	This probably due large part postgenomic events complex diverse nature neuronal humoral regulatory circuits well compensatory changes development
0.39352274.11796702.html.plaintext.txt	169	Many prominent changes phenotypes became visible postgenomic conditioning pain stimulus SD forth exemplified several instances review
0.39352274.11796702.html.plaintext.txt	170	Gene targeting either introduces specific mutations creates null mutations KO excessive expression TG obviously powerful tool biology
0.39352274.11796702.html.plaintext.txt	171	However experiments carried mice possible extrapolate results even speculate human neural systems basis nonhuman usually nonprimate neural systems
0.39352274.11796702.html.plaintext.txt	172	Furthermore data sometimes difficult interpret polymorphism genetic background
0.39352274.11796702.html.plaintext.txt	173	Nevertheless gratifying see increasing numbers genetically manipulated models produced tested numerous laboratories yielding wealth new insights mystery sleep
0.39352274.11796702.html.plaintext.txt	174	The author expresses deep gratitude Y
0.39352274.11796702.html.plaintext.txt	175	Tobler collaboration andor help preparation manuscript
0.39352274.11796702.html.plaintext.txt	176	The work laboratory mainly supported Health Science Research Grant Ministry Health Labor Welfare Japan 100107 O
0.39352274.11796702.html.plaintext.txt	177	Hayaishi grants Special Coordination Funds Promoting Science Technology Ministry Education Culture Sports Science Technology Japan O
0.39352274.11796702.html.plaintext.txt	178	Address reprint requests correspondence O
0.39352274.11796702.html.plaintext.txt	179	Hayaishi Osaka Bioscience Institute 6 2 4 Furuedai Suita Osaka 565 0874 Japan E mail hayaishiatobi
0.39352274.11796702.html.plaintext.txt	180	REFERENCES TOP ABSTRACT INTRODUCTION HOMEOSTATIC REGULATION OF NREM
0.39352274.11796702.html.plaintext.txt	181	FOS EXPERIMENTS AND PGD2 H1R GENE AND THE
0.39352274.11796702.html.plaintext.txt	182	SUMMARY AND CONCLUSIONS REFERENCES
0.39352274.11796702.html.plaintext.txt	183	Abe H Takeshita T Nagata K Arita T Endo Y Fujita T Takayama H Kubo M Sugamura K
0.39352274.11796702.html.plaintext.txt	184	Molecular cloning chromosome mapping characterization mouse CRTH2 gene putative member leukocyte chemoattractant receptor family
0.39352274.11796702.html.plaintext.txt	185	Gene 227 71 77 1999ISIMedline
0.39352274.11796702.html.plaintext.txt	186	Calcium signaling systems neurons synaptic plasticity sleep
0.39352274.11796702.html.plaintext.txt	187	Strasbourg Human Frontier Science Program 2000 p
0.39352274.11796702.html.plaintext.txt	188	Boutrel B Franc B Hen R Hamon M Adrien J
0.39352274.11796702.html.plaintext.txt	189	Key role 5 HT1B receptors regulation paradoxical sleep evidenced 5 HT1B knock mice
0.39352274.11796702.html.plaintext.txt	190	J Neurosci 19 3204 3212 1999AbstractFree Full Text
0.39352274.11796702.html.plaintext.txt	191	Brown RE Stevens DR Haas HL
0.39352274.11796702.html.plaintext.txt	192	The physiology brain histamine
0.39352274.11796702.html.plaintext.txt	193	Prog Neurobiol 63 637 672 2001ISIMedline
0.39352274.11796702.html.plaintext.txt	194	Chemelli RM Willie JT Sinton CM Elmquist JK Scammell T Lee C Richardson JA Williams SC Xiong Y Kizanuki Y Fitch TE Nakazato M Hammer RE Saper CB Yanagisawa M
0.39352274.11796702.html.plaintext.txt	195	Narcolepsy orexin knockout mice molecular genetics sleep regulation
0.39352274.11796702.html.plaintext.txt	196	Cell 98 437 451 1999ISIMedline
0.39352274.11796702.html.plaintext.txt	197	Chen JF Moratalla R Impagnatiello F Grandy DK Cuellar B Rubinstein M Beilstein MA Hackett E Fink JS Low MJ Ongini E Schwarzschild MA
0.39352274.11796702.html.plaintext.txt	198	The role D2 dopamine receptor D2R A2A adenosine receptor A2AR mediated behavioral cellular responses revealed A2A D2 receptor knockout mice
0.39352274.11796702.html.plaintext.txt	199	Proc Natl Acad Sci USA 98 1970 1975 2001AbstractFree Full Text
0.39352274.11796702.html.plaintext.txt	200	Eguchi N Pinzar E Inui T Kuwahata Y Mochizuki T Urade Y Hayaishi O
0.39352274.11796702.html.plaintext.txt	201	Sleep gene knockout transgenic mice lipocalin type prostaglandin D synthase
0.39352274.11796702.html.plaintext.txt	202	In Oxygen LifeOygenases Oxidases Lipid Mediators edited Ishimura Y
0.39352274.11796702.html.plaintext.txt	203	Franken P Lopez Molina L Marcacci L Schibler U Tafti M
0.39352274.11796702.html.plaintext.txt	204	The transcription factor DBP affects circadian sleep consolidation rhythmic EEG activity
0.39352274.11796702.html.plaintext.txt	205	J Neurosci 20 617 625 2000AbstractFree Full Text
0.39352274.11796702.html.plaintext.txt	206	Sleep wake regulation prostaglandin D2 E2
0.39352274.11796702.html.plaintext.txt	207	J Biol Chem 263 14593 14596 1988Free Full Text
0.39352274.11796702.html.plaintext.txt	208	Molecular mechanisms sleep wake regulation roles prostaglandin D2 E2
0.39352274.11796702.html.plaintext.txt	209	FASEB J 5 2575 2581 1991AbstractFree Full Text
0.39352274.11796702.html.plaintext.txt	210	Prostaglandin D2 sleepa molecular genetic approach
0.39352274.11796702.html.plaintext.txt	211	J Sleep Res 8 Suppl 1 60 64 1999ISIMedline
0.39352274.11796702.html.plaintext.txt	212	Molecular mechanisms sleep wake regulation role prostaglandin D2
0.39352274.11796702.html.plaintext.txt	213	Philos Trans R Soc Lond B Biol Sci 355 275 280 2000ISIMedline
0.39352274.11796702.html.plaintext.txt	214	Hirai H Tanaka K Yoshie O Ogawa K Kenmotsu K Takamori Y Ichimasa M Sugamura K Nakamura M Takano S Nagata K
0.39352274.11796702.html.plaintext.txt	215	Prostaglandin D2 selectively induces chemotaxis T helper type 2 cells eosinophils basophils via seven transmembrane receptor CRTH2
0.39352274.11796702.html.plaintext.txt	216	J Exp Med 193 255 261 2001AbstractFree Full Text
0.39352274.11796702.html.plaintext.txt	217	Hirata M Kakizuka A Aizawa M Ushikubi F Narumiya S
0.39352274.11796702.html.plaintext.txt	218	Molecular characterization mouse prostaglandin D receptor functional expression cloned gene
0.39352274.11796702.html.plaintext.txt	219	Proc Natl Acad Sci USA 91 11192 11196 1994AbstractFree Full Text
0.39352274.11796702.html.plaintext.txt	220	Huang ZL Qu WM Li WD Mochizuki T Eguchi N Watanabe T Urade Y Hayaishi O
0.39352274.11796702.html.plaintext.txt	221	Arousal effect orexin A depends activation histaminergic system
0.39352274.11796702.html.plaintext.txt	222	Proc Natl Acad Sci USA 98 9965 9970 2001AbstractFree Full Text
0.39352274.11796702.html.plaintext.txt	223	Ikeda M Sugiyama T Kuwahata Y Hirono M Moriya T Eguchi N Urade Y Yoshioka T Hayaishi O
0.39352274.11796702.html.plaintext.txt	224	Irregular REM sleep structure mice lacking phospholipase C 4
0.39352274.11796702.html.plaintext.txt	225	Soc Neurosci Abstr 26 1516 2000
0.39352274.11796702.html.plaintext.txt	226	Inoue I Yanai K Kitamura D Taniuchi I Kobayashi T Niimura K Watanabe T Watanabe T
0.39352274.11796702.html.plaintext.txt	227	Impaired locomotor activity exploratory behavior mice lacking histamine H1 receptors
0.39352274.11796702.html.plaintext.txt	228	Proc Natl Acad Sci USA 93 13316 13320 1996AbstractFree Full Text
0.39352274.11796702.html.plaintext.txt	229	The hypocretinorexin ligand receptor system implications sleep sleep disorders
0.39352274.11796702.html.plaintext.txt	230	Trends Neurosci 23 359 365 2000ISIMedline
0.39352274.11796702.html.plaintext.txt	231	Brain structure mechanisms involved control cortical activation wakefulness emphasis posterior hypothalamus histaminergic neurons
0.39352274.11796702.html.plaintext.txt	232	Sleep Med Rev 4 471 503 2000ISI
0.39352274.11796702.html.plaintext.txt	233	Lin L Faraco J Li R Kadotani H Rogers W Lin X Qui X de Jong PJ Nishino S Mignot E
0.39352274.11796702.html.plaintext.txt	234	The sleep disorder canine narcolepsy caused mutation hypocretin orexin receptor 2 gene
0.39352274.11796702.html.plaintext.txt	235	Cell 98 365 376 1999ISIMedline
0.39352274.11796702.html.plaintext.txt	236	Matsuoka T Hirata M Tanaka H Takahashi Y Murata T Kabashima K Sugimoto Y Kobayashi T Ushikubi F Aze Y Eguchi N Urade Y Yoshida N Kimura K Mizoguchi A Honda Y Nagai H Narumiya S
0.39352274.11796702.html.plaintext.txt	237	Prostaglandin D2 mediator allergic asthma
0.39352274.11796702.html.plaintext.txt	238	Science 287 2013 2017 2000AbstractFree Full Text
0.39352274.11796702.html.plaintext.txt	239	Mizoguchi A Eguchi N Kimura K Kiyohara Y Qu WM Huang ZL Mochizuki T Lazarus M Kobayashi T Kaneko T Narumiya S Urade Y Hayaishi O
0.39352274.11796702.html.plaintext.txt	240	Exclusive localization prostaglandin D receptors arachnoid trabecular cells mouse basal forebrain involvement regulation non rapid eye movement sleep
0.39352274.11796702.html.plaintext.txt	241	Proc Natl Acad Sci USA 98 11674 11679 2001AbstractFree Full Text
0.39352274.11796702.html.plaintext.txt	242	Monti JM Orellana C Boussard M Jantos H Olivera S
0.39352274.11796702.html.plaintext.txt	243	Sleep variables unaltered zolantidine rats histamine H2 receptors involved sleep regulation Brain Res Bull 25 229 231 1990ISIMedline
0.39352274.11796702.html.plaintext.txt	244	Pentreath VW Rees K Owolabi OA Philip KA Duoa F
0.39352274.11796702.html.plaintext.txt	245	The somnogenic T lymphocyte suppressor prostaglandin D2 selectively elevated cerebrospinal fluid advanced sleeping sickness patients
0.39352274.11796702.html.plaintext.txt	246	Trans R Soc Trop Med Hyg 84 795 799 1990ISIMedline
0.39352274.11796702.html.plaintext.txt	247	Pinzar E Kanaoka Y Inui T Eguchi N Urade Y Hayaishi O
0.39352274.11796702.html.plaintext.txt	248	Prostaglandin D synthase gene involved regulation non rapid eye movement sleep
0.39352274.11796702.html.plaintext.txt	249	Proc Natl Acad Sci USA 97 4903 4907 2000AbstractFree Full Text
0.39352274.11796702.html.plaintext.txt	250	Qu WM Huang ZL Mochizuki T Kuwahata Y Eguchi N Narumiya S Chen JF Urade Y Hayaishi O
0.39352274.11796702.html.plaintext.txt	251	The somnogenic effect PGD2 gene manipulated mice Abstract
0.39352274.11796702.html.plaintext.txt	252	Annu Meeting Jpn Neurosci Soc 24th Kyoto 2001 p
0.39352274.11796702.html.plaintext.txt	253	Roberts JL II Sweetman BJ Lewis RA Austen KF Oates JA
0.39352274.11796702.html.plaintext.txt	254	Increased production prostaglandin D2 patients systemic mastocytosis
0.39352274.11796702.html.plaintext.txt	255	N Engl J Med 303 1400 1404 1980ISIMedline
0.39352274.11796702.html.plaintext.txt	256	Sallanon M Denoyer M Kitahama K Aubert C Gay N Jouvet M
0.39352274.11796702.html.plaintext.txt	257	Long lasting insomnia induced preoptic neuron lesions transient reversal mucimal injection posterior hypothalamus cat
0.39352274.11796702.html.plaintext.txt	258	Neuroscience 32 669 683 1989ISIMedline
0.39352274.11796702.html.plaintext.txt	259	Satoh S Matsumura H Hayaishi O
0.39352274.11796702.html.plaintext.txt	260	Involvement adenosine A2A receptor sleep promotion
0.39352274.11796702.html.plaintext.txt	261	Eur J Pharmacol 351 155 162 1998ISIMedline
0.39352274.11796702.html.plaintext.txt	262	Scammell T Gerashchenko D Urade Y Onoe H Saper C Hayaishi O
0.39352274.11796702.html.plaintext.txt	263	Activation ventrolateral preoptic neurons somnogen prostaglandin D2
0.39352274.11796702.html.plaintext.txt	264	Proc Natl Acad Sci USA 95 7754 7759 1998AbstractFree Full Text
0.39352274.11796702.html.plaintext.txt	265	Scammell TE Estabrook IV McCarthy MT Chemelli RM Yanagisawa M Miller MS Saper CB
0.39352274.11796702.html.plaintext.txt	266	Hypothalamic arousal regions activated modafinil induced wakefulness
0.39352274.11796702.html.plaintext.txt	267	J Neurosci 20 8620 8628 2000AbstractFree Full Text
0.39352274.11796702.html.plaintext.txt	268	Computational neurobiology sleep rhythms
0.39352274.11796702.html.plaintext.txt	269	Strasbourg Human Frontier Science Program 2000 p
0.39352274.11796702.html.plaintext.txt	270	Sherin JE Elmquist JK Torrealba F Saper CB
0.39352274.11796702.html.plaintext.txt	271	Innervation histaminergic tuberomammillary neurons GABAergic galaninergic neurons ventrolateral preoptic nucleus rat
0.39352274.11796702.html.plaintext.txt	272	J Neurosci 18 4705 4721 1998AbstractFree Full Text
0.39352274.11796702.html.plaintext.txt	273	Sherin JE Shiromani PJ McCarley RW Saper CB
0.39352274.11796702.html.plaintext.txt	274	Activation ventrolateral preoptic neurons sleep
0.39352274.11796702.html.plaintext.txt	275	Science 271 216 219 1996Abstract
0.39352274.11796702.html.plaintext.txt	276	Genetic approaches sleep sleep disorders
0.39352274.11796702.html.plaintext.txt	277	J Sleep Res 8 Suppl 1 1 68 1999
0.39352274.11796702.html.plaintext.txt	278	Prostaglandin D2 sleep regulation
0.39352274.11796702.html.plaintext.txt	279	Biochim Biophys Acta 1436 606 615 1999ISIMedline
0.39352274.11796702.html.plaintext.txt	280	World Federation Sleep Research Societies
0.39352274.11796702.html.plaintext.txt	281	Abstracts WFSRS Third International Congress October 5 9
0.39352274.11796702.html.plaintext.txt	282	J APPL PHYSIOL 922863 868 8750 758702 5
0.39352274.11796702.html.plaintext.txt	283	00 Copyright 2002 American Physiological Society
0.42022583.11842076.html.plaintext.txt	0	HIGHLIGHTED TOPICS Functional Genomics Sleep Circadian Rhythm Invited Review Genetic dissection sleep Mehdi Tafti1 Paul Franken2
0.42022583.11842076.html.plaintext.txt	1	1 Biochemistry Clinical Neurophysiology Unit Department Psychiatry University Geneva CH 1225 Geneva Switzerland 2 Department Biological Sciences Stanford University Stanford California 94305
0.42022583.11842076.html.plaintext.txt	2	ABSTRACT TOP ABSTRACT INTRODUCTION CLASSICAL GENETICS AND SLEEP MOLECULAR GENETICS AND SLEEP CANDIDATE GENE APPROACH DISCOVERY OF NEW SLEEP
0.42022583.11842076.html.plaintext.txt	3	Recent advances genomics open new avenues analysis complex behaviors sleep
0.42022583.11842076.html.plaintext.txt	4	In analysis mouse model species choice amenable high throughput phenotype genotype analysis
0.42022583.11842076.html.plaintext.txt	5	With use mouse model unprecedented progress understanding sleep physiology treatment sleep disorders awaited
0.42022583.11842076.html.plaintext.txt	6	This review intended provide overview available methods techniques genetic dissection sleep mice
0.42022583.11842076.html.plaintext.txt	7	Limits advantages different approaches discussed highlight necessity combining methods avoid erroneous interpretations
0.42022583.11842076.html.plaintext.txt	8	The gap understanding mechanisms sleep functions may bridged finding molecular bases
0.42022583.11842076.html.plaintext.txt	9	quantitative trait loci quantitative trait nucleotides mutagenesis transgenic mice gene knockout gene expression profiling gene translation regulation
0.42022583.11842076.html.plaintext.txt	10	INTRODUCTION TOP ABSTRACT INTRODUCTION CLASSICAL GENETICS AND SLEEP MOLECULAR GENETICS AND SLEEP CANDIDATE GENE APPROACH DISCOVERY OF NEW SLEEP
0.42022583.11842076.html.plaintext.txt	11	WHY WE SLEEP IS A LONG STANDING question modern neuroscience still unable answer
0.42022583.11842076.html.plaintext.txt	12	However substantial progress made understanding mechanisms underlying different aspects sleep physiology
0.42022583.11842076.html.plaintext.txt	13	We know neuronal substrates neurochemical messengers regulatory processes involved initiating maintaining sleep
0.42022583.11842076.html.plaintext.txt	14	How understanding sleep toward function Can molecular genetics bring new insights Here first give historical perspective genetics sleep continue review available methods genetic dissection sleep experimental approach used conjunction state art electrophysiological neuroanatomic pharmacological techniques already used great success sleep research
0.42022583.11842076.html.plaintext.txt	15	We also caution making premature interpretations molecular findings complex traits attempted within general physiology intact organism
0.42022583.11842076.html.plaintext.txt	16	CLASSICAL GENETICS AND SLEEP TOP ABSTRACT INTRODUCTION CLASSICAL GENETICS AND SLEEP MOLECULAR GENETICS AND SLEEP CANDIDATE GENE APPROACH DISCOVERY OF NEW SLEEP
0.42022583.11842076.html.plaintext.txt	17	Before introduction molecular biology genetic studies traits phenotypes based either observation resemblance related individuals crossing experiments experimental individuals carrying divergent phenotypes
0.42022583.11842076.html.plaintext.txt	18	Simple laws discovered according simple monogenic autosomal recessive phenotypes segregate inherited basis assumptions molecular substrates
0.42022583.11842076.html.plaintext.txt	19	However types traits far less prevalent cannot attributed influence single genes
0.42022583.11842076.html.plaintext.txt	20	Nevertheless shortly introduction electroencephalography EEG Vogel 82 one first notice even complex phenotype like EEG strong genetic control
0.42022583.11842076.html.plaintext.txt	21	Segregation analysis pedigrees carrying rare EEG variants concordant classical genetic laws suggesting presence single gene effects 83 85
0.42022583.11842076.html.plaintext.txt	22	Results twin studies also indicated EEG patterns monozygotic MZ twins much higher resemblance dizygotic DZ twins unrelated subjects 33 82 92 confirming highly complex functional brain phenotype might tightly controlled genes little affected environment
0.42022583.11842076.html.plaintext.txt	23	The study genetics sleep approximately dated back publication Geyer 1937 26 reported higher concordance sleep habits MZ twins DZ twins
0.42022583.11842076.html.plaintext.txt	24	Gedda 23 reported rare cases concordant long sleepers 15 h MZ twins
0.42022583.11842076.html.plaintext.txt	25	Gedda Brenci 24 first estimated heritability percentage variance explained additive effects genes sleep duration 30
0.42022583.11842076.html.plaintext.txt	26	These authors later confirmed sleep duration highly similar twins living apart 25 discounting influence possible environmental effects
0.42022583.11842076.html.plaintext.txt	27	More recent observations twins indicated even pattern rapid eye movements present higher concordance MZ DZ twins 8 40 50 variance sleep duration presence sleep disorder accounted genetic effects 30 50
0.42022583.11842076.html.plaintext.txt	28	Zung Wilson 94 performed first polygraphic sleep recordings twins 1966 found temporal sequence sleep stages almost completely concordant MZ twins
0.42022583.11842076.html.plaintext.txt	29	Between 1983 1998 detailed polygraphic analyses performed twins studies reported surprising similarities MZ twins 31 39 41 87
0.42022583.11842076.html.plaintext.txt	30	Experimental genetics sleep mice pioneered Valatx early 1970s
0.42022583.11842076.html.plaintext.txt	31	Over time span 15 years Valatxs group 72 77 conducted several crossing experiments recorded sleep hundreds inbred recombinant inbred RI hybrid mice mainly follow segregation paradoxical sleep PS amount
0.42022583.11842076.html.plaintext.txt	32	These studies together diallelique reciprocal crossing several inbred strains sleep experiment mice performed Friedmann 22 clearly indicated although aspects sleep may follow simple segregation classical genetic laws cannot predict others
0.42022583.11842076.html.plaintext.txt	33	MOLECULAR GENETICS AND SLEEP TOP ABSTRACT INTRODUCTION CLASSICAL GENETICS AND SLEEP MOLECULAR GENETICS AND SLEEP CANDIDATE GENE APPROACH DISCOVERY OF NEW SLEEP
0.42022583.11842076.html.plaintext.txt	34	Although classical genetic sleep studies favor strong genetic basis sleep still clue possible molecular mechanisms
0.42022583.11842076.html.plaintext.txt	35	The first attempts identify molecular basis sleep based assumption must genes change expression according behavioral state sleep vs
0.42022583.11842076.html.plaintext.txt	36	wake andor time spent particular state
0.42022583.11842076.html.plaintext.txt	37	Closely related examples come circadian field dramatic changes expression several clock genes occur according strict circadian pattern reviewed Ref
0.42022583.11842076.html.plaintext.txt	38	The two process model sleep regulation 10 remarkable predictions homeostatic aspects sleep motivated first molecular investigation sleep
0.42022583.11842076.html.plaintext.txt	39	Because sleep need intensity homeostatically regulated deprivation sleep lead change expression genes products necessary recovery least involved sleep regulation
0.42022583.11842076.html.plaintext.txt	40	54 performed first substractive hybridization sleep deprived vs
0.42022583.11842076.html.plaintext.txt	41	control rats isolated several clones increased decreased relative expression among neurogranin dendrin later identified 47 48
0.42022583.11842076.html.plaintext.txt	42	The sleep deprivation paradigm since become method choice gene expression experiments aimed uncovering molecular bases sleep regulatory processes reviewed Ref
0.42022583.11842076.html.plaintext.txt	43	Our laboratory 56 already discussed several conceptual problems approach
0.42022583.11842076.html.plaintext.txt	44	In summary two major limitations
0.42022583.11842076.html.plaintext.txt	45	First fact expression many genes varies vigilance state rather actively involved vigilance state regulation
0.42022583.11842076.html.plaintext.txt	46	This weakness correlative gene expression overcome confirming involvement identified genes loss function gain function experiments
0.42022583.11842076.html.plaintext.txt	47	Second high complexity mammalian brain mRNA populations technical limitation however overcome recent developments gene expression profiling see
0.42022583.11842076.html.plaintext.txt	48	Nevertheless identification cortistatin orexin 12 13 specific actions sleep shows gene expression investigation highly successful
0.42022583.11842076.html.plaintext.txt	49	Transgenic methods based random gene integration homologous recombination gave rise strong hope uncover molecular bases many phenotypes including complex ones
0.42022583.11842076.html.plaintext.txt	50	These techniques used address consequences overexpression ectopic expression time tissue specific expression gain loss function candidate gene
0.42022583.11842076.html.plaintext.txt	51	Potential advantages problems addressed several reviews recent review see Ref
0.42022583.11842076.html.plaintext.txt	52	With exception orexinhypocretin system see best knowledge single gene manipulation performed specifically investigate consequences sleep
0.42022583.11842076.html.plaintext.txt	53	However many investigators field benefit availability transgenic models answer sleep related questions
0.42022583.11842076.html.plaintext.txt	54	The accumulated results indicate transgenic mice studies published thus far see Table 1 report sleep related abnormalities strongly suggesting either nonspecific effects gene manipulations andor complex integrative nature sleep makes highly sensitive many physiological changes
0.42022583.11842076.html.plaintext.txt	55	View table Table 1
0.42022583.11842076.html.plaintext.txt	56	Effects gene manipulation sleep
0.42022583.11842076.html.plaintext.txt	57	CANDIDATE GENE APPROACH TOP ABSTRACT INTRODUCTION CLASSICAL GENETICS AND SLEEP MOLECULAR GENETICS AND SLEEP CANDIDATE GENE APPROACH DISCOVERY OF NEW SLEEP
0.42022583.11842076.html.plaintext.txt	58	The straightforward approach consider candidate gene based previous evidence implication sleep
0.42022583.11842076.html.plaintext.txt	59	As indicated sleep physiology pharmacology studies identified essential systems candidate genes chosen
0.42022583.11842076.html.plaintext.txt	60	With use approach studies differential expression tyrosine hydroxylase 53 growth hormone releasing hormone 6 interleukin 1 43 somatostatin 63 brain derived neurotrophic factor 5 shown play potential role sleep
0.42022583.11842076.html.plaintext.txt	61	Sleep studies transgenic mice Table 1 also used approach
0.42022583.11842076.html.plaintext.txt	62	This powerful approach also combined recent techniques gene identification
0.42022583.11842076.html.plaintext.txt	63	The major disadvantage approach obviously nothing new learned terms sleep gene discovery
0.42022583.11842076.html.plaintext.txt	64	A unique coincidental sleep related gene discovery concerns orexin system
0.42022583.11842076.html.plaintext.txt	65	Orexin A B hypothalamic neuropeptides acting orexin 1 2 receptors first thought involved feeding behavior 13 55
0.42022583.11842076.html.plaintext.txt	66	Mignots group 38 identified linkage analysis positional cloning mutations orexin 2 receptor gene cause canine narcolepsy animal model human sleep disorder narcolepsy
0.42022583.11842076.html.plaintext.txt	67	Independently almost simultaneously Yanagisawas group 7 interested role orexins feeding behavior discovered mouse phenotype similar canine human narcolepsy targeted deletion preproorexin gene
0.42022583.11842076.html.plaintext.txt	68	More recently orexin system also implicated etiology human narcolepsy narcoleptic patients undetectable orexin A levels cerebrospinal fluid 49 small number postmortem cases dramatic reduction number orexin containing neurons observed hypothalamus 51 65
0.42022583.11842076.html.plaintext.txt	69	These unexpected observations led Sakurais group 29 generate first transgenic mice specifically investigate role orexin system vigilance states
0.42022583.11842076.html.plaintext.txt	70	These transgenic mice carry promoter human preproorexin gene ligated truncated human ataxin 3 gene induce cell death
0.42022583.11842076.html.plaintext.txt	71	The specific expression transgene construct orexin containing neurons induces apoptosis 4 15 wk age
0.42022583.11842076.html.plaintext.txt	72	Adult orexinataxin 3 mice show narcolepsy hypophagia obesity 29
0.42022583.11842076.html.plaintext.txt	73	However although causal implication orexin system narcolepsy established direct causal involvement normal sleep regulation often claimed 3 14 28 34 64 89 91 remains elucidated
0.42022583.11842076.html.plaintext.txt	74	DISCOVERY OF NEW SLEEP GENES TOP ABSTRACT INTRODUCTION CLASSICAL GENETICS AND SLEEP MOLECULAR GENETICS AND SLEEP CANDIDATE GENE APPROACH DISCOVERY OF NEW SLEEP
0.42022583.11842076.html.plaintext.txt	75	The systematic search genes affecting particular phenotype needs cover whole genome organism
0.42022583.11842076.html.plaintext.txt	76	The genome wide search mapping experiments make priori assumptions gene systems involved although approach may lead already known physiological mechanisms strength unknown andor unexpected systems may discovered
0.42022583.11842076.html.plaintext.txt	77	The orexin success story canine narcolepsy unique best example approach field sleep research
0.42022583.11842076.html.plaintext.txt	78	Therefore genome wide search constitutes method choice discover new sleep genes
0.42022583.11842076.html.plaintext.txt	79	The fundamental basis approach linkage disequilibrium closely localized genes
0.42022583.11842076.html.plaintext.txt	80	If gene affecting trait must addition gene genetic material tightly linked segregating generation generation together trait study
0.42022583.11842076.html.plaintext.txt	81	Therefore instead testing genes organism check cosegregation trait linkage one needs test small panel genes regular intervals throughout genome obtain sufficient information large chromosomal pieces transmitted single unit
0.42022583.11842076.html.plaintext.txt	82	To follow segregation genes must polymorphic nucleotide variation individual individual may case sequence gene may unknown
0.42022583.11842076.html.plaintext.txt	83	A powerful substitute provided highly polymorphic elements restriction fragment length polymorphisms RFLPs simple sequence length polymorphisms SSLPs single nucleotide polymorphisms SNPs forth mostly found noncoding genetic material
0.42022583.11842076.html.plaintext.txt	84	The polymorphic markers tested accurate mapping
0.42022583.11842076.html.plaintext.txt	85	A major question big effect gene detected
0.42022583.11842076.html.plaintext.txt	86	orexin 2 receptor produce remarkable changes trait readily recognized e
0.42022583.11842076.html.plaintext.txt	87	monogenic autosomal recessive canine narcolepsy whereas natural variations genes controlling complex traits may subtle effects
0.42022583.11842076.html.plaintext.txt	88	Therefore genome wide approaches dissect complex traits highly sensitive detect genes variable effects trait
0.42022583.11842076.html.plaintext.txt	89	Basically two major approaches available mutagenesis quantitative trait loci QTL analysis
0.42022583.11842076.html.plaintext.txt	90	The mutagenesis approach straightforward mutagen like N ethyl N nitrosurea used mutate random whole genome followed high throughput screening mutant offspring detect major effect given phenotype
0.42022583.11842076.html.plaintext.txt	91	Both dominant recessive mutations screened way single gene mutation pathological condition
0.42022583.11842076.html.plaintext.txt	92	Once mutated gene localized candidate gene positional cloning approaches used identification ultimately functional analysis performed gain loss function
0.42022583.11842076.html.plaintext.txt	93	The remarkable demonstration technique provided isolation Clock one key mammalian circadian clock genes 1 35 81
0.42022583.11842076.html.plaintext.txt	94	However genetic screens approach fully penetrant dominant recessive mutations therefore cannot identify small effect sequence variations may turn essential aspects phenotype
0.42022583.11842076.html.plaintext.txt	95	In addition currently available technologies recording analyzing sleep thousands mice mutant screen seem feasible least single academic laboratory
0.42022583.11842076.html.plaintext.txt	96	QTL analysis proposed powerful approach genetic dissection complex traits 11 17 36
0.42022583.11842076.html.plaintext.txt	97	Although natural allelic variation genes small effect mapped QTL analysis final identification sequence variants quantitative trait nucleotides QTNs Ref
0.42022583.11842076.html.plaintext.txt	98	42 QTL region biologically significant effects phenotype may represent prohibitive efforts terms phenotyping genotyping
0.42022583.11842076.html.plaintext.txt	99	An excellent example QTL analysis understanding complex traits recently provided Takahashis group 57 circadian behavior mice
0.42022583.11842076.html.plaintext.txt	100	Although molecular machinery circadian timekeeping system discovered mainly direct molecular techniques mutagenesis identified genes explain complexity observed circadian behavior
0.42022583.11842076.html.plaintext.txt	101	For instance none clock genes found involved approximately 1 h difference free running period BALBc C57BL6 inbred mouse strains
0.42022583.11842076.html.plaintext.txt	102	Takahashis group 57 used QTL analysis BALBc x C57BL6 CXB intercross discovered several new loci epistatic interaction
0.42022583.11842076.html.plaintext.txt	103	QTL ANALYSIS OF SLEEP AMOUNT AND DISTRIBUTION TOP ABSTRACT INTRODUCTION CLASSICAL GENETICS AND SLEEP MOLECULAR GENETICS AND SLEEP CANDIDATE GENE APPROACH DISCOVERY OF NEW SLEEP
0.42022583.11842076.html.plaintext.txt	104	The complex nature sleep reflected high intra interspecies phenotypic variability
0.42022583.11842076.html.plaintext.txt	105	For instance 24 h amount sleep shows highly significant differences inbred mouse strains 21 22 74
0.42022583.11842076.html.plaintext.txt	106	We shown AKR mice sleep 3 h DBA mice 24 h period 21
0.42022583.11842076.html.plaintext.txt	107	As differences period circadian rhythms single gene many genes complex interactions may found account difference
0.42022583.11842076.html.plaintext.txt	108	We therefore initiated series experiments dissect different phenotypic aspects sleep mice QTL analysis
0.42022583.11842076.html.plaintext.txt	109	Table 2 summarizes main quantitative aspects sleep inbred strains mice differed
0.42022583.11842076.html.plaintext.txt	110	Note differences high low strains consistent two studies performed 25 years apart usually differences two extreme strains expressed standard deviations twice large Ref
0.42022583.11842076.html.plaintext.txt	111	74 due smaller within strain standard deviations based repeated measures data Ref
0.42022583.11842076.html.plaintext.txt	112	74 based 5 day continuous recordings instead single 24 h recordings Ref
0.42022583.11842076.html.plaintext.txt	113	View table Table 2
0.42022583.11842076.html.plaintext.txt	114	Difference amount SWS PS extreme inbred mouse strains
0.42022583.11842076.html.plaintext.txt	115	QTL analysis performed several segregating mouse populations including intercross backcross advanced intercross backcross RI heterogeneous stocks 11 63
0.42022583.11842076.html.plaintext.txt	116	Basically two inbred mouse strains differing trait interest crossed F1 offspring either intercrossed generate F2 backcrossed one progenitor strains generate backcross populations
0.42022583.11842076.html.plaintext.txt	117	Further random intercross backcross generations performed generate advanced intercross backcross populations
0.42022583.11842076.html.plaintext.txt	118	To generate RI sets F2 mice brother x sister mated full homozygosity thereby fixing unique sets recombinations several inbred lines
0.42022583.11842076.html.plaintext.txt	119	Heterogeneous stocks generated intercrossing several inbred mouse strains many generations therefore represent higher rates recombination polymorphism useful fine mapping 44 63
0.42022583.11842076.html.plaintext.txt	120	Although RIs usually suitable QTL mapping due limited progenitor strains number QTLs large effects may provide significant mapping accuracy fourfold increase recombination compared F2 population 11
0.42022583.11842076.html.plaintext.txt	121	Also complex phenotypes high variability use RIs advantageous several individuals per strain tested instead example single F2 animal
0.42022583.11842076.html.plaintext.txt	122	Therefore first step performed QTL analysis two RI sets
0.42022583.11842076.html.plaintext.txt	123	In seven CXB RIs QTLs identified amount PS chromosomes 5 7 12 17 61
0.42022583.11842076.html.plaintext.txt	124	Toth Williams 71 conducted similar study 13 CXB RIs reported provisional QTLs chromosomes 4 16 17 amount PS light period
0.42022583.11842076.html.plaintext.txt	125	Because small number CXB RIs n 7 13 none QTLs identified could satisfy standard significance levels 37
0.42022583.11842076.html.plaintext.txt	126	Also discrepancy two referenced works indicates linkage study replication needed especially findings based limited number animals andor strains recent review see also Ref
0.42022583.11842076.html.plaintext.txt	127	QTL analysis 25 C57BL6 x DBA2 BXD RIs identified first significant QTL amount PS 12 h light period chromosome 1 60
0.42022583.11842076.html.plaintext.txt	128	We estimated BXD RIs 40 60 variance sleep amounts accounted additive effects 6 15 genes confirming polygenic basis differences sleep amounts
0.42022583.11842076.html.plaintext.txt	129	QTL ANALYSIS OF THE SLEEP EEG TOP ABSTRACT INTRODUCTION CLASSICAL GENETICS AND SLEEP MOLECULAR GENETICS AND SLEEP CANDIDATE GENE APPROACH DISCOVERY OF NEW SLEEP
0.42022583.11842076.html.plaintext.txt	130	Quantitative EEG analysis means fast Fourier transform analysis robust technique evaluate functional changes central nervous system including changes vigilance states 2
0.42022583.11842076.html.plaintext.txt	131	Slow wave sleep characterized oscillations delta 1 4 Hz spindle 11 15 Hz frequency ranges whereas PS especially rodents characterized theta oscillations 5 9 Hz
0.42022583.11842076.html.plaintext.txt	132	Wakefulness encompasses variety behaviors characteristic EEG pattern
0.42022583.11842076.html.plaintext.txt	133	Waking EEG analysis twins demonstrated spectral profiles among heritable traits humans reviewed Ref
0.42022583.11842076.html.plaintext.txt	134	79 heritability estimates ranging 75 90 80
0.42022583.11842076.html.plaintext.txt	135	We shown several spectral characteristics sleep Fig
0.42022583.11842076.html.plaintext.txt	136	1 differ significantly inbred mouse strains 20
0.42022583.11842076.html.plaintext.txt	137	Among theta peak frequency PS showed highest difference inbred strains 80 interstrain variability could attributed genetic effects
0.42022583.11842076.html.plaintext.txt	138	We established intercross backcross CXB mice single gene may explain phenotypic variance major gene 62
0.42022583.11842076.html.plaintext.txt	139	A high resolution QTL mapping needed localize underlying gene
0.42022583.11842076.html.plaintext.txt	140	View larger version 45K Fig
0.42022583.11842076.html.plaintext.txt	141	Bottom 10 electroencephalogram EEG sample paradoxical sleep PS left slow wave sleep SWS right 1 representative mouse inbred strains EEG characteristics differed
0.42022583.11842076.html.plaintext.txt	142	AK AKRJ BR C57BRcdJ C BALBcByJ D2 DBA2J
0.42022583.11842076.html.plaintext.txt	143	During PS EEG dominated theta oscillations 5 9 Hz
0.42022583.11842076.html.plaintext.txt	144	During SWS EEG composed delta 1 4 Hz theta sigma 11 15 Hz oscillations
0.42022583.11842076.html.plaintext.txt	145	Top relative contribution frequency EEG components quantified spectral analysis
0.42022583.11842076.html.plaintext.txt	146	Average theta frequency PS 1
0.42022583.11842076.html.plaintext.txt	147	5 Hz faster BR compared AK mice
0.42022583.11842076.html.plaintext.txt	148	The spectral profiles SWS EEG C D2 mice display large differences relative contribution delta sigma frequency components
0.42022583.11842076.html.plaintext.txt	149	Spectral profiles based 4 epochs scored PS SWS baseline 12 h light period n 7strain
0.42022583.11842076.html.plaintext.txt	150	Another aspect sleep EEG considerable importance homeostatic regulation change delta power
0.42022583.11842076.html.plaintext.txt	151	EEG power 1 4 Hz range function prior wakefulness duration
0.42022583.11842076.html.plaintext.txt	152	Relative delta power used index sleep need sleep intensity mammalian species studied far
0.42022583.11842076.html.plaintext.txt	153	Sleep loss induces proportional predictable increase delta power differs significantly inbred mouse strains 18 21
0.42022583.11842076.html.plaintext.txt	154	We used delta power rebound 6 h sleep deprivation map underlying genes BXD RIs 18
0.42022583.11842076.html.plaintext.txt	155	The results confirmed rate sleep need accumulates varies greatly genotype
0.42022583.11842076.html.plaintext.txt	156	One significant QTL identified chromosome 13 accounted 50 genetic variance trait
0.42022583.11842076.html.plaintext.txt	157	These two examples suggest quantitative sleep EEG parameters stronger genetic control sleep amounts therefore suitable quantitative genetic dissection
0.42022583.11842076.html.plaintext.txt	158	Sleep amounts mammals may approximated techniques EEG use piezoelectric films would make high throughput genetic analysis feasible
0.42022583.11842076.html.plaintext.txt	159	However success may limited due highly polygenic nature sleep amounts suggesting presence many genes small effects
0.42022583.11842076.html.plaintext.txt	160	On hand quantitative EEG analysis dramatically limits wide range use involves implantation recovery adaptation cabling time intensive analysis may turn successful due limited number underlying genes presence major genes
0.42022583.11842076.html.plaintext.txt	161	FROM QTL TO MOLECULAR BASIS TOP ABSTRACT INTRODUCTION CLASSICAL GENETICS AND SLEEP MOLECULAR GENETICS AND SLEEP CANDIDATE GENE APPROACH DISCOVERY OF NEW SLEEP
0.42022583.11842076.html.plaintext.txt	162	QTL analysis map gene genetic effect large chromosomal region usually 20 30 cM
0.42022583.11842076.html.plaintext.txt	163	These large regions may contain single major gene several genes small effects
0.42022583.11842076.html.plaintext.txt	164	Also QTLs may interact epistasis effect difficult detect QTL mapping experiments
0.42022583.11842076.html.plaintext.txt	165	The first step make sure region contains QTLs large enough effect
0.42022583.11842076.html.plaintext.txt	166	One possibility transfer QTL region one inbred strain background another inbred background repeated backcrossing selection make congenic strain
0.42022583.11842076.html.plaintext.txt	167	We reviewed sleep amount data available eight congenic strains generated transferring minor histocompatibility genes inbred strain BALBc inbred background C57BL6 60
0.42022583.11842076.html.plaintext.txt	168	In almost cases results indicated even transferred pieces chromosomes contained large effect QTL detected CXB RIs clear effect could observed resulting congenic strain
0.42022583.11842076.html.plaintext.txt	169	This finding strongly suggests 1 many genes involved 2 interaction epistasis 3 even major QTL identified effect may vary genetic background genetic background due action modifier genes 45
0.42022583.11842076.html.plaintext.txt	170	Once QTL region verified next step finely map QTL smallest chromosomal region 11 17 amenable candidate gene analysis
0.42022583.11842076.html.plaintext.txt	171	The final identification functional QTNs sequence variants difficult part since QTNs may found every kilobases
0.42022583.11842076.html.plaintext.txt	172	Therefore combination several approaches necessary mapping candidate gene analysis
0.42022583.11842076.html.plaintext.txt	173	High resolution QTL mapping conjunction future developments high throughput phenotyping genotyping availability whole genome sequences several major mouse strains identify candidate genes investigated
0.42022583.11842076.html.plaintext.txt	174	All candidate genes mutated either classical homologous recombination knockout newly developed serial nested chromosomal deletions 59
0.42022583.11842076.html.plaintext.txt	175	Systematic crosses increasing decreasing QTL allele complete set mutants physically identify functional QTN
0.42022583.11842076.html.plaintext.txt	176	Because QTNs probably involved gene regulation rather mutations affecting protein function gene expression profiling high throughput genotyping technologies e
0.42022583.11842076.html.plaintext.txt	177	microarray TaqMan gene translation posttranslational protein analyses used uncover molecular mechanisms involved
0.42022583.11842076.html.plaintext.txt	178	Note finding molecular basis mutagenesis experiment follows approximately time labor intensive procedure
0.42022583.11842076.html.plaintext.txt	179	CONCLUSIONS TOP ABSTRACT INTRODUCTION CLASSICAL GENETICS AND SLEEP MOLECULAR GENETICS AND SLEEP CANDIDATE GENE APPROACH DISCOVERY OF NEW SLEEP
0.42022583.11842076.html.plaintext.txt	180	The challenge finding molecular bases sleep requires demanding efforts terms genetic genomic resources also terms future developments high throughput phenotyping techniques
0.42022583.11842076.html.plaintext.txt	181	If enough effort financial resources given develop simplified automated sleep recording devices major limitation overcome
0.42022583.11842076.html.plaintext.txt	182	Both high numbers QTL mutant screen experiments thus become feasible
0.42022583.11842076.html.plaintext.txt	183	Once entire mouse genome sequence becomes available genome wide assessment spatial temporal expression genes identification every conceivable sequence variation provide speedy molecular analysis complex traits sleep
0.42022583.11842076.html.plaintext.txt	184	The genetics sleep may also complemented genetic analysis rest activity flies 27
0.42022583.11842076.html.plaintext.txt	185	Considering still know little molecular basis sleep ineffective current treatments common sleep disorders insomnia hypersomnia believe molecular genetic approaches still best hope developing better therapies uncovering sleep functions
0.42022583.11842076.html.plaintext.txt	186	In review tried show many techniques combinations used answer basic questions
0.42022583.11842076.html.plaintext.txt	187	However relying solely large effect genes revealed mutagenesis candidate gene approaches may bring erroneous interpretations complex polygenic nature sleep mechanisms
0.42022583.11842076.html.plaintext.txt	188	Taftis laboratory supported Swiss National Science Foundation Grants 31
0.42022583.11842076.html.plaintext.txt	189	The National Heart Lung Blood Institute Grant HL 64148 supported P
0.42022583.11842076.html.plaintext.txt	190	Address reprint requests correspondence M
0.42022583.11842076.html.plaintext.txt	191	Tafti HUG Belle Idee Biochemistry Clinical Neurophysiology Unit Chemin du Petit Bel Air 2 CH 1225 Chene Bourg Switzerland E mail taftiatcmu
0.42022583.11842076.html.plaintext.txt	192	REFERENCES TOP ABSTRACT INTRODUCTION CLASSICAL GENETICS AND SLEEP MOLECULAR GENETICS AND SLEEP CANDIDATE GENE APPROACH DISCOVERY OF NEW SLEEP
0.42022583.11842076.html.plaintext.txt	193	Antoch MP Song EJ Chang AM Vitaterna MH Zhao Y Wilsbacher LD Sangoram AM King DP Pinto LH Takahashi JS
0.42022583.11842076.html.plaintext.txt	194	Functional identification mouse circadian Clock gene transgenic BAC rescue
0.42022583.11842076.html.plaintext.txt	195	Cell 89 655 667 1997ISIMedline
0.42022583.11842076.html.plaintext.txt	196	Borbely AA Baumann F Brandeis D Strauch I Lehmann D
0.42022583.11842076.html.plaintext.txt	197	Sleep deprivation effect sleep stages EEG power density man
0.42022583.11842076.html.plaintext.txt	198	Electroencephalogr Clin Neurophysiol 51 483 495 1981ISIMedline
0.42022583.11842076.html.plaintext.txt	199	Bourgin P Huitron Resendiz S Spier AD Fabre V Morte B Criado JR Sutcliffe JG Henriksen SJ de Lecea L
0.42022583.11842076.html.plaintext.txt	200	Hypocretin 1 modulates rapid eye movement sleep activation locus coeruleus neurons
0.42022583.11842076.html.plaintext.txt	201	J Neurosci 20 7760 7765 2000AbstractFree Full Text
0.42022583.11842076.html.plaintext.txt	202	Boutrel B Franc B Hen R Hamon M Adrien J
0.42022583.11842076.html.plaintext.txt	203	Key role 5 HT1B receptors regulation paradoxical sleep evidenced 5 HT1B knock mice
0.42022583.11842076.html.plaintext.txt	204	J Neurosci 19 3204 3212 1999AbstractFree Full Text
0.42022583.11842076.html.plaintext.txt	205	Bova R Micheli MR Qualadrucci P Zucconi GG
0.42022583.11842076.html.plaintext.txt	206	BDNF trkB mRNAs oscillate rat brain light dark cycle
0.42022583.11842076.html.plaintext.txt	207	Brain Res Mol Brain Res 57 321 324 1998ISIMedline
0.42022583.11842076.html.plaintext.txt	208	Bredow S Taishi P Obel F Guha Thakurta N Krueger JM
0.42022583.11842076.html.plaintext.txt	209	Hypothalamic growth hormone releasing hormone mRNA varies across day rats
0.42022583.11842076.html.plaintext.txt	210	Neuroreport 7 2501 2505 1996ISIMedline
0.42022583.11842076.html.plaintext.txt	211	Chemelli RM Willie JT Sinton CM Elmquist JK Scammell T Lee C Richardson JA Williams SC Xiong Y Kisanuki Y Fitch TE Nakazato M Hammer RE Saper CB Yanagisawa M
0.42022583.11842076.html.plaintext.txt	212	Narcolepsy orexin knockout mice molecular genetics sleep regulation
0.42022583.11842076.html.plaintext.txt	213	Cell 98 437 451 1999ISIMedline
0.42022583.11842076.html.plaintext.txt	214	Chouvet G Blois R Debilly G Jouvet M
0.42022583.11842076.html.plaintext.txt	215	The structure occurrence rapid eye movements paradoxical sleep similar homozygotic twins
0.42022583.11842076.html.plaintext.txt	216	CR Seances Acad Sci III 296 1063 1068 1983
0.42022583.11842076.html.plaintext.txt	217	Gene expression brain across sleep waking cycle
0.42022583.11842076.html.plaintext.txt	218	Brain Res 885 303 321 2000ISIMedline
0.42022583.11842076.html.plaintext.txt	219	Daan S Beersma DG Borbely AA
0.42022583.11842076.html.plaintext.txt	220	Timing human sleep recovery process gated circadian pacemaker
0.42022583.11842076.html.plaintext.txt	221	Am J Physiol Regulatory Integrative Comp Physiol 246 R161 R183 1984AbstractFree Full Text
0.42022583.11842076.html.plaintext.txt	222	Experimental strategies genetic dissection complex traits animal models
0.42022583.11842076.html.plaintext.txt	223	Nat Genet 18 19 24 1998ISIMedline
0.42022583.11842076.html.plaintext.txt	224	De Lecea L Criado JR Prospero Garcia O Gautvik KM Schweitzer P Danielson PE Dunlop CL Siggins GR Henriksen SJ Sutcliffe JG
0.42022583.11842076.html.plaintext.txt	225	A cortical neuropeptide neuronal depressant sleep modulating properties
0.42022583.11842076.html.plaintext.txt	226	De Lecea L Kilduff TS Peyron C Gao X Foye PE Danielson PE Fukuhara C Battenberg EL Gautvik VT Bartlett FS II Frankel WN van den Pol AN Bloom FE Gautvik KM Sutcliffe JG
0.42022583.11842076.html.plaintext.txt	227	The hypocretins hypothalamus specific peptides neuroexcitatory activity
0.42022583.11842076.html.plaintext.txt	228	Proc Natl Acad Sci USA 95 322 327 1998AbstractFree Full Text
0.42022583.11842076.html.plaintext.txt	229	Estabrooke IV McCarthy MT Ko E Chou TC Chemelli RM Yanagisawa M Saper CB Scammell TE
0.42022583.11842076.html.plaintext.txt	230	Fos expression orexin neurons varies behavioral state
0.42022583.11842076.html.plaintext.txt	231	J Neurosci 21 1656 1662 2001AbstractFree Full Text
0.42022583.11842076.html.plaintext.txt	232	Fang J Wang Y Krueger JM
0.42022583.11842076.html.plaintext.txt	233	Mice lacking TNF 55 kDa receptor fail sleep TNF treatment
0.42022583.11842076.html.plaintext.txt	234	J Neurosci 17 5949 5955 1997AbstractFree Full Text
0.42022583.11842076.html.plaintext.txt	235	Fang J Wang Y Krueger JM
0.42022583.11842076.html.plaintext.txt	236	Effects interleukin 1 sleep mediated type I receptor
0.42022583.11842076.html.plaintext.txt	237	Am J Physiol Regulatory Integrative Comp Physiol 274 R655 R660 1998AbstractFree Full Text
0.42022583.11842076.html.plaintext.txt	238	Finding molecular basis quantitative traits successes pitfalls
0.42022583.11842076.html.plaintext.txt	239	Nat Rev Genet 2 437 445 2001ISIMedline
0.42022583.11842076.html.plaintext.txt	240	Franken P Chollet D Tafti M
0.42022583.11842076.html.plaintext.txt	241	The homeostatic regulation sleep need genetic control
0.42022583.11842076.html.plaintext.txt	242	J Neurosci 21 2610 2621 2001AbstractFree Full Text
0.42022583.11842076.html.plaintext.txt	243	Franken P Lopez Molina L Marcacci L Schibler U Tafti M
0.42022583.11842076.html.plaintext.txt	244	The transcription factor DBP affects circadian sleep consolidation rhythmic EEG activity
0.42022583.11842076.html.plaintext.txt	245	J Neurosci 20 617 625 2000AbstractFree Full Text
0.42022583.11842076.html.plaintext.txt	246	Franken P Malafosse A Tafti M
0.42022583.11842076.html.plaintext.txt	247	Genetic variation EEG activity sleep inbred mice
0.42022583.11842076.html.plaintext.txt	248	Am J Physiol Regulatory Integrative Comp Physiol 275 R1127 R1137 1998AbstractFree Full Text
0.42022583.11842076.html.plaintext.txt	249	Franken P Malafosse A Tafti M
0.42022583.11842076.html.plaintext.txt	250	Genetic determinants sleep regulation inbred mice
0.42022583.11842076.html.plaintext.txt	251	Sleep 22 155 169 1999ISIMedline
0.42022583.11842076.html.plaintext.txt	252	A diallel analysis genetic underpinnings mouse sleep
0.42022583.11842076.html.plaintext.txt	253	Physiol Behav 12 169 175 1974ISIMedline
0.42022583.11842076.html.plaintext.txt	254	Rome Orizzonte Medico 1951 p
0.42022583.11842076.html.plaintext.txt	255	Sleep dream characteristics twins
0.42022583.11842076.html.plaintext.txt	256	Acta Genet Med Gemellol Roma 28 237 239 1979Medline
0.42022583.11842076.html.plaintext.txt	257	Twins living apart test progress report
0.42022583.11842076.html.plaintext.txt	258	Acta Genet Med Gemellol Roma 32 17 22 1983Medline
0.42022583.11842076.html.plaintext.txt	259	Ueber den Schlaf von Zwillingen
0.42022583.11842076.html.plaintext.txt	260	Z Indukt Abstamm Verebungsl 78 524 527 1937
0.42022583.11842076.html.plaintext.txt	261	Greenspan RJ Tononi G Cirelli C Shaw PJ
0.42022583.11842076.html.plaintext.txt	262	Trends Neurosci 24 142 145 2001ISIMedline
0.42022583.11842076.html.plaintext.txt	263	Hagan JJ Leslie RA Patel S Evans ML Wattam TA Holmes S Benham CD Taylor SG Routledge C Hemmati P Munton RP Ashmeade TE Shah AS Hatcher JP Hatcher PD Jones DN Smith MI Piper DC Hunter AJ Porter RA Upton N
0.42022583.11842076.html.plaintext.txt	264	Orexin A activates locus coeruleus cell firing increases arousal rat
0.42022583.11842076.html.plaintext.txt	265	Proc Natl Acad Sci USA 96 10911 10916 1999AbstractFree Full Text
0.42022583.11842076.html.plaintext.txt	266	Hara J Beuckmann CT Nambu T Willie JT Chemelli RM Sinton CM Sugiyama F Yagami K Goto K Yanagisawa M Sakurai T
0.42022583.11842076.html.plaintext.txt	267	Genetic ablation orexin neurons mice results narcolepsy hypophagia obesity
0.42022583.11842076.html.plaintext.txt	268	Neuron 30 345 354 2001ISIMedline
0.42022583.11842076.html.plaintext.txt	269	Heath A Kendler KS Eaves LJ Martin NG
0.42022583.11842076.html.plaintext.txt	270	Evidence genetic influences sleep disturbance sleep patterns twins
0.42022583.11842076.html.plaintext.txt	271	Sleep 13 318 335 1990ISIMedline
0.42022583.11842076.html.plaintext.txt	272	Sleep characteristics twins
0.42022583.11842076.html.plaintext.txt	273	Jpn J Psychiatry Neurol 40 35 46 1986Medline
0.42022583.11842076.html.plaintext.txt	274	Huang ZL Qu WM Li WD Mochizuki T Eguchi N Watanabe T Urade Y Hayaishi O
0.42022583.11842076.html.plaintext.txt	275	Arousal effect orexin A depends activation histaminergic system
0.42022583.11842076.html.plaintext.txt	276	Proc Natl Acad Sci USA 98 9965 9970 2001AbstractFree Full Text
0.42022583.11842076.html.plaintext.txt	277	Juel Nielsen N Harvald B
0.42022583.11842076.html.plaintext.txt	278	The electroencephalogram uniovular twins brought apart
0.42022583.11842076.html.plaintext.txt	279	Acta Genet Basel 8 57 64 1958Medline
0.42022583.11842076.html.plaintext.txt	280	The hypocretinorexin ligand receptor system implications sleep sleep disorders
0.42022583.11842076.html.plaintext.txt	281	Trends Neurosci 23 359 365 2000ISIMedline
0.42022583.11842076.html.plaintext.txt	282	King DP Zhao Y Sangoram AM Wilsbacher LD Tanaka M Antoch MP Steeves TD Vitaterna MH Kornhauser JM Lowrey PL Turek FW Takahashi JS
0.42022583.11842076.html.plaintext.txt	283	Positional cloning mouse circadian clock gene
0.42022583.11842076.html.plaintext.txt	284	Cell 89 641 653 1997ISIMedline
0.42022583.11842076.html.plaintext.txt	285	Mapping mendelian factors underlying quantitative traits using RFLP linkage maps
0.42022583.11842076.html.plaintext.txt	286	Genetics 121 185 199 1989AbstractFree Full Text
0.42022583.11842076.html.plaintext.txt	287	Genetic dissection complex traits
0.42022583.11842076.html.plaintext.txt	288	Science 265 2037 2048 1994ISIMedline
0.42022583.11842076.html.plaintext.txt	289	Lin L Faraco J Li R Kadotani H Rogers W Lin X Qiu X de Jong PJ Nishino S Mignot E
0.42022583.11842076.html.plaintext.txt	290	The sleep disorder canine narcolepsy caused mutation hypocretin orexin receptor 2 gene
0.42022583.11842076.html.plaintext.txt	291	Cell 98 365 376 1999ISIMedline
0.42022583.11842076.html.plaintext.txt	292	J Sleep Res 8 Suppl1 11 13 1999ISIMedline
0.42022583.11842076.html.plaintext.txt	293	Linkowski P Kerkhofs M Hauspie R Mendlewicz J
0.42022583.11842076.html.plaintext.txt	294	Genetic determinants EEG sleep study twins living apart
0.42022583.11842076.html.plaintext.txt	295	Electroencephalogr Clin Neurophysiol 79 114 118 1991ISIMedline
0.42022583.11842076.html.plaintext.txt	296	Linkowski P Kerkhofs M Hauspie R Susanne C Mendlewicz J
0.42022583.11842076.html.plaintext.txt	297	EEG sleep patterns man twin study
0.42022583.11842076.html.plaintext.txt	298	Electroencephalogr Clin Neurophysiol 73 279 284 1989ISIMedline
0.42022583.11842076.html.plaintext.txt	299	Lyman RF Lai C MacKay TF
0.42022583.11842076.html.plaintext.txt	300	Linkage disequilibrium mapping molecular polymorphisms scabrous locus associated naturally occurring variation bristle number Drosophila melanogaster
0.42022583.11842076.html.plaintext.txt	301	Genet Res 74 303 311 1999ISIMedline
0.42022583.11842076.html.plaintext.txt	302	Mackiewicz M Sollars PJ Ogilvie MD Pack AI
0.42022583.11842076.html.plaintext.txt	303	Modulation IL 1 gene expression rat CNS sleep deprivation
0.42022583.11842076.html.plaintext.txt	304	Neuroreport 7 529 533 1996ISIMedline
0.42022583.11842076.html.plaintext.txt	305	Mott R Talbot CJ Turri MG Collins AC Flint J
0.42022583.11842076.html.plaintext.txt	306	A new method fine mapping quantitative trait loci outbred animal stocks
0.42022583.11842076.html.plaintext.txt	307	Proc Natl Acad Sci USA 97 12649 12654 2000AbstractFree Full Text
0.42022583.11842076.html.plaintext.txt	308	Modifier genes mice humans
0.42022583.11842076.html.plaintext.txt	309	Nat Rev Genet 2 165 174 2001ISIMedline
0.42022583.11842076.html.plaintext.txt	310	Naylor E Bergmann BM Krauski K Zee PC Takahashi JS Vitaterna MH Turek FW
0.42022583.11842076.html.plaintext.txt	311	The circadian clock mutation alters sleep homeostasis mouse
0.42022583.11842076.html.plaintext.txt	312	J Neurosci 20 8138 8143 2000AbstractFree Full Text
0.42022583.11842076.html.plaintext.txt	313	Neuner Jehle M Denizot JP Borbely AA Mallet J
0.42022583.11842076.html.plaintext.txt	314	Characterization sleep deprivation induced expression modulation dendrin novel dendritic protein rat brain neurons
0.42022583.11842076.html.plaintext.txt	315	J Neurosci Res 46 138 151 1996ISIMedline
0.42022583.11842076.html.plaintext.txt	316	Neuner Jehle M Rhyner TA Borbely AA
0.42022583.11842076.html.plaintext.txt	317	Sleep deprivation differentially alters mRNA protein levels neurogranin rat brain
0.42022583.11842076.html.plaintext.txt	318	Brain Res 685 143 153 1995ISIMedline
0.42022583.11842076.html.plaintext.txt	319	Nishino S Ripley B Overeem S Lammers GJ Mignot E
0.42022583.11842076.html.plaintext.txt	320	Hypocretin orexin deficiency human narcolepsy
0.42022583.11842076.html.plaintext.txt	321	Lancet 355 39 40 2000ISIMedline
0.42022583.11842076.html.plaintext.txt	322	Partinen M Kaprio J Koskenvuo M Putkonen P Langinvainio H
0.42022583.11842076.html.plaintext.txt	323	Genetic environmental determination human sleep
0.42022583.11842076.html.plaintext.txt	324	Sleep 6 179 185 1983ISIMedline
0.42022583.11842076.html.plaintext.txt	325	Peyron C Faraco J Rogers W Ripley B Overeem S Charnay Y Nevsimalova S Aldrich M Reynolds D Albin R Li R Hungs M Pedrazzoli M Padigaru M Kucherlapati M Fan J Maki R Lammers GJ Bouras C Kucherlapati R Nishino S Mignot E
0.42022583.11842076.html.plaintext.txt	326	A mutation case early onset narcolepsy generalized absence hypocretin peptides human narcoleptic brains
0.42022583.11842076.html.plaintext.txt	327	Nat Med 6 991 997 2000ISIMedline
0.42022583.11842076.html.plaintext.txt	328	Pinzar E Kanaoka Y Inui T Eguchi N Urade Y Hayaishi O
0.42022583.11842076.html.plaintext.txt	329	Prostaglandin D synthase gene involved regulation non rapid eye movement sleep
0.42022583.11842076.html.plaintext.txt	330	Proc Natl Acad Sci USA 97 4903 4907 2000AbstractFree Full Text
0.42022583.11842076.html.plaintext.txt	331	Porkka Heiskanen T Smith SE Taira T Urban JH Levine JE Turek FW Stenberg D
0.42022583.11842076.html.plaintext.txt	332	Noradrenergic activity rat brain rapid eye movement sleep deprivation rebound sleep
0.42022583.11842076.html.plaintext.txt	333	Am J Physiol Regulatory Integrative Comp Physiol 268 R1456 R1463 1995AbstractFree Full Text
0.42022583.11842076.html.plaintext.txt	334	Rhyner TA Biguet NF Berrard S Borbely AA Mallet J
0.42022583.11842076.html.plaintext.txt	335	An efficient approach selective isolation specific transcripts complex brain mRNA populations
0.42022583.11842076.html.plaintext.txt	336	J Neurosci Res 16 167 181 1986ISIMedline
0.42022583.11842076.html.plaintext.txt	337	Sakurai T Amemiya A Ishii M Matsuzaki I Chemelli RM Tanaka H Williams SC Richardson JA Kozlowski GP Wilson S Arch JR Buckingham RE Haynes AC Carr SA Annan RS McNulty DE Liu WS Terrett JA Elshourbagy NA Bergsma DJ Yanagisawa M
0.42022583.11842076.html.plaintext.txt	338	Orexins orexin receptors family hypothalamic neuropeptides G protein coupled receptors regulate feeding behavior
0.42022583.11842076.html.plaintext.txt	339	Cell 92 573 585 1998ISIMedline
0.42022583.11842076.html.plaintext.txt	340	Molecular approaches towards isolation sleep related genes
0.42022583.11842076.html.plaintext.txt	341	J Sleep Res 8 Suppl 1 1 10 1999
0.42022583.11842076.html.plaintext.txt	342	Shimomura K Low Zeddies SS King DP Steeves TD Whiteley A Kushla J Zemenides PD Lin A Vitaterna MH Churchill GA Takahashi JS
0.42022583.11842076.html.plaintext.txt	343	Genome wide epistatic interaction analysis reveals complex genetic determinants circadian behavior mice
0.42022583.11842076.html.plaintext.txt	344	Genome Res 11 959 980 2001AbstractFree Full Text
0.42022583.11842076.html.plaintext.txt	345	Shiromani PJ Basheer R Thakkar J Wagner D Greco MA Charness ME
0.42022583.11842076.html.plaintext.txt	346	Sleep wakefulness c fos fos B gene knockout mice
0.42022583.11842076.html.plaintext.txt	347	Brain Res Mol Brain Res 80 75 87 2000ISIMedline
0.42022583.11842076.html.plaintext.txt	348	Su H Wang X Bradley A
0.42022583.11842076.html.plaintext.txt	349	Nested chromosomal deletions induced retroviral vectors mice
0.42022583.11842076.html.plaintext.txt	350	Nat Genet 24 92 95 2000ISIMedline
0.42022583.11842076.html.plaintext.txt	351	Tafti M Chollet D Valatx JL Franken P
0.42022583.11842076.html.plaintext.txt	352	Quantitative trait loci approach genetics sleep recombinant inbred mice
0.42022583.11842076.html.plaintext.txt	353	J Sleep Res 8 Suppl 1 37 43 1999ISIMedline
0.42022583.11842076.html.plaintext.txt	354	Tafti M Franken P Kitahama K Malafosse A Jouvet M Valatx JL
0.42022583.11842076.html.plaintext.txt	355	Localization candidate genomic regions influencing paradoxical sleep mice
0.42022583.11842076.html.plaintext.txt	356	Neuroreport 8 3755 3758 1997ISIMedline
0.42022583.11842076.html.plaintext.txt	357	Tafti M Malafosse A Franken P
0.42022583.11842076.html.plaintext.txt	358	Genetic determinants theta rhythm mice
0.42022583.11842076.html.plaintext.txt	359	J Sleep Res 7 Suppl2 269 1998
0.42022583.11842076.html.plaintext.txt	360	Talbot CJ Nicod A Cherny SS Fulker DW Collins AC Flint J
0.42022583.11842076.html.plaintext.txt	361	High resolution mapping quantitative trait loci outbred mice
0.42022583.11842076.html.plaintext.txt	362	Nat Genet 21 305 308 1999ISIMedline
0.42022583.11842076.html.plaintext.txt	363	Terao A Peyron C Ding J Wurts SW Edgar DM Heller HC Kilduff TS
0.42022583.11842076.html.plaintext.txt	364	Prepro hypocretin prepro orexin expression unaffected short term sleep deprivation rats mice
0.42022583.11842076.html.plaintext.txt	365	Sleep 23 867 874 2000ISIMedline
0.42022583.11842076.html.plaintext.txt	366	Thannickal TC Moore RY Nienhuis R Ramanathan L Gulyani S Aldrich M Cornford M Siegel JM
0.42022583.11842076.html.plaintext.txt	367	Reduced number hypocretin neurons human narcolepsy
0.42022583.11842076.html.plaintext.txt	368	Neuron 27 469 474 2000ISIMedline
0.42022583.11842076.html.plaintext.txt	369	Tobler I Gaus SE Deboer T Achermann P Fischer M Rulicke T Moser M Oesch B McBride PA Manson JC
0.42022583.11842076.html.plaintext.txt	370	Altered circadian activity rhythms sleep mice devoid prion protein
0.42022583.11842076.html.plaintext.txt	371	Nature 380 639 642 1996ISIMedline
0.42022583.11842076.html.plaintext.txt	372	Tobler I Kopp C Deboer T Rudolph U
0.42022583.11842076.html.plaintext.txt	373	Diazepam induced changes sleep role 1 GABAA receptor subtype
0.42022583.11842076.html.plaintext.txt	374	Proc Natl Acad Sci USA 98 6464 6469 2001AbstractFree Full Text
0.42022583.11842076.html.plaintext.txt	375	Toppila J Alanko L Asikainen M Tobler I Stenberg D Porkka Heiskanen T
0.42022583.11842076.html.plaintext.txt	376	Sleep deprivation increases somatostatin growth hormone releasing hormone messenger RNA rat hypothalamus
0.42022583.11842076.html.plaintext.txt	377	J Sleep Res 6 171 178 1997ISIMedline
0.42022583.11842076.html.plaintext.txt	378	Identifying genetic influences sleep approach discovering mechanisms sleep regulation
0.42022583.11842076.html.plaintext.txt	379	Behav Genet 31 39 46 2001ISIMedline
0.42022583.11842076.html.plaintext.txt	380	Cytokine microbially induced sleep responses interleukin 10 deficient mice
0.42022583.11842076.html.plaintext.txt	381	Am J Physiol Regulatory Integrative Comp Physiol 280 R1806 R1814 2001AbstractFree Full Text
0.42022583.11842076.html.plaintext.txt	382	A quantitative genetic analysis slow wave sleep rapid eye movement sleep CXB recombinant inbred mice
0.42022583.11842076.html.plaintext.txt	383	Behav Genet 29 329 337 1999ISIMedline
0.42022583.11842076.html.plaintext.txt	384	Possible embryonic origin sleep interstrain differences mouse
0.42022583.11842076.html.plaintext.txt	385	Maturation nervous system
0.42022583.11842076.html.plaintext.txt	386	Prog Brain Res 48 385 391 1978Medline
0.42022583.11842076.html.plaintext.txt	387	Genetics model studying sleep waking cycle
0.42022583.11842076.html.plaintext.txt	388	Exp Brain Res Suppl 8 135 145 1984
0.42022583.11842076.html.plaintext.txt	389	Facteurs genetiques dans le determinisme du cycle veille sommeil chez la souris
0.42022583.11842076.html.plaintext.txt	390	Brain Res 69 315 330 1974ISIMedline
0.42022583.11842076.html.plaintext.txt	391	Valatx JL Bugat R Jouvet M
0.42022583.11842076.html.plaintext.txt	392	Genetic studies sleep mice
0.42022583.11842076.html.plaintext.txt	393	Nature 238 226 227 1972ISIMedline
0.42022583.11842076.html.plaintext.txt	394	Valatx JL Cespuglio R Paut L Bailey DW
0.42022583.11842076.html.plaintext.txt	395	Etude genetique du sommeil paradoxal chez la souris
0.42022583.11842076.html.plaintext.txt	396	Liaison possible avec les genes de coloration
0.42022583.11842076.html.plaintext.txt	397	Waking Sleeping 4 175 183 1980Medline
0.42022583.11842076.html.plaintext.txt	398	Valatx JL Chouvet G Kitahama K
0.42022583.11842076.html.plaintext.txt	399	Genetics sleep learning processes possible relationships
0.42022583.11842076.html.plaintext.txt	400	In Genetics Environment Intelligence edited Oliverio A
0.42022583.11842076.html.plaintext.txt	401	Valatx JL Douhet P Bucchini D
0.42022583.11842076.html.plaintext.txt	402	Human insulin gene insertion mice
0.42022583.11842076.html.plaintext.txt	403	Effects sleep wake cycle J Sleep Res 8 Suppl1 65 68 1999ISIMedline
0.42022583.11842076.html.plaintext.txt	404	Van Beijsterveldt CE Boomsma DI
0.42022583.11842076.html.plaintext.txt	405	Genetics human electroencephalogram EEG event related brain potentials ERPs review
0.42022583.11842076.html.plaintext.txt	406	Hum Genet 94 319 330 1994ISIMedline
0.42022583.11842076.html.plaintext.txt	407	Van Beijsterveldt CE Molenaar PC de Geus EJ Boomsma DI
0.42022583.11842076.html.plaintext.txt	408	Heritability human brain functioning assessed electroencephalography
0.42022583.11842076.html.plaintext.txt	409	Am J Hum Genet 58 562 573 1996ISIMedline
0.42022583.11842076.html.plaintext.txt	410	Vitaterna MH King DP Chang AM Kornhauser JM Lowrey PL McDonald JD Dove WF Pinto LH Turek FW Takahashi JS
0.42022583.11842076.html.plaintext.txt	411	Mutagenesis mapping mouse gene Clock essential circadian behavior
0.42022583.11842076.html.plaintext.txt	412	Science 264 719 725 1994ISIMedline
0.42022583.11842076.html.plaintext.txt	413	Uber die Erblichkeit des normalen Electroencephalogramms
0.42022583.11842076.html.plaintext.txt	414	Stuttgart Germany Thieme 1958
0.42022583.11842076.html.plaintext.txt	415	The genetic basis normal human electroencephalogram
0.42022583.11842076.html.plaintext.txt	416	Humangenetik 10 91 114 1970ISIMedline
0.42022583.11842076.html.plaintext.txt	417	Zur genetischen Grundlage fronto prazentraler b Wellen Gruppen im EEG des Menschen
0.42022583.11842076.html.plaintext.txt	418	Humangenetik 2 227 237 1966ISIMedline
0.42022583.11842076.html.plaintext.txt	419	Zur genetischen Grundlage occipitaler langsamer b Wellen Gruppen im EEG des Menschen
0.42022583.11842076.html.plaintext.txt	420	Humangenetik 2 238 245 1966ISIMedline
0.42022583.11842076.html.plaintext.txt	421	Circadian rhythm genetics flies mice humans
0.42022583.11842076.html.plaintext.txt	422	Nat Genet 26 23 27 2000ISIMedline
0.42022583.11842076.html.plaintext.txt	423	Relationships sleep characteristics identical fraternal twins
0.42022583.11842076.html.plaintext.txt	424	Arch Gen Psychiatry 40 1093 1095 1983Abstract
0.42022583.11842076.html.plaintext.txt	425	Transgenic animals integrative biology approaches interpretations outcome
0.42022583.11842076.html.plaintext.txt	426	J Appl Physiol 88 1119 1126 2000AbstractFree Full Text
0.42022583.11842076.html.plaintext.txt	427	Willie JT Chemelli RM Sinton CM Yanagisawa M
0.42022583.11842076.html.plaintext.txt	428	To eat sleep Orexin regulation feeding wakefulness
0.42022583.11842076.html.plaintext.txt	429	Annu Rev Neurosci 24 429 458 2001ISIMedline
0.42022583.11842076.html.plaintext.txt	430	Wisor JP Nishino S Sora I Uhl GH Mignot E Edgar DM
0.42022583.11842076.html.plaintext.txt	431	Dopaminergic role stimulant induced wakefulness
0.42022583.11842076.html.plaintext.txt	432	J Neurosci 21 1787 1794 2001AbstractFree Full Text
0.42022583.11842076.html.plaintext.txt	433	Xi M Morales FR Chase MH
0.42022583.11842076.html.plaintext.txt	434	Effects sleep wakefulness injection hypocretin 1 orexin A laterodorsal tegmental nucleus cat
0.42022583.11842076.html.plaintext.txt	435	Brain Res 901 259 264 2001ISIMedline
0.42022583.11842076.html.plaintext.txt	436	Young JP Lader MH Fenton GW
0.42022583.11842076.html.plaintext.txt	437	A twin study genetic influences electroencephalogram
0.42022583.11842076.html.plaintext.txt	438	J Med Genet 9 13 16 1972ISIMedline
0.42022583.11842076.html.plaintext.txt	439	Zhang J Obal F Jr Fang J Collins BJ Krueger JM
0.42022583.11842076.html.plaintext.txt	440	Non rapid eye movement sleep suppressed transgenic mice deficiency somatotropic system
0.42022583.11842076.html.plaintext.txt	441	Neurosci Lett 220 97 100 1996ISIMedline
0.42022583.11842076.html.plaintext.txt	442	Sleep dream patterns twins
0.42022583.11842076.html.plaintext.txt	443	Markov analysis genetic trait
0.42022583.11842076.html.plaintext.txt	444	Rec Adv Biol Psychiatry 9 119 130 1966
0.42022583.11842076.html.plaintext.txt	445	J APPL PHYSIOL 9231339 1347 8750 758702 5
0.42022583.11842076.html.plaintext.txt	446	00 Copyright 2002 American Physiological Society
0.09784351.9373235.html.plaintext.txt	0	Evolving Views Major Histocompatibility Complex
0.09784351.9373235.html.plaintext.txt	1	From Department Pediatrics Yale Child Health Research Center Yale University School Medicine Department Genetics Boyer Center Molecular Medicine Yale University School Medicine New Haven CT
0.09784351.9373235.html.plaintext.txt	2	INTRODUCTION Introduction References
0.09784351.9373235.html.plaintext.txt	3	THE MAJOR HISTOCOMPATIBILITY complex MHC extended cluster genes remarkable number importance immunological functions encode
0.09784351.9373235.html.plaintext.txt	4	Historically interest MHC emanated tissue transplantation experiments hence reference histocompatibility
0.09784351.9373235.html.plaintext.txt	5	Now know highly conserved region encodes genes many important varied functions immune nonimmune nature
0.09784351.9373235.html.plaintext.txt	6	One family MHC genes human leukocyte antigen HLA genes polymorphic yet discovered hundreds alleles described far
0.09784351.9373235.html.plaintext.txt	7	110 Serotyping polymorphisms permitted genetic mapping loci early disease association studies
0.09784351.9373235.html.plaintext.txt	8	In addition polymorphisms permitted extensive population studies revealing number interesting MHC associations phenomena
0.09784351.9373235.html.plaintext.txt	9	Recent cDNA selections2 genomic sequencing cosmid screenings shown existence large number genes MHC including number expressed selectively cells immune system
0.09784351.9373235.html.plaintext.txt	10	2 8 In review discuss recent data considerably expands number immune related genes encoded MHC review factors may underlie large scale organization
0.09784351.9373235.html.plaintext.txt	11	The MHC includes coding regions well known eponymous polymorphic surface antigens HLA class I class II type respectively present antigen CD8 CD4 T cells
0.09784351.9373235.html.plaintext.txt	12	Intervening class II class I region human MHC class III region includes genes several components complement system
0.09784351.9373235.html.plaintext.txt	13	910 Genes class II region found encode components cytoplasmic proteasome degrades proteins peptides11 well peptide transporters loading peptides onto class I proteins
0.09784351.9373235.html.plaintext.txt	14	12 The class II region also encodes DM gene facilitates loading assembly class II proteins
0.09784351.9373235.html.plaintext.txt	15	1314 Just centromeric class I region cluster genes encoding three inflammation related proteins tumor necrosis factor TNF lymphotoxin LTA lymphotoxin LTB
0.09784351.9373235.html.plaintext.txt	16	15 18 Remarkably list immune system related genes chromosome segments potentially derived duplications parts MHC grown substantially within last year
0.09784351.9373235.html.plaintext.txt	17	The MHC major biomedical interest contribution transplant rejection variation individuals susceptibility variety autoimmune disorders
0.09784351.9373235.html.plaintext.txt	18	19 23 In number cases clear susceptibility determined variation protein sequence class II molecules
0.09784351.9373235.html.plaintext.txt	19	However discussed possibility must still entertained polymorphism immune system related genes MHC also contribute diseases
0.09784351.9373235.html.plaintext.txt	20	In addition role influencing propensity known autoimmune diseases insulin dependent diabetes mellitus multiple sclerosis systemic lupus erythematosus myasthenia gravis rheumatoid arthritis reviewed Thomson 199523 MHC contains genes contributing several hereditary disorders either autoimmune nature role autoimmunity uncertain
0.09784351.9373235.html.plaintext.txt	21	These include ankylosing spondyloarthropathies clear association class I allele HLA B27 narcolepsy equally clearly associated certain class II alleles
0.09784351.9373235.html.plaintext.txt	22	The MHC also includes genes steroid 21 hydroxylase hemochromatosis
0.09784351.9373235.html.plaintext.txt	23	Deficiency 21 hydroxylase causes adrenogenital syndrome hemochromatosis one common simple Mendelian disorders man
0.09784351.9373235.html.plaintext.txt	24	Recently major quantitative trait locus dyslexia mapped distal MHC
0.09784351.9373235.html.plaintext.txt	25	This actively pursued several groups
0.09784351.9373235.html.plaintext.txt	26	The MHC extensively studied large number excellent reviews exist range related topics
0.09784351.9373235.html.plaintext.txt	27	11012192026 50 The present review largely restricted newest developments recognition complexity role human MHC immuno hematologic systems relationship among segments MHC
0.09784351.9373235.html.plaintext.txt	28	A SUBREGION OF THE MHC CONTAINS AN UNUSUAL CONCENTRATION OF GENES RELATED TO INFLAMMATION
0.09784351.9373235.html.plaintext.txt	29	By convention MHC divided three contiguous regions approximate location genes shared characteristics Fig 1
0.09784351.9373235.html.plaintext.txt	30	Most centromeric chromosome 6p class II region contains 17 known HLA class II genes pseudogenes
0.09784351.9373235.html.plaintext.txt	31	5 Contiguous class III region encodes several components complement system
0.09784351.9373235.html.plaintext.txt	32	Telomeric class III region class I region encodes 18 HLA class I related genes pseudogenes
0.09784351.9373235.html.plaintext.txt	33	Recently number genes putatively involved inflammation identified central MHC telomeric end class III region
0.09784351.9373235.html.plaintext.txt	34	As presented group genes may roles various aspects stress inflammation infection
0.09784351.9373235.html.plaintext.txt	35	We suggest concentration genes sufficiently distinct designated class IV region
0.09784351.9373235.html.plaintext.txt	36	View larger version 16K Fig 1
0.09784351.9373235.html.plaintext.txt	37	Map MHC showing proposed class IV region
0.09784351.9373235.html.plaintext.txt	38	Physical map organization human MHC selected genes
0.09784351.9373235.html.plaintext.txt	39	Expressed HLA class I class II genes rectangles positioned horizontal meridian
0.09784351.9373235.html.plaintext.txt	40	Genes putative immune function triangles genes circles elevated horizontal meridian
0.09784351.9373235.html.plaintext.txt	41	A blow view proposed class IV region shown beneath
0.09784351.9373235.html.plaintext.txt	42	Physical distances approximate derived sources referenced text unpublished data
0.09784351.9373235.html.plaintext.txt	43	Symbols known genes conventional abbreviations defined text
0.09784351.9373235.html.plaintext.txt	44	5 ZNF 173 ZNF 178 zinc finger genes map vicinity HLA A
0.09784351.9373235.html.plaintext.txt	45	A cluster genes three related cytokines TNF LTA LTB lies telomeric end class III region42 shortly centromeric class I related genes
0.09784351.9373235.html.plaintext.txt	46	TNF extensively studied47 plays important role inflammation bacterial51 viral infection52 tumor cachexia immune response
0.09784351.9373235.html.plaintext.txt	47	It produced variety cells including prominently monocytes macrophages T cell subsets
0.09784351.9373235.html.plaintext.txt	48	In mice variants TNF gene affect levels TNF production associated variations level susceptibility renal disease lupus like syndrome
0.09784351.9373235.html.plaintext.txt	49	53 Polymorphisms human TNF gene associated increased susceptibility fatal cerebral malaria54 rheumatoid arthritis inflammatory bowel disease55 perhaps autoimmune disorders
0.09784351.9373235.html.plaintext.txt	50	LTA also called TNF actions similar TNF cellular basis pattern expression considerably limited
0.09784351.9373235.html.plaintext.txt	51	Remarkably deletion LTA gene leads specific absence lymph nodes Peyers patches splenic germinal centers mice6061 whereas mice lacking TNF develop lymph nodes Peyers patches lack splenic primary B cell follicles
0.09784351.9373235.html.plaintext.txt	52	62 Deletion p55 TNF receptor results normal lymph node development architecture normal migration lymphocytes lamina propria epithelium small intestine organized Peyers patches absence germinal centers
0.09784351.9373235.html.plaintext.txt	53	63 Based observations speculated effect LTA development lymphoid organs may mediated distinct receptors functioning organ specific context
0.09784351.9373235.html.plaintext.txt	54	LTB also called TNF C membrane bound molecule forms heterotrimer LTA
0.09784351.9373235.html.plaintext.txt	55	18 This LTA LTB complex induce activation NF B certain cell lines binding LTB receptor member TNF receptor family
0.09784351.9373235.html.plaintext.txt	56	6465 NF B pleiotropic transcription factor capable activating expression great variety genes critical immunoinflammatory response
0.09784351.9373235.html.plaintext.txt	57	65 The LTA LTB complex also weakly cytotoxic tumor cells appear induce apoptosis
0.09784351.9373235.html.plaintext.txt	58	Within 15 kb upstream human TNF cluster gene designated B144 LST 1 leukocyte specific transcript66 homologue partial cDNA first identified mouse
0.09784351.9373235.html.plaintext.txt	59	67 The transcript gene expressed exclusively monocytes macrophages T cells
0.09784351.9373235.html.plaintext.txt	60	Expression gene RNA level increased various activating stimuli particular interferon IFN
0.09784351.9373235.html.plaintext.txt	61	The probable gene product encoded open reading frame whose cognate amino acid sequence 50 identical humans mouse
0.09784351.9373235.html.plaintext.txt	62	The amino acid sequence contains long hydrophobic region near N terminus otherwise shows apparent relationship proteins known function
0.09784351.9373235.html.plaintext.txt	63	The interpretation open reading frame regulation gene complicated remarkable degree alternative splicing seen mRNA products
0.09784351.9373235.html.plaintext.txt	64	The B144 RNA actually ensemble related sequences derived four alternative 5 exons 3 internal exons well several forms 3 exon
0.09784351.9373235.html.plaintext.txt	65	Exons 5 6 may associated 5 exons may separately jointly omitted final mRNA product
0.09784351.9373235.html.plaintext.txt	66	The result 24 forms mRNA may seen U937 monocyte cells
0.09784351.9373235.html.plaintext.txt	67	Some forms could encode altered forms putative protein others affect 5 untranslated region
0.09784351.9373235.html.plaintext.txt	68	The gene also peculiar one spliced form apparently GA dinucleotide first bases 5 end intron
0.09784351.9373235.html.plaintext.txt	69	The first two bases introns generally GT occasional GC B144 splice site highly unusual perhaps unique
0.09784351.9373235.html.plaintext.txt	70	The mouse gene also seems multiple alternative splice forms cultured cells
0.09784351.9373235.html.plaintext.txt	71	The amount B144 mRNA cells quite substantial would surprising protein formed significant amounts although presently publications characterizing putative protein
0.09784351.9373235.html.plaintext.txt	72	A second gene 1C7 preferentially expressed monocytes certain hematopoietic cell lines lies immediately adjacent B14468 3 ends two mRNA templates come within bases overlapping
0.09784351.9373235.html.plaintext.txt	73	The gene encodes least three differentially spliced mRNAs
0.09784351.9373235.html.plaintext.txt	74	Each mRNA encodes potential leader sequence internal membrane anchor segment three forms differ length sequence carboxy terminal intracytoplasmic domain
0.09784351.9373235.html.plaintext.txt	75	The encoded product weak similarity surface antigens CTLA4
0.09784351.9373235.html.plaintext.txt	76	Recently another MHC encoded monocyte lymphocyte specific cDNA called AIF 1 identified elevated level expression experimental cardiac transplants
0.09784351.9373235.html.plaintext.txt	77	69 72 Separately gene characterized termed G1
0.09784351.9373235.html.plaintext.txt	78	73 The gene transcript lies shortly centromeric B144
0.09784351.9373235.html.plaintext.txt	79	It highly conserved rodents humans
0.09784351.9373235.html.plaintext.txt	80	The mRNA upregulated interferon expressed subset macrophages infiltrating allografts
0.09784351.9373235.html.plaintext.txt	81	The putative amino acid translation lacks hydrophobic leader sequence
0.09784351.9373235.html.plaintext.txt	82	However strong homology EF hand protein motif found calcium binding proteins involved neutrophil activation74 also myeloid chemoattractant protein
0.09784351.9373235.html.plaintext.txt	83	75 Not cytokine genes encode leader sequences remains possible AIF 1 protein may secreted released injured cells
0.09784351.9373235.html.plaintext.txt	84	The function gene remains unknown
0.09784351.9373235.html.plaintext.txt	85	In region MHC telomeric TNF cluster gene protein contains certain motifs similar seen I B called I B Like IkBL
0.09784351.9373235.html.plaintext.txt	86	76 The role I B negative regulation NF B hence inflammatory response well known paradigm transcriptional control involving regulation phosphorylation ubiquitination protein degradation
0.09784351.9373235.html.plaintext.txt	87	By analogy MHC encoded IkBL molecule candidate regulator inflammatory responses although described widely expressed
0.09784351.9373235.html.plaintext.txt	88	Rather surprisingly functional data available molecule
0.09784351.9373235.html.plaintext.txt	89	Centromeric Hsp70 genes43 lies SKI2W77 79 gene encoding protein substantial similarity yeast Ski2 superkiller 2 protein80 including RNA helicase motifs
0.09784351.9373235.html.plaintext.txt	90	Ski2 makes yeast cells resistant killer toxin RNA viruses virtue ability block translation nonpolyadenylated noncapped viral mRNAs targeted degradation
0.09784351.9373235.html.plaintext.txt	91	8182 This gene plays partially redundant essential role normal yeast growth83 antiviral effect well
0.09784351.9373235.html.plaintext.txt	92	Because homologies yeast gene remains possible one role human gene mediator antiviral effects particularly RNA viruses use nonpolyadenylated RNA life cycle
0.09784351.9373235.html.plaintext.txt	93	The MIC MHC class I related family8485 group homologous genes pseudogenes interspersed distal class III class I region MHC
0.09784351.9373235.html.plaintext.txt	94	The structure genes predicted coding products resemble class I genes clearly divergent family
0.09784351.9373235.html.plaintext.txt	95	They also characterized large first introns
0.09784351.9373235.html.plaintext.txt	96	The members group known expressed mRNA MIC A B whose genes lie telomeric IkBL gene centromeric HLA B
0.09784351.9373235.html.plaintext.txt	97	The MIC A protein expressed properly folded independently 2 microglobulin preferentially expressed intestinal mucosa
0.09784351.9373235.html.plaintext.txt	98	86 Curiously transcription MIC A upregulated heat shock
0.09784351.9373235.html.plaintext.txt	99	Thus gene shares properties class I genes per se least one functional feature would relate heat shock genes located centromerically
0.09784351.9373235.html.plaintext.txt	100	Overall central MHC complement region class III class I region least seven genes implicated degree inflammatory responses
0.09784351.9373235.html.plaintext.txt	101	There also eighth gene 1C7 yet studied functionally whose pattern expression consistent similar role
0.09784351.9373235.html.plaintext.txt	102	In addition IkBL molecule near one end cluster least potential candidate role inflammation
0.09784351.9373235.html.plaintext.txt	103	The BAT1 gene D6S81E also region encodes RNA helicase conceivably could play role complex splicing B144 well genes
0.09784351.9373235.html.plaintext.txt	104	87 At centromeric end region number genes unknown function broad expression also genes three heat shock proteins88 whose expression may elevated inflammation
0.09784351.9373235.html.plaintext.txt	105	Heat shock proteins also implicated mediating antiviral effects prostaglandins
0.09784351.9373235.html.plaintext.txt	106	89 Overall suggest segment MHC given separate designation class IV region recognition multiple potential roles inflammation stress responses
0.09784351.9373235.html.plaintext.txt	107	ADDITIONAL IMMUNE RELATED GENES ARE DISTRIBUTED THROUGH THE ENTIRE MHC
0.09784351.9373235.html.plaintext.txt	108	The genes mentioned paragraphs cited reviews encode substantial number structurally remotely related totally unrelated proteins expressed specifically within function interacting cells immune system
0.09784351.9373235.html.plaintext.txt	109	Gene linkage consequence duplication divergence seem adequate explanation clustering
0.09784351.9373235.html.plaintext.txt	110	Ascertainment bias conceivable explanation intensity immune system gene cluster investigated
0.09784351.9373235.html.plaintext.txt	111	This explanation seems progressively less likely immune system genes divergent structure discovered within cluster
0.09784351.9373235.html.plaintext.txt	112	The recent finding distal MHC additional three four genes different families expressed selectively immunocytes seems make coincidence argument almost untenable
0.09784351.9373235.html.plaintext.txt	113	Further genes unknown function yet unknown degree polymorphism potential contribution association MHC haplotypes propensity autoimmune disorders interest
0.09784351.9373235.html.plaintext.txt	114	The recently detected immune system genes distal MHC include following
0.09784351.9373235.html.plaintext.txt	115	Ubiquitin 76 amino acid peptide whose sequence remarkably conserved among eukaryotes
0.09784351.9373235.html.plaintext.txt	116	It expressed almost cells body generic function become attached proteins target degradation proteasome system
0.09784351.9373235.html.plaintext.txt	117	Ubiquitin plays role diverse variety cellular processes including chromatin structure cell cycle control modification cell receptors DNA repair processes gene silencing activation degradation NF B
0.09784351.9373235.html.plaintext.txt	118	90 However curious ubiquitin initially studied peptide might transcellular effects modulating activity immunocytes
0.09784351.9373235.html.plaintext.txt	119	Several genes encoding ubiquitin homologues discovered including least two non MHC genes implicated function immune system
0.09784351.9373235.html.plaintext.txt	120	One ISG1591 94 encodes protein homologous ubiquitin dimer expressed unstimulated cells induced IFN variety cell types
0.09784351.9373235.html.plaintext.txt	121	After interferon treatment newly synthesized ISG15 found intracellularly
0.09784351.9373235.html.plaintext.txt	122	Pulse chase experiments show 24 hours 50 labeled ISG15 found extracellularly
0.09784351.9373235.html.plaintext.txt	123	The question whether protein transcellular effect vivo remains unaddressed
0.09784351.9373235.html.plaintext.txt	124	The primary product ISG15 gene contains extension eight amino acids beyond C terminal diglycine characteristic ubiquitin
0.09784351.9373235.html.plaintext.txt	125	96 This C terminal extension rapidly removed intracellularly
0.09784351.9373235.html.plaintext.txt	126	The primary translation product demonstrated effect cells
0.09784351.9373235.html.plaintext.txt	127	In contrast processed product active low nanogram per milliliter level inducing IFN production T cells
0.09784351.9373235.html.plaintext.txt	128	97 This peptide also induces remarkable proliferation activation natural killer NK cells B cell depleted mononuclear cell populations
0.09784351.9373235.html.plaintext.txt	129	98 The effect NK cells requires presence T cells cannot accounted IFN interferon
0.09784351.9373235.html.plaintext.txt	130	Nakamura et al99 investigating ubiquitin homologue synthesized T cells acts nonantigen specific suppresser factor B cells
0.09784351.9373235.html.plaintext.txt	131	Isolation sequencing protein known MNSF monoclonal nonspecific suppressor factor followed cloning cDNA showed protein ubiquitin homologue despite apparent larger molecular weight isolated cells
0.09784351.9373235.html.plaintext.txt	132	The distal MHC encodes molecule known FAT10 homologous ubiquitin divergent ISG15 MNSF either two ubiquitin
0.09784351.9373235.html.plaintext.txt	133	The homology ubiquitin extends preservation C terminal diglycine appears necessary transfer ubiquitin molecules well internal lysines flanking sequence ubiquitinylation occurs
0.09784351.9373235.html.plaintext.txt	134	The molecule strongly expressed RNA level B lymphoblastoid lines IFN inducible others
0.09784351.9373235.html.plaintext.txt	135	In vivo found thymus lesser degree spleen
0.09784351.9373235.html.plaintext.txt	136	It expressed Jurkat T cells variety cell lines
0.09784351.9373235.html.plaintext.txt	137	A mouse homologue exists 50 conservation amino acid sequence
0.09784351.9373235.html.plaintext.txt	138	Experimental investigations function FAT10 beginning unpublished data
0.09784351.9373235.html.plaintext.txt	139	A transcription factor like gene family
0.09784351.9373235.html.plaintext.txt	140	The distal MHC encodes family least five genes share C terminal homology domain butyrophilin6101 dubbed CTB box 102 extends 100 amino acids length
0.09784351.9373235.html.plaintext.txt	141	103 Butyrophilin protein coats fat globules milk encoded distal MHC
0.09784351.9373235.html.plaintext.txt	142	The function conserved CTB box domain unknown although degree conservation suggests may motif interaction second protein family proteins
0.09784351.9373235.html.plaintext.txt	143	The proteins family encoded genes strictly within MHC somewhat divergent N terminal structures
0.09784351.9373235.html.plaintext.txt	144	One generally expressed gene ZNF173 Acid Finger Protein 102 several earmarks transcription factor including paired zinc fingers acidic domain
0.09784351.9373235.html.plaintext.txt	145	Two members family ZNF178 960 205 encode proteins resembling ZNF173 lacking acidic domain could potentially act transcriptional activator
0.09784351.9373235.html.plaintext.txt	146	One 960 205 limited pattern expression including undefined cell types within spleen unpublished data August 1995
0.09784351.9373235.html.plaintext.txt	147	As discussed telomeric boundary MHC recently extended include region around hemochromatosis locus
0.09784351.9373235.html.plaintext.txt	148	Between olfactory receptor cluster hemochromatosis locus Fig 1 gene yet another orphan protein immune system whose mRNA far found thymus unpublished data July 1996
0.09784351.9373235.html.plaintext.txt	149	It aptly called thymus specific serine protease TSSP
0.09784351.9373235.html.plaintext.txt	150	The predicted protein hydrophobic leader sequence suggesting either membrane bound secreted
0.09784351.9373235.html.plaintext.txt	151	Because lacks clear internal membrane anchor sequence latter likely interest immunologists learn function gene
0.09784351.9373235.html.plaintext.txt	152	Recently RNA transcript encoded FAT 9104 gene containing sequences one human MHC olfactory receptor like genes detected spleen mRNA
0.09784351.9373235.html.plaintext.txt	153	Closer examination showed olfactory receptor antisense sequence included probable 3 untranslated region novel FAT 9 transcript
0.09784351.9373235.html.plaintext.txt	154	unpublished data June 1995 This transcript putatively encodes protein 130 amino acids
0.09784351.9373235.html.plaintext.txt	155	On Northern blots found predominantly lymph nodes compared spleen thymus bone marrow variety tissues organs
0.09784351.9373235.html.plaintext.txt	156	The encoded protein obvious homologies proteins database
0.09784351.9373235.html.plaintext.txt	157	Therefore FAT 9 seems represent yet another example MHC gene functions specifically immune system
0.09784351.9373235.html.plaintext.txt	158	Other genes within MHC may involved specifically immune processes
0.09784351.9373235.html.plaintext.txt	159	The homology murine class II region human class II striking except insertion 60 kb murine class II region containing H2K genes
0.09784351.9373235.html.plaintext.txt	160	46 The murine KE5 gene lies centromeric H2K reported expressed lymphatic tissues
0.09784351.9373235.html.plaintext.txt	161	105 KE5 lies within collagen gene mapping centromeric H2K reported expressed lymphatic tissue functional significance unclear
0.09784351.9373235.html.plaintext.txt	162	The recently described HCGVIII transcript4 reported expressed intestine lymphoid tissues yet another candidate gene specific functions immune system
0.09784351.9373235.html.plaintext.txt	163	In addition several genes whose expression limited immunocytes number broadly expressed genes MHC potential less specific roles immune system
0.09784351.9373235.html.plaintext.txt	164	One example PBX2 also known G17 located approximately 250 kb telomeric HLA DRa
0.09784351.9373235.html.plaintext.txt	165	88106 Although functional data available PBX2 non MHC PBX gene implicated human leukemia presumably formation oncogenic fusion product via chromosome 119 translocation
0.09784351.9373235.html.plaintext.txt	166	107 Further experiments suggest PBX genes modify specificity clustered homeobox genes forming heterodimers directly bind DNA
0.09784351.9373235.html.plaintext.txt	167	The clustered homeobox genes expressed different patterns various stages lineages hematopoietic system may modulate expansion various hematopoietic precursors
0.09784351.9373235.html.plaintext.txt	168	In view concentration immune related genes appears unlikely clustering immune functions within MHC coincidence
0.09784351.9373235.html.plaintext.txt	169	As partly discussed suggestion may regional subspecialization immune functions within MHC beyond simply explained local gene duplication
0.09784351.9373235.html.plaintext.txt	170	This description strikingly apt well studied antigen presentation functions proximal MHC could also apply cluster complement components cluster inflammation stress response genes
0.09784351.9373235.html.plaintext.txt	171	A large fraction immune system related genes MHC IFN responsive
0.09784351.9373235.html.plaintext.txt	172	Although proposals concerning reasons clustering quite speculative question arises whether clustering may promoted long range gene control perhaps level chromatin organization DNA looping
0.09784351.9373235.html.plaintext.txt	173	An alternative proposal cause clustering diverse genes immune system particular allelic forms one locus create proteins interact preferentially products one another allelic form second locus
0.09784351.9373235.html.plaintext.txt	174	109 The two alleles would therefore preferentially co inherited
0.09784351.9373235.html.plaintext.txt	175	This hypothesis simplest form difficulty evidence protein protein interactions products several relevant immune system genes
0.09784351.9373235.html.plaintext.txt	176	Consideration population genetics MHC suggests alternative explanation clustering genes
0.09784351.9373235.html.plaintext.txt	177	Class I II alleles general show high rate accumulation various forms mutation least peptide binding regions
0.09784351.9373235.html.plaintext.txt	178	45 As extensively discussed others class I3741 class II alleles also subject gene conversion like events110 112 well recombination point mutations
0.09784351.9373235.html.plaintext.txt	179	This high degree polymorphism believed driven selection particular alleles response rapidly evolving parasites kinship recognition see
0.09784351.9373235.html.plaintext.txt	180	Certain allelic variants influence predisposition toward various diseases including common autoimmune disorders
0.09784351.9373235.html.plaintext.txt	181	It possible particular haplotype expanded population genes alleles act either protect environmental stress modifiers potential adverse effects particular class I class II alleles also selected
0.09784351.9373235.html.plaintext.txt	182	For example inconceivable class II allele associated early onset severe autoimmune disease might become associated alleles linked genes protective effect particular autoimmune disorder
0.09784351.9373235.html.plaintext.txt	183	The consequences could even include paradoxical effect alleles protective development disease would found higher incidence affected individuals controls
0.09784351.9373235.html.plaintext.txt	184	The large number alleles peptide binding regions classical MHC surface antigen genes commonly attributed selection immune resistance parasites
0.09784351.9373235.html.plaintext.txt	185	1 However kin recognition43 potential effects mating preferences relative fertility frequency abortions could also favor high level heterozygosity expansion rare alleles odorant determining genes MHC
0.09784351.9373235.html.plaintext.txt	186	If peptide binding regions class I class II antigens mechanism odorant determining molecules effects could contribute selection diversity regions
0.09784351.9373235.html.plaintext.txt	187	In regard portions olfactory receptor genes show relatively high level nonsynonymous substitutions compared synonymous nucleotide substitutions113114 reminiscent similar phenomenon coding regions peptide binding segments MHC class I class II genes Ig related genes115 flowering plant self incompatibility loci
0.09784351.9373235.html.plaintext.txt	188	Shortly distal HLA F gene human MHC contains group genes encode 7 transmembrane segment receptors olfactory receptor family104 Fig 1
0.09784351.9373235.html.plaintext.txt	189	A role receptors olfaction specific expression olfactory receptor epithelium yet directly shown although similarity genes receptors known expressed olfactory tissue makes plausible suggestion
0.09784351.9373235.html.plaintext.txt	190	Physiologically genes curiosity reports urine odorants determine several types reproductive behavior including fetal retention mating type preference mouse differences odor determined genes linked MHC
0.09784351.9373235.html.plaintext.txt	191	Studies mice congenic except MHC suggest 50 total difference odorant stimulus strains mice may caused genes MHC mice distinguish odor urine two strains differ mutation single class I gene
0.09784351.9373235.html.plaintext.txt	192	118 Humans also distinguish urine odors mice different MHC haplotypes
0.09784351.9373235.html.plaintext.txt	193	119 Cross breeding studies mice suggest preference mice certain MHC determined odors may learned rather genetically irreversibly determined
0.09784351.9373235.html.plaintext.txt	194	120 It yet known mouse MHC also olfactory receptor genes
0.09784351.9373235.html.plaintext.txt	195	It claimed humans evidence preference particular MHC determined variations sweat odors121 preference may change hormonal status individual
0.09784351.9373235.html.plaintext.txt	196	However clear data literature showing MHC determined mating type preference humans122 caution raised precise interpretation mouse experiments
0.09784351.9373235.html.plaintext.txt	197	123 It also curious subset olfactory receptor like genes expressed sperm number species
0.09784351.9373235.html.plaintext.txt	198	124 The occurrence olfactory receptors within MHC may favor selection certain receptor alleles matched subset MHC determined odorants haplotypes carry certain matched alleles would selective advantage population
0.09784351.9373235.html.plaintext.txt	199	If odorant discrimination learned could implications population genetics MHC species odorant attraction repulsion important
0.09784351.9373235.html.plaintext.txt	200	Depending manner psychological imprinting social population structure species imaginable learned haplotype discrimination could stronger driving force heterozygosity genetically determined haplotype discrimination
0.09784351.9373235.html.plaintext.txt	201	This could individual might learn discriminate self haplotypes also haplotypes present early environment
0.09784351.9373235.html.plaintext.txt	202	Also diversification MHC alleles result selection kin recognition evolving parasites mutually exclusive mechanisms
0.09784351.9373235.html.plaintext.txt	203	Recurrent spontaneous abortions infertility reported associated sharing HLA antigens husband wife although also number negative studies125 128 subject somewhat controversial
0.09784351.9373235.html.plaintext.txt	204	These studies difficult outbred nature human population polymorphism MHC
0.09784351.9373235.html.plaintext.txt	205	In particular possible synergistic additive effect one locus within MHC would difficult detect populations
0.09784351.9373235.html.plaintext.txt	206	Recent investigators suggested different regions MHC may affect different aspects fertility125 including suggestion homozygosity DR may affect fertilization implantation homozygosity HLA B may affect fetal loss
0.09784351.9373235.html.plaintext.txt	207	A higher expected ratio heterozygosity homozygosity MHC loci seen several different populations129 131 suggested consequence loss MHC homozygotes due increased susceptibility infections
0.09784351.9373235.html.plaintext.txt	208	Alternatively may due undefined disadvantage pregnancy accruing fetuses histocompatible mother
0.09784351.9373235.html.plaintext.txt	209	However reduction homozygotic individuals seen even developed countries127128 current generation would expected show significant reduction homozygotes due fetal wastage postnatal morbidity due infection
0.09784351.9373235.html.plaintext.txt	210	Studies reduced reproductive effectiveness couples sharing HLA alleles studies homozygosity single MHC loci would fully reflect effects might seen comparisons made entire haplotypes
0.09784351.9373235.html.plaintext.txt	211	The studies South Dakota Hutterite population valuable regard
0.09784351.9373235.html.plaintext.txt	212	These individuals reproductively isolated group derived relatively small number individuals North European origin apparently fewer 70 founders
0.09784351.9373235.html.plaintext.txt	213	132 They also traditionally large families
0.09784351.9373235.html.plaintext.txt	214	In group reduction number individuals sharing MHC haplotypes one third statistically expected level quite remarkable
0.09784351.9373235.html.plaintext.txt	215	127132 This suggests diversity MHC haplotypes may favored reasons parasite resistance perhaps mechanism avoiding inbred populations
0.09784351.9373235.html.plaintext.txt	216	Studies limited population Amerindians suggests production viable offspring discriminates MHC homozygosity rather concordance maternal fetal haplotypes
0.09784351.9373235.html.plaintext.txt	217	133 In one studies parents sharing MHC haplotype produced excess offspring heterozygous haploidentical mother less expected number MHC homozygous offspring
0.09784351.9373235.html.plaintext.txt	218	This could occur zygotes homozygous MHC region markedly less viable example recessive lethal alleles MHC
0.09784351.9373235.html.plaintext.txt	219	This effect would extend across number haplotypes requiring unlikely occurrence mutually complementing sets recessive lethals haplotype
0.09784351.9373235.html.plaintext.txt	220	133 In view absence comments contrary individuals born homozygous MHC haplotypes apparently show congenital abnormalities suggest developmental difficulties
0.09784351.9373235.html.plaintext.txt	221	In addition Hedrick134 presented quantitative arguments likelihood recessive lethal alleles explaining population deficits MHC homozygotes
0.09784351.9373235.html.plaintext.txt	222	The preferential occurrence heterozygosity would compatible principle kin recognition effects avoid breeding
0.09784351.9373235.html.plaintext.txt	223	This could operative level mating type preference preferential fertilization ovum sperm different MHC haplotype decreased survival zygote embryo consequence homozygosity MHC loci
0.09784351.9373235.html.plaintext.txt	224	A speculative explanation consistent Hutterite Amerindian data might selective failure fertilization ova haplotype identical sperm
0.09784351.9373235.html.plaintext.txt	225	Presumably would occur consequence gamete marking accomplished postmeiosis I gene expression
0.09784351.9373235.html.plaintext.txt	226	Immune attack fetal cells could consistent mechanisms self recognition used NK cells
0.09784351.9373235.html.plaintext.txt	227	Killing NK cells inhibited presence complete set self class I antigens
0.09784351.9373235.html.plaintext.txt	228	Therefore homozygous fetal cells would susceptible killing incomplete set maternal self antigens
0.09784351.9373235.html.plaintext.txt	229	However fetuses histocompatible mother well cell killing would also inhibited recognition foreign antigens fetal cells
0.09784351.9373235.html.plaintext.txt	230	Presumably recognition would mediated T cell receptor
0.09784351.9373235.html.plaintext.txt	231	THE HEMOCHROMATOSIS GENE AN EXAMPLE OF RECOMBINATION SUPPRESSION
0.09784351.9373235.html.plaintext.txt	232	Hereditary hemochromatosis recognized 20 years ago recessive disorder linked MHC class I region reviewed Chu et al135
0.09784351.9373235.html.plaintext.txt	233	With prevalence rate 3 51000 whites hemochromatosis counted among common autosomal recessive diseases
0.09784351.9373235.html.plaintext.txt	234	The underlying pathophysiology unknown Von Recklinghausen172 others century ago originally described triad diabetes hepatomegaly skin hyperpigmentation
0.09784351.9373235.html.plaintext.txt	235	Although know clinical manifestations caused iron overload resulting malregulated dietary iron absorption precise molecular pathway remains unknown
0.09784351.9373235.html.plaintext.txt	236	The recent identification HLA like gene mutation frequently associated disease136 well observation 2 microglobulin deficient mice develop similar iron overload syndrome137 suggests immune system functionally linked iron metabolism
0.09784351.9373235.html.plaintext.txt	237	Early genetic mapping studies reproducibly independently showed genetic localization hemochromatosis gene vicinity distal MHC
0.09784351.9373235.html.plaintext.txt	238	Studies within pedigrees linkage showed phenotype segregated HLA A gene
0.09784351.9373235.html.plaintext.txt	239	138139 Studies large populations linkage disequilibrium showed strong association HLA A3 allele
0.09784351.9373235.html.plaintext.txt	240	140 143 Additional studies showed HLA A3 single marker extended haplotype spans distance HLA B beyond HLA A144 almost always associated phenotype
0.09784351.9373235.html.plaintext.txt	241	In mapping studies Mendelian traits diastrophic dysplasia linkage disequilibrium studies able pinpoint gene location less 60 kb
0.09784351.9373235.html.plaintext.txt	242	145 It surprising given linkage disequilibrium HLA A3 Feder et al136 found hemochromatosis gene HFE candidate mutation 4 megabases Mb telomeric HLA A considerable distance view genetic data
0.09784351.9373235.html.plaintext.txt	243	The HFE gene shares approximately 58 homology HLA A2 amino acid level less 45 similarity nucleotide level
0.09784351.9373235.html.plaintext.txt	244	It retains many structural hallmarks MHC class I molecules signal sequence 1 2 domains peptide binding Ig like 3 domain transmembrane region cytoplasmic region
0.09784351.9373235.html.plaintext.txt	245	A single mutation described Cys282Tyr disrupts disulfide bridge 3 domain class I genes posited associate 2 microglobulin
0.09784351.9373235.html.plaintext.txt	246	Eighty three percent unrelated American patients found homozygous mutation Feder report carrier frequency 6
0.09784351.9373235.html.plaintext.txt	247	Presumably Cys282Tyr mutation interferes association HFE 2 microglobulin class I molecules shown important intracellular transport protein endoplasmic reticulum cell surface
0.09784351.9373235.html.plaintext.txt	248	The involvement class I gene iron transport supported studies showing iron overload mice homozygous knockout 2 microglobulin
0.09784351.9373235.html.plaintext.txt	249	137 However mechanistic connection intestinal iron absorption known function class I genes obscure
0.09784351.9373235.html.plaintext.txt	250	Although extensively searched autoimmunity part pathophysiology hemochromatosis
0.09784351.9373235.html.plaintext.txt	251	Northern blot analysis shows HFE 4 kb mRNA weakly expressed many tissues
0.09784351.9373235.html.plaintext.txt	252	The published cDNA smaller mRNA 2
0.09784351.9373235.html.plaintext.txt	253	3 kb 5 untranslated region
0.09784351.9373235.html.plaintext.txt	254	The Cys282Tyr mutation single described mutation consistently associated disease bearing chromosomes
0.09784351.9373235.html.plaintext.txt	255	A second much less common mutation described well appear increase risk disease
0.09784351.9373235.html.plaintext.txt	256	Presumably mutations HFE yet discovered analysis region far proven elusive
0.09784351.9373235.html.plaintext.txt	257	Interestingly Feder et al find linkage disequilibrium 6p21
0.09784351.9373235.html.plaintext.txt	258	3 markers hemochromatosis chromosomes lacking Cys282Tyr mutation
0.09784351.9373235.html.plaintext.txt	259	The lack linkage disequilibrium interpreted evidence additional nonlinked locus causing hemochromatosis phenotype
0.09784351.9373235.html.plaintext.txt	260	In follow studies Australia Jazwinska et al146 recently reported severest phenotype found patients ancestral haplotype spanning region HLA B beyond HLA F Fig 1
0.09784351.9373235.html.plaintext.txt	261	Because patients homozygous Cys282Tyr mutation suggested second modifier gene close HFE varied haplotype
0.09784351.9373235.html.plaintext.txt	262	In contrast Feder et al found United States hemochromatosis phenotypes associated homozygote Cys282Tyr heterozygote Cys282Tyr homozygote non Cys282Tyr mutations could differentiated clinical grounds
0.09784351.9373235.html.plaintext.txt	263	Although association Cys282Tyr mutation hemochromatosis compelling argument causation explanation non Cys282Tyr patients lacking
0.09784351.9373235.html.plaintext.txt	264	It possible cases non Cys282Tyr hemochromatosis caused alternative mutations HFE
0.09784351.9373235.html.plaintext.txt	265	However proof awaits cloning remaining 1
0.09784351.9373235.html.plaintext.txt	266	7 kb HFE cDNA identification alternative mutations
0.09784351.9373235.html.plaintext.txt	267	Curiously new syndrome liver iron overload normal transferrin saturation recently described Pippard147 Moirand et al
0.09784351.9373235.html.plaintext.txt	268	148 This discovery adds weight speculation Feder et al mutations genes may cause clinical picture indistinguishable hemochromatosis
0.09784351.9373235.html.plaintext.txt	269	The hemochromatosis phenotype Cys282Tyr mutation common MHC haplotype A3B7 widespread distribution among white populations including Great Britain France Italy Germany Sweden Norway Australia United States
0.09784351.9373235.html.plaintext.txt	270	135 The high prevalence distribution strongly suggest mutation arose ancestral chromosome ancient event perhaps Celtic Scandinavian population
0.09784351.9373235.html.plaintext.txt	271	Based estimated incidence hemochromatosis high carrier frequency frequency Cys282Tyr mutation estimated Cys282Tyr mutation may present least 50 100 million individuals
0.09784351.9373235.html.plaintext.txt	272	Given plausible value coefficient selection mutation must occurred much 100 generations ago
0.09784351.9373235.html.plaintext.txt	273	The physical distance HLA A hemochromatosis gene 4 megabases
0.09784351.9373235.html.plaintext.txt	274	If rate recombination region comparable average rate genome one would expect 4 meioses would result separation HLA A HFE markers
0.09784351.9373235.html.plaintext.txt	275	At recombination frequency linkage disequilibrium dissipated relatively short period time yet
0.09784351.9373235.html.plaintext.txt	276	Possible explanations preservation linkage disequilibrium 4 Mb region include multiple identical HFE mutations haplotypic background recent origin HFE mutation recombination suppression perhaps simultaneous selection HLA A alleles HLA A3 hemochromatosis mutation
0.09784351.9373235.html.plaintext.txt	277	Of first two explanations less likely
0.09784351.9373235.html.plaintext.txt	278	The possibility identical HFE mutation could occur multiple times haplotypic background suggests might inherently unstable sequence HFE gene trinucleotide repeat known expand successive generations CpG dinucleotide
0.09784351.9373235.html.plaintext.txt	279	The HFE mutation associated common haplotype A3B7 G A transition nucleotide 845 open reading frame causes Cys282Tyr missense mutation
0.09784351.9373235.html.plaintext.txt	280	Furthermore work others shown mutation stable families yet examples spontaneous mutations type reported
0.09784351.9373235.html.plaintext.txt	281	Simultaneous selection alleles multiple loci recombination suppression difficult explanations dismiss
0.09784351.9373235.html.plaintext.txt	282	It possible certain genetic advantage offered combination alleles genes distributed region including HLA genes even perhaps extending HFE gene
0.09784351.9373235.html.plaintext.txt	283	However simultaneous coselection alleles ends region responsible maintenance linkage disequilibrium intervening alleles might consistently retained haplotype
0.09784351.9373235.html.plaintext.txt	284	This observed among hemochromatosis chromosomes genes found distal region might interact proximal HLA genes thereby promote selection
0.09784351.9373235.html.plaintext.txt	285	Linkage disequilibrium portions MHC particularly region HLA A HLA B suggest either recombination suppression coselection alleles several loci may operative combinations alleles
0.09784351.9373235.html.plaintext.txt	286	130 The A1B8 haplotype long renowned high disequilibrium149 occurs 7 French families illustrating high association alleles two loci may exhibit
0.09784351.9373235.html.plaintext.txt	287	The investigators studying interpreted data suggestive selection although distinction made coselection operating several loci recombination suppression region
0.09784351.9373235.html.plaintext.txt	288	In contrast A2 show linkage disequilibrium HLA B alleles suggesting selection phenomenon low recombination rate apply possible haplotypes
0.09784351.9373235.html.plaintext.txt	289	Studies syntenic region mouse suggest significant recombination suppression haplotype specific
0.09784351.9373235.html.plaintext.txt	290	The linkage data distal HLA A somewhat limited
0.09784351.9373235.html.plaintext.txt	291	The Genethon sex averaged linkage map151 shows recombinants 186 meioses derived eight CEPH families studied markers adjacent interspersed HLA A HFE
0.09784351.9373235.html.plaintext.txt	292	The major hemochromatosis mutation strong linkage disequilibrium markers near HLA A
0.09784351.9373235.html.plaintext.txt	293	The A3B7 hemochromatosis haplotype comprises 40 hemochromatosis bearing chromosomes
0.09784351.9373235.html.plaintext.txt	294	141 Compared genome wide averages recombination region hemochromatosis mutation bearing chromosomes suppressed
0.09784351.9373235.html.plaintext.txt	295	A common extended haplotype described normal European control populations associated A1B8 extends least 4 Mb HLA B
0.09784351.9373235.html.plaintext.txt	296	Recombination suppression coselection favorable alleles plausible explanations persistence linkage disequilibrium haplotypes
0.09784351.9373235.html.plaintext.txt	297	The three independent histone clusters mapping region136 Fig 1 unpublished data July 1996 may also relevant recombination suppression
0.09784351.9373235.html.plaintext.txt	298	If haplotype specific heterogeneity rate recombination tempting consider may modulated haplotype specific local sequences
0.09784351.9373235.html.plaintext.txt	299	Preferred sites recombination identified class II class III regions mouse150 human genome152 seem general feature throughout MHC
0.09784351.9373235.html.plaintext.txt	300	153 In cases rate recombination within relatively short region less 2000 bases may elevated several orders magnitude average rate genome whole
0.09784351.9373235.html.plaintext.txt	301	Therefore MHC recombinants obtained laboratory crosses particular pair strains may occur within hotspot
0.09784351.9373235.html.plaintext.txt	302	150 The hotspot thought resolution point joint molecules two DNA duplexes become separated
0.09784351.9373235.html.plaintext.txt	303	The phenomenon complex particular hot spot operative certain haplotypes genetic backgrounds may sex specific
0.09784351.9373235.html.plaintext.txt	304	150 Recombination may152 may require perfect homology across hotspot154 differences hotspot activity may due variation number copies relatively simple repetitive sequences present tandem arrays recombination site
0.09784351.9373235.html.plaintext.txt	305	155 Recombination occurs number copies least one set repeats chromosomes
0.09784351.9373235.html.plaintext.txt	306	The activity hotspot seems require instigator sequences present haplotypes located distance region recombination actually occurs
0.09784351.9373235.html.plaintext.txt	307	Recent work yeast mating type loci also shown chromosomal regions may exhibit regulated activation recombination regulation may involve short regions cis active DNA sequence together trans acting proteins
0.09784351.9373235.html.plaintext.txt	308	The area recombination activated may several orders magnitude larger cis active DNA sequences interact relevant proteins
0.09784351.9373235.html.plaintext.txt	309	In particular 700 bp sequence identified activates recombination along 90000 bp region yeast chromosome
0.09784351.9373235.html.plaintext.txt	310	156 This occurs cells one two mating types perhaps consequence expression mating type specific DNA binding protein
0.09784351.9373235.html.plaintext.txt	311	The region recombination actually occurs 17000 bases removed 700 bp instigator sequence
0.09784351.9373235.html.plaintext.txt	312	Phenomenologically similar deduced MHC detailed mechanisms cases remain worked
0.09784351.9373235.html.plaintext.txt	313	The class II class III regions human mouse roughly colinear good correspondence presence linear order specific genes two species
0.09784351.9373235.html.plaintext.txt	314	Persuasive evidence exists chromosomes 1q22 23 9q34
0.09784351.9373235.html.plaintext.txt	315	3 contain multigene segments DNA paralogous class II III perhaps IV regions MHC chromosome 6
0.09784351.9373235.html.plaintext.txt	316	157 For example gene one three members RXR steroid receptor family located centromeric class II region chromosome 6 chromosomes 1 9 presumably paralogous positions
0.09784351.9373235.html.plaintext.txt	317	A similar situation occurs respect PBX genes Notch homologue genes several homologues shared least two three chromosomal regions
0.09784351.9373235.html.plaintext.txt	318	The chromosome 1 duplication particularly striking falls region class I like CD1 genes lie
0.09784351.9373235.html.plaintext.txt	319	Also OTF3 maps MHC HLA A E OTF2 maps unknown site chromosome 1
0.09784351.9373235.html.plaintext.txt	320	Most recently new class I gene called MR1 identified long arm chromosome 1158 although reported location somewhat telomeric remainder MHC like genes referred
0.09784351.9373235.html.plaintext.txt	321	It yet known whether MR1 polymorphic expressed protein level
0.09784351.9373235.html.plaintext.txt	322	Unfortunately regions chromosomes 1 9 mapped sufficient resolution see closely organization paralogous regions match either present MHC plausible model precursor MHC
0.09784351.9373235.html.plaintext.txt	323	Among things observations raise interesting possibility additional immune system genes located paralogous regions chromosomes 1 9 perhaps 19 class I like zinc 2 glycoprotein gene located
0.09784351.9373235.html.plaintext.txt	324	As discussed class II class I genes show extensive allelic variability due point mutations intra locus recombinations intra locus gene conversion like events
0.09784351.9373235.html.plaintext.txt	325	In addition relationship class I regions various mammals complex multiple cycles expansion contraction must occurred account genetic structure region inter intra species differences
0.09784351.9373235.html.plaintext.txt	326	36159160 The human MHC overall contains least 28 class I related genes gene fragments including 18 19 analyzed Geraghty et al161 5 MIC genes pseudogenes84 least 2 class I segments near MIC A B respectively class I related sequence class II region162 hemochromatosis gene
0.09784351.9373235.html.plaintext.txt	327	HFE one genes confidently ortholog specific mouse gene reflection massive changes created cycles expansion contraction since divergence progenitors two mammals
0.09784351.9373235.html.plaintext.txt	328	One striking feature divergence murine human class I regions resulted presence functional subfamilies class I genes species missing
0.09784351.9373235.html.plaintext.txt	329	Thus mouse contains family TL genes largely unknown function29 also H2 M genes interesting property binding specifically formyl methionine containing peptides occur amino terminus bacterial mitochondrial proteins
0.09784351.9373235.html.plaintext.txt	330	163 Both types class I genes detected probably completely missing humans
0.09784351.9373235.html.plaintext.txt	331	Conversely humans nonclassical class I heavy chain genes including HLA G gene164 expressed specific locations placental fetal cells165 may serve prevent NK cell rejection fetuses166 also early stages embryogenesis
0.09784351.9373235.html.plaintext.txt	332	167 Very recently mouse class I genes found may preferentially expressed early development quite unclear whether homologues either structure evolutionary relationship even function human HLA G gene
0.09784351.9373235.html.plaintext.txt	333	As described humans also family five genes pseudogenes termed MIC85 PERB168 genes
0.09784351.9373235.html.plaintext.txt	334	These encode least one expressed product MIC A protein polymorphic induced heat shock expressed preferentially intestinal mucosa precise function yet known
0.09784351.9373235.html.plaintext.txt	335	Comparable products undetectable mouse
0.09784351.9373235.html.plaintext.txt	336	The MIC genes clearly structurally related class I genes terms structure proteins encode position seven introns located homologous positions coding sequences
0.09784351.9373235.html.plaintext.txt	337	The structure MIC genes differs class I genes contain long 10 kb first intron
0.09784351.9373235.html.plaintext.txt	338	This intron contains first exon transcript derived complementary strand
0.09784351.9373235.html.plaintext.txt	339	A spliced form transcript one MIC pseudogenes detected contains additional exons DNA upstream MIC transcription initiation site
0.09784351.9373235.html.plaintext.txt	340	168 This complex two interspersed genes pseudogenes occurs twice centromeric HLA B three times HLA E HLA F distal MHC accounting least part observation repeated blocks sequence regions MHC
0.09784351.9373235.html.plaintext.txt	341	The mouse MHC complex apparently lacks genes MIC series human lacks extensive series TL genes mouse
0.09784351.9373235.html.plaintext.txt	342	2 MOG suggests either entire region human MHC HLA A HLA F compressed less 150 kb mouse contains single H2M class I gene169 inversion occurred one end point lying B30
0.09784351.9373235.html.plaintext.txt	343	This evidence remarkably extensive rearrangements deletions expansions occurred vertebrate MHC class I region
0.09784351.9373235.html.plaintext.txt	344	The hemochromatosis gene containing region chromosome 6p located 4 Mb telomeric HLA F
0.09784351.9373235.html.plaintext.txt	345	The hemochromatosis region also appears originated large duplication involving histone genes136 perhaps RET finger like gene170 addition class I gene
0.09784351.9373235.html.plaintext.txt	346	The exact duplication region defined yet apparently lacks olfactory receptor genes located nearest class I gene proximal histone gene cluster
0.09784351.9373235.html.plaintext.txt	347	As indicated paragraphs MHC exhibits several singular characteristics including clustering genes disparate structure function within immuno hematopoietic system evidence rapid evolution relative nonrepetitive sequence portions genome evidence variation rates intra MHC recombination
0.09784351.9373235.html.plaintext.txt	348	We speculate phenomena may related following way
0.09784351.9373235.html.plaintext.txt	349	Class I class II genes MHC particular appear subject selective pressures diversification operate short time scale relative evolutionary events
0.09784351.9373235.html.plaintext.txt	350	Environmental stresses may also put selective pressure alleles immune system genes
0.09784351.9373235.html.plaintext.txt	351	In addition resulting rapid shifts allele abundance composition class I class II genes whether due parasite driven selection effects MHC procreation may result emergence autoimmune phenomena putting secondary selective pressure genes immune system diminish incidence consequences autoimmunity
0.09784351.9373235.html.plaintext.txt	352	Also extreme divergence class I regions mammals compared even class II region raises question whether evolutionary pressures class I genes beyond arising presentation peptides T cell receptor
0.09784351.9373235.html.plaintext.txt	353	The presence immune system genes chromosomal region therefore linkage disequilibrium classical MHC genes provides opportunity simultaneous selection optimal alleles genes among variety chromosomes carrying newly selected class I II allele
0.09784351.9373235.html.plaintext.txt	354	This diminishes rate disruption favored combinations alleles would result recombination reassortment chromosomes meiosis
0.09784351.9373235.html.plaintext.txt	355	If recombination rates MHCs would optimal low rate recombination sufficient generate favorable combinations alleles low enough limit genetic burden recombinant nonoptimal chromosomal segments
0.09784351.9373235.html.plaintext.txt	356	171 However different MHC regions exhibit heterogeneous rates recombination controlled least part sequences within MHC
0.09784351.9373235.html.plaintext.txt	357	This permits recombination alleles generate among others favorable combinations chromosomal segments may relatively locked recombination suppression
0.09784351.9373235.html.plaintext.txt	358	These chromosomal segments would advantageous thus expanded generating extended haplotypes show linkage disequilibrium population
0.09784351.9373235.html.plaintext.txt	359	The considerations could apply occurrence olfactory receptor genes linked MHC
0.09784351.9373235.html.plaintext.txt	360	If class I genes particular determinants odor reviewed might coselection receptors responsive nonresponsive class I determined odors
0.09784351.9373235.html.plaintext.txt	361	The MHC long known play major role determination genetic susceptibility autoimmune disorders large part due polymorphisms class II genes
0.09784351.9373235.html.plaintext.txt	362	However least cases evidence strong non class II genes MHC also play role predisposition autoimmunity
0.09784351.9373235.html.plaintext.txt	363	The identification additional genes region modify propensity autoimmune diseases could important diagnostic therapeutic implications
0.09784351.9373235.html.plaintext.txt	364	In recent years analyses MHC encoded transcripts shown within MHC 10 different structurally diverse families genes whose patterns expression indicate specific role immune system
0.09784351.9373235.html.plaintext.txt	365	The number different MHC genes functioning immune response extensive regions linkage disequilibrium seen instances MHC make particularly difficult use positional genetic approaches assign disease contributions particular gene products
0.09784351.9373235.html.plaintext.txt	366	Short understanding regulation function protein level effect amino acid nucleotide sequence variations could predicted perhaps best genetic approach look sense changes codons variation known promoter elements gene test large populations see correlation disease manifestations independent disequilibrium class II genes
0.09784351.9373235.html.plaintext.txt	367	This could difficult number reasons least extensive degree linkage disequilibrium consequent occurrence extended haplotypes region
0.09784351.9373235.html.plaintext.txt	368	An increasing amount genomic sequence data MHC emerging available directly Sanger Centre ftpftp
0.09784351.9373235.html.plaintext.txt	369	Tapasin transmembrane glycoprotein mediates calreticulin bound MHC class I molecule interactions TAP recently mapped close MHC
0.09784351.9373235.html.plaintext.txt	370	Submitted March 27 1997 accepted June 16 1997
0.09784351.9373235.html.plaintext.txt	371	supported March Dimes Birth Defects Research Foundation Clinical Research Grant No
0.09784351.9373235.html.plaintext.txt	372	6 FY96 0272 National Institutes Health NIH Grant No
0.09784351.9373235.html.plaintext.txt	373	supported NIH Outstanding Investigator Award CA42556 11
0.09784351.9373235.html.plaintext.txt	374	Address reprint requests Jeffrey R
0.09784351.9373235.html.plaintext.txt	375	Gruen MD Yale Child Health Research Center Department Pediatrics Yale University School Medicine 464 Congress Ave New Haven CT 06520 8081
0.09784351.9373235.html.plaintext.txt	376	The name given Feder et al HLA H
0.09784351.9373235.html.plaintext.txt	377	This nomenclature confusing previously dubbed HFE years ago anticipation discovery HLA H already used designate MHC class I gene several years earlier mapped HLA A HLA G
0.09784351.9373235.html.plaintext.txt	378	We refer new gene simply HFE remainder review
0.09784351.9373235.html.plaintext.txt	379	The authors thank Drs Frank Black Chris Bowlus Nancy Ruddle Judith Kidd Gordon Shepherd Ruma Raha Chowdhury helpful comments corrections manuscript
0.09784351.9373235.html.plaintext.txt	380	We also thank colleagues helpful discussions materials provided Drs Duncan Campbell Peter Lengyel John Trowsdale
0.09784351.9373235.html.plaintext.txt	381	REFERENCES Introduction References 1
0.09784351.9373235.html.plaintext.txt	382	Parham P Ohta T Population biology antigen presentation MHC class I molecules
0.09784351.9373235.html.plaintext.txt	383	Science 27267 1996Abstract 2
0.09784351.9373235.html.plaintext.txt	384	Parimoo S Patanjali SR Shukla H Chaplin DD Weissman SM cDNA selection Efficient PCR approach selection cDNAs encoded large chromosomal DNA fragments
0.09784351.9373235.html.plaintext.txt	385	Proc Nat Acad Sci USA 889623 1991Abstract 3
0.09784351.9373235.html.plaintext.txt	386	Goei VL Parimoo S Capossela A Chu TW Gruen JR Isolation novel non HLA gene fragments hemochromatosis region 6p21
0.09784351.9373235.html.plaintext.txt	387	3 cDNA hybridization selection
0.09784351.9373235.html.plaintext.txt	388	Am J Hum Genet 54244 1994Medline Order article via Infotrieve 4
0.09784351.9373235.html.plaintext.txt	389	Pichon L Giffon T Chauvel B Carn G Bouric P El Kahloun A Legall JY David V Physical map HLA AHLA F subregion identification two new coding sequences
0.09784351.9373235.html.plaintext.txt	390	Immunogenetics 43175 1996Medline Order article via Infotrieve 5
0.09784351.9373235.html.plaintext.txt	391	Campbell RD Trowsdale J A map human major histocompatibility complex
0.09784351.9373235.html.plaintext.txt	392	Gruen JR Nalabolu SR Chu TW Bowlus C Fan WF Goei VL Wei H Sivakamasundari R Liu YC Xu HX Parimoo S Nallur G Ajioka R Shukla H Bray Ward P Pan J Weissman SM A transcription map major histocompatibility complex MHC class I region
0.09784351.9373235.html.plaintext.txt	393	Genomics 3670 1996Medline Order article via Infotrieve 7
0.09784351.9373235.html.plaintext.txt	394	Fan W Cai W Parimoo S Lennon GG Weissman SM Identification seven new human MHC class I region genes around HLA F locus
0.09784351.9373235.html.plaintext.txt	395	Immunogenetics 4497 1996Medline Order article via Infotrieve 8
0.09784351.9373235.html.plaintext.txt	396	Lepourcelet M Andrieux N Giffon J Pichon L Hampe A Galibert F Mosser J Systematic sequencing human HLA AHLA F region Establishment cosmid contig identification new gene cluster within 37 kb sequence
0.09784351.9373235.html.plaintext.txt	397	Genomics 37316 1996Medline Order article via Infotrieve 9
0.09784351.9373235.html.plaintext.txt	398	Aguado B Milner CM Campbell RD Genes MHC class III region functions proteins encode Browning M McMichael A eds HLA MHC Genes Molecules Function
0.09784351.9373235.html.plaintext.txt	399	Oxford UK BIOS Scientific Publishers 1996 p 39 10
0.09784351.9373235.html.plaintext.txt	400	Klein J The Natural History Major Histocompatibility Complex
0.09784351.9373235.html.plaintext.txt	401	Trowsdale J Molecular genetics HLA class I class II regions Browning M McMichael A eds HLA MHC Genes Molecules Function
0.09784351.9373235.html.plaintext.txt	402	Oxford UK BIOS Scientific Publishers 1996 p 22 12
0.09784351.9373235.html.plaintext.txt	403	Cresswell P Androlewicz MJ Ortmann B Assembly transport class I MHC peptide complexes
0.09784351.9373235.html.plaintext.txt	404	Ciba Found Symp 187150 1994Medline Order article via Infotrieve 13
0.09784351.9373235.html.plaintext.txt	405	Cresswell P Antigen presentation
0.09784351.9373235.html.plaintext.txt	406	Getting peptides MHC class II molecules
0.09784351.9373235.html.plaintext.txt	407	Curr Biol 4541 1994Medline Order article via Infotrieve 14
0.09784351.9373235.html.plaintext.txt	408	Ceman S Rudersdorf RA Petersen JM DeMars R DMA DMB genes class II region human MHC needed class II associated antigen processing
0.09784351.9373235.html.plaintext.txt	409	J Immunol 1542545 1995AbstractFree Full Text 15
0.09784351.9373235.html.plaintext.txt	410	Nedospasov SA Hirt B Shakhov AN Dobrynin VN Kawashima E Accolla RS Jongeneel CV The genes tumor necrosis factor TNF alpha lymphotoxin TNF beta tandemly arranged chromosome 17 mouse
0.09784351.9373235.html.plaintext.txt	411	Nucleic Acids Res 147713 1986Abstract 16
0.09784351.9373235.html.plaintext.txt	412	Muller U Jongeneel CV Nedospasov SA Lindahl KF Steinmetz M Tumour necrosis factor lymphotoxin genes map close H 2D mouse major histocompatibility complex
0.09784351.9373235.html.plaintext.txt	413	Nature 325265 1987Medline Order article via Infotrieve 17
0.09784351.9373235.html.plaintext.txt	414	Gardner SM Mock BA Hilgers J Huppi KE Roeder WD Mouse lymphotoxin tumor necrosis factor Structural analysis cloned genes physical linkage chromosomal position
0.09784351.9373235.html.plaintext.txt	415	J Immunol 139476 1987AbstractFree Full Text 18
0.09784351.9373235.html.plaintext.txt	416	Browning JL Ngam ek A Lawton P DeMarinis J Tizard R Chow EP Hession C OBrine Greco B Foley SF Ware CF Lymphotoxin beta novel member TNF family forms heteromeric complex lymphotoxin cell surface
0.09784351.9373235.html.plaintext.txt	417	Cell 72847 1993Medline Order article via Infotrieve 19
0.09784351.9373235.html.plaintext.txt	418	Campbell RD Milner CM MHC genes autoimmunity
0.09784351.9373235.html.plaintext.txt	419	Curr Opin Immunol 5887 1993Medline Order article via Infotrieve 20
0.09784351.9373235.html.plaintext.txt	420	Corzo D Salazar M Granja CB Yunis EJ Advances HLA genetics
0.09784351.9373235.html.plaintext.txt	421	Exp Clin Immunogenet 12156 1995Medline Order article via Infotrieve 21
0.09784351.9373235.html.plaintext.txt	422	Tomlinson IP Bodmer WF The HLA system analysis multifactorial genetic disease
0.09784351.9373235.html.plaintext.txt	423	Trends Genet 11493 1995Medline Order article via Infotrieve 22
0.09784351.9373235.html.plaintext.txt	424	Tisch R McDevitt H Insulin dependent diabetes mellitus
0.09784351.9373235.html.plaintext.txt	425	Cell 85291 1996Medline Order article via Infotrieve 23
0.09784351.9373235.html.plaintext.txt	426	Thomson G HLA disease associations Models study complex human genetic disorders
0.09784351.9373235.html.plaintext.txt	427	Crit Rev Clin Lab Sci 32183 1995Medline Order article via Infotrieve 24
0.09784351.9373235.html.plaintext.txt	428	Cardon LR Smith SD Fulker DW Kimberling WJ Pennington BF DeFries JC Quantitative trait locus reading disability chromosome 6
0.09784351.9373235.html.plaintext.txt	429	Science 266276 1994Medline Order article via Infotrieve 25
0.09784351.9373235.html.plaintext.txt	430	Grigorenko EL Wood FB Meyer MS Hart LA Speed WC Shuster A Pauls DL Susceptibility loci distinct components developmental dyslexia chromosomes 6 15
0.09784351.9373235.html.plaintext.txt	431	Am J Hum Genet 6027 1997Medline Order article via Infotrieve 26
0.09784351.9373235.html.plaintext.txt	432	Bodmer WF Evolution function HLA region
0.09784351.9373235.html.plaintext.txt	433	Cancer Surv 225 1995Medline Order article via Infotrieve 27
0.09784351.9373235.html.plaintext.txt	434	Campbell RD Trowsdale J Map human MHC
0.09784351.9373235.html.plaintext.txt	435	Immunol Today 14349 1993Medline Order article via Infotrieve 28
0.09784351.9373235.html.plaintext.txt	436	Cresswell P Assembly transport function MHC class II molecules
0.09784351.9373235.html.plaintext.txt	437	Ann Rev Immunol 12259 1994Medline Order article via Infotrieve 29
0.09784351.9373235.html.plaintext.txt	438	Flaherty L Elliott E Tine JA Walsh AC Waters JB Immunogenetics Q TL regions mouse
0.09784351.9373235.html.plaintext.txt	439	Crit Rev Immunol 10131 1990Medline Order article via Infotrieve 30
0.09784351.9373235.html.plaintext.txt	440	Girdlestone J Transcriptional regulation MHC class I genes
0.09784351.9373235.html.plaintext.txt	441	Eur J Immunogenet 23395 1996Medline Order article via Infotrieve 31
0.09784351.9373235.html.plaintext.txt	442	Gunther E Current status molecular genetic analysis rat major histocompatibility complex
0.09784351.9373235.html.plaintext.txt	443	Folia Biologica 42129 1996Medline Order article via Infotrieve 32
0.09784351.9373235.html.plaintext.txt	444	Hughes AL Origin evolution HLA class I pseudogenes
0.09784351.9373235.html.plaintext.txt	445	Mol Biol Evol 12247 1995Abstract 33
0.09784351.9373235.html.plaintext.txt	446	Kasahara M Kandil E Saltercid L Flajnik MF Origin evolution class I gene family Why mammalian class I genes encoded outside major histocompatibility complex Res Immunol 147278 1996Medline Order article via Infotrieve 34
0.09784351.9373235.html.plaintext.txt	447	Kaufman J Volk H Wallny HJ A minimal essential MHC unrecognized MHC Two extremes selection polymorphism
0.09784351.9373235.html.plaintext.txt	448	Immunol Rev 14363 1995Medline Order article via Infotrieve 35
0.09784351.9373235.html.plaintext.txt	449	Kronenberg M Brines R Kaufman J MHC evolution A long term investment defense
0.09784351.9373235.html.plaintext.txt	450	Immunol Today 154 1994Medline Order article via Infotrieve 36
0.09784351.9373235.html.plaintext.txt	451	Le Bouteiller P HLA class I chromosomal region genes products Facts questions
0.09784351.9373235.html.plaintext.txt	452	Crit Rev Immunol 1489 1994Medline Order article via Infotrieve 37
0.09784351.9373235.html.plaintext.txt	453	Lienert K Parham P Evolution MHC class I genes higher primates
0.09784351.9373235.html.plaintext.txt	454	Immunol Cell Biol 74349 1996Medline Order article via Infotrieve 38
0.09784351.9373235.html.plaintext.txt	455	Lunney JK Current status swine leukocyte antigen complex
0.09784351.9373235.html.plaintext.txt	456	Vet Immunol Immunopathol 4319 1994Medline Order article via Infotrieve 39
0.09784351.9373235.html.plaintext.txt	457	Browning M McMichael A HLA MHC Genes Molecules Function
0.09784351.9373235.html.plaintext.txt	458	Oxford UK BIOS Scientific Publishers 1996 40
0.09784351.9373235.html.plaintext.txt	459	McDevitt H Evolution MHC class II allelic diversity
0.09784351.9373235.html.plaintext.txt	460	Immunol Rev 143113 1995Medline Order article via Infotrieve 41
0.09784351.9373235.html.plaintext.txt	461	Parham P The rise fall great class I genes
0.09784351.9373235.html.plaintext.txt	462	Semin Immunol 6373 1994Medline Order article via Infotrieve 42
0.09784351.9373235.html.plaintext.txt	463	Peelman LJ Chardon P Vaiman M Mattheeuws M Van Zeveren A Van de Weghe A Bouquet Y Campbell RD A detailed physical map porcine major histocompatibility complex MHC class III region Comparison human mouse MHC class III regions
0.09784351.9373235.html.plaintext.txt	464	Mammalian Genome 7363 1996Medline Order article via Infotrieve 43
0.09784351.9373235.html.plaintext.txt	465	Potts WK Wakeland EK Evolution MHC genetic diversity A tale incest pestilence sexual preference
0.09784351.9373235.html.plaintext.txt	466	Trends Genet 9408 1993Medline Order article via Infotrieve 44
0.09784351.9373235.html.plaintext.txt	467	Teitell M Cheroutre H Panwala C Holcombe H Eghtesady P Kronenberg M Structure function H 2 T Tla region class I MHC molecules
0.09784351.9373235.html.plaintext.txt	468	Crit Rev Immunol 141 27 1994Medline Order article via Infotrieve 45
0.09784351.9373235.html.plaintext.txt	469	Thomson G HLA population genetics
0.09784351.9373235.html.plaintext.txt	470	Baillieres Clin Endocrinol Metab 5247 1991Medline Order article via Infotrieve 46
0.09784351.9373235.html.plaintext.txt	471	Trowsdale J Both man bird beast Comparative organization MHC genes
0.09784351.9373235.html.plaintext.txt	472	Immunogenetics 411 1995Medline Order article via Infotrieve 47
0.09784351.9373235.html.plaintext.txt	473	Van Ostade X Tavernier J Fiers W Structure activity studies human tumour necrosis factors
0.09784351.9373235.html.plaintext.txt	474	Protein Eng 75 1994Abstract 48
0.09784351.9373235.html.plaintext.txt	475	Watkins DI MHC nonhuman primates
0.09784351.9373235.html.plaintext.txt	476	Curr Topics Microbiol Immunol 188145 1994Medline Order article via Infotrieve 49
0.09784351.9373235.html.plaintext.txt	477	Watkins DI The evolution major histocompatibility class I genes primates
0.09784351.9373235.html.plaintext.txt	478	Crit Rev Immunol 151 1995Medline Order article via Infotrieve 50
0.09784351.9373235.html.plaintext.txt	479	Parham P Adams EJ Arnett KL The origins HLA ABC polymorphism
0.09784351.9373235.html.plaintext.txt	480	Immunol Rev 143141 1995Medline Order article via Infotrieve 51
0.09784351.9373235.html.plaintext.txt	481	Acton RD Dahlberg PS Uknis ME Klaerner HG Fink GS Norman JG Dunn DL Differential sensitivity escherichia coli infection mice lacking tumor necrosis factor p55 interleukin 1 p80 receptors
0.09784351.9373235.html.plaintext.txt	482	Arch Surg 1311216 1996Abstract 52
0.09784351.9373235.html.plaintext.txt	483	Czarniecki CW The role tumor necrosis factor viral disease
0.09784351.9373235.html.plaintext.txt	484	Antiviral Res 22223 1993Medline Order article via Infotrieve 53
0.09784351.9373235.html.plaintext.txt	485	Jacob CO Lewis GD McDevitt HO MHC class II associated variation production tumor necrosis factor mice humans Relevance pathogenesis autoimmune diseases
0.09784351.9373235.html.plaintext.txt	486	Immunol Res 10156 1991Medline Order article via Infotrieve 54
0.09784351.9373235.html.plaintext.txt	487	McGuire W Hill AV Allsopp CE Greenwood BM Kwiatkowski D Variation TNF alpha promoter region associated susceptibility cerebral malaria
0.09784351.9373235.html.plaintext.txt	488	Nature 371508 1994Medline Order article via Infotrieve 55
0.09784351.9373235.html.plaintext.txt	489	Louis E Satsangi J Roussomoustakaki M Parkes M Fanning G Welsh K Jewell D Cytokine gene polymorphisms inflammatory bowel disease
0.09784351.9373235.html.plaintext.txt	490	Daser A Mitchison H Mitchison A Muller B Non classical MHC genetics immunological disease man mouse The key role pro inflammatory cytokine genes
0.09784351.9373235.html.plaintext.txt	491	Cytokine 8593 1996Medline Order article via Infotrieve 57
0.09784351.9373235.html.plaintext.txt	492	Elliott MJ Feldmann M Maini RN TNF alpha blockade rheumatoid arthritis Rationale clinical outcomes mechanisms action
0.09784351.9373235.html.plaintext.txt	493	Int J Immunopharmacol 17141 1995Medline Order article via Infotrieve 58
0.09784351.9373235.html.plaintext.txt	494	Mulcahy B Waldron Lynch F McDermott MF Adams C Amos CI Zhu DK Ward RH Clegg DO Shanahan F Molloy MG OGara F Genetic variability tumor necrosis factor lymphotoxin region influences susceptibility rheumatoid arthritis
0.09784351.9373235.html.plaintext.txt	495	Am J Hum Genet 59676 1996Medline Order article via Infotrieve 59
0.09784351.9373235.html.plaintext.txt	496	Verjans GM Messer G Weiss EH van der Linden SM Kijlstra A Polymorphism tumor necrosis factor region relation disease An overview
0.09784351.9373235.html.plaintext.txt	497	Rheum Dis Clin N Am 18177 1992Medline Order article via Infotrieve 60
0.09784351.9373235.html.plaintext.txt	498	Matsumoto M Mariathasan S Nahm MH Baranyay F Peschon JJ Chaplin DD Role lymphotoxin type I TNF receptor formation germinal centers
0.09784351.9373235.html.plaintext.txt	499	Science 2711289 1996Abstract 61
0.09784351.9373235.html.plaintext.txt	500	Matsumoto M Lo SF Carruthers CJ Min J Mariathasan S Huang G Plas DR Martin SM Geha RS Nahm MH Chaplin DD Affinity maturation without germinal centres lymphotoxin alpha deficient mice
0.09784351.9373235.html.plaintext.txt	501	Nature 382462 1996Medline Order article via Infotrieve 62
0.09784351.9373235.html.plaintext.txt	502	Pasparakis M Alexopoulou L Episkopou V Kollias G Immune inflammatory responses TNF alpha deficient mice A critical requirement TNF alpha formation primary B cell follicles follicular dendritic cell networks germinal centers maturation humoral immune response
0.09784351.9373235.html.plaintext.txt	503	Neumann B Luz A Pfeffer K Holzmann B Defective peyers patch organogenesis mice lacking 55 kd receptor tumor necrosis factor
0.09784351.9373235.html.plaintext.txt	504	J Exp Med 184259 1996Abstract 64
0.09784351.9373235.html.plaintext.txt	505	Armitage RJ Tumor necrosis factor receptor superfamily members ligands
0.09784351.9373235.html.plaintext.txt	506	Curr Opin Immunol 6407 1994Medline Order article via Infotrieve 65
0.09784351.9373235.html.plaintext.txt	507	Mackay F Majeau GR Hochman PS Browning JL Lymphotoxin beta receptor triggering induces activation nuclear factor beta b transcription factor cell types
0.09784351.9373235.html.plaintext.txt	508	J Biol Chem 27124934 1996AbstractFree Full Text 66
0.09784351.9373235.html.plaintext.txt	509	Holzinger I de Baey A Messer G Kick G Zwierzina H Weiss EH Cloning genomic characterization LST1 A new gene human TNF region
0.09784351.9373235.html.plaintext.txt	510	Immunogenetics 42315 1995Medline Order article via Infotrieve 67
0.09784351.9373235.html.plaintext.txt	511	Tsuge I Shen FW Steinmetz M Boyse EA A gene H 2SH 2D interval major histocompatibility complex transcribed B cells macrophages
0.09784351.9373235.html.plaintext.txt	512	Immunogenetics 26378 1987Medline Order article via Infotrieve 68
0.09784351.9373235.html.plaintext.txt	513	Nalabolu SR Shukla H Nallur G Parimoo S Weissman SM Genes 220 kb region spanning TNF cluster human MHC
0.09784351.9373235.html.plaintext.txt	514	Genomics 31215 1996Medline Order article via Infotrieve 69
0.09784351.9373235.html.plaintext.txt	515	Russell ME Wallace AF Hancock WW Sayegh MH Adams DH Sibinga NE Wyner LR Karnovsky MJ Upregulation cytokines associated macrophage activation Lewis F344 rat transplantation model chronic cardiac rejection
0.09784351.9373235.html.plaintext.txt	516	Transplantation 59572 1995Medline Order article via Infotrieve 70
0.09784351.9373235.html.plaintext.txt	517	Utans U Quist WC McManus BM Wilson JE Arceci RJ Wallace AF Russell ME Allograft inflammatory factory 1
0.09784351.9373235.html.plaintext.txt	518	A cytokine responsive macrophage molecule expressed transplanted human hearts
0.09784351.9373235.html.plaintext.txt	519	Transplantation 611387 1996Medline Order article via Infotrieve 71
0.09784351.9373235.html.plaintext.txt	520	Utans U Arceci RJ Yamashita Y Russell ME Cloning characterization allograft inflammatory factor 1 A novel macrophage factor identified rat cardiac allografts chronic rejection
0.09784351.9373235.html.plaintext.txt	521	J Clin Invest 952954 1995Medline Order article via Infotrieve 72
0.09784351.9373235.html.plaintext.txt	522	Utans U Liang P Wyner LR Karnovsky MJ Russell ME Chronic cardiac rejection Identification five upregulated genes transplanted hearts differential mRNA display
0.09784351.9373235.html.plaintext.txt	523	Proc Nat Acad Sci USA 916463 1994Abstract 73
0.09784351.9373235.html.plaintext.txt	524	Olavsen MG Thomson W Cheng J Campbell RD Characterization novel gene G1 class III region human MHA Tsuji K Aziawa M Sasazuki T eds Proceedings 11th International Histocompatibility Workshop vol 2
0.09784351.9373235.html.plaintext.txt	525	Oxford UK Oxford Press 1993 p 190 74
0.09784351.9373235.html.plaintext.txt	526	Hessian PA Edgeworth J Hogg N MRP 8 MRP 14 two abundant Ca2 binding proteins neutrophils monocytes
0.09784351.9373235.html.plaintext.txt	527	J Leukoc Biol 53197 1993Abstract 75
0.09784351.9373235.html.plaintext.txt	528	Devery JM King NJ Geczy CL Acute inflammatory activity S100 protein CP 10
0.09784351.9373235.html.plaintext.txt	529	Activation neutrophils vivo vitro
0.09784351.9373235.html.plaintext.txt	530	J Immunol 1521888 1994AbstractFree Full Text 76
0.09784351.9373235.html.plaintext.txt	531	Albertella MR Campbell RD Characterization novel gene human major histocompatibility complex encodes potential new member I kappa B family proteins
0.09784351.9373235.html.plaintext.txt	532	Hum Molec Genet 3793 1994Abstract 77
0.09784351.9373235.html.plaintext.txt	533	Dangel AW Shen L Mendoza AR Wu LC Yu CY Human helicase gene SKI2W HLA class III region exhibits striking structural similarities yeast antiviral gene SKI2 human gene KIAA0052 Emergence new gene family
0.09784351.9373235.html.plaintext.txt	534	Nucleic Acids Res 232120 1995Abstract 78
0.09784351.9373235.html.plaintext.txt	535	Albertella MR Jones H Thomson W Olavesen MG Campbell RD Localization eight additional genes human major histocompatibility complex including gene encoding casein kinase II beta subunit CSNK2B
0.09784351.9373235.html.plaintext.txt	536	Genomics 36240 1996Medline Order article via Infotrieve 79
0.09784351.9373235.html.plaintext.txt	537	Lee SG Lee I Park SH Kang C Song K Identification characterization human cDNA homologous yeast SKI2
0.09784351.9373235.html.plaintext.txt	538	Genomics 25660 1995Medline Order article via Infotrieve 80
0.09784351.9373235.html.plaintext.txt	539	Liang S Hitomi M Hu YH Liu Y Tartakoff AM A DEAD box family protein required nucleocytoplasmic transport yeast mRNA
0.09784351.9373235.html.plaintext.txt	540	Mol Cell Biol 165139 1996Abstract 81
0.09784351.9373235.html.plaintext.txt	541	Masison DC Blanc A Ribas JC Carroll K Sonenberg N Wickner RB Decoying cap mRNA degradation system double stranded RNA virus polyA mRNA surveillance yeast antiviral system
0.09784351.9373235.html.plaintext.txt	542	Mol Cell Biol 152763 1995Abstract 82
0.09784351.9373235.html.plaintext.txt	543	Widner WR Wickner RB Evidence SKI antiviral system Saccharomyces cerevisiae acts blocking expression viral mRNA
0.09784351.9373235.html.plaintext.txt	544	Mol Cell Biol 134331 1993Abstract 83
0.09784351.9373235.html.plaintext.txt	545	Johnson AW Kolodner RD Synthetic lethality sep1 xrn1 ski2 sep1 xrn1 ski3 mutants Saccharomyces cerevisiae independent killer virus suggests general role genes translation control
0.09784351.9373235.html.plaintext.txt	546	Mol Cell Biol 152719 1995Abstract 84
0.09784351.9373235.html.plaintext.txt	547	Bahram S Spies T The MIC gene family
0.09784351.9373235.html.plaintext.txt	548	Res Immunol 147328 1996Medline Order article via Infotrieve 85
0.09784351.9373235.html.plaintext.txt	549	Bahram S Bresnahan M Geraghty DE Spies T A second lineage mammalian major histocompatibility complex class I genes
0.09784351.9373235.html.plaintext.txt	550	Proc Nat Acad Sci USA 916259 1994Abstract 86
0.09784351.9373235.html.plaintext.txt	551	Groh V Bahram S Bauer S Herman A Beauchamp M Spies T Cell stress regulated human major histocompatibility complex class I gene expressed gastrointestinal epithelium
0.09784351.9373235.html.plaintext.txt	552	Proc Nat Acad Sci USA 9312445 1996AbstractFree Full Text 87
0.09784351.9373235.html.plaintext.txt	553	Peelman LJ Chardon P Nunes M Renard C Geffrotin C Vaiman M Van Zeveren A Coppieters W van de Weghe A Bouquet Y Choy WW Strominger JL Spies T The BAT1 gene MHC encodes evolutionarily conserved putative nuclear RNA helicase DEAD family
0.09784351.9373235.html.plaintext.txt	554	Genomics 26210 1995Medline Order article via Infotrieve 88
0.09784351.9373235.html.plaintext.txt	555	Snoek M Jansen M Olavesen MG Campbell RD Teuscher C van Vugt H Three Hsp70 genes located C4 H 2D region Possible candidates Orch 1 locus
0.09784351.9373235.html.plaintext.txt	556	Genomics 15350 1993Medline Order article via Infotrieve 89
0.09784351.9373235.html.plaintext.txt	557	Santoro MG Heat shock proteins virus replication hsp70s mediators antiviral effects prostaglandins
0.09784351.9373235.html.plaintext.txt	558	Experientia 501039 1994Medline Order article via Infotrieve 90
0.09784351.9373235.html.plaintext.txt	559	Hochstrasser M Protein degradation regulation Ub judge
0.09784351.9373235.html.plaintext.txt	560	Cell 84813 1996Medline Order article via Infotrieve 91
0.09784351.9373235.html.plaintext.txt	561	Haas AL Ahrens P Bright PM Ankel H Interferon induces 15 kilodalton protein exhibiting marked homology ubiquitin
0.09784351.9373235.html.plaintext.txt	562	J Biol Chem 26211315 1987AbstractFree Full Text 92
0.09784351.9373235.html.plaintext.txt	563	Feltham N Fahey D Knight E Jr A growth inhibitory protein secreted human diploid fibroblasts
0.09784351.9373235.html.plaintext.txt	564	Partial purification characterization
0.09784351.9373235.html.plaintext.txt	565	J Biol Chem 2622176 1987AbstractFree Full Text 93
0.09784351.9373235.html.plaintext.txt	566	Farrell PJ Broeze RJ Lengyel P Accumulation mRNA protein interferon treated Ehrlich ascites tumour cells
0.09784351.9373235.html.plaintext.txt	567	Nature 279523 1979Medline Order article via Infotrieve 94
0.09784351.9373235.html.plaintext.txt	568	Korant BD Blomstrom DC Jonak GJ Knight E Jr Interferon induced proteins
0.09784351.9373235.html.plaintext.txt	569	Purification characterization 15000 dalton protein human bovine cells induced interferon
0.09784351.9373235.html.plaintext.txt	570	J Biol Chem 25914835 1984AbstractFree Full Text 95
0.09784351.9373235.html.plaintext.txt	571	DCunha J Ramanujam S Wagner RJ Witt PL Knight E Borden EC In vitro vivo secretion human ISG15 IFN induced immunomodulatory cytokine
0.09784351.9373235.html.plaintext.txt	572	J Immunol 1574100 1996Abstract 96
0.09784351.9373235.html.plaintext.txt	573	Knight E Jr Fahey D Cordova B Hillman M Kutny R Reich N Blomstrom D A 15 kDa interferon induced protein derived COOH terminal processing 17 kDa precursor
0.09784351.9373235.html.plaintext.txt	574	J Biol Chem 2634520 1988AbstractFree Full Text 97
0.09784351.9373235.html.plaintext.txt	575	Recht M Borden EC Knight E Jr A human 15 kDa IFN induced protein induces secretion IFN gamma
0.09784351.9373235.html.plaintext.txt	576	J Immunol 1472617 1991AbstractFree Full Text 98
0.09784351.9373235.html.plaintext.txt	577	DCunha J Knight E Jr Haas AL Truitt RL Borden EC Immunoregulatory properties ISG15 interferon induced cytokine
0.09784351.9373235.html.plaintext.txt	578	Proc Nat Acad Sci USA 93211 1996AbstractFree Full Text 99
0.09784351.9373235.html.plaintext.txt	579	Nakamura M Ogawa H Tsunematsu T Characterization monoclonal nonspecific suppressor factor MNSF use monoclonal antibody
0.09784351.9373235.html.plaintext.txt	580	J Immunol 1381799 1987AbstractFree Full Text 100
0.09784351.9373235.html.plaintext.txt	581	Nakamura M Xavier RM Tanigawa Y Ubiquitin like moiety monoclonal nonspecific suppressor factor beta responsible activity
0.09784351.9373235.html.plaintext.txt	582	J Immunol 156532 1996Abstract 101
0.09784351.9373235.html.plaintext.txt	583	Vernet C Boretto J Mattei MG Takahashi M Jack LJ Mather IH Rouquier S Pontarotti P Evolutionary study multigenic families mapping close human MHC class I region
0.09784351.9373235.html.plaintext.txt	584	J Mol Evol 37600 1993Medline Order article via Infotrieve 102
0.09784351.9373235.html.plaintext.txt	585	Chu TW Capossela A Coleman R Goei VL Nallur G Gruen JR Cloning new finger protein gene ZNF173 within class I region human MHC
0.09784351.9373235.html.plaintext.txt	586	Genomics 29229 1995Medline Order article via Infotrieve 103
0.09784351.9373235.html.plaintext.txt	587	Pham Dinh D Mattei MG Nussbaum JL Roussel G Pontarotti P Roeckel N Mather IH Artzt K Lindahl KF Dautigny A Myelinoligodendrocyte glycoprotein member subset immunoglobulin superfamily encoded within major histocompatibility complex
0.09784351.9373235.html.plaintext.txt	588	Proc Nat Acad Sci USA 907990 1993AbstractFree Full Text 104
0.09784351.9373235.html.plaintext.txt	589	Fan W Liu YC Parimoo S Weissman SM Olfactory receptor like genes located human major histocompatibility complex
0.09784351.9373235.html.plaintext.txt	590	Genomics 27119 1995Medline Order article via Infotrieve 105
0.09784351.9373235.html.plaintext.txt	591	Janatipour M Naumov Y Ando A Sugimura K Okamoto N Tsuji K Abe K Inoko H Search MHC associated genes human Five new genes centromeric HLA DP yet unknown functions
0.09784351.9373235.html.plaintext.txt	592	Immunogenetics 35272 1992Medline Order article via Infotrieve 106
0.09784351.9373235.html.plaintext.txt	593	Aguado B Campbell RD The novel gene G17 located human major histocompatibility complex encodes PBX2 homeodomain containing protein
0.09784351.9373235.html.plaintext.txt	594	Genomics 25650 1995Medline Order article via Infotrieve 107
0.09784351.9373235.html.plaintext.txt	595	Kamps M Look T Baltimore D The human t1 19 translocation pre B ALL produces multiple nuclear E2A Pbx1 fusion proteins differing transforming potentials
0.09784351.9373235.html.plaintext.txt	596	Genes Dev 5358 1991Abstract 108
0.09784351.9373235.html.plaintext.txt	597	Lawrence H Sauvageau G Humphries R Largman C The role HOX homeobox genes normal leukemic hematopoiesis
0.09784351.9373235.html.plaintext.txt	598	Stem Cells 14281 1996Abstract 109
0.09784351.9373235.html.plaintext.txt	599	Porter RR The complement components coded major histocompatibility complexes biological activities
0.09784351.9373235.html.plaintext.txt	600	Immunol Rev 877 1985Medline Order article via Infotrieve 110
0.09784351.9373235.html.plaintext.txt	601	Huang MM Erlich HA Goodman MF Arnheim N Analysis mutational changes HLA locus single human sperm
0.09784351.9373235.html.plaintext.txt	602	Devlin JJ Weiss EH Paulson M Flavell RA Duplicated gene pairs alleles class I genes Qa2 region murine major histocompatibility complex A comparison
0.09784351.9373235.html.plaintext.txt	603	EMBO J 43203 1985Abstract 112
0.09784351.9373235.html.plaintext.txt	604	Slightom JL Blechl AE Smithies O Human fetal G gamma A gamma globin genes Complete nucleotide sequences suggest DNA exchanged duplicated genes
0.09784351.9373235.html.plaintext.txt	605	Cell 21627 1980Medline Order article via Infotrieve 113
0.09784351.9373235.html.plaintext.txt	606	Hughes AL Hughes MK Adaptive evolution rat olfactory receptor gene family
0.09784351.9373235.html.plaintext.txt	607	J Mol Evol 36249 1993Medline Order article via Infotrieve 114
0.09784351.9373235.html.plaintext.txt	608	Singer MS Weisingerlewin Y Lancet D Shepherd GM Positive selection moments identify potential functional residues human olfactory receptors
0.09784351.9373235.html.plaintext.txt	609	Recep Channels 4141 1996Medline Order article via Infotrieve 115
0.09784351.9373235.html.plaintext.txt	610	Hughes AL Rapid evolution immunoglobulin superfamily c2 domains expressed immune system cells
0.09784351.9373235.html.plaintext.txt	611	Mol Biol Evol 141 1997Abstract 116
0.09784351.9373235.html.plaintext.txt	612	Richman AD Uyenoyama MK Kohn JR Allelic diversity gene genealogy self incompatibility locus Solanaceae
0.09784351.9373235.html.plaintext.txt	613	Science 2731212 1996Abstract 117
0.09784351.9373235.html.plaintext.txt	614	Clark AG Kao TH Excess nonsynonymous substitution shared polymorphic sites among self incompatibility alleles Solanaceae
0.09784351.9373235.html.plaintext.txt	615	Proc Natl Acad Sci USA 889823 1991Abstract 118
0.09784351.9373235.html.plaintext.txt	616	Yamazaki K Beauchamp GK Shen FW Bard J Boyse EA A distinctive change odortype determined H 2DL mutation
0.09784351.9373235.html.plaintext.txt	617	Immunogenetics 34129 1991Medline Order article via Infotrieve 119
0.09784351.9373235.html.plaintext.txt	618	Gilbert AN Yamazaki K Beauchamp GK Thomas L Olfactory discrimination mouse strains Mus musculus major histocompatibility types humans Homo sapiens
0.09784351.9373235.html.plaintext.txt	619	J Comp Psychol 100262 1986Medline Order article via Infotrieve 120
0.09784351.9373235.html.plaintext.txt	620	Yamazaki K Beauchamp GK Kupniewski D Bard J Thomas L Boyse EA Familial imprinting determines H 2 selective mating preferences
0.09784351.9373235.html.plaintext.txt	621	Science 2401331 1988Medline Order article via Infotrieve 121
0.09784351.9373235.html.plaintext.txt	622	Wedekind C Seebeck T Bettens F Paepke AJ MHC dependent mate preferences humans
0.09784351.9373235.html.plaintext.txt	623	Proc R Soc London B Biol Sci 260245 1995Medline Order article via Infotrieve 122
0.09784351.9373235.html.plaintext.txt	624	Jin K Speed TP Thomson G Tests random mating highly polymorphic locus application HLA data
0.09784351.9373235.html.plaintext.txt	625	Biometrics 511064 1995Medline Order article via Infotrieve 123
0.09784351.9373235.html.plaintext.txt	626	Hughes AL Hughes MK Natural selection peptide binding regions major histocompatibility complex molecules
0.09784351.9373235.html.plaintext.txt	627	Immunogenetics 42233 1995Medline Order article via Infotrieve 124
0.09784351.9373235.html.plaintext.txt	628	Vanderhaeghen P Schurmans S Vassart G Parmentier M Specific repertoire olfactory receptor genes male germ cells several mammalian species
0.09784351.9373235.html.plaintext.txt	629	Jin K Ho HN Speed TP Gill TR Reproductive failure major histocompatibility complex
0.09784351.9373235.html.plaintext.txt	630	Am J Hum Genet 561456 1995Medline Order article via Infotrieve 126
0.09784351.9373235.html.plaintext.txt	631	Hoshiai H Ishikawa M Noda K Takahama K Fukaya T Yajima A Influence HLA antigens reproduction among Japanese population Study haplotypes 247 families
0.09784351.9373235.html.plaintext.txt	632	Berliner Munchener Tierarztliche Wochenschrift 172139 1994 127
0.09784351.9373235.html.plaintext.txt	633	Kostyu DD HLA Fertile territory developmental genes Crit Rev Immunol 1429 1994Medline Order article via Infotrieve 128
0.09784351.9373235.html.plaintext.txt	634	Ober C Current topic HLA reproduction Lessons studies Hutterites
0.09784351.9373235.html.plaintext.txt	635	Placenta 16569 1995Medline Order article via Infotrieve 129
0.09784351.9373235.html.plaintext.txt	636	Degos L Colombani J Chaventre A Bengtson B Jacquard A Selective pressure HL A polymorphism
0.09784351.9373235.html.plaintext.txt	637	Nature 24962 1974Medline Order article via Infotrieve 130
0.09784351.9373235.html.plaintext.txt	638	Klitz W Thomson G Borot N Chambon Thomsen A Evolutionary population perspectives human HLA complex
0.09784351.9373235.html.plaintext.txt	639	Hedrick PW Thomson G Maternal fetal interactions maintenance HLA polymorphism
0.09784351.9373235.html.plaintext.txt	640	Genetics 119205 1988AbstractFree Full Text 132
0.09784351.9373235.html.plaintext.txt	641	Dawson DV Ober C Kostyu DD Extended HLA profile inbred isolate The Schmiedeleut Hutterites South Dakota
0.09784351.9373235.html.plaintext.txt	642	Genet Epidemiol 1247 1995Medline Order article via Infotrieve 133
0.09784351.9373235.html.plaintext.txt	643	Black FL Mother child HLA compatibility ratios children Amerinidian parents share common haplotypes
0.09784351.9373235.html.plaintext.txt	644	Am J Hum Genet 37133 1985Medline Order article via Infotrieve 134
0.09784351.9373235.html.plaintext.txt	645	Hedrick PW Evolution HLA Possible explanations deficiency homozygotes two populations
0.09784351.9373235.html.plaintext.txt	646	Hum Hered 40213 1990Medline Order article via Infotrieve 135
0.09784351.9373235.html.plaintext.txt	647	Chu TW Bowlus CL Gruen JR Disorders iron metabolism related disorders Rimoin DL Connor JM Pyeritz RE Emery AEH eds Emery Rimoins Principles Practice Medical Genetics ed 3
0.09784351.9373235.html.plaintext.txt	648	Edinburgh UK Churchill Livingston 1997 p 2047 136
0.09784351.9373235.html.plaintext.txt	649	Feder JN Gnirke A Thomas W Tsuchihashi Z Ruddy DA Basava A Dormishian F Domingo R Jr
0.09784351.9373235.html.plaintext.txt	650	Ellis MC Fullan A Hinton LM Jones NL Kimmel BE Kronmal GS Lauer P Lee VK Loeb DB Mapa FA McClelland E Meyer NC Mintier GA Moeller N Moore T Morikang E Wolff RR Prass CE Quintana L Starnes SM Schatzman RE Brunke KJ Drayna DT Risch NJ Bacon BR Wolff RK A novel MHC class I like gene mutated patients hereditary haemochromatosis
0.09784351.9373235.html.plaintext.txt	651	Nat Genet 13399 1996Medline Order article via Infotrieve 137
0.09784351.9373235.html.plaintext.txt	652	Rothenberg BE Voland JR Beta2 knockout mice develop parenchymal iron overload A putative role class I genes major histocompatibility complex iron metabolism
0.09784351.9373235.html.plaintext.txt	653	Proc Nat Acad Sci USA 931529 1996AbstractFree Full Text 138
0.09784351.9373235.html.plaintext.txt	654	Simon M Alexandre JL Fauchet R Genetet B Bourel M The genetics hemochromatosis
0.09784351.9373235.html.plaintext.txt	655	Prog Med Genet 4135 1980Medline Order article via Infotrieve 139
0.09784351.9373235.html.plaintext.txt	656	Kravitz K Skolnick M Cannings C Carmelli D Baty B Amos DB Johnsson A Mendell N Edwards C Cartwright G Genetic linkage hereditary hemochromatosis HLA
0.09784351.9373235.html.plaintext.txt	657	Am J Hum Genet 31601 1979Medline Order article via Infotrieve 140
0.09784351.9373235.html.plaintext.txt	658	Jazwinska EC Lee SC Webb SI Halliday JW Powell LW Localization hemochromatosis gene close D6S105
0.09784351.9373235.html.plaintext.txt	659	Am J Hum Genet 53347 1993Medline Order article via Infotrieve 141
0.09784351.9373235.html.plaintext.txt	660	Raha Chowdhury R Bowen DJ Stone C Pointon JJ Terwilliger JD Shearman JD Robson KJH Bomford A Worwood M New polymorphic microsatellite markers place haemochromatosis gene telomeric D6S105
0.09784351.9373235.html.plaintext.txt	661	Hum Mol Genet 41869 1995Abstract 142
0.09784351.9373235.html.plaintext.txt	662	Gandon G Jouanolle AM Chauvel B Mauvieux V le Treut A Feingold J Le Gall JY David V Yaouanq J Linkage disequilibrium extended haplotypes HLA A D6S105 region Implications mapping hemochromatosis gene HFE
0.09784351.9373235.html.plaintext.txt	663	Hum Genet 97103 1996Medline Order article via Infotrieve 143
0.09784351.9373235.html.plaintext.txt	664	Yaouanq J Perichon M Chorney M Pontarotti P Le Treut A El Kahloun A Mauvieux V Blayau M Jouanolle AM Chauvel B Moirand R Nouel O Le Gall JY Feingold J David V Anonymous marker loci within 400 kb HLA A generate haplotypes linkage disequilibrium hemochromatosis gene HFE
0.09784351.9373235.html.plaintext.txt	665	Am J Hum Genet 54252 1994Medline Order article via Infotrieve 144
0.09784351.9373235.html.plaintext.txt	666	Raha Chowdhury R Bowen DJ Burnett AK Worwood M Allelic associations homozygosity loci HLA B D6S299 genetic haemochromatosis
0.09784351.9373235.html.plaintext.txt	667	J Med Genet 32446 1995Abstract 145
0.09784351.9373235.html.plaintext.txt	668	Hastbacka J de la Chapelle A Kaitila I Sistonen P Weaver A Lander E Linkage disequilibrium mapping isolated founder populations Diastrophic dysplasia Finland
0.09784351.9373235.html.plaintext.txt	669	Nat Genet 2204 1992Medline Order article via Infotrieve 146
0.09784351.9373235.html.plaintext.txt	670	Jazwinska EC Cullen LM Busfield F Pyper WR Webb SI Powell LW Morris CP Walsh TP Haemochromatosis HLA H
0.09784351.9373235.html.plaintext.txt	671	Nat Genet 14249 1996Medline Order article via Infotrieve 147
0.09784351.9373235.html.plaintext.txt	672	Pippard MJ Detection iron overload
0.09784351.9373235.html.plaintext.txt	673	Lancet 34973 1997Medline Order article via Infotrieve 148
0.09784351.9373235.html.plaintext.txt	674	Moirand R Mortaji AM Loreal O Paillard F Brissot P Deugnier Y A new syndrome liver iron overload normal transferrin saturation
0.09784351.9373235.html.plaintext.txt	675	Lancet 34995 1997Medline Order article via Infotrieve 149
0.09784351.9373235.html.plaintext.txt	676	Thomsen M Neubegauer M Arnaud J Borot N Sevooon A Baur M Cambon Thomsen M Recombination fractions HLA system based data set Provinces Francasises Indications haplotype specific recombination rates
0.09784351.9373235.html.plaintext.txt	677	Eur J Immunogenet 2133 1994Medline Order article via Infotrieve 150
0.09784351.9373235.html.plaintext.txt	678	Shiroishi T Koide T Yoshino M Sagai T Moriwaki K Hotspots homologous recombination mouse meiosis
0.09784351.9373235.html.plaintext.txt	679	Adv Biophys 31119 1995Medline Order article via Infotrieve 151
0.09784351.9373235.html.plaintext.txt	680	Dib C Faure S Fizames C Samson D Drouot N Vignal A Millasseau P Marc S Hazan J Seboun E Lathrop M Gyapay G Morissette J Weissenbach J A comprehensive genetic map human genome based 5264 microsatellites
0.09784351.9373235.html.plaintext.txt	681	Nature 380152 1996Medline Order article via Infotrieve 152
0.09784351.9373235.html.plaintext.txt	682	Cullen M Erlich H Klitz W Carrington M Molecular mapping recombination hotspot located second intron human TAP2 locus
0.09784351.9373235.html.plaintext.txt	683	Am J Hum Genet 561350 1995Medline Order article via Infotrieve 153
0.09784351.9373235.html.plaintext.txt	684	Yoshino M Sagai T Lindahl KF Toyoda Y Shirayoshi Y Matsumoto K Sugaya K Ikemura T Moriwaki K Shiroishi T Recombination class III region mouse major histocompatibility complex
0.09784351.9373235.html.plaintext.txt	685	Immunogenetics 40280 1994Medline Order article via Infotrieve 154
0.09784351.9373235.html.plaintext.txt	686	Yoshino M Sagai T Moriwaki K Shiroishi T Meiotic recombination Lmp2 hotspot tolerates minor sequence divergence homologous chromosomes
0.09784351.9373235.html.plaintext.txt	687	Immunogenetics 4380 1996Medline Order article via Infotrieve 155
0.09784351.9373235.html.plaintext.txt	688	Yoshino M Sagai T Lindahl KF Toyoda Y Moriwaki K Shiroishi T Allele dependent recombination frequency Homology requirement meiotic recombination hot spot mouse major histocompatibility complex
0.09784351.9373235.html.plaintext.txt	689	Genomics 27298 1995Medline Order article via Infotrieve 156
0.09784351.9373235.html.plaintext.txt	690	Wu XH Haber JE A 700 bp cis acting region controls mating type dependent recombination along entire left arm yeast chromosome III
0.09784351.9373235.html.plaintext.txt	691	Cell 87277 1996Medline Order article via Infotrieve 157
0.09784351.9373235.html.plaintext.txt	692	Katsanis N Fitzgibbon J Fisher E Paralogy mapping Identification region human MHC triplicated onto human chromosomes 1 9 allows prediction isolation novel PBX NOTCH loci
0.09784351.9373235.html.plaintext.txt	693	Genomics 35101 1996Medline Order article via Infotrieve 158
0.09784351.9373235.html.plaintext.txt	694	Hashimoto K Hirai M Kurosawa Y A gene outside human MHC related classical HLA class I genes
0.09784351.9373235.html.plaintext.txt	695	Science 269693 1995Medline Order article via Infotrieve 159
0.09784351.9373235.html.plaintext.txt	696	Venditti CP Chorney MJ Class I gene contraction within HLA A subregion human MHC
0.09784351.9373235.html.plaintext.txt	697	Genomics 141003 1992Medline Order article via Infotrieve 160
0.09784351.9373235.html.plaintext.txt	698	Schmidt CM Orr HT HLA G transgenic mice A model studying expression function maternalfetal interface
0.09784351.9373235.html.plaintext.txt	699	Immunol Rev 14753 1995Medline Order article via Infotrieve 161
0.09784351.9373235.html.plaintext.txt	700	Geraghty DE Koller BH Hansen JA Orr HT The HLA class I gene family includes least six genes twelve pseudogenes gene fragments
0.09784351.9373235.html.plaintext.txt	701	J Immunol 1491934 1992AbstractFree Full Text 162
0.09784351.9373235.html.plaintext.txt	702	Abdulla S Alderton RP Glynne RJ Gut IG Hosking LK Jackson A Kelly A Newell WR Radley E Sanseau P Thorpe KL Trowsdale J Beck S DNA sequencing MHC class II region chromosome 6 sequencing effort Sanger Centre
0.09784351.9373235.html.plaintext.txt	703	DNA Sequence 75 1996Medline Order article via Infotrieve 163
0.09784351.9373235.html.plaintext.txt	704	Fischer Lindahl K Hermel E Loveland BE Wang CR Maternally transmitted antigen mice A model transplantation antigen
0.09784351.9373235.html.plaintext.txt	705	Annu Rev Immunol 9351 1991Medline Order article via Infotrieve 164
0.09784351.9373235.html.plaintext.txt	706	Heinrichs H Orr HT HLA non A B C class I genes Their structure expression
0.09784351.9373235.html.plaintext.txt	707	Immunol Res 9265 1990Medline Order article via Infotrieve 165
0.09784351.9373235.html.plaintext.txt	708	Kovats S Main EK Librach C Stubblebine M Fisher SJ DeMars R A class I antigen HLA G expressed human trophoblasts
0.09784351.9373235.html.plaintext.txt	709	Science 248220 1990Medline Order article via Infotrieve 166
0.09784351.9373235.html.plaintext.txt	710	Pazmany L Mandelboim O Valesgomez M Davis DM Reyburn HT Strominger JL Protection natural killer cell mediated lysis HLA G expression target cells
0.09784351.9373235.html.plaintext.txt	711	Science 274792 1996AbstractFree Full Text 167
0.09784351.9373235.html.plaintext.txt	712	Jurisicova A Casper RF MacLusky NJ Mills GB Librach CL HLA G expression preimplantation human embryo development
0.09784351.9373235.html.plaintext.txt	713	Proc Nat Acad Sci USA 93161 1996AbstractFree Full Text 168
0.09784351.9373235.html.plaintext.txt	714	Pichon L Hampe A Giffon T Carn G Legall JY David V A new non HLA multigene family associated PERB11 family within MHC class I region
0.09784351.9373235.html.plaintext.txt	715	Immunogenetics 44259 1996Medline Order article via Infotrieve 169
0.09784351.9373235.html.plaintext.txt	716	Jones EP Xiao H Schultz RA Flaherty L Trachtulec Z Vincek V Larin Z Lehrach H Lindahl KF MHC class I gene organization 1
0.09784351.9373235.html.plaintext.txt	717	5 Mb YAC contigs H2 M region
0.09784351.9373235.html.plaintext.txt	718	Genomics 2740 1995Medline Order article via Infotrieve 170
0.09784351.9373235.html.plaintext.txt	719	Amadou C Ribouchon MT Mattei MG Jenkins NA Gilbert DJ Copeland NG Avoustin P Pontarotti P Localization new genes markers distal part human major histocompatibility complex MHC region comparison mouse New insights evolution mammalian genomes
0.09784351.9373235.html.plaintext.txt	720	Genomics 269 1995Medline Order article via Infotrieve 171
0.09784351.9373235.html.plaintext.txt	721	Franklin I Lewontin RC Is gene unit selection Genetics 65707 1970Free Full Text 172
0.09784351.9373235.html.plaintext.txt	722	Von Recklinghausen FD Uber Haemochromatose
0.09784351.9373235.html.plaintext.txt	723	Berl Klin Wschr 26925 1899 173
0.09784351.9373235.html.plaintext.txt	724	Ortmann B Copeman J Lehner PJ Sadasivan B Herberg JA Grandea AG Riddell SR Tampe R Spies T Trowsdale T Cresswell P A critical role tapasin assembly function multimeric MHC class I TAP complexes
0.09784351.9373235.html.plaintext.txt	725	Science 2771306 1997AbstractFree Full Text 1997 The American Society Hematology
0.11980948.12663466.html.plaintext.txt	0	Ghrelin Directly Interacts With Neuropeptide Y Containing Neurons Rat Arcuate Nucleus Ca2 Signaling via Protein Kinase A N Type Channel Dependent Mechanisms Cross Talk With Leptin Orexin Daisuke Kohno12 Hong Zhi Gao13 Shinji Muroya14 Sakae Kikuyama2 Toshihiko Yada1
0.11980948.12663466.html.plaintext.txt	1	1 Department Physiology Jichi Medical School School Medicine Minamikawachi Tochigi Japan 2 Department Biology School Education Waseda University Nishi Waseda Shinjuku ku Tokyo Japan 3 Department Anatomy School Medicine Kagoshima University Kagoshima Japan 4 Department Psychiatry Kagoshima University School Medicine Kagoshima Japan
0.11980948.12663466.html.plaintext.txt	2	ABSTRACT TOP ABSTRACT RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES Ghrelin newly discovered peptide released stomach neurons hypothalamic arcuate nucleus ARC potently stimulates growth hormone release food intake
0.11980948.12663466.html.plaintext.txt	3	Neuropeptide Y NPY neurons ARC play important role stimulation food intake
0.11980948.12663466.html.plaintext.txt	4	The present study aimed determine whether ghrelin directly activates NPY neurons explore signaling mechanisms
0.11980948.12663466.html.plaintext.txt	5	Whether neurons respond ghrelin could regulated orexin leptin also examined
0.11980948.12663466.html.plaintext.txt	6	We isolated single neurons ARC rats measured cytosolic Ca2 concentration Ca2i fura 2 fluorescence imaging
0.11980948.12663466.html.plaintext.txt	7	Ghrelin 10 12 10 8 moll concentration dependently increased Ca2i occurred 35 ARC neurons
0.11980948.12663466.html.plaintext.txt	8	Approximately 80 ghrelin responsive neurons proved NPY containing immunocytochemical staining 58 glucose sensitive neurons judged responses lowering glucose concentrations
0.11980948.12663466.html.plaintext.txt	9	The Ca2i responses ghrelin markedly attenuated inhibitors protein kinase A PKA protein kinase C blocker N type L type Ca2 channels
0.11980948.12663466.html.plaintext.txt	10	Orexin increased Ca2i leptin attenuated ghrelin induced Ca2i increases majority 80 ghrelin responsive NPY neurons
0.11980948.12663466.html.plaintext.txt	11	These results demonstrate ghrelin directly interacts NPY neurons ARC induce Ca2 signaling via PKA N type Ca2 channel dependent mechanisms
0.11980948.12663466.html.plaintext.txt	12	The integration stimulatory effects ghrelin orexin inhibitory effect leptin may play important role regulation activity NPY neurons thereby feeding
0.11980948.12663466.html.plaintext.txt	13	Ghrelin endogenous ligand growth hormone secretagogue GHS receptor GHSR synthesized abundantly stomach much lesser extent hypothalamic arcuate nucleus ARC 1
0.11980948.12663466.html.plaintext.txt	14	Peripheral intracerebroventricular ICV injection ghrelin releases growth hormone stimulates food intake increases body weight mice rats humans 1 8
0.11980948.12663466.html.plaintext.txt	15	ICV injection antighrelin IgG suppresses starvation induced feeding 3
0.11980948.12663466.html.plaintext.txt	16	The daily pattern plasma ghrelin levels normal humans characterized preprandial rise postprandial fall 9
0.11980948.12663466.html.plaintext.txt	17	These findings suggested ghrelin plays physiological role meal initiation
0.11980948.12663466.html.plaintext.txt	18	The neuropeptide Y NPY containing neurons localized ARC implicated stimulation food intake injection NPY hypothalamus rats potently stimulates food intake 10 NPY secretion hypothalamus increased fasting 11
0.11980948.12663466.html.plaintext.txt	19	Regarding possible link ghrelin NPY neurons ARC shown GHSR mRNA expressed 94 NPY neurons ARC double labeling situ hybridization histochemistry 12
0.11980948.12663466.html.plaintext.txt	20	Systemic ICV administration ghrelin causes ARC neurons express Fos Egr 1 313 15 90 Fos positive neurons express NPY mRNA 13
0.11980948.12663466.html.plaintext.txt	21	Moreover ghrelin increases expression NPY mRNA 3 5 ICV administration NPY Y1 antagonist suppresses ghrelin stimulated food intake 3 515
0.11980948.12663466.html.plaintext.txt	22	These findings suggest NPY neurons ARC could important effector orexigenic action ghrelin
0.11980948.12663466.html.plaintext.txt	23	The second messenger systems GHSR fully elucidated
0.11980948.12663466.html.plaintext.txt	24	Signaling pathways artificial GHS act GHSR pituitary cells investigated
0.11980948.12663466.html.plaintext.txt	25	GHRP 2 GHS increases intracellular cAMP levels ovine rat pituitary somatotropes 1617
0.11980948.12663466.html.plaintext.txt	26	GHRP 6 stimulates GH release rat pituitary cells activating protein kinase C PKC 1718
0.11980948.12663466.html.plaintext.txt	27	Thus post GHSR pathway could involve Gs andor Gq proteins
0.11980948.12663466.html.plaintext.txt	28	However intracellular signaling ghrelin orexigenic action effector neurons well understood
0.11980948.12663466.html.plaintext.txt	29	Therefore first aim present study examine whether ghrelin directly interacts NPY neurons ARC explore signal transduction mechanisms special attention toward Ca2 signaling
0.11980948.12663466.html.plaintext.txt	30	Leptin adipocyte derived potent anorexic peptide
0.11980948.12663466.html.plaintext.txt	31	The leptin receptor present NPY neurons ARC leptin exerts anorexic effect partly suppression NPY neurons 19
0.11980948.12663466.html.plaintext.txt	32	Coinjection leptin decreases stimulatory effect ghrelin feeding free fed rats 3
0.11980948.12663466.html.plaintext.txt	33	Orexin A B orexigenic peptides produced cell bodies located lateral hypothalamus 20
0.11980948.12663466.html.plaintext.txt	34	The orexin 1 receptor localized NPY containing neurons ARC 21 orexin induced feeding inhibited NPY Y1 andor Y5 receptor antagonists 22 24 suggesting orexin could elicit feeding via NPY neurons
0.11980948.12663466.html.plaintext.txt	35	Therefore second aim present study examine whether subset NPY neurons ARC could serve common target ghrelin leptin orexins
0.11980948.12663466.html.plaintext.txt	36	We found ghrelin increases Ca2i 80 NPY neurons via mechanisms involving protein kinase A PKA N type Ca2 channels majority ghrelin activated NPY neurons also regulated orexin A leptin
0.11980948.12663466.html.plaintext.txt	37	RESEARCH DESIGN AND METHODS TOP ABSTRACT RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES Animals preparation single neurons ARC
0.11980948.12663466.html.plaintext.txt	38	Adult male Sprague Dawley SD rats maintained 12 h lightdark cycle given conventional food water ad libitum
0.11980948.12663466.html.plaintext.txt	39	The ARC isolated brain 5 7 week old SD rats single neurons prepared according procedures reported previously 2526 slight modifications
0.11980948.12663466.html.plaintext.txt	40	Briefly rats anesthetized intraperitoneal injection carbamic acid ethyl ester 900 mgkg decapitated brain removed
0.11980948.12663466.html.plaintext.txt	41	Brain slices containing ARC prepared whole ARC left right sides punched
0.11980948.12663466.html.plaintext.txt	42	The dissected tissues washed 10 mmoll HEPES buffered Krebs Ringer bicarbonate buffer HKRB containing 10 mmoll glucose
0.11980948.12663466.html.plaintext.txt	43	Then incubated HKRB supplemented 20 unitsml papain Sigma Chemical St
0.11980948.12663466.html.plaintext.txt	44	015 mgml deoxyribonuclease 0
0.11980948.12663466.html.plaintext.txt	45	75 mgml BSA 15 min 36 degrees C shaking water bath followed gentle mechanical trituration 5 10 min
0.11980948.12663466.html.plaintext.txt	46	After trituration cell suspension centrifuged 100g 5 min
0.11980948.12663466.html.plaintext.txt	47	The pellet resuspended HKRB distributed onto coverslips
0.11980948.12663466.html.plaintext.txt	48	The cells kept 18 degrees C moisture saturated dishes 10 h
0.11980948.12663466.html.plaintext.txt	49	The animal protocols approved Jichi Medical School Institute Animal Care Use Committee accord Japanese Physiological Society guidelines animal care
0.11980948.12663466.html.plaintext.txt	50	Measurements Ca2i single ARC neurons
0.11980948.12663466.html.plaintext.txt	51	At 2 12 h cell preparation Ca2i measured radiometric fura 2 microfluorometry combination digital imaging previously reported 2526
0.11980948.12663466.html.plaintext.txt	52	Briefly following incubation 2 micromoll fura 2AM Dojin Chemical Kumamoto Japan 1 h 18 degrees C cells mounted chamber superfused HKRB 1 mlmin 33 degrees C
0.11980948.12663466.html.plaintext.txt	53	Fluorescence images due excitation 340 380 nm detected every 8
0.11980948.12663466.html.plaintext.txt	54	0 intensified charge coupled device ICCD camera ratio image produced Argus 50 system Hamamatsu Photonics Hamamatsu Japan
0.11980948.12663466.html.plaintext.txt	55	Ratio values converted Ca2i according calibration curves 27
0.11980948.12663466.html.plaintext.txt	56	All agents dissolved DMSO distilled water stock diluted superfusate HKRB le11000
0.11980948.12663466.html.plaintext.txt	57	1 DMSO administered alone effect Ca2i ARC neurons
0.11980948.12663466.html.plaintext.txt	58	Data taken cells identified neurons procedures reported previously 2526
0.11980948.12663466.html.plaintext.txt	59	Briefly single cells immunoreactive microtubule associated protein 2 neuron specific marker showed relatively large diameter 10 microm clear round nuclei phase contrast microscope
0.11980948.12663466.html.plaintext.txt	60	Data taken cells fulfilled criteria neurons
0.11980948.12663466.html.plaintext.txt	61	Immunocytochemistry identification NPY neurons
0.11980948.12663466.html.plaintext.txt	62	After Ca2i measurement cells fixed 4 paraformaldehyde overnight
0.11980948.12663466.html.plaintext.txt	63	They incubated first rabbit antiserum NPY DiaSorin Stillwater MN dilution 110000 24 h 4 degrees C followed biotinylated antibodies raised rabbit IgG Vector Laboratories Burlingame CA diluted 200 fold 1 h avidin peroxidase complex Vector 1 h
0.11980948.12663466.html.plaintext.txt	64	The sections developed 33 diaminobenzidine
0.11980948.12663466.html.plaintext.txt	65	Control experiments carried omitting primary antiserum
0.11980948.12663466.html.plaintext.txt	66	Correlation Ca2i immunocytochemical data performed procedure reported previously 25 27
0.11980948.12663466.html.plaintext.txt	67	In brief end Ca2i imaging took phase contrast photographs cells microscopic field subjected Ca2i measurements
0.11980948.12663466.html.plaintext.txt	68	Based photographs cells Ca2i recorded correlated corresponding immunocytochemical results
0.11980948.12663466.html.plaintext.txt	69	Criteria Ca2i responses inhibition determination response amplitude
0.11980948.12663466.html.plaintext.txt	70	Ghrelin forskolin 12 0 tetradecanoylphorbol 13 acetate TPA orexin administered 4 5 min 20 min superfusion solution
0.11980948.12663466.html.plaintext.txt	71	Amplitudes Ca2i increases response agents calculated subtracting prestimulatory basal Ca2i levels peak Ca2i levels
0.11980948.12663466.html.plaintext.txt	72	When increases Ca2i took place within 5 min addition agents amplitudes 150 nmoll larger considered responses
0.11980948.12663466.html.plaintext.txt	73	Repetitive additions ghrelin twice induced repeated Ca2i increases
0.11980948.12663466.html.plaintext.txt	74	Therefore test effects drugs second challenge ghrelin performed presence drugs
0.11980948.12663466.html.plaintext.txt	75	Alternatively pretreatment neurons drugs performed second challenge ghrelin
0.11980948.12663466.html.plaintext.txt	76	When amplitude Ca2i response second addition ghrelin reduced le40 compared control Ca2i response first addition ghrelin without drugs considered inhibition
0.11980948.12663466.html.plaintext.txt	77	The measurements carried HKRB solution composed 129 mmoll NaCl 5
0.11980948.12663466.html.plaintext.txt	78	2 mmoll MgSO4 10 mmoll HEPES pH 7
0.11980948.12663466.html.plaintext.txt	79	Kangawa later obtained Peptide Institute Osaka Japan
0.11980948.12663466.html.plaintext.txt	80	Conotoxin GVIA orexin A obtained Peptide Institute
0.11980948.12663466.html.plaintext.txt	81	Fura 2 acetoxymethylester Dojin Chemical Kumamoto Japan nitrendipine Yoshitomi Pharmaceutical Industries Osaka Japan H89 H85 Seikagaku Tokyo Japan calphostin C bisindolylmaleimide I Calbiochem La Jolla CA
0.11980948.12663466.html.plaintext.txt	82	All chemicals Sigma
0.11980948.12663466.html.plaintext.txt	83	Data presentation statistical analysis
0.11980948.12663466.html.plaintext.txt	84	The data presented mean plus minus SE n number neurons
0.11980948.12663466.html.plaintext.txt	85	Each study based least seven neurons prepared least three rats
0.11980948.12663466.html.plaintext.txt	86	A total 535 neurons examined
0.11980948.12663466.html.plaintext.txt	87	Student paired unpaired test used evaluate differences values P 0
0.11980948.12663466.html.plaintext.txt	88	RESULTS TOP ABSTRACT RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES Ghrelin increases Ca2i ARC neurons major populations NPY neurons glucose sensitive neurons
0.11980948.12663466.html.plaintext.txt	89	Single neurons isolated ARC superfused HKRB subjected Ca2i measurements fura 2 fluorescence imaging
0.11980948.12663466.html.plaintext.txt	90	The addition ghrelin 10 10 moll 4 5 min superfusion solution increased Ca2i 114 330 neurons examined 35 Fig
0.11980948.12663466.html.plaintext.txt	91	In randomly selected responsive neurons peak Ca2i responses significantly higher basal Ca2i peak Ca2i 485
0.11980948.12663466.html.plaintext.txt	92	The ghrelin induced Ca2i increase took place long lasting 7 30 min manner majority neurons Fig
0.11980948.12663466.html.plaintext.txt	93	Among 59 neurons responded ghrelin 48 neurons 81 proved NPY containing subsequent immunocytochemical staining using anti NPY antibody Fig
0.11980948.12663466.html.plaintext.txt	94	On hand among 14 neurons responded ghrelin 8 neurons 58 exhibited Ca2i increases response lowering glucose concentration 10 2
0.11980948.12663466.html.plaintext.txt	95	8 mmoll thus showing glucose sensitive neurons Fig
0.11980948.12663466.html.plaintext.txt	96	These results indicate ghrelin directly targets NPY neuron glucose sensitive neuron ARC former constitutes dominant population 81 among ghrelin responsive neurons
0.11980948.12663466.html.plaintext.txt	97	View larger version 27K FIG
0.11980948.12663466.html.plaintext.txt	98	Ghrelin increases Ca2i NPY neurons ARC
0.11980948.12663466.html.plaintext.txt	99	A B Ghrelin 10 10 moll increased Ca2i single ARC neuron A proved NPY containing subsequent immunocytochemical staining anti NPY antibody arrow B
0.11980948.12663466.html.plaintext.txt	100	The bar tracing specifies period exposure ghrelin
0.11980948.12663466.html.plaintext.txt	101	Glucose concentration 10 mmoll throughout measurement
0.11980948.12663466.html.plaintext.txt	102	C Among 59 neurons exhibited Ca2i increases response ghrelin 48 neurons 81 NPY containing neurons
0.11980948.12663466.html.plaintext.txt	103	View larger version 20K FIG
0.11980948.12663466.html.plaintext.txt	104	Ghrelin increases Ca2i glucose sensitive neurons ARC
0.11980948.12663466.html.plaintext.txt	105	A Ghrelin responsive neurons exhibited Ca2i increases response lowering glucose concentration 10 2
0.11980948.12663466.html.plaintext.txt	106	8 mmoll showing glucose sensitive neurons
0.11980948.12663466.html.plaintext.txt	107	The result shown representative eight neurons ARC n 8
0.11980948.12663466.html.plaintext.txt	108	The bars tracing specify periods exposure agents indicated
0.11980948.12663466.html.plaintext.txt	109	Unless otherwise specified glucose concentration 10 mmoll
0.11980948.12663466.html.plaintext.txt	110	B Among 14 neurons responded ghrelin 8 neurons 57 glucose sensitive neurons
0.11980948.12663466.html.plaintext.txt	111	Concentration dependent effects ghrelin increase Ca2i
0.11980948.12663466.html.plaintext.txt	112	Ghrelin concentration range 10 14 10 8 moll administered single ARC neurons
0.11980948.12663466.html.plaintext.txt	113	Ghrelin 10 14 moll increased Ca2i none 32 neurons 0 10 12 moll 8 38 neurons 21 10 10 moll 114 330 neurons 35 10 8 moll 16 39 neurons 41 showing concentration dependent effect Fig
0.11980948.12663466.html.plaintext.txt	114	In neuron exemplified Fig
0.11980948.12663466.html.plaintext.txt	115	3A 10 10 moll ghrelin induced oscillatory Ca2i increase 10 8 moll ghrelin sustained Ca2i increase larger amplitude
0.11980948.12663466.html.plaintext.txt	116	View larger version 17K FIG
0.11980948.12663466.html.plaintext.txt	117	Concentration dependent effects ghrelin increase Ca2i ARC neurons
0.11980948.12663466.html.plaintext.txt	118	A Sequential addition ghrelin 10 10 moll 10 8 moll increased Ca2i ARC neuron
0.11980948.12663466.html.plaintext.txt	119	B Concentration response relationship
0.11980948.12663466.html.plaintext.txt	120	Response expressed percentage cells exhibited Ca2i increases response ghrelin
0.11980948.12663466.html.plaintext.txt	121	The numbers point indicate number neurons responded number neurons examined
0.11980948.12663466.html.plaintext.txt	122	Inhibition ghrelin induced Ca2i increases Ca2 free condition N type Ca2 channel blocker
0.11980948.12663466.html.plaintext.txt	123	The second addition ghrelin neuron carried absence Ca2 presence drugs
0.11980948.12663466.html.plaintext.txt	124	In Ca2 free condition added Ca2 0
0.11980948.12663466.html.plaintext.txt	125	1 mmoll EGTA Ca2i increase response ghrelin abolished seven neurons Fig
0.11980948.12663466.html.plaintext.txt	126	4A E F bringing Ca2 back HKRB Ca2i response ghrelin restored showing inhibition reversible
0.11980948.12663466.html.plaintext.txt	127	The ghrelin induced Ca2i increase also inhibited N type Ca2 channel blocker conotoxin GIVA 500 nmoll reversible manner 12 13 neurons Fig
0.11980948.12663466.html.plaintext.txt	128	4B E mean amplitude Ca2i increase Ca2i Amp significantly reduced compared response second addition ghrelin without blocker control 51
0.11980948.12663466.html.plaintext.txt	129	3 nmoll 9 control P 0
0.11980948.12663466.html.plaintext.txt	130	In contrast L type Ca2 channel blocker nitrendipine 2 micromoll failed affect ghrelin induced Ca2i increase majority neurons n 12 suppressed response minor fraction neurons n 5 Ca2i Amp 259
0.11980948.12663466.html.plaintext.txt	131	A blocker endoplasmic reticulum ER Ca2 pump thapsigargin 1 micromoll effect ghrelin induced Ca2i increase Ca2i Amp 418
0.11980948.12663466.html.plaintext.txt	132	8 nmoll 9 moderately elevated basal Ca2i Fig
0.11980948.12663466.html.plaintext.txt	133	View larger version 35K FIG
0.11980948.12663466.html.plaintext.txt	134	Ghrelin induced Ca2i increases inhibited Ca2 free condition blocker N type Ca2 channels
0.11980948.12663466.html.plaintext.txt	135	A D Ghrelin induced Ca2i increases abolished Ca2 free condition A n 7
0.11980948.12663466.html.plaintext.txt	136	They markedly inhibited conotoxin GVIA B blocker N type Ca2 channels n 12 including 8 NPY containig neurons slightly suppressed unaltered nitrendipine C blocker L type Ca2 channels
0.11980948.12663466.html.plaintext.txt	137	Thapsigargin D inhibitor Ca2 pump ER failed significantly affect ghrelin induced Ca2i increases
0.11980948.12663466.html.plaintext.txt	138	E Incidence response control test conditions expressed percentage cells exhibited Ca2i responses second addition ghrelin cell
0.11980948.12663466.html.plaintext.txt	139	The numbers bar indicate number neurons responded number neurons examined
0.11980948.12663466.html.plaintext.txt	140	F The amplitude ghrelin induced Ca2i increases control conditions Ca2 free conditions conotoxin
0.11980948.12663466.html.plaintext.txt	141	The number bar indicates number neurons examined
0.11980948.12663466.html.plaintext.txt	142	001 control Ca2 free groups P 0
0.11980948.12663466.html.plaintext.txt	143	005 control conotoxin groups
0.11980948.12663466.html.plaintext.txt	144	Ghrelin induced Ca2i increase inhibited inhibitor PKA PKC
0.11980948.12663466.html.plaintext.txt	145	After pretreatment neurons PKA inhibitor H89 10 micromoll Ca2i response ghrelin markedly significantly inhibited Ca2i Amp 143
0.11980948.12663466.html.plaintext.txt	146	In contrast H85 10 micromoll related compound H89 without inhibitory action PKA significant effect ghrelin induced Ca2i increase Ca2i Amp 312
0.11980948.12663466.html.plaintext.txt	147	Neither calphostin C 100 nmoll bisindolylmaleimide I 2 micromoll specific PKC inhibitors affected ghrelin induced Ca2i increase Ca2i Amp 348
0.11980948.12663466.html.plaintext.txt	148	3 nmoll 10 calphostin C 426
0.11980948.12663466.html.plaintext.txt	149	1 4 bisindolylmaleimide I Fig
0.11980948.12663466.html.plaintext.txt	150	View larger version 33K FIG
0.11980948.12663466.html.plaintext.txt	151	Ghrelin induced Ca2i increases inhibited PKA inhibitor
0.11980948.12663466.html.plaintext.txt	152	Pretreatment 10 micromoll H89 PKA inhibitor inhibited ghrelin induced Ca2i increases ARC neurons n 9 including 7 NPY containing neurons A whereas pretreatment 10 micromoll H85 analog H89 without inhibitory action PKA little effect B
0.11980948.12663466.html.plaintext.txt	153	Neither 100 nmoll calphostin C C 2 micromoll bisindolylmaleimide I D specific PKC inhibitors affected ghrelin induced Ca2i increases
0.11980948.12663466.html.plaintext.txt	154	E The incidence responses control conditions inhibitors expressed percentage cells exhibited Ca2i responses second addition ghrelin cell
0.11980948.12663466.html.plaintext.txt	155	F The amplitude ghrelin induced Ca2i increases control conditions pretreated H89 H85
0.11980948.12663466.html.plaintext.txt	156	05 control H89 groups H89 H85 groups
0.11980948.12663466.html.plaintext.txt	157	No significant difference control H85 groups
0.11980948.12663466.html.plaintext.txt	158	Forskolin TPA increase Ca2i ghrelin responsive neurons
0.11980948.12663466.html.plaintext.txt	159	An adenylate cyclase activator forskolin 10 micromoll increased Ca2i 14 16 88 ghrelin responsive neurons Ca2i Amp 377
0.11980948.12663466.html.plaintext.txt	160	A PKC activator TPA 100 nmoll also increased Ca2i 11 17 65 ghrelin responsive neurons Ca2i Amp 337
0.11980948.12663466.html.plaintext.txt	161	Thus ghrelin responsive neurons highly overlapped neurons responding forskolin lesser extent responding TPA
0.11980948.12663466.html.plaintext.txt	162	Furthermore forskolin TPA increased Ca2i similar pattern ghrelin
0.11980948.12663466.html.plaintext.txt	163	View larger version 29K FIG
0.11980948.12663466.html.plaintext.txt	164	Forskolin TPA increase Ca2i ghrelin responsive neurons 10 micromoll forskolin adenylate cyclase activator A 100 nmoll TPA PKC activator B increased Ca2i ghrelin responsive neurons
0.11980948.12663466.html.plaintext.txt	165	C The incidence Ca2i responses forskolin TPA ghrelin responsive neurons expressed percentage
0.11980948.12663466.html.plaintext.txt	166	Ghrelin orexin increase Ca2i neurons
0.11980948.12663466.html.plaintext.txt	167	Ghrelin orexin 10 10 moll sequentially administered increased Ca2i neurons ARC similar pattern comparable amplitudes Fig
0.11980948.12663466.html.plaintext.txt	168	Among 17 neurons examined 12 neurons including 8 NPY containing neurons responded ghrelin orexin A 3 neurons responded ghrelin 2 neurons responded orexin A Fig
0.11980948.12663466.html.plaintext.txt	169	Thus ghrelin responsive neurons extensively overlapped orexin responsive neurons 80 Fig
0.11980948.12663466.html.plaintext.txt	170	View larger version 16K FIG
0.11980948.12663466.html.plaintext.txt	171	Ghrelin orexin A increase Ca2i NPY neurons
0.11980948.12663466.html.plaintext.txt	172	A Ghrelin responsive neurons also exhibited Ca2i responses 10 10 moll orexin A
0.11980948.12663466.html.plaintext.txt	173	B Twelve neurons responded ghrelin orexin 3 neurons ghrelin 2 neurons orexin among 17 neurons responded either two peptides
0.11980948.12663466.html.plaintext.txt	174	The ghrelin orexin responsive neurons included eight NPY containing neurons
0.11980948.12663466.html.plaintext.txt	175	Ghrelin induced Ca2i increase counteracted leptin
0.11980948.12663466.html.plaintext.txt	176	When 10 10 moll ghrelin administered 20 min Ca2i increased continuous manner eight responsive neurons ARC examined Fig
0.11980948.12663466.html.plaintext.txt	177	The continuous Ca2i increase markedly reduced subsequent administration 10 10 moll leptin 11 14 79 ghrelin responsive neurons Fig
0.11980948.12663466.html.plaintext.txt	178	The ghrelin leptin responsive neurons included seven NPY containing neurons
0.11980948.12663466.html.plaintext.txt	179	When 10 10 moll leptin administered first ghrelin added ghrelin induced Ca2i increase also reduced three nine responding neurons leptin little effect basal Ca2i 10 mmoll glucose Fig
0.11980948.12663466.html.plaintext.txt	180	View larger version 33K FIG
0.11980948.12663466.html.plaintext.txt	181	Ghrelin increases Ca2i leptin suppresses NPY neurons
0.11980948.12663466.html.plaintext.txt	182	A Ghrelin administered alone 20 min increased Ca2i continuously ARC neurons n 8
0.11980948.12663466.html.plaintext.txt	183	B C Leptin 10 10 moll suppressed ghrelin induced Ca2i increases 11 14 ghrelin responsive neurons
0.11980948.12663466.html.plaintext.txt	184	The ghrelin leptin responsive neurons included seven NPY containing neurons
0.11980948.12663466.html.plaintext.txt	185	D Leptin 10 10 moll added advance suppressed Ca2i responses subsequent administration ghrelin n 3
0.11980948.12663466.html.plaintext.txt	186	DISCUSSION TOP ABSTRACT RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES This study presents novel findings neuronal signaling mechanisms orexigenic action ghrelin hypothalamus
0.11980948.12663466.html.plaintext.txt	187	First demonstrated ghrelin concentration dependently increases Ca2i NPY containing neurons glucose sensitive neurons ARC
0.11980948.12663466.html.plaintext.txt	188	The Ca2i increase often results depolarization plasma membrane key signal triggering release neurotransmittershormones gene expression 2728
0.11980948.12663466.html.plaintext.txt	189	Therefore Ca2i increase good indicator neuronal activation
0.11980948.12663466.html.plaintext.txt	190	Therefore findings strongly suggest ghrelin directly activates NPY neurons glucose sensitive neurons ARC neuronal systems implicated stimulation feeding
0.11980948.12663466.html.plaintext.txt	191	We previously showed majority glucose sensitive neurons ARC NPY neurons 25
0.11980948.12663466.html.plaintext.txt	192	Second ghrelin induced Ca2i increase depends Ca2 influx N type Ca2 channels cAMP PKA pathway
0.11980948.12663466.html.plaintext.txt	193	Third target neurons ghrelin ARC extensively overlap orexin leptin
0.11980948.12663466.html.plaintext.txt	194	It reported concentration leptin cerebrospinal fluid measured radioimmunoassay 1
0.11980948.12663466.html.plaintext.txt	195	6 x 10 11 moll orexin 8 x 10 11 moll 29
0.11980948.12663466.html.plaintext.txt	196	Although concentration ghrelin cerebrospinal fluid available ghrelin transported blood brain barrier rate similar peptides including leptin 30 estimated ghrelin concentration brain 10 12 moll
0.11980948.12663466.html.plaintext.txt	197	These values may reflect physiological concentrations peptides brain
0.11980948.12663466.html.plaintext.txt	198	The concentration ghrelin leptin orexin used present study 10 10 moll close values therefore effects observed could physiological
0.11980948.12663466.html.plaintext.txt	199	It previously shown GHSR ghrelin receptor abundant NPY neurons ARC 12 ghrelin induced food intake inhibited antagonist NPY Y1 receptor 3 515
0.11980948.12663466.html.plaintext.txt	200	These reports suggested involvement NPY neurons ghrelin signaling pathway orexigenic effect
0.11980948.12663466.html.plaintext.txt	201	The present study clearly demonstrated ghrelin directly activates substantial population 35 ARC neurons high 80 ghrelin responsive neurons NPY containing neurons
0.11980948.12663466.html.plaintext.txt	202	In pharmacological experiments study signaling mechanisms ghrelin immunocytochemical identification NPY neurons following Ca2i measurements carried experiments H89 conotoxin
0.11980948.12663466.html.plaintext.txt	203	However examined 7 17 ghrelin responsive neurons pharmacological experiment major population 80 ghrelin responsive neurons proved NPY containing Fig
0.11980948.12663466.html.plaintext.txt	204	1 result obtained may largely solely reflect NPY neurons
0.11980948.12663466.html.plaintext.txt	205	Ghrelin induced Ca2i increases inhibited Ca2 free condition blocker N type Ca2 channels slightly suppressed blocker L type Ca2 channels
0.11980948.12663466.html.plaintext.txt	206	Thapsigargin inhibitor Ca2 pump ER consequently Ca2 release ER effect ghrelin induced Ca2i increases
0.11980948.12663466.html.plaintext.txt	207	The results N type Ca2 channel blocker obtained mainly immunocytochemically identified NPY neurons
0.11980948.12663466.html.plaintext.txt	208	These data indicate ghrelin increases Ca2i mainly via Ca2 influx N type Ca2 channels
0.11980948.12663466.html.plaintext.txt	209	It shown N type Ca2 channels involved release NPY stimulated high potassium 31
0.11980948.12663466.html.plaintext.txt	210	It reported NPY Y2 receptor NPY neurons linked decrease Ca2 currents due inhibition N type Ca2 channels 32
0.11980948.12663466.html.plaintext.txt	211	Thus N type Ca2 channels could play pivotal role regulation Ca2 influx Ca2i NPY neurons
0.11980948.12663466.html.plaintext.txt	212	The second messenger systems ghrelin NPY neurons adequately elucidated
0.11980948.12663466.html.plaintext.txt	213	In present study adenylate cyclase activator forskolin PKC activator TPA increased Ca2i indicating cAMP PKA PKC pathways capable activating Ca2 signaling
0.11980948.12663466.html.plaintext.txt	214	Furthermore specific PKA inhibitor H89 nonspecific inhibitor H85 PKC inhibitors significantly suppressed ghrelin induced Ca2i increase
0.11980948.12663466.html.plaintext.txt	215	The results PKA inhibitor obtained mainly immunocytochemically identified NPY neurons
0.11980948.12663466.html.plaintext.txt	216	These results reveal PKA required ghrelin activate Ca2 signaling NPY neurons ARC
0.11980948.12663466.html.plaintext.txt	217	There two possible explanations role PKA
0.11980948.12663466.html.plaintext.txt	218	First basal activity PKA may required ghrelin produce Ca2 signaling
0.11980948.12663466.html.plaintext.txt	219	Second ghrelin GHSR system may activate Gs adenylate cyclase cAMP PKA cascade turn leads Ca2 influx Ca2i increase
0.11980948.12663466.html.plaintext.txt	220	The PKA mediated facilitation Ca2 influx Ca2i increase indicated cardiac muscle pancreatic ss cells 2833
0.11980948.12663466.html.plaintext.txt	221	It shown PKA indispensable CREB phosphorylation cAMP response element mediated gene expression NPY neurons fasted state 34
0.11980948.12663466.html.plaintext.txt	222	Ghrelin could couple fasting activation PKA release peptide greatly stimulated fasting 9
0.11980948.12663466.html.plaintext.txt	223	These findings present study others indicate PKA important ghrelin induced activation NPY neurons
0.11980948.12663466.html.plaintext.txt	224	Whether ghrelin induced Ca2 signaling NPY neurons depends basal PKA activity requires activation PKA peptide remains clarified
0.11980948.12663466.html.plaintext.txt	225	In present study ghrelin orexin increased Ca2i neurons ARC
0.11980948.12663466.html.plaintext.txt	226	The majority ghrelin responsive neurons 80 also responded orexin vise versa 86 showing two populations responders highly overlapped
0.11980948.12663466.html.plaintext.txt	227	The ghrelin orexin responsive neurons included eight NPY containing neurons
0.11980948.12663466.html.plaintext.txt	228	The orexin 1 receptor reportedly expressed 90 NPY neurons 35
0.11980948.12663466.html.plaintext.txt	229	Our results clearly demonstrate presence subset NPY neurons serves common target ghrelin orexin
0.11980948.12663466.html.plaintext.txt	230	It shown fasting lowering glucose concentrations increase level ghrelin 9 activate orexin neurons 2636 suggesting release two peptides regulated parallel
0.11980948.12663466.html.plaintext.txt	231	Our finding indicates ghrelin orexin may also cooperate common effector site NPY neurons ARC could result efficient stimulation NPY mediated neural signaling feeding
0.11980948.12663466.html.plaintext.txt	232	We found leptin suppresses ghrelin induced Ca2i increase majority ghrelin responsive neurons 79
0.11980948.12663466.html.plaintext.txt	233	The ghrelin leptin responsive neurons included seven NPY containing neurons
0.11980948.12663466.html.plaintext.txt	234	Thus NPY neurons ARC regulated reciprocally ghrelin leptin
0.11980948.12663466.html.plaintext.txt	235	This accord report 57 Fos positive cells ventromedial ARC due intraperitoneal injection ghrelin also immunoreactive leptin receptor 37
0.11980948.12663466.html.plaintext.txt	236	The recently reported action leptin antagonize cAMP elevation 38 40 possible mechanism leptin counteracts effect ghrelin dependent cAMP PKA demonstrated present study
0.11980948.12663466.html.plaintext.txt	237	The action leptin could also involve phosphoinositide 3 kinase 38 41
0.11980948.12663466.html.plaintext.txt	238	Furthermore found orexin induced Ca2i increase NPY neurons ARC inhibited leptin T
0.11980948.12663466.html.plaintext.txt	239	Thus NPY neurons regulated directly cooperatively ghrelin orexin leptin important regulators feeding
0.11980948.12663466.html.plaintext.txt	240	In conclusion data demonstrate ghrelin directly interacts NPY neurons ARC elicit Ca2 signaling via PKA N type Ca2 channel dependent mechanisms
0.11980948.12663466.html.plaintext.txt	241	This could serve major neuronal signaling mechanism ghrelin stimulates NPY release thereby feeding
0.11980948.12663466.html.plaintext.txt	242	The ghrelin responsive neurons highly overlapped orexin leptin responsive neurons
0.11980948.12663466.html.plaintext.txt	243	The integration stimulatory effects ghrelin orexin inhibitory effect leptin may play important role regulation activity NPY neurons thereby feeding
0.11980948.12663466.html.plaintext.txt	244	ACKNOWLEDGMENTS This work supported Grant Aid Scientific Research Japan Society Promotion Science 12470231 grants Japan Diabetes Foundation National Cardiovascular Research Institute Asahi Life Foundation Adult Diseases Institute T
0.11980948.12663466.html.plaintext.txt	245	Nakazato providing ghrelin helpful discussions
0.11980948.12663466.html.plaintext.txt	246	FOOTNOTES Address correspondence reprint requests Dr
0.11980948.12663466.html.plaintext.txt	247	Toshihiko Yada Department Physiology Division Integrative Physiology Jichi Medical School School Medicine Minamikawachi Kawachi Tochigi 329 0498 Japan
0.11980948.12663466.html.plaintext.txt	248	Received publication 17 September 2001 accepted revised form 13 January 2003
0.11980948.12663466.html.plaintext.txt	249	ARC arcuate nucleus ER endoplasmic reticulum GHS growth hormone secretagogue GHSR GHS receptor HKRB HEPES buffered Krebs Ringer bicarbonate buffer ICV intracerebroventricular NPY neuropeptide Y PKA protein kinase A PKC protein kinase C TPA 12 0 tetradecanoylphorbol 13 acetate
0.11980948.12663466.html.plaintext.txt	250	REFERENCES TOP ABSTRACT RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES Kojima M Hosoda H Date Y Nakazato M Matsuo H Kangawa K Ghrelin growth hormone releasing acylated peptide stomach
0.11980948.12663466.html.plaintext.txt	251	Nature 402656 6601999Medline Tschop M Similey DL Heiman ML Ghrelin induces adiposity rodents
0.11980948.12663466.html.plaintext.txt	252	Nature 407908 9132000Medline Nakazato M Murakami N Date Y Kojima M Matsuo Kangawa K Matsukura S A role ghrelin central regulation feeding
0.11980948.12663466.html.plaintext.txt	253	Nature 409194 1982001Medline Shintani M Ogawa Y Ebihara K Aizawa Abe M Miyanaga F Takaya K Hayashi T Inoue G Hosoda K Kojima M Kangawa K Nakao K Ghrelin endogenous growth hormone secretagogue novel orexigenic peptide antagonizes leptin action activation hypothalamic neuropeptide YY1 receptor pathway
0.11980948.12663466.html.plaintext.txt	254	Diabetes 50227 2322001AbstractFree Full Text Asakawa A Inui A Kaga T Yuzuriha H Nagata T Ueno N Makino S Fujimiya M Niijima A Fujino MA Kasuga M Ghrelin appetite stimulatory signal stomach structural resemblance motilin
0.11980948.12663466.html.plaintext.txt	255	Gastroenterology 120337 3452001Medline Wren AM Small CJ Ward HL Murphy KG Dakin CL Taheri S Kennedy AR Roberts GH Morgan DG Ghatei MA Bloom SR The novel hypothalamic peptide ghrelin stimulates food intake growth hormone secretion
0.11980948.12663466.html.plaintext.txt	256	Endocrinology 1414325 43282000AbstractFree Full Text Wren AM Seal LJ Cohen MA Bynes AE Frost GS Murphy KG Dhillo WS Ghatei MA Bloom SR Ghrelin enhances appetite increases food intake humans
0.11980948.12663466.html.plaintext.txt	257	J Clin Endocrinol Metab 865992 59952001AbstractFree Full Text Inui A Ghrelin orexigenic somatotrophic signal stomach
0.11980948.12663466.html.plaintext.txt	258	Nat Rev Neurosci 2551 5602001Medline Cummings DE Purnell JQ Fravo RS Schmidova K Wisse BE Weigle DS A preprandial rise plasma ghrelin levels suggests role meal initiation humans
0.11980948.12663466.html.plaintext.txt	259	Diabetes 501714 17192001AbstractFree Full Text Stanley BG Kyrkouli SE Lampert S Leibowitz SF Neuropeptide Y chronically injected hypothalamus powerful neurochemical inducer hyperphagia obesity
0.11980948.12663466.html.plaintext.txt	260	Peptides 71189 11921986Medline Kalra SP Dube MG Sahu A Phelps CP Kalra PS Neuropeptide Y secretion increases paraventricular nucleus association increased appetite food
0.11980948.12663466.html.plaintext.txt	261	Proc Natl Acad Sci U S A 8810931 109351991Abstract Willesen MG Kristensen P Romer J Co localization growth hormone secretagogue receptor NPY mRNA arcuate nucleus rat
0.11980948.12663466.html.plaintext.txt	262	Neuroendocrinology 70306 3161999Medline Wang L Saint Pierre DH Tache Y Peripheral ghrelin selectively increases Fos expression neuropeptide Y synthesizing neurons mouse hypothalamic arcuate nucleus
0.11980948.12663466.html.plaintext.txt	263	Neurosci Lett 32547 512002Medline Hewson AK Dickson SL Systemic administration ghrelin induces Fos Egr 1 proteins hypothalamic arcuate nucleus fasted fed rats
0.11980948.12663466.html.plaintext.txt	264	J Neuroendocrinol 121047 10492000Medline Lawrence CB Snape AC Baudoin FM Luckman SM Acute central ghrelin GH secretagogues induce feeding activate brain appetite centers
0.11980948.12663466.html.plaintext.txt	265	Endocrinology 143155 1622002AbstractFree Full Text Wu D Chen C Zhang J Bowers CY Clarke IJ The effects GH releasing peptide 6 GHRP 6 GHRP 2 intracellular adenosine 35 monophosphate cAMP levels GH secretion ovine rat somatotrophs
0.11980948.12663466.html.plaintext.txt	266	J Endocrinol 148197 2051996Abstract Chen C Growth Hormone secretagogue actions pituitary gland multiple receptors multiple ligands Clin Exp Pharmacol Physiol 27323 3292000Medline Cheng K Chan WW Butler B Barreto A Jr
0.11980948.12663466.html.plaintext.txt	267	Smith RG Evidence role protein kinase C His D Trp Ala Trp D Phe Lys NH2 induced growth hormone release rat primary pituitary cells
0.11980948.12663466.html.plaintext.txt	268	Endocrinology 1293337 33421991Abstract Friedman JM Halaas JL Leptin regulation body weight mammals
0.11980948.12663466.html.plaintext.txt	269	Nature 395763 7701998Medline Sakurai T Amemiya A Ishii M Matsuzaki I Chemelli RM Tanaka H Williams SC Richardson JA Kozlowski GP Wilson S Arch JR Buckingham RE Haynes AC Carr SA Annan RS McNulty DE Liu WS Terrett JA Elshourbagy NA Bergsma DJ Yanagisawa M Orexins orexin receptors family hypothalamic neuropeptides G protein coupled receptors regulate feeding behavior
0.11980948.12663466.html.plaintext.txt	270	Cell 92573 5851998Medline Suzuki R Shimojima H Funahashi H Nakajo S Yamada S Guan JL Tsurugano S Uehara K Takeyama Y KikuyamaS Shioda S Orexin 1 receptor immunoreactivity chemically identified target neurons rat hypothalamus
0.11980948.12663466.html.plaintext.txt	271	Neurosci Lett 3245 82002Medline Jain MR Horvath TL Kalra PS Kalra SP Evidence NPY Y1 receptors involved stimulation feeding orexins hypocretins sated rats
0.11980948.12663466.html.plaintext.txt	272	Regul Pept 8719 242000Medline Yamanaka A Kunii K Nambu T Tsujino N Sakai A Matsuzaki I Miwa Y Goto K Sakurai T Orexin induced food intake involves neuropeptide Y pathway
0.11980948.12663466.html.plaintext.txt	273	Brain Res 859404 4092000Medline Dube MG Horvath TL Kalra PS Kalra SP Evidence NPY Y5 receptor involvement food intake elicited orexin A sated rats
0.11980948.12663466.html.plaintext.txt	274	Peptides 211557 15602000Medline Muroya S Yada T Shioda S Takigawa M Glucose sensitive neurons rat arcuate nucleus contain neuropeptide Y
0.11980948.12663466.html.plaintext.txt	275	Neurosci Lett 264113 1161999Medline Muroya S Uramura K Sakurai T Takigawa M Yada T Lowering glucose concentrations increases cytosolic Ca2 orexin neurons rat lateral hypothalamus
0.11980948.12663466.html.plaintext.txt	276	Neurosci Lett 309165 1682001Medline Yada T Sakurada M Ihida K Nakata M Murata F Arimura A Kikuchi M Pituitary adenylate cyclase activating polypeptide extraordinarily potent intra pancreatic regulator insulin secretion islet ss cells
0.11980948.12663466.html.plaintext.txt	277	J Biol Chem 2691290 12931994AbstractFree Full Text Yada T Itoh K Nakata M Glucagon like peptide 1 7 36amide rise cyclic AMP increase cytosolic free Ca2 rat pancreatic ss cells enhancing Ca2 channel activity
0.11980948.12663466.html.plaintext.txt	278	Endocrinology 1331685 16921993Abstract Nishino S Ripley B Overeem S Nevsimalova S Lammers GJ Vankova J Okun M Rogers W Brooks S Mignot E Low cerebrospinal fluid hypocretin Orexin altered energy homeostasis human narcolepsy
0.11980948.12663466.html.plaintext.txt	279	Ann Neurol 50381 3882001Medline Banks WA Kastin AJ Huang W Jaspan JB Maness LM Leptin enters brain saturable system indipendent insulin
0.11980948.12663466.html.plaintext.txt	280	Peptides 17305 3111996Medline King PJ Widdowson PS Doods HN Williams G Regulation neuropeptide Y release neuropeptide Y receptor ligands calcium channel antagonists hypothalamic slices
0.11980948.12663466.html.plaintext.txt	281	J Neurochem 73641 6461999Medline Chen X DiMaggio DA Han SP Westfall TC Autoreceptor induced inhibition neuropeptide Y release PC 12 cells mediated Y2 receptors
0.11980948.12663466.html.plaintext.txt	282	Am J Physiol 273H1737 H17441997AbstractFree Full Text Trautwein W Hescheler J Regulation cardiac L type calcium current phosphorylation G proteins
0.11980948.12663466.html.plaintext.txt	283	Annu Rev Physiol 52257 2741990Medline Shimizu Albergine M Ippolito DL Beavo JA Downregulation fasting induced cAMP response element mediated gene induction leptin neuropeptide Y neurons arcuate nucleus
0.11980948.12663466.html.plaintext.txt	284	J Neurosci 211238 12462001AbstractFree Full Text Backberg M Hervieu G Wilson S Meister B Orexin receptor 1 OX R1 immunoreactivity chemically identified neurons hypothalamus focus orexin targets involved control food water intake
0.11980948.12663466.html.plaintext.txt	285	Eur J Neurosci 15315 3282002Medline Moriguchi T Sakurai T Nambu T Yanagisawa M Goto K Neurons containing orexin lateral hypothalamic area adult rat brain activated insulin induced acute hypoglycemia
0.11980948.12663466.html.plaintext.txt	286	Neurosci Lett 264101 1041999Medline Traebert M Riediger T Whitebread S Scharrer E Schmid HA Ghrelin acts leptin responsive neurones rat arcuate nucleus
0.11980948.12663466.html.plaintext.txt	287	J Neuroendocrinol 14580 5862002Medline Zhao AZ Bornfieldt KE Beavo JA Leptin inhibits insulin secretion activation phosphodiesterase 3B
0.11980948.12663466.html.plaintext.txt	288	J Clin Invest 102869 8731998AbstractFree Full Text Zhao AZ Shinohara MM Huang D Shimizu M Eldar Finkelman H Krebs EG Beavo JA Bornfield KE Leptin induces insulin like signaling antagonizes cAMP elevation glucagon hepatocytes
0.11980948.12663466.html.plaintext.txt	289	J Biol Chem 27511348 113542000AbstractFree Full Text Zhao AZ Huan JN Gupta S Pal R Sahu A A phosphatidylinositol 3 kinase phosphodiesterase 3B cyclic AMP pathway hypothalamic action leptin feeding
0.11980948.12663466.html.plaintext.txt	290	Nat Neurosci 5727 7282002Medline Shanley LJ Irving AJ Rae MG Ashford ML Harvey J Leptin inhibits rat hippocampal neurons via activation large conductance calcium activated K channels
0.11980948.12663466.html.plaintext.txt	291	Nat Neurosci 5299 3002002Medline
0.0967214.12399421.html.plaintext.txt	0	Combined Blockade Both micro Opioid Receptors Prevents Acute Orexigenic Action Agouti Related Protein S
0.0967214.12399421.html.plaintext.txt	1	Department Animal Physiology S
0.0967214.12399421.html.plaintext.txt	2	University Groningen 9750 AA Haren Groningen The Netherlands Department Psychiatry D
0.0967214.12399421.html.plaintext.txt	3	University Cincinnati Cincinnati Ohio 45267
0.0967214.12399421.html.plaintext.txt	4	Address correspondence requests reprints Randy J
0.0967214.12399421.html.plaintext.txt	5	Department Psychiatry University Cincinnati Cincinnati Ohio 45267 0559
0.0967214.12399421.html.plaintext.txt	6	Abstract Top Abstract Introduction Materials Methods Results Discussion References Agouti related protein AgRP endogenous antagonist melanocortin 3 4 receptor hypothalamus
0.0967214.12399421.html.plaintext.txt	7	Central administration AgRP produces robust increase food intake effect blocked administration nonspecific opioid receptor antagonist
0.0967214.12399421.html.plaintext.txt	8	Such results implicate opioid receptors critical mediating effects AgRP
0.0967214.12399421.html.plaintext.txt	9	To determine opioid receptor subtype critical first determined highest i3vt administered third ventricle dose two specific opioid antagonists Binaltorphine ss funaltrexamine influence food intake
0.0967214.12399421.html.plaintext.txt	10	Then rats pretreated either two antagonists i3vt AgRP access high fat diet
0.0967214.12399421.html.plaintext.txt	11	For neither micro specific antagonist effect block effects AgRP food intake
0.0967214.12399421.html.plaintext.txt	12	However administration micro receptor antagonists significantly reduce effect AgRP
0.0967214.12399421.html.plaintext.txt	13	The current results implicate opioid receptors critical downstream mediators potent effects AgRP increase food intake indicate either micro receptor activation sufficient AgRP effect
0.0967214.12399421.html.plaintext.txt	14	Introduction Top Abstract Introduction Materials Methods Results Discussion References CONSIDERABLE EVIDENCE LINKS central nervous system CNS melanocortin MC system control food intake body weight 1 2
0.0967214.12399421.html.plaintext.txt	15	The MCs family peptides include ss MSH ACTH
0.0967214.12399421.html.plaintext.txt	16	MSH agonist MC3 4 receptors central administration MSH synthetic analogs MTII reduce food intake body weight 3 4
0.0967214.12399421.html.plaintext.txt	17	A unique feature MC system addition well documented role endogenous agonists also important role endogenous antagonists various MC receptors
0.0967214.12399421.html.plaintext.txt	18	The first antagonist described MC system agouti signaling protein ASP
0.0967214.12399421.html.plaintext.txt	19	ASP acts periphery alter MC1 receptor signaling regulate peripheral skin hair color 5
0.0967214.12399421.html.plaintext.txt	20	Overexpression ASP results yellow coat color via MC1 receptor 6
0.0967214.12399421.html.plaintext.txt	21	Overexpression ASP also results increased food intake obesity via interaction MC3 4 receptors CNS 4
0.0967214.12399421.html.plaintext.txt	22	Given ASP normally found CNS role ASP regulating MC receptor signaling brain unlikely
0.0967214.12399421.html.plaintext.txt	23	However homolog ASP termed agouti related protein AgRP made arcuate nucleus hypothalamus population neurons adjacent overlapping neurons produce MSH 7 8 9
0.0967214.12399421.html.plaintext.txt	24	AgRP acts antagonist MC3 MC4 receptors 7 10
0.0967214.12399421.html.plaintext.txt	25	Hence AgRP opposes actions MSH
0.0967214.12399421.html.plaintext.txt	26	Consistent AgRP MSH precursor proopiomelanocortin regulated opposite directions energy balance leptin
0.0967214.12399421.html.plaintext.txt	27	Food deprivation decreases proopiomelanocortin gene expression whereas increases AgRP gene expression arcuate nucleus 11 12 13
0.0967214.12399421.html.plaintext.txt	28	Overexpression AgRP results obese phenotype similar mice overexpress ASP 10
0.0967214.12399421.html.plaintext.txt	29	When biologically active fragment AgRP administered third ventricle i3vt rats increase food intake lasts 6 d 14 15
0.0967214.12399421.html.plaintext.txt	30	Although short term effects AgRP seem depend antagonism identified MC receptors long term effects 14
0.0967214.12399421.html.plaintext.txt	31	Moreover like neuropeptide Y NPY orexigenic effect AgRP blocked nonspecific opioid receptor antagonist naloxone 16 17
0.0967214.12399421.html.plaintext.txt	32	Thus potent effects AgRP increase food intake depend critically activation opioid receptors
0.0967214.12399421.html.plaintext.txt	33	Opioid receptors come three identified subtypes micro 18 micro strongly implicated control food intake 19
0.0967214.12399421.html.plaintext.txt	34	Thus aim experiments assess role specific opioid receptor subtypes mediating effects AgRP increase food intake
0.0967214.12399421.html.plaintext.txt	35	Materials Methods Top Abstract Introduction Materials Methods Results Discussion References Animals Male Long Evans rats Harlan Indianapolis IN experiment 1 Taconic Farms Inc
0.0967214.12399421.html.plaintext.txt	36	Germantown NY experiment 2 weighing 350 450 g onset experiments individually housed maintained temperature controlled 21 plus minus 1 C room 12 h light 12 h dark cycle
0.0967214.12399421.html.plaintext.txt	37	Surgery A guide sleeve Plastics One Guide 22 G catalog
0.0967214.12399421.html.plaintext.txt	38	C313G obdurator 18 G catalog
0.0967214.12399421.html.plaintext.txt	39	C313 DC aimed third cerebral ventricle implanted
0.0967214.12399421.html.plaintext.txt	40	Coordinates midline 2
0.0967214.12399421.html.plaintext.txt	41	5 mm ventral dura bregma vertical coordinates Paxinos Watson 1986
0.0967214.12399421.html.plaintext.txt	42	After minimum 10 d recovery accuracy placement verified injection i3vt 10 ng angiotensin saline injector inserted guide sleeve
0.0967214.12399421.html.plaintext.txt	43	Only rats drank 5 ml hour injection used experiments
0.0967214.12399421.html.plaintext.txt	44	Chemicals AgRP83 132 purchased Phoenix Pharmaceuticals Inc
0.0967214.12399421.html.plaintext.txt	45	Nor Binaltorphimine NorBNI hydrochloride ss funaltrexamine ss FNA hydrochloride purchased Sigma St
0.0967214.12399421.html.plaintext.txt	46	NorBNI widely used selective antagonist opioid receptors 20 21 ss FNA widely used selective micro opioid receptor antagonist 18 22
0.0967214.12399421.html.plaintext.txt	47	The selective antagonist action ss FNA unique time course becoming selective action apparent 20 h administration 23
0.0967214.12399421.html.plaintext.txt	48	Thus experiments ss FNA actually administered 20 h food intake measurements
0.0967214.12399421.html.plaintext.txt	49	AgRP dissolved physiological saline served control solution
0.0967214.12399421.html.plaintext.txt	50	NorBNI ss FNA dissolved 100 methanol served control solution
0.0967214.12399421.html.plaintext.txt	51	All solutions administered i3vt 2 microl vol
0.0967214.12399421.html.plaintext.txt	52	Feeding schedule The animals access high fat HF modified AIN 93M purified pelleted rodent diet Dyets Inc
0.0967214.12399421.html.plaintext.txt	53	Bethlehem PA see Table 1 diet composition 2 h day starting lights
0.0967214.12399421.html.plaintext.txt	54	For remaining 22 h rats access pelleted laboratory chow Harlan Teklad Indianapolis IN
0.0967214.12399421.html.plaintext.txt	55	This paradigm used produces reliable 2 h intakes AgRP ligands opioid receptors potently influence intake preferred HF diet diets 24
0.0967214.12399421.html.plaintext.txt	56	Consequently opioids important mediating effects AgRP likely observed HF feeding alternative paradigms
0.0967214.12399421.html.plaintext.txt	57	Water available ad libitum
0.0967214.12399421.html.plaintext.txt	58	Body weights baseline food intake measured throughout experiment
0.0967214.12399421.html.plaintext.txt	59	Macronutrient composition pelleted rodent chow HF diet
0.0967214.12399421.html.plaintext.txt	60	Experiment 1 dose response determination opioid receptor antagonist The first goal determine subthreshold dose opioid antagonists use subsequent experiments
0.0967214.12399421.html.plaintext.txt	61	To end focused low end dose effect curve accurately determine highest dose NorBNI clearly subthreshold
0.0967214.12399421.html.plaintext.txt	62	effect food intake
0.0967214.12399421.html.plaintext.txt	63	Four groups naive rats n 5 6group administered NorBNI i3vt 1 h presentation HF diet 0 1 5 10 nmol subsequent consumption HF diet chow measured
0.0967214.12399421.html.plaintext.txt	64	Data analyzed one way ANOVA followed Dunnet tests compare dose vehicle control
0.0967214.12399421.html.plaintext.txt	65	Experiment 2 dose response determination micro opioid receptor antagonist Rats experiment 1 used experiment 2 7 d experimental manipulations baseline intakes body weight returned normal occurred within 48 h
0.0967214.12399421.html.plaintext.txt	66	Analogous experiment 1 determined i3vt dose effect curve micro selective antagonist ss FNA administering 0 0
0.0967214.12399421.html.plaintext.txt	67	5 1 5 nmol doses 20 h access HF diet measuring subsequent HF chow consumption
0.0967214.12399421.html.plaintext.txt	68	Data analyzed one way ANOVA followed Dunnet tests compare dose vehicle control
0.0967214.12399421.html.plaintext.txt	69	Experiment 3 effect NorBNI AgRP83 132 induced food intake On experimental day rats received two i3vt injections
0.0967214.12399421.html.plaintext.txt	70	The first occurred 1 h second contained NorBNI highest subthreshold dose determined experiment 1 vehicle
0.0967214.12399421.html.plaintext.txt	71	The second injection contained either saline AgRP 1 nmol
0.0967214.12399421.html.plaintext.txt	72	The second injection occurred 30 min lights therefore 30 min access HF diet
0.0967214.12399421.html.plaintext.txt	73	Each rat n 22 tested twice 7 d apart two four conditions 1 methanol saline 2 NorBNI 5 nmol saline 3 methanol AgRP 1 nmol 4 NorBNI 5 nmol AgRP 1 nmol
0.0967214.12399421.html.plaintext.txt	74	saline within subjects factor whereas NorBNI vs
0.0967214.12399421.html.plaintext.txt	75	methanol subjects factor condition order counterbalanced across subjects
0.0967214.12399421.html.plaintext.txt	76	Food intake measured every 30 min access HF diet
0.0967214.12399421.html.plaintext.txt	77	After 2 h HF diet replaced chow chow intake recorded remaining 22 h data analyzed using mixed model ANOVA followed Tukey post hoc tests
0.0967214.12399421.html.plaintext.txt	78	Experiment 4 effect ss FNA AgRP83 132 induced food intake Experiment 4 used separate group naive animals n 18 design exactly parallels experiment 3 except selective opioid antagonist ss FNA maximally subthreshold dose determined experiment 2 0
0.0967214.12399421.html.plaintext.txt	79	1 nmol methanol given 20 h AgRP saline administration
0.0967214.12399421.html.plaintext.txt	80	Again food intake measured every 30 min access HF diet
0.0967214.12399421.html.plaintext.txt	81	After 2 h HF diet replaced chow chow intake recorded remaining 22 h data analyzed using mixed model ANOVA followed Tukey post hoc tests
0.0967214.12399421.html.plaintext.txt	82	Experiment 5 effect combined NorBNI ss FNA AgRP83 132 induced food intake The goal determine whether combined blockade micro opioid receptors attenuates AgRP induced food intake
0.0967214.12399421.html.plaintext.txt	83	Rats experiment 3 experiment 4 used experiment least 7 d rest food intake body weight returned baseline levels
0.0967214.12399421.html.plaintext.txt	84	On test day animals received three separate injections
0.0967214.12399421.html.plaintext.txt	85	Twenty hours receiving either AgRP saline rats received injection either methanol ss FNA 0
0.0967214.12399421.html.plaintext.txt	86	Methanol NorBNI 5 nmol injected 1 h final injection saline AgRP 1 nmol
0.0967214.12399421.html.plaintext.txt	87	At lights animals given access HF diet 2 h
0.0967214.12399421.html.plaintext.txt	88	Food intake measured every 30 min
0.0967214.12399421.html.plaintext.txt	89	After 2 h HF diet replaced chow chow intake measured remaining 22 h
0.0967214.12399421.html.plaintext.txt	90	Each animal run one condition n 6 7group Data analyzed two way ANOVA followed Tukey post hoc tests
0.0967214.12399421.html.plaintext.txt	91	Results Top Abstract Introduction Materials Methods Results Discussion References Experiment 1 effect NorBNI food intake The dose effect curve NorBNI depicted Fig
0.0967214.12399421.html.plaintext.txt	92	The one way ANOVA 2 h cumulative intake significant F3 18 3
0.0967214.12399421.html.plaintext.txt	93	Injection 10 nmol NorBNI significantly reduced intake HF diet first 2 h dark phase compared vehicle P 0
0.0967214.12399421.html.plaintext.txt	94	The total 2 h intake representative intake earlier times data shown
0.0967214.12399421.html.plaintext.txt	95	The 5 nmol dose reliable effect 2 h intake therefore highest subthreshold dose use subsequent experiments see Fig
0.0967214.12399421.html.plaintext.txt	96	No dose NorBNI reduced chow intake subsequent 22 h data shown
0.0967214.12399421.html.plaintext.txt	97	In experiments methanol used vehicle
0.0967214.12399421.html.plaintext.txt	98	Under conditions methanol shown toxic neurons
0.0967214.12399421.html.plaintext.txt	99	To determine whether methanol could independently influence food intake rats compared food intake day beginning injections methanol alone condition
0.0967214.12399421.html.plaintext.txt	100	On methanol alone day rats ate 13
0.0967214.12399421.html.plaintext.txt	101	96 g whereas noninjection day rats consumed 14
0.0967214.12399421.html.plaintext.txt	102	05 paired sample test indicating paradigm methanol alone significant effect intake
0.0967214.12399421.html.plaintext.txt	103	View larger version 19K Figure 1
0.0967214.12399421.html.plaintext.txt	104	Mean 2 h intake HF diet various doses NorBNI
0.0967214.12399421.html.plaintext.txt	105	05 compared vehicle treatment
0.0967214.12399421.html.plaintext.txt	106	Experiment 2 effect ss FNA food intake The dose effect curve ss FNA depicted Fig
0.0967214.12399421.html.plaintext.txt	107	The one way ANOVA 2 h cumulative intake significant F3 18 3
0.0967214.12399421.html.plaintext.txt	108	05 post hoc analyses revealed injection 1 nmol ss FNA significantly suppressed 2 h intake HF diet compared vehicle P 0
0.0967214.12399421.html.plaintext.txt	109	There nonsignificant trend P 0
0.0967214.12399421.html.plaintext.txt	110	5 nmol dose inhibit food intake see Fig
0.0967214.12399421.html.plaintext.txt	111	Consequently chose use 0
0.0967214.12399421.html.plaintext.txt	112	1 nmol highest clearly subthreshold dose experiments
0.0967214.12399421.html.plaintext.txt	113	Chow intake following 22 h reduced dose ss FNA
0.0967214.12399421.html.plaintext.txt	114	View larger version 16K Figure 2
0.0967214.12399421.html.plaintext.txt	115	Mean 2 h intake HF diet various doses ss FNA
0.0967214.12399421.html.plaintext.txt	116	05 compared vehicle treatment
0.0967214.12399421.html.plaintext.txt	117	Experiment 3 effect NorBNI AgRP83 132 induced food intake As previously reported 17 AgRP significantly increased intake HF diet F1 16 8
0.0967214.12399421.html.plaintext.txt	118	3 subsequent chow intake data shown
0.0967214.12399421.html.plaintext.txt	119	There effect NorBNI influence food intake F1 16 1
0.0967214.12399421.html.plaintext.txt	120	05 significant interaction AgRP NorBNI F1 16 0
0.0967214.12399421.html.plaintext.txt	121	Thus unlike subthreshold doses nonspecific opioid antagonist naloxone NorBNI reduce AgRP orexigenic effect 2 h
0.0967214.12399421.html.plaintext.txt	122	It noted baseline food intakes uninjected days vehicle injected days lower experiments 3 4 5 experiments 1 2
0.0967214.12399421.html.plaintext.txt	123	Experiments 3 4 5 run summer months ambient temperature ambient humidity higher February experiments 1 2 run
0.0967214.12399421.html.plaintext.txt	124	Despite vivarium temperature humidity controlled observed experiments animal rooms higher levels humidity summer reduces consumption HF diet
0.0967214.12399421.html.plaintext.txt	125	Importantly dose NorBNI determined subthreshold experiment 1 remained subthreshold experiment 3 despite lower baseline food intakes
0.0967214.12399421.html.plaintext.txt	126	View larger version 23K Figure 3
0.0967214.12399421.html.plaintext.txt	127	Mean 2 h intake HF diet i3vt AgRP vehicle pretreatment subthreshold dose 5 nmol selective opioid receptor antagonist NorBNI
0.0967214.12399421.html.plaintext.txt	128	05 compared vehiclevehicle condition
0.0967214.12399421.html.plaintext.txt	129	Experiment 4 effect ss FNA AgRP83 132 induced food intake Similar occurred experiment 3 AgRP significantly increased intake HF diet see Fig
0.0967214.12399421.html.plaintext.txt	130	01 subsequent chow intake data shown
0.0967214.12399421.html.plaintext.txt	131	ss FNA alter food intake F1 14 2
0.0967214.12399421.html.plaintext.txt	132	1 alter increase 2 h food intake caused AgRP see Fig
0.0967214.12399421.html.plaintext.txt	133	8 act alter AgRP effect time point data shown
0.0967214.12399421.html.plaintext.txt	134	Thus unlike subthreshold doses nonspecific antagonist naloxone ss FNA reduce AgRP orexigenic effect
0.0967214.12399421.html.plaintext.txt	135	View larger version 25K Figure 4
0.0967214.12399421.html.plaintext.txt	136	Mean 2 h intake HF diet i3vt AgRP vehicle pretreatment subthreshold dose 0
0.0967214.12399421.html.plaintext.txt	137	1 nmol micro selective opioid receptor antagonist ss FNA
0.0967214.12399421.html.plaintext.txt	138	05 compared vehiclevehicle condition
0.0967214.12399421.html.plaintext.txt	139	Experiment 5 effect combined NorBNI ss FNA AgRP83 132 induced food intake Vehicle treated rats two methanol injections one saline injection showed normal 2 h food consumption comparable baseline food intake experiments indicating complicated procedure stressful well handled animals
0.0967214.12399421.html.plaintext.txt	140	As observed experiments 3 4 AgRP significantly increased HF diet F1 17 7
0.0967214.12399421.html.plaintext.txt	141	5 chow intake data shown compared baseline condition
0.0967214.12399421.html.plaintext.txt	142	The combined administration NorBNI ss FNA significantly attenuated effect AgRP increase intake HF diet interaction F1 17 7
0.0967214.12399421.html.plaintext.txt	143	Importantly occurred despite fact combined administration two opioid receptor antagonists doses effect food intake absence AgRP F1 17 3
0.0967214.12399421.html.plaintext.txt	144	The effect AgRP increase 22 h chow intake altered combined opioid receptor antagonists data shown
0.0967214.12399421.html.plaintext.txt	145	View larger version 23K Figure 5
0.0967214.12399421.html.plaintext.txt	146	Mean 2 h intake HF diet i3vt AgRP vehicle pretreatment subthreshold doses combined NorBNI ss FNA
0.0967214.12399421.html.plaintext.txt	147	05 compared vehiclevehicle treatment
0.0967214.12399421.html.plaintext.txt	148	Discussion Top Abstract Introduction Materials Methods Results Discussion References AgRP83 132 i3vt elicits robust increase food intake lasts long 6 d 14
0.0967214.12399421.html.plaintext.txt	149	We previously reported subthreshold dose general opioid receptor antagonist naloxone injected simultaneously AgRP could attenuate acute hyperphagic effect without altering unique long term effects AgRP
0.0967214.12399421.html.plaintext.txt	150	These results implicate opioid receptor activation mediating ability AgRP acutely increase food intake 17
0.0967214.12399421.html.plaintext.txt	151	The current data extend results interesting anticipated way
0.0967214.12399421.html.plaintext.txt	152	Unlike results naloxone highest subthreshold doses either micro selective antagonist alone reduce ability AgRP increase intake
0.0967214.12399421.html.plaintext.txt	153	However micro antagonists combined doses effect food intake administered without AgRP significantly attenuated ability AgRP increase intake HF diet
0.0967214.12399421.html.plaintext.txt	154	Like naloxone effect associated acute effects AgRP combined micro receptor antagonism could block long term effects AgRP
0.0967214.12399421.html.plaintext.txt	155	These data therefore consistent hypothesis acute effect AgRP increase food intake depends activation opioid receptors
0.0967214.12399421.html.plaintext.txt	156	However data also indicate either micro opioid receptor activation sufficient mediate effects AgRP receptor subtypes blocked AgRP longer activate critical aspects CNS circuitry necessary increase food intake acutely
0.0967214.12399421.html.plaintext.txt	157	This result potentially analogous NPY suprathreshold doses either micro receptor antagonists reduce orexigenic effect NPY 25
0.0967214.12399421.html.plaintext.txt	158	However experiments determined whether combined micro receptor blockade would inhibit NPY induced feeding
0.0967214.12399421.html.plaintext.txt	159	NPY AgRP largely colocalized within arcuate nucleus hypothalamus 8 9 26 mRNA elevated fasting also obob dbdb mice 27
0.0967214.12399421.html.plaintext.txt	160	Moreover acute effects NPY AgRP associated recruitment many brain regions 28
0.0967214.12399421.html.plaintext.txt	161	Consequently current data extend similarity NPY AgRP include recruiting opioid receptor subtypes
0.0967214.12399421.html.plaintext.txt	162	Several lines evidence implicate opioid system control food intake 29
0.0967214.12399421.html.plaintext.txt	163	Microinjection experiments identified numerous sites every level neuroaxis opioid agonist antagonists affect food intake review see Ref
0.0967214.12399421.html.plaintext.txt	164	In particular whereas opioid agonists antagonists increase decrease food intake respectively also influence food choice
0.0967214.12399421.html.plaintext.txt	165	Both micro selective antagonists found decrease intake HF diet greater extent decrease intake high carbohydrate diet 31
0.0967214.12399421.html.plaintext.txt	166	Controversy exists however whether effect opioids alter animal choice macronutrients simply drive organism consume already preferred food 32
0.0967214.12399421.html.plaintext.txt	167	Regardless interpretation consistent important role opioid receptor subtypes mediating effects AgRP
0.0967214.12399421.html.plaintext.txt	168	Similar occurs manipulation opioid receptor signaling administration AgRP selectively increases intake preferred HF diet 17
0.0967214.12399421.html.plaintext.txt	169	Additionally stimulation micro receptors nucleus accumbens preferentially enhances HF feeding 33
0.0967214.12399421.html.plaintext.txt	170	Such strong parallels AgRP opioid receptor ligands food intake food selection strengthen hypothesis two systems interact important way influence food intake food choice
0.0967214.12399421.html.plaintext.txt	171	The opioid system encompasses number distributed receptor populations well number endogenous ligands receptors
0.0967214.12399421.html.plaintext.txt	172	In experiments opioid receptor antagonists delivered third ventricle hence close hypothalamus
0.0967214.12399421.html.plaintext.txt	173	However given lipophyllic nature compounds rostral caudal flow cerebrospinal fluid ventricular system likely antagonists could interact opioid receptors variety neuroanatomical sites 34
0.0967214.12399421.html.plaintext.txt	174	Although experiments therefore cannot determine exact location critical micro opioid receptors clues derived areas show increases fos like immunoreactivity third ventricular administration AgRP
0.0967214.12399421.html.plaintext.txt	175	Two hours AgRP administration fos increased accumbens shell lateral septum paraventricular dorsomedial nuclei hypothalamus
0.0967214.12399421.html.plaintext.txt	176	After 24 h fos increased accumbens shell lateral septum central nucleus amygdala lateral hypothalamus nucleus solitary tract 35
0.0967214.12399421.html.plaintext.txt	177	All regions show evidence micro receptor binding andor expression nucleus solitary tract lateral hypothalamus show high levels binding receptors 33 36 37
0.0967214.12399421.html.plaintext.txt	178	Future research need address whether activation either micro receptor subtypes sufficient produce AgRP effects neuroanatomical sites occurs result activation disparate sites
0.0967214.12399421.html.plaintext.txt	179	A separate related question endogenous opioid ligand ligands blocked specific receptor antagonists increased release AgRP administration
0.0967214.12399421.html.plaintext.txt	180	The search specific functions opioid ligands hampered fact interact multiple subtypes opioid receptors 20 38 recent demonstration opioid receptor subtypes make heterodimers 39
0.0967214.12399421.html.plaintext.txt	181	Nevertheless ss endorphin dynorphin high affinity micro opioid receptors 40 41 42 ss endorphin made arcuate nucleus hypothalamus 43 cells hypothesized express MC3 receptor 44 45 nucleus solitary tract region high MC4 receptor expression
0.0967214.12399421.html.plaintext.txt	182	Thus possible AgRP given third ventricle could exert direct effects one ss endorphin populations
0.0967214.12399421.html.plaintext.txt	183	Food intake stimulated ss endorphin significantly dose dependently attenuated pretreatment either micro selective antagonists 46 47
0.0967214.12399421.html.plaintext.txt	184	47 antagonists worked high equimolar doses relative ss FNA conceivable could exerting effects multiple rather specific opioid receptors
0.0967214.12399421.html.plaintext.txt	185	Because none antagonist doses used Silva study completely eliminated ss endorphin induced feeding proposed analogous findings AgRP blockade multiple opioid receptors might necessary produce effect
0.0967214.12399421.html.plaintext.txt	186	Dynorphin made paraventricular nucleus lateral area hypothalamus regions express high levels MC4 receptor 48
0.0967214.12399421.html.plaintext.txt	187	Both group Berthoud colleagues 35 shown AgRP induced fos lateral hypothalamus colocalized orexin A immunoreactivity
0.0967214.12399421.html.plaintext.txt	188	Because dynorphin heavily colocalized orexin A lateral hypothalamus 49 provides direct evidence AgRP activate dynorphin containing neurons
0.0967214.12399421.html.plaintext.txt	189	Use either mice targeted deletion ss endorphin 50 51 dynorphin could clarify role two opioid peptides orexigenic actions AgRP
0.0967214.12399421.html.plaintext.txt	190	The exact role opioid system control food intake remains uncertain
0.0967214.12399421.html.plaintext.txt	191	Given large number different receptors ligands however likely role one dimensional rather encompasses number aspects ingestive behavior 19
0.0967214.12399421.html.plaintext.txt	192	The present data point specific role micro opioid receptors mediating effects hypothalamic MC system
0.0967214.12399421.html.plaintext.txt	193	This intimate relationship MC system points long term regulation energy balance one important roles played opioid system
0.0967214.12399421.html.plaintext.txt	194	Future research need address functional interactions opioid system hypothalamic peptides also explore potential involvement opioid system etiology treatment disorders energy balance regulation obesity
0.0967214.12399421.html.plaintext.txt	195	Footnotes This work supported funds NIH DK 54080 DK 17844 DK 56863 funds Procter amp Gamble Cincinnati OH
0.0967214.12399421.html.plaintext.txt	196	Abbreviations AgRP Agouti related protein ASP agouti signaling protein CNS central nervous system ss FNA ss funaltrexamine HF high fat i3vt administered third ventricle MC melanocortin NorBNI Binaltorphine NPY neuropeptide Y
0.0967214.12399421.html.plaintext.txt	197	Accepted publication July 22 2002
0.0967214.12399421.html.plaintext.txt	198	References Top Abstract Introduction Materials Methods Results Discussion References Cone RD 1999 The central melanocortin system energy homeostasis
0.0967214.12399421.html.plaintext.txt	199	Trends Endocrinol Metab 10211 216CrossRefMedline Benoit SC Schwartz MW Baskin DG Woods SC Seeley RJ 2000 CNS melanocortin system involvement regulation food intake body weight
0.0967214.12399421.html.plaintext.txt	200	Horm Behav 37299 308CrossRefMedline Thiele T van DG Yagaloff K Fisher S Schwartz M Burn P Seeley R 1998 Central infusion melanocortin agonist MTII rats assessment c fos expression taste aversion
0.0967214.12399421.html.plaintext.txt	201	Am J Physiol 274R248 R254 Fan W Boston B Kesterson R Hruby V Cone R 1997 Role melanocortinergic neurons feeding agouti obesity syndrome
0.0967214.12399421.html.plaintext.txt	202	Nature 385 165 168 Cone RD Lu D Koppula S Vage DI Klungland H Boston B Chen W Orth DN Pouton C Kesterson RA 1996 The melanocortin receptors agonists antagonists hormonal control pigmentation
0.0967214.12399421.html.plaintext.txt	203	Recent Prog Horm Res 51287 320Medline Ollmann MM Lamoreux ML Wilson BD Barsh GS 1998 Interaction agouti protein melanocortin 1 receptor vitro vivo
0.0967214.12399421.html.plaintext.txt	204	Genes Dev 12316 330AbstractFree Full Text Fong T Mao C MacNeil T Kalyani R Smith T Weinberg D Tota M Van dPL 1997 ART protein product agouti related transcript antagonist MC 3 MC 4 receptors
0.0967214.12399421.html.plaintext.txt	205	Biochem Biophy Res Commun 237629 631CrossRefMedline Hahn TM Breininger JF Baskin DG Schwartz MW 1998 Coexpression Agrp NPY fasting activated hypothalamic neurons
0.0967214.12399421.html.plaintext.txt	206	Nat Neurosci 1271 272CrossRefMedline Chen P Li C Haskell Luevano C Cone RD Smith MS 1999 Altered expression agouti related protein colocalization neuropeptide Y arcuate nucleus hypothalamus lactation
0.0967214.12399421.html.plaintext.txt	207	Endocrinology 1402645 2650AbstractFree Full Text Ollmann M Wilson B Yang Y Kerns J Chen Y Gantz I Barsh G 1997 Antagonism central melanocortin receptors vitro vivo agouti related protein
0.0967214.12399421.html.plaintext.txt	208	Science 278135 138AbstractFree Full Text Schwartz MW Seeley RJ Weigle DS Burn P Campfield LA Baskin DG 1997 Leptin increases hypothalamic proopiomelanocortin POMC mRNA expression rostral arcuate nucleus
0.0967214.12399421.html.plaintext.txt	209	Diabetes 462119 2123Abstract Elias CF Aschkenasi C Lee C Kelly J Ahima RS Bjorbaek C Flier JS Saper CB Elmquist JK 1999 Leptin differentially regulates NPY POMC neurons projecting lateral hypothalamic area
0.0967214.12399421.html.plaintext.txt	210	Neuron 23775 786CrossRefMedline Mizuno T Kleopoulos S Bergen H Roberts J Priest C Mobbs C 1998 Hypothalamic pro opiomelanocortin mRNA reduced fasting obob dbdb mice stimulated leptin
0.0967214.12399421.html.plaintext.txt	211	Diabetes 47294 297Abstract Hagan MM Rushing PA Pritchard LM Schwartz MW Strack AM Van der Ploeg HT Woods SC Seeley RJ 2000 Long term orexigenic effects AgRP 83 132 involve mechanisms melanocortin receptor blockade
0.0967214.12399421.html.plaintext.txt	212	Am J Physiol 279R47 R52 Rossi M Kim M Morgan D Small C Edwards C Sunter D Abusnana S Goldstone A Russell S Stanley S Smith D Yagaloff K Ghatei M Bloom S 1998 A C terminal fragment agouti related protein increases feeding antagonizes effect melanocyte stimulating hormone vivo
0.0967214.12399421.html.plaintext.txt	213	Endocrinology 1394428 4431AbstractFree Full Text Kotz CM Grace MK Briggs J Levine AS Billington CJ 1995 Effects opioid antagonists naloxone naltrexone neuropeptide Y induced feeding brown fat thermogenesis rat
0.0967214.12399421.html.plaintext.txt	214	J Clin Invest 96 163 170 Hagan MM Rushing PA Benoit SC Woods SC Seeley RJ 2001 Opioid receptor involvement effect AgRP 83 132 food intake food selection
0.0967214.12399421.html.plaintext.txt	215	Am J Physiol Regul Integr Comp Physiol 280R814 R821 Schmidhammer H 1998 Opioid receptor antagonists
0.0967214.12399421.html.plaintext.txt	216	Prog Med Chem 35 83 132 Glass MJ Billington CJ Levine AS 1999 Opioids food intake distributed functional neural pathways Neuropeptides 33360 368CrossRefMedline Takemori AE Ho BY Naeseth JS Portoghese PS 1988 Nor Binaltorphimine highly selective opioid antagonist analgesic receptor binding assays
0.0967214.12399421.html.plaintext.txt	217	J Pharmacol Exp Ther 246255 258Abstract Levine AS Grace M Billington CJ Portoghese PS 1990 Nor Binaltorphimine decreases deprivation opioid induced feeding
0.0967214.12399421.html.plaintext.txt	218	Brain Res 53460 64CrossRefMedline Leventhal L Kirkham TC Cole JL Bodnar RJ 1995 Selective actions central micro opioid antagonists upon sucrose intake sham fed rats
0.0967214.12399421.html.plaintext.txt	219	Brain Res 685205 210CrossRefMedline Ward SJ Portoghese PS Takemori AE 1982 Pharmacological characterization vivo novel opiate ss funaltrexamine
0.0967214.12399421.html.plaintext.txt	220	J Pharmacol Exp Ther 220 494 498 Koch JE Bodnar RJ 1994 Selective alterations macronutrient intake food deprived glucoprivic rats centrally administered opioid receptor subtype antagonists rats
0.0967214.12399421.html.plaintext.txt	221	Brain Res 657191 201CrossRefMedline Kotz CM Grace MK Billington CJ Levine AS 1993 The effect norbinaltorphimine ss funaltrexamine naltrindole NPY induced feeding
0.0967214.12399421.html.plaintext.txt	222	Brain Res 631325 328CrossRefMedline Broberger C De Lecea L Sutcliffe JG Hokfelt T 1998 Hypocretinorexin melanin concentrating hormone expressing cells form distinct populations rodent lateral hypothalamus relationship neuropeptide Y agouti gene related protein systems
0.0967214.12399421.html.plaintext.txt	223	CO2 S 602Abstract Hagan MM Benoit SC Rushing PA Pritchard LM Woods SC Seeley RJ 2001 Immediate prolonged patterns agouti related peptide 83 132 induced c fos activation hypothalamic extrahypothalamic sites
0.0967214.12399421.html.plaintext.txt	224	Endocrinology 1421050 1056AbstractFree Full Text Glass MJ Billington CJ Levine AS 1999 Opioids food intake distributed functional neuronal pathways Neuropeptides 33360 368CrossRefMedline Glass MJ Grace M Cleary JP Billington CJ Levine AS 1996 Potency naloxone anorectic effect rats dependent diet preference
0.0967214.12399421.html.plaintext.txt	225	Am J Physiol 271R217 R221 Islam AK Bodnar RJ 1990 Selective opioid receptor antagonist effects upon intake high fat diet rats
0.0967214.12399421.html.plaintext.txt	226	Brain Res 508293 296CrossRefMedline Giraudo SQ Grace MK Billington CJ Levine AS 1999 Differential effects neuropeptide Y micro agonist DAMGO palatability vs
0.0967214.12399421.html.plaintext.txt	227	Brain Res 834160 163CrossRefMedline Zhang M Gosnell BA Kelley AE 1998 Intake high fat food selectively enhanced micro opioid receptor stimulation within nucleus accumbens
0.0967214.12399421.html.plaintext.txt	228	J Pharmacol Exp Ther 285908 914AbstractFree Full Text Schroeder RL Weinger MB Vakassian L Koob GF 1991 Methylnaloxonium diffuses rat brain slowly naloxone direct intracerebral injection
0.0967214.12399421.html.plaintext.txt	229	Neurosci Lett 121173 177CrossRefMedline Zheng H Corkern M Crousillac S Patterson L Phifer C Berthoud H 2002 Neurochemical phenotype hypothalamic neurons showing fos expression 23 hours following intracranial AgRP
0.0967214.12399421.html.plaintext.txt	230	Am J Physiol 282R1773 R1781 Mansour A Fox CA Burke S Meng F Thompson RC Akil H Watson SJ 1994 micro opioid receptor mRNA expression rat CNS situ hybridization study
0.0967214.12399421.html.plaintext.txt	231	J Comp Neurol 350412 438Medline Mansour A Fox CA Thompson RC Akil H Watson SJ 1994 micro Opioid receptor mRNA expression rat CNS comparison micro receptor binding
0.0967214.12399421.html.plaintext.txt	232	Brain Res 643245 265Medline Rothman RB Bykov V Mahboubi A Long JB Jiang Q Porreca F de Costa BR Jacobson AE Rice KC Holaday JW 1991 Interaction ss funaltrexamine 3HcycloFOXY binding rat brain evidence ss FNA alkylates opioid receptor complex
0.0967214.12399421.html.plaintext.txt	233	Synapse 886 99Medline Gomes I Jordan BA Gupta A Trapaidze N Nagy V Devi LA 2000 Heterodimerization micro opioid receptors role opiate synergy
0.0967214.12399421.html.plaintext.txt	234	J Neurosci 20RC110 Chang KJ Cooper BR Hazum E Cuatrecasas P 1979 Multiple opiate receptors different regional distribution brain differential binding opiates opioid peptides
0.0967214.12399421.html.plaintext.txt	235	Mol Pharmacol 1691 104Abstract Schulz R Wuster M Herz A 1979 Supersensitivity opioids following chronic blockade endorphin action naloxone
0.0967214.12399421.html.plaintext.txt	236	Naunyn Schmiedebergs Arch Pharmacol 30693 96Medline Akil H Hewlett WA Barchas JD Li CH 1980 Binding 3H ss endorphin rat brain membranes characterization opiate properties interaction ACTH
0.0967214.12399421.html.plaintext.txt	237	Eur J Pharmacol 641 8CrossRefMedline Watson SJ Akil H Richard 3rd CW Barchas JD 1978 Evidence two separate opiate peptide neuronal systems
0.0967214.12399421.html.plaintext.txt	238	Nature 275226 228Medline Haskell Luevano C Chen P Li C Chang K Smith MS Cameron JL Cone RD 1999 Characterization neuroanatomical distribution agouti related protein immunoreactivity rhesus monkey rat
0.0967214.12399421.html.plaintext.txt	239	Endocrinology 1401408 1415AbstractFree Full Text Bagnol D Lu XY Kaelin CB Day HE Ollmann M Gantz I Akil H Barsh GS Watson SJ 1999 Anatomy endogenous antagonist relationship agouti related protein proopiomelanocortin brain
0.0967214.12399421.html.plaintext.txt	240	J Neurosci 19RC26 Olson GA Olson RD Kastin AJ 1990 Endogenous opiates 1989
0.0967214.12399421.html.plaintext.txt	241	Peptides 111277 1304CrossRefMedline Silva RM Hadjimarkou MM Rossi GC Pasternak GW Bodnar RJ 2001 ss Endorphin induced feeding pharmacological characterization using selective opioid antagonists antisense probes rats
0.0967214.12399421.html.plaintext.txt	242	J Pharmacol Exp Ther 297590 596AbstractFree Full Text Watson SJ Khachaturian H Taylor L Fischli W Goldstein A Akil H 1983 Pro dynorphin peptides found neurons throughout rat brain immunocytochemical study
0.0967214.12399421.html.plaintext.txt	243	Proc Natl Acad Sci USA 80891 894Abstract Chou TC Lee CE Lu J Elmquist JK Hara J Willie JT Beuckmann CT Chemelli RM Sakurai T Yanagisawa M Saper CB Scammell TE 2001 Orexin hypocretin neurons contain dynorphin
0.0967214.12399421.html.plaintext.txt	244	J Neurosci 21RC168 Rubinstein M Mogil JS Japon M Chan EC Allen RG Low MJ 1996 Absence opioid stress induced analgesia mice lacking ss endorphin site directed mutagenesis
0.0967214.12399421.html.plaintext.txt	245	Proc Natl Acad Sci USA 933995 4000AbstractFree Full Text Bernstein HG Keilhoff G Seidel B Stanarius A Huang PL Fishman MC Reiser M Bogerts B Wolf G 1998 Expression hypothalamic peptides mice lacking neuronal nitric oxide synthase reduced ss END immunoreactivity arcuate nucleus
0.0967214.12399421.html.plaintext.txt	246	Neuroendocrinology 68403 411CrossRefMedline
0.23939125.12519822.html.plaintext.txt	0	Time Wake Up Individual Variation Sleep Needs Scott A
0.23939125.12519822.html.plaintext.txt	1	Yale Child Health Research Center Yale University New Haven Connecticut 06520
0.23939125.12519822.html.plaintext.txt	2	Address correspondence requests reprints Scott A
0.23939125.12519822.html.plaintext.txt	3	Yale Child Health Research Center Yale University New Haven Connecticut 06520
0.23939125.12519822.html.plaintext.txt	4	In novel important set clinical studies reported issue JCEM Aeschbach et al
0.23939125.12519822.html.plaintext.txt	5	1 examined long short sleepers sleep greater 9 h less 6 h per night respectively
0.23939125.12519822.html.plaintext.txt	6	Assessing melatonin cortisol levels monitoring body temperature found longer biological night long sleepers short sleepers characterized greater duration nocturnal melatonin secretion later early morning temperature nadirs cortisol peaks 1
0.23939125.12519822.html.plaintext.txt	7	Thus physiological processes mark output circadian timing system parallel sleep duration
0.23939125.12519822.html.plaintext.txt	8	The findings Aeschbach et al
0.23939125.12519822.html.plaintext.txt	9	1 give credence everyday observations sleep needs vary individually suggest amount sleep need reflects intrinsic factors
0.23939125.12519822.html.plaintext.txt	10	These observations also underlie difficult change sleep patterns fighting inherent physiology
0.23939125.12519822.html.plaintext.txt	11	The notion one sleep duration intrinsically determined widespread implications many disciplines including industry healthcare education
0.23939125.12519822.html.plaintext.txt	12	Sleep debt caused sleep deprivation recognized cause industrial accidents impaired worker productivity 2
0.23939125.12519822.html.plaintext.txt	13	For example roadway accidents common sleep deprived truck drivers 3
0.23939125.12519822.html.plaintext.txt	14	The productivity air traffic controllers adversely affected shift work well 4
0.23939125.12519822.html.plaintext.txt	15	The excessive work hours medical house officers work night call raised concern patient safety
0.23939125.12519822.html.plaintext.txt	16	Understandably issue caught scrutiny legislators regulatory agencies 5
0.23939125.12519822.html.plaintext.txt	17	These efforts resulted new policies limit work hours medical staff
0.23939125.12519822.html.plaintext.txt	18	Not curtailing sleep adults name productivity educational system cutting sleep children adolescents
0.23939125.12519822.html.plaintext.txt	19	In many educational districts school day begins early morning hours 6
0.23939125.12519822.html.plaintext.txt	20	It uncommon see children standing street corners awaiting school buses early morning darkness
0.23939125.12519822.html.plaintext.txt	21	Reflecting fact difficult advance hands one biological clock irrespective age adverse effects reduced sleep early morning awakening academic performance increasingly recognized children adolescents 6
0.23939125.12519822.html.plaintext.txt	22	We live society control photic environment simple flip switch convenient clap hands
0.23939125.12519822.html.plaintext.txt	23	Using alarm clocks planned schedules believe override natural sleep needs
0.23939125.12519822.html.plaintext.txt	24	We believe comfortably live lives synchrony 24 h light dark cycle reverse days nights without penalty
0.23939125.12519822.html.plaintext.txt	25	However reflected ever increasing number businesses devoted optimizing schedules shift workers difficult willfully change sleep habits hands circadian clock
0.23939125.12519822.html.plaintext.txt	26	It thought exposing shift workers bright light night circadian clock could reset
0.23939125.12519822.html.plaintext.txt	27	Yet unless stringent efforts made limit daytime lighting exposure resetting biological clock occur melatonin cortisol rhythms may remain phase periods sleep wakefulness 7
0.23939125.12519822.html.plaintext.txt	28	Individuals working night may thus phase optimal periods alertness task performance
0.23939125.12519822.html.plaintext.txt	29	Efforts develop agents reset circadian clock
0.23939125.12519822.html.plaintext.txt	30	jet lag drugs also largely unrealized 8
0.23939125.12519822.html.plaintext.txt	31	Despite popular hype melatonin conveniently shift circadian phase data support notion striking show modest effects best 9 10
0.23939125.12519822.html.plaintext.txt	32	Just difficult change one circadian phase observations Aeschbach et al
0.23939125.12519822.html.plaintext.txt	33	1 provide basis difficult change sleep habits
0.23939125.12519822.html.plaintext.txt	34	Because duration biological night varies individually may difficult individuals adapt condensed sleep schedules others
0.23939125.12519822.html.plaintext.txt	35	Strategies guidelines aimed improving health productivity shift workers may therefore effective individuals ineffective others
0.23939125.12519822.html.plaintext.txt	36	The biological basis variability sleep duration unknown present remains intriguing issue
0.23939125.12519822.html.plaintext.txt	37	An evolving body evidence suggests sleep cycle circadian rhythmicity integrally related circadian system influencing timing duration sleep
0.23939125.12519822.html.plaintext.txt	38	Expressed circadian rhythms like sleep wake cycle rhythms hormone production generated regulated biological clock located suprachiasmatic nuclei SCN anterior hypothalamus 11
0.23939125.12519822.html.plaintext.txt	39	Damage nuclei results episodes sleep wakefulness occurring throughout 24 h day rather consolidated night
0.23939125.12519822.html.plaintext.txt	40	SCN damage also results increase total duration sleep primates 12
0.23939125.12519822.html.plaintext.txt	41	Over past decade dissection molecular hands circadian clock lead fascinating new insights
0.23939125.12519822.html.plaintext.txt	42	The generation circadian rhythms seems related complex interaction handful transcriptional regulators kinases resulting 24 h cycles protein expression action SCN 11
0.23939125.12519822.html.plaintext.txt	43	In mammals factors include proteins PERIOD CLOCK CRY BMAL casein kinase 1 11
0.23939125.12519822.html.plaintext.txt	44	Mutations factors discovered recently
0.23939125.12519822.html.plaintext.txt	45	In humans mutations PERIOD 2 associated advanced circadian phase syndrome 13
0.23939125.12519822.html.plaintext.txt	46	Individuals condition wake early morning retire bed early evening hours
0.23939125.12519822.html.plaintext.txt	47	In animals mutations CLOCK result abnormal disorganized sleep problems 14
0.23939125.12519822.html.plaintext.txt	48	Mutations casein kinase 1 result short circadian day period 15
0.23939125.12519822.html.plaintext.txt	49	Whereas possible localize circadian clock mammals discrete region brain brain regions involved sleep organization far diffuse involving complex subcortical networks 16
0.23939125.12519822.html.plaintext.txt	50	Similar clock gene mutations providing insights biological basis circadian rhythmicity discovery novel proteins also provided insights pathogenesis sleep disorders 17 18 19
0.23939125.12519822.html.plaintext.txt	51	The inability produce respond orexinhypocretin found cause narcolepsy 17 likely seminal discovery lead new diagnostic tests treatment disorder 17
0.23939125.12519822.html.plaintext.txt	52	By coupling knowledge basic clock sleep mechanisms powerful genetic approaches permit identification specific genes small cohorts likely identification elucidation factors regulate duration timing sleep 18
0.23939125.12519822.html.plaintext.txt	53	The continued characterization individual variation sleep identification families cohorts unusual sleep circadian properties also greatly enhance genetic approaches regard
0.23939125.12519822.html.plaintext.txt	54	Thus may someday learn individuals ability stay watch David Letterman 11 o clock news whereas others retire news 10 o clock
0.23939125.12519822.html.plaintext.txt	55	Society industry medicine becoming increasingly aware importance sleep proper timing sleep cycles reflected sleep work hour related laws
0.23939125.12519822.html.plaintext.txt	56	However compared advances understanding basic sleep circadian physiology molecular biology public attention arena lagged considerably
0.23939125.12519822.html.plaintext.txt	57	We readily manipulate photic environment yet stubbornly recognize difficult overcome mother nature change timing amount sleep need
0.23939125.12519822.html.plaintext.txt	58	Increasingly seem value alarm clocks internal clocks
0.23939125.12519822.html.plaintext.txt	59	Thus important challenge modern fluid society able accommodate normal circadian cycle individual sleep requirements name progress productivity
0.23939125.12519822.html.plaintext.txt	60	Abbreviation SCN Suprachiasmatic nuclei
0.23939125.12519822.html.plaintext.txt	61	Aeschbach D Sher L Postolache TT Matthews JR Jackson MA Wehr TA 2003 A longer biological night long sleepers short sleepers
0.23939125.12519822.html.plaintext.txt	62	J Clin Endocrinol Metab 8826 30AbstractFree Full Text Bonnet MH Arand DL 1995 We chronically sleep deprived
0.23939125.12519822.html.plaintext.txt	63	Sleep 18908 911Medline Braver ER Pantula JF 1998 The sleep long haul truck drivers
0.23939125.12519822.html.plaintext.txt	64	N Engl J Med 338389 discussion 391Free Full Text Luna TD 1997 Air traffic controller shiftwork implications aviation safety A review
0.23939125.12519822.html.plaintext.txt	65	Aviat Space Environ Med 6869 79Medline Gaba DM Howard SK 2002 Fatigue among clinicians safety patients
0.23939125.12519822.html.plaintext.txt	66	N Engl J Med 3471249 1255Free Full Text Carskadon MA Wolfson AR Acebo C Tzischinsky O Seifer R 1998 Adolescent sleep patterns circadian timing sleepiness transition early school days
0.23939125.12519822.html.plaintext.txt	67	Sleep 21871 881Medline Czeisler CA Johnson MP Duffy JF Brown EN Ronda JM Kronauer RE 1990 Exposure bright light darkness treat physiologic maladaptation night work
0.23939125.12519822.html.plaintext.txt	68	N Engl J Med 3221253 1259Abstract Dawson D Armstrong SM 1996 Chronobiotics drugs shift rhythms
0.23939125.12519822.html.plaintext.txt	69	Pharmacol Ther 6915 36CrossRefMedline Hao H Rivkees S 2000 Melatonin shift circadian phase baboons
0.23939125.12519822.html.plaintext.txt	70	J Clin Endocrinol Metab 853618 3622AbstractFree Full Text Sharkey KM Eastman CI 2002 Melatonin phase shifts human circadian rhythms placebo controlled simulated night work study
0.23939125.12519822.html.plaintext.txt	71	Am J Physiol Regul Integr Comp Physiol 282R454 R63 Reppert SM Weaver DR 2002 Coordination circadian timing mammals
0.23939125.12519822.html.plaintext.txt	72	Nature 418935 941CrossRefMedline Edgar DM Dement WC Fuller CA 1993 Effect SCN lesions sleep squirrel monkeys evidence opponent processes sleep wake regulation
0.23939125.12519822.html.plaintext.txt	73	J Neurosci 131065 1079Abstract Toh KL Jones CR He Y Eide EJ Hinz WA Virshup DM Ptacek LJ Fu YH 2001 An hPer2 phosphorylation site mutation familial advanced sleep phase syndrome
0.23939125.12519822.html.plaintext.txt	74	Science 2911040 1043AbstractFree Full Text Naylor E Bergmann BM Krauski K Zee PC Takahashi JS Vitaterna MH Turek FW 2000 The circadian clock mutation alters sleep homeostasis mouse
0.23939125.12519822.html.plaintext.txt	75	J Neurosci 208138 8143AbstractFree Full Text Eide EJ Virshup DM 2001 Casein kinase I another cog circadian clockworks
0.23939125.12519822.html.plaintext.txt	76	Chronobiol Int 18389 398CrossRefMedline Pace Schott EF Hobson JA 2002 The neurobiology sleep genetics cellular physiology subcortical networks
0.23939125.12519822.html.plaintext.txt	77	Nat Rev Neurosci 3591 605Medline Taheri S Zeitzer JM Mignot E 2002 The role hypocretins orexins sleep regulation narcolepsy
0.23939125.12519822.html.plaintext.txt	78	Annu Rev Neurosci 25283 313CrossRefMedline Tafti M Franken P 2002 Invited review genetic dissection sleep
0.23939125.12519822.html.plaintext.txt	79	J Appl Physiol 921339 1347AbstractFree Full Text Franken P Chollet D Tafti M 2001 The homeostatic regulation sleep need genetic control
0.23939125.12519822.html.plaintext.txt	80	J Neurosci 212610 2621AbstractFree Full Text This Article Full Text PDF Submit related Letter Editor Purchase Article View Shopping Cart Alert article cited Alert eLetters posted Alert correction posted Citation Map Services Email article friend Similar articles journal Similar articles PubMed Alert new issues journal Download citation manager Request Copyright Permission Google Scholar Articles Rivkees S
0.23939125.12519822.html.plaintext.txt	81	Articles citing Article PubMed PubMed Citation Articles Rivkees S
0.23939125.12519822.html.plaintext.txt	82	HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS Endocrinology Endocrine Reviews J
0.23939125.12519822.html.plaintext.txt	83	Molecular Endocrinology Recent Prog
0.16720255.15271651.html.plaintext.txt	0	Orexin A stimulate food intake old rats Saeko Takano12 Setsuko Kanai1 Hiroko Hosoya1 Minoru Ohta1 Hiroshi Uematsu2 Kyoko Miyasaka1
0.16720255.15271651.html.plaintext.txt	1	1Department Clinical Physiology Tokyo Metropolitan Institute Gerontology Tokyo 173 0015 2Gerodontology Department Gerodontology Division Gerontology Gerodontology Graduate School Tokyo Medical Dental University Tokyo 113 8549 Japan
0.16720255.15271651.html.plaintext.txt	2	Submitted 13 May 2004 accepted final form 13 July 2004
0.16720255.15271651.html.plaintext.txt	3	ABSTRACT TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES Aging associated progressive decrease appetite food intake
0.16720255.15271651.html.plaintext.txt	4	Both A B orexins expressed specific neurons lateral hypothalamic area implicated regulation sleep feeding
0.16720255.15271651.html.plaintext.txt	5	In study stimulatory effect intracerebroventricular administration orexins food intake compared young 4 mo old old 25 27 mo old male Wistar rats
0.16720255.15271651.html.plaintext.txt	6	A stainless steel cannula implanted stereotactically left lateral ventricle
0.16720255.15271651.html.plaintext.txt	7	After 7 day recovery period different doses 0 30 nmol orexins injected left lateral ventricle without anesthesia
0.16720255.15271651.html.plaintext.txt	8	Food water consumptions measured 1 2 4 h injection
0.16720255.15271651.html.plaintext.txt	9	The protein levels orexin receptors specific receptor orexin A OX1R receptor orexin A B OX2R hypothalamus determined Western blot analysis compared young old rats
0.16720255.15271651.html.plaintext.txt	10	Intracerebroventricular administration orexin A stimulated food intake dose dependent manner young rats
0.16720255.15271651.html.plaintext.txt	11	However effects observed dose old rats
0.16720255.15271651.html.plaintext.txt	12	The protein level OX1R hypothalamus significantly lower old rats young rats although protein level OX2R comparable groups
0.16720255.15271651.html.plaintext.txt	13	Results present study indicate function orexin system diminished old rats
0.16720255.15271651.html.plaintext.txt	14	The decrease OX1R protein level hypothalamus could responsible orexin As lack stimulation food intake old rats
0.16720255.15271651.html.plaintext.txt	15	age anorexia aging brain hypothalamus orexin receptor
0.16720255.15271651.html.plaintext.txt	16	AGING IS ASSOCIATED WITH A progressive decrease appetite food intake 14 15
0.16720255.15271651.html.plaintext.txt	17	The decline food intake often happens healthy elderly persons predisposes pathological weight loss protein energy malnutrition thereby raising morbidity mortality
0.16720255.15271651.html.plaintext.txt	18	The reasons decline food intake multifactorial
0.16720255.15271651.html.plaintext.txt	19	Although sensitivity CCK classic neuropeptide shows satiety effect enhanced old animals 21 mechanism underlying effect elucidated 12
0.16720255.15271651.html.plaintext.txt	20	Orexins appetite stimulating peptides discovered 1998 18
0.16720255.15271651.html.plaintext.txt	21	Classified orexin A orexin B neuropeptides endogenous ligands orphan G protein coupled receptor
0.16720255.15271651.html.plaintext.txt	22	Orexin A 33 amino acids orexin B 28 amino acids peptides produced single precursor polypeptide preproorexin
0.16720255.15271651.html.plaintext.txt	23	Two orexin receptor subtypes identified orexin 1 receptor OX1R selective orexin A whereas orexin 2 receptor OX2R nonselective receptor orexin A B neuropeptide agonists
0.16720255.15271651.html.plaintext.txt	24	Orexins expressed almost exclusively lateral hypothalamic area 18 region classically implicated control mammalian feeding behavior 19
0.16720255.15271651.html.plaintext.txt	25	When administered centrally rats peptides stimulate food consumption dose dependently 18
0.16720255.15271651.html.plaintext.txt	26	In addition preproorexin mRNA level upregulated fasting 18
0.16720255.15271651.html.plaintext.txt	27	These findings suggested orexin neuropeptide system plays significant role feeding behavior orexins therefore categorized orexigenic appetite stimulating factors
0.16720255.15271651.html.plaintext.txt	28	Moreover reported 13 orexin A stimulates pancreatic exocrine secretion via vagal efferent nerves orexin A may important candidate mediator cephalic phase secretory response feeding
0.16720255.15271651.html.plaintext.txt	29	In present study determine mechanism age associated decrease appetite food intake compared food intake young old male rats indication stimulatory effect intracerebroventricular administration orexins
0.16720255.15271651.html.plaintext.txt	30	We also examined protein expression orexin receptors hypothalamus important region brain regulation food intake
0.16720255.15271651.html.plaintext.txt	31	MATERIALS AND METHODS TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES All animal procedures accord Guiding Principles Care Use Animals approved Physiological Society Japan
0.16720255.15271651.html.plaintext.txt	32	The procedures also approved Ethics Committee Animal Experimentation Tokyo Metropolitan Institute Gerontology
0.16720255.15271651.html.plaintext.txt	33	Synthetic orexin A 33 amino acid peptide orexin B 28 amino acid peptide purchased Peptide Institute Osaka Japan
0.16720255.15271651.html.plaintext.txt	34	A stainless steel cannula 22 gauge guide cannula 28 gauge insert Plastic One Roanoke VA used study
0.16720255.15271651.html.plaintext.txt	35	For Western blot analysis used primary antibody OX1R OX1R11 A OX2R OX2R11 A Alpha Diagnostic International San Antonio TX secondary anti rabbit IgG horseradish peroxidase linked whole antibody Amersham Life Sciences Piscataway NJ
0.16720255.15271651.html.plaintext.txt	36	Young 4 mo old 260 335 g body wt old 25 27 mo old 365 440 g body wt Wistar rats purchased Shizuoka Jikken Dobutsu Shizuoka Japan 4 wk age maintained specific pathogen free aging farm institute
0.16720255.15271651.html.plaintext.txt	37	They given commercial rat chow CRF 1 Oriental Yeast Tokyo Japan kept room controlled temperature 23 plus minus 1 degrees C 1212 h light dark cycle starting 0800
0.16720255.15271651.html.plaintext.txt	38	The rats anesthetized intraperitoneal injection pentobarbital sodium 3 4 mg100 g body wt
0.16720255.15271651.html.plaintext.txt	39	For intracerebroventricular injection orexins stainless steel cannula implanted stereotactically left lateral ventricle using following coordinates bregma anteroposterior 1
0.16720255.15271651.html.plaintext.txt	40	After operation rats maintained individual cages 1 ratcage conditions controlled temperature 24 degrees C illumination 1212 h light dark cycle 7 days
0.16720255.15271651.html.plaintext.txt	41	Each rat provided food water ad libitum
0.16720255.15271651.html.plaintext.txt	42	Each mock injected handled 10 min daily minimize injection induced stress throughout 7 day recovery period
0.16720255.15271651.html.plaintext.txt	43	Effects orexins food water intake
0.16720255.15271651.html.plaintext.txt	44	We measured food water consumptions young old rats nighttime 1730 0930 total 16 h without treatment comparison
0.16720255.15271651.html.plaintext.txt	45	Orexins dissolved 1 BSAsaline
0.16720255.15271651.html.plaintext.txt	46	After 7 day recovery period experiment conducted without overnight fasting
0.16720255.15271651.html.plaintext.txt	47	At 1000 190 200 g rat chow CRF 1 water supplied orexins injected intracerebroventriculaly
0.16720255.15271651.html.plaintext.txt	48	Different doses orexin A 0
0.16720255.15271651.html.plaintext.txt	49	0 nmol10 microl injected subsequently respective 7 day recovery period one rat
0.16720255.15271651.html.plaintext.txt	50	0 nmol10 microl administered old rats confirm biological effect
0.16720255.15271651.html.plaintext.txt	51	0 nmol10 microl also determined another animal
0.16720255.15271651.html.plaintext.txt	52	Physiological saline administered vehicle
0.16720255.15271651.html.plaintext.txt	53	Injection given 20 using 50 microl Hamilton microsyringe injectors left place 10 injection ensure complete dispersal peptide
0.16720255.15271651.html.plaintext.txt	54	The remaining chow water weighed 1 2 4 h injection estimate food intake water consumption time points
0.16720255.15271651.html.plaintext.txt	55	At end experiment rat killed black ink injected lateral ventricle
0.16720255.15271651.html.plaintext.txt	56	The success cannulation verified visualization
0.16720255.15271651.html.plaintext.txt	57	Determination orexin receptors Western blot analysis
0.16720255.15271651.html.plaintext.txt	58	Young n 3 old n 3 rats killed guillotine 1000 1100 without treatment whole brains immediately removed
0.16720255.15271651.html.plaintext.txt	59	The hypothalamus quickly dissected stored 80 degrees C later experiments
0.16720255.15271651.html.plaintext.txt	60	The dissection hypothalamus carried according method Gispen et al
0.16720255.15271651.html.plaintext.txt	61	Each tissue sample separately homogenized lysis buffer
0.16720255.15271651.html.plaintext.txt	62	The respective hypothalamus homogenates 100 microg protein OX1R 200 microg protein OX2R separated SDS 10 polyacrylamide gel
0.16720255.15271651.html.plaintext.txt	63	The proteins electrophoretically transferred polyvinylidene difluoride membrane Bio Rad Hercules CA blocked 5 skim milk 1 h room temperature
0.16720255.15271651.html.plaintext.txt	64	The membrane incubated polyclonal rabbit antibody 1500 OX1R11 A 1400 OX2R21 A Alpha Diagnostics International San Antonio TX overnight 4 degrees C
0.16720255.15271651.html.plaintext.txt	65	After three washes membrane incubated secondary anti rabbit IgG 125000 OX1R 130000 OX2R 1 h room temperature
0.16720255.15271651.html.plaintext.txt	66	After three additional washes immunoreactive bands detected using Enhanced Chemiluminescence Assay System Plus Amersham Biosciences Little Chalfont UK 5
0.16720255.15271651.html.plaintext.txt	67	Autoradiograms underwent semiquantitative densitometric analysis
0.16720255.15271651.html.plaintext.txt	68	The data expressed means plus minus SE
0.16720255.15271651.html.plaintext.txt	69	The optical density immunoreactive bands calculated using NIH Image software package
0.16720255.15271651.html.plaintext.txt	70	All results expressed means plus minus SE
0.16720255.15271651.html.plaintext.txt	71	Results analyzed one way ANOVA repeated measures multiple ANOVA MANOVA followed Fishers protected least significant difference test
0.16720255.15271651.html.plaintext.txt	72	RESULTS TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES Food water consumptions nighttime young old rats
0.16720255.15271651.html.plaintext.txt	73	The food intake old rats significantly less young rats 10
0.16720255.15271651.html.plaintext.txt	74	080 g mean plus minus SE old rats vs
0.16720255.15271651.html.plaintext.txt	75	05 whereas water consumption different two groups 18
0.16720255.15271651.html.plaintext.txt	76	472 g mean plus minus SE old rats vs
0.16720255.15271651.html.plaintext.txt	77	Because body weight old rats significantly higher young rats indicated values food water intake relative body weight g100 g body wt
0.16720255.15271651.html.plaintext.txt	78	Food consumption nighttime significantly less old rats young rats P 0
0.16720255.15271651.html.plaintext.txt	79	Similarly water consumption old rats significantly less young rats P 0
0.16720255.15271651.html.plaintext.txt	80	View larger version 10K Fig
0.16720255.15271651.html.plaintext.txt	81	Food water consumptions nighttime
0.16720255.15271651.html.plaintext.txt	82	Food intake A water intake B young old rats 1 night
0.16720255.15271651.html.plaintext.txt	83	Food water intake shown relative body weight
0.16720255.15271651.html.plaintext.txt	84	All values means plus minus SE
0.16720255.15271651.html.plaintext.txt	85	The number rats group indicated parentheses P 0
0.16720255.15271651.html.plaintext.txt	86	0001 significant difference young rats ANOVA followed Fishers protected least significant difference test
0.16720255.15271651.html.plaintext.txt	87	Effects orexin A food water intake
0.16720255.15271651.html.plaintext.txt	88	Analysis multiple comparison test repeated measures MANOVA revealed intracerebroventricular injection orexin A stimulated food intake dose dependent manner 1 2 4 h young rats although effect 0
0.16720255.15271651.html.plaintext.txt	89	25 nmol orexin A significant Fig
0.16720255.15271651.html.plaintext.txt	90	The integrated food intake 4 h period shown Fig
0.16720255.15271651.html.plaintext.txt	91	Both 1 3 nmol orexin A significantly increased food intake
0.16720255.15271651.html.plaintext.txt	92	View larger version 34K Fig
0.16720255.15271651.html.plaintext.txt	93	Effect intracerebroventricular injection orexin A food intake
0.16720255.15271651.html.plaintext.txt	94	A time course effect injection 0
0.16720255.15271651.html.plaintext.txt	95	Food intake measured 1 2 4 h injection
0.16720255.15271651.html.plaintext.txt	96	B effect integrated food intake 4 h young rats
0.16720255.15271651.html.plaintext.txt	97	C time course effect injection 0
0.16720255.15271651.html.plaintext.txt	98	0 30 nmol food intake old rats
0.16720255.15271651.html.plaintext.txt	99	No significant effect observed
0.16720255.15271651.html.plaintext.txt	100	D effect integrated food intake 4 h old rats
0.16720255.15271651.html.plaintext.txt	101	No significant effect observed
0.16720255.15271651.html.plaintext.txt	102	Food intake shown relative body weight
0.16720255.15271651.html.plaintext.txt	103	All values means plus minus SE
0.16720255.15271651.html.plaintext.txt	104	The number rats group indicated parentheses P 0
0.16720255.15271651.html.plaintext.txt	105	001 significant difference saline control
0.16720255.15271651.html.plaintext.txt	106	In contrast significant increase observed old rats even higher doses 1 3 30 nmol applied Fig
0.16720255.15271651.html.plaintext.txt	107	The two higher doses orexin A tended increase water intake young rats difference significant F 2
0.16720255.15271651.html.plaintext.txt	108	0522 4 h water intake Fig
0.16720255.15271651.html.plaintext.txt	109	No effect dose observed old rats Fig
0.16720255.15271651.html.plaintext.txt	110	View larger version 37K Fig
0.16720255.15271651.html.plaintext.txt	111	Effect intracerebroventricular injection orexin A water intake
0.16720255.15271651.html.plaintext.txt	112	No significant effect observed results
0.16720255.15271651.html.plaintext.txt	113	A time course effect injection 0
0.16720255.15271651.html.plaintext.txt	114	0 nmol water intake young rats
0.16720255.15271651.html.plaintext.txt	115	Water intake measured 1 2 4 h injection
0.16720255.15271651.html.plaintext.txt	116	B effect integrated water intake 4 h young rats
0.16720255.15271651.html.plaintext.txt	117	C time course effect injection 0
0.16720255.15271651.html.plaintext.txt	118	0 30 nmol water intake old rats
0.16720255.15271651.html.plaintext.txt	119	D effect integrated water intake 4 h old rats
0.16720255.15271651.html.plaintext.txt	120	Water intake shown relative body weight
0.16720255.15271651.html.plaintext.txt	121	All values means plus minus SE
0.16720255.15271651.html.plaintext.txt	122	The number rats group indicated parentheses
0.16720255.15271651.html.plaintext.txt	123	Effects orexin B food water intake
0.16720255.15271651.html.plaintext.txt	124	Intracerebroventricular injection orexin B slightly increased food intake young old rats effect significant
0.16720255.15271651.html.plaintext.txt	125	The integrated food intake 4 h shown Fig
0.16720255.15271651.html.plaintext.txt	126	Orexin B stimulate water intake dose either young old rats Fig
0.16720255.15271651.html.plaintext.txt	127	View larger version 24K Fig
0.16720255.15271651.html.plaintext.txt	128	Effect intracerebroventricular injection orexin B food water intake
0.16720255.15271651.html.plaintext.txt	129	No significant effect observed results
0.16720255.15271651.html.plaintext.txt	130	0 nmol integrated food intake 4 h young rats
0.16720255.15271651.html.plaintext.txt	131	B effect integrated food intake 4 h old rats
0.16720255.15271651.html.plaintext.txt	132	0 nmol integrated water intake 4 h young rats
0.16720255.15271651.html.plaintext.txt	133	D effect integrated water intake 4 h old rats
0.16720255.15271651.html.plaintext.txt	134	Food water intake shown relative body weight
0.16720255.15271651.html.plaintext.txt	135	All values means plus minus SE
0.16720255.15271651.html.plaintext.txt	136	The number rats group indicated parentheses
0.16720255.15271651.html.plaintext.txt	137	Determination orexin receptors
0.16720255.15271651.html.plaintext.txt	138	Western blot analysis using anti OX1R antibody OX1R11 A detected specific bands corresponding 54 kDa Fig
0.16720255.15271651.html.plaintext.txt	139	The intensity band hypothalamus old rats significantly lower young rats ANOVA P 0
0.16720255.15271651.html.plaintext.txt	140	View larger version 18K Fig
0.16720255.15271651.html.plaintext.txt	141	Western blot analysis showing optical density
0.16720255.15271651.html.plaintext.txt	142	Western blot analysis orexin 1 receptor OX1R selective orexin A A orexin 2 receptor OX2R selective orexin A B B hypothalamus young old rats
0.16720255.15271651.html.plaintext.txt	143	Band intensity expressed optical density
0.16720255.15271651.html.plaintext.txt	144	All values means plus minus SE
0.16720255.15271651.html.plaintext.txt	145	The number rats group indicated parentheses
0.16720255.15271651.html.plaintext.txt	146	An example Western blot analysis presented top A B
0.16720255.15271651.html.plaintext.txt	147	05 significant difference young rats ANOVA followed Fishers protected least significant difference test
0.16720255.15271651.html.plaintext.txt	148	Western blot analysis using anti OX2R antibody OX2R11 A detected three bands hypothalamus young old rats 79 53 43 kDa
0.16720255.15271651.html.plaintext.txt	149	Because OX2R pure protein 52
0.16720255.15271651.html.plaintext.txt	150	5 kDa 1 compared intensity 53 kDa immunosignal young old rats Fig
0.16720255.15271651.html.plaintext.txt	151	The intensity 53 kDa bands higher old rats compared young ones difference significant
0.16720255.15271651.html.plaintext.txt	152	DISCUSSION TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES The present study showed intracerebroventricular injection orexin A 3 nmol stimulated food intake dose dependent manner young rats previously reported 4 18 20 22
0.16720255.15271651.html.plaintext.txt	153	However effect observed old rats
0.16720255.15271651.html.plaintext.txt	154	To distinguish whether old rats response orexin A blunted orexin A response effect 10 fold higher dose 30 nmol orexin A determined old rats
0.16720255.15271651.html.plaintext.txt	155	Again stimulation observed
0.16720255.15271651.html.plaintext.txt	156	Therefore concluded old rats true insensitivity feeding effect orexin A
0.16720255.15271651.html.plaintext.txt	157	To examine mechanism underlying effect orexin A measured protein levels receptor hypothalamus compared levels young old rats
0.16720255.15271651.html.plaintext.txt	158	The protein level OX1R significantly lower old rats young
0.16720255.15271651.html.plaintext.txt	159	The band intensity old rats 45 less young rats
0.16720255.15271651.html.plaintext.txt	160	This result indicates decrease OX1R protein level hypothalamus could responsible lack orexin A stimulatory effect food intake old rats
0.16720255.15271651.html.plaintext.txt	161	However cannot answer question 50 reduction protein level OX1R would yield 100 reduction behavioral response
0.16720255.15271651.html.plaintext.txt	162	Because several neural pathways involved orexigenic action orexins 16 aging change pathways might implicated
0.16720255.15271651.html.plaintext.txt	163	Another hypothesis age related decrease food intake orexin A secondary phenomenon due decline ability orexin increase arousal
0.16720255.15271651.html.plaintext.txt	164	This problem discussed previous reports 16 22 24 although record awakening time present study
0.16720255.15271651.html.plaintext.txt	165	16 reported changes food intake independent changes sleepwake cycles
0.16720255.15271651.html.plaintext.txt	166	Moreover selective OX1R antagonist SB 334867 reduced orexin A induced food intake 4
0.16720255.15271651.html.plaintext.txt	167	Previously abnormality OX2R shown cause canine narcolepsy 7
0.16720255.15271651.html.plaintext.txt	168	Because OX2R expression decrease age study decrease food intake old rats seem depend level arousal
0.16720255.15271651.html.plaintext.txt	169	A previous study 6 reported central administration orexins stimulated water intake significantly
0.16720255.15271651.html.plaintext.txt	170	However observed two higher doses orexin A significantly increase water intake even young rats
0.16720255.15271651.html.plaintext.txt	171	The differences study Kunii et al
0.16720255.15271651.html.plaintext.txt	172	6 present study different doses orexin A applied experimental conditions
0.16720255.15271651.html.plaintext.txt	173	6 determined effects 3 30 nmol orexins whereas used 0
0.16720255.15271651.html.plaintext.txt	174	25 3 nmol also measured water intake without feeding whereas measured water food consumptions simultaneously
0.16720255.15271651.html.plaintext.txt	175	A recent study 17 reported preproorexin gene expression contents orexins rat brain decreased course aging
0.16720255.15271651.html.plaintext.txt	176	There also report 25 site specific decrease immunostaining orexin observed locus coeruleus old cats
0.16720255.15271651.html.plaintext.txt	177	These reports indicate deterioration orexin system old animals
0.16720255.15271651.html.plaintext.txt	178	We measure orexin A content brain whether content decreased age remains unknown
0.16720255.15271651.html.plaintext.txt	179	However orexin A bind OX1R OX2R specificity OX1R orexin A high 18 age associated change OX1R could biologically important orexin A
0.16720255.15271651.html.plaintext.txt	180	Our observation leads us propose age associated decline OX1R may related age associated decline appetite food intake
0.16720255.15271651.html.plaintext.txt	181	On hand orexin B showed significant effect either young old rats
0.16720255.15271651.html.plaintext.txt	182	The present observation compatible previous studies 2 8 central orexin B less effective stimulant food intake orexin A
0.16720255.15271651.html.plaintext.txt	183	The protein level OX2R significantly different young old rats
0.16720255.15271651.html.plaintext.txt	184	23 measured mRNA levels OX1R OX2R eight brain regions 3 12 18 24 mo old C57BL6 mice
0.16720255.15271651.html.plaintext.txt	185	They observed declining trend OX2R mRNA level hypothalamus although age related change OX1R mRNA expression
0.16720255.15271651.html.plaintext.txt	186	These differences might due species difference although precise mechanism unknown
0.16720255.15271651.html.plaintext.txt	187	In conclusion function orexin system stimulating feeding behavior reduced old rats compared young ones
0.16720255.15271651.html.plaintext.txt	188	The decrease OX1R protein level hypothalamus could responsible orexin As lack stimulatory effect food intake old rats
0.16720255.15271651.html.plaintext.txt	189	GRANTS TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES This research supported part Health Sciences Research Grants H13 21EBM 018 Ministry Health Labour Welfare Japan
0.16720255.15271651.html.plaintext.txt	190	FOOTNOTES Address reprint requests correspondence K
0.16720255.15271651.html.plaintext.txt	191	Clinical Physiology Tokyo Metropolitan Institute Gerontology 35 2 Sakaecho Itabashiku Tokyo 173 0015 Japan E mail miyasakaattmig
0.16720255.15271651.html.plaintext.txt	192	The costs publication article defrayed part payment page charges
0.16720255.15271651.html.plaintext.txt	193	The article must therefore hereby marked advertisement accordance 18 U
0.16720255.15271651.html.plaintext.txt	194	Section 1734 solely indicate fact
0.16720255.15271651.html.plaintext.txt	195	REFERENCES TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES Cluderay JE Harrison DC Hervieu GJ
0.16720255.15271651.html.plaintext.txt	196	Protein distribution orexin 2 receptor rat central nervous system
0.16720255.15271651.html.plaintext.txt	197	Regul Pept 104 131 144 2002
0.16720255.15271651.html.plaintext.txt	198	CrossRefISIMedline Dube MG Kalra SP Kalra PS
0.16720255.15271651.html.plaintext.txt	199	Food intake elicited central administration orexinshypocretins identification hypothalamic sites action
0.16720255.15271651.html.plaintext.txt	200	Brain Res 842 473 477 1999
0.16720255.15271651.html.plaintext.txt	201	CrossRefISIMedline Gispen WH Schotman P de Kloet ER
0.16720255.15271651.html.plaintext.txt	202	Brain RNA hypophysectomy topographical study
0.16720255.15271651.html.plaintext.txt	203	Neuroendocrinology 9 285 296 1972
0.16720255.15271651.html.plaintext.txt	204	CrossRefISIMedline Haynes AC Jackson B Chapman H Tadayyon M Johns A Porter RA Arch JR
0.16720255.15271651.html.plaintext.txt	205	A selective orexin 1 receptor antagonist reduces food consumption male female rats
0.16720255.15271651.html.plaintext.txt	206	CrossRefISIMedline Irving EA Harrison DC Babbs AJ Mayes AC Campbell CA Hunter AJ Upton N Parsons AA
0.16720255.15271651.html.plaintext.txt	207	Increased cortical expression orexin 1 receptor following permanent middle cerebral artery occlusion rat
0.16720255.15271651.html.plaintext.txt	208	Neurosci Lett 324 53 56 2002
0.16720255.15271651.html.plaintext.txt	209	CrossRefISIMedline Kunii K Yamanaka A Nambu T Matsuzaki I Goto K Sakurai T
0.16720255.15271651.html.plaintext.txt	210	Orexinshypocretins regulate drinking behaviour
0.16720255.15271651.html.plaintext.txt	211	Brain Res 842 256 261 1999
0.16720255.15271651.html.plaintext.txt	212	CrossRefISIMedline Lin L Faraco J Li R Kadotani H Rogers W Lin X Qiu X de Jong PJ Nishino S Mignot E
0.16720255.15271651.html.plaintext.txt	213	The sleep disorder canine narcolepsy caused mutation hypocretin orexin receptor 2 gene
0.16720255.15271651.html.plaintext.txt	214	ISIMedline Lubkin M Stricker Krongrad A
0.16720255.15271651.html.plaintext.txt	215	Independent feeding metabolic actions orexins mice
0.16720255.15271651.html.plaintext.txt	216	Biochem Biophys Res Commun 253 241 245 1998
0.16720255.15271651.html.plaintext.txt	217	CrossRefISIMedline Masuda M Kanai S Miyasaka K
0.16720255.15271651.html.plaintext.txt	218	Central somatostatin prevents vagal efferent nerve excitation produced TRH 2 deoxy D glucose
0.16720255.15271651.html.plaintext.txt	219	Am J Physiol Gastrointest Liver Physiol 272 G351 G356 1997
0.16720255.15271651.html.plaintext.txt	220	AbstractFree Full Text Masuda M Kanai S Miyasaka K
0.16720255.15271651.html.plaintext.txt	221	Inhibitory effect central dopamine basal pancreatic secretion conscious rats
0.16720255.15271651.html.plaintext.txt	222	Am J Physiol Gastrointest Liver Physiol 274 G29 G34 1998
0.16720255.15271651.html.plaintext.txt	223	AbstractFree Full Text Masuda M Kanai S Miyasaka K Funakoshi A
0.16720255.15271651.html.plaintext.txt	224	Somatostatin inhibits pancreatic exocrine secretion centrally via sympathetic nerves conscious rats
0.16720255.15271651.html.plaintext.txt	225	J Auton Nerv Syst 56 31 37 1995
0.16720255.15271651.html.plaintext.txt	226	CrossRefISIMedline Miyasaka K Kanai S Masuda M Ohta M Kawanami T Matsumoto M Funakoshi A
0.16720255.15271651.html.plaintext.txt	227	Gene expressions cholecystokinin CCK CCK receptors satiety effect young old male rats
0.16720255.15271651.html.plaintext.txt	228	Arch Gerontol Geriatr 21 147 155 1995
0.16720255.15271651.html.plaintext.txt	229	CrossRefISI Miyasaka K Masuda M Kanai S Sato N Kurosawa M Funakoshi A
0.16720255.15271651.html.plaintext.txt	230	Central orexin A stimulates pancreatic exocrine secretion via vagus
0.16720255.15271651.html.plaintext.txt	231	CrossRefISIMedline Morley JE
0.16720255.15271651.html.plaintext.txt	232	Decreased food intake aging
0.16720255.15271651.html.plaintext.txt	233	J Gerontol A Biol Sci Med Sci 56 81 88 2001
0.16720255.15271651.html.plaintext.txt	234	AbstractFree Full Text Morley JE Silver AJ
0.16720255.15271651.html.plaintext.txt	235	Neurobiol Aging 9 9 16 1988
0.16720255.15271651.html.plaintext.txt	236	ISIMedline Muroya S Funahashi H Yamanaka A Kohno D Uramura K Nambu T Shibahara M Kuramochi M Takigawa M Yanagisawa M Sakurai T Shioda S Yada T
0.16720255.15271651.html.plaintext.txt	237	Orexins hypocretins directly interact neuropeptide Y POMC glucose responsive neurons regulate Ca2 signaling reciprocal manner leptin orexigenic neuronal pathways mediobasal hypothalamus
0.16720255.15271651.html.plaintext.txt	238	Eur J Neurosci 19 1524 1534 2004
0.16720255.15271651.html.plaintext.txt	239	CrossRefISIMedline Porkka Heiskanen T Alanko L Kalinchuk A Heiskanen S Stenberg D
0.16720255.15271651.html.plaintext.txt	240	The effect age prepro orexin gene expression contents orexin A B rat brain
0.16720255.15271651.html.plaintext.txt	241	Neurobiol Aging 25 231 238 2004
0.16720255.15271651.html.plaintext.txt	242	CrossRefISIMedline Sakurai T Amemiya A Ishii M Matsuzaki I Chemelli RM Tanaka H Williams SC Richardson JA Kozlowski GP Wilson S Arch JR Buckingham RE Haynes AC Carr SA Annan RS McNulty DE Liu WS Terrett JA Elshourbagy NA Bergsma DJ Yanagisawa M
0.16720255.15271651.html.plaintext.txt	243	Orexins orexin receptors family hypothalamic neuropeptides G protein coupled receptors regulate feeding behavior
0.16720255.15271651.html.plaintext.txt	244	ISIMedline Saper CB Swanson LW Cowan WM
0.16720255.15271651.html.plaintext.txt	245	An autoradiographic study efferent connections lateral hypothalamic area rat
0.16720255.15271651.html.plaintext.txt	246	J Comp Neurol 183 689 706 1979
0.16720255.15271651.html.plaintext.txt	247	ISIMedline Shiraishi T Oomura Y Sasaki K Wayner MJ
0.16720255.15271651.html.plaintext.txt	248	Effects leptin orexin A food intake feeding related hypothalamic neurons
0.16720255.15271651.html.plaintext.txt	249	Physiol Behav 71 251 261 2000
0.16720255.15271651.html.plaintext.txt	250	CrossRefISIMedline Silver AJ Morley JE
0.16720255.15271651.html.plaintext.txt	251	Role CCK regulation food intake
0.16720255.15271651.html.plaintext.txt	252	Prog Neurobiol 36 23 34 1991
0.16720255.15271651.html.plaintext.txt	253	CrossRefISIMedline Smart D Haynes AC Williams G Arch JR
0.16720255.15271651.html.plaintext.txt	254	Orexins treatment obesity
0.16720255.15271651.html.plaintext.txt	255	Eur J Pharmacol 440 199 212 2002
0.16720255.15271651.html.plaintext.txt	256	CrossRefISIMedline Terao A Apte Deshpande A Morairty S Freund YR Kilduff TS
0.16720255.15271651.html.plaintext.txt	257	Age related decline hypocretin orexin receptor 2 messenger RNA levels mouse brain
0.16720255.15271651.html.plaintext.txt	258	Neurosci Lett 332 190 194 2002
0.16720255.15271651.html.plaintext.txt	259	CrossRefISIMedline Willie JT Chemelli RM Sinton CM Yanagisawa M
0.16720255.15271651.html.plaintext.txt	260	To eat sleep Orexin regulation feeding wakefulness
0.16720255.15271651.html.plaintext.txt	261	Annu Rev Neurosci 24 429 458 2001
0.16720255.15271651.html.plaintext.txt	262	CrossRefISIMedline Zhang JH Sampogna S Morales FR Chase MH
0.16720255.15271651.html.plaintext.txt	263	Age related changes hypocretin orexin immunoreactivity cat brainstem
0.16720255.15271651.html.plaintext.txt	264	Brain Res 930 206 211 2002
0.088994086.10830275.html.plaintext.txt	0	Agouti Related Protein Like Immunoreactivity Characterization Release Hypothalamic Tissue Presence Serum1 Ji Yao Li Susan Finniss Ying Kui Yang Qun Zeng Song Yi Qu Greg Barsh2 Chris Dickinson Ira Gantz
0.088994086.10830275.html.plaintext.txt	1	University Michigan Ann Arbor Michigan 48109 0682 Howard Hughes Medical Institute Departments Pediatrics Genetics G
0.088994086.10830275.html.plaintext.txt	2	Stanford University Stanford California 94305 5428
0.088994086.10830275.html.plaintext.txt	3	Address correspondence requests reprints Ira Gantz M
0.088994086.10830275.html.plaintext.txt	4	Medical Center Drive Ann Arbor Michigan 48109 0682
0.088994086.10830275.html.plaintext.txt	5	Abstract Top Abstract Introduction Materials Methods Results Discussion References A novel RIA used examine release agouti related protein like immunoreactivity AGRP LI perfused rat hypothalamic tissue slices characterize AGRP LI rat serum
0.088994086.10830275.html.plaintext.txt	6	A continuous low level basal AGRP LI release observed hypothalami rats fed ad libitum rats killed
0.088994086.10830275.html.plaintext.txt	7	Basal AGRP LI release 3 fold greater rats fasted 48 h
0.088994086.10830275.html.plaintext.txt	8	In fasted animals leptin dose dependently suppressed basal AGRP LI release
0.088994086.10830275.html.plaintext.txt	9	In fed animals change basal AGRP LI release detected response 10 6 M MSH orexin B melanin concentrating hormone serotonin
0.088994086.10830275.html.plaintext.txt	10	HPLC analysis AGRP LI rat serum identified single peak eluted close proximity synthetic AGRP 87 132 mouse Leu127ProAGRP identical peak seen hypothalamic adrenal tissue extracts
0.088994086.10830275.html.plaintext.txt	11	The serum concentration AGRP LI rats fed ad libitum 0
0.088994086.10830275.html.plaintext.txt	12	323 nmolliter mean plus minus SE
0.088994086.10830275.html.plaintext.txt	13	Food deprivation resulted slow statistically significant rise serum immunoreactivity 48 h 1
0.088994086.10830275.html.plaintext.txt	14	118 nmolliter mean plus minus SE
0.088994086.10830275.html.plaintext.txt	15	Bilateral adrenalectomy change serum levels AGRP LI
0.088994086.10830275.html.plaintext.txt	16	These studies demonstrate rat different levels basal hypothalamic AGRP LI release fed fasted states fasted rat release profoundly suppressed leptin
0.088994086.10830275.html.plaintext.txt	17	These studies also suggest AGRP present systemic circulation rats
0.088994086.10830275.html.plaintext.txt	18	Introduction Top Abstract Introduction Materials Methods Results Discussion References AGOUTI RELATED protein AGRP orexigenic neuropeptide produced neuropeptide Y NPY containing neurons medial portion arcuate nucleus hypothalamus functions central control feeding behavior 1 2 3 4 5
0.088994086.10830275.html.plaintext.txt	19	Its mechanism action appears competitive antagonism MSH potent satiety inducing agent produced POMC producing neurons located laterally arcuate nucleus 2 3 4 6 7
0.088994086.10830275.html.plaintext.txt	20	Pharmacological studies using cloned melanocortin receptors MCRs demonstrated AGRP potent antagonist MSH action MC3R MC4R also potency MC5R 6
0.088994086.10830275.html.plaintext.txt	21	Both MC3R MC4R expressed within hypothalamic feeding centers
0.088994086.10830275.html.plaintext.txt	22	Therefore MCR subtypes must considered potential targets AGRP action central processes regulating food intake
0.088994086.10830275.html.plaintext.txt	23	However genetic pharmacological models firmly established role MC4R feeding behavior participation MC3R events inferred distribution messenger RNA mRNA 5 8 9 10 11
0.088994086.10830275.html.plaintext.txt	24	Release AGRP hypothalamus previously examined due lack reliable RIA
0.088994086.10830275.html.plaintext.txt	25	Therefore factors affecting acute release AGRP surmised studies examined changes level mRNA various conditions
0.088994086.10830275.html.plaintext.txt	26	Factors presently known alter AGRP mRNA levels arcuate nucleus include fasting leptin
0.088994086.10830275.html.plaintext.txt	27	AGRP mRNA levels increased normal mice fasted genetically obese mice lack leptin obob receptor dbdb 1 3 7
0.088994086.10830275.html.plaintext.txt	28	Administration exogenous leptin normal mice obob mice also shown reduce AGRP mRNA levels 12
0.088994086.10830275.html.plaintext.txt	29	Because AGRP NPY produced neuron 4 agents known affect NPY synthesis release might conceivably also influence synthesis release AGRP
0.088994086.10830275.html.plaintext.txt	30	Leptin shown decrease NPY mRNA levels 13 14
0.088994086.10830275.html.plaintext.txt	31	However acute effects leptin NPY release conflicting
0.088994086.10830275.html.plaintext.txt	32	Leptin reported decrease NPY release perfused hypothalami lean Zucker rats 15
0.088994086.10830275.html.plaintext.txt	33	In contrast vivo studies Long Evans rats failed demonstrate acute effect leptin NPY release paraventricular nucleus PVN hypothalamic region believed major site release NPY produced arcuate nucleus 16
0.088994086.10830275.html.plaintext.txt	34	In vivo studies serotonin antagonist methysergide shown increase NPY secretion 5 HT1B2C receptor agonist m CPP shown reduce NPY protein levels PVN rat 17 18
0.088994086.10830275.html.plaintext.txt	35	Therefore leptin serotonin might expected acute effect hypothalamic AGRP release
0.088994086.10830275.html.plaintext.txt	36	In rat human arcuate nucleus AGRP NPY MSH containing neurons send projections lateral hypothalamus 19 20
0.088994086.10830275.html.plaintext.txt	37	This hypothalamic region contains neurons produce orexigenic agents melanin concentrating hormone MCH orexin A B
0.088994086.10830275.html.plaintext.txt	38	This anatomical arrangement consistent widely held concept arcuate nucleus provides important neurochemical input lateral hypothalamus
0.088994086.10830275.html.plaintext.txt	39	However fibers lateral hypothalamic area also reported project medial hypothalamus 21 22
0.088994086.10830275.html.plaintext.txt	40	This raises possibility orexigenic agents produced lateral hypothalamus could reciprocally influence release NPY AGRP AGRP NPY containing neurons
0.088994086.10830275.html.plaintext.txt	41	To date majority investigations focused AGRP orexigenic role hypothalamus
0.088994086.10830275.html.plaintext.txt	42	Nonetheless worthwhile note expression AGRP mRNA reported number sites
0.088994086.10830275.html.plaintext.txt	43	In humans rodents adrenal glands cortex medulla appear site highest level AGRP mRNA expression hypothalamus 1 3
0.088994086.10830275.html.plaintext.txt	44	AGRP mRNA also documented subthalamic nucleus lung testis humans rodents reported lung kidney testis ovary muscle tissues 1 3
0.088994086.10830275.html.plaintext.txt	45	The function AGRP extra hypothalamic sites presently unknown
0.088994086.10830275.html.plaintext.txt	46	Although distribution MCRs peripheral tissues humans rodents extensively studied expression several MCR subtypes sensitive action AGRP reported peripheral tissues
0.088994086.10830275.html.plaintext.txt	47	Available data indicates humans rodents MC3R MC5R mRNA expressed gastrointestinal tract andor pancreas 23 24
0.088994086.10830275.html.plaintext.txt	48	In rodents expression MC5R mRNA reported adrenal glands skeletal muscle lacrimal glands 23 24 25
0.088994086.10830275.html.plaintext.txt	49	Within context information sought establish RIA could used explore central peripheral actions AGRP
0.088994086.10830275.html.plaintext.txt	50	The present studies used RIA characterize basal AGRP LI release perfused rat hypothalamic slices identify factors influence release
0.088994086.10830275.html.plaintext.txt	51	In addition RIA used explore whether rodent serum contains AGRP LI attempted identify tissue source immunoreactivity
0.088994086.10830275.html.plaintext.txt	52	Materials Methods Top Abstract Introduction Materials Methods Results Discussion References AGRP RIA AGRP 87 132 mouse Leu127ProAGRP full length AGRP minus signal sequence synthesized Gryphon Sciences S
0.088994086.10830275.html.plaintext.txt	53	The recombinant human agouti protein used previously described 6
0.088994086.10830275.html.plaintext.txt	54	MSH ACTH Nle4 DPhe7 MSH NDP MSH purchased Peninsula Laboratories Inc
0.088994086.10830275.html.plaintext.txt	55	Leptin purchased Calbiochem San Diego CA
0.088994086.10830275.html.plaintext.txt	56	Orexin A B MCH purchased Phoenix Pharmaceuticals Inc
0.088994086.10830275.html.plaintext.txt	57	NPY purchased American Peptide Co
0.088994086.10830275.html.plaintext.txt	58	Serotonin 1 m chlorophenyl piperazine m CPP obtained Sigma St
0.088994086.10830275.html.plaintext.txt	59	A rabbit polyclonal anti AGRP antibody raised partially purified recombinant human AGRP diluted titer 1200000
0.088994086.10830275.html.plaintext.txt	60	This antibody previously characterized immunohistochemical studies found specific AGRP 7
0.088994086.10830275.html.plaintext.txt	61	125I AGRP 87 132 prepared simple oxidative methods using chloramine T Na125I Amersham Pharmacia Biotech previously described 6
0.088994086.10830275.html.plaintext.txt	62	4 mgml solution chloramine T Sigma 50 mM sodium phosphate pH 7
0.088994086.10830275.html.plaintext.txt	63	4 added 15 sec reaction stopped 50 microl 4
0.088994086.10830275.html.plaintext.txt	64	8 mgml solution sodium metabisulfite Sigma
0.088994086.10830275.html.plaintext.txt	65	The reaction mixture diluted 800 microl 50 mM ammonium acetate pH 5
0.088994086.10830275.html.plaintext.txt	66	8 purified reverse phase chromatography using C18 column
0.088994086.10830275.html.plaintext.txt	67	100 microl 2 solution BSA immediately added fractions containing radioactivity
0.088994086.10830275.html.plaintext.txt	68	05 M sodium phosphate buffer pH 7
0.088994086.10830275.html.plaintext.txt	69	0 containing 2 mM EDTA 200 mgliter sodium azide 1 gliter BSA
0.088994086.10830275.html.plaintext.txt	70	When antibody diluted 1200000 using 5000 cpm 125I AGRP 87 132 dose half maximal inhibition specific binding ID50 10 fmolml
0.088994086.10830275.html.plaintext.txt	71	Under conditions cross reactivity observed recombinant agouti protein MSH ACTH NDP MSH leptin orexin B neuropeptide Y
0.088994086.10830275.html.plaintext.txt	72	0038 cross reactivity noted orexin A
0.088994086.10830275.html.plaintext.txt	73	Measurement AGRP like immunoreactivity tissue For characterization AGRP LI tissue freshly dissected rat tissues homogenized 3 acetic acid 10 mlg tissue centrifuged 3000 rpm 4 C 10 min
0.088994086.10830275.html.plaintext.txt	74	Supernatants titrated pH 7
0.088994086.10830275.html.plaintext.txt	75	0 stored 20 C used
0.088994086.10830275.html.plaintext.txt	76	For chromatographic analysis AGRP LI molecular forms samples diluted 1 10 buffer A 50 mM ammonium acetate pH 5
0.088994086.10830275.html.plaintext.txt	77	The material assayed loaded FPLC HR 55 pepRPC C18 column Amersham Pharmacia Biotech Piscataway NJ previously equilibrated buffer A
0.088994086.10830275.html.plaintext.txt	78	After absorbance 280 nm A280 returned baseline following sample application column eluted buffer B buffer A 75 acetonitrile linear gradient flow rate 1 mlmin 1 ml fractions collected
0.088994086.10830275.html.plaintext.txt	79	The recovery synthetic AGRP 87 132 C18 column 80
0.088994086.10830275.html.plaintext.txt	80	Measurement AGRP like immunoreactivity serum Serum could directly assayed AGRP LI interfering proteins blood
0.088994086.10830275.html.plaintext.txt	81	Therefore serum AGRP LI characterized HPLC described
0.088994086.10830275.html.plaintext.txt	82	In addition measurement serum AGRP LI experiments using groups rats required assay large number samples limited volume serum AGRP LI assay developed using C18 cartridge
0.088994086.10830275.html.plaintext.txt	83	For experiments serum diluted 10 fold buffer A loaded onto C18 environmental cartridge Waters Corp
0.088994086.10830275.html.plaintext.txt	84	Samples eluted 60 acetonitrile lyophilization
0.088994086.10830275.html.plaintext.txt	85	Lyophilized samples reconstituted distilled water assay
0.088994086.10830275.html.plaintext.txt	86	Recovery synthetic AGRP 87 132 30
0.088994086.10830275.html.plaintext.txt	87	Because relatively poor recovery sought compare serum measurement using C18 cartridge standard HPLC
0.088994086.10830275.html.plaintext.txt	88	The two methods measurement resulted nearly identical determinations serum AGRP concentration
0.088994086.10830275.html.plaintext.txt	89	Therefore two methods differed percentage AGRP LI recovered serum
0.088994086.10830275.html.plaintext.txt	90	AGRP LI tissues serum also characterized ion exchange chromatography
0.088994086.10830275.html.plaintext.txt	91	Tissue extracts sera diluted 10 fold 50 mM MES pH 5
0.088994086.10830275.html.plaintext.txt	92	5 applied FPLC HR 55 Mono S cation exchange column previously equilibrated diluting buffer
0.088994086.10830275.html.plaintext.txt	93	After A280 returned baseline following sample application column eluted NaCl gradient flow rate 1 mlmin 1 ml fractions collected
0.088994086.10830275.html.plaintext.txt	94	Hypothalamic tissue perfusion Male Sprague Dawley rats weighing 280 300 g housed conditions controlled temperature 20 plus minus 2 C lighting 0700 1900 h
0.088994086.10830275.html.plaintext.txt	95	Animals housed Unit Laboratory Animal Medicine facilities University Michigan animal experiments approved University Committee Use Care Animals
0.088994086.10830275.html.plaintext.txt	96	Rats killed cervical dislocation decapitated
0.088994086.10830275.html.plaintext.txt	97	Hypothalami harvested 1000 h 1100 h avoid circadian variation
0.088994086.10830275.html.plaintext.txt	98	Hypothalami rapidly removed dissecting brain optic chiasm rostrally hypothalamic fissures laterally mammillary bodies caudally ventral surface thalamus dorsally
0.088994086.10830275.html.plaintext.txt	99	Hypothalami separated five coronal slices using razor blade
0.088994086.10830275.html.plaintext.txt	100	Eight hypothalami used experiment
0.088994086.10830275.html.plaintext.txt	101	The perfusion system consisted fixed stem jacketed tissue vessel Harvard Apparatus Cambridge MA constant temperature circulating water bath HAAKE Karlsruhe Germany peristaltic pump Harvard Apparatus
0.088994086.10830275.html.plaintext.txt	102	The perfusion chamber kept 37 C continuously perfused modified Krebs Ringer bicarbonate buffer composition mM NaCl 120 KCl 5 CaCl2 2
0.088994086.10830275.html.plaintext.txt	103	4 supplemented 2 gliter glucose 0
0.088994086.10830275.html.plaintext.txt	104	1 BSA aerated 95 O25 CO2 flow rate 0
0.088994086.10830275.html.plaintext.txt	105	Samples collected ice 10 min intervals stored 70 C
0.088994086.10830275.html.plaintext.txt	106	Before RIA determinations samples 2 ml lyophilized reconstituted 0
0.088994086.10830275.html.plaintext.txt	107	NPY measured using commercially available NPY RIA kit Peninsula Laboratories Inc
0.088994086.10830275.html.plaintext.txt	108	Each experiment repeated least four times
0.088994086.10830275.html.plaintext.txt	109	The effect concentration leptin hypothalamic AGRP LI release determined separate experiments
0.088994086.10830275.html.plaintext.txt	110	50 mM potassium chloride KCl depolarization used test tissue viability end experiments
0.088994086.10830275.html.plaintext.txt	111	In perfusion studies AGRP LI expressed fmol release per mg hypothalamic protein minimize small differences might result use slightly differing amounts tissue
0.088994086.10830275.html.plaintext.txt	112	Total protein determined colorometric assay Bio Rad Laboratories Inc
0.088994086.10830275.html.plaintext.txt	113	Bilateral adrenalectomy Three groups rats used experiment
0.088994086.10830275.html.plaintext.txt	114	Group 1 consisted 8 animals bilateral adrenalectomies Group 2 consisted 8 animals bilateral adrenalectomies corticosterone replacement Group 3 consisted 8 animals sham operation
0.088994086.10830275.html.plaintext.txt	115	Bilateral adrenalectomies performed flank incision using xylazine 3 mgkg ketamine 120 mgkg anesthesia
0.088994086.10830275.html.plaintext.txt	116	Sham operations performed manipulating animal identical manner without removal adrenal glands
0.088994086.10830275.html.plaintext.txt	117	Completeness bilateral adrenalectomy confirmed measurement serum corticosterone using RIA Diagnostic Products Corp
0.088994086.10830275.html.plaintext.txt	118	Adrenalectomized animals received 0
0.088994086.10830275.html.plaintext.txt	119	9 NaCl drinking water
0.088994086.10830275.html.plaintext.txt	120	Group 2 received corticosterone replacement daily injection 1
0.088994086.10830275.html.plaintext.txt	121	30 previously described 26
0.088994086.10830275.html.plaintext.txt	122	5 ml blood collected ether anesthesia assay AGRP LI 1 week 2 weeks 3 weeks
0.088994086.10830275.html.plaintext.txt	123	Northern blot analysis AGRP mRNA Individual hypothalami fed fasted rats dissected stored liquid nitrogen
0.088994086.10830275.html.plaintext.txt	124	Total RNA extracted using Trizol Reagent Life Technologies Inc
0.088994086.10830275.html.plaintext.txt	125	Twenty five micrograms total RNA loaded per well electrophoresed denaturing gel 2
0.088994086.10830275.html.plaintext.txt	126	RNA transferred nylon membrane hybridized random primed 32P labeled partial length rat AGRP complementary DNA cDNA probe
0.088994086.10830275.html.plaintext.txt	127	A random primed 32P labeled glyceraldehyde 3 phosphate dehydrogenase GAPD used check equivalency well loading
0.088994086.10830275.html.plaintext.txt	128	Blots hybridized overnight 42 C buffer containing 50 formamide 1 x Denhardt 6 x SSPE 0
0.088994086.10830275.html.plaintext.txt	129	5 SDS salmon sperm DNA 100 microgml
0.088994086.10830275.html.plaintext.txt	130	Final wash conditions 55 C 0
0.088994086.10830275.html.plaintext.txt	131	Blots exposed 12 h using Kodak XAR film Eastman Kodak Co
0.088994086.10830275.html.plaintext.txt	132	RNA quantified using Hewlett Packard Co
0.088994086.10830275.html.plaintext.txt	133	ScanJet 4CT scanner NIH Image 1
0.088994086.10830275.html.plaintext.txt	134	Statistical analysis Physiological data expressed mean plus minus SE
0.088994086.10830275.html.plaintext.txt	135	Two way ANOVA repeated measures used compare basal release AGRP LI NPY hypothalami fed 48 h fasted rats see Figs
0.088994086.10830275.html.plaintext.txt	136	2 6 comparison serum levels AGRP LI adrenalectomy experiments see Fig
0.088994086.10830275.html.plaintext.txt	137	One way ANOVA followed Tukey Kramer posthoc test used analyze leptin inhibition AGRP LI NPY release hypothalami 48 h fasted rats see Figs
0.088994086.10830275.html.plaintext.txt	138	One way ANOVA followed Dunnett method multiple comparison used analyze dose dependency leptin inhibition AGRP LI release hypothalami 48 h fasted rats see Fig
0.088994086.10830275.html.plaintext.txt	139	4 rise serum AGRP LI 24 48 h fasted rats see Fig
0.088994086.10830275.html.plaintext.txt	140	Student test used determine statistical significance change hypothalamic AGRP mRNA 48 h fasted rats see Fig
0.088994086.10830275.html.plaintext.txt	141	View larger version 32K Figure 2
0.088994086.10830275.html.plaintext.txt	142	Comparison basal AGRP LI release hypothalami rats fed ad libitum fasted 48 h rats killed
0.088994086.10830275.html.plaintext.txt	143	View larger version 50K Figure 6
0.088994086.10830275.html.plaintext.txt	144	Comparison basal NPY release hypothalami rats fed ad libitum fasted 48 h rats killed
0.088994086.10830275.html.plaintext.txt	145	View larger version 29K Figure 9
0.088994086.10830275.html.plaintext.txt	146	Effect bilateral adrenalectomy rat serum AGRP LI
0.088994086.10830275.html.plaintext.txt	147	View larger version 45K Figure 3
0.088994086.10830275.html.plaintext.txt	148	Leptin inhibition AGRP LI release hypothalami rats fasted 48 h rats killed
0.088994086.10830275.html.plaintext.txt	149	This graph depicts response 10 7 M leptin
0.088994086.10830275.html.plaintext.txt	150	View larger version 55K Figure 7
0.088994086.10830275.html.plaintext.txt	151	Leptin inhibition NPY release hypothalami rats fasted 48 h rats killed
0.088994086.10830275.html.plaintext.txt	152	The graph depicts response 10 6 M leptin
0.088994086.10830275.html.plaintext.txt	153	View larger version 46K Figure 4
0.088994086.10830275.html.plaintext.txt	154	Dose dependent suppression basal hypothalamic AGRP LI release leptin rats fasted 48 h
0.088994086.10830275.html.plaintext.txt	155	Suppression 40 min used calculate dose response
0.088994086.10830275.html.plaintext.txt	156	View larger version 55K Figure 8
0.088994086.10830275.html.plaintext.txt	157	Rise serum AGRP LI rats fasted 24 48 h P 0
0.088994086.10830275.html.plaintext.txt	158	View larger version 35K Figure 5
0.088994086.10830275.html.plaintext.txt	159	Increase hypothalamic AGRP mRNA rats fasted 48 h
0.088994086.10830275.html.plaintext.txt	160	Equivalency well loading checked measuring glyceraldehyde 3 phosphate dehydrogenase GAPD P 0
0.088994086.10830275.html.plaintext.txt	161	Results Top Abstract Introduction Materials Methods Results Discussion References Tissue serum AGRP like immunoreactivity AGRP LI found central peripheral tissues Table 1
0.088994086.10830275.html.plaintext.txt	162	The greatest concentrations AGRP LI present hypothalamus adrenal gland
0.088994086.10830275.html.plaintext.txt	163	Very low levels AGRP LI noted brain striatum thalamus
0.088994086.10830275.html.plaintext.txt	164	No AGRP LI detectable brain cortex liver tissue
0.088994086.10830275.html.plaintext.txt	165	When characterized reverse phase C18 HPLC synthetic AGRP 87 132 eluted single peak earlier peak full length Leu127ProAGRP
0.088994086.10830275.html.plaintext.txt	166	Hypothalamic tissue AGRP LI eluted single peak close elution position AGRP 87 132 Fig
0.088994086.10830275.html.plaintext.txt	167	1 peak adrenal tissue AGRP LI superimposable peak observed hypothalamic tissue except amount immunoreactivity less
0.088994086.10830275.html.plaintext.txt	168	AGRP LI eluted C18 environmental cartridge found coelute serum applied directly C18 HPLC column
0.088994086.10830275.html.plaintext.txt	169	AGRP LI present rat serum eluted near immunoreactivity found hypothalamus Fig
0.088994086.10830275.html.plaintext.txt	170	Further characterization rat tissue serum AGRP LI cation exchange chromatography revealed AGRP LI eluted single peak somewhat later synthetic AGRP 87 132 suggesting positively charged synthetic peptide Fig
0.088994086.10830275.html.plaintext.txt	171	While chromatography data suggest posttranslational processing tissue serum AGRP analysis required
0.088994086.10830275.html.plaintext.txt	172	Concentrations AGRP LI different tissues rats fed ad libitum killed
0.088994086.10830275.html.plaintext.txt	173	View larger version 19K Figure 1
0.088994086.10830275.html.plaintext.txt	174	A C18 chromatograph AGRP LI rat hypothalamic tissue serum
0.088994086.10830275.html.plaintext.txt	175	B Mono S chromatograph AGRP LI rat hypothalamic tissue serum
0.088994086.10830275.html.plaintext.txt	176	AGRP LI release perfused hypothalamic tissue slices As shown Fig
0.088994086.10830275.html.plaintext.txt	177	2 continuous low level AGRP LI released hypothalami rats fed ad libitum killed 0
0.088994086.10830275.html.plaintext.txt	178	5 fmol releasemg hypothalamic protein
0.088994086.10830275.html.plaintext.txt	179	In contrast significantly greater amount AGRP LI 1
0.088994086.10830275.html.plaintext.txt	180	2 fmol releasemg hypothalamic protein released hypothalami 48 h fasted rats
0.088994086.10830275.html.plaintext.txt	181	Comparison 13 time points administration 50 mM KCl revealed difference AGRP LI release hypothalami fed 48 h fasted animals statistically significant P 0
0.088994086.10830275.html.plaintext.txt	182	On average AGRP LI release 3 fold greater 48 h fasted rats
0.088994086.10830275.html.plaintext.txt	183	Analysis last two time periods Fig
0.088994086.10830275.html.plaintext.txt	184	2 revealed also statistically significant greater amount KCl induced AGRP LI released hypothalami 48 h fasted vs
0.088994086.10830275.html.plaintext.txt	185	In time period 15 perfusion hypothalami 48 h fasted rats 50 mM KCl resulted 262 increase AGRP LI mean basal release
0.088994086.10830275.html.plaintext.txt	186	The response KCl administration toward end perfusion studies demonstrates tissue viability also presence substantial additional AGRP LI stores
0.088994086.10830275.html.plaintext.txt	187	Time appear effect basal AGRP LI release basal NPY release see Fig
0.088994086.10830275.html.plaintext.txt	188	7 time course studies
0.088994086.10830275.html.plaintext.txt	189	3 addition leptin perfusate caused inhibition AGRP LI release hypothalami 48 h fasted rats
0.088994086.10830275.html.plaintext.txt	190	Comparison 40 min administration 10 7 M leptin baseline period 40 min leptin infused revealed inhibition statistically significant P 0
0.088994086.10830275.html.plaintext.txt	191	During time period leptin infusion inhibition reached statistical significance 30 min P 0
0.088994086.10830275.html.plaintext.txt	192	A persistent leptin effect remained least 30 min cessation leptin infusion maximal inhibition AGRP LI occurring 70 min initiation leptin
0.088994086.10830275.html.plaintext.txt	193	Compared AGRP LI released 40 min baseline time period maximal inhibition 90
0.088994086.10830275.html.plaintext.txt	194	Figure 4 demonstrates dose dependency leptin inhibition AGRP LI
0.088994086.10830275.html.plaintext.txt	195	In comparison 10 7 M leptin 10 6 M leptin also caused maximal inhibition 70 min time 95 inhibition observed
0.088994086.10830275.html.plaintext.txt	196	No increase basal release AGRP LI observed fed animals response MSH 10 8 M 10 7 M 10 6 M orexin B 10 6 M MCH 10 7 M 10 6 M serotonin 10 6 M m CPP 10 6 M
0.088994086.10830275.html.plaintext.txt	197	In 48 h fasted rats neither orexin B 10 6 M serotonin 10 6 M altered baseline release AGRP LI
0.088994086.10830275.html.plaintext.txt	198	Cross reactivity antibody made impossible accurately determine effect orexin A hypothalamic AGRP LI release high doses orexin A effect seen 10 7 M 10 8 M orexin A
0.088994086.10830275.html.plaintext.txt	199	We also measured AGRP mRNA levels detected statistically significant 2
0.088994086.10830275.html.plaintext.txt	200	NPY release perfused hypothalamic tissue slices NPY release determined samples used determine AGRP LI release
0.088994086.10830275.html.plaintext.txt	201	6 amount NPY release greater hypothalami 48 h fasted rats hypothalami rats fed ad libitum killed P 0
0.088994086.10830275.html.plaintext.txt	202	On average fasted animals released 80 NPY
0.088994086.10830275.html.plaintext.txt	203	7 leptin 10 6 M inhibited NPY release hypothalami 48 h fasted rats
0.088994086.10830275.html.plaintext.txt	204	Comparison 40 min time period administration leptin baseline time period 40 min time period leptin infused reveals inhibition statistically significant P 0
0.088994086.10830275.html.plaintext.txt	205	Statistically significant inhibition reached 40 min P 0
0.088994086.10830275.html.plaintext.txt	206	As case AGRP LI residual effect leptin NPY release persisted least 30 min cessation NPY infusion
0.088994086.10830275.html.plaintext.txt	207	Compared average release NPY 40 min baseline time period maximal inhibition NPY occurred 1 h beginning leptin infusion 33
0.088994086.10830275.html.plaintext.txt	208	We observe increase NPY release fed animals administration orexin B 10 6 M MCH 10 6 M
0.088994086.10830275.html.plaintext.txt	209	Although could determine effects high dose orexin A AGRP LI cross reactivity previously mentioned observe increase NPY release fed animals response high dose orexin A 10 6 M
0.088994086.10830275.html.plaintext.txt	210	Effect fasting bilateral adrenalectomy serum AGRP like immunoreactivity A slow rise serum AGRP LI occurred 48 h fast Fig
0.088994086.10830275.html.plaintext.txt	211	At 24 h increase serum AGRP LI statistically significant
0.088994086.10830275.html.plaintext.txt	212	However increase serum AGRP LI reach statistical significance 48 h
0.088994086.10830275.html.plaintext.txt	213	Bilateral adrenalectomy without corticosterone replacement significant effect serum AGRP like immunoreactivity fed animals Fig
0.088994086.10830275.html.plaintext.txt	214	Serum corticosterone levels found negligible rats undergone bilateral adrenalectomy
0.088994086.10830275.html.plaintext.txt	215	Bilateral adrenalectomy also lead changes level hypothalamic AGRP mRNA data shown
0.088994086.10830275.html.plaintext.txt	216	Discussion Top Abstract Introduction Materials Methods Results Discussion References In studies development specific AGRP RIA enabled us examine several previously unexplored aspects AGRP physiology
0.088994086.10830275.html.plaintext.txt	217	The actual release AGRP hypothalamus previously reported using RIA able examine effects fasting basal release AGRP effects certain chemical messengers release
0.088994086.10830275.html.plaintext.txt	218	Second RIA allowed us examine serum presence AGRP investigate possibility adrenal gland source immunoreactivity
0.088994086.10830275.html.plaintext.txt	219	This facet studies prompted observation adrenal gland second greatest level AGRP mRNA expression body hypothalamus tissue known secretion regulatory factors bloodstream
0.088994086.10830275.html.plaintext.txt	220	At inception studies hypothesized adrenal AGRP might secreted systemic circulation act peripheral MCRs
0.088994086.10830275.html.plaintext.txt	221	Although serum levels AGRP LI observe within physiologic range adrenal gland appear contribute immunoreactivity
0.088994086.10830275.html.plaintext.txt	222	Specificity AGRP RIA To ensure veracity findings critically examined specificity AGRP RIA
0.088994086.10830275.html.plaintext.txt	223	Several lines evidence support contention RIA specific
0.088994086.10830275.html.plaintext.txt	224	First preliminary experiments found low ID50 10 fmolml AGRP 87 132 cross reactivity number peptides including MSH NPY orexin B leptin agouti protein
0.088994086.10830275.html.plaintext.txt	225	The latter notable agouti protein shares AGRP similar cysteine rich C terminal motif
0.088994086.10830275.html.plaintext.txt	226	Moreover antibody recognizes AGRP C terminus AGRP 87 132 portion molecule critical bioactivity pharmacological studies 6
0.088994086.10830275.html.plaintext.txt	227	Second concentrations AGRP LI observed tissue extracts listed Table 1 correlate well levels mRNA known present tissues
0.088994086.10830275.html.plaintext.txt	228	For example AGRP mRNA expressed highest levels hypothalamus next highest level expression adrenal glands 1 3
0.088994086.10830275.html.plaintext.txt	229	Consistent data observed AGRP LI greatest hypothalamus followed adrenal gland
0.088994086.10830275.html.plaintext.txt	230	Similarly AGRP mRNA reported liver Northern blot PCR 1 3 consistent data AGRP LI detected extracted hepatic tissue
0.088994086.10830275.html.plaintext.txt	231	In addition increase basal release hypothalamic AGRP LI observed fasted rats correlated increase mRNA observed similarly fasted rats
0.088994086.10830275.html.plaintext.txt	232	Third results chromatographic analysis strongly support specificity RIA
0.088994086.10830275.html.plaintext.txt	233	Both tissue serum AGRP LI eluted single peak close elution position synthetic AGRP 87 132
0.088994086.10830275.html.plaintext.txt	234	An important control serum data observation AGRP LI eluted C18 environmental cartridge coeluted serum applied directly C18 HPLC column similar amounts
0.088994086.10830275.html.plaintext.txt	235	This observation indicates significant difference two assay methods C18 cartridge vs
0.088994086.10830275.html.plaintext.txt	236	C18 HPLC C18 cartridge results significantly lower recovery AGRP LI
0.088994086.10830275.html.plaintext.txt	237	Nonetheless cartridge method facilitates analysis multiple samples
0.088994086.10830275.html.plaintext.txt	238	Release AGRP LI hypothalamic slices In studies able confirm release AGRP LI correlates changes AGRP mRNA previously observed fed fasted states leptin administration 7 12
0.088994086.10830275.html.plaintext.txt	239	In studies noted 3 fold increase hypothalamic AGRP LI released hypothalami 48 h fasted rats
0.088994086.10830275.html.plaintext.txt	240	This change correlates nicely nearly 3 fold increase AGRP mRNA observed studies Fig
0.088994086.10830275.html.plaintext.txt	241	However increase AGRP mRNA observed rat studies much less 15 fold increase AGRP mRNA noted mouse 1 7 may reflect interspecies differences
0.088994086.10830275.html.plaintext.txt	242	described 91 reduction AGRP concentrations 10 day food restricted rats hypothesized marked reduction AGRP physiological state might expected associated increased AGRP concentrations due increased peptide release 27
0.088994086.10830275.html.plaintext.txt	243	Although measure static concentrations AGRP LI 48 fasted rats results consistent hypothesis increased AGRP release physiological states associated hunger
0.088994086.10830275.html.plaintext.txt	244	In experiments observed basal release AGRP LI hypothalamus varies nutritional state animal fed vs
0.088994086.10830275.html.plaintext.txt	245	We also observed fat hormone leptin profound influence release
0.088994086.10830275.html.plaintext.txt	246	This effect obvious fasted animals AGRP LI levels elevated
0.088994086.10830275.html.plaintext.txt	247	The observed suppression AGRP LI leptin fasted rats one would expect hormone provides feedback hypothalamus regarding adequacy nutritional intake
0.088994086.10830275.html.plaintext.txt	248	We also observed significant decrease NPY release leptin administration previously noted Lee et al
0.088994086.10830275.html.plaintext.txt	249	These data indicate leptin concomitantly affects AGRP NPY release AGRP NPY containing arcuate nucleus neuron
0.088994086.10830275.html.plaintext.txt	250	While present studies unable distinguish whether observed AGRP LI release governed constitutive regulated pathways released pathways fact KCl depolarization caused large release AGRP LI suggests least AGRP stored released regulated pathway
0.088994086.10830275.html.plaintext.txt	251	This consistent notion AGRP important regulatory neuropeptide merely protein released constitutively cells
0.088994086.10830275.html.plaintext.txt	252	Several pieces data indicate observed leptin suppression AGRP LI release hypothalamus fasted animals specific effect
0.088994086.10830275.html.plaintext.txt	253	Importantly response dose dependent induced peptide agents used studies
0.088994086.10830275.html.plaintext.txt	254	In addition simultaneous inhibition NPY release observed makes likelihood nonspecific AGRP response less likely
0.088994086.10830275.html.plaintext.txt	255	Thus hypothesize effect leptin AGRP LI release result action leptin leptin receptors known present AGRP NPY containing neuron 7 20
0.088994086.10830275.html.plaintext.txt	256	However vitro system perfusate bathed entire hypothalamus leptin containing perfusate could influenced release chemical messengers hypothalamic neurons expressing leptin receptors also affect AGRP release
0.088994086.10830275.html.plaintext.txt	257	It therefore conceivable leptin effect observed studies represents summation response AGRP NPY containing neuron
0.088994086.10830275.html.plaintext.txt	258	Nonetheless data consistent hypothesis leptin predominant regulator AGRP release
0.088994086.10830275.html.plaintext.txt	259	Contrary expectations found increase release AGRP LI administration orexin B hypothalami fed animals
0.088994086.10830275.html.plaintext.txt	260	This surprising view work van den Pol et al
0.088994086.10830275.html.plaintext.txt	261	found arcuate nucleus neurons nanomolar sensitivity orexin capable releasing GABA glutamate axons terminals adjacent AGRP NPY containing cell response orexin 28
0.088994086.10830275.html.plaintext.txt	262	Electron microscopy studies performed Horvath et al
0.088994086.10830275.html.plaintext.txt	263	also identified abundance presynaptic orexin immunoreactive boutons abutting NPY containing neurons 21
0.088994086.10830275.html.plaintext.txt	264	This latter observation would strongly suggest presence orexin receptors AGRP NPY containing neuron
0.088994086.10830275.html.plaintext.txt	265	We also anticipated MCH might effect hypothalamic AGRP LI release MCH projections lateral hypothalamus arcuate nucleus previously observed 22
0.088994086.10830275.html.plaintext.txt	266	However noted actual presence MCH receptors AGRP NPY containing neuron knowledge documented
0.088994086.10830275.html.plaintext.txt	267	That m CPP cause change hypothalamic AGRP LI release fasted rats also somewhat unexpected
0.088994086.10830275.html.plaintext.txt	268	Because hypophagic effect serotonin thought mediated serotonin 5HT1B2C receptor observation serotonin cause change AGRP LI might interpreted consistent conflicting positive negative effects biogenic amine NPY release reported literature 17 18
0.088994086.10830275.html.plaintext.txt	269	However lack suppression basal AGRP LI release administration selective 5HT1B2C agonist m CPP could construed inconsistent data Dryden et al
0.088994086.10830275.html.plaintext.txt	270	observed decrease NPY levels PVN presumed reflect effect m CPP AGRP NPY containing neuron arcuate nucleus sc ip administration agent 18
0.088994086.10830275.html.plaintext.txt	271	Nonetheless vivo model used latter study differs significantly perfusion model therefore firm conclusions drawn regarding potential discrepancy
0.088994086.10830275.html.plaintext.txt	272	Several possible explanations exist lack change AGRP LI response orexin B MCH m CPP
0.088994086.10830275.html.plaintext.txt	273	First must acknowledge hypothalamic perfusion system might sensitive enough system detect small changes AGRP LI release produced agents
0.088994086.10830275.html.plaintext.txt	274	However case important corollary might orexin B MCH m CPP relatively weak regulators AGRP
0.088994086.10830275.html.plaintext.txt	275	We feel sensitivity RIA issue half dose AGRP 87 132 suggests assay sensitive enough detect reasonably small changes AGRP LI
0.088994086.10830275.html.plaintext.txt	276	A second possibility orexin MCH m CPP applied hypothalamic slices stimulate neurons bearing receptors hypothalamic nuclei
0.088994086.10830275.html.plaintext.txt	277	The summation response might result observable change AGRP LI release
0.088994086.10830275.html.plaintext.txt	278	A third possible explanation orexin B MCH m CPP directly affect acute release AGRP NPY
0.088994086.10830275.html.plaintext.txt	279	Rather possible agents act modulating membrane potential AGRP NPY containing neuron mechanism determine subsequent response AGRP NPY containing neuron agents leptin
0.088994086.10830275.html.plaintext.txt	280	In scenario effect orexin B MCH m CPP AGRP release would indirect experimental model would observe change AGRP LI release response three agents
0.088994086.10830275.html.plaintext.txt	281	A similar lack observable effect would occur orexin MCH serotonin acted regulating transcription AGRP mRNA subsequently influencing pool AGRP available released physiological conditions decreasing serum leptin levels
0.088994086.10830275.html.plaintext.txt	282	Comparison NPY AGRP LI release hypothalamic slices Because AGRP NPY produced released arcuate nucleus neurons simultaneously examined AGRP LI NPY release perfused hypothalami fed fasted rats
0.088994086.10830275.html.plaintext.txt	283	Similar AGRP LI release continuous basal NPY release observed fed fasted state Figs
0.088994086.10830275.html.plaintext.txt	284	NPY release 80 greater hypothalami 48 h fasted vs
0.088994086.10830275.html.plaintext.txt	285	An increase NPY release PVN food deprived rats previously reported 29 30
0.088994086.10830275.html.plaintext.txt	286	These latter studies suggest PVN predominant source NPY released perfused hypothalami present studies
0.088994086.10830275.html.plaintext.txt	287	Comparing percent increase NPY AGRP LI release occurred fasted animals reveals NPY release increased lesser degree AGRP LI 80 vs
0.088994086.10830275.html.plaintext.txt	288	Similar AGRP LI release NPY release perfused hypothalami inhibited leptin time course leptin induced NPY suppression recovery paralleled AGRP LI Figs
0.088994086.10830275.html.plaintext.txt	289	However leptin inhibition reached statistical significance sooner case AGRP LI release vs
0.088994086.10830275.html.plaintext.txt	290	In addition comparing maximal inhibition AGRP LI NPY release 10 6 M leptin reveals NPY release inhibited lesser extent AGRP LI release 33 vs
0.088994086.10830275.html.plaintext.txt	291	Although purely speculative data may indicate leptin greater role regulating AGRP release NPY release andor leptin mediates effects regulation AGRP release regulation NPY release
0.088994086.10830275.html.plaintext.txt	292	The last two statements viewed caution physiological consequences relative percent increases decreases release two agents cannot determined present studies
0.088994086.10830275.html.plaintext.txt	293	Presence AGRP LI adrenal tissue serum Our studies indicate level AGRP mRNA expression adrenal tissue correlates well substantial stores AGRP protein detected organ
0.088994086.10830275.html.plaintext.txt	294	On basis wet tissue weight adrenal approximately 16 AGRP protein observed hypothalamus fed rat
0.088994086.10830275.html.plaintext.txt	295	Our chromatographic characterization AGRP LI suggests AGRP present systemic circulation slightly less nanomolar concentrations fed animal increases slightly one nanomolar 48 h fasted rat
0.088994086.10830275.html.plaintext.txt	296	However origin serum AGRP LI detected studies remains crucial unresolved question
0.088994086.10830275.html.plaintext.txt	297	Our adrenalectomy experiments indicate adrenal AGRP unlikely source serum AGRP LI
0.088994086.10830275.html.plaintext.txt	298	The results experiments would also suggest adrenal AGRP likely yet unidentified paracrine role adrenal physiology
0.088994086.10830275.html.plaintext.txt	299	One potential source serum AGRP LI could hypothalamus
0.088994086.10830275.html.plaintext.txt	300	In rat AGRP containing fibers recently noted project arcuate nucleus median eminence posterior pituitary conceivably could released systemic circulation 7
0.088994086.10830275.html.plaintext.txt	301	In regard important note compensatory increase hypothalamic AGRP mRNA seen adrenalectomized animals
0.088994086.10830275.html.plaintext.txt	302	This certainly consistent lack change serum concentration AGRP LI observed animals
0.088994086.10830275.html.plaintext.txt	303	However direct studies would required conclude hypothalamic AGRP actually reaches systemic circulation
0.088994086.10830275.html.plaintext.txt	304	Despite fact origin serum AGRP LI unclear levels AGRP LI observed rat serum potentially physiological range
0.088994086.10830275.html.plaintext.txt	305	Although purely speculative AGRP bloodstream would likely function modulator peripheral MCR activity tissues pancreas gastrointestinal tract contain receptors sensitive actions
0.088994086.10830275.html.plaintext.txt	306	The concentration AGRP found rat serum close IC50 AGRP 87 132 observed pharmacological studies cloned human MC3R approximately 1 nanomolar 6
0.088994086.10830275.html.plaintext.txt	307	However AGRP 87 132 much lower affinity human MC5R another peripherally expressed MCR could potential target serum AGRP
0.088994086.10830275.html.plaintext.txt	308	In regard examined binding affinity AGRP rat MC3R MC5R
0.088994086.10830275.html.plaintext.txt	309	Species differences ligand binding affinity uncommon binding affinity AGRP could quite different rat receptors
0.088994086.10830275.html.plaintext.txt	310	The recent identification mahogany protein postulated low affinity receptor agouti protein may also relevance discussion 31 32
0.088994086.10830275.html.plaintext.txt	311	Whether mahogany protein similar molecule exists functions increase local concentrations AGRP peripheral tissues presently unknown
0.088994086.10830275.html.plaintext.txt	312	Acknowledgments We thank Achamyeleh Gebremariam assistance statistical analysis data Xinyun Lu helpful comments manuscript
0.088994086.10830275.html.plaintext.txt	313	Footnotes 1 This work supported NIH 1RO1 DK 54032 01 I
0.088994086.10830275.html.plaintext.txt	314	B funds University Michigan Gastrointestinal Peptide Research Center NIH Grant P30 DK 34933
0.088994086.10830275.html.plaintext.txt	315	This work also supported Knoll Pharmaceutical Co
0.088994086.10830275.html.plaintext.txt	316	Weight Risk Investigators Study Council grant
0.088994086.10830275.html.plaintext.txt	317	2 Associate Investigator Howard Hughes Medical Institute
0.088994086.10830275.html.plaintext.txt	318	References Top Abstract Introduction Materials Methods Results Discussion References Shutter JR Graham M Kinsey AC Scully S Luthy R Stark KL 1997 Hypothalamic expression ART novel gene related agouti regulated obese diabetic mutant mice
0.088994086.10830275.html.plaintext.txt	319	Genes Dev 11593 602Abstract Fong TM Mao C MacNeil T Kalyani R Smith T Weinberg D Tota MR Van der Ploeg LHT 1997 ART antagonist MC 3 MC 4 receptors
0.088994086.10830275.html.plaintext.txt	320	Biochem Biophys Res Commun 237629 631CrossRefMedline Ollmann MM Wilson BD Yang Y K Kerns JA Chen Y Gantz I Barsh GS 1997 Antagonism central melanocortin receptors vitro vivo agouti related protein
0.088994086.10830275.html.plaintext.txt	321	Science 278135 138AbstractFree Full Text Hahn TM Breininger JF Baskin DG Schwartz MW 1998 Coexpression AGRP NPY fasting activated hypothalamic neurons
0.088994086.10830275.html.plaintext.txt	322	Nature Neurosci 1271 272CrossRefMedline Rossi M Kim MS Morgan DGA Small CJ Edwards CMB Sunter D Abusnana S Goldstone AP Russell SH Stanley SA Smith DM Yagaloff K Ghatei MA Bloom SR 1998 A C terminal fragment Agouti related protein increases feeding antagonizes effect alpha melanocyte stimulating hormone vivo
0.088994086.10830275.html.plaintext.txt	323	Endocrinology 1394428 4431AbstractFree Full Text Yang Y K Thompson D Dickinson CJ Wilken J Barsh GS Kent SBH Gantz I 1999 Biological activities chemically synthesized variants agouti related protein
0.088994086.10830275.html.plaintext.txt	324	Mol Endocrinol 13148 155AbstractFree Full Text Wilson BD Bagnol D Kaelin CB Ollmann MM Gantz I Watson SJ Barsh GS 1999 Physiological anatomical circuitry Agouti related protein leptin signaling
0.088994086.10830275.html.plaintext.txt	325	Endocrinology 1402387 2397AbstractFree Full Text Huszar D Lynch CA Fairchild Huntress V Dunmore J H Fang Q Berkemeier LR Gu W Kesterson RA Boston BA Cone RD Smith FJ Campfield LA Burn P Lee F 1997 Targeted disruption MC4R results obesity mice
0.088994086.10830275.html.plaintext.txt	326	Cell 88131 141Medline Yeo GSH Farooqi IS Aminian S Halsall DJ Stanhope RG O Rahilly S 1998 A frameshift mutation MC4R associated dominantly inherited human obesity
0.088994086.10830275.html.plaintext.txt	327	Nat Genet 20111 112CrossRefMedline Vaisse C Clement K Guy Grand B Froguel P 1998 A frameshift mutation human MC4R associated dominant form obesity
0.088994086.10830275.html.plaintext.txt	328	Nat Genet 20113 114CrossRefMedline Bagnol D Lu X Y Kailin CB Day HEW Ollmann M Gantz I Akil H Barsh GS Watson SJ 1999 Anatomy endogenous antagonistrelationship AGRP POMC brain
0.088994086.10830275.html.plaintext.txt	329	J Neurosci 19RC26 1 7 Mizuno TM Mobbs CV 1999 Hypothalamic agouti related protein messenger RNA inhibited leptin stimulated fasting
0.088994086.10830275.html.plaintext.txt	330	Endocrinology 140814 817AbstractFree Full Text Stephens TW Basinski M Bristo PK Bue Valleskey JM Burgett SG Craft L Hale J Hoffmann J Hsiung HM Kriauciunas A MacKellar W Rosteck Jr PR Schoner B Smith D Tinsley FC Zhang X Y Heiman M 1995 The role neuropeptide Y antiobesity action obese gene product
0.088994086.10830275.html.plaintext.txt	331	Nature 377530 532CrossRefMedline Xu B Dube MG Kalra PS Farmerie WG Kaibara A Moldawer LL Martin D Kalra SP 1998 Anorectic effects cytokine ciliary neurotropic factor mediated hypothalamic neuropeptide Y comparison leptin
0.088994086.10830275.html.plaintext.txt	332	Endocrinology 139466 473AbstractFree Full Text Lee J Morris MJ 1998 Modulation NPY overflow leptin rat hypothalamus cerebral cortex medulla
0.088994086.10830275.html.plaintext.txt	333	NeuroReport 91575 1580Medline Beck B Kozak R Stricker Krongrad A Burlet C 1998 Neuropeptide Y release paraventricular nucleus Long Evans rats treated leptin
0.088994086.10830275.html.plaintext.txt	334	Biochem Biophys Res Commun 242636 639CrossRefMedline Dryden S Wang Q Frankish HM Pickavance L Williams G 1995 The 5HT antagonist methysergide increases NPY synthesis secretion hypothalamus rat
0.088994086.10830275.html.plaintext.txt	335	Brain Res 69912 18CrossRefMedline Dryden S Wang Q Frankish HM Williams G 1996 Differential effects 5 HT1B2C receptor agonist mCPP 5 HT1A agonist flesinoxan hypothalamic NPY rat evidence NPY may mediate serotonin effects food intake
0.088994086.10830275.html.plaintext.txt	336	Peptides 17943 949CrossRefMedline Elias CF Saper CB Maratos Flier E Tritos NA Lee C Kelly J Tatro JB Hoffman GE Ollmann MM Barsh GS Sakurai T Yanagisawa M Elmquist JK 1998 Chemically defined projections linking mediobasal hypothalamus lateral hypothalamic area
0.088994086.10830275.html.plaintext.txt	337	CO2 S 1087AbstractFree Full Text Bittencourt JC Presse F Arias C Peto C Vaughan J Nahon J L Vale W Sawchenko PE 1992 The melanin concentrating hormone system rat brain immuno hybridization histochemical characterization
0.088994086.10830275.html.plaintext.txt	338	J Comp Neurol 319218 245Medline Gantz I Konda Y Tashiro T Shimoto Y Miwa H Munzert G Watson SJ DelValle J Yamada T 1993 Molecular cloning novel MCR
0.088994086.10830275.html.plaintext.txt	339	J Biol Chem 2688248 8250 Griffon N Mignon V Facchinetti P Diaz J Schwartz J C Sokoloff P 1994 Molecular cloning characterization rat fifth melanocortin receptor
0.088994086.10830275.html.plaintext.txt	340	Biochem Biophys Res Commun 2001007 1014CrossRefMedline Chen W Kelly MA Opitz Araya X Thomas RE Low MJ Cone RD 1997 Exocrine gland dysfunction MC5R deficient mice evidence coordinated regulation exocrine gland function melanocortin peptides
0.088994086.10830275.html.plaintext.txt	341	Cell 91789 798Medline Lucas LR Pompei P Ono J McEwen BS 1998 Effects adrenal steroids basal ganglia neuropeptide mRNA tyrosine hydroxylase radioimmunoreactive levels adrenalectomized rat
0.088994086.10830275.html.plaintext.txt	342	J Neurochem 71833 843Medline Harrold JA Williams G Widdowson PS 1999 Changes hypothalamic AGRP MSH POMC concentrations dietary obese food restricted rats
0.088994086.10830275.html.plaintext.txt	343	Biochem Biophys Res Commun 258574 577CrossRefMedline van den Pol AN Gao X B Obrietan K Kilduff TS Belousov AG 1998 Presynaptic postsynaptic actions modulation neuroendocrine neurons new hypothalamic peptide hypocretinorexin
0.088994086.10830275.html.plaintext.txt	344	J Neurosci 187962 7971AbstractFree Full Text Kalra SP Dube MG Sahu A Phelps CP Kalra PS 1991 Neuropeptide Y secretion increases paraventricular nucleus association increased appetite food
0.088994086.10830275.html.plaintext.txt	345	Proc Natl Acad Sci USA 8810931 10935Abstract Dube MG Sahu A Kalra PS Kalra SP 1992 Neuropeptide Y release elevated microdissected paraventricular nucleus food deprived rats vitro study
0.088994086.10830275.html.plaintext.txt	346	Endocrinology 131684 688Abstract Nagle DL McGrail SH Vitale J Woolf EA Durssalt Jr BJ DiRocco L Holmgren L Montagno J Bork P Huszar D Fairchild Huntress V Ge P Keilty J Ebeling C Baldini L Gilchrist J Burn P Carlson GA Moore KJ 1999 The mahogany protein receptor involved suppression obesity
0.088994086.10830275.html.plaintext.txt	347	Nature 398148 152CrossRefMedline Gunn TM Miller KA He L Hyman RW Davis RW Azarani A Schlossman SF Duke Cohan JS Barsh GS 1999 The mouse mahogany locus encodes transmembrane form human attractin
0.088994086.10830275.html.plaintext.txt	348	Nature 398152 156CrossRefMedline
0.21321544.12639935.html.plaintext.txt	0	Ghrelin Induced Food Intake Is Mediated via Orexin Pathway Koji Toshinai Yukari Date Noboru Murakami Mitsushi Shimada Muhtashan S
0.21321544.12639935.html.plaintext.txt	1	Mondal Takuya Shimbara Jian Lian Guan Qing Ping Wang Hisayuki Funahashi Takeshi Sakurai Seiji Shioda Shigeru Matsukura Kenji Kangawa Masamitsu Nakazato
0.21321544.12639935.html.plaintext.txt	2	Department Internal Medicine K
0.21321544.12639935.html.plaintext.txt	3	Miyazaki Medical College Miyazaki 889 1692 Japan Department Veterinary Physiology N
0.21321544.12639935.html.plaintext.txt	4	University Miyazaki Miyazaki 889 2151 Japan First Department Internal Medicine M
0.21321544.12639935.html.plaintext.txt	5	Oita Medical University Oita 879 5593 Japan Department Anatomy J
0.21321544.12639935.html.plaintext.txt	6	Showa University School Medicine Tokyo 142 8555 Japan Department Pharmacology University Tsukuba T
0.21321544.12639935.html.plaintext.txt	7	Ibaraki 305 8575 Japan National Cardiovascular Center Research Institute Y
0.21321544.12639935.html.plaintext.txt	8	Address correspondence requests reprints Masamitsu Nakazato M
0.21321544.12639935.html.plaintext.txt	9	Third Department Internal Medicine Miyazaki Medical College Kiyotake Miyazaki 889 1692 Japan
0.21321544.12639935.html.plaintext.txt	10	Abstract Top Abstract Introduction Materials Methods Results Discussion References The hypothalamus regulates energy intake integrating degree starvation satiation status environment variety neuronal blood derived signals
0.21321544.12639935.html.plaintext.txt	11	Ghrelin peptide produced stomach hypothalamus stimulates feeding GH secretion
0.21321544.12639935.html.plaintext.txt	12	Centrally administered ghrelin exerts orexigenic activity neuropeptide Y NPY agouti related protein systems
0.21321544.12639935.html.plaintext.txt	13	The interaction ghrelin hypothalamic orexigenic peptides however clarified
0.21321544.12639935.html.plaintext.txt	14	Here investigated anatomical interactions functional relationship ghrelin two orexigenic peptides orexin melanin concentrating hormone MCH present lateral hypothalamus
0.21321544.12639935.html.plaintext.txt	15	Ghrelin immunoreactive axonal terminals made direct synaptic contacts orexin producing neurons
0.21321544.12639935.html.plaintext.txt	16	Intracerebroventricular administration ghrelin induced Fos expression marker neuronal activation orexin producing neurons MCH producing neurons
0.21321544.12639935.html.plaintext.txt	17	Ghrelin remained competent induce Fos expression orexin producing neurons following pretreatment anti NPY IgG
0.21321544.12639935.html.plaintext.txt	18	Pretreatment anti orexin A IgG anti orexin B IgG anti MCH IgG attenuated ghrelin induced feeding
0.21321544.12639935.html.plaintext.txt	19	Administration NPY receptor antagonist attenuated ghrelin induced feeding rats treated anti orexin IgGs
0.21321544.12639935.html.plaintext.txt	20	Ghrelin induced feeding also suppressed orexin knockout mice
0.21321544.12639935.html.plaintext.txt	21	This study identifies novel hypothalamic pathway links ghrelin orexin regulation feeding behavior energy homeostasis
0.21321544.12639935.html.plaintext.txt	22	Introduction Top Abstract Introduction Materials Methods Results Discussion References GHRELIN WAS ORIGINALLY isolated human rat stomach cognate endogenous ligand GH secretagogue receptor GHS R Ref
0.21321544.12639935.html.plaintext.txt	23	This 28 amino acid peptide posttranslational n octanoyl modification indispensable activity
0.21321544.12639935.html.plaintext.txt	24	Ghrelin stimulates GH release peripherally centrally administered rats applied directly rat primary pituitary cells 1 2 3
0.21321544.12639935.html.plaintext.txt	25	In addition ghrelin administration increases food intake body weight gain 3 4 5 6 7 8 9
0.21321544.12639935.html.plaintext.txt	26	Whereas ghrelin secretion regulated negative energy balance conditions including starvation insulin induced hypoglycemia cachexia anorexia nervosa regulated conditions positive energy balance feeding hyperglycemia obesity 10 11 12 13 14
0.21321544.12639935.html.plaintext.txt	27	Gastric ghrelin enters brain across blood brain barrier 15
0.21321544.12639935.html.plaintext.txt	28	Recently stomach derived ghrelin signals starvation reported relayed hindbrain via vagus afferent nerve 16
0.21321544.12639935.html.plaintext.txt	29	Although ghrelin predominantly produced endocrine cells stomach 17 18 also synthesized hypothalamic arcuate nucleus 1 19 critical region feeding
0.21321544.12639935.html.plaintext.txt	30	The ghrelin receptor however extensively distributed throughout brain areas lateral hypothalamus LH arcuate nucleus 20 21
0.21321544.12639935.html.plaintext.txt	31	Both areas contain several subsets neurons produce neuropeptides implicated feeding regulation including neuropeptide Y NPY agouti related protein AgRP cocaine amphetamine regulated transcript proopiomelanocortin melanin concentrating hormone MCH orexins orexin A orexin B also termed hypocretins 22 23
0.21321544.12639935.html.plaintext.txt	32	Centrally administered ghrelin may interact peptides regulate food intake energy homeostasis
0.21321544.12639935.html.plaintext.txt	33	Although mechanism ghrelin orexigenic activity related NPY AgRP pathways 6 7 24 interaction ghrelin energy regulating systems unclear
0.21321544.12639935.html.plaintext.txt	34	Orexin A B produced 130 amino acid prepro orexin precursor LH 46 amino acid sequence identity stimulate food intake 25
0.21321544.12639935.html.plaintext.txt	35	MCH 19 amino acid neuropeptide whose neurons coextensive colocalized orexin neurons LH 26 also stimulates feeding centrally administered 27
0.21321544.12639935.html.plaintext.txt	36	Using electron microscope immunohistochemistry immunofluorescence microscopy investigated anatomical distributions ghrelin orexin MCH
0.21321544.12639935.html.plaintext.txt	37	We also examined ghrelin induced expression c fos marker neuronal activation 28 orexin MCH expressing neurons
0.21321544.12639935.html.plaintext.txt	38	To investigate functional relationship ghrelin orexins MCH examined effect pretreatment anti orexin A B IgGs anti MCH IgG ghrelin inducing feeding
0.21321544.12639935.html.plaintext.txt	39	We also studied ghrelin induced food intake orexin knockout mice
0.21321544.12639935.html.plaintext.txt	40	We demonstrate ghrelin interacts orexin system induce feeding
0.21321544.12639935.html.plaintext.txt	41	Materials Methods Top Abstract Introduction Materials Methods Results Discussion References Animals Animals housed individually plastic cages 22 plus minus 1 C 12 h light 12 h dark cycle light 0700 1900 h given standard laboratory chow water ad libitum
0.21321544.12639935.html.plaintext.txt	42	Male Wistar rats weighing 300 350 g Charles River Japan Inc
0.21321544.12639935.html.plaintext.txt	43	Shiga Japan orexin knockout mice 12 wk old male generated targeted mutation embryonic stem cells 29 wild type littermates used accordance guidelines Japanese Physiological Society animal care
0.21321544.12639935.html.plaintext.txt	44	Following anesthesia ip injection sodium pentobarbital Abbot Laboratories Chicago IL intracerebroventricular icv cannula implanted lateral cerebral ventricle described 30 31
0.21321544.12639935.html.plaintext.txt	45	Proper placement cannulae verified upon completion experiment dye administration
0.21321544.12639935.html.plaintext.txt	46	Only animals demonstrating progressive weight gain surgery used subsequent experiments
0.21321544.12639935.html.plaintext.txt	47	Electron microscope immunohistochemistry Forty eight hours perfusion three Wistar rats injected colchicine 200 microg per rat lateral ventricles increase immunostaining ghrelin orexin expressing neurons
0.21321544.12639935.html.plaintext.txt	48	Following anesthesia ip injection sodium pentobarbital rats perfused ascending aorta 10 min 100 ml 0
0.21321544.12639935.html.plaintext.txt	49	9 saline 40 min 500 ml fixative 4 paraformaldehyde 0
0.21321544.12639935.html.plaintext.txt	50	The brain removed immediately postfixed fixative 2 4 h 4 C
0.21321544.12639935.html.plaintext.txt	51	The brain cut 30 40 microm thick sections using Oxford vibratome Oxford Instruments Abingdon UK
0.21321544.12639935.html.plaintext.txt	52	Sections incubated 12 h rabbit anti ghrelin antiserum
0.21321544.12639935.html.plaintext.txt	53	G606 final dilution 132000 Ref
0.21321544.12639935.html.plaintext.txt	54	17 4 C visualized avidin biotin complex ABC method Vectastain Elite ABC kit Vector Laboratories Inc
0.21321544.12639935.html.plaintext.txt	55	02 33 diaminobenzidine tetrahydrochloride DAB Sigma St Louis MO 0
0.21321544.12639935.html.plaintext.txt	56	005 hydrogen peroxide 50 mM Tris HCl pH 7
0.21321544.12639935.html.plaintext.txt	57	Sections subjected either direct observation light microscope silver gold intensification SGI Ref
0.21321544.12639935.html.plaintext.txt	58	Sections treated SGI incubated goat anti orexin A antiserum Santa Cruz Biotechnology Inc
0.21321544.12639935.html.plaintext.txt	59	Santa Cruz CA dilution 120000 24 h 4 C visualized ABC
0.21321544.12639935.html.plaintext.txt	60	Orexin A labeling performed using DAB without SGI
0.21321544.12639935.html.plaintext.txt	61	For examination electron microscopy sections postfixed 1 OsO4 0
0.21321544.12639935.html.plaintext.txt	62	4 1 h 4 C dehydrated graded series ethanol concentrations embedded Epon Araldite Structure Probe Inc
0.21321544.12639935.html.plaintext.txt	63	Ultrathin sections cut examined H 7000 electron microscope Hitachi Tokyo Japan
0.21321544.12639935.html.plaintext.txt	64	As control anti ghrelin antiserum either omitted replaced normal rabbit goat serum
0.21321544.12639935.html.plaintext.txt	65	Immunofluorescence double staining Following perfusion 2 paraformaldehyde brains three Wistar rats removed immersed 12 h fixative 4 C
0.21321544.12639935.html.plaintext.txt	66	Samples transferred 30 solution sucrose
0.21321544.12639935.html.plaintext.txt	67	Brains quickly frozen Tissue Tek O
0.21321544.12639935.html.plaintext.txt	68	compound Sakura Finetechnical Co
0.21321544.12639935.html.plaintext.txt	69	Tokyo Japan cut 7 microm thick coronal sections cryostat Microm HM 500 Microm Heidelberg Germany
0.21321544.12639935.html.plaintext.txt	70	Sections incubated 2 d goat anti orexin A antiserum dilution 110000 4 C Alexa 488 conjugated donkey antigoat IgG antibody Molecular Probes Inc
0.21321544.12639935.html.plaintext.txt	71	Eugene OR dilution 1400 2 h
0.21321544.12639935.html.plaintext.txt	72	After washing phosphate buffer saline pH 7
0.21321544.12639935.html.plaintext.txt	73	4 samples incubated 2 d rabbit anti ghrelin antibody 4 C
0.21321544.12639935.html.plaintext.txt	74	Slides incubated Alexa 546 labeled goat antirabbit IgG antibody Molecular Probes Inc dilution 1400
0.21321544.12639935.html.plaintext.txt	75	Samples observed Olympus AX 70 fluorescence microscope Olympus Co
0.21321544.12639935.html.plaintext.txt	76	Fos expression Ghrelin Peptide Institute Inc
0.21321544.12639935.html.plaintext.txt	77	Osaka Japan 500 pmol10 microl saline saline injected icv rats n 3 per group 90 min transcardial perfusion 4 paraformaldehyde fixative
0.21321544.12639935.html.plaintext.txt	78	Also rats n 3 per group administered anti NPY IgG Peptide Institute Inc
0.21321544.12639935.html.plaintext.txt	79	5 microg5 microl saline control serum IgG 0
0.21321544.12639935.html.plaintext.txt	80	5 microg5 microl saline icv 3 h icv ghrelin 500 pmol10 microl saline administration
0.21321544.12639935.html.plaintext.txt	81	5 microg sufficient suppress ghrelin induced feeding 7
0.21321544.12639935.html.plaintext.txt	82	Following transcardial perfusion 90 min later tuberal hypothalamus cut 40 microm thick sections
0.21321544.12639935.html.plaintext.txt	83	Sections incubated 2 d goat anti Fos antiserum Santa Cruz Biotechnology Inc
0.21321544.12639935.html.plaintext.txt	84	dilution 11500 stained ABC
0.21321544.12639935.html.plaintext.txt	85	A proportion hypothalamic sections additionally stained either rabbit anti orexin A antiserum 32 rabbit anti MCH antiserum Phoenix Pharmaceuticals Inc
0.21321544.12639935.html.plaintext.txt	86	We quantitated number neurons orexin MCH Fos colocalization light microscope counting two randomly selected visual fields two sections rat
0.21321544.12639935.html.plaintext.txt	87	Food intake Rabbit anti orexin A anti orexin B antisera produced described elsewhere 32
0.21321544.12639935.html.plaintext.txt	88	We purified anti orexin A IgG anti orexin B IgG Affi gel protein A affinity Bio Rad Laboratories Inc
0.21321544.12639935.html.plaintext.txt	89	Hercules CA either CNBr Sepharose coupled Bio Rad Laboratories Inc
0.21321544.12639935.html.plaintext.txt	90	orexin A orexin B affinity chromatography
0.21321544.12639935.html.plaintext.txt	91	We determined quantity purified IgG using DC protein assay kit Bio Rad Laboratories Inc
0.21321544.12639935.html.plaintext.txt	92	Because anti orexin A IgG cross react orexin B anti orexin B cross react orexin A two IgGs given concurrently icv administration
0.21321544.12639935.html.plaintext.txt	93	Rats n 8 10 per group given icv administration anti orexin A IgG 0
0.21321544.12639935.html.plaintext.txt	94	25 microg anti orexin B IgG 0
0.21321544.12639935.html.plaintext.txt	95	5 microg control serum IgG 0
0.21321544.12639935.html.plaintext.txt	96	We measured dark phase food intake 12 h
0.21321544.12639935.html.plaintext.txt	97	Ghrelin 200 pmol injected icv 1100 h rats n 10 12 per group 3 h icv administration anti orexin A B IgGs 0
0.21321544.12639935.html.plaintext.txt	98	25 microg anti MCH IgG 0
0.21321544.12639935.html.plaintext.txt	99	5 microg control serum IgG 0
0.21321544.12639935.html.plaintext.txt	100	5 microg 2 h food intake measured
0.21321544.12639935.html.plaintext.txt	101	Ghrelin 200 pmol also administrated rats n 6 8 per group icv concurrently either NPY receptor antagonist 1229U91 30 microg Y1 NPY receptor antagonist 33 kind gift Banyu Pharmaceuticals Tokyo Japan control serum IgG 3 h icv administration either anti orexin A B IgGs 0
0.21321544.12639935.html.plaintext.txt	102	25 microg control serum IgG 0
0.21321544.12639935.html.plaintext.txt	103	Ghrelin 200 pmol2 microl saline also administered icv orexin knockout mice n 7 wild type lettermates n 7
0.21321544.12639935.html.plaintext.txt	104	Following injection rats mice returned cages food intake measured 2 h treatment
0.21321544.12639935.html.plaintext.txt	105	Statistical analysis The means plus minus SEM determined one way ANOVA followed unpaired test
0.21321544.12639935.html.plaintext.txt	106	Differences considered significant P 0
0.21321544.12639935.html.plaintext.txt	107	Results Top Abstract Introduction Materials Methods Results Discussion References Immunoelectron microscopy immunofluoroscence double staining Ghrelin immunoreactive neuronal axons terminals contained large dense cored synaptic vesicles indicated DAB SGI reaction products Fig
0.21321544.12639935.html.plaintext.txt	108	Orexin expression visualized DAB labeled structures seen light dark gray Fig
0.21321544.12639935.html.plaintext.txt	109	Orexin producing neurons dendritic processes often received synapses ghrelin containing axon terminals Fig
0.21321544.12639935.html.plaintext.txt	110	No positive DAB reaction products detected anti ghrelin antiserum omitted replaced normal rabbit goat serum data shown
0.21321544.12639935.html.plaintext.txt	111	View larger version 93K Figure 1
0.21321544.12639935.html.plaintext.txt	112	The innervation ghrelin immunoreactive axons orexin producing neurons
0.21321544.12639935.html.plaintext.txt	113	A B electron micrographs whereas C D immunofluorescent micrographs
0.21321544.12639935.html.plaintext.txt	114	A A ghrelin immunoreactive axon terminal G makes synapse arrow orexin immunoreactive perikaryon O
0.21321544.12639935.html.plaintext.txt	115	The perikaryon contains many dense cored vesicles closed arrowheads immunopositive orexin
0.21321544.12639935.html.plaintext.txt	116	B A ghrelin immunoreactive axon terminal G makes symmetrical synapse arrow orexin immunoreactive dendrite OD
0.21321544.12639935.html.plaintext.txt	117	Ghrelin immunoreactive axon terminal contains immunopositive dense cored vesicles open arrowhead
0.21321544.12639935.html.plaintext.txt	118	C Ghrelin producing neurons red fluorescence orexin producing neurons green fluorescence localized arcuate nucleus LH respectively
0.21321544.12639935.html.plaintext.txt	119	D A higher magnification area outlined C
0.21321544.12639935.html.plaintext.txt	120	Ghrelin immunoreactive fibers red found close proximity orexin producing neurons green
0.21321544.12639935.html.plaintext.txt	121	Arrows indicate apposition ghrelin fibers orexin neurons
0.21321544.12639935.html.plaintext.txt	122	ARC Arcuate nucleus f fornix VMH ventromedial hypothalamus III third ventricle
0.21321544.12639935.html.plaintext.txt	123	2 microm C 100 microm D 10 microm
0.21321544.12639935.html.plaintext.txt	124	Ghrelin expressing neurons predominantly found hypothalamic arcuate nucleus whereas orexin producing neurons restricted LH Fig
0.21321544.12639935.html.plaintext.txt	125	Dense populations ghrelin containing fibers small number orexin containing fibers identified arcuate nucleus Fig
0.21321544.12639935.html.plaintext.txt	126	Ghrelin fibers also found LH Fig
0.21321544.12639935.html.plaintext.txt	127	Subpopulations ghrelin immunoreactive terminals directly contacted orexin containing neurons LH Fig
0.21321544.12639935.html.plaintext.txt	128	Fos expression Following icv administration ghrelin Fos immunoreactive neurons observed LH
0.21321544.12639935.html.plaintext.txt	129	Ghrelin found induce Fos expression 23 plus minus 8 orexin immunoreactive neurons double immunohistochemistry Fig
0.21321544.12639935.html.plaintext.txt	130	Ghrelin however induce Fos expression MCH immunoreactive neurons Fig
0.21321544.12639935.html.plaintext.txt	131	Despite pretreatment anti NPY control serum IgG ghrelin remained capable inducing Fos expression orexin immunoreactive neurons Fig
0.21321544.12639935.html.plaintext.txt	132	View larger version 116K Figure 2
0.21321544.12639935.html.plaintext.txt	133	Fos expression determined immunohistochemistry LH following icv administration ghrelin
0.21321544.12639935.html.plaintext.txt	134	A Costaining arrows Fos dark blue black orexin brown neurons rats given ghrelin
0.21321544.12639935.html.plaintext.txt	135	B Fos dark blue black expressed MCH containing neurons arrows brown following ghrelin administration
0.21321544.12639935.html.plaintext.txt	136	C Costaining arrows Fos dark blue black orexin brown ghrelin treated rats following anti NPY IgG 0
0.21321544.12639935.html.plaintext.txt	137	D Costaining arrows Fos dark blue black orexin brown ghrelin treated rats following control IgG 0
0.21321544.12639935.html.plaintext.txt	138	Rats received 500 pmol ghrelin
0.21321544.12639935.html.plaintext.txt	139	Effects orexins MCH ghrelin induced feeding We coadministered anti orexin A IgG anti orexin B IgG block activities orexins
0.21321544.12639935.html.plaintext.txt	140	We first examined effect anti orexin A B IgGs anti MCH IgG suppression feeding
0.21321544.12639935.html.plaintext.txt	141	They significantly reduced dark phase food intake comparison control IgG treatment Fig
0.21321544.12639935.html.plaintext.txt	142	We next investigated effect endogenous orexin MCH blockade ghrelin induced feeding
0.21321544.12639935.html.plaintext.txt	143	Ghrelin increased 2 h food intake rats following icv administration control IgG Fig
0.21321544.12639935.html.plaintext.txt	144	Pretreatment anti orexin A B IgGs however reduced ghrelin induced food intake one half level seen rats given control IgG ghrelin Fig
0.21321544.12639935.html.plaintext.txt	145	Pretreatment anti MCH IgG affect ghrelin induced feeding Fig
0.21321544.12639935.html.plaintext.txt	146	Ghrelin induced food intake orexin deficient mice significantly reduced comparison wild type littermates Fig
0.21321544.12639935.html.plaintext.txt	147	Y1 NPY receptor antagonist affect 2 h food intake
0.21321544.12639935.html.plaintext.txt	148	Coadministration ghrelin Y1 NPY receptor antagonist also reduced ghrelin induced feeding 41 Fig
0.21321544.12639935.html.plaintext.txt	149	The combination ghrelin Y1 NPY receptor antagonist coadministration icv administration anti orexin A B IgGs additively reduced ghrelin induced feeding 87 Fig
0.21321544.12639935.html.plaintext.txt	150	View larger version 21K Figure 3
0.21321544.12639935.html.plaintext.txt	151	The effect icv administration anti orexin A 0
0.21321544.12639935.html.plaintext.txt	152	25 microg IgGs anti MCH IgG 0
0.21321544.12639935.html.plaintext.txt	153	5 microg 12 h dark phase food intake 1900 0700 h
0.21321544.12639935.html.plaintext.txt	154	View larger version 17K Figure 4
0.21321544.12639935.html.plaintext.txt	155	The effect administration anti orexin A 0
0.21321544.12639935.html.plaintext.txt	156	25 microg IgGs anti MCH IgG 0
0.21321544.12639935.html.plaintext.txt	157	5 microg ghrelin induced feeding
0.21321544.12639935.html.plaintext.txt	158	A Two hour food intake measured ghrelin treated 200 pmol rats following either anti orexin A B IgGs control IgG
0.21321544.12639935.html.plaintext.txt	159	B Two hour food intake ghrelin treated 200 pmol rats following anti MCH IgG control IgG
0.21321544.12639935.html.plaintext.txt	160	View larger version 17K Figure 5
0.21321544.12639935.html.plaintext.txt	161	The effect icv ghrelin 200 pmol vehicle injection feeding orexin knockout mice wild type littermates
0.21321544.12639935.html.plaintext.txt	162	View larger version 16K Figure 6
0.21321544.12639935.html.plaintext.txt	163	Suppressive effect Y1 antagonist Y1 NPY receptor antagonist anti orexin A 0
0.21321544.12639935.html.plaintext.txt	164	25 microg IgGs ghrelin induced feeding
0.21321544.12639935.html.plaintext.txt	165	control vehicle control IgG
0.21321544.12639935.html.plaintext.txt	166	ghrelin Y1 antagonist control IgG
0.21321544.12639935.html.plaintext.txt	167	Discussion Top Abstract Introduction Materials Methods Results Discussion References This study demonstrates synaptic contact ghrelin containing axons orexin producing neurons rat hypothalamus
0.21321544.12639935.html.plaintext.txt	168	In addition identified functional interaction ghrelin orexins
0.21321544.12639935.html.plaintext.txt	169	Icv administration ghrelin stimulates GH secretion food intake 1 2 3 4 5 6 7 8 9 ghrelin induced feeding thought occur independently GH icv administered ghrelin also increased food intake spontaneous GH deficient rats 6 7
0.21321544.12639935.html.plaintext.txt	170	Ghrelin stimulates feeding NPY AgRP 6 7 orexigenic peptides colocalized neurons hypothalamic arcuate nucleus 34
0.21321544.12639935.html.plaintext.txt	171	Ghrelin receptor mRNA expressed NPYAgRP neurons arcuate nucleus 35
0.21321544.12639935.html.plaintext.txt	172	Centrally administered ghrelin induced Fos expression approximately 40 NPYAgRP neurons 7 increased NPY AgRP mRNA levels 5 6 7 24
0.21321544.12639935.html.plaintext.txt	173	Ghrelin receptor mRNA also present LH rats 21 region implicated regulation feeding behavior energy homeostasis
0.21321544.12639935.html.plaintext.txt	174	Animals LH lesions exhibit decreased food intake 36 37 whereas electrical stimulation LH satiated state promotes feeding 37 38
0.21321544.12639935.html.plaintext.txt	175	Orexin MCH orexigenic neuropeptides synthesized specifically LH 22 25 26 27 32 39 40
0.21321544.12639935.html.plaintext.txt	176	Ghrelin fibers project LH synapse orexin immunoreactive neurons
0.21321544.12639935.html.plaintext.txt	177	Icv administration ghrelin induced Fos expression orexin expressing neurons MCH expressing neurons result consistent recent finding icv administration GHRP 6 synthetic GH releasing hexapeptide binds ghrelin receptor 41 induced Fos similar neuronal pattern 9
0.21321544.12639935.html.plaintext.txt	178	These findings indicate ghrelin may stimulate feeding orexin system NPY AgRP systems
0.21321544.12639935.html.plaintext.txt	179	Several peptidergic monoaminergic systems participate regulation feeding energy homeostasis hypothalamus link neuronal circuits
0.21321544.12639935.html.plaintext.txt	180	NPY fibers directly project orexin neurons 42 43 icv injection anti orexin antiserum NPY injection significantly attenuated NPY induced feeding 44 indicating NPY interacts orexin anatomically functionally
0.21321544.12639935.html.plaintext.txt	181	As ghrelin induces feeding activation NPY system sought investigate activation orexin producing neurons ghrelin via NPY system
0.21321544.12639935.html.plaintext.txt	182	We therefore examined ghrelin induced Fos expression orexin producing neurons following pretreatment anti NPY IgG
0.21321544.12639935.html.plaintext.txt	183	Ghrelin remained competent induce Fos expression orexin producing neurons following pretreatment anti NPY IgG suggesting ghrelin activates orexin producing neurons manner independent NPY
0.21321544.12639935.html.plaintext.txt	184	Orexin regulates feeding energy homeostasis also sleep wakefulness neuroendocrine homeostasis autonomic functions 25 29 40 45 46
0.21321544.12639935.html.plaintext.txt	185	Ghrelin induced Fos expression approximately 23 orexin immunoreactive neurons
0.21321544.12639935.html.plaintext.txt	186	As 33 orexin immunoreactive neurons glucosensitive 47 subset neurons express receptor leptin 42 satiation signal produced adipocytes part orexin expressing neurons may play crucial role regulation feeding energy homeostasis
0.21321544.12639935.html.plaintext.txt	187	To investigate functional relationship ghrelin either orexins MCH examined effect anti orexin A B IgGs anti MCH IgG pretreatment ghrelin induced feeding
0.21321544.12639935.html.plaintext.txt	188	Food intake induced ghrelin attenuated anti orexin A B IgGs anti MCH IgG pretreatment
0.21321544.12639935.html.plaintext.txt	189	In addition ghrelin induced food intake mice deficient orexin significantly lower seen wild type littermates
0.21321544.12639935.html.plaintext.txt	190	These data suggest centrally administered ghrelin increases food intake action orexin system
0.21321544.12639935.html.plaintext.txt	191	To date six functional NPY receptors Y1 Y6 identified 48 49
0.21321544.12639935.html.plaintext.txt	192	NPY stimulates feeding predominantly Y1 NPY receptor 33 50
0.21321544.12639935.html.plaintext.txt	193	Icv injection Y1 NPY receptor antagonist significantly reduced ghrelin induced food intake
0.21321544.12639935.html.plaintext.txt	194	Moreover coadministration ghrelin Y1 NPY receptor antagonist following anti orexin A B IgGs pretreatment abolished ghrelin induced feeding
0.21321544.12639935.html.plaintext.txt	195	Therefore ghrelin likely interacts NPY orexin systems induce feeding
0.21321544.12639935.html.plaintext.txt	196	Feeding behavior involves complicated integration large number learning memory cognitive emotional somatosensorimotor autonomic events
0.21321544.12639935.html.plaintext.txt	197	Icv administration ghrelin strongly induces Fos hypothalamus brain stem hippocampus dentate gyrus piriform cortex 7
0.21321544.12639935.html.plaintext.txt	198	Centrally administered ghrelin may regulate feeding energy homeostasis direct activation orexin NPY pathways also influences learning memory state mood formation emotion
0.21321544.12639935.html.plaintext.txt	199	Further investigation ghrelin interactions neuronal systems provide novel insights regulation feeding energy homeostasis
0.21321544.12639935.html.plaintext.txt	200	Footnotes This study supported part The 21st Century COE Program grants aid Ministry Education Culture Sports Science Technology Japan Ministry Health Labor Welfare Japan Uehara Memorial Foundation Ono Medical Research Foundation Mitsui Life Social Welfare Foundation Yamanouchi Foundation Research Metabolic Disorders M
0.21321544.12639935.html.plaintext.txt	201	The Foundation Growth Science Japan Narishige Research Foundation Y
0.21321544.12639935.html.plaintext.txt	202	Abbreviations ABC Avidin biotin complex AgRP Agouti related protein DAB 33 diaminobenzidine tetrahydrochloride GHS R GH secretagogue receptor icv intracerebroventricular LH lateral hypothalamus MCH melanin concentrating hormone NPY neuropeptide Y SGI silver gold intensification
0.21321544.12639935.html.plaintext.txt	203	Accepted publication December 11 2002
0.21321544.12639935.html.plaintext.txt	204	References Top Abstract Introduction Materials Methods Results Discussion References Kojima M Hosoda H Date Y Nakazato M Matsuo H Kangawa K 1999 Ghrelin novel growth hormone releasing acylated peptide stomach
0.21321544.12639935.html.plaintext.txt	205	Nature 402656 660CrossRefMedline Date Y Murakami N Kojima M Kuroiwa T Matsukura S Kangawa K Nakazato M 2000 Central effects novel acylated peptide ghrelin growth hormone release rats
0.21321544.12639935.html.plaintext.txt	206	Biochem Biophys Res Commun 275477 480CrossRefMedline Wren AM Small CJ Ward HL Murphy KG Dakin CLD Taheri S Kennedy AR Roberts GH Morgan DGA Ghatei MA Bloom SR 2000 The novel hypothalamic peptide ghrelin stimulates food intake growth hormone secretion
0.21321544.12639935.html.plaintext.txt	207	Endocrinology 1414325 4328AbstractFree Full Text Tschop M Smiley DL Heiman M 2000 Ghrelin induces adiposity rodents
0.21321544.12639935.html.plaintext.txt	208	Nature 407908 913CrossRefMedline Asakawa A Inui A Kaga T Yuzuriha H Nagata T Ueno N Makino S Fujimiya M Niijima A Fujino MA Kasuga M 2001 Ghrelin appetite stimulatory signal stomach structural resemblance motilin
0.21321544.12639935.html.plaintext.txt	209	Gastroenterology 120337 345Medline Shintani M Ogawa Y Ebihara K Aizawa Abe M Miyanaga F Takaya K Hayashi T Inoue G Hosoda K Kojima M Kangawa K Nakao K 2001 Ghrelin endogenous growth hormone secretagogue novel orexigenic peptide antagonizes leptin action activation hypothalamic neuropeptide YY1 receptor pathway
0.21321544.12639935.html.plaintext.txt	210	Diabetes 50227 232AbstractFree Full Text Nakazato M Murakami N Date Y Kojima M Matsuo H Kangawa K Matsukura S 2001 A role ghrelin central regulation feeding
0.21321544.12639935.html.plaintext.txt	211	Nature 409194 198CrossRefMedline Wren AM Small CJ Abbptt CR Dhillo WS Seal LJ Cohen RL Batterham RL Ward HL Taheri S Stanley SA Ghatei MA Bloom SR 2001 Ghrelin causes hyperphagia obesity rats
0.21321544.12639935.html.plaintext.txt	212	Diabetes 502540 2547AbstractFree Full Text Lawrence CB Snape AC Baudoin FM Luckman SM 2002 Acute central ghrelin GH secretagogues induce feeding activate brain appetite centers
0.21321544.12639935.html.plaintext.txt	213	Endocrinology 143155 162AbstractFree Full Text Tschop M Weyer C Tataranni PA Devanarayan V Ravussin E Heiman ML 2001 Circulating ghrelin levels decreased human obesity
0.21321544.12639935.html.plaintext.txt	214	Diabetes 50707 709AbstractFree Full Text Nagaya N Uematsu M Kojima M Date Y Nakazato M Okumura H Hosoda H Shimizu W Yamagishi M Oya H Koh H Yutani C Kangawa K 2001 Elevated circulating level ghrelin cachexia associated chronic heart failure relationships ghrelin anaboliccatabolic factors
0.21321544.12639935.html.plaintext.txt	215	Circulation 1042034 2038AbstractFree Full Text Toshinai K Mondal MS Nakazato M Date Y Murakami N Kojima M Kangawa K Matsukura S 2001 Upregulation ghrelin expression stomach upon fasting insulin induced hypoglycemia leptin administration
0.21321544.12639935.html.plaintext.txt	216	Biochem Biophys Res Commun 2811220 1225CrossRefMedline Inui A 2001 Ghrelin orexigenic somatotrophic signal stomach
0.21321544.12639935.html.plaintext.txt	217	Nat Rev Neurosci 2551 560CrossRefMedline Shiiya T Nakazato M Mizuta M Date Y Mondal MS Tanaka M Nozoe S Hosoda H Kangawa K Matsukura S 2002 Plasma ghrelin levels lean obese humans effect glucose ghrelin secretion
0.21321544.12639935.html.plaintext.txt	218	J Clin Endocrinol Metab 87240 244AbstractFree Full Text Banks WA Tschop M Robinson SM Heiman ML 2002 Extent direction ghrelin transport across blood brain barrier determined unique primary structure
0.21321544.12639935.html.plaintext.txt	219	J Pharmacol Exp Therap 302822 827AbstractFree Full Text Date Y Murakami N Toshinai K Matsukura S Niijima A Matsuo H Kangawa K Nakazato M 2002 The role gastric afferent vagal nerve ghrelin induced feeding growth hormone secretion
0.21321544.12639935.html.plaintext.txt	220	Gastroenterology 1231120 1128CrossRefMedline Date Y Kojima M Hosoda H Sawaguchi A Mondal MS Suganuma T Matsukura S Kangawa K Nakazato M 2000 Ghrelin novel growth hormone releasing acylated peptide synthesized distinct endocrine cell type gastrointestinal tracts rats humans
0.21321544.12639935.html.plaintext.txt	221	Endocrinology 1414255 4261AbstractFree Full Text Dornonville de la Cour C Bjorkqvist M Sandvik AK Bakke I Zhao CM Chen D Hakanson R 2001 A like cells rat stomach contain ghrelin operate gastrin control
0.21321544.12639935.html.plaintext.txt	222	Regul Pept 99141 150CrossRefMedline Lu S Guan JL Wang QP Uehara K Yamada S Goto N Date Y Nakazato M Kojima M Kangawa K Shioda S 2002 Immunocytochemical observation ghrelin containing neurons rat arcuate nucleus
0.21321544.12639935.html.plaintext.txt	223	Neurosci Lett 321157 160CrossRefMedline Guan XM Yu H Palyha OC McKee KK Feighner SD Sirinathsinghji DJ Smith RG van del Ploeg LH Howard AD 1997 Distribution mRNA encoding growth hormone secretagogue receptor brain peripheral tissues
0.21321544.12639935.html.plaintext.txt	224	Brain Res Mol Brain Res 4823 29CrossRefMedline Mitchell V Bouret S Beauvillain JC Schilling A Perret M Kordon C Epelbaum J 2001 Comparative distribution mRNA encoding growth hormone secretagogue receptor GHS R Microcebus murinus primate lemurian rat forebrain pituitary
0.21321544.12639935.html.plaintext.txt	225	CO2 327AbstractFree Full Text Schwartz MW Woods SC Porte Jr D Seeley RJ Baskin DG 2000 Central nervous system control food intake
0.21321544.12639935.html.plaintext.txt	226	Nature 404661 671Medline Kamegai J Tamura H Shimizu T Ishii S Sugihara H Wakabayashi I 2001 Chronic central infusion ghrelin increases hypothalamic neuropeptide Y agouti related protein mRNA levels body weight rats
0.21321544.12639935.html.plaintext.txt	227	Diabetes 502438 2443AbstractFree Full Text Sakurai T Amemiya A Ishii M Matsuzaki I Chemelli RM Tanaka H Williams SC Richardson JA Kozlowski GP Wilson S Arch JRS Buckingham RE Haynes AC Carr SA Annan RS McNulty DE Liu WS Terrett JA Elshourbagy NA Bergsma DJ Yanagisawa M 1998 Orexins orexin receptors family hypothalamic neuropeptides G protein coupled receptors regulate feeding behavior
0.21321544.12639935.html.plaintext.txt	228	Cell 92573 585Medline Elias CF Saper CB Maratos Flier E Tritos NA Lee C Kelly J Tatro JB Hoffman GE Ollmann MM Barsh GS Sakurai T Yanagisawa M Elmquist JK 1998 Chemically defined projections linking mediobasal hypothalamus lateral hypothalamic area
0.21321544.12639935.html.plaintext.txt	229	CO2 R 246CrossRefMedline Sagar SM Sharp FR Curran T 1988 Expression c fos protein brain metabolic mapping cellular level
0.21321544.12639935.html.plaintext.txt	230	Science 2401328 1331Medline Chemelli RM Willie JT Sinton CM Elmquist JK Scammell T Lee C Richardson JA Williams SC Xiong Y Kisanuki Y Fitch TE Nakazato M Hammer RE Saper CB Yanagisawa M 1999 Narcolepsy orexin knockout mice molecular genetics sleep regulation
0.21321544.12639935.html.plaintext.txt	231	Cell 98437 451Medline Ida T Nakahara K Katayama T Murakami N Nakazato M 1999 Effect lateral cerebroventricular injection appetite stimulating neuropeptide orexin neuropeptide Y various behavioral activities rats
0.21321544.12639935.html.plaintext.txt	232	Brain Res 821526 552CrossRefMedline Kanatani A Mashiko S Murai N Sugimoto N Ito J Fukuroda T Fukami T Morin N MacNeil DJ Van der Ploeg LH Saga Y Nishimura S Ihara M 2000 Role Y1 receptor regulation neuropeptide Y mediated feeding comparison wild type Y1 receptor deficient Y5 receptor deficient mice
0.21321544.12639935.html.plaintext.txt	233	Endocrinology 1411011 1016AbstractFree Full Text Date Y Ueta Y Yamashita H Yamaguchi H Matsukura S Kangawa K Sakurai T Yanagisawa M Nakazato M 1999 Orexins orexigenic hypothalamic peptides interact autonomic neuroendocrine neuroregulatory systems
0.21321544.12639935.html.plaintext.txt	234	Proc Natl Acad Sci USA 96748 753AbstractFree Full Text Kanatani A Ishihara A Asahi S Tanaka T Ozaki S Ihara M 1996 Potent neuropeptide Y Y1 receptor antagonist 1229U91 blockade neuropeptide Y induced physiological food intake
0.21321544.12639935.html.plaintext.txt	235	Endocrinology 1373177 3182Abstract Hahn TM Breininger JF Baskin DG Schwartz MW 1998 Coexpression AGRP NPY fasting activated hypothalamic neurons
0.21321544.12639935.html.plaintext.txt	236	Nat Neurosci 1271 272CrossRefMedline Willesen MG Kristensen P Romer J 1999 Co localization growth hormone secretagogue receptor NPY mRNA arcuate nucleus rat
0.21321544.12639935.html.plaintext.txt	237	Neuroendocrinology 70306 316CrossRefMedline Oomura Y 1980 Input output organization hypothalamus relating food intake behavior
0.21321544.12639935.html.plaintext.txt	238	In Morgane PJ Panksepp J eds
0.21321544.12639935.html.plaintext.txt	239	New York Marcel Dekker 557 620 Bernardis LL Bellinger LL 1996 The lateral hypothalamic area revisited ingestive behavior
0.21321544.12639935.html.plaintext.txt	240	Neurosci Biobehav Rev 20189 287CrossRefMedline Takaki A Aou S Oomura Y Okada E Hori T 1992 Feeding suppression elicited electrical chemical stimulations monkey hypothalamus
0.21321544.12639935.html.plaintext.txt	241	Am J Physiol 262R586 R594 Bittencourt JC Presse F Arias C Peto C Vaughan J Nahon JL Vale W Sawchenko PE 1992 The melanin concentrating hormone system rat brain immuno hybridization histochemical characterization
0.21321544.12639935.html.plaintext.txt	242	J Comp Neurol 319218 245Medline Clegg DJ Air EL Woods SC Seeley RJ 2002 Eating elicited orexin A melanin concentrating hormone opioid mediated
0.21321544.12639935.html.plaintext.txt	243	Endocrinology 1432995 3000AbstractFree Full Text Luckman SM Rosenzweig I Dickson SL 1999 Activation arcuate nucleus neurons systemic administration leptin growth hormone releasing peptide 6 normal fasted rats
0.21321544.12639935.html.plaintext.txt	244	Neuroendocrinology 7093 100CrossRefMedline Horvath TL Diano S van den Pol AN 1999 Synaptic interaction hypocretin orexin neuropeptide Y cells rodent primate hypothalamus novel circuit implicated metabolic endocrine regulations
0.21321544.12639935.html.plaintext.txt	245	J Neurosci 191072 1087AbstractFree Full Text Broberger C De Lecea L Sutcliffe JG Hokfelt T 1998 Hypocretinorexin melanin concentrating hormone expressing cells form distinct populations rodent lateral hypothalamus relationship neuropeptide Y agouti gene related protein systems
0.21321544.12639935.html.plaintext.txt	246	CO2 S 273Medline Shirasaka T Nakazato M Matsukura S Takasaki M Kannan H 1999 Sympathetic cardiovascular actions orexins conscious rats
0.21321544.12639935.html.plaintext.txt	247	Am J Physiol 277R1780 R1785 Lin L Faraco J Li R Kadotani H Rogers W Lin X Qiu X de Jong PJ Nishino S Mignot E 1999 The sleep disorder canine narcolepsy caused mutation hypocretin orexin receptor 2 gene
0.21321544.12639935.html.plaintext.txt	248	Cell 98365 376Medline Moriguchi T Sakurai T Nambu T Yanagisawa M Goto K 1999 Neurons containing orexin lateral hypothalamic area adult rat brain activated insulin induced acute hypoglycemia
0.21321544.12639935.html.plaintext.txt	249	Neurosci Lett 264101 104CrossRefMedline Inui A 2000 Transgenic approach study body weight regulation
0.21321544.12639935.html.plaintext.txt	250	Pharmacol Rev 5235 61AbstractFree Full Text Michel MC Beck Sickinger A Doods HC Herzog H Larhammar D Quirion R Schwartz T Westfall T 1998 XVI International Union Pharmacology recommendations nomenclature neuropeptide Y peptide YY pancreatic polypeptide receptors
0.21321544.12639935.html.plaintext.txt	251	Pharmacol Rev 50143 150AbstractFree Full Text Wieland HA Engel W Eberlein W Rudolf K Doods HN 1998 Subtype selectivity novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO3304 effect feeding rodents
0.21321544.12639935.html.plaintext.txt	252	Br J Pharmacol 125549 555Abstract
0.2210986.14656716.html.plaintext.txt	0	Orexin A hypocretin 1 injected hypothalamic paraventricular nucleus spontaneous physical activity rats Kohji Kiwaki1 Catherine M
0.2210986.14656716.html.plaintext.txt	1	Kotz234 Chuanfeng Wang2 Lorraine Lanningham Foster1 James A
0.2210986.14656716.html.plaintext.txt	2	1Endocrine Research Unit Mayo Clinic Mayo Foundation Rochester 55905 2Veterans Affairs Medical Center 3Minnesota Obesity Center Minneapolis 55417 4Departments Food Science Nutrition University Minnesota Saint Paul Minnesota 55108
0.2210986.14656716.html.plaintext.txt	3	Submitted 24 March 2003 accepted final form 21 November 2003
0.2210986.14656716.html.plaintext.txt	4	ABSTRACT TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES In humans nonexercise activity thermogenesis NEAT increases positive energy balance
0.2210986.14656716.html.plaintext.txt	5	The mediator interaction positive energy balance physical activity unknown
0.2210986.14656716.html.plaintext.txt	6	In study address hypothesis orexin A acts hypothalamic paraventricular nucleus PVN increase nonfeeding associated physical activity
0.2210986.14656716.html.plaintext.txt	7	PVN cannulated rats injected either orexin A vehicle light dark cycle
0.2210986.14656716.html.plaintext.txt	8	Spontaneous physical activity SPA measured using arrays infrared activity sensors night vision videotaped recording VTR
0.2210986.14656716.html.plaintext.txt	9	O2 consumption CO2 production measured indirect calorimetry
0.2210986.14656716.html.plaintext.txt	10	Feeding behavior assessed VTR
0.2210986.14656716.html.plaintext.txt	11	Regardless time point injection orexin A 1 nmol associated dramatic increases SPA 2 h injection orexin A 6
0.2210986.14656716.html.plaintext.txt	12	95 x 103 beam break count n 24 vehicle 1
0.2210986.14656716.html.plaintext.txt	13	This increase SPA accompanied compatible increase O2 consumption
0.2210986.14656716.html.plaintext.txt	14	Duration feeding increased orexin A injected early light phase accounted 3
0.2210986.14656716.html.plaintext.txt	15	5 increased physical activity
0.2210986.14656716.html.plaintext.txt	16	In dose response experiment increases SPA correlated dose orexin A linearly 2 nmol
0.2210986.14656716.html.plaintext.txt	17	PVN injections orexin receptor antagonist SB 334867 associated decreases SPA attenuated effects PVN injected orexin A
0.2210986.14656716.html.plaintext.txt	18	Thus orexin A act PVN increase nonfeeding associated physical activity suggesting neuropeptide might mediator NEAT
0.2210986.14656716.html.plaintext.txt	19	energy expenditure hypothalamus obesity nonexercise activity thermogenesis
0.2210986.14656716.html.plaintext.txt	20	OBESITY AFFECTS ONE THIRD American population second leading cause death United States smoking 1
0.2210986.14656716.html.plaintext.txt	21	Treatment obesity proven difficult intractability may due fact energy balance regulated multiple complex mechanisms fully understood 4
0.2210986.14656716.html.plaintext.txt	22	Maintenance body weight achieved intricate balance energy intake expenditure
0.2210986.14656716.html.plaintext.txt	23	We found changes nonexercise activity thermogenesis NEAT mediate resistance weight gain overfeeding sedentary adults 32
0.2210986.14656716.html.plaintext.txt	24	There evidence spontaneous physical activity SPA familial 63 shows marked interindividual differences contribution daily energy expenditure 49 however mediator interaction overfeeding physical activity unknown
0.2210986.14656716.html.plaintext.txt	25	Orexins A B also known hypocretin 1 2 recently identified neuropeptides synthesized exclusively lateral hypothalamus area classically believed crucial feeding center 25
0.2210986.14656716.html.plaintext.txt	26	Initial interest neuropeptides concentrated orexigenic actions since central injection orexins increased food intake prepro orexin mRNA shown upregulated fasting 50
0.2210986.14656716.html.plaintext.txt	27	Apart appetite regulation orexins implicated central nervous system CNS regulation arousal sleep cardiovascular function temperature metabolic rate locomotor activity pituitary secretion glucose homeostasis gastric acid secretion 17 37 48 51 53 58
0.2210986.14656716.html.plaintext.txt	28	12 reported following intracerebroventricular administration orexin A hypothalamic c fos marker neuronal activation highly expressed hypothalamic paraventricular nucleus PVN orexin A injected directly PVN stimulated food intake although effect powerful
0.2210986.14656716.html.plaintext.txt	29	These authors suggested PVN might primary site action orexins orexigenic role rather orexins might perform role via PVN
0.2210986.14656716.html.plaintext.txt	30	The PVN demonstrated one sites innervated orexin containing neurons 39 44 express orexin receptor 2 36 62
0.2210986.14656716.html.plaintext.txt	31	These observations intrigued us wondered whether spontaneous physical activity SPA random rather intricately regulated CNS
0.2210986.14656716.html.plaintext.txt	32	Furthermore would propose interaction overfeeding physical activity undergoes processing within hypothalamus due role energy homeostasis
0.2210986.14656716.html.plaintext.txt	33	In study address hypothesis orexin A acts PVN increase SPA independently feeding behavior
0.2210986.14656716.html.plaintext.txt	34	Our approach inject orexin A PVN measure SPA thermogenesis feeding behavior use arrays infrared activity sensors indirect calorimetry infrared 24 h videotaping
0.2210986.14656716.html.plaintext.txt	35	Additionally observed effects orexin receptor antagonist selective orexin 1 receptor OX1R SB 334867 injected PVN
0.2210986.14656716.html.plaintext.txt	36	MATERIALS AND METHODS TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES Animals
0.2210986.14656716.html.plaintext.txt	37	Male Sprague Dawley rats Charles River Wilmington MA 250 300 g time surgery housed individually cages 1212 h light dark photocycle lights 700 AM room 22 plus minus 2 degrees C
0.2210986.14656716.html.plaintext.txt	38	Food Laboratory Rodents Diet 5001 PMI Nutrition International St
0.2210986.14656716.html.plaintext.txt	39	Louis MO water allowed ad libitum
0.2210986.14656716.html.plaintext.txt	40	The protocol approved Mayo Foundation Institutional Animal Care Use Committee
0.2210986.14656716.html.plaintext.txt	41	Cannulation Verification Placement
0.2210986.14656716.html.plaintext.txt	42	Rats anesthetized ketamine xylazine mixture 10010 mgkg body wt ip fitted 28 gauge stainless steel cannula placed right PVN
0.2210986.14656716.html.plaintext.txt	43	Stereotaxic coordinates determined rat brain atlas Paxinos Watson 42 follows 0
0.2210986.14656716.html.plaintext.txt	44	The injector extended 1 mm beyond end guide cannula
0.2210986.14656716.html.plaintext.txt	45	For cannulations incisor bar set 3
0.2210986.14656716.html.plaintext.txt	46	At least 10 days elapsed following surgery experimental trials
0.2210986.14656716.html.plaintext.txt	47	After experiments brains dissected stored 10 formaldehyde solution placement verification histology
0.2210986.14656716.html.plaintext.txt	48	This verification performed blinded fashion whereby physical activity data unknown histologist
0.2210986.14656716.html.plaintext.txt	49	A cannula deemed incorrect actual injection site farther 0
0.2210986.14656716.html.plaintext.txt	50	25 mm away targeted site
0.2210986.14656716.html.plaintext.txt	51	This rationale based diffusion coefficients injection volume delivered 40 previous data 28 60
0.2210986.14656716.html.plaintext.txt	52	Rats misplaced cannulas excluded data analysis studies 1 3
0.2210986.14656716.html.plaintext.txt	53	The number rats listed experimental design represents number rats final analysis cannulas correctly placed
0.2210986.14656716.html.plaintext.txt	54	Orexin A Phoenix Pharmaceuticals Mountain View CA dissolved artificial cerebrospinal fluid aCSF
0.2210986.14656716.html.plaintext.txt	55	The dose orexin A 1 nmol used study based previous studies observed feeding PVN injection orexin A 10 12 56
0.2210986.14656716.html.plaintext.txt	56	SB 334867 1 2 methylbenzoxazol 6 yl 3 15naphthyridin 4 yl urea hydrochloride synthesized GlaxoSmithKline 11 19 dissolved 5 DMSO aCSF
0.2210986.14656716.html.plaintext.txt	57	SB 334867 50 fold higher affinity OX1R orexin 2 receptor OX2R 11
0.2210986.14656716.html.plaintext.txt	58	Injection cannulas 33 gauge purchased Plastics One Roanoke VA
0.2210986.14656716.html.plaintext.txt	59	They fabricated inserted maximum depth protrude 1
0.2210986.14656716.html.plaintext.txt	60	0 mm beyond tip guide cannulas
0.2210986.14656716.html.plaintext.txt	61	5 microl either orexin A dissolved aCSF aCSF alone studies 1 2 either orexin A dissolved 5 DMSO aCSF SB 334867 5 DMSO aCSF 5 DMSO aCSF alone study 3 injected slowly 30 injector left place additional 10 ensure extrusion tip minimize distribution drug upward cannula tract
0.2210986.14656716.html.plaintext.txt	62	After injection cannula withdrawn stylet replaced
0.2210986.14656716.html.plaintext.txt	63	All injections unilateral right PVN
0.2210986.14656716.html.plaintext.txt	64	The total number injections animal one three study 1 seven eight studies 2 3
0.2210986.14656716.html.plaintext.txt	65	In previous studies demonstrated lack demonstrable tissue damage 50 repeated injections measured gliosis around injection site 46
0.2210986.14656716.html.plaintext.txt	66	Injection sites examined light microscopy tissue damage present studies none found
0.2210986.14656716.html.plaintext.txt	67	We compared SPA first second third injection PVN 1 nmol orexin A vehicle study 1 significant difference data shown
0.2210986.14656716.html.plaintext.txt	68	Measurement O2 Consumption CO2 Production SPA Duration Feeding Behavior
0.2210986.14656716.html.plaintext.txt	69	O2 consumption CO2 production measured using customized high precision single chamber indirect calorimeter Columbus Instruments Columbus OH reported previously 29 33
0.2210986.14656716.html.plaintext.txt	70	Thermogenesis calculated O2 consumption CO2 production
0.2210986.14656716.html.plaintext.txt	71	Calibration calorimeter performed measurement
0.2210986.14656716.html.plaintext.txt	72	The animal placed inside cylindrical calorimeter chamber acrylic diameter 30 cm height 20 cm volume 15 liters along food water bowls study 1 without food water studies 2 3
0.2210986.14656716.html.plaintext.txt	73	The chamber lid attached sealed room air pumped atmospheric pressure chamber 0
0.2210986.14656716.html.plaintext.txt	74	Data O2 consumption CO2 production collected every minute 24 h stored personal computer
0.2210986.14656716.html.plaintext.txt	75	Each data point identified time stamp
0.2210986.14656716.html.plaintext.txt	76	SPA measured simultaneously O2 consumption CO2 production measurements
0.2210986.14656716.html.plaintext.txt	77	Measurements performed using customized high precision racks collimated infrared activity sensors Columbus Instruments placed around acrylic chamber
0.2210986.14656716.html.plaintext.txt	78	There 45 collimated beams infrared light crossing 30 cm diameter cage allowing detection 1 cm movement three orthogonal axes
0.2210986.14656716.html.plaintext.txt	79	Photosensors registered activity unit time beam interrupted
0.2210986.14656716.html.plaintext.txt	80	In fashion activity detected simultaneously three axes forward backward side side
0.2210986.14656716.html.plaintext.txt	81	Data SPA summed every minute stored PC use time stamp identification
0.2210986.14656716.html.plaintext.txt	82	Data thereby derived simultaneously O2 consumption SPA animal minute minute 24 h measurement period
0.2210986.14656716.html.plaintext.txt	83	Duration SPA defined duration activity sensors read greater zero
0.2210986.14656716.html.plaintext.txt	84	An 8 mm charge coupled device video camera infrared digital time recording capabilities used measuring feeding behavior
0.2210986.14656716.html.plaintext.txt	85	The experiments videotaped overhead duration feeding behavior measured investigators blinded whether animal received orexin A aCSF
0.2210986.14656716.html.plaintext.txt	86	On test days rats first acclimated experimental 15 liter cylindrical cages 24 h
0.2210986.14656716.html.plaintext.txt	87	Food water pots placed floor cylindrical cage access ad libitum acclimation period
0.2210986.14656716.html.plaintext.txt	88	Pots prevented tipping using purposely built acrylic plate designed
0.2210986.14656716.html.plaintext.txt	89	The unmanned animal room sound plus light proof locked throughout experiments
0.2210986.14656716.html.plaintext.txt	90	Study 1 effect orexin A injected different time points SPA O2 consumption feeding behavior
0.2210986.14656716.html.plaintext.txt	91	In three separate experiments rats injected 1 nmol orexin A n 15 volume 0
0.2210986.14656716.html.plaintext.txt	92	5 microl aCSF n 22 different times day experiment 1 injection 800 AM 400 PM n 5 orexin A 1200 aCSF experiment 2 injection 200 PM n 6 orexin A aCSF experiment 3 injection 1200 PM 700 PM n 4 orexin A aCSF
0.2210986.14656716.html.plaintext.txt	93	O2 consumption measured experiment 1
0.2210986.14656716.html.plaintext.txt	94	Food water pots placed floor cage access ad libitum observation
0.2210986.14656716.html.plaintext.txt	95	Twenty four hour food consumption measured weighing food 800 AM experiment 1 200 PM experiment 2 1200 noon experiment 3
0.2210986.14656716.html.plaintext.txt	96	Study 2 relationship dose orexin A effect SPA thermogenesis
0.2210986.14656716.html.plaintext.txt	97	Each rat n 5 injected intervals 24 h different doses orexin A 0
0.2210986.14656716.html.plaintext.txt	98	5 1 2 nmol vehicle light cycle
0.2210986.14656716.html.plaintext.txt	99	The order injections different doses orexin A vehicle randomized
0.2210986.14656716.html.plaintext.txt	100	After injections SPA thermogenesis measured 2 h
0.2210986.14656716.html.plaintext.txt	101	Food water provided 2 h 2 h observation
0.2210986.14656716.html.plaintext.txt	102	Study 3 effect SB 334867 SPA thermogenesis
0.2210986.14656716.html.plaintext.txt	103	Two injections spaced 5 min apart 1 vehicle plus vehicle 2 20 microg SB 334867 plus vehicle 3 vehicle plus 1 nmol orexin A 4 20 microg SB 334867 plus 1 nmol orexin A given rat n 5 intervals 24 h light cycle
0.2210986.14656716.html.plaintext.txt	104	The order injections 1 4 randomized
0.2210986.14656716.html.plaintext.txt	105	After injections SPA thermogenesis measured 2 h
0.2210986.14656716.html.plaintext.txt	106	Food water provided 2 h 2 h observation
0.2210986.14656716.html.plaintext.txt	107	The results expressed means plus minus SE Figs
0.2210986.14656716.html.plaintext.txt	108	SPA O2 consumption thermogenesis feeding behavior analyzed using Mann Whitneys U test
0.2210986.14656716.html.plaintext.txt	109	Comparison SPA induced orexin A different time points made Kruskal Wallis rank test
0.2210986.14656716.html.plaintext.txt	110	Correlation orexin A induced SPA feeding behavior analyzed Spearmans rank correlation test
0.2210986.14656716.html.plaintext.txt	111	Correlation SPA thermogenesis dose response experiment analyzed Pearsons correlation test
0.2210986.14656716.html.plaintext.txt	112	05 considered statistically significant
0.2210986.14656716.html.plaintext.txt	113	View larger version 31K Fig
0.2210986.14656716.html.plaintext.txt	114	Twenty four hour time course effect orexin A spontaneous physical activity SPA A O2 consumption B
0.2210986.14656716.html.plaintext.txt	115	Rats received paraventricular nucleus PVN injection artificial cerebrospinal fluid aCSF 1 nmol orexin A 800 AM 400 PM
0.2210986.14656716.html.plaintext.txt	116	SPA shown mean total beam breaks plus minus SE 1 h group A left difference mean SPA orexin A group aCSF group A right
0.2210986.14656716.html.plaintext.txt	117	O2 consumption shown mean mlkg body wt plus minus SE 1 h group B left difference mean O2 consumption orexin A group aCSF group B right
0.2210986.14656716.html.plaintext.txt	118	Significant difference respective aCSF control group orexin A group aCSF group orexin A group aCSF group
0.2210986.14656716.html.plaintext.txt	119	Open horizontal bars lights period filled horizontal bars lights period
0.2210986.14656716.html.plaintext.txt	120	View larger version 20K Fig
0.2210986.14656716.html.plaintext.txt	121	Effect orexin A injection different time points SPA A B feeding behavior C
0.2210986.14656716.html.plaintext.txt	122	Rats received PVN injection aCSF 1 nmol orexin A different times 800 AM 400 PM experiment 1 200 PM experiment 2 1200 noon 700 PM experiment 3
0.2210986.14656716.html.plaintext.txt	123	Data means plus minus SE shown total beam breaks 2 h injection A duration SPA 2 h injection B total duration feeding behavior 2 h injection C
0.2210986.14656716.html.plaintext.txt	124	Significant difference respective aCSF control group
0.2210986.14656716.html.plaintext.txt	125	View larger version 18K Fig
0.2210986.14656716.html.plaintext.txt	126	Effect orexin A SPA duration feeding behavior
0.2210986.14656716.html.plaintext.txt	127	SPA duration feeding 2 h PVN injection orexin A animal across 3 experiments plotted
0.2210986.14656716.html.plaintext.txt	128	SPA represented beam break count A duration min B
0.2210986.14656716.html.plaintext.txt	129	View larger version 36K Fig
0.2210986.14656716.html.plaintext.txt	130	Relationship dose orexin A effect SPA A thermogenesis B
0.2210986.14656716.html.plaintext.txt	131	Rats received PVN injection aCSF different dose orexin A light cycle
0.2210986.14656716.html.plaintext.txt	132	Data means plus minus SE shown total beam breaks 2 h injection A thermogenesis 2 h injection B
0.2210986.14656716.html.plaintext.txt	133	Significant difference respective aCSF vehicle control group
0.2210986.14656716.html.plaintext.txt	134	View larger version 26K Fig
0.2210986.14656716.html.plaintext.txt	135	Effect orexin receptor antagonist SB 334867 SPA A thermogenesis B
0.2210986.14656716.html.plaintext.txt	136	Rats received PVN injection vehicle vehicle 20 microg SB 334867 vehicle vehicle 1 nmol orexin A 20 microg SB 334867 1 nmol orexin A light cycle
0.2210986.14656716.html.plaintext.txt	137	Data means plus minus SE shown total beam breaks 2 h injection A thermogenesis 2 h injection B
0.2210986.14656716.html.plaintext.txt	138	Significant difference 2 groups
0.2210986.14656716.html.plaintext.txt	139	View larger version 48K Fig
0.2210986.14656716.html.plaintext.txt	140	Photomicrograph histological verification correct placement injections hypothalamic PVN A diagrams coronal section depicting actual injection sites B
0.2210986.14656716.html.plaintext.txt	141	V3 3rd ventricle opt optic tract
0.2210986.14656716.html.plaintext.txt	142	Sites deemed correctly located sites deemed incorrectly located B
0.2210986.14656716.html.plaintext.txt	143	In section B number top left shows anteroposterior distance bregma
0.2210986.14656716.html.plaintext.txt	144	RESULTS TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES Effect Orexin A SPA O2 Consumption
0.2210986.14656716.html.plaintext.txt	145	Adult male Sprague Dawley rats microinjected right lateral PVN 1 nmol orexin A vehicle aCSF different times day experiment 1 injections 800 AM 400 PM experiment 2 200 PM experiment 3 1200 noon 700 PM light 700 AM light 700 PM
0.2210986.14656716.html.plaintext.txt	146	Figure 1 represents mean 24 h time course SPA Fig
0.2210986.14656716.html.plaintext.txt	147	1A oxygen consumption Fig
0.2210986.14656716.html.plaintext.txt	148	Orexin A associated increase SPA 1 2 h injection followed decrease SPA 1 3 h afterward
0.2210986.14656716.html.plaintext.txt	149	The pattern SPA observed orexin A injections experiments 2 3 data shown
0.2210986.14656716.html.plaintext.txt	150	Transition O2 consumption response orexin A similar SPA orexin A associated increase O2 consumption 1 2 h injection
0.2210986.14656716.html.plaintext.txt	151	Regardless time point injection orexin A associated dramatic increases SPA 2 h injection Fig
0.2210986.14656716.html.plaintext.txt	152	With experiments combined mean plus minus SD SPA 2 h injection follows orexin A 6
0.2210986.14656716.html.plaintext.txt	153	95 x 103 beam break count vehicle 1
0.2210986.14656716.html.plaintext.txt	154	injections 24 orexin A treated animals 38 aCSF treated animals
0.2210986.14656716.html.plaintext.txt	155	Interestingly difference total SPA 24 h orexin A vehicle three experiments orexin A 3
0.2210986.14656716.html.plaintext.txt	156	86 x 104 beam break count n 15 vehicle 3
0.2210986.14656716.html.plaintext.txt	157	52 x 104 beam break count n 22
0.2210986.14656716.html.plaintext.txt	158	Types orexin A induced physical activity primarily intense grooming face washing behavior secondarily rearing searching behavior
0.2210986.14656716.html.plaintext.txt	159	These behaviors appeared immediately 5 min injections
0.2210986.14656716.html.plaintext.txt	160	After review videotaped recording apparent intensity orexin A induced behavior greater similar types spontaneous activities grooming rearing observed absence experimental manipulations
0.2210986.14656716.html.plaintext.txt	161	Effect Orexin A Feeding Behavior
0.2210986.14656716.html.plaintext.txt	162	It known orexin A associated increased feeding behavior
0.2210986.14656716.html.plaintext.txt	163	Duration feeding behavior 2 h injection measured blinded fashion using videotaped recording
0.2210986.14656716.html.plaintext.txt	164	For five time points throughout day one time point 800 AM duration feeding behavior longer orexin A injected animals aCSF Fig
0.2210986.14656716.html.plaintext.txt	165	The effect orexin A feeding behavior accounted 3
0.2210986.14656716.html.plaintext.txt	166	5 n 5 increase SPA time point
0.2210986.14656716.html.plaintext.txt	167	Figure 3 represents relationship SPA duration feeding behavior 2 h injection experiments
0.2210986.14656716.html.plaintext.txt	168	There correlation SPA duration feeding behavior induced orexin A
0.2210986.14656716.html.plaintext.txt	169	In three experiments difference 24 h food consumption aCSF orexin A orexin A 24
0.2210986.14656716.html.plaintext.txt	170	Relationship Between Dose Orexin A Its Effect SPA Thermogenesis
0.2210986.14656716.html.plaintext.txt	171	To establish dose response relationship different doses orexin A 0
0.2210986.14656716.html.plaintext.txt	172	0625 2 nmol injected PVN
0.2210986.14656716.html.plaintext.txt	173	For 2 h injection SPA thermogenesis measured without food water
0.2210986.14656716.html.plaintext.txt	174	4B well correlated dose orexin A examined range
0.2210986.14656716.html.plaintext.txt	175	125 nmol associated significant increase SPA lower dose 0
0.2210986.14656716.html.plaintext.txt	176	0625 nmol associated significant increase thermogenesis
0.2210986.14656716.html.plaintext.txt	177	There strong correlation SPA difference SPA orexin A vehicle thermogenesis difference thermogenesis orexin A vehicle r 0
0.2210986.14656716.html.plaintext.txt	178	Effect SB 334867 SPA Thermogenesis
0.2210986.14656716.html.plaintext.txt	179	To establish specificity effect orexin A PVN orexin receptor antagonist SB 334867 injected PVN
0.2210986.14656716.html.plaintext.txt	180	SB 334867 20 microg associated decreases SPA partially attenuated effect orexin A SPA Fig
0.2210986.14656716.html.plaintext.txt	181	Verification Injection Sites
0.2210986.14656716.html.plaintext.txt	182	Figure 6A illustrates example histological verification correct location injections PVN
0.2210986.14656716.html.plaintext.txt	183	Figure 6B illustrates map actual injection sites demonstrates injections deemed correctly incorrectly located
0.2210986.14656716.html.plaintext.txt	184	All animals underwent histological confirmation cannula placement
0.2210986.14656716.html.plaintext.txt	185	Investigators blinded orexin response
0.2210986.14656716.html.plaintext.txt	186	In nine incorrectly cannulated rats mean plus minus SD SPA 2 h injection follows 1 nmol orexin A 2
0.2210986.14656716.html.plaintext.txt	187	17 x 103 beam break count vehicle 2
0.2210986.14656716.html.plaintext.txt	188	injections 15 orexin A 8 vehicle
0.2210986.14656716.html.plaintext.txt	189	There significant difference SPA orexin A vehicle animals
0.2210986.14656716.html.plaintext.txt	190	DISCUSSION TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES The energy cost associated SPA may carefully modulated rather spontaneous
0.2210986.14656716.html.plaintext.txt	191	We proposed potential mediator SPA orexin A
0.2210986.14656716.html.plaintext.txt	192	Furthermore thought orexin A might mediate effect via PVN
0.2210986.14656716.html.plaintext.txt	193	To address hypothesis orexin A PVN mediates SPA injected rats orexin A vehicle control monitored SPA use infrared beams videotape recording
0.2210986.14656716.html.plaintext.txt	194	The data demonstrated orexin A animals cannula sited PVN associated dramatic increases SPA 2 h injection
0.2210986.14656716.html.plaintext.txt	195	After 2 h SPA return baseline animals appeared compensate become sedentary controls next 1 3 h
0.2210986.14656716.html.plaintext.txt	196	Increases SPA 2 h injection dose dependent
0.2210986.14656716.html.plaintext.txt	197	In incorrectly cannulated rats increase SPA observed orexin A injection
0.2210986.14656716.html.plaintext.txt	198	These data demonstrate potential role orexin A PVN SPA moreover demonstrate SPA may intricately modulated neurohumoral factors hypothalamus
0.2210986.14656716.html.plaintext.txt	199	To establish specificity effect orexin A PVN observed effect orexin receptor antagonist SB 334867 injected PVN
0.2210986.14656716.html.plaintext.txt	200	Decreases SPA followed antagonist injection partially blocked effect orexin A SPA thermogenesis
0.2210986.14656716.html.plaintext.txt	201	SB 334867 50 fold higher affinity OX1R OX2R 11
0.2210986.14656716.html.plaintext.txt	202	In rat brain differential expression OX1R OX2R reported OX2R predominantly expressed PVN 36 62
0.2210986.14656716.html.plaintext.txt	203	OX1R considered selective receptor orexin A OX2R considered nonselective receptor orexin A orexin B
0.2210986.14656716.html.plaintext.txt	204	Despite lower affinity OX2R high concentration SB 334867 site PVN might attenuate effect orexin A via block OX2R however also reported intraperitoneal injection compound attenuated orexin A evoked grooming 11 selective OX2R antagonist needed verify role receptor subtype effect orexin A PVN
0.2210986.14656716.html.plaintext.txt	205	Our data consistent observations regarding neurohumoral role orexin A
0.2210986.14656716.html.plaintext.txt	206	Central orexin systems may critical regulators sleepwake states based neuroanatomic genetic data 7 8 13 34 41 44
0.2210986.14656716.html.plaintext.txt	207	Specifically orexin A may activate arousal centers 17
0.2210986.14656716.html.plaintext.txt	208	Our observations PVN injected orexin A induces SPA compatible fact orexin A acts maintain waking state 47
0.2210986.14656716.html.plaintext.txt	209	The behaviors observed response orexin A injection consistent wakefulness namely intense grooming face washing behavior rearing searching activity
0.2210986.14656716.html.plaintext.txt	210	Several reports also describe immediate increase grooming face washing activity locomotor activity intracerebroventricular injection orexin A 17 21 22 24 38
0.2210986.14656716.html.plaintext.txt	211	Additionally reports showing relationship endogenous orexin locomotor activity
0.2210986.14656716.html.plaintext.txt	212	27 showed orexin A release cerebrospinal fluid higher active waking quiet waking cats
0.2210986.14656716.html.plaintext.txt	213	15 reported Fos expression orexin neurons correlated locomotor activity rats
0.2210986.14656716.html.plaintext.txt	214	18 showed genetic ablation orexin neurons mice resulted decrease spontaneous motor activity transgenic mice became obese despite hypophagia
0.2210986.14656716.html.plaintext.txt	215	These reports also strongly suggest orexin plays role regulation SPA
0.2210986.14656716.html.plaintext.txt	216	Corticotropin releasing factor CRF suggested involved orexin A induced behaviors 21 known grooming behavior closely associated environmental stress 16 intracerebroventricular administration orexin A increases plasma corticosterone 17 31 adreno corticotropin levels 23 52
0.2210986.14656716.html.plaintext.txt	217	Intracerebroventricular administration CRF increased grooming behavior 30 intracerebroventricular administration helical CRF CRF antagonist blocked orexin induced behaviors specifically grooming face washing 22
0.2210986.14656716.html.plaintext.txt	218	In terms brain concentration CRF synthesized mainly PVN 55 peptide also thought integral energy balance
0.2210986.14656716.html.plaintext.txt	219	The PVN one sites densely innervated orexin containing neurons expresses OX2R 8 36 62
0.2210986.14656716.html.plaintext.txt	220	Thus results consistent thesis orexin A stimulates specific behaviors via CRF
0.2210986.14656716.html.plaintext.txt	221	The dopaminergic system also suggested mediate orexin A induced activity grooming behavior
0.2210986.14656716.html.plaintext.txt	222	Involvement ventral tegmental area dopaminergic system intraventricularly administered orexin induced hyperactivity rats demonstrated 38
0.2210986.14656716.html.plaintext.txt	223	Further study needed determine downstream pathways orexin A induced hyperactivity
0.2210986.14656716.html.plaintext.txt	224	It known orexin A injected PVN induces feeding
0.2210986.14656716.html.plaintext.txt	225	However data demonstrate PVN injected orexin A induced feeding behavior injected early light cycle feeding behavior minimal control animals
0.2210986.14656716.html.plaintext.txt	226	There relation magnitude orexin A induced SPA duration feeding behavior
0.2210986.14656716.html.plaintext.txt	227	In words PVN injected orexin A increase SPA without induction feeding behavior
0.2210986.14656716.html.plaintext.txt	228	This elevation activity without concomitant feeding behavior consistent previous studies examining effect orexin A injected lateral hypothalamus another brain site integral energy homeostasis 20
0.2210986.14656716.html.plaintext.txt	229	The early light cycle feeding induced PVN injected orexin A study agreement data others indicating orexin A injected ventricles lateral hypothalamus stimulates feeding light cycle 20 67
0.2210986.14656716.html.plaintext.txt	230	The reason stimulation feeding orexin A injection occurs light cycle remains unclear
0.2210986.14656716.html.plaintext.txt	231	It demonstrated orexin A injected lateral hypothalamus twofold greater feeding response orexin A food restricted rats high level rate feeding 60
0.2210986.14656716.html.plaintext.txt	232	Thus level andor rate feeding unlikely related lack feeding orexin dark cycle
0.2210986.14656716.html.plaintext.txt	233	14 reported orexin A induced icv administration feeding largely circadian dependent orexin A induced increase grooming moderately circadian dependent
0.2210986.14656716.html.plaintext.txt	234	These authors suggested possibility increase feeding appeared largely reflect wake increase actions
0.2210986.14656716.html.plaintext.txt	235	Other reports regarding orexin A injection PVN shown variable results 10 12 56
0.2210986.14656716.html.plaintext.txt	236	12 reported PVN injected orexin A 0
0.2210986.14656716.html.plaintext.txt	237	3 nmol stimulated food intake although effect powerful
0.2210986.14656716.html.plaintext.txt	238	10 showed 1 nmol orexin A injected PVN stimulated food intake reported behavioral effects feeding drinking
0.2210986.14656716.html.plaintext.txt	239	Differences dose orexin A 0
0.2210986.14656716.html.plaintext.txt	240	03 1 nmol injected light cycle reports generally moderate effect orexin A feeding may explain discrepant results feeding response three reports
0.2210986.14656716.html.plaintext.txt	241	In present study injected 1 nmol orexin A observed increased feeding injected early light cycle also observed remarkably increased physical activity
0.2210986.14656716.html.plaintext.txt	242	This observation contrasts somewhat Dube et al
0.2210986.14656716.html.plaintext.txt	243	however examine SPA
0.2210986.14656716.html.plaintext.txt	244	We recorded animals behavior using videotaped recording quantified activity using arrays infrared activity sensors
0.2210986.14656716.html.plaintext.txt	245	Our results suggest orexin A PVN acts predominantly increase nonfeeding physical activity
0.2210986.14656716.html.plaintext.txt	246	Levels SPA humans cluster families 63 mice within strains 5
0.2210986.14656716.html.plaintext.txt	247	These observations suggest identifiable genetic components may exist account variance NEAT
0.2210986.14656716.html.plaintext.txt	248	Additionally observed NEAT increase positive energy balance 32
0.2210986.14656716.html.plaintext.txt	249	Recently decreased plasma orexin A levels obese individuals demonstrated 2
0.2210986.14656716.html.plaintext.txt	250	Because orexin A pass blood brain barrier 26 peripheral orexin A levels might reflect CNS levels
0.2210986.14656716.html.plaintext.txt	251	In mouse hypothalamus age related decline OX2R messenger RNA levels shown 59 known old rats decreased activity 43
0.2210986.14656716.html.plaintext.txt	252	The decline orexin obesity aging may support hypothesis orexin A PVN mediator NEAT
0.2210986.14656716.html.plaintext.txt	253	Lubkin Stricker Krongrad 35 reported intracerebroventricular injection orexin A resulted increase metabolic rate dependent increase activity mice
0.2210986.14656716.html.plaintext.txt	254	We measured O2 consumption CO2 production indirect calorimetry
0.2210986.14656716.html.plaintext.txt	255	Increased O2 consumption accompanied increased activity thermogenic response orexin A clearly tracks orexin A effect SPA
0.2210986.14656716.html.plaintext.txt	256	Thus consider increase O2 consumption thermogenesis result increase SPA associated orexin A
0.2210986.14656716.html.plaintext.txt	257	The reason contrast may due differences injection site studies site specific injections reach much limited receptor population ventricular injections
0.2210986.14656716.html.plaintext.txt	258	With ventricular injection unknown injectate ultimately predominantly reaches thus effects observed could result stimulation receptors multiple locations
0.2210986.14656716.html.plaintext.txt	259	Unlike neuropeptide Y potent orexigenic hypothermic signal clearly defined pattern energy balance states orexin A activity energy balance states appears complicated
0.2210986.14656716.html.plaintext.txt	260	Some studies show difference orexin A activity fasting 3 45 65 whereas others show elevated orexin expression activity fasting 50 66 69
0.2210986.14656716.html.plaintext.txt	261	Orexin A activity states positive energy balance thoroughly tested
0.2210986.14656716.html.plaintext.txt	262	One study showed high fat feeding increased gene expression orexin A 64 consistent hypothesis increased orexin activity positive energy balance
0.2210986.14656716.html.plaintext.txt	263	However studies obese animal models show either decreases orexin A expression activity 6 54 68 change 57 61
0.2210986.14656716.html.plaintext.txt	264	These conflicting data likely represent complicated role orexin A energy balance although orexin administration stimulates feeding also elevates activity perhaps predominantly enhances thermogenesis
0.2210986.14656716.html.plaintext.txt	265	Therefore one cannot simply place orexin A class obesity promoting neuropeptides basis feeding stimulatory properties
0.2210986.14656716.html.plaintext.txt	266	This clearly illustrated data Hara et al
0.2210986.14656716.html.plaintext.txt	267	18 demonstrated loss orexin A activity resulted obese animal model
0.2210986.14656716.html.plaintext.txt	268	Although animals ate less also much less active
0.2210986.14656716.html.plaintext.txt	269	The obese state animals study indicates decreased energy expenditure brought loss orexin A function clearly potent hypophagia affecting energy balance
0.2210986.14656716.html.plaintext.txt	270	Thus although present data others 18 64 indicate positive energy balance may stimulate orexin A studies examining endogenous orexin A activity lean obese animal models overfeeding paradigms help determine role orexin A plays modulating NEAT
0.2210986.14656716.html.plaintext.txt	271	In summary injection orexin A PVN dramatically increases SPA
0.2210986.14656716.html.plaintext.txt	272	The increase SPA 2 h occurs regardless time injection
0.2210986.14656716.html.plaintext.txt	273	The effect orexin A SPA appears predominantly increase general activity
0.2210986.14656716.html.plaintext.txt	274	However concur others orexin A via PVN also stimulates feeding behavior
0.2210986.14656716.html.plaintext.txt	275	Orexin A therefore appears neurohumoral mediator SPA NEAT feeding
0.2210986.14656716.html.plaintext.txt	276	Its role physiology energy balance requires investigation
0.2210986.14656716.html.plaintext.txt	277	GRANTS TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES This work supported National Institute Diabetes Digestive Kidney Diseases Grants DK 56650 DK 63226 DK 57573 Department Veterans Affairs Novo Nordisk Bagsv230rd Denmark
0.2210986.14656716.html.plaintext.txt	278	ACKNOWLEDGMENTS We thank Mary Mullet expert technical assistance stereotaxic surgery Shelly K
0.2210986.14656716.html.plaintext.txt	279	McCrady Lana Nysse technical help
0.2210986.14656716.html.plaintext.txt	280	FOOTNOTES Address reprint requests correspondence J
0.2210986.14656716.html.plaintext.txt	281	Levine Endocrine Research Unit Joseph 5 194 Mayo Clinic Rochester 200 First St
0.2210986.14656716.html.plaintext.txt	282	SW Rochester MN 55905 E mail levine
0.2210986.14656716.html.plaintext.txt	283	The costs publication article defrayed part payment page charges
0.2210986.14656716.html.plaintext.txt	284	The article must therefore hereby marked advertisement accordance 18 U
0.2210986.14656716.html.plaintext.txt	285	Section 1734 solely indicate fact
0.2210986.14656716.html.plaintext.txt	286	REFERENCES TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES Anonymous
0.2210986.14656716.html.plaintext.txt	287	Surgeon generals report physical activity health
0.2210986.14656716.html.plaintext.txt	288	From Centers Disease Control Prevention
0.2210986.14656716.html.plaintext.txt	289	CrossRefISIMedline Adam JA Menheere PP van Dielen FM Soeters PB Buurman WA Greve JW
0.2210986.14656716.html.plaintext.txt	290	Decreased plasma orexin A levels obese individuals
0.2210986.14656716.html.plaintext.txt	291	Int J Obes Relat Metab Disord 26 274 276 2002
0.2210986.14656716.html.plaintext.txt	292	CrossRefMedline Bertile F Oudart H Criscuolo F Maho YL Raclot T
0.2210986.14656716.html.plaintext.txt	293	Hypothalamic gene expression long term fasted rats relationship body fat
0.2210986.14656716.html.plaintext.txt	294	Biochem Biophys Res Commun 303 1106 13 2003
0.2210986.14656716.html.plaintext.txt	295	CrossRefISIMedline Bray GA Bouchard C James WPT
0.2210986.14656716.html.plaintext.txt	296	Brownlow BS Petro A Feinglos MN Surwit RS
0.2210986.14656716.html.plaintext.txt	297	The role motor activity diet induced obesity C57Bl6J mice
0.2210986.14656716.html.plaintext.txt	298	CrossRefISIMedline Cai XJ Lister CA Buckingham RE Pickavance L Wilding J Arch JR Wilson S Williams G
0.2210986.14656716.html.plaintext.txt	299	Down regulation orexin gene expression severe obesity rats studies Zucker fatty Zucker diabetic fatty rats effects rosiglitazone
0.2210986.14656716.html.plaintext.txt	300	Brain Res Mol Brain Res 77 131 137 2000
0.2210986.14656716.html.plaintext.txt	301	ISIMedline Chemelli RM Willie JT Sinton CM Elmquist JK Scammell T Lee C Richardson JA Williams SC Xiong Y Kisanuki Y Fitch TE Nakazato M Hammer RE Saper CB Yanagisawa M
0.2210986.14656716.html.plaintext.txt	302	Narcolepsy orexin knockout mice molecular genetics sleep regulation
0.2210986.14656716.html.plaintext.txt	303	ISIMedline Date Y Ueta Y Yamashita H Yamaguchi H Matsukura S Kangawa K Sakurai T Yanagisawa M Nakazato M
0.2210986.14656716.html.plaintext.txt	304	Orexins orexigenic hypothalamic peptides interact autonomic neuroendocrine neuroregulatory systems
0.2210986.14656716.html.plaintext.txt	305	Proc Natl Acad Sci USA 96 748 753 1999
0.2210986.14656716.html.plaintext.txt	306	AbstractFree Full Text Diano S Horvath B Urbanski HF Sotonyi P Horvath TL
0.2210986.14656716.html.plaintext.txt	307	Fasting activates nonhuman primate hypocretin orexin system postsynaptic targets
0.2210986.14656716.html.plaintext.txt	308	Endocrinology 144 3774 3778 2003
0.2210986.14656716.html.plaintext.txt	309	AbstractFree Full Text Dube MG Kalra SP Kalra PS
0.2210986.14656716.html.plaintext.txt	310	Food intake elicited central administration orexinshypocretins identification hypothalamic sites action
0.2210986.14656716.html.plaintext.txt	311	CrossRefISIMedline Duxon MS Stretton J Starr K Jones DN Holland V Riley G Jerman J Brough S Smart D Johns A Chan W Porter RA Upton N
0.2210986.14656716.html.plaintext.txt	312	Evidence orexin A evoked grooming rat mediated orexin 1 OX1 receptors downstream 5 HT2C receptor involvement
0.2210986.14656716.html.plaintext.txt	313	Psychopharmacology Berl 153 203 209 2001
0.2210986.14656716.html.plaintext.txt	314	CrossRefISIMedline Edwards CM Abusnana S Sunter D Murphy KG Ghatei MA Bloom SR
0.2210986.14656716.html.plaintext.txt	315	The effect orexins food intake comparison neuropeptide Y melanin concentrating hormone galanin
0.2210986.14656716.html.plaintext.txt	316	J Endocrinol 160 R7 R12 1999
0.2210986.14656716.html.plaintext.txt	317	Abstract Espana RA Baldo BA Kelley AE Berridge CW
0.2210986.14656716.html.plaintext.txt	318	Wake promoting sleep suppressing actions hypocretin orexin basal forebrain sites action
0.2210986.14656716.html.plaintext.txt	319	Neuroscience 106 699 715 2001
0.2210986.14656716.html.plaintext.txt	320	CrossRefISIMedline Espana RA Plahn S Berridge CW
0.2210986.14656716.html.plaintext.txt	321	Circadian dependent circadian independent behavioral actions hypocretinorexin
0.2210986.14656716.html.plaintext.txt	322	CrossRefISIMedline Estabrooke IV McCarthy MT Ko E Chou TC Chemelli RM Yanagisawa M Saper CB Scammell TE
0.2210986.14656716.html.plaintext.txt	323	Fos expression orexin neurons varies behavioral state
0.2210986.14656716.html.plaintext.txt	324	J Neurosci 21 1656 1662 2001
0.2210986.14656716.html.plaintext.txt	325	AbstractFree Full Text Gispen WH Isaacson RL
0.2210986.14656716.html.plaintext.txt	326	ACTH induced excessive grooming rat
0.2210986.14656716.html.plaintext.txt	327	Pharmacol Ther 12 209 246 1981
0.2210986.14656716.html.plaintext.txt	328	CrossRefISIMedline Hagan JJ Leslie RA Patel S Evans ML Wattam TA Holmes S Benham CD Taylor SG Routledge C Hemmati P Munton RP Ashmeade TE Shah AS Hatcher JP Hatcher PD Jones DN Smith MI Piper DC Hunter AJ Porter RA Upton N
0.2210986.14656716.html.plaintext.txt	329	Orexin activates locus coeruleus cell firing increases arousal rat
0.2210986.14656716.html.plaintext.txt	330	Proc Natl Acad Sci USA 96 10911 10916 1999
0.2210986.14656716.html.plaintext.txt	331	AbstractFree Full Text Hara J Beuckmann CT Nambu T Willie JT Chemelli RM Sinton CM Sugiyama F Yagami K Goto K Yanagisawa M Sakurai T
0.2210986.14656716.html.plaintext.txt	332	Genetic ablation orexin neurons mice results narcolepsy hypophagia obesity
0.2210986.14656716.html.plaintext.txt	333	CrossRefISIMedline Haynes AC Jackson B Chapman H Tadayyon M Johns A Porter RA Arch JR
0.2210986.14656716.html.plaintext.txt	334	A selective orexin 1 receptor antagonist reduces food consumption male female rats
0.2210986.14656716.html.plaintext.txt	335	CrossRefISIMedline Haynes AC Jackson B Overend P Buckingham RE Wilson S Tadayyon M Arch JR
0.2210986.14656716.html.plaintext.txt	336	Effects single chronic intracerebroventricular administration orexins feeding rat
0.2210986.14656716.html.plaintext.txt	337	CrossRefISIMedline Ida T Nakahara K Katayama T Murakami N Nakazato M
0.2210986.14656716.html.plaintext.txt	338	Effect lateral cerebroventricular injection appetite stimulating neuropeptide orexin neuropeptide Y various behavioral activities rats
0.2210986.14656716.html.plaintext.txt	339	CrossRefISIMedline Ida T Nakahara K Murakami T Hanada R Nakazato M Murakami N
0.2210986.14656716.html.plaintext.txt	340	Possible involvement orexin stress reaction rats
0.2210986.14656716.html.plaintext.txt	341	Biochem Biophys Res Commun 270 318 323 2000
0.2210986.14656716.html.plaintext.txt	342	CrossRefISIMedline Jaszberenyi M Bujdoso E Pataki I Telegdy G
0.2210986.14656716.html.plaintext.txt	343	Effects orexins hypothalamic pituitary adrenal system
0.2210986.14656716.html.plaintext.txt	344	J Neuroendocrinol 12 1174 1178 2000
0.2210986.14656716.html.plaintext.txt	345	CrossRefISIMedline Jones DN Gartlon J Parker F Taylor SG Routledge C Hemmati P Munton RP Ashmeade TE Hatcher JP Johns A Porter RA Hagan JJ Hunter AJ Upton N
0.2210986.14656716.html.plaintext.txt	346	Effects centrally administered orexin B orexin A role orexin 1 receptors orexin B induced hyperactivity
0.2210986.14656716.html.plaintext.txt	347	Psychopharmacology Berl 153 210 218 2001
0.2210986.14656716.html.plaintext.txt	348	CrossRefISIMedline Kalra SP Dube MG Pu S Xu B Horvath TL Kalra PS
0.2210986.14656716.html.plaintext.txt	349	Interacting appetite regulating pathways hypothalamic regulation body weight
0.2210986.14656716.html.plaintext.txt	350	AbstractFree Full Text Kastin AJ Akerstrom V
0.2210986.14656716.html.plaintext.txt	351	Orexin A orexin B rapidly enters brain blood simple diffusion
0.2210986.14656716.html.plaintext.txt	352	J Pharmacol Exp Ther 289 219 223 1999
0.2210986.14656716.html.plaintext.txt	353	AbstractFree Full Text Kiyashchenko LI Mileykovskiy BY Maidment N Lam HA Wu MF John J Peever J Siegel JM
0.2210986.14656716.html.plaintext.txt	354	Release hypocretin orexin waking sleep states
0.2210986.14656716.html.plaintext.txt	355	J Neurosci 22 5282 5286 2002
0.2210986.14656716.html.plaintext.txt	356	AbstractFree Full Text Kotz CM Glass MJ Levine AS Billington CJ
0.2210986.14656716.html.plaintext.txt	357	Regional effect naltrexone nucleus solitary tract blockade NPY induced feeding
0.2210986.14656716.html.plaintext.txt	358	Am J Physiol Regul Integr Comp Physiol 278 R499 R503 2000
0.2210986.14656716.html.plaintext.txt	359	AbstractFree Full Text Kotz CM Teske JA Levine JA Wang C
0.2210986.14656716.html.plaintext.txt	360	Feeding activity induced orexin A lateral hypothalamus rats
0.2210986.14656716.html.plaintext.txt	361	CrossRefISIMedline Krahn DD Gosnell BA Levine AS Morley JE
0.2210986.14656716.html.plaintext.txt	362	Behavioral effects corticotropin releasing factor localization characterization central effects
0.2210986.14656716.html.plaintext.txt	363	CrossRefISIMedline Kuru M Ueta Y Serino R Nakazato M Yamamoto Y Shibuya I Yamashita H
0.2210986.14656716.html.plaintext.txt	364	Centrally administered orexinhypocretin activates HPA axis rats
0.2210986.14656716.html.plaintext.txt	365	Neuroreport 11 1977 1980 2000
0.2210986.14656716.html.plaintext.txt	366	ISIMedline Levine JA Eberhardt NL Jensen MD
0.2210986.14656716.html.plaintext.txt	367	Role nonexercise activity thermogenesis resistance fat gain humans
0.2210986.14656716.html.plaintext.txt	368	AbstractFree Full Text Levine JA Nygren J Short KR Nair KS
0.2210986.14656716.html.plaintext.txt	369	Effect hyperthyroidism spontaneous physical activity energy expenditure rats
0.2210986.14656716.html.plaintext.txt	370	J Appl Physiol 94 165 170 2003
0.2210986.14656716.html.plaintext.txt	371	AbstractFree Full Text Lin L Faraco J Li R Kadotani H Rogers W Lin X Qiu X de Jong PJ Nishino S Mignot E
0.2210986.14656716.html.plaintext.txt	372	The sleep disorder canine narcolepsy caused mutation hypocretin orexin receptor 2 gene
0.2210986.14656716.html.plaintext.txt	373	ISIMedline Lubkin M Stricker Krongrad A
0.2210986.14656716.html.plaintext.txt	374	Independent feeding metabolic actions orexins mice
0.2210986.14656716.html.plaintext.txt	375	Biochem Biophys Res Commun 253 241 245 1998
0.2210986.14656716.html.plaintext.txt	376	CrossRefISIMedline Marcus JN Aschkenasi CJ Lee CE Chemelli RM Saper CB Yanagisawa M Elmquist JK
0.2210986.14656716.html.plaintext.txt	377	Differential expression orexin receptors 1 2 rat brain
0.2210986.14656716.html.plaintext.txt	378	CrossRefISIMedline Moriguchi T Sakurai T Nambu T Yanagisawa M Goto K
0.2210986.14656716.html.plaintext.txt	379	Neurons containing orexin lateral hypothalamic area adult rat brain activated insulin induced acute hypoglycemia
0.2210986.14656716.html.plaintext.txt	380	Neurosci Lett 264 101 104 1999
0.2210986.14656716.html.plaintext.txt	381	CrossRefISIMedline Nakamura T Uramura K Nambu T Yada T Goto K Yanagisawa M Sakurai T
0.2210986.14656716.html.plaintext.txt	382	Orexin induced hyperlocomotion stereotypy mediated dopaminergic system
0.2210986.14656716.html.plaintext.txt	383	CrossRefISIMedline Nambu T Sakurai T Mizukami K Hosoya Y Yanagisawa M Goto K
0.2210986.14656716.html.plaintext.txt	384	Distribution orexin neurons adult rat brain
0.2210986.14656716.html.plaintext.txt	385	CrossRefISIMedline Nicholson C
0.2210986.14656716.html.plaintext.txt	386	Diffusion injected volume substance brain tissue arbitrary volume fraction tortuosity
0.2210986.14656716.html.plaintext.txt	387	CrossRefISIMedline Nishino S Ripley B Overeem S Lammers GJ Mignot E
0.2210986.14656716.html.plaintext.txt	388	Hypocretin orexin deficiency human narcolepsy
0.2210986.14656716.html.plaintext.txt	389	CrossRefISIMedline Paxinos G Watson C
0.2210986.14656716.html.plaintext.txt	390	The Rat Brain Stereotaxic Coordinates
0.2210986.14656716.html.plaintext.txt	391	Circadian rhythms patterns running wheel activity feeding drinking behaviors old male rats
0.2210986.14656716.html.plaintext.txt	392	Physiol Behav 33 615 620 1984
0.2210986.14656716.html.plaintext.txt	393	CrossRefISIMedline Peyron C Tighe DK van den Pol AN de Lecea L Heller HC Sutcliffe JG Kilduff TS
0.2210986.14656716.html.plaintext.txt	394	Neurons containing hypocretin orexin project multiple neuronal systems
0.2210986.14656716.html.plaintext.txt	395	J Neurosci 18 9996 10015 1998
0.2210986.14656716.html.plaintext.txt	396	AbstractFree Full Text Phillips Singh D Li Q Takeuchi S Ohkubo T Sharp PJ Boswell T
0.2210986.14656716.html.plaintext.txt	397	Fasting differentially regulates expression agouti related peptide pro opiomelanocortin prepro orexin vasoactive intestinal polypeptide mRNAs hypothalamus Japanese quail
0.2210986.14656716.html.plaintext.txt	398	Cell Tissue Res 313 217 225 2003
0.2210986.14656716.html.plaintext.txt	399	CrossRefISIMedline Picker MJ Allen RM Morgan D Levine AS OHare E Cleary JP
0.2210986.14656716.html.plaintext.txt	400	Effects neuropeptide Y discriminative stimulus antinociceptive properties morphine
0.2210986.14656716.html.plaintext.txt	401	Pharmacol Biochem Behav 64 161 164 1999
0.2210986.14656716.html.plaintext.txt	402	CrossRefISIMedline Piper DC Upton N Smith MI Hunter AJ
0.2210986.14656716.html.plaintext.txt	403	The novel brain neuropeptide orexin A modulates sleep wake cycle rats
0.2210986.14656716.html.plaintext.txt	404	Eur J Neurosci 12 726 730 2000
0.2210986.14656716.html.plaintext.txt	405	CrossRefISIMedline Pu S Jain MR Kalra PS Kalra SP
0.2210986.14656716.html.plaintext.txt	406	Orexins novel family hypothalamic neuropeptides modulate pituitary luteinizing hormone secretion ovarian steroid dependent manner
0.2210986.14656716.html.plaintext.txt	407	CrossRefISIMedline Rising R Harper IT Fontvielle AM Ferraro RT Spraul M Ravussin E
0.2210986.14656716.html.plaintext.txt	408	Determinants total daily energy expenditure variability physical activity
0.2210986.14656716.html.plaintext.txt	409	Am J Clin Nutr 59 800 804 1994
0.2210986.14656716.html.plaintext.txt	410	Abstract Sakurai T Amemiya A Ishii M Matsuzaki I Chemelli RM Tanaka H Williams SC Richardson JA Kozlowski GP Wilson S Arch JR Buckingham RE Haynes AC Carr SA Annan RS McNulty DE Liu WS Terrett JA Elshourbagy NA Bergsma DJ Yanagisawa M
0.2210986.14656716.html.plaintext.txt	411	Orexins orexin receptors family hypothalamic neuropeptides G protein coupled receptors regulate feeding behavior
0.2210986.14656716.html.plaintext.txt	412	ISIMedline Samson WK Gosnell B Chang JK Resch ZT Murphy TC
0.2210986.14656716.html.plaintext.txt	413	Cardiovascular regulatory actions hypocretins brain
0.2210986.14656716.html.plaintext.txt	414	CrossRefISIMedline Samson WK Taylor MM Follwell M Ferguson AV
0.2210986.14656716.html.plaintext.txt	415	Orexin actions hypothalamic paraventricular nucleus physiological consequences cellular correlates
0.2210986.14656716.html.plaintext.txt	416	CrossRefISIMedline Siegel JM
0.2210986.14656716.html.plaintext.txt	417	Narcolepsy key role hypocretins orexins
0.2210986.14656716.html.plaintext.txt	418	ISIMedline Stricker Krongrad A Richy S Beck B
0.2210986.14656716.html.plaintext.txt	419	Orexinshypocretins obob mouse hypothalamic gene expression peptide content metabolic effects
0.2210986.14656716.html.plaintext.txt	420	CrossRefISIMedline Swanson LW Sawchenko PE Lind RW
0.2210986.14656716.html.plaintext.txt	421	Regulation multiple peptides CRF parvocellular neurosecretory neurons implications stress response
0.2210986.14656716.html.plaintext.txt	422	Prog Brain Res 68 169 190 1986
0.2210986.14656716.html.plaintext.txt	423	ISIMedline Sweet DC Levine AS Billington CJ Kotz CM
0.2210986.14656716.html.plaintext.txt	424	Feeding response central orexins
0.2210986.14656716.html.plaintext.txt	425	CrossRefISIMedline Taheri S Gardiner J Hafizi S Murphy K Dakin C Seal L Small C Ghatei M Bloom S
0.2210986.14656716.html.plaintext.txt	426	Orexin A immunoreactivity preproorexin mRNA brain Zucker WKY rats
0.2210986.14656716.html.plaintext.txt	427	ISIMedline Takahashi N Okumura T Yamada H Kohgo Y
0.2210986.14656716.html.plaintext.txt	428	Stimulation gastric acid secretion centrally administered orexin A conscious rats
0.2210986.14656716.html.plaintext.txt	429	Biochem Biophys Res Commun 254 623 627 1999
0.2210986.14656716.html.plaintext.txt	430	CrossRefISIMedline Terao A Apte Deshpande A Morairty S Freund YR Kilduff TS
0.2210986.14656716.html.plaintext.txt	431	Age related decline hypocretin orexin receptor 2 messenger RNA levels mouse brain
0.2210986.14656716.html.plaintext.txt	432	Neurosci Lett 332 190 194 2002
0.2210986.14656716.html.plaintext.txt	433	CrossRefISIMedline Thorpe AJ Mullet MA Wang CF Kotz CM
0.2210986.14656716.html.plaintext.txt	434	Regional metabolic circadian specificity lateral hypothalamus orexin A feeding stimulation
0.2210986.14656716.html.plaintext.txt	435	Am J Physiol Regul Integr Comp Physiol 284 R1409 R1417 2003
0.2210986.14656716.html.plaintext.txt	436	AbstractFree Full Text Tritos NA Mastaitis JW Kokkotou E Maratos Flier E
0.2210986.14656716.html.plaintext.txt	437	Characterization melanin concentrating hormone preproorexin expression murine hypothalamus
0.2210986.14656716.html.plaintext.txt	438	CrossRefISIMedline Trivedi P Yu H MacNeil DJ Van der Ploeg LH Guan XM
0.2210986.14656716.html.plaintext.txt	439	Distribution orexin receptor mRNA rat brain
0.2210986.14656716.html.plaintext.txt	440	CrossRefISIMedline Webb P Annis JF Troutman SJ Jr
0.2210986.14656716.html.plaintext.txt	441	Energy balance man measured direct indirect calorimetry
0.2210986.14656716.html.plaintext.txt	442	Am J Clin Nutr 33 1287 1298 1980
0.2210986.14656716.html.plaintext.txt	443	Abstract Wortley KE Chang GQ Davydova Z Leibowitz SF
0.2210986.14656716.html.plaintext.txt	444	Peptides regulate food intake orexin gene expression increased states hypertriglyceridemia
0.2210986.14656716.html.plaintext.txt	445	Am J Physiol Regul Integr Comp Physiol 284 R1454 R1465 2003
0.2210986.14656716.html.plaintext.txt	446	AbstractFree Full Text Wu MF John J Maidment N Lam HA Siegel JM
0.2210986.14656716.html.plaintext.txt	447	Hypocretin release normal narcoleptic dogs food sleep deprivation eating movement
0.2210986.14656716.html.plaintext.txt	448	Am J Physiol Regul Integr Comp Physiol 283 R1079 R1086 2002
0.2210986.14656716.html.plaintext.txt	449	AbstractFree Full Text Yamanaka A Beuckmann CT Willie JT Hara J Tsujino N Mieda M Tominaga M Yagami K Sugiyama F Goto K Yanagisawa M Sakurai T
0.2210986.14656716.html.plaintext.txt	450	Hypothalamic orexin neurons regulate arousal according energy balance mice
0.2210986.14656716.html.plaintext.txt	451	ISIMedline Yamanaka A Sakurai T Katsumoto T Yanagisawa M Goto K
0.2210986.14656716.html.plaintext.txt	452	Chronic intracerebroventricular administration orexin A rats increases food intake daytime effect body weight
0.2210986.14656716.html.plaintext.txt	453	CrossRefISIMedline Yamamoto Y Ueta Y Date Y Nakazato M Hara Y Serino R Nomura M Shibuya I Matsukura S Yamashita H
0.2210986.14656716.html.plaintext.txt	454	Down regulation prepro orexin gene expression genetically obese mice
0.2210986.14656716.html.plaintext.txt	455	Brain Res Mol Brain Res 65 14 22 1999
0.2210986.14656716.html.plaintext.txt	456	ISIMedline Yamamoto Y Ueta Y Serino R Nomura M Shibuya I Yamashita H
0.2210986.14656716.html.plaintext.txt	457	Effects food restriction hypothalamic prepro orexin gene expression genetically obese mice
0.2210986.14656716.html.plaintext.txt	458	Brain Res Bull 51 515 521 2000
0.4064973.15172887.html.plaintext.txt	0	Pulsatile LH release diminished whereas FSH secretion normal hypocretin deficient narcoleptic men S
0.4064973.15172887.html.plaintext.txt	1	Departments 1General Internal Medicine 2Endocrinology 3Neurology Leiden University Medical Center 2300 RC Leiden The Netherlands
0.4064973.15172887.html.plaintext.txt	2	Submitted 9 February 2004 accepted final form 27 May 2004
0.4064973.15172887.html.plaintext.txt	3	ABSTRACT TOP ABSTRACT METHODS RESULTS DISCUSSION REFERENCES Hypocretin orexin peptides involved regulation energy balance pituitary hormone release
0.4064973.15172887.html.plaintext.txt	4	Narcolepsy sleep disorder characterized disruption hypocretin neurotransmission
0.4064973.15172887.html.plaintext.txt	5	Pituitary LH secretion diminished hypocretin deficient animal models intracerebroventricular administration hypocretin 1 activates hypothalamo pituitary gonadal axis rats
0.4064973.15172887.html.plaintext.txt	6	We evaluated whether hypocretin deficiency affects gonadotropin release humans
0.4064973.15172887.html.plaintext.txt	7	To end deconvolved 24 h serum concentrations LH FSH seven hypocretin deficient narcoleptic males N seven controls C matched age body mass index sex
0.4064973.15172887.html.plaintext.txt	8	Basal plasma concentrations testosterone estradiol sex hormone binding globulin similar groups
0.4064973.15172887.html.plaintext.txt	9	Mean 24 h LH concentration significantly lower narcolepsy patients 3
0.4064973.15172887.html.plaintext.txt	10	01 primarily due reduction pulsatile LH secretion 23
0.4064973.15172887.html.plaintext.txt	11	9 C U l 1 24 h 1 P 0
0.4064973.15172887.html.plaintext.txt	12	The orderliness LH FSH secretion quantitated approximate entropy statistic greater patients controls
0.4064973.15172887.html.plaintext.txt	13	In contrast features FSH release similar narcoleptic control groups
0.4064973.15172887.html.plaintext.txt	14	Also LH FSH secretions response intravenous administration 100 microg GnRH similar patients controls
0.4064973.15172887.html.plaintext.txt	15	These data indicate endogenous hypocretins involved regulation hypothalamo pituitary gonadal axis activity humans
0.4064973.15172887.html.plaintext.txt	16	In particular reduced LH release face normal pituitary responsivity GnRH stimulation narcoleptic men suggests hypocretins promote endogenous GnRH secretion
0.4064973.15172887.html.plaintext.txt	17	orexin luteinizing hormone follicle stimulating hormone testosterone estradiol circadian rhythm deconvolution analysis
0.4064973.15172887.html.plaintext.txt	18	NARCOLEPSY IS CHARACTERIZED excessive daytime sleepiness cataplexy hypnagogic hallucinations sleep paralysis 30
0.4064973.15172887.html.plaintext.txt	19	It caused progressive loss hypocretin neurons brain 28 31
0.4064973.15172887.html.plaintext.txt	20	Hypocretin neuronal cell bodies located exclusively lateral hypothalamusperifornical area 41 axonal projections throughout central nervous system predict diverse biological actions 7
0.4064973.15172887.html.plaintext.txt	21	Indeed hypocretin peptides 1 2 also called orexin A B appear affect feeding behavior energy expenditure arousal autonomic outflow variety neuroendocrine ensembles 9 10 43 49
0.4064973.15172887.html.plaintext.txt	22	Therefore apart well recognized neurological manifestations clinical syndrome hypocretin deficiency humans may encompass broad spectrum behavioral endocrine metabolic anomalies
0.4064973.15172887.html.plaintext.txt	23	In keeping postulate recently identified aberrations pituitary adrenal somatotropic ensembles circulating leptin concentrations hypocretin deficient narcoleptic men 15 17 29
0.4064973.15172887.html.plaintext.txt	24	The septal preoptic arcuate nuclei among many brain sites receiving hypocretin inputs 7 26 32 46
0.4064973.15172887.html.plaintext.txt	25	These nuclei involved control hypothalamo pituitary gonadal HPG axis 50
0.4064973.15172887.html.plaintext.txt	26	Furthermore intracerebroventricular administration hypocretins acutely induces LH release ovarian steroid primed ovariectomized rats 37
0.4064973.15172887.html.plaintext.txt	27	Also hypocretin 1 promotes gonadotropin releasing hormone GnRH release hypothalamic explants male rats 40 intracerebroventricular administration anti hypocretin antibody completely abolishes preovulatory LH surge intact female rats 14
0.4064973.15172887.html.plaintext.txt	28	Thus available data suggest endogenous hypocretin peptides stimulate LH release rodents
0.4064973.15172887.html.plaintext.txt	29	It currently unknown whether peptides exert analogous effects humans
0.4064973.15172887.html.plaintext.txt	30	As far aware impact hypocretins FSH secretion investigated date
0.4064973.15172887.html.plaintext.txt	31	The present study conducted evaluate role endogenous hypocretins regulation gonadotropin release human
0.4064973.15172887.html.plaintext.txt	32	We specifically hypothesized hypocretin deficiency narcoleptic men would blunt spontaneous pituitary LH release
0.4064973.15172887.html.plaintext.txt	33	METHODS TOP ABSTRACT METHODS RESULTS DISCUSSION REFERENCES Subjects
0.4064973.15172887.html.plaintext.txt	34	We included seven male patients outpatient clinic Department Neurology Leiden University
0.4064973.15172887.html.plaintext.txt	35	The diagnosis narcolepsy cataplexy made clinical grounds physician experienced narcolepsy G
0.4064973.15172887.html.plaintext.txt	36	Also result multiple sleep latency test typical narcolepsy patients 23
0.4064973.15172887.html.plaintext.txt	37	In addition patients HLA DR2DQB10602 positive 22 lacked hypocretin 1 cerebrospinal fluid measurements previously described 28
0.4064973.15172887.html.plaintext.txt	38	All subjects free medication 3 patients discontinued medication 2 wk study
0.4064973.15172887.html.plaintext.txt	39	Two three narcoleptic subjects used psychostimulants methylfenidate modafinil one tricyclic antidepressant clomipramine
0.4064973.15172887.html.plaintext.txt	40	Weight height subjects measured well waist hip circumference
0.4064973.15172887.html.plaintext.txt	41	The waist hip ratio WHR used relative measure abdominal fat mass
0.4064973.15172887.html.plaintext.txt	42	Total body fat mass determined dual energy X ray absorptiometry Hologic QDR4500 Waltham MA
0.4064973.15172887.html.plaintext.txt	43	Seven male control subjects recruited advertisements local newspapers
0.4064973.15172887.html.plaintext.txt	44	Controls matched age body mass index total fat mass WHR since narcoleptics moderately obese 16
0.4064973.15172887.html.plaintext.txt	45	Subjects eligible study exclusion hypertension defined repeated blood pressure measurement systolic 160 mmHg diastolic 90 mmHg known history pituitary disease recent body weight change 3 kg weight gain loss within previous 3 mo fasting blood glucose 7
0.4064973.15172887.html.plaintext.txt	46	Written informed consent obtained subjects
0.4064973.15172887.html.plaintext.txt	47	The study approved ethics committee Leiden University Medical Center
0.4064973.15172887.html.plaintext.txt	48	Subjects admitted Clinical Research Center morning
0.4064973.15172887.html.plaintext.txt	49	Drawing blood performed standardized dark light alimentary conditions
0.4064973.15172887.html.plaintext.txt	50	During 24 h study occasion three standardized meals served 0900 1300 1800 Nutridrink 1
0.4064973.15172887.html.plaintext.txt	51	5 kcalml 1500 1800 kcalday macronutrient composition per 100 ml 5 g protein 6
0.4064973.15172887.html.plaintext.txt	52	9 g carbohydrate Nutricia Zoetermeer Netherlands
0.4064973.15172887.html.plaintext.txt	53	Subjects remained sedentary throughout study except bathroom visits
0.4064973.15172887.html.plaintext.txt	54	Lights switched 2300
0.4064973.15172887.html.plaintext.txt	55	Upon arrival intravenous cannula inserted antecubital vein 1 h start blood sampling performed 10 min intervals 24 h long line prevent sleep disturbance
0.4064973.15172887.html.plaintext.txt	56	Samples allowed clot centrifuged 4 degrees C 20 min serum frozen 20 degrees C assay
0.4064973.15172887.html.plaintext.txt	57	Sleep registration using portable electroencephalogram system Porti Twente Medical Systems Enschede Netherlands confirmed abnormally distributed 24 h total sleep well REM sleep narcoleptic subjects normal distribution sleep stages control subjects
0.4064973.15172887.html.plaintext.txt	58	On separate occasion blood drawn 0800 overnight fast measurement LH FSH testosterone estradiol sex hormone binding globulin SHBG concentrations
0.4064973.15172887.html.plaintext.txt	59	Subsequently GnRH test performed 42 whereby 100 microg gonadoreline Aventis Pharma Hoevelaken Netherlands given intravenous bolus serum LH concentrations measured every 10 min 90 min thereafter
0.4064973.15172887.html.plaintext.txt	60	Serum LH FSH concentrations measured time resolved immunofluorometric assays Wallac Turku Finland coefficients variation CV 3
0.4064973.15172887.html.plaintext.txt	61	8 concentration range 5
0.4064973.15172887.html.plaintext.txt	62	3 concentration range 5
0.4064973.15172887.html.plaintext.txt	63	Testosterone measured coated tube radioimmunoassay RIA Diagnostic Products Los Angeles CA CV 10
0.4064973.15172887.html.plaintext.txt	64	6 concentration range 2
0.4064973.15172887.html.plaintext.txt	65	SHBG measured immunoradiometric assay Spectria Espoo Finland serum estradiol RIA Diagnostic Systems Laboratory Webster TX
0.4064973.15172887.html.plaintext.txt	66	All samples gonadotropin 24 h profile processed assay procedure
0.4064973.15172887.html.plaintext.txt	67	In addition leptin concentration measured every 20 min sample RIA Linco Research St
0.4064973.15172887.html.plaintext.txt	68	The detection limit assay 0
0.4064973.15172887.html.plaintext.txt	69	3 concentration range 4
0.4064973.15172887.html.plaintext.txt	70	Details leptin secretion narcolepsy previously published report 24 h mean leptin concentration relation LH parameters testosterone 15
0.4064973.15172887.html.plaintext.txt	71	Deconvolution analysis 47 used estimate four secretory clearance measures interest 1 number locations secretory events 2 amplitudes secretory bursts 3 durations randomly dispersed LH FSH secretory bursts 4 endogenous single component subject specific plasma half lives LH FSH
0.4064973.15172887.html.plaintext.txt	72	It assumed gonadotropin distribution volumes LH FSH half lives time concentration invariant
0.4064973.15172887.html.plaintext.txt	73	The following parameters calculated half duration secretory bursts duration secretory burst half maximal amplitude hormone half life burst frequency amplitude secretory burst maximal secretory rate attained within burst mass secreted per burst basal secretion rate LH pulsatile secretion rate product burst frequency mean burst mass total secretion sum basal pulsatile
0.4064973.15172887.html.plaintext.txt	74	Based recent validation studies men deconvolution analysis carried 95 joint statistical confidence intervals calculated LH FSH amplitudes 13 25
0.4064973.15172887.html.plaintext.txt	75	The univariate approximate entropy ApEn statistic developed quantify degree irregularity disorderliness time series 33
0.4064973.15172887.html.plaintext.txt	76	Technically ApEn quantifies summed logarithmic likelihood templates length m patterns data similar within r remain similar within tolerance r next incremental comparison formally defined elsewhere 34
0.4064973.15172887.html.plaintext.txt	77	The ApEn calculation provides single nonnegative number ensemble estimate relative process randomness wherein larger ApEn values denote greater irregularity
0.4064973.15172887.html.plaintext.txt	78	Cross ApEn X ApEn quantifies joint pattern synchrony two separate parallel time series standardization z score transformation 36 38
0.4064973.15172887.html.plaintext.txt	79	In present analysis calculated X ApEn assuming r 20 SD individual time series m 1 hence use designation X ApEn 1 20
0.4064973.15172887.html.plaintext.txt	80	This parameter set affords sensitive valid statistically well replicated ApEn X ApEn metrics assessing hormone time series length 35 36
0.4064973.15172887.html.plaintext.txt	81	Both ApEn X ApEn results reported ratio absolute value mean 1000 randomly shuffled data series values approaching 1
0.4064973.15172887.html.plaintext.txt	82	Results expressed means plus minus SE unless stated otherwise
0.4064973.15172887.html.plaintext.txt	83	Students one tailed test used evaluate priori hypothesis LH secretion reduced narcoleptic men
0.4064973.15172887.html.plaintext.txt	84	All comparisons statistically evaluated two tailed Students test Kolmogorov Smirnov test two samples appropriate
0.4064973.15172887.html.plaintext.txt	85	Statistical analysis performed using Systat release 10
0.4064973.15172887.html.plaintext.txt	86	RESULTS TOP ABSTRACT METHODS RESULTS DISCUSSION REFERENCES Subjects
0.4064973.15172887.html.plaintext.txt	87	Narcoleptic patients N controls C comparable age 46
0.4064973.15172887.html.plaintext.txt	88	1 C yr body mass index 28
0.4064973.15172887.html.plaintext.txt	89	Gonadal steroid hormone concentrations similar narcoleptics controls testosterone 23
0.4064973.15172887.html.plaintext.txt	90	The mean plasma LH concentration significantly lower narcoleptic patients 3
0.4064973.15172887.html.plaintext.txt	91	01 whereas FSH concentration similar groups 3
0.4064973.15172887.html.plaintext.txt	92	1 shows 24 h serum LH FSH concentration vs
0.4064973.15172887.html.plaintext.txt	93	time narcoleptic subjects controls
0.4064973.15172887.html.plaintext.txt	94	View larger version 42K Fig
0.4064973.15172887.html.plaintext.txt	95	A serum LH concentrations 7 narcoleptic subjects 7 controls
0.4064973.15172887.html.plaintext.txt	96	Blood samples drawn every 10 min 24 h
0.4064973.15172887.html.plaintext.txt	97	Data shown means SE
0.4064973.15172887.html.plaintext.txt	98	Lights 2300 0800
0.4064973.15172887.html.plaintext.txt	99	Meals served 0900 1300 1800
0.4064973.15172887.html.plaintext.txt	100	The deconvolution derived parameter estimates LH FSH secretion elimination given Tables 1 2 respectively
0.4064973.15172887.html.plaintext.txt	101	Pulsatile secretion LH diminished narcoleptic subjects 23
0.4064973.15172887.html.plaintext.txt	102	9 C U l 1 24 h 1 P 0
0.4064973.15172887.html.plaintext.txt	103	02 result concerted effects reduced burst frequency burst mass
0.4064973.15172887.html.plaintext.txt	104	Total LH secretion also less narcoleptic patients P 0
0.4064973.15172887.html.plaintext.txt	105	In contrast features FSH release similar narcoleptics controls
0.4064973.15172887.html.plaintext.txt	106	Also plasma LH FSH half lives different groups
0.4064973.15172887.html.plaintext.txt	107	Representative 24 h LH FSH secretory profiles calculated deconvolution analysis corresponding curves serum concentration data shown Figs
0.4064973.15172887.html.plaintext.txt	108	Deconvolution derived features LH secretion
0.4064973.15172887.html.plaintext.txt	109	Deconvolution derived features FSH secretion
0.4064973.15172887.html.plaintext.txt	110	View larger version 28K Fig
0.4064973.15172887.html.plaintext.txt	111	Representative 24 h LH secretory profiles C D corresponding plasma concentration series intrasample dose dependent standard deviations fitted curves calculated deconvolution A B narcoleptic patient A C matched control B D
0.4064973.15172887.html.plaintext.txt	112	Note decreased pulsatile secretion narcoleptic patient
0.4064973.15172887.html.plaintext.txt	113	Time depicted minutes elapsed 1st sample taken
0.4064973.15172887.html.plaintext.txt	114	View larger version 32K Fig
0.4064973.15172887.html.plaintext.txt	115	Representative 24 h FSH secretory profiles C D corresponding plasma concentration series intrasample dose dependent standard deviations fitted curves calculated deconvolution A B narcoleptic patient A C matched control B D
0.4064973.15172887.html.plaintext.txt	116	Time depicted minutes elapsed first sample taken
0.4064973.15172887.html.plaintext.txt	117	Both basal serum gonadotropin levels LH 3
0.4064973.15172887.html.plaintext.txt	118	43 maximal concentrations response GnRH stimulation LH 16
0.4064973.15172887.html.plaintext.txt	119	43 similar groups
0.4064973.15172887.html.plaintext.txt	120	The individual LH FSH responses displayed Fig
0.4064973.15172887.html.plaintext.txt	121	View larger version 19K Fig
0.4064973.15172887.html.plaintext.txt	122	Individual LH TSH increases iv injection 100 microg LHRH 7 narcoleptic patients matched controls
0.4064973.15172887.html.plaintext.txt	123	Mean increases LH FSH respectively similar studied groups
0.4064973.15172887.html.plaintext.txt	124	The mean 24 h leptin concentration patients 5
0.4064973.15172887.html.plaintext.txt	125	1 microgl controls 11
0.4064973.15172887.html.plaintext.txt	126	No significant correlations present 24 h LH secretion mean 24 h leptin concentration either combined groups R 0
0.4064973.15172887.html.plaintext.txt	127	07 separately patients R 0
0.4064973.15172887.html.plaintext.txt	128	Between 24 h leptin concentration serum testosterone significant inverse linear correlation found displayed Fig
0.4064973.15172887.html.plaintext.txt	129	View larger version 15K Fig
0.4064973.15172887.html.plaintext.txt	130	Linear relationship mean 24 h leptin concentration 20 min sampling serum testosterone concentration
0.4064973.15172887.html.plaintext.txt	131	Note inverse relationship measures
0.4064973.15172887.html.plaintext.txt	132	ApEn ratio values LH lower patients compared controls denoting regular secretion N 0
0.4064973.15172887.html.plaintext.txt	133	The individual data displayed Fig
0.4064973.15172887.html.plaintext.txt	134	Similarly ApEn ratio FSH also smaller patients 0
0.4064973.15172887.html.plaintext.txt	135	The X ApEn ratio LH FSH concentration series lower patients controls indicating increased synchrony hormones patients compared controls N 0
0.4064973.15172887.html.plaintext.txt	136	X ApEn ratio leptin concentration series 20 min data LH series 20 min data differ groups N 0
0.4064973.15172887.html.plaintext.txt	137	View larger version 15K Fig
0.4064973.15172887.html.plaintext.txt	138	Aproximate entropy ApEn ratios LH FSH secretion cross ApEn ratio LH FSH series
0.4064973.15172887.html.plaintext.txt	139	Lower values denote orderliness secretion
0.4064973.15172887.html.plaintext.txt	140	DISCUSSION TOP ABSTRACT METHODS RESULTS DISCUSSION REFERENCES This study shows average 24 h plasma LH concentration reduced hypocretin deficient narcoleptic men whereas gonadal steroid hormone levels normal
0.4064973.15172887.html.plaintext.txt	141	The reduction plasma LH concentration narcoleptics accounted diminution pulsatile LH release 30 compared healthy controls cannot attributed insensitivity pituitary gonadotrophs GnRH stimulation
0.4064973.15172887.html.plaintext.txt	142	LH burst frequency burst mass reduced narcoleptic men
0.4064973.15172887.html.plaintext.txt	143	In contrast plasma FSH concentrations various features FSH secretion similar narcoleptics controls
0.4064973.15172887.html.plaintext.txt	144	These data suggest endogenous hypocretin peptides stimulate pulsatile LH release men
0.4064973.15172887.html.plaintext.txt	145	In particular fact spontaneous LH secretion blunted whereas pituitary responsiveness GnRH stimulation intact narcoleptic subjects suggests hypocretin deficiency primarily inhibits hypothalamic GnRH release
0.4064973.15172887.html.plaintext.txt	146	This inference agrees studies male rats showing hypocretin 1 promotes GnRH release hypothalamic explants 40
0.4064973.15172887.html.plaintext.txt	147	Moreover hypocretin inputs abundant preoptic area contains many GnRH neurons 50 coexpress hypocretin 1 receptors direct contact hypocretin fibers 3
0.4064973.15172887.html.plaintext.txt	148	These physiological anatomical observations obviously support notion hypocretin peptides involved regulation GnRH release
0.4064973.15172887.html.plaintext.txt	149	The fact FSH secretion diminished whereas LH release narcoleptic subjects may imply hypocretins specifically modulate GnRH burst frequency LH secretion particularly enhanced high frequency bursts whereas low frequency bursts predominantly promote FSH release 20
0.4064973.15172887.html.plaintext.txt	150	ApEn quantitates relative orderliness reproducibility subordinate nonpulsatile secretory patterns neurohormone time series reflects feedforward feedback adjustments driven pathophysiological changes interglandular communication
0.4064973.15172887.html.plaintext.txt	151	In view unchanged testosterone feedback signal patients increased LH FSH regularity increased synchrony hormones might reflect diminished GnRH input signal unchanged pituitary responsiveness toward neurohormone 48
0.4064973.15172887.html.plaintext.txt	152	Alternatively hypoleptinemia may blunt LH release narcoleptic patients
0.4064973.15172887.html.plaintext.txt	153	We previously shown 15 plasma leptin concentration considerably reduced narcoleptic men
0.4064973.15172887.html.plaintext.txt	154	Leptin emerged important modulator HPG axis 5
0.4064973.15172887.html.plaintext.txt	155	Indeed leptin deficient obob mice hypogonadotropic sterile recombinant leptin administration rescues defects obob males 24 females 6
0.4064973.15172887.html.plaintext.txt	156	Moreover circadian rhythm plasma leptin levels synchronous LH concentrations 18 reduction LH secretion induced fasting rat humans reversed leptin administration 1 4 8
0.4064973.15172887.html.plaintext.txt	157	These data indicate leptin stimulates LH release genetic andor physiological alterations circulating leptin levels impact pituitary gonadotropin release
0.4064973.15172887.html.plaintext.txt	158	In context conceivable reduction plasma leptin concentration narcoleptics 15 involved diminution pituitary LH release patients mentioned could demonstrate linear correlation mean circulating leptin concentration LH production
0.4064973.15172887.html.plaintext.txt	159	Notwithstanding diminished LH production testosterone concentration unchanged patients
0.4064973.15172887.html.plaintext.txt	160	Recently become clear leptin involved local regulation testosterone synthesis secretion male rat gonad 44
0.4064973.15172887.html.plaintext.txt	161	Direct evidence action humans available inverse relation serum testosterone leptin demonstrated 19
0.4064973.15172887.html.plaintext.txt	162	Therefore inhibitory effect leptin testosterone adrenal hormone secretion might relevant narcoleptic patients narcoleptics exhibit 50 reduction circulating leptin concentration may unleash gonadal testosterone secretion compensate diminished LH drive 15
0.4064973.15172887.html.plaintext.txt	163	The finding inverse relationship testosterone leptin subjects reinforces view
0.4064973.15172887.html.plaintext.txt	164	Prepro orexin mRNA orexin receptors expressed various endocrine nonendocrine tissues 11 instance orexins modulate directly human porcine adrenal stereoidogenic function 21 27
0.4064973.15172887.html.plaintext.txt	165	Relevant present investigation recent finding mRNA expression OX1 OX2 receptor male rat gonad 2
0.4064973.15172887.html.plaintext.txt	166	Activation OX1 receptor stimulates testosterone secretion vivo vitro suggesting physiological modulating role orexin system concert leptin ghrelin testicular level 45
0.4064973.15172887.html.plaintext.txt	167	The significance findings human physiology needs explored
0.4064973.15172887.html.plaintext.txt	168	However OX1 OX2 receptor expression demonstrated male human reproductive system including testis suggesting orexins directly impact gonadal hormone release humans well rodents 12
0.4064973.15172887.html.plaintext.txt	169	The impact alterations HPG ensemble described fertility narcoleptic men remains definitely determined
0.4064973.15172887.html.plaintext.txt	170	Some early reports suggested narcolepsy associated impaired fertility 39 since suggestions confirmed far aware
0.4064973.15172887.html.plaintext.txt	171	Moreover clinical impression narcoleptic male patients less fertile gonadal hormone concentrations plasma normal narcoleptics despite reduction LH levels
0.4064973.15172887.html.plaintext.txt	172	Thus seems unlikely partial hypogonadotropism observed clinical sequelae
0.4064973.15172887.html.plaintext.txt	173	Nevertheless view findings males warranted investigate narcoleptic females across menstrual cycle putative defects ovarian function
0.4064973.15172887.html.plaintext.txt	174	In conclusion hypocretin deficient narcoleptic men reduced circulating LH levels brought diminution pulsatile LH release
0.4064973.15172887.html.plaintext.txt	175	In contrast FSH secretion normal patients
0.4064973.15172887.html.plaintext.txt	176	The pituitary sensitivity GnRH stimulation normal narcoleptics suggests reduction hypothalamic GnRH release underlies blunted LH secretion accordance view increased orderliness secretion gonadotropins
0.4064973.15172887.html.plaintext.txt	177	Both hypocretin deficiency per se hypoleptinemia may involved changes HPG axis narcoleptic males
0.4064973.15172887.html.plaintext.txt	178	ACKNOWLEDGMENTS We gratefully acknowledge skillful assistance E
0.4064973.15172887.html.plaintext.txt	179	Sierat van der Steen study occasions
0.4064973.15172887.html.plaintext.txt	180	FOOTNOTES Address reprint requests correspondence H
0.4064973.15172887.html.plaintext.txt	181	General Internal Medicine C1 R39 PO Box 9600 2300 RC Leiden The Netherlands E mail h
0.4064973.15172887.html.plaintext.txt	182	The costs publication article defrayed part payment page charges
0.4064973.15172887.html.plaintext.txt	183	The article must therefore hereby marked advertisement accordance 18 U
0.4064973.15172887.html.plaintext.txt	184	Section 1734 solely indicate fact
0.4064973.15172887.html.plaintext.txt	185	REFERENCES TOP ABSTRACT METHODS RESULTS DISCUSSION REFERENCES Ahima RS Prabakaran D Mantzoros C Qu D Lowell B Maratos Flier E Flier JS
0.4064973.15172887.html.plaintext.txt	186	Role leptin neuroendocrine response fasting
0.4064973.15172887.html.plaintext.txt	187	CrossRefISIMedline Barreirro ML Pineda R Navarro VM Lopez M Suominen JS Pinella L Searis R Toppara J Aguilar E Dieguez C Tena Sempera M
0.4064973.15172887.html.plaintext.txt	188	Orexin 1 receptor messenger ribonucleic acid expression stimulation testosterone secretion orexin A rat testis
0.4064973.15172887.html.plaintext.txt	189	Endocrinology 145 2297 2306 2004
0.4064973.15172887.html.plaintext.txt	190	AbstractFree Full Text Campbell RE Grove KL Smith MS
0.4064973.15172887.html.plaintext.txt	191	Gonadotropin releasing hormone neurons coexpress orexin 1 receptor immunoreactivity receive direct contacts orexin fibers
0.4064973.15172887.html.plaintext.txt	192	Endocrinology 144 1542 1548 2003
0.4064973.15172887.html.plaintext.txt	193	AbstractFree Full Text han JL Heist K DePaoli AM Veldhuis JD Montzoros CS
0.4064973.15172887.html.plaintext.txt	194	The role falling leptin levels neuroendocrine metabolic adaptation short term starvation healthy men
0.4064973.15172887.html.plaintext.txt	195	J Clin Invest 111 1409 1421 2003
0.4064973.15172887.html.plaintext.txt	196	AbstractFree Full Text Chehab FF
0.4064973.15172887.html.plaintext.txt	197	Leptin regulator adipose mass reproduction
0.4064973.15172887.html.plaintext.txt	198	Trends Pharmacol Sci 21 309 314 2000
0.4064973.15172887.html.plaintext.txt	199	CrossRefISIMedline Chehab FF Lim ME Lu R
0.4064973.15172887.html.plaintext.txt	200	Correction sterility defect homozygous obese female mice treatment human recombinant leptin
0.4064973.15172887.html.plaintext.txt	201	Nat Genet 12 318 320 1996
0.4064973.15172887.html.plaintext.txt	202	ISIMedline Date Y Ueta Y Yamashita H Yamaguchi H Matsukura S Kangawa K Sakurai T Yanagisawa M Nakazato M
0.4064973.15172887.html.plaintext.txt	203	Orexins orexigenic hypothalamic peptides interact autonomic neuroendocrine neuroregulatory systems
0.4064973.15172887.html.plaintext.txt	204	Proc Natl Acad Sci USA 96 748 753 1999
0.4064973.15172887.html.plaintext.txt	205	AbstractFree Full Text Gonzalez LC Pinilla L Tena Sempere M Aguilar E
0.4064973.15172887.html.plaintext.txt	206	Leptin 116 130 stimulates prolactin luteinizing hormone secretion fasted adult male rats
0.4064973.15172887.html.plaintext.txt	207	Neuroendocrinology 70 213 220 1999
0.4064973.15172887.html.plaintext.txt	208	CrossRefISIMedline Hagan JJ Leslie RA Patel S Evans ML Wattam TA Holmes S Benham CD Taylor SG Routledge C Hemmati P Munton RP Ashmeade TE Shah AS Hatcher JP Hatcher PD Jones DN Smith MI Piper DC Hunter AJ Porter RA Upton N
0.4064973.15172887.html.plaintext.txt	209	Orexin A activates locus coeruleus cell firing increases arousal rat
0.4064973.15172887.html.plaintext.txt	210	Proc Natl Acad Sci USA 96 10911 10916
0.4064973.15172887.html.plaintext.txt	211	AbstractFree Full Text Hara J Beuckmann CT Nambu T Willie JT Chemelli RM Sinton CM Sugiyama F Yagami K Goto K Yanagisawa M Sakurai T
0.4064973.15172887.html.plaintext.txt	212	Genetic ablation orexin neurons mice results narcolepsy hypophagia obesity
0.4064973.15172887.html.plaintext.txt	213	CrossRefISIMedline Johren O Neidert SJ Kummer M Dendorfer A Dominiak P
0.4064973.15172887.html.plaintext.txt	214	Preproorexin orexin receptor mRNAs differentially expressed peripheral tissues male female rats
0.4064973.15172887.html.plaintext.txt	215	Endocrinology 142 3324 3331 2001
0.4064973.15172887.html.plaintext.txt	216	AbstractFree Full Text Karteris E Chen J Randeva HS
0.4064973.15172887.html.plaintext.txt	217	Expression human prepro orexin signalling characteristics orexin receptors male reproductive system
0.4064973.15172887.html.plaintext.txt	218	J Clin Endocrinol Metab 89 1957 1962 2004
0.4064973.15172887.html.plaintext.txt	219	AbstractFree Full Text Keenan DM Veldhuis JD
0.4064973.15172887.html.plaintext.txt	220	Disruption hypothalamic luteinizing hormone pulsing mechanism aging men
0.4064973.15172887.html.plaintext.txt	221	Am J Physiol Regul Integr Comp Physiol 281 R1917 R1924 2001
0.4064973.15172887.html.plaintext.txt	222	AbstractFree Full Text Kohsaka A Watanabe H Kakizaki Y Suda T Schioth HB
0.4064973.15172887.html.plaintext.txt	223	A significant participation orexin A potent orexigenic peptide preovulatory luteinizing hormone prolactin surges rat
0.4064973.15172887.html.plaintext.txt	224	Brain Res 898166 170 2001
0.4064973.15172887.html.plaintext.txt	225	CrossRefISIMedline Kok SW Meinders AE Overeem S Lammers GJ Roelfsema F Frolich M Pijl H
0.4064973.15172887.html.plaintext.txt	226	Reduction plasma leptin levels loss circadian rhythmicity hypocretin orexin deficient narcoleptic humans
0.4064973.15172887.html.plaintext.txt	227	J Clin Endocrinol Metab 87805 809 2002
0.4064973.15172887.html.plaintext.txt	228	AbstractFree Full Text Kok SW Overeem S Visscher TL Lammers GJ Seidell JC Pijl H Meinders AE
0.4064973.15172887.html.plaintext.txt	229	Hypocretin deficiency narcoleptic humans associated abdominal obesity
0.4064973.15172887.html.plaintext.txt	230	Obes Res 11 1147 1154 2003
0.4064973.15172887.html.plaintext.txt	231	AbstractFree Full Text Kok SW Roelfsema F Overeem S Lammers GJ Strijers RL Frolich M Meinders AE Pijl H
0.4064973.15172887.html.plaintext.txt	232	Dynamics pituitary adrenal ensemble hypocretin deficient narcoleptic humans blunted basal adrenocorticotropin release evidence normal time keeping master pacemaker
0.4064973.15172887.html.plaintext.txt	233	J Clin Endocrinol Metab 87 5085 5091 2002
0.4064973.15172887.html.plaintext.txt	234	AbstractFree Full Text Licinio J Negrao AB Mantzoros C Kaklamani V Wong ML Bongiorno PB Mulla A Cearnal L Veldhuis JD Flier JS McCann SM Gold PW
0.4064973.15172887.html.plaintext.txt	235	Synchronicity frequently sampled 24 h concentrations circulating leptin luteinizing hormone estradiol healthy women
0.4064973.15172887.html.plaintext.txt	236	Proc Natl Acad Sci USA 95 2541 2546 1998
0.4064973.15172887.html.plaintext.txt	237	AbstractFree Full Text Luukkaa V Pesonen U Huhtaniemi I Lehtonen A Tilvis R Tuomiletho J Koulu M Huupponen R
0.4064973.15172887.html.plaintext.txt	238	Inverse correlation serum testosterone leptin men
0.4064973.15172887.html.plaintext.txt	239	J Clin Endocrinol Metab 83 3243 3246 1998
0.4064973.15172887.html.plaintext.txt	240	AbstractFree Full Text Marshall JC Eagleson CA McCartney CR
0.4064973.15172887.html.plaintext.txt	241	Mol Cell Endocrinol 186 227 230 2002
0.4064973.15172887.html.plaintext.txt	242	CrossRefISI Mazzochi G Malendowicz LK Gottardo L Aragona F Nussdorfer GG
0.4064973.15172887.html.plaintext.txt	243	Orexin A stimulates cortisol secretion human adrenal cortical cells activation adenylate cyclase dependent signalling cascade
0.4064973.15172887.html.plaintext.txt	244	J Clin Endocrinol Metab 86 778 782 2001
0.4064973.15172887.html.plaintext.txt	245	AbstractFree Full Text Mignot E
0.4064973.15172887.html.plaintext.txt	246	Genetic familial aspects narcolepsy
0.4064973.15172887.html.plaintext.txt	247	Neurology 50 Suppl 1 S16 S22 1998
0.4064973.15172887.html.plaintext.txt	248	Mitler MM Van den Hoed J Carskadon MA Richardson G Park R Guilleminault C Dement WC
0.4064973.15172887.html.plaintext.txt	249	REM sleep episodes multiple sleep latency test narcoleptic patients
0.4064973.15172887.html.plaintext.txt	250	Electroencephalogr Clin Neurophysiol 46 479 481 1979
0.4064973.15172887.html.plaintext.txt	251	CrossRefISIMedline Mounzih K Lu R Chehab FF
0.4064973.15172887.html.plaintext.txt	252	Leptin treatment rescues sterility genetically obese obob males
0.4064973.15172887.html.plaintext.txt	253	Endocrinology 138 1190 1193 1997
0.4064973.15172887.html.plaintext.txt	254	AbstractFree Full Text Mulligan T Iranmanesh A Veldhuis JD
0.4064973.15172887.html.plaintext.txt	255	Pulsatile iv infusion recombinant human LH leuprolide suppressed men unmasks impoverished Leydig cell secretory responsiveness midphysiological LH drive aging male
0.4064973.15172887.html.plaintext.txt	256	J Clin Endocrinol Metab 86 5547 5553 2001
0.4064973.15172887.html.plaintext.txt	257	AbstractFree Full Text Nambu T Sakurai T Mizukami K Hosoya Y Yanagisawa M Goto K
0.4064973.15172887.html.plaintext.txt	258	Distribution orexin neurons adult rat brain
0.4064973.15172887.html.plaintext.txt	259	Brain Res 827 243 260 1999
0.4064973.15172887.html.plaintext.txt	260	CrossRefISIMedline Nanmoku T Isobe K Sakurai T Yamanaka A Takekoshi Kawakami Y Goto K Nakai T
0.4064973.15172887.html.plaintext.txt	261	Effects orexin cultured porcine adrenal medullary cortex cells
0.4064973.15172887.html.plaintext.txt	262	Regul Pept 104 125 130 2002
0.4064973.15172887.html.plaintext.txt	263	CrossRefISIMedline Nishino S Ripley B Overeem S Lammers GJ Mignot E
0.4064973.15172887.html.plaintext.txt	264	Hypocretin orexin deficiency human narcolepsy
0.4064973.15172887.html.plaintext.txt	265	CrossRefISIMedline Overeem S Kok SW Lammers GJ Vein AA Frolich M Meinders AE Roelfsema F Pijl H
0.4064973.15172887.html.plaintext.txt	266	The somatotropic axis hypocretin deficient narcoleptic humans altered circadian distribution GH secretory events
0.4064973.15172887.html.plaintext.txt	267	Am J Physiol Endocrinol Metab 284 E641 E647 2003
0.4064973.15172887.html.plaintext.txt	268	AbstractFree Full Text Overeem S Mignot E van Dijk JG Lammers GJ
0.4064973.15172887.html.plaintext.txt	269	Narcolepsy clinical features new pathophysiologic insights future perspectives
0.4064973.15172887.html.plaintext.txt	270	J Clin Neurophysiol 18 78 105 2001
0.4064973.15172887.html.plaintext.txt	271	ISIMedline Peyron C Faraco J Rogers W Ripley B Overeem S Charnay Y Nevsimalova S Aldrich M Reynolds D Albin R Li R Hungs M Pedrazzoli M Padigaru M Kucherlapati M Fan J Maki R Lammers GJ Bouras C Kucherlapati R Nishino S Mignot E
0.4064973.15172887.html.plaintext.txt	272	A mutation case early onset narcolepsy generalized absence hypocretin peptides human narcoleptic brains
0.4064973.15172887.html.plaintext.txt	273	CrossRefISIMedline Peyron C Tighe DK van den Pol AN de Lecea L Heller HC Sutcliffe JG Kilduff TS
0.4064973.15172887.html.plaintext.txt	274	Neurons containing hypocretin orexin project multiple neuronal systems
0.4064973.15172887.html.plaintext.txt	275	J Neurosci 18 9996 10015 1998
0.4064973.15172887.html.plaintext.txt	276	AbstractFree Full Text Pincus SM
0.4064973.15172887.html.plaintext.txt	277	Approximate entropy measure system complexity
0.4064973.15172887.html.plaintext.txt	278	Proc Natl Acad Sci USA 88 2297 2301 1991
0.4064973.15172887.html.plaintext.txt	279	Abstract Pincus SM Goldberger AL
0.4064973.15172887.html.plaintext.txt	280	Physiological time series analysis regularity quantifies Am J Physiol Heart Circ Physiol 266 H1643 H1656 1994
0.4064973.15172887.html.plaintext.txt	281	AbstractFree Full Text Pincus SM Hartman ML Roelfsema F Thorner MO Veldhuis JD
0.4064973.15172887.html.plaintext.txt	282	Hormone pulsatility via coarse short time sampling
0.4064973.15172887.html.plaintext.txt	283	Am J Physiol Endocrinol Metab 277 E948 E957 1999
0.4064973.15172887.html.plaintext.txt	284	AbstractFree Full Text Pincus SM Mulligan T Iranmanesh A Gheorghiu S Godschalk M Veldhuis JD
0.4064973.15172887.html.plaintext.txt	285	Older males secrete luteinizing hormone irregularly jointly asynchronously younger males
0.4064973.15172887.html.plaintext.txt	286	Proc Natl Acad Sci USA 93 14100 14105 1996
0.4064973.15172887.html.plaintext.txt	287	AbstractFree Full Text Pu S Jain MR Kalra PS Kalra SP
0.4064973.15172887.html.plaintext.txt	288	Orexins novel family hypothalamic neuropeptides modulate pituitary luteinizing hormone secretion ovarian steroid dependent manner
0.4064973.15172887.html.plaintext.txt	289	Regul Pept 78 133 136 1998
0.4064973.15172887.html.plaintext.txt	290	CrossRefISIMedline Roelfsema F Pincus SM Veldhuis JD
0.4064973.15172887.html.plaintext.txt	291	Patients Cushings disease secrete adrenocorticotropin cortisol jointly asynchronously healthy subjects
0.4064973.15172887.html.plaintext.txt	292	J Clin Endocrinol Metab 83 688 692 1998
0.4064973.15172887.html.plaintext.txt	293	AbstractFree Full Text Roth B
0.4064973.15172887.html.plaintext.txt	294	In Narcolepsy Hypersomnia edited Roth B Broughton R
0.4064973.15172887.html.plaintext.txt	295	Russell SH Small CJ Kennedy AR Stanley SA Seth A Murphy KG Taheri S Ghatei MA Bloom SR
0.4064973.15172887.html.plaintext.txt	296	Orexin A interactions hypothalamo pituitary gonadal axis
0.4064973.15172887.html.plaintext.txt	297	Endocrinology 142 5294 5302 2001
0.4064973.15172887.html.plaintext.txt	298	AbstractFree Full Text Sakurai T Amemiya A Ishii M Matsuzaki I Chemelli RM Tanaka H Williams SC Richardson JA Kozlowski GP Wilson S Arch JR Buckingham RE Haynes AC Carr SA Annan RS McNulty DE Liu WS Terrett JA Elshourbagy NA Bergsma DJ Yanagisawa M
0.4064973.15172887.html.plaintext.txt	299	Orexins orexin receptors family hypothalamic neuropeptides G protein coupled receptors regulate feeding behavior
0.4064973.15172887.html.plaintext.txt	300	ISIMedline Snyder PJ Reitano JF Utiger RD
0.4064973.15172887.html.plaintext.txt	301	Serum LH FSH responses synthetic gonadotropin releasing hormone normal men
0.4064973.15172887.html.plaintext.txt	302	J Clin Endocrinol Metab 41 938 945 1975
0.4064973.15172887.html.plaintext.txt	303	Abstract Taylor MM Samson WK
0.4064973.15172887.html.plaintext.txt	304	The side orexins endocrine metabolic actions
0.4064973.15172887.html.plaintext.txt	305	Am J Physiol Endocrinol Metab 284 E13 E17 2003
0.4064973.15172887.html.plaintext.txt	306	AbstractFree Full Text Tena Sempere M Barreiro ML
0.4064973.15172887.html.plaintext.txt	307	Leptin male reproduction testis paradigm
0.4064973.15172887.html.plaintext.txt	308	Mol Cell Endocrinol 188 9 13 2002
0.4064973.15172887.html.plaintext.txt	309	CrossRefISIMedline Tena Sempere M Barreiro ML Gonzales LC Gaytan F Zhang FP Caminos JE Pinilla L Casanueva FF Dieguez C Aguilar E
0.4064973.15172887.html.plaintext.txt	310	Novel expression functional role ghrelin rat testis
0.4064973.15172887.html.plaintext.txt	311	Endocrinology 143 717 725 2002
0.4064973.15172887.html.plaintext.txt	312	AbstractFree Full Text Trivedi P Yu H MacNeil DJ Van der Ploeg LH Guan XM
0.4064973.15172887.html.plaintext.txt	313	Distribution orexin receptor mRNA rat brain
0.4064973.15172887.html.plaintext.txt	314	Febs Lett 438 71 75 1998 Corrigenda Febs Lett 442 122 1999
0.4064973.15172887.html.plaintext.txt	315	CrossRefISIMedline Veldhuis JD Carlson ML Johnson ML
0.4064973.15172887.html.plaintext.txt	316	The pituitary gland secretes bursts appraising nature glandular secretory impulses simultaneous multiple parameter deconvolution plasma hormone concentrations
0.4064973.15172887.html.plaintext.txt	317	Proc Natl Acad Sci USA 84 7686 7690 1987
0.4064973.15172887.html.plaintext.txt	318	Abstract Veldhuis JD Johnson ML Veldhuis OL Straume M Pincus SM
0.4064973.15172887.html.plaintext.txt	319	Impact pulsatility ensemble orderliness approximate entropy neurohormone secretion
0.4064973.15172887.html.plaintext.txt	320	Am J Physiol Regul Integr Comp Physiol 281 R1975 R1985 2001
0.4064973.15172887.html.plaintext.txt	321	AbstractFree Full Text Willie JT Chemelli RM Sinton CM Yanagisawa M
0.4064973.15172887.html.plaintext.txt	322	To eat sleep Orexin regulation feeding wakefulness
0.4064973.15172887.html.plaintext.txt	323	Annu Rev Neurosci 24 429 458 2001
0.4064973.15172887.html.plaintext.txt	324	CrossRefISIMedline Wray S
0.4064973.15172887.html.plaintext.txt	325	Development gonadotropin releasing hormone 1 neurons
0.4064973.15172887.html.plaintext.txt	326	Front Neuroendocrinol 23 292 316 2002
0.14565748.12351581.html.plaintext.txt	0	The allelic structure common disease Desmond J
0.14565748.12351581.html.plaintext.txt	1	1Department Molecular Medical Pharmacology 2Crump Institute Molecular Imaging 3Department Microbiology Immunology Molecular Genetics 4Department Medicine 5Department Human Genetics University California Los Angeles CA 90095 USA
0.14565748.12351581.html.plaintext.txt	2	Received June 28 2002 Accepted July 27 2002
0.14565748.12351581.html.plaintext.txt	3	ABSTRACT TOP ABSTRACT PROPERTIES OF ALLELIC SPACE INFERENCES FROM HUMAN POPULATION
0.14565748.12351581.html.plaintext.txt	4	LINKAGE DISEQUILIBRIUM THE FUTURE OF HUMAN
0.14565748.12351581.html.plaintext.txt	5	REFERENCES A better understanding allelic structure common human disease loci may help identification responsible genes thus topic considerable practical importance
0.14565748.12351581.html.plaintext.txt	6	If alleles locus account majority disease risk screening causative factors greatly simplified
0.14565748.12351581.html.plaintext.txt	7	In contrast large numbers independent alleles responsible dramatic improvements genotyping speed necessary placing dream personalized medicine far future
0.14565748.12351581.html.plaintext.txt	8	In review evidence optimistic pessimistic viewpoints discussed
0.14565748.12351581.html.plaintext.txt	9	It appears neither position proved disproved available evidence indicates common diseases due least part genes small number disease associated alleles
0.14565748.12351581.html.plaintext.txt	10	One early dreams human genome project goal personalized medicine
0.14565748.12351581.html.plaintext.txt	11	The vision individual would compact disk containing unique DNA sequence guiding myriad decisions lifestyle disease prevention treatment conceivably even career choice
0.14565748.12351581.html.plaintext.txt	12	At present DNA sequencing technology nowhere near cheap enough fast enough allow dream
0.14565748.12351581.html.plaintext.txt	13	Nevertheless genotyping technologies made dramatic strides last decade technologies may fast enough allow interrogation relevant disease alleles given individual
0.14565748.12351581.html.plaintext.txt	14	The feasibility approach depends critically allelic structure human disease genes
0.14565748.12351581.html.plaintext.txt	15	If 30 000 genes make important contributions disease susceptibility 1000 alleles gene total 3x107 genotypings reliably performed daunting prospect
0.14565748.12351581.html.plaintext.txt	16	However 1000 genes make appreciable contributions human disease genes 4 relevant alleles number genotypings performed 4000 highly feasible
0.14565748.12351581.html.plaintext.txt	17	In review look present knowledge allelic complexity human disease genes well providing brief glance future
0.14565748.12351581.html.plaintext.txt	18	PROPERTIES OF ALLELIC SPACE TOP ABSTRACT PROPERTIES OF ALLELIC SPACE INFERENCES FROM HUMAN POPULATION
0.14565748.12351581.html.plaintext.txt	19	LINKAGE DISEQUILIBRIUM THE FUTURE OF HUMAN
0.14565748.12351581.html.plaintext.txt	20	REFERENCES A perhaps oversimplified aid visualizing properties human disease genes provided Figure 1
0.14565748.12351581.html.plaintext.txt	21	This figure depicts three dimensional allelic space axes disease frequency number responsible loci mean number alleles locus
0.14565748.12351581.html.plaintext.txt	22	Regarding second axis number responsible loci genetic traits traditionally divided monogenic single gene simple trait polygenic many genes multifactorial complex interactions multiple genes environment
0.14565748.12351581.html.plaintext.txt	23	Because single locus responsible monogenic disorders identification relevant loci usually straightforward provided sufficient number multiplex families available
0.14565748.12351581.html.plaintext.txt	24	In contrast genetics complex traits remains murky success identifying responsible loci elusive
0.14565748.12351581.html.plaintext.txt	25	This many genes environment conspire together series complicated epistatic synergistic relationships cause final disease phenotype
0.14565748.12351581.html.plaintext.txt	26	In general number loci identified linkage given complex disease trait less 10 linkage expected identify major contributing loci
0.14565748.12351581.html.plaintext.txt	27	Since exceptions genes responsible complex traits yet identified remains open question number alleles locus
0.14565748.12351581.html.plaintext.txt	28	View larger version 25K Figure 1
0.14565748.12351581.html.plaintext.txt	29	This three dimensional space provides aid visualizing possible structures polymorphism human disease genes
0.14565748.12351581.html.plaintext.txt	30	For monogenic disorders rare diseases green bar complex allelic spectra high number alleles per locus common diseases yellow bar simple spectra low number alleles per locus
0.14565748.12351581.html.plaintext.txt	31	Special cases gray bar exist situations heterozygous advantage population bottlenecks
0.14565748.12351581.html.plaintext.txt	32	For common complex disease traits situation less clear
0.14565748.12351581.html.plaintext.txt	33	Two extreme models interaction model CDCV hypothesis dark blue bar genetic heterogeneity model red bar
0.14565748.12351581.html.plaintext.txt	34	However two extreme models also formally possible small number loci large number alleles cyan bar large number loci large number alleles magenta bar
0.14565748.12351581.html.plaintext.txt	35	Considerations human population genetics 2 suggest one four extreme models small number loci large number alleles cyan bar unlikely
0.14565748.12351581.html.plaintext.txt	36	However present data insufficient confidently place complex disease traits remaining three extremes indicated two dimensional gray surface
0.14565748.12351581.html.plaintext.txt	37	In figure following examples employed 2 10 monogenic rare retinoblastoma monogenic common glucose 6 phosphate dehydrogenase deficiency South China monogenic special case ss thalassemia Sardinia complex interaction model Alzheimers disease speculative complex genetic heterogeneity model colon cancer speculative
0.14565748.12351581.html.plaintext.txt	38	No known examples yet exist two hypothetical cases common complex diseases caused small number loci large number alleles large number loci large number alleles
0.14565748.12351581.html.plaintext.txt	39	For clarity disease frequencies monogenic common complex disorders rounded 10 1 within one order magnitude known frequency
0.14565748.12351581.html.plaintext.txt	40	In cases complex diseases Alzheimers disease colon cancer assigned values number loci number alleles per locus highly speculative
0.14565748.12351581.html.plaintext.txt	41	For purposes figure assumed Alzheimers disease example interaction model whereas colon cancer example genetic heterogeneity model
0.14565748.12351581.html.plaintext.txt	42	Although assumptions conjectural evidence favor genetic heterogeneity model cancer 10
0.14565748.12351581.html.plaintext.txt	43	Two extreme models usually envisaged complex disease traits Fig
0.14565748.12351581.html.plaintext.txt	44	One idea common alleles handful loci interact cause disease
0.14565748.12351581.html.plaintext.txt	45	This referred interaction model common diseasecommon variant CDCV hypothesis
0.14565748.12351581.html.plaintext.txt	46	The competing notion rare alleles numerous loci single handedly cause disease
0.14565748.12351581.html.plaintext.txt	47	This referred genetic heterogeneity model
0.14565748.12351581.html.plaintext.txt	48	Two extreme models also formally possible complex disease traits caused small number loci large number alleles caused large number loci large number alleles Fig
0.14565748.12351581.html.plaintext.txt	49	One last two alternatives small number loci large number alleles rendered unlikely considerations human population structure see
0.14565748.12351581.html.plaintext.txt	50	However remaining three extremes complex disease traits could occupy middle ground
0.14565748.12351581.html.plaintext.txt	51	INFERENCES FROM HUMAN POPULATION STRUCTURE TOP ABSTRACT PROPERTIES OF ALLELIC SPACE INFERENCES FROM HUMAN POPULATION
0.14565748.12351581.html.plaintext.txt	52	LINKAGE DISEQUILIBRIUM THE FUTURE OF HUMAN
0.14565748.12351581.html.plaintext.txt	53	REFERENCES Reich Lander 2 provided simple framework understanding allelic spectra number frequency disease predisposing alleles human disease genes
0.14565748.12351581.html.plaintext.txt	54	In addition work provides justification CDCV hypothesis
0.14565748.12351581.html.plaintext.txt	55	There large amount evidence suggesting dramatic expansion human population 18 000 150 000 years 700 6000 generations ago
0.14565748.12351581.html.plaintext.txt	56	This resulted increased effective population size 104 individuals present size 6x109
0.14565748.12351581.html.plaintext.txt	57	Assume expansion one allele rare disease gene one allele common gene Fig
0.14565748.12351581.html.plaintext.txt	58	With notable exceptions available evidence suggests fairly similar mutation rates genes 10 6 10 5 per gene per generation 3 7
0.14565748.12351581.html.plaintext.txt	59	For rare disease number individuals expanded population still small hence relative terms quickly swamped newly mutated alleles
0.14565748.12351581.html.plaintext.txt	60	In contrast population reservoir common disease gene large takes long time alleles taken new mutations
0.14565748.12351581.html.plaintext.txt	61	In addition face similar mutation rates lower prevalence rare diseases implies higher allele disappearance rate negative selection diseases common diseases
0.14565748.12351581.html.plaintext.txt	62	Both effects reservoir effect selection pressure imply population expansion allelic spectra became diverse much quickly rare diseases common
0.14565748.12351581.html.plaintext.txt	63	In long run however expected spectra rare common diseases become equally diverse Fig
0.14565748.12351581.html.plaintext.txt	64	Reich Lander estimate intermediate stage presently exists population rare diseases diverse allelic structure common disorders simple structure
0.14565748.12351581.html.plaintext.txt	65	A prediction theory rare disorders largely consist recent alleles whereas common disorders consist old ancestral alleles
0.14565748.12351581.html.plaintext.txt	66	View larger version 14K Figure 2
0.14565748.12351581.html.plaintext.txt	67	A A dramatic population expansion leads increased numbers individuals single allele rare 5 squares common 25 circles disease gene
0.14565748.12351581.html.plaintext.txt	68	Because rare disease gene strong negative selection three alleles disappear population replaced three new alleles
0.14565748.12351581.html.plaintext.txt	69	Thus 25 40 alleles represent ancestral allele
0.14565748.12351581.html.plaintext.txt	70	In contrast common disease gene much less strong negative selection one allele lost replaced three new alleles
0.14565748.12351581.html.plaintext.txt	71	The proportion ancestral alleles hence 2427 89
0.14565748.12351581.html.plaintext.txt	72	Consequently common disease gene much simpler allelic structure present population rare gene
0.14565748.12351581.html.plaintext.txt	73	B Graphical depiction A
0.14565748.12351581.html.plaintext.txt	74	The population expansion leads proportionate increases single allele common disease gene red rare disease gene blue
0.14565748.12351581.html.plaintext.txt	75	In present human population rapid loss alleles smaller population reservoir rare disease gene lead allelic spectrum gene becoming relatively much diverse common gene
0.14565748.12351581.html.plaintext.txt	76	However far distant future equilibrium common disease gene expected catch rare gene allelic spectra genes equally diverse
0.14565748.12351581.html.plaintext.txt	77	ALLELIC STRUCTURE OF SIMPLE DISEASES TOP ABSTRACT PROPERTIES OF ALLELIC SPACE INFERENCES FROM HUMAN POPULATION
0.14565748.12351581.html.plaintext.txt	78	LINKAGE DISEQUILIBRIUM THE FUTURE OF HUMAN
0.14565748.12351581.html.plaintext.txt	79	REFERENCES Since 1000 Mendelian monogenic disease genes identified understanding complexity considerable
0.14565748.12351581.html.plaintext.txt	80	In general rare diseases strong negative selection exhibit large allelic diversity 8
0.14565748.12351581.html.plaintext.txt	81	An exception pattern high allelic diversity rare disorders alleles also provide heterozygous advantage
0.14565748.12351581.html.plaintext.txt	82	One example provided thalassemias confer resistance malaria
0.14565748.12351581.html.plaintext.txt	83	Once arisen strong positive selective pressure conferred single alleles ensures relatively rapid spread population
0.14565748.12351581.html.plaintext.txt	84	Another exception high allelic diversity rare disorders occurs population bottleneck results greatly simplified spectra
0.14565748.12351581.html.plaintext.txt	85	For example among Finnish Ashkenazi Jewish populations numerous examples disease individual alleles show greatly elevated frequencies compared populations
0.14565748.12351581.html.plaintext.txt	86	Overall monogenic disorders good agreement theoretical predictions Reich Lander 2 available data
0.14565748.12351581.html.plaintext.txt	87	ALLELIC STRUCTURE OF COMPLEX DISEASES TOP ABSTRACT PROPERTIES OF ALLELIC SPACE INFERENCES FROM HUMAN POPULATION
0.14565748.12351581.html.plaintext.txt	88	LINKAGE DISEQUILIBRIUM THE FUTURE OF HUMAN
0.14565748.12351581.html.plaintext.txt	89	REFERENCES For common complex disorders relatively data diversity allelic spectra due difficulty identifying responsible genes
0.14565748.12351581.html.plaintext.txt	90	The known examples however tend support interaction model CDCV hypothesis since genes small number common disease associated alleles Table 1
0.14565748.12351581.html.plaintext.txt	91	With couple possible exceptions genesloci listed Table 1 confirmed multiple studies unlikely represent type 1 errors
0.14565748.12351581.html.plaintext.txt	92	It noted however listed genes may fully representative common disease genes since genes small number common alleles would easier identify association genes large number rare alleles
0.14565748.12351581.html.plaintext.txt	93	Three lines evidence supporting common diseasecommon variant hypothesis Another valid test CDCV hypothesis examine genetic complexity quantitative traits related common disease blood pressure body mass index plasma lipids
0.14565748.12351581.html.plaintext.txt	94	One well studied group phenotypes comprises levels compositions plasma lipoproteins strongly associated coronary heart disease
0.14565748.12351581.html.plaintext.txt	95	With exception mutations LDL receptor underlie familial hypercholesterolemia relatively common monogenic disorder known variations associated traits due small number common alleles Table 1
0.14565748.12351581.html.plaintext.txt	96	A corollary CDCV hypothesis individual carry susceptibility genes numerous disorders
0.14565748.12351581.html.plaintext.txt	97	This point difficult examine systematically humans although clearly older individuals frequently suffer host common maladies
0.14565748.12351581.html.plaintext.txt	98	A convincing example provided surveying inbred mouse strains differences disease related traits
0.14565748.12351581.html.plaintext.txt	99	Table 1 lists common diseases related traits differing two inbred strains DBA2J C57BL6J
0.14565748.12351581.html.plaintext.txt	100	Many traits analyzed genetic crosses two strains known due multiple quantitative trait loci QTL
0.14565748.12351581.html.plaintext.txt	101	One might argue since mice maintained continuous brother sister mating many generations numerous mutations fixed responsible trait differences
0.14565748.12351581.html.plaintext.txt	102	A counter argument however fact number loci observed DBA2JxC57BL6J cross also observed crosses strains cases loci syntenic human loci corresponding traits 9
0.14565748.12351581.html.plaintext.txt	103	Apart examples rapid fall disease rates relatives affected observed common diseases argues interaction model heterogeneity model
0.14565748.12351581.html.plaintext.txt	104	In addition many common diseases exhibit high ratio relative risk monozygotic twins dizygotic twins also consistent genetics multifactorial threshold model 210
0.14565748.12351581.html.plaintext.txt	105	For example common disease familial combined hyperlipidemia prevalence 1 2 exhibits apparent dominant mode inheritance many generations yet clearly complex 11
0.14565748.12351581.html.plaintext.txt	106	Furthermore inheritance cancers ways consistent heterogeneity model see
0.14565748.12351581.html.plaintext.txt	107	Other challenges CDCV hypothesis also area cancer presented breast cancer genes BRCA1 BRCA2 12
0.14565748.12351581.html.plaintext.txt	108	These loci contribute relatively common genetic disorder many different rare mutations even Ashkenazi population see
0.14565748.12351581.html.plaintext.txt	109	In addition even CDCV hypothesis true disease genes may dominated alleles large numbers minor alleles
0.14565748.12351581.html.plaintext.txt	110	In case cystic fibrosis 67 disease alleles Caucasian population accounted single mutation
0.14565748.12351581.html.plaintext.txt	111	Nevertheless total number known disease alleles exceeds 100 8
0.14565748.12351581.html.plaintext.txt	112	DO ALL COMMON DISEASES HAVE A SIMILAR ALLELIC STRUCTURE TOP ABSTRACT PROPERTIES OF ALLELIC SPACE INFERENCES FROM HUMAN POPULATION
0.14565748.12351581.html.plaintext.txt	113	LINKAGE DISEQUILIBRIUM THE FUTURE OF HUMAN
0.14565748.12351581.html.plaintext.txt	114	REFERENCES The general allelic architecture various diseases classes genes may differ depending biological mechanisms involved
0.14565748.12351581.html.plaintext.txt	115	Mitchison 13 made analogy mutations coding regions hardware mutations regulatory regions software
0.14565748.12351581.html.plaintext.txt	116	He divides genes extrovert concerned outside world e
0.14565748.12351581.html.plaintext.txt	117	immunoglobulins olfactory receptors numerous introvert genes concerned cellular homeostasis e
0.14565748.12351581.html.plaintext.txt	118	transcription signal transduction neurotransmission
0.14565748.12351581.html.plaintext.txt	119	Mitchison suggests extrovert genes hardware variation coding regions common introvert genes genetic variation mild effects occurs software regulatory regions
0.14565748.12351581.html.plaintext.txt	120	Many instances promoter variation software found pharmacogenomics psychiatry 14
0.14565748.12351581.html.plaintext.txt	121	One example provided 44 bp insertiondeletion polymorphism promoter region human serotonin transporter 5 HTT gene
0.14565748.12351581.html.plaintext.txt	122	This polymorphism associated affective illness anxiety related traits also alters 5 HTT gene expression since short promoter less active long promoter
0.14565748.12351581.html.plaintext.txt	123	Another example promoter polymorphism found 5 lipoxygenase 5 LO gene
0.14565748.12351581.html.plaintext.txt	124	This gene displays variations number GC rich Sp1 Egr 1 transcription factor binding sites influence promoter efficiency methylation 15
0.14565748.12351581.html.plaintext.txt	125	The resulting variations 5 LO levels may relevant inflammatory response asthma 16
0.14565748.12351581.html.plaintext.txt	126	It pertinent note whereas understanding kinds variations occur Mendelian diseases extensive knowledge variations explain common disease limited
0.14565748.12351581.html.plaintext.txt	127	Relevant transcriptional regulation one approach identification common disease gene candidates survey cases controls using expression array analysis
0.14565748.12351581.html.plaintext.txt	128	In regard noteworthy one third known common disease genes Table 1 affect expression levels 8
0.14565748.12351581.html.plaintext.txt	129	Interesting evidence inheritance cancers distinct common diseases provided Risch 10
0.14565748.12351581.html.plaintext.txt	130	With exceptions different cancers roughly familial relative risk FRR although FRR increases early age onset
0.14565748.12351581.html.plaintext.txt	131	Traditionally studies attribute large environmental component cancer
0.14565748.12351581.html.plaintext.txt	132	The relevant evidence includes observations dramatic shifts cancer incidence due population migrations
0.14565748.12351581.html.plaintext.txt	133	However careful evaluation twin family studies suggest genetics also plays large part cancer risk 10
0.14565748.12351581.html.plaintext.txt	134	A key quantity RMD FRR ratio monozygotic MZ dizygotic DZ twins
0.14565748.12351581.html.plaintext.txt	135	The idea MZ DZ twins comparable sharing environmental factors difference concordance rates MZ DZ twins must reflect genetic factors
0.14565748.12351581.html.plaintext.txt	136	For disease due single rare dominant gene RMD2 recessive rare gene RMD4 diminishes toward 2 allele common
0.14565748.12351581.html.plaintext.txt	137	For multiple loci RMD become large
0.14565748.12351581.html.plaintext.txt	138	For cancers RMD2 compared much higher ratios many complex diseases schizophrenia multiple sclerosis autism
0.14565748.12351581.html.plaintext.txt	139	These data consistent either rare dominant alleles additive gene effects cancer rather interactive multigenic model
0.14565748.12351581.html.plaintext.txt	140	LINKAGE DISEQUILIBRIUM TOP ABSTRACT PROPERTIES OF ALLELIC SPACE INFERENCES FROM HUMAN POPULATION
0.14565748.12351581.html.plaintext.txt	141	LINKAGE DISEQUILIBRIUM THE FUTURE OF HUMAN
0.14565748.12351581.html.plaintext.txt	142	REFERENCES Related CVCD hypothesis idea diagnostic costs reduced manageable levels using linkage disequilibrium
0.14565748.12351581.html.plaintext.txt	143	The idea great population expansion sufficiently recent large blocks haplotypes likely conserved genomes
0.14565748.12351581.html.plaintext.txt	144	If true would greatly reduce density single nucleotide polymorphisms SNPs required association studies expense genotyping
0.14565748.12351581.html.plaintext.txt	145	An implicit assumption approach common haplotypes responsible common diseases
0.14565748.12351581.html.plaintext.txt	146	Estimates extent LD obtained sampling various restricted genomic regions 17 well 51 autosomal regions spanning total 13 megabases 18
0.14565748.12351581.html.plaintext.txt	147	In addition somatic cell genetics used analyze LD entire chromosome 21 19
0.14565748.12351581.html.plaintext.txt	148	From LD sampling average distance useful LD preserved 50 60 kb
0.14565748.12351581.html.plaintext.txt	149	However considerable variability loci LD found far away 500 kb regions useful disequilibrium found
0.14565748.12351581.html.plaintext.txt	150	The chromosome 21 study found considerable linkage disequilibrium long blocks conserved haplotypes
0.14565748.12351581.html.plaintext.txt	151	Interestingly greater 80 haplotype structure could defined less 10 SNPs
0.14565748.12351581.html.plaintext.txt	152	Based studies appears extent linkage disequilibrium genome region population specific
0.14565748.12351581.html.plaintext.txt	153	The dark side linkage disequilibrium revealed recent study identify genes chromosome 5 involved Crohns disease 20
0.14565748.12351581.html.plaintext.txt	154	Although region linkage disequilibrium associated disease identified lack recombination events within relevant haplotype block precluded identification responsible gene
0.14565748.12351581.html.plaintext.txt	155	Thus although existence large haplotype blocks good news point view cheap diagnostics may hinder definitive identification responsible genes associated biological insights
0.14565748.12351581.html.plaintext.txt	156	In situation use alternate populations may come rescue allowing subdivision large regions linkage disequilibrium
0.14565748.12351581.html.plaintext.txt	157	For narcolepsy possible identify recombination event Japanese family broke haplotype block HLA region allowing finer mapping responsible gene 21
0.14565748.12351581.html.plaintext.txt	158	Alternatively scientists may rely animal models mouse ultimately identify causative gene
0.14565748.12351581.html.plaintext.txt	159	THE FUTURE OF HUMAN GENETICS TOP ABSTRACT PROPERTIES OF ALLELIC SPACE INFERENCES FROM HUMAN POPULATION
0.14565748.12351581.html.plaintext.txt	160	LINKAGE DISEQUILIBRIUM THE FUTURE OF HUMAN
0.14565748.12351581.html.plaintext.txt	161	REFERENCES Despite continued improvements genotyping speed power technologies unlimited
0.14565748.12351581.html.plaintext.txt	162	At present hopes focused exploiting structure human population realize dream individualized genotyping
0.14565748.12351581.html.plaintext.txt	163	This population structure results recent dramatic expansion theorized result simple allelic spectra common disease genes considerable linkage disequilibrium
0.14565748.12351581.html.plaintext.txt	164	There presently insufficient data know whether expectations realized although promising hints
0.14565748.12351581.html.plaintext.txt	165	Although particular alleles haplotypes may numerically rare population whole nevertheless likely individual harbor significant number variants
0.14565748.12351581.html.plaintext.txt	166	In addition estimates gene mutation rates imply individual three de novo gene mutations within genome
0.14565748.12351581.html.plaintext.txt	167	Thus even interaction model proves true loci personalized medicine still benefit individually tailored genotyping
0.14565748.12351581.html.plaintext.txt	168	The distinctions interaction genetic heterogeneity models restated using following question In human population would rather know rare severe genetic mutations e
0.14565748.12351581.html.plaintext.txt	169	nonsense frameshift non synonymous would rather know common variations With present limitations speed genotyping lack knowledge genetic causation common human disease best choice two alternatives unclear
0.14565748.12351581.html.plaintext.txt	170	Of course optimal situation would know answer questions
0.14565748.12351581.html.plaintext.txt	171	Thus need ever rapid genotyping sequencing technologies likely continue foreseeable future
0.14565748.12351581.html.plaintext.txt	172	ACKNOWLEDGEMENTS This work supported grants US NIH HL028481 HL030568 DA015802
0.14565748.12351581.html.plaintext.txt	173	FOOTNOTES To correspondence addressed Pharmacology UCLA School Medicine 23 120 CHS Box 951735 Los Angeles CA 90095 1735 USA
0.14565748.12351581.html.plaintext.txt	174	Tel 1 3102060086 Fax 1 3108256267
0.14565748.12351581.html.plaintext.txt	175	edu u d Correspondence may also addressed A
0.14565748.12351581.html.plaintext.txt	176	Lusis Microbiology Immunology Molecular Genetics UCLA 3730 MRL Box 951679 Los Angeles CA 90095 1679 USA
0.14565748.12351581.html.plaintext.txt	177	Tel 1 3108251359 Fax 1 3107947345
0.14565748.12351581.html.plaintext.txt	178	REFERENCES TOP ABSTRACT PROPERTIES OF ALLELIC SPACE INFERENCES FROM HUMAN POPULATION
0.14565748.12351581.html.plaintext.txt	179	LINKAGE DISEQUILIBRIUM THE FUTURE OF HUMAN
0.14565748.12351581.html.plaintext.txt	180	2000 Use population isolates mapping complex traits
0.14565748.12351581.html.plaintext.txt	181	2001 On allelic spectrum human disease
0.14565748.12351581.html.plaintext.txt	182	1995 Achondroplasia defined recurrent G380R mutations FGFR3
0.14565748.12351581.html.plaintext.txt	183	2000 The origins patterns implications human spontaneous mutation
0.14565748.12351581.html.plaintext.txt	184	1999 High genomic deleterious mutation rates hominids
0.14565748.12351581.html.plaintext.txt	185	2001 Deficient DNA mismatch repair common etiologic risk factor colon cancer
0.14565748.12351581.html.plaintext.txt	186	1998 Ionizing radiation genetic risks IX
0.14565748.12351581.html.plaintext.txt	187	Estimates frequencies mendelian diseases spontaneous mutation rates human populations 1998 perspective
0.14565748.12351581.html.plaintext.txt	188	8 Online Mendelian Inheritance Man
0.14565748.12351581.html.plaintext.txt	189	2001 The genetic epidemiology cancer interpreting family twin studies implications molecular genetic approaches
0.14565748.12351581.html.plaintext.txt	190	1999 A genome scan familial combined hyperlipidemia reveals evidence locus chromosome 11
0.14565748.12351581.html.plaintext.txt	191	1996 Ashkenazi Jewish population frequencies common mutations BRCA1 BRCA2
0.14565748.12351581.html.plaintext.txt	192	1997 Partitioning genetic variation regulatory coding gene segments predominance software variation genes encoding introvert proteins
0.14565748.12351581.html.plaintext.txt	193	2001 Functionally gene linked polymorphic regions genetically controlled neurotransmitters metabolism
0.14565748.12351581.html.plaintext.txt	194	2002 The 5 lipoxygenase promoter regulated DNA methylation
0.14565748.12351581.html.plaintext.txt	195	1999 Mutations human 5 lipoxygenase gene
0.14565748.12351581.html.plaintext.txt	196	2002 Hypertension genetics single nucleotide polymorphisms common disease common variant hypothesis
0.14565748.12351581.html.plaintext.txt	197	2002 The structure haplotype blocks human genome
0.14565748.12351581.html.plaintext.txt	198	2001 Blocks limited haplotype diversity revealed high resolution scanning human chromosome 21
0.14565748.12351581.html.plaintext.txt	199	2001 Genetic variation 5q31 cytokine gene cluster confers susceptibility Crohn disease
0.14565748.12351581.html.plaintext.txt	200	2000 Identification telomeric boundary HLA region potential predisposition human narcolepsy
0.14565748.12351581.html.plaintext.txt	201	2001 A frameshift mutation NOD2 associated susceptibility Crohns disease
0.14565748.12351581.html.plaintext.txt	202	2001 Association NOD2 leucine rich repeat variants susceptibility Crohns disease
0.14565748.12351581.html.plaintext.txt	203	1999 Low serum paraoxonase risk factor atherosclerotic disease Chem
0.14565748.12351581.html.plaintext.txt	204	1999 From genome aetiology multifactorial disease type 1 diabetes
0.14565748.12351581.html.plaintext.txt	205	2001 Challenges identifying genetic variation affecting susceptibility type 2 diabetes examples studies calpain 10 gene
0.14565748.12351581.html.plaintext.txt	206	2001 Calpains play role insulin secretion action
0.14565748.12351581.html.plaintext.txt	207	2002 Lipoprotein lipid metabolism
0.14565748.12351581.html.plaintext.txt	208	edsEmery Rimoins Principles Practice Medical Genetics 4th edn
0.14565748.12351581.html.plaintext.txt	209	Churchill Livingstone London pp
0.14565748.12351581.html.plaintext.txt	210	2001 An apolipoprotein influencing triglycerides humans mice revealed comparative sequencing
0.14565748.12351581.html.plaintext.txt	211	1998 Human serum paraoxonase
0.1154272.14871886.html.plaintext.txt	0	Reductions circulating anabolic hormones induced sustained sleep deprivation rats Carol A
0.1154272.14871886.html.plaintext.txt	1	1Department Neurology The Medical College Wisconsin Milwaukee Wisconsin 53226 2Department Pharmacology Toxicology University Utah Health Sciences Center Salt Lake City Utah 84112
0.1154272.14871886.html.plaintext.txt	2	Submitted 5 December 2003 accepted final form 2 February 2004
0.1154272.14871886.html.plaintext.txt	3	ABSTRACT TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES The main systemic disorders resulting prolonged sleep deprivation laboratory animals negative energy balance low circulating thyroid hormones host defense impairments
0.1154272.14871886.html.plaintext.txt	4	Low thyroid hormones previously found caused altered regulation level hypothalamus possible pituitary involvement
0.1154272.14871886.html.plaintext.txt	5	The present studies investigated effects sleep deprivation major anabolic hormonal systems
0.1154272.14871886.html.plaintext.txt	6	Plasma growth hormone GH concentrations major secretory bursts characterized
0.1154272.14871886.html.plaintext.txt	7	Insulin like growth factor I IGF I evaluated integrative marker peripheral GH effector activity
0.1154272.14871886.html.plaintext.txt	8	Prolactin PRL assessed basal concentrations stimulating pituitary exogenous thyrotropin releasing hormone
0.1154272.14871886.html.plaintext.txt	9	Leptin studied linkage metabolic signs sleep loss correspondence altered neuroendocrine regulation disease states
0.1154272.14871886.html.plaintext.txt	10	Last plasma corticosterone measured investigate degree hypothalamic pituitary adrenal activation
0.1154272.14871886.html.plaintext.txt	11	Sleep deprivation produced disk water method well established means selective deprivation sleep noninterference normal waking behaviors
0.1154272.14871886.html.plaintext.txt	12	Hormone concentrations determined sham comparisons intervals baseline experimental periods lasting least 15 days partially totally sleep deprived rats
0.1154272.14871886.html.plaintext.txt	13	The results indicate high amplitude pulses GH nearly abolished concentrations GH IGF I PRL leptin suppressed sleep deprivation
0.1154272.14871886.html.plaintext.txt	14	Corticosterone concentration relatively unaffected
0.1154272.14871886.html.plaintext.txt	15	Features results low GH low IGF I indicate failed negative feedback point hypothalamic mechanisms containing foci responsible peripheral signs
0.1154272.14871886.html.plaintext.txt	16	growth hormone thyroxine prolactin insulin like growth factor I leptin corticosterone
0.1154272.14871886.html.plaintext.txt	17	SLEEP IS CONSIDERED CRITICAL maintenance health 2 14 49b 77a support life 18 35 54
0.1154272.14871886.html.plaintext.txt	18	Some clinical states associated abnormal sleep include pulmonary cardiovascular disorders cerebrovascular disease thrombotic disease epilepsy arthritis mood disorders chronic pain shortened life span reviewed Refs
0.1154272.14871886.html.plaintext.txt	19	The physical consequences sleep deprivation localized
0.1154272.14871886.html.plaintext.txt	20	Evidence studies laboratory animals suggest multitropic factors immune hormonal systems contribute absence localization
0.1154272.14871886.html.plaintext.txt	21	The three principal consequences prolonged sleep deprivation rat progressively deepening negative energy balance 8 18 23 reduced thyroid hormone concentrations 8 19 20 abnormal control microorganisms 22
0.1154272.14871886.html.plaintext.txt	22	Sleep deprived rats become strikingly progressively hyperphagic gain weight
0.1154272.14871886.html.plaintext.txt	23	The negative energy balance due malabsorption calories 8 diabetes 18 may metabolic response infectious processes
0.1154272.14871886.html.plaintext.txt	24	Abnormal control microorganisms discovered detection live pathogenic bacteria normally sterile body tissues 16 22
0.1154272.14871886.html.plaintext.txt	25	This deficiency host defense system earliest clinically biologically significant sign far discovered occurring within five experimental days outward appearance animal healthy metabolic changes marked later become
0.1154272.14871886.html.plaintext.txt	26	The third principal feature hypothyroxinemia manifested progressive decline thyroxine T4 triiodothyronine T3 T4 eventually reaching levels assay detection cases 20
0.1154272.14871886.html.plaintext.txt	27	After average 3 wk signs result advanced morbidity scrawny feeble appearance decreased food intake peak consumption hypothermia 8 18 primary bacteremia poor absent inflammatory responses 16 subsequent lethality 53
0.1154272.14871886.html.plaintext.txt	28	Recent findings alterations thyroid hormones sleep deprived rats point brain essential site sleep deprivation effects
0.1154272.14871886.html.plaintext.txt	29	A progressive decline plasma T4 sleep deprived rats accompanied increase plasma thyroid stimulating hormone TSH whereas low plasma T4 normally potent stimulant pituitary TSH secretion 71
0.1154272.14871886.html.plaintext.txt	30	Challenge tests TSH release pituitary exogenous administration hypothalamic peptide thyrotropin releasing hormone TRH revealed normal stimulated release TSH appropriate increase circulating T4 T3 20
0.1154272.14871886.html.plaintext.txt	31	Examination paraventricular nucleus PVN hypothalamus revealed eventual tripling TRH transcript levels experimental animals suggesting compensatory response low T4 presumably increased negative feedback hypothalamus
0.1154272.14871886.html.plaintext.txt	32	Even TSH failed respond increased TRH biosynthesis 19
0.1154272.14871886.html.plaintext.txt	33	These data suggest TRH stimulation TSH inhibited one locus sleep deprivations effects TRH translation release hypothalamus
0.1154272.14871886.html.plaintext.txt	34	Relatively little known regarding neuroendocrine consequences sustained sleep deprivation whether broad pituitary hypothalamic involvement
0.1154272.14871886.html.plaintext.txt	35	One objectives present series experiments determine whether chronic sleep deprivation also affects secretion growth hormone GH prolactin PRL
0.1154272.14871886.html.plaintext.txt	36	Alteration pleiotropic functions could provide future avenues discovery sleep deprivation specifically results health consequences
0.1154272.14871886.html.plaintext.txt	37	Linkage GH PRL secretion non rapid eye movement NREM sleep repeatedly demonstrated humans
0.1154272.14871886.html.plaintext.txt	38	Plasma peak GH concentration generally coincides sleep onset delayed sleep delayed
0.1154272.14871886.html.plaintext.txt	39	Smaller GH peaks generally coincide subsequent slow wave sleep phases 52 56 64 73
0.1154272.14871886.html.plaintext.txt	40	PRL concentrations elevated sleep even sleep delayed 74
0.1154272.14871886.html.plaintext.txt	41	Short term sleep deprivation 24 36 h blunts amplitude major GH secretory periods time 10 11 whereas sleep sleep deprivation associated return normal amplitudes 11 59 73
0.1154272.14871886.html.plaintext.txt	42	Similarly GH pulses rats abolished short term sleep deprivation 3 h 34
0.1154272.14871886.html.plaintext.txt	43	Whether abolishment would persist beyond 3 h whether acute reaction unknown
0.1154272.14871886.html.plaintext.txt	44	The proximal hypothalamic mechanisms regulating GH secretion pituitary growth hormone releasing hormone GHRH somatostatin somatotropin release inhibiting factor SRIF operate reciprocal manner
0.1154272.14871886.html.plaintext.txt	45	Previous studies shown short term sleep deprivation 6 8 h reduce content GHRH hypothalamus 26 result increased GHRH mRNA PVN increased SRIF mRNA arcuate nucleus hypothalamus 69
0.1154272.14871886.html.plaintext.txt	46	Whether changes important hypophysioportal stimulation GH secretion unknown whereas hypotheses exist role regulation sleep behavior 26
0.1154272.14871886.html.plaintext.txt	47	Furthermore GHRH binding receptor mRNA levels decreased 50 hypothalamus rats sleep deprived 8 h whereas pituitary levels remain unchanged
0.1154272.14871886.html.plaintext.txt	48	These latter findings interpreted indicating downregulation receptors response GHRH release 27
0.1154272.14871886.html.plaintext.txt	49	In addition role lactation PRL major anabolic hormone cytokine 5
0.1154272.14871886.html.plaintext.txt	50	Short term sleep deprivation sleep fragmentation humans associated lower nocturnal PRL levels sleep occurs 74 77
0.1154272.14871886.html.plaintext.txt	51	PRL considered sleep promoting laboratory animals 50 80 reduced 24 72 h 48 h sleep deprivation combined
0.1154272.14871886.html.plaintext.txt	52	confounded constant forced locomotion 33
0.1154272.14871886.html.plaintext.txt	53	Deficiency PRL results grossly reduced immunocompetency laboratory animals 49 sleep deprived rats share resemblance
0.1154272.14871886.html.plaintext.txt	54	It also unknown present whether sustained sleep deprivation affects secretion adipocyte derived hormone leptin acts hypothalamus
0.1154272.14871886.html.plaintext.txt	55	Leptin endocrine actions pleiotropic effects include major role regulation energy balance reviewed Refs
0.1154272.14871886.html.plaintext.txt	56	Several lines evidence suggest link hormone different pathophysiological changes resulting sleep deprivation
0.1154272.14871886.html.plaintext.txt	57	For example decreased leptin concentrations occur decreased fat reserve impairments immunity reviewed Ref
0.1154272.14871886.html.plaintext.txt	58	25 consequences sleep deprivation
0.1154272.14871886.html.plaintext.txt	59	On hand increases leptin secretion associated increased sympathetic activation 58 elevated metabolic rate 45 decreased body weight 12 also produced prolonged sleep deprivation reviewed Ref
0.1154272.14871886.html.plaintext.txt	60	Leptin also increases response exposure bacterial cell components reviewed Ref
0.1154272.14871886.html.plaintext.txt	61	30 would expected event resulting bacterial translocation efforts control posttranslocation survival sleep deprived animals 22
0.1154272.14871886.html.plaintext.txt	62	In humans substantially reduced leptin concentrations found narcoleptic patients abnormal sleep architecture 36 60 mildly reduced leptin concentrations found normal subjects conditions acute sleep reduction 62
0.1154272.14871886.html.plaintext.txt	63	The objective present studies determine whether chronic sleep deprivation changes regulation GH PRL leptin nature alterations
0.1154272.14871886.html.plaintext.txt	64	The effects sleep deprivation determined concentrations insulin like growth factor I IGF I principal physiological mediator many GH actions concentrations corticosterone high levels associated endocrine abnormalities disease states reviewed Ref
0.1154272.14871886.html.plaintext.txt	65	To end employed well established procedure producing sleep deprivation 9 examined effects hormonal secretory patterns intervals first two thirds typical survival period rats times advanced morbidity
0.1154272.14871886.html.plaintext.txt	66	The present results indicate abnormally low concentrations GH IGF I PRL leptin appropriately increased PRL release stimulated
0.1154272.14871886.html.plaintext.txt	67	These results provide evidence altered hormonal regulation level hypothalamus implicate suppression anabolic hormones among important health consequences sleep deprivation
0.1154272.14871886.html.plaintext.txt	68	MATERIALS AND METHODS TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES Animals surgical procedures
0.1154272.14871886.html.plaintext.txt	69	All procedures carried accordance National Institutes Health guidelines care use animals approved animal study protocol
0.1154272.14871886.html.plaintext.txt	70	Normal male Sprague Dawley rats aged 25 plus minus 2 SD wk weighing 559 plus minus 130 SD g time surgery obtained Harlan Laboratories Frederick MD Indianapolis IN
0.1154272.14871886.html.plaintext.txt	71	All surgical procedures including catheter insertions performed single episode anesthesia avoid confounding effects anesthesia surgery sleep deprivation period
0.1154272.14871886.html.plaintext.txt	72	Rats anesthetized ketamine hydrochloride 100 mgkg ip xylazine hydrochloride 2
0.1154272.14871886.html.plaintext.txt	73	4 mgkg im atropine sulfate 0
0.1154272.14871886.html.plaintext.txt	74	Supplementary doses ketamine hydrochloride 10 mgkg ip provided needed
0.1154272.14871886.html.plaintext.txt	75	Surgery included implantation cortical EEG muscle electrodes electrophysiographic determination sleep stages wakefulness described previously 9
0.1154272.14871886.html.plaintext.txt	76	To enable repeated sampling blood freely moving animals venous catheter inserted external jugular advanced right atrium described previously 9 20 23
0.1154272.14871886.html.plaintext.txt	77	The catheter sutured neck muscles threaded subcutaneously exit scalp back head anchored electrode head plug assembly
0.1154272.14871886.html.plaintext.txt	78	Catheter tubing extended along 45 cm EEG recording cable attached swivel commutator counterbalanced boom assembly permitted daily blood sampling without handling animal
0.1154272.14871886.html.plaintext.txt	79	Catheters flushed daily heparinized saline containing small amount ampicillin 1
0.1154272.14871886.html.plaintext.txt	80	Beginning 4 days surgery 75 units streptokinase 150 microl heparinized saline infused 1 mlmin fill catheter lumen procedures reduce occurrence fibrin clot blockages
0.1154272.14871886.html.plaintext.txt	81	Rats permitted least 7 days recovery surgery study
0.1154272.14871886.html.plaintext.txt	82	The rats sleep deprived serve yoked comparison housed apparatus described
0.1154272.14871886.html.plaintext.txt	83	After week allotted recovery rats fed ad libitum balanced purified diet isocaloric normal augmented protein 40
0.1154272.14871886.html.plaintext.txt	84	3 minerals fiber vitamins 3
0.1154272.14871886.html.plaintext.txt	85	8 calg metabolizable energy used previous studies comparison 19 20 23
0.1154272.14871886.html.plaintext.txt	86	Food water intake body weight recorded daily
0.1154272.14871886.html.plaintext.txt	87	Special food tubes waste receptacle afforded accurate measurement food consumption 9
0.1154272.14871886.html.plaintext.txt	88	Ambient light constant diminish influence circadian rhythm factors study 15
0.1154272.14871886.html.plaintext.txt	89	Ambient temperature kept constant 28 degrees C within thermoneutral zone rats 63 means thermostatically controlled heat lamps
0.1154272.14871886.html.plaintext.txt	90	Procedure producing sleep deprivation yoked controls
0.1154272.14871886.html.plaintext.txt	91	The experimental apparatus procedures used present experiments Bergmann Rechtschaffen method 9 subsequent minor modifications
0.1154272.14871886.html.plaintext.txt	92	The method validated selectivity sleep deprivation 8 9 18 23 53 features benign arousal stimulus freedom movement comparison conditions partial full sleep opportunities described detail illustrated elsewhere 9 23
0.1154272.14871886.html.plaintext.txt	93	Briefly two animals housed identical experimental conditions either side large round platform 46 cm diameter divided Plexiglas wall
0.1154272.14871886.html.plaintext.txt	94	One rat designated sleep deprivation rat designated yoked animal subjected experimental variables yet allowed opportunities sleep
0.1154272.14871886.html.plaintext.txt	95	Beneath around platform shallow water serves soft boundary
0.1154272.14871886.html.plaintext.txt	96	The rats almost always avoid water stay platform eat sleep explore normally
0.1154272.14871886.html.plaintext.txt	97	Recording EEG variables rats freely moving conditions accomplished connecting long recording cable attached head electrode assembly 360 degrees commutator counterbalanced boom assembly
0.1154272.14871886.html.plaintext.txt	98	During 7 day period basal measurements platform rotated one time per hour 6 acquaint rats platform movement
0.1154272.14871886.html.plaintext.txt	99	The method produces consistent amount sleep reduction studies 16 18 21 23
0.1154272.14871886.html.plaintext.txt	100	Under baseline conditions sleep occurs average 53 time
0.1154272.14871886.html.plaintext.txt	101	The sleep comprises 48 NREM sleep comparable human stages 1 4 6 paradoxical sleep PS also known rapid eye movement sleep
0.1154272.14871886.html.plaintext.txt	102	After baseline period experimental period begins
0.1154272.14871886.html.plaintext.txt	103	Detection sleep onset sleep deprived rat programmed microprocessing amplitude changes cortical EEG cortical theta electromyographic variables results 6 forced locomotion rats sufficient produce arousal
0.1154272.14871886.html.plaintext.txt	104	This repeated upon subsequent sleep onset sleep deprived rat resulting wakefulness sustained 90 total time
0.1154272.14871886.html.plaintext.txt	105	The 10 time consists mostly transitional sleep fragmented high amplitude NREM sleep
0.1154272.14871886.html.plaintext.txt	106	PS comprises 1 total time
0.1154272.14871886.html.plaintext.txt	107	The yoked rat may sleep platform stationery sleep deprived rat engaged behaviors trying sleep
0.1154272.14871886.html.plaintext.txt	108	Yoked animals awake 58 time obtain NREM PS sleep 38 3 total time respectively
0.1154272.14871886.html.plaintext.txt	109	Each yoked animal frequently awakened asleep sleep normally occupies 50 time yoked rat paired sleep deprived rat may fall asleep thus triggering platform rotation
0.1154272.14871886.html.plaintext.txt	110	Yoked rats therefore partially sleep deprived usually exhibit several signs direction sleep deprived rats degree e
0.1154272.14871886.html.plaintext.txt	111	The yoked animals considered important showing severe morbidity death sleep deprived rats due experimental conditions extraneous sleep loss matched groups 54
0.1154272.14871886.html.plaintext.txt	112	In addition yoked rats viewed comprising part dose response curve wherein partial sleep deprivation intermediate sleep loss total sleep loss
0.1154272.14871886.html.plaintext.txt	113	Eight sets experiments one pair sleep deprived yoked rats carried determination plasma IGF I leptin corticosterone changes food intake body weight
0.1154272.14871886.html.plaintext.txt	114	In subset four experiments serial blood sampling protocols followed determination basal stimulated PRL secretion characteristics pulsatile GH secretion
0.1154272.14871886.html.plaintext.txt	115	The duration experiment 4 6 wk period included least 7 days recovery surgery 7 days baseline conditions 15 experimental days
0.1154272.14871886.html.plaintext.txt	116	In addition operated animals intended serve back animals apparatus postsurgery recovery period catheter become nonpatent one first two rats
0.1154272.14871886.html.plaintext.txt	117	Five animals used purpose continued study home cage animals determinations plasma IGF I leptin corticosteroids changes food intake body weight
0.1154272.14871886.html.plaintext.txt	118	The home cage control animals subjected daily procedures rats housed apparatus except housed cylindrical cages 30 cm OD 30 cm high permitted uninterrupted sleep
0.1154272.14871886.html.plaintext.txt	119	General procedure sampling blood measurement blood hormone concentrations
0.1154272.14871886.html.plaintext.txt	120	Blood specimens collected starting time day according rotating schedule permitted determination factors study intervals across baseline experimental periods
0.1154272.14871886.html.plaintext.txt	121	IGF I leptin corticosterone determined one times consecutive 4 day interval experimental period whereas pulsatile GH basal stimulated PRL release determined weekly
0.1154272.14871886.html.plaintext.txt	122	Briefly small amount blood aspirated clear catheter clots initial 100 units heparin 0
0.1154272.14871886.html.plaintext.txt	123	15 ml heparin whole blood withdrawn discarded
0.1154272.14871886.html.plaintext.txt	124	A blood sample drawn placed microcentrifuge tube ice
0.1154272.14871886.html.plaintext.txt	125	The volume drawn replaced equivalent volume heparinized saline injected catheter minimize hypovolemia
0.1154272.14871886.html.plaintext.txt	126	Specimens centrifuged cold 8000 g 10 min plasma pipetted chilled microcentrifuge tubes subsequent storage 80 degrees C
0.1154272.14871886.html.plaintext.txt	127	To help prevent anemia red blood cells RBCs resuspended heparinized saline injected catheter flushed heparinized saline
0.1154272.14871886.html.plaintext.txt	128	This general protocol applied plasma samples stored determination IGF I leptin corticosterone elaborated protocols described
0.1154272.14871886.html.plaintext.txt	129	Determination major GH secretory periods
0.1154272.14871886.html.plaintext.txt	130	Basal pulsatile GH assessed subset four sleep deprived yoked pairs means blood collection animal every 20 min across 6 h period 57 65
0.1154272.14871886.html.plaintext.txt	131	Previous studies determined GH secretory pattern affected constant illumination 65
0.1154272.14871886.html.plaintext.txt	132	The protocol determination GH secretory pulses sleep deprived yoked rat conducted one time 7 day baseline period 6 7 day intervals experimental period
0.1154272.14871886.html.plaintext.txt	133	The total amount blood drawn rat 0
0.1154272.14871886.html.plaintext.txt	134	7 mlh volume RBC replacement given throughout 6 h period
0.1154272.14871886.html.plaintext.txt	135	Blood collected day sampling GH secretory episodes
0.1154272.14871886.html.plaintext.txt	136	Determinations basal PRL secretory periods stimulated PRL release
0.1154272.14871886.html.plaintext.txt	137	PRL secretion exhibits low amplitude pulsatility 40 42 therefore measurements integrated time better reflect basal PRL secretion singular determinations
0.1154272.14871886.html.plaintext.txt	138	Blood sampled six times 10 min intervals 50 min period based data Lopez et al
0.1154272.14871886.html.plaintext.txt	139	40 PRL pulse lasts 16 25 min would expected occur every 40 min
0.1154272.14871886.html.plaintext.txt	140	The protocol conducted subset experiments major GH secretory periods determined different days baseline period one time per week experimental period
0.1154272.14871886.html.plaintext.txt	141	The total volume blood drawn protocol 1
0.1154272.14871886.html.plaintext.txt	142	8 ml volume RBC replacement
0.1154272.14871886.html.plaintext.txt	143	PRL challenge tests intravenous TRH bolus injection completed one time baseline period one time per week experimental period experimental subgroup
0.1154272.14871886.html.plaintext.txt	144	Blood sampled immediately 10 20 40 min intravenous administration TRH 10 microgkg based previous studies 40 48
0.1154272.14871886.html.plaintext.txt	145	The total volume blood drawn 2
0.1154272.14871886.html.plaintext.txt	146	1 ml volume RBC replacement
0.1154272.14871886.html.plaintext.txt	147	GH PRL antisera reference hormone provided Dr
0.1154272.14871886.html.plaintext.txt	148	Parlow National Hormone Pituitary Program National Institute Diabetes Digestive Kidney Diseases
0.1154272.14871886.html.plaintext.txt	149	The low detection limit GH assay 2
0.1154272.14871886.html.plaintext.txt	150	4 pgml high detection limit 466 583 pgml
0.1154272.14871886.html.plaintext.txt	151	The low high sensitivities PRL 0
0.1154272.14871886.html.plaintext.txt	152	The intra assay coefficients variation CVs GH PRL 10
0.1154272.14871886.html.plaintext.txt	153	Determinations basal plasma IGF I leptin corticosteroids performed using commercial RIA enzyme immunoassay kits
0.1154272.14871886.html.plaintext.txt	154	The sensitivity range IGF I 127 4714 ngml Diagnostic Systems Laboratories Webster TX
0.1154272.14871886.html.plaintext.txt	155	The intra interassay CVs 4
0.1154272.14871886.html.plaintext.txt	156	The low high detection limits leptin 0
0.1154272.14871886.html.plaintext.txt	157	5 50 ngml Linco Research St
0.1154272.14871886.html.plaintext.txt	158	Charles MO intra interassay CVs 4 6 respectively
0.1154272.14871886.html.plaintext.txt	159	The low high detection limits corticosterone 20 2000 ngml Diagnostic Systems Laboratories intra interassay CVs 5 6 respectively
0.1154272.14871886.html.plaintext.txt	160	Determinations made duplicate
0.1154272.14871886.html.plaintext.txt	161	Values fell range assay detection set equal lower upper limit sensitivity respectively
0.1154272.14871886.html.plaintext.txt	162	Apart baseline period data rat experimental period truncated 16 days experimental conditions continued longer
0.1154272.14871886.html.plaintext.txt	163	This permitted values IGF I leptin corticosterone food intake changes body weight partitioned four consecutive 4 day intervals
0.1154272.14871886.html.plaintext.txt	164	The data averaged across 4 day interval rat averaged within intervals experimental group
0.1154272.14871886.html.plaintext.txt	165	These data compared means unbalanced two way repeated measures ANOVA
0.1154272.14871886.html.plaintext.txt	166	One yoked subject eliminated study electrode assembly became detached skull resulting imbalance number subjects per group
0.1154272.14871886.html.plaintext.txt	167	Occasionally missing values within subject across time typically result indwelling catheter nonpatency day blood collection particular factor insufficient specimen volume analysis
0.1154272.14871886.html.plaintext.txt	168	Missing values given 4 day bin replaced interpolation extrapolation isolated instances
0.1154272.14871886.html.plaintext.txt	169	Interpolations extrapolations limited two 1 yoked 1 home cage data points leptin IGF I one data point corticosterone
0.1154272.14871886.html.plaintext.txt	170	Subject values excluded toto given analysis two 4 day values missing
0.1154272.14871886.html.plaintext.txt	171	Exclusions included one yoked rat determination leptin IGF I one sleep deprived rat determination food intake one animal sleep deprived yoked home cage groups analysis corticosterone
0.1154272.14871886.html.plaintext.txt	172	For analyses statistical significance considered P 0
0.1154272.14871886.html.plaintext.txt	173	Post hoc comparisons performed means Students tests
0.1154272.14871886.html.plaintext.txt	174	Such comparisons included analysis changes group particular time points baseline specific 4 day interval groups particular time point
0.1154272.14871886.html.plaintext.txt	175	Paired tests used possible comparison unpaired means performed occasions data could paired exclusion subject
0.1154272.14871886.html.plaintext.txt	176	Nonsignificant statistical differences designated significant
0.1154272.14871886.html.plaintext.txt	177	Variance given mean plus minus SE unless specifically noted mean plus minus SD
0.1154272.14871886.html.plaintext.txt	178	Characteristics GH pulsatile secretion analyzed ULTRA statistical algorithm separate small peaks background variation according guidelines described Van Cauter 72
0.1154272.14871886.html.plaintext.txt	179	In ULTRA CV assay used determine whether increments decrements chronological data points within range expected variation
0.1154272.14871886.html.plaintext.txt	180	The number CVs used determines threshold significant change typically two three CVs applied 72
0.1154272.14871886.html.plaintext.txt	181	In way increments decrements hormonal concentration may considered part pulse values criterion threshold assay variability thus limiting false positive pulses
0.1154272.14871886.html.plaintext.txt	182	In analysis used three times CV radioactive counts per minute ranged 4
0.1154272.14871886.html.plaintext.txt	183	8 constant algorithm signifying significant change previous subsequent values across values within particular assay
0.1154272.14871886.html.plaintext.txt	184	Characterization GH PRL secretion based following parameters given Lafuente et al
0.1154272.14871886.html.plaintext.txt	185	40 1 minimum maximum values observed 2 integrative value average value samples collected period observation 3 absolute amplitude difference concentration peak minimum values 4 relative amplitude ratio absolute amplitude minimum value
0.1154272.14871886.html.plaintext.txt	186	Pulses GH detected ULTRA additionally assessed frequency instances two peaks captured 6 h sampling period
0.1154272.14871886.html.plaintext.txt	187	Parameters characterizing PRL GH concentrations compared priori Students test P 0
0.1154272.14871886.html.plaintext.txt	188	05 considered statistically significant
0.1154272.14871886.html.plaintext.txt	189	RESULTS TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES Physiological variables
0.1154272.14871886.html.plaintext.txt	190	Sleep deprived rats became hyperphagic Fig
0.1154272.14871886.html.plaintext.txt	191	1A eventually consuming nearly two times basal amounts food group sleep deprived vs
0.1154272.14871886.html.plaintext.txt	192	05 group x time sleep deprived vs
0.1154272.14871886.html.plaintext.txt	193	Yoked animals also exhibited increased food consumption time 40 50 group x time interaction yoked vs
0.1154272.14871886.html.plaintext.txt	194	home cage control F330 8
0.1154272.14871886.html.plaintext.txt	195	Despite increased food intake sleep deprived rats showed evidence weight loss relative yoked rats group x time F339 6
0.1154272.14871886.html.plaintext.txt	196	01 especially home cage controls F333 44
0.1154272.14871886.html.plaintext.txt	197	01 latter gained weight without increase food intake Fig
0.1154272.14871886.html.plaintext.txt	198	Body weight losses 2 5 sleep deprived rats first 8 days observation eventually body weight dropped 10 days 13 16
0.1154272.14871886.html.plaintext.txt	199	View larger version 18K Fig
0.1154272.14871886.html.plaintext.txt	200	Mean percentage change means plus minus SE individual baseline values food intake A body weight B sleep deprived food intake n 7 body weight n 8 yoked n 7 operated home cage control n 5 rats 4 day intervals experimental period
0.1154272.14871886.html.plaintext.txt	201	Basal GH IGF I concentrations
0.1154272.14871886.html.plaintext.txt	202	Basal GH secretion determined analysis blood specimens collected every 20 min 6 h periods four sleep deprived four yoked animals baseline four sleep deprived three yoked animals days 4 6 four sleep deprived two yoked animals days 11 14 experimental period
0.1154272.14871886.html.plaintext.txt	203	The different group numbers reflect varying success maintaining catheter patency 30 days surgery
0.1154272.14871886.html.plaintext.txt	204	Only 5 399 data points comprising secretory GH profiles analyzed missing values replaced interpolation
0.1154272.14871886.html.plaintext.txt	205	Analysis GH secretory periods revealed near abolishment major GH peaks sleep deprived rats
0.1154272.14871886.html.plaintext.txt	206	Representative profiles GH secretory periods baseline experimental period shown yoked rat sleep deprived rat Fig
0.1154272.14871886.html.plaintext.txt	207	During baseline period high amplitude GH peaks
0.1154272.14871886.html.plaintext.txt	208	300 ngml 50 maximal values measured detected eight animals occasional intermediate peaks
0.1154272.14871886.html.plaintext.txt	209	150 300 ngml additionally detected animals
0.1154272.14871886.html.plaintext.txt	210	Of pulses detected baseline 60 considered large pulses 300 ngml 8 considered intermediate 32 considered small 150 ngml
0.1154272.14871886.html.plaintext.txt	211	During experimental period sleep deprived rats high amplitude pulses one intermediate amplitude pulse single individual observed
0.1154272.14871886.html.plaintext.txt	212	The remaining 94 pulses considered small
0.1154272.14871886.html.plaintext.txt	213	In contrast large pulses continued observed yoked subjects time point comprised 52 pulses
0.1154272.14871886.html.plaintext.txt	214	Overall frequency pulses determined using ULTRA regardless amplitude appreciably different among conditions
0.1154272.14871886.html.plaintext.txt	215	Per 6 h period study 3
0.1154272.14871886.html.plaintext.txt	216	6 SD pulses baseline conditions compared 3
0.1154272.14871886.html.plaintext.txt	217	View larger version 17K Fig
0.1154272.14871886.html.plaintext.txt	218	Pulsatile growth hormone GH concentrations representative cases yoked animal sleep deprived animal paired together experimental conditions baseline period weeks 1 2 experimental period
0.1154272.14871886.html.plaintext.txt	219	Data truncated 6 4 h purposes illustration show peak concentrations
0.1154272.14871886.html.plaintext.txt	220	Major GH secretory periods abolished rats totally sleep deprived
0.1154272.14871886.html.plaintext.txt	221	Four eight animals displayed one high amplitude GH pulse 6 h time frame blood sampling baseline conditions sleep deprivation thus allowed calculation frequency major GH secretory episodes animals
0.1154272.14871886.html.plaintext.txt	222	During baseline peak peak interpulse interval high amplitude GH episodes five animals 3
0.1154272.14871886.html.plaintext.txt	223	2 SD h n 4 experimental period yoked animals 3
0.1154272.14871886.html.plaintext.txt	224	7 SD h n 2 considered equivalent previous investigations animal models 57 65
0.1154272.14871886.html.plaintext.txt	225	A comparison could made sleep deprived animals high amplitude pulses uniformly abolished experimental period
0.1154272.14871886.html.plaintext.txt	226	The average GH value determinations 6 h sampling period integrative measurement GH secretion Fig
0.1154272.14871886.html.plaintext.txt	227	Sleep deprived animals displayed significant decrease GH concentration experimental period compared baseline period week 1 paired t3 12
0.1154272.14871886.html.plaintext.txt	228	005 compared yoked animals week 1 unpaired t5 9
0.1154272.14871886.html.plaintext.txt	229	The decrease baseline GH concentrations week 1 71 sleep deprived animals 38 yoked animals yoked animals statistically different baseline
0.1154272.14871886.html.plaintext.txt	230	View larger version 43K Fig
0.1154272.14871886.html.plaintext.txt	231	Integrative GH concentration expressed average value GH determined 19 consecutive blood samples collected 6 h sampling period means plus minus SE baseline experimental conditions sleep deprived rats n 4 bar yoked rats n 4 baseline n 3 week 1 n 2 week 2
0.1154272.14871886.html.plaintext.txt	232	Comparisons statistically significant baseline weeks 1 2 sleep deprived rats sleep deprived rats yoked rats weeks 1 2
0.1154272.14871886.html.plaintext.txt	233	The significant decrease plasma IGF I concentrations sleep deprived rats shown Fig
0.1154272.14871886.html.plaintext.txt	234	4 consistent absence high amplitude pulses overall suppression GH concentration
0.1154272.14871886.html.plaintext.txt	235	The concentrations plasma IGF I significantly lower sleep deprived rats compared yoked rats F111 15
0.1154272.14871886.html.plaintext.txt	236	01 home cage rats F111 32
0.1154272.14871886.html.plaintext.txt	237	Yoked animals group show suppression IGF I time except insofar IGF I concentrations elevated home cage animals percent change baseline yoked vs
0.1154272.14871886.html.plaintext.txt	238	01 sleep permitted ad libitum positive correlation IGF I concentration body weight r 0
0.1154272.14871886.html.plaintext.txt	239	View larger version 18K Fig
0.1154272.14871886.html.plaintext.txt	240	Change plasma IGF I expressed percent change individual values grouped baseline means plus minus SE sleep deprived n 8 yoked n 6 operated home cage n 5 rats baseline consecutive 4 day intervals experimental period
0.1154272.14871886.html.plaintext.txt	241	Group differences sleep deprived yoked sleep deprived home cage yoked home cage statistically significant 2 way repeated measures ANOVA
0.1154272.14871886.html.plaintext.txt	242	Basal stimulated PRL concentrations
0.1154272.14871886.html.plaintext.txt	243	Basal PRL secretion determined animal subset baseline week 1
0.1154272.14871886.html.plaintext.txt	244	days 4 6 week 2 days 11 14 experimental period sampling blood six times 50 min period
0.1154272.14871886.html.plaintext.txt	245	Four animals comprised results group except last time period three animals comprised yoked group due nonpatency one catheter
0.1154272.14871886.html.plaintext.txt	246	The resulting baseline values plus minus SD 8 animals comparable previous reports male rats 40 42 minimum 0
0.1154272.14871886.html.plaintext.txt	247	During weeks 1 2 experimental period sleep deprived rats showed significant decrease baseline average PRL concentration compared yoked rats weeks 1 2 1 tailed paired tests 2
0.1154272.14871886.html.plaintext.txt	248	By week 2 sleep deprived animals also displayed significant decrease maximum PRL value expressed percentage change baseline 57
0.1154272.14871886.html.plaintext.txt	249	8 mean plus minus SD compared 152
0.1154272.14871886.html.plaintext.txt	250	4 mean plus minus SD yoked animals paired t3 2
0.1154272.14871886.html.plaintext.txt	251	Also week 2 sleep deprived animals showed significant percentage decrease baseline absolute PRL amplitude 49
0.1154272.14871886.html.plaintext.txt	252	5 mean plus minus SD compared 16
0.1154272.14871886.html.plaintext.txt	253	6 mean plus minus SD yoked animals paired t2 2
0.1154272.14871886.html.plaintext.txt	254	The decreases PRL parameters suggest diminished secretion lower amplitude sleep deprivation
0.1154272.14871886.html.plaintext.txt	255	View larger version 19K Fig
0.1154272.14871886.html.plaintext.txt	256	Mean percentage change plus minus SE individual baseline values prolactin average value across 50 min observation periods sleep deprived n 4 yoked n 4 baseline week 1 n 3 week 2 rats weeks 1 2 experimental period
0.1154272.14871886.html.plaintext.txt	257	Statistical significance groups
0.1154272.14871886.html.plaintext.txt	258	Stimulated release PRL TRH administration assessed measurement PRL plasma collected 10 20 40 min TRH administration
0.1154272.14871886.html.plaintext.txt	259	Four animals comprised results group except last time period two animals comprised yoked group nonpatency two catheters
0.1154272.14871886.html.plaintext.txt	260	The data yoked subjects week 2 insufficient statistical tests shown comparison
0.1154272.14871886.html.plaintext.txt	261	The absolute relative amplitudes time 0 peak concentration differ sleep deprived rats compared baseline yoked animals
0.1154272.14871886.html.plaintext.txt	262	The relative amplitude shown Fig
0.1154272.14871886.html.plaintext.txt	263	The average value PRL 40 min TRH stimulation significantly changed baseline 56 plus minus 25 mean plus minus SD week 1 paired t3 3
0.1154272.14871886.html.plaintext.txt	264	05 51 plus minus 16 mean plus minus SD week 2 paired t3 3
0.1154272.14871886.html.plaintext.txt	265	The average value PRL yoked rats TRH stimulation showed strong tendency toward decreased amounts compared baseline values
0.1154272.14871886.html.plaintext.txt	266	Two yoked animals showed higher post TRH average PRL values week 1 compared individual baseline values occur sleep deprived animals studied
0.1154272.14871886.html.plaintext.txt	267	View larger version 23K Fig
0.1154272.14871886.html.plaintext.txt	268	Change plasma prolactin PRL concentration bolus dose thyrotropin releasing hormone TRH
0.1154272.14871886.html.plaintext.txt	269	The change expressed A ratio change amplitude relative pre TRH concentration means plus minus SE B average value PRL 40 min poststimulation period means plus minus SE
0.1154272.14871886.html.plaintext.txt	270	Group means shown sleep deprived n 4 yoked n 4 baseline week 1 n 3 week 2 experimental period rats
0.1154272.14871886.html.plaintext.txt	271	Statistical significance groups
0.1154272.14871886.html.plaintext.txt	272	Plasma leptin corticosterone concentrations
0.1154272.14871886.html.plaintext.txt	273	Leptin concentrations suppressed early continuously sleep deprived yoked animals compared operated home cage controls percent change group x time interactions sleep deprived vs
0.1154272.14871886.html.plaintext.txt	274	7 sleep deprived yoked animals differ
0.1154272.14871886.html.plaintext.txt	275	The average leptin value across 4 day intervals sleep deprived yoked animals 1
0.1154272.14871886.html.plaintext.txt	276	Operated comparison animals showed evidence increased leptin concentrations correspond postsurgery weight gain increasing adiposity r 0
0.1154272.14871886.html.plaintext.txt	277	No significant differences plasma corticosterone concentrations found group interaction group time
0.1154272.14871886.html.plaintext.txt	278	The absolute concentrations corticosterone baseline consecutive 4 day intervals experimental period shown Fig
0.1154272.14871886.html.plaintext.txt	279	View larger version 22K Fig
0.1154272.14871886.html.plaintext.txt	280	Change plasma leptin expressed percent change individual values grouped baseline means plus minus SE sleep deprived n 8 yoked n 6 operated home cage n 5 rats baseline consecutive 4 day intervals experimental period
0.1154272.14871886.html.plaintext.txt	281	Group comparisons sleep deprived yoked groups home cage group statistically significant 2 way repeated measures ANOVA
0.1154272.14871886.html.plaintext.txt	282	View larger version 33K Fig
0.1154272.14871886.html.plaintext.txt	283	Mean basal plasma corticosteroid concentrations mean plus minus SE sleep deprived n 7 yoked n 6 operated home cage n 4 rats baseline consecutive 4 day intervals experimental period
0.1154272.14871886.html.plaintext.txt	284	Group differences group x time interactions statistically significant
0.1154272.14871886.html.plaintext.txt	285	DISCUSSION TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES The major findings present studies prolonged sleep deprivation rats produced profound decreases circulating GH IGF I PRL leptin
0.1154272.14871886.html.plaintext.txt	286	The suppressions occurred within early phase chronic sleep deprivation time overt appearance animals relatively healthy
0.1154272.14871886.html.plaintext.txt	287	Reduced secretion hormones sustained throughout experimental period occurred conjunction weight loss dramatically increased food consumption latter reported previously 18 23
0.1154272.14871886.html.plaintext.txt	288	Considered together prior demonstration laboratory sleep deprivation produces hypothyroxinemia central origin 20 present results indicate sleep deprivation results sustains wide range neuroendocrine disruptions
0.1154272.14871886.html.plaintext.txt	289	The nature disruptions points altered central regulation level hypothalamus
0.1154272.14871886.html.plaintext.txt	290	GH secretion assessed measurement major GH secretory periods subgroup sleep deprived yoked comparisons studied intensive blood sampling protocols freely moving conditions
0.1154272.14871886.html.plaintext.txt	291	Sleep deprived animals showed diminished circulating GH prevailing absence major secretory GH bursts observed baseline periods
0.1154272.14871886.html.plaintext.txt	292	IGF I considered main effector molecule GH secretion many tissues also consistently suppressed sleep deprived rats 31 42 throughout 4 day interval observation concomitant robust food intake
0.1154272.14871886.html.plaintext.txt	293	Measurement circulating IGF I levels well nourished subjects believed reflect 24 h secretion GH pituitary gland reviewed Ref
0.1154272.14871886.html.plaintext.txt	294	Yoked animals partial sleep deprivation conditions showed strong tendency overall decrease baseline GH concentration showed evidence relatively well preserved major GH secretory periods high amplitude pulses relatively unchanged duration frequency
0.1154272.14871886.html.plaintext.txt	295	Taken together results provide evidence diminished GH availability effector activity periphery totally sleep deprived rats
0.1154272.14871886.html.plaintext.txt	296	PRL GH share 40 homology GH substitute PRL deficiency extent reviewed Ref
0.1154272.14871886.html.plaintext.txt	297	Sleep deprived animals also showed large reduction 52 basal circulating PRL first days sleep deprivation maintenance suppressed concentrations experimental period
0.1154272.14871886.html.plaintext.txt	298	By comparison yoked animals partial sleep deprivation variously affected individual instances sometimes increased PRL concentration
0.1154272.14871886.html.plaintext.txt	299	Challenge tests pituitary secretion PRL TRH administration yielded initial PRL response proportional normal sleep deprived yoked rats
0.1154272.14871886.html.plaintext.txt	300	However total amount poststimulation PRL secreted 40 min significantly less sleep deprived rats baseline period reflecting diminished basal concentrations
0.1154272.14871886.html.plaintext.txt	301	Yoked animals conditions partial sleep deprivation tended show direction change post TRH PRL concentrations totally sleep deprived rats
0.1154272.14871886.html.plaintext.txt	302	Both experimental groups sleep deprived rats partially sleep deprived yoked rats showed significant reductions circulating leptin concentrations
0.1154272.14871886.html.plaintext.txt	303	This finding effectively ruled hyperleptinemia plausible mediator sleep deprivation signs activation sympathetic nervous system increased energy expenditure loss weight suppression IGF I
0.1154272.14871886.html.plaintext.txt	304	Rather plasma levels leptin appeared reflect energy stores became inadequate eventually manifested animals increased food consumption failure gain weight
0.1154272.14871886.html.plaintext.txt	305	Leptin considered critical peripheral hormonal signal status body energy stores brain functions within long term homeostatic system balancing food intake energy expenditure requiring time gear adaptive responses negative energy balance reviewed Ref
0.1154272.14871886.html.plaintext.txt	306	Low leptin increased corticosterone concentrations reciprocal responses negative energy balance starvation reviewed Ref
0.1154272.14871886.html.plaintext.txt	307	24 experimentally induced insulin deficient diabetes 4
0.1154272.14871886.html.plaintext.txt	308	In states increased glucocorticoids known alter functions carried hypothalamic pituitary axis suppress immunity reviewed Ref
0.1154272.14871886.html.plaintext.txt	309	The present results suggest reciprocal relationship associated circumstances extend de facto sleep deprived state
0.1154272.14871886.html.plaintext.txt	310	In rats rendered diabetic 4 rats fasted 4 72 h 46 75 76 increases corticosterone typically three fivefold
0.1154272.14871886.html.plaintext.txt	311	In rats studies behavioral stress increases corticosterone ninefold 29 51 PRL increased 67
0.1154272.14871886.html.plaintext.txt	312	By comparison present study sleep deprived rats showed mild tendency increased corticosteroid concentrations 50 recorded various times two groups
0.1154272.14871886.html.plaintext.txt	313	This result replicates previous findings 8 20 corroborates mild unchanged values found results human studies selective sleep deprivation 37 38 70
0.1154272.14871886.html.plaintext.txt	314	Although changes corticosteroid receptors sensitivity catabolism cannot yet ruled corticosterone concentration sleep deprived rats appears consistent may expected mobilize fuel support metabolic cellular requirements
0.1154272.14871886.html.plaintext.txt	315	As hypothalamic pituitary adrenal axis thus appear overactivated implying corticosterone modulatory role either suppression anabolic hormones suppression immunity sleep deprived rats
0.1154272.14871886.html.plaintext.txt	316	Further studies necessary characterize mechanisms underlying suppression GH PRL IGF I leptin elucidated present studies inappropriately low TSH shown previously 19 20
0.1154272.14871886.html.plaintext.txt	317	However several lines evidence suggest hypothalamus primary locus affected sleep deprivation possible secondary pituitary involvement
0.1154272.14871886.html.plaintext.txt	318	For example normal conditions decrease IGF I associated increase GH release via long negative feedback loop brain reviewed Refs
0.1154272.14871886.html.plaintext.txt	319	The specific feedback mechanisms IGF I GH mechanisms hypothalamus well elucidated believed involve increased inhibitory tone SRIF reduced GHRH reviewed Ref
0.1154272.14871886.html.plaintext.txt	320	68 normally operate reciprocal manner regulate GH secretion
0.1154272.14871886.html.plaintext.txt	321	For reduced IGF I negative feedback hypothalamus fail increase GH would suggest increased SRIF tone andor decreased GHRH
0.1154272.14871886.html.plaintext.txt	322	Evidence consistent framework finding Gardi et al
0.1154272.14871886.html.plaintext.txt	323	26 short term sleep deprivation rats reduces amounts GHRH tends increase amounts SRIF hypothalamus findings Toppila et al
0.1154272.14871886.html.plaintext.txt	324	69 show increases SRIF mRNA arcuate nucleus short term sleep deprivation
0.1154272.14871886.html.plaintext.txt	325	PRL different pituitary hormones target organs supply feedback hormones
0.1154272.14871886.html.plaintext.txt	326	The primary influence PRL secretion inhibition hypothalamus
0.1154272.14871886.html.plaintext.txt	327	In present study absolute concentration PRL diminished sleep deprived rats yet exogenous stimulation hypothalamic peptide TRH led PRL response comparable relative amplitude baseline comparison conditions suggesting PRL synthesis storage primary reason low circulating PRL
0.1154272.14871886.html.plaintext.txt	328	This finding consistent previous studies showed appropriate pituitary response TSH release TRH administration 20 points insufficient stimulation pituitary sleep deprivation manner would resulted maintenance normal peripheral PRL concentrations
0.1154272.14871886.html.plaintext.txt	329	It possible decrease circulating leptin consequent sleep deprivation induced negative energy balance contributes reductions GH PRL secretion inappropriately low TSH concentrations associated hypothyroxinemia
0.1154272.14871886.html.plaintext.txt	330	Leptin exerts negative feedback directly hypothalamus reviewed Refs
0.1154272.14871886.html.plaintext.txt	331	Low circulating leptin conditions negative energy balance induced experimental means potent signal increased mRNA expression secretion neuropeptide Y agouti related peptide hypothalamus reduced signaling melanocyte stimulating hormone precursor proopiomelanocortin reviewed Ref
0.1154272.14871886.html.plaintext.txt	332	These changes relevant determining mediation increased food intake causal direction altered regulation neuroendocrine peptides development negative energy balance
0.1154272.14871886.html.plaintext.txt	333	Diminished leptin associated abolition GH secretory peaks administration leptin associated restoration peaks 66 affecting GHRH SRIF 78
0.1154272.14871886.html.plaintext.txt	334	Similarly decreased leptin resulting food deprivation associated decreased circulating thyroid hormones PRL administration leptin conditions reverses hormonal changes 1 28 41 79
0.1154272.14871886.html.plaintext.txt	335	However present results suggest leptin may necessary sufficient factor reduction hormones since partially sleep deprived rats showed equivalent reductions leptin secretion less interference pituitary hormone secretion
0.1154272.14871886.html.plaintext.txt	336	A growing body evidence indicates central integration leptin signaling central control leptin concentrations
0.1154272.14871886.html.plaintext.txt	337	The hormonal changes sleep deprived rats may viewed either dysfunctional adaptive responses
0.1154272.14871886.html.plaintext.txt	338	On one hand abundant evidence diseases central locus hypothalamic dysfunction produce peripheral effects changes neuroendocrine regulation reviewed Ref
0.1154272.14871886.html.plaintext.txt	339	On hand low leptin suppression anabolic hormones may viewed adaptive responses negative energy balance evidenced progressive food intake body weight changes sleep deprived rats
0.1154272.14871886.html.plaintext.txt	340	Suggestions central effects sleep deprivation considered dysfunctional rather adaptive come examples contrast sleep deprived starved rats
0.1154272.14871886.html.plaintext.txt	341	Quite opposite starved rats declines T4 T3 sleep deprived rats consistent metabolic activation downregulation
0.1154272.14871886.html.plaintext.txt	342	The ratio T3 T4 dramatically increased 8 indicating strong preference metabolically active form thyroid hormone without increase reverse T3 metabolically inactive pathway
0.1154272.14871886.html.plaintext.txt	343	Also contrast starvation sleep deprivation associated 100 fold increase T4 T3 conversion enzyme 5 deiodinase type II brown adipose tissue 3 consistent experimental hypothyroidism 13 61 suggesting central changes regulation anabolic hormones produce state peripheral mechanisms show activities consistent compensation
0.1154272.14871886.html.plaintext.txt	344	The clinical implications suppression hormones based many pleiotropic actions
0.1154272.14871886.html.plaintext.txt	345	Deficiency PRL induced hypophysectomy reduces circulating PRL 50 control values associated normocytic anemia grossly reduced immunocompetence decreased body weight several abnormalities 49 shared sleep deprived animals
0.1154272.14871886.html.plaintext.txt	346	GH widespread effects growth metabolism tissues including increasing DNA RNA protein synthesis mitosis reviewed Ref
0.1154272.14871886.html.plaintext.txt	347	Suppression leptin would expected extend beyond effects energy balance include numerous effects
0.1154272.14871886.html.plaintext.txt	348	For example leptin deficient obob mice show many endocrine metabolic abnormalities including decreased body temperature immune defects reviewed Ref
0.1154272.14871886.html.plaintext.txt	349	Decreases IGF I would expected diminish many effector functions include autocrine paracrine growth factor mediation mitosis differentiation chemotaxis apoptosis many tissues reviewed Ref
0.1154272.14871886.html.plaintext.txt	350	Administration IGF I burn injury improves body weight gut mucosal weight stimulates mucosal DNA protein content reduces incidence bacterial translocation 32
0.1154272.14871886.html.plaintext.txt	351	The endocrine immune systems intricately linked hormonal changes may contributing decreased resistance infectious disease animal model
0.1154272.14871886.html.plaintext.txt	352	Deficiencies GH IGF I PRL thyroid hormones leptin induced sleep deprivation affect health provide one explanation absence localization specific sleep deprivation effects
0.1154272.14871886.html.plaintext.txt	353	Low basal PRL lack reciprocal relationships IGF I GH leptin corticosterone point hypothalamus locus sleep deprivation effects key factors interact presentation integrated signals pituitary
0.1154272.14871886.html.plaintext.txt	354	GRANTS TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES Portions work presented 16th European Sleep Research Society Congress Reykjavik Iceland June 2002
0.1154272.14871886.html.plaintext.txt	355	The principal research support provided National Institutes Health NIH NS 38733
0.1154272.14871886.html.plaintext.txt	356	Additional support provided NIH Grants HL 59271 HD 13703
0.1154272.14871886.html.plaintext.txt	357	The Veterans Administration University Tennessee Memphis TN provided facilities part research
0.1154272.14871886.html.plaintext.txt	358	ACKNOWLEDGMENTS We express appreciation Christa D
0.1154272.14871886.html.plaintext.txt	359	Laatsch Jason Scott technical assistance
0.1154272.14871886.html.plaintext.txt	360	FOOTNOTES Address reprint requests correspondence C
0.1154272.14871886.html.plaintext.txt	361	Everson Medical College Wisconsin Neurology Research 151 VA Medical Center Bldg
0.1154272.14871886.html.plaintext.txt	362	70 D 117 5000 West National Ave
0.1154272.14871886.html.plaintext.txt	363	Milwaukee WI 53295 E mail ceversonatmcw
0.1154272.14871886.html.plaintext.txt	364	The costs publication article defrayed part payment page charges
0.1154272.14871886.html.plaintext.txt	365	The article must therefore hereby marked advertisement accordance 18 U
0.1154272.14871886.html.plaintext.txt	366	Section 1734 solely indicate fact
0.1154272.14871886.html.plaintext.txt	367	REFERENCES TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION GRANTS REFERENCES Ahima RS Prabakaran D Mantzoros C Qu D Lowell B Maratos Flier E Flier JS
0.1154272.14871886.html.plaintext.txt	368	Role leptin neuroendocrine response fasting
0.1154272.14871886.html.plaintext.txt	369	CrossRefISIMedline Aurell J Elmqvist D
0.1154272.14871886.html.plaintext.txt	370	Sleep surgical intensive care unit continuous polygraphic recording sleep nine patients receiving postoperative care
0.1154272.14871886.html.plaintext.txt	371	Br Med J Clin Res Ed 290 1029 1032 1985
0.1154272.14871886.html.plaintext.txt	372	Medline Balzano S Bergmann BM Gilliland MA Silva JE Rechtschaffen A Refetoff S
0.1154272.14871886.html.plaintext.txt	373	Effect total sleep deprivation 5 deiodinase activity rat brown adipose tissue
0.1154272.14871886.html.plaintext.txt	374	Endocrinology 127 882 890 1990
0.1154272.14871886.html.plaintext.txt	375	Abstract Barber M Kasturi BS Austin ME Patel KP MohanKumar SM MohanKumar PS
0.1154272.14871886.html.plaintext.txt	376	Diabetes induced neuroendocrine changes rats role brain monoamines insulin leptin
0.1154272.14871886.html.plaintext.txt	377	Brain Res 964 128 135 2003
0.1154272.14871886.html.plaintext.txt	378	CrossRefISIMedline Ben Jonathan N Mershon JL Allen DL Steinmetz RW
0.1154272.14871886.html.plaintext.txt	379	Extrapituitary prolactin distribution regulation functions clinical aspects
0.1154272.14871886.html.plaintext.txt	380	Endocr Rev 17 639 669 1996
0.1154272.14871886.html.plaintext.txt	381	ISIMedline Bergmann BM Everson CA Kushida CA Fang VS Leitch CA Schoeller DA Refetoff S Rechtschaffen A
0.1154272.14871886.html.plaintext.txt	382	ISIMedline Bergmann BM Kushida CA Everson CA Gilliland MA Obermeyer W Rechtschaffen A
0.1154272.14871886.html.plaintext.txt	383	ISIMedline Brandenberger G Gronfier C Chapotot F Simon C Piquard F
0.1154272.14871886.html.plaintext.txt	384	Effect sleep deprivation overall 24 h growth hormone secretion Abstract
0.1154272.14871886.html.plaintext.txt	385	CrossRefISIMedline Brun J Chamba G Khalfallah Y Girard P Boissy I Bastuji H Sassolas G Claustrat B
0.1154272.14871886.html.plaintext.txt	386	Effect modafinil plasma melatonin cortisol growth hormone rhythms rectal temperature performance healthy subjects 36 h sleep deprivation
0.1154272.14871886.html.plaintext.txt	387	J Sleep Res 7 105 114 1998
0.1154272.14871886.html.plaintext.txt	388	CrossRefISIMedline Chen G Koyama K Yuan X Lee Y Zhou YT ODoherty R Newgard CB Unger RH
0.1154272.14871886.html.plaintext.txt	389	Disappearance body fat normal rats induced adenovirus mediated leptin gene therapy
0.1154272.14871886.html.plaintext.txt	390	Proc Natl Acad Sci USA 93 14795 14799 1996
0.1154272.14871886.html.plaintext.txt	391	AbstractFree Full Text Croteau W Davey JC Galton VA St
0.1154272.14871886.html.plaintext.txt	392	Cloning mammalian type II iodothyronine deiodinase
0.1154272.14871886.html.plaintext.txt	393	A selenoprotein differentially expressed regulated human rat brain tissues
0.1154272.14871886.html.plaintext.txt	394	J Clin Invest 98 405 417 1996
0.1154272.14871886.html.plaintext.txt	395	AbstractFree Full Text Cureton Lane RA Fontaine DK
0.1154272.14871886.html.plaintext.txt	396	Sleep pediatric ICU empirical investigation
0.1154272.14871886.html.plaintext.txt	397	Am J Crit Care 6 56 63 1997
0.1154272.14871886.html.plaintext.txt	398	Medline Eastman C Rechtschaffen A
0.1154272.14871886.html.plaintext.txt	399	Circadian temperature wake rhythms rats exposed prolonged continuous illumination
0.1154272.14871886.html.plaintext.txt	400	Physiol Behav 31 417 427 1983
0.1154272.14871886.html.plaintext.txt	401	CrossRefISIMedline Everson CA
0.1154272.14871886.html.plaintext.txt	402	Sustained sleep deprivation impairs host defense
0.1154272.14871886.html.plaintext.txt	403	Am J Physiol Regul Integr Comp Physiol 265 R1148 R1154 1993
0.1154272.14871886.html.plaintext.txt	404	AbstractFree Full Text Everson CA
0.1154272.14871886.html.plaintext.txt	405	Clinical manifestations prolonged sleep deprivation
0.1154272.14871886.html.plaintext.txt	406	In Sleep Science Integrating Basic Research Clinical Practice Monographs Clinical Neuroscience edited Schwartz WJ
0.1154272.14871886.html.plaintext.txt	407	Everson CA Bergmann BM Rechtschaffen A
0.1154272.14871886.html.plaintext.txt	408	ISIMedline Everson CA Nowak TA
0.1154272.14871886.html.plaintext.txt	409	Hypothalamic thyrotropin releasing hormone mRNA responses hypothyroxinemia induced sleep deprivation
0.1154272.14871886.html.plaintext.txt	410	Am J Physiol Endocrinol Metab 283 E85 E93 2002
0.1154272.14871886.html.plaintext.txt	411	AbstractFree Full Text Everson CA Reed HL
0.1154272.14871886.html.plaintext.txt	412	Pituitary peripheral thyroid hormone responses thyrotropin releasing hormone sustained sleep deprivation freely moving rats
0.1154272.14871886.html.plaintext.txt	413	Endocrinology 136 1426 1434 1995
0.1154272.14871886.html.plaintext.txt	414	Abstract Everson CA Smith CB Sokoloff L
0.1154272.14871886.html.plaintext.txt	415	Effects prolonged sleep deprivation local rates cerebral energy metabolism freely moving rats
0.1154272.14871886.html.plaintext.txt	416	J Neurosci 14 6769 6778 1994
0.1154272.14871886.html.plaintext.txt	417	Abstract Everson CA Toth LA
0.1154272.14871886.html.plaintext.txt	418	Systemic bacterial invasion induced sleep deprivation
0.1154272.14871886.html.plaintext.txt	419	Am J Physiol Regul Integr Comp Physiol 278 R905 R916 2000
0.1154272.14871886.html.plaintext.txt	420	AbstractFree Full Text Everson CA Wehr TA
0.1154272.14871886.html.plaintext.txt	421	Nutritional metabolic adaptations prolonged sleep deprivation rat
0.1154272.14871886.html.plaintext.txt	422	Am J Physiol Regul Integr Comp Physiol 264 R376 R387 1993
0.1154272.14871886.html.plaintext.txt	423	AbstractFree Full Text Flier JS
0.1154272.14871886.html.plaintext.txt	424	Clinical review 94 Whats name In search leptins physiologic role
0.1154272.14871886.html.plaintext.txt	425	J Clin Endocrinol Metab 83 1407 1413 1998
0.1154272.14871886.html.plaintext.txt	426	The function leptin nutrition weight physiology
0.1154272.14871886.html.plaintext.txt	427	Nutr Rev 60 S1 S14 S85 S87 2002
0.1154272.14871886.html.plaintext.txt	428	Gardi J Obal FJ Fang J Zhang J Krueger JM
0.1154272.14871886.html.plaintext.txt	429	Diurnal variations sleep deprivation induced changes rat hypothalamic GHRH somatostatin contents
0.1154272.14871886.html.plaintext.txt	430	Am J Physiol Regul Integr Comp Physiol 277 R1339 R1344 1999
0.1154272.14871886.html.plaintext.txt	431	AbstractFree Full Text Gardi J Taishi P Speth R Obal FJ Krueger JM
0.1154272.14871886.html.plaintext.txt	432	Sleep loss alters hypothalamic growth hormone releasing hormone receptors rats
0.1154272.14871886.html.plaintext.txt	433	Neurosci Lett 329 69 72 2002
0.1154272.14871886.html.plaintext.txt	434	CrossRefISIMedline Gonzalez LC Pinilla L Tena Sempere M Aguilar E
0.1154272.14871886.html.plaintext.txt	435	Leptin116 130 stimulates prolactin luteinizing hormone secretion fasted adult male rats
0.1154272.14871886.html.plaintext.txt	436	Neuroendocrinology 70 213 220 1999
0.1154272.14871886.html.plaintext.txt	437	CrossRefISIMedline Hajos Korcsok E Robinson DD Yu JH Fitch CS Walker E Merchant KM
0.1154272.14871886.html.plaintext.txt	438	Rapid habituation hippocampal serotonin norepinephrine release anxiety related behaviors plasma corticosterone levels repeated footshock stress rats
0.1154272.14871886.html.plaintext.txt	439	Pharmacol Biochem Behav 74 609 616 2003
0.1154272.14871886.html.plaintext.txt	440	CrossRefISIMedline Halle M Persson PB
0.1154272.14871886.html.plaintext.txt	441	Role leptin leptin receptor inflammation
0.1154272.14871886.html.plaintext.txt	442	Am J Physiol Regul Integr Comp Physiol 284 R760 R762 2003
0.1154272.14871886.html.plaintext.txt	443	Physiological roles leptin endocrine system differences mice humans
0.1154272.14871886.html.plaintext.txt	444	Crit Rev Clin Lab Sci 36 575 655 1999
0.1154272.14871886.html.plaintext.txt	445	ISIMedline Huang KF Chung DH Herndon DN
0.1154272.14871886.html.plaintext.txt	446	Insulinlike growth factor 1 IGF 1 reduces gut atrophy bacterial translocation severe burn injury
0.1154272.14871886.html.plaintext.txt	447	Abstract Inoue S Honda K Wada M
0.1154272.14871886.html.plaintext.txt	448	Effects total sleep deprivation serum LH FSH PRL male rats reference age strain differences
0.1154272.14871886.html.plaintext.txt	449	Rep Inst Med Dent Engineer 14 175 176 1980
0.1154272.14871886.html.plaintext.txt	450	Ultradian rhythm growth hormone secretion sleep adult male rat
0.1154272.14871886.html.plaintext.txt	451	J Physiol 353 305 315 1984
0.1154272.14871886.html.plaintext.txt	452	Kok SW Meinders AE Overeem S Lammers GJ Roelfsema F Frolich M Pijl H
0.1154272.14871886.html.plaintext.txt	453	Reduction plasma leptin levels loss circadian rhythmicity hypocretin orexin deficient narcoleptic humans
0.1154272.14871886.html.plaintext.txt	454	J Clin Endocrinol Metab 87 805 809 2002
0.1154272.14871886.html.plaintext.txt	455	AbstractFree Full Text Kollar E Slater G Palmer J Doctor R Mandell A
0.1154272.14871886.html.plaintext.txt	456	Stress subjects undergoing sleep deprivation
0.1154272.14871886.html.plaintext.txt	457	Psychosom Med 28 101 113 1966
0.1154272.14871886.html.plaintext.txt	458	ISIMedline Kollar EJ Pasnau RO Rubin RT Naitoh P Slater GG Kales A
0.1154272.14871886.html.plaintext.txt	459	Psychological psychophysiological biochemical correlates prolonged sleep deprivation
0.1154272.14871886.html.plaintext.txt	460	Am J Psychiatry 126 488 497 1969
0.1154272.14871886.html.plaintext.txt	461	ISIMedline Kripke DF Garfinkel L Wingard DL Klauber MR Marler MR
0.1154272.14871886.html.plaintext.txt	462	Mortality associated sleep duration insomnia
0.1154272.14871886.html.plaintext.txt	463	Arch Gen Psychiatry 59 131 136 2002
0.1154272.14871886.html.plaintext.txt	464	AbstractFree Full Text Lafuente A Marco J Esquifino AI
0.1154272.14871886.html.plaintext.txt	465	Physiological roles thyrotrophin releasing hormone vasoactive intestinal peptide pulsatile secretory patterns prolactin pituitary grafted female rats
0.1154272.14871886.html.plaintext.txt	466	J Endocrinol 142 581 586 1994
0.1154272.14871886.html.plaintext.txt	467	Abstract Legradi G Emerson CH Ahima RS Flier JS Lechan RM
0.1154272.14871886.html.plaintext.txt	468	Leptin prevents fasting induced suppression prothyrotropin releasing hormone messenger ribonucleic acid neurons hypothalamic paraventricular nucleus
0.1154272.14871886.html.plaintext.txt	469	Endocrinology 138 2569 2576 1997
0.1154272.14871886.html.plaintext.txt	470	AbstractFree Full Text Lopez F Dominguez JR Sanchez Franco F Negro Vilar A
0.1154272.14871886.html.plaintext.txt	471	Role dopamine vasoactive intestinal peptide control pulsatile prolactin secretion
0.1154272.14871886.html.plaintext.txt	472	Endocrinology 124 527 535 1989
0.1154272.14871886.html.plaintext.txt	473	Disorders growth development
0.1154272.14871886.html.plaintext.txt	474	In Endocrinology Metabolism 4th ed
0.1154272.14871886.html.plaintext.txt	475	edited Felig P Frohman LA
0.1154272.14871886.html.plaintext.txt	476	New York McGraw Hill 2001 p
0.1154272.14871886.html.plaintext.txt	477	In Endocrinology Metabolism 4th ed
0.1154272.14871886.html.plaintext.txt	478	edited Felig P Frohman LA
0.1154272.14871886.html.plaintext.txt	479	New York McGraw Hill 2001 p
0.1154272.14871886.html.plaintext.txt	480	Mistry AM Swick AG Romsos DR
0.1154272.14871886.html.plaintext.txt	481	Leptin rapidly lowers food intake elevates metabolic rates lean obob mice
0.1154272.14871886.html.plaintext.txt	482	J Nutr 127 2065 2072 1997
0.1154272.14871886.html.plaintext.txt	483	AbstractFree Full Text Mitev Y Almeida OF Patchev V
0.1154272.14871886.html.plaintext.txt	484	Pituitary adrenal function hypothalamic beta endorphin release vitro following food deprivation
0.1154272.14871886.html.plaintext.txt	485	In Endocrinology Metabolism 4th ed
0.1154272.14871886.html.plaintext.txt	486	edited Felig P Frohman LA
0.1154272.14871886.html.plaintext.txt	487	New York McGraw Hill 2001 p
0.1154272.14871886.html.plaintext.txt	488	Mueller GP Chen HJ Meites J
0.1154272.14871886.html.plaintext.txt	489	In vivo stimulation prolactin release rat synthetic TRH
0.1154272.14871886.html.plaintext.txt	490	Proc Soc Exp Biol Med 144 613 615 1973
0.1154272.14871886.html.plaintext.txt	491	Hypophysectomized rats depend residual prolactin survival
0.1154272.14871886.html.plaintext.txt	492	Endocrinology 128 2776 2784 1991
0.1154272.14871886.html.plaintext.txt	493	Abstract National Commission Sleep Disorders Research
0.1154272.14871886.html.plaintext.txt	494	Wake America national sleep alert
0.1154272.14871886.html.plaintext.txt	495	In Executive Summary Executive Report United States Congress Secretary U
0.1154272.14871886.html.plaintext.txt	496	Department Health Human Services
0.1154272.14871886.html.plaintext.txt	497	Washington DC National Commission Sleep Disorders Research 1993 p
0.1154272.14871886.html.plaintext.txt	498	Treatment sleep disorders older people
0.1154272.14871886.html.plaintext.txt	499	In NIH Consensus Development Conference
0.1154272.14871886.html.plaintext.txt	500	Washington DC National Institutes Health 1990
0.1154272.14871886.html.plaintext.txt	501	Obal FJ Kacsoh B Bredow S Guha Thakurta N Krueger JM
0.1154272.14871886.html.plaintext.txt	502	Sleep rats rendered chronically hyperprolactinemic anterior pituitary grafts
0.1154272.14871886.html.plaintext.txt	503	Brain Res 755 130 136 1997
0.1154272.14871886.html.plaintext.txt	504	CrossRefISIMedline Ohata H Arai K Shibasaki T
0.1154272.14871886.html.plaintext.txt	505	Effect chronic administration CRF1 receptor antagonist CRA1000 locomotor activity endocrine responses stress
0.1154272.14871886.html.plaintext.txt	506	Eur J Pharmacol 457 201 206 2002
0.1154272.14871886.html.plaintext.txt	507	CrossRefISIMedline Parker DC Sassin JF Mace JW Gotlin RW Rossman LG
0.1154272.14871886.html.plaintext.txt	508	Human growth hormone release sleep electroencephalographic correlation
0.1154272.14871886.html.plaintext.txt	509	J Clin Endocrinol Metab 29 871 874 1969
0.1154272.14871886.html.plaintext.txt	510	ISIMedline Rechtschaffen A Bergmann BM Everson CA Kushida CA Gilliland MA
0.1154272.14871886.html.plaintext.txt	511	Integration discussion findings
0.1154272.14871886.html.plaintext.txt	512	ISIMedline Rechtschaffen A Gilliland MA Bergmann BM Winter JB
0.1154272.14871886.html.plaintext.txt	513	Physiological correlates prolonged sleep deprivation rats
0.1154272.14871886.html.plaintext.txt	514	ISIMedline Ross R Miell J Freeman E Jones J Matthews D Preece M Buchanan C
0.1154272.14871886.html.plaintext.txt	515	Critically ill patients high basal growth hormone levels attenuated oscillatory activity associated low levels insulin like growth factor I
0.1154272.14871886.html.plaintext.txt	516	Clin Endocrinol Oxf 35 45 54 1991
0.1154272.14871886.html.plaintext.txt	517	Sassin JF Parker DC Mace JW Gotlin RW Johnson LC Rossman LG
0.1154272.14871886.html.plaintext.txt	518	Human growth hormone release relation slow wave sleep sleep walking cycles
0.1154272.14871886.html.plaintext.txt	519	ISIMedline Sato M Murao K Niimi M Tamaki M Takahara J
0.1154272.14871886.html.plaintext.txt	520	Effects long term infusion growth hormone GH releasing factor pulsatile GH secretion male rat
0.1154272.14871886.html.plaintext.txt	521	CrossRefISIMedline Satoh N Ogawa Y Katsuura G Numata Y Tsuji T Hayase M Ebihara K Masuzaki H Hosoda K Yoshimasa Y Nakao K
0.1154272.14871886.html.plaintext.txt	522	Sympathetic activation leptin via ventromedial hypothalamus leptin induced increase catecholamine secretion
0.1154272.14871886.html.plaintext.txt	523	Diabetes 48 1787 1793 1999
0.1154272.14871886.html.plaintext.txt	524	Abstract Scheen AJ Byrne MM Plat L Leproult R Van Cauter E
0.1154272.14871886.html.plaintext.txt	525	Relationships sleep quality glucose regulation normal humans
0.1154272.14871886.html.plaintext.txt	526	Am J Physiol Endocrinol Metab 271 E261 E270 1996
0.1154272.14871886.html.plaintext.txt	527	AbstractFree Full Text Schuld A Blum WF Uhr M Haack M Kraus T Holsboer F Pollmacher T
0.1154272.14871886.html.plaintext.txt	528	Reduced leptin levels human narcolepsy
0.1154272.14871886.html.plaintext.txt	529	Neuroendocrinology 72 195 198 2000
0.1154272.14871886.html.plaintext.txt	530	CrossRefISIMedline Silva JE Larsen PR
0.1154272.14871886.html.plaintext.txt	531	Interrelationships among thyroxine growth hormone sympathetic nervous system regulation 5 iodothyronine deiodinase rat brown adipose tissue
0.1154272.14871886.html.plaintext.txt	532	J Clin Invest 77 1214 1223 1986
0.1154272.14871886.html.plaintext.txt	533	ISIMedline Spiegel K Laproult R Copinschi G Van Cauter E
0.1154272.14871886.html.plaintext.txt	534	Impact sleep length 24 h leptin profile
0.1154272.14871886.html.plaintext.txt	535	Maximal REM sleep time defines narrower thermoneutral zone minimal metabolic rate
0.1154272.14871886.html.plaintext.txt	536	Physiol Behav 26 687 690 1981
0.1154272.14871886.html.plaintext.txt	537	CrossRefISIMedline Takahashi Y Kipnis DM Daughaday WH
0.1154272.14871886.html.plaintext.txt	538	Growth hormone secretion sleep
0.1154272.14871886.html.plaintext.txt	539	J Clin Invest 47 2079 2090 1968
0.1154272.14871886.html.plaintext.txt	540	ISIMedline Tannenbaum G Martin J
0.1154272.14871886.html.plaintext.txt	541	Evidence endogenous ultradian rhythm governing growth hormone secretion rat
0.1154272.14871886.html.plaintext.txt	542	Endocrinology 98 562 570 1976
0.1154272.14871886.html.plaintext.txt	543	Abstract Tannenbaum GS Gurd W Lapointe M
0.1154272.14871886.html.plaintext.txt	544	Leptin potent stimulator spontaneous pulsatile growth hormone GH secretion GH response GH releasing hormone
0.1154272.14871886.html.plaintext.txt	545	Endocrinology 139 3871 3875 1998
0.1154272.14871886.html.plaintext.txt	546	AbstractFree Full Text Terry LC Saunders A Audet J Willoughby JO Brazeau P Martin JB
0.1154272.14871886.html.plaintext.txt	547	Physiologic secretion growth hormone prolactin male female rats
0.1154272.14871886.html.plaintext.txt	548	Clin Endocrinol Oxf 6 19S 28S 1977
0.1154272.14871886.html.plaintext.txt	549	Medline Thissen JP Underwood LE Ketelslegers JM
0.1154272.14871886.html.plaintext.txt	550	Regulation insulin like growth factor I starvation injury
0.1154272.14871886.html.plaintext.txt	551	ISIMedline Toppila J Alanko L Asikainen M Tobler I Stenberg D Porkka Heiskanen T
0.1154272.14871886.html.plaintext.txt	552	Sleep deprivation increases somatostatin growth hormone releasing hormone messenger RNA rat hypothalamus
0.1154272.14871886.html.plaintext.txt	553	J Sleep Res 6 171 178 1997
0.1154272.14871886.html.plaintext.txt	554	CrossRefISIMedline Tyler DB Marx W Goodman J
0.1154272.14871886.html.plaintext.txt	555	Effect prolonged wakefulness urinary excretion 17 ketosteroids
0.1154272.14871886.html.plaintext.txt	556	Proc Soc Exp Biol Med 62 38 40 1946
0.1154272.14871886.html.plaintext.txt	557	Thyrotropin releasing hormone thyrotropin secretion
0.1154272.14871886.html.plaintext.txt	558	J Lab Clin Med 109 327 335 1987
0.1154272.14871886.html.plaintext.txt	559	Estimating false positive false negative errors analyses hormonal pulsatility
0.1154272.14871886.html.plaintext.txt	560	Am J Physiol Endocrinol Metab 254 E786 E794 1988
0.1154272.14871886.html.plaintext.txt	561	AbstractFree Full Text Van Cauter E Kerkhofs M Caufriez A Van Onderbergen A Thorner MO Copinschi G
0.1154272.14871886.html.plaintext.txt	562	A quantitative estimation growth hormone secretion normal man reproducibility relation sleep time day
0.1154272.14871886.html.plaintext.txt	563	J Clin Endocrinol Metab 74 1441 1450 1992
0.1154272.14871886.html.plaintext.txt	564	Abstract Van Cauter E Spiegel K
0.1154272.14871886.html.plaintext.txt	565	Hormones metabolism sleep
0.1154272.14871886.html.plaintext.txt	566	In Sleep Science Integrating Basic Research Clinical Practice edited Schwartz WJ
0.1154272.14871886.html.plaintext.txt	567	Van Haasteren GA Linkels E Klootwijk W van Toor H Rondeel JM Themmen AP de Jong FH Valentijn K Vaudry H Bauer K Visser TJ de Greef WJ
0.1154272.14871886.html.plaintext.txt	568	Starvation induced changes hypothalamic content prothyrotrophin releasing hormone proTRH mRNA hypothalamic release proTRH derived peptides role adrenal gland
0.1154272.14871886.html.plaintext.txt	569	J Endocrinol 145 143 153 1995
0.1154272.14871886.html.plaintext.txt	570	Abstract Vila R Adan C Grasa MM Masanes RM Esteve M Cabot C Fernandez Lopez JA Remesar X Alemany M
0.1154272.14871886.html.plaintext.txt	571	Effect food deprivation rat plasma estrone fatty acid esters
0.1154272.14871886.html.plaintext.txt	572	Diabetes Obes Metab 1 353 356 1995
0.1154272.14871886.html.plaintext.txt	573	CrossRef Von Treuer K Norman TR Armstrong SM
0.1154272.14871886.html.plaintext.txt	574	Overnight human plasma melatonin cortisol prolactin TSH conditions normal sleep sleep deprivation sleep recovery
0.1154272.14871886.html.plaintext.txt	575	J Pineal Res 20 7 14 1996
0.1154272.14871886.html.plaintext.txt	576	ISIMedline Watanabe H Habu S
0.1154272.14871886.html.plaintext.txt	577	Leptin regulates growth hormone releasing factor somatostatin alpha melanocyte stimulating hormone neuropeptide Y release rat hypothalamus vivo relation growth hormone secretion
0.1154272.14871886.html.plaintext.txt	578	J Neurosci 22 6265 6271 2002
0.1154272.14871886.html.plaintext.txt	579	AbstractFree Full Text Watanabe H Schioth HB Suda T
0.1154272.14871886.html.plaintext.txt	580	Stimulation prolactin secretion chronic acute administration leptin rat
0.1154272.14871886.html.plaintext.txt	581	Brain Res 887 426 431 2000
0.1154272.14871886.html.plaintext.txt	582	CrossRefISIMedline Zhang SQ Inoue S Kimura M
0.1154272.14871886.html.plaintext.txt	583	Sleep promoting activity prolactin releasing peptide PrRP rat
0.1154272.14871886.html.plaintext.txt	584	Neuroreport 12 3173 3176 2001
0.44176623.15625087.html.plaintext.txt	0	Altered setting pituitary thyroid ensemble hypocretin deficient narcoleptic men Simon W
0.44176623.15625087.html.plaintext.txt	1	Kok1 Ferdinand Roelfsema2 Sebastiaan Overeem3 Gert Jan Lammers3 Marijke Frolich1 A
0.44176623.15625087.html.plaintext.txt	2	Edo Meinders1 Hanno Pijl1
0.44176623.15625087.html.plaintext.txt	3	Departments 1General Internal Medicine 2Endocrinology 3Neurology Leiden University Medical Center Leiden The Netherlands
0.44176623.15625087.html.plaintext.txt	4	Submitted 23 July 2004 accepted final form 16 December 2004
0.44176623.15625087.html.plaintext.txt	5	ABSTRACT TOP ABSTRACT METHODS RESULTS DISCUSSION REFERENCES Narcolepsy sleep disorder caused disruption hypocretin orexin neurotransmission
0.44176623.15625087.html.plaintext.txt	6	Injection hypocretin 1 acutely suppresses TRH TSH release rats
0.44176623.15625087.html.plaintext.txt	7	In contrast subchronic administration appear affect hypothalamo pituitary thyroid ensemble animals
0.44176623.15625087.html.plaintext.txt	8	We explored 7 patients 7 controls whether hypocretin deficiency impacts circulating TSH levels circadian timing TSH release narcoleptic humans
0.44176623.15625087.html.plaintext.txt	9	Plasma TSH concentration profiles blood samples taken 10 min intervals 24 h TSH levels response TRH injection analyzed Cluster robust regression approximate entropy ApEn deconvolution
0.44176623.15625087.html.plaintext.txt	10	Circulating TSH levels lower patients primarily attributable lower pulse amplitude nadir concentrations
0.44176623.15625087.html.plaintext.txt	11	TSH secretion correlated positively mean 24 h leptin levels R2 0
0.44176623.15625087.html.plaintext.txt	12	02 negatively amount sleep R2 0
0.44176623.15625087.html.plaintext.txt	13	Pattern synchrony 24 h leptin TSH concentrations demonstrated significant cross correlation cross ApEn analyses differences controls patients
0.44176623.15625087.html.plaintext.txt	14	Sleep onset closely associated fall circulating TSH
0.44176623.15625087.html.plaintext.txt	15	Features diurnal rhythmicity circulating TSH fluctuations similar patients controls acrophase occurring shortly midnight
0.44176623.15625087.html.plaintext.txt	16	Thyroxine triiodothyronine concentrations similar patients controls display diurnal rhythm
0.44176623.15625087.html.plaintext.txt	17	The response plasma TSH levels TRH also similar groups
0.44176623.15625087.html.plaintext.txt	18	Sleep patterns narcoleptics significantly disorderly compared controls measured ApEn P 0
0.44176623.15625087.html.plaintext.txt	19	In summary circulating TSH concentrations low hypocretin deficient narcoleptic men could attributable low plasma leptin levels andor abnormal sleep wake cycle
0.44176623.15625087.html.plaintext.txt	20	narcolepsy thyroid stimulating hormone orexin sleep entropy
0.44176623.15625087.html.plaintext.txt	21	NARCOLEPSY IS A NEUROLOGICAL DISORDER characterized excessive daytime sleepiness EDS hypnagogic hallucinations cataplexy sleep paralysis 41 affects 20 60 every 100000 subjects US Europe 32
0.44176623.15625087.html.plaintext.txt	22	Disruption hypocretin orexin neurotransmission underlies disease animals humans 28 39
0.44176623.15625087.html.plaintext.txt	23	Hypocretins hypocretin 1 2 also called orexin A B produced small group neurons lateral hypothalamus project widely throughout central nervous system CNS 8 56
0.44176623.15625087.html.plaintext.txt	24	The paraventricular nucleus PVN among various brain sites receive hypocretin input signals 7
0.44176623.15625087.html.plaintext.txt	25	This nucleus harbors neurons synthesize thyrotropin releasing hormone TRH involved regulation hypothalamo pituitary thyroid HPT axis 24
0.44176623.15625087.html.plaintext.txt	26	During starvation thyroid hormone secretion suppressed 2 52 whereas preprohypocretin mRNA upregulated lateral hypothalamus 4
0.44176623.15625087.html.plaintext.txt	27	This led us hypothesize hypocretin neural circuits modulate activity hypothalamic TRH neurons thereby impact HPT axis
0.44176623.15625087.html.plaintext.txt	28	Studies putative effects hypocretin peptides HPT axis animals incomplete results conflicting
0.44176623.15625087.html.plaintext.txt	29	A single intravenous intracerebroventricular injection hypocretin 1 rats acutely decreased plasma TSH concentrations hypothalamic TRH release 34
0.44176623.15625087.html.plaintext.txt	30	In contrast several papers report hypocretin 1 measurable effect pituitary thyroid axis 16 20 53 54 whereas circulating TSH shown increase response central administration hypocretin 2 20
0.44176623.15625087.html.plaintext.txt	31	Thus although topography hypocretin thyrotrope neural circuits suggests TRH neuronal activity governed hypocretin input nature signal
0.44176623.15625087.html.plaintext.txt	32	excitatory inhibitory remains unclear hypocretin 1 2 may differential effects result distinct chemical structure
0.44176623.15625087.html.plaintext.txt	33	We previously reported circulating leptin levels low male narcoleptic patients 22
0.44176623.15625087.html.plaintext.txt	34	Because leptin stimulatory effects HPT axis conceivable relative hypoleptinemia downregulates HPT axis activity narcolepsy
0.44176623.15625087.html.plaintext.txt	35	In addition typical disruption sleep wake cycle associated narcolepsy may also impact TSH release sleep inhibits TSH secretion healthy subjects 42
0.44176623.15625087.html.plaintext.txt	36	To gain insight regulation HPT axis hypocretin deficient humans analyzed 24 h plasma TSH thyroid hormone concentrations relation leptin sleep seven narcoleptic men seven healthy controls
0.44176623.15625087.html.plaintext.txt	37	METHODS TOP ABSTRACT METHODS RESULTS DISCUSSION REFERENCES Subjects
0.44176623.15625087.html.plaintext.txt	38	We included seven male patients mean age 46
0.44176623.15625087.html.plaintext.txt	39	1 yr range 26 71 yr outpatient clinic Department Neurology Leiden University Medical Center
0.44176623.15625087.html.plaintext.txt	40	The diagnosis narcolepsy cataplexy made clinical grounds physician experienced narcolepsy G
0.44176623.15625087.html.plaintext.txt	41	Multiple sleep latency testing showed results typical narcolepsy 33
0.44176623.15625087.html.plaintext.txt	42	All patients HLA DR2DQB10602 positive lacked hypocretin 1 cerebrospinal fluid measurements previously described 39
0.44176623.15625087.html.plaintext.txt	43	All subjects free medication 3 patients discontinued medication 2 wk study
0.44176623.15625087.html.plaintext.txt	44	Two patients used psychostimulants methylfenidate modafinil one tricyclic antidepressant clomipramine treatment narcolepsy
0.44176623.15625087.html.plaintext.txt	45	Weight height subjects measured well waist hip circumference
0.44176623.15625087.html.plaintext.txt	46	The waist hip ratio WHR used relative measure abdominal fat mass
0.44176623.15625087.html.plaintext.txt	47	Total body fat mass determined dual energy X ray absorptiometry QDR4500 Hologic Waltham MA
0.44176623.15625087.html.plaintext.txt	48	Seven male control subjects mean age 46
0.44176623.15625087.html.plaintext.txt	49	9 yr range 26 72 yr recruited advertisements local newspapers
0.44176623.15625087.html.plaintext.txt	50	They matched age body mass index BMI total fat mass WHR since narcoleptics moderately obese 23
0.44176623.15625087.html.plaintext.txt	51	Subjects eligible study exclusion hypertension defined repeated blood pressure measurement systolic 160 mmHg diastolic 90 mmHg known history pituitary disease recent weight change 3 kg weight gain loss within previous 3 mo fasting blood glucose 7
0.44176623.15625087.html.plaintext.txt	52	Written informed consent obtained subjects
0.44176623.15625087.html.plaintext.txt	53	The study approved ethics committee Leiden University Medical Center
0.44176623.15625087.html.plaintext.txt	54	Subjects admitted Clinical Research Center morning 24 h study occasion
0.44176623.15625087.html.plaintext.txt	55	During 24 h study occasion three standardized meals served 0900 1300 1800 Nutridrink 1
0.44176623.15625087.html.plaintext.txt	56	5 kcalml 1500 1800 kcalday macronutrient composition per 100 ml 5 g protein 6
0.44176623.15625087.html.plaintext.txt	57	9 g carbohydrate Nutricia Zoetermeer The Netherlands
0.44176623.15625087.html.plaintext.txt	58	Subjects remained sedentary throughout study except bathroom visits
0.44176623.15625087.html.plaintext.txt	59	Lights switched 2300
0.44176623.15625087.html.plaintext.txt	60	Upon arrival intravenous cannula inserted antecubital vein 1 h start blood sampling
0.44176623.15625087.html.plaintext.txt	61	Blood samples collected S monovetten Sarstedt Etten Leur The Netherlands three way stopcock attached 0
0.44176623.15625087.html.plaintext.txt	62	9 NaCl heparin 1 Uml infusion 500 ml24 h keep cannula clotting
0.44176623.15625087.html.plaintext.txt	63	Blood collected 10 min intervals 24 h
0.44176623.15625087.html.plaintext.txt	64	It sampled long line prevent sleep disturbance investigative manipulations
0.44176623.15625087.html.plaintext.txt	65	Samples clotted centrifuged 4 degrees C 20 min serum frozen 20 degrees C assay
0.44176623.15625087.html.plaintext.txt	66	Plasma TSH concentration measured every sample
0.44176623.15625087.html.plaintext.txt	67	Total thyroxine T4 triiodothyronine T3 concentrations measured hourly relatively long plasma half lives
0.44176623.15625087.html.plaintext.txt	68	The plasma free T4 concentration measured morning
0.44176623.15625087.html.plaintext.txt	69	On separate occasion TRH stimulation test carried five patients five controls
0.44176623.15625087.html.plaintext.txt	70	In fasting state 200 microg TRH injected intravenously blood samples taken 10 min intervals 3 h
0.44176623.15625087.html.plaintext.txt	71	Thyroid hormone assays performed automated systems total T4 measured fluorescence immunoenzymometric assay FIEMA Abbott Diagnostics Division Hoofddorp The Netherlands T3 fluorescence enzymeimmunoassay FEIA Abbott Diagnostics Division
0.44176623.15625087.html.plaintext.txt	72	The free T4 concentration measured electrochemoluminescence immunoassay Roche Diagnostics Nederland Almere The Netherlands
0.44176623.15625087.html.plaintext.txt	73	TSH measured time resolved immunofluorometric assay Wallac Turku Finland
0.44176623.15625087.html.plaintext.txt	74	The detection limit TSH assay 0
0.44176623.15625087.html.plaintext.txt	75	05 mUl interassay coefficient variation CV 5
0.44176623.15625087.html.plaintext.txt	76	In addition plasma leptin concentration measured every 20 min sample RIA Linco Research St
0.44176623.15625087.html.plaintext.txt	77	The detection limit assay 0
0.44176623.15625087.html.plaintext.txt	78	3 concentration range 4
0.44176623.15625087.html.plaintext.txt	79	A detailed description circulating leptin levels narcoleptic men previously published 22
0.44176623.15625087.html.plaintext.txt	80	Here correlated 24 h mean leptin concentration TSH secretion also 20 min leptin data relation reconstituted 20 min plasma TSH profile
0.44176623.15625087.html.plaintext.txt	81	During 24 h sampling procedure sleep recorded polygraphically using Porti 5 ambulant electroencephalogram recording system Twente Medical Systems International Enschede The Netherlands scored EEG 2100 review software Nihon Kohden Tokyo Japan
0.44176623.15625087.html.plaintext.txt	82	An experienced technician blinded subject study visually scored sleep recordings 30 epochs means standardized criteria 49
0.44176623.15625087.html.plaintext.txt	83	For present study used distribution amount sleep across 24 h
0.44176623.15625087.html.plaintext.txt	84	Cluster used detection discrete TSH peaks
0.44176623.15625087.html.plaintext.txt	85	This computerized pulse algorithm largely model free identifies statistically significant pulses relation dose dependent measurement error hormone time series
0.44176623.15625087.html.plaintext.txt	86	For present analysis 2 x 1 test cluster configuration used two data points test nadir one test peak statistic 2
0.44176623.15625087.html.plaintext.txt	87	0 downstrokes minimizes false positive false negative peaks
0.44176623.15625087.html.plaintext.txt	88	The locations widths significant concentration peaks identified total number peaks counted mean peak interval calculated minutes
0.44176623.15625087.html.plaintext.txt	89	In addition following pulse parameters determined peak height highest value attained within peak incremental peak amplitude difference peak height prepeak nadir area peak
0.44176623.15625087.html.plaintext.txt	90	Interpulse valleys identified regions embracing nadirs intervening upstrokes
0.44176623.15625087.html.plaintext.txt	91	The total area curve also calculated well summed pulse areas 59
0.44176623.15625087.html.plaintext.txt	92	The 24 h TSH secretion rate calculated Pulse
0.44176623.15625087.html.plaintext.txt	93	This deconvolution method waveform independent used estimating hormone secretion rate time point well total 24 h rate 60
0.44176623.15625087.html.plaintext.txt	94	The method requires priori specification plasma half life
0.44176623.15625087.html.plaintext.txt	95	For present analysis used two compartment model fast component 18 plus minus 3 min slow component 90 plus minus 5 min fractional contribution 0
0.44176623.15625087.html.plaintext.txt	96	32 slow component overall decay data kindly provided Dr
0.44176623.15625087.html.plaintext.txt	97	Veldhuis Mayo Clinic Rochester MN
0.44176623.15625087.html.plaintext.txt	98	The mass TSH released TRH injection also calculated deconvolution
0.44176623.15625087.html.plaintext.txt	99	On separarate occasion patients received 200 microg TRH intravenously morning blood samples drawn injection 10 min intervals 180 min
0.44176623.15625087.html.plaintext.txt	100	The univariate approximate entropy ApEn statistic developed quantify degree irregularity disorderliness time series 44 62
0.44176623.15625087.html.plaintext.txt	101	Technically ApEn quantifies summed logarithmic likelihood templates length m patterns data similar within r remain similar within tolerance r next incremental comparison formally defined elsewhere 45
0.44176623.15625087.html.plaintext.txt	102	The ApEn calculation provides single nonnegative number ensemble estimate relative process randomness wherein larger ApEn values denote greater irregularity
0.44176623.15625087.html.plaintext.txt	103	Cross ApEn X ApEn quantifies joint pattern synchrony two separate parallel time series standardization z score transformation 47 51
0.44176623.15625087.html.plaintext.txt	104	In present analysis calculated X ApEn leptin TSH sleep TSH assuming r 20 SD individual time series m 1 hence use designation X ApEn 1 20
0.44176623.15625087.html.plaintext.txt	105	This parameter set affords sensitive valid statistically well replicated ApEn X ApEn metrics assessing hormone time series length 46
0.44176623.15625087.html.plaintext.txt	106	Both ApEn X ApEn results reported absolute values ratio absolute value mean 1000 randomly shuffled data series values approaching 1
0.44176623.15625087.html.plaintext.txt	107	Nyctohemeral 24 h rhythmicity
0.44176623.15625087.html.plaintext.txt	108	Diurnal variations plasma TSH concentrations calculated data fitted robust curve fitting algorithm 3 5
0.44176623.15625087.html.plaintext.txt	109	The acrophase maximal value fitted curve
0.44176623.15625087.html.plaintext.txt	110	The amplitude rhythm defined one half difference nocturnal zenith daytime nadir
0.44176623.15625087.html.plaintext.txt	111	The relative amplitude maximal percent increase nadir value
0.44176623.15625087.html.plaintext.txt	112	The relation sleep onset decrease TSH concentration quantified hypergeometric joint binomial distribution 61
0.44176623.15625087.html.plaintext.txt	113	This program calculates probability events pulses time series two occur randomly
0.44176623.15625087.html.plaintext.txt	114	Results presented means plus minus SE unless stated otherwise
0.44176623.15625087.html.plaintext.txt	115	Comparisons made two tailed Students test unpaired data necessary logarithmic transformation limit variability
0.44176623.15625087.html.plaintext.txt	116	In addition used Kolmogorov Smirnov test
0.44176623.15625087.html.plaintext.txt	117	Relations variables analyzed regression techniques
0.44176623.15625087.html.plaintext.txt	118	Calculations performed Systat version 11 Systat Richmond CA
0.44176623.15625087.html.plaintext.txt	119	RESULTS TOP ABSTRACT METHODS RESULTS DISCUSSION REFERENCES Plasma Hormone Concentrations
0.44176623.15625087.html.plaintext.txt	120	Figure 1 shows average 24 h serum TSH concentration vs
0.44176623.15625087.html.plaintext.txt	121	time narcoleptic subjects N matched controls C
0.44176623.15625087.html.plaintext.txt	122	The mean 24 h plasma TSH concentration significantly lower narcoleptic patients 1
0.44176623.15625087.html.plaintext.txt	123	In contrast mean hourly plasma total T4 T3 different patients controls Table 1
0.44176623.15625087.html.plaintext.txt	124	Also basal free T4 measurements similar groups 14
0.44176623.15625087.html.plaintext.txt	125	The circadian plasma T4 T3 levels display significant diurnal rhythm
0.44176623.15625087.html.plaintext.txt	126	View larger version 36K Fig
0.44176623.15625087.html.plaintext.txt	127	Twenty four hour thyroid stimulating hormone TSH concentrations 7 narcoleptic patients 7 controls
0.44176623.15625087.html.plaintext.txt	128	Data shown means SE bars
0.44176623.15625087.html.plaintext.txt	129	Mean 24 h serum TSH thyroid hormone concentrations narcoleptic patients healthy controls
0.44176623.15625087.html.plaintext.txt	130	The results Cluster analysis summarized Table 2
0.44176623.15625087.html.plaintext.txt	131	TSH pulse frequency mean pulse interval differ patients controls
0.44176623.15625087.html.plaintext.txt	132	Mean pulse area smaller patients controls primarily caused diminution pulse height pulse amplitude
0.44176623.15625087.html.plaintext.txt	133	The integrated total area TSH curve AUC also lower patients controls 2260 plus minus 390 vs
0.44176623.15625087.html.plaintext.txt	134	4140 plus minus 520 mUl P 0
0.44176623.15625087.html.plaintext.txt	135	The mean nadir concentration 50 lower patients controls
0.44176623.15625087.html.plaintext.txt	136	Cluster analysis 24 h serum TSH concentration series narcolepsy controls
0.44176623.15625087.html.plaintext.txt	137	The acrophase time maximal TSH occurred 24
0.44176623.15625087.html.plaintext.txt	138	Nadir concentrations reached 15
0.44176623.15625087.html.plaintext.txt	139	The amplitude rhythm smaller patients controls 0
0.44176623.15625087.html.plaintext.txt	140	009 percent increase TSH concentration similar two groups 93 plus minus 16 vs
0.44176623.15625087.html.plaintext.txt	141	115 plus minus 21 P 0
0.44176623.15625087.html.plaintext.txt	142	Examples representative TSH profiles fitted curves shown Fig
0.44176623.15625087.html.plaintext.txt	143	View larger version 34K Fig
0.44176623.15625087.html.plaintext.txt	144	Plasma TSH concentration series 2 patients top 2 controls bottom
0.44176623.15625087.html.plaintext.txt	145	The locally weighted robust regression line data points also shown
0.44176623.15625087.html.plaintext.txt	146	The percentage wakefulness calculated 10 min bins displayed top panels
0.44176623.15625087.html.plaintext.txt	147	On different occasion response TSH TRH investigated
0.44176623.15625087.html.plaintext.txt	148	The total mass TSH released calculated deconvolution analysis 27
0.44176623.15625087.html.plaintext.txt	149	Maximal TSH values reached 20 30 min TRH injection different patients controls 20 min P 0
0.44176623.15625087.html.plaintext.txt	150	View larger version 15K Fig
0.44176623.15625087.html.plaintext.txt	151	TSH increase injection 100 microg thyrotropin releasing hormone TRH 5 narcoleptic patients 5 controls
0.44176623.15625087.html.plaintext.txt	152	Basal TSH concentrations differed significantly P 0
0.44176623.15625087.html.plaintext.txt	153	Maximal values 20 30 min different total TSH mass secreted similar patients controls
0.44176623.15625087.html.plaintext.txt	154	Data shown means plus minus SE
0.44176623.15625087.html.plaintext.txt	155	Figure 4 shows correlation leptin TSH concentrations
0.44176623.15625087.html.plaintext.txt	156	The synchronicity leptin TSH series similar patients controls X ApEn score leptin leading TSH 1
0.44176623.15625087.html.plaintext.txt	157	Expressed ratio random series X ApEn ratio patients 0
0.44176623.15625087.html.plaintext.txt	158	The ratios differed significantly random series 4 SDs
0.44176623.15625087.html.plaintext.txt	159	The linear relation mean 24 h leptin concentration 24 h TSH secretion rate determined deconvolution analysis depicted Fig
0.44176623.15625087.html.plaintext.txt	160	View larger version 30K Fig
0.44176623.15625087.html.plaintext.txt	161	Regression TSH leptin concentrations 7 narcoleptic patients 7 controls
0.44176623.15625087.html.plaintext.txt	162	Data represent samples obtained 20 min intervals 24 h study
0.44176623.15625087.html.plaintext.txt	163	View larger version 13K Fig
0.44176623.15625087.html.plaintext.txt	164	Linear regression mean 24 h leptin concentration TSH secretion estimated deconvolution analysis
0.44176623.15625087.html.plaintext.txt	165	Narcoleptic patients shown circles controls triangles
0.44176623.15625087.html.plaintext.txt	166	Narcoleptic patients slept longer sampling protocol
0.44176623.15625087.html.plaintext.txt	167	2 sleep patterns expressed percentage awake TSH concentration profiles displayed two patients two controls
0.44176623.15625087.html.plaintext.txt	168	In patients controls except one highly significant concordance sleep onset decrease TSH concentrations present P values ranging 0
0.44176623.15625087.html.plaintext.txt	169	Total sleep duration correlated negatively 24 h TSH secretion R2 0
0.44176623.15625087.html.plaintext.txt	170	The relation sleep TSH concentrations also explored ApEn analyses
0.44176623.15625087.html.plaintext.txt	171	Sleep ApEn 1 20 ApEn 1 20 ratio significantly increased compared controls denoting increased sleep disorderliness narcoleptic patients Fig
0.44176623.15625087.html.plaintext.txt	172	X ApEn analysis demonstrated coupling sleep TSH controls patients mutual differences
0.44176623.15625087.html.plaintext.txt	173	View larger version 16K Fig
0.44176623.15625087.html.plaintext.txt	174	Approximate entropy ApEn cross ApEn X ApEn sleep joint synchrony sleep TSH 7 narcoleptic N patients 7 age body fat mass matched controls C
0.44176623.15625087.html.plaintext.txt	175	Statistical comparisons made 2 tailed Students test unpaired data
0.44176623.15625087.html.plaintext.txt	176	DISCUSSION TOP ABSTRACT METHODS RESULTS DISCUSSION REFERENCES The present paper presents first detailed description plasma TSH concentration profiles hypocretin deficient narcoleptic humans
0.44176623.15625087.html.plaintext.txt	177	The average TSH concentration significantly lower narcoleptic men specifically attributable reduction TSH pulse amplitude whereas number TSH pulses similar patients controls
0.44176623.15625087.html.plaintext.txt	178	The circadian fluctuation plasma TSH concentrations comparable narcoleptics controls
0.44176623.15625087.html.plaintext.txt	179	Circulating leptin TSH secretion appeared correlate positively whereas sleep inversely associated TSH release
0.44176623.15625087.html.plaintext.txt	180	Despite significantly lower plasma TSH concentration narcoleptics T4 T3 concentrations similar patients controls
0.44176623.15625087.html.plaintext.txt	181	TSH synthesis secretion primarily regulated TRH feedforward input feedback inhibition thyroid hormones
0.44176623.15625087.html.plaintext.txt	182	A host hormones neurotransmitters including somatostatin catecholamines various cytokines leptin modulate neuroendocrine ensemble 13 58
0.44176623.15625087.html.plaintext.txt	183	In addition sleep inhibitory effect TSH secretion 1 42
0.44176623.15625087.html.plaintext.txt	184	TRH synthesized thyrotropic area PVN anterior pituitary acts promote TSH secretion endocrine paracrine mechanisms respectively 58
0.44176623.15625087.html.plaintext.txt	185	Although hypocretin neuronal cell bodies heavily project PVN 43 currently unknown whether hypocretin axons actually synapse TRH neurons
0.44176623.15625087.html.plaintext.txt	186	It therefore uncertain whether hypocretins directly modulate TRH synthesis release thus affect TSH secretion
0.44176623.15625087.html.plaintext.txt	187	Also experiments investigating impact exogenous hypocretin peptides TSH release rodents yielded inconclusive results
0.44176623.15625087.html.plaintext.txt	188	Intracerebroventricular intravenous injection hypocretin 1 either reduced plasma TSH levels showed effect TSH andor TRH release 16 34 53 54
0.44176623.15625087.html.plaintext.txt	189	Thus seems unlikely hypocretin deficiency per se inhibits TRH secretion reduce TSH levels narcoleptic humans
0.44176623.15625087.html.plaintext.txt	190	We 22 previously showed circulating leptin levels 50 lower narcoleptic patients controls matched age body fat mass
0.44176623.15625087.html.plaintext.txt	191	Here show circulating leptin levels TSH secretion rates correlated positively narcoleptic men
0.44176623.15625087.html.plaintext.txt	192	Other studies revealed leptin intimately involved regulation HPT axis
0.44176623.15625087.html.plaintext.txt	193	Specifically reduction circulating leptin mediates inhibition HPT axis activity starvation 13
0.44176623.15625087.html.plaintext.txt	194	Leptin acts primarily integrate activities neuronal circuits orchestrate energy balance 40
0.44176623.15625087.html.plaintext.txt	195	In context leptin activates melanocyte stimulating hormone MSH cocaine amphetamine regulated transcript CART whereas inhibits neuropeptide Y NPY agouti related peptide AgRP
0.44176623.15625087.html.plaintext.txt	196	TRH neurons receive functional inputs neurotransmitters 10 12 25 26 57 NPYAgRP inhibit TRH release 21 whereas MSHCART promote TRH secretion 11 21
0.44176623.15625087.html.plaintext.txt	197	In addition leptin directly stimulate prepro TRH mRNA synthesis processing promote TRH release via activation leptin receptors TRH neurons 37
0.44176623.15625087.html.plaintext.txt	198	Moreover fact leptin leptin receptors expressed rodent anterior pituitary cells suggests leptin may also impact TSH secretion directly 19
0.44176623.15625087.html.plaintext.txt	199	Diurnal pulsatile leptin TSH levels exhibit strong pattern synchrony healthy humans whereas TSH release gets disorganized circadian rhythm phase shifted leptin deficient human subjects 31
0.44176623.15625087.html.plaintext.txt	200	In present study also demonstrate strong pattern synchrony leptin TSH patients controls
0.44176623.15625087.html.plaintext.txt	201	These data clearly suggest leptin involved regulation TSH release rodents humans
0.44176623.15625087.html.plaintext.txt	202	Thus fact TSH release rates positively correlated circulating leptin levels present study supports certainly prove contention hypoleptinemia blunts TSH secretion narcoleptic patients
0.44176623.15625087.html.plaintext.txt	203	Diminished dopaminergic tone may also blunt TSH secretion narcoleptic subjects diminution TRH release
0.44176623.15625087.html.plaintext.txt	204	Studies using canine model narcolepsy suggest hypoactivity dopaminergic noradrenergic circuits among major pathophysiological mechanisms narcolepsy 38
0.44176623.15625087.html.plaintext.txt	205	Recent vivo brain imaging studies humans support notion 9 disease currently treated symptomatically drugs enhance monoaminergic
0.44176623.15625087.html.plaintext.txt	206	dopamine norepinephrine neurotransmissions 38
0.44176623.15625087.html.plaintext.txt	207	In vitro vivo studies clearly show hypocretin peptides stimulate dopaminergic neurons various brain sites 16 36 also suggests hypocretin deficiency may silence dopaminergic circuits
0.44176623.15625087.html.plaintext.txt	208	Dopamine promotes TRH release via hypothalamic dopamine D2 receptors 27
0.44176623.15625087.html.plaintext.txt	209	Therefore hypocretin deficiency may blunt TRH thereby TSH release diminution dopaminergic neurotransmission hypothalamus
0.44176623.15625087.html.plaintext.txt	210	However role dopamine regulation TSH secretion complex view fact monoamine inhibits TSH release level pituitary 6 14
0.44176623.15625087.html.plaintext.txt	211	This observation implies reduced dopaminergic tone would lead increase circulating TSH narcoleptic subjects
0.44176623.15625087.html.plaintext.txt	212	In context seems important mention prolactin secretion also controlled dopamine pituitary level altered narcoleptic patients S
0.44176623.15625087.html.plaintext.txt	213	Thus role dopamine pathophysiology low plasma TSH levels narcoleptic humans remains uncertain
0.44176623.15625087.html.plaintext.txt	214	Other clinical features narcolepsy also suggest TRH deficiency hypoleptinemia unknown causes may involved pathophysiology disease
0.44176623.15625087.html.plaintext.txt	215	EDS cataplexy reflections depressed activity CNS
0.44176623.15625087.html.plaintext.txt	216	Accordingly current options treatment narcolepsy include CNS stimulants EDS antidepressants cataplexy 41
0.44176623.15625087.html.plaintext.txt	217	TRH receptors distributed widely CNS 15 TRH diverse neuromodulating actions 15 48
0.44176623.15625087.html.plaintext.txt	218	Among many features CNS stimulant antidepressant effects 18 29
0.44176623.15625087.html.plaintext.txt	219	Interestingly chronic administration TRH analog increases wakefulness ameliorates cataplexy narcoleptic dogs 50 may imply diminished TRH tone involved pathogenesis narcoleptic symptoms
0.44176623.15625087.html.plaintext.txt	220	However fact circulating prolactin levels normal narcoleptic humans unpublished observation argues exclude primary TRH deficiency patients TRH involved regulation prolactin release
0.44176623.15625087.html.plaintext.txt	221	Sleep inhibitory effect TSH release demonstrated human normal light dark cycle sleep light dark cycle manipulations 1 17
0.44176623.15625087.html.plaintext.txt	222	The underlying neuroendocrine mechanisms known
0.44176623.15625087.html.plaintext.txt	223	In present study sleep plasma TSH levels inversely associated sleep periods invariably followed reduction TSH concentration patients controls suggesting hypocretins involved coupling sleep TSH release
0.44176623.15625087.html.plaintext.txt	224	The present data also suggest fact patients slept longer controls may contributed reduction TSH levels
0.44176623.15625087.html.plaintext.txt	225	Hypersensitivity thyroid gland TSH stimulation may also contribute alterations pituitary thyroid ensemble described
0.44176623.15625087.html.plaintext.txt	226	Despite fact TSH levels reduced narcoleptic subjects plasma T4 T3 concentrations similar healthy controls completely within normal range
0.44176623.15625087.html.plaintext.txt	227	This may imply thyroid sensitive TSH stimulation narcoleptics unfortunately study yield data support notion
0.44176623.15625087.html.plaintext.txt	228	Thyroid hypersensitivity TSH may brought reduction sympathetic tone patients 55 TSH induced T4 release inhibited 1 adrenergic receptor stimulation 30 35
0.44176623.15625087.html.plaintext.txt	229	This putative resetting pituitary thyroid axis could fully explain observations
0.44176623.15625087.html.plaintext.txt	230	In case fact thyroid hormone levels within normal range narcoleptics indicates patients euthyroid
0.44176623.15625087.html.plaintext.txt	231	However remains established whether ensemble acts appropriately conditions greater metabolic demands growth cold adaptation pregnancy
0.44176623.15625087.html.plaintext.txt	232	Our data clearly show ApEn statistic appropriately detect disorderliness sleep patterns narcoleptic humans
0.44176623.15625087.html.plaintext.txt	233	Thus conceivable application ApEn analysis sleep patterns effect drug therapy sleep disorders physiological studies sleep related neuroendocrine phenomena might contribute understanding complicated networks involved
0.44176623.15625087.html.plaintext.txt	234	In conclusion present study shows circulating TSH concentrations reduced face normal plasma thyroid hormone concentrations hypocretin deficient narcoleptic humans
0.44176623.15625087.html.plaintext.txt	235	Hypoleptinemia disorderly sleep episodes longer duration may involved pathophysiology neuroendocrine feature narcolepsy
0.44176623.15625087.html.plaintext.txt	236	View larger version 53K Fig
0.44176623.15625087.html.plaintext.txt	237	ACKNOWLEDGMENTS We gratefully acknowledge work performed following collaborators E
0.44176623.15625087.html.plaintext.txt	238	Sierat van der Steen technical support M
0.44176623.15625087.html.plaintext.txt	239	Haasnoot van der Bent performing TSH T4 T3 assays
0.44176623.15625087.html.plaintext.txt	240	FOOTNOTES Address reprint requests correspondence H
0.44176623.15625087.html.plaintext.txt	241	General Internal Medicine C1 R39 PO Box 9600 2300 RC Leiden The Netherlands E mail h
0.44176623.15625087.html.plaintext.txt	242	The costs publication article defrayed part payment page charges
0.44176623.15625087.html.plaintext.txt	243	The article must therefore hereby marked advertisement accordance 18 U
0.44176623.15625087.html.plaintext.txt	244	Section 1734 solely indicate fact
0.44176623.15625087.html.plaintext.txt	245	REFERENCES TOP ABSTRACT METHODS RESULTS DISCUSSION REFERENCES Allan JS Czeisler CA
0.44176623.15625087.html.plaintext.txt	246	Persistence circadian thyrotropin rhythm constant conditions light induced shifts circadian phase
0.44176623.15625087.html.plaintext.txt	247	J Clin Endocrinol Metab 79 508 512 1994
0.44176623.15625087.html.plaintext.txt	248	Abstract Blake NG Johnson MR Eckland DJ Foster OJ Lightman SL
0.44176623.15625087.html.plaintext.txt	249	Effect food deprivation altered thyroid status hypothalamic pituitary thyroid axis rat
0.44176623.15625087.html.plaintext.txt	250	J Endocrinol 133 183 188 1992
0.44176623.15625087.html.plaintext.txt	251	Abstract Buxton OM Frank SA LHermite Baleriaux M Leproult R Turek FW Van Cauter E
0.44176623.15625087.html.plaintext.txt	252	Roles intensity duration nocturnal exercise causing phase delays human circadian rhythms
0.44176623.15625087.html.plaintext.txt	253	Am J Physiol Endocrinol Metab 273 E536 E542 1997
0.44176623.15625087.html.plaintext.txt	254	AbstractFree Full Text Cai XJ Widdowson PS Harrold J Wilson S Buckingham RE Arch JR Tadayyon M Clapham JC Wilding J Williams G
0.44176623.15625087.html.plaintext.txt	255	Hypothalamic orexin expression modulation blood glucose feeding
0.44176623.15625087.html.plaintext.txt	256	Diabetes 48 2132 2137 1999
0.44176623.15625087.html.plaintext.txt	257	Robust locally weighted regression smoothing scatter plots
0.44176623.15625087.html.plaintext.txt	258	J Am Stat Assoc 74 829 836 1979
0.44176623.15625087.html.plaintext.txt	259	ISI Cooper DS Klibanski A Ridgway EC
0.44176623.15625087.html.plaintext.txt	260	Dopaminergic modulation TSH subunits vivo vitro studies
0.44176623.15625087.html.plaintext.txt	261	Clin Endocrinol Oxf 18 265 275 1983
0.44176623.15625087.html.plaintext.txt	262	ISIMedline Date Y Ueta Y Yamashita H Yamaguchi H Matsukura S Kangawa K Sakurai T Yanagisawa M Nakazato M
0.44176623.15625087.html.plaintext.txt	263	Orexins orexigenic hypothalamic peptides interact autonomic neuroendocrine neuroregulatory systems
0.44176623.15625087.html.plaintext.txt	264	Proc Natl Acad Sci USA 96 748 753 1999
0.44176623.15625087.html.plaintext.txt	265	AbstractFree Full Text De Lecea L Kilduff TS Peyron C Gao X Foye PE Danielson PE Fukuhara C Battenberg EL Gautvik VT Bartlett FS Frankel WN van den Pol AN Bloom FE Gautvik KM Sutcliffe JG
0.44176623.15625087.html.plaintext.txt	266	The hypocretins hypothalamus specific peptides neuroexcitatory activity
0.44176623.15625087.html.plaintext.txt	267	Proc Natl Acad Sci USA 95 322 327 1998
0.44176623.15625087.html.plaintext.txt	268	AbstractFree Full Text Eisensehr I Linke R Tatsch K Von Lindeiner H Kharraz B Gildehaus FJ Eberle R Pollmacher T Schuld A Noachtar S
0.44176623.15625087.html.plaintext.txt	269	Alteration striatal dopaminergic system human narcolepsy
0.44176623.15625087.html.plaintext.txt	270	Neurology 60 1817 1819 2003
0.44176623.15625087.html.plaintext.txt	271	AbstractFree Full Text Fekete C Kelly J Mihaly E Sarkar S Rand WM Legradi G Emerson CH Lechan RM
0.44176623.15625087.html.plaintext.txt	272	Neuropeptide Y central inhibitory action hypothalamic pituitary thyroid axis
0.44176623.15625087.html.plaintext.txt	273	Endocrinology 142 2606 2613 2001
0.44176623.15625087.html.plaintext.txt	274	AbstractFree Full Text Fekete C Legradi G Mihaly E Huang QH Tatro JB Rand WM Emerson CH Lechan RM
0.44176623.15625087.html.plaintext.txt	275	alpha Melanocyte stimulating hormone contained nerve terminals innervating thyrotropin releasing hormone synthesizing neurons hypothalamic paraventricular nucleus prevents fasting induced suppression prothyrotropin releasing hormone gene expression
0.44176623.15625087.html.plaintext.txt	276	J Neurosci 20 1550 1558 2000
0.44176623.15625087.html.plaintext.txt	277	AbstractFree Full Text Fekete C Mihaly E Luo LG Kelly J Clausen JT Mao Q Rand WM Moss LG Kuhar M Emerson CH Jackson IM Lechan RM
0.44176623.15625087.html.plaintext.txt	278	Association cocaine amphetamine regulated transcript immunoreactive elements thyrotropin releasing hormone synthesizing neurons hypothalamic paraventricular nucleus role regulation hypothalamic pituitary thyroid axis fasting
0.44176623.15625087.html.plaintext.txt	279	J Neurosci 20 9224 9234 2000
0.44176623.15625087.html.plaintext.txt	280	AbstractFree Full Text Flier JS Harris M Hollenberg AN
0.44176623.15625087.html.plaintext.txt	281	Leptin nutrition thyroid wherefore wiring
0.44176623.15625087.html.plaintext.txt	282	J Clin Invest 105 859 861 2000
0.44176623.15625087.html.plaintext.txt	283	Free Full Text Foord SM Peters J Scanlon MF Rees SB Hall R
0.44176623.15625087.html.plaintext.txt	284	Dopaminergic control TSH secretion isolated rat pituitary cells
0.44176623.15625087.html.plaintext.txt	285	FEBS Lett 121 257 259 1980
0.44176623.15625087.html.plaintext.txt	286	CrossRefISIMedline Gershengorn MC Osman R
0.44176623.15625087.html.plaintext.txt	287	Molecular cellular biology thyrotropin releasing hormone receptors
0.44176623.15625087.html.plaintext.txt	288	Physiol Rev 76 175 191 1996
0.44176623.15625087.html.plaintext.txt	289	AbstractFree Full Text Hagan JJ Leslie RA Patel S Evans ML Wattam TA Holmes S Benham CD Taylor SG Routledge C Hemmati P Munton RP Ashmeade TE Shah AS Hatcher JP Hatcher PD Jones DN Smith MI Piper DC Hunter AJ Porter RA Upton N
0.44176623.15625087.html.plaintext.txt	290	Orexin A activates locus coeruleus cell firing increases arousal rat
0.44176623.15625087.html.plaintext.txt	291	Proc Natl Acad Sci USA 96 10911 10916 1999
0.44176623.15625087.html.plaintext.txt	292	AbstractFree Full Text Hirschfeld U Moreno Reyes R Akseki E LHermite Baleriaux M Leproult R Copinschi G Van Cauter E
0.44176623.15625087.html.plaintext.txt	293	Progressive elevation plasma thyrotropin adaptation simulated jet lag effects treatment bright light zolpidem
0.44176623.15625087.html.plaintext.txt	294	J Clin Endocrinol Metab 81 3270 3277 1996
0.44176623.15625087.html.plaintext.txt	295	N Engl J Med 306 145 155 1982
0.44176623.15625087.html.plaintext.txt	296	ISIMedline Jin L Zhang S Burguera BG Couce ME Osamura RY Kulig E Lloyd RV
0.44176623.15625087.html.plaintext.txt	297	Leptin leptin receptor expression rat mouse pituitary cells
0.44176623.15625087.html.plaintext.txt	298	Endocrinology 141 333 339 2000
0.44176623.15625087.html.plaintext.txt	299	AbstractFree Full Text Jones DN Gartlon J Parker F Taylor SG Routledge C Hemmati P Munton RP Ashmeade TE Hatcher JP Johns A Porter RA Hagan JJ Hunter AJ Upton N
0.44176623.15625087.html.plaintext.txt	300	Effects centrally administered orexin B orexin A role orexin 1 receptors orexin B induced hyperactivity
0.44176623.15625087.html.plaintext.txt	301	Psychopharmacology Berl 153 210 218 2001
0.44176623.15625087.html.plaintext.txt	302	CrossRefISIMedline Kim MS Small CJ Stanley SA Morgan DG Seal LJ Kong WM Edwards CM Abusnana S Sunter D Ghatei MA Bloom SR
0.44176623.15625087.html.plaintext.txt	303	The central melanocortin system affects hypothalamo pituitary thyroid axis may mediate effect leptin
0.44176623.15625087.html.plaintext.txt	304	J Clin Invest 105 1005 1011 2000
0.44176623.15625087.html.plaintext.txt	305	AbstractFree Full Text Kok SW Meinders AE Overeem S Lammers GJ Roelfsema F Frolich M Pijl H
0.44176623.15625087.html.plaintext.txt	306	Reduction plasma leptin levels loss circadian rhythmicity hypocretin orexin deficient narcoleptic humans
0.44176623.15625087.html.plaintext.txt	307	J Clin Endocrinol Metab 87 805 809 2002
0.44176623.15625087.html.plaintext.txt	308	AbstractFree Full Text Kok SW Overeem S Visscher TL Lammers GJ Seidell JC Pijl H Meinders AE
0.44176623.15625087.html.plaintext.txt	309	Hypocretin deficiency narcoleptic humans associated abdominal obesity
0.44176623.15625087.html.plaintext.txt	310	Obes Res 11 1147 1154 2003
0.44176623.15625087.html.plaintext.txt	311	AbstractFree Full Text Lechan RM Jackson IM
0.44176623.15625087.html.plaintext.txt	312	Immunohistochemical localization thyrotropin releasing hormone rat hypothalamus pituitary
0.44176623.15625087.html.plaintext.txt	313	Endocrinology 111 55 65 1982
0.44176623.15625087.html.plaintext.txt	314	Abstract Legradi G Lechan RM
0.44176623.15625087.html.plaintext.txt	315	The arcuate nucleus major source neuropeptide Y innervation thyrotropin releasing hormone neurons hypothalamic paraventricular nucleus
0.44176623.15625087.html.plaintext.txt	316	Endocrinology 139 3262 3270 1998
0.44176623.15625087.html.plaintext.txt	317	AbstractFree Full Text Legradi G Lechan RM
0.44176623.15625087.html.plaintext.txt	318	Agouti related protein containing nerve terminals innervate thyrotropin releasing hormone neurons hypothalamic paraventricular nucleus
0.44176623.15625087.html.plaintext.txt	319	Endocrinology 140 3643 3652 1999
0.44176623.15625087.html.plaintext.txt	320	AbstractFree Full Text Lewis BM Dieguez C Lewis MD Scanlon MF
0.44176623.15625087.html.plaintext.txt	321	Dopamine stimulates release thyrotrophin releasing hormone perfused intact rat hypothalamus via hypothalamic D2 receptors
0.44176623.15625087.html.plaintext.txt	322	J Endocrinol 115 419 424 1987
0.44176623.15625087.html.plaintext.txt	323	Abstract Lin L Faraco J Li R Kadotani H Rogers W Lin X Qiu X de Jong PJ Nishino S Mignot E
0.44176623.15625087.html.plaintext.txt	324	The sleep disorder canine narcolepsy caused mutation hypocretin orexin receptor 2 gene
0.44176623.15625087.html.plaintext.txt	325	CrossRefISIMedline Lloyd RL Pekary AE Sattin A Amundson T
0.44176623.15625087.html.plaintext.txt	326	Antidepressant effects thyrotropin releasing hormone analogues using rodent model depression
0.44176623.15625087.html.plaintext.txt	327	Pharmacol Biochem Behav 70 15 22 2001
0.44176623.15625087.html.plaintext.txt	328	CrossRefISIMedline Maayan ML Sellitto RV Volpert EM
0.44176623.15625087.html.plaintext.txt	329	Dopamine L dopa inhibition thyrotropin stimulated thyroidal thyroxine release
0.44176623.15625087.html.plaintext.txt	330	Endocrinology 118 632 636 1986
0.44176623.15625087.html.plaintext.txt	331	Abstract Mantzoros CS Ozata M Negrao AB Suchard MA Ziotopoulou M Caglayan S Elashoff RM Cogswell RJ Negro P Liberty V Wong ML Veldhuis J Ozdemir IC Gold PW Flier JS Licinio J
0.44176623.15625087.html.plaintext.txt	332	Synchronicity frequently sampled thyrotropin TSH leptin concentrations healthy adults leptin deficient subjects evidence possible partial TSH regulation leptin humans
0.44176623.15625087.html.plaintext.txt	333	J Clin Endocrinol Metab 86 3284 3291 2001
0.44176623.15625087.html.plaintext.txt	334	AbstractFree Full Text Mignot E
0.44176623.15625087.html.plaintext.txt	335	Genetic familial aspects narcolepsy
0.44176623.15625087.html.plaintext.txt	336	Neurology 50 S16 S22 1998
0.44176623.15625087.html.plaintext.txt	337	ISIMedline Mitler MM Van den Hoed J Carskadon MA Richardson G Park R Guilleminault C Dement WC
0.44176623.15625087.html.plaintext.txt	338	REM sleep episodes Multple Sleep Latency Test narcoleptic patients
0.44176623.15625087.html.plaintext.txt	339	Electroencephalogr Clin Neurophysiol 46 479 481 1979
0.44176623.15625087.html.plaintext.txt	340	CrossRefISIMedline Mitsuma T Hirooka Y Mori Y Kayama M Adachi K Rhue N Ping J Nogimori T
0.44176623.15625087.html.plaintext.txt	341	Effects orexin A thyrotropin releasing hormone thyrotropin secretion rats
0.44176623.15625087.html.plaintext.txt	342	Horm Metab Res 31 606 609 1999
0.44176623.15625087.html.plaintext.txt	343	ISIMedline Muraki T Uzumaki H Nakadate T Kato R
0.44176623.15625087.html.plaintext.txt	344	Involvement alpha 1 adrenergic receptors inhibitory effect catecholamines thyrotropin induced release thyroxine mouse thyroid
0.44176623.15625087.html.plaintext.txt	345	Endocrinology 110 51 54 1982
0.44176623.15625087.html.plaintext.txt	346	Abstract Nakamura T Uramura K Nambu T Yada T Goto K Yanagisawa M Sakurai T
0.44176623.15625087.html.plaintext.txt	347	Orexin induced hyperlocomotion stereotypy mediated dopaminergic system
0.44176623.15625087.html.plaintext.txt	348	Brain Res 873 181 187 2000
0.44176623.15625087.html.plaintext.txt	349	CrossRefISIMedline Nillni EA Vaslet C Harris M Hollenberg A Bjorbak C Flier JS
0.44176623.15625087.html.plaintext.txt	350	Leptin regulates prothyrotropin releasing hormone biosynthesis
0.44176623.15625087.html.plaintext.txt	351	Evidence direct indirect pathways
0.44176623.15625087.html.plaintext.txt	352	J Biol Chem 275 36124 36133 2000
0.44176623.15625087.html.plaintext.txt	353	AbstractFree Full Text Nishino S Okura M Mignot E
0.44176623.15625087.html.plaintext.txt	354	Narcolepsy genetic predisposition neuropharmacological mechanisms
0.44176623.15625087.html.plaintext.txt	355	Sleep Med Rev 4 57 99 2000
0.44176623.15625087.html.plaintext.txt	356	CrossRefISIMedline Nishino S Ripley B Overeem S Lammers GJ Mignot E
0.44176623.15625087.html.plaintext.txt	357	Hypocretin orexin deficiency human narcolepsy
0.44176623.15625087.html.plaintext.txt	358	CrossRefISIMedline Niswender KD Schwartz MW
0.44176623.15625087.html.plaintext.txt	359	Insulin leptin revisited adiposity signals overlapping physiological intracellular signaling capabilities
0.44176623.15625087.html.plaintext.txt	360	Front Neuroendocrinol 24 1 10 2003
0.44176623.15625087.html.plaintext.txt	361	CrossRefISIMedline Overeem S Mignot E van Dijk JG Lammers GJ
0.44176623.15625087.html.plaintext.txt	362	Narcolepsy clinical features new pathophysiologic insights future perspectives
0.44176623.15625087.html.plaintext.txt	363	J Clin Neurophysiol 18 78 105 2001
0.44176623.15625087.html.plaintext.txt	364	ISIMedline Parker DC Pekary AE Hershman JM
0.44176623.15625087.html.plaintext.txt	365	Effect normal reversed sleep wake cycles upon nyctohemeral rhythmicity plasma thyrotropin evidence suggestive inhibitory influence sleep
0.44176623.15625087.html.plaintext.txt	366	J Clin Endocrinol Metab 43 318 329 1976
0.44176623.15625087.html.plaintext.txt	367	Abstract Peyron C Tighe DK van den Pol AN de Lecea L Heller HC Sutcliffe JG Kilduff TS
0.44176623.15625087.html.plaintext.txt	368	Neurons containing hypocretin orexin project multiple neuronal systems
0.44176623.15625087.html.plaintext.txt	369	J Neurosci 18 9996 10015 1998
0.44176623.15625087.html.plaintext.txt	370	AbstractFree Full Text Pincus SM
0.44176623.15625087.html.plaintext.txt	371	Approximate entropy measure system complexity
0.44176623.15625087.html.plaintext.txt	372	Proc Natl Acad Sci USA 88 2297 2301 1991
0.44176623.15625087.html.plaintext.txt	373	AbstractFree Full Text Pincus SM Goldberger AL
0.44176623.15625087.html.plaintext.txt	374	Physiological time series analysis regularity quantify Am J Physiol Heart Circ Physiol 266 H1643 H1656 1994
0.44176623.15625087.html.plaintext.txt	375	AbstractFree Full Text Pincus SM Hartman ML Roelfsema F Thorner MO Veldhuis JD
0.44176623.15625087.html.plaintext.txt	376	Hormone pulsatility discrimination via course short time sampling
0.44176623.15625087.html.plaintext.txt	377	Am J Physiol Endocrinol Metab 277 E948 E957 1999
0.44176623.15625087.html.plaintext.txt	378	AbstractFree Full Text Pincus SM Mulligan T Iranmanesh A Gheorghiu S Godschalk M Veldhuis JD
0.44176623.15625087.html.plaintext.txt	379	Older males secrete luteinizing hormone testosterone irregularly jointly asynchronously younger males
0.44176623.15625087.html.plaintext.txt	380	Proc Natl Acad Sci USA 93 14100 14105 1996
0.44176623.15625087.html.plaintext.txt	381	AbstractFree Full Text Prokai L
0.44176623.15625087.html.plaintext.txt	382	Central nervous system effects thyrotropin releasing hormone analogues opportunities perspectives drug discovery development
0.44176623.15625087.html.plaintext.txt	383	Prog Drug Res 59 133 169 2002
0.44176623.15625087.html.plaintext.txt	384	Medline Rechtschaffen A Kales A
0.44176623.15625087.html.plaintext.txt	385	A Manual Standardized Terminology Techniques Scoring System Sleep Stages Human Subjects
0.44176623.15625087.html.plaintext.txt	386	Los Angeles UCLA Brain Information ServiceBrain Research Institute 1968
0.44176623.15625087.html.plaintext.txt	387	Riehl J Honda K Kwan M Hong J Mignot E Nishino S
0.44176623.15625087.html.plaintext.txt	388	Chronic oral administration CG 3703 thyrotropin releasing hormone analog increases wake decreases cataplexy canine narcolepsy
0.44176623.15625087.html.plaintext.txt	389	Neuropsychopharmacol 23 34 45 2000
0.44176623.15625087.html.plaintext.txt	390	CrossRefISIMedline Roelfsema F Pincus SM Veldhuis JD
0.44176623.15625087.html.plaintext.txt	391	Patients Cushings disease secrete adrenocorticotropin cortisol jointly asynchronously healthy subjects
0.44176623.15625087.html.plaintext.txt	392	J Clin Endocrinol Metab 83 688 692 1998
0.44176623.15625087.html.plaintext.txt	393	AbstractFree Full Text Romijn JA Adriaanse R Brabant G Prank K Endert E Wiersinga WM
0.44176623.15625087.html.plaintext.txt	394	Pulsatile secretion thyrotropin fasting decrease thyrotropin pulse amplitude
0.44176623.15625087.html.plaintext.txt	395	J Clin Endocrinol Metab 70 1631 1636 1990
0.44176623.15625087.html.plaintext.txt	396	Abstract Russell SH Kim MS Small CJ Abbott CR Morgan DG Taheri S Murphy KG Todd JF Ghatei MA Bloom SR
0.44176623.15625087.html.plaintext.txt	397	Central administration orexin A suppresses basal domperidone stimulated plasma prolactin
0.44176623.15625087.html.plaintext.txt	398	J Neuroendocrinol 12 1213 1218 2000
0.44176623.15625087.html.plaintext.txt	399	CrossRefISIMedline Russell SH Small CJ Sunter D Morgan I Dakin CL Cohen MA Bloom SR
0.44176623.15625087.html.plaintext.txt	400	Chronic intraparaventricular nuclear administration orexin A male rats alter thyroid axis uncoupling protein 1 brown adipose tissue
0.44176623.15625087.html.plaintext.txt	401	Regul Pept 104 61 68 2002
0.44176623.15625087.html.plaintext.txt	402	CrossRefISIMedline Sachs C Kaijser L
0.44176623.15625087.html.plaintext.txt	403	Autonomic regulation cardiopulmonary functions sleep apnea syndrome narcolepsy
0.44176623.15625087.html.plaintext.txt	404	ISIMedline Sakurai T Amemiya A Ishii M Matsuzaki I Chemelli RM Tanaka H Williams SC Richardson JA Kozlowski GP Wilson S Arch JR Buckingham RE Haynes AC Carr SA Annan RS McNulty DE Liu WS Terrett JA Elshourbagy NA Bergsma DJ Yanagisawa M
0.44176623.15625087.html.plaintext.txt	405	Orexins orexin receptors family hypothalamic neuropeptides G protein coupled receptors regulate feeding behavior
0.44176623.15625087.html.plaintext.txt	406	CrossRefISIMedline Sarkar S Legradi G Lechan RM
0.44176623.15625087.html.plaintext.txt	407	Intracerebroventricular administration alpha melanocyte stimulating hormone increases phosphorylation CREB TRH CRH producing neurons hypothalamic paraventricular nucleus
0.44176623.15625087.html.plaintext.txt	408	CrossRefISIMedline Scanlon MF Toft AD
0.44176623.15625087.html.plaintext.txt	409	Regulation thyrotropin secretion
0.44176623.15625087.html.plaintext.txt	410	In Werner Ingbars The thyroid
0.44176623.15625087.html.plaintext.txt	411	A Fundamental Clinical Text edited Braverman LE Utiger RD
0.44176623.15625087.html.plaintext.txt	412	Philadelphia PA Lippincott Williams Wilkins 2000 p
0.44176623.15625087.html.plaintext.txt	413	Cluster analysis simple versatile robust algorithm endocrine pulse detection
0.44176623.15625087.html.plaintext.txt	414	Am J Physiol Endocrinol Metab 250 E486 E493 1986
0.44176623.15625087.html.plaintext.txt	415	AbstractFree Full Text Veldhuis JD Johnson ML
0.44176623.15625087.html.plaintext.txt	416	Deconvolution analysis hormone data
0.44176623.15625087.html.plaintext.txt	417	Methods Enzymol 210 539 575 1992
0.44176623.15625087.html.plaintext.txt	418	ISIMedline Veldhuis JD Johnson ML Seneta E Iranmanesh A
0.44176623.15625087.html.plaintext.txt	419	Temporal coupling among luteinizing hormone follicle stimulating hormone beta endorphin cortisol pulse episodes vivo
0.44176623.15625087.html.plaintext.txt	420	Acta Endocrinol Copenh 126 193 200 1992
0.44176623.15625087.html.plaintext.txt	421	Medline Veldhuis JD Pincus SM
0.44176623.15625087.html.plaintext.txt	422	Orderliness hormone release patterns complementary measure conventional pulsatile circadian analyses
0.44176623.15625087.html.plaintext.txt	423	Eur J Endocrinol 138 358 362 1998
0.44176623.15625087.html.plaintext.txt	424	Free Full Text This Article Abstract Full Text PDF All Versions Article 2885E892 recent 00327
0.44176623.15625087.html.plaintext.txt	425	2004v1 Alert article cited Alert correction posted Citation Map Services Email article friend Similar articles journal Similar articles ISI Web Science Similar articles PubMed Alert new issues journal Download citation manager Search citing articles ISI Web Science 1 Google Scholar Articles Kok S
0.44176623.15625087.html.plaintext.txt	426	Articles citing Article PubMed PubMed Citation Articles Kok S
0.44176623.15625087.html.plaintext.txt	427	HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS Visit Other APS Journals Online Copyright 2005 American Physiological Society
0.105649576.10587584.html.plaintext.txt	0	Profound obesity associated balanced translocation disrupts SIM1 gene J
0.105649576.10587584.html.plaintext.txt	1	Eugene McDermott Center Human Growth Development Department Internal Medicine The University Texas Southwestern Medical School 6000 Harry Hines Boulevard Dallas TX 75235 USA 1Children Nutrition Research Center Department Pediatrics Baylor College Medicine 1100 Bates Street Houston TX 77030 USA
0.105649576.10587584.html.plaintext.txt	2	Received 13 September 1999 Revised Accepted 27 October 1999
0.105649576.10587584.html.plaintext.txt	3	ABSTRACT TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES Studies mice humans revealed number genes mutated result severe obesity
0.105649576.10587584.html.plaintext.txt	4	We studied unique girl early onset obesity de novo balanced translocation chromo somes 1p22
0.105649576.10587584.html.plaintext.txt	5	Her weight gain likely due excessive food intake since measured energy expenditure normal
0.105649576.10587584.html.plaintext.txt	6	We cloned sequenced translocation breakpoints
0.105649576.10587584.html.plaintext.txt	7	The translocation appear affect transcription unit 1p disrupts SIM1 gene 6q
0.105649576.10587584.html.plaintext.txt	8	SIM1 encodes human homolog Drosophila Sim Single minded tran scription factor involved midline neurogenesis prototypical member bHLH PAS basic helix loop helix period aryl hydrocarbon receptor Single minded gene family
0.105649576.10587584.html.plaintext.txt	9	Our subject trans location separates 5 promoter region bHLH domain 3 PAS putative transcriptional regulation domains
0.105649576.10587584.html.plaintext.txt	10	The transcriptional targets SIM1 known
0.105649576.10587584.html.plaintext.txt	11	Mouse Sim1 expressed developing kidney central nervous system essential formation supraoptic paraventricular PVN nuclei hypothalamus
0.105649576.10587584.html.plaintext.txt	12	Previous neuroanatomical pharmacological studies implicated PVN regulation body weight PVN neurons express melanocortin 4 receptor appear physiological targets melanocyte stimulating hormone inhibits food intake
0.105649576.10587584.html.plaintext.txt	13	We hypothesize haploinsufficiency SIM1 possibly acting upstream downstream melanocortin 4 receptor PVN responsible severe obesity subject
0.105649576.10587584.html.plaintext.txt	14	INTRODUCTION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES The prevalence obesity increasing USA developed countries
0.105649576.10587584.html.plaintext.txt	15	A 20 increase body weight associated increased incidence non insulin dependent diabetes mellitus hypertension osteoarthritis hyper lipidemia
0.105649576.10587584.html.plaintext.txt	16	Numerous family twin adoption studies past 60 years indicate heritability obesity order 0
0.105649576.10587584.html.plaintext.txt	17	8 12 cases pattern inheritance polygenic
0.105649576.10587584.html.plaintext.txt	18	Genetic studies humans laboratory animals mapped quantitative trait loci influence body weight diabetes susceptibility 3 molecular nature genes yet unknown
0.105649576.10587584.html.plaintext.txt	19	In contrast studies monogenic obesity mice greatly advanced knowledge endocrine metabolic pathways regulating body weight
0.105649576.10587584.html.plaintext.txt	20	Five mouse spontaneous obesity mutations cloned diabetes fat obese tubby yellow
0.105649576.10587584.html.plaintext.txt	21	The famous obese encodes leptin 4 diabetes encodes leptin receptor 5 7
0.105649576.10587584.html.plaintext.txt	22	Leptin polypeptide hormone secreted adipocytes hypothalamus receives signal responds negatively regulating food intake
0.105649576.10587584.html.plaintext.txt	23	Fat encodes carboxypeptidase E enzyme necessary normal processing neuropeptides proopiomelanocortin POMC involved central control feeding behavior well processing hormones proinsulin regulate peripheral energy metabolism 8
0.105649576.10587584.html.plaintext.txt	24	Yellow mutation causing ectopic expression Agouti gene encodes competitive antagonist melanocyte stimulating hormone MSH signaling 9
0.105649576.10587584.html.plaintext.txt	25	Predictably screening morbidly obese humans identified rare mutations genes including leptin 10 leptin receptor 11
0.105649576.10587584.html.plaintext.txt	26	Human mutations associated obesity also discovered genes encoding elements pathways POMC 12 prohormone convertase I 13 cooperates carboxypeptidase E prohormone processing melanocortin 4 receptor MC4R 1415 key hypothalamic target MSH 16
0.105649576.10587584.html.plaintext.txt	27	Clinical metabolic studies rare human patients complemented studies laboratory rodents defining roles molecules energy balance revealed interesting species differences e
0.105649576.10587584.html.plaintext.txt	28	association leptin deficiency hypercortisolemia mice humans 10
0.105649576.10587584.html.plaintext.txt	29	We report clinical molecular studies unique patient obesity balanced 1p6q chromosome translocation
0.105649576.10587584.html.plaintext.txt	30	The results suggest unsuspected role transcription factor regulation food intake
0.105649576.10587584.html.plaintext.txt	31	The transcription factor SIM1 critical formation supraoptic paraventricular hypothalamic nuclei mice
0.105649576.10587584.html.plaintext.txt	32	The latter nucleus well known involved energy homeostasis 17
0.105649576.10587584.html.plaintext.txt	33	Our data suggest SIM1 plays role function
0.105649576.10587584.html.plaintext.txt	34	RESULTS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES Clinical studies The proband SW116 referred pediatric geneticist age 18 months excessive growth
0.105649576.10587584.html.plaintext.txt	35	A prenatal karyotype performed advanced maternal age revealed de novo balanced translocation short arm chromosome 1 long arm chromosome 6 karyotype 46XXt16p22
0.105649576.10587584.html.plaintext.txt	36	She delivered term Cesarean section uncomplicated pregnancy
0.105649576.10587584.html.plaintext.txt	37	7 kg National Center Health Statistics NCHS Z score 1
0.105649576.10587584.html.plaintext.txt	38	Accelerating growth noted age 3 months 25 months weighed 19
0.105649576.10587584.html.plaintext.txt	39	She dysmorphic apart obesity features suggestive Prader Willi Bardet Biedl well defined syndromes
0.105649576.10587584.html.plaintext.txt	40	An umbilical hernia present infancy resolved without treatment
0.105649576.10587584.html.plaintext.txt	41	The father 188 cm tall weighed 104 kg body mass index BMI 29
0.105649576.10587584.html.plaintext.txt	42	4 mother 160 cm tall weighed 54 kg BMI 21
0.105649576.10587584.html.plaintext.txt	43	1 male sib age 51 months 111 cm tall 1
0.105649576.10587584.html.plaintext.txt	44	Abdominal computerized tomography CT pituitary magnetic resonance imaging proband normal
0.105649576.10587584.html.plaintext.txt	45	Laboratory tests revealed slightly elevated serum insulin 16 microUml normal 2 13 microUml normal thyroid stimulating hormone glucose growth hormone somatomedin C calcium phosphate slightly depressed cortisol 5
0.105649576.10587584.html.plaintext.txt	46	Repeat tests age 53 months normal except radiographic bone age measurement 82 months
0.105649576.10587584.html.plaintext.txt	47	Serum leptin concentrations 16 24 ngml 38 53 months age respectively commensurate obesity 1819
0.105649576.10587584.html.plaintext.txt	48	The proband height curve remained stable 3 SD whereas weight weight height curves continue deviate upward Fig
0.105649576.10587584.html.plaintext.txt	49	Her rate weight gain comparable girls mutations leptin leptin receptor Fig
0.105649576.10587584.html.plaintext.txt	50	The mother noted mild hyperphagia beginning around age 4 years
0.105649576.10587584.html.plaintext.txt	51	There evidence developmental delay preschool difficulties precocious puberty
0.105649576.10587584.html.plaintext.txt	52	View larger version 27K Figure 1
0.105649576.10587584.html.plaintext.txt	53	Weight A height B weight stature curves C
0.105649576.10587584.html.plaintext.txt	54	Thick line SW116 thin line mean dashed line plus minus 3 SD 52
0.105649576.10587584.html.plaintext.txt	55	D Weight curve SW116 compared girls mutations leptin triangles 10 leptin receptor genes diamonds 11
0.105649576.10587584.html.plaintext.txt	56	Negative inflections represent dietary andor pharmacological interventions
0.105649576.10587584.html.plaintext.txt	57	SW116 body composition food intake energy expenditure studied age 67 months
0.105649576.10587584.html.plaintext.txt	58	Fat mass 52 generalized distribution
0.105649576.10587584.html.plaintext.txt	59	A 3 day food intake record mother indicated energy intake 5017 kJday
0.105649576.10587584.html.plaintext.txt	60	Her basal sleeping metabolic rates measured 24 h calorimetry slightly greater predicted equations derived calorimetry 318 girls unpublished data Fig
0.105649576.10587584.html.plaintext.txt	61	The 24 h respiratory quotient normal 0
0.105649576.10587584.html.plaintext.txt	62	Total energy expenditure free living state measured doubly labeled water method 8314 kJday significantly greater reported energy intake
0.105649576.10587584.html.plaintext.txt	63	The ratio total energy expenditure basal metabolic rate index physical activity level 1
0.105649576.10587584.html.plaintext.txt	64	45 within range measurements 1
0.105649576.10587584.html.plaintext.txt	65	5 observed series 101 normal 8 year old girls unpublished data
0.105649576.10587584.html.plaintext.txt	66	Observation ad libitum consumption revealed aggressive voracious appetite
0.105649576.10587584.html.plaintext.txt	67	View larger version 41K Figure 2
0.105649576.10587584.html.plaintext.txt	68	Energy expenditure measurements
0.105649576.10587584.html.plaintext.txt	69	Basal metabolic rate BMR sleeping metabolic rate SMR total energy expenditure TEE measured 24 h calorimetry SW116 open bars compared values predicted gender age race body weight hatched fat free mass fat mass stippled
0.105649576.10587584.html.plaintext.txt	70	Gray bar SW116 TEE measured doubly labeled water method
0.105649576.10587584.html.plaintext.txt	71	Molecular studies Review cytogenetic literature revealed two patients complex phenotypes included early onset obesity small interstitial deletions 6q 2021 potentially overlapping SW116 breakpoint Fig
0.105649576.10587584.html.plaintext.txt	72	We hypothesized SW116 unusual growth due haploinsufficiency gene 6q
0.105649576.10587584.html.plaintext.txt	73	We tested number CEPH megaYACs YAC yeast artificial chromosome Whitehead Institute contig fluorescence situ hybridization FISH patient cell line identified one clone y852C9 gave signals der1 der6 chromosomes well chromosome 6 data shown
0.105649576.10587584.html.plaintext.txt	74	Sequence tagged sites STSs mapping YAC clone used isolate smaller Washington University YAC yA35F11 also crossed breakpoint FISH allowed us map breakpoint D6S475 WI6516
0.105649576.10587584.html.plaintext.txt	75	We isolated bacterial artificial chromosome BAC clones using markers WI6516 AFM176xg9 D6S475 sequenced ends clones generate additional STS markers
0.105649576.10587584.html.plaintext.txt	76	A BAC P1 artificial chromosome PAC contig Fig
0.105649576.10587584.html.plaintext.txt	77	4 constructed iterative library screening end sequencing STS content mapping
0.105649576.10587584.html.plaintext.txt	78	We confirmed BAC b325C19 crossed breakpoint FISH also found del6q16
0.105649576.10587584.html.plaintext.txt	79	2q21 subject reported Villa et al
0.105649576.10587584.html.plaintext.txt	80	3 deleted probe data shown
0.105649576.10587584.html.plaintext.txt	81	View larger version 31K Figure 3
0.105649576.10587584.html.plaintext.txt	82	Cytogenetic abnormalities 6q associated obesity
0.105649576.10587584.html.plaintext.txt	83	A Partial karyotype SW116 showing balanced translocation
0.105649576.10587584.html.plaintext.txt	84	B Idiograms chromosome 6 depicting SW116 translocation breakpoint arrow two interstitial deletions associated obesity 2021
0.105649576.10587584.html.plaintext.txt	85	View larger version 30K Figure 4
0.105649576.10587584.html.plaintext.txt	86	Large insert clone contigs containing translocation breakpoints
0.105649576.10587584.html.plaintext.txt	87	y YAC b BAC P PAC T T7 end S Sp6 end
0.105649576.10587584.html.plaintext.txt	88	To facilitate breakpoint mapping made somatic cell hybrid selectively retaining der1 chromosome
0.105649576.10587584.html.plaintext.txt	89	STS content mapping using hybrid allowed us position chromosome 6 breakpoint contig map chromosome 1 breakpoint markers WI7492 D1S1673
0.105649576.10587584.html.plaintext.txt	90	Three BAC clones containing D1S1673 isolated STSs generated end sequences
0.105649576.10587584.html.plaintext.txt	91	All three clones crossed breakpoint STS content mapping FISH data shown
0.105649576.10587584.html.plaintext.txt	92	Database searches revealed match one end BAC clone b353H2 crosses 6q breakpoint 177 kb contiguous genomic sequence 6q16 deposited GenBank accession
0.105649576.10587584.html.plaintext.txt	93	Additional genomic sequence BAC clone b21C21 crossing 1p breakpoint generated Sanger Center GenBank accession
0.105649576.10587584.html.plaintext.txt	94	We used genomic sequences design additional primers used fine map breakpoints polymerase chain reaction PCR data shown
0.105649576.10587584.html.plaintext.txt	95	Restriction fragments either side translocation detected novel der6 junction fragment Fig
0.105649576.10587584.html.plaintext.txt	96	Similar results obtained der1 chromosome data shown indicating translocation accompanied large concomitant deletion
0.105649576.10587584.html.plaintext.txt	97	We PCR amplified sequenced junctions found translocation deleted single base pair chromosome 6 none chromosome 1 Fig
0.105649576.10587584.html.plaintext.txt	98	View larger version 77K Figure 5
0.105649576.10587584.html.plaintext.txt	99	Novel junction fragment SW116
0.105649576.10587584.html.plaintext.txt	100	A Genomic DNA SW116 parents digested XbaI hybridized fragment chromosome 6 left
0.105649576.10587584.html.plaintext.txt	101	The blot stripped rehybridized fragment chromosome 1 right
0.105649576.10587584.html.plaintext.txt	102	B Sequences junction fragments SW116 versus normal chromosome 6 GenBank accession
0.105649576.10587584.html.plaintext.txt	103	Z86062 nucleotides 54278 54308 normal chromosome 1 GenBank accession
0.105649576.10587584.html.plaintext.txt	104	8 GI5777829 nucleotides 80545 80574 reverse complement
0.105649576.10587584.html.plaintext.txt	105	The translocation disrupts SIM1 BLAST analysis 84 kb contiguous genomic sequence BAC clone b21C21 well exon trapping experiments using clones b261L4 b219G7 failed identify 1p22 transcription units disrupted translocation data shown
0.105649576.10587584.html.plaintext.txt	106	In contrast sequence mapping data indicated 6q breakpoint lies within known gene SIM1
0.105649576.10587584.html.plaintext.txt	107	Inspection intronexon structure SIM1 indicated translocation breakpoint falls within first intron separates 5 flanking sequence first exon downstream exons Fig
0.105649576.10587584.html.plaintext.txt	108	View larger version 20K Figure 6
0.105649576.10587584.html.plaintext.txt	109	SIM1 gene structure translocation breakpoint SW116
0.105649576.10587584.html.plaintext.txt	110	Structure human SIM1 gene A protein B
0.105649576.10587584.html.plaintext.txt	111	Gray areas coding regions hatched areas functional domains arrows translocation breakpoint
0.105649576.10587584.html.plaintext.txt	112	To determine whether proband SIM1 allele normal PCR amplified sequenced SIM1 exons splice sites data shown
0.105649576.10587584.html.plaintext.txt	113	She heterozygous silent CT substitution nucleotide 1328 exon 9 coding sequence
0.105649576.10587584.html.plaintext.txt	114	Thus SW116 presumably heterozygous loss function SIM1 mutation
0.105649576.10587584.html.plaintext.txt	115	Attempts detect SIM1 transcripts reverse transcription RT PCR RNA control patient lymphoblastoid cells unsuccessful
0.105649576.10587584.html.plaintext.txt	116	SIM1 mutations probably common cause early onset obesity We performed mutation detection using single strand conformation polymorphism SSCP analysis limited DNA sequencing samples 45 markedly obese children referred pediatric endocrinologist
0.105649576.10587584.html.plaintext.txt	117	We found coding splice site mutations data shown
0.105649576.10587584.html.plaintext.txt	118	The CT silent substitution SW116 appears common polymorphism
0.105649576.10587584.html.plaintext.txt	119	Eight 45 obese children heterozygous T allele remaining subjects homozygous C allele
0.105649576.10587584.html.plaintext.txt	120	In comparison 9 33 controls heterozygous T allele remainder homozygous C allele
0.105649576.10587584.html.plaintext.txt	121	There significant association obesity polymorphism 2 0
0.105649576.10587584.html.plaintext.txt	122	DISCUSSION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES We identified mutation SIM1 gene girl profound obesity increased linear growth
0.105649576.10587584.html.plaintext.txt	123	We suspect weight gain must involve occult food consumption since measured energy expenditure normal significantly greater reported caloric intake
0.105649576.10587584.html.plaintext.txt	124	We hypothesize SIM1 haploinsufficiency causes phenotype
0.105649576.10587584.html.plaintext.txt	125	If hypothesis correct obesity due SIM1 mutations would expected show autosomal dominant inheritance
0.105649576.10587584.html.plaintext.txt	126	We cannot test prediction kindred since translocation occurred de novo
0.105649576.10587584.html.plaintext.txt	127	We find additional SIM1 mutations SSCP 45 children marked obesity mutations may identified screening larger numbers subjects sensitive techniques
0.105649576.10587584.html.plaintext.txt	128	2 reported large genetic studies studies specifically examined subjects severe early onset obesity
0.105649576.10587584.html.plaintext.txt	129	2 availability SIM1 genomic sequences facilitate testing associations obesity SIM1 gene
0.105649576.10587584.html.plaintext.txt	130	We cannot exclude possibility one SIM1 gene fragments expressed part fusion gene although identify transcription units close proximity breakpoints
0.105649576.10587584.html.plaintext.txt	131	It also possible truncated SIM1 transcript produces dominant negative protein
0.105649576.10587584.html.plaintext.txt	132	The reported interstitial 6q deletions associated early onset obesity consistent haploinsufficiency model
0.105649576.10587584.html.plaintext.txt	133	Screening additional patients early onset obesity might reveal additional microscopic submicroscopic deletions SIM1
0.105649576.10587584.html.plaintext.txt	134	Position effects expression nearby genes could also account phenotype proband
0.105649576.10587584.html.plaintext.txt	135	Inspection human transcript map revealed obvious candidate genes near either translocation breakpoint
0.105649576.10587584.html.plaintext.txt	136	The leptin receptor gene LEPR maps 1p31 20 Mb 1p breakpoint locus appeared intact FISH data shown
0.105649576.10587584.html.plaintext.txt	137	The human obesity related trait genetically mapped near either breakpoint quantitative trait locus 24 h respiratory quotient linked D1S550 1p31 p21 study Pima Indians 22
0.105649576.10587584.html.plaintext.txt	138	However locus unlikely relevant subject phenotype since 24 h respiratory quotient normal
0.105649576.10587584.html.plaintext.txt	139	It also possible phenotype proband translocation coincidental
0.105649576.10587584.html.plaintext.txt	140	Indeed father brother carry translocation large
0.105649576.10587584.html.plaintext.txt	141	However unlike proband father obesity developed adulthood brother growth sufficiently abnormal bring medical attention
0.105649576.10587584.html.plaintext.txt	142	Nevertheless complex trait genetic background environmental factors undoubtedly contribute severity phenotype
0.105649576.10587584.html.plaintext.txt	143	SIM1 mammalian homolog Drosophila transcription factor Single minded prototypical member bHLH PAS basic helix loop helix period aryl hydrocarbon receptor Single minded family proteins
0.105649576.10587584.html.plaintext.txt	144	Homozygous loss function mutations Drosophila Single minded result failure formation midline central nervous system structures 23
0.105649576.10587584.html.plaintext.txt	145	Two mouse genes Sim1 Sim2 cloned nucleotide sequence homology 24
0.105649576.10587584.html.plaintext.txt	146	Both homologs also present humans predicted mouse human SIM1 proteins show 96 amino acid identity 25
0.105649576.10587584.html.plaintext.txt	147	Dimerization bHLH PAS proteins bHLH PAS proteins aryl hydrocarbon receptor nuclear translocator necessary function 26
0.105649576.10587584.html.plaintext.txt	148	Specificity dimerization mediated least part PAS domains 27
0.105649576.10587584.html.plaintext.txt	149	The translocation SW116 separates promoter bHLH encoding exon 1 SIM1 downstream portion gene encoding PAS transcriptional regulatory domains probably represents loss function mutation
0.105649576.10587584.html.plaintext.txt	150	By northern blot analysis mouse Sim1 expressed adult kidney 2428
0.105649576.10587584.html.plaintext.txt	151	Whole mount situ hybridization embryonic day 16
0.105649576.10587584.html.plaintext.txt	152	5 mouse embryos revealed expression restricted kidney tubules spinal cord parts midbrain forebrain
0.105649576.10587584.html.plaintext.txt	153	Particularly interesting Sim1 expression anterior hypothalamic nuclei forebrain
0.105649576.10587584.html.plaintext.txt	154	29 determined Sim1 highly expressed supraoptic SON paraventricular PVN anterior periventricular aPV nuclei hypothalamus newborn mice
0.105649576.10587584.html.plaintext.txt	155	Both SON PVN neuroendocrine functions
0.105649576.10587584.html.plaintext.txt	156	The PVN produces corticotropin releasing factor CRF thyrotropin releasing hormone TRH whereas PVN SON produce oxytocin arginine vasopressin AVP
0.105649576.10587584.html.plaintext.txt	157	The aPV produces somatostatin also impinges pituitary
0.105649576.10587584.html.plaintext.txt	158	Targeted inactivation Sim1 confirmed critical role development neuroendocrine lineages hypothalamus 29
0.105649576.10587584.html.plaintext.txt	159	In mice lacking SIM1 nuclei hypocellular lack least five types secretory neuron identified expression oxytocin vasopressin TRH corticotropin releasing hormone somatostatin due failure terminal neuronal differentiation
0.105649576.10587584.html.plaintext.txt	160	These animals die shortly birth presumably due multiple hypothalamic pituitary axis HPA deficits
0.105649576.10587584.html.plaintext.txt	161	There discernible phenotype tissues
0.105649576.10587584.html.plaintext.txt	162	No growth abnormality heterozygotes reported preclude human SIM1 heterozyogous phenotype examples genes haploinsufficient humans laboratory mice e
0.105649576.10587584.html.plaintext.txt	163	endothelin B receptor 3031 Sonic hedgehog 32
0.105649576.10587584.html.plaintext.txt	164	Detailed studies Sim1 heterozygous mice progress
0.105649576.10587584.html.plaintext.txt	165	Sim1 continues expressed PVN adult mice unpublished data suggesting SIM1 participates post developmental HPA functions
0.105649576.10587584.html.plaintext.txt	166	These functions presently obscure since SIM1 transcriptional targets known
0.105649576.10587584.html.plaintext.txt	167	Expression Sim1 PVN intriguing regard obesity since nucleus critical integration signals governing appetite energy expenditure 17
0.105649576.10587584.html.plaintext.txt	168	Lesions rat PVN result obesity microinjection PVN virtually known orexigenic neuro transmitters neuropeptides stimulates feeding
0.105649576.10587584.html.plaintext.txt	169	Conversely microinjection anorexic peptides CRF leptin attenuates post fasting food intake
0.105649576.10587584.html.plaintext.txt	170	PVN neurons also express MC4R 33 neuropeptide Y receptors Y1 34 Y5 35 galanin galanin receptors 1 2 36 CRF CRF receptor 3738 orexin 2 hypocretin receptor 39
0.105649576.10587584.html.plaintext.txt	171	This nucleus appears important mediator anorexigenic orexigenic signals 17
0.105649576.10587584.html.plaintext.txt	172	Mutations MC4R gene shown cause obesity increased linear growth mice humans 1415
0.105649576.10587584.html.plaintext.txt	173	The increased linear growth phenotype general feature monogenic obesity since leptin deficiency increase linear growth humans 40 fact impairs linear growth mice
0.105649576.10587584.html.plaintext.txt	174	In regard proband tall stature coincident expression SIM1 MC4R PVN suggest genes may belong physiological even molecular pathway regulating growth energy balance
0.105649576.10587584.html.plaintext.txt	175	Alternatively proband stature may reflect increased growth velocity without change final height noted obese children ascribed increased insulin levels 41
0.105649576.10587584.html.plaintext.txt	176	Previous genetic pharmacological studies identified number signaling molecules important hypothalamic regulation energy balance 17 studies examined nuclear transcription
0.105649576.10587584.html.plaintext.txt	177	The transcription factor Fos induced rapidly response cytokine related signals induction used map leptin responsive neurons hypothalamus 42
0.105649576.10587584.html.plaintext.txt	178	Mice lacking another transcription factor expressed hypothalamus nHLH2 show adult onset obesity possibly quantitative defect POMC levels arcuate nucleus 43
0.105649576.10587584.html.plaintext.txt	179	It seems likely changes hypothalamic gene expression mediated transcription factors nHLH2 SIM1 play role long term regulation food intake energy expenditure
0.105649576.10587584.html.plaintext.txt	180	MATERIALS AND METHODS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES Clinical studies Studies approved Institutional Review Boards University Texas Southwestern Medical School Baylor College Medicine informed consent obtained studies
0.105649576.10587584.html.plaintext.txt	181	Body weight measured digital balance height measured stadiometer
0.105649576.10587584.html.plaintext.txt	182	Skinfold circumference measurements taken various sites body
0.105649576.10587584.html.plaintext.txt	183	Dual energy X ray absorptiometry DXA Hologic 4500A Madison WI used measure fat mass fat free mass total body bone mineral content
0.105649576.10587584.html.plaintext.txt	184	A 3 day food intake record kept child parents instruction registered dietitian
0.105649576.10587584.html.plaintext.txt	185	The food intake records converted nutrient intakes energy protein fat carbohydrate using Minnesota Nutrition Data System
0.105649576.10587584.html.plaintext.txt	186	Energy expenditure measured metabolic research unit calorimetry free living state doubly labeled water method
0.105649576.10587584.html.plaintext.txt	187	Energy expenditure measured 24 h room respiration calorimeter
0.105649576.10587584.html.plaintext.txt	188	The operation calibration calorimeters described detail previously 44
0.105649576.10587584.html.plaintext.txt	189	Energy expenditure computed 1 min intervals O2 consumption CO2 production used calculate 24 h total energy expenditure basal metabolic rate sleeping metabolic rate respiratory quotient
0.105649576.10587584.html.plaintext.txt	190	Total energy expenditure 14 day period calculated fractional turnover rates 2H 18O following oral ingestion 100 mgkg 2H2O 125 mgkg 18O water 45
0.105649576.10587584.html.plaintext.txt	191	Isotope dilution spaces used compute total body water
0.105649576.10587584.html.plaintext.txt	192	Baseline urine samples collected
0.105649576.10587584.html.plaintext.txt	193	Subsequently one daily urine sample collected home next 14 days
0.105649576.10587584.html.plaintext.txt	194	The 2H 18O abundances urine samples measured gas isotope ratio mass spectrometry
0.105649576.10587584.html.plaintext.txt	195	CO2 production VCO2 calculated dilution spaces fractional turnover rates 2H 18O using multipoint slope intercept method
0.105649576.10587584.html.plaintext.txt	196	Fractionated insensible water losses calculated ventilatory volume body surface area expressed functions CO2 production
0.105649576.10587584.html.plaintext.txt	197	Total energy expenditure calculated using Weir equation 46
0.105649576.10587584.html.plaintext.txt	198	Molecular studies Epstein Barr virus immortalized cell lines generated SW116 parents standard methods
0.105649576.10587584.html.plaintext.txt	199	The balanced translocation verified two color FISH previously described 47 using whole chromosome paints chromosomes 1 6
0.105649576.10587584.html.plaintext.txt	200	A somatic cell hybrid retaining der1 chromosome constructed fusing patient lymphoblastoid cells thymidine kinase deficient Chinese hamster cells 48 using polyethylene glycol 4000 Life Technologies Rockville MD
0.105649576.10587584.html.plaintext.txt	201	Colonies selected presence hypoxanthine aminopterin thymidine
0.105649576.10587584.html.plaintext.txt	202	After 10 serial passages DNA extracted clones tested PCR various chromosome 1 6 STS markers
0.105649576.10587584.html.plaintext.txt	203	BAC clones isolated PCR screening pooled DNAs Research Genetics Huntsville AL
0.105649576.10587584.html.plaintext.txt	204	YAC clone y852C9 obtained local copy CEPH library
0.105649576.10587584.html.plaintext.txt	205	YAC clone yA35F11 isolated PCR screening pooled DNAs Washington University library
0.105649576.10587584.html.plaintext.txt	206	YACs BACs used FISH described previously 47
0.105649576.10587584.html.plaintext.txt	207	PAC clones isolated arrayed library 49 filter hybridization
0.105649576.10587584.html.plaintext.txt	208	BAC PAC ends sequenced using either Thermo Sequenase cycle sequencing kit Amersham Pharmacia Biotech Uppsala Sweden ABI PRISM 310 automated sequencer Perkin Elmer Applied Biosystems Foster City CA according manufacturers instructions
0.105649576.10587584.html.plaintext.txt	209	Exon trapping experiments performed using BAC clones b261L4 b219G7 described 50
0.105649576.10587584.html.plaintext.txt	210	PCR Southern blotting performed using standard protocols 51
0.105649576.10587584.html.plaintext.txt	211	Genomic DNA SW116 parents digested XbaI hybridized KpnI XbaI fragment chromosome 1 GenBank accession
0.105649576.10587584.html.plaintext.txt	212	AL049861 nucleotides 83 014 85 386
0.105649576.10587584.html.plaintext.txt	213	After exposure phosphoimager screen filter stripped reprobed HindIII fragment chromosome 6 GenBank accession
0.105649576.10587584.html.plaintext.txt	214	Z86062 nucleotides 54 268 54 318
0.105649576.10587584.html.plaintext.txt	215	Primer pairs GACCCCTTCACTCTGCTGTAACC TCGCCGAGCCCTGTGGAGAC CATCTTTTGTCTCCCCTCCTGAAC CAAAAGGGTACTCTAG CCGACTCC used PCR amplify der6 der1 junction sequences respectively
0.105649576.10587584.html.plaintext.txt	216	Products sequenced directly using ABI 310 sequencer
0.105649576.10587584.html.plaintext.txt	217	SSCP performed using MDE gel matrix FMC Bioproducts Rockland ME according manufacturer instructions
0.105649576.10587584.html.plaintext.txt	218	Primers used amplify SIM1 exons follows
0.105649576.10587584.html.plaintext.txt	219	AGAAGAAAGGGGGAACAAGACACA exon 1
0.105649576.10587584.html.plaintext.txt	220	TGTGGCTGAGTCTCCCTCCCTATC exon 6
0.105649576.10587584.html.plaintext.txt	221	ATGGTGGCTGATTAAGGGCTTTGT exon 9
0.105649576.10587584.html.plaintext.txt	222	TGGAGTTCGGGAACCCTTTCAC exon 10
0.105649576.10587584.html.plaintext.txt	223	CATAGTAAATGCTGGTAATGGGGTAT exon 11
0.105649576.10587584.html.plaintext.txt	224	The exon 10 11 products digested HhaI MnlI respectively prior SSCP
0.105649576.10587584.html.plaintext.txt	225	ACKNOWLEDGEMENTS We thank R
0.105649576.10587584.html.plaintext.txt	226	Ouyang assistance contig construction P
0.105649576.10587584.html.plaintext.txt	227	White DNA samples obese children S
0.105649576.10587584.html.plaintext.txt	228	Gregory Sanger Center DNA sequencing J
0.105649576.10587584.html.plaintext.txt	229	Hoo cells 6q deletion patient R
0.105649576.10587584.html.plaintext.txt	230	Unger leptin measurements C
0.105649576.10587584.html.plaintext.txt	231	Michaud communicating unpublished data H
0.105649576.10587584.html.plaintext.txt	232	Magargal helpful comments manuscript patient SW116 parents physicians G
0.105649576.10587584.html.plaintext.txt	233	This work supported American Diabetes Association US Department Agriculture Medical Scientist Training Program UT Southwestern
0.105649576.10587584.html.plaintext.txt	234	FOOTNOTES To correspondence addressed
0.105649576.10587584.html.plaintext.txt	235	Tel 1 214 648 1600 Fax 1 214 648 1666 Email azndrew
0.105649576.10587584.html.plaintext.txt	236	REFERENCES TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES 1 Stunkard A
0.105649576.10587584.html.plaintext.txt	237	1986 An adoption study human obesity
0.105649576.10587584.html.plaintext.txt	238	1990 The body mass index twins reared apart
0.105649576.10587584.html.plaintext.txt	239	1999 The human obesity gene map 1998 update
0.105649576.10587584.html.plaintext.txt	240	1994 Positional cloning mouse obese gene human homologue
0.105649576.10587584.html.plaintext.txt	241	1995 Identification expression cloning leptin receptor OB R
0.105649576.10587584.html.plaintext.txt	242	1996 Abnormal splicing leptin receptor diabetic mice
0.105649576.10587584.html.plaintext.txt	243	1996 Evidence diabetes gene encodes leptin receptor identification mutation leptin receptor gene dbdb mice
0.105649576.10587584.html.plaintext.txt	244	1995 Hyperproinsulinaemia obese fatfat mice associated carboxypeptidase E mutation reduces enzyme activity
0.105649576.10587584.html.plaintext.txt	245	1993 Cloning mouse agouti gene predicts secreted protein ubiquitously expressed mice carrying lethal yellow mutation
0.105649576.10587584.html.plaintext.txt	246	1997 Congenital leptin deficiency associated severe early onset obesity humans
0.105649576.10587584.html.plaintext.txt	247	1998 A mutation human leptin receptor gene causes obesity pituitary dysfunction
0.105649576.10587584.html.plaintext.txt	248	1998 Severe early onset obesity adrenal insufficiency red hair pigmentation caused POMC mutations humans
0.105649576.10587584.html.plaintext.txt	249	1997 Obesity impaired prohormone processing associated mutations human prohormone convertase 1 gene
0.105649576.10587584.html.plaintext.txt	250	1998 A frameshift mutation MC4R associated dominant form obesity
0.105649576.10587584.html.plaintext.txt	251	1998 A frameshift mutation MC4R associated dominantly inherited human obesity
0.105649576.10587584.html.plaintext.txt	252	1997 Targeted disruption melanocortin 4 receptor results obesity mice
0.105649576.10587584.html.plaintext.txt	253	1999 Interacting appetite regulating pathways hypothalamic regulation body weight
0.105649576.10587584.html.plaintext.txt	254	1998 Leptin levels non obese obese children young adults type 1 diabetes mellitus
0.105649576.10587584.html.plaintext.txt	255	1997 Serum leptin levels normal children relationship age gender body mass index pituitary gonadal hormones pubertal stage
0.105649576.10587584.html.plaintext.txt	256	1988 6q1 monosomy distinctive syndrome
0.105649576.10587584.html.plaintext.txt	257	1995 De novo interstitial deletion q16
0.105649576.10587584.html.plaintext.txt	258	1998 Autosomal genomic scan loci linked obesity energy metabolism Pima Indians
0.105649576.10587584.html.plaintext.txt	259	1990 The single minded gene Drosophila required expression genes important development CNS midline cells
0.105649576.10587584.html.plaintext.txt	260	1996 Expression patterns two murine homologs Drosophila single minded suggest possible roles embryonic patterning pathogenesis Down syndrome
0.105649576.10587584.html.plaintext.txt	261	1997 Cloning two human homologs Drosophila single minded gene SIM1 chromosome 6q SIM2 21q within Down syndrome chromosomal region
0.105649576.10587584.html.plaintext.txt	262	1997 Single minded two genes three chromosomes
0.105649576.10587584.html.plaintext.txt	263	1997 The PAS domain confers target gene specificity Drosophila bHLHPAS proteins
0.105649576.10587584.html.plaintext.txt	264	1996 Two new members murine Sim gene family transcriptional repressors show different expression patterns mouse embryogenesis
0.105649576.10587584.html.plaintext.txt	265	1998 Development neuroendocrine lineages requires bHLH PAS transcription factor SIM1
0.105649576.10587584.html.plaintext.txt	266	1994 Targeted natural piebald lethal mutations endothelin B receptor gene produce megacolon associated spotted coat color mice
0.105649576.10587584.html.plaintext.txt	267	1994 A missense mutation endothelin B receptor gene multigenic Hirschsprung disease
0.105649576.10587584.html.plaintext.txt	268	1996 Mutations human Sonic Hedgehog gene cause holoprosencephaly
0.105649576.10587584.html.plaintext.txt	269	1994 Localization melanocortin 4 receptor MC4 R neuroendocrine autonomic control circuits brain
0.105649576.10587584.html.plaintext.txt	270	1996 Expression neuropeptide Y Y1 receptor mRNA human brain situ hybridization study
0.105649576.10587584.html.plaintext.txt	271	1996 A receptor subtype involved neuropeptide Y induced food intake
0.105649576.10587584.html.plaintext.txt	272	1998 Galanin galanin receptor systems hypothalamic paraventricular supraoptic nuclei
0.105649576.10587584.html.plaintext.txt	273	Some recent findings future challenges
0.105649576.10587584.html.plaintext.txt	274	1996 Expression corticotropin releasing factor receptors brain lean obese Zucker rats
0.105649576.10587584.html.plaintext.txt	275	Endocrinology 137 4786 4795
0.105649576.10587584.html.plaintext.txt	276	1996 Identification targets leptin action rat hypothalamus
0.105649576.10587584.html.plaintext.txt	277	1998 Distribution orexin receptor mRNA rat brain
0.105649576.10587584.html.plaintext.txt	278	1995 Growth charts growth velocity bone development childhood obesity
0.105649576.10587584.html.plaintext.txt	279	1996 Leptin activation hypothalamus
0.105649576.10587584.html.plaintext.txt	280	1997 Hypogonadism obesity mice targeted deletion Nhlh2 gene
0.105649576.10587584.html.plaintext.txt	281	1995 Closed loop control carbon dioxide concentration pressure improves response room respiration calorimeters
0.105649576.10587584.html.plaintext.txt	282	45 IDEC Group 1990 The Doubly Labeled Water Method Measuring Energy Expenditure Technical Recommendations Use Humans
0.105649576.10587584.html.plaintext.txt	283	International Atomic Energy Agency Vienna Austria
0.105649576.10587584.html.plaintext.txt	284	1949 New methods calculating metabolic rate special reference protein metabolism
0.105649576.10587584.html.plaintext.txt	285	1997 Prune belly syndrome anomalies stillborn fetus ring X chromosome lacking XIST
0.105649576.10587584.html.plaintext.txt	286	1979 Regional localization human gene loci chromosome 9 studies somatic cell hybrids containing human translocations
0.105649576.10587584.html.plaintext.txt	287	1994 A new bacteriophage P1 derived vector propagation large human DNA fragments
0.105649576.10587584.html.plaintext.txt	288	1999 New gene family defined MORC nuclear protein required mouse spermatogenesis
0.105649576.10587584.html.plaintext.txt	289	1989 Molecular Cloning A Laboratory Manual
0.105649576.10587584.html.plaintext.txt	290	Cold Spring Harbor Press Cold Spring Harbor NY
0.105649576.10587584.html.plaintext.txt	291	1977 The presentation use height weight data comparing nutritional status groups children age 10 years
0.18602495.16160021.html.plaintext.txt	0	Shared genetic risk factors obstructive sleep apnea obesity Sanjay R
0.18602495.16160021.html.plaintext.txt	1	Division Sleep Medicine Brigham Women Hospital Boston Massachusetts
0.18602495.16160021.html.plaintext.txt	2	ABSTRACT TOP ABSTRACT FAMILIAL AGGREGATION OF OBESITY
0.18602495.16160021.html.plaintext.txt	3	SHARED SUSCEPTIBILITY GENES GENE x ENVIRONMENT INTERACTION FUTURE DIRECTIONS GRANTS REFERENCES Both obesity obstructive sleep apnea OSA complex disorders multiple risk factors interact complicated fashion determine overall phenotype
0.18602495.16160021.html.plaintext.txt	4	In addition environmental risk factors disorder strong genetic basis likely due summation small moderate effects large number genetic loci
0.18602495.16160021.html.plaintext.txt	5	Obesity strong risk factor sleep apnea data suggest sleep apnea may influence obesity
0.18602495.16160021.html.plaintext.txt	6	It therefore surprising many susceptibility genes obesity OSA shared
0.18602495.16160021.html.plaintext.txt	7	Current research suggests approximately half genetic variance apnea hypopnea index shared obesity phenotypes
0.18602495.16160021.html.plaintext.txt	8	Genetic polymorphisms increase weight also risk factors apnea
0.18602495.16160021.html.plaintext.txt	9	In addition given interrelated pathways regulating weight intermediate phenotypes sleep apnea ventilatory control upper airway muscle function sleep characteristics likely genes pleiotropic effects independently impacting obesity OSA traits
0.18602495.16160021.html.plaintext.txt	10	Other genetic loci likely interact obesity influence development OSA gene environment type effect
0.18602495.16160021.html.plaintext.txt	11	Conversely environmental stressors intermittent hypoxia sleep fragmentation produced OSA may interact obesity susceptibility genes modulate importance loci defining obesity related traits
0.18602495.16160021.html.plaintext.txt	12	susceptibility genes pleiotropy gene x environment effects
0.18602495.16160021.html.plaintext.txt	13	OBSTRUCTIVE SLEEP APNEA OSA disorder characterized repetitive collapse upper airway sleep one common respiratory disorders estimated prevalence 24 9 among middle aged American men women respectively 92
0.18602495.16160021.html.plaintext.txt	14	Obesity modern Western society also extremely common
0.18602495.16160021.html.plaintext.txt	15	As 2002 nearly one third US adults met clinical criteria obesity prevalence appears increasing 27
0.18602495.16160021.html.plaintext.txt	16	That obesity OSA often colocalize surprise
0.18602495.16160021.html.plaintext.txt	17	Other perhaps male gender obesity strongest risk factor development OSA
0.18602495.16160021.html.plaintext.txt	18	Relative stable weight 10 increase weight 4 yr associated sixfold increase risk developing moderate severe OSA 58
0.18602495.16160021.html.plaintext.txt	19	Weight loss trials found significant reductions apnea severity moderate weight loss 69 74
0.18602495.16160021.html.plaintext.txt	20	However mechanisms obesity causes OSA completely defined many potential pathways hypothesized 93
0.18602495.16160021.html.plaintext.txt	21	Perhaps obvious fat deposition neck airway lumen may lead increased collapsibility upper airway
0.18602495.16160021.html.plaintext.txt	22	In addition adiposity chest abdomen may result reductions lung volumes
0.18602495.16160021.html.plaintext.txt	23	Recent studies suggest reduced lung volume may independently predispose upper airway collapse 37
0.18602495.16160021.html.plaintext.txt	24	Another possible mechanism relating obesity sleep apnea via hormonal effects adipose tissue
0.18602495.16160021.html.plaintext.txt	25	Leptin hormone produced adipose tissue important effects weight regulation stimulating hypothalamic satiety centers 6 34 57
0.18602495.16160021.html.plaintext.txt	26	Human obesity typically associated elevated leptin levels suggesting state leptin resistance 15
0.18602495.16160021.html.plaintext.txt	27	Besides regulating weight leptin may important effects ventilatory drive
0.18602495.16160021.html.plaintext.txt	28	Leptin deficient mice hypoventilate blunted response hypercapnia 53 84
0.18602495.16160021.html.plaintext.txt	29	Administration leptin corrects abnormalities independent changes weight 53
0.18602495.16160021.html.plaintext.txt	30	Through effects ventilatory control elevated leptin levels underlying leptin resistant state may play pathogenic role development OSA
0.18602495.16160021.html.plaintext.txt	31	It also possible OSA may play causal role development obesity
0.18602495.16160021.html.plaintext.txt	32	OSA patients elevated leptin levels compared weight matched controls OSA treatment lowers levels 39 53 55
0.18602495.16160021.html.plaintext.txt	33	These findings suggest OSA may cause leptin resistance thus propensity weight gain
0.18602495.16160021.html.plaintext.txt	34	Not sleep disruption common result OSA reduce serum leptin levels also increases levels appetite stimulating hormone ghrelin 76 82
0.18602495.16160021.html.plaintext.txt	35	These findings associated increases hunger appetite scores 76
0.18602495.16160021.html.plaintext.txt	36	Epidemiological studies consistently implicate reduced sleep risk factor development obesity 36 47 70 82 87 89
0.18602495.16160021.html.plaintext.txt	37	Although overall weight appear fall treatment OSA one study find amount fat inside abdominal cavity visceral fat diminishes 10
0.18602495.16160021.html.plaintext.txt	38	This fat compartment appears unique hormonal effects amount visceral adipose tissue strongly associated metabolic complications obesity insulin resistance dyslipidemia measures subcutaneous fat overall obesity 28 29
0.18602495.16160021.html.plaintext.txt	39	FAMILIAL AGGREGATION OF OBESITY AND SLEEP APNEA TOP ABSTRACT FAMILIAL AGGREGATION OF OBESITY
0.18602495.16160021.html.plaintext.txt	40	SHARED SUSCEPTIBILITY GENES GENE x ENVIRONMENT INTERACTION FUTURE DIRECTIONS GRANTS REFERENCES That obesity large part genetically determined known almost three decades 26
0.18602495.16160021.html.plaintext.txt	41	A large twin study estimated heritability weight 78 79
0.18602495.16160021.html.plaintext.txt	42	That say 78 variability weight across population explained shared intrafamilial factors
0.18602495.16160021.html.plaintext.txt	43	Subsequent studies demonstrated adopted children body size closely resembling biological parents adopted parents 80
0.18602495.16160021.html.plaintext.txt	44	Studies Finland United Kingdom estimated heritability body mass index BMI 60 80 42 61
0.18602495.16160021.html.plaintext.txt	45	Linkage obesity related phenotypes investigated 50 genomewide scans date dozens candidate loci genes identified 3 59
0.18602495.16160021.html.plaintext.txt	46	Similarly familial factors known influence OSA risk nearly 25 years 77
0.18602495.16160021.html.plaintext.txt	47	Since several groups quantified familial risk OSA studying widely different populations
0.18602495.16160021.html.plaintext.txt	48	All studies identified strong heritable component OSA 30 32 49 62 66
0.18602495.16160021.html.plaintext.txt	49	Family based studies suggest risk OSA approximately twice great among relatives apneic persons 30 66
0.18602495.16160021.html.plaintext.txt	50	In addition dose response relationship exists risk OSA increases increasing number apneic relatives 66
0.18602495.16160021.html.plaintext.txt	51	Quantitative apnea related phenotypes also demonstrate substantial heritability
0.18602495.16160021.html.plaintext.txt	52	A study elderly twins found heritability respiratory disturbance index oxygen desaturation index nearly 40 7
0.18602495.16160021.html.plaintext.txt	53	SHARED SUSCEPTIBILITY GENES TOP ABSTRACT FAMILIAL AGGREGATION OF OBESITY
0.18602495.16160021.html.plaintext.txt	54	SHARED SUSCEPTIBILITY GENES GENE x ENVIRONMENT INTERACTION FUTURE DIRECTIONS GRANTS REFERENCES Given strong genetic components obesity apnea phenotypes well tight association multiple interweaving links two diseases would surprising exist common susceptibility genes obesity OSA
0.18602495.16160021.html.plaintext.txt	55	In fact suggested familial aggregation OSA may simply reflection found obesity
0.18602495.16160021.html.plaintext.txt	56	Even controlling BMI significant familial aggregation OSA persists 32 66
0.18602495.16160021.html.plaintext.txt	57	Furthermore study nonobese apneic patients also demonstrated strong heritability OSA 49
0.18602495.16160021.html.plaintext.txt	58	That case surprise given pathophysiological pathways apnea development craniofacial structure ventilatory control also demonstrated heritable component 13 32 49 63 65
0.18602495.16160021.html.plaintext.txt	59	Thus susceptibility genes OSA exclusively genes modulating obesity
0.18602495.16160021.html.plaintext.txt	60	That mean however overlap exists
0.18602495.16160021.html.plaintext.txt	61	Clearly given strong effect obesity OSA pathogenesis genetic variant predisposes obesity secondarily also lead development OSA
0.18602495.16160021.html.plaintext.txt	62	Thus obesity gene might also considered apnea gene
0.18602495.16160021.html.plaintext.txt	63	However obesity monolithic process
0.18602495.16160021.html.plaintext.txt	64	Clearly forms obesity important role pathogenesis sleep apnea
0.18602495.16160021.html.plaintext.txt	65	For example fat deposition neck much important fat deposition limbs 17
0.18602495.16160021.html.plaintext.txt	66	An android fat deposition pattern excess subcutaneous truncal abdominal fat visceral adiposity also found closely predict OSA overall obesity 31 72
0.18602495.16160021.html.plaintext.txt	67	Therefore genetic polymorphisms influence fat deposition sites important OSA genes
0.18602495.16160021.html.plaintext.txt	68	There wealth evidence fat distribution pattern phenotypes genetically driven
0.18602495.16160021.html.plaintext.txt	69	Large differences patterns fat deposition exist across inbred strains cattle suggesting important role genetics 83
0.18602495.16160021.html.plaintext.txt	70	Among humans even correction overall obesity measures fat deposition pattern aggregate within families
0.18602495.16160021.html.plaintext.txt	71	The ratio subscapular skinfold thickness subscapular plus suprailiac thicknesses measure android fat pattern reported heritability 43 71
0.18602495.16160021.html.plaintext.txt	72	Measures central obesity BMI adjusted waist circumference ratio trunk extremity skinfold ratio heritabilities 29 48 40
0.18602495.16160021.html.plaintext.txt	73	These findings strongly support hypothesis genetic polymorphisms specifically promote fat deposition subcutaneous regions torso around abdominal viscera
0.18602495.16160021.html.plaintext.txt	74	Through mechanism variants would promote development obesity OSA
0.18602495.16160021.html.plaintext.txt	75	Another type potential genetic interaction obesity OSA one particular polymorphism leads obesity OSA independent mechanisms Fig
0.18602495.16160021.html.plaintext.txt	76	For example impacting leptin function genetic polymorphism may reduce satiety also increase ventilatory instability
0.18602495.16160021.html.plaintext.txt	77	This referred genetic pleiotropy
0.18602495.16160021.html.plaintext.txt	78	Pleiotropic genetic effects clearly described situations
0.18602495.16160021.html.plaintext.txt	79	A well known example APOE locus codes apolipoprotein E
0.18602495.16160021.html.plaintext.txt	80	The 4 allele APOE important risk factor atherosclerotic heart disease well Alzheimer dementia 24 91
0.18602495.16160021.html.plaintext.txt	81	The circadian regulatory gene CLOCK also appears influence multiple biological systems
0.18602495.16160021.html.plaintext.txt	82	CLOCK knockout mice profound disruptions circadian rhythmicity surprising animals would abnormal timings feeding activity 88
0.18602495.16160021.html.plaintext.txt	83	In addition however mutant animals demonstrate overall increase caloric intake associated phenotype obesity metabolic syndrome 85
0.18602495.16160021.html.plaintext.txt	84	Similarly given large number neurological metabolic mechanical overlaps obesity OSA likely polymorphism affecting one biochemical system may affect risk disorders via multiple paths
0.18602495.16160021.html.plaintext.txt	85	For example disruptions orexin system could potentially result common link obesity OSA
0.18602495.16160021.html.plaintext.txt	86	Orexinergic neurons lateral hypothalamus play important role sustaining wakefulness projections wake promoting areas brain 21
0.18602495.16160021.html.plaintext.txt	87	Loss neurons associated narcolepsy phenotype 60
0.18602495.16160021.html.plaintext.txt	88	These neurons name orexin implies also play important role stimulating appetite projecting arcuate nucleus hypothalamus 68
0.18602495.16160021.html.plaintext.txt	89	Thus mutations affecting orexin orexin receptor proteins involved downstream signaling orexin binding might simultaneously affect metabolic sleep related function
0.18602495.16160021.html.plaintext.txt	90	Several potential candidate genes listed Table 1
0.18602495.16160021.html.plaintext.txt	91	View larger version 13K Fig
0.18602495.16160021.html.plaintext.txt	92	Both obesity sleep apnea heavily influenced underlying genotype
0.18602495.16160021.html.plaintext.txt	93	Some susceptibility genes act directly one phenotype causal relationships obesity sleep apnea indirect effects
0.18602495.16160021.html.plaintext.txt	94	Other loci pleiotropic effects impacting susceptibility obesity sleep apnea via independent mechanisms
0.18602495.16160021.html.plaintext.txt	95	Candidate genes might link genetic mechanisms obesity sleep apnea either pleiotropy gene x environment interactions
0.18602495.16160021.html.plaintext.txt	96	The recently reported linkage scans Cleveland Family Study represent first genomewide linkage studies OSA phenotypes 54 55
0.18602495.16160021.html.plaintext.txt	97	The results provide insight possible genetic overlaps obesity OSA
0.18602495.16160021.html.plaintext.txt	98	Linkage apnea hypopnea index AHI measure OSA BMI measure obesity tested across autosomal chromosomes Caucasian African American cohort
0.18602495.16160021.html.plaintext.txt	99	The heritability AHI groups 33 whereas heritability BMI 50
0.18602495.16160021.html.plaintext.txt	100	After controlling BMI significant heritability AHI remained supporting notion genetic susceptibility OSA completely defined weight
0.18602495.16160021.html.plaintext.txt	101	In multivariate modeling larger subset Cleveland Family Study obesity measures BMI serum leptin explained 50 55 genetic variance AHI 56
0.18602495.16160021.html.plaintext.txt	102	This suggests half genetic determinants AHI obesity related half obesity independent
0.18602495.16160021.html.plaintext.txt	103	Linkage findings described logarithmic odds LOD score measure odds ratio linkage linkage
0.18602495.16160021.html.plaintext.txt	104	Although none linkage findings either racial group achieved genomewide significance LOD 3
0.18602495.16160021.html.plaintext.txt	105	3 46 several regions intermediate LOD scores indicative possible linkage setting complex multifactorial diseases obesity OSA 90
0.18602495.16160021.html.plaintext.txt	106	Furthermore change linkage evidence AHI adjustment BMI provides insight mechanisms action susceptibility locus present
0.18602495.16160021.html.plaintext.txt	107	Among Caucasians LOD score 1
0.18602495.16160021.html.plaintext.txt	108	7 BMI chromosome 12p 54
0.18602495.16160021.html.plaintext.txt	109	After adjustment BMI maximal LOD AHI region dropped 0
0.18602495.16160021.html.plaintext.txt	110	4 whereas LOD BMI adjusted AHI fell 0
0.18602495.16160021.html.plaintext.txt	111	These data suggest susceptibility gene AHI exists region likely mediates effect apnea via obesity
0.18602495.16160021.html.plaintext.txt	112	On hand maximal LOD AHI 1
0.18602495.16160021.html.plaintext.txt	113	4 found 19q linkage evidence BMI region 54
0.18602495.16160021.html.plaintext.txt	114	Adjustment BMI effect AHI LOD suggesting susceptibility gene region exerts effect AHI obesity independent mechanisms
0.18602495.16160021.html.plaintext.txt	115	A different pattern linkage findings found short arm chromosome 2
0.18602495.16160021.html.plaintext.txt	116	Among Caucasians maximal LOD AHI 1
0.18602495.16160021.html.plaintext.txt	117	1 region suggesting susceptibility locus phenotypes might exist region 54
0.18602495.16160021.html.plaintext.txt	118	However adjustment BMI dropped LOD AHI 1
0.18602495.16160021.html.plaintext.txt	119	3 suggesting obesity effect locus fully explain apnea effect
0.18602495.16160021.html.plaintext.txt	120	This may represent two independent loci one influencing AHI one BMI
0.18602495.16160021.html.plaintext.txt	121	Another possibility one locus 2p regulating AHI BMI via independent mechanisms
0.18602495.16160021.html.plaintext.txt	122	A strong candidate gene phenotypes region proopiomelanocortin POMC
0.18602495.16160021.html.plaintext.txt	123	3 encodes number hormones including melanocyte stimulating hormone MSH
0.18602495.16160021.html.plaintext.txt	124	POMC neurons arcuate nucleus hypothalamus important energy homeostasis via MSH
0.18602495.16160021.html.plaintext.txt	125	Leptin anorexic activity mediated via depolarization neurons use MSH agonist decreases body fat leptin levels humans 16 25
0.18602495.16160021.html.plaintext.txt	126	Obesity phenotypes consistently linked POMC locus 14 33 38 67 haplotypes gene associated leptin levels 38 50 severe mutations gene produce severe childhood obesity phenotype 44
0.18602495.16160021.html.plaintext.txt	127	Leptin effects ventilatory drive mouse models also mediated via MSH suggesting pathway may independently predispose apnea well 64
0.18602495.16160021.html.plaintext.txt	128	Evidence pleiotropy also exists chromosome 8q
0.18602495.16160021.html.plaintext.txt	129	Among African Americans Cleveland Family Study peak LOD scores 1
0.18602495.16160021.html.plaintext.txt	130	6 AHI BMI respectively 55
0.18602495.16160021.html.plaintext.txt	131	Again controlling BMI AHI LOD dropped 1
0.18602495.16160021.html.plaintext.txt	132	1 suggesting obesity apnea promoting effects region independent
0.18602495.16160021.html.plaintext.txt	133	A potential candidate locus region COH1 gene 8q22 23
0.18602495.16160021.html.plaintext.txt	134	This gene encodes transmembrane protein presumed role vesicle mediated sorting intracellular protein transport basis structure 43
0.18602495.16160021.html.plaintext.txt	135	Severe mutations gene associated Cohen syndrome autosomal recessive condition characterized truncal obesity 9
0.18602495.16160021.html.plaintext.txt	136	Other findings include facial dysmorphism mental retardation ocular anomalies
0.18602495.16160021.html.plaintext.txt	137	The craniofacial abnormalities include microcephaly facial hypotonia laryngomalacia could predispose OSA
0.18602495.16160021.html.plaintext.txt	138	Thus mutations gene milder common may play role via separate pathways contributing nonsyndromic forms obesity OSA
0.18602495.16160021.html.plaintext.txt	139	The serotoninergic system another common pathway could link obesity OSA
0.18602495.16160021.html.plaintext.txt	140	Serotonin important effects stimulation satiety centers arcuate nucleus 5
0.18602495.16160021.html.plaintext.txt	141	In addition serotonin potentiates hypoglossal neural output increases upper airway dilator muscle activity 45 75
0.18602495.16160021.html.plaintext.txt	142	Thus reductions serotoninergic activity increasing appetite could promote obesity lowering muscle tone upper airway could promote OSA
0.18602495.16160021.html.plaintext.txt	143	Both linkage haplotype association studies Finnish population suggest serotonin related gene Xq24 associated obesity 51 81
0.18602495.16160021.html.plaintext.txt	144	The SLC6A14 gene encodes sodium chloride dependent transporter neutral cationic amino acids appears play important role transport tryptophan precursor serotonin central nervous system 73
0.18602495.16160021.html.plaintext.txt	145	A French study confirmed association polymorphism obesity association hunger satiety scores also found 19
0.18602495.16160021.html.plaintext.txt	146	Whether polymorphism associated OSA via independent obesity effects yet studied OSA linkage scans reported thus far included sex chromosomes
0.18602495.16160021.html.plaintext.txt	147	GENE x ENVIRONMENT INTERACTION TOP ABSTRACT FAMILIAL AGGREGATION OF OBESITY
0.18602495.16160021.html.plaintext.txt	148	SHARED SUSCEPTIBILITY GENES GENE x ENVIRONMENT INTERACTION FUTURE DIRECTIONS GRANTS REFERENCES Another potential method genetic interaction obesity OSA form gene environment effect adverse effects obesity OSA thought environmental stressors Fig
0.18602495.16160021.html.plaintext.txt	149	Each methods obesity predisposes OSA influenced individual underlying genetic susceptibility
0.18602495.16160021.html.plaintext.txt	150	An increase fat deposition around upper airway likely produce apnea individuals lower ability respond stressor due reduced upper airway dilator muscle tone
0.18602495.16160021.html.plaintext.txt	151	Conversely obesogenic effects OSA may influenced underlying genetic milieu
0.18602495.16160021.html.plaintext.txt	152	Genetic polymorphisms may modulate effect exposure sleep fragmentation OSA leptin ghrelin dynamics
0.18602495.16160021.html.plaintext.txt	153	Other polymorphisms might influence effect hormonal perturbations producing weight gain
0.18602495.16160021.html.plaintext.txt	154	View larger version 24K Fig
0.18602495.16160021.html.plaintext.txt	155	Sleep apnea susceptibility genes may interact obesity numerous mechanisms influence sleep apnea predisposition
0.18602495.16160021.html.plaintext.txt	156	Genetic polymorphisms may modulate degree obesity alters ventilatory drive reduces lung volume narrows upper airway
0.18602495.16160021.html.plaintext.txt	157	Other polymorphisms may affect degree stresses result development sleep apnea
0.18602495.16160021.html.plaintext.txt	158	Similarly obesity susceptibility genes may interact sleep apnea potential effect obesity
0.18602495.16160021.html.plaintext.txt	159	The peroxisome proliferator activated receptor PPARG gene located chromosome 3p25 encodes protein key component nuclear transcription factor important adipocyte differentiation 4
0.18602495.16160021.html.plaintext.txt	160	Variants gene implicated risk factors development obesity 4 18 20 48 86
0.18602495.16160021.html.plaintext.txt	161	Because hypoxia known suppress PPARG gene transcription 94 95 importance mild defect PPARG function may become magnified setting recurrent exposure hypoxia OSA
0.18602495.16160021.html.plaintext.txt	162	Thus PPARG allelic variants may play much important role determining obesity phenotypes individuals OSA OSA may play much important role promoting weight gain among mutation PPARG
0.18602495.16160021.html.plaintext.txt	163	Similarly effects uncoupling protein 1 UCP1 UCP2 two obesity candidate genes may influenced OSA
0.18602495.16160021.html.plaintext.txt	164	These genes encode uncoupling proteins mitochondrial proton channels divert energy ATP synthesis thermogenesis 2
0.18602495.16160021.html.plaintext.txt	165	In activation increases energy consumption
0.18602495.16160021.html.plaintext.txt	166	Polymorphisms genes associated obesity phenotypes 8 12 22 23 52
0.18602495.16160021.html.plaintext.txt	167	Interestingly sleep deprivation rodent models shown increase expression UCP1 UCP2 11 41 suggesting sleep disruption OSA may influence expression genes thus relative importance variant loci determining obesity risk
0.18602495.16160021.html.plaintext.txt	168	FUTURE DIRECTIONS TOP ABSTRACT FAMILIAL AGGREGATION OF OBESITY
0.18602495.16160021.html.plaintext.txt	169	SHARED SUSCEPTIBILITY GENES GENE x ENVIRONMENT INTERACTION FUTURE DIRECTIONS GRANTS REFERENCES There appear multiple causal pathways linking obesity sleep apnea
0.18602495.16160021.html.plaintext.txt	170	Although obesity clearly strong risk factor OSA research needed better define potential risk OSA carries promoting weight gain
0.18602495.16160021.html.plaintext.txt	171	Both diseases also clearly strong genetic basis
0.18602495.16160021.html.plaintext.txt	172	Although work begun identify specific genetic polymorphisms confer risk development disorders clearly much needs accomplished arena
0.18602495.16160021.html.plaintext.txt	173	A recent workshop sponsored American Thoracic Society laid recommendations future research aimed dissecting genetic bases sleep disordered breathing 78
0.18602495.16160021.html.plaintext.txt	174	A chief objective development novel phenotypes including biomarkers closely reflect one molecular pathways rather overarching syndrome defined AHI
0.18602495.16160021.html.plaintext.txt	175	These simpler phenotypes could amenable genetic analysis fewer sources variance global measure apnea
0.18602495.16160021.html.plaintext.txt	176	The holds true obesity research use specific phenotypes fat deposition patterns would provide better insight molecular mechanisms underlying obesity also better understanding obesity OSA interrelate
0.18602495.16160021.html.plaintext.txt	177	The use dense single nucleotide polymorphism maps allow better resolution linkage findings narrow candidate loci
0.18602495.16160021.html.plaintext.txt	178	A better understanding neurobiology molecular pathways underlying obesity sleep apnea also allow rational selection candidate genes test association disorders
0.18602495.16160021.html.plaintext.txt	179	Ultimately use gene knockout animal models important establish causality identified associations
0.18602495.16160021.html.plaintext.txt	180	In performing genetic studies important simultaneously consider disorders given close relationship
0.18602495.16160021.html.plaintext.txt	181	Methodology conducting bivariate linkage scans already developed evidence suggest strategy powerful traditional univariate approaches 1
0.18602495.16160021.html.plaintext.txt	182	Not many genetic variants influence development OSA causing obesity vice versa likely also variants pleiotropic effects predisposing obesity OSA via independent mechanisms
0.18602495.16160021.html.plaintext.txt	183	Identifying genes understanding function provide novel insights shared pathogenesis diseases
0.18602495.16160021.html.plaintext.txt	184	Finally possibility genetic polymorphisms may affect susceptibility disease confers toward ignored
0.18602495.16160021.html.plaintext.txt	185	Incorporating model gene x environment interaction future study designs along understanding effects obesity OSA allow better delineation OSA susceptibility genes vice versa
0.18602495.16160021.html.plaintext.txt	186	Similarly use model along information genetics obesity would allow complete understanding OSA may impact obesity
0.18602495.16160021.html.plaintext.txt	187	GRANTS TOP ABSTRACT FAMILIAL AGGREGATION OF OBESITY
0.18602495.16160021.html.plaintext.txt	188	SHARED SUSCEPTIBILITY GENES GENE x ENVIRONMENT INTERACTION FUTURE DIRECTIONS GRANTS REFERENCES Research support provided American Heart Association Scientist Development Grant National Heart Lung Blood Institute Grant HL 60292
0.18602495.16160021.html.plaintext.txt	189	FOOTNOTES Address reprint requests correspondence S
0.18602495.16160021.html.plaintext.txt	190	Patel BWH Sleep Disorders Program BIDMC Brigham Women Hospital 75 Francis St
0.18602495.16160021.html.plaintext.txt	191	Boston MA 02115 e mail spatelatpartners
0.18602495.16160021.html.plaintext.txt	192	REFERENCES TOP ABSTRACT FAMILIAL AGGREGATION OF OBESITY
0.18602495.16160021.html.plaintext.txt	193	SHARED SUSCEPTIBILITY GENES GENE x ENVIRONMENT INTERACTION FUTURE DIRECTIONS GRANTS REFERENCES Almasy L Dyer TD Blangero J
0.18602495.16160021.html.plaintext.txt	194	Bivariate quantitative trait linkage analysis pleiotropy versus co incident linkages
0.18602495.16160021.html.plaintext.txt	195	Genet Epidemiol 14 953 958 1997
0.18602495.16160021.html.plaintext.txt	196	AbstractFree Full Text Bell CG Walley AJ Froguel P
0.18602495.16160021.html.plaintext.txt	197	Nat Rev Gen 6 221 234 2005
0.18602495.16160021.html.plaintext.txt	198	ISIMedline Berger J Moller DE
0.18602495.16160021.html.plaintext.txt	199	The mechanisms action PPARs
0.18602495.16160021.html.plaintext.txt	200	Annu Rev Med 53 409 435 2002
0.18602495.16160021.html.plaintext.txt	201	CrossRefISIMedline Blundell JE Goodson S Halford JC
0.18602495.16160021.html.plaintext.txt	202	Regulation appetite role leptin signalling systems drive satiety
0.18602495.16160021.html.plaintext.txt	203	Int J Obes Relat Metab Disord 25 Suppl 1 S29 S34 2001
0.18602495.16160021.html.plaintext.txt	204	CrossRef Campfield LA Smith FJ Guisez Y Devos R Burn P
0.18602495.16160021.html.plaintext.txt	205	Recombinant mouse OB protein evidence peripheral signal linking adiposity central neural networks
0.18602495.16160021.html.plaintext.txt	206	ISIMedline Carmelli D Colrain IM Swan GE Bliwise DL
0.18602495.16160021.html.plaintext.txt	207	Genetic environmental influences sleep disordered breathing older male twins
0.18602495.16160021.html.plaintext.txt	208	ISIMedline Cassell PG Neverova M Janmohamed S Uwakwe N Qureshi A McCarthy MI Saker PJ Albon L Kopelman P Noonan K Easlick J Ramachandran A Snehalatha C Pecqueur C Ricquier D Warden C Hitman GA
0.18602495.16160021.html.plaintext.txt	209	An uncoupling protein 2 gene variant associated raised body mass index Type II diabetes
0.18602495.16160021.html.plaintext.txt	210	Diabetologia 42 688 692 1999
0.18602495.16160021.html.plaintext.txt	211	CrossRefISIMedline Chandler KE Kidd A Al Gazali L Kolehmainen J Lehesjoki AE Black GC Clayton Smith J
0.18602495.16160021.html.plaintext.txt	212	Diagnostic criteria clinical characteristics natural history Cohen syndrome
0.18602495.16160021.html.plaintext.txt	213	J Med Genet 40 233 241 2003
0.18602495.16160021.html.plaintext.txt	214	AbstractFree Full Text Chin K Shimizu K Nakamura T Noboru N Masuzaki H Ogawa Y Mishima M Nakamura T Nakao K Ohi M
0.18602495.16160021.html.plaintext.txt	215	Changes intra abdominal visceral fat serum leptin levels patients obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapy
0.18602495.16160021.html.plaintext.txt	216	Circulation 100 706 712 1999
0.18602495.16160021.html.plaintext.txt	217	AbstractFree Full Text Cirelli C Tononi G
0.18602495.16160021.html.plaintext.txt	218	Uncoupling proteins sleep deprivation
0.18602495.16160021.html.plaintext.txt	219	Arch Ital Biol 142 541 549 2004
0.18602495.16160021.html.plaintext.txt	220	ISIMedline Clement K Ruiz J Cassard Doulcier AM Bouillaud F Ricquier D Basdevant A Guy Grand B Froguel P
0.18602495.16160021.html.plaintext.txt	221	Additive effect A G 3826 variant uncoupling protein gene Trp64Arg mutation beta 3 adrenergic receptor gene weight gain morbid obesity
0.18602495.16160021.html.plaintext.txt	222	Int J Obes Relat Metab Disord 20 1062 1066 1996
0.18602495.16160021.html.plaintext.txt	223	Medline Collins DD Scoggin CH Zwillich CW Weil JV
0.18602495.16160021.html.plaintext.txt	224	Hereditary aspects decreased hypoxic response
0.18602495.16160021.html.plaintext.txt	225	J Clin Invest 62 105 110 1978
0.18602495.16160021.html.plaintext.txt	226	ISIMedline Comuzzie AG Hixson JE Almasy L Mitchell BD Mahaney MC Dyer TD Stern MP MacCluer JW Blangero J
0.18602495.16160021.html.plaintext.txt	227	A major quantitative trait locus determining serum leptin levels fat mass located human chromosome 2
0.18602495.16160021.html.plaintext.txt	228	Nat Genet 15 273 276 1997
0.18602495.16160021.html.plaintext.txt	229	CrossRefISIMedline Considine RV Sinha MK Heiman ML Kriauciunas A Stephens TW Nyce MR Ohannesian JP Marco CC McKee LJ Bauer TL Caro JF
0.18602495.16160021.html.plaintext.txt	230	Serum immunoreactive leptin concentrations normal weight obese humans
0.18602495.16160021.html.plaintext.txt	231	N Engl J Med 334 292 295 1996
0.18602495.16160021.html.plaintext.txt	232	AbstractFree Full Text Cowley MA Smart JL Rubinstein M Cerdan MG Diano S Horvath TL Cone RD Low MJ
0.18602495.16160021.html.plaintext.txt	233	Leptin activates anorixegenic POMC neurons neural network arcuate nucleus
0.18602495.16160021.html.plaintext.txt	234	CrossRefISIMedline Davies RJ Ali NJ Stradling JR
0.18602495.16160021.html.plaintext.txt	235	Neck circumference clinical features diagnosis obstructive sleep apnoea syndrome
0.18602495.16160021.html.plaintext.txt	236	Abstract Deeb SS Fajas L Nemoto M Pihlajamaki J Mykkanen L Kuusisto J Laakso M Fujimoto W Auwerx J
0.18602495.16160021.html.plaintext.txt	237	A Pro12Ala substitution PPARgamma2 associated decreased receptor activity lower body mass index improved insulin sensitivity
0.18602495.16160021.html.plaintext.txt	238	Nat Genet 20 284 287 1998
0.18602495.16160021.html.plaintext.txt	239	CrossRefISIMedline Durand E Boutin P Meyre D Charles MA Clement K Dina C Froguel P
0.18602495.16160021.html.plaintext.txt	240	Polymorphisms amino acid transporter solute carrier family 6 neurotransmitter transporter member 14 gene contribute polygenic obesity French Caucasians
0.18602495.16160021.html.plaintext.txt	241	Diabetes 53 2483 2486 2004
0.18602495.16160021.html.plaintext.txt	242	AbstractFree Full Text Ek J Urhammer SA Sorensen TI Andersen T Auwerx J Pedersen O
0.18602495.16160021.html.plaintext.txt	243	Homozygosity Pro12Ala variant peroxisome proliferation activated receptor gamma2 PPAR gamma2 divergent modulating effects body mass index obese lean Caucasian men
0.18602495.16160021.html.plaintext.txt	244	Diabetologia 42 892 895 1999
0.18602495.16160021.html.plaintext.txt	245	CrossRefISIMedline Espana RA Scammell TE
0.18602495.16160021.html.plaintext.txt	246	Sleep neurobiology clinician
0.18602495.16160021.html.plaintext.txt	247	ISIMedline Esterbauer H Schneitler C Oberkofler H Ebenbichler C Paulweber B Sandhofer F Ladurner G Hell E Strosberg AD Patsch JR Krempler F Patsch W
0.18602495.16160021.html.plaintext.txt	248	A common polymorphism promoter UCP2 associated decreased risk obesity middle aged humans
0.18602495.16160021.html.plaintext.txt	249	CrossRefISIMedline Evans D Minouchehr S Hagemann G Mann WA Wendt D Wolf A Beisiegel U
0.18602495.16160021.html.plaintext.txt	250	Frequency interaction polymorphisms beta3 adrenergic receptor uncoupling proteins 1 2 obesity Germans
0.18602495.16160021.html.plaintext.txt	251	Int J Obes Relat Metab Disord 24 1239 1245 2000
0.18602495.16160021.html.plaintext.txt	252	CrossRefMedline Farrer LA Cupples LA Haines JL Hyman B Kukull WA Mayeux R Myers RH Pericak Vance MA Risch N van Duijn CM
0.18602495.16160021.html.plaintext.txt	253	Effects age sex ethnicity association apolipoprotein E genotype Alzheimer disease
0.18602495.16160021.html.plaintext.txt	254	A meta analysis APOE Alzheimer Disease Meta Analysis Consortium
0.18602495.16160021.html.plaintext.txt	255	Abstract Fehm HL Smolnik R Kern W McGregor GP Bickel U Born J
0.18602495.16160021.html.plaintext.txt	256	The melanocortin melanocyte stimulating hormoneadrenocorticotropin4 10 decreases body fat humans
0.18602495.16160021.html.plaintext.txt	257	J Clin Endocrinol Metab 86 1144 1148 2001
0.18602495.16160021.html.plaintext.txt	258	AbstractFree Full Text Feinleib M Garrison RJ Fabsitz R Christian JC Hrubec Z Borhani NO Kannel WB Rosenman R Schwartz JT Wagner JO
0.18602495.16160021.html.plaintext.txt	259	The NHLBI twin study cardiovascular disease risk factors methodology summary results
0.18602495.16160021.html.plaintext.txt	260	Am J Epidemiol 106 284 285 1977
0.18602495.16160021.html.plaintext.txt	261	ISIMedline Flegal KM Carroll MD Ogden CL Johnson CL
0.18602495.16160021.html.plaintext.txt	262	Prevalence trends obesity among US adults 1999 2000
0.18602495.16160021.html.plaintext.txt	263	AbstractFree Full Text Fujioka S Matsuzawa Y Tokunaga K Kawamoto T Kobatake T Keno Y Kotani K Yoshida S Tarui S
0.18602495.16160021.html.plaintext.txt	264	Improvement glucose lipid metabolism associated selective reduction intra abdominal visceral fat premenopausal women visceral fat obesity
0.18602495.16160021.html.plaintext.txt	265	Int J Obes 15 853 859 1991
0.18602495.16160021.html.plaintext.txt	266	ISIMedline Fujioka S Matsuzawa Y Tokunaga K Tarui S
0.18602495.16160021.html.plaintext.txt	267	Contribution intra abdominal fat accumulation impairment glucose lipid metabolism human obesity
0.18602495.16160021.html.plaintext.txt	268	CrossRefISIMedline Gislason T Johannsson JH Haraldsson A Olafsdottir BR Jonsdottir H Kong A Frigge ML Jonsdottir GM Hakonarson H Gulcher J Stefansson K
0.18602495.16160021.html.plaintext.txt	269	Familial predisposition cosegregation analysis adult obstructive sleep apnea sudden infant death syndrome
0.18602495.16160021.html.plaintext.txt	270	Am J Respir Crit Care Med 166 833 838 2002
0.18602495.16160021.html.plaintext.txt	271	AbstractFree Full Text Grunstein R Wilcox I Yang TS Gould Y Hedner J
0.18602495.16160021.html.plaintext.txt	272	Snoring sleep apnoea men association central obesity hypertension
0.18602495.16160021.html.plaintext.txt	273	Int J Obes Relat Metab Disord 17 533 540 1993
0.18602495.16160021.html.plaintext.txt	274	Medline Guilleminault C Partinen M Hollman K Powell N Stoohs R
0.18602495.16160021.html.plaintext.txt	275	Familial aggregates obstructive sleep apnea syndrome
0.18602495.16160021.html.plaintext.txt	276	AbstractFree Full Text Hager J Dina C Francke S Dubois S Houari M Vatin V Vaillant E Lorentz N Basdevant A Clement K Guy Grand B Froguel P
0.18602495.16160021.html.plaintext.txt	277	A genome wide scan human obesity genes reveals major susceptibility locus chromosome 10
0.18602495.16160021.html.plaintext.txt	278	Nat Genet 20 304 308 1998
0.18602495.16160021.html.plaintext.txt	279	CrossRefISIMedline Halaas JL Gajiwala KS Maffei M Cohen SL Chait BT Rabinowitz D Lallone RL Burley SK Friedman JM
0.18602495.16160021.html.plaintext.txt	280	Weight reducing effects plasma protein encoded obese gene
0.18602495.16160021.html.plaintext.txt	281	ISIMedline Harsch IA Konturek PC Koebnick C Kuehnlein PP Fuchs FS Pour Schahin S Wiest GH Hahn EG Lohmann T Ficker JH
0.18602495.16160021.html.plaintext.txt	282	Leptin ghrelin levels patients obstructive sleep apnoea effect CPAP treatment
0.18602495.16160021.html.plaintext.txt	283	Eur Respir J 22 251 257 2003
0.18602495.16160021.html.plaintext.txt	284	AbstractFree Full Text Hasler G Buysse DJ Klaghofer R Gamma A Ajdacic V Eich D Rossler W Angst J
0.18602495.16160021.html.plaintext.txt	285	The association sleep duration obesity young adults 13 year prospective study
0.18602495.16160021.html.plaintext.txt	286	ISIMedline Heinzer RC Stanchina ML Malhotra A Fogel RB Patel SR Jordan AS Schory K White DP
0.18602495.16160021.html.plaintext.txt	287	Lung volume continuous positive airway pressure requirements obstructive sleep apnea
0.18602495.16160021.html.plaintext.txt	288	Am J Respir Crit Care Med 172 114 117 2005
0.18602495.16160021.html.plaintext.txt	289	AbstractFree Full Text Hixson JE Almasy L Cole S Birnbaum S Mitchell BD Mahaney MC Stern MP MacCluer JW Blangero J Comuzzie AG
0.18602495.16160021.html.plaintext.txt	290	Normal variation leptin levels associated polymorphisms proopiomelanocortin gene POMC
0.18602495.16160021.html.plaintext.txt	291	J Clin Endocrinol Metab 84 3187 3191 1999
0.18602495.16160021.html.plaintext.txt	292	AbstractFree Full Text Ip MSM Lam KSL Ho CM Tsang KWT Lam WK
0.18602495.16160021.html.plaintext.txt	293	Serum leptin vascular risk factors obstructive sleep apnea
0.18602495.16160021.html.plaintext.txt	294	AbstractFree Full Text Katzmarzyk PT Malina RM Perusse L Rice T Province MA Rao DC Bouchard C
0.18602495.16160021.html.plaintext.txt	295	Familial resemblance fatness fat distribution
0.18602495.16160021.html.plaintext.txt	296	Am J Hum Biol 12 395 404 2000
0.18602495.16160021.html.plaintext.txt	297	AbstractFree Full Text Koeppen Schomerus G Wardle J Plomin R
0.18602495.16160021.html.plaintext.txt	298	A genetic analysis weight overweight 4 year old twin pairs
0.18602495.16160021.html.plaintext.txt	299	Int J Obes Relat Metab Disord 25 838 844 2001
0.18602495.16160021.html.plaintext.txt	300	Medline Kolehmainen J Black GC Saarinen A Chandler K Clayton Smith J Traskelin AL Perveen R Kivitie Kallio S Norio R Warburg M Fryns JP de la Chapelle A Lehesjoki AE
0.18602495.16160021.html.plaintext.txt	301	Cohen syndrome caused mutations novel gene COH1 encoding transmembrane protein presumed role vesicle mediated sorting intracellular protein transport
0.18602495.16160021.html.plaintext.txt	302	Am J Hum Genet 72 1359 1369 2003
0.18602495.16160021.html.plaintext.txt	303	CrossRefISIMedline Krude H Biebermann H Luck W Horn R Brabant G Gruters A
0.18602495.16160021.html.plaintext.txt	304	Severe early onset obesity adrenal insufficiency red hair pigmentation caused POMC mutations humans
0.18602495.16160021.html.plaintext.txt	305	Nat Genet 19 155 157 1998
0.18602495.16160021.html.plaintext.txt	306	CrossRefISIMedline Kubin L Tojima H Davies RO Pack AI
0.18602495.16160021.html.plaintext.txt	307	Serotonergic excitatory drive hypoglossal motoneurons decerebrate cat
0.18602495.16160021.html.plaintext.txt	308	Neurosci Lett 139 243 248 1992
0.18602495.16160021.html.plaintext.txt	309	CrossRefISIMedline Lander E Kruglyak L
0.18602495.16160021.html.plaintext.txt	310	Genetic dissection complex traits guidelines interpreting reporting linkage results
0.18602495.16160021.html.plaintext.txt	311	Nat Genet 11 241 247 1995
0.18602495.16160021.html.plaintext.txt	312	CrossRefISIMedline Locard E Mamelle N Billette A Miginiac M Munoz F Rey S
0.18602495.16160021.html.plaintext.txt	313	Risk factors obesity five year old population
0.18602495.16160021.html.plaintext.txt	314	Parental versus environmental factor
0.18602495.16160021.html.plaintext.txt	315	Int J Obes Relat Metab Disord 16 721 729 1992
0.18602495.16160021.html.plaintext.txt	316	Effect peroxisome proliferator activated receptor gamma gene Pro12Ala variant body mass index meta analysis
0.18602495.16160021.html.plaintext.txt	317	J Med Genet 40 773 780 2003
0.18602495.16160021.html.plaintext.txt	318	Free Full Text Mathur R Douglas NJ
0.18602495.16160021.html.plaintext.txt	319	Family studies patients sleep apnea hypopnea syndrome
0.18602495.16160021.html.plaintext.txt	320	Ann Intern Med 122 174 178 1995
0.18602495.16160021.html.plaintext.txt	321	AbstractFree Full Text Miraglia del Giudice E Cirillo G Santoro N D Urso L Carbone MT Di Toro R Perrone L
0.18602495.16160021.html.plaintext.txt	322	Molecular screening proopiomelanocortin POMC gene Italian obese children report three new mutations
0.18602495.16160021.html.plaintext.txt	323	Int J Obes Relat Metab Disord 25 61 67 2001
0.18602495.16160021.html.plaintext.txt	324	CrossRefMedline Ohman M Oksanen L Kaprio J Koskenvuo M Mustajoki P Rissanen A Salmi J Kontula K Peltonen L
0.18602495.16160021.html.plaintext.txt	325	Genome wide linkage scan obesity Finnish sibpairs reveals linkage chromosome Xq24
0.18602495.16160021.html.plaintext.txt	326	J Clin Endocrinol Metab 85 3183 3190 2000
0.18602495.16160021.html.plaintext.txt	327	AbstractFree Full Text Oppert JM Vohl MC Chagnon M Dionne FT Cassard Doulcier AM Ricquier D Perusse L Bouchard C
0.18602495.16160021.html.plaintext.txt	328	DNA polymorphism uncoupling protein UCP gene human body fat
0.18602495.16160021.html.plaintext.txt	329	Int J Obes Relat Metab Disord 18 526 531 1994
0.18602495.16160021.html.plaintext.txt	330	Medline O Donnell CP Schaub CD Haines AS Berkowitz DE Tankersley CG Schwartz AR Smith PL
0.18602495.16160021.html.plaintext.txt	331	Leptin prevents respiratory depression obesity
0.18602495.16160021.html.plaintext.txt	332	Am J Respir Crit Care Med 159 1477 1484 1999
0.18602495.16160021.html.plaintext.txt	333	AbstractFree Full Text Palmer LJ Buxbaum SG Larkin E Patel SR Elston RC Tishler PV Redline S
0.18602495.16160021.html.plaintext.txt	334	A whole genome scan obstructive sleep apnea obesity
0.18602495.16160021.html.plaintext.txt	335	Am J Hum Genet 72 340 350 2003
0.18602495.16160021.html.plaintext.txt	336	CrossRefISIMedline Palmer LJ Buxbaum SG Larkin EK Patel SR Elston RC Tishler PV Redline S
0.18602495.16160021.html.plaintext.txt	337	Whole genome scan obstructive sleep apnea obesity African American families
0.18602495.16160021.html.plaintext.txt	338	Am J Respir Crit Care Med 169 1314 1321 2004
0.18602495.16160021.html.plaintext.txt	339	AbstractFree Full Text Patel SR Larkin EK Palmer LJ Tishler PV Elston RC White DP Redline S
0.18602495.16160021.html.plaintext.txt	340	Shared genetic variance sleep apnea related metabolic traits Abstract
0.18602495.16160021.html.plaintext.txt	341	Am J Respir Crit Care Med 169 A759 2004
0.18602495.16160021.html.plaintext.txt	342	Pelleymounter MA Cullen MJ Baker MB Hecht R Winters D Boone T Collins F
0.18602495.16160021.html.plaintext.txt	343	Effects obese gene product body weight regulation obob mice
0.18602495.16160021.html.plaintext.txt	344	ISIMedline Peppard PE Young T Palta M Dempsey J Skatrud J
0.18602495.16160021.html.plaintext.txt	345	Longitudinal study moderate weight change sleep disordered breathing
0.18602495.16160021.html.plaintext.txt	346	AbstractFree Full Text Perusse L Rankinen T Zuberi A Chagnon YC Weisnagel SJ Argyropoulos G Walts B Snyder EE Bouchard C
0.18602495.16160021.html.plaintext.txt	347	The human obesity gene map 2004 update
0.18602495.16160021.html.plaintext.txt	348	Peyron C Faraco J Rogers W Ripley B Overeem S Charnay Y Nevsimalova S Aldrich M Reynolds D Albin R Li R Hungs M Pedrazzoli M Padigaru M Kucherlapati M Fan J Maki R Lammers GJ Bouras C Kucherlapati R Nishino S Mignot E
0.18602495.16160021.html.plaintext.txt	349	A mutation case early onset narcolepsy generalized absence hypocretin peptides human narcoleptic brains
0.18602495.16160021.html.plaintext.txt	350	CrossRefISIMedline Pietilainen KH Kaprio J Rissanen A Winter T Rimpela A Viken RJ Rose RJ
0.18602495.16160021.html.plaintext.txt	351	Distribution heritability BMI Finnish adolescents aged 16y 17y study 4884 twins 2509 singletons
0.18602495.16160021.html.plaintext.txt	352	Int J Obes Relat Metab Disord 23 107 115 1999
0.18602495.16160021.html.plaintext.txt	353	CrossRefMedline Pillar G Lavie P
0.18602495.16160021.html.plaintext.txt	354	Assessment role inheritance sleep apnea syndrome
0.18602495.16160021.html.plaintext.txt	355	Am J Respir Crit Care Med 151 688 691 1995
0.18602495.16160021.html.plaintext.txt	356	Abstract Pillar G Schnall RP Peled N Oliven A Lavie P
0.18602495.16160021.html.plaintext.txt	357	Impaired respiratory response resistive loading sleep healthy offspring patients obstructive sleep apnea
0.18602495.16160021.html.plaintext.txt	358	Am J Respir Crit Care Med 155 1602 1608 1997
0.18602495.16160021.html.plaintext.txt	359	Abstract Polotsky VY Smaldone MC Scharf MT Li J Tankersley CG Smith PL Schwartz AR O Donnell CP
0.18602495.16160021.html.plaintext.txt	360	Impact interrupted leptin pathways ventilatory control
0.18602495.16160021.html.plaintext.txt	361	J Appl Physiol 96 991 998 2004
0.18602495.16160021.html.plaintext.txt	362	AbstractFree Full Text Redline S Leitner J Arnold J Tishler PV Altose MD
0.18602495.16160021.html.plaintext.txt	363	Ventilatory control abnormalities familial sleep apnea
0.18602495.16160021.html.plaintext.txt	364	Am J Respir Crit Care Med 156 155 160 1997
0.18602495.16160021.html.plaintext.txt	365	AbstractFree Full Text Redline S Tishler PV Tosteson TD Williamson J Kump K Browner I Ferrette V Krejci P
0.18602495.16160021.html.plaintext.txt	366	The familial aggregation obstructive sleep apnea
0.18602495.16160021.html.plaintext.txt	367	Am J Respir Crit Care Med 151 682 687 1995
0.18602495.16160021.html.plaintext.txt	368	Abstract Rotimi CN Comuzzie AG Lowe WL Luke A Blangero J Cooper RS
0.18602495.16160021.html.plaintext.txt	369	The quantitative trait locus chromosome 2 serum leptin levels confirmed African Americans
0.18602495.16160021.html.plaintext.txt	370	Free Full Text Sakurai T Amemiya A Ishii M Matsuzaki I Chemelli RM Tanaka H Williams SC Richardson JA Kozlowski GP Wilson S Arch JR Buckingham RE Haynes AC Carr SA Annan RS McNulty DE Liu WS Terrett JA Elshourbagy NA Bergsma DJ Yanagisawa M
0.18602495.16160021.html.plaintext.txt	371	Orexins orexin receptors family hypothalamic neuropeptides G protein coupled receptors regulate feeding behavior
0.18602495.16160021.html.plaintext.txt	372	CrossRefISIMedline Schwartz AR Gold AR Schubert N Stryzak A Wise RA Permutt S Smith PL
0.18602495.16160021.html.plaintext.txt	373	Effect weight loss upper airway collapsibility obstructive sleep apnea
0.18602495.16160021.html.plaintext.txt	374	Am Rev Respir Dis 144 494 498 1991
0.18602495.16160021.html.plaintext.txt	375	ISIMedline Sekine M Yamagami T Handa K Saito T Nanri S Kawaminami K Tokui N Yoshida K Kagamimori S
0.18602495.16160021.html.plaintext.txt	376	A dose response relationship short sleeping hours childhood obesity results Toyama Birth Cohort Study
0.18602495.16160021.html.plaintext.txt	377	Child Care Health Dev 28 163 170 2002
0.18602495.16160021.html.plaintext.txt	378	CrossRefISIMedline Selby JV Newman B Quesenberry CP Jr Fabsitz RR King MC Meaney FJ
0.18602495.16160021.html.plaintext.txt	379	Evidence genetic influence central body fat middle aged twins
0.18602495.16160021.html.plaintext.txt	380	ISIMedline Sharma SK Kurian S Malik V Mohan A Banga A Pandey RM Handa KK Mukhopadhyay S
0.18602495.16160021.html.plaintext.txt	381	A stepped approach prediction obstructive sleep apnea overtly asymptomatic obese subjects hospital based study
0.18602495.16160021.html.plaintext.txt	382	CrossRefISIMedline Sloan JL Mager S
0.18602495.16160021.html.plaintext.txt	383	Cloning functional expression human Na Cl dependent neutral cationic amino acid transporter B0
0.18602495.16160021.html.plaintext.txt	384	J Biol Chem 274 23740 23745 1999
0.18602495.16160021.html.plaintext.txt	385	AbstractFree Full Text Smith PL Gold AR Meyers DA Haponik EF Bleecker ER
0.18602495.16160021.html.plaintext.txt	386	Weight loss mildly moderately obese patients obstructive sleep apnea
0.18602495.16160021.html.plaintext.txt	387	Ann Intern Med 103 850 855 1985
0.18602495.16160021.html.plaintext.txt	388	ISIMedline Sood S Liu X Liu H Nolan P Horner RL
0.18602495.16160021.html.plaintext.txt	389	5 HT hypoglossal motor nucleus respiratory control genioglossus muscle anesthetized rats
0.18602495.16160021.html.plaintext.txt	390	Respir Physiol Neurobiol 138 205 221 2003
0.18602495.16160021.html.plaintext.txt	391	CrossRefISIMedline Spiegel K Tasali E Penev P Van Cauter E
0.18602495.16160021.html.plaintext.txt	392	Sleep curtailment healthy young men associated decreased leptin levels elevated ghrelin levels increased hunger appetite
0.18602495.16160021.html.plaintext.txt	393	Ann Intern Med 141 846 850 2004
0.18602495.16160021.html.plaintext.txt	394	AbstractFree Full Text Strohl KP Saunders NA Feldman NT Hallett M
0.18602495.16160021.html.plaintext.txt	395	Obstructive sleep apnea family members
0.18602495.16160021.html.plaintext.txt	396	N Engl J Med 299 969 973 1978
0.18602495.16160021.html.plaintext.txt	397	Abstract Strohl KP Tankersley C Cohen MM Elston RC Gozal D Haddad G Jacob H Kiley J Kinane B Lifton RP Mignot E Mockrin S Neubauer J Redline S
0.18602495.16160021.html.plaintext.txt	398	Finding genetic mechanisms syndromes sleep disordered breathing ATS Statement
0.18602495.16160021.html.plaintext.txt	399	New York American Thoracic Society 1999 httpwww
0.18602495.16160021.html.plaintext.txt	400	orgstatementssleepdisordersleep
0.18602495.16160021.html.plaintext.txt	401	Stunkard AJ Foch TT Hrubec Z
0.18602495.16160021.html.plaintext.txt	402	Abstract Stunkard AJ Sorenson TI Hanis C Teasdale TW Chakraborty R Schull WJ Schulsinger F
0.18602495.16160021.html.plaintext.txt	403	An adoption study human obesity
0.18602495.16160021.html.plaintext.txt	404	N Engl J Med 314 193 198 1986
0.18602495.16160021.html.plaintext.txt	405	Abstract Suviolahti E Oksanen LJ Ohman M Cantor RM Ridderstrale M Tuomi T Kaprio J Rissanen A Mustajoki P Jousilahti P Vartiainen E Silander K Kilpikari R Salomaa V Groop L Kontula K Peltonen L Pajukanta P
0.18602495.16160021.html.plaintext.txt	406	The SLC6A14 gene shows evidence association obesity
0.18602495.16160021.html.plaintext.txt	407	J Clin Invest 112 1762 1772 2003
0.18602495.16160021.html.plaintext.txt	408	AbstractFree Full Text Taheri S Lin L Austin D Young T Mignot E
0.18602495.16160021.html.plaintext.txt	409	Short sleep duration associated reduced leptin elevated ghrelin increased body mass index
0.18602495.16160021.html.plaintext.txt	410	CrossRefISI Talamantes MA Long CR Smith GC Jenkins TG Ellis WC Cartwright TC
0.18602495.16160021.html.plaintext.txt	411	Characterization cattle five breed diallel VI
0.18602495.16160021.html.plaintext.txt	412	Fat deposition patterns serially slaughtered bulls
0.18602495.16160021.html.plaintext.txt	413	J Anim Sci 62 1259 1266 1986
0.18602495.16160021.html.plaintext.txt	414	ISIMedline Tankersley CG O Donnell C Daood MJ Watchko JF Mitzner W Schwartz A Smith P
0.18602495.16160021.html.plaintext.txt	415	Leptin attenuates respiratory complications associated obese phenotype
0.18602495.16160021.html.plaintext.txt	416	J Appl Physiol 85 2261 2269 1998
0.18602495.16160021.html.plaintext.txt	417	AbstractFree Full Text Turek FW Joshu C Kohsaka A Lin E Ivanova G McDearmon E Laposky A Losee Olson S Easton A Jensen DR Eckel RH Takahashi JS Bass J
0.18602495.16160021.html.plaintext.txt	418	Obesity metabolic syndrome circadian Clock mutant mice
0.18602495.16160021.html.plaintext.txt	419	Science 308 1043 1045 2005
0.18602495.16160021.html.plaintext.txt	420	Valve R Sivenius K Miettinen R Pihlajamaki J Rissanen A Deeb SS Auwerx J Uusitupa M Laakso M
0.18602495.16160021.html.plaintext.txt	421	Two polymorphisms peroxisome proliferator activated receptor gamma gene associated severe overweight among obese women
0.18602495.16160021.html.plaintext.txt	422	J Clin Endocrinol Metab 84 3708 3712 1999
0.18602495.16160021.html.plaintext.txt	423	AbstractFree Full Text Vioque J Torres A Quiles J
0.18602495.16160021.html.plaintext.txt	424	Time spent watching television sleep duration obesity adults living Valencia Spain
0.18602495.16160021.html.plaintext.txt	425	Int J Obes Relat Metab Disord 24 1683 1688 2000
0.18602495.16160021.html.plaintext.txt	426	CrossRefMedline Vitaterna MH King DP Chang AM Kornhauser JM Lowrey PL McDonald JD Dove WF Pinto LH Turek FW Takahashi JS
0.18602495.16160021.html.plaintext.txt	427	Mutagenesis mapping mouse gene Clock essential circadian behavior
0.18602495.16160021.html.plaintext.txt	428	ISIMedline Von Kries R Toschke AM Wurmser H Sauerwald T Koletzko B
0.18602495.16160021.html.plaintext.txt	429	Reduced risk overweight obesity 5 6 year old children duration sleep cross sectional study
0.18602495.16160021.html.plaintext.txt	430	Int J Obes Relat Metab Disord 26 710 716 2002
0.18602495.16160021.html.plaintext.txt	431	CrossRefMedline Weeks DE Conley YP Mah TS Paul TO Morse L Ngo Chang J Dailey JP Ferrell RE Gorin MB
0.18602495.16160021.html.plaintext.txt	432	A full genome scan age related maculopathy
0.18602495.16160021.html.plaintext.txt	433	Hum Mol Genet 9 1329 1349 2000
0.18602495.16160021.html.plaintext.txt	434	AbstractFree Full Text Wilson PW Schaefer EJ Larson MG Ordovas JM
0.18602495.16160021.html.plaintext.txt	435	Apolipoprotein E alleles risk coronary disease
0.18602495.16160021.html.plaintext.txt	436	Arterioscler Thromb Vasc Biol 16 1250 1255 1996
0.18602495.16160021.html.plaintext.txt	437	AbstractFree Full Text Young T Palta M Dempsey J Skatrud J Weber S Badr S
0.18602495.16160021.html.plaintext.txt	438	The occurrence sleep disordered breathing among middle aged adults
0.18602495.16160021.html.plaintext.txt	439	N Engl J Med 328 1230 1235 1993
0.18602495.16160021.html.plaintext.txt	440	AbstractFree Full Text Young T Peppard PE Gottlieb DJ
0.18602495.16160021.html.plaintext.txt	441	Epidemiology obstructive sleep apnea
0.18602495.16160021.html.plaintext.txt	442	Am J Respir Crit Care Med 165 1217 1239 2002
0.18602495.16160021.html.plaintext.txt	443	AbstractFree Full Text Yun Z Maecker HL Johnson RS Giaccia AJ
0.18602495.16160021.html.plaintext.txt	444	Inhibition PPAR gamma 2 gene expression HIF 1 regulated gene DEC1Stra13 mechanism regulation adipogenesis hypoxia
0.18602495.16160021.html.plaintext.txt	445	CrossRefISIMedline Zhou S Lechpammer S Greenberger J Glowacki J
0.18602495.16160021.html.plaintext.txt	446	Hypoxia inhibition adipocytogenesis human bone marrow stromal cells requires TGFbetaSmad3 signaling
0.18602495.16160021.html.plaintext.txt	447	J Biol Chem 280 22688 22696 2005
0.11429769.11978759.html.plaintext.txt	0	Different RPGR exon ORF15 mutations Canids provide insights photoreceptor cell degeneration Qi Zhang1 Gregory M
0.11429769.11978759.html.plaintext.txt	1	Johnson1 Sue Pearce Kelling1 Brian Tulloch3 Raf Vervoort34 Alan F
0.11429769.11978759.html.plaintext.txt	2	1Baker Institute 2Department Biomedical Sciences Cornell University Ithaca New York USA 3MRC Human Genetics Unit Western General Hospital Edinburgh UK 4Laboratory Glycobiology Developmental Genetics Center Human Genetics University Leuven Leuven Belgium
0.11429769.11978759.html.plaintext.txt	3	DDBJEMBLGenBank accession nos
0.11429769.11978759.html.plaintext.txt	4	ABSTRACT TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION METHODS REFERENCES The canine disease X linked progressive retinal atrophy XLPRA similar human RP3 X linked form retinitis pigmentosa maps region X chromosome
0.11429769.11978759.html.plaintext.txt	5	Analysis physical map XLPRA RP3 intervals shows high degree conservation terms genes order
0.11429769.11978759.html.plaintext.txt	6	We found different mutations exon ORF15 RPGR gene two distinct mutant dog strains XLPRA1 XLPRA2
0.11429769.11978759.html.plaintext.txt	7	Microdeletions resulting premature stop frameshift mutation result different retinal phenotypes allele specific consistent mutation
0.11429769.11978759.html.plaintext.txt	8	The phenotype associated frameshift mutation XLPRA2 severe manifests retinal development phenotype resulting XLPRA1 nonsense mutation expressed normal photoreceptor morphogenesis
0.11429769.11978759.html.plaintext.txt	9	Splicing RPGR mRNA transcripts retina complex either exon ORF15 exon 19 terminal exon
0.11429769.11978759.html.plaintext.txt	10	The retina predominant transcript contains ORF15 terminal exon expressed normal mutant retinas
0.11429769.11978759.html.plaintext.txt	11	The frameshift mutation dramatically alters deduced amino acid sequence protein aggregates endoplasmic reticulum transfected cells
0.11429769.11978759.html.plaintext.txt	12	The cellular molecular results two canine RPGR exon ORF15 mutations implications understanding phenotypic variability found human RP3 families carry similar mutations
0.11429769.11978759.html.plaintext.txt	13	INTRODUCTION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION METHODS REFERENCES Vision begins highly specialized photoreceptor cells retina
0.11429769.11978759.html.plaintext.txt	14	These cells adjacent retinal pigment epithelium RPE interact synergy maintain retinal function viability
0.11429769.11978759.html.plaintext.txt	15	A multiplicity mutations identified cause naturally occurring experimental degeneration 1
0.11429769.11978759.html.plaintext.txt	16	The human diseases predominantly associated early rod photoreceptor degeneration collectively termed retinitis pigmentosa RP
0.11429769.11978759.html.plaintext.txt	17	Some responsible genes involved phototransduction maintaining photoreceptor structure RPE retinoid metabolism
0.11429769.11978759.html.plaintext.txt	18	However remains large number diseases caused genes whose function poorly understood including RP3 form X linked RP XLRP caused mutations RP GTPase regulator RPGR gene 2
0.11429769.11978759.html.plaintext.txt	19	XLRP population prevalence 1 25 000 represents severe class RP early onset night blindness visual field loss eventual loss central acuity 34
0.11429769.11978759.html.plaintext.txt	20	Of five XLRP loci identified causal mutations established RP2 5 RP3 2
0.11429769.11978759.html.plaintext.txt	21	The RP3 region spans 500 600 kb Xp21
0.11429769.11978759.html.plaintext.txt	22	1 includes TCTE1L SRPX RPGR OTC 2
0.11429769.11978759.html.plaintext.txt	23	This locus accounts approximately 60 90 affected XLRP pedigrees although previous studies found RPGR mutations 20 families 267
0.11429769.11978759.html.plaintext.txt	24	More recently novel protein coding sequences identified regions formerly regarded introns RPGR
0.11429769.11978759.html.plaintext.txt	25	One exon ORF15 mutational hot spot mutations exon account majority RP3 cases 8
0.11429769.11978759.html.plaintext.txt	26	The role RPGR retinal function unknown
0.11429769.11978759.html.plaintext.txt	27	The first 10 exons encode domain highly conserved species consisting six tandem repeats 52 54 amino acids homologous repeat structure RCC1 protein 2
0.11429769.11978759.html.plaintext.txt	28	Rpgr knockout mice exons 4 6 replaced selectable marker results lack Rpgr expression develop slowly progressive post developmental photoreceptor degeneration 9
0.11429769.11978759.html.plaintext.txt	29	The RCC1 domain used bait yeast two hybrid screens resulting identification two interacting proteins delta subunit rod specific cyclic GMP phosphodiesterase 10 RPGR interacting protein RPGRIP 1112
0.11429769.11978759.html.plaintext.txt	30	RPGRIP co localizes RPGR photoreceptor outer segment 12 connecting cilium 13 may involved structural transport functions respectively
0.11429769.11978759.html.plaintext.txt	31	There little known function C terminal half RPGR particularly exon ORF15 mutations located 8
0.11429769.11978759.html.plaintext.txt	32	An alternative approach address question functional role domain identify species naturally occurring mutations region examine resultant phenotypes
0.11429769.11978759.html.plaintext.txt	33	Such comparative genomic approach possible dogs sufficient resources map positionally clone disease genes 14
0.11429769.11978759.html.plaintext.txt	34	Canine progressive retinal atrophy PRA comprises several naturally occurring retinal diseases similar phenotype RP
0.11429769.11978759.html.plaintext.txt	35	Six distinct autosomal one X linked loci identified 15
0.11429769.11978759.html.plaintext.txt	36	XLPRA Siberian husky spontaneous animal model XLRP 1617 disease mapped short arm X chromosome showed recombinants RPGR
0.11429769.11978759.html.plaintext.txt	37	Prior recognition novel ORF15 exon human RPGR characterized RPGR splice variants found mutations 18
0.11429769.11978759.html.plaintext.txt	38	The original XLPRA disorder renamed XLPRA1 distinguish second disease XLPRA2 mapping locus
0.11429769.11978759.html.plaintext.txt	39	Recombination events located disease interval microsatellite markers associated TCTE1L OTC 19 markers define less 1 cM zero recombination region homologous RP3 interval containing TCTE1L SRPX RPGR OTC orthologs
0.11429769.11978759.html.plaintext.txt	40	In present study completed cloning characterization canine RPGR including 10 kb intron 15 containing exon ORF15
0.11429769.11978759.html.plaintext.txt	41	We found three distinct microdeletions exon ORF15 canids one benign two disease associated provide insights structure function RPGR C terminal domain human disease
0.11429769.11978759.html.plaintext.txt	42	RESULTS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION METHODS REFERENCES Comparative mapping XLPRA1XLPRA2 RP3 To construct physical map used published human gene sequence data RP3 interval retrieve canine BACs made contig extending XK OTC
0.11429769.11978759.html.plaintext.txt	43	This established gene order XLPRA RP3 regions Fig
0.11429769.11978759.html.plaintext.txt	44	We found recombinations 364 2107 flanking markers 19 effectively reducing interval 550 kb region extending TCTE1L OTC including SRPX RPGR
0.11429769.11978759.html.plaintext.txt	45	Among four genes excluded TCTE1L direct cDNA sequencing focused efforts canine ortholog exon ORF15
0.11429769.11978759.html.plaintext.txt	46	View larger version 29K Figure 1
0.11429769.11978759.html.plaintext.txt	47	Comparative linkage physical maps RP3 XLPRA intervals linkage distances expressed centiMorgans cM orientation Xp given tel cen
0.11429769.11978759.html.plaintext.txt	48	A RP3 flanking region HSXp21
0.11429769.11978759.html.plaintext.txt	49	1 linkage map based GeneMap99 physical map Meindl et al
0.11429769.11978759.html.plaintext.txt	50	Sequences AL121578 AL121577 AF241726 taken NCBI Nucleotide database
0.11429769.11978759.html.plaintext.txt	51	Note contig gap SRPX OTC
0.11429769.11978759.html.plaintext.txt	52	The linkage map taken Zhang et al
0.11429769.11978759.html.plaintext.txt	53	The physical map consistent human data terms conserved orthologs order Xp
0.11429769.11978759.html.plaintext.txt	54	Cloning RPGR exon ORF15 identification three microdeletions canids Primers intron 14 exon 16 used amplify 10 kb intron 15 BAC clone positive RPGR
0.11429769.11978759.html.plaintext.txt	55	The product cloned directly sequenced using vector primers followed gene specific primer walking
0.11429769.11978759.html.plaintext.txt	56	Exon ORF15 GenBank accession
0.11429769.11978759.html.plaintext.txt	57	AF385629 transcribed continuously exon 15 extends 2
0.11429769.11978759.html.plaintext.txt	58	8 kb intron 15 unusually rich purines 70 repetitive sequences
0.11429769.11978759.html.plaintext.txt	59	The stop codon TAA polyA signal AAUAAA positions 1717 1719 2805 2810 respectively
0.11429769.11978759.html.plaintext.txt	60	Two unstable signals AUUUA recognition sites RNase E activity 20 found 3 UTR
0.11429769.11978759.html.plaintext.txt	61	As humans dog exon encodes set charged amino acids Arg Lys Asp Glu alternated glycines encoded proteins identical number glutamic aspartic acid residues similar isoelectric point 4
0.11429769.11978759.html.plaintext.txt	62	However instead repetitive EEEGEGEGE sequence humans 8 dog sequence contains GEEEGEEEE GEGEEEEG EEEGEEEGEE repeats
0.11429769.11978759.html.plaintext.txt	63	The C terminal 35 amino acids highly conserved human dog
0.11429769.11978759.html.plaintext.txt	64	Because premature stop codons mutant exon ORF15 sequences XLPRA1 2 encode proteins lacking C terminal tail
0.11429769.11978759.html.plaintext.txt	65	Three microdeletions found canids 100 bp region nucleotides 1001 1100 exon ORF15
0.11429769.11978759.html.plaintext.txt	66	In red wolves three nucleotide deletion eliminates glutamic acid alter remainder protein cause disease see
0.11429769.11978759.html.plaintext.txt	67	A five nucleotide deletion delGAGAA 1028 1032 identified XLPRA1
0.11429769.11978759.html.plaintext.txt	68	In XLPRA2 two nucleotide deletion delGA 1084 1085 identified 51 nucleotides 3 site XLPRA1 deletion Figs 2 3
0.11429769.11978759.html.plaintext.txt	69	View larger version 30K Figure 2
0.11429769.11978759.html.plaintext.txt	70	Mutation analyses exon ORF15 canids
0.11429769.11978759.html.plaintext.txt	71	A Wild type nucleotide sequence mutation region canine exon ORF15 encompassing nucleotides 1001 1100
0.11429769.11978759.html.plaintext.txt	72	The three deletions illustrated top lines
0.11429769.11978759.html.plaintext.txt	73	The electropherograms show deletions affected carrier dogs XLPRA1 B XLPRA2 C
0.11429769.11978759.html.plaintext.txt	74	View larger version 27K Figure 3
0.11429769.11978759.html.plaintext.txt	75	Segregation deletions XLPRA1 A XLPRA2 B pedigrees
0.11429769.11978759.html.plaintext.txt	76	In XLPRA1 carrier normal 1 mutant 2 alleles slower migrating heteroduplex bands H
0.11429769.11978759.html.plaintext.txt	77	Because small size difference normal mutant alleles XLPRA2 PCR products tested sample genetically normal dog mixed denaturing 98 degrees C 10 minutes incubated 68 degrees C 1 hour
0.11429769.11978759.html.plaintext.txt	78	For dog two lanes sample alone S mixed test normal samples show heteroduplex H shown normal 1 affected 2 alleles
0.11429769.11978759.html.plaintext.txt	79	A compound heterozygous female C produces offspring XLPRA1 XLPRA2
0.11429769.11978759.html.plaintext.txt	80	Alleles 1 3 wild type allele 2 4 XLPRA1 XLPRA2 respectively
0.11429769.11978759.html.plaintext.txt	81	The XLPRA1 mutation causes frameshift immediate premature stop truncated protein missing 230 C terminal amino acids causing slight decrease isoelectric point 3
0.11429769.11978759.html.plaintext.txt	82	By mutation scanning also found five nucleotide deletion Samoyed breed clinically similar X linked retinal degeneration data shown
0.11429769.11978759.html.plaintext.txt	83	The XLPRA2 mutation results frameshift significantly changes deduced peptide sequence causing increased isoelectric point 4
0.11429769.11978759.html.plaintext.txt	84	01 leads inclusion 34 additional basic residues prematurely terminating translation 71 amino acids downstream
0.11429769.11978759.html.plaintext.txt	85	We produced several compound heterozygotes showed severe clinical phenotype either XLPRA1 XLPRA2 hemizygotes heterozygotes see
0.11429769.11978759.html.plaintext.txt	86	Figure 3C illustrates independent segregation two mutant alleles male progeny compound heterozygote
0.11429769.11978759.html.plaintext.txt	87	Exon ORF15 deletions determine retinal phenotype Severe abnormalities retinal structure function found XLPRA allele specific
0.11429769.11978759.html.plaintext.txt	88	As previously reported photoreceptors XLPRA1 retina developed functioned normally 17
0.11429769.11978759.html.plaintext.txt	89	Retinal function remained normal 6 months age later decrease amplitude dark adapted rod cone responses Fig
0.11429769.11978759.html.plaintext.txt	90	Morphologically XLPRA1 photoreceptors remained normal young adulthood thereafter rods showed distinct irregularities outer segments followed degeneration
0.11429769.11978759.html.plaintext.txt	91	Cone abnormalities appeared less severe proportionally larger number cones remained visual cell layer late disease Fig
0.11429769.11978759.html.plaintext.txt	92	All affected males showed end stage retinal disease 4 years age
0.11429769.11978759.html.plaintext.txt	93	View larger version 122K Figure 4
0.11429769.11978759.html.plaintext.txt	94	ERG I pathology II situ hybridization III normal XLPRA
0.11429769.11978759.html.plaintext.txt	95	I Each panel shows responses scotopically balanced red blue stimuli white light 5 Hz rod 30 Hz cone stimuli
0.11429769.11978759.html.plaintext.txt	96	In XLPRA1 ERG develops normally A1 70 days remains normal early adulthood
0.11429769.11978759.html.plaintext.txt	97	Amplitudes decrease age A2 1
0.11429769.11978759.html.plaintext.txt	98	XLPRA2 shows rod cone responses reduced amplitude abnormal waveform early B1 70 days B2 4 months
0.11429769.11978759.html.plaintext.txt	99	By 1 year B3 rod responses nearly absent distinct cone signals prolonged timing remain
0.11429769.11978759.html.plaintext.txt	100	5 years XLPRA2 E2 years carriers retain normal ERG waveforms lower amplitudes especially XLPRA2
0.11429769.11978759.html.plaintext.txt	101	Vertical lines arrows light stimulus onset calibration marker 100 microV 50 ms except rod flicker 100 ms
0.11429769.11978759.html.plaintext.txt	102	II In XLPRA1 retina RPE normal A 9
0.11429769.11978759.html.plaintext.txt	103	developing outer segment OS abnormalities B 13 months
0.11429769.11978759.html.plaintext.txt	104	Degeneration occurs subsequently rate severity varies affected animals C 15 months D 3 years
0.11429769.11978759.html.plaintext.txt	105	Remaining cones prominent oblique arrows
0.11429769.11978759.html.plaintext.txt	106	XLPRA2 retina develops abnormally outer segments disorganized disoriented early E 1 month photoreceptors degenerate rapidly F 4 months G 7 months H 1
0.11429769.11978759.html.plaintext.txt	107	XLPRA1 carrier outside areas patchy retinal degeneration shows lower number normal surviving photoreceptors I 5 years
0.11429769.11978759.html.plaintext.txt	108	XLPRA2 carrier J K 1 year shows patchy degeneration J horizontal bracket abnormally developed photoreceptors
0.11429769.11978759.html.plaintext.txt	109	The compound heterozygote L 9
0.11429769.11978759.html.plaintext.txt	110	7 months shows advanced degeneration
0.11429769.11978759.html.plaintext.txt	111	Calibration bar 50 microm horizontal arrowhead external limiting membrane
0.11429769.11978759.html.plaintext.txt	112	III Paired brightfield A1 B1 C1 D1 combined brightfieldepipolarization A2 B2 C2 D2 images normal A B 10 months XLPRA1 retinas 3
0.11429769.11978759.html.plaintext.txt	113	3 C 11 D months hybridized antisense A C D sense B exon ORF15 probes nucleotides 800 1451
0.11429769.11978759.html.plaintext.txt	114	Normal mutant show pattern intensity hybridization
0.11429769.11978759.html.plaintext.txt	115	In peripheral retina older mutant D label present photoreceptor number decreased
0.11429769.11978759.html.plaintext.txt	116	The wavy lines panels C12 represent photographic apposition RPE retina
0.11429769.11978759.html.plaintext.txt	117	Calibration bar D2 26 microm arrows cone IS
0.11429769.11978759.html.plaintext.txt	118	In contrast retinal development aberrant XLPRA2
0.11429769.11978759.html.plaintext.txt	119	ERG abnormalities evident 5 6 weeks age responses low amplitude abnormal waveform deteriorated age Fig
0.11429769.11978759.html.plaintext.txt	120	There relative preservation cone flicker responses rod function severely compromised cone signals abnormally small older animals increased timing
0.11429769.11978759.html.plaintext.txt	121	In parallel photoreceptor morphogenesis abnormal
0.11429769.11978759.html.plaintext.txt	122	Outer segments highly disorganized disoriented develop Fig
0.11429769.11978759.html.plaintext.txt	123	4IIE visual cell degeneration present 4 months progresses Fig
0.11429769.11978759.html.plaintext.txt	124	By 2 years end stage degeneration present affected animals Fig
0.11429769.11978759.html.plaintext.txt	125	Cone abnormalities less severe proportionally larger number cones remained late disease
0.11429769.11978759.html.plaintext.txt	126	In heterozygotes retinal functional abnormalities reflected underlying photoreceptor pathology
0.11429769.11978759.html.plaintext.txt	127	Low amplitude responses present young adult carriers either genotype Fig
0.11429769.11978759.html.plaintext.txt	128	4IC E progressive loss function found XLPRA2 data shown
0.11429769.11978759.html.plaintext.txt	129	Other foci patchy retinal degeneration remaining photoreceptors XLPRA1 heterozygotes normal Fig
0.11429769.11978759.html.plaintext.txt	130	This case XLPRA2 since carrier retina failed develop normally surviving photoreceptors showed severe structural abnormalities compare Fig
0.11429769.11978759.html.plaintext.txt	131	Such severe pathology XLPRA2 carriers indicates mutation kills mutant photoreceptors early development produces collateral damage surviving normal ones
0.11429769.11978759.html.plaintext.txt	132	When allele expressed already compromised retina compound heterozygote disease severe Fig
0.11429769.11978759.html.plaintext.txt	133	Expression profile RPGR splice variants protein normal mutant retinas To understand disease mechanism resulting exon ORF15 mutations characterized RPGR alternative splicing detail examined expression normal mutant retina using probes different regions RPGR cDNA Fig
0.11429769.11978759.html.plaintext.txt	134	View larger version 24K Figure 5
0.11429769.11978759.html.plaintext.txt	135	Schematic representation genomic organization canine RPGR A drawn scale location probes used identify retinal expressed transcripts B 18 C new transcript ORF15 terminal exon
0.11429769.11978759.html.plaintext.txt	136	Note brackets C identify exons ORF 14 exons 14 14a ORF15 exon 15 transcribed portion intron 15 8
0.11429769.11978759.html.plaintext.txt	137	An asterisk identifies approximate position microdeletions associated XLPRA1 XLPRA2
0.11429769.11978759.html.plaintext.txt	138	Exon ORF 15 transcribed RCC1 like domain exon 14a
0.11429769.11978759.html.plaintext.txt	139	RPGR expression examined using normal retinal RNA sample loaded separate lanes gel hybridized probes corresponding different exons Fig
0.11429769.11978759.html.plaintext.txt	140	Probes exons 3 10 14a ORF15 detected two novel common bands 8
0.11429769.11978759.html.plaintext.txt	141	0 kb suggesting exons part transcript exon ORF15 transcribed
0.11429769.11978759.html.plaintext.txt	142	We also demonstrate exon 14a expression retina transcription frame exon ORF15 Fig
0.11429769.11978759.html.plaintext.txt	143	View larger version 61K Figure 6
0.11429769.11978759.html.plaintext.txt	144	A Antisense RNA probes different exons RPGR hybridized total retinal RNA 20 microglane
0.11429769.11978759.html.plaintext.txt	145	Probe locations follows exons 3 10 nucleotides 258 1330 exons 16 19 nucleotides 1681 2374 exon14a nucleotides 1842 2428 exon ORF15 nucleotides 803 1603
0.11429769.11978759.html.plaintext.txt	146	B RPGR expression different tissues
0.11429769.11978759.html.plaintext.txt	147	Antisense probes exons 3 10 top exons 16 19 middle hybridized dog tissue blot containing 20 microg total RNAlane
0.11429769.11978759.html.plaintext.txt	148	Bottom panel shows blot hybridized 18S cDNA probe
0.11429769.11978759.html.plaintext.txt	149	C Expression RPGR normal 7
0.11429769.11978759.html.plaintext.txt	150	7 months XLPRA1 2 non allelic autosomal retinal diseases affected samples pre degenerate stages 4 6 weeks age
0.11429769.11978759.html.plaintext.txt	151	Antisense RNA probes hybridized total retinal RNA 20 microglane normal pre degenerate retinas XLPRA1 prcd XLPRA2 rcd1
0.11429769.11978759.html.plaintext.txt	152	The rcd1 prcd samples serve disease controls animals age affected non allelic autosomal retinal diseases comparable phenotype XLPRA1 prcd XLPRA2 rcd1 15
0.11429769.11978759.html.plaintext.txt	153	The bottom panel shows hybridization 18S cDNA probe blot
0.11429769.11978759.html.plaintext.txt	154	D Western blot RPGR retinal tissues normal affected dogs
0.11429769.11978759.html.plaintext.txt	155	Proteins 50 microg total proteinlane cytosol top membrane bottom fractions labeled DR 39 RPGR 254 antibodies respectively
0.11429769.11978759.html.plaintext.txt	156	Sample source age listed lane
0.11429769.11978759.html.plaintext.txt	157	Tissue expression profile reveals ORF15 retina predominant terminal exon
0.11429769.11978759.html.plaintext.txt	158	Using probes exons 3 10 16 19 found respectively 3
0.11429769.11978759.html.plaintext.txt	159	8 kb bands northern blots Fig
0.11429769.11978759.html.plaintext.txt	160	8 kb band ubiquitously expressed tissues 3
0.11429769.11978759.html.plaintext.txt	161	2 kb band appears represent non specific binding since consistently found repeat blotting tissues
0.11429769.11978759.html.plaintext.txt	162	The exon 3 10 probe shows two major high molecular size transcripts 8
0.11429769.11978759.html.plaintext.txt	163	0 kb expression cerebellum similar retina low levels brain regions Fig
0.11429769.11978759.html.plaintext.txt	164	9 kb transcript hardly detectable liver heart
0.11429769.11978759.html.plaintext.txt	165	The results obtained exon ORF15 probe data shown
0.11429769.11978759.html.plaintext.txt	166	The size 5 kb transcript expressed predominantly retina matches expected sequence length 5284 bp exon ORF15 used terminal exon
0.11429769.11978759.html.plaintext.txt	167	XLPRA mutant retinas express RPGR transcripts
0.11429769.11978759.html.plaintext.txt	168	We examined expression pre degenerate 4 6 weeks age XLPRA retinas using probes exons 3 10 ORF15
0.11429769.11978759.html.plaintext.txt	169	At age retinas show cellular degeneration although abnormalities outer segment structure present XLPRA2
0.11429769.11978759.html.plaintext.txt	170	In addition normals also used controls retinas animals age non allelic autosomal retinal diseases comparable phenotypes XLPRA1 prcd XLPRA2 rcd1 15
0.11429769.11978759.html.plaintext.txt	171	In affected controls probes detected bands 8
0.11429769.11978759.html.plaintext.txt	172	9 5 kb XLPRA1 transcript abundance normal
0.11429769.11978759.html.plaintext.txt	173	Although distinct message found XLPRA2 probes found slightly lower levels expression Fig
0.11429769.11978759.html.plaintext.txt	174	These results indicate RPGR exon ORF15 transcribed mutant retinas
0.11429769.11978759.html.plaintext.txt	175	We used situ hybridization examine expression exon ORF15 retina predominant transcript
0.11429769.11978759.html.plaintext.txt	176	Comparable intense accumulation silver grains found normal XLPRA1 affected retinas tissues available XLPRA2 animals
0.11429769.11978759.html.plaintext.txt	177	Label found RPE photoreceptor inner segments nuclear layers cone inner segments showed dense clusters label
0.11429769.11978759.html.plaintext.txt	178	No difference label intensity distribution found normal XLPRA1 affected animals compare Fig
0.11429769.11978759.html.plaintext.txt	179	In older affected animals label intensity reduced secondary loss visual cells remaining cells showed normal label distribution Fig
0.11429769.11978759.html.plaintext.txt	180	The control sense probe showed low diffuse labeling normal Fig
0.11429769.11978759.html.plaintext.txt	181	4IIIB12 mutant data shown
0.11429769.11978759.html.plaintext.txt	182	Antibody DR 39 raised peptides human RPGR exons 13 14 detected 100 kDa band cytosol membrane fractions Fig
0.11429769.11978759.html.plaintext.txt	183	We also found 95 kDa major band smaller 90 kDa band membrane fraction RPGR 254 antibody raised C terminal 254 residues RPGR Fig
0.11429769.11978759.html.plaintext.txt	184	6D lower panel could identify specific bands cytosolic fraction using antibody
0.11429769.11978759.html.plaintext.txt	185	However differences found control mutant samples indication antibodies failed detect proteins containing exon ORF15
0.11429769.11978759.html.plaintext.txt	186	RPGR photoreceptor specific proteins normally expressed mutant retina
0.11429769.11978759.html.plaintext.txt	187	We used different RPGR antibodies obtained results normal mutant retinas Fig
0.11429769.11978759.html.plaintext.txt	188	The polyclonal RPGR 33606 antibody intensely labeled outer segments Fig
0.11429769.11978759.html.plaintext.txt	189	7A12 results previously reported 12
0.11429769.11978759.html.plaintext.txt	190	In contrast antibody DR 39 intensely labeled inner segments inner nuclear ganglion cells Fig
0.11429769.11978759.html.plaintext.txt	191	The intensity distribution labeling normal mutant retina even photoreceptor degeneration started Fig
0.11429769.11978759.html.plaintext.txt	192	The three antibodies opsin PDE rod cGMP channel protein subunit produced labeling normal mutant Fig
0.11429769.11978759.html.plaintext.txt	193	7 columns 5 7 even eyes showed disease associated pathology
0.11429769.11978759.html.plaintext.txt	194	The normal labeling photoreceptor specific proteins examined indicates polarized distribution mutant visual cells altered
0.11429769.11978759.html.plaintext.txt	195	View larger version 113K Figure 7
0.11429769.11978759.html.plaintext.txt	196	Expression photoreceptor proteins normal A XLPRA1 B disease stage C early disease XLPRA2 D dogs following ages A 9
0.11429769.11978759.html.plaintext.txt	197	3 months D 7 weeks columns 1 2 5 7 16 weeks columns 3 4
0.11429769.11978759.html.plaintext.txt	198	A C 2 microm DGD sections D 10 microm cryosections
0.11429769.11978759.html.plaintext.txt	199	Columns 1 2 3 4 paired Nomarski 13 immunofluorescence 24 images using RPGR 33606 DR 39 antibodies
0.11429769.11978759.html.plaintext.txt	200	Other columns represent single images sections labeled antibodies opsin PDE rod cGMP channel protein subunit
0.11429769.11978759.html.plaintext.txt	201	The pattern intensity labeling found normal mutant retinas
0.11429769.11978759.html.plaintext.txt	202	XLPRA2 mutant proteins aggregate ER We examined subcellular localization normal mutant exon ORF15GFP fusion proteins using transfected COS7 cells
0.11429769.11978759.html.plaintext.txt	203	Signal normal protein mainly cytoplasmic diffuse faint nuclear presence Fig
0.11429769.11978759.html.plaintext.txt	204	8B similar results obtained following transfection GFP vector alone Fig
0.11429769.11978759.html.plaintext.txt	205	8A exon ORF15 nonsense mutation XLPRA1 Fig
0.11429769.11978759.html.plaintext.txt	206	In contrast frameshift mutation XLPRA2 showed intense accumulation protein aggregates distinct perinuclear subcellular compartment Fig
0.11429769.11978759.html.plaintext.txt	207	There faint diffuse signal rest cytoplasm minimal signal nucleus
0.11429769.11978759.html.plaintext.txt	208	Staining endoplasmic reticular ER specific marker confirms co localization aggregates ER Fig
0.11429769.11978759.html.plaintext.txt	209	View larger version 90K Figure 8
0.11429769.11978759.html.plaintext.txt	210	Transient expression different GFP exon ORF15 constructs COS7 cells
0.11429769.11978759.html.plaintext.txt	211	There similar distribution cells expressing vector A wild type B XLPRA1 GFP exon ORF15 C constructs
0.11429769.11978759.html.plaintext.txt	212	However XLPRA2 construct results GFP fluorescence aggregates around nucleus D
0.11429769.11978759.html.plaintext.txt	213	The XLPRA2 GFP exon ORF15 protein aggregates E1 ER E2 co localize E3
0.11429769.11978759.html.plaintext.txt	214	DISCUSSION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION METHODS REFERENCES Physical mapping XLPRA interval shows strong homology region Xp humans dogs terms genes order
0.11429769.11978759.html.plaintext.txt	215	We mapped two distinct X linked retinal disorders region found disease associated mutations RPGR exon ORF15
0.11429769.11978759.html.plaintext.txt	216	The specificity mutations confirmed finding sequence abnormalities characterized RPGR transcripts 18 present study
0.11429769.11978759.html.plaintext.txt	217	Additionally scanned presence mutations 137 dogs 211 chromosomes 20 different breeds found deletions XLPRA1 Siberian husky Samoyed XLPRA2 mongrel derived affected carrier dogs thus confirming mutations polymorphisms
0.11429769.11978759.html.plaintext.txt	218	We also scanned 20 wolves 29 chromosomes 19 red wolves 1 black wolf found deletion two aged heterozygous red wolves asymptomatic
0.11429769.11978759.html.plaintext.txt	219	Based lack retinal disease phenotype females deletion likely rare benign polymorphism 8
0.11429769.11978759.html.plaintext.txt	220	A hotspot RPGR mutations humans occurs approximately 1 kb purine rich region exon ORF15 frame mutations premature stop associated disease
0.11429769.11978759.html.plaintext.txt	221	Of 34 novel RP3 mutations reported recently 23 one two four five nucleotide deletions resulted frameshift premature termination translation 8
0.11429769.11978759.html.plaintext.txt	222	It proposed purine rich region may adopt unusual non B DNA conformations show sequence motifs similar DNA polymerase arrest sites found near deletion hotspots lead microdeletions following slipped strand mispairing events 2122
0.11429769.11978759.html.plaintext.txt	223	We found similar microdeletions present study suggesting RPGR exon ORF15 appears mutation hotspot canids
0.11429769.11978759.html.plaintext.txt	224	Our studies demonstrate nature RPGR exon ORF15 deletions determine retinal phenotype
0.11429769.11978759.html.plaintext.txt	225	Both disorders distinct remained even though diseases present mixed breed dogs genetic background
0.11429769.11978759.html.plaintext.txt	226	This indicates phenotype results differences two mutant proteins vivo
0.11429769.11978759.html.plaintext.txt	227	The normal retinal development XLPRA1 argues C terminal 230 amino acids encoded exon ORF15 vital functional structural differentiation rods cones
0.11429769.11978759.html.plaintext.txt	228	The argument proposed role RCC1 like domain since photoreceptor development normal Rpgr knockout mouse 9
0.11429769.11978759.html.plaintext.txt	229	However severe disease develops young adult animals indicates RPGR plays essential role photoreceptor viability
0.11429769.11978759.html.plaintext.txt	230	In contrast abnormal retinal development occurs XLPRA2 rapid degeneration ensues suggests mutation disrupts critical differentiation rods cones causes early degeneration
0.11429769.11978759.html.plaintext.txt	231	Analysis heterozygous retinas provides insights role mutant alleles retinal development maintenance
0.11429769.11978759.html.plaintext.txt	232	Through random X inactivation 23 approximately 50 retinal cells express mutant normal RPGR expression mutant gene examined milieu half photoreceptors genetically normal
0.11429769.11978759.html.plaintext.txt	233	Carriers either disease show ophthalmoscopically visible patchy retinal degeneration indication mosaicism hallmark retinal random X inactivation 24
0.11429769.11978759.html.plaintext.txt	234	These changes variable extent severity evident carriers time young adults time advanced age
0.11429769.11978759.html.plaintext.txt	235	These abnormalities stationary XLPRA1 XLPRA2 carriers often show progressive disease results advanced retinal degeneration 5 6 years age older
0.11429769.11978759.html.plaintext.txt	236	In contrast lack disease aged heterozygous red wolves suggests three nucleotide deletion benign polymorphism
0.11429769.11978759.html.plaintext.txt	237	The severe retinal disease phenotype canine XLPRA comparable reported human patients RPGR mutations given caveat least humans limited number phenotype genotype correlation studies reported
0.11429769.11978759.html.plaintext.txt	238	With exception two reports retrospectively represent mutations exon ORF15 2526 others limited primarily exons 1 10 e
0.11429769.11978759.html.plaintext.txt	239	These studies show comparably severe clinical phenotypes XLRP patients found two canine models
0.11429769.11978759.html.plaintext.txt	240	Also majority carriers show clinical disease varying mild severe impaired night vision visual field loss 324
0.11429769.11978759.html.plaintext.txt	241	In families disease sufficiently severe females considered semidominant 28
0.11429769.11978759.html.plaintext.txt	242	Examination exon ORF15 identified null alleles four nine families J
0.11429769.11978759.html.plaintext.txt	243	Rozet personal communication 26 July 2001
0.11429769.11978759.html.plaintext.txt	244	Expression studies RPGR shown alternative splicing complex species specific variants may exist
0.11429769.11978759.html.plaintext.txt	245	The splice variants reported RPGR mainly exon 13 especially brain testes 1825
0.11429769.11978759.html.plaintext.txt	246	Additionally alternative exon usage introns found frequently RPGR transcripts example exon 14a intron 14 mouse 25 dog 18 exons 15a 15b1 15b2 ORF15 intron 15 human mouse cow dog 8 present study exon 19a mouse intron 18 25
0.11429769.11978759.html.plaintext.txt	247	The alternative splicing exon usage suggests different RPGR protein isoforms produced specific functions vivo
0.11429769.11978759.html.plaintext.txt	248	The exon 16 19 probe mainly detected 8
0.11429769.11978759.html.plaintext.txt	249	9 kb band failed detect 5 kb band recognized probes exons 3 10 exon 14a ORF15
0.11429769.11978759.html.plaintext.txt	250	This result suggests exon ORF15 used terminal exon 5 kb band alternatively spliced exons 16 19 8
0.11429769.11978759.html.plaintext.txt	251	We found putative consensus splice donor site conserved human dog located stop codon 3 coding region exon ORF15
0.11429769.11978759.html.plaintext.txt	252	This may splice exon ORF15 exons 16 19 translate polypeptide frame include exon ORF15 exons 16 19
0.11429769.11978759.html.plaintext.txt	253	In case putative protein regain C terminal isoprenylation site CTIL located alternative terminal exon 19 2
0.11429769.11978759.html.plaintext.txt	254	Higher molecular weight mRNA bands reported previously including 3
0.11429769.11978759.html.plaintext.txt	255	5 20 kb eye brain 25 present study
0.11429769.11978759.html.plaintext.txt	256	Recently 6 kb band reported human retina ORF15 exon 3 19 probes 29
0.11429769.11978759.html.plaintext.txt	257	9 kb band match known sizes RPGR sequences
0.11429769.11978759.html.plaintext.txt	258	This suggests additional undiscovered exons alternative polyadenylation sites used RPGR processing
0.11429769.11978759.html.plaintext.txt	259	In addition exon ORF15 probe consistently detected two bands similar intensity 8
0.11429769.11978759.html.plaintext.txt	260	9 kb another slightly smaller size Fig
0.11429769.11978759.html.plaintext.txt	261	6A suggests different splice variants may exist
0.11429769.11978759.html.plaintext.txt	262	The spatial relevance predominant 5 kb splice variant expressed retina mutations found exon ORF15 may explain observed phenotype confined retina
0.11429769.11978759.html.plaintext.txt	263	The transfection data emphasize differences expression profiles two mutant exon ORF15 proteins
0.11429769.11978759.html.plaintext.txt	264	In vitro XLPRA1 premature stop mutant behaves similarly wild type protein whereas XLPRA2 frameshift protein aggregates ER compartment
0.11429769.11978759.html.plaintext.txt	265	In examining transfection results attach significance presence absence GFP nuclear labeling since may result protein cleavage small proportion constructs GFP enters nucleus weak nuclear localization vector
0.11429769.11978759.html.plaintext.txt	266	Aggregation XLPRA2 mutant exon ORF15 protein may result additional abnormal residues impair proper folding
0.11429769.11978759.html.plaintext.txt	267	The vitro results consistent phenotypic differences found two diseases
0.11429769.11978759.html.plaintext.txt	268	Based presence retinal transcripts exon ORF15 normal XLPRA mutant retinas different phenotypes two diseases propose XLPRA1 mutation causes loss function critical visual cells development essential later sustained viability
0.11429769.11978759.html.plaintext.txt	269	In contrast XLPRA2 mutation affects photoreceptors early development devastating consequences retina
0.11429769.11978759.html.plaintext.txt	270	The results studies highlight importance RPGR exon ORF15 photoreceptor function viability
0.11429769.11978759.html.plaintext.txt	271	They indicate different retinal phenotypes result mutations novel exon situation similar human RP3 families
0.11429769.11978759.html.plaintext.txt	272	Finally show value canine model tools available comparative genomic analysis aid understanding gene function diseases importance humans species
0.11429769.11978759.html.plaintext.txt	273	METHODS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION METHODS REFERENCES Animals pedigrees tissue collection Two different outcrossed pedigrees used develop meiotic map canine Xp fine map XLPRA1 XLPRA2 identify disease causing mutations RPGR
0.11429769.11978759.html.plaintext.txt	274	All procedures involving tissue collection done anesthesia immediately following euthanasia barbiturate overdose
0.11429769.11978759.html.plaintext.txt	275	Blood samples red wolves collected sedation ophthalmic examination wolves maintained display breeding zoo nature center
0.11429769.11978759.html.plaintext.txt	276	We also examined tested members pedigree Samoyed dogs X linked retinal degeneration clinically identical XLPRA1
0.11429769.11978759.html.plaintext.txt	277	Canine BAC library screening meiotic radiation hybrid RH physical mapping The RPCI81 Canine BAC library used httpwww
0.11429769.11978759.html.plaintext.txt	278	Canine specific probes TCTE1L SRPX RPGR OTC prepared PCR using degenerate primers purified BAC DNA digested identify microsatellite markers hybridization
0.11429769.11978759.html.plaintext.txt	279	The experimental details meiotic RH mapping described 19
0.11429769.11978759.html.plaintext.txt	280	The contig built BAC clones positive TCTE1L SRPX RPGR OTC extended end sequencing
0.11429769.11978759.html.plaintext.txt	281	The size BAC clones determined using NotI digestion fingerprinting EcoRV separation pulsed field gel electrophoresis
0.11429769.11978759.html.plaintext.txt	282	The BLAST search end internal sequences exons conserved regions human dog also used contig assembly
0.11429769.11978759.html.plaintext.txt	283	Cloning canine RPGR intron 15 exon ORF15 mutation identification The intron 15 sequence amplified long range PCR forward primer RGF9 intron 14 5 GAAAGTAAGCATGGTCTCTATCCACC 3 reverse primer RGR1 exon 16 5 CAAGTTCCTCAGCCATATCCTCTGG 3
0.11429769.11978759.html.plaintext.txt	284	The 10 kb PCR product cloned TOPO XL vector Invitrogen Carlsbad CA
0.11429769.11978759.html.plaintext.txt	285	For mutation analyses flanking primers designed normal sequence used scan mutation PCR conditions 98 degrees C 2 min 34 cycles 98 degrees C 30 62 degrees C 30 72 degrees C 1 min primer pairs listed PCR products separated 8 polyacrylamide gel
0.11429769.11978759.html.plaintext.txt	286	forward primer RGF14 5 AAGGGGAGGAGAAAGGGGAGGCT 3
0.11429769.11978759.html.plaintext.txt	287	reverse primer RGR13 5 TCCCTCTTCCTCCTCCCCTTCATA 3
0.11429769.11978759.html.plaintext.txt	288	reverse primer RGR12 5 TCCCCTACTTCCTCTTCCCTCTCA 3
0.11429769.11978759.html.plaintext.txt	289	Sequencing done Taq cycle sequencing using DyeDeoxy terminators Applied Biosystems ABI 377 automated DNA sequencer
0.11429769.11978759.html.plaintext.txt	290	Electroretinography ERG morphology studies ERGs recorded isofluorane anesthetized dogs stimuli conditions designed enable separate evaluation rod cone mediated responses 30 preparation eyecups morphological examination utilized triple fixation protocol 30
0.11429769.11978759.html.plaintext.txt	291	One micrometer sections plastic embedded retina extending optic disc superior inferior periphery used analysis
0.11429769.11978759.html.plaintext.txt	292	Immunocytochemistry situ hybridization Immunocytochemistry done using normal affected retinas collected light fixed 4 paraformaldehyde processed DGD control XLPRA1 cut 2 microm 31 OCT control XLPRA2 cut 10 microm using standard methods
0.11429769.11978759.html.plaintext.txt	293	Different antibodies RPGR retinal proteins used identified target source reference
0.11429769.11978759.html.plaintext.txt	294	For RPGR polyclonal RPGR 254 C terminal 254 amino acids RPGR partial exon 14 exons 15 19 9 b polyclonal RPGR 33606 human RCC1 like domain residues 96 116 coded partial exon 4 5 12 c polyclonal DR 39 targets 13 amino acids coded human RPGR exons 13 14 F
0.11429769.11978759.html.plaintext.txt	295	For Opsin monoclonal R2 12N 32
0.11429769.11978759.html.plaintext.txt	296	For PDE polyclonal anti mouse 31
0.11429769.11978759.html.plaintext.txt	297	For rod cGMP channel protein subunit monoclonal anti bovine 33
0.11429769.11978759.html.plaintext.txt	298	With exception polyclonal RPGR 33606 antibody RPGR antibodies required antigen retrieval step heating slides 0
0.11429769.11978759.html.plaintext.txt	299	01 M citric acid 10 min microwave 70 power
0.11429769.11978759.html.plaintext.txt	300	Antibodies directed exon ORF15 polyclonal antibodies synthetic peptides human nos 1877 1878 mouse nos 1875 1876 F
0.11429769.11978759.html.plaintext.txt	301	Manson used lack specificity data shown
0.11429769.11978759.html.plaintext.txt	302	For situ hybridization paraformaldehyde fixedDGD embedded sections 2 microm hybridized antisense sense RNA probes prepared linearized exon ORF15 plasmid DNA
0.11429769.11978759.html.plaintext.txt	303	The slides coated Kodak NTB2 emulsion exposed 1 4 weeks 4 degrees C developed stained toluidine blue
0.11429769.11978759.html.plaintext.txt	304	Probes synthesized using MaxiScript kit Ambion Austin TX labeled 35S UTP 1250 Cimmol NEN Life Science
0.11429769.11978759.html.plaintext.txt	305	Western northern blots Western analysis RPGR cytosolic membrane fractions done using antibodies RPGR 254 DR 39
0.11429769.11978759.html.plaintext.txt	306	The procedure described previously 3435
0.11429769.11978759.html.plaintext.txt	307	Retinal tissues homogenized centrifuged separate cytosolic fraction crude pellets containing cell nuclei membranes sonicated centrifuged
0.11429769.11978759.html.plaintext.txt	308	The proteins 50 microglane separated 10 SDS PAGE bands nylon membrane Imobilon visualized using enhanced chemiluminescence western blotting detection kit Amersham
0.11429769.11978759.html.plaintext.txt	309	The northern analysis method detailed previously 33
0.11429769.11978759.html.plaintext.txt	310	Twenty micrograms total RNA separated 1 agarose0
0.11429769.11978759.html.plaintext.txt	311	66 M formaldehyde gel transferred nylon membrane
0.11429769.11978759.html.plaintext.txt	312	Single strand RNA probe prepared using MAXIscript vitro transcription kit Ambion
0.11429769.11978759.html.plaintext.txt	313	PCR products corresponding different parts RPGR transcripts ligated pCRII TOPO dual promoter vector Invitrogen
0.11429769.11978759.html.plaintext.txt	314	The linearized plasmid DNA used antisense probe synthesis using 32PUTP
0.11429769.11978759.html.plaintext.txt	315	Probes northern analysis made different regions RPGR using following PCR primers
0.11429769.11978759.html.plaintext.txt	316	RPGR3 forward 5 GGCAGTAACAACTGGGGTCAGTTAG 3
0.11429769.11978759.html.plaintext.txt	317	RPGR10 reverse 5 CTCTCCCTCTCTCTTCGCCGCA 3
0.11429769.11978759.html.plaintext.txt	318	RGR16 reverse 5 ATCTCCCTGAAGGATCTGTGCCG 3
0.11429769.11978759.html.plaintext.txt	319	RPGR27 forward 5 GACATAGGTAATGACTCAGGCCAG 3
0.11429769.11978759.html.plaintext.txt	320	RPGR28 reverse 5 AATTTGGACAGTATGTGTTCGGTC 3
0.11429769.11978759.html.plaintext.txt	321	RGF8 forward 5 AAGAACCAGAGGATATGGCTGAGG 3
0.11429769.11978759.html.plaintext.txt	322	RGR16 reverse 5 GTGGCCTTAA CTGTTCAGTG TTGG 3
0.11429769.11978759.html.plaintext.txt	323	The GenBank accession numbers exon14a nucleotides1842 2428 exons 16 19 nucleotides 1681 2374 sequences AF148800 AF148798 respectively
0.11429769.11978759.html.plaintext.txt	324	Transfection expression normal mutant RPGR exon ORF15 COS7 cells DMEM 5 FCS penicillin 100 Uml streptomycin 130 microgml 37 degrees C 5 CO2 transfected using 6 microl FuGENE 6 Roche added 2
0.11429769.11978759.html.plaintext.txt	325	0 microg DNA green fluorescent protein GFP vector GFP vector containing one three canine ORF15 sequences wild type XLPRA1 XLPRA2
0.11429769.11978759.html.plaintext.txt	326	After 48 h incubation cells washed PBS fixed methanol 2 min 20 degrees C
0.11429769.11978759.html.plaintext.txt	327	Some fixed cells incubated anti Golgi clone 58K 9 Sigma anti ER Anti KDEL Bioquote primary antibodies visualized Texas Red conjugated secondary Jackson Labs
0.11429769.11978759.html.plaintext.txt	328	All slides mounted Vectashield Vector Laboratories Inc
0.11429769.11978759.html.plaintext.txt	329	Burlingame CA containing DAPI 1
0.11429769.11978759.html.plaintext.txt	330	ACKNOWLEDGEMENTS The authors grateful staff RDS facility Julie Alling assistance tissue sections Barbara Zangerl providing unpublished microsatellite data Keith Watamura assistance figures Dr A
0.11429769.11978759.html.plaintext.txt	331	Swaroop helpful discussions Kathie Weeks staffs WNC Nature Center Ross Park Zoo help Red Wolf project Drs P
0.11429769.11978759.html.plaintext.txt	332	Molday providing antibodies
0.11429769.11978759.html.plaintext.txt	333	This work supported NEINIH grants EY06855 EY13132 Foundation Fighting Blindness British Retinitis Pigmentosa Society Guide Dogs Blind Association Van Sloun Fund Canine Genetic Research Baker Institute Inherited Eye Disease Gift Fund
0.11429769.11978759.html.plaintext.txt	334	FOOTNOTES To correspondence addressed James A
0.11429769.11978759.html.plaintext.txt	335	Baker Institute Animal Health College Veterinary Medicine Cornell University Ithaca NY 14853 USA
0.11429769.11978759.html.plaintext.txt	336	Tel1607 256 5620 Fax 1607 256 5689 Email gda1atcornell
0.11429769.11978759.html.plaintext.txt	337	AF385629 AF148800 AF148798
0.11429769.11978759.html.plaintext.txt	338	REFERENCES TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION METHODS REFERENCES 1 Phelan J
0.11429769.11978759.html.plaintext.txt	339	2000 A brief review retinitis pigmentosa identified retinitis pigmentosa genes
0.11429769.11978759.html.plaintext.txt	340	1996 A gene RPGR homology RCC1 guanine nucleotide exchange factor mutated X linked retinitis pigmentosa RP3
0.11429769.11978759.html.plaintext.txt	341	1988 X linked retinitis pigmentosa
0.11429769.11978759.html.plaintext.txt	342	1997 Phenotypes three Swedish families X linked retinitis pigmentosa caused different mutations RPGR gene
0.11429769.11978759.html.plaintext.txt	343	1998 Positional cloning gene X linked retinitis pigmentosa 2
0.11429769.11978759.html.plaintext.txt	344	1997 Spectrum mutations RPGR gene identified 20 families X linked retinitis pigmentosa
0.11429769.11978759.html.plaintext.txt	345	1997 Analysis RPGR gene 11 pedigrees Retinitis Pigmentosa type 3 genotype Paucity mutations coding region splice defects two families
0.11429769.11978759.html.plaintext.txt	346	2000 Mutational hot spot within new RPGR exon X linked retinitis pigmentosa
0.11429769.11978759.html.plaintext.txt	347	2000 A retinitis pigmentosa GTPase regulator RPGR deficient mouse model X linked retinitis pigmentosa RP3
0.11429769.11978759.html.plaintext.txt	348	1999 The retinitis pigmentosa GTPase regulator RPGR interacts delta subunit rod cyclic GMP phosphodiesterase
0.11429769.11978759.html.plaintext.txt	349	2000 Identification novel protein interacting RPGR
0.11429769.11978759.html.plaintext.txt	350	2000 The retinitis pigmentosa GTPase regulator RPGR interacts novel transport like proteins outer segments rod photoreceptors
0.11429769.11978759.html.plaintext.txt	351	2001 Retinitis pigmentosa GTPase regulator RPGR interacting protein stably associated photoreceptor ciliary axoneme anchors RPGR connecting cilium
0.11429769.11978759.html.plaintext.txt	352	1999 The sleep disorder canine narcolepsy caused mutation Hypocretin Orexin receptor 2 gene
0.11429769.11978759.html.plaintext.txt	353	1998 Diseases retinal pigment epithelium photoreceptor complex non rodent animal models
0.11429769.11978759.html.plaintext.txt	354	eds Retinal Pigment Epithelium Current Aspects Function Disease
0.11429769.11978759.html.plaintext.txt	355	Oxford University Press New York pp
0.11429769.11978759.html.plaintext.txt	356	1994 XLPRA canine retinal degeneration inherited X linked trait
0.11429769.11978759.html.plaintext.txt	357	1999 Retinal pathology canine X linked progressive retinal atrophy locus homolog RP3
0.11429769.11978759.html.plaintext.txt	358	2000 Mapping X linked progressive retinal atrophy XLPRA canine homolog retinitis pigmentosa 3 RP3
0.11429769.11978759.html.plaintext.txt	359	2001 Fine mapping canine XLPRA establishes homology human canine RP3 intervals
0.11429769.11978759.html.plaintext.txt	360	1995 A human RNase E like activity cleaves RNA sequences involved mRNA stability control
0.11429769.11978759.html.plaintext.txt	361	1982 Specific sequences native DNA arrest synthesis DNA polymerase alpha
0.11429769.11978759.html.plaintext.txt	362	1996 Mutagenesis mammalian cells induced triple helix formation transcription coupled repair
0.11429769.11978759.html.plaintext.txt	363	1988 The William Allan Memorial Award Address X chromosome inactivation location expression X linked genes
0.11429769.11978759.html.plaintext.txt	364	2000 A longitudinal study visual function carriers X linked recessive retinitis pigmentosa
0.11429769.11978759.html.plaintext.txt	365	Ophthalmology 107 386 396
0.11429769.11978759.html.plaintext.txt	366	1999 RPGR transcription studies mouse human tissues reveal retina specific isoform disrupted patient X linked retinitis pigmentosa
0.11429769.11978759.html.plaintext.txt	367	2000 Remapping RP15 locus X linked cone rod degeneration Xp11
0.11429769.11978759.html.plaintext.txt	368	1 identification de novo insertion RPGR exon ORF15
0.11429769.11978759.html.plaintext.txt	369	2000 X linked retinitis pigmentosa mutation spectrum RPGR RP2 genes correlation visual function
0.11429769.11978759.html.plaintext.txt	370	1997 Severe manifestations carrier females X linked retinitis pigmentosa
0.11429769.11978759.html.plaintext.txt	371	2001 DNA sequence comparison human mouse retinitis pigmentosa GTPase regulator RPGR identifies tissue specific exons putative regulatory elements
0.11429769.11978759.html.plaintext.txt	372	1987 Retinal degenerations dog IV
0.11429769.11978759.html.plaintext.txt	373	Early retinal degeneration erd Norwegian elkhounds
0.11429769.11978759.html.plaintext.txt	374	1997 Differential expression photoreceptor specific proteins disease degeneration progressive rod cone degeneration prcd retina
0.11429769.11978759.html.plaintext.txt	375	1991 Anti rhodopsin monoclonal antibodies defined specificity characterization application
0.11429769.11978759.html.plaintext.txt	376	1997 Canine rod photoreceptor cGMP gated channel protein alpha subunit studies expression gene characterization cDNA
0.11429769.11978759.html.plaintext.txt	377	1996 The expression cytosolic phospholipase A2 prostaglandin endoperoxide synthase ovine maternal uterine fetal tissues late gestation labor
0.11429769.11978759.html.plaintext.txt	378	Endocrinology 137 4010 4017
0.11429769.11978759.html.plaintext.txt	379	1999 Suppression subtractive hybridization identified marked increase thrombospondin 1 associated parturition pregnant sheep myometrium
0.11429769.11978759.html.plaintext.txt	380	Endocrinology 140 2364 2371
0.32579625.12933647.html.plaintext.txt	0	Fasting Activates Nonhuman Primate Hypocretin Orexin System Its Postsynaptic Targets Sabrina Diano Balazs Horvath Henryk F
0.32579625.12933647.html.plaintext.txt	1	Urbanski Peter Sotonyi Tamas L
0.32579625.12933647.html.plaintext.txt	2	Departments Obstetrics Gynecology S
0.32579625.12933647.html.plaintext.txt	3	Yale University School Medicine New Haven Connecticut 06520 Division Neuroscience H
0.32579625.12933647.html.plaintext.txt	4	Oregon Regional Primate Research Center Beaverton Oregon 97006 Department Anatomy Histology P
0.32579625.12933647.html.plaintext.txt	5	Szent Istvan University School Veterinary Medicine Budapest Hungary 1071
0.32579625.12933647.html.plaintext.txt	6	Address correspondence requests reprints Tamas L
0.32579625.12933647.html.plaintext.txt	7	Horvath Department Obstetrics Gynecology Yale Medical School 333 Cedar Street FMB 339 New Haven Connecticut 06520
0.32579625.12933647.html.plaintext.txt	8	In rodents hypocretin HCRT also called orexin influences variety endocrine autonomic metabolic functions
0.32579625.12933647.html.plaintext.txt	9	The present study undertaken determine whether HCRT producing circuit involved hypothalamic regulation homeostasis primates well
0.32579625.12933647.html.plaintext.txt	10	We studied female monkeys Cercopithecus aethiops either fed fasted 24 h
0.32579625.12933647.html.plaintext.txt	11	Immunocytochemistry revealed HCRT producing perikarya exclusively lateral hypothalamus perifornical region dorsomedial hypothalamus monkey brain
0.32579625.12933647.html.plaintext.txt	12	HCRT axons axon terminals present different parts hypothalamus adjacent forebrain thalamic nuclei
0.32579625.12933647.html.plaintext.txt	13	The 24 h fast resulted approximately 50 decline circulating leptin levels significantly elevated c fos expression perifornical region dorsomedial ventromedial arcuate nuclei medial preoptic area
0.32579625.12933647.html.plaintext.txt	14	In dorsomedial nucleus perifornical region fasted monkeys three times HCRT neurons expressed nuclear c fos normally fed controls
0.32579625.12933647.html.plaintext.txt	15	Neurons different parts hypothalamus basal forebrain expressed c fos contain HCRT targets HCRT immunopositive boutons establishing asymmetric synapses
0.32579625.12933647.html.plaintext.txt	16	In arcuate nucleus subsets HCRT targeted c fos expressing cells contained neuropeptide Y
0.32579625.12933647.html.plaintext.txt	17	The present study provides first experimental evidence implicate HCRT hypothalamic regulation homeostasis primates
0.32579625.12933647.html.plaintext.txt	18	The fact lateral hypothalamic cells leptin receptors activated metabolic challenge innervate diverse brain regions indicates HCRT system may key integrator environmental cues regulation diverse brain activity
0.32579625.12933647.html.plaintext.txt	19	ENERGY HOMEOSTASIS IS regulated discrete central nervous system circuits predominantly hypothalamic areas sensitive peripheral metabolic signals 1
0.32579625.12933647.html.plaintext.txt	20	A great part current understanding human physiology disorders hypothalamus inferred rodent models whereas little known primate hypothalamic circuits control homeostasis
0.32579625.12933647.html.plaintext.txt	21	In particular clear whether peptidergic circuits known involved hypothalamic regulation rodent homeostasis similar functions primate brain
0.32579625.12933647.html.plaintext.txt	22	Hypocretin HCRT also called orexin peptide produced exclusively hypothalamus 2 3 4 emerged important regulator autonomic endocrine metabolic functions rodents 3 5 6
0.32579625.12933647.html.plaintext.txt	23	HCRT cells rats monkeys found express leptin receptor immunoreactivity provide synaptic input distinct hypothalamic brainstem circuits known participate central regulation endocrine metabolic autonomic systems 4 7
0.32579625.12933647.html.plaintext.txt	24	Although determination synaptic interactions HCRT hypothalamic systems provided map via signals may travel within hypothalamus demonstrate whether signaling modality involved homeostatic regulation
0.32579625.12933647.html.plaintext.txt	25	For determination cytochemical identification c fos indicator cell activity different metabolic conditions may used
0.32579625.12933647.html.plaintext.txt	26	After metabolic challenge distinct populations hypothalamic neurons begin express c fos rats 8 well monkeys 9
0.32579625.12933647.html.plaintext.txt	27	Using paradigm current study aimed determine whether monkey hypothalamus HCRT cells postsynaptic targets activated metabolic challenge fasting
0.32579625.12933647.html.plaintext.txt	28	0 kg female African green monkeys Cercopithecus aethiops n 6 used
0.32579625.12933647.html.plaintext.txt	29	All monkeys previously ovariectomized use unrelated experiment three monkeys killed fasting food withdrawal 24 h whereas three killed without fasting
0.32579625.12933647.html.plaintext.txt	30	The primate tissue collected protocols approved Yale Animal Care Use Committee
0.32579625.12933647.html.plaintext.txt	31	After receiving lethal dose anesthetic monkeys killed transcardial perfusion 500 ml heparinized saline 0
0.32579625.12933647.html.plaintext.txt	32	9 followed 2000 ml fixative consisting 4 paraformaldehyde 15 saturated picric acid 0
0.32579625.12933647.html.plaintext.txt	33	1 M phosphate buffer PB pH 7
0.32579625.12933647.html.plaintext.txt	34	The mediobasal hypothalamus dissected postfixed additional 1
0.32579625.12933647.html.plaintext.txt	35	5 h glutaraldehyde free fixative
0.32579625.12933647.html.plaintext.txt	36	Tissue blocks washed stored 0
0.32579625.12933647.html.plaintext.txt	37	Light electron microscopic double immunostaining Light microscopic double immunostaining HCRT c fos carried according previously published protocol
0.32579625.12933647.html.plaintext.txt	38	Sections incubated one primary antisera rabbit anti HCRT 12000 processed avidin biotin peroxidase technique
0.32579625.12933647.html.plaintext.txt	39	The immunoreaction visualized modified version nickel diaminobenzidine DAB reaction 15 mg DAB 0
0.32579625.12933647.html.plaintext.txt	40	12 mg glucose oxidase 12 mg ammonium chloride 600 microl 0
0.32579625.12933647.html.plaintext.txt	41	05 M nickel ammonium sulfate 600 microl 10 ss D glucose 30 ml PB resulting dark blue reaction product
0.32579625.12933647.html.plaintext.txt	42	After several rinses PB sections incubated sheep anti c fos 12000 Cambridge Research Biochemicals Inc
0.32579625.12933647.html.plaintext.txt	43	Wilmington DE 24 h 4 C processed peroxidase anti peroxidase technique
0.32579625.12933647.html.plaintext.txt	44	The tissue bound peroxidase visualized DAB reaction 15 mg DAB 165 microl 0
0.32579625.12933647.html.plaintext.txt	45	3 H2O2 30 ml PB resulting light brown reaction product
0.32579625.12933647.html.plaintext.txt	46	After visualization tissue antigens sections processed electron microscopy 1 OsO4 PB 30 min
0.32579625.12933647.html.plaintext.txt	47	dehydrated increasing ethanol concentrations using 1 uranyl acetate 70 ethanol 30 min flat embedded araldite liquid release coated slides Electron Microscopy Sciences Fort Washington PA
0.32579625.12933647.html.plaintext.txt	48	The specificity HCRT antisera thoroughly tested us others previous studies 2 4
0.32579625.12933647.html.plaintext.txt	49	Analysis c fos expressing cells single double labeled c fos HCRT material To estimate induction c fos expression primate hypothalamus 24 h fasting matching sections hypothalami control fasted monkeys coincubated vials either single immunostaining c fos double immunostaining c fos HCRT see
0.32579625.12933647.html.plaintext.txt	50	To ensure matching sections coprocessed sections selected using comparative assessment location following anatomical landmarks optic chiasm tract shape third ventricle anterior commissure fornix mammilo thalamic tract median eminence
0.32579625.12933647.html.plaintext.txt	51	One group sections either control experimental marked placing notch one side tissue block vibratome sectioning
0.32579625.12933647.html.plaintext.txt	52	The analyzer blind code revealed collection counts
0.32579625.12933647.html.plaintext.txt	53	When immunostaining completed three sets coincubations six monkeys three control three experimental matching sections placed slides coverslipped analyzed using light microscopy
0.32579625.12933647.html.plaintext.txt	54	The number c fos immunolabeled cells labeled HCRT labeled antigens noted several nuclei hypothalamus see
0.32579625.12933647.html.plaintext.txt	55	Only cells surface section counted
0.32579625.12933647.html.plaintext.txt	56	Guided stereotaxic atlas African Green monkey 10 following hypothalamic areas analyzed medial preoptic area MPOA parvicellular magnocellular paraventricular nucleus arcuate infundibular nucleus ARC dorsomedial hypothalamic nucleus ventromedial nucleus lateral hypothalamus perifornical region
0.32579625.12933647.html.plaintext.txt	57	After determining mean values Student test used comparison
0.32579625.12933647.html.plaintext.txt	58	Significance concluded P 0
0.32579625.12933647.html.plaintext.txt	59	Light microscopic triple immunostaining Because HCRT present neuronal perikarya ARC c fos expressed cell nuclei neuropeptide Y NPY expressed cytoplasm neurons triple labeled hypothalamic sections using triple labeling protocol 4
0.32579625.12933647.html.plaintext.txt	60	Sections first incubated 24 h room temperature mixture HCRT c fos antisera processed avidin biotin peroxidase tissue bound peroxidase visualized nickel diaminobenzidine reaction resulting dark blue black color
0.32579625.12933647.html.plaintext.txt	61	Subsequently sections immunostained NPY using sheep anti NPY Auspep Pty Ltd
0.32579625.12933647.html.plaintext.txt	62	Perkwille Australia peroxidase antiperoxidase method tissue bound peroxidase visualized DAB reaction give light brown reaction product
0.32579625.12933647.html.plaintext.txt	63	Leptin measurements All blood samples collected morning serum stored frozen
0.32579625.12933647.html.plaintext.txt	64	Samples collected animals fasted
0.32579625.12933647.html.plaintext.txt	65	Leptin measured using primate leptin RIA kit Linco Research Inc
0.32579625.12933647.html.plaintext.txt	66	The minimum detectable concentration 95 binding 0
0.32579625.12933647.html.plaintext.txt	67	7 ng ml interassay coefficient variation 6 serum samples assayed together single RIA
0.32579625.12933647.html.plaintext.txt	68	A Student test two tail probabilities used statistical comparisons leptin values two groups
0.32579625.12933647.html.plaintext.txt	69	Significance concluded P 0
0.32579625.12933647.html.plaintext.txt	70	Circulating leptin levels fasted normally fed control African green monkeys The circulating leptin level values differ fasted control groups 0 h 6
0.32579625.12933647.html.plaintext.txt	71	05 significantly lower fasted animals 24 h fast 2
0.32579625.12933647.html.plaintext.txt	72	The overall pattern HCRT immunolabeling monkey corresponded earlier description 4 7
0.32579625.12933647.html.plaintext.txt	73	HCRT immunoreactive perikarya present exclusively lateral hypothalamus perifornical region lesser extent dorsomedial hypothalamus whereas projections abundant different hypothalamic nuclei
0.32579625.12933647.html.plaintext.txt	74	We detected obvious differences HCRT immunoreactivity hypothalamus control vs
0.32579625.12933647.html.plaintext.txt	75	In accordance recent report 9 c fos immunoreactivity detected different parts hypothalamus fasted normally fed control monkeys
0.32579625.12933647.html.plaintext.txt	76	In control animals moderate number c fos labeled nuclei homogenously distributed MPOA periventricular regions paraventricular nucleus parvo magnocellular regions anterior hypothalamus suprachiasmatic arcuate dorsomedial ventromedial nuclei lateral hypothalamus perifornical region
0.32579625.12933647.html.plaintext.txt	77	The number c fos expressing cells individual hypothalamic subnuclei fasted monkeys distinctly different control values Fig
0.32579625.12933647.html.plaintext.txt	78	In fasted animals significantly higher number c fos expressing cells detected MPOA 235 plus minus 22 vs
0.32579625.12933647.html.plaintext.txt	79	489 plus minus 35 P 0
0.32579625.12933647.html.plaintext.txt	80	05 lateral hypothalamus perifornical LH PF region 343 plus minus 17 vs
0.32579625.12933647.html.plaintext.txt	81	889 plus minus 41 P 0
0.32579625.12933647.html.plaintext.txt	82	1 A B arcuate 205 plus minus 34 vs
0.32579625.12933647.html.plaintext.txt	83	341 plus minus 42 P 0
0.32579625.12933647.html.plaintext.txt	84	05 dorsomedial nuclei 276 plus minus 41 vs
0.32579625.12933647.html.plaintext.txt	85	452 plus minus 26 P 0
0.32579625.12933647.html.plaintext.txt	86	View larger version 82K FIG
0.32579625.12933647.html.plaintext.txt	87	Light micrographs monkey perifornical region pf immunostaining c fos taken control A fasted animals B
0.32579625.12933647.html.plaintext.txt	88	C Bar graph showing number c fos immunoreactive nuclei different parts hypothalamus control white bars fasted black bars animals
0.32579625.12933647.html.plaintext.txt	89	In addition differences albeit nonsignificant detected ventromedial 224 plus minus 36 vs
0.32579625.12933647.html.plaintext.txt	90	196 plus minus 13 P 0
0.32579625.12933647.html.plaintext.txt	91	05 parvicellular paraventricular 246 plus minus 27 vs
0.32579625.12933647.html.plaintext.txt	92	316 plus minus 39 P 0
0.32579625.12933647.html.plaintext.txt	93	05 magnocellular paraventricular hypothalamic nuclei 325 plus minus 40 vs
0.32579625.12933647.html.plaintext.txt	94	287 plus minus 33 P 0
0.32579625.12933647.html.plaintext.txt	95	However noted low sample values n 3 may mask significant differences might detected higher number animals studied
0.32579625.12933647.html.plaintext.txt	96	c fos expression HCRT cells c fos immunoreactivity detected cell nuclei HCRT immunoreactive cells control 24 h fasted animals Fig
0.32579625.12933647.html.plaintext.txt	97	There difference mean number HCRT labeled cells control fasted animals 502 plus minus 24 vs
0.32579625.12933647.html.plaintext.txt	98	535 plus minus 33 P 0
0.32579625.12933647.html.plaintext.txt	99	However percentage HCRT cells expressing nuclear c fos robustly significantly elevated fasted animals compared control values P 0
0.32579625.12933647.html.plaintext.txt	100	In control LH PF 135 plus minus 35 HCRT cells exhibited nuclear c fos labeling represented 26
0.32579625.12933647.html.plaintext.txt	101	8 total HCRT cells counted
0.32579625.12933647.html.plaintext.txt	102	In contrast fasted animals 418 plus minus 38 HCRT cells exhibited c fos immunoreactivity represented 78
0.32579625.12933647.html.plaintext.txt	103	1 total HCRT cells counted Fig
0.32579625.12933647.html.plaintext.txt	104	The number c fos expressing neurons contained HCRT control monkeys 135 plus minus 35 represented approximately 75 cells c fos immunopositive 182 plus minus 29 LH PF region
0.32579625.12933647.html.plaintext.txt	105	This ratio remains similar fasted animals 418 38 total c fos immunolabaled nuclei 562 plus minus 42 HCRT immunoreactive perikarya Fig
0.32579625.12933647.html.plaintext.txt	106	View larger version 77K FIG
0.32579625.12933647.html.plaintext.txt	107	Fasting induced c fos expression associated exclusively cell nuclei A C
0.32579625.12933647.html.plaintext.txt	108	In perifornical region many nuclear c fos labeled cells red nuclei B D also immunopositive HCRT
0.32579625.12933647.html.plaintext.txt	109	Bar scales A C 10 microm A B 100 microm C D
0.32579625.12933647.html.plaintext.txt	110	E Bar graph showing c fos immunoreactive HCRT neurons white bars total HCRT neurons black bars counted control fasted animals
0.32579625.12933647.html.plaintext.txt	111	F Bar graph showing c fos immunoreactive HCRT neurons white bars total c fos immunolabeled neurons black bars counted control fasted animals
0.32579625.12933647.html.plaintext.txt	112	Hypocretin axons synapse c fos containing cells When analyzed light microscopy apparent control fasted animals c fos immunolabeled cells surrounded numerous HCRT immunopositive boutons Fig
0.32579625.12933647.html.plaintext.txt	113	In regions significant elevations c fos labeling fasting MPOA ARC LH PF dorsomedial nucleus found c fos immunolabeled cells either control experimental group contacted numerous HCRT labeled axon terminals
0.32579625.12933647.html.plaintext.txt	114	Synaptic membrane specializations HCRT boutons c fos expressing cells asymmetrical contacts Fig
0.32579625.12933647.html.plaintext.txt	115	In ARC increased c fos expression detected fasting hypothalamic NPY producing cells located HCRT axons close proximity perikarya contained NPY c fos Fig
0.32579625.12933647.html.plaintext.txt	116	View larger version 173K FIG
0.32579625.12933647.html.plaintext.txt	117	In regions monkey hypothalamus c fos induction observed fasting cell nuclei HCRT boutons observed close apposition activated cells A electron microscopy showed B C contacts synapses arrows C point membrane specializations
0.32579625.12933647.html.plaintext.txt	118	Bar scales 10 microm A 1 microm B C
0.32579625.12933647.html.plaintext.txt	119	View larger version 134K FIG
0.32579625.12933647.html.plaintext.txt	120	A subset fasting activated HCRT targeted cells NPY cells ARC
0.32579625.12933647.html.plaintext.txt	121	The present study provides first suggestive evidence HCRT system nonhuman primates involved hypothalamic signal transduction associated metabolic alterations
0.32579625.12933647.html.plaintext.txt	122	The fact short term food withdrawal underlies robust activation transcriptional mechanisms primate lateral hypothalamic HCRT system together widespread distribution HCRT projections homeostatic centers beyond argues coordinating role HCRT autonomic endocrine metabolic processes
0.32579625.12933647.html.plaintext.txt	123	This assertion line evidence available role HCRT modulation food intake blood pressure arousal 3 5 6 11 12
0.32579625.12933647.html.plaintext.txt	124	In previous study 4 monkey ARC found receive robust HCRT innervation HCRT axons heavily innervating NPY cells 4
0.32579625.12933647.html.plaintext.txt	125	Whether ARC NPY system may participate modulation HCRT food intake primates suggested rat 13 14 remains tested
0.32579625.12933647.html.plaintext.txt	126	The present observation HCRT input fasting activated NPY cells African green monkey lends support possibility
0.32579625.12933647.html.plaintext.txt	127	Nevertheless also conceivable activation HCRT neurons fasting occurs secondary activation ARC
0.32579625.12933647.html.plaintext.txt	128	However ARC NPY cells likely protected blood brain barrier direct projection ARC lateral hypothalamus robust nonhuman primate 4
0.32579625.12933647.html.plaintext.txt	129	It may also plausible HCRT system heavily involved regulation sleepwake cycles disturbance sleep fasting affects HCRT neuronal function
0.32579625.12933647.html.plaintext.txt	130	Alternatively metabolic signals affect HCRT cells fasting sleep disturbances may consequence HCRT neuronal activation
0.32579625.12933647.html.plaintext.txt	131	Leptin receptor immunoreactivity detected primate lateral hypothalamic HCRT cells 4 leptin suggested cross blood brain barrier 15
0.32579625.12933647.html.plaintext.txt	132	Thus observed induction c fos gene expression HCRT cells may direct consequence diminishing leptin levels observed short term fasting
0.32579625.12933647.html.plaintext.txt	133	However fasting paradigms particularly used primates allow distinction effect particular hormones underlie complex responses variety endocrine mechanisms
0.32579625.12933647.html.plaintext.txt	134	For example rodent evidence available indicate circulating insulin andor glucose levels regulatory influence hypothalamic HCRT expression 16
0.32579625.12933647.html.plaintext.txt	135	Future studies determine extent contribution involved humoral metabolic signals activation primate HCRT systems
0.32579625.12933647.html.plaintext.txt	136	Interestingly hypothalamic nuclei including ARC LH PF dorsomedial nucleus MPOA short term fasting induced c fos expression robustly activated cells received multiple HCRT inputs
0.32579625.12933647.html.plaintext.txt	137	In rodents HCRT exerts excitatory postsynaptic currents 17 intracerebroventricular administration HCRT induces c fos expression manner dissimilar describe nonhuman primate 18 19
0.32579625.12933647.html.plaintext.txt	138	Because synaptic membrane specializations HCRT axons c fos expressing perikarya primate hypothalamus asymmetrical stimulatory synapses activation hypothalamic circuitry metabolic challenge may mediated part HCRT system
0.32579625.12933647.html.plaintext.txt	139	We thank Anthony van den Pol providing HCRT antisera
0.32579625.12933647.html.plaintext.txt	140	This work supported NIH Grant RR 14451
0.32579625.12933647.html.plaintext.txt	141	Albert Szent Gyorgyi Fellow
0.32579625.12933647.html.plaintext.txt	142	Abbreviations ARC Arcuate nucleus DAB diaminobenzidine HCRT hypocretin LH PF lateral hypothalamus perifornical MPOA medial preoptic area NPY neuropeptide Y PB phosphate buffer
0.32579625.12933647.html.plaintext.txt	143	Accepted publication June 24 2003
0.32579625.12933647.html.plaintext.txt	144	Kalra SP Xu B Dube MG Pu S Horvath TL Kalra PS 1999 Interacting appetite regulating pathways hypothalamic regulation body weight
0.32579625.12933647.html.plaintext.txt	145	Endocr Rev 2067 100 de Lecea L Kilduff TS Peyron C Gao XB Foye PE Danielson PE Fukuhara C Battenberg ELF Gautvik VT Bartlett II FS Frankel WN van den Pol AN Bloom FE Gautvik KM Sutcliffe JG 1998 The hypocretins two hypothalamic peptides neuroexcitatory activity
0.32579625.12933647.html.plaintext.txt	146	Proc Natl Acad Sci USA 95322 327AbstractFree Full Text Sakurai T Amemiya A Ishii M Matsuzaki I Chemelli RM Tanaka H Williams SC Richardson JA Kozlowski GP Wilson S Arch JRS Buckingham RE Haynes AC Carr SA Annan RS McNulty DE Liu W S Terrett JA Elshourbagy NA Bergsma DJ Yanagisawa M 1998 Orexins orexin receptors family hypothalamic neuropeptides G protein coupled receptors regulate feeding behavior
0.32579625.12933647.html.plaintext.txt	147	Cell 92573 585Medline Horvath TL Diano S van den Pol AN 1999 Synaptic interaction hypocretin orexin neuropeptide Y cells rodent primate hypothalamus novel circuit implicated metabolic endocrine regulations
0.32579625.12933647.html.plaintext.txt	148	J Neurosci 191072 1087AbstractFree Full Text Chemelli RM Willie JT Sinton CM Elmquist JK Scammell T Lee C Richardson JA Williams SC Xiong Y Kisanuki Y Fitch TE Nakazato M Hammer RE Saper CB Yanagisawa M 1999 Narcolepsy orexin knockout mice molecular genetics sleep regulation
0.32579625.12933647.html.plaintext.txt	149	Cell 98437 451Medline Lin L Faraco J Li R Kadotani H Rogers W Lin X Qiu X de Jong PJ Nishino S Mignot E 1999 The sleep disorder canine narcolepsy caused mutation hypocretin orexin receptor 2 gene
0.32579625.12933647.html.plaintext.txt	150	Cell 98365 376Medline Horvath TL Peyron C Diano S Ivanov A Aston Jones G Kilduff TS van den Pol AN 1999 Hypocretin orexin activation synaptic innervation locus coeruleus noradrenergic system
0.32579625.12933647.html.plaintext.txt	151	CO2 U 231CrossRefMedline Caston Balderrama AL Cameron JL Hoffman GE 1998 Immunocytochemical localization Fos perfused nonhuman primate brain tissue fixation antisera selection
0.32579625.12933647.html.plaintext.txt	152	J Histochem Cytochem 46547 556AbstractFree Full Text Contreras CM Mexicano G Guzman Flores C 1981 A stereotaxic brain atlas green monkey Cecopithecus aethiops aethiops
0.32579625.12933647.html.plaintext.txt	153	Bol Estud Med Biol 31383 428Medline Samson WK Gosnell B Chang JK Resch ZT Murphy TC 1999 Cardiovascular regulatory actions hypocretins brain
0.32579625.12933647.html.plaintext.txt	154	Brain Res 83248 253 Kukkonen JP Holmqvist T Ammoun S Akerman KE 2002 Functions orexinergichypocretinergic system
0.32579625.12933647.html.plaintext.txt	155	Am J Physiol Cell Physiol 283C1567 C1591 Jain MR Horvath TL Kalra PS Kalra SP 1999 Evidence NPY Y1 receptors involved stimulation feeding orexins hypocretins sated rats
0.32579625.12933647.html.plaintext.txt	156	Regul Pept 8719 24 Lopez M Seoane LM Garcia Mdel C Dieguez C Senaris R 2002 Neuropeptide Y agouti related peptide melanin concentrating hormone target peptide orexin A feeding actions rat hypothalamus
0.32579625.12933647.html.plaintext.txt	157	Neuroendocrinology 7534 44CrossRefMedline Bjorbaek C Elmquist JK Michl P Ahima RS Vanbueren A Mccall AL Flier JS 1998 Expression leptin receptor isoform rat brain microvessels
0.32579625.12933647.html.plaintext.txt	158	Endocrinology 1393485 3491AbstractFree Full Text Cai XJ Widdowson PS Harrold J Wilson S Buckingham RE Arch JR Tadayyon M Clapham JC Wilding J Williams G 1999 Hypothalamic orexin expression modulation blood glucose feeding
0.32579625.12933647.html.plaintext.txt	159	Diabetes 112132 2137 van den Pol AN Gao XB Obrietan K Kilduff T Belousov A 1998 Pre postsynaptic actions modulation neuroendocrine neurons new hypothalamic peptide hypocretinorexin
0.32579625.12933647.html.plaintext.txt	160	J Neurosci 187962 7971AbstractFree Full Text Date Y Ueta Y Yamashita H Yamaguchi H Matsukura S Kangawa K Sakurai T Yanagisawa M Nakazato M 1999 Orexins orexigenic hypothalamic peptides interact autonomic neuroendocrine neuroregulatory systems
0.32579625.12933647.html.plaintext.txt	161	Proc Natl Acad Sci USA 96748 753AbstractFree Full Text Mullett MA Billington CJ Levine AS Kotz CM 2000 Hypocretin I lateral hypothalamus activates key feeding regulatory brain sites
0.32579625.12933647.html.plaintext.txt	162	Neuroreport 11103 108Medline
0.18986537.11878678.html.plaintext.txt	0	Editorial I Central noradrenergic neurones mechanism general anaesthesia K
0.18986537.11878678.html.plaintext.txt	1	Modern anaesthetics main safe predictable use highly efficient
0.18986537.11878678.html.plaintext.txt	2	Moreover could argued without properties major advances surgical practice often highlighted media could taken place
0.18986537.11878678.html.plaintext.txt	3	However example pharmacology production anaesthetic state remains somewhat mystery
0.18986537.11878678.html.plaintext.txt	4	This mystery results controversies related existence unitary anaesthetic target site
0.18986537.11878678.html.plaintext.txt	5	From direct observation clinical anaesthesia seems unlikely different anaesthetic agents produce different types anaesthesia
0.18986537.11878678.html.plaintext.txt	6	GABAA receptors long held unifying cellular target exceptions others also suggested
0.18986537.11878678.html.plaintext.txt	7	In editorial consider evidence support role noradrenergic transmission wiring target anaesthetic action
0.18986537.11878678.html.plaintext.txt	8	The clear role system analgesia considered
0.18986537.11878678.html.plaintext.txt	9	Norepinephrine major central nervous system neurotransmitter brainstem
0.18986537.11878678.html.plaintext.txt	10	Noradrenergic neurones great importance regulation range behaviours including sleep wake cycle feeding thermoregulation attention motor activity growth development
0.18986537.11878678.html.plaintext.txt	11	1 In addition many studies suggesting noradrenergic systems may involved production anaesthetic state
0.18986537.11878678.html.plaintext.txt	12	In brain A1 A2 A5 A7 noradrenergic clusters constituting lateral tegmental area project thalamus hypothalamus
0.18986537.11878678.html.plaintext.txt	13	2 The locus coeruleus A6 cluster distinct lateral tegmental area innervates cerebral cortex hippocampus cerebellum spinal cord
0.18986537.11878678.html.plaintext.txt	14	The activity locus coeruleus neurones slow regular wakefulness
0.18986537.11878678.html.plaintext.txt	15	3 In contrast animal becomes drowsy entering slow wave REM sleep decrease discharge rate REM sleep neurones silent
0.18986537.11878678.html.plaintext.txt	16	3 Interestingly noradrenergic projections cerebrocortex originate locus coeruleus
0.18986537.11878678.html.plaintext.txt	17	The preoptic area receives input locus coeruleus A6 lateral tegmental group A1 A2 A5 A7 noradrenergic neurones
0.18986537.11878678.html.plaintext.txt	18	4 In addition neurones preoptic area project back locus coeruleus
0.18986537.11878678.html.plaintext.txt	19	5 This area plays important role sleep hypnosis
0.18986537.11878678.html.plaintext.txt	20	What role noradrenergic neurones area Most previous studies6 suggest norepinephrine neurones preoptic area may contribute wakefulness direct activation injection norepinephrine area inhibits sleep
0.18986537.11878678.html.plaintext.txt	21	However several studies also suggest norepinephrine neurones may involved induction sleep
0.18986537.11878678.html.plaintext.txt	22	7 8 Mohan Kumar colleagues7 reported microinjection norepinephrine medial preoptic area destruction ventral noradrenergic bundle induced sleep
0.18986537.11878678.html.plaintext.txt	23	This group also reported mild reduction sleep increase wakefulness destruction catecholaminergic terminals medial preoptic area bilateral intracerebral injection 6 hydroxydopamine
0.18986537.11878678.html.plaintext.txt	24	8 Thus appears noradrenergic fibres medial preoptic area may hypnogenic
0.18986537.11878678.html.plaintext.txt	25	Central noradrenergic neurones regulated ss adrenergic receptors
0.18986537.11878678.html.plaintext.txt	26	It reported 1 adrenoceptor antagonist prazosin given orally increased active waking slow wave sleep decreased paradoxical sleep rat
0.18986537.11878678.html.plaintext.txt	27	9 In contrast 1 adrenoceptor stimulation systemic methoxamine increased aroused wakefulness decreased slow wave sleep paradoxical sleep cats
0.18986537.11878678.html.plaintext.txt	28	10 In addition prazosin increased 1 agonist ST 587 decreased duration thiopental anaesthesia rats
0.18986537.11878678.html.plaintext.txt	29	11 Matsumoto colleagues also reported direct intracerebroventricular administration methoxamine dose dependently reduced pentobarbital anaesthesia time mice
0.18986537.11878678.html.plaintext.txt	30	12 Most central physiological effects 2 agonists attributed 2 adrenoceptors present locus coeruleus
0.18986537.11878678.html.plaintext.txt	31	13 In rats microinjection 2 agonist dexmedetomedine locus coeruleus per se produces anaesthesia defined loss righting reflex
0.18986537.11878678.html.plaintext.txt	32	14 2 Agonists also reduce anaesthetic requirement human many species
0.18986537.11878678.html.plaintext.txt	33	15 In contrast data 2 antagonist yohimbine decreases sleep16 anaesthesia time15 variety non human species
0.18986537.11878678.html.plaintext.txt	34	The Angel group showed propranolol non selective ss antagonist dose dependently increased sleep time16 thiopental anaesthesia time11 rats
0.18986537.11878678.html.plaintext.txt	35	However failed show effect selective ss1 antagonists metoprolol atenolol
0.18986537.11878678.html.plaintext.txt	36	11 17 They also studied role ss2 adrenoceptors sleep general anaesthesia11 16 17 found selective ss2 antagonist ICI 118551 increased sleep time16 duration thiopental anaesthesia
0.18986537.11878678.html.plaintext.txt	37	17 Collectively data indicate effects non selective antagonist propranolol may mediated via ss2 adrenoceptors
0.18986537.11878678.html.plaintext.txt	38	The recently identified rat hypothalamus neuropeptides orexin A B18 endogenous agonists G protein coupled orexin 1 OX1 OX2 receptors
0.18986537.11878678.html.plaintext.txt	39	18 Orexin A equal affinity OX1 OX2 orexin B higher affinity OX2
0.18986537.11878678.html.plaintext.txt	40	Orexins receptors widely distributed brain
0.18986537.11878678.html.plaintext.txt	41	18 Orexins activate locus coeruleus noradrenergic system activation may increase arousal locomotor activity
0.18986537.11878678.html.plaintext.txt	42	19 In addition several reports20 suggest link orexin receptors narcolepsy
0.18986537.11878678.html.plaintext.txt	43	Therefore modulation noradrenergic neurones orexins receptors may contribute control sleep wake cycle
0.18986537.11878678.html.plaintext.txt	44	Moreover suggest neuropeptides receptors may also involved general anaesthesia although remains examined
0.18986537.11878678.html.plaintext.txt	45	Based considerations others began systematic evaluation range anaesthetic agents central norepinephrine release using vivo microdialysis techniques
0.18986537.11878678.html.plaintext.txt	46	Mizuno colleagues reported intraperitoneal pentobarbital inhibited norepinephrine release medial preoptic area rats
0.18986537.11878678.html.plaintext.txt	47	4 In addition shown systemic administration midazolam propofol significantly reduced norepinephrine release medial prefrontal cortex21 pentobarbital ineffective
0.18986537.11878678.html.plaintext.txt	48	22 As noradrenergic neurones prefrontal cortex receive innervation locus coeruleus3 activity noradrenergic neurones prefrontal cortex indirectly reflects locus coeruleus activity
0.18986537.11878678.html.plaintext.txt	49	Thus anaesthetics activate enhance GABAA receptors may reduce noradrenergic neuronal activity
0.18986537.11878678.html.plaintext.txt	50	In contrast ketamine21 22 nitrous oxide xenon23 NMDA receptor antagonistic actions markedly increased norepinephrine release prefrontal cortex preoptic area rats
0.18986537.11878678.html.plaintext.txt	51	Clearly anaesthetic modulation norepinephrine release depends type anaesthetic
0.18986537.11878678.html.plaintext.txt	52	This might argue noradrenergic transmission anaesthetic target
0.18986537.11878678.html.plaintext.txt	53	However already mentioned unitary site highly unlikely
0.18986537.11878678.html.plaintext.txt	54	Loss consciousness results reduction cerebral activity also result cerebral excitation occurs convulsions
0.18986537.11878678.html.plaintext.txt	55	In addition sleepiness induced hypothermia also increased body temperature activates heat sensitive neurones preoptic area
0.18986537.11878678.html.plaintext.txt	56	24 We feel wakefulness may occur set range range exceeded unconsciousness may occur
0.18986537.11878678.html.plaintext.txt	57	In support hypothesis found physostigmine reported antagonize ketamine anaesthesia reduced duration ketamine anaesthesia ketamine increased norepinephrine release rat prefrontal cortex
0.18986537.11878678.html.plaintext.txt	58	Collectively data presented editorial provide compelling evidence favour role noradrenergic transmission control wakefulness production mysterious anaesthetic state
0.18986537.11878678.html.plaintext.txt	59	University Hirosaki School Medicine
0.18986537.11878678.html.plaintext.txt	60	Neurotransmitter modulated ionic currents brainstem neurons targets
0.18986537.11878678.html.plaintext.txt	61	In Steriade M McCarley RW eds
0.18986537.11878678.html.plaintext.txt	62	Brainstem Control Wakefulness Sleep
0.18986537.11878678.html.plaintext.txt	63	New York Plenum Press 1990 164 203
0.18986537.11878678.html.plaintext.txt	64	Survey chemically defined cell groups pathways
0.18986537.11878678.html.plaintext.txt	65	Chemoarchitecture Brain
0.18986537.11878678.html.plaintext.txt	66	Berlin Springer Verlag 1985 7 113
0.18986537.11878678.html.plaintext.txt	67	Relationship locus coeruleus discharge rates rates norepinephrine release within neocortex assessed vivo microdialysis
0.18986537.11878678.html.plaintext.txt	68	Neuroscience1999 93 1263 70ISIMedline
0.18986537.11878678.html.plaintext.txt	69	Pentobarbital sodium inhibits release noradrenaline medial preoptic area
0.18986537.11878678.html.plaintext.txt	70	Neurosci Lett1994 170 111 3ISIMedline
0.18986537.11878678.html.plaintext.txt	71	Noradrenergic inputs sleep related neurons preoptic area locus coeruleus ventrolateral medulla rat
0.18986537.11878678.html.plaintext.txt	72	Neurosci Res 1994 19 39 50ISIMedline
0.18986537.11878678.html.plaintext.txt	73	Noradrenaline inhibits preoptic sleep active neurons 2 receptors rat
0.18986537.11878678.html.plaintext.txt	74	Neurosci Res1995 21 323 30ISIMedline
0.18986537.11878678.html.plaintext.txt	75	7 Mohan Kumar V Sharma R Wadhwa S Manchanda SK
0.18986537.11878678.html.plaintext.txt	76	Sleep inducing function noradrenergic fibers medial preoptic area
0.18986537.11878678.html.plaintext.txt	77	Brain Res Bull 1993 32 153 8ISIMedline
0.18986537.11878678.html.plaintext.txt	78	Changes sleep wakefulness 6 hydroxydopamine lesion preoptic area
0.18986537.11878678.html.plaintext.txt	79	Neuroscience 2000 98 549 53ISIMedline
0.18986537.11878678.html.plaintext.txt	80	Effects selective alpha 1 adrenoceptor blocker prazocin EEG sleep waking stages rat
0.18986537.11878678.html.plaintext.txt	81	Neuropsychobiology1989 21 100 3ISIMedline
0.18986537.11878678.html.plaintext.txt	82	Effects methoxamine alpha 1 adrenoceptor agonist prazosin alpha 1 antagonist stages sleep waking cycle cat
0.18986537.11878678.html.plaintext.txt	83	Acta Physiol Scand 1984 120 363 72ISIMedline
0.18986537.11878678.html.plaintext.txt	84	Anaesthesia role adrenergic mechanisms
0.18986537.11878678.html.plaintext.txt	85	Eur J Pharmacol 1983 91 29 39ISIMedline
0.18986537.11878678.html.plaintext.txt	86	12 Matsumoto K Kohno SI Ojima K Watanabe H
0.18986537.11878678.html.plaintext.txt	87	Flumazenil FG7142 reverses decrease pentobarbital sleep caused activation central noradrenergic systems mice
0.18986537.11878678.html.plaintext.txt	88	Brain Res 1997 754 325 28ISIMedline
0.18986537.11878678.html.plaintext.txt	89	Spatiotemporal interaction 2 autoreceptors noradrenaline transporters rat locus coeruleus implications volume transmission
0.18986537.11878678.html.plaintext.txt	90	J Neurochem 2000 74 2350 8ISIMedline
0.18986537.11878678.html.plaintext.txt	91	14 Nacif CoelhoC Correa Sales C Chang LL Maze M
0.18986537.11878678.html.plaintext.txt	92	Perturbation ion channel conductance alters hypnotic response 2 adrenergic agonist dexmedetomidine locus coeruleus rat
0.18986537.11878678.html.plaintext.txt	93	Anesthesiology 1994 81 1527 34ISIMedline
0.18986537.11878678.html.plaintext.txt	94	Alpha 2 adrenergic agonists defining role clinical anesthesia
0.18986537.11878678.html.plaintext.txt	95	Anesthesiology 1991 74 581 605ISIMedline
0.18986537.11878678.html.plaintext.txt	96	Alterations sleeping time rat induced drugs modulate central monoaminergic systems
0.18986537.11878678.html.plaintext.txt	97	Br J Anaesth 1990 64 594 600Abstract
0.18986537.11878678.html.plaintext.txt	98	Brain noradrenaline anaesthesia characterization beta receptor
0.18986537.11878678.html.plaintext.txt	99	Neuropharmacology 1983 22 1065 9ISIMedline
0.18986537.11878678.html.plaintext.txt	100	Orexins new family neuropeptides
0.18986537.11878678.html.plaintext.txt	101	Br J Anaesth1999 83 695 7Free Full Text
0.18986537.11878678.html.plaintext.txt	102	19 Hagan JJ Leslie RA Patel S et al
0.18986537.11878678.html.plaintext.txt	103	Orexin A activates locus coeruleus cell firing increases arousal rat
0.18986537.11878678.html.plaintext.txt	104	Proc Natl Acad Sci USA 1999 96 10911 6AbstractFree Full Text
0.18986537.11878678.html.plaintext.txt	105	20 Lin L Faraco J Li R et al
0.18986537.11878678.html.plaintext.txt	106	The sleep disorder canine narcolepsy caused mutation hypocretin orexin receptor 2 gene
0.18986537.11878678.html.plaintext.txt	107	Cell 1999 98 365 76ISIMedline
0.18986537.11878678.html.plaintext.txt	108	21 Kubota K Hirota K Yoshida H et al
0.18986537.11878678.html.plaintext.txt	109	Effects sedatives noradrenaline release medial prefrontal cortex rats
0.18986537.11878678.html.plaintext.txt	110	GABAA receptor activator vs NMDA receptor inhibitor
0.18986537.11878678.html.plaintext.txt	111	Psychopharmacology 1999 146 335 8ISIMedline
0.18986537.11878678.html.plaintext.txt	112	22 Kubota T Anzawa N Hirota K Yoshida H Matsuki A
0.18986537.11878678.html.plaintext.txt	113	Effects ketamine pentobarbital norepinephrine release median frontal cortex rats
0.18986537.11878678.html.plaintext.txt	114	Can J Anaesth 1999 46 388 92Abstract
0.18986537.11878678.html.plaintext.txt	115	23 Yoshida H Kushikata T Kubota T Hirota K Ishihara H Matsuki A
0.18986537.11878678.html.plaintext.txt	116	Increased norepinephrine release anterior posterior hypothalamus following xenon inhalation
0.18986537.11878678.html.plaintext.txt	117	Can J Anesth 2001 48 651 5AbstractFree Full Text
0.18986537.11878678.html.plaintext.txt	118	24 Alam MN McGinity D Szymusiak R
0.18986537.11878678.html.plaintext.txt	119	Neuronal discharge preopticanterior hypothalamus thermosensitive neurons relation NREM sleep
0.18986537.11878678.html.plaintext.txt	120	Am J Physiol 1995 269 R1240 9AbstractFree Full Text
0.18986537.11878678.html.plaintext.txt	121	25 Kubota K Hirota K Anzawa N Yoshida H Takahashi S Matsuki A
0.18986537.11878678.html.plaintext.txt	122	Physostigmine antagonizes ketamine induced noradrenaline release medial prefrontal cortex rats
0.18986537.11878678.html.plaintext.txt	123	Brain Res 1999 840 175 8ISIMedline
0.17200397.15961555.html.plaintext.txt	0	Orexin Expression Function Glucocorticoid Manipulation Stress Feeding Studies Gemma K
0.17200397.15961555.html.plaintext.txt	1	Al Barazanji Shelagh Wilson Declan N
0.17200397.15961555.html.plaintext.txt	2	Henry Wellcome Laboratory Integrative Neuroscience Endocrinology G
0.17200397.15961555.html.plaintext.txt	3	University Bristol Bristol BS1 3NY United Kingdom Department Biology D
0.17200397.15961555.html.plaintext.txt	4	Psychiatry Centre Excellence Drug Discovery CEDD Discovery Research S
0.17200397.15961555.html.plaintext.txt	5	GlaxoSmithKline Harlow Essex CM19 5AW United Kingdom Metabolic Diseases K
0.17200397.15961555.html.plaintext.txt	6	Metabolic Viral Diseases CEDD GlaxoSmithKline Research Triangle Park North Carolina 27709
0.17200397.15961555.html.plaintext.txt	7	Address correspondence requests reprints Dr
0.17200397.15961555.html.plaintext.txt	8	Harbuz Henry Wellcome Laboratory Integrative Neuroscience Endocrinology Dorothy Hodgkin Building Whitson Street Bristol BS1 3NY United Kingdom
0.17200397.15961555.html.plaintext.txt	9	Abstract Top Abstract Introduction Materials Methods Results Discussion References We investigated effects glucocorticoid manipulation orexin A induced feeding prepro orexin mRNA levels lateral hypothalamic area LHA rat brain
0.17200397.15961555.html.plaintext.txt	10	Adrenalectomy ADX reduced orexin A induced feeding 4 h 60 compared shams effect reversed corticosterone CORT replacement
0.17200397.15961555.html.plaintext.txt	11	ADX effect prepro orexin mRNA levels LHA either morning evening however message regulated CORT morning evening
0.17200397.15961555.html.plaintext.txt	12	An increased number emulsion grains per cell LHA suggests specific increase prepro orexin mRNA due increased number cells expressing message
0.17200397.15961555.html.plaintext.txt	13	Prepro orexin mRNA levels LHA elevated 4 h injection lipopolysaccharide compared saline injected controls
0.17200397.15961555.html.plaintext.txt	14	Partial complete abolition orexin A induced feeding ADX suggests orexin A induced feeding may mediated glucocorticoid dependent glucocorticoid independent pathways
0.17200397.15961555.html.plaintext.txt	15	In morning increased prepro orexin mRNA CORT replacement demonstrates orexin expression sensitive increased concentrations glucocorticoids
0.17200397.15961555.html.plaintext.txt	16	However lack effect ADX prepro orexin mRNA levels suggests endogenous glucocorticoids involved tonic regulation basal prepro orexin expression
0.17200397.15961555.html.plaintext.txt	17	Overall data constitute body evidence integrated relationship central orexin expression stress glucocorticoid manipulation feeding patterns rat
0.17200397.15961555.html.plaintext.txt	18	Introduction Top Abstract Introduction Materials Methods Results Discussion References OREXIN OX A AND OX B also known hypocretins closely related neuropeptides derived single gene processed 130 residue 131 residues humans prepro OX precursor protein 1
0.17200397.15961555.html.plaintext.txt	19	OX A 33 residue peptide identical sequence humans rodents whereas human rat OX B differ two residues
0.17200397.15961555.html.plaintext.txt	20	OX A OX B activate two G protein coupled receptors known OX 1 OX 2 OX 1 receptor greater affinity OX A OX B whereas OX 2 receptor similar affinity ligands
0.17200397.15961555.html.plaintext.txt	21	Central nervous system CNS distribution orexins similar rats humans lateral hypothalamic area LHA predominant region synthesis 1
0.17200397.15961555.html.plaintext.txt	22	The LHA long implicated feeding behavior initial observations highlighted role orexins stimulating appetite 2
0.17200397.15961555.html.plaintext.txt	23	However clear orexins also involved regulation sleep arousal locomotor activity neuroendocrine responses 3 4 therefore orexigenic activity may secondary behavioral traits influence feeding
0.17200397.15961555.html.plaintext.txt	24	In behavioral studies orexins modulate stress related behavior grooming chewing inedible material 5 6 7
0.17200397.15961555.html.plaintext.txt	25	Orexin containing neurones project LHA many CNS areas involved mediating stress including paraventricular nucleus PVN hypothalamus arcuate nucleus ARC locus coeruleus 8 9 10
0.17200397.15961555.html.plaintext.txt	26	OX 1 OX 2 receptors widely differentially distributed throughout CNS including PVN suprachiasmatic nucleus supraoptic nucleus ARC hypothalamus also locus coeruleus hippocampus 11 12 13 14
0.17200397.15961555.html.plaintext.txt	27	These areas individual synergistic involvement regulating circadian rhythm behavioral neuroendocrine responses stressors
0.17200397.15961555.html.plaintext.txt	28	The hypothalamo pituitary adrenal HPA axis one principal pathways mediating neuroendocrine responses stress
0.17200397.15961555.html.plaintext.txt	29	Hypothalamic neuropeptides corticotropin releasing factor CRF arginine vasopressin AVP stimulate release proopiomelanocortin derived peptide ACTH anterior pituitary consequent release glucocorticoids adrenal cortex
0.17200397.15961555.html.plaintext.txt	30	Corticosterone CORT principal glucocorticoid rodents acts glucocorticoid receptors hippocampus hypothalamus mineralocorticoid receptors within hippocampus negatively regulate HPA axis activity 15
0.17200397.15961555.html.plaintext.txt	31	Many studies demonstrated orexins influence HPA axis activity
0.17200397.15961555.html.plaintext.txt	32	Plasma ACTH CORT concentrations elevated rats intracerebroventricular icv OX A administration 5 16 17 18 19 20 21 22 23
0.17200397.15961555.html.plaintext.txt	33	This accompanied induction c fos mRNA 17 AVP CRF mRNAs 20 parvocellular subdivision PVN
0.17200397.15961555.html.plaintext.txt	34	In addition vitro studies revealed release CRF peptide AVP hypothalamic explants 19
0.17200397.15961555.html.plaintext.txt	35	OX B also reported stimulate HPA axis activity 16
0.17200397.15961555.html.plaintext.txt	36	Orexin expression rat LHA increased stressors immobilization 23 cold stress 23 hypoglycemia 24
0.17200397.15961555.html.plaintext.txt	37	Reduced secretion plasma ACTH cortisol reported patients narcolepsy 25 condition associated orexin deficiency
0.17200397.15961555.html.plaintext.txt	38	Therefore considerable evidence orexins modulate HPA axis activity orexin expression responsive alterations HPA axis activity
0.17200397.15961555.html.plaintext.txt	39	It well documented glucocorticoid administration stimulates feeding conversely glucocorticoid deficiency results loss appetite weight loss adrenalectomized ADX rats exhibit decreased feeding reversed CORT administration 26 27
0.17200397.15961555.html.plaintext.txt	40	Therefore orexins may exert direct effect appetite regulation within hypothalamus may act indirectly stimulate feeding increased CORT secretion
0.17200397.15961555.html.plaintext.txt	41	To test hypothesis designed experiments investigate effect ADX without CORT replacement OX A induced feeding determine whether endogenous CORT involved OX A induced feeding behavior
0.17200397.15961555.html.plaintext.txt	42	We also investigated effects glucocorticoid manipulation orexin expression morning evening determine whether orexin expression exhibits diurnal rhythm expression 28 29 may correlated diurnal rhythm HPA axis activity
0.17200397.15961555.html.plaintext.txt	43	Finally investigated effects orexin expression lipopolysaccharide LPS immunological stressor elicits robust prolonged activation HPA axis 30 31
0.17200397.15961555.html.plaintext.txt	44	Materials Methods Top Abstract Introduction Materials Methods Results Discussion References Animals Adult male Sprague Dawley rats 200 250 g Charles River Margate Kent UK housed individually controlled light temperature 21 plus minus 2 C free access water standard rat pelleted chow maintained 12 h light 12 h dark cycle lights 0600 h
0.17200397.15961555.html.plaintext.txt	45	All procedures carried accordance Animals Scientific Procedures Act 1986 United Kingdom
0.17200397.15961555.html.plaintext.txt	46	Surgical procedures Intracerebroventricular cannulation
0.17200397.15961555.html.plaintext.txt	47	All rats anesthetized im injection Domitor medetomidine HCl 0
0.17200397.15961555.html.plaintext.txt	48	04 ml per 100 g Pfizer Sandwich Kent UK ip injection Sublimaze fentanyl 0
0.17200397.15961555.html.plaintext.txt	49	9 ml per 100 g Janssen Cilag High Wycombe Buckinghamshire UK
0.17200397.15961555.html.plaintext.txt	50	Rats positioned stereotaxic frame implanted 22 gauge stainless steel guide cannula left lateral ventricle brain sterile conditions
0.17200397.15961555.html.plaintext.txt	51	The cannula secured surface skull jeweler screws dental cement
0.17200397.15961555.html.plaintext.txt	52	Stereotaxic coordinates left brain ventricle follows 0
0.17200397.15961555.html.plaintext.txt	53	5 mm lateral midline 4
0.17200397.15961555.html.plaintext.txt	54	1 mm vertical skull surface incisor bar 3
0.17200397.15961555.html.plaintext.txt	55	On completion surgery anesthesia reversed ip 5050 mixture Antisedan atipamezole HCl 0
0.17200397.15961555.html.plaintext.txt	56	02 ml per 100 g Pfizer Nubain nalbuphine HCl 0
0.17200397.15961555.html.plaintext.txt	57	02 ml per 100 g DuPont Pharmaceuticals Stevenage Hertfordshire UK
0.17200397.15961555.html.plaintext.txt	58	After implantation guide cannula correct placement checked using gravitational flow sterile saline filled cannula
0.17200397.15961555.html.plaintext.txt	59	Rats bilaterally ADX via dorsal approach
0.17200397.15961555.html.plaintext.txt	60	A small incision made along midline back rib cage connective tissue fat displaced small hole made muscle either side back using blunt cut scissors
0.17200397.15961555.html.plaintext.txt	61	The adrenals excised curved forceps
0.17200397.15961555.html.plaintext.txt	62	Each adrenal checked remained intact excision
0.17200397.15961555.html.plaintext.txt	63	Only animals complete removal adrenals considered ADX
0.17200397.15961555.html.plaintext.txt	64	After surgery ADX animals immediately given 0
0.17200397.15961555.html.plaintext.txt	65	9 saline drink maintain salt balance
0.17200397.15961555.html.plaintext.txt	66	Surgery sham animals identical adrenals removed
0.17200397.15961555.html.plaintext.txt	67	Animals allowed 7 d postoperative recovery handled daily
0.17200397.15961555.html.plaintext.txt	68	Effects glucocorticoids OX A induced feeding Thirty two rats bilaterally ADX whereas 16 rats subjected sham ADX
0.17200397.15961555.html.plaintext.txt	69	Animals returned home cages ADX animals immediately given 0
0.17200397.15961555.html.plaintext.txt	70	9 saline whereas two groups ADX rats given 0
0.17200397.15961555.html.plaintext.txt	71	9 saline supplemented CORT Sigma Poole Dorset UK either 25 mgliter low CORT 125 mgliter high CORT
0.17200397.15961555.html.plaintext.txt	72	These concentrations CORT selected within basal physiological range endogenous CORT 27
0.17200397.15961555.html.plaintext.txt	73	On morning experimentation sham ADX animals divided two groups n 9 equal mean body weights receive icv injection either OX A 30 micrograt 5 microl 0
0.17200397.15961555.html.plaintext.txt	74	This dose equivalent 8 nmol falls within accepted range 3 30 nmol 2 used extensively
0.17200397.15961555.html.plaintext.txt	75	Both low CORT high CORT replacement groups also received icv injection either OX A 30 micrograt saline
0.17200397.15961555.html.plaintext.txt	76	An icv injection cannula extension tubing preloaded drug vehicle inserted guide cannula
0.17200397.15961555.html.plaintext.txt	77	Injections given period 1 min
0.17200397.15961555.html.plaintext.txt	78	The needle left position minute ensure complete dispersal peptide
0.17200397.15961555.html.plaintext.txt	79	Injections given 0900 1000 h
0.17200397.15961555.html.plaintext.txt	80	Preweighed food pellets water bottles supplied icv injection
0.17200397.15961555.html.plaintext.txt	81	Food intake determined 1 2 3 4 h time points icv injection
0.17200397.15961555.html.plaintext.txt	82	After 4 h rats killed decapitation trunk blood collected chilled EDTA tubes ice centrifugation collect plasma
0.17200397.15961555.html.plaintext.txt	83	ACTH measured RIA prior extraction plasma Seppak columns 32
0.17200397.15961555.html.plaintext.txt	84	Assay sensitivity 10 pgml
0.17200397.15961555.html.plaintext.txt	85	Total CORT measured unextracted plasma house RIA 33
0.17200397.15961555.html.plaintext.txt	86	The radioactive tracer I125 CORT ICN Biomedicals Basingstoke Hampshire UK specific activity 0
0.17200397.15961555.html.plaintext.txt	87	The sensitivity assay 5 ngml
0.17200397.15961555.html.plaintext.txt	88	Both ACTH CORT primary antisera kindly supplied G
0.17200397.15961555.html.plaintext.txt	89	Makara Hungarian Academy Sciences Budapest Hungary
0.17200397.15961555.html.plaintext.txt	90	All samples either ACTH CORT processed assay intraassay variation less 10
0.17200397.15961555.html.plaintext.txt	91	Distribution prepro OX expression lateral hypothalamus Two male Sprague Dawley rats killed decapitation brains removed stored 80 C sectioning
0.17200397.15961555.html.plaintext.txt	92	Coronal brain sections 12 microm collected LHA PVN cryostat immediately stored 80 C
0.17200397.15961555.html.plaintext.txt	93	Two sections collected every four sections 48 50 sections collected animal
0.17200397.15961555.html.plaintext.txt	94	Prepro OX expression investigated using situ hybridization performed described previously 34 35
0.17200397.15961555.html.plaintext.txt	95	Sections warmed room temperature 10 min fixed 4 formaldehyde 5 min washed twice PBS incubated 0
0.17200397.15961555.html.plaintext.txt	96	Sections dehydrated graded ethanol washes 70 1 min 80 1 min 95 2 min 100 1 min delipidated chloroform 100 5 min rehydrated 100 1 min 95 1 min ethanol drying air
0.17200397.15961555.html.plaintext.txt	97	The probe used 33 mer oligonucleotide complementary nucleotides 242 275 exonic sequence rat prepro OX mRNA 5 TGCCCGCGGCGTGGTTGCCAGCTCCGTGCAACA 3 GenBank accession
0.17200397.15961555.html.plaintext.txt	98	Probes labeled 3 end 35S ATP column purified NucTrap probe purification columns Stratagene UK
0.17200397.15961555.html.plaintext.txt	99	Probes labeled specific activity 1
0.17200397.15961555.html.plaintext.txt	100	Forty five microliters hybridization buffer 50 formamide 4x saline sodium citrate SSC 0
0.17200397.15961555.html.plaintext.txt	101	5 mgml sheared single stranded salmon sperm DNA 0
0.17200397.15961555.html.plaintext.txt	102	5 x Denhardt solution 10 dextran sulfate containing labeled probe 100000 cpm applied slide
0.17200397.15961555.html.plaintext.txt	103	Hybridization performed overnight 37 C
0.17200397.15961555.html.plaintext.txt	104	All sections experiment processed time
0.17200397.15961555.html.plaintext.txt	105	The sections washed four times 55 C 1x SSC 1x SSC 0
0.17200397.15961555.html.plaintext.txt	106	0 followed two 30 min washes room temperature 1x SSC remove nonspecific binding two brief rinses distilled water
0.17200397.15961555.html.plaintext.txt	107	The sections air dried exposed Amersham HyperfilmMP Amersham International Aylesbury Buckinghamshire UK together 14C labeled standard 14 d
0.17200397.15961555.html.plaintext.txt	108	The autoradiographic images probe bound brain sections analyzed using densitometry method described previously 35 using Image software
0.17200397.15961555.html.plaintext.txt	109	The results presented arbitrary values prepro OX expression LHA
0.17200397.15961555.html.plaintext.txt	110	Effect adrenalectomy glucocorticoid manipulation prepro OX expression lateral hypothalamus Fifteen rats bilaterally ADX described whereas 12 rats subjected sham ADX
0.17200397.15961555.html.plaintext.txt	111	9 saline whereas seven ADX rats eight sham ADX rats given 0
0.17200397.15961555.html.plaintext.txt	112	9 saline supplemented CORT high CORT 125 mgliter described
0.17200397.15961555.html.plaintext.txt	113	The remaining sham ADX animals given tap water drink
0.17200397.15961555.html.plaintext.txt	114	Animals placed regimen 7 d handled daily
0.17200397.15961555.html.plaintext.txt	115	On morning experiment rats killed decapitation brains removed trunk blood collected chilled EDTA tubes ice ACTH CORT RIAs described
0.17200397.15961555.html.plaintext.txt	116	Sections cut cryostat two LHA areas determined distribution study LHA1 Bregma 2
0.17200397.15961555.html.plaintext.txt	117	44 mm atlas Paxinos Watson 36
0.17200397.15961555.html.plaintext.txt	118	Nine consecutive coronal lateral hypothalamic brain sections collected spanning 108 microm slide three sections encompassing 84 microm LHA allow apparent variation prepro OX expression demonstrated present LHA results distribution study
0.17200397.15961555.html.plaintext.txt	119	Prepro OX mRNA measurement situ hybridization performed described
0.17200397.15961555.html.plaintext.txt	120	All ADX ADX CORT hybridized sections dipped autoradiographic emulsion exposed 4 C 1 wk
0.17200397.15961555.html.plaintext.txt	121	All sections processed time
0.17200397.15961555.html.plaintext.txt	122	The slides developed fixed counterstained methyl green
0.17200397.15961555.html.plaintext.txt	123	Seven emulsion dipped slides per treatment analyzed cellular level counting number labeled cells silver grains per cell
0.17200397.15961555.html.plaintext.txt	124	At least two five cells per section minimum eight cells per slide three sections per slide randomly selected x200 magnification microscope Leica Heidelberg Germany saved images
0.17200397.15961555.html.plaintext.txt	125	Silver grains counted hand microscope images enlarged 100 Photo Editor Microsoft Redmond CA
0.17200397.15961555.html.plaintext.txt	126	Silver grains dotted onto plastic sheets attached monitor screen counted
0.17200397.15961555.html.plaintext.txt	127	Silver grains individual cell counted three times manner
0.17200397.15961555.html.plaintext.txt	128	Sixty one 67 cells counted treatment
0.17200397.15961555.html.plaintext.txt	129	Effect diurnal variation prepro OX expression ADX rats given glucocorticoid replacement Thirty three rats bilaterally ADX whereas 13 rats subjected sham ADX described previously
0.17200397.15961555.html.plaintext.txt	130	Seventeen ADX rats given 0
0.17200397.15961555.html.plaintext.txt	131	9 saline whereas 16 given 0
0.17200397.15961555.html.plaintext.txt	132	9 saline supplemented CORT 125 mgliter
0.17200397.15961555.html.plaintext.txt	133	All sham animals supplied tap water drink
0.17200397.15961555.html.plaintext.txt	134	Animals left regimen 7 d handled daily
0.17200397.15961555.html.plaintext.txt	135	On morning experimentation five sham eight ADX seven ADX CORT rats killed decapitation morning 0900 1000 h remaining animals killed evening 1800 h
0.17200397.15961555.html.plaintext.txt	136	Brains trunk blood collected described previously prepro OX measurements sectioning performed described
0.17200397.15961555.html.plaintext.txt	137	Effects LPS injection prepro OX mRNA All animals received ip injection 0900 1000 h either LPS 250 micrograt 0
0.17200397.15961555.html.plaintext.txt	138	9 saline Escherichia coli Serotype 055B5 Sigma saline
0.17200397.15961555.html.plaintext.txt	139	Animals killed decapitation 4 h injection
0.17200397.15961555.html.plaintext.txt	140	Brains trunk blood collected prepro OX mRNA measured described
0.17200397.15961555.html.plaintext.txt	141	Plasma ACTH CORT measured RIAs
0.17200397.15961555.html.plaintext.txt	142	Statistics Statistical comparisons multiple groups made using Fisher protected least significant difference test one way ANOVA
0.17200397.15961555.html.plaintext.txt	143	For LPS study Student test used
0.17200397.15961555.html.plaintext.txt	144	All values expressed mean plus minus SEM
0.17200397.15961555.html.plaintext.txt	145	All analyses generated using Statview
0.17200397.15961555.html.plaintext.txt	146	Results Top Abstract Introduction Materials Methods Results Discussion References Effects glucocorticoids OX A induced feeding Plasma ACTH CORT measured confirm success ADX
0.17200397.15961555.html.plaintext.txt	147	Four h icv injection ADX rats concentrations CORT limit detection 5 ngml compared sham vehicle group 31 plus minus 7 ngml sham OX A group 24 plus minus 8 ngml
0.17200397.15961555.html.plaintext.txt	148	There significant difference plasma CORT concentrations sham OX A sham vehicle groups
0.17200397.15961555.html.plaintext.txt	149	Plasma CORT concentrations low CORT high CORT replacement groups 7
0.17200397.15961555.html.plaintext.txt	150	Plasma ACTH concentrations significantly elevated ADX groups compared sham groups increase ACTH attenuated high CORT low CORT replacement Table 1
0.17200397.15961555.html.plaintext.txt	151	Plasma ACTH concentrations pgml 4 h intracerebroventricular administration orexin saline
0.17200397.15961555.html.plaintext.txt	152	After 4 h food intake significantly greater sham OX A 4
0.17200397.15961555.html.plaintext.txt	153	6 g group compared sham vehicle group 0
0.17200397.15961555.html.plaintext.txt	154	ADX significantly reduced OX A induced food intake 2
0.17200397.15961555.html.plaintext.txt	155	7 g 60 reduction reversed high CORT 4
0.17200397.15961555.html.plaintext.txt	156	8 g low CORT replacement
0.17200397.15961555.html.plaintext.txt	157	Food intake significantly greater ADX OX A rats 2
0.17200397.15961555.html.plaintext.txt	158	7 g compared sham vehicle 0
0.17200397.15961555.html.plaintext.txt	159	View larger version 26K FIG
0.17200397.15961555.html.plaintext.txt	160	Effect ADX corticosterone replacement cumulative food intake 4 h single icv injection OX A 30 micrograt vehicle 5 microlrat conscious rats
0.17200397.15961555.html.plaintext.txt	161	Values mean plus minus SEM n 7 8group
0.17200397.15961555.html.plaintext.txt	162	05 compared ADX vehicle sham vehicle groups P 0
0.17200397.15961555.html.plaintext.txt	163	05 compared ADX orexin A group P 0
0.17200397.15961555.html.plaintext.txt	164	05 compared ADX vehicle group
0.17200397.15961555.html.plaintext.txt	165	Distribution prepro OX expression lateral hypothalamus There considerable variation prepro OX mRNA expression levels throughout LHA Fig
0.17200397.15961555.html.plaintext.txt	166	However sections collected caudal PVN area 1
0.17200397.15961555.html.plaintext.txt	167	34 mm end anterior commissure profile expression tended peak trough around similar areas cases prepro OX levels overlapped two animals
0.17200397.15961555.html.plaintext.txt	168	Areas LH1 LH2 areas overlap prepro OX mRNA two brains clearly defined anatomically therefore permitted greater reproducibility
0.17200397.15961555.html.plaintext.txt	169	View larger version 25K FIG
0.17200397.15961555.html.plaintext.txt	170	A comparison prepro OX mRNA distribution LHA two control rats
0.17200397.15961555.html.plaintext.txt	171	LHA1 LHA2 represent areas sectioned prepro OX mRNA measurement
0.17200397.15961555.html.plaintext.txt	172	Effect adrenalectomy glucocorticoid manipulation prepro OX expression lateral hypothalamus Concentrations plasma CORT measured confirm success ADX
0.17200397.15961555.html.plaintext.txt	173	All ADX rats concentrations plasma CORT limit assay detection 5 ngml compared sham group 21 plus minus 11 ngml
0.17200397.15961555.html.plaintext.txt	174	ADX animals CORT replacement CORT concentrations 43 plus minus 12 ngml compared sham CORT group 126 plus minus 53 ngml
0.17200397.15961555.html.plaintext.txt	175	There effect ADX prepro OX mRNA levels LHA1 Fig
0.17200397.15961555.html.plaintext.txt	176	3B areas compared sham animals
0.17200397.15961555.html.plaintext.txt	177	Both sham ADX groups CORT replacement significantly elevated levels prepro OX mRNA LHA1 LHA2 compared sham ADX groups without CORT replacement
0.17200397.15961555.html.plaintext.txt	178	View larger version 38K FIG
0.17200397.15961555.html.plaintext.txt	179	Morning levels prepro OX mRNA LHA1 A LHA2 B rats 7 d ADX sham surgery without corticosterone replacement
0.17200397.15961555.html.plaintext.txt	180	mRNA levels expressed percentage control group mean plus minus SEM n 5 6group
0.17200397.15961555.html.plaintext.txt	181	05 compared sham group P 0
0.17200397.15961555.html.plaintext.txt	182	Representative autoradiographic images prepro OX mRNA expression distribution LHA2 area shown Fig
0.17200397.15961555.html.plaintext.txt	183	4 treatment groups
0.17200397.15961555.html.plaintext.txt	184	Photomicrographs emulsion dipped slides showing prepro OX mRNA expression individual cells shown Fig
0.17200397.15961555.html.plaintext.txt	185	These images demonstrate prepro OX mRNA expressed cells different size
0.17200397.15961555.html.plaintext.txt	186	The number silver grains per cell individual prepro OX gene expressing cells emulsion dipped slides significantly P 0
0.17200397.15961555.html.plaintext.txt	187	001 increased LHA ADX rats receiving CORT replacement compared ADX rats Fig
0.17200397.15961555.html.plaintext.txt	188	The amount orexin expression remarkably consistent given treatment 125 plus minus 4 grainscell ADX group compared 187 plus minus 6 grainscell ADX CORT group
0.17200397.15961555.html.plaintext.txt	189	There significant difference number cells expressing prepro OX mRNA ADX 61 cells ADXCORT 67 cells counted selected fields view
0.17200397.15961555.html.plaintext.txt	190	View larger version 103K FIG
0.17200397.15961555.html.plaintext.txt	191	Representative autoradiographic images prepro OX mRNA distribution LHA2 ADX CORT replaced ADX ADX CORT rats 12 microm brain coronal sections
0.17200397.15961555.html.plaintext.txt	192	View larger version 43K FIG
0.17200397.15961555.html.plaintext.txt	193	Photomicrographs emulsion dipped slides hybridized 35S labeled oligonucleotide probe complementary mRNA prepro OX LHA2 ADX CORT replaced ADX ADX CORT rats
0.17200397.15961555.html.plaintext.txt	194	Lateral hypothalamic cells counterstained 0
0.17200397.15961555.html.plaintext.txt	195	1 methyl green 12 microm brain coronal sections
0.17200397.15961555.html.plaintext.txt	196	View larger version 19K FIG
0.17200397.15961555.html.plaintext.txt	197	Number prepro OX emulsion grains per cell LHA rats 7 d ADX surgery without CORT replacement
0.17200397.15961555.html.plaintext.txt	198	Values mean plus minus SEM n 7group eight nine cells counted per animal
0.17200397.15961555.html.plaintext.txt	199	Effect diurnal variation orexin expression adrenalectomized rats glucocorticoid replacement Plasma CORT concentrations sham animals significantly higher P 0
0.17200397.15961555.html.plaintext.txt	200	001 evening 111 plus minus 24 ngml compared morning 20 plus minus 8 ngml
0.17200397.15961555.html.plaintext.txt	201	Plasma CORT morning evening ADX groups limit detection 5 ngml
0.17200397.15961555.html.plaintext.txt	202	CORT replacement ADX animals resulted similar morning 43 plus minus 12 ngml evening concentrations 36 plus minus 14 ngml significantly different morning concentrations sham group
0.17200397.15961555.html.plaintext.txt	203	ADX effect morning levels prepro OX mRNA LHA1 whereas CORT replacement regulated orexin mRNA sham ADX groups Fig
0.17200397.15961555.html.plaintext.txt	204	Consistent observation significant effect ADX prepro OX mRNA expression LHA1 area morning evening Fig
0.17200397.15961555.html.plaintext.txt	205	CORT replacement significantly elevated prepro OX mRNA levels morning compared sham ADX groups increase observed evening Fig
0.17200397.15961555.html.plaintext.txt	206	View larger version 35K FIG
0.17200397.15961555.html.plaintext.txt	207	Morning 0900 h evening 1800 h levels prepro OX mRNA LHA2 ADX rats 7 d surgery without CORT replacement
0.17200397.15961555.html.plaintext.txt	208	Values mean plus minus SEM n 5 9group
0.17200397.15961555.html.plaintext.txt	209	01 compared groups
0.17200397.15961555.html.plaintext.txt	210	Effect LPS stress prepro OX expression LPS evoked 4 fold increase plasma CORT concentrations 184 plus minus 44 ngml compared saline controls 49 plus minus 17 ngml
0.17200397.15961555.html.plaintext.txt	211	There significant 60 increase prepro OX mRNA expression LHA1 4 h LPS injection compared saline injected rats Fig
0.17200397.15961555.html.plaintext.txt	212	View larger version 15K FIG
0.17200397.15961555.html.plaintext.txt	213	Levels prepro OX mRNA LHA1 4 h ip injection LPS 250 microg
0.17200397.15961555.html.plaintext.txt	214	mRNA expressed percentage control group mean plus minus SEM n 7group
0.17200397.15961555.html.plaintext.txt	215	01 compared saline treated animals
0.17200397.15961555.html.plaintext.txt	216	Discussion Top Abstract Introduction Materials Methods Results Discussion References Our data reveal integrated relationship central orexin expression endogenous glucocorticoid concentrations feeding patterns rat
0.17200397.15961555.html.plaintext.txt	217	Our observation central administration OX A increases food intake agreement groups demonstrated OX A stimulates feeding early light phase intact rats 2 37 38
0.17200397.15961555.html.plaintext.txt	218	We demonstrate first time glucocorticoids exert important influence OX A induced feeding behavior
0.17200397.15961555.html.plaintext.txt	219	ADX significantly reduces orexin A induced feeding phenomenon reversible CORT replacement physiological concentrations
0.17200397.15961555.html.plaintext.txt	220	These data provide evidence endogenous CORT exert important influence OX A induced food intake
0.17200397.15961555.html.plaintext.txt	221	However ADX completely block OX A induced feeding results 60 reduction suggests pathway mediating orexin induced food intake independent glucocorticoids
0.17200397.15961555.html.plaintext.txt	222	One recent study investigated effect ADX OX A induced feeding 39
0.17200397.15961555.html.plaintext.txt	223	In contrast findings investigators observed effect ADX OX A induced food intake 2 h period 39
0.17200397.15961555.html.plaintext.txt	224	This may due suboptimal doses OX A employed dose range 1
0.17200397.15961555.html.plaintext.txt	225	5 6 nmol compared 8 nmol present study latter dose considered optimal OX A induced feeding behavior 2
0.17200397.15961555.html.plaintext.txt	226	These findings may also result shorter period food intake studied maximum 2 h compared maximum 4 h study
0.17200397.15961555.html.plaintext.txt	227	39 seems evident ADX associated decreased food intake higher doses OX A 2 h time point small increase food intake response OX A sham rats permit ADX effect reach significance
0.17200397.15961555.html.plaintext.txt	228	The larger dose orexin used elicited greater food intake sham rats compared observed Drazen et al
0.17200397.15961555.html.plaintext.txt	229	39 consequently able observe significant reproducible decrease orexin induced food intake ADX rats
0.17200397.15961555.html.plaintext.txt	230	Initially experiment performed ADX sham groups given orexin saline
0.17200397.15961555.html.plaintext.txt	231	Consequent observation significant decrease orexin induced food intake ADX group repeated experiment expanded include low CORT high CORT replacement groups
0.17200397.15961555.html.plaintext.txt	232	Our observations reproducible time points full study repeated 40
0.17200397.15961555.html.plaintext.txt	233	This together ability physiological concentrations CORT reverse effects ADX orexin induced food intake increases confidence endogenous glucocorticoids exert physiologically relevant control orexin induced feeding behavior
0.17200397.15961555.html.plaintext.txt	234	Our observation orexin induced food intake decreased 60 ADX rats evidence significant component eating behavior dependent endogenous CORT
0.17200397.15961555.html.plaintext.txt	235	It known CORT directly stimulate appetite 41 indirect effects appetite CORT mediated hypothalamic neuropeptides well understood
0.17200397.15961555.html.plaintext.txt	236	A number mechanisms may invoked explain relationship among CORT OX A food intake
0.17200397.15961555.html.plaintext.txt	237	CORT may stimulate endogenous orexin expression action glucocorticoid receptors within LHA intermediary nuclei may act via orexin peptide release within PVNARC areas hypothalamus CORT may stimulate food intake consequent orexin activation HPA axis activity
0.17200397.15961555.html.plaintext.txt	238	There also possibility CORT may exert effect food intake via peptides modulate appetite rather directly orexins
0.17200397.15961555.html.plaintext.txt	239	There well defined pathway glucocorticoid feedback CRF expression PVN release median eminence 42
0.17200397.15961555.html.plaintext.txt	240	CRF inhibits food intake therefore increased CORT could increase food intake inhibitory action CRF
0.17200397.15961555.html.plaintext.txt	241	Orexin induced feeding enhanced CRF receptor antagonist suggesting CRF involvement 43
0.17200397.15961555.html.plaintext.txt	242	Neuropeptide Y NPY also possible mediator orexin induced feeding
0.17200397.15961555.html.plaintext.txt	243	Glucocorticoid manipulation results marked similarity orexin NPY effects feeding
0.17200397.15961555.html.plaintext.txt	244	ADX reduced NPY induced food intake 60 similar effects ADX orexin induced feeding reversed CORT replacement 44
0.17200397.15961555.html.plaintext.txt	245	NPY potent known inducer food intake 45 orexin induced feeding blocked Y1 receptor antagonist 46
0.17200397.15961555.html.plaintext.txt	246	Therefore conceivable orexin exerts principal glucocorticoid dependent actions food intake NPY direct effects CORT NPY orexin expression explains observations
0.17200397.15961555.html.plaintext.txt	247	However observed 40 increase food intake response OX A ADX rats complete absence CORT strong evidence glucocorticoid independent central pathway direct orexin induced food intake may mediated NPY
0.17200397.15961555.html.plaintext.txt	248	In situ hybridization histochemistry confirmed prepro orexin expression restricted LHA extensions perifornical nucleus posterior hypothalamic areas agreement previously reported studies 37
0.17200397.15961555.html.plaintext.txt	249	A novel finding distribution study prepro OX mRNA expression measured coronal sequential sections running 1044 microm throughout LHA shows considerable differences sections emphasizing importance consistent choice sections hybridization measuring prepro OX mRNA LHA treatment groups
0.17200397.15961555.html.plaintext.txt	250	This observation confirms need use anatomical markers ensure consistency sectioning samples
0.17200397.15961555.html.plaintext.txt	251	We observed regulation morning evening prepro OX mRNA LHA CORT administration
0.17200397.15961555.html.plaintext.txt	252	Increased blood CORT may regulate orexin expression large population glucocorticoid receptor positive cells within LHA 47 48
0.17200397.15961555.html.plaintext.txt	253	Emulsion staining established significant difference number cells expressing prepro OX treatment groups
0.17200397.15961555.html.plaintext.txt	254	Therefore increases prepro OX mRNA observed response CORT represent increased expression prepro OX within cells LHA
0.17200397.15961555.html.plaintext.txt	255	There slight increase prepro OX mRNA expression sham group evening compared morning although statistically significant
0.17200397.15961555.html.plaintext.txt	256	Plasma CORT levels significantly increased evening compared morning sham animals agreement previous studies demonstrating diurnal variations HPA axis activity 49
0.17200397.15961555.html.plaintext.txt	257	However important note CORT levels similar morning evening replacement groups significantly different morning levels sham animals
0.17200397.15961555.html.plaintext.txt	258	It possible increase evening prepro OX expression although statistically significant may consequence circadian increase endogenous circulating CORT
0.17200397.15961555.html.plaintext.txt	259	This increase may sufficient mask stimulatory effects orexin expression exogenous CORT
0.17200397.15961555.html.plaintext.txt	260	Further investigations interrelationships circadian cycles HPA axis activity orexin expression undoubtedly shed light regulatory mechanisms controlling highly integrated modalities sleep wake patterns feeding behavior
0.17200397.15961555.html.plaintext.txt	261	We found effect ADX alone orexin expression LHA suggests basal orexin expression rats tonic regulation endogenous glucocorticoids
0.17200397.15961555.html.plaintext.txt	262	In contrast decrease prepro OX mRNA expression 5 d ADX reported 50
0.17200397.15961555.html.plaintext.txt	263	However data HPA axis activity presented study difficult determine effectiveness ADX surgery
0.17200397.15961555.html.plaintext.txt	264	In addition information sections sliced within LHA
0.17200397.15961555.html.plaintext.txt	265	Given variability prepro OX expression observed throughout LHA important choice section justified well defined
0.17200397.15961555.html.plaintext.txt	266	The decrease orexin expression ADX reversed dexamethasone replacement 50 observation consistent data demonstrating CORT regulation orexin expression sham animals
0.17200397.15961555.html.plaintext.txt	267	A decrease prepro OX mRNA levels LHA 10 d ADX also reported phenomenon could reversed CORT 39
0.17200397.15961555.html.plaintext.txt	268	Discrepancies data published reports effects ADX prepro OX mRNA expression LHA 39 50 lack agreement effects exogenous glucocorticoids may due methodological differences
0.17200397.15961555.html.plaintext.txt	269	Our experiment used 7 d ADX CORT replacement compared previous studies using 5 d ADX dexamethasone 50 10 d ADX CORT 39
0.17200397.15961555.html.plaintext.txt	270	It instructive compare discrepancies literature NPY expression ADX
0.17200397.15961555.html.plaintext.txt	271	Although general consensus NPY regulated glucocorticoids reports differ effects NPY expression eliminating endogenous cortisosterone ADX
0.17200397.15961555.html.plaintext.txt	272	Short term ADX 4 d alter NPY peptide levels ARC PVN 51 whereas group observed long term ADX 12 d deceased NPY peptide levels areas 52
0.17200397.15961555.html.plaintext.txt	273	ADX 7 d effect NPY immunoreactivity hypothalamic areas one notable exception PVN 53
0.17200397.15961555.html.plaintext.txt	274	A longer term ADX 12 d effect prepro NPY mRNA ARC 54 peptide levels measured study
0.17200397.15961555.html.plaintext.txt	275	Either dexamethasone CORT replacement regulated NPY mRNA dexamethasone much potent 53
0.17200397.15961555.html.plaintext.txt	276	Therefore effects glucocorticoid manipulation orexin expression NPY may dependent period ADX concentration type glucocorticoid whether orexin peptide mRNA measured specifically defined hypothalamic site selected analysis
0.17200397.15961555.html.plaintext.txt	277	Finally demonstrated single injection LPS immunological stressor regulate prepro OX mRNA expression LHA
0.17200397.15961555.html.plaintext.txt	278	Increases prepro OX mRNA reported response stressors robustly stimulate HPA axis immobilization cold stress 23 hypoglycemia 24
0.17200397.15961555.html.plaintext.txt	279	The present study expands repertoire stressors include immune mediated stress
0.17200397.15961555.html.plaintext.txt	280	LPS potent stimulator HPA axis activity subsequently CORT release possible increase prepro OX mRNA may result increasing blood CORT concentrations
0.17200397.15961555.html.plaintext.txt	281	Further work necessary elucidate whether increased orexin response LPS direct result LPS induced CORT release indirectly response increased cytokines
0.17200397.15961555.html.plaintext.txt	282	We may briefly speculate physiological importance increased orexin expression response immunological stimulus
0.17200397.15961555.html.plaintext.txt	283	Orexins demonstrated analgesic properties inflammatory induced hyperalgesia OX 1 receptor antagonist SB 334867 A reduces OX A mediated analgesia 55
0.17200397.15961555.html.plaintext.txt	284	This suggests may hypothalamic mechanism involving orexin analgesic agent neurogenic pain
0.17200397.15961555.html.plaintext.txt	285	It also possible onset inflammation acute phase response LPS plays crucial role important maintain homeostatic control peripheral release inflammatory cytokines increased secretion CORT immunological stimulus activate hypothalamic components drive HPA axis activity including orexins
0.17200397.15961555.html.plaintext.txt	286	In conclusion data establish OX A induced feeding prepro OX mRNA expression sensitive glucocorticoid manipulation
0.17200397.15961555.html.plaintext.txt	287	Up regulation prepro OX expression response CORT may circadian related levels increased morning evening
0.17200397.15961555.html.plaintext.txt	288	However studies required determine mechanisms underlying data
0.17200397.15961555.html.plaintext.txt	289	These observations highlight interdependence orexins HPA axis activity provide insights role glucocorticoids regulating centrally mediated orexin induced feeding orexin expression within brain
0.17200397.15961555.html.plaintext.txt	290	Footnotes This work supported Needham Cooper Trust UK GlaxoSmithKline Neuroendocrine Charitable Trust UK Ph
0.17200397.15961555.html.plaintext.txt	291	The results work presented part 85th Annual Meeting The Endocrine Society Philadelphia Pennsylvania June 2003 Abstract P3 193
0.17200397.15961555.html.plaintext.txt	292	First Published Online June 16 2005
0.17200397.15961555.html.plaintext.txt	293	Abbreviations ADX Adrenalectomized ARC arcuate nucleus AVP arginine vasopressin CNS central nervous system CORT corticosterone CRF corticotropin releasing factor HPA hypothalamo pituitary adrenal icv intracerebroventricular LHA lateral hypothalamic area LPS lipopolysaccharide NPY neuropeptide Y OX orexin PVN paraventricular nucleus SSC saline sodium citrate
0.17200397.15961555.html.plaintext.txt	294	Accepted publication June 6 2005
0.17200397.15961555.html.plaintext.txt	295	References Top Abstract Introduction Materials Methods Results Discussion References Willie JT Chemelli RM Sinton CM Yanagisawa M 2001 To eat sleep Orexin regulation feeding wakefulness
0.17200397.15961555.html.plaintext.txt	296	Annu Rev Neurosci 24429 458CrossRefMedline Sakurai T Amemiya A Ishi M Matsuzak I Chemell RM Tanaka H Williams SC Richardson JA Kozlowsk GP Wilson S Arch JR Buckingham RE Haynes AC Carr SA Annan RS McNulty DE Liu WS Terrett JA Elshourbagy NA Bergsma DJ Yanagisawa M 1998 Orexins orexin receptors family hypothalamic neuropeptides G protein coupled receptors regulate feeding behaviour
0.17200397.15961555.html.plaintext.txt	297	Cell 92573 595CrossRefMedline Taheri S Bloom S 2001 Orexinshypocretins waking scientific world
0.17200397.15961555.html.plaintext.txt	298	Clin Endocrinol Oxf 54421 429CrossRefMedline Taylor MM Samson WK 2003 The side orexins endocrine metabolic actions
0.17200397.15961555.html.plaintext.txt	299	Am J Physiol Endocrinol Metab 284E13 E17 Hagan JJ Leslie RA Patel S Evans ML Wattam TA Holmes S Benham CD Taylor SG Routledge C Hemmati P Munton RP Ashmeade TE Shah AS Hatcher JP Hatcher PD Jones DNC Smith MI Piper DC Hunter AJ Porter RA Upton N 1999 Orexin A activates locus coeruleus cell firing increases arousal rat
0.17200397.15961555.html.plaintext.txt	300	Proc Natl Acad Sci USA 9610911 10916AbstractFree Full Text Espana RA Plahn S Berridge CW 2002 Circadian dependent circadian independent behavioral actions hypocretinorexin
0.17200397.15961555.html.plaintext.txt	301	Brain Res 94224 236CrossRef Duxon MS Stretton J Starr K Jones DNC Holland V Riley G Jerman J Brough S Smart D Johns A Chan W Porter RA Upton N 2001 Evidence orexin A evoked grooming rat mediated orexin 1 OX1 receptors downstream 5 HT2C receptor involvement
0.17200397.15961555.html.plaintext.txt	302	Psychopharmacology Berl 153203 209CrossRefMedline Date Y Ueta Y Yamashita H Yamaguchi H Matsukura S Kangawa K Sakurai T Yanagisawa M Nakazato M 1999 Orexins orexigenic hypothalamic peptides interact autonomic neuroendocrine neuroregulatory systems
0.17200397.15961555.html.plaintext.txt	303	Proc Natl Acad Sci USA 96748 753AbstractFree Full Text Peyron C Tighe DK van den Pol AN de Lecea L Heller HC Sutcliffe JG Kilduff TS 1998 Neurons containing hypocretin orexin project multiple neuronal systems
0.17200397.15961555.html.plaintext.txt	304	J Neurosci 189996 10015AbstractFree Full Text Horvath TL Peyron C Diano S Ivanov A Aston Jones G Kilduff TS van Den Pol AN 1999 Hypocretin orexin activation synaptic innervation locus coeruleus noradrenergic system
0.17200397.15961555.html.plaintext.txt	305	CO2 U 144CrossRefMedline Backberg M Hervieu G Wilson S Meister B 2002 Orexin receptor 1 OX R1 immunoreactivity chemically identified neurons hypothalamus focus orexin targets involved control food water intake
0.17200397.15961555.html.plaintext.txt	306	Eur J Neurosci 15315 328CrossRefMedline Hervieu GJ Cluderay JE Harrison DC Roberts JC Leslie RA 2001 Gene expression protein distribution orexin 1 receptor rat brain spinal cord
0.17200397.15961555.html.plaintext.txt	307	Neuroscience 103777 797CrossRefMedline Trivedi P Yu H MacNeil DJ Van der Ploeg LH Guan XM 1998 Distribution orexin receptor mRNA rat brain
0.17200397.15961555.html.plaintext.txt	308	FEBS Lett 43871 75CrossRefMedline Buckingham JC Cowell A M Gillies GE Herbison AE Steel JH 1997 The neuroendocrine system anatomy physiology responses stress
0.17200397.15961555.html.plaintext.txt	309	In Buckingham JC Cowell A M Gillies GE eds
0.17200397.15961555.html.plaintext.txt	310	Stress stress hormones immune system
0.17200397.15961555.html.plaintext.txt	311	London John Wiley Sons 9 47 Jaszberenyi M Bujdoso E Pataki I Telegdy G 2000 Effects orexins hypothalamic pituitary adrenal system
0.17200397.15961555.html.plaintext.txt	312	J Neuroendocrinol 121174 1178CrossRefMedline Kuru M Ueta Y Serino R Nakazato M Yamamoto Y Shibuya I Yamashita H 2000 Centrally administered orexinhypocretin activates HPA axis rats
0.17200397.15961555.html.plaintext.txt	313	Neuroreport 111977 1980Medline Jones DNC Gartlon J Parker F Taylor SG Routledge C Hemmati P Munton RP Ashmeade TE Hatcher JP Johns A Porter RA Hagan JJ Hunter AJ Upton N 2001 Effects centrally administered orexin B orexin A role orexin 1 receptors orexin B induced hyperactivity
0.17200397.15961555.html.plaintext.txt	314	Psychopharmacology Berl 153210 218CrossRefMedline Russell SH Small CJ Dakin CL Abbott CR Morgan DG Ghatei MA Bloom SR 2001 The central effects orexin A hypothalamic pituitary adrenal axis vivo vitro male rats
0.17200397.15961555.html.plaintext.txt	315	J Neuroendocrinol 13561 566CrossRefMedline Al Barazanji KA Wilson S Baker J Jessop DS Harbuz MS 2001 Central orexin A activates hypothalamic pituitary adrenal axis stimulates hypothalamic corticotropin releasing factor arginine vasopressin neurones conscious rats
0.17200397.15961555.html.plaintext.txt	316	J Neuroendocrinol 13421 424CrossRefMedline Samson WK Taylor MM Follwell M Ferguson AV 2002 Orexin actions hypothalamic paraventricular nucleus physiological consequences cellular correlates
0.17200397.15961555.html.plaintext.txt	317	Regul Pept 10497 103CrossRefMedline Brunton PJ Russell JA 2003 Hypothalamic pituitary adrenal responses centrally administered orexin A suppressed pregnant rats
0.17200397.15961555.html.plaintext.txt	318	J Neuroendocrinol 15633 637CrossRefMedline Ida T Nakahara K Murakami T Hanada R Nakazato M Murakami N 2000 Possible involvement orexin stress reaction rats
0.17200397.15961555.html.plaintext.txt	319	Biochem Biophys Res Commun 270318 323CrossRefMedline Griffond B Risold PY Jacquemard C Colard C Fellmann D 1999 Insulin induced hypoglycemia increases preprohypocretin orexin mRNA rat lateral hypothalamic area
0.17200397.15961555.html.plaintext.txt	320	Neurosci Lett 26277 80CrossRefMedline Kok SW Roelfsema F Overeem S Lammers GJ Strijers RL Frolich M Meinders AE Pijl H 2002 Dynamics pituitary adrenal ensemble hypocretin deficient narcoleptic humans blunted basal adrenocorticotropin release evidence normal time keeping master pacemaker
0.17200397.15961555.html.plaintext.txt	321	J Clin Endocrinol Metab 875085 5091AbstractFree Full Text Dallman MF Strack AM Akana SF Bradbury MJ Hanson ES Scribner KA Smith M 1993 Feast famine critical role glucocorticoids insulin daily energy flow
0.17200397.15961555.html.plaintext.txt	322	Front Neuroendocrinol 14303 347CrossRefMedline Dallman MF Akana SF Strack AM Hanson ES Sebastian RJ 1995 The neural network regulates energy balance responsive glucocorticoids insulin also regulates HPA axis responsivity site proximal CRF neurons
0.17200397.15961555.html.plaintext.txt	323	Ann NY Acad Sci 771730 742Abstract Taheri S Sunter D Dakin C Moyes S Seal L Gardiner J Rossi M Ghatei Bloom S 2000 Diurnal variation orexin A immunoreactivity prepro orexin mRNA rat central nervous system
0.17200397.15961555.html.plaintext.txt	324	Neurosci Lett 279109 112CrossRefMedline Fujiki N Yoshida Y Ripley B Honda K Mignot E Nishino S 2001 Changes CSF hypocretin 1 orexin A levels rats across 24 hours response food deprivation
0.17200397.15961555.html.plaintext.txt	325	Neuroreport 12993 997CrossRefMedline Harbuz MS Lightman SL 1992 Stress hypothalamo pituitary adrenal axis acute chronic immunological activation
0.17200397.15961555.html.plaintext.txt	326	J Endocrinol 134327 329Medline Turnbull AV Rivier CL 1999 Regulation hypothalamic pituitary adrenal axis cytokines actions mechanisms action
0.17200397.15961555.html.plaintext.txt	327	Physiol Rev 791 71AbstractFree Full Text Jessop DS Eckland DJA Todd K Lightman SL 1989 Osmotic regulation hypothalamo neurointermediate lobe corticotrophin releasing factor 41 rat
0.17200397.15961555.html.plaintext.txt	328	J Endocrinol 120119 124Abstract Harbuz MS Jessop DS Lightman SL Chowdrey HS 1994 The effects restraint hypertonic saline stress corticotrophin releasing factor arginine vasopressin proenkephalin A mRNAs CFY Sprague Dawley Wistar strains rat
0.17200397.15961555.html.plaintext.txt	329	Brain Res 6676 12CrossRefMedline Young 3rd WS Mezey E Siegel RE 1986b Quantitative situ hybridization histochemistry reveals increased levels corticotropin releasing factor mRNA adrenalectomy rats
0.17200397.15961555.html.plaintext.txt	330	Neurosci Lett 70198 203 Harbuz MS Lightman SL 1989 Responses hypothalamic pituitary mRNA physical psychological stress rat
0.17200397.15961555.html.plaintext.txt	331	J Endocrinol 12705 711 Paxinos G Watson C 1998 The rat brain stereotaxic coordinates
0.17200397.15961555.html.plaintext.txt	332	London Academic Press Edwards CMB Abusnana S Sunter D Murphy KG Ghatei MA Bloom SR 1999 The effect orexins food intake comparison neuropeptide Y melanin concentrating hormone galanin
0.17200397.15961555.html.plaintext.txt	333	J Endocrinol 1607 12CrossRef Haynes AC Jackson B Overend P Buckingham RE Wilson S Tadayyon M Arch JR 1999 Effects single chronic intracerebroventricular administration orexins feeding rat
0.17200397.15961555.html.plaintext.txt	334	Peptides 201099 1105CrossRefMedline Drazen DL Coolen LM Strader AD Wortman MD Woods SC Seeley RJ 2004 Differential effects adrenalectomy melanin concentrating hormone orexin A
0.17200397.15961555.html.plaintext.txt	335	Endocrinology 1453404 3412AbstractFree Full Text Ford GK Al Barazanji KA Wilson S Harbuz MS Jessop DS 2002 Effects glucocorticoid manipulation orexin A induced food intake rats
0.17200397.15961555.html.plaintext.txt	336	Br J Pharmacol Proc Suppl 135109P Tataranni PA Larson DE Snitker S Young JB Flatt JP Ravussin E 1996 Effects glucocorticoids energy metabolism food intake humans
0.17200397.15961555.html.plaintext.txt	337	Am J Physiol 271E317 E325 Dallman MF Akana SF Strack AM Scribner KS Pecoraro N La Fleur SE Houshyar H Gomez F 2004 Chronic stress induced effects corticosterone brain direct indirect
0.17200397.15961555.html.plaintext.txt	338	Ann NY Acad Sci 1018141 150AbstractFree Full Text Ida T Nakahara K Kuroiwa T Fukui K Nakazato M Murakami T Murakami N 2000 Both corticotropin releasing factor neuropeptide Y involved effect orexin hypocretin food intake rats
0.17200397.15961555.html.plaintext.txt	339	Neurosci Lett 293119 122CrossRefMedline Stanley BG Lanthier D Chin AS Leibowitz SF 1989 Suppression neuropeptide Y elicited eating adrenalectomy hypophysectomy reversal corticosterone
0.17200397.15961555.html.plaintext.txt	340	Brain Res 50132 36CrossRefMedline Kalra SP Dube MG Pu S Xu B Horvath TL Kalra PS 1999 Interacting appetite regulating pathways hypothalamic regulation body weight
0.17200397.15961555.html.plaintext.txt	341	Endocr Rev 2068 100AbstractFree Full Text Jain MR Horvath TL Kalra PS Kalra SP 2000 Evidence NPY Y1 receptors involved stimulation feeding orexins hypocretins sated rats
0.17200397.15961555.html.plaintext.txt	342	Regul Pept 8719 24CrossRefMedline Cintra A Zoli M Rosen L Agnati LF Okret S Wikstrom AC Gustaffsson JA Fuxe K 1994 Mapping computer assisted morphometry microdensitometry glucocorticoid receptor immunoreactive neurons glial cells rat central nervous system
0.17200397.15961555.html.plaintext.txt	343	Neuroscience 62843 897CrossRefMedline Morimoto M Morita N Ozawa H Yokoyama K Kawata M 1996 Distribution glucocorticoid receptor immunoreactivity mRNA rat brain immunohistochemical situ hybridization study
0.17200397.15961555.html.plaintext.txt	344	Neurosci Res 26235 269CrossRefMedline Watts AG Tanimura S Sanchez Watts G 2004 Corticotropin releasing hormone arginine vasopressin gene transcription hypothalamic paraventricular nucleus unstressed rats daily rhythms interactions corticosterone
0.17200397.15961555.html.plaintext.txt	345	Endocrinology 145529 540AbstractFree Full Text Stricker Krongrad A Beck B 2002 Modulation hypothalamic hypocretinorexin mRNA expression glucocorticoids
0.17200397.15961555.html.plaintext.txt	346	Biochem Biophys Res Commun 296129 133CrossRefMedline Rivet JM Castagne V Corder R Gaillard R Mormede P 1989 Study influence stress adrenalectomy central peripheral neuropeptide Y levels
0.17200397.15961555.html.plaintext.txt	347	Comparison catecholamines
0.17200397.15961555.html.plaintext.txt	348	Neuroendocrinology 50413 420Medline Pralong FP Corder R Gaillard RC 1993 The effects chronic glucocorticoid excess adrenalectomy stress neuropeptide Y individual rat hypothalamic nuclei
0.17200397.15961555.html.plaintext.txt	349	Neuropeptides 25223 231CrossRefMedline Akabayashi A Watanabe Y Wahlestedt C McEwen BS Paez X Leibowitz SF 1994 Hypothalamic neuropeptide Y gene expression receptor activity relation circulating corticosterone adrenalectomized rats
0.17200397.15961555.html.plaintext.txt	350	Brain Res 665201 212CrossRefMedline Larsen P Jessop D Chowdrey H Lightman S Mikkelsen J 1994 Chronic administration glucocorticoids directly upregulates prepro neuropeptide Y Y1 receptor mRNA levels arcuate nucleus rat
0.17200397.15961555.html.plaintext.txt	351	J Neuroendocrinol 6153 160Medline Bingham S Davey PT Babbs AJ Irving EA Sammons MJ Wyles M Jeffrey P Cutler L Riba I Johns A Porter RA Upton N Hunter AJ Parsons AA 2001 Orexin A hypothalamic peptide analgesic properties
0.17200397.15961555.html.plaintext.txt	352	Pain 9281 90CrossRefMedline This Article Abstract Full Text PDF All Versions Article 14693724 recent Author Manuscript PDF Purchase Article View Shopping Cart Alert article cited Alert correction posted Citation Map Services Email article friend Similar articles journal Similar articles PubMed Alert new issues journal Download citation manager Request Copyright Permission Google Scholar Articles Ford G
0.17200397.15961555.html.plaintext.txt	353	Articles citing Article PubMed PubMed Citation Articles Ford G
0.17200397.15961555.html.plaintext.txt	354	HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS Endocrinology Endocrine Reviews J
0.17200397.15961555.html.plaintext.txt	355	Molecular Endocrinology Recent Prog
0.35575834.12419707.html.plaintext.txt	0	INVITED REVIEW Functions orexinergichypocretinergic system Jyrki P
0.35575834.12419707.html.plaintext.txt	1	Kukkonen1 Tomas Holmqvist1 Sylwia Ammoun1 Karl E
0.35575834.12419707.html.plaintext.txt	2	1 Laboratory Cell Physiology Department Neuroscience Division Physiology Uppsala University Biomedical Center SE 75123 Uppsala Sweden 2 Department Neurobiology A
0.35575834.12419707.html.plaintext.txt	3	Virtanen Institute Molecular Sciences University Kuopio BioTeknia FIN 70210 Kuopio Finland
0.35575834.12419707.html.plaintext.txt	4	ABSTRACT TOP ABSTRACT INTRODUCTION OVERVIEW OF OREXINS AND
0.35575834.12419707.html.plaintext.txt	5	CELLULAR RESPONSES TO OREXINS DISTRIBUTION OF OREXINERGIC
0.35575834.12419707.html.plaintext.txt	6	SYSTEMIC EFFECTS OF OREXINS FUTURE PERSPECTIVES REFERENCES
0.35575834.12419707.html.plaintext.txt	7	Orexin A orexin B hypothalamic peptides act targets via two G protein coupled receptors OX1 OX2 receptors
0.35575834.12419707.html.plaintext.txt	8	In central nervous system cell bodies producing orexins localized narrow region within lateral hypothalamus project mainly regions involved feeding sleep autonomic functions
0.35575834.12419707.html.plaintext.txt	9	Via putative pre postsynaptic effects orexins increase synaptic activity regions
0.35575834.12419707.html.plaintext.txt	10	In isolated neurons cells expressing recombinant receptors orexins cause Ca2 elevation mainly dependent influx
0.35575834.12419707.html.plaintext.txt	11	The activity orexinergic cells appears controlled feeding sleep related signals via variety neurotransmittershormones brain tissues
0.35575834.12419707.html.plaintext.txt	12	Orexins orexin receptors also found outside central nervous system particularly organs involved feeding energy metabolism e
0.35575834.12419707.html.plaintext.txt	13	gastrointestinal tract pancreas adrenal gland
0.35575834.12419707.html.plaintext.txt	14	In present review focus physiological properties cells secrete respond orexins
0.35575834.12419707.html.plaintext.txt	15	sleep feeding calcium neuron neuroendocrine regulation
0.35575834.12419707.html.plaintext.txt	16	INTRODUCTION TOP ABSTRACT INTRODUCTION OVERVIEW OF OREXINS AND
0.35575834.12419707.html.plaintext.txt	17	CELLULAR RESPONSES TO OREXINS DISTRIBUTION OF OREXINERGIC
0.35575834.12419707.html.plaintext.txt	18	SYSTEMIC EFFECTS OF OREXINS FUTURE PERSPECTIVES REFERENCES
0.35575834.12419707.html.plaintext.txt	19	OUR KNOWLEDGE orexinergic system initiated 1998 two independent groups approaches reviewed Refs
0.35575834.12419707.html.plaintext.txt	20	In January 1998 group Sutcliffe published study 37 predicted particular rat hypothalamic mRNA species clone 35 Ref
0.35575834.12419707.html.plaintext.txt	21	50 would code precursor peptide 130 amino acids aa length molecule would generate two separate peptides 39 29 aa lengths
0.35575834.12419707.html.plaintext.txt	22	The peptides named hypocretins basis hypothalamic localization proposed sequence similarity secretin family peptides however orexin B bears significant resemblance secretin
0.35575834.12419707.html.plaintext.txt	23	The precursor peptide would thus preprohypocretin two final peptides hypocretin hcrt 1 hcrt 2
0.35575834.12419707.html.plaintext.txt	24	Simultaneously work group Sutcliffe group Yanagisawa 154 isolated hypothalamic 33 aa peptide activated orphan receptor HFGAN72
0.35575834.12419707.html.plaintext.txt	25	This receptor found also respond another peptide 28 aa length
0.35575834.12419707.html.plaintext.txt	26	A second receptor cloned basis sequence similarity HFGAN72 receptor also responded isolated peptides Ca2 elevation
0.35575834.12419707.html.plaintext.txt	27	On basis peptide sequences Sakurai coworkers 154 cloned cDNA precursor peptide 130 aa rat
0.35575834.12419707.html.plaintext.txt	28	The peptides named orexins increased food intake nonfasted rats injected lateral ventricle
0.35575834.12419707.html.plaintext.txt	29	The precursor peptide thus became preproorexin 33 28 aa final peptides orexin A orexin B respectively receptors OX1 OX2 receptors
0.35575834.12419707.html.plaintext.txt	30	Both preprohypocretin preproorexin found preferentially rat brain specifically hypothalamus 37 154
0.35575834.12419707.html.plaintext.txt	31	Cellular systemic responses peptides observed rat
0.35575834.12419707.html.plaintext.txt	32	Application hcrt 2 increased postsynaptic current frequency rat hypothalamic neurons culture 37 orexin A B increased food intake nonfasted rats 154
0.35575834.12419707.html.plaintext.txt	33	It soon became clear peptides isolated two groups principle identical
0.35575834.12419707.html.plaintext.txt	34	However error peptide sequences deduced de Lecea coworkers 37 authors refer accepted sequences Sakurai et al
0.35575834.12419707.html.plaintext.txt	35	154 de Lecea et al
0.35575834.12419707.html.plaintext.txt	36	37 even using hypocretin nomenclature
0.35575834.12419707.html.plaintext.txt	37	Therefore current praxis makes preproorexin preprohypocretin orexin A hcrt 1 orexin B hcrt 2 OX1 receptor hcrtr 1 OX2 receptor hcrtr 2
0.35575834.12419707.html.plaintext.txt	38	There ongoing argument concerning nomenclature used
0.35575834.12419707.html.plaintext.txt	39	To avoid confusion sequences use orexin nomenclature throughout review
0.35575834.12419707.html.plaintext.txt	40	Today wealth information concerning anatomic architecture orexinergic system well systemic effects orexins
0.35575834.12419707.html.plaintext.txt	41	The prominent well demonstrated effect orexins undoubtedly regulation sleepwakefulness reviewed Refs
0.35575834.12419707.html.plaintext.txt	42	Although many responses shown physiological significance less clear
0.35575834.12419707.html.plaintext.txt	43	Effects feeding behavior demonstrated multitude studies results somewhat contradictory
0.35575834.12419707.html.plaintext.txt	44	The current view orexins may rather regulate short term appetite energy metabolism feeding associated processes e
0.35575834.12419707.html.plaintext.txt	45	gastrointestinal functions mastication
0.35575834.12419707.html.plaintext.txt	46	Orexins also affect hormonal secretion well demonstrated effects hormones involved stress response energy metabolism glucocorticoids norepinephrine
0.35575834.12419707.html.plaintext.txt	47	At time information concerning regulatory mechanisms orexinergic systems targets cellular level lagging behind
0.35575834.12419707.html.plaintext.txt	48	In review try create comprehensive picture orexins proven putative physiological role
0.35575834.12419707.html.plaintext.txt	49	The main emphasis placed functional properties interactions orexin producing orexin responding cells
0.35575834.12419707.html.plaintext.txt	50	OVERVIEW OF OREXINS AND OREXIN RECEPTORS TOP ABSTRACT INTRODUCTION OVERVIEW OF OREXINS AND
0.35575834.12419707.html.plaintext.txt	51	CELLULAR RESPONSES TO OREXINS DISTRIBUTION OF OREXINERGIC
0.35575834.12419707.html.plaintext.txt	52	SYSTEMIC EFFECTS OF OREXINS FUTURE PERSPECTIVES REFERENCES
0.35575834.12419707.html.plaintext.txt	53	Genetics Chemistry Orexins
0.35575834.12419707.html.plaintext.txt	54	Mammalian human pig dog rat mouse preproorexin composed 130 131 aa 37 41 73 154 155
0.35575834.12419707.html.plaintext.txt	55	The human preproorexin gene chromosome 17 thoroughly characterized 155
0.35575834.12419707.html.plaintext.txt	56	It composed two exons latter includes whole coding region final peptides
0.35575834.12419707.html.plaintext.txt	57	2 kb promoter region preproorexin gene seems enough direct expression downstream gene lateral hypothalamus mouse 155
0.35575834.12419707.html.plaintext.txt	58	This utilized cause selective depletion orexinergic neurons transgenic mice expressing preproorexin ataxin 3 fusion protein 60
0.35575834.12419707.html.plaintext.txt	59	In mice orexinergic neurons progressively lost postnatally
0.35575834.12419707.html.plaintext.txt	60	For transcription essential part suggested 450 bp proximal gene 185
0.35575834.12419707.html.plaintext.txt	61	Cleavage one molecule preproorexin modification leads production one molecule orexin A orexin B however HPLC detection orexins human brain suggests two fivefold higher levels orexin B orexin A several areas central nervous system CNS 34 35 125 126
0.35575834.12419707.html.plaintext.txt	62	Mammalian orexin A rat 33 aa peptide two intrachain disulfide bridges orexin B 28 aa linear peptide Fig
0.35575834.12419707.html.plaintext.txt	63	There substantial sequence identity COOH termini peptides
0.35575834.12419707.html.plaintext.txt	64	In addition orexin B secretin contain identical stretch seven amino acids
0.35575834.12419707.html.plaintext.txt	65	Orexin A B likely COOH terminally amidated NH2 terminal glutamine residue orexin A may modified pyroglutamoyl residue 154 however posttranslational modifications experimentally verified rat
0.35575834.12419707.html.plaintext.txt	66	Orexin A human pig dog rat mouse identical Fig
0.35575834.12419707.html.plaintext.txt	67	1B whereas orexin B pig dog differs one amino acid orexin B rat mouse two amino acids human orexin B Fig
0.35575834.12419707.html.plaintext.txt	68	The three dimensional structure orexin A known orexin B determined consist two helices 60 80 degrees angle 100
0.35575834.12419707.html.plaintext.txt	69	View larger version 25K Fig
0.35575834.12419707.html.plaintext.txt	70	Alignment orexin A orexin B peptide sequences different species A C
0.35575834.12419707.html.plaintext.txt	71	Gray boxes indicate dissimilar amino acids compared human orexin variants
0.35575834.12419707.html.plaintext.txt	72	Cystine bridges orexin A shown A black lines
0.35575834.12419707.html.plaintext.txt	73	D OX1 receptor antagonist SB 334867
0.35575834.12419707.html.plaintext.txt	74	Orexin A seems much higher stability orexin B physiological milieu 89 may explain orexin A readily detected cerebrospinal fluid CSF orexin B 148
0.35575834.12419707.html.plaintext.txt	75	Orexin A also displays much higher lipid solubility orexin B probably making orexin Ain contrast orexin Bblood brain barrier permeant 89
0.35575834.12419707.html.plaintext.txt	76	Orexin immunoreactivity found putative endocrine release sites hypothalamus neurohypophysis pancreas see offering interesting possibility orexins could also act hormones CNS periphery
0.35575834.12419707.html.plaintext.txt	77	Yet indirect evidence suggests orexin A plasma originates peripheral sources 32 brain penetration intravenous orexin A seen rat 11
0.35575834.12419707.html.plaintext.txt	78	Orexins Xenopus laevis also described 163
0.35575834.12419707.html.plaintext.txt	79	In species preproorexin rather similar humans overall identity 56
0.35575834.12419707.html.plaintext.txt	80	Xenopus orexin A 31 aa long lacking two NH2 terminal amino acids seen human orexin A contains 6 aa substitutions compared human orexin A Fig
0.35575834.12419707.html.plaintext.txt	81	Xenopus orexin B 28 aa long contains 7 aa substitutions compared human orexin B Fig
0.35575834.12419707.html.plaintext.txt	82	Both Xenopus orexins supposed posttranslationally modified way rat orexins disulfide bridges COOH terminal amidation except Xenopus orexin A contain NH2 terminal pyroglutamoyl residue
0.35575834.12419707.html.plaintext.txt	83	Orexin A preproorexin mRNA concentrations show circadian variation rats 1212 h light dark cycle 47 176 196
0.35575834.12419707.html.plaintext.txt	84	Preproorexin mRNA orexin A concentration hypothalamus reach maximum around light onset somewhat later minimum light offset somewhat later
0.35575834.12419707.html.plaintext.txt	85	Measurements orexin A pons intracisternal space also show diurnal variation time points shifted compared hypothalamus 47 176
0.35575834.12419707.html.plaintext.txt	86	126 find circadian variation hypothalamic orexin A B concentration time points 5 h dark 5 h light onset may unfortunately chosen light results Ref
0.35575834.12419707.html.plaintext.txt	87	There appear bilateral connections suprachiasmatic nucleus orexinergic neurons rat posterior hypothalamus 1 36 64 121 125 may indicate reciprocal regulation circadian rhythms
0.35575834.12419707.html.plaintext.txt	88	Two receptors responding orexin stimulation cloned
0.35575834.12419707.html.plaintext.txt	89	These receptors called OX1 OX2 receptors form subclass class A G protein coupled receptors class A peptide receptor orexin neuropeptide FF receptors orexin receptors
0.35575834.12419707.html.plaintext.txt	90	Both receptors rather average G protein coupled receptors modestly long NH2 COOH termini neither long short i3 loops Fig
0.35575834.12419707.html.plaintext.txt	91	OX1 receptor chromosome 1 425 aa long OX2 receptor chromosome 6 444 aa long humans overall 64 sequence identity
0.35575834.12419707.html.plaintext.txt	92	In gene identity one amino acid disputed based Entrez search covering variety databases SwissProt variety published references OX1 receptor aa 280 i3 loop either Gly Ala OX2 receptor aa 308 sixth transmembrane segment either Val Ile
0.35575834.12419707.html.plaintext.txt	93	Amino acids subject polymorphismsmutations also marked Fig
0.35575834.12419707.html.plaintext.txt	94	2 see also Narcolepsy Disorder Orexinergic System
0.35575834.12419707.html.plaintext.txt	95	The gene transcript receptor composed 5 untranslated region seven separate exons codes part final protein six introns
0.35575834.12419707.html.plaintext.txt	96	High sequence identity 91 98 comparison made Blast httpwww
0.35575834.12419707.html.plaintext.txt	97	govBLAST seen cloned mammalian species human pig dog rat mouse variants
0.35575834.12419707.html.plaintext.txt	98	Two neuropeptide FF receptors 14 28 closely related orexin receptors gross sequence identity low 31 35 human receptors longer stretches high identity found identity nearly similar degree observed neuropeptide FF receptor instance neuropeptide Y NPY receptors
0.35575834.12419707.html.plaintext.txt	99	Furthermore orexin receptors 28 31 identical many peptide receptors including NPY Y2 thyrotropin TSH releasing hormone TRH NK2 tachykinin receptors
0.35575834.12419707.html.plaintext.txt	100	Therefore grouping orexin neuropeptide FF receptors family questionable
0.35575834.12419707.html.plaintext.txt	101	View larger version 45K Fig
0.35575834.12419707.html.plaintext.txt	102	Human orexin receptor sequences putative 7 transmembrane plots
0.35575834.12419707.html.plaintext.txt	103	Sequences SwissProt Ref
0.35575834.12419707.html.plaintext.txt	104	Putative transmembrane domains represented GPCRDB database Ref
0.35575834.12419707.html.plaintext.txt	105	The putative N glycosylation sites calculated NetNGlyc R
0.35575834.12419707.html.plaintext.txt	106	Brunak unpublished httpwww
0.35575834.12419707.html.plaintext.txt	107	dkservicesNetNGlyc putative phosphorylation sites protein kinase A PKA C PKC Ca2calmodulin kinase II CaMKII PhosphoBase Ref
0.35575834.12419707.html.plaintext.txt	108	Possible palmitoylated cysteines also shown
0.35575834.12419707.html.plaintext.txt	109	Amino acids may represent polymorphisms marked see Orexin Receptors Narcolepsy Disorder Orexinergic System
0.35575834.12419707.html.plaintext.txt	110	CELLULAR RESPONSES TO OREXINS TOP ABSTRACT INTRODUCTION OVERVIEW OF OREXINS AND
0.35575834.12419707.html.plaintext.txt	111	CELLULAR RESPONSES TO OREXINS DISTRIBUTION OF OREXINERGIC
0.35575834.12419707.html.plaintext.txt	112	SYSTEMIC EFFECTS OF OREXINS FUTURE PERSPECTIVES REFERENCES
0.35575834.12419707.html.plaintext.txt	113	In original studies orexin receptors two cellular responses identified recombinantly expressed orexin receptor strongly elevated Ca2 Chinese hamster ovary CHO K1 cells 154 whereas hypothalamic neurons increased action potential frequency observed 37
0.35575834.12419707.html.plaintext.txt	114	Many systemic responses described thereafter molecular mechanisms cases investigated detail
0.35575834.12419707.html.plaintext.txt	115	Both OX1 OX2 receptors elevate Ca2 recombinantly expressed CHO cells 67 107 138 154 168
0.35575834.12419707.html.plaintext.txt	116	Because orexin receptors caused Ca2 elevations high magnitude cell line devoid voltage gated Ca2 channels thought couple phospholipase C inositol 145 trisphosphate IP3 Ca2 release cascade via Gq family G proteins
0.35575834.12419707.html.plaintext.txt	117	The orexins subsequently shown elevate intracellular Ca2 neuronal cell cultures hypothalamus cortex 183 184
0.35575834.12419707.html.plaintext.txt	118	The Ca2 elevations neurons found independent intracellular release require extracellular Ca2 Fig
0.35575834.12419707.html.plaintext.txt	119	The requirement extracellular Ca2 typical property Gq mediated response consists Ca2 release intracellular stores followed capacitative Ca2 entry refill stores
0.35575834.12419707.html.plaintext.txt	120	The observed Ca2 elevation neurons blocked bisindoylmaleimide protein kinase C inhibitor
0.35575834.12419707.html.plaintext.txt	121	It therefore suggested orexin receptors would activate protein kinase C would phosphorylate thereby activate voltage gated Ca2 channels 183
0.35575834.12419707.html.plaintext.txt	122	Similar findings described Uramura et al
0.35575834.12419707.html.plaintext.txt	123	181 isolated rat ventral tegmental neurons
0.35575834.12419707.html.plaintext.txt	124	Orexin A determined elevate intracellular Ca2 via activation nitrendipine conotoxin sensitive Ca2 channels
0.35575834.12419707.html.plaintext.txt	125	The response also sensitive calphostin C inhibitor protein kinase C D609 inhibitor phosphatidylcholine specific phospholipase C suggested following activation sequence orexin receptor phosphatidylcholine specific phospholipase C protein kinase C N L type voltage gated Ca2 channels influx Ca2
0.35575834.12419707.html.plaintext.txt	126	Ca2 elevation also measured cultured rat embryonic spinal cord neurons although source Ca2 investigated 182
0.35575834.12419707.html.plaintext.txt	127	Indirect evidence rat locus ceruleus tuberomamillary nucleus also suggests activation Ca2 influx 44 70
0.35575834.12419707.html.plaintext.txt	128	View larger version 20K Fig
0.35575834.12419707.html.plaintext.txt	129	Extracellular Ca2 dependence orexin stimulated Ca2 response rat medial hypothalamic neurons culture
0.35575834.12419707.html.plaintext.txt	130	The data demonstrate extracellular Ca2 dependence orexin stimulated Ca2 response
0.35575834.12419707.html.plaintext.txt	131	Cells stimulated 1 microM rat hcrt 2 H presence 1 mM 0 mM 0 Ca2EGTA extracellular Ca2 concentration Ca2o intracellular Ca2 levels monitored fura 2 methodology
0.35575834.12419707.html.plaintext.txt	132	As shown response hypocretin 2 completely blocked removal extracellular Ca2
0.35575834.12419707.html.plaintext.txt	133	The experiment performed continuous presence 1 microM tetrodotoxin TTX
0.35575834.12419707.html.plaintext.txt	134	Rat hcrt 2 identical rat orexin B2 28
0.35575834.12419707.html.plaintext.txt	135	183 permission Copyright 1998 Society Neuroscience
0.35575834.12419707.html.plaintext.txt	136	What general role Ca2 influx orexin receptor mediated cellular responses In neuronal cells Ca2 influx observed fura 2 measurements 181 182 184 also suggested electrophysiological measurements 44 70
0.35575834.12419707.html.plaintext.txt	137	Because orexins may depolarize neurons via block K channels see Depolarizing actions Ca2 influx may even result indirect activation voltage gated Ca2 channels
0.35575834.12419707.html.plaintext.txt	138	The situation may complex sites discussed
0.35575834.12419707.html.plaintext.txt	139	107 discovered removal extracellular Ca2 caused significant 8 100 fold drop potency orexin A OX1 receptor Fig
0.35575834.12419707.html.plaintext.txt	140	In respects results Smart et al
0.35575834.12419707.html.plaintext.txt	141	168 suggest qualities expected Gq dependent signaling sensitivity phospholipase C inhibitor U 73122 rapid transient spike extracellular Ca2 dependent secondary phase capacitative Ca2 entry
0.35575834.12419707.html.plaintext.txt	142	In contrast detailed analysis Ca2 signaling CHO cells indicated dependence Ca2 response extracellular Ca2 due activation Ca2 influx pathway 107
0.35575834.12419707.html.plaintext.txt	143	The Ca2 response abolished membrane potential held close reversal potential Ca2 Fig
0.35575834.12419707.html.plaintext.txt	144	4B Ca2 elevation could observed returning negative holding potential 107
0.35575834.12419707.html.plaintext.txt	145	In addition orexin A activated influx Mn2 ions conditions intracellular release occurred
0.35575834.12419707.html.plaintext.txt	146	The primary response OX1 receptor stimulation CHO cells thus receptor operated Ca2 influx 107
0.35575834.12419707.html.plaintext.txt	147	This Ca2 influx amplifies phosphatidylinositol specific phospholipase C absence Ca2 influx IP3 production Ca2 release occur potency 100 times lower presence Ca2 influx
0.35575834.12419707.html.plaintext.txt	148	Ca2 elevation alone sufficient activate phospholipase C cells suggesting Ca2 influx acts concert G protein mediated mechanism
0.35575834.12419707.html.plaintext.txt	149	The identity Ca2 influx pathway activation mechanism orexin receptors remains unresolved however potency pharmacological blockers suggests different molecular entity store operated Ca2 channel CHO cells 96
0.35575834.12419707.html.plaintext.txt	150	It thus seems neuronal nonneuronal cells orexin receptors activate Ca2 influx phosphatidylinositol specific phospholipase C pathway view supported study orexin receptors heterologously expressed variety different cell types Holmqvist Akerman Kukkonen unpublished observation
0.35575834.12419707.html.plaintext.txt	151	In recent study orexin A B equipotently increased norepinephrine release rat cerebrocortical slices
0.35575834.12419707.html.plaintext.txt	152	When extracellular Ca2 removed maximum responses peptides lowered 50 EC50 values shifted 10 fold higher concentrations 66
0.35575834.12419707.html.plaintext.txt	153	Although response mechanisms clarified direct Ca2 measurements overall pattern similar seen recombinant CHO cells 107
0.35575834.12419707.html.plaintext.txt	154	View larger version 15K Fig
0.35575834.12419707.html.plaintext.txt	155	Extracellular Ca2 dependence orexin stimulated Ca2 response CHO cells expressing human OX1 receptors CHO hOX1
0.35575834.12419707.html.plaintext.txt	156	A reduction Ca2o 140 nM shifts orexin A concentration response curve 2 orders magnitude right
0.35575834.12419707.html.plaintext.txt	157	B orexin A mediated Ca2 response blocked reducing driving force Ca2 entry
0.35575834.12419707.html.plaintext.txt	158	A CHO hOX1 cell patch clamped whole cell configuration regulate membrane potential therefore driving force Ca2 entry Ca2 transients measured fura 2
0.35575834.12419707.html.plaintext.txt	159	Gray boxes black bars indicate presence 10 nM orexin A bath
0.35575834.12419707.html.plaintext.txt	160	Under light gray box cells exposed orexin A holding potential 60 mV dark gray box cells exposed orexin A holding potential 50 40 mV
0.35575834.12419707.html.plaintext.txt	161	Inset voltage application profile
0.35575834.12419707.html.plaintext.txt	162	Ca2 response orexin A seen negative holding potential indicates Ca2 influx required response
0.35575834.12419707.html.plaintext.txt	163	Functional experiments indicate addition Ca2 release activation store operated Ca2 channels several types Ca2 influx pathways activated G protein coupled receptors reviewed Ref
0.35575834.12419707.html.plaintext.txt	164	Although cases mechanisms clarified pathways may activated directly G protein subunits second messengers
0.35575834.12419707.html.plaintext.txt	165	These pathways may identical related transient receptor potential TRP ion channel family reviewed Ref
0.35575834.12419707.html.plaintext.txt	166	The TRP genes encode family 20 proteins
0.35575834.12419707.html.plaintext.txt	167	Many TRP gene products form Ca2 permeable nonselective cation channels members TRP superfamily even inherent protein kinase ADP ribose pyrophosphatase domains
0.35575834.12419707.html.plaintext.txt	168	TRP channels widely expressed mammalian cells activated Gq coupled receptor stimulation activation mechanisms many cases unknown
0.35575834.12419707.html.plaintext.txt	169	It interesting see whether TRP channels held responsible orexin receptor mediated Ca2 influx
0.35575834.12419707.html.plaintext.txt	170	Characterization receptor mediated electrical responses neuronal preparations performed common electrophysiological techniques
0.35575834.12419707.html.plaintext.txt	171	In many situations intracellular recordings difficult extracellular electrodes practical use likely induce much less cellular damage
0.35575834.12419707.html.plaintext.txt	172	On hand response measurements usually limited registration action potential frequency
0.35575834.12419707.html.plaintext.txt	173	Measurements intracellular electrodes normal microelectrodes performed feedback amplification allowing voltage current clamp free running mode case voltage changes monitored
0.35575834.12419707.html.plaintext.txt	174	These latter methods importantly offer better possibilities investigation mechanisms underlying electrical activity extracellular electrodes
0.35575834.12419707.html.plaintext.txt	175	Recordings neurons usually performed slices similar preparations cells synaptically coupled
0.35575834.12419707.html.plaintext.txt	176	The cell measured thus target upstream signals rather responding directly orexins
0.35575834.12419707.html.plaintext.txt	177	The usual way eliminating secondary effects far upstream measured cell use tetrodotoxin TTX
0.35575834.12419707.html.plaintext.txt	178	By blocking voltage gated Na channels hinders action potential propagation neurons
0.35575834.12419707.html.plaintext.txt	179	However TTX instance block direct effects orexins presynaptic terminal immediately upstream cell investigated
0.35575834.12419707.html.plaintext.txt	180	Therefore TTX exclusively separate pre postsynaptic effects
0.35575834.12419707.html.plaintext.txt	181	Presynaptic voltage gated Ca2 channelsand therefore transmitter releasecan blocked example Co2 Cd2 Ni2 specific drugs toxins
0.35575834.12419707.html.plaintext.txt	182	However orexin receptors may activate Ca2 channels sensitive inhibitors see Ca2 Elevation
0.35575834.12419707.html.plaintext.txt	183	On hand blockers may also affect instance orexin activated Ca2 channels voltage gated channels
0.35575834.12419707.html.plaintext.txt	184	This may lead block pre postsynaptic responses orexin
0.35575834.12419707.html.plaintext.txt	185	As example Ni2 blocks voltage gated Ca2 channel orexin activated non voltage gated Ca2 channels 96 even NaCa2 exchanger 91
0.35575834.12419707.html.plaintext.txt	186	Synaptic isolation performed using medium low extracellular Ca2 0
0.35575834.12419707.html.plaintext.txt	187	3 mM high extracellular Mg2 4 mM
0.35575834.12419707.html.plaintext.txt	188	This widely used method appears block electrically evoked synaptic transmission mechanistic basis unclear
0.35575834.12419707.html.plaintext.txt	189	Similarly unknown whether method would affect orexin mediated presynaptic responses mediated voltage gated Ca2 channels Ca2 release
0.35575834.12419707.html.plaintext.txt	190	It also difficult preclude possible postsynaptic effects
0.35575834.12419707.html.plaintext.txt	191	Some methods give clearer separation pre postsynaptic responses
0.35575834.12419707.html.plaintext.txt	192	Dissociation cells removes presynaptic contacts
0.35575834.12419707.html.plaintext.txt	193	However even case possible although unlikely responses mediated indirect messengers released neighboring cells
0.35575834.12419707.html.plaintext.txt	194	Measurement synaptic activity method often used studies receptor coupled mechanisms
0.35575834.12419707.html.plaintext.txt	195	Increaseddecreased frequency excitatory inhibitory postsynaptic currents EPSC IPSC respectively orexins suggests stimulatory effect transmitter release
0.35575834.12419707.html.plaintext.txt	196	When amplitude synaptic current increased difficult conclude whether response pre postsynaptic
0.35575834.12419707.html.plaintext.txt	197	The common electrophysiological response orexins appears increase spontaneous evoked action potential frequency observed extracellular intracellular electrodes
0.35575834.12419707.html.plaintext.txt	198	Increased action potential frequency measured hypothalamus rat tuberomamillary nucleus magnocellular preoptic nucleus lateral hypothalamic glucose sensitive responsive indifferent neurons definition see Responses orexinergic cells feeding stimuli arcuate nucleus paraventricular nucleus Refs
0.35575834.12419707.html.plaintext.txt	199	8 42 44 103 147 159 164 165 195 brain stem rat locus ceruleus substantia nigra pars reticulata dorsal motor nucleus vagus mouse laterodorsal tegmental nucleus Refs
0.35575834.12419707.html.plaintext.txt	200	15 19 56 70 75 93 170 spinal cord rat preganglionic sympathetic neurons intermediolateral cell column thoracic lumbar cord Ref
0.35575834.12419707.html.plaintext.txt	201	3 peripheral neurons guinea pig ileal S type submucosal neurons Ref
0.35575834.12419707.html.plaintext.txt	202	In contrast orexin A suppresses firing rate glucose responsive neurons rat ventromedial hypothalamic nucleus antagonizing effect glucose 164
0.35575834.12419707.html.plaintext.txt	203	Action potentials enhancement orexins blocked TTX 3 44 54 70 75 165 170 195 usually synaptic isolation low Ca2 high Mg2 8 42 93 147 voltage gated Ca2 channel block Cd2 170
0.35575834.12419707.html.plaintext.txt	204	The latter data therefore suggest orexins would directly affect postsynaptic neurons sites reservations methodological shortcomings see
0.35575834.12419707.html.plaintext.txt	205	It also noted putative presynaptic block applied minority studies
0.35575834.12419707.html.plaintext.txt	206	Interestingly TTX insensitive response observed rat locus ceruleus
0.35575834.12419707.html.plaintext.txt	207	Hypocretin 2 orexin B depolarizes increases spontaneous firing frequency locus ceruleus slices 70
0.35575834.12419707.html.plaintext.txt	208	In presence TTX spontaneous spikes vanish orexin B still causes small depolarization 3
0.35575834.12419707.html.plaintext.txt	209	4 mV electrical discharges although spikes slower spontaneous spikes
0.35575834.12419707.html.plaintext.txt	210	These spikes may caused Ca2 channels TTX insensitive Na channels
0.35575834.12419707.html.plaintext.txt	211	More detailed analysis individual synaptic currents shows enhancement synaptic activity orexins increase spontaneous evoked EPSC rat hypothalamus rat superficial dorsal horn mouse laterodorsal tegmental nucleus Refs
0.35575834.12419707.html.plaintext.txt	212	19 37 49 54 183 184 IPSC rat hypothalamic superficial dorsal horn neurons Refs
0.35575834.12419707.html.plaintext.txt	213	EPSCs IPSCs blocked TTX rat superficial dorsal horn mouse laterodorsal tegmental nucleus 19 54 rat hypothalamus 49 183
0.35575834.12419707.html.plaintext.txt	214	Therefore orexin receptor mediating putative presynaptic responses may lie farther upstream rat superficial dorsal horn mouse laterodorsal tegmental nucleus
0.35575834.12419707.html.plaintext.txt	215	In sites depolarization mediated orexins persists presence TTX suggesting orexin receptors expressed cell investigated upstream neuron
0.35575834.12419707.html.plaintext.txt	216	In cases released transmitters causing postsynaptic currents investigated receptor blockers
0.35575834.12419707.html.plaintext.txt	217	In mouse laterodorsal tegmental neurons orexin mediated elevation EPSC frequency attenuated ionotropic glutamate receptor block whereas postsynaptic depolarization response affected 19
0.35575834.12419707.html.plaintext.txt	218	In rat embryonic hypothalamic neurons culture hypocretin 2 orexin B increases IPSC EPSC frequency TTX insensitive manner 49 183
0.35575834.12419707.html.plaintext.txt	219	The former blocked GABAA receptor block latter ionotropic glutamate receptor block
0.35575834.12419707.html.plaintext.txt	220	In rat superficial dorsal horn neurons orexin B mediated increase IPSC frequency inhibited glycine receptor block 54
0.35575834.12419707.html.plaintext.txt	221	Amplitudes postsynaptic currents potentials also sometimes affected reported guinea pig ileal submucosal ganglia reduced excitatory postsynaptic potential EPSP inhibitory postsynaptic potential IPSP amplitude Ref
0.35575834.12419707.html.plaintext.txt	222	92 mouse laterodorsal tegmental nucleus increased EPSC amplitude Ref
0.35575834.12419707.html.plaintext.txt	223	19 rat arcuate nucleus increased IPSP amplitude Ref
0.35575834.12419707.html.plaintext.txt	224	Increased amplitude postsynaptic potentials currents specify pre postsynaptic mechanism cases
0.35575834.12419707.html.plaintext.txt	225	Depolarization inward current often measured response orexin application
0.35575834.12419707.html.plaintext.txt	226	This depolarization also results investigated without exception increased action potential frequency often depolarization studied presence TTX block disturbance Fig
0.35575834.12419707.html.plaintext.txt	227	Depolarizations maximum magnitude 3 10 mV observedmainly free running electrodesin hypothalamus rat tuberomamillary nucleus paraventricular nucleus lateral hypothalamic glucose sensitive neurons Refs
0.35575834.12419707.html.plaintext.txt	228	8 44 103 159 165 brain stem rat locus ceruleus dorsal motor nucleus vagus Refs
0.35575834.12419707.html.plaintext.txt	229	56 70 75 80 170 spinal cord rat intermediolateral cell column Ref
0.35575834.12419707.html.plaintext.txt	230	3 periphery guinea pig ileal S type submucosal neurons Ref
0.35575834.12419707.html.plaintext.txt	231	Inward currents observed rat locus ceruleus 150 pA Ref
0.35575834.12419707.html.plaintext.txt	232	170 dorsal motor nucleus vagus 30 pA Ref
0.35575834.12419707.html.plaintext.txt	233	75 superficial dorsal horn 35 pA Ref
0.35575834.12419707.html.plaintext.txt	234	54 mouse laterodorsal tegmental nucleus 20 pA Ref
0.35575834.12419707.html.plaintext.txt	235	View larger version 49K Fig
0.35575834.12419707.html.plaintext.txt	236	Orexin mediated increase action potential frequency A depolarization B rat hypothalamic tuberomamillary nucleus neurons slice preparation
0.35575834.12419707.html.plaintext.txt	237	Whole cell recordings performed intracellular microelectrodes free running mode
0.35575834.12419707.html.plaintext.txt	238	Cells stimulated 300 nM orexin A indicated
0.35575834.12419707.html.plaintext.txt	239	Experiment B performed presence 300 nM TTX
0.35575834.12419707.html.plaintext.txt	240	44 Copyright 2001 Society Neuroscience
0.35575834.12419707.html.plaintext.txt	241	The orexin stimulated increases current probably reflect direct effects orexin
0.35575834.12419707.html.plaintext.txt	242	Evidence includes stable currents lack effect TTX synaptic block kinds elimination EPSCs
0.35575834.12419707.html.plaintext.txt	243	What mechanism depolarization In rat lateral hypothalamic glucose sensitive neurons locus ceruleus autonomic preganglionic neurons intermediolateral cell column dorsal motor nucleus vagus guinea pig ileal S type submucosal neurons increased input resistance 2 85 measured co occur depolarization 3 75 80 92 103
0.35575834.12419707.html.plaintext.txt	244	This suggests orexins may inhibit K channels also suggested reduced afterhyperpolarization amplitude observed rat locus ceruleus guinea pig ileal submucosal ganglia 70 92
0.35575834.12419707.html.plaintext.txt	245	Also current voltage relationship measured suggests K channel inhibition rat locus ceruleus dorsal motor nucleus vagus Refs
0.35575834.12419707.html.plaintext.txt	246	On hand orexins may activate Ca2 dependent K channels suggested mouse peritoneal macrophages 76
0.35575834.12419707.html.plaintext.txt	247	It interesting orexins instead inhibit slow afterhyperpolarization locus ceruleus thought depend Ca2 activated K channels
0.35575834.12419707.html.plaintext.txt	248	It possible orexins elevate Ca2 sites signals generated receptor activation counteract effect Ca2 elevation
0.35575834.12419707.html.plaintext.txt	249	In cases reduced input resistance noise associated orexin induced depolarization
0.35575834.12419707.html.plaintext.txt	250	This seen rat tuberomamillary nucleus 44 rat lumbar spinal cord 54 mouse laterodorsal tegmental nucleus 19
0.35575834.12419707.html.plaintext.txt	251	In hypothalamic histaminergic tuberomamillary nucleus orexin A B depolarize increase firing rate 8 44 195 Fig
0.35575834.12419707.html.plaintext.txt	252	This depolarization abolished removal extracellular Na virtually unaffected increase extracellular K 44
0.35575834.12419707.html.plaintext.txt	253	Pharmacological block NaCa2 exchanger reduces depolarization suggesting may mediated Ca2 elevation induced activation electrogenic NaCa2 exchange
0.35575834.12419707.html.plaintext.txt	254	The residual depolarization blocked Ni2 may suggest putatively underlying Ca2 current also slightly depolarize cells
0.35575834.12419707.html.plaintext.txt	255	Even rat dorsal motor nucleus vagus part current appears depend Na remaining part may caused K channel block 75
0.35575834.12419707.html.plaintext.txt	256	Finally clear change input resistance may seen rat hypothalamic paraventricular nucleus 165 locus ceruleus 56 170 intermediolateral cell column 3
0.35575834.12419707.html.plaintext.txt	257	This could occur increased conductance caused opening ion channels Na Ca2 compensated closure channels K orexins rather affected transporters
0.35575834.12419707.html.plaintext.txt	258	Even single cell orexins may utilize several mechanisms depolarization 44 75
0.35575834.12419707.html.plaintext.txt	259	Summary orexin effects electrical activity neurons
0.35575834.12419707.html.plaintext.txt	260	Thus orexins often increase neuronal activity via presynaptic effects increased transmitter release via unknown mechanisms via postsynaptic depolarization block K channels activation cation channels electrogenic transporters
0.35575834.12419707.html.plaintext.txt	261	Some effects putative K channel inhibition typical Gq coupled receptors see e
0.35575834.12419707.html.plaintext.txt	262	Other mechanisms may secondary Ca2 elevation may depend activation nonselective cation channels like TRP channels
0.35575834.12419707.html.plaintext.txt	263	On particular neurons orexins may also cause inhibition via increased inhibitory transmitter release via decreased postsynaptic effects excitatory transmitters
0.35575834.12419707.html.plaintext.txt	264	It unclear direct indirect roles Ca2 transients play electrical responses orexins much effort put investigation date
0.35575834.12419707.html.plaintext.txt	265	Independent method measurement electrical activity effects orexins usually slow onset action 10 4 min recovery even slower see e
0.35575834.12419707.html.plaintext.txt	266	3 9 19 44 54 75 93 103 159 165 195
0.35575834.12419707.html.plaintext.txt	267	Most studies performed slices preparation perfusion orexins may slow
0.35575834.12419707.html.plaintext.txt	268	However rather superficial neurons patched obvious reason perfusate would reach neurons immediately
0.35575834.12419707.html.plaintext.txt	269	Furthermore similar slow onset 10 20 lag 1 min maximum delayed offset 2 min complete decay removal seen dissociated neurons 195
0.35575834.12419707.html.plaintext.txt	270	Therefore possible orexins affect ion channels via e
0.35575834.12419707.html.plaintext.txt	271	phosphorylation rather direct G protein interaction
0.35575834.12419707.html.plaintext.txt	272	Some results indicate involvement protein kinase A C orexin responses 93 181 183
0.35575834.12419707.html.plaintext.txt	273	Orexin B reported reduce N methyl D aspartate NMDA induced current amplitude 19 enhance GABA induced current amplitude 48 dissociated rat nucleus accumbens cells 113 could also possibly phosphorylation dependent event
0.35575834.12419707.html.plaintext.txt	274	As discussed Increased synaptic activity orexins may increase transmitter release indicated increaseddecreased synaptic potential frequency
0.35575834.12419707.html.plaintext.txt	275	These direct indications presynaptic effects orexins presence TTX rather certainly suggest presynaptic site orexin effects
0.35575834.12419707.html.plaintext.txt	276	Inhibition K stimulated serotonin release orexin A B rat hypothalamic synaptosomes also directly shows presynaptic site action 140
0.35575834.12419707.html.plaintext.txt	277	There also indirect indications orexin stimulated transmitter release vitro slice norepinephrine rat cerebral cortex Ref
0.35575834.12419707.html.plaintext.txt	278	66 vivo microdialysis histamine rat anterior hypothalamus Ref
0.35575834.12419707.html.plaintext.txt	279	In cases impossible tell whether orexins directly affect releasing neurons upstream neurons complex mechanism suggested delayed 6 min response rat cerebrocortical slices
0.35575834.12419707.html.plaintext.txt	280	cAMP elevation response orexin stimulation reported rat human adrenal cortices putatively via OX1 receptors 110 117
0.35575834.12419707.html.plaintext.txt	281	In contrast primary cultures rat hypothalamic neurons elevation cAMP seen 183
0.35575834.12419707.html.plaintext.txt	282	Elevation cAMP may occur several mechanisms depending isoform adenylyl cyclase expressed
0.35575834.12419707.html.plaintext.txt	283	Adenylyl cyclase isoforms differentially activated Ca2 protein kinase C G protein subunits 171 expression adenylyl cyclase isoforms may different adrenal cortex hypothalamus
0.35575834.12419707.html.plaintext.txt	284	G proteins might also expressed tissue specifically OX1 OX2 receptors could couple different G proteins
0.35575834.12419707.html.plaintext.txt	285	OX2 receptors reported couple Gi Gs Go Gq proteins human fetal adrenal glands 88 Gi Gs Gq Go proteins adult human adrenal glands 146 measured GTP azidoanilide labeling method
0.35575834.12419707.html.plaintext.txt	286	Orexin receptors may also couple protein kinase cascades involved cell growth differentiation death
0.35575834.12419707.html.plaintext.txt	287	These effects clearly seen orexin receptors expressed CHO cells S
0.35575834.12419707.html.plaintext.txt	288	Kukkonen unpublished observation
0.35575834.12419707.html.plaintext.txt	289	One immediate indications rapid activation mitogen activated protein kinase MAPK pathways seen OX1 receptor stimulation Fig
0.35575834.12419707.html.plaintext.txt	290	View larger version 28K Fig
0.35575834.12419707.html.plaintext.txt	291	Mitogen activated protein kinase MAPK activation response OX1 receptor stimulation CHO hOX1 cells S
0.35575834.12419707.html.plaintext.txt	292	Kukkonen unpublished observation
0.35575834.12419707.html.plaintext.txt	293	Extracellular signal regulated kinase ERK1 2 activation measured blotting respective phosphorylated species specific antibodies
0.35575834.12419707.html.plaintext.txt	294	Both 3 100 nM orexin A lead rapid 3 min activation mainly ERK2 response clearly decreased 30 min time point lower concentration
0.35575834.12419707.html.plaintext.txt	295	OX1 OX2 receptors already shown original study different binding affinities orexin A B 154
0.35575834.12419707.html.plaintext.txt	296	When expressed recombinantly CHO cells OX1 receptor 10 times higher affinity orexin A orexin B whereas OX2 receptor binds orexin A B equal affinity
0.35575834.12419707.html.plaintext.txt	297	The selectivity seen respect Ca2 elevation thus orexin A activates OX1 receptors 10 times potently orexin B 138 154 168
0.35575834.12419707.html.plaintext.txt	298	Thus evidence selectivity OX1 receptor nonselectivity OX2 receptor orexin A B based solely studies Ca2 elevation recombinant CHO cells
0.35575834.12419707.html.plaintext.txt	299	It difficult find exclusive expression one subtype tissue cases support selectivity found orexin A 5
0.35575834.12419707.html.plaintext.txt	300	5 fold potent increasing electrical activity rat locus ceruleus OX1 expression dominates 170
0.35575834.12419707.html.plaintext.txt	301	In isolated human adrenocortical cells OX1 mRNA also predominantly found orexin A orexin B stimulates cortisol secretion 117
0.35575834.12419707.html.plaintext.txt	302	In tissues OX2 expression dominates rat tuberomamillary nucleus orexin A B essentially equipotent stimulating electrical activity
0.35575834.12419707.html.plaintext.txt	303	Orexin A B also equally potent releasing catecholamines human pheochromocytoma cells express OX2 mRNA 116
0.35575834.12419707.html.plaintext.txt	304	On hand putatively OX2 mediated adrenocorticotropic hormone ACTH release 10 fold less sensitive orexin B orexin A 13 158
0.35575834.12419707.html.plaintext.txt	305	It generally dangerous rely called selective agonists efficacies dependent receptor G protein expression levels
0.35575834.12419707.html.plaintext.txt	306	For pharmacological reasons chemical differences orexin A B see Genetics Chemistry Orexins conclusions receptor subtype involvement based potency orexin variants 42 113 138 158 probably avoided
0.35575834.12419707.html.plaintext.txt	307	Some studies report higher potency orexin B orexin A respect responses 76 85 unexplainable basis recombinant pharmacology
0.35575834.12419707.html.plaintext.txt	308	Even pharmacological selectivity respect interaction orexin A B orexin receptor subtypes occur tissues physiological significance would unclear
0.35575834.12419707.html.plaintext.txt	309	Molecular determinants required orexin peptides binding activation orexin receptors investigated CHO cells
0.35575834.12419707.html.plaintext.txt	310	Comparison structures activities orexin A B suggests NH2 terminal amino acids less important receptor binding activation COOH terminal amino acids 33
0.35575834.12419707.html.plaintext.txt	311	Truncation orexin A orexin A15 33 reduces potency OX1 OX2 receptors 20 60 fold 33 138 truncation successively abolishes Ca2 response least OX1 33
0.35575834.12419707.html.plaintext.txt	312	Mutation cystine forming cysteines alanines orexin A reduces potency mutant peptides OX1 OX2 receptors 10 fold 138
0.35575834.12419707.html.plaintext.txt	313	However difficult judge whether effect due lost disulfide bridges exchanged cysteines
0.35575834.12419707.html.plaintext.txt	314	One one replacement amino acid orexin A15 33 alanine alanine scan revealed regions particular importance orexin A activation OX1 receptor particular leucines 19 20 COOH terminal aa 26 33 seem great importance 33
0.35575834.12419707.html.plaintext.txt	315	Kukkonen unpublished observations OX1 OX2 receptors approximately equally sensitive NH2 terminal truncation alanine scan orexin peptides
0.35575834.12419707.html.plaintext.txt	316	The amino acids importance largely described Ref
0.35575834.12419707.html.plaintext.txt	317	Changeremoval amino acids affects OX1 OX2 receptors interesting differences seen potency response
0.35575834.12419707.html.plaintext.txt	318	Interestingly none mutated peptides without activity antagonists
0.35575834.12419707.html.plaintext.txt	319	Xenopus orexin B proposed 10 fold higher affinity potency Xenopus orexin A human OX2 receptor expressed CHO cells 163
0.35575834.12419707.html.plaintext.txt	320	Both Xenopus orexin A B equipotent human OX1 receptor
0.35575834.12419707.html.plaintext.txt	321	Synthetic peptides hcrt 1 hcrt 2 based originally described hypocretin sequences 37 shown 1000 fold less potent corresponding orexin peptides respect Ca2 elevation recombinant CHO cells 167
0.35575834.12419707.html.plaintext.txt	322	In 50 studies cellular responses rather high concentrations 100 nM orexins used evoke response
0.35575834.12419707.html.plaintext.txt	323	Even EC50 values determined rather high e
0.35575834.12419707.html.plaintext.txt	324	200 nM orexin A rat locus ceruleus increased firing Ref
0.35575834.12419707.html.plaintext.txt	325	On hand even subnanomolar concentrations evoke responses e
0.35575834.12419707.html.plaintext.txt	326	Ca2 response rat ventral tegmental neurons Ref
0.35575834.12419707.html.plaintext.txt	327	To resolve mechanical basis experiments could performed recombinant expression systems different expression levels measurement different responses
0.35575834.12419707.html.plaintext.txt	328	Another reason high concentrations required tissues may use orexin B OX1 receptor use hypocretins based original sequences weak potencies reported recombinant systems hold true tissues see
0.35575834.12419707.html.plaintext.txt	329	At moment reliable vivo selectivity obtained known orexin receptor agonists
0.35575834.12419707.html.plaintext.txt	330	Recently synthesis orexin receptor subtype selective antagonist reported 145 169
0.35575834.12419707.html.plaintext.txt	331	This antagonist SB 334867 Fig
0.35575834.12419707.html.plaintext.txt	332	1D displays 100 fold higher affinity OX1 OX2 receptor
0.35575834.12419707.html.plaintext.txt	333	This selectivity successfully utilized vivo experiments elucidate role OX1 receptors systemic effects orexins see SYSTEMIC EFFECTS OF OREXINS
0.35575834.12419707.html.plaintext.txt	334	Unfortunately antagonist able block OX2 receptors available
0.35575834.12419707.html.plaintext.txt	335	Conclusions role OX1 receptors physiological processes based solely SB 334867 orexin receptor subtypes may overlapping interacting roles
0.35575834.12419707.html.plaintext.txt	336	However SB 334867 uniquely useful tool orexin receptor investigations
0.35575834.12419707.html.plaintext.txt	337	From perspective unfortunate SB 334867 widely available orexin receptor researchers
0.35575834.12419707.html.plaintext.txt	338	Recently variety peptide transmitters including secretin NPY variants reported inhibit orexin A binding membrane preparations endogenous recombinant cells expressing OX1 receptors even nanomolar affinity 87
0.35575834.12419707.html.plaintext.txt	339	These results interpreted indicate interaction orexinergic NPYergic systems see Connections orexinergic pathways feeding regulating transmittershormones could occur orexin receptor level
0.35575834.12419707.html.plaintext.txt	340	These results binding could however verified functional experiments binding experiments intact cells 67 169
0.35575834.12419707.html.plaintext.txt	341	Other peptides secretin pituitary adenylate cyclase activating polypeptide PACAP NPY variants display detectable affinity activity OX1 OX2 receptors 67 169
0.35575834.12419707.html.plaintext.txt	342	67 likely peptides affect intracellular process instance G protein binding receptor required high affinity agonist binding therefore reduce orexin binding particular preparations
0.35575834.12419707.html.plaintext.txt	343	Therefore secretin used define specific orexin A binding lead possibly erroneous conclusions 86 188
0.35575834.12419707.html.plaintext.txt	344	DISTRIBUTION OF OREXINERGIC CELLS AND OREXIN RECEPTORS TOP ABSTRACT INTRODUCTION OVERVIEW OF OREXINS AND
0.35575834.12419707.html.plaintext.txt	345	CELLULAR RESPONSES TO OREXINS DISTRIBUTION OF OREXINERGIC
0.35575834.12419707.html.plaintext.txt	346	SYSTEMIC EFFECTS OF OREXINS FUTURE PERSPECTIVES REFERENCES
0.35575834.12419707.html.plaintext.txt	347	The distribution orexinergic cells investigated molecular biological immunological methods give rather similar results
0.35575834.12419707.html.plaintext.txt	348	The main peptide investigated orexin A comparison distribution orexin A orexin B preproorexin suggests extensive colocalization
0.35575834.12419707.html.plaintext.txt	349	Therefore data pooled
0.35575834.12419707.html.plaintext.txt	350	Most data orexin distribution originate rat investigated vertebrate species given similar results
0.35575834.12419707.html.plaintext.txt	351	Orexinergic Cell Bodies Rat CNS
0.35575834.12419707.html.plaintext.txt	352	In rat brain orexinergic cell bodies found solely hypothalamus
0.35575834.12419707.html.plaintext.txt	353	Within hypothalamus cell bodies reside bilaterally symmetrically lateral parts probably abundantly perifornical areas 17 24 31 36 37 56 58 69 70 131
0.35575834.12419707.html.plaintext.txt	354	Orexinergic cells interspersed among melanocyte concentrating hormone MCH ergic cells 24 143
0.35575834.12419707.html.plaintext.txt	355	However overlap areas complete 17 MCHergic cells clearly different orexinergic cells 17 43 58 143 although otherwise share properties orexinergic cells 1 69 71
0.35575834.12419707.html.plaintext.txt	356	Isolated orexinergic cell bodies also reported median eminence posterior dorsal dorsomedial hypothalamus arcuate subincertal nuclei 24 31 143
0.35575834.12419707.html.plaintext.txt	357	Orexinergic neurons variable size diameter cell body 15 40 microm shape spherical fusiform multipolar 24 31 36 131 assumed number 1100 3400 whole rat brain 61 143
0.35575834.12419707.html.plaintext.txt	358	Because orexinergic cells shown project orexinergic cells within hypothalamus 69 might different populations orexinergic cells within hypothalamus
0.35575834.12419707.html.plaintext.txt	359	Preproorexin mRNA protein even detected ependymal cell layer 97 143 orexin A found choroid plexi 31
0.35575834.12419707.html.plaintext.txt	360	It would interesting find whether expression occurs ependymal cells instance neuronal stem cells
0.35575834.12419707.html.plaintext.txt	361	Orexinergic Projections Rat CNS
0.35575834.12419707.html.plaintext.txt	362	Orexinergic fibers visualized mainly using orexin A immunohistochemistry
0.35575834.12419707.html.plaintext.txt	363	For orexin A smooth varicose fibers observed 31 143 varicose fibers appear ones often seen although result might also caused easier detection kind processes
0.35575834.12419707.html.plaintext.txt	364	A studies investigating orexin B distribution report projection sites similar orexin A 31 36
0.35575834.12419707.html.plaintext.txt	365	Despite low number orexinergic cell bodies hypothalamus orexinergic fibers project widely CNS
0.35575834.12419707.html.plaintext.txt	366	The important orexinergic projection areas within hypothalamus two thalamic nuclei brain stem whole length spinal cord Table 1 see also Fig
0.35575834.12419707.html.plaintext.txt	367	Interested readers recommended consult original papers detailed 24 31 34 36 37 61 69 71 97 125 126 154 182
0.35575834.12419707.html.plaintext.txt	368	View table Table 1
0.35575834.12419707.html.plaintext.txt	369	Orexin distribution rat central nervous system
0.35575834.12419707.html.plaintext.txt	370	View larger version 27K Fig
0.35575834.12419707.html.plaintext.txt	371	Orexinergic pathways according Refs
0.35575834.12419707.html.plaintext.txt	372	24 31 34 36 37 61 69 71 125 126 154 182 orexin receptor mRNA distribution according Refs
0.35575834.12419707.html.plaintext.txt	373	Only minority sites shown
0.35575834.12419707.html.plaintext.txt	374	The density hatching 3 different levels indicates OX1 OX2 receptor mRNA expression levels
0.35575834.12419707.html.plaintext.txt	375	It noted subregions within marked regions display different expression e
0.35575834.12419707.html.plaintext.txt	376	hypothalamus cannot shown figure
0.35575834.12419707.html.plaintext.txt	377	When data 2 references diverging even contradictory average taken
0.35575834.12419707.html.plaintext.txt	378	Arcn arcuate nucleus CA1 3 areas hippocampus cC cingulate cortex CMn centromedial nucleus dR dorsal raphe nucleus LC locus ceruleus mE median eminence mR median raphe nucleus nST nucleus solitary tract olfB olfactory bulb olfT olfactory tubercle PVn paraventricular nucleus thalamus hypothalamus Rm nucleus raphe magnus Ro nucleus raphe obscurus SCn suprachiasmatic nucleus SOn supraoptic nucleus STn spinal trigeminal nucleus TMn tuberomamillary nucleus VAMn ventral anteromedial nucleus
0.35575834.12419707.html.plaintext.txt	379	Orexins CNS Other Species
0.35575834.12419707.html.plaintext.txt	380	Only studies conducted species rat
0.35575834.12419707.html.plaintext.txt	381	However studies performed results seem good agreement studies rat
0.35575834.12419707.html.plaintext.txt	382	In several vertebrate species Table 2 orexinergic cells found hypothalamic areas similar rat
0.35575834.12419707.html.plaintext.txt	383	The cells assumed number 20000 50000 83000 dog human brain respectively 148 178
0.35575834.12419707.html.plaintext.txt	384	The projection areas also appear similar rat species Table 2 however studies limited areas investigated making full conclusions impossible
0.35575834.12419707.html.plaintext.txt	385	Also species orexinergic neurites often determined varicose
0.35575834.12419707.html.plaintext.txt	386	View table Table 2
0.35575834.12419707.html.plaintext.txt	387	Distribution orexinergic cells pathways species
0.35575834.12419707.html.plaintext.txt	388	Similarly orexins orexin receptor distribution investigated molecular biological immunological methods
0.35575834.12419707.html.plaintext.txt	389	Almost data originate rat
0.35575834.12419707.html.plaintext.txt	390	Altogether orexin receptors found projection sites orexinergic neurons see suggests orexinergic neurons contact many different transmitter systems see
0.35575834.12419707.html.plaintext.txt	391	Most studies specified whether expression seen neurons cells although electrophysiological measurements whenever performed indicate activation neurons
0.35575834.12419707.html.plaintext.txt	392	Levels orexin receptors necessarily fully follow density orexinergic innervation
0.35575834.12419707.html.plaintext.txt	393	Only cases synaptic contacts anatomically shown 48 55 70 195
0.35575834.12419707.html.plaintext.txt	394	Localization orexinergic cellsprocesses close ventricular surfaces 24 31 97 143 suggests orexins could act paracrine endocrine fashion
0.35575834.12419707.html.plaintext.txt	395	Similar amounts OX1 OX2 mRNA found rat brain whole OX1 OX2 receptor mRNAs mostly show similar distribution although differences seen Fig
0.35575834.12419707.html.plaintext.txt	396	Most interesting areas essentially one subtype expressed 111 180
0.35575834.12419707.html.plaintext.txt	397	However mRNA expression may directly correspond receptor protein expression discussed van den Pol et al
0.35575834.12419707.html.plaintext.txt	398	The correlation receptor distribution different functions orexinergic system shown Table 3
0.35575834.12419707.html.plaintext.txt	399	While article review studies expression OX1 OX2 receptor protein rat CNS published 30 64
0.35575834.12419707.html.plaintext.txt	400	A particularly interesting finding expression OX2 receptor protein molecular granular layers cerebellum 30 earlier studies failed detect orexin receptors mRNA cerebellum although orexinergic fibers projecting cerebellum
0.35575834.12419707.html.plaintext.txt	401	Otherwise immunohistochemical studies suggest distribution generally similar mRNA measurements although differences seen
0.35575834.12419707.html.plaintext.txt	402	For instance greater overlap expression OX1 OX2 receptors suggested basis immunological studies situ hybridization
0.35575834.12419707.html.plaintext.txt	403	As discussed authors differences may degree related fact mRNA measurements visualize expressing cell bodies whereas immunohistochemistry indicates actual cellular localization protein
0.35575834.12419707.html.plaintext.txt	404	Both receptor mRNA protein measurements semiquantitative rather quantitative allow absolute comparison subtype expression within site
0.35575834.12419707.html.plaintext.txt	405	View table Table 3
0.35575834.12419707.html.plaintext.txt	406	Orexin receptor mRNA distribution respect postulated functions
0.35575834.12419707.html.plaintext.txt	407	Coexpression Connections Orexins With Other Transmitters
0.35575834.12419707.html.plaintext.txt	408	Despite partial overlap distribution orexinergic MCHergic cell bodies coexpression peptides cells Refs
0.35575834.12419707.html.plaintext.txt	409	In contrast essentially orexin prodynorphin expression colocalizes lateral hypothalamus 10 27
0.35575834.12419707.html.plaintext.txt	410	Orexinergic neurons may also coexpress transmitters galanin 58 glutamate 1
0.35575834.12419707.html.plaintext.txt	411	View larger version 26K Fig
0.35575834.12419707.html.plaintext.txt	412	Some connections lateral hypothalamic orexinergic neurons transmittershormones
0.35575834.12419707.html.plaintext.txt	413	Orexinergic cells also express dynorphin least also express Ob Rb long form leptin receptor leptin receptor activated promoter element STAT3
0.35575834.12419707.html.plaintext.txt	414	Subpopulations orexinergic cells may release galanin glutamate references see text
0.35575834.12419707.html.plaintext.txt	415	Thin black arrows indicate input orexinergic cells thick gray arrows indicate orexinergic output
0.35575834.12419707.html.plaintext.txt	416	Anatomic loci Arcn LC laterodorsal tegmental nucleus LDTn lateral hypothalamus LH hypothalamic periventricular nucleus PeVn preoptic area POA PVn raphe nuclei Raphe n SCn substantia nigra SN TMn ventral tegmental area VTA
0.35575834.12419707.html.plaintext.txt	417	ACh acetylcholine AGRP agouti gene related peptide AVP arginine vasopressin CART cocaineamphetamine regulated transcript CRF corticotropin releasing hormone DA dopamine 5 HT 5 hydroxytryptamine serotonin Glu glutamate HA histamine MCH melanocyte concentrating hormone NE norepinephrine NPY neuropeptide Y POMC proopiomelanocortin SSt somatostatin VIP vasoactive intestinal peptide
0.35575834.12419707.html.plaintext.txt	418	View larger version 14K Fig
0.35575834.12419707.html.plaintext.txt	419	Some connections orexins appetite regulating transmittershormones hypothalamus
0.35575834.12419707.html.plaintext.txt	420	Arrows marked indicate stimulation inhibition respectively neuronal activity release synthesis hormones affected site plus minus indicates either stimulatory inhibitory effects different conditions toward similar cells different anatomic loci
0.35575834.12419707.html.plaintext.txt	421	Unmarked arrows indicate connections unknown effects
0.35575834.12419707.html.plaintext.txt	422	As indicated text orexinergic neurons may either respond glucose reciprocal connections glucose sensitive GSN glucose responding GRN neurons
0.35575834.12419707.html.plaintext.txt	423	Thus clear whether effect glucose neurons LH Arcn direct mediated sensor neurons therefore glucose GSN GRN grouped figure dotted line
0.35575834.12419707.html.plaintext.txt	424	Solid lines indicate anatomically defined hypothalamic areas
0.35575834.12419707.html.plaintext.txt	425	Vasoactive intestinal peptide VIP vasopressin NPY containing neurons innervate orexinergic neurons hypothalamus Refs
0.35575834.12419707.html.plaintext.txt	426	On hand orexinergic nerves lateral hypothalamus innervate neuronal circuits utilize many different transmitters instance norepinephrine dopamine serotonin histamine acetylcholine vasopressin VIP somatostatin corticotropin releasing hormone CRF NPYagouti gene related peptide AGRP proopiomelanocortin POMC cocaine amphetamine regulated transcript CART GABA MCH glutamate Figs
0.35575834.12419707.html.plaintext.txt	427	8 9 anatomy see e
0.35575834.12419707.html.plaintext.txt	428	5 31 36 131 143 even functional responses orexins shown sites e
0.35575834.12419707.html.plaintext.txt	429	9 18 19 42 44 49 56 70 80 93 113 130 159 165 170 183 195 see CELLULAR RESPONSES TO OREXINS
0.35575834.12419707.html.plaintext.txt	430	Orexinergic neurons even make contact orexinergic neurons within hypothalamus 5 69
0.35575834.12419707.html.plaintext.txt	431	Connections orexinergic pathways feeding regulating transmittershormones
0.35575834.12419707.html.plaintext.txt	432	Orexins first isolated appetite increasing peptides although view later disputed
0.35575834.12419707.html.plaintext.txt	433	Several hypothalamic sites involved regulation feeding lateral hypothalamic area parvocellular paraventricular nucleus ventromedial nucleus arcuate nucleus innervated orexinergic fibers lateral hypothalamic area see e
0.35575834.12419707.html.plaintext.txt	434	Both OX1 OX2 receptors may expressed projection areas 111
0.35575834.12419707.html.plaintext.txt	435	There abundant connections orexin feeding regulating transmittershormones leptin NPY MCH POMC CART galanin AGRP Figs
0.35575834.12419707.html.plaintext.txt	436	Almost orexin positive cells also express leptin receptor even STAT3the leptin receptor activated promoter elementand orexin coexpressed Refs
0.35575834.12419707.html.plaintext.txt	437	8 see also Effects orexins gastrointestinal tract organs feedingenergy metabolism
0.35575834.12419707.html.plaintext.txt	438	On hand leptin receptor positive cells lateral hypothalamic areas orexinergic cell bodies lie orexin positive 58
0.35575834.12419707.html.plaintext.txt	439	Other cells express leptin receptors MCHergic neurons lateral hypothalamus NPY AGRP POMC CARTergic cells arcuate nucleus Refs
0.35575834.12419707.html.plaintext.txt	440	Orexinergic fibers project NPY POMCergic cells arcuate nucleus 69
0.35575834.12419707.html.plaintext.txt	441	On hand NPYAGRP POMCergic fibers likely arcuate nucleus project orexin MCHergic cells lateral hypothalamus 17 43 55 69 71
0.35575834.12419707.html.plaintext.txt	442	Orexinergic cells lateral hypothalamus also contain feeding regulating transmitters dynorphin galanin Refs
0.35575834.12419707.html.plaintext.txt	443	9 may enhance effects orexins feeding
0.35575834.12419707.html.plaintext.txt	444	Responses orexinergic cells feeding stimuli
0.35575834.12419707.html.plaintext.txt	445	Hypoglycemia induced various means shown increase c fos see orexin preproorexin mRNA expression subpopulation orexinergic cells lateral hypothalamus 16 20 22 53 99 105 127 see also Effects orexins gastrointestinal tract organs feedingenergy metabolism
0.35575834.12419707.html.plaintext.txt	446	Fasting also abolishes circadian variation CSF orexin levels 47
0.35575834.12419707.html.plaintext.txt	447	The lateral hypothalamic area well hypothalamic regions contains neurons activated decreased levels glucose glucose sensitive neurons neurons activated elevated levels glucose glucose responsive neurons Ref
0.35575834.12419707.html.plaintext.txt	448	129 almost half histochemically defined orexinergic neurons rat lateral hypothalamus directly responded lowering extracellular glucose increase cytosolic Ca2 thus glucose sensitive neurons lateral hypothalamus may orexinergic
0.35575834.12419707.html.plaintext.txt	449	103 identified glucose sensitive responsive indifferent populations among rat hypothalamic neurons responded orexin stimulation depolarization increased firing rate
0.35575834.12419707.html.plaintext.txt	450	In contrast orexin A suppressed firing rate glucose responsive neurons rat ventromedial hypothalamic nucleus 164
0.35575834.12419707.html.plaintext.txt	451	Orexinergic neurons may also make contact andor contacted glucose sensitive responsive neurons brain areas lateral hypothalamus ventromedial hypothalamus arcuate nucleus nucleus solitary tract Ref
0.35575834.12419707.html.plaintext.txt	452	101 see also anatomic studies orexinergic projections
0.35575834.12419707.html.plaintext.txt	453	Leptin thought one major negative regulators orexin expression hypothalamus see Effects Orexins Feeding Behavior probably directly via leptin receptors orexinergic cells via leptin receptors feeding controlling cells connected orexinergic cells see
0.35575834.12419707.html.plaintext.txt	454	Attempts elucidate leptin orexin interaction measurement orexin orexin mRNA levels made rodent model systems defective leptin signaling fafa Zucker rats dbdb mice devoid functional leptin receptors obob mice devoid leptin reviewed Ref
0.35575834.12419707.html.plaintext.txt	455	The results however contradictory conclusion drawn leptin necessarily required keep orexin expression low
0.35575834.12419707.html.plaintext.txt	456	However also often knockout systems difficult evaluate physiological role possible multiple disturbances redundancy signaling compensatory mechanisms
0.35575834.12419707.html.plaintext.txt	457	Orexins Orexin Receptors Outside CNS
0.35575834.12419707.html.plaintext.txt	458	Orexin immunoreactivity preproorexin mRNA found variety peripheral organs mainly rat
0.35575834.12419707.html.plaintext.txt	459	The cells expressing orexins cases identified include neurons endocrine cells
0.35575834.12419707.html.plaintext.txt	460	pituitary pineal gland may originate neurons hypothalamus peripheral neurons appear peripheral origin
0.35575834.12419707.html.plaintext.txt	461	Orexin receptorsreceptor mRNA mainly found organs orexins
0.35575834.12419707.html.plaintext.txt	462	The cell types expressing orexin receptors might include least endocrine muscle nerve cells 84 92 108 117 133
0.35575834.12419707.html.plaintext.txt	463	Even periphery expression subtypes varies different tissues
0.35575834.12419707.html.plaintext.txt	464	Orexin orexin receptor immunoreactivity found gastrointestinal tract pancreas rat guinea pig human Refs
0.35575834.12419707.html.plaintext.txt	465	Substantial levels orexin A B OX1 OX2 mRNA protein found rat pituitary 13 35 84 Johren et al
0.35575834.12419707.html.plaintext.txt	466	84 found preproorexin OX1 mRNA rat testis
0.35575834.12419707.html.plaintext.txt	467	Both OX1 mRNA OX2 mRNA immunoreactivity found rat human adrenal glands 12 84 104 108 109 although subtype expression different layers somewhat disputed may differences species see e
0.35575834.12419707.html.plaintext.txt	468	Only OX1 mRNA found kidney thyroid OX2 mRNA lung 84
0.35575834.12419707.html.plaintext.txt	469	Orexinergic fibers extend CNS toward rat pineal gland OX2 mRNA detected pineal gland 121
0.35575834.12419707.html.plaintext.txt	470	View table Table 4
0.35575834.12419707.html.plaintext.txt	471	View table Table 5
0.35575834.12419707.html.plaintext.txt	472	Orexin receptors periphery
0.35575834.12419707.html.plaintext.txt	473	However expression preproorexin orexin receptor message stomach gut pancreas lung kidney pituitary adrenal gland disputed 31 84 154
0.35575834.12419707.html.plaintext.txt	474	Some differences may explained less sensitive methods Northern blotting failing detect signal sensitive methods PCR situ hybridization
0.35575834.12419707.html.plaintext.txt	475	In contrast difficult explain opposite receptor subtype expression reported human adrenal cortex 117 146
0.35575834.12419707.html.plaintext.txt	476	SYSTEMIC EFFECTS OF OREXINS TOP ABSTRACT INTRODUCTION OVERVIEW OF OREXINS AND
0.35575834.12419707.html.plaintext.txt	477	CELLULAR RESPONSES TO OREXINS DISTRIBUTION OF OREXINERGIC
0.35575834.12419707.html.plaintext.txt	478	SYSTEMIC EFFECTS OF OREXINS FUTURE PERSPECTIVES REFERENCES
0.35575834.12419707.html.plaintext.txt	479	The location orexinergic cells projections contacts transmitter systems suggest role eating sleepwakefulness neuroendocrine autonomic functions
0.35575834.12419707.html.plaintext.txt	480	It sometimes difficult judge basis available experimental evidence whether particular systemic response orexins caused indirectly directly target organs
0.35575834.12419707.html.plaintext.txt	481	In cases direct effects orexins isolated organs even isolated cells demonstrated trying highlight kind evidence
0.35575834.12419707.html.plaintext.txt	482	Effects Orexins Feeding Behavior
0.35575834.12419707.html.plaintext.txt	483	In original publication dealing orexins shown intracerebroventricular injection orexins induces feeding rats 154
0.35575834.12419707.html.plaintext.txt	484	When injected different hypothalamic sites rat orexin A effective narrow area perifornical area lateral hypothalamus dorsomedial paraventricular nuclei preoptic area arcuate ventromedial nucleus whereas orexin B inactive 39 173
0.35575834.12419707.html.plaintext.txt	485	Some hypothalamic nuclei possibly involved feeding responses orexins listed Table 3
0.35575834.12419707.html.plaintext.txt	486	Intraperitoneally injected OX1 receptor antagonist SB 334867 inhibits baseline feeding normal weight gain feeding response orexin injection hypothalamus 62 150
0.35575834.12419707.html.plaintext.txt	487	The feeding stimulating effect fasting blocked intracisternally administered anti orexin A antibodies 192 intraperitoneal SB 334867 62
0.35575834.12419707.html.plaintext.txt	488	This suggests least OX1 receptor involved natural regulation feeding orexin receptor subtypes expressed nuclei involved regulation feeding Refs
0.35575834.12419707.html.plaintext.txt	489	Orexin A increases c fos expression areas energy regulatory sites within hypothalamus limbic region hindbrain 128
0.35575834.12419707.html.plaintext.txt	490	As mentioned see CELLULAR RESPONSES TO OREXINS orexins belong regulatory network peptides including NPY MCH AGRP galanin POMC products CART dynorphin regulate feeding behavior
0.35575834.12419707.html.plaintext.txt	491	Orexins appear act upstream NPY antagonists NPY Y1 Y5 receptors block orexin stimulated feeding 38 81
0.35575834.12419707.html.plaintext.txt	492	The degree orexins regulate long term food intake subject debate data indicate rather orexin induced food intake acute effect evened compensatory decrease food intake within 24 h see e
0.35575834.12419707.html.plaintext.txt	493	It speculated part orexin induced food intake secondary increased wakefulness activity therefore following increased energy expenditure
0.35575834.12419707.html.plaintext.txt	494	A general view emerging different results orexins may participate short term regulation energy homeostasis initiating feeding response falls glucose subsequent increase glucose leptin visceral signals would decrease orexin turn would terminate behavior food ingestion Refs
0.35575834.12419707.html.plaintext.txt	495	Mapping orexinergic projections indicates orexins could also involved overall regulation feeding
0.35575834.12419707.html.plaintext.txt	496	For instance nucleus solitary tract sensory trigeminal nucleus lamina 1 10 sacral cord receive afferents mouth gastrointestinal tract dorsal motor nucleus vagus motor trigeminal nucleus intermediolateral cell column sacral parasympathetic nucleus give rise nerves innervate gastrointestinal tract muscles mastication 31 34 36 131 143 182 198
0.35575834.12419707.html.plaintext.txt	497	Therefore tempting suggest central orexinergic nerves could involved primary eating process via sensory motor innervation mouth passage food gastrointestinal tract via sensory motor secretomotor innervation intestines
0.35575834.12419707.html.plaintext.txt	498	Peripheral orexinergic neurons endocrine release orexins e
0.35575834.12419707.html.plaintext.txt	499	enterochromaffin cells could affect intestinal motility endo exocrine secretion uptake sensory signaling gastrointestinal tract see Effects orexins gastrointestinal tract organs feedingenergy metabolism
0.35575834.12419707.html.plaintext.txt	500	Some direct data 6 106 124 175 186 197 indirect observations narcoleptic patients animal models 23 60 162 193 suggest orexins may affect metabolic rate heat loss related processes
0.35575834.12419707.html.plaintext.txt	501	An overall role energy metabolism also suggested effects orexins release hormones especially adrenal steroids see Orexins AutonomicEndocrine Functions
0.35575834.12419707.html.plaintext.txt	502	Involvement Orexins SleepWakefulness
0.35575834.12419707.html.plaintext.txt	503	Regulation sleepwakefulness well demonstrated systemic effect orexinergic pathways
0.35575834.12419707.html.plaintext.txt	504	At anatomic level orexinergic neurons present project multitude nuclei different levels CNS involved sleeparousal
0.35575834.12419707.html.plaintext.txt	505	Orexin receptorsreceptor mRNAs observed areas
0.35575834.12419707.html.plaintext.txt	506	OX1 OX2 receptor mRNA expression within areas suggests receptor subtypes involved Table 3
0.35575834.12419707.html.plaintext.txt	507	Injection orexin A rat cerebral ventricles specific CNS sites rat cat increases wakefulness decreases sleep 15 45 56 72 120 144
0.35575834.12419707.html.plaintext.txt	508	Most markedly effects seen decreased rapid eye movement REM sleep slow wave sleep episode number duration
0.35575834.12419707.html.plaintext.txt	509	A profound role histaminergic systems processes suggested results show effects orexin A mouse blocked histamine H1 receptor antagonists gene disruption 72 195
0.35575834.12419707.html.plaintext.txt	510	Narcoleptic dogs disrupted OX2 receptors decreased brain histamine content 134 OX2 receptor seems responsible orexin effects tuberomamillary nucleus even rat 44 195
0.35575834.12419707.html.plaintext.txt	511	Expression c fos shown increase mainly orexin positive cells hypothalamus time normal waking rats c fos expression also increased sleep deprivation antinarcoleptic drugs metamphetamine mofanadil 23 46 161
0.35575834.12419707.html.plaintext.txt	512	Cellular responses orexins observed areas involved sleep
0.35575834.12419707.html.plaintext.txt	513	Orexins excite neurons rat locus ceruleus 56 70 80 170 dorsal raphe nucleus 18 tuberomamillary nucleus 9 44 mouse laterodorsal tegmental nucleus 19 see CELLULAR RESPONSES TO OREXINS
0.35575834.12419707.html.plaintext.txt	514	Even areas OX1 OX2 receptors seem overlapping roles
0.35575834.12419707.html.plaintext.txt	515	Orexinergic systems sleep wakefulness well knockout phenotypes discussed Narcolepsy Disorder Orexinergic System
0.35575834.12419707.html.plaintext.txt	516	Orexins AutonomicEndocrine Functions
0.35575834.12419707.html.plaintext.txt	517	Orexinergic efferents project particular areas brain stem spinal cord suggest direct involvement autonomic afferents efferents pain transmission 11 31 34 122 182
0.35575834.12419707.html.plaintext.txt	518	Autonomic effects manifested increased blood pressure heart rate intestinal motility see gastric acid secretion 138 177 sympathetic nerve activity 98 124 166 response intracerebroventricular orexin A
0.35575834.12419707.html.plaintext.txt	519	When administered intravenously orexin A induces analgesia thermal nociception paradigms 11
0.35575834.12419707.html.plaintext.txt	520	This effect orexin A blocked OX1 receptor antagonist SB 334867even baselinebut naloxone suggesting opiate independent mechanism
0.35575834.12419707.html.plaintext.txt	521	Orexins may affect water balance via effects drinking watersalt homeostasis mechanisms involved blood pressure regulation suggested anatomy projections 24 31 34 36 37 61 69 71 125 126 154 182
0.35575834.12419707.html.plaintext.txt	522	In fact intracerebroventricular orexin A B increase water intake rat 98 149
0.35575834.12419707.html.plaintext.txt	523	Injection orexin A B particular brain stem sites increases mean arterial pressure heart rate rat 3 25 156 166
0.35575834.12419707.html.plaintext.txt	524	To extent effects may mediated increased release hormones norepinephrine 3 166
0.35575834.12419707.html.plaintext.txt	525	Release many hormones hypothalamus shown affected orexins
0.35575834.12419707.html.plaintext.txt	526	Orexins may regulate hypothalamo hypophysial hormone secretion indirectly via neuronal circuits even direct effect hypophysis possible orexins found median eminence 35 125 mRNA orexin receptor subtypes found anterior intermediate hypophysial lobes 35
0.35575834.12419707.html.plaintext.txt	527	13 identify coexpression growth hormone OX1 receptors acidophil cells adenohypophysis coexpression ACTH OX2 receptors pars intermedia basophil cells adenohypophysis
0.35575834.12419707.html.plaintext.txt	528	Orexins orexin receptors also found low levels posterior hypophysial lobe
0.35575834.12419707.html.plaintext.txt	529	Altogether OX1 OX2 mRNA expressed areas involved neuroendocrine regulation 111
0.35575834.12419707.html.plaintext.txt	530	Stimulatory effect release multiple levels hypothalamo hypophysio adrenal axis reported see Orexinergic regulation hypothalamo hypophysio adrenal axis stress response
0.35575834.12419707.html.plaintext.txt	531	Orexin A injected intravenously directly hypothalamic paraventricular nucleus decreases TSH release rat 123 153 change seen plasma levels thyroid hormones 123 153
0.35575834.12419707.html.plaintext.txt	532	Intracerebroventricular orexin A decreases growth hormone release rat 56
0.35575834.12419707.html.plaintext.txt	533	Effects release hormones also reported results equivocal
0.35575834.12419707.html.plaintext.txt	534	Some release effects shown hypothalamic explants vitro orexin A stimulates release neurotensin NPY VIP somatostatin luteinizing hormone releasing hormone LHRH decreases release TRH effect release dopamine vasopressin MCH 123 151 152
0.35575834.12419707.html.plaintext.txt	535	Orexinergic regulation hypothalamo hypophysio adrenal axis stress response
0.35575834.12419707.html.plaintext.txt	536	Intracerebroventricular administration orexin A increases plasma levels CRF ACTH corticosterone vasopressin epinephrine rat 2 56 78 82 83 85 151 152
0.35575834.12419707.html.plaintext.txt	537	CRF release suggested mediated elevated NPY acting Y1 receptors 83 152 placing NPY downstream orexins even system
0.35575834.12419707.html.plaintext.txt	538	Orexin A even stimulate CRF release vitro 151
0.35575834.12419707.html.plaintext.txt	539	A CRF receptor antagonist reported block orexin stimulated plasma corticosterone elevation rat 82 159 hand orexins reported inhibit CRF stimulated ACTH release cultured rat adenohypophysial cells 158
0.35575834.12419707.html.plaintext.txt	540	Orexins also reported stimulate release corticosteronecortisol 108 110 117 aldosterone 108 132 rat porcine human adrenal glandsadrenal cells vitro
0.35575834.12419707.html.plaintext.txt	541	This release independent ACTH 110 117
0.35575834.12419707.html.plaintext.txt	542	Corticosteronecortisol release determined co occur cAMP elevation probably depend rat 110 human 117
0.35575834.12419707.html.plaintext.txt	543	This together lack additivity orexin A ACTH suggests peptides utilize mechanism glucocorticoid release 117
0.35575834.12419707.html.plaintext.txt	544	In contrast direct effect rat adrenal slices seen Jaszberenyi et al
0.35575834.12419707.html.plaintext.txt	545	In study long term 7 day exposure orexin A orexin B plasma levels aldosterone corticosterone CRF ACTH elevated rat 108
0.35575834.12419707.html.plaintext.txt	546	Release epinephrine norepinephrine rat adrenal medulla increased intracerebroventricular orexins 166 similar although smaller effect seen cultured porcine adrenal medullar cells 132
0.35575834.12419707.html.plaintext.txt	547	Both OX1 OX2 receptor mRNA suggested expressed rat adrenal medulla 104 although studies present opposing views 84
0.35575834.12419707.html.plaintext.txt	548	Orexin mediated increases CRF ACTH corticosterone aldosterone vasopressin epinephrine release suggest orexins could mediate stress responses
0.35575834.12419707.html.plaintext.txt	549	Interesting context orexins increase particular stereotypic behavioral patterns grooming face washing burrowing may related activation stress response 40 45 77 78
0.35575834.12419707.html.plaintext.txt	550	Orexin A induced grooming inhibited OX1 receptor block SB 334867 40 CRF receptor antagonist inhibits orexin induced face washing grooming 50 shift rest locomotor activity 70 80 78
0.35575834.12419707.html.plaintext.txt	551	Involvement complex pathways highlighted inhibitory effects dopamine serotonin receptor antagonists 40 115 130
0.35575834.12419707.html.plaintext.txt	552	It noted orexins increase wakefulness andor activity rat therefore important able separate effects stress response
0.35575834.12419707.html.plaintext.txt	553	Effects orexins gastrointestinal tract organs feedingenergy metabolism
0.35575834.12419707.html.plaintext.txt	554	In gastrointestinal tract neurons endocrine cells may express orexins 92 133
0.35575834.12419707.html.plaintext.txt	555	In neurons orexin immunoreactivity seen submucosal myenteric plexi
0.35575834.12419707.html.plaintext.txt	556	Orexinergic neurons plexi suggested sensory secretomotor basis coexpression markers VIP choline acetyltransferase 92 133
0.35575834.12419707.html.plaintext.txt	557	The neurites project orexin containing cells mucosa muscle layers submucosal blood vessels
0.35575834.12419707.html.plaintext.txt	558	In guinea pig orexin positive neurons submucosal myenteric plexi express leptin receptors well 92
0.35575834.12419707.html.plaintext.txt	559	Fasting increases number orexin A immunoreactive submucosal neurons guinea pig also become positive phospho cAMP response element binding protein pCREB 92
0.35575834.12419707.html.plaintext.txt	560	This similar c fos expression indicates activation neurons suggesting fasting activates central peripheral orexinergic systems
0.35575834.12419707.html.plaintext.txt	561	Also endocrine cells gut stomachsome enterochromaffin express serotonindisplay orexin immunoreactivity mouse rat guinea pig human 92 133
0.35575834.12419707.html.plaintext.txt	562	Interestingly enterochromaffin cells rat also 1 express orexin receptors OX2 2 localized close proximity orexinergic nerve fibers 133
0.35575834.12419707.html.plaintext.txt	563	At cellular level orexin A induces electrical responses guinea pig submucosal neurons see CELLULAR RESPONSES TO OREXINS
0.35575834.12419707.html.plaintext.txt	564	Thus orexinergic neurons gastrointestinal tract could affect intestinal secretion uptake endocrine secretion sensory signaling intestinal motility
0.35575834.12419707.html.plaintext.txt	565	Different effects intestinal motility patterns indeed measured mouse rat small intestine 133 160 guinea pig distal colon 92
0.35575834.12419707.html.plaintext.txt	566	Different orexin receptor subtypes different distribution gastrointestinal tract OX1 receptor immunoreactivity solely expressed submucosal myenteric neurons whereas OX2 receptor immunoreactivity seen enterochromaffin cells rat 133
0.35575834.12419707.html.plaintext.txt	567	Energy metabolism regulated several hormones important pancreatic glucagon insulin hypophysial growth hormone glucocorticoids norepinephrine thyroid hormones
0.35575834.12419707.html.plaintext.txt	568	Effects orexins glucocorticoid growth hormone release discussed
0.35575834.12419707.html.plaintext.txt	569	Insulin release somewhat increased rat intracerebroventricular 114 subcutaneous 137 174 injection orexin A also rat pancreas vitro 137
0.35575834.12419707.html.plaintext.txt	570	Extrinsic neurons rat guinea pig pancreatic ganglia display orexin OX1 OX2 receptor immunoreactivity 92
0.35575834.12419707.html.plaintext.txt	571	Plasma leptin also increased subcutaneous injection orexin A B rat although suggested occur via increased insulin release 174
0.35575834.12419707.html.plaintext.txt	572	Narcolepsy Disorder Orexinergic System
0.35575834.12419707.html.plaintext.txt	573	Narcolepsy disorder short characterized abnormal inclusion REM sleep features muscle paralysis hallucinations waking state sleepwaking transition state
0.35575834.12419707.html.plaintext.txt	574	In addition hypersomnia often observed
0.35575834.12419707.html.plaintext.txt	575	Narcolepsy humans usually sporadic disease strong association major histocompatibility complex antigens especially HLA DRB115 HLA DQA10102 HLA DQB10602 long time suggested relate autoimmune process
0.35575834.12419707.html.plaintext.txt	576	Yet autoantibodies signs ongoing previous inflammation hard find reviewed Refs
0.35575834.12419707.html.plaintext.txt	577	This could however caused 1 fact postmortem narcoleptic brains usually investigated years disease onset 2 dispersed nature orexinergic cells
0.35575834.12419707.html.plaintext.txt	578	Orexin A undetectable CSF human narcoleptic patients 32 135 number orexinergic neurons postmortem narcoleptic brains much reduced 142 178 even signs gliosis observed 178
0.35575834.12419707.html.plaintext.txt	579	At time MCHergic neurons brain areas present normal numbers 142 178
0.35575834.12419707.html.plaintext.txt	580	This together animal model systems see led hypothesis narcolepsy disease orexinergic neurons
0.35575834.12419707.html.plaintext.txt	581	As support one clearly debilitating preproorexin orexin receptor mutation found human subjects Ref
0.35575834.12419707.html.plaintext.txt	582	In mouse depletion hypothalamus orexins results narcoleptic phenotype
0.35575834.12419707.html.plaintext.txt	583	This accomplished genetic disruption preproorexin gene orexin knockout mouse Ref
0.35575834.12419707.html.plaintext.txt	584	23 genetic destruction orexinergic cells preproorexin ataxin 3 knockin mouse 60 toxic destruction orexinergic cells hypothalamic injection orexin B saporin conjugate 52
0.35575834.12419707.html.plaintext.txt	585	In dogs narcolepsy mainly familial disorder
0.35575834.12419707.html.plaintext.txt	586	Recently familial canine narcolepsy Doberman pinschers Labrador retrievers shown caused mutations OX2 receptor gene 102
0.35575834.12419707.html.plaintext.txt	587	In cases mutations cause premature amino acid chain termination
0.35575834.12419707.html.plaintext.txt	588	When expressed heterologously HEK293 cells mutant receptors mainly remain intracellular compartments neither bind orexin A activate Ca2 mobilization 73
0.35575834.12419707.html.plaintext.txt	589	Point mutation Glu54Lys NH2 terminusfirst transmembrane segment junction OX2 receptor also leads reduced orexin A binding 400 fold reduced potency Ca2 elevation expressed HEK293 cells 73
0.35575834.12419707.html.plaintext.txt	590	The 10 reported mutations preproorexin OX2 receptor genes thought represent benign polymorphisms 73
0.35575834.12419707.html.plaintext.txt	591	Sporadic cases canine narcolepsy suggested caused lack orexins 148
0.35575834.12419707.html.plaintext.txt	592	OX1 OX2 receptor gene abnormalities considered responsible human narcoleptic cases 26 single base changes 11 aa changes found healthy narcoleptic human subjects Refs
0.35575834.12419707.html.plaintext.txt	593	139 142 see also Genetics Chemistry Orexins introns coding regions supposed represent benign polymorphisms
0.35575834.12419707.html.plaintext.txt	594	One polymorphism concerns reported sequence OX1 receptors aa 280 see Genetics Chemistry Orexins although could sequencing error
0.35575834.12419707.html.plaintext.txt	595	One mutation Leu16Arg found 5 signal peptide region human preproorexin gene probably results early onset severe narcolepsy 142
0.35575834.12419707.html.plaintext.txt	596	When transiently expressed Neuro 2A cells mutated peptide apparently accumulated tubular network presumably smooth endoplasmic reticulum ER contrast wild type preproorexin appeared vesicles
0.35575834.12419707.html.plaintext.txt	597	Another point mutation 5 untranslated region may involved disease process presence particular type tissue antigen HLA DR2 Ref
0.35575834.12419707.html.plaintext.txt	598	Insertion adenosine 593 promoter region found one narcoleptic patient although effect pathogenicity unclear 51
0.35575834.12419707.html.plaintext.txt	599	Thus strong evidence narcolepsy caused reduced orexinergic signaling via either destruction orexinergic neurons defective orexin peptides receptors although larger population studies necessary confirm
0.35575834.12419707.html.plaintext.txt	600	OX2 receptor appears especially involved dog would promote role nuclei relying receptor subtype tuberomamillary nucleus although possible OX1 OX2 receptors different distributions rats humans compared dogs
0.35575834.12419707.html.plaintext.txt	601	Orexinergic disorders may also provide interesting information role orexins feeding
0.35575834.12419707.html.plaintext.txt	602	Patients narcolepsy show somewhat increased body mass index compared healthy subjects 162
0.35575834.12419707.html.plaintext.txt	603	Both two previously described kinds orexin transgenic mice hypophagic preproorexin knockout mice lean 23 opposed orexinergic neuron deficient mice obese 60
0.35575834.12419707.html.plaintext.txt	604	It thus possible preproorexin knockout mice develop compensatory mechanisms weight regulation whereas orexinergic neuron deficient mice lose orexinergic neurons postnatally see Genetics Chemistry Orexins able
0.35575834.12419707.html.plaintext.txt	605	Another interesting possibility recently proposed Chou et al
0.35575834.12419707.html.plaintext.txt	606	Essentially mouse lateral hypothalamic orexinergic neurons express dynorphin 10 27 removal orexinergic neuron deficient mice might responsible pronounced phenotype
0.35575834.12419707.html.plaintext.txt	607	FUTURE PERSPECTIVES TOP ABSTRACT INTRODUCTION OVERVIEW OF OREXINS AND
0.35575834.12419707.html.plaintext.txt	608	CELLULAR RESPONSES TO OREXINS DISTRIBUTION OF OREXINERGIC
0.35575834.12419707.html.plaintext.txt	609	SYSTEMIC EFFECTS OF OREXINS FUTURE PERSPECTIVES REFERENCES
0.35575834.12419707.html.plaintext.txt	610	Although anatomic architecture orexinergic system CNS well characterized several open questions actual roles orexins central peripheral functions
0.35575834.12419707.html.plaintext.txt	611	What mechanisms action orexins cellular level Have orexin receptors identified Are presynaptic inhibitory orexin receptors brain The limited access orexin responding neurons experimental problem
0.35575834.12419707.html.plaintext.txt	612	There several limitations concerning methods available characterization functional properties cells slice preparations acutely isolated cells
0.35575834.12419707.html.plaintext.txt	613	Model systems based cultured neurons even neuronal stem cells might provide important improvement studies orexin signaling
0.35575834.12419707.html.plaintext.txt	614	The CHO cell lines available provided insight functions orexinergic system enabled screening orexin receptor ligands data obtained may relevant nervous system
0.35575834.12419707.html.plaintext.txt	615	Recombinant models based neurons neuronlike cells might therefore provide information signal pathways used orexins
0.35575834.12419707.html.plaintext.txt	616	What role orexin cells play regulation feeding Available information suggests least one population orexinergic cells lateral hypothalamus directly monitors responds changes glucose concentration environment may also directly respond signals inhibiting feeding leptin
0.35575834.12419707.html.plaintext.txt	617	Are orexinergic cells ones project areas brain involved feeding behavior Orexin receptors expressed high numbers several regions within hypothalamus
0.35575834.12419707.html.plaintext.txt	618	Do regulate release feeding related neurotransmitters The regulation feeding seems complex involving many neuropeptides seems gross redundancy system
0.35575834.12419707.html.plaintext.txt	619	Blocking orexinergic system various means reduce feeding permanent deletion orexinergic system marginal controversial effects
0.35575834.12419707.html.plaintext.txt	620	Thus even increase rather expected decrease body mass may occur deletions different components orexinergic system
0.35575834.12419707.html.plaintext.txt	621	The role orexins sleep seems clearer light connection narcoleptic phenotype orexin cell loss similar symptomatology occurring functional orexin orexin receptor loss
0.35575834.12419707.html.plaintext.txt	622	In context also appears quite clear major part orexin effects mediated via monoaminergic systems regulate cholinergic pathways involved initiation REM sleep reviewed e
0.35575834.12419707.html.plaintext.txt	623	Yet unclear activity orexinergic cells regulated
0.35575834.12419707.html.plaintext.txt	624	Use orexin antagonists hypnotics could prove rewarding many commonly used hypnotics interfere REM sleep cause tolerance addiction memory disturbances
0.35575834.12419707.html.plaintext.txt	625	An interesting question whether overlap cells regulating feeding sleep lateral hypothalamus
0.35575834.12419707.html.plaintext.txt	626	Is instance feeding behavior associated arousal effects orexins Possibilities future devise better pharmacological methods identification different orexinergic neurons well manipulating function hopefully give answers questions
0.35575834.12419707.html.plaintext.txt	627	One intriguing questions concerns roles orexins play periphery
0.35575834.12419707.html.plaintext.txt	628	Do act hormonesparacrine mediators The presence orexins receptors many peripheral organs intestine endocrine pancreas adrenals pituitary suggests may case
0.35575834.12419707.html.plaintext.txt	629	Could orexins even transmit signals periphery CNS As discussed studies available suggest separate peripheral central orexinergic systems
0.35575834.12419707.html.plaintext.txt	630	In studies changes central orexin concentrations reflected periphery narcoleptics devoid central orexins orexins still found plasma
0.35575834.12419707.html.plaintext.txt	631	This may indicate plasma orexin levels reflect peripherally produced orexins
0.35575834.12419707.html.plaintext.txt	632	Are peripheral orexin receptors similar central At least adrenal cortical zona fasciculatareticularis orexin receptors appear couple cAMP elevation Ca2 elevation
0.35575834.12419707.html.plaintext.txt	633	Does reflect different receptor subtypesas suggested studiesor coupling different signal pathways Cell lines primary cultures peripheral tissues provide lot missing information context
0.35575834.12419707.html.plaintext.txt	634	We acknowledge van den Pol et al
0.35575834.12419707.html.plaintext.txt	635	44 allowed reproduction Figs
0.35575834.12419707.html.plaintext.txt	636	This study supported European Union Contract QLG3 CT 2002 00826 grants Swedish Medical Research Council Cancer Research Fund Sweden Lars Hierta Foundation Academy Finland Sigrid Juselius Foundation
0.35575834.12419707.html.plaintext.txt	637	Address reprint requests correspondence J
0.35575834.12419707.html.plaintext.txt	638	BMC PO Box 572 SE 75123 Uppsala Sweden E mail jkukkoneatfysiologi
0.35575834.12419707.html.plaintext.txt	639	REFERENCES TOP ABSTRACT INTRODUCTION OVERVIEW OF OREXINS AND
0.35575834.12419707.html.plaintext.txt	640	CELLULAR RESPONSES TO OREXINS DISTRIBUTION OF OREXINERGIC
0.35575834.12419707.html.plaintext.txt	641	SYSTEMIC EFFECTS OF OREXINS FUTURE PERSPECTIVES REFERENCES
0.35575834.12419707.html.plaintext.txt	642	Abrahamson EE Leak RK Moore RY
0.35575834.12419707.html.plaintext.txt	643	The suprachiasmatic nucleus projects posterior hypothalamic arousal systems
0.35575834.12419707.html.plaintext.txt	644	Neuroreport 12 435 440 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	645	Al Barazanji KA Wilson S Baker J Jessop DS Harbuz MS
0.35575834.12419707.html.plaintext.txt	646	Central orexin A activates hypothalamic pituitary adrenal axis stimulates hypothalamic corticotropin releasing factor arginine vasopressin neurones conscious rats
0.35575834.12419707.html.plaintext.txt	647	J Neuroendocrinol 13 421 424 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	648	Antunes VR Brailoiu GC Kwok EH Scruggs P Dun NJ
0.35575834.12419707.html.plaintext.txt	649	Orexinshypocretins excite rat sympathetic preganglionic neurons vivo vitro
0.35575834.12419707.html.plaintext.txt	650	Am J Physiol Regul Integr Comp Physiol 281 R1801 R1807 2001AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	651	Arihara Z Takahashi K Murakami O Totsune K Sone M Satoh F Ito S Hayashi Y Sasano H Mouri T
0.35575834.12419707.html.plaintext.txt	652	Orexin A human brain tumor tissues ganglioneuroblastoma neuroblastoma
0.35575834.12419707.html.plaintext.txt	653	Peptides 21 565 570 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	654	Backberg M Hervieu G Wilson S Meister B
0.35575834.12419707.html.plaintext.txt	655	Orexin receptor 1 OX R1 immunoreactivity chemically identified neurons hypothalamus focus orexin targets involved control food water intake
0.35575834.12419707.html.plaintext.txt	656	Eur J Neurosci 15 315 328 2002ISIMedline
0.35575834.12419707.html.plaintext.txt	657	Balasko M Szelenyi Z Szekely M
0.35575834.12419707.html.plaintext.txt	658	Central thermoregulatory effects neuropeptide Y orexin A rats
0.35575834.12419707.html.plaintext.txt	659	Acta Physiol Hung 86 219 222 1999Medline
0.35575834.12419707.html.plaintext.txt	660	Receptor activated Ca2 inflow animal cells variety pathways tailored meet different intracellular Ca2 signalling requirements
0.35575834.12419707.html.plaintext.txt	661	Biochem J 337 153 169 1999ISIMedline
0.35575834.12419707.html.plaintext.txt	662	Bayer L Colard C Nguyen NU Risold PY Fellmann D Griffond B
0.35575834.12419707.html.plaintext.txt	663	Alteration expression hypocretin orexin gene 2 deoxyglucose rat lateral hypothalamic area
0.35575834.12419707.html.plaintext.txt	664	Neuroreport 11 531 533 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	665	Bayer L Eggermann E Serafin M Saint Mleux B Machard D Jones B Muhlethaler M
0.35575834.12419707.html.plaintext.txt	666	Orexins hypocretins directly excite tuberomammillary neurons
0.35575834.12419707.html.plaintext.txt	667	Eur J Neurosci 14 1571 1575 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	668	Bayer L Mairet Coello G Risold PY Griffond B
0.35575834.12419707.html.plaintext.txt	669	Orexinhypocretin neurons chemical phenotype possible interactions melanin concentrating hormone neurons
0.35575834.12419707.html.plaintext.txt	670	Regul Pept 104 33 39 2002ISIMedline
0.35575834.12419707.html.plaintext.txt	671	Bingham S Davey PT Babbs AJ Irving EA Sammons MJ Wyles M Jeffrey P Cutler L Riba I Johns A Porter RA Upton N Hunter AJ Parsons AA
0.35575834.12419707.html.plaintext.txt	672	Orexin A hypothalamic peptide analgesic properties
0.35575834.12419707.html.plaintext.txt	673	Pain 92 81 90 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	674	Blanco M Garcia Caballero T Fraga M Gallego R Cuevas J Forteza J Beiras A Dieguez C
0.35575834.12419707.html.plaintext.txt	675	Cellular localization orexin receptors human adrenal gland adrenocortical adenomas pheochromocytomas
0.35575834.12419707.html.plaintext.txt	676	Regul Pept 104 161 165 2002ISIMedline
0.35575834.12419707.html.plaintext.txt	677	Blanco M Lopez M Garcia Caballero T Gallego R Vazquez Boquete A Morel G Senaris R Casanueva F Dieguez C Beiras A
0.35575834.12419707.html.plaintext.txt	678	Cellular localization orexin receptors human pituitary
0.35575834.12419707.html.plaintext.txt	679	J Clin Endocrinol Metab 86 1616 1619 2001AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	680	Bonini JA Jones KA Adham N Forray C Artymyshyn R Durkin MM Smith KE Tamm JA Boteju LW Lakhlani PP Raddatz R Yao WJ Ogozalek KL Boyle N Kouranova EV Quan Y Vaysse PJ Wetzel JM Branchek TA Gerald C Borowsky B
0.35575834.12419707.html.plaintext.txt	681	Identification characterization two G protein coupled receptors neuropeptide FF
0.35575834.12419707.html.plaintext.txt	682	J Biol Chem 275 39324 39331 2000AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	683	Bourgin P Huitron Resendiz S Spier AD Fabre V Morte B Criado JR Sutcliffe JG Henriksen SJ de Lecea L
0.35575834.12419707.html.plaintext.txt	684	Hypocretin 1 modulates rapid eye movement sleep activation locus coeruleus neurons
0.35575834.12419707.html.plaintext.txt	685	J Neurosci 20 7760 7765 2000AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	686	Briski KP Sylvester PW
0.35575834.12419707.html.plaintext.txt	687	Hypothalamic orexin A immunopositive neurons express Fos response central glucopenia
0.35575834.12419707.html.plaintext.txt	688	Neuroreport 12 531 534 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	689	Broberger C De Lecea L Sutcliffe JG Hokfelt T
0.35575834.12419707.html.plaintext.txt	690	Hypocretinorexin melanin concentrating hormone expressing cells form distinct populations rodent lateral hypothalamus relationship neuropeptide Y agouti gene related protein systems
0.35575834.12419707.html.plaintext.txt	691	J Comp Neurol 402 460 474 1998ISIMedline
0.35575834.12419707.html.plaintext.txt	692	Brown RE Sergeeva O Eriksson KS Haas HL
0.35575834.12419707.html.plaintext.txt	693	Orexin A excites serotonergic neurons dorsal raphe nucleus rat
0.35575834.12419707.html.plaintext.txt	694	Neuropharmacology 40 457 459 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	695	Burlet S Tyler CJ Leonard CS
0.35575834.12419707.html.plaintext.txt	696	Direct indirect excitation laterodorsal tegmental neurons HypocretinOrexin peptides implications wakefulness narcolepsy
0.35575834.12419707.html.plaintext.txt	697	J Neurosci 22 2862 2872 2002AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	698	Cai XJ Evans ML Lister CA Leslie RA Arch JR Wilson S Williams G
0.35575834.12419707.html.plaintext.txt	699	Hypoglycemia activates orexin neurons selectively increases hypothalamic orexin B levels responses inhibited feeding possibly mediated nucleus solitary tract
0.35575834.12419707.html.plaintext.txt	700	Diabetes 50 105 112 2001AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	701	Cai XJ Liu XH Evans M Clapham JC Wilson S Arch JR Morris R Williams G
0.35575834.12419707.html.plaintext.txt	702	Orexins feeding special occasions everyday occurrence Regul Pept 104 1 9 2002ISIMedline
0.35575834.12419707.html.plaintext.txt	703	Cai XJ Widdowson PS Harrold J Wilson S Buckingham RE Arch JR Tadayyon M Clapham JC Wilding J Williams G
0.35575834.12419707.html.plaintext.txt	704	Hypothalamic orexin expression modulation blood glucose feeding
0.35575834.12419707.html.plaintext.txt	705	Diabetes 48 2132 2137 1999Abstract
0.35575834.12419707.html.plaintext.txt	706	Chemelli RM Willie JT Sinton CM Elmquist JK Scammell T Lee C Richardson JA Williams SC Xiong Y Kisanuki Y Fitch TE Nakazato M Hammer RE Saper CB Yanagisawa M
0.35575834.12419707.html.plaintext.txt	707	Narcolepsy orexin knockout mice molecular genetics sleep regulation
0.35575834.12419707.html.plaintext.txt	708	Cell 98 437 451 1999ISIMedline
0.35575834.12419707.html.plaintext.txt	709	Chen CT Dun SL Kwok EH Dun NJ Chang JK
0.35575834.12419707.html.plaintext.txt	710	Orexin A like immunoreactivity rat brain
0.35575834.12419707.html.plaintext.txt	711	Neurosci Lett 260 161 164 1999ISIMedline
0.35575834.12419707.html.plaintext.txt	712	Chen CT Hwang LL Chang JK Dun NJ
0.35575834.12419707.html.plaintext.txt	713	Pressor effects orexins injected intracisternally rostral ventrolateral medulla anesthetized rats
0.35575834.12419707.html.plaintext.txt	714	Am J Physiol Regul Integr Comp Physiol 278 R692 R697 2000AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	715	Nature 407 554 556 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	716	Chou TC Lee CE Lu J Elmquist JK Hara J Willie JT Beuckmann CT Chemelli RM Sakurai T Yanagisawa M Saper CB Scammell TE
0.35575834.12419707.html.plaintext.txt	717	Orexin hypocretin neurons contain dynorphin
0.35575834.12419707.html.plaintext.txt	718	J Neurosci 21 RC168 2001AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	719	Cikos S Gregor P Koppel J
0.35575834.12419707.html.plaintext.txt	720	Sequence tissue distribution novel G protein coupled receptor expressed prominently human placenta
0.35575834.12419707.html.plaintext.txt	721	Biochem Biophys Res Commun 256 352 356 1999ISIMedline
0.35575834.12419707.html.plaintext.txt	722	Clapham DE Runnels LW Strubing C
0.35575834.12419707.html.plaintext.txt	723	Nat Rev Neurosci 2 387 396 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	724	Cluderay JE Harrison DC Hervieu GJ
0.35575834.12419707.html.plaintext.txt	725	Protein distribution orexin 2 receptor rat central nervous system
0.35575834.12419707.html.plaintext.txt	726	Regul Pept 104 131 144 2002ISIMedline
0.35575834.12419707.html.plaintext.txt	727	Cutler DJ Morris R Sheridhar V Wattam TA Holmes S Patel S Arch JR Wilson S Buckingham RE Evans ML Leslie RA Williams G
0.35575834.12419707.html.plaintext.txt	728	Differential distribution orexin A orexin B immunoreactivity rat brain spinal cord
0.35575834.12419707.html.plaintext.txt	729	Peptides 20 1455 1470 1999ISIMedline
0.35575834.12419707.html.plaintext.txt	730	Dalal MA Schuld A Haack M Uhr M Geisler P Eisensehr I Noachtar S Pollmacher T
0.35575834.12419707.html.plaintext.txt	731	Normal plasma levels orexin A hypocretin 1 narcoleptic patients
0.35575834.12419707.html.plaintext.txt	732	Neurology 56 1749 1751 2001AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	733	Darker JG Porter RA Eggleston DS Smart D Brough SJ Sabido David C Jerman JC
0.35575834.12419707.html.plaintext.txt	734	Structure activity analysis truncated orexin A analogues orexin 1 receptor
0.35575834.12419707.html.plaintext.txt	735	Bioorg Med Chem Lett 11 737 740 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	736	Date Y Mondal MS Matsukura S Nakazato M
0.35575834.12419707.html.plaintext.txt	737	Distribution orexin A orexin B hypocretins rat spinal cord
0.35575834.12419707.html.plaintext.txt	738	Neurosci Lett 288 87 90 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	739	Date Y Mondal MS Matsukura S Ueta Y Yamashita H Kaiya H Kangawa K Nakazato M
0.35575834.12419707.html.plaintext.txt	740	Distribution orexinhypocretin rat median eminence pituitary
0.35575834.12419707.html.plaintext.txt	741	Brain Res Mol Brain Res 76 1 6 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	742	Date Y Ueta Y Yamashita H Yamaguchi H Matsukura S Kangawa K Sakurai T Yanagisawa M Nakazato M
0.35575834.12419707.html.plaintext.txt	743	Orexins orexigenic hypothalamic peptides interact autonomic neuroendocrine neuroregulatory systems
0.35575834.12419707.html.plaintext.txt	744	Proc Natl Acad Sci USA 96 748 753 1999AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	745	De Lecea L Kilduff TS Peyron C Gao X Foye PE Danielson PE Fukuhara C Battenberg EL Gautvik VT Bartlett FS Frankel WN van den Pol AN Bloom FE Gautvik KM Sutcliffe JG
0.35575834.12419707.html.plaintext.txt	746	The hypocretins hypothalamus specific peptides neuroexcitatory activity
0.35575834.12419707.html.plaintext.txt	747	Proc Natl Acad Sci USA 95 322 327 1998AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	748	Dube MG Horvath TL Kalra PS Kalra SP
0.35575834.12419707.html.plaintext.txt	749	Evidence NPY Y5 receptor involvement food intake elicited orexin A sated rats
0.35575834.12419707.html.plaintext.txt	750	Peptides 21 1557 1560 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	751	Dube MG Kalra SP Kalra PS
0.35575834.12419707.html.plaintext.txt	752	Food intake elicited central administration orexinshypocretins identification hypothalamic sites action
0.35575834.12419707.html.plaintext.txt	753	Brain Res 842 473 477 1999ISIMedline
0.35575834.12419707.html.plaintext.txt	754	Duxon MS Stretton J Starr K Jones DN Holland V Riley G Jerman J Brough S Smart D Johns A Chan W Porter RA Upton N
0.35575834.12419707.html.plaintext.txt	755	Evidence orexin A evoked grooming rat mediated orexin 1 OX1 receptors downstream 5 HT2C receptor involvement
0.35575834.12419707.html.plaintext.txt	756	Psychopharmacology Berl 153 203 209 2001Medline
0.35575834.12419707.html.plaintext.txt	757	Dyer CJ Touchette KJ Carroll JA Allee GL Matteri RL
0.35575834.12419707.html.plaintext.txt	758	Cloning porcine prepro orexin cDNA effects intramuscular injection synthetic porcine orexin B feed intake young pigs
0.35575834.12419707.html.plaintext.txt	759	Domest Anim Endocrinol 16 145 148 1999ISIMedline
0.35575834.12419707.html.plaintext.txt	760	Eggermann E Serafin M Bayer L Machard D Saint Mleux B Jones BE Muhlethaler M
0.35575834.12419707.html.plaintext.txt	761	Orexinshypocretins excite basal forebrain cholinergic neurones
0.35575834.12419707.html.plaintext.txt	762	Neuroscience 108 177 181 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	763	Elias CF Saper CB Maratos Flier E Tritos NA Lee C Kelly J Tatro JB Hoffman GE Ollmann MM Barsh GS Sakurai T Yanagisawa M Elmquist JK
0.35575834.12419707.html.plaintext.txt	764	Chemically defined projections linking mediobasal hypothalamus lateral hypothalamic area
0.35575834.12419707.html.plaintext.txt	765	J Comp Neurol 402 442 459 1998ISIMedline
0.35575834.12419707.html.plaintext.txt	766	Eriksson KS Sergeeva O Brown RE Haas HL
0.35575834.12419707.html.plaintext.txt	767	Orexinhypocretin excites histaminergic neurons tuberomammillary nucleus
0.35575834.12419707.html.plaintext.txt	768	J Neurosci 21 9273 9279 2001AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	769	Espana RA Baldo BA Kelley AE Berridge CW
0.35575834.12419707.html.plaintext.txt	770	Wake promoting sleep suppressing actions hypocretin orexin basal forebrain sites action
0.35575834.12419707.html.plaintext.txt	771	Neuroscience 106 699 715 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	772	Estabrooke IV McCarthy MT Ko E Chou TC Chemelli RM Yanagisawa M Saper CB Scammell TE
0.35575834.12419707.html.plaintext.txt	773	Fos expression orexin neurons varies behavioral state
0.35575834.12419707.html.plaintext.txt	774	J Neurosci 21 1656 1662 2001AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	775	Fujiki N Yoshida Y Ripley B Honda K Mignot E Nishino S
0.35575834.12419707.html.plaintext.txt	776	Changes CSF hypocretin 1 orexin A levels rats across 24 hours response food deprivation
0.35575834.12419707.html.plaintext.txt	777	Neuroreport 12 993 997 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	778	Fung SJ Yamuy J Sampogna S Morales FR Chase MH
0.35575834.12419707.html.plaintext.txt	779	Hypocretin orexin input trigeminal hypoglossal motoneurons cat double labeling immunohistochemical study
0.35575834.12419707.html.plaintext.txt	780	Brain Res 903 257 262 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	781	Melanin concentrating hormone depresses synaptic activity glutamate GABA neurons rat lateral hypothalamus
0.35575834.12419707.html.plaintext.txt	782	J Physiol 533 237 252 2001AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	783	Gautvik KM de Lecea L Gautvik VT Danielson PE Tranque P Dopazo A Bloom FE Sutcliffe JG
0.35575834.12419707.html.plaintext.txt	784	Overview prevalent hypothalamus specific mRNAs identified directional tag PCR subtraction
0.35575834.12419707.html.plaintext.txt	785	Proc Natl Acad Sci USA 93 8733 8738 1996AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	786	Gencik M Dahmen N Wieczorek S Kasten M Bierbrauer J Anghelescu I Szegedi A Menezes Saecker AM Epplen JT
0.35575834.12419707.html.plaintext.txt	787	A prepro orexin gene polymorphism associated narcolepsy
0.35575834.12419707.html.plaintext.txt	788	Neurology 56 115 117 2001AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	789	Gerashchenko D Kohls MD Greco M Waleh NS Salin Pascual R Kilduff TS Lappi DA Shiromani PJ
0.35575834.12419707.html.plaintext.txt	790	Hypocretin 2 saporin lesions lateral hypothalamus produce narcoleptic like sleep behavior rat
0.35575834.12419707.html.plaintext.txt	791	J Neurosci 21 7273 7283 2001AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	792	Griffond B Risold PY Jacquemard C Colard C Fellmann D
0.35575834.12419707.html.plaintext.txt	793	Insulin induced hypoglycemia increases preprohypocretin orexin mRNA rat lateral hypothalamic area
0.35575834.12419707.html.plaintext.txt	794	Neurosci Lett 262 77 80 1999ISIMedline
0.35575834.12419707.html.plaintext.txt	795	Grudt TJ van den Pol AN Perl ER
0.35575834.12419707.html.plaintext.txt	796	Hypocretin 2 orexin B modulation superficial dorsal horn activity rat
0.35575834.12419707.html.plaintext.txt	797	J Physiol 538 517 525 2002AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	798	Guan JL Saotome T Wang QP Funahashi H Hori T Tanaka S Shioda S
0.35575834.12419707.html.plaintext.txt	799	Orexinergic innervation POMC containing neurons rat arcuate nucleus
0.35575834.12419707.html.plaintext.txt	800	Neuroreport 12 547 551 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	801	Hagan JJ Leslie RA Patel S Evans ML Wattam TA Holmes S Benham CD Taylor SG Routledge C Hemmati P Munton RP Ashmeade TE Shah AS Hatcher JP Hatcher PD Jones DN Smith MI Piper DC Hunter AJ Porter RA Upton N
0.35575834.12419707.html.plaintext.txt	802	Orexin A activates locus coeruleus cell firing increases arousal rat
0.35575834.12419707.html.plaintext.txt	803	Proc Natl Acad Sci USA 96 10911 10916 1999AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	804	Hakansson ML Brown H Ghilardi N Skoda RC Meister B
0.35575834.12419707.html.plaintext.txt	805	Leptin receptor immunoreactivity chemically defined target neurons hypothalamus
0.35575834.12419707.html.plaintext.txt	806	J Neurosci 18 559 572 1998AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	807	Hakansson M de Lecea L Sutcliffe JG Yanagisawa M Meister B
0.35575834.12419707.html.plaintext.txt	808	Leptin receptor STAT3 immunoreactivities hypocretinorexin neurones lateral hypothalamus
0.35575834.12419707.html.plaintext.txt	809	J Neuroendocrinol 11 653 663 1999ISIMedline
0.35575834.12419707.html.plaintext.txt	810	Hamilton SE Loose MD Qi M Levey AI Hille B McKnight GS Idzerda RL Nathanson NM
0.35575834.12419707.html.plaintext.txt	811	Disruption m1 receptor gene ablates muscarinic receptor dependent M current regulation seizure activity mice
0.35575834.12419707.html.plaintext.txt	812	Proc Natl Acad Sci USA 94 13311 13316 1997AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	813	Hara J Beuckmann CT Nambu T Willie JT Chemelli RM Sinton CM Sugiyama F Yagami K Goto K Yanagisawa M Sakurai T
0.35575834.12419707.html.plaintext.txt	814	Genetic ablation orexin neurons mice results narcolepsy hypophagia obesity
0.35575834.12419707.html.plaintext.txt	815	Neuron 30 345 354 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	816	Harrison TA Chen CT Dun NJ Chang JK
0.35575834.12419707.html.plaintext.txt	817	Hypothalamic orexin A immunoreactive neurons project rat dorsal medulla
0.35575834.12419707.html.plaintext.txt	818	Neurosci Lett 273 17 20 1999ISIMedline
0.35575834.12419707.html.plaintext.txt	819	Haynes AC Jackson B Chapman H Tadayyon M Johns A Porter RA Arch JR
0.35575834.12419707.html.plaintext.txt	820	A selective orexin 1 receptor antagonist reduces food consumption male female rats
0.35575834.12419707.html.plaintext.txt	821	Regul Pept 96 45 51 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	822	Haynes AC Jackson B Overend P Buckingham RE Wilson S Tadayyon M Arch JR
0.35575834.12419707.html.plaintext.txt	823	Effects single chronic intracerebroventricular administration orexins feeding rat
0.35575834.12419707.html.plaintext.txt	824	Peptides 20 1099 1105 1999ISIMedline
0.35575834.12419707.html.plaintext.txt	825	Hervieu GJ Cluderay JE Harrison DC Roberts JC Leslie RA
0.35575834.12419707.html.plaintext.txt	826	Gene expression protein distribution orexin 1 receptor rat brain spinal cord
0.35575834.12419707.html.plaintext.txt	827	Neuroscience 103 777 797 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	828	Inhibition Gi activated potassium channel GIRK14 Gq coupled m1 muscarinic acetylcholine receptor
0.35575834.12419707.html.plaintext.txt	829	J Biol Chem 276 5505 5510 2001AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	830	Hirota K Kushikata T Kudo M Kudo T Lambert DG Matsuki A
0.35575834.12419707.html.plaintext.txt	831	Orexin A B evoke noradrenaline release rat cerebrocortical slices
0.35575834.12419707.html.plaintext.txt	832	Br J Pharmacol 134 1461 1466 2001AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	833	Holmqvist T Akerman KEO Kukkonen JP
0.35575834.12419707.html.plaintext.txt	834	High specificity human orexin receptors orexins neuropeptide Y neuropeptides
0.35575834.12419707.html.plaintext.txt	835	Neurosci Lett 305 177 180 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	836	Horn F Weare J Beukers MW Horsch S Bairoch A Chen W Edvardsen O Campagne F Vriend G
0.35575834.12419707.html.plaintext.txt	837	GPCRDB information system G protein coupled receptors
0.35575834.12419707.html.plaintext.txt	838	Nucleic Acids Res 26 275 279 1998AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	839	Horvath TL Diano S van den Pol AN
0.35575834.12419707.html.plaintext.txt	840	Synaptic interaction hypocretin orexin neuropeptide Y cells rodent primate hypothalamus novel circuit implicated metabolic endocrine regulations
0.35575834.12419707.html.plaintext.txt	841	J Neurosci 19 1072 1087 1999AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	842	Horvath TL Peyron C Diano S Ivanov A Aston Jones G Kilduff TS van Den Pol AN
0.35575834.12419707.html.plaintext.txt	843	Hypocretin orexin activation synaptic innervation locus coeruleus noradrenergic system
0.35575834.12419707.html.plaintext.txt	844	J Comp Neurol 415 145 159 1999ISIMedline
0.35575834.12419707.html.plaintext.txt	845	Horvath TL Warden CH Hajos M Lombardi A Goglia F Diano S
0.35575834.12419707.html.plaintext.txt	846	Brain uncoupling protein 2 uncoupled neuronal mitochondria predict thermal synapses homeostatic centers
0.35575834.12419707.html.plaintext.txt	847	J Neurosci 19 10417 10427 1999AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	848	Huang ZL Qu WM Li WD Mochizuki T Eguchi N Watanabe T Urade Y Hayaishi O
0.35575834.12419707.html.plaintext.txt	849	Arousal effect orexin A depends activation histaminergic system
0.35575834.12419707.html.plaintext.txt	850	Proc Natl Acad Sci USA 98 9965 9970 2001AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	851	Hungs M Fan J Lin L Lin X Maki RA Mignot E
0.35575834.12419707.html.plaintext.txt	852	Identification functional analysis mutations hypocretin orexin genes narcoleptic canines
0.35575834.12419707.html.plaintext.txt	853	Genome Res 11 531 539 2001AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	854	Hypocretinorexin sleep narcolepsy
0.35575834.12419707.html.plaintext.txt	855	Bioessays 23 397 408 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	856	Hwang LL Chen CT Dun NJ
0.35575834.12419707.html.plaintext.txt	857	Mechanisms orexin induced depolarizations rat dorsal motor nucleus vagus neurones vitro
0.35575834.12419707.html.plaintext.txt	858	J Physiol 537 511 520 2001AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	859	Ichinose M Asai M Sawada M Sasaki K Oomura Y
0.35575834.12419707.html.plaintext.txt	860	Induction outward current orexin B mouse peritoneal macrophages
0.35575834.12419707.html.plaintext.txt	861	FEBS Lett 440 51 54 1998ISIMedline
0.35575834.12419707.html.plaintext.txt	862	Ida T Nakahara K Katayama T Murakami N Nakazato M
0.35575834.12419707.html.plaintext.txt	863	Effect lateral cerebroventricular injection appetite stimulating neuropeptide orexin neuropeptide Y various behavioral activities rats
0.35575834.12419707.html.plaintext.txt	864	Brain Res 821 526 529 1999ISIMedline
0.35575834.12419707.html.plaintext.txt	865	Ida T Nakahara K Murakami T Hanada R Nakazato M Murakami N
0.35575834.12419707.html.plaintext.txt	866	Possible involvement orexin stress reaction rats
0.35575834.12419707.html.plaintext.txt	867	Biochem Biophys Res Commun 270 318 323 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	868	Ishizuka T Yamamoto Y Yamatodani A
0.35575834.12419707.html.plaintext.txt	869	The effect orexin A B histamine release anterior hypothalamus rats
0.35575834.12419707.html.plaintext.txt	870	Neurosci Lett 323 93 96 2002ISIMedline
0.35575834.12419707.html.plaintext.txt	871	Ivanov A Aston Jones G
0.35575834.12419707.html.plaintext.txt	872	Hypocretinorexin depolarizes decreases potassium conductance locus coeruleus neurons
0.35575834.12419707.html.plaintext.txt	873	Neuroreport 11 1755 1758 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	874	Jain MR Horvath TL Kalra PS Kalra SP
0.35575834.12419707.html.plaintext.txt	875	Evidence NPY Y1 receptors involved stimulation feeding orexins hypocretins sated rats
0.35575834.12419707.html.plaintext.txt	876	Regul Pept 87 19 24 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	877	Jaszberenyi M Bujdoso E Pataki I Telegdy G
0.35575834.12419707.html.plaintext.txt	878	Effects orexins hypothalamic pituitary adrenal system
0.35575834.12419707.html.plaintext.txt	879	J Neuroendocrinol 12 1174 1178 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	880	Jaszberenyi M Bujdoso E Telegdy G
0.35575834.12419707.html.plaintext.txt	881	The role neuropeptide Y orexin induced hypothalamic pituitary adrenal activation
0.35575834.12419707.html.plaintext.txt	882	J Neuroendocrinol 13 438 441 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	883	Johren O Neidert SJ Kummer M Dendorfer A Dominiak P
0.35575834.12419707.html.plaintext.txt	884	Prepro orexin orexin receptor mRNAs differentially expressed peripheral tissues male female rats
0.35575834.12419707.html.plaintext.txt	885	Endocrinology 142 3324 3331 2001AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	886	Jones DN Gartlon J Parker F Taylor SG Routledge C Hemmati P Munton RP Ashmeade TE Hatcher JP Johns A Porter RA Hagan JJ Hunter AJ Upton N
0.35575834.12419707.html.plaintext.txt	887	Effects centrally administered orexin B orexin A role orexin 1 receptors orexin B induced hyperactivity
0.35575834.12419707.html.plaintext.txt	888	Psychopharmacology Berl 153 210 218 2001Medline
0.35575834.12419707.html.plaintext.txt	889	Kane JK Parker SL Matta SG Fu Y Sharp BM Li MD
0.35575834.12419707.html.plaintext.txt	890	Nicotine regulates expression orexin receptors rat brain
0.35575834.12419707.html.plaintext.txt	891	Endocrinology 141 3623 3629 2000AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	892	Kane JK Tanaka H Parker SL Yanagisawa M Li MD
0.35575834.12419707.html.plaintext.txt	893	Sensitivity orexin A binding phospholipase C inhibitors neuropeptide Y secretin
0.35575834.12419707.html.plaintext.txt	894	Biochem Biophys Res Commun 272 959 965 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	895	Karteris E Randeva HS Grammatopoulos DK Jaffe RB Hillhouse EW
0.35575834.12419707.html.plaintext.txt	896	Expression coupling characteristics crh orexin type 2 receptors human fetal adrenals
0.35575834.12419707.html.plaintext.txt	897	J Clin Endocrinol Metab 86 4512 4519 2001AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	898	Orexin A orexin B rapidly enters brain blood simple diffusion
0.35575834.12419707.html.plaintext.txt	899	J Pharmacol Exp Ther 289 219 223 1999AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	900	The hypocretinorexin ligand receptor system implications sleep sleep disorders
0.35575834.12419707.html.plaintext.txt	901	Trends Neurosci 23 359 365 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	902	Kimura J Miyamae S Noma A
0.35575834.12419707.html.plaintext.txt	903	Identification sodium calcium exchange current single ventricular cells guinea pig
0.35575834.12419707.html.plaintext.txt	904	J Physiol 384 199 222 1987Abstract
0.35575834.12419707.html.plaintext.txt	905	Orexin synthesis response gut
0.35575834.12419707.html.plaintext.txt	906	Neuron 24 941 951 1999ISIMedline
0.35575834.12419707.html.plaintext.txt	907	Korotkova TM Eriksson KS Haas HL Brown RE
0.35575834.12419707.html.plaintext.txt	908	Selective excitation GABAergic neurons substantia nigra rat orexinhypocretin vitro
0.35575834.12419707.html.plaintext.txt	909	Regul Pept 104 83 89 2002ISIMedline
0.35575834.12419707.html.plaintext.txt	910	Krahn LE Black JL Silber MH
0.35575834.12419707.html.plaintext.txt	911	Narcolepsy new understanding irresistible sleep
0.35575834.12419707.html.plaintext.txt	912	Mayo Clin Proc 76 185 194 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	913	Kreegipuu A Blom N Brunak S
0.35575834.12419707.html.plaintext.txt	914	PhosphoBase database phosphorylation sites release 2
0.35575834.12419707.html.plaintext.txt	915	Nucleic Acids Res 27 237 239 1999AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	916	Kukkonen JP Akerman KEO Orexin receptors couple Ca2 channels different store operated Ca2 channels
0.35575834.12419707.html.plaintext.txt	917	Neuroreport 12 2017 2020 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	918	Kummer M Neidert SJ Johren O Dominiak P
0.35575834.12419707.html.plaintext.txt	919	Orexin hypocretin gene expression rat ependymal cells
0.35575834.12419707.html.plaintext.txt	920	Neuroreport 12 2117 2120 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	921	Kunii K Yamanaka A Nambu T Matsuzaki I Goto K Sakurai T
0.35575834.12419707.html.plaintext.txt	922	Orexinshypocretins regulate drinking behaviour
0.35575834.12419707.html.plaintext.txt	923	Brain Res 842 256 261 1999ISIMedline
0.35575834.12419707.html.plaintext.txt	924	Kurose T Ueta Y Yamamoto Y Serino R Ozaki Y Saito J Nagata S Yamashita H
0.35575834.12419707.html.plaintext.txt	925	Effects restricted feeding activity hypothalamic Orexin OX A containing neurons OX2 receptor mRNA level paraventricular nucleus rats
0.35575834.12419707.html.plaintext.txt	926	Regul Pept 104 145 151 2002ISIMedline
0.35575834.12419707.html.plaintext.txt	927	Lee JH Bang E Chae KJ Kim JY Lee DW Lee W
0.35575834.12419707.html.plaintext.txt	928	Solution structure new hypothalamic neuropeptide human hypocretin 2orexin B
0.35575834.12419707.html.plaintext.txt	929	Eur J Biochem 266 831 839 1999AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	930	Levin BE Dunn Meynell AA Routh VH
0.35575834.12419707.html.plaintext.txt	931	Brain glucose sensing body energy homeostasis role obesity diabetes
0.35575834.12419707.html.plaintext.txt	932	Am J Physiol Regul Integr Comp Physiol 276 R1223 R1231 1999AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	933	Lin L Faraco J Li R Kadotani H Rogers W Lin X Qiu X de Jong PJ Nishino S Mignot E
0.35575834.12419707.html.plaintext.txt	934	The sleep disorder canine narcolepsy caused mutation hypocretin orexin receptor 2 gene
0.35575834.12419707.html.plaintext.txt	935	Cell 98 365 376 1999ISIMedline
0.35575834.12419707.html.plaintext.txt	936	Liu XH Morris R Spiller D White M Williams G
0.35575834.12419707.html.plaintext.txt	937	Orexin preferentially excites glucose sensitive neurons lateral hypothalamus rat vitro
0.35575834.12419707.html.plaintext.txt	938	Diabetes 50 2431 2437 2001AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	939	Lopez M Senaris R Gallego R Garcia Caballero T Lago F Seoane L Casanueva F Dieguez C
0.35575834.12419707.html.plaintext.txt	940	Orexin receptors expressed adrenal medulla rat
0.35575834.12419707.html.plaintext.txt	941	Endocrinology 140 5991 5994 1999AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	942	Lopez M Seoane L Garcia MC Lago F Casanueva FF Senaris R Dieguez C
0.35575834.12419707.html.plaintext.txt	943	Leptin regulation prepro orexin orexin receptor mRNA levels hypothalamus
0.35575834.12419707.html.plaintext.txt	944	Biochem Biophys Res Commun 269 41 45 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	945	Lubkin M Stricker Krongrad A
0.35575834.12419707.html.plaintext.txt	946	Independent feeding metabolic actions orexins mice
0.35575834.12419707.html.plaintext.txt	947	Biochem Biophys Res Commun 253 241 245 1998ISIMedline
0.35575834.12419707.html.plaintext.txt	948	Lund PE Shariatmadari R Uustare A Detheux M Parmentier M Kukkonen JP Akerman KEO The orexin OX1 receptor activates novel Ca2 influx pathway necessary coupling phospholipase C
0.35575834.12419707.html.plaintext.txt	949	J Biol Chem 275 30806 30812 2000AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	950	Malendowicz LK Hochol A Ziolkowska A Nowak M Gottardo L Nussdorfer GG
0.35575834.12419707.html.plaintext.txt	951	Prolonged orexin administration stimulates steroid hormone secretion acting directly rat adrenal gland
0.35575834.12419707.html.plaintext.txt	952	Int J Mol Med 7 401 404 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	953	Malendowicz LK Jedrzejczak N Belloni AS Trejter M Hochol A Nussdorfer GG
0.35575834.12419707.html.plaintext.txt	954	Effects orexins A B secretory proliferative activity immature regenerating rat adrenal glands
0.35575834.12419707.html.plaintext.txt	955	Histol Histopathol 16 713 717 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	956	Malendowicz LK Tortorella C Nussdorfer GG
0.35575834.12419707.html.plaintext.txt	957	Orexins stimulate corticosterone secretion rat adrenocortical cells activation adenylate cyclase dependent signaling cascade
0.35575834.12419707.html.plaintext.txt	958	J Steroid Biochem Mol Biol 70 185 188 1999ISIMedline
0.35575834.12419707.html.plaintext.txt	959	Marcus JN Aschkenasi CJ Lee CE Chemelli RM Saper CB Yanagisawa M Elmquist JK
0.35575834.12419707.html.plaintext.txt	960	Differential expression orexin receptors 1 2 rat brain
0.35575834.12419707.html.plaintext.txt	961	J Comp Neurol 435 6 25 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	962	G protein mediated gating inward rectifier K channels
0.35575834.12419707.html.plaintext.txt	963	Eur J Biochem 267 5830 5836 2000AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	964	Martin G Fabre V Siggins GR de Lecea L
0.35575834.12419707.html.plaintext.txt	965	Interaction hypocretins neurotransmitters nucleus accumbens
0.35575834.12419707.html.plaintext.txt	966	Regul Pept 104 111 117 2002ISIMedline
0.35575834.12419707.html.plaintext.txt	967	Matsumura K Tsuchihashi T Abe I
0.35575834.12419707.html.plaintext.txt	968	Central orexin A augments sympathoadrenal outflow conscious rabbits
0.35575834.12419707.html.plaintext.txt	969	Hypertension 37 1382 1387 2001AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	970	Matsuzaki I Sakurai T Kunii K Nakamura T Yanagisawa M Goto K
0.35575834.12419707.html.plaintext.txt	971	Involvement serotonergic system orexin induced behavioral alterations rats
0.35575834.12419707.html.plaintext.txt	972	Regul Pept 104 119 123 2002ISIMedline
0.35575834.12419707.html.plaintext.txt	973	Mazzocchi G Malendowicz LK Aragona F Rebuffat P Gottardo L Nussdorfer GG
0.35575834.12419707.html.plaintext.txt	974	Human pheochromocytomas express orexin receptor type 2 gene display vitro secretory response orexins A B
0.35575834.12419707.html.plaintext.txt	975	J Clin Endocrinol Metab 86 4818 4821 2001AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	976	Mazzocchi G Malendowicz LK Gottardo L Aragona F Nussdorfer GG
0.35575834.12419707.html.plaintext.txt	977	Orexin A stimulates cortisol secretion human adrenocortical cells activation adenylate cyclase dependent signaling cascade
0.35575834.12419707.html.plaintext.txt	978	J Clin Endocrinol Metab 86 778 782 2001AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	979	McGranaghan PA Piggins HD
0.35575834.12419707.html.plaintext.txt	980	Orexin A like immunoreactivity hypothalamus thalamus Syrian hamster Mesocricetus auratus Siberian hamster Phodopus sungorus special reference circadian structures
0.35575834.12419707.html.plaintext.txt	981	Brain Res 904 234 244 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	982	Control food intake via leptin receptors hypothalamus
0.35575834.12419707.html.plaintext.txt	983	Vitam Horm 59 265 304 2000Medline
0.35575834.12419707.html.plaintext.txt	984	Methippara MM Alam MN Szymusiak R McGinty D
0.35575834.12419707.html.plaintext.txt	985	Effects lateral preoptic area application orexin A sleep wakefulness
0.35575834.12419707.html.plaintext.txt	986	Neuroreport 11 3423 3426 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	987	Mikkelsen JD Hauser F deLecea L Sutcliffe JG Kilduff TS Calgari C Pevet P Simonneaux V
0.35575834.12419707.html.plaintext.txt	988	Hypocretin orexin rat pineal gland central transmitter effects noradrenaline induced release melatonin
0.35575834.12419707.html.plaintext.txt	989	Eur J Neurosci 14 419 425 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	990	Mintz EM van den Pol AN Casano AA Albers HE
0.35575834.12419707.html.plaintext.txt	991	Distribution hypocretin orexin immunoreactivity central nervous system Syrian hamsters Mesocricetus auratus
0.35575834.12419707.html.plaintext.txt	992	J Chem Neuroanat 21 225 238 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	993	Mitsuma T Hirooka Y Mori Y Kayama M Adachi K Rhue N Ping J Nogimori T
0.35575834.12419707.html.plaintext.txt	994	Effects orexin A thyrotropin releasing hormone thyrotropin secretion rats
0.35575834.12419707.html.plaintext.txt	995	Horm Metab Res 31 606 609 1999ISIMedline
0.35575834.12419707.html.plaintext.txt	996	Monda M Viggiano A Mondola P De Luca V
0.35575834.12419707.html.plaintext.txt	997	Inhibition prostaglandin synthesis reduces hyperthermic reactions induced hypocretin 1orexin A
0.35575834.12419707.html.plaintext.txt	998	Brain Res 909 68 74 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	999	Mondal MS Nakazato M Date Y Murakami N Hanada R Sakata T Matsukura S
0.35575834.12419707.html.plaintext.txt	1000	Characterization orexin A orexin B microdissected rat brain nuclei contents two obese rat models
0.35575834.12419707.html.plaintext.txt	1001	Neurosci Lett 273 45 48 1999ISIMedline
0.35575834.12419707.html.plaintext.txt	1002	Mondal MS Nakazato M Date Y Murakami N Yanagisawa M Matsukura S
0.35575834.12419707.html.plaintext.txt	1003	Widespread distribution orexin rat brain regulation upon fasting
0.35575834.12419707.html.plaintext.txt	1004	Biochem Biophys Res Commun 256 495 499 1999ISIMedline
0.35575834.12419707.html.plaintext.txt	1005	Moriguchi T Sakurai T Nambu T Yanagisawa M Goto K
0.35575834.12419707.html.plaintext.txt	1006	Neurons containing orexin lateral hypothalamic area adult rat brain activated insulin induced acute hypoglycemia
0.35575834.12419707.html.plaintext.txt	1007	Neurosci Lett 264 101 104 1999ISIMedline
0.35575834.12419707.html.plaintext.txt	1008	Mullett MA Billington CJ Levine AS Kotz CM
0.35575834.12419707.html.plaintext.txt	1009	Hypocretin I lateral hypothalamus activates key feeding regulatory brain sites
0.35575834.12419707.html.plaintext.txt	1010	Neuroreport 11 103 108 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	1011	Muroya S Uramura K Sakurai T Takigawa M Yada T
0.35575834.12419707.html.plaintext.txt	1012	Lowering glucose concentrations increases cytosolic Ca2 orexin neurons rat lateral hypothalamus
0.35575834.12419707.html.plaintext.txt	1013	Neurosci Lett 309 165 168 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	1014	Nakamura T Uramura K Nambu T Yada T Goto K Yanagisawa M Sakurai T
0.35575834.12419707.html.plaintext.txt	1015	Orexin induced hyperlocomotion stereotypy mediated dopaminergic system
0.35575834.12419707.html.plaintext.txt	1016	Brain Res 873 181 187 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	1017	Nambu T Sakurai T Mizukami K Hosoya Y Yanagisawa M Goto K
0.35575834.12419707.html.plaintext.txt	1018	Distribution orexin neurons adult rat brain
0.35575834.12419707.html.plaintext.txt	1019	Brain Res 827 243 260 1999ISIMedline
0.35575834.12419707.html.plaintext.txt	1020	Nanmoku T Isobe K Sakurai T Yamanaka A Takekoshi K Kawakami Y Goto K Nakai T
0.35575834.12419707.html.plaintext.txt	1021	Effects orexin cultured porcine adrenal medullary cortex cells
0.35575834.12419707.html.plaintext.txt	1022	Regul Pept 104 125 130 2002ISIMedline
0.35575834.12419707.html.plaintext.txt	1023	Naslund E Ehrstrom M Ma J Hellstrom PM Kirchgessner AL
0.35575834.12419707.html.plaintext.txt	1024	Localization effects orexin fasting motility rat duodenum
0.35575834.12419707.html.plaintext.txt	1025	Am J Physiol Gastrointest Liver Physiol 282 G470 G479 2002AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	1026	Nishino S Fujiki N Ripley B Sakurai E Kato M Watanabe T Mignot E Yanai K
0.35575834.12419707.html.plaintext.txt	1027	Decreased brain histamine content hypocretinorexin receptor 2 mutated narcoleptic dogs
0.35575834.12419707.html.plaintext.txt	1028	Neurosci Lett 313 125 128 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	1029	Nishino S Ripley B Overeem S Lammers GJ Mignot E
0.35575834.12419707.html.plaintext.txt	1030	Hypocretin orexin deficiency human narcolepsy
0.35575834.12419707.html.plaintext.txt	1031	Lancet 355 39 40 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	1032	Localization hypocretin like immunoreactivity brain diurnal rodent Arvicanthis niloticus
0.35575834.12419707.html.plaintext.txt	1033	J Chem Neuroanat 23 49 58 2002ISIMedline
0.35575834.12419707.html.plaintext.txt	1034	Nowak KW Mackowiak P Switonska MM Fabis M Malendowicz LK
0.35575834.12419707.html.plaintext.txt	1035	Acute orexin effects insulin secretion rat vivo vitro studies
0.35575834.12419707.html.plaintext.txt	1036	Life Sci 66 449 454 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	1037	Okumura T Takeuchi S Motomura W Yamada H Egashira Si S Asahi S Kanatani A Ihara M Kohgo Y
0.35575834.12419707.html.plaintext.txt	1038	Requirement intact disulfide bonds orexin A induced stimulation gastric acid secretion mediated OX1 receptor activation
0.35575834.12419707.html.plaintext.txt	1039	Biochem Biophys Res Commun 280 976 981 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	1040	Olafsdottir BR Rye DB Scammell TE Matheson JK Stefansson K Gulcher JR
0.35575834.12419707.html.plaintext.txt	1041	Polymorphisms hypocretinorexin pathway genes narcolepsy
0.35575834.12419707.html.plaintext.txt	1042	Neurology 57 1896 1899 2001AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	1043	Orlando G Brunetti L Di Nisio C Michelotto B Recinella L Ciabattoni G Vacca M
0.35575834.12419707.html.plaintext.txt	1044	Effects cocaine amphetamine regulated transcript peptide leptin orexins hypothalamic serotonin release
0.35575834.12419707.html.plaintext.txt	1045	Eur J Pharmacol 430 269 272 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	1046	Overeem S Mignot E Gert van Dijk J Lammers GJ
0.35575834.12419707.html.plaintext.txt	1047	Narcolepsy clinical features new pathophysiologic insights future perspectives
0.35575834.12419707.html.plaintext.txt	1048	J Clin Neurophysiol 18 78 105 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	1049	Peyron C Faraco J Rogers W Ripley B Overeem S Charnay Y Nevsimalova S Aldrich M Reynolds D Albin R Li R Hungs M Pedrazzoli M Padigaru M Kucherlapati M Fan J Maki R Lammers GJ Bouras C Kucherlapati R Nishino S Mignot E
0.35575834.12419707.html.plaintext.txt	1050	A mutation case early onset narcolepsy generalized absence hypocretin peptides human narcoleptic brains
0.35575834.12419707.html.plaintext.txt	1051	Nat Med 6 991 997 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	1052	Peyron C Tighe DK van den Pol AN de Lecea L Heller HC Sutcliffe JG Kilduff TS
0.35575834.12419707.html.plaintext.txt	1053	Neurons containing hypocretin orexin project multiple neuronal systems
0.35575834.12419707.html.plaintext.txt	1054	J Neurosci 18 9996 10015 1998AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	1055	Piper DC Upton N Smith MI Hunter AJ
0.35575834.12419707.html.plaintext.txt	1056	The novel brain neuropeptide orexin A modulates sleep wake cycle rats
0.35575834.12419707.html.plaintext.txt	1057	Eur J Neurosci 12 726 730 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	1058	Porter RA Chan WN Coulton S Johns A Hadley MS Widdowson K Jerman JC Brough SJ Coldwell M Smart D Jewitt F Jeffrey P Austin N
0.35575834.12419707.html.plaintext.txt	1059	13 Biarylureas selective non peptide antagonists orexin 1 receptor
0.35575834.12419707.html.plaintext.txt	1060	Bioorg Med Chem Lett 11 1907 1910 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	1061	Randeva HS Karteris E Grammatopoulos D Hillhouse EW
0.35575834.12419707.html.plaintext.txt	1062	Expression orexin A functional orexin type 2 receptors human adult adrenals implications adrenal function energy homeostasis
0.35575834.12419707.html.plaintext.txt	1063	J Clin Endocrinol Metab 86 4808 4813 2001AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	1064	Rauch M Riediger T Schmid HA Simon E
0.35575834.12419707.html.plaintext.txt	1065	Orexin A activates leptin responsive neurons arcuate nucleus
0.35575834.12419707.html.plaintext.txt	1066	Pflugers Arch 440 699 703 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	1067	Ripley B Fujiki N Okura M Mignot E Nishino S
0.35575834.12419707.html.plaintext.txt	1068	Hypocretin levels sporadic familial cases canine narcolepsy
0.35575834.12419707.html.plaintext.txt	1069	Neurobiol Dis 8 525 534 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	1070	Rodgers RJ Halford JC Nunes de Souza RL Canto de Souza AL Piper DC Arch JR Blundell JE
0.35575834.12419707.html.plaintext.txt	1071	Dose response effects orexin A food intake behavioural satiety sequence rats
0.35575834.12419707.html.plaintext.txt	1072	Regul Pept 96 71 84 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	1073	Rodgers RJ Halford JC Nunes de Souza RL Canto de Souza AL Piper DC Arch JR Upton N Porter RA Johns A Blundell JE
0.35575834.12419707.html.plaintext.txt	1074	SB 334867 selective orexin 1 receptor antagonist enhances behavioural satiety blocks hyperphagic effect orexin A rats
0.35575834.12419707.html.plaintext.txt	1075	Eur J Neurosci 13 1444 1452 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	1076	Russell SH Kim MS Small CJ Abbott CR Morgan DG Taheri S Murphy KG Todd JF Ghatei MA Bloom SR
0.35575834.12419707.html.plaintext.txt	1077	Central administration orexin A suppresses basal domperidone stimulated plasma prolactin
0.35575834.12419707.html.plaintext.txt	1078	J Neuroendocrinol 12 1213 1218 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	1079	Russell SH Small CJ Dakin CL Abbott CR Morgan DG Ghatei MA Bloom SR
0.35575834.12419707.html.plaintext.txt	1080	The central effects orexin A hypothalamic pituitary adrenal axis vivo vitro male rats
0.35575834.12419707.html.plaintext.txt	1081	J Neuroendocrinol 13 561 566 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	1082	Russell SH Small CJ Sunter D Morgan I Dakin CL Cohen MA Bloom SR
0.35575834.12419707.html.plaintext.txt	1083	Chronic intraparaventricular nuclear administration orexin A male rats alter thyroid axis uncoupling protein 1 brown adipose tissue
0.35575834.12419707.html.plaintext.txt	1084	Regul Pept 104 61 68 2002ISIMedline
0.35575834.12419707.html.plaintext.txt	1085	Sakurai T Amemiya A Ishii M Matsuzaki I Chemelli RM Tanaka H Williams SC Richardson JA Kozlowski GP Wilson S Arch JR Buckingham RE Haynes AC Carr SA Annan RS McNulty DE Liu WS Terrett JA Elshourbagy NA Bergsma DJ Yanagisawa M
0.35575834.12419707.html.plaintext.txt	1086	Orexins orexin receptors family hypothalamic neuropeptides G protein coupled receptors regulate feeding behavior
0.35575834.12419707.html.plaintext.txt	1087	Cell 92 573 585 1998ISIMedline
0.35575834.12419707.html.plaintext.txt	1088	Sakurai T Moriguchi T Furuya K Kajiwara N Nakamura T Yanagisawa M Goto K
0.35575834.12419707.html.plaintext.txt	1089	Structure function human prepro orexin gene
0.35575834.12419707.html.plaintext.txt	1090	J Biol Chem 274 17771 17776 1999AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	1091	Samson WK Gosnell B Chang JK Resch ZT Murphy TC
0.35575834.12419707.html.plaintext.txt	1092	Cardiovascular regulatory actions hypocretins brain
0.35575834.12419707.html.plaintext.txt	1093	Brain Res 831 248 253 1999ISIMedline
0.35575834.12419707.html.plaintext.txt	1094	Trends Endocrinol Metab 11 257 262 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	1095	Hypocretinorexin suppresses corticotroph responsiveness vitro
0.35575834.12419707.html.plaintext.txt	1096	Am J Physiol Regul Integr Comp Physiol 281 R1140 R1145 2001AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	1097	Samson WK Taylor MM Follwell M Ferguson AV
0.35575834.12419707.html.plaintext.txt	1098	Orexin actions hypothalamic paraventricular nucleus physiological consequences cellular correlates
0.35575834.12419707.html.plaintext.txt	1099	Regul Pept 104 97 103 2002ISIMedline
0.35575834.12419707.html.plaintext.txt	1100	Satoh Y Uchida M Fujita A Nishio H Takeuchi T Hata F
0.35575834.12419707.html.plaintext.txt	1101	Possible role orexin A nonadrenergic noncholinergic inhibitory response muscle mouse small intestine
0.35575834.12419707.html.plaintext.txt	1102	Eur J Pharmacol 428 337 342 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	1103	Scammell TE Estabrooke IV McCarthy MT Chemelli RM Yanagisawa M Miller MS Saper CB
0.35575834.12419707.html.plaintext.txt	1104	Hypothalamic arousal regions activated modafinil induced wakefulness
0.35575834.12419707.html.plaintext.txt	1105	J Neurosci 20 8620 8628 2000AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	1106	Schuld A Hebebrand J Geller F Pollmacher T
0.35575834.12419707.html.plaintext.txt	1107	Increased body mass index patients narcolepsy
0.35575834.12419707.html.plaintext.txt	1108	Lancet 355 1274 1275 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	1109	Shibahara M Sakurai T Nambu T Takenouchi T Iwaasa H Egashira SI Ihara M Goto K
0.35575834.12419707.html.plaintext.txt	1110	Structure tissue distribution pharmacological characterization Xenopus orexins
0.35575834.12419707.html.plaintext.txt	1111	Peptides 20 1169 1176 1999ISIMedline
0.35575834.12419707.html.plaintext.txt	1112	Shiraishi T Oomura Y Sasaki K Wayner MJ
0.35575834.12419707.html.plaintext.txt	1113	Effects leptin orexin A food intake feeding related hypothalamic neurons
0.35575834.12419707.html.plaintext.txt	1114	Physiol Behav 71 251 261 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	1115	Shirasaka T Miyahara S Kunitake T Jin QH Kato K Takasaki M Kannan H
0.35575834.12419707.html.plaintext.txt	1116	Orexin depolarizes rat hypothalamic paraventricular nucleus neurons
0.35575834.12419707.html.plaintext.txt	1117	Am J Physiol Regul Integr Comp Physiol 281 R1114 R1118 2001AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	1118	Shirasaka T Nakazato M Matsukura S Takasaki M Kannan H
0.35575834.12419707.html.plaintext.txt	1119	Sympathetic cardiovascular actions orexins conscious rats
0.35575834.12419707.html.plaintext.txt	1120	Am J Physiol Regul Integr Comp Physiol 277 R1780 R1785 1999AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	1121	Smart D Jerman JC Brough SJ Neville WA Jewitt F Porter RA
0.35575834.12419707.html.plaintext.txt	1122	The hypocretins weak agonists recombinant human orexin 1 orexin 2 receptors
0.35575834.12419707.html.plaintext.txt	1123	Br J Pharmacol 129 1289 1291 2000AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	1124	Smart D Jerman JC Brough SJ Rushton SL Murdock PR Jewitt F Elshourbagy NA Ellis CE Middlemiss DN Brown F
0.35575834.12419707.html.plaintext.txt	1125	Characterization recombinant human orexin receptor pharmacology Chinese hamster ovary cell line using FLIPR
0.35575834.12419707.html.plaintext.txt	1126	Br J Pharmacol 128 1 3 1999AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	1127	Smart D Sabido David C Brough SJ Jewitt F Johns A Porter RA Jerman JC
0.35575834.12419707.html.plaintext.txt	1128	SB 334867 A first selective orexin 1 receptor antagonist
0.35575834.12419707.html.plaintext.txt	1129	Br J Pharmacol 132 1179 1182 2001AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	1130	Soffin EM Evans ML Gill CH Harries MH Benham CD Davies CH
0.35575834.12419707.html.plaintext.txt	1131	SB 334867 A antagonises orexin mediated excitation locus coeruleus
0.35575834.12419707.html.plaintext.txt	1132	Neuropharmacology 42 127 133 2002ISIMedline
0.35575834.12419707.html.plaintext.txt	1133	Sunahara RK Dessauer CW Gilman AG
0.35575834.12419707.html.plaintext.txt	1134	Complexity diversity mammalian adenylyl cyclases
0.35575834.12419707.html.plaintext.txt	1135	Annu Rev Pharmacol Toxicol 36 461 480 1996ISIMedline
0.35575834.12419707.html.plaintext.txt	1136	Sutcliffe JG de Lecea L
0.35575834.12419707.html.plaintext.txt	1137	The hypocretins excitatory neuromodulatory peptides multiple homeostatic systems including sleep feeding
0.35575834.12419707.html.plaintext.txt	1138	J Neurosci Res 62 161 168 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	1139	Sweet DC Levine AS Billington CJ Kotz CM
0.35575834.12419707.html.plaintext.txt	1140	Feeding response central orexins
0.35575834.12419707.html.plaintext.txt	1141	Brain Res 821 535 538 1999ISIMedline
0.35575834.12419707.html.plaintext.txt	1142	Switonska MM Kaczmarek P Malendowicz LK Nowak KW
0.35575834.12419707.html.plaintext.txt	1143	Orexins adipoinsular axis function rat
0.35575834.12419707.html.plaintext.txt	1144	Regul Pept 104 69 73 2002ISIMedline
0.35575834.12419707.html.plaintext.txt	1145	Szekely M Petervari E Balasko M Hernadi I Uzsoki B
0.35575834.12419707.html.plaintext.txt	1146	Effects orexins energy balance thermoregulation
0.35575834.12419707.html.plaintext.txt	1147	Regul Pept 104 47 53 2002ISIMedline
0.35575834.12419707.html.plaintext.txt	1148	Taheri S Sunter D Dakin C Moyes S Seal L Gardiner J Rossi M Ghatei M Bloom S
0.35575834.12419707.html.plaintext.txt	1149	Diurnal variation orexin A immunoreactivity prepro orexin mRNA rat central nervous system
0.35575834.12419707.html.plaintext.txt	1150	Neurosci Lett 279 109 112 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	1151	Takahashi N Okumura T Yamada H Kohgo Y
0.35575834.12419707.html.plaintext.txt	1152	Stimulation gastric acid secretion centrally administered orexin A conscious rats
0.35575834.12419707.html.plaintext.txt	1153	Biochem Biophys Res Commun 254 623 627 1999ISIMedline
0.35575834.12419707.html.plaintext.txt	1154	Thannickal TC Moore RY Nienhuis R Ramanathan L Gulyani S Aldrich M Cornford M Siegel JM
0.35575834.12419707.html.plaintext.txt	1155	Reduced number hypocretin neurons human narcolepsy
0.35575834.12419707.html.plaintext.txt	1156	Neuron 27 469 474 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	1157	Current concepts etiology diagnosis treatment narcolepsy
0.35575834.12419707.html.plaintext.txt	1158	Sleep Med 2 5 17 2001Medline
0.35575834.12419707.html.plaintext.txt	1159	Trivedi P Yu H MacNeil DJ Van der Ploeg LH Guan XM
0.35575834.12419707.html.plaintext.txt	1160	Distribution orexin receptor mRNA rat brain
0.35575834.12419707.html.plaintext.txt	1161	FEBS Lett 438 71 75 1998ISIMedline
0.35575834.12419707.html.plaintext.txt	1162	Uramura K Funahashi H Muroya S Shioda S Takigawa M Yada T
0.35575834.12419707.html.plaintext.txt	1163	Orexin activates phospholipase C protein kinase C mediated Ca2 signaling dopamine neurons ventral tegmental area
0.35575834.12419707.html.plaintext.txt	1164	Neuroreport 12 1885 1889 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	1165	Hypothalamic hypocretin orexin robust innervation spinal cord
0.35575834.12419707.html.plaintext.txt	1166	J Neurosci 19 3171 3182 1999AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	1167	Van den Pol AN Gao XB Obrietan K Kilduff TS Belousov AB
0.35575834.12419707.html.plaintext.txt	1168	Presynaptic postsynaptic actions modulation neuroendocrine neurons new hypothalamic peptide hypocretinorexin
0.35575834.12419707.html.plaintext.txt	1169	J Neurosci 18 7962 7971 1998AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	1170	Van den Pol AN Patrylo PR Ghosh PK Gao XB
0.35575834.12419707.html.plaintext.txt	1171	Lateral hypothalamus early developmental expression response hypocretin orexin
0.35575834.12419707.html.plaintext.txt	1172	J Comp Neurol 433 349 363 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	1173	Waleh NS Apte Deshpande A Terao A Ding J Kilduff TS
0.35575834.12419707.html.plaintext.txt	1174	Modulation promoter region prepro hypocretin alpha interferon
0.35575834.12419707.html.plaintext.txt	1175	Gene 262 123 128 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	1176	Wang J Osaka T Inoue S
0.35575834.12419707.html.plaintext.txt	1177	Energy expenditure intracerebroventricular administration orexin anesthetized rats
0.35575834.12419707.html.plaintext.txt	1178	Neurosci Lett 315 49 52 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	1179	Ion channel regulation G proteins
0.35575834.12419707.html.plaintext.txt	1180	Physiol Rev 75 865 885 1995AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	1181	Wieland HA Soll RM Doods HN Stenkamp D Hurnaus R Lammle B Beck Sickinger AG
0.35575834.12419707.html.plaintext.txt	1182	The SK N MC cell line expresses orexin binding site different recombinant orexin 1 type receptor
0.35575834.12419707.html.plaintext.txt	1183	Eur J Biochem 269 1128 1135 2002AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	1184	Williams G Harrold JA Cutler DJ
0.35575834.12419707.html.plaintext.txt	1185	The hypothalamus regulation energy homeostasis lifting lid black box
0.35575834.12419707.html.plaintext.txt	1186	Proc Nutr Soc 59 385 396 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	1187	Willie JT Chemelli RM Sinton CM Yanagisawa M
0.35575834.12419707.html.plaintext.txt	1188	To eat sleep Orexin regulation feeding wakefulness
0.35575834.12419707.html.plaintext.txt	1189	Annu Rev Neurosci 24 429 458 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	1190	Xi MC Morales FR Chase MH
0.35575834.12419707.html.plaintext.txt	1191	Effects sleep wakefulness injection hypocretin 1 orexin A laterodorsal tegmental nucleus cat
0.35575834.12419707.html.plaintext.txt	1192	Brain Res 901 259 264 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	1193	Yamada H Okumura T Motomura W Kobayashi Y Kohgo Y
0.35575834.12419707.html.plaintext.txt	1194	Inhibition food intake central injection anti orexin antibody fasted rats
0.35575834.12419707.html.plaintext.txt	1195	Biochem Biophys Res Commun 267 527 531 2000ISIMedline
0.35575834.12419707.html.plaintext.txt	1196	Yamamoto Y Ueta Y Date Y Nakazato M Hara Y Serino R Nomura M Shibuya I Matsukura S Yamashita H
0.35575834.12419707.html.plaintext.txt	1197	Down regulation prepro orexin gene expression genetically obese mice
0.35575834.12419707.html.plaintext.txt	1198	Brain Res Mol Brain Res 65 14 22 1999ISIMedline
0.35575834.12419707.html.plaintext.txt	1199	Yamanaka A Sakurai T Katsumoto T Yanagisawa M Goto K
0.35575834.12419707.html.plaintext.txt	1200	Chronic intracerebroventricular administration orexin A rats increases food intake daytime effect body weight
0.35575834.12419707.html.plaintext.txt	1201	Brain Res 849 248 252 1999ISIMedline
0.35575834.12419707.html.plaintext.txt	1202	Yamanaka A Tsujino N Funahashi H Honda K Guan JL Wang QP Tominaga M Goto K Shioda S Sakurai T
0.35575834.12419707.html.plaintext.txt	1203	Orexins activate histaminergic neurons via orexin 2 receptor
0.35575834.12419707.html.plaintext.txt	1204	Biochem Biophys Res Commun 290 1237 1245 2002ISIMedline
0.35575834.12419707.html.plaintext.txt	1205	Yoshida Y Fujiki N Nakajima T Ripley B Matsumura H Yoneda H Mignot E Nishino S
0.35575834.12419707.html.plaintext.txt	1206	Fluctuation extracellular hypocretin 1 orexin A levels rat relation light dark cycle sleep wake activities
0.35575834.12419707.html.plaintext.txt	1207	Eur J Neurosci 14 1075 1081 2001ISIMedline
0.35575834.12419707.html.plaintext.txt	1208	Yoshimichi G Yoshimatsu H Masaki T Sakata T
0.35575834.12419707.html.plaintext.txt	1209	Orexin A regulates body temperature coordination arousal status
0.35575834.12419707.html.plaintext.txt	1210	Exp Biol Med Maywood 226 468 476 2001AbstractFree Full Text
0.35575834.12419707.html.plaintext.txt	1211	Orexin B immunoreactive fibers terminals innervate sensory motor neurons jaw elevator muscles rat
0.35575834.12419707.html.plaintext.txt	1212	Synapse 44 106 110 2002ISIMedline
0.35575834.12419707.html.plaintext.txt	1213	Am J Physiol Cell Physiol 2836C1567 C1591 0363 614302 5
0.35575834.12419707.html.plaintext.txt	1214	00 Copyright 2002 American Physiological Society
0.12856172.11564668.html.plaintext.txt	0	Minireview Ghrelin Regulation Energy Balance A Hypothalamic Perspective Tamas L
0.12856172.11564668.html.plaintext.txt	1	Horvath Sabrina Diano Peter Sotonyi Mark Heiman Matthias Tschop
0.12856172.11564668.html.plaintext.txt	2	Reproductive Neuroscience Unit T
0.12856172.11564668.html.plaintext.txt	3	Department Obstetrics Gynecology Department Neurobiology T
0.12856172.11564668.html.plaintext.txt	4	Yale Medical School New Haven Connecticut 06520 Department Anatomy Histology P
0.12856172.11564668.html.plaintext.txt	5	Faculty Veterinary Science Szent Istvan University Budapest Hungary 1400 Lilly Research Laboratories M
0.12856172.11564668.html.plaintext.txt	6	Address correspondence requests reprints Tamas Horvath Department ObstetricsGynecology Yale Medical School 333 Cedar Street FMB 339 New Haven Connecticut 06520
0.12856172.11564668.html.plaintext.txt	7	Abstract Top Abstract Introduction Discovery Ghrelin Sources Ghrelin Ghrelin GH Secretion Ghrelin Energy Balance Ghrelin Brain Centers
0.12856172.11564668.html.plaintext.txt	8	References The recently discovered hormone ghrelin recognized important regulator GH secretion energy homeostasis
0.12856172.11564668.html.plaintext.txt	9	Orexigenic adipogenic ghrelin produced stomach intestine placenta pituitary possibly hypothalamus
0.12856172.11564668.html.plaintext.txt	10	The concentration circulating ghrelin principally derived stomach influenced acute chronic changes nutritional state
0.12856172.11564668.html.plaintext.txt	11	To date studies focused role ghrelin GH secretion function complementing leptin action prevent energy deficits
0.12856172.11564668.html.plaintext.txt	12	The potential significance ghrelin etiology obesity cachexia well regulation growth processes subject ongoing discussions
0.12856172.11564668.html.plaintext.txt	13	A large quantity information based clinical trials experimental studies ghrelin previously available synthetic ghrelin receptor agonists GH secretagogues must integrated rapidly increasing amount data central regulation metabolism appetite
0.12856172.11564668.html.plaintext.txt	14	In overview summarize recent findings strategies integration ghrelin neuroendocrine networks regulate energy homeostasis
0.12856172.11564668.html.plaintext.txt	15	Introduction Top Abstract Introduction Discovery Ghrelin Sources Ghrelin Ghrelin GH Secretion Ghrelin Energy Balance Ghrelin Brain Centers
0.12856172.11564668.html.plaintext.txt	16	References OBESITY AND RELATED disorders among leading causes illness mortality developed world 1
0.12856172.11564668.html.plaintext.txt	17	To better understand pathophysiological mechanisms underlie metabolic disorders increasing attention paid central regulatory elements energy homeostasis including food intake energy expenditure 2 3 4 5
0.12856172.11564668.html.plaintext.txt	18	The past two decades provided overwhelming evidence critical role hypothalamic peptidergic systems play central regulation appetite metabolism 6 7
0.12856172.11564668.html.plaintext.txt	19	The discovery ghrelin 8 9 10 11 influence appetite fuel utilization body weight body composition complementary ghrelin GH releasing effect 12 adds yet another component complexity central regulation energy balance
0.12856172.11564668.html.plaintext.txt	20	Discovery Ghrelin Top Abstract Introduction Discovery Ghrelin Sources Ghrelin Ghrelin GH Secretion Ghrelin Energy Balance Ghrelin Brain Centers
0.12856172.11564668.html.plaintext.txt	21	References Reverse pharmacology may appropriate term describe road ghrelin discovery
0.12856172.11564668.html.plaintext.txt	22	First synthetic agonists ghrelin like activity GH releasing peptides GHRPs GH secretagogues GHSs discovered Bowers co workers late seventies 9 13 14 15 followed cloning ghrelin GHS receptor GHS R 1996 Smith co workers 16 17 18
0.12856172.11564668.html.plaintext.txt	23	Subsequently elegant studies Kojima co workers led identification acylated 28 residue peptide endogenous bioactive ligand GHS R 8 9 10 11
0.12856172.11564668.html.plaintext.txt	24	It called ghrelin term contains ghre etymological root growth many languages
0.12856172.11564668.html.plaintext.txt	25	GH relin suffix releasing substances generic names according USP Dictionary USAN International Drug Names also represents abbreviation growth hormone release characteristic effect ghrelin 8 11
0.12856172.11564668.html.plaintext.txt	26	The Ser3 acylation seems responsible bioactivity ghrelin modification observed first time mammalian physiology
0.12856172.11564668.html.plaintext.txt	27	There data support tempting speculation purpose modification increase ghrelin lipophilic properties facilitate transport across blood brain barrier
0.12856172.11564668.html.plaintext.txt	28	However octanoyl side chain essential binding activation GHS R subtype 1a vitro 19
0.12856172.11564668.html.plaintext.txt	29	Ghrelin might also bind different GHS R subtypes receptor families octanoyl side chain needed
0.12856172.11564668.html.plaintext.txt	30	Detection purification gastric enzyme responsible acylation ghrelin may shed light fascinating question possibly even reveal existence putative hormones carrying modification
0.12856172.11564668.html.plaintext.txt	31	Sources Ghrelin Top Abstract Introduction Discovery Ghrelin Sources Ghrelin Ghrelin GH Secretion Ghrelin Energy Balance Ghrelin Brain Centers
0.12856172.11564668.html.plaintext.txt	32	References Ghrelin predominantly produced stomach 8 20 21 22 whereas substantially lower amounts derived bowel 21 22 pituitary 23 kidney 24 placenta 25 hypothalamus 8 22
0.12856172.11564668.html.plaintext.txt	33	Although majority circulating ghrelin produced stomach sources may increase ghrelin secretion compensatory manner
0.12856172.11564668.html.plaintext.txt	34	After gastrectomy example plasma ghrelin level surprisingly reduced 65 26
0.12856172.11564668.html.plaintext.txt	35	One urgent debatable hypotheses whether ghrelin produced physiologically relevant amounts hypothalamus
0.12856172.11564668.html.plaintext.txt	36	This unresolved issue focus several research groups
0.12856172.11564668.html.plaintext.txt	37	Data published presented recent meetings accordance ongoing investigations shown ghrelin present several regions hypothalamus use immunohistochemical detection methods 8 22
0.12856172.11564668.html.plaintext.txt	38	Depending ghrelin epitope recognized antibody use ghrelin positive cells identified varying hypothalamic areas whereas antisera successfully used RIAs
0.12856172.11564668.html.plaintext.txt	39	Detection hypothalamic ghrelin mRNA use PCR accomplished 8 however issue needs investigated detection regional distribution ghrelin mRNA situ hybridization
0.12856172.11564668.html.plaintext.txt	40	At point clear detection ghrelin hypothalamus using immunohistochemistry reflects ghrelin peptide produced hypothalamic neurons ghrelin peptide derived stomach
0.12856172.11564668.html.plaintext.txt	41	It seems logical gastric ghrelin reflects acute nutritional state
0.12856172.11564668.html.plaintext.txt	42	However even minimal ghrelin expression hypothalamus 8 12 circulating placental ghrelin pregnancy 25 may significantly influence food intake nutrition partitioning fat utilization
0.12856172.11564668.html.plaintext.txt	43	Regardless source end likely modulation hypothalamic circuits ghrelin mediates changes energy homeostasis
0.12856172.11564668.html.plaintext.txt	44	Ghrelin GH Secretion Top Abstract Introduction Discovery Ghrelin Sources Ghrelin Ghrelin GH Secretion Ghrelin Energy Balance Ghrelin Brain Centers
0.12856172.11564668.html.plaintext.txt	45	References Based rodent experiments 27 28 29 clinical studies 30 31 32 33 evident ghrelin indeed potent GH releasing agent
0.12856172.11564668.html.plaintext.txt	46	However significant correlation seems exist plasma ghrelin concentrations circulating levels GH IGF I unpublished data Tschop et al
0.12856172.11564668.html.plaintext.txt	47	even though ghrelin GH increase fasting 34 35
0.12856172.11564668.html.plaintext.txt	48	Very recent data indicate ghrelin induced GH secretion directly opposed somatostatin action also involves mediation GHRH 33 36 37
0.12856172.11564668.html.plaintext.txt	49	However ghrelin also releases GH vitro primary rat pituitary cells 8 12 GHRP 2 potent ghrelin receptor agonist releases GH vivo patients GHRH receptor mutations 38
0.12856172.11564668.html.plaintext.txt	50	This indicates existence GHRH independent effects ghrelin GH secretion mediated hypophyseal GHS Rs originally cloned pituitary 16
0.12856172.11564668.html.plaintext.txt	51	Alternatively ghrelin may stimulate unidentified hypothalamic agent U factor turn stimulates GH release 39
0.12856172.11564668.html.plaintext.txt	52	Ghrelin Energy Balance Top Abstract Introduction Discovery Ghrelin Sources Ghrelin Ghrelin GH Secretion Ghrelin Energy Balance Ghrelin Brain Centers
0.12856172.11564668.html.plaintext.txt	53	References The first published evidence involvement ghrelin regulation appetite provided Ghigo co workers 30
0.12856172.11564668.html.plaintext.txt	54	They described 3 4 healthy volunteers spontaneously reported hunger following ghrelin administration side effect clinical study analyzing GH release 30
0.12856172.11564668.html.plaintext.txt	55	This hunger inducing effect ghrelin confirmed two studies 3 7 33 9 11 individuals report hunger sensation ghrelin injection 40
0.12856172.11564668.html.plaintext.txt	56	A large number animal studies added strength argument ghrelin involved regulation energy balance
0.12856172.11564668.html.plaintext.txt	57	For example exogenous ghrelin induces adiposity rodents stimulating acute increase food intake well reduction fat utilization 12 41 42 43 44 45 46
0.12856172.11564668.html.plaintext.txt	58	Adipogenic well orexigenic effects ghrelin independent ability stimulate GH secretion 12 46 likely mediated specific central network neurons also modulated leptin 2 3 4 5 6 7 9 12 41 42 43 44 45 46
0.12856172.11564668.html.plaintext.txt	59	Regulation ghrelin secretion well biological effects appear opposite leptin
0.12856172.11564668.html.plaintext.txt	60	However teleological point view ghrelin leptin might really complementary players one regulatory system developed inform central nervous system current status acute chronic energy balance 12 38 39 40 41 42 43 44 45 46 47 48 49
0.12856172.11564668.html.plaintext.txt	61	In addition specific role ghrelin might ensure provision calories GH requires growth repair 41
0.12856172.11564668.html.plaintext.txt	62	In humans circulating ghrelin levels decreased chronic obesity 48 acute caloric intake 26 34 47 states positive energy balance whereas plasma levels ghrelin increased fasting 12 34 cachectic patients anorexia nervosa 26
0.12856172.11564668.html.plaintext.txt	63	Of course yet proven rather modest changes circulating ghrelin 100 fmol range physiological relevance hypothalamic receptor sites
0.12856172.11564668.html.plaintext.txt	64	One plausible explanation ghrelin indeed hormone signaling need conserve energy 12 ghrelin secretion triggered counter deficit energy storage prevent starvation cachexia
0.12856172.11564668.html.plaintext.txt	65	A recent study shows pre meal rise human plasma ghrelin suggesting possible role ghrelin hunger signal triggering meal initiation 34
0.12856172.11564668.html.plaintext.txt	66	In rodents fasting hypoglycemia increase ghrelin levels whereas intake food especially carbohydrates dextrose decreases ghrelin secretion 12 41 50
0.12856172.11564668.html.plaintext.txt	67	We speculate obvious connection glucose levels ghrelin secretion GH secretion likely involved physiological mechanism diagnostic procedures oral glucose tolerance testing acromegaly insulin tolerance testing GH deficiency
0.12856172.11564668.html.plaintext.txt	68	Differential effects ghrelin might mediated separate ghrelin GHS R subtypes recently suggested Thorner co workers 51
0.12856172.11564668.html.plaintext.txt	69	Based series elaborate studies using GHS R antagonists D Lys3GHRP 6 BMS 265711 also NPY antagonist NPY Y1 R antagonist D Trp32NPY showed orexigenic effect ghrelin dissociated GH releasing effects suggesting distinct GHS R subtypes
0.12856172.11564668.html.plaintext.txt	70	Based observation differential orexigenic effects hexarelin analogs GH secretagogue actions pituitary gland 52 53 existence additional subtypes GHS R 16 17 18 previously hypothesized
0.12856172.11564668.html.plaintext.txt	71	The putative adipogenic effects ghrelin humans remains shown possible ghrelin different effects energy balance humans rodents
0.12856172.11564668.html.plaintext.txt	72	In addition ghrelin induced adiposity could transient effect therapeutic potential ghrelin cachectic humans might therefore turn disappointing efficacy leptin therapy human obesity 5 54
0.12856172.11564668.html.plaintext.txt	73	Carefully conducted clinical studies focusing body composition well long term studies ghrelin treatment rodents necessary address question
0.12856172.11564668.html.plaintext.txt	74	Ghrelin Brain Centers Energy Balance Top Abstract Introduction Discovery Ghrelin Sources Ghrelin Ghrelin GH Secretion Ghrelin Energy Balance Ghrelin Brain Centers
0.12856172.11564668.html.plaintext.txt	75	References Our current understanding involvement different hypothalamic systems metabolic regulation arises early degeneration studies rats
0.12856172.11564668.html.plaintext.txt	76	Destruction distinct hypothalamic regions particularly ventromedial nucleus also areas paraventricular dorsomedial nuclei induced hyperphagia 55 56 57 58 59 60
0.12856172.11564668.html.plaintext.txt	77	In contrast discrete lesions placed lateral hypothalamus 61 62 reduced food intake
0.12856172.11564668.html.plaintext.txt	78	During last two decades substantial amount research demonstrated NPY administered cerebral ventricles 63 specific hypothalamic sites 64 induced food intake
0.12856172.11564668.html.plaintext.txt	79	However addition NPY several hypothalamic peptides found affect appetite feeding behavior details see Refs
0.12856172.11564668.html.plaintext.txt	80	Appetite stimulating neuropeptides include melanin concentrating hormone hypocretinsorexins produced distinct subset neurons lateral hypothalamus perifornical region 65 66 67 68 agouti related protein AGRP coproduced NPY arcuate nucleus neurons 69 70 71
0.12856172.11564668.html.plaintext.txt	81	Appetite suppressing neuropeptides include POMC derivate MSH 6 7 72 produced arcuate nucleus perikarya 73
0.12856172.11564668.html.plaintext.txt	82	An important milestone link central regulation metabolism peripheral levels energy storage discovery adipose hormone leptin
0.12856172.11564668.html.plaintext.txt	83	Genetic mouse rat mutants including dbdb obob mice fafa rats become strikingly obese
0.12856172.11564668.html.plaintext.txt	84	Molecular analysis shown primary genetic defect animals relates either abolished leptin production obob mice impaired leptin receptors dbdb mice fafa rats leptin R 5 74 75 76 77
0.12856172.11564668.html.plaintext.txt	85	Similar examples obesity humans found associated mutation leptin leptin receptor 78 79 80
0.12856172.11564668.html.plaintext.txt	86	Leptin released adipose tissue suggested key signal reflecting adipose stores
0.12856172.11564668.html.plaintext.txt	87	Leptin receptors found hypothalamus particularly arcuate nucleus leptin thought exert primary feedback signaling 81 82 83 84 85 86 87
0.12856172.11564668.html.plaintext.txt	88	Recent experiments rodents primates attempting tie together diverse hypothalamic peptidergic systems hormone receptors including leptin receptors decipher hypothalamic signaling modality underlying regulation daily energy homeostasis 81 82 83 84 85 86 87 88 89 90 91 92
0.12856172.11564668.html.plaintext.txt	89	A schematic illustration interactions way ghrelin signaling may integrated circuits shown Fig
0.12856172.11564668.html.plaintext.txt	90	View larger version 61K Figure 1
0.12856172.11564668.html.plaintext.txt	91	Schematic representation interaction key hypothalamic peptidergic systems central regulation daily energy homeostasis relationship peripheral putative hypothalamic ghrelin
0.12856172.11564668.html.plaintext.txt	92	Ghrelin hunger signal released stomach circulation may produced subset hypothalamic neurons red
0.12856172.11564668.html.plaintext.txt	93	Leptin satiety signal released white adipose tissue WAT circulatory system
0.12856172.11564668.html.plaintext.txt	94	Ghrelin red arrows leptin orange arrows directly target hypothalamus brain stem areas
0.12856172.11564668.html.plaintext.txt	95	While brain stem areas drawing illustrated efferent targets hypothalamic circuits critical pathways exists brain stem hypothalamus well mediate ascending ghrelin leptin signaling
0.12856172.11564668.html.plaintext.txt	96	AGRP produced NPY cells yellow acts block inhibitory action POMC derivate MSH green feeding
0.12856172.11564668.html.plaintext.txt	97	Both AGRPNPY POMC cells apparent targets direct ghrelin action via GHS R
0.12856172.11564668.html.plaintext.txt	98	The NPY neurons receive lateral hypothalamic input including HCRT brown melanin concentrating hormone MCH blue innervation project number regions brain particularly implicated feeding mechanisms including paraventricular nucleus PVN lateral hypothalamus LH ventromedial nucleus VMH perifornical region PF dorsomedial nucleus DMH
0.12856172.11564668.html.plaintext.txt	99	The regions also receive direct lateral hypothalamic input well innervation MSH cells
0.12856172.11564668.html.plaintext.txt	100	These regions turn project large black arrow widely throughout brain loci including medial thalamic nuclei MT central gray cg dorsal motor nucleus vagus DMV cortex nucleus solitary tract NTS locus coeruleus LC spinal cord amygdala
0.12856172.11564668.html.plaintext.txt	101	Ghrelin targeted arcuate nucleus neurons may also affect neuroendocrine cells responsible regulation pituitary hormone secretions including gonadotrophs LHFSH TSH ACTH GH
0.12856172.11564668.html.plaintext.txt	102	It yet determined role central vs
0.12856172.11564668.html.plaintext.txt	103	peripheral ghrelin plays regulation circuitry sites subcellular levels ghrelin signaling interacting leptin
0.12856172.11564668.html.plaintext.txt	104	Peripheral ghrelin mainly produced gastrointestinal tract 8 10 22 23 24
0.12856172.11564668.html.plaintext.txt	105	It reaches ghrelin receptors anterior pituitary potentially mediobasal mediolateral hypothalamus general circulation stimulate GH release regulate energy homeostasis 12
0.12856172.11564668.html.plaintext.txt	106	It remains determined whether circulating ghrelin reach brain areas outside blood brain barrier ventromedial arcuate nucleus 93 ability target areas protected blood brain barrier
0.12856172.11564668.html.plaintext.txt	107	Areas protected blood brain barrier include hypothalamic nuclei rest brain 93
0.12856172.11564668.html.plaintext.txt	108	Ghrelin containing cells also present mediobasal hypothalamus GHRH cells neuronal network regulates energy balance located 8 22
0.12856172.11564668.html.plaintext.txt	109	Detailed phenotypes macroscopic connectivity different hypothalamic networks regulating metabolism described numerous recent outstanding reviews 2 3 4 5 6 7
0.12856172.11564668.html.plaintext.txt	110	Among hypothalamic peptidergic circuits particular significance attributed arcuate nucleus opiate neurons produce MSH main anorexigen energy expenditure enhancer 72 interrelationship another group arcuate nucleus neurons produce NPY endogenous antagonist MSH AGRP 69
0.12856172.11564668.html.plaintext.txt	111	The interaction two distinct populations cells currently considered primum movens regulation energy homeostasis
0.12856172.11564668.html.plaintext.txt	112	However peptidergic circuits within hypothalamus including lateral hypothalamic orexinhypocretin melanin concentrating hormone producing cells appear respond peripheral metabolic signals alter food intake well energy expenditure 65 66 67 68
0.12856172.11564668.html.plaintext.txt	113	In light aforementioned excellent reviews 2 3 4 5 6 7 avoid depth description peptidergic systems attempt emphasize better appreciation neuronal doctrine integration emerging experimental data ghrelin
0.12856172.11564668.html.plaintext.txt	114	In brain receptors ghrelin detected multiple hypothalamic nuclei well hippocampus substantia nigra ventral tegmental area dorsal median raphe nuclei 8 94 95 96 97 98
0.12856172.11564668.html.plaintext.txt	115	In series experiments Dickson co workers first using synthetic GHS R agonist ghrelin provided evidence novel metabolic hormone fact interacts aforementioned hypothalamic peptidergic systems central regulation metabolism 99 100 101 102 103
0.12856172.11564668.html.plaintext.txt	116	For example found following central ghrelin administration c fos early proto oncogen reflects cellular activity induced medial arcuate nucleus NPYAGRP cells located 103
0.12856172.11564668.html.plaintext.txt	117	It also shown Y1 receptor antagonists well melanocortin agonists antisera NPY AGRP may interfere ghrelin feeding inducing effect 42 43 46
0.12856172.11564668.html.plaintext.txt	118	However absence NPY genetically engineered NPY ko mice diminish ghrelin induced feeding adiposity suggesting key role AGRP mediation ghrelin effects energy balance 12
0.12856172.11564668.html.plaintext.txt	119	The effect ghrelin metabolism seems exact opposite leptin 2 3 4 5 6 7 9 10 12
0.12856172.11564668.html.plaintext.txt	120	In obesity plasma leptin levels elevated ghrelin plasma levels decreased indicating physiological adaptations positive energy balance rather involvement etiology obesity 48 49
0.12856172.11564668.html.plaintext.txt	121	Of course important note ghrelin regulated acutely like satiety factor leptin levels regulated meals rather actual increase adipose stores
0.12856172.11564668.html.plaintext.txt	122	Ghrelin Hypothalamic Signaling Requires Synapses Top Abstract Introduction Discovery Ghrelin Sources Ghrelin Ghrelin GH Secretion Ghrelin Energy Balance Ghrelin Brain Centers
0.12856172.11564668.html.plaintext.txt	123	References Figure 1 depicts highly complex interaction variety hypothalamic peptidergic systems including putative ghrelin network central regulation energy balance
0.12856172.11564668.html.plaintext.txt	124	It noted however drawing inclusive represents tip iceberg
0.12856172.11564668.html.plaintext.txt	125	There many hypothalamic extra hypothalamic neurotransmitters neuropeptides act via aforementioned circuits example coexistence GABA NPY 91 separate pathways example ciliary neurotrophic growth factor CNTF 104 105 interconnected illustrated systems review see Refs
0.12856172.11564668.html.plaintext.txt	126	In addition receptors different neuropeptides well peripheral hormones affect metabolism including insulin thyroid hormones gonadal steroids glucocorticoids also present regions
0.12856172.11564668.html.plaintext.txt	127	During food deprivation leptin levels rapidly decline 106 NPYAGRP production elevated POMC neurons suppressed 106 107 108 109 110 circulating ghrelin levels increase 12 33 41 48 suggesting leptin ghrelin coregulate hypothalamic peptidergic systems opposite ways
0.12856172.11564668.html.plaintext.txt	128	These observations support hypothesis ghrelin hunger signal counterpart leptin aiming prevent energy deficit
0.12856172.11564668.html.plaintext.txt	129	However considering extreme complexity hypothalamic interactions different peptidergic circuits peripheral hormone receptors necessary determine hierarchy direction signaling flow within systems understand ghrelin central effect metabolic regulation
0.12856172.11564668.html.plaintext.txt	130	For multidisciplinary approach mandatory
0.12856172.11564668.html.plaintext.txt	131	The hypothalamus composed complicated set regulatory neurons cases cannot identified traditional means cell segregation
0.12856172.11564668.html.plaintext.txt	132	location soma size dendritic arbor
0.12856172.11564668.html.plaintext.txt	133	Therefore identify specific types neurons cytochemistry must used
0.12856172.11564668.html.plaintext.txt	134	In addition brain areas primary mode communication hypothalamic peptidergic circuits via synapses
0.12856172.11564668.html.plaintext.txt	135	The reliable way assessing synapses use conventional electron microscopy electrophysiology proximity different cells assessed light microscopy convincing indicator neuronal interaction
0.12856172.11564668.html.plaintext.txt	136	Thus determination qualitative quantitative synaptological relationship GHS Rs ghrelin producing neurons key hypothalamic peptidergic systems receptors important step gaining insight hypothalamic signaling modality ghrelin
0.12856172.11564668.html.plaintext.txt	137	Of course anatomical experiments alone sufficient determine actual involvement presynaptic ghrelin system regulation postsynaptic circuit provides invaluable map necessary correct interpretation data gathered tools
0.12856172.11564668.html.plaintext.txt	138	In fact anatomical studies need complemented parallel electrophysiological analyses
0.12856172.11564668.html.plaintext.txt	139	An elegant example approach recent work Cowley colleagues 111 leptin effect analyzed genetically tagged arcuate nucleus MSH cells qualitative synaptology cells simultaneously assessed
0.12856172.11564668.html.plaintext.txt	140	That approach eliminated pitfalls individual experimental techniques immediately provided comprehensive view given hypothalamic neuronal system 111
0.12856172.11564668.html.plaintext.txt	141	The significance determining spatial relationship different afferents using anatomical electrophysiological tools may appreciated one considers synapse potently able affect postsynaptic cells located proximally either cell body postsynaptic dendrite located distally
0.12856172.11564668.html.plaintext.txt	142	In addition previous electrophysiological 111 112 113 morphological observations 92 111 indicate extensive interaction exists presynaptic terminals affect hypothalamic cells arcuate nucleus NPYAGRP MSH cell bodies located model efferent target parvicellular paraventricular nucleus
0.12856172.11564668.html.plaintext.txt	143	The impact ghrelin arcuate parvicellular paraventricular nucleus neurons readily dependent synaptic organization postsynaptic cells interaction systems presynaptically
0.12856172.11564668.html.plaintext.txt	144	One best examples illustrate synaptologic interaction relationship NPYAGRP MSH systems
0.12856172.11564668.html.plaintext.txt	145	Electrophysiological anatomical observations pointed arcuate paraventricular nuclei primary sites interplay AGRP MSH systems 111 114
0.12856172.11564668.html.plaintext.txt	146	Because ghrelin action appears mediated NPYAGRP system unlikely ghrelin act arcuate nucleus well paraventricular nucleus modulate interaction NPYAGRP MSH
0.12856172.11564668.html.plaintext.txt	147	It may peripheral central ghrelin contribute equally regulation hypothalamic areas also conceivable stomach derived ghrelin affects arcuate nucleus blood brain barrier less effective whereas hypothalamic ghrelin involved modulation hypothalamic sites within blood brain barrier paraventricular nucleus
0.12856172.11564668.html.plaintext.txt	148	An alternative equally feasible pathway ghrelin signaling stomach via ascending neural network vagus nerve brain stem nuclei ultimately reaches hypothalamus 43
0.12856172.11564668.html.plaintext.txt	149	When electrophysiological anatomical techniques combined conventional physiological molecular biological approaches well recently developed revolutionary tracing technique DeFalco et al
0.12856172.11564668.html.plaintext.txt	150	115 allows tracing inputs chemically identified subpopulations neurons reasonable expect thorough understanding ghrelin action achieved faster pace great advances made toward general understanding hypothalamic machinery metabolism regulation
0.12856172.11564668.html.plaintext.txt	151	Acknowledgments We thankful Michael Statnick Paul Burn Jose Caro Marya Shanabrough critical review
0.12856172.11564668.html.plaintext.txt	152	Footnotes This work supported NIH Grants MH 59847 RR 14451
0.12856172.11564668.html.plaintext.txt	153	Abbreviations AGRP Agouti related protein GHRP GH releasing peptide GHS GH secretagogue GHS R GHS receptor
0.12856172.11564668.html.plaintext.txt	154	Accepted publication July 27 2001
0.12856172.11564668.html.plaintext.txt	155	References Top Abstract Introduction Discovery Ghrelin Sources Ghrelin Ghrelin GH Secretion Ghrelin Energy Balance Ghrelin Brain Centers
0.12856172.11564668.html.plaintext.txt	156	References Mokdad AH Serdula MK Dietz WH Bowman BA Marks JS Koplan JP 2000 The continuing epidemic obesity United States
0.12856172.11564668.html.plaintext.txt	157	JAMA 2841650 1651Free Full Text Kalra SP Dube MG Pu S Xu B Horvath TL Kalra PS 1999 Interacting appetite regulating pathways hypothalamic regulation body weight
0.12856172.11564668.html.plaintext.txt	158	Endocr Rev 2068 100AbstractFree Full Text Schwartz MW Woods SC Porte Jr D Seeley RJ Baskin DG 2000 Central nervous system control food intake
0.12856172.11564668.html.plaintext.txt	159	Nature 404661 671Medline Elmquist JK Maratos Flier E Saper CB Flier JS 1998 Unraveling central nervous system pathways underlying responses leptin
0.12856172.11564668.html.plaintext.txt	160	Nature Neuroscience 6445 450CrossRef Friedman JM Halaas JL 1998 Leptin regulation body weight mammals
0.12856172.11564668.html.plaintext.txt	161	Nature 395763 770CrossRefMedline Ahima RS Osei SY 2001 Molecular regulation eating behavior new insights prospects therapeutic strategies
0.12856172.11564668.html.plaintext.txt	162	Trends Mol Med 7205 213CrossRefMedline Spiegelman BM Flier JS 2001 Obesity regulation energy balance
0.12856172.11564668.html.plaintext.txt	163	Cell 104531 543Medline Kojima M Hosoda H Date Y Nakazato M Matsuo H Kangawa K 1999 Ghrelin growth hormone releasing acylated peptide stomach
0.12856172.11564668.html.plaintext.txt	164	Nature 402656 660CrossRefMedline Bowers CY 2001 Unnatural growth hormone releasing peptide begets natural ghrelin
0.12856172.11564668.html.plaintext.txt	165	J Clin Endocrinol Metab 861464 1469Free Full Text Kojima M Hosoda H Matsuo H Kangawa K 2001 Ghrelin discovery natural endogenous ligand growth hormone secretagogue receptor
0.12856172.11564668.html.plaintext.txt	166	Trends Endocrinol Metab 12118 122CrossRefMedline Hosoda H Kojima M Matsuo H Kangawa K 2000 Purification characterization rat des Gln14 Ghrelin second endogenous ligand growth hormone secretagogue receptor
0.12856172.11564668.html.plaintext.txt	167	J Biol Chem 27521995 2000AbstractFree Full Text Tschop M Smiley D Heiman ML 2000 Ghrelin induces adiposity rodents
0.12856172.11564668.html.plaintext.txt	168	Nature 407908 913CrossRefMedline Momany FA Bowers CY Reynolds GA Chang D Hong A Newlander K 1981 Design synthesis biological activity peptides release growth hormone vitro
0.12856172.11564668.html.plaintext.txt	169	Endocrinology 10831 39Abstract Bowers CY Momany F Reynolds GA Chang D Hong A Chang K 1980 Structure activity relationships synthetic pentapeptide specifically releases growth hormone vitro
0.12856172.11564668.html.plaintext.txt	170	Endocrinology 106663 667Medline Bowers CY 1998 Growth hormone releasing peptide GHRP
0.12856172.11564668.html.plaintext.txt	171	Cell Mol Life Sci 541316 1329CrossRefMedline Howard AD Feighner SD Cully DF et al
0.12856172.11564668.html.plaintext.txt	172	1996 A receptor pituitary hypothalamus functions growth hormone release
0.12856172.11564668.html.plaintext.txt	173	Science 273974 977Abstract Smith RG Pong SS Hickey G et al
0.12856172.11564668.html.plaintext.txt	174	1996 Modulation pulsatile GH release novel receptor hypothalamus pituitary gland
0.12856172.11564668.html.plaintext.txt	175	Rec Prog Horm Res 51261 286Medline Smith RG Van der Ploeg LH Howard AD et al
0.12856172.11564668.html.plaintext.txt	176	1997 Peptidomimetic regulation growth hormone secretion
0.12856172.11564668.html.plaintext.txt	177	Endocr Rev 18621 645AbstractFree Full Text Bednarek MA Feighner SD Pong SS et al
0.12856172.11564668.html.plaintext.txt	178	2000 Structure function studies new growth hormone releasing peptide ghrelin minimal sequence ghrelin necessary activation growth hormone secretagogue receptor 1a
0.12856172.11564668.html.plaintext.txt	179	J Med Chem 434370 4376CrossRefMedline Dornonville de la Cour C Bjorkqvist M Sandvik AK et al
0.12856172.11564668.html.plaintext.txt	180	2001 A like cells rat stomach contain ghrelin operate gastrin control
0.12856172.11564668.html.plaintext.txt	181	Regul Pept 99141 150CrossRefMedline Date Y Kojima M Hosoda H et al
0.12856172.11564668.html.plaintext.txt	182	2000 Ghrelin novel growth hormone releasing acylated peptide synthesized distinct endocrine cell type gastrointestinal tracts rats humans
0.12856172.11564668.html.plaintext.txt	183	Endocrinology 1414255 4261AbstractFree Full Text Kagotani Y Sakata I Yamazaki M Nakamura K Hayashi Y Kangawa K 2001 Localization ghrelin immunopositive cells rat hypothalamus intestinal tract
0.12856172.11564668.html.plaintext.txt	184	Proceedings 83rd Annual Meeting The Endocrine Society Denver CO 2001 p
0.12856172.11564668.html.plaintext.txt	185	337 Korbonits M Kojima M Kangawa K Grossman AB 2001 Presence ghrelin normal adenomatous human pituitary
0.12856172.11564668.html.plaintext.txt	186	Endocrine 14101 104Medline Mori K Yoshimoto A Takaya K et al
0.12856172.11564668.html.plaintext.txt	187	2000 Kidney produces novel acylated peptide ghrelin
0.12856172.11564668.html.plaintext.txt	188	FEBS Lett 486213 216CrossRefMedline Gualillo O Caminos J Blanco M et al
0.12856172.11564668.html.plaintext.txt	189	2001 Ghrelin novel placental derived hormone
0.12856172.11564668.html.plaintext.txt	190	Endocrinology 142788 794AbstractFree Full Text Ariyasu H Takaya K Tagami T et al
0.12856172.11564668.html.plaintext.txt	191	2001 Plasma ghrelin levels influenced acute chronic feeding states humans
0.12856172.11564668.html.plaintext.txt	192	Proceedings 83rd Annual Meeting The Endocrine Society Denver CO 2001 p 336 Date Y Murakami N Kojima M et al
0.12856172.11564668.html.plaintext.txt	193	2000 Central effects novel acylated peptide ghrelin growth hormone release rats
0.12856172.11564668.html.plaintext.txt	194	Biochem Biophys Res Commun 275477 480CrossRefMedline Seoane LM Tovar S Baldelli R et al
0.12856172.11564668.html.plaintext.txt	195	2000 Ghrelin elicits marked stimulatory effect GH secretion freely moving rats
0.12856172.11564668.html.plaintext.txt	196	Eur J Endocrinol 143R7 R9 Tolle V Zizzari P Tomasetto C Rio MC Epelbaum J Bluet Pajot MT 2001 In vivo vitro effects ghrelinmotilin related peptide growth hormone secretion rat
0.12856172.11564668.html.plaintext.txt	197	Neuroendocrinology 7354 61CrossRefMedline Arvat E Di Vito L Broglio F et al
0.12856172.11564668.html.plaintext.txt	198	2000 Preliminary evidence Ghrelin natural GH secretagogue GHS receptor ligand strongly stimulates GH secretion humans
0.12856172.11564668.html.plaintext.txt	199	J Endocrinol Invest 23493 495Medline Peino R Baldelli R Rodriguez Garcia J et al
0.12856172.11564668.html.plaintext.txt	200	2000 Ghrelin induced growth hormone secretion humans
0.12856172.11564668.html.plaintext.txt	201	Eur J Endocrinol 143R11 R14 Takaya K Ariyasu H Kanamoto N et al
0.12856172.11564668.html.plaintext.txt	202	2000 Ghrelin strongly stimulates growth hormone release humans
0.12856172.11564668.html.plaintext.txt	203	J Clin Endocrinol Metab 854908 4911AbstractFree Full Text Arvat E Maccario M Di Vito L et al
0.12856172.11564668.html.plaintext.txt	204	2001 Endocrine activities ghrelin natural growth hormone secretagogue GHS humans comparison interactions hexarelin nonnatural peptidyl GHS GH releasing hormone
0.12856172.11564668.html.plaintext.txt	205	J Clin Endocrinol Metab 861169 1174AbstractFree Full Text Cummings E Purnell JQ Frayo SR Schmidova K Wisse BE Weigle DS 2001 A preprandial rise plasma ghrelin levels suggests role meal initiation humans
0.12856172.11564668.html.plaintext.txt	206	Diabetes 501714 1719AbstractFree Full Text Maccario M Aimaretti G Corneli G et al
0.12856172.11564668.html.plaintext.txt	207	2000 Short term fasting abolishes sex related difference GH leptin secretion humans
0.12856172.11564668.html.plaintext.txt	208	Am J Physiol Endocrinol Metab 279E411 E416 Gurd W Parent G Eniojukan R Bowers CY Tannenbaum GS 2001 Interrelationship novel peptide ghrelin somatostatinGHRH inregulation pulsatile GH secretion
0.12856172.11564668.html.plaintext.txt	209	Proceedings 83rd Annual Meeting The Endocrine Society Denver CO 2001 p 72 Tannenbaum GS Bowers CY 2001 Interactions growth hormone secretagogues growth hormone releasing hormonesomatostatin
0.12856172.11564668.html.plaintext.txt	210	Endocrine 1421 27Medline Gondo RG Aguiar Oliveira MH Hayashida CY et al
0.12856172.11564668.html.plaintext.txt	211	2001 Growth hormone releasing peptide 2 stimulates GH secretion GH deficient patients mutated GH releasing hormone receptor
0.12856172.11564668.html.plaintext.txt	212	J Clin Endocrinol Metab 863279 3283AbstractFree Full Text Bowers CY 1998 Synergistic release growth hormone GHRP GHRH Scope implication
0.12856172.11564668.html.plaintext.txt	213	Growth hormone secretagogues clinical practice
0.12856172.11564668.html.plaintext.txt	214	1 27 Broglio F Arvat E Benso A et al
0.12856172.11564668.html.plaintext.txt	215	Ghrelin natural GH secretagogue produced stomach induces hyperglycemia reduces insulin secretion humans
0.12856172.11564668.html.plaintext.txt	216	J Clin Endocrinol Metab press Heiman ML Tschop M 2001 Ghrelin acts provide calories growth hormone requires growth repair
0.12856172.11564668.html.plaintext.txt	217	Proceedings 83rd Annual Meeting The Endocrine Society Denver CO 2001 p 33 Shintani M Ogawa Y Ebihara K et al
0.12856172.11564668.html.plaintext.txt	218	2001 Ghrelin endogenous growth hormone secretagogue novel orexigenic peptide antagonizes leptin action activation hypothalamic neuropeptide YY1 receptor pathway
0.12856172.11564668.html.plaintext.txt	219	Diabetes 50227 232AbstractFree Full Text Asakawa A Inui A Kaga T et al
0.12856172.11564668.html.plaintext.txt	220	2001 Ghrelin appetite stimulatory signal stomach structural resemblance motilin
0.12856172.11564668.html.plaintext.txt	221	Gastroenterology 120337 345Medline Kamegai J Tamura H Shimizu T Ishii S Sugihara H Wakabayashi I 2000 Central effect ghrelin endogenous growth hormone secretagogue hypothalamic peptide gene expression
0.12856172.11564668.html.plaintext.txt	222	Endocrinology 1414797 4800AbstractFree Full Text Wren AM Small CJ Ward HL et al
0.12856172.11564668.html.plaintext.txt	223	2000 The novel hypothalamic peptide ghrelin stimulates food intake growth hormone secretion
0.12856172.11564668.html.plaintext.txt	224	Endocrinology 1414325 4328AbstractFree Full Text Nakazato M Murakami N Date Y et al
0.12856172.11564668.html.plaintext.txt	225	2001 A role ghrelin central regulation feeding
0.12856172.11564668.html.plaintext.txt	226	Nature 409194 198CrossRefMedline Tschop M Wawarta R Riepl RL et al
0.12856172.11564668.html.plaintext.txt	227	2001 Post prandial decrease circulating human ghrelin levels
0.12856172.11564668.html.plaintext.txt	228	J Endocrinol Invest 24RC19 RC21 Tschop M Weyer C Tataranni PA Devanarayan V Ravussin E Heiman ML 2001 Circulating ghrelin levels decreased human obesity
0.12856172.11564668.html.plaintext.txt	229	Diabetes 50707 709AbstractFree Full Text Ravussin E Tschop M Heiman ML Bouchard C 2001 Plasma ghrelin concentration energy balance overfeeding negative energy balance studies twins
0.12856172.11564668.html.plaintext.txt	230	J Clin Endocrinol Metab 864547 4551AbstractFree Full Text Toshinai K Mondal MS Nakazato M et al
0.12856172.11564668.html.plaintext.txt	231	2001 Upregulation Ghrelin expression stomach upon fasting insulin induced hypoglycemia leptin administration
0.12856172.11564668.html.plaintext.txt	232	Biochem Biophys Res Commun 2811220 1225CrossRefMedline Toth DW Hellmann PH Gordon DA et al
0.12856172.11564668.html.plaintext.txt	233	2001 Evidence orexigenic effect ghrelin mediated distinct GHS R subtype
0.12856172.11564668.html.plaintext.txt	234	Proceedings 83rd Annual Meeting The Endocrine Society Denver CO 2001 p 169 Chen C 2000 Growth hormone secretagogue actions pituitary gland multiple receptors multiple ligands Clin Exp Pharmacol Physiol 27323 329CrossRefMedline Torsello A Locatelli V Melis MR et al
0.12856172.11564668.html.plaintext.txt	235	2000 Differential orexigenic effects hexarelin analogs rat hypothalamus indication multiple growth hormone secretagogue receptor subtypes
0.12856172.11564668.html.plaintext.txt	236	Neuroendocrinology 72327 332CrossRefMedline Heymsfield SB Greenberg AS Fujioka K et al
0.12856172.11564668.html.plaintext.txt	237	1999 Recombinant leptin weight loss obese lean adults randomized controlled dose escalation trial
0.12856172.11564668.html.plaintext.txt	238	JAMA 2821568 75AbstractFree Full Text Brobeck JR 1946 Mechanism development obesity animals hypothalamic lesions
0.12856172.11564668.html.plaintext.txt	239	Physiol Rev 26541 559Free Full Text Powley TL Opsahl CH Cox JE Weingarten HP 1980 The role hypothalamus energy homeostasis
0.12856172.11564668.html.plaintext.txt	240	In Morgane PJ Panskepp J eds
0.12856172.11564668.html.plaintext.txt	241	Part A Behavioral studies hypothalamus
0.12856172.11564668.html.plaintext.txt	242	pp 211 298 Bernadis LL Berlinger LL 1987 The dorsomedial hypothalamic nucleus revisited
0.12856172.11564668.html.plaintext.txt	243	Brain Res 434321 381Medline Aravich PF Scalfani A 1983 Paraventricular hypothalamic lesions medial hypothalamic cuts produce similar hyperphagia syndromes
0.12856172.11564668.html.plaintext.txt	244	Behav Neurosci 97970 983CrossRefMedline Weingarten HP Chang P McDonald TJ 1985 Comparisons metabolic behavioral disturbances following paraventricular ventromedial hypothalamic lesions
0.12856172.11564668.html.plaintext.txt	245	Brain Res Bull 141551 1559 Tokunaga K Fukushima M Kemnitz JW Bray GA 1986 Comparison ventromedial paraventricular lesions rats become obese
0.12856172.11564668.html.plaintext.txt	246	Am J Physiol 251R1221 R1227 Powley TL Keesey RE 1970 Relationship body weight lateral hypothalamic feeding syndrome
0.12856172.11564668.html.plaintext.txt	247	J Comp Physiol Psychol 7025 36Medline van den Pol AN 1982 Lateral hypothalamic damage body weight regulation role gender diet lesion placement
0.12856172.11564668.html.plaintext.txt	248	Am J Physiol 243R265 R274 Clark JT Kalra PS Crowley WR Kalra SP 1984 Neuropeptide Y human pancreatic polypeptide stimulate feeding behavior rats
0.12856172.11564668.html.plaintext.txt	249	Endocrinology 115427 429Abstract Stanley BG Chin AS Leibovitz SF 1985 Feeding drinking elicited central injection neuropeptide Y evidence hypothalamic sites action
0.12856172.11564668.html.plaintext.txt	250	Brain Res Bull 14521 524CrossRefMedline de Lecea L Kilduff TS Peyron C et al
0.12856172.11564668.html.plaintext.txt	251	1998 The hypocretins two hypothalamic peptides neuroexcitatory activity
0.12856172.11564668.html.plaintext.txt	252	Proc Natl Acad Sci USA 95322 327AbstractFree Full Text Sakurai T Amemiya A Ishii M et al
0.12856172.11564668.html.plaintext.txt	253	1998 Orexins orexin receptors family hypothalamic neuropeptides G protein coupled receptors regulate feeding behavior
0.12856172.11564668.html.plaintext.txt	254	Cell 92573 585Medline Bittencourt JC Presse F Arias C et al
0.12856172.11564668.html.plaintext.txt	255	1992 The melanin concentrating hormone system rat brain immuno hybridization histochemical characterization
0.12856172.11564668.html.plaintext.txt	256	J Comp Neurol 319218 245Medline Qu D Ludwig DS Gammeltoft S et al
0.12856172.11564668.html.plaintext.txt	257	1996 A role melanin concentrating hormone central regulation feeding behavior
0.12856172.11564668.html.plaintext.txt	258	Nature 380243 247CrossRefMedline Lu D Willard D Patel IR et al
0.12856172.11564668.html.plaintext.txt	259	1994 Agouti protein antagonist melanocyte stimulating hormone receptor
0.12856172.11564668.html.plaintext.txt	260	Nature 371799 802CrossRefMedline Ollmann MM Wilson BD Yang YK et al
0.12856172.11564668.html.plaintext.txt	261	1997 Antagonism central melanocortin receptors vitro vivo agouti related protein
0.12856172.11564668.html.plaintext.txt	262	Science 278135 138AbstractFree Full Text Fan W Boston BA Kesterson RA Hruby VJ Cone RD 1997 Role melanocortinergic neurons feeding agouti obesity syndrome
0.12856172.11564668.html.plaintext.txt	263	Nature 385165 168CrossRefMedline Hahn TM Breininger JF Baskin DG Schwartz MW 1998 Coexpression Agrp NPY fasting activated hypothalamic neurons
0.12856172.11564668.html.plaintext.txt	264	Nature Neurosci 1271 272CrossRefMedline Mezey E Kiss JZ Mueller GP Eskay R Odonohue TL Palkovits M 1985 Distribution pro opiomelanocortin derived peptides adrenocorticotrope hormone melanocyte stimulating hormone ss endorphin ACTH MSH ss END rat hypothalamus
0.12856172.11564668.html.plaintext.txt	265	Brain Res 328341 347CrossRefMedline Halaas JL Gajiwala KS Maffei SL et al
0.12856172.11564668.html.plaintext.txt	266	1995 Weight reducing effects plasma protein encoded obese gene
0.12856172.11564668.html.plaintext.txt	267	Science 269543 546Medline Pelleymounter MA Cullen MJ Baker MB et al
0.12856172.11564668.html.plaintext.txt	268	1995 Effects obese gene product body weight regulation obob mice
0.12856172.11564668.html.plaintext.txt	269	Science 269540 543Medline Campfield LA Smith FJ Guisez Y Devos R Burn P 1995 Recombinant mouse OB protein evidence peripheral signal linking adiposity central neural networks
0.12856172.11564668.html.plaintext.txt	270	Science 269546 549Medline Leibel RL Chung WK Chua Jr SC 1997 The molecular genetics rodent single gene obesities
0.12856172.11564668.html.plaintext.txt	271	J Biol Chem 27231937 31940Free Full Text Strobel A Issad T Camoin L Ozata M Strosberg AD 1998 A leptin missense mutation associated hypogonadism morbid obesity
0.12856172.11564668.html.plaintext.txt	272	Nat Genet 18213 215CrossRefMedline Montague CT Farooqi IS Whitehead JP et al
0.12856172.11564668.html.plaintext.txt	273	1997 Congenital leptin deficiency associated severe early onset obesity humans
0.12856172.11564668.html.plaintext.txt	274	Nature 387903 908CrossRefMedline Clement K Vaisse C Lahlou N et al
0.12856172.11564668.html.plaintext.txt	275	1998 A mutation human leptin receptor gene causes obesity pituitary dysfunction
0.12856172.11564668.html.plaintext.txt	276	Nature 392398 401CrossRefMedline Mercer JG Hoggard N Williams LM et al
0.12856172.11564668.html.plaintext.txt	277	1996 Localization leptin receptor mRNA long splice variant O Rb mouse hypothalamus adjacent brain regions situ hybridization
0.12856172.11564668.html.plaintext.txt	278	FEBS Lett 387113 116CrossRefMedline Diano S Kalra SP Horvath TL 1998 Leptin receptor immunoreactivity associated Golgi apparatus hypothalamic cells
0.12856172.11564668.html.plaintext.txt	279	J Neuroendocrinol 9647 650CrossRef Elmquist JK Elias CF Saper CB 1999 From lesions leptin hypothalamic control food intake body weight
0.12856172.11564668.html.plaintext.txt	280	Neuron 2221 232 Elmquist JK Bjorbaek C Ahima RS Flier JS Saper CB 1998 Distributions leptin receptor mRNA isoforms rat brain
0.12856172.11564668.html.plaintext.txt	281	CO2 2 572AbstractFree Full Text Yarnell DO Knight DS Hamilton K Tulp O Tso P 1998 Localization leptin receptor immunoreactivity lean obese zucker rat brain
0.12856172.11564668.html.plaintext.txt	282	Brain Res 78580 90CrossRefMedline Schwartz MW Seeley RJ Campfield LA Burn P Baskin DG 1996 Identification leptin action rat hypothalamus
0.12856172.11564668.html.plaintext.txt	283	J Clin Invest 981101 1106AbstractFree Full Text Broberger C de Lecea L Sutcliffe JG Hokfelt T 1998 Hypocretinorexin melanin concentrating hormone expressing cells distinct populations rodent lateral hypothalamus relationship neuropeptide Y agouti gene related protein systems
0.12856172.11564668.html.plaintext.txt	284	CO2 R 588Medline Horvath TL Bechmann I Kalra SP Naftolin F Leranth C 1997 Heterogeneity neuropeptide Y containing neurons rat arcuate nucleus GABAergic non GABAergic subpopulations
0.12856172.11564668.html.plaintext.txt	285	Brain Res 756283 286CrossRefMedline Horvath TL Diano S van den Pol AN 1999 Synaptic interaction hypocretin orexin neuropeptide Y cells rodent primate hypothalamus novel circuit implicated metabolic endocrine regulations
0.12856172.11564668.html.plaintext.txt	286	J Neurosci 191072 1087AbstractFree Full Text Merchenthaler I 1991 Neurons access general circulation central nervous system rat retrograde tracing study fluoro gold
0.12856172.11564668.html.plaintext.txt	287	Neuroscience 44655 662CrossRefMedline Guan XM Yu H Palyha OC et al
0.12856172.11564668.html.plaintext.txt	288	1997 Distribution mRNA encoding growth hormone secretagogue receptor brain peripheral tissues
0.12856172.11564668.html.plaintext.txt	289	Brain Res Mol Brain Res 4823 29CrossRefMedline Tannenbaum GS Lapointe M Beaudet A Howard AD 1998 Expression growth hormone secretagogue receptors growth hormone releasing hormone neurons mediobasal hypothalamus
0.12856172.11564668.html.plaintext.txt	290	Endocrinology 1394420 4423AbstractFree Full Text Shuto Y Shibasaki T Wada K et al
0.12856172.11564668.html.plaintext.txt	291	2001 Generation polyclonal antiserum growth hormone secretagogue receptor GHS R evidence GHS R exists hypothalamus pituitary stomach rats
0.12856172.11564668.html.plaintext.txt	292	Life Sci 68991 996CrossRefMedline Willesen MG Kristensen P Romer J 1999 Co localization growth hormone secretagogue receptor NPY mRNA arcuate nucleus rat
0.12856172.11564668.html.plaintext.txt	293	Neuroendocrinology 70306 316CrossRefMedline Smith RG Leonard R Bailey AR et al
0.12856172.11564668.html.plaintext.txt	294	2001 Growth hormone secretagogue receptor family members ligands
0.12856172.11564668.html.plaintext.txt	295	Endocrine 149 14Medline Luckman SM Rosenzweig I Dickson SL 1999 Activation arcuate nucleus neurons systemic administration leptin growth hormone releasing peptide 6 normal fasted rats
0.12856172.11564668.html.plaintext.txt	296	Neuroendocrinology 7093 100CrossRefMedline Dickson SL Leng G Robinson IC 1993 Systemic administration growth hormone releasing peptide activates hypothalamic arcuate neurons
0.12856172.11564668.html.plaintext.txt	297	Neuroscience 52303 306CrossRefMedline Dickson SL Luckman SM 1997 Induction c fos messenger ribonucleic acid neuropeptide Y growth hormone GH releasing factor neurons rat arcuate nucleus following systemic injection GH secretagogue GH releasing peptide 6
0.12856172.11564668.html.plaintext.txt	298	Endocrinology 138771 777AbstractFree Full Text Bailey AR Von Englehardt N Leng G Smith RG Dickson SL 2000 Growth hormone secretagogue activation arcuate nucleus brainstem occurs via non noradrenergic pathway
0.12856172.11564668.html.plaintext.txt	299	J Neuroendocrinol 12191 197CrossRefMedline Hewson AK Dickson SL 2000 Systemic administration ghrelin induces Fos Egr 1 proteins hypothalamic arcuate nucleus fasted fed rats
0.12856172.11564668.html.plaintext.txt	300	J Neuroendocrinol 121047 1049CrossRefMedline Lambert PD Anderson KD Sleeman MW et al
0.12856172.11564668.html.plaintext.txt	301	2001 Ciliary neurotrophic factor activates leptin like pathways reduces body fat without cachexia rebound weight gain even leptin resistant obesity
0.12856172.11564668.html.plaintext.txt	302	Proc Natl Acad Sci USA 984652 4657AbstractFree Full Text Kalra SP 2001 Circumventing leptin resistance weight control
0.12856172.11564668.html.plaintext.txt	303	Proc Natl Acad Sci USA 984279 4281Free Full Text Saladin R De Vos P Guerre Millo M et al
0.12856172.11564668.html.plaintext.txt	304	1995 Transient increase obese gene expression food intake insulin administration
0.12856172.11564668.html.plaintext.txt	305	Nature 377527 529CrossRefMedline Sahu A Kalra PS Kalra SP 1988 Food deprivation ingestion induced reciprocal changes neuropeptide Y concentrations paraventricular nucleus
0.12856172.11564668.html.plaintext.txt	306	Peptides 983 86CrossRefMedline Sahu A White JD Kalra PS Kalra SP 1992 Hypothalamic neuropeptide Y gene expression rats scheduled feeding regimen
0.12856172.11564668.html.plaintext.txt	307	Mol Brain Res 1515 18Medline Sahu A 1998 Evidence suggesting galanin GAL melanin concentrating hormone MCH neurotensin NT proopiomelanocortin POMC neuropeptide Y NPY targets leptin signaling hypothalamus
0.12856172.11564668.html.plaintext.txt	308	Endocrinology 139795 798AbstractFree Full Text Schwartz MW Seeley RJ Woods SC et al
0.12856172.11564668.html.plaintext.txt	309	1997 Leptin increases hypothalamic pro opiomelanocortin mRNA expression rostral arcuate nucleus
0.12856172.11564668.html.plaintext.txt	310	Diabetes 462119 2123Abstract Cowley MA Smart JL Rubinstein M et al
0.12856172.11564668.html.plaintext.txt	311	2001 Leptin activates anorexigenic POMC neurons neural network arcuate nucleus
0.12856172.11564668.html.plaintext.txt	312	Nature 411480 484CrossRefMedline Cowley MA Pronchuk N Fan W Dinulescu DM Colmers WF Cone RD 1999 Integration NPY AGRP melanocortin signals hypothalamic paraventricular nucleus evidence cellular basis adipostat
0.12856172.11564668.html.plaintext.txt	313	Neuron 24155 163Medline van den Pol AN Gao XB Obrietan K Kilduff T Belousov A 1998 Pre postsynaptic actions modulation neuroendocrine neurons new hypothalamic peptide hypocretinorexin
0.12856172.11564668.html.plaintext.txt	314	J Neurosci 187962 7971AbstractFree Full Text Broberger C Johansen J Johansson C Schalling M Hokfelt T 1998 The neuropeptide Yagouti gene related protein AGRP brain circuitry normal anorectic monosodium glutamate treated mice
0.12856172.11564668.html.plaintext.txt	315	Proc Natl Acad Sci USA 9515043 10048AbstractFree Full Text DeFalco J Tomishima M Liu H et al
0.12856172.11564668.html.plaintext.txt	316	2001 Virus assisted mapping neural inputs feeding center hypothalamus
0.12856172.11564668.html.plaintext.txt	317	Science 2912608 2613AbstractFree Full Text
